{"docstore/metadata": {"fcafdb20-17e8-445e-a7d6-7c5d1c14996d": {"doc_hash": "d10c6b45a0dfb27ef95edf4cd23cd9614ef422c29f6fe6eb50e79bff6ed0b03a"}, "7615fb8b-f8a3-43e6-b5fa-6b7042933f04": {"doc_hash": "0e08bb4017b77a26ce4f373b377a1e0946dac0dbf3d1705bef04fb517271d691"}, "c5ace680-1a06-40a1-b05e-c466202222f8": {"doc_hash": "f14886db27d370426b7b1bea94f37440400f5959289d63a58479e43e77526525"}, "3f425aad-9cbd-4c0f-9788-8a1c28fc8736": {"doc_hash": "d1b1b58489d5346c04f7789ef35a8342bf7923a99fefa84d5aa45cbd5e0dff24"}, "15d14d4e-85d9-4ee6-82bf-cde584513288": {"doc_hash": "76a3c2fa907997b864457a03b6d19293f75907d8de5645904817946b64a02a48"}, "3776cd45-8e7c-44c4-b92f-824e4df55a2b": {"doc_hash": "2ca64f244d6f07d27b64bc2dd52072e693d751714b215fd4881b6f1507807a04"}, "941d163f-8a67-4980-a6a7-659a390d3f12": {"doc_hash": "b46d2095d74986d642987e3d9b6a62f267c6df312af829e37c800bb7642ab40c"}, "8570a108-4af9-44bc-b05b-0542b8b981cb": {"doc_hash": "0719df24b02ce213429aa95ee747b8357fc457916d13a2039a8b4e6fe4014bdd"}, "cae001d1-adc4-43c4-86eb-3afca61af625": {"doc_hash": "b1f4d710103d927292b9193f69bd0532c0d26a099a278ceb44762edf5fe56a3b"}, "2f7c8d7a-d2ef-4aad-aaba-9896ae465fd3": {"doc_hash": "a10b5381543bb4a03146a0843b699689e5791f1566b22fd85b6f8757ed5df432"}, "828511b8-a12b-4753-ba7b-e47d9cf3dcb7": {"doc_hash": "a48df3ff7deca7f4c3016ed0b522fa588c7107a6b89f86dfb7e32b46a18c983b"}, "3a972395-e60a-416e-8ee3-8753f826199b": {"doc_hash": "95742f1bfe203c67154af278904dab9b584815141333fcbff2e5d606ca9d97fd"}, "9b05e3fc-b17f-4677-9647-a6dec50e6e20": {"doc_hash": "9bbcc7bc26e230775b1fac88e023c8debe0010dcaff26d5cbd8d95ec9a29d4b2"}, "7d6502f2-57f3-4c3f-bdc7-c90afb45915b": {"doc_hash": "29d84caa04647b169ffaa188fe9f2a7f9dc5d4dd18c56a23097b6bb88cddea5a"}, "4279f1b2-5420-4e50-ac08-2744d393c439": {"doc_hash": "6aac7cb8feaec2eee0b363b315e5f70e7122bcffba847e4e4c56b5a9adc3455d"}, "0da85362-fd5e-4050-9131-3ef70de211ca": {"doc_hash": "1e3e47ed1467e935a21f4949ddc132420479a6f0f829ade5262bf8c8db87f318"}, "af3e5d0d-5513-4835-98f2-476cfd9c6166": {"doc_hash": "a97f0bc647a8e4715933d69f272a1a861de041bcb5a5681eead04626d306ebee"}, "93113a58-04e3-484d-9264-50186f64c354": {"doc_hash": "ec8256382c2ceee5abcbb5f68bb78f8815ba1f86e3bd12deb24977c28b7e059d"}, "079d1128-1182-4299-a9eb-957a6f2268de": {"doc_hash": "68d8049214c3c741236485f17fd071b2ffb294969cee1d268902f1ec49207aca"}, "c15526a3-5091-4246-a0a4-434fb0ca4a4d": {"doc_hash": "fae853fa4f07a1f92cc07be20996a5af9f6696368c6ce35d3db092a797d78168"}, "5f6a2b73-3193-4933-9e31-37d3af8dfdfc": {"doc_hash": "d4c72cb77c65e8f8144b4e9479ed3761bd3e8d87267e2d46201c5f19a72d6229"}, "5e71608c-4196-415a-b44c-d5e95bfff7e2": {"doc_hash": "2e3d6cc7623fd56a7185976f9b44da2bbfb2cabe742fa884de1771c4e7b3d296"}, "de62df33-9d10-461c-93a3-ec27958e2ca0": {"doc_hash": "eac0283d0d374ab923f8e030ac9d1d30f1f688237cb2dd64e37378ecf4902e53"}, "44f90b55-11c6-4256-82a9-e2ef30fbde41": {"doc_hash": "dae860bfabc0f7d99381df48996d196b3564355629ec7f86ea5a52d041f9ae1a"}, "d7cbcd75-bd03-464a-b8ae-5a51caf94e39": {"doc_hash": "0516a1652032d44e0995cadf12e998e09cfebbd37aa237ffe2ceddb70024fa5c"}, "1fbfbe0c-2791-427c-987f-43948b0bb4b5": {"doc_hash": "9a025a2947fe0fef97b7a487e78f829c0b31f69ee766bc2856676a9432651f2f"}, "594dca8c-e0a5-4bfc-a824-86502d359579": {"doc_hash": "90a1887a8b1a652ab48ebfce3acc866d677bcc0f37c8d16a0005f3a07dd6e8b4"}, "d482a4d3-4034-4b44-a781-6c5c9e859994": {"doc_hash": "6ed8bd95b4e0ea773b79467364eecb135b0a55e21b39b6c35e7d644021a4a4b0"}, "b1cb14d6-ae35-4f96-9313-019e65289ce6": {"doc_hash": "c168a8d3ba99c8855103d9bfba6ca7c24c7ecac74d1c8c0902d269c6788b0181"}, "15eaeebb-8425-4573-b4f8-ad5506a004d8": {"doc_hash": "2a5e4c39827720c8db8079342a3378cbb9203925d2c67655b965ed30cd38648d"}, "0b3fd5bd-b588-44f3-85d3-3e8bf2656b50": {"doc_hash": "bbe6ab53c9105e5cbc856553cb802afa7191bc07405f54aaa0ae446060f28b01"}, "22079c30-189e-47fb-9e31-1ff8663dc7a1": {"doc_hash": "0be02cd8a1dfe2a605fe392078b6663508e8501004279f0af28f76fce5614349"}, "6b4c360b-9f6c-40a8-870f-d036e6c87169": {"doc_hash": "0523f8dbca0ca428f46c74bf5dcb076ea4bd488a5f7e6ba39760f24ef3f3057e"}, "1bf7379f-8602-4e66-af52-cc9264bdfb8b": {"doc_hash": "507d09f4218b8809f5ca0dd093ad7e9e2cf57c560756a8d77c1a5e97b7195b55"}, "79a479cf-2a72-4463-96b0-b4880b1d4e4d": {"doc_hash": "07790ae1a0af4037fa58aefd6fc8f16374286b2c85de85966e7222f31374dd87"}, "c530fd5c-b2f8-401a-9a29-5215a0c47658": {"doc_hash": "d11dbd866ff65e2e0d9cd3992169b5cf442eefc184ffbf2aeb307e51139e06ee"}, "3384ed57-4045-425a-b8f1-c654c2a8a73d": {"doc_hash": "603df265e0576daeea03ebc8b1b19de86c29437dfa243616ed4989e2433815ee"}, "2bed1749-f5a5-4300-9721-36e2ad829cf6": {"doc_hash": "b74662159b1e3f4af1f31de61f6614dd98c466fc3fc4e5bafb380d904bf9182f"}, "e14c7d12-a39d-419c-a7ca-d0fdb0b07031": {"doc_hash": "3dc6d2632df4081ded09d3049ccb22ff1d8f0e927e6fe022fcef1d422790c0ef"}, "99296c5d-32e1-4b4d-a657-f0e871e56802": {"doc_hash": "bb82f105184f441b48b766fe52bb14f9ead4bbc09e0c52113bf7d2a748ccf33f"}, "908b3b4e-ed97-42f2-8ca5-d60cea7282f8": {"doc_hash": "6c54102f255173e6603018e6d78d1225353a7b0416aa54cebe2f49c5cbdba245"}, "c8282bc5-7db4-4ff5-9a00-f83862a31bdd": {"doc_hash": "b69fac6c2016f573d1687b02273b179a3def2e1c2957d23dc72eaf805148b912"}, "658041f7-1a75-45e5-9166-74a09afe9067": {"doc_hash": "590aff72d5ac3ee4159e288bafc022108b11a3e1b9f344a86beaf197ae456483"}, "b3dad03b-ba50-4f54-98e8-473a177d1427": {"doc_hash": "82b71ca3d7bf1e22307726818a115f47437dbb12d1ee6191dad19ec9934b477d"}, "70550d91-4501-440b-ad3f-df051e933ddc": {"doc_hash": "708f9e2064ab4ad542f26979579fc875c226a10514edf65e6119b9fff55d5de0"}, "2078a7ef-0deb-4e51-9a34-2a6b244b2883": {"doc_hash": "eebb7ac01a90c507d65d8013cc211dc5735b044bbe106e73a99562a658d05adb"}, "51955358-2582-40f8-8e7e-d511f8faf5a0": {"doc_hash": "4f0635bc929e6182fbfaaf67d47bcb7bf682732852e46cedad89fde5ef53abb1"}, "ba8fe3fd-a1ff-4583-be3a-beddd7a15063": {"doc_hash": "5dd50946c28ef229c8244c52dd398888a80199032b84962170cd39f4f4d7f91f"}, "8b00ebf7-29dc-46f4-b862-5efecbd04c5c": {"doc_hash": "281d96ff2d58ffb6d241988550da8de7621583d10637fb01662a1b4fba28a8b4"}, "bcdd4836-ebbf-4c04-8e9e-8af4dec9e84a": {"doc_hash": "17d257c0401b81e64d91e65a4207a1005efb832bdabdd13be6cb4b293c863d2b"}, "6035df52-14a5-4cca-a2e5-19cff4afdafe": {"doc_hash": "76ad50e86386b98cb710652806a60f407929829287fde925d417168248040198"}, "78c73c04-8b2f-4f42-a213-6259dc336682": {"doc_hash": "7afafa8e6bda619cc4ddac766c41897a0bd3eb7402c65fcafe88713c87abf2cb"}, "e11608ce-d26d-4203-8630-0d2508febe0b": {"doc_hash": "c3c28e04b0b63062834fae1bd59100948c263d5d04e3da65f1d2f2b683010c1f"}, "81e1d798-1bfd-462d-ac36-6018ccdc7ebb": {"doc_hash": "554809fc850fd036575e31fb9b555f6e218a5c22dd355e1987205dd6ba90b9b7"}, "27ffb3b2-48a9-4a85-b79b-a6f6013be127": {"doc_hash": "e26f9b231dde1b2bede1575e791c34497dfec78887787ac2fffd68f18588743b"}, "a062f408-cca8-4285-b43d-d48467b85d84": {"doc_hash": "e745288f4872149e140b5e41f76a9939916616c977bcfe61de16c282f6c4433f"}, "a3d78e9e-5f47-4340-b9af-46e122ecc6da": {"doc_hash": "369a1b4100dc59c3315f4c17c05a91b16d75e959fd46e8ca7bced4cc9f25afcb"}, "6d9c5893-68df-4492-9028-62947bd4bd11": {"doc_hash": "9dce1d435e2b75548564ef17da3315fcda9b70897dd65623acc5d8ddfe6fcb24"}, "c9ec9ee5-d94d-443b-b077-a01837ce388e": {"doc_hash": "8ef9fddd9b23ecfa15ce6b5a5fd2a5815597dc9700107d47c5d617c2b21c9c53"}, "65bb7f4c-96c9-4b42-aebb-4cf8a07de432": {"doc_hash": "ab3209eda1d42d498e05fa6e9a7e4600f469d4daebd47fb08fb2426d7cde8fff"}, "f1034205-ec22-4323-90e1-61b097f416b6": {"doc_hash": "801aa74ddf74175c2d6283fabb51a4ddfb387dcb78486203dc71ad7c2b3c9aad"}, "e2be68db-4b11-48fd-8093-6a5fd63ffcc8": {"doc_hash": "4fcdc2de7c7de7ae33aef3e6b1b54b5a50e57fc771755d6b2f02a8c987cc3813"}, "6921c743-b569-4c9a-b209-0dde6cda3360": {"doc_hash": "6388029f829c41909d07316dddefdbce0e6f2a39e13402e4ed32c1872ab0f2b1"}, "450fe8d5-b6d6-4ba4-9a37-6b9d30d26896": {"doc_hash": "558aabb128f14bd82988ea1f68c9f8a712be9580d6a7b9a01a87ca8a0070b53d"}, "a8560344-4639-4b3a-9a5c-08d39756a0a0": {"doc_hash": "c1d253b5aafe13acb22b20ae0f1627a2a4d8006ecfd4400e86ee3421c6ab7b46"}, "9a974675-1543-485b-8a0e-453a07de9de0": {"doc_hash": "06a99abd1f5db65ccd317b41ee8ad1cd31a0a3f59a4ab42e908a476b25875ae3"}, "74114646-4f81-43dc-af85-77c29c539fd8": {"doc_hash": "62bfbe890826ca5182264f78a1c81e409373a6909926a696cd314a88d7fa78e4"}, "3d804f4d-a7c5-4462-8099-169f3811144e": {"doc_hash": "cf9c00a682f402cdc513191e93c78b98a9160af43e39c5b352028574e6ce5108"}, "dd3bc350-7901-436f-b9b6-a997a2b19634": {"doc_hash": "fed83e5525b505fb18bcd173b7fa5d40899c6cc1d85d99df1f905e8328469bc1"}, "cade7345-df33-4c0f-bd62-c80c8ba7746a": {"doc_hash": "29bf1f51eb9623fe9f08f7af3f841e48bdda7dc935bedf51bfc3d45984bfe996"}, "43b6cb1d-07e3-415a-a978-f2020428c3d3": {"doc_hash": "32813027cbfeb7417b9fed56dcfabf545f30fcae5cd41b95f18f8a9a8de860c5"}, "bf8a63ae-d6ac-4202-91b2-5a96a3fa89a1": {"doc_hash": "a8c502aa20901762c698142262f714bddfb8ea9cfe6469aa289569b6d293ceac"}, "d03d9f54-81b3-4196-a99c-9db97f30d2b1": {"doc_hash": "725dfd52a8231e0e8e57e8c43eed6d648f17b41cb7dbdcae93f905759a0c17b8"}, "e1cc4655-10bc-4df8-be0f-7b8e5bf6e239": {"doc_hash": "4ada690c85ac9e3b0100ef888d44203b479fea32bd890c89ca6c77b5e0714407"}, "56ec57f9-fb89-404b-90c0-2db9b4aa4340": {"doc_hash": "a17713e6a89c46ac31e8ec4474079a048842ded50ccc220ea7cd209fe7f6c69c"}, "129a3d8d-314d-4348-8021-1d217135191c": {"doc_hash": "625111e981afd15b1597461e177a4969f3594c33b84f160daafa2f78277c10bd"}, "1b1bce34-5f15-445b-b63a-fb601060da3d": {"doc_hash": "de3d891550d3bf7cf6ba31dd2691a126acf71f07fa5e58e82e8a97d7dce2454d"}, "febd1297-d15c-49b5-819a-af5360d5de5f": {"doc_hash": "c02cada3a6b144b7e7668528f48c1302986671997f50671f00554239879ceb66"}, "2af5eadf-433a-4790-b65e-cb4559ced482": {"doc_hash": "127e56c2fbed8422b103ad179b3b5f54d4b27d66ededa43628bd9a98cbed082b"}, "d723e63d-7991-461c-b9bd-2366ccff8ec9": {"doc_hash": "78bf85fd2e9b9a2c54e02e6f6625924369a36c1dcd769d351511c6e55553d92f"}, "c9c26e69-9411-4fbf-9e2d-563c1e4eaae2": {"doc_hash": "8462d64ac5017f540dd3689a0806b19130ded53817e7dd60d326166a53102be2"}, "61a9d5e2-dd35-47f4-928b-b92e930e5b0b": {"doc_hash": "071f0ce5b61812b3274dbdf30916e3df8f1d39da0cc47e65aa2ab150ee0d4848"}, "f2f99320-8681-427e-8ad9-6f9ffec4f753": {"doc_hash": "f218d1695336fb8c882503b9c6a9b436fd5678db04c27752f7a96c4bdbd1011a"}, "499f733c-5204-45b4-94d0-18bafa91b4f1": {"doc_hash": "ce3ffa3d3689ee5f8f81b7db365eee3701643246b1ac0463820e8322cda910a1"}, "497f0518-c964-43d5-aa9f-1192b65512cf": {"doc_hash": "51367757fb0a4620063b96d4fa9a758547b89e1c9be08442347e70cca51c5df0"}, "b2655f5a-84c8-4f92-9300-c6d606b26525": {"doc_hash": "5a6b66fd3fe6329334aa57835dbfcfdc9500bbfd2d542442610abb9906ecc5f5"}, "0092d6d0-4c6b-47ff-98f7-07d31290fccd": {"doc_hash": "763b0e6f92fa4a06756bbee01754e5a154929498267f6e47445a1aed2c777d6e"}, "3dc9ec91-2f71-4e61-b257-16970c36950e": {"doc_hash": "95f2f6dfc68dc3a3aa88fd53d7b0edac537ddb511bf42d2c91394d585efca1c1"}, "dbfcaf4d-6935-46c0-9bd3-609b4e5b0b11": {"doc_hash": "090832958a314349b757d78c3d19aaa333f5168c700881b1156cfbb1f34d7ec5"}, "c977b057-87fc-4bcc-a9cb-efd109f7f647": {"doc_hash": "3b2bfb19fee7fc2058e161e7c47a70f862b78e550d5ad71c244d28b6c6239460"}, "294d557d-9b83-4742-bd60-5d62568ededc": {"doc_hash": "fc61e44c713b6a9159377244a02e56343290e8ecd27cd9d1e89541f8223b088a"}, "e1dafaea-68ff-4ec8-be24-69ce949d0dd9": {"doc_hash": "3c498cb4bf7b42702944e254e02373de14da88ccf7c54b15fbffff585330d142"}, "0d624cea-4278-4749-a2ce-8e50aef53acb": {"doc_hash": "ceeb2b3a93e7520e72f5ba8d7a648c986ebe9b3175ec5185f9dae3ee62415aaf"}, "75c5e054-2896-4d08-a3bb-91740e395995": {"doc_hash": "457ca713c984c1fbcda72bc725a1337c3d1f53a92b9f881e5ab01d177135255f"}, "b6e6393c-e92e-450d-8c9b-fc352baf87a7": {"doc_hash": "06d09412e31428b5ca41344209b7c051195bbb3cbe1e55475577e2797d3e1eab"}, "53e6292d-1e83-42e4-b6dc-bceabdf1d4c0": {"doc_hash": "45030031b0a71fd5155585335c42f82805ef71350bd6ca102f588245c44522f9"}, "7780c047-eb3e-473e-8acf-3b944fd6f31f": {"doc_hash": "5bb361ad94cf680eefc4f15f48752fa394a439fa649db6f5f37d21cf4b1bb614"}, "6f62f37e-f4a3-43c0-9080-77f8346a2020": {"doc_hash": "f93594907bc364512421834e1c7bb10573ae01878f210cfc75e4bdc54228d9d9"}, "308d2295-23ee-409e-a65c-3f0dc22224a9": {"doc_hash": "98a04cd57ab487642d80b2a59bc9092930ab04fe20c540aefddae2ab5422e6f3"}, "6a568460-1181-4d32-8607-d1b2d35c8532": {"doc_hash": "a4a78a5d526fa3cab66d0f90442c3f3d3eeb57ce927e067f62369f5e19c2a16f"}, "214bd709-c9ad-4e86-a0f4-9e49ca0f0c81": {"doc_hash": "e5e47e1b8144f9d0a18d03586b3b2ebfdbec0e33a2848c54088876cb253a9ab8"}, "d8336305-9a0c-4ec9-ac8a-7228c69ebaae": {"doc_hash": "56d22c74a5b3095724840c17fca877c17ca7962f899620d814eb8fcd075de57e"}, "22d45598-3642-4ba5-8f1e-9f9a1b6763ea": {"doc_hash": "23ec2f85ebbfc8902b30c128527f8523557d3aa240e9ad2a798993d3cc8a6df1"}, "2c0ef8eb-a886-4e70-997a-1fa14c346775": {"doc_hash": "4d8d74bc74cdf43ac27a20fcd0686431b822f54236ea7ee4f793710051cff805"}, "77acc0c9-c14f-4835-a16b-09aacfab1515": {"doc_hash": "adea90d143896e7c8fb5cbac1ca3f70ada8b0e1bac99c2880f995cf0dcaa86fe"}, "a1562efc-fd6d-4a02-b226-8c2de23051dc": {"doc_hash": "77876c9c9f0be33d38829555b7a0ae441d55c4d73541b1a71c383421d395f9f1"}, "a3da02d9-0ef5-4d12-86cd-20c3bf49619e": {"doc_hash": "49a31532048c1cc86e6a77f49ff2827320e67b1eaa2996bb6d1a57c6a78ea6dd"}, "aa8cfa7b-f1d1-45d1-8132-f4dc9ef32c7f": {"doc_hash": "199c6404c93e2b566e3ee7c47701ab599a11fb5e80d7bcaaa6040a923907da5a"}, "ae16b974-9580-4b9b-85c6-f0b1e0ec5863": {"doc_hash": "17053b3b34c00fff3ef991acc7c31633a3735f392bc7632dbd326c42b6f89d4e"}, "7a04d29d-348f-4dfd-983b-95481be8ed5d": {"doc_hash": "2daf7b7fa7ef2544a14403d831808c8825d7c3d6bbe13991a67ceae7ea70e828"}, "909ef4bc-c346-4d4d-a14c-6437c7a77f8a": {"doc_hash": "0456000c02de83903367efdd264ea06f817a6d18ffbe1216279104cced5bb6aa"}, "293d3dd2-4207-4918-8049-d8c74b271234": {"doc_hash": "176fbb47bac59d694c60b6293bdba063204842d6810a249128754311e5350a13"}, "564a9e18-4c73-4729-98a9-a9d3ab4d2ec7": {"doc_hash": "960100b3242c606bdf1484c670902265a5f9fc8c140fbea54b38ee9c77c943f2"}, "2a6f412d-ce95-4338-b1bd-ba6ff0e7620a": {"doc_hash": "8508ef1d9ee590d8918a5a8a56cf298029c8ae0bc02d5b0e994f383d57c6ff79"}, "35d4df38-3fc8-4a8e-9b3f-1e3765dc1317": {"doc_hash": "7d1ebbf2b950e13677447d260a8fe5e24b275373511123674dc41593c94f0bd3"}, "ec0a9fe5-cbe6-48fe-a2b2-4e4ad8883689": {"doc_hash": "957d0f3c42a138669d89573e376fab27d81b12024aca8038f2036390bfaf5af8"}, "57d9a66c-5946-4fc4-90fe-24cb0a081bc7": {"doc_hash": "168342127d5f7c1712b1dc1fdabfd25112176d8fc89aff19e2c419c5388a8fe4"}, "a2c734b0-5860-4c19-9b5a-da9049c3bc6a": {"doc_hash": "1723c371ce4bc43eeddf2f46c0bb8e3a42273d2b950ab4ad33b1cdf0d9b78a23"}, "8e77d825-9af7-40a6-b5a3-fe52dd525979": {"doc_hash": "d7c7ebefed55e94d554c234f5d6e9219ad9bf789ae92b8c46e616cc2ba19f35b"}, "ac488468-5dde-4301-a83e-02b77c245e03": {"doc_hash": "c0378ccaf3f0245cd91dadf406f0b0591956eb2be84e86228265ee9f6f3c6421"}, "a03b5f7c-31a3-4a1d-b1b7-17ff04bf6ba4": {"doc_hash": "a052bbd8e16be5760a7eec9d2c7a109d4e3d103d42b1e21089a158abe8385669"}, "40611d6d-b3cb-4872-84be-26d52f2651f1": {"doc_hash": "271c23c609c0fe52113c9645a57bfa3b932a506f6573fb03855ee2d91d0d9ced"}, "7fba9d68-cfe4-4482-9332-5be804a45b0e": {"doc_hash": "007db78694479157212307b4fb4a8f86d6f7755e8bfa3a0ed9e02b9694eb80d1"}, "eac0587c-90c9-4dec-8912-292984126700": {"doc_hash": "4a1de5081bc0224cece1872bc2a002adf35c68e12e3142ab87f4992b7a446824"}, "9bc7d0e6-1094-45e2-8915-b7c788b51d34": {"doc_hash": "4eaaec8c087205be477bd6ff580331427b5188018f5aee750fb1cc4ecf209a23"}, "b14ab2bf-687b-4049-9439-793d9236eb40": {"doc_hash": "74537f71f804410130dff3bf54e1877d7d90d6ba9f613f21a6fe8a4ef91c2b07"}, "e81b6ab0-b708-4e5a-89a1-3a9951b1c48b": {"doc_hash": "0bc12746449ebcc2e6edd5f8393385af84b7ae8d0a71d26900f2c3c65834c35a"}, "791c605f-8fa4-4e78-a496-e81363747043": {"doc_hash": "7ab6c0722c821d4a444cc84e417fc9cc10416a9a9146135ba5da3bc3281869cb"}, "4f1c118c-5f29-4f8c-828d-3897e47c7395": {"doc_hash": "64150d83559a56867732a7efa3ea7afc198f980b53c5bb4f37fff5bb102fef51"}, "4381a3ec-5afd-40c9-80fd-aa0c7006832d": {"doc_hash": "e8f94d271fd1de14447fe299f6aa5a8b7546ff197ba6e838a1c610a4b9d03fea"}, "e060e4b0-03ea-41b6-85e3-74028079cab7": {"doc_hash": "bf096b7633ace6f06098486ee1985292014f6919ab03dfec17fefa9daa7189bc"}, "8de63600-5448-4594-8b4c-4730801289f5": {"doc_hash": "cbb01b2bf83c694af1faff69e6a1986977120ce5ff698984cb94a23f3cc9b44c"}, "bf53f581-7fd8-443e-a1b0-f6f068cf17b0": {"doc_hash": "34a48aa82348e4f72294cab127662cbcc876925b4596b3d72e9b5b8eb2992c36"}, "2271885f-5b4e-4bab-8576-17d8b95d4b5e": {"doc_hash": "551468edc5a6fa728ffbed887662fc5ae52153836267311d23e338629476d8f0"}, "97e6ddf2-c869-4e4e-a168-2c79fb3c066c": {"doc_hash": "0047634df51ff63169669d67164d79fa5c538263aa19665e5e458fda82c5129d"}, "435d2bed-395c-4005-bc82-c32d54ae76dc": {"doc_hash": "d6300c8e441e48e82ffd7e98b7870ab86af4b8c5fecf63c7f122bfed87155ed5"}, "5b1afa22-1cf9-4b13-b9ac-88dfad11b609": {"doc_hash": "d1e6ea3569253ce6e4d8828147297a45b2eeb1431b573f8b32b97a8d70ee6c7f"}, "6eacb740-4094-4656-9bce-8835a525588c": {"doc_hash": "e0424d60c3ee6a78df9a2351583c5525247e9effb10cea0205a84fa95c12cac4"}, "c206e343-4de3-4480-89fe-628fdde1fc33": {"doc_hash": "edd9b5ce03c0db4a3a4291fe4df143e3f5532c7f3b8cf8f131e7961a1da58d3a"}, "21503d1b-22e0-4184-97d0-dc5c03cc1614": {"doc_hash": "b8c9723ab0a251966c7fd81ae7348751f44b47b4937cefa3a0469a59328e2f36"}, "030e1b01-2c6a-49ce-9127-f8f903a57931": {"doc_hash": "6a678fbe59618471fb58a1b6ae2ec71b8cd3cea7ca66a44ef87b4f573a775f12"}, "c05d366b-a447-4e4e-9c3b-6ad3370ec275": {"doc_hash": "12a72a255fe96aa913bf28625febbeed82fe82fa78ec695219ec9610cf47c3e1"}, "9ed73236-ee95-47e7-ba47-0ff771745167": {"doc_hash": "2b5c1b7b2cdd2a91e0111361764eaf49463da8f4b91133907c862d146b442187"}, "f57efef7-ee22-481b-a982-a19cda834a56": {"doc_hash": "1ca78c08f56b7a42de6e0e4f303fa9fb06e08b4f3b721c6242d173874eb24a21"}, "a9ee7d11-645f-40a4-b551-3e47a094f88d": {"doc_hash": "bced8b4c115c0a8c50fd8e3da170dcde9f97f0b8b8a645da2ad21225153220a1"}, "8e3bbbbd-c484-4701-b55f-f3ff5bf5d270": {"doc_hash": "ba4ceb60ddc29611482565cc355f98eb5c9359b381f89360c71a78f9eae9cdad"}, "246da383-007c-40f5-9e07-52978ed27ff3": {"doc_hash": "86aa8c8c2c0b1c8b9c173d4e78cfd92ff63e29f1064d5a6b3a3e624cc4b56ac7"}, "f9167ad1-3346-48a9-93e8-edfbce751368": {"doc_hash": "f01d10dee3714f8031e5fd2bb34b91b98c8fcdb86d8a429a71cb3dfd5f9d6cf3"}, "8e7b362b-ba79-4efb-96cd-4cb7c846478c": {"doc_hash": "9395faaf730f9bee72a690173a2b57fe3c181b76246c724ab23dfa0343bbd950"}, "5bc95d67-0d72-4412-bf5a-5172e84319b8": {"doc_hash": "ee018c62bb027f3872e67810b8b89a61862dc748d92fb48a670479191b39fe8e"}, "f4679746-da20-41d2-a25c-795291ab8b8a": {"doc_hash": "7997724eb7e679161ae7989953c6639182b233ff2d573431f65ee206ad7410f7"}, "ae226c3c-c038-4624-9284-5fbbfe47bbea": {"doc_hash": "2b271dc30df7333e596765ba1380d40578a87a28936aff9a9f20880ff3de128c"}, "542c8b40-9cf3-4a9c-aad5-27012a9996a3": {"doc_hash": "020030301c91340cde41dba799bdc56cda2ee5de0ea65f33a31e93d8e37593e3"}, "91bddacf-cd2f-4c81-803d-a86c7ee80760": {"doc_hash": "9b5a13d36330cac63a172593496b75d9031c04a3253614cf6d5bac72ca370440"}, "1496756e-98b3-4bb1-a501-495032819b45": {"doc_hash": "2bea62b19c495900aac0fdb89b9b47814df173aaf7346323396fe14835beecf2"}, "8cf0f982-ecbc-475e-8fdf-5c64f7cecc65": {"doc_hash": "df5499291180da5533021d817239e445e071053e5d8f2e82f68c8f8a2669a5c0"}, "75d8f244-a93d-4b9b-9512-fb21f520f46e": {"doc_hash": "c79613c32cde6fba9fa3576b3e650ff0c5e72f214c862e80697a29e74fa62546"}, "bc352a85-5a34-4d4a-97c7-67b76e24a6d4": {"doc_hash": "9e49d20588e94d124c6c3613f55f0fbae6529e1142281f23466e2144ff9a758c"}, "4072f42b-68f6-4a52-8031-6f80911f6710": {"doc_hash": "eae3326a81acab76b58a7a19fbcdffce61dab5506ec0a4ef8d1b28c3fb6f525d"}, "49dd2f6c-e887-42e8-8e0d-2e128d60528e": {"doc_hash": "bae0af2c187062bb123e53fb3289434519aaedbcf51927a5633e79a2c5f196ec"}, "11e84fae-1e34-4e1c-9a58-86837f43a59d": {"doc_hash": "414444c2125c1ecae08c1209e31c589b56e1af017e30b9bfc87448abec4f039e"}, "7931f1c4-128f-4709-8056-4bf960d42db7": {"doc_hash": "87c6d998f756f3eb916619066ac8d1a659ff34a08b1985a324e904a42dd43dc1"}, "cea44dd8-5338-4c4f-abf9-0e0d213eb9a6": {"doc_hash": "f5867c23f0da70b9d677bb7b17e3cbddaed43365e1d3044cb4c0035e1ef9dd54"}, "b43fddb6-756b-489a-8670-ace506a7abbb": {"doc_hash": "dcda86a7d0a21c1d424b0fefcbb387bbd71e2b69961505de276db09b4277cd5c"}, "73db6c07-77c0-4cab-a4ba-0bd3750cb631": {"doc_hash": "17c3171f7f1a26548fc24b8ba79620dbbafe324b3e9e237c4cd31b83afdbc33f"}, "9877bf10-b115-48fe-8c2e-66c629be8f75": {"doc_hash": "39d60ea5351cb79572b840dafe39a67e30097ca966c2dbd839b1606069da84cb"}, "4f3c95a1-4cfb-4d75-a2d9-fe8c5a33863d": {"doc_hash": "2dd0e397f5fe6aaed5b39ced745c9de32750ee2167dd47c27b3d40aa9539dd94"}, "2b56d50e-f6b5-474e-abfd-b06218e34944": {"doc_hash": "95ad371b65f05be30ad8a4794991d3db5324f2d50844a199152e2d444c20210f"}, "e93cbc83-a580-4625-87e6-17f9db8913be": {"doc_hash": "49adeef016bacb0129b725a48e03b089324c83367637734b9593a4eb84ba367d"}, "ad56a9c0-aa40-4727-bf9e-6b8ca39bdf10": {"doc_hash": "7d2001aa97dae90348d3e22497abdfd753467d999da23cb0db8d910e2a8e7029"}, "1696972d-c8a4-41ab-b5ef-0228bb2b3856": {"doc_hash": "dde34d779610541c4742369207b1a7c72f5626889d64cfa35090bc3bee97ab79"}, "e438cf8e-2226-4f9a-9a0d-22a5a48dae2b": {"doc_hash": "f42cffbb5de45e574cbd1c732ae8d75f28643cb02ba0ad22ef90ea833dcd67b6"}, "c5d6ca34-cfea-462a-bb1c-af5c81b2c3be": {"doc_hash": "9657ff1c0e7f665e52a9e915fce7249c31b296d10a462888677c18e2ed2c1795"}, "24425805-887b-40f9-91a9-4bda703eb256": {"doc_hash": "f4c96853d99960c02d15d6ece6e67c7de5cc468cce4aa7efececab1a0c2c8cfb"}, "c2728a74-50f1-4ac3-b094-aea4f31588e7": {"doc_hash": "4122faef2f03f252372327de6eabe112e8b05f407b0c0a5681b63ceafc6206bb"}, "31ebf525-54dd-4950-ab06-ae76adec9500": {"doc_hash": "9373e4c0f52baa4b202c2d0fc1edd51e446ef6f50cf8efe8abe7473dd98ad386"}, "4d118d30-4238-4f1d-a4a8-31eba1249335": {"doc_hash": "d81bce3521d2397e1765b1f9e91fc956e1a18eedd6355dc162c5937d821dddb6"}, "50dcb2bb-c9de-4bcc-bc44-2fa401cc6212": {"doc_hash": "867273c60bbeddc645e94fd9092dbfc2b256c159013fc8c3a0cbd16d32684bef"}, "260a4db7-fd27-4359-a785-340f37d1cbdc": {"doc_hash": "256e8e77ee5bc21959e3079a1c8f9b8cfa35b8a816975399589861f1fbcb0175"}, "f09ace58-9832-49e1-9617-c686dee41acd": {"doc_hash": "bc8ce18ec8907ff2d67bf5006e95a82b1a47d81b7e87181ac6891d650b53366f"}, "f8412b97-801c-4078-b3f0-11a9da9c93b2": {"doc_hash": "526f08d34e727ad22e053cc3eb6f81382b79bd247602fd33479b2266cea5db69"}, "5bd94dbb-390f-4db0-b3d3-61c283a2eaff": {"doc_hash": "7081f8eaedbd9795fd6e82ad9ca7769f5d2b8517febfe5303166ba2c94eed3d3"}, "3d905851-4130-45cd-8546-ca1a9beab4e7": {"doc_hash": "9b3003d24747e1f96cfd67e8415f3390d05a2c8b064b89d40acbf7cfe38a9ed6"}, "a46bb72b-542d-4b72-82af-dafa633e36f5": {"doc_hash": "722852345518740746e1491cf3f7d43aec2eeadf9bc14c816d9f4262e0ebaf5b"}, "18bbd4d1-f1aa-4c0b-8c79-d081b384a8c9": {"doc_hash": "e33c1ff0a6a3bc279fc4c183fbc7a9f97c3ee1bd1e65320a69fbadd68d01c37e"}, "fcb5e6a0-13e2-41b5-a6fa-0b6e2ddecd6f": {"doc_hash": "565723967a199baa8103a46434551bcf438baaf1035a401252ed88abbba8987b"}, "8d2260b4-6745-4abf-9f33-31eaf7e2fd18": {"doc_hash": "79b60996aa4002dfa896f01a6752f9506209e3103b98c7671080bde8430dd146"}, "6c024988-e89a-4a16-bbeb-ea705895d90d": {"doc_hash": "6fb660378e942feac9ff68c6bdd5e107e36b95a78d1dadcce89624879374d67a"}, "0079d93c-c190-4fdf-b157-3933b9b3de1b": {"doc_hash": "c7249d00f3e3898f152819d1a4093a0de781011773b6c922f758ed3e2e9219f9"}, "88dbf91d-f674-4fc7-b569-b4001345ff8d": {"doc_hash": "de5720e351db73c14dac9fad258282dea94938adb81497d3606a95acb597c9f3"}, "eab224ef-ab6e-405c-b6f7-7166e27f8fca": {"doc_hash": "daafb1eb8d8024f222deea0dcb4ccdfca805cae995ed07983d5ad6595b94ab9e"}, "df56b0b3-c088-466d-9c74-49053c197dc3": {"doc_hash": "18ef31c8f318aff1b1499cd13637a422ee834c2505bc325e00d5ea0964b81abe"}, "b1772033-2f7e-40f7-afac-d11b453ab5eb": {"doc_hash": "f24016b8a6cb13098c11c5fb864cb1b2a0b73e98b4fbd7b84c2d10d616fa3616"}, "79fcf648-6310-445a-994a-055634fdde6e": {"doc_hash": "08dbe0a50fb522e780ce1bfd2b33b776d3864f02faab3492cb54b38347d86672"}, "79b95236-feba-4772-8bc8-fcb7d855741b": {"doc_hash": "32c1d982f2938175404c2a026046bf6a5a7fb416df5239e39d2804d10671b58f"}, "be3e7298-81c1-4b09-a799-c4c1dae2f437": {"doc_hash": "89c53b05964aa1ec20e18309b0440dcfa6f4db0e1307d55f8b305f5dac031f14"}, "fb20ccba-8a5d-462b-bee4-c62cd771bf7e": {"doc_hash": "82c8329c784128afb560294e625ea31c3d8872eaa11fbf8b92ec639a05bd596b"}, "4fc61af8-c675-4b20-a609-0ed71fb58577": {"doc_hash": "89e1ddcafd2ffe006ae0941cc3dd34ed7e0f65331486e32b90180416858cb204"}, "048ba738-8346-44db-ae8a-12fc0cb71c3b": {"doc_hash": "b56f9b265f740c590cbb320df7e4a2fa5c43c4be45bbe432c3033dacacd3b888"}, "fbc18e2c-c059-4693-b4aa-fb44fec21890": {"doc_hash": "29eb13a3fe5fb4c33a4de211be73b6847bb2ce0da694933b637a99de407135a1"}, "71716cb6-c757-42be-b092-8fa400362616": {"doc_hash": "de62b78c3b6dc44b1b955b1f08b0423e5a68f425ec29ae3db59da93e4fba7837"}, "2c80e8b8-a470-4dbf-acbd-1e0f0dbb3c99": {"doc_hash": "2a7cf27af7af97badd766cfddfc323b4059a4f65e75ff857ffe6b2723626a3b2"}, "9b1f5988-b92f-497c-8c79-72a1a574a741": {"doc_hash": "055d50e06cd0f9e53035d2f0416c6dfd3b09221927939d1d18cd6cc224e3aa54"}, "c32e19bf-848d-4924-b748-f6a7f601dc13": {"doc_hash": "e1934ab4b8ba6870ba753e4b82b9487b59c982f244ee7f8e2b2ee7b1de860bf6"}, "d13505f7-dd0c-498f-9eab-ca9f7072fa80": {"doc_hash": "e42be77134942f28f0d3c62cca88082e8225f6f5e3a68e288ada8855032ef623"}, "22a197d3-9f2e-4534-820c-280bffcb0bba": {"doc_hash": "5c46fa94ac8153cdcdce5c1c8c759a2b00496154631ac93fe32e7684d22a5b66"}, "93adc781-e6ce-428b-8f9b-576b47eda196": {"doc_hash": "98ae1dabfc3d5b05730bcc50632960ca90e9aa3574fad6ff7b05fe7a870246ae"}, "a132a296-bb8a-4ecf-9d1c-bde59c9013b4": {"doc_hash": "8408ff504b54843eb8f5005ccf89fee13fa4c4647534143b055e1175f29e3f6f"}, "31300f5b-592a-47db-bbaa-b8c13172ff82": {"doc_hash": "72d10ff142968c0c45a2cb65bbdc3a7a367034c4b6297799c1579f8fb4132bfc"}, "95a10889-f1e1-4ada-93a9-5967531bd1d3": {"doc_hash": "c4f287670264d45579e65c7faf4945bc4ffaa2f1e3be30d6aaa89ffd38d57d2a"}, "9f8eae01-241f-4769-b3dd-5ef6529bd4b3": {"doc_hash": "95149a8ee75b9c24deea03240038771e21d37fbc580648499b79de28d108f4c0"}, "8535767b-9d2b-4c9c-b00f-ced9974c2a0b": {"doc_hash": "62c5d7a983414622c6a626f173212b4ea9de78d2fafcdf1492c84b2c029dfb9a"}, "ce974273-6283-469e-8dcd-3582376f0e34": {"doc_hash": "891af55de6a9c374fd339d3f6926f567a65bf05e405cb6ea541f491ca8c34bf6"}, "9af1dc8b-612a-4de7-8cdb-c73e94b51232": {"doc_hash": "64026de9005f4680dbc8759c3cc35713f9a1e994a228a45b7b0a88370920e10d"}, "ef8859e9-2f3e-417b-a6de-20fdf31b652b": {"doc_hash": "1a7c6828958f1a3ed70e2b0b3e2615223a58335b466ed4ddd801fb7d4aeced2b"}, "ff4ee3f4-1ded-4d86-8bfd-a50bd8619dfa": {"doc_hash": "7f309f26783c57679ccbc0783c5eddacd95afdaf1e17a1cf365ecaeb8b3086d0"}, "7e057d4e-cb0d-433c-ad65-7571ed9e5185": {"doc_hash": "a8491ae0eaffcb2585a3579f13683c4ca6b5522a2b3eb09426654e0ce7628754"}, "8d2bfa1f-9f97-46be-8769-02f3df84764a": {"doc_hash": "efb0254fdc8b7c5b80e84ca36bb70f53fbef0f1363eb61fef8aa2f76d093ac66"}, "f8f7ce99-4073-48ec-b1c8-718e9c7f2ab0": {"doc_hash": "fa8706b9a35afdacd8b458effdcd63cfc2dbb115be844cc93520d2e8611ebea3"}, "d5830389-43af-4fe3-a87e-11089ade4bd2": {"doc_hash": "ad2062005db33e89bb55112275d0cfb78ff5752537a96db3af9e4352358a3a26"}, "01ca76b8-edaf-446d-a53c-4b4782950ed6": {"doc_hash": "65bf1c8537e8f7602622e876461fe0e10eb9b71a2581a669d8f07f5c5841dd68"}, "6d1169d6-a5c3-4663-b3f4-6d70fdb63b27": {"doc_hash": "394017b06bfebd063c93a224241c6db4d4cbd16eb9353d95e29d5f32f338797e"}, "ab567a98-8a3c-4159-ab7d-278a0e3e5a60": {"doc_hash": "2d820f6852dfeeaca50598e0e09f713c89115eb77158e0900ecacfb8d82e450c"}, "9de117d3-7e3e-40ab-95d7-1085c37d1dd5": {"doc_hash": "6f631fc360d23c4c910c7f33f14e0007551480ea3385b66d8da336363328d249"}, "d818f800-cdaf-48ab-8f7a-48b627453477": {"doc_hash": "90b8225f45bc8cc7e14601c8ac800fcbba61b7a3ec2505f986f3cf2cb3bf08eb"}, "7fa8f6a9-46d7-43d1-a6bb-583df068f766": {"doc_hash": "306aab113d76cc5ef066b3984121f61a81ad18662ebb2508b3b96be6821af510"}, "1de3562f-583a-46aa-8d21-587c90caf7af": {"doc_hash": "30f53aec5bd6a3a35552761c32561316d061c9c5bf7a9af8653670ec24d52e12"}, "7b99c844-154a-4e9d-b73e-58ec2cdab29a": {"doc_hash": "4164fb1dfddd7c131bc7df4311d979acf7f3b27409182294c82467205f44f7aa"}, "b0494a81-d4c3-4f12-93a6-7da0dcf2b21c": {"doc_hash": "5fd648241537fe05f6711984d6374b98ca5699e5efe83728e32d7de1c1013b0e"}, "9b9c978a-8220-4fc7-885f-0dd9d04226f5": {"doc_hash": "89be740b826ff6edc521c7b585b386c90c2b58053136be77674a9724e045ef1a"}, "81c9ae9b-1edb-4b53-b7e6-2162a925b758": {"doc_hash": "0700afdf5d62ea70da13df038bbf4d990280b1403fecd2387343c6b7b2613eae"}, "d42e5afb-96c3-4d7c-992a-ef3a1e468e4b": {"doc_hash": "b4b2a975411b8e151c2e5853f4a2ed6355670695496e6e6eadcd5fe65d97e2a2"}, "18fab913-8352-41c1-bcb0-ef1a64500fce": {"doc_hash": "afec437a1211aa4f56cfeb2bbc7d38fff9804847438187b30ea9c50a963dd591"}, "214f13ba-61fe-4460-9a07-55037f4a88f6": {"doc_hash": "7543fc4842cd97be00d67a07455d004fd4ba21adb4ec4eae1eeff1068ea52e5b"}, "a8dcce3b-0ed4-4cb7-8f47-3bd7915f3849": {"doc_hash": "e88bdaf9c32320b31b7c8cb1e084354cc96d906dabaeee31925ed2e69a4272eb"}, "07f0fdf4-d6ec-4fb7-857e-35569f1d7b9d": {"doc_hash": "bcecfc5aea09d24687bbcccd2b4925325606f672508542bf811472effee5c028"}, "1f24b60f-9bea-4a3b-a677-50b88f2cf0f4": {"doc_hash": "4bd9afd0e299c1be63100f1e8a0cb66363e160109ac0f07976d59e0d040a419b"}, "fa797b6c-e946-45f2-82f8-945d7a7f94e1": {"doc_hash": "247d13cb72930add9ca4ba1f190ad757bdcefa2c9f59b17404bf9fd67480d6cd"}, "d94325cd-066b-4086-b1c5-7e9667cfa643": {"doc_hash": "25428a7abac15344813e5f8e8e8f0236def60f663af832b41eddfc1c4b61d72d"}, "954de1be-9c9e-4f9c-ae8a-184f5c3e0047": {"doc_hash": "b6e93499e7624c9d8e1e502d74d946074085ca909afc94f3b87f99758bdd8315"}, "40e27d3b-71eb-4d03-8fef-db32a071df69": {"doc_hash": "81e840bbb37b51cce539766e971daa88d0aaa820b713b2ab46065398c1f99d5a"}, "8732b692-cc00-4955-83e8-6f8063505d08": {"doc_hash": "7872a7048bddb485851050cf32311e88fdd73ac1f47b3d9cd0e930d3c7e90724"}, "ba8a5c9f-4382-47cc-94e5-9a3a2537bf8d": {"doc_hash": "3f89606a44044f220f87663d04acdf8634e9ff4daa2a9b469591e62231f9e56c"}, "c119cca9-d28e-4455-9140-d834c68fe01b": {"doc_hash": "fdfff8aef86036636c3d83c2826cf5b117e668fc2d9d0fec453b2790f384a786"}, "2fdb4fa7-c200-4201-8429-a2d681d09298": {"doc_hash": "d5ae44572d27b25a1516e493ce7ef5ead0116052bf28353e44345ba458bf45c7", "ref_doc_id": "fcafdb20-17e8-445e-a7d6-7c5d1c14996d"}, "bdeb64e2-f767-4ce0-acd2-6c5719b80cd2": {"doc_hash": "aa4004685ab8588350abba920d31eef930f06e8f541491fcfb202fbf6164db07", "ref_doc_id": "fcafdb20-17e8-445e-a7d6-7c5d1c14996d"}, "c5a7d310-4b5d-4878-bfa1-2409c8cfdc1a": {"doc_hash": "36753b5972cc31c1cc2d7d7c384b71b55b979a07d69f7233e93b2497a89a746f", "ref_doc_id": "7615fb8b-f8a3-43e6-b5fa-6b7042933f04"}, "eb979e76-5f9d-49ee-91d4-119b07f3d765": {"doc_hash": "bcdccf8376d188901213a632343e771034877d7ca465dcbad3b70b949a318234", "ref_doc_id": "7615fb8b-f8a3-43e6-b5fa-6b7042933f04"}, "a1efdc81-27ff-48b6-a1ce-c8e77ffda8e4": {"doc_hash": "66dbae1a7b878a313c7d38032c91ef329f843545dd1f79d841ba6745df5b4b04", "ref_doc_id": "7615fb8b-f8a3-43e6-b5fa-6b7042933f04"}, "e0a959f8-33b9-4957-85c7-c395a6cb9eef": {"doc_hash": "914f469d1101f1b0cb92f5e624ad99a7820a60714e542a0b1fef4aadbcfc0bdf", "ref_doc_id": "c5ace680-1a06-40a1-b05e-c466202222f8"}, "76b2a880-f229-4fe3-946e-a2ab1650efc0": {"doc_hash": "5ebd97f40cb918ab22a39445be6df5ef5dd35b45320291884425b5d4ad9b7589", "ref_doc_id": "c5ace680-1a06-40a1-b05e-c466202222f8"}, "245f742f-eb78-4522-a9d6-7afa1ef6d9be": {"doc_hash": "eb09fe58f92d95c6b0c07f559ae9d2a8057acbf03e09eca7a06135ed1314618f", "ref_doc_id": "c5ace680-1a06-40a1-b05e-c466202222f8"}, "70ed48ba-8204-479b-839e-7608555fccac": {"doc_hash": "6f1dc92684fc72e81a8b1a413713b4adb1e736af222925a794af4de99aa51f53", "ref_doc_id": "3f425aad-9cbd-4c0f-9788-8a1c28fc8736"}, "73c43bdc-bd9a-4217-8c3e-45220c47c1ec": {"doc_hash": "8164b85455da73e34f34048579f3fa31ed1785fac38dea29cba61395aa1132aa", "ref_doc_id": "3f425aad-9cbd-4c0f-9788-8a1c28fc8736"}, "10869f2b-992d-4e26-bd74-960550008f0b": {"doc_hash": "2ec92fe16f20bc0708a62c5803bb84189245e1a6808abf199495d989b0efa824", "ref_doc_id": "3f425aad-9cbd-4c0f-9788-8a1c28fc8736"}, "5fe813a4-5e82-48fb-b1d8-1b50feda60c2": {"doc_hash": "350e4807f8d20e0b13a52a7f23a8e2d1d7efad3f8c9827159deb15dbf8d0b5f1", "ref_doc_id": "15d14d4e-85d9-4ee6-82bf-cde584513288"}, "7c0a60c6-5f61-4926-895f-6d8f2e2317c3": {"doc_hash": "a3a6082957905b2fe7f1369e61330abcd9b64c3dbdb77e6d9a23deb0988a001d", "ref_doc_id": "15d14d4e-85d9-4ee6-82bf-cde584513288"}, "952777a9-ccb1-4a20-b9ee-e4e3e613353d": {"doc_hash": "a88ff5c98f8ae1fab2348bc8971e735a88c944ada540a93a7ba1b04643f47b88", "ref_doc_id": "15d14d4e-85d9-4ee6-82bf-cde584513288"}, "874fc012-0462-49c1-b9e9-cb33cee6af92": {"doc_hash": "4dab18a7378e28f87e07e0d288f5ba6506e73d5525e6aa8ae7deb0d02ca5bd2e", "ref_doc_id": "3776cd45-8e7c-44c4-b92f-824e4df55a2b"}, "d5afc1ac-b2ad-46db-a1ef-fde22601ee46": {"doc_hash": "b3ef28497e34a05629d057c393d9117c4d3d8079bef793c0d3088905346a3506", "ref_doc_id": "3776cd45-8e7c-44c4-b92f-824e4df55a2b"}, "24f61020-1798-4c35-914a-f6f4db55fead": {"doc_hash": "5cc2a1442c85426de180e0e9a35a401ee2924f774f00fc2884d8c3bd0ec57320", "ref_doc_id": "941d163f-8a67-4980-a6a7-659a390d3f12"}, "8c55acdc-aa90-42c9-b13f-eb5a2283c074": {"doc_hash": "a1cbc6972ef4a833e9e80075d926c756059b8ddff39253cfda1d37e6a8cae19a", "ref_doc_id": "941d163f-8a67-4980-a6a7-659a390d3f12"}, "4fc29b02-6e32-4fec-9aae-d08fa59013e2": {"doc_hash": "b686bb5dbb3b487642e3df1322a6b94787844d113bfaaa29ccd39fcc11e5ff79", "ref_doc_id": "941d163f-8a67-4980-a6a7-659a390d3f12"}, "cc2e3dfc-455c-4801-bab0-2ee4918b8104": {"doc_hash": "4c305fb01e1506722cdd038dd127fed40ce47eed1bdf500d35a103a839324559", "ref_doc_id": "8570a108-4af9-44bc-b05b-0542b8b981cb"}, "efe38aa5-38fc-4847-942b-f908c3404fa1": {"doc_hash": "651b6578cde1b1993e35ba7873282ba80982e9c96afdd95e025edf3c8f5d6833", "ref_doc_id": "8570a108-4af9-44bc-b05b-0542b8b981cb"}, "cf136d6f-3cfb-42ea-ba45-e262ca420deb": {"doc_hash": "1765809ab7abee36f1bace70e8b77ac57703160845664934c116747cd83cf82e", "ref_doc_id": "8570a108-4af9-44bc-b05b-0542b8b981cb"}, "32df878e-ccb6-465a-b087-b932a2eae4f1": {"doc_hash": "6ea95ad970869234b63bd2a195e123508e83273cb0d5e491b930fc8d0ab30467", "ref_doc_id": "8570a108-4af9-44bc-b05b-0542b8b981cb"}, "1a40e132-e141-4b98-a0fe-a344cc83118a": {"doc_hash": "4f1abbd02dd00d631689a1822d8e533a6398b839bac88e077bd015408a20da6c", "ref_doc_id": "cae001d1-adc4-43c4-86eb-3afca61af625"}, "063b122e-f554-4cf0-8ce9-7272157bcc1f": {"doc_hash": "c5adfed87e4ac2aa5cfdce3e73475239c4fb0964cf6283d54eff5e3777aaca9a", "ref_doc_id": "cae001d1-adc4-43c4-86eb-3afca61af625"}, "5aef06d6-8c6e-4c71-b920-2b8c1263762e": {"doc_hash": "da3cf16b43f40a12f281fa9a6fe2f36fb6daef0e9cbdad6a994b8c37dcfc7157", "ref_doc_id": "cae001d1-adc4-43c4-86eb-3afca61af625"}, "03c0b38f-6305-479c-969e-ec320ac92403": {"doc_hash": "7bd4013fe964d45cdf7b4bd8c2b8fcde604b4ecab552f048b12699c9081d820f", "ref_doc_id": "2f7c8d7a-d2ef-4aad-aaba-9896ae465fd3"}, "4677d591-1e95-4b09-a467-e6228ae59ef6": {"doc_hash": "12cbd2aaf9a2bee7e2c7199ad9ff8f20fbcc6b54bba5114ccf47756dd75c3b16", "ref_doc_id": "2f7c8d7a-d2ef-4aad-aaba-9896ae465fd3"}, "b09397fa-f09d-4ff0-b5a1-ad177b774a43": {"doc_hash": "14e26a8e8d05899bc733c13e1ee01c3dc1284c553477deab7e699bd8c5729bde", "ref_doc_id": "2f7c8d7a-d2ef-4aad-aaba-9896ae465fd3"}, "7ba3e3a6-a4b0-47b9-b4c7-dbe42ca09ea6": {"doc_hash": "83dd72595db2aac1f7b499021d78b31d56187c5b63dad20efca5a22338551f72", "ref_doc_id": "828511b8-a12b-4753-ba7b-e47d9cf3dcb7"}, "9124c946-e401-4a32-8a0f-aaff3b5b66d4": {"doc_hash": "4e5d55e34f2c10609918d190f730536f6cf01aada10f74079e909a217f1f0765", "ref_doc_id": "828511b8-a12b-4753-ba7b-e47d9cf3dcb7"}, "0155966f-6ce8-4ec7-a084-f1d776b0dc42": {"doc_hash": "ec90213bb7814c6b4484b45aa8b69fd62a83f5da5d3d017f88020c2205cc45fe", "ref_doc_id": "828511b8-a12b-4753-ba7b-e47d9cf3dcb7"}, "d7dcb739-a0d4-4909-9b8d-0c3913e4b394": {"doc_hash": "8d2f5a4d87b37788ea05ef6476aa0f75c552e081b2187d8d82985ee28c39e549", "ref_doc_id": "828511b8-a12b-4753-ba7b-e47d9cf3dcb7"}, "1bb202b5-9551-4c8d-a01c-409089254c9c": {"doc_hash": "e06f0542484f79549a9d01cc4413643a39a7a2871e32904b1b0ab542ead0f29d", "ref_doc_id": "3a972395-e60a-416e-8ee3-8753f826199b"}, "f0b0fe86-9411-4cdc-91d4-cbb729228d87": {"doc_hash": "884e1c52749d6aca085dcf4e41d690f3a21143f5965de2287e8a821a6c7872ab", "ref_doc_id": "3a972395-e60a-416e-8ee3-8753f826199b"}, "e5816868-b895-40ca-b935-c8d9510839b7": {"doc_hash": "59637754e3852671016fb5e075c9f785b5127f39cabd2d3142dcbb52f814838b", "ref_doc_id": "3a972395-e60a-416e-8ee3-8753f826199b"}, "e17d8cfe-da6a-4c89-b96c-dbc6de3572ff": {"doc_hash": "e45c5168b7018313d3bf6238bf7317d6f0a99fb59962f88e1a0f65bf63e371bb", "ref_doc_id": "9b05e3fc-b17f-4677-9647-a6dec50e6e20"}, "8d0e428e-a991-49d7-a3e8-7e26ecf661d5": {"doc_hash": "a93dda53d6771783e2568838c087670c2b3dde70029f234f6860b0fb4ebbb14c", "ref_doc_id": "9b05e3fc-b17f-4677-9647-a6dec50e6e20"}, "5745f265-e2fc-4e88-8e18-155b236ea65a": {"doc_hash": "e0153f67a87fb7f5ea01557e79e1a056ea5f36f9bcada2cd83e2b98c4b19f409", "ref_doc_id": "7d6502f2-57f3-4c3f-bdc7-c90afb45915b"}, "5252bef4-897e-42fc-a092-3088f01ea356": {"doc_hash": "c3a9d30c047f10a7e4a551314f2230108cfc4d7aee6ff45e6a8d8d2134756c50", "ref_doc_id": "7d6502f2-57f3-4c3f-bdc7-c90afb45915b"}, "a2a903a3-47f6-44e0-bafd-e1f521262852": {"doc_hash": "04eb68f12aefd808a2f810143cb214c2e20fae36f8387374858735c36330a7ac", "ref_doc_id": "4279f1b2-5420-4e50-ac08-2744d393c439"}, "553e70cc-761d-45be-9849-0ba22b1f5203": {"doc_hash": "8c2b443cf08c34a5998b593f0410b5a0171347f048b446e2e932a3cbcef9e4d0", "ref_doc_id": "4279f1b2-5420-4e50-ac08-2744d393c439"}, "5c0ba1df-1189-474d-91fa-d41c9d2e5179": {"doc_hash": "8d4483ed82e0e60e48362fc37b00d1f75842d5d579a1f67049024332ae303d12", "ref_doc_id": "4279f1b2-5420-4e50-ac08-2744d393c439"}, "a95b3bf3-0e78-4670-8f29-c2e50ece54ae": {"doc_hash": "19c16ddde20f11c7fd6d05af1e7425c292a4ee44f1e819999e99e6c70b3d4992", "ref_doc_id": "0da85362-fd5e-4050-9131-3ef70de211ca"}, "4c3ae163-aa2d-4933-8fca-56a604a28081": {"doc_hash": "3f627f15e99af00997aff2ef80d1d5f596355a0eac4a7bbaac0063d0704c6ef4", "ref_doc_id": "0da85362-fd5e-4050-9131-3ef70de211ca"}, "783c2bac-ee48-4f04-82d6-ff2cda0bc295": {"doc_hash": "228bb1e6458038875d0a6eeab90713049840b2da6d783056825f618e1c918cae", "ref_doc_id": "0da85362-fd5e-4050-9131-3ef70de211ca"}, "655b23ba-a878-4609-875b-4daa07cdffbc": {"doc_hash": "5109ff826cd07ffd617852ec4ef0cf3909cc9144ac4ff037e0c6a53fa35be2d8", "ref_doc_id": "af3e5d0d-5513-4835-98f2-476cfd9c6166"}, "af102b20-6331-44c9-b41a-e29d9e41cfc3": {"doc_hash": "d1db6eb81ffe40e398358ff40fef9929cc4fca4a36abcf16cbf615bee8808b3b", "ref_doc_id": "af3e5d0d-5513-4835-98f2-476cfd9c6166"}, "f2aaaa25-6ee5-42e3-9331-fdd27ecb3c81": {"doc_hash": "5e36ef0565c7b437dbcaec5c5330a282bff7bae045ef9ad423558504fa1afa7d", "ref_doc_id": "af3e5d0d-5513-4835-98f2-476cfd9c6166"}, "7efe0c89-0145-45e1-9506-9ba1ba22e386": {"doc_hash": "e8dc5a1f72a90641d855bafe2f6c968ceea21b05e3039cc62db324810a40c565", "ref_doc_id": "93113a58-04e3-484d-9264-50186f64c354"}, "7b58cad0-3073-4098-a806-67e19794ec05": {"doc_hash": "1b689815e8738aebb31f1b555d0d0959060c66c8ad84eba5c2e8bd19b8368af3", "ref_doc_id": "93113a58-04e3-484d-9264-50186f64c354"}, "70faf334-60ed-4408-9216-877197a4a0f1": {"doc_hash": "4a1f2f8ea3ab87d7c5fe44190401057f4e387b19813564136a9067b5f097bebf", "ref_doc_id": "93113a58-04e3-484d-9264-50186f64c354"}, "058cf7ee-0382-44d7-9411-b36359d29449": {"doc_hash": "8e5d330ff554d5959019799fee21f8adffc791efce7691863f4b62bb83f2cb53", "ref_doc_id": "079d1128-1182-4299-a9eb-957a6f2268de"}, "4906fad2-ac6e-4c0b-ac80-b1bf4acdc990": {"doc_hash": "c343fa17165819639e6c1853156144c3c0411fb8fd463c5c3c678c06629c73c0", "ref_doc_id": "079d1128-1182-4299-a9eb-957a6f2268de"}, "a43583c4-5298-4773-b216-b8e628c41783": {"doc_hash": "864ae9f55f29371c1ccb8947716b8db6885db71c09f568fa06271565b6228d33", "ref_doc_id": "079d1128-1182-4299-a9eb-957a6f2268de"}, "4baea7a8-f486-4ba9-b338-f79a0e16c12e": {"doc_hash": "baea1e78284ac0d9eb9a6b4ab105e89c9b4b3c9b6bbc487552cb0ab1c0398e01", "ref_doc_id": "c15526a3-5091-4246-a0a4-434fb0ca4a4d"}, "8b8070ea-4dc4-4e18-922d-a1375b847187": {"doc_hash": "f577072e385625b11ea71480f73e94a692661c33c11c59a538991e7db0df1272", "ref_doc_id": "c15526a3-5091-4246-a0a4-434fb0ca4a4d"}, "0452f960-a521-4c64-bf2f-e030f92ba7a7": {"doc_hash": "e0ed7f3865d11886124dc4451ef99d303879da84e486c00c10b20d62263dbc3e", "ref_doc_id": "c15526a3-5091-4246-a0a4-434fb0ca4a4d"}, "5aa81f2f-d413-4ee7-a3d0-9ff437be7c60": {"doc_hash": "35cf3e36d983298bf5525fefabdfc585c8c10d603fda81dbfc0b185f696db5e5", "ref_doc_id": "5f6a2b73-3193-4933-9e31-37d3af8dfdfc"}, "9a96132b-91f0-4920-8f77-144aa07f0b4e": {"doc_hash": "dc95b24006c409fbc09f309a496d1f4ce4f91efd0d3cb84c19347d15d9f689cb", "ref_doc_id": "5f6a2b73-3193-4933-9e31-37d3af8dfdfc"}, "14aad8e8-dadf-4764-9633-49aacd48798a": {"doc_hash": "d0871d33d3395c2d2c784b41df322b0942b5c06f3e0864329a2c3b12f21421eb", "ref_doc_id": "5f6a2b73-3193-4933-9e31-37d3af8dfdfc"}, "515931d6-6a17-4ea6-a50c-7b967589a833": {"doc_hash": "6c5bb8efefb20e5c96fb9731de519de1fb01325778f70308260a9706a5a07564", "ref_doc_id": "5e71608c-4196-415a-b44c-d5e95bfff7e2"}, "d33eca29-8fb1-4b73-b950-4e6168ee138f": {"doc_hash": "992446d4e2cd9fc1d2a8b22553223b42347bfecf1583ba1a83afe87ae28c58ea", "ref_doc_id": "5e71608c-4196-415a-b44c-d5e95bfff7e2"}, "acbee753-6c1e-4b34-8655-211db4f730e7": {"doc_hash": "0234a8d2f8567e8602dcd60c4e5a4adcadd6de8b9879e634e8e4cdedff0128b0", "ref_doc_id": "5e71608c-4196-415a-b44c-d5e95bfff7e2"}, "8a741009-a7fe-4a85-8613-863cf6d56b4e": {"doc_hash": "02964abcf6b53f55bb7454d1b4955b75bf2f856571084c8a32dd02e7b71d21d8", "ref_doc_id": "de62df33-9d10-461c-93a3-ec27958e2ca0"}, "d448e218-66be-49f0-9ae4-424c29008da9": {"doc_hash": "a0832babaf825167fb49a2ab7cf6e9be62ca0010cb5c07bf34b35ef0531f22ea", "ref_doc_id": "de62df33-9d10-461c-93a3-ec27958e2ca0"}, "f51ad937-e036-430a-ae2b-d94ea21912b0": {"doc_hash": "b7b9c636c0829bef8278ad609457103b502fb489c60099230340d4025ce63046", "ref_doc_id": "de62df33-9d10-461c-93a3-ec27958e2ca0"}, "df934db4-9119-45c4-94ca-204ebfaf339c": {"doc_hash": "ffaadaedab16ae54977cb28aa30e4c147899543ef58943697a7fa891a0ba15e8", "ref_doc_id": "44f90b55-11c6-4256-82a9-e2ef30fbde41"}, "3cf38749-39f6-4c64-be6f-e1baede76898": {"doc_hash": "b39b3e5a5094a9003e7ff1b751fc1454f7c49406e445c7cf93ef419e760c1145", "ref_doc_id": "d7cbcd75-bd03-464a-b8ae-5a51caf94e39"}, "269cbc03-5966-443a-a8b5-40aae7e51523": {"doc_hash": "4b5067529571dae175643fd769c24b353a1de1bc0b7deeab11252941143693a7", "ref_doc_id": "d7cbcd75-bd03-464a-b8ae-5a51caf94e39"}, "4fe56716-f118-4a6c-93c0-ae307ad51bc9": {"doc_hash": "51212f997fc41118265922b0a0ee96f005fce097868517c840b3e68da1cde91e", "ref_doc_id": "1fbfbe0c-2791-427c-987f-43948b0bb4b5"}, "b359e1a2-e044-4059-a188-dea823a3c3c4": {"doc_hash": "f04259657395be5903a04eda80e3778fef46b0079f421632a4c43aceeb5dd14f", "ref_doc_id": "1fbfbe0c-2791-427c-987f-43948b0bb4b5"}, "04ebe7f3-9094-42a2-94c3-2124b936ea72": {"doc_hash": "5feffbbd49792314309fe2f69e8f4244e43cc5db0d79e2e9a8d906d61a145dd2", "ref_doc_id": "594dca8c-e0a5-4bfc-a824-86502d359579"}, "b843c23b-2ee8-4382-aee1-75ba97b901c9": {"doc_hash": "d3a01af07b88cb2175d07a2934c3a8ce4d1bc0ff6fc12945a66daa35b885a1bf", "ref_doc_id": "594dca8c-e0a5-4bfc-a824-86502d359579"}, "64b28b46-fa0c-43a4-b3df-61ea93c17f89": {"doc_hash": "8dc829700ce001a986cc8e4b0a4c49768d20d89c264b8330417c70939ea1f57d", "ref_doc_id": "594dca8c-e0a5-4bfc-a824-86502d359579"}, "a50e3672-1d7f-4bee-af81-59cd61609b1d": {"doc_hash": "56851708524c87cfbd3e60cce74cc33c26c8c11fe4fef908d265239cb16e0c3c", "ref_doc_id": "594dca8c-e0a5-4bfc-a824-86502d359579"}, "ed1776e9-0c0f-46ff-bfae-4891c0bda0bd": {"doc_hash": "70755fcb556d483ddd3cf799cd5862d53ddcf977c78fb88800b242db069b3d34", "ref_doc_id": "594dca8c-e0a5-4bfc-a824-86502d359579"}, "ed421f85-1279-41cd-bac4-a3e3a787212d": {"doc_hash": "535649a1af5de4727808682f986a490027cea45586e5e0ecd9ca95b2aa228e6d", "ref_doc_id": "d482a4d3-4034-4b44-a781-6c5c9e859994"}, "3d1796e4-2819-4f48-bf97-2c29ff8e59ae": {"doc_hash": "10e635b98825608a7f347864be33c1e5e80f77f5bbfbc5426dd1c2a86635c4a6", "ref_doc_id": "d482a4d3-4034-4b44-a781-6c5c9e859994"}, "28a53ade-3861-4406-aa32-e358e5e55c13": {"doc_hash": "916cd5379c44c912ccfff65f73f86090e643c860880ad7ca13c287059f9c6aa3", "ref_doc_id": "d482a4d3-4034-4b44-a781-6c5c9e859994"}, "26720d43-e80a-41f5-9012-2c51e449a2cc": {"doc_hash": "a35756b615ed01a5855b1e94f2a899b163a96a82523426cdb22c48a45cb8b7ca", "ref_doc_id": "d482a4d3-4034-4b44-a781-6c5c9e859994"}, "ffb266a5-eb7f-4e01-94eb-104caef7754b": {"doc_hash": "3c912bc90140a009ce3ac55faea29326a4ea3691a7d58ee9f5d38417dc306d63", "ref_doc_id": "d482a4d3-4034-4b44-a781-6c5c9e859994"}, "9e91a6eb-4572-4da5-a272-024090f74374": {"doc_hash": "17edfbf6ed21e61b86ce77d5a5645a49ce1741df10c43417095d601ea41a4048", "ref_doc_id": "b1cb14d6-ae35-4f96-9313-019e65289ce6"}, "c33930e5-fd98-49d9-9322-03ab6fc6c192": {"doc_hash": "4f0d88a842065ff8e765dc6b7e1f5b63d7a956d0451a72345cca441d90724bf3", "ref_doc_id": "b1cb14d6-ae35-4f96-9313-019e65289ce6"}, "8f7b14b2-880f-4431-84a8-5a1e7157c853": {"doc_hash": "8027710fb811041fe3722d5579897d205cb0a6628ba73551ada703bfcb27d5ab", "ref_doc_id": "b1cb14d6-ae35-4f96-9313-019e65289ce6"}, "c91cd50a-7c10-4140-9eb6-7a231676ef36": {"doc_hash": "82847449b5a2ae23a2db36d121e5785628b7237d010d6959fd5a04e92cf53b28", "ref_doc_id": "b1cb14d6-ae35-4f96-9313-019e65289ce6"}, "a6490233-bb34-4703-9dd0-0ed6723205af": {"doc_hash": "bbd0f6c0675650dfdd08fa688d05c5d802d08ace55b14e532eade83763628e0a", "ref_doc_id": "15eaeebb-8425-4573-b4f8-ad5506a004d8"}, "dcfbfebf-4e80-41b2-b100-4cbab2852b38": {"doc_hash": "6aae8ef18f94fc674928d5dadb2377328aee69c748472f22750da9819d8e4c3b", "ref_doc_id": "15eaeebb-8425-4573-b4f8-ad5506a004d8"}, "11be1cfb-f293-4ef4-8095-b3f325bc0d3c": {"doc_hash": "32e46b3103a39e6568267cbd2276b10ad9453e0864f508a2276b0a19599e20b5", "ref_doc_id": "15eaeebb-8425-4573-b4f8-ad5506a004d8"}, "c21f7c64-5ebe-4898-9c4f-afc31baf427a": {"doc_hash": "ace5f4cb8f7873f211485b0fb248fdf1e6f40ccbcd1eb3852868f53e102156ae", "ref_doc_id": "15eaeebb-8425-4573-b4f8-ad5506a004d8"}, "a4e8da5e-065a-4439-b902-ccd022ae5dd0": {"doc_hash": "7755885caf0e1c7567adade96d54a67c5a690548cbb175c8635406936ba77f59", "ref_doc_id": "15eaeebb-8425-4573-b4f8-ad5506a004d8"}, "662d137a-a681-43fe-8402-1c086d498576": {"doc_hash": "bd4c55e0deea9f4e0f031d43021c7a59b7898ca0262727ed1fa28068e437da0a", "ref_doc_id": "0b3fd5bd-b588-44f3-85d3-3e8bf2656b50"}, "42226b1b-aea4-4a7d-96f5-be3250d84dda": {"doc_hash": "2f95010d28d054add0cec27c287948db1aba69bf9292ee09f8a2b479f9272784", "ref_doc_id": "0b3fd5bd-b588-44f3-85d3-3e8bf2656b50"}, "d5d50f40-ad14-4f6b-8a91-07f86ff4b776": {"doc_hash": "7de1df02b34cee4ca3c8c55fe7ec1325d76542bf494a634f94ebc0260409669a", "ref_doc_id": "0b3fd5bd-b588-44f3-85d3-3e8bf2656b50"}, "69c72682-29bf-4080-8613-3df5d4cfb35e": {"doc_hash": "aa2a10ef4d2c940e5ac2c37a9ddc42a22ab7e1a80db3255b5304851980d429d7", "ref_doc_id": "0b3fd5bd-b588-44f3-85d3-3e8bf2656b50"}, "94608b5c-aff4-4b58-aab7-f26613fc89a8": {"doc_hash": "42bdd8b72802af648d516e27332274a232baf9f332c80abd19e1bfa83ad3ced3", "ref_doc_id": "22079c30-189e-47fb-9e31-1ff8663dc7a1"}, "f1b06c17-56e3-4038-8fce-4af042bdf511": {"doc_hash": "69ab7576a095ced010e9e8878a89212e579b62f0711232f65da6c2afb3f98f39", "ref_doc_id": "22079c30-189e-47fb-9e31-1ff8663dc7a1"}, "fb19423b-0e26-4186-9e7c-5c5aac9aa862": {"doc_hash": "be20b6a3a196473f4334e859bf3db59cd1740db495484c3fe98d10481350f252", "ref_doc_id": "22079c30-189e-47fb-9e31-1ff8663dc7a1"}, "a110bd64-fd10-48b1-a20a-4e5cf32dec25": {"doc_hash": "8b9ab9ce88e7ae2d046f238f88f514020111985fe9ffbab3c9dc3e4b630c372b", "ref_doc_id": "6b4c360b-9f6c-40a8-870f-d036e6c87169"}, "54a6f7e1-24e2-44f0-b6b2-6c5a49d5ca46": {"doc_hash": "2ef15668360acffd3b682814315711f7fc4cbe64b8a6697f25cf55e27d6fa8aa", "ref_doc_id": "6b4c360b-9f6c-40a8-870f-d036e6c87169"}, "4b30e0c8-7572-4896-a557-8dd115b8fc75": {"doc_hash": "3a8805aa45bc19a87978fd838711c6f2b1e3057bd19be0df4e435041cff4e85f", "ref_doc_id": "6b4c360b-9f6c-40a8-870f-d036e6c87169"}, "d737fc20-f005-4ade-b5bc-9cf786d5319e": {"doc_hash": "71b93b9dce88ee2e9104ef9e7a0d33ee49c645b9949765f4e44c7dab0b52d216", "ref_doc_id": "1bf7379f-8602-4e66-af52-cc9264bdfb8b"}, "056a4d22-1aba-495c-90b1-9a38173466b6": {"doc_hash": "31496407ab8018cd587b9b1af828fa5cb1982c1f2a93fbc8de9f8c5a825404e5", "ref_doc_id": "1bf7379f-8602-4e66-af52-cc9264bdfb8b"}, "cf64b3c2-b4c8-4684-b868-dcd2d8eff077": {"doc_hash": "9892fda0ea17d2f110678ace297ada8cbd63fe0ec5672314012305f9e3b94324", "ref_doc_id": "1bf7379f-8602-4e66-af52-cc9264bdfb8b"}, "5bf03a61-51a3-43ab-af97-94617be05f29": {"doc_hash": "8556ea7f64836e386293babc9c10b030ddd14a3d17a3189ef2fcbbb36e0fcee1", "ref_doc_id": "79a479cf-2a72-4463-96b0-b4880b1d4e4d"}, "9d69f9d1-d119-41ab-842b-bef2765ac58f": {"doc_hash": "bbe19de780a53d7e00b7288824b960e451f4d8bfd1acc10d60f19db7af2aef7e", "ref_doc_id": "79a479cf-2a72-4463-96b0-b4880b1d4e4d"}, "9d09547d-a37a-4da6-9639-caee71004d81": {"doc_hash": "4f1f3caae45b92b103a81b6a297dcd0c9c2cccd8c1ff7d06d34f8f75657cbf1b", "ref_doc_id": "79a479cf-2a72-4463-96b0-b4880b1d4e4d"}, "15939ba6-4113-420f-9138-d277c8e17549": {"doc_hash": "959db8a4f0f09d6d449ac1b894b8210393c8235c47ff732c7a9cec07ad377175", "ref_doc_id": "c530fd5c-b2f8-401a-9a29-5215a0c47658"}, "97716d14-bb84-4bff-9928-7e2f9da5d4e5": {"doc_hash": "d9205a94bab99b6e7a9913d2109fc0e220ed5c89dcfb88473b9eace6d0d4a3e5", "ref_doc_id": "c530fd5c-b2f8-401a-9a29-5215a0c47658"}, "728e6ba6-610e-490d-a14f-b14860d6520d": {"doc_hash": "dc915a09db397c3cfc198a71ab746e700436ab17b17c954fc2e8e7c96886305e", "ref_doc_id": "c530fd5c-b2f8-401a-9a29-5215a0c47658"}, "cb5e4a93-c1ce-4f04-8261-261d1c27a3f4": {"doc_hash": "e0277a968b5c4da256b96245f29bd2e25188003ed1e4bfe59453bf82819bbf02", "ref_doc_id": "3384ed57-4045-425a-b8f1-c654c2a8a73d"}, "d9e42c6a-e2df-4dc8-a6ed-4e6943cbdf22": {"doc_hash": "3f1812818aea61251ece780a2ed12364598a1ecaf68bcee250cf52f747258d05", "ref_doc_id": "3384ed57-4045-425a-b8f1-c654c2a8a73d"}, "847fd2e4-ee3c-46b6-8afc-22641b581e23": {"doc_hash": "cd1d642818f9c42cdc56ee58798233d6693e725a733bfea958b678c9dcd44060", "ref_doc_id": "3384ed57-4045-425a-b8f1-c654c2a8a73d"}, "c3fcf789-a758-4065-8f92-e6155bc44a3e": {"doc_hash": "5b5da6148a5d43c37d8ad287cb546ac0874fc8ff6c0705eb54a6ea1b2599a371", "ref_doc_id": "3384ed57-4045-425a-b8f1-c654c2a8a73d"}, "da95f77e-63f3-42d4-8297-6feddc5b841b": {"doc_hash": "1a339b5cbf5f5d119d93e98f1fdad5615ac2447b3396ac25f0bcf1fec8d2b729", "ref_doc_id": "2bed1749-f5a5-4300-9721-36e2ad829cf6"}, "dbd9bf29-7754-4ed3-b887-f3a05e8fa8ed": {"doc_hash": "5f729064ba9dbd58d8832d0f59ed81c2276f0e51eb4125c090f8605ba44f50ef", "ref_doc_id": "2bed1749-f5a5-4300-9721-36e2ad829cf6"}, "c0c24fd2-0349-4dc7-8ac6-d8f1d6eebd54": {"doc_hash": "452c42a8ad35fc17ea9823311a68f82d31309bc9f065ed3dd9273e6845143b9a", "ref_doc_id": "2bed1749-f5a5-4300-9721-36e2ad829cf6"}, "dc0009d5-e47a-4ee9-9370-00d5844aa05f": {"doc_hash": "5f61c27cedf900692f40f8a501824ccd8aa7f76645be570c228bfc6954a8719c", "ref_doc_id": "e14c7d12-a39d-419c-a7ca-d0fdb0b07031"}, "61de57de-f2aa-43f4-ab25-b74313ee4d8c": {"doc_hash": "67b86a98f681c569b602489317d2ce1d53691d04c506689f0f61e826a4cc9be9", "ref_doc_id": "e14c7d12-a39d-419c-a7ca-d0fdb0b07031"}, "5ddff8d7-c1ce-40d1-b257-fc7e8f9ff9b5": {"doc_hash": "9ab60538179533cd2f96f59897ab751600ea644ef43ef6e72084be6d8e2630bc", "ref_doc_id": "e14c7d12-a39d-419c-a7ca-d0fdb0b07031"}, "22ee08d7-615c-4b7b-ad9f-f4d7b98de330": {"doc_hash": "ae146813d332501da7188208c779cfa9555f2b9b0751ca4ef2a8cd1740c6f4b3", "ref_doc_id": "99296c5d-32e1-4b4d-a657-f0e871e56802"}, "a7047167-62b3-4e36-97a2-7982c8c8cb45": {"doc_hash": "12d6ab59db71175885dc3792d079ad54555df15d0c531e452413f0ef3104d1c5", "ref_doc_id": "99296c5d-32e1-4b4d-a657-f0e871e56802"}, "6a5a14ba-7954-491e-ba99-1b0a12c500a9": {"doc_hash": "96f0ea50d3b18e95d47aacc14b1070a5475b73422c61fa9adec2e0c3be74629e", "ref_doc_id": "99296c5d-32e1-4b4d-a657-f0e871e56802"}, "4f469750-5982-48fe-8575-9f11431cf462": {"doc_hash": "b2107dbf23d5fbb246c4bbf97d0f9fe86a8a2fe321a2512f48b056675b62f7b3", "ref_doc_id": "908b3b4e-ed97-42f2-8ca5-d60cea7282f8"}, "bab16cde-4fe3-44b4-b043-ed3bb7c3c5d7": {"doc_hash": "359b2200d6d03fe619c9de5907ed163bebd3a1dfb3fb1359b1fd6b04f971fa0a", "ref_doc_id": "908b3b4e-ed97-42f2-8ca5-d60cea7282f8"}, "4c5d3504-34ca-418f-9082-9a71e458a090": {"doc_hash": "f3eb841d8913f58d1acb7380cb9d3751bdbcb959b6e4f6648f3b9ff43048c665", "ref_doc_id": "908b3b4e-ed97-42f2-8ca5-d60cea7282f8"}, "a7f56be9-db3a-462b-9ea3-b4e13e3a98fa": {"doc_hash": "9a350282e15d73070f000d0a01074213e35419f30b82879befabf90e6b27fb3a", "ref_doc_id": "c8282bc5-7db4-4ff5-9a00-f83862a31bdd"}, "989bc4f7-4731-4759-939e-15fc1ff55a48": {"doc_hash": "641653e94c325a4f787b85af0f6070a35d877ddeaae638bd677248d4a94d3afd", "ref_doc_id": "c8282bc5-7db4-4ff5-9a00-f83862a31bdd"}, "f8b9626f-ebdf-4a24-a844-8c5553281001": {"doc_hash": "dfe0af55b764667f38914aba207e69341103242574013957a9a1222aebae8384", "ref_doc_id": "c8282bc5-7db4-4ff5-9a00-f83862a31bdd"}, "88852ba1-148b-4dba-880b-d6c938012bdb": {"doc_hash": "9528c200d56a5f40fbd21669459f46e6d9dcd7715abcd949972771719324db75", "ref_doc_id": "658041f7-1a75-45e5-9166-74a09afe9067"}, "5a08bf95-5091-4619-906e-cd1df120f674": {"doc_hash": "2b55b81e4289b1622029bef84d6a1f9f18af69fa3b0d0f47d306311935397a14", "ref_doc_id": "658041f7-1a75-45e5-9166-74a09afe9067"}, "d032b227-7831-4594-bc88-cb74df82b9c6": {"doc_hash": "d07a8d2fcc83471b39365a1f13a493b7f5e2ba036e8b3f8221569d6b9b0f0850", "ref_doc_id": "658041f7-1a75-45e5-9166-74a09afe9067"}, "d8435ffb-c86b-4abc-91db-9ed92cfa77c7": {"doc_hash": "f877d0f36734ea84daf6f29343c7030a4b0492fc0539a37a19ae80ae41070350", "ref_doc_id": "b3dad03b-ba50-4f54-98e8-473a177d1427"}, "aba3ddd9-7d03-41ec-93df-6615623959c6": {"doc_hash": "82ef7a0383c42b601b68661ad50fab294eb14ffbe1e04ebf5774aee1a2d350b4", "ref_doc_id": "b3dad03b-ba50-4f54-98e8-473a177d1427"}, "de06f9a1-1ac7-48d8-8f6a-7044ea11082c": {"doc_hash": "36654f84ed0e033c3c353302a8d0376fef2ecd404752479627c9e3cd207265a0", "ref_doc_id": "70550d91-4501-440b-ad3f-df051e933ddc"}, "c1d38ccf-9456-438d-8b53-3f75e2b65ed2": {"doc_hash": "7964c8141036b69dd87567a786f4286921e24f4106a51f9f2f2c6e83daa48cf3", "ref_doc_id": "70550d91-4501-440b-ad3f-df051e933ddc"}, "b284a456-b0ce-4384-9c07-a900b37fcc86": {"doc_hash": "e93e6dbb1da88bea398dd024dbc90919346401d6a16125d02bb963fd99078e5c", "ref_doc_id": "70550d91-4501-440b-ad3f-df051e933ddc"}, "9f10cf6b-5c37-49c7-9538-8df4d98968b8": {"doc_hash": "a9eebbc7b60722c70c95e54ab5b6f3229e120a6e9d6f749ad3d5e87b0e8ecc9e", "ref_doc_id": "2078a7ef-0deb-4e51-9a34-2a6b244b2883"}, "af9ac5ce-823e-41c6-83c6-891ca6c956e2": {"doc_hash": "283cccc9a113216e42ccb9dd7ac8ac22df5cc14d7c73ff95ee59aae402314053", "ref_doc_id": "2078a7ef-0deb-4e51-9a34-2a6b244b2883"}, "753aeab6-4cdf-4cc0-af0b-22672272f8e3": {"doc_hash": "65c435fc38302e69a73f284ae28c0c8122ecdcfe06ff78c08c94bbdffc33ab88", "ref_doc_id": "2078a7ef-0deb-4e51-9a34-2a6b244b2883"}, "16a1af56-fce2-4fab-9f94-5765cc9523be": {"doc_hash": "78b825853c69f600e7c5488e1ab19cd55d8a0b6e2eade1b5df8d17316a762e09", "ref_doc_id": "51955358-2582-40f8-8e7e-d511f8faf5a0"}, "2fe3ea18-97a3-4e67-ba3b-2ac756633525": {"doc_hash": "ef2b656a4d3fcbcd5b5dcf4cdc392fae557db2a9605f80c3e95e972caa9110c2", "ref_doc_id": "51955358-2582-40f8-8e7e-d511f8faf5a0"}, "77af1fe9-dced-4a0a-8bd1-45466b4264d3": {"doc_hash": "a8cec74c0e1dca1a4cd98ab480449b120d9ce4c23b374ec30f04a5cfaa19bb7a", "ref_doc_id": "51955358-2582-40f8-8e7e-d511f8faf5a0"}, "5e44687e-c9de-4923-9de4-c5bf17d6cb9d": {"doc_hash": "0b11d4af30e0332ab2d1023e2af75fd94d28a5925de36fee2c7994238ec04a65", "ref_doc_id": "ba8fe3fd-a1ff-4583-be3a-beddd7a15063"}, "b4389582-5d43-4557-9285-4377c53faf73": {"doc_hash": "2d8dcf4f8ca1e3caf471272fdb613269cbd7253081b230f5abdca0e07ea6abeb", "ref_doc_id": "ba8fe3fd-a1ff-4583-be3a-beddd7a15063"}, "3d787d5e-1758-43ee-9a7a-e5114f1325a0": {"doc_hash": "84b9204f5f9dd2e0946da90407bbf7eb75d6b5dbc033d96104107a03821caf77", "ref_doc_id": "ba8fe3fd-a1ff-4583-be3a-beddd7a15063"}, "772b089c-c817-44fd-bce7-935155f3d728": {"doc_hash": "92e290b6e80d68dd3a416ba235ffaeed88e2d00431f561275d117d2afb7b74df", "ref_doc_id": "8b00ebf7-29dc-46f4-b862-5efecbd04c5c"}, "b17e3e2c-c860-4977-8262-cef4d36987db": {"doc_hash": "b3f458c82829b6167cb4de124b9b55bc1d71cf5032789f47eba1279687f488c1", "ref_doc_id": "8b00ebf7-29dc-46f4-b862-5efecbd04c5c"}, "92a06d7b-5173-4079-b573-704462dc60e7": {"doc_hash": "278f070232e4b8be3ad0757882c31017d1db6666332fdceff168971f035eb300", "ref_doc_id": "8b00ebf7-29dc-46f4-b862-5efecbd04c5c"}, "9d85a5bf-9aa9-45f7-9119-9e60620dbcca": {"doc_hash": "620dc74e5ae1a595673a2f85a47145a4a75713c35bcab203a0f1d5c551c66e0d", "ref_doc_id": "8b00ebf7-29dc-46f4-b862-5efecbd04c5c"}, "c31d7e66-7adc-450e-8088-6512ac569478": {"doc_hash": "9e3d5220219e89391eb92f7ee9a07fc50fcc5bf118708a68d2248e4d98ed4daa", "ref_doc_id": "bcdd4836-ebbf-4c04-8e9e-8af4dec9e84a"}, "ebc418e0-7168-4da3-82b6-4f84c23f3fb2": {"doc_hash": "956bcf003ce1ce67441f1fd015c9c05cf245548f4f8cd1a9b62593baa8ce1df1", "ref_doc_id": "bcdd4836-ebbf-4c04-8e9e-8af4dec9e84a"}, "78af2811-9fbc-4ccd-883f-3ff9fdcba9c2": {"doc_hash": "eca6af53510673c76b744554e90aa41def82f85aae74b8f2021612d4c43a893d", "ref_doc_id": "6035df52-14a5-4cca-a2e5-19cff4afdafe"}, "fd16c0f1-9ec8-4eb5-8071-81bd2f24adf8": {"doc_hash": "1132cb60283d1d4768f50722c8ccd5e7137d54b2f9c1f27611bd60244e2a343e", "ref_doc_id": "6035df52-14a5-4cca-a2e5-19cff4afdafe"}, "2d513e46-6cd2-4e08-ae60-29b85d2a0c10": {"doc_hash": "fb2018db10a0fba73af94403a276356ab1a52cadb9dfe8d80cb3ef962275d6ad", "ref_doc_id": "6035df52-14a5-4cca-a2e5-19cff4afdafe"}, "e89eb6ae-fa5d-4525-ac74-bf2e12367684": {"doc_hash": "95ba2dec989d61fe32aa00698125e4727ed2830cf82e4bac9269708a12654f65", "ref_doc_id": "78c73c04-8b2f-4f42-a213-6259dc336682"}, "4c25198e-e46b-4ef2-b557-9fa5793c391f": {"doc_hash": "7c04ae4ffdff2ce147c8ed25218d511601209070bfba059968c0e340b52bf5e6", "ref_doc_id": "78c73c04-8b2f-4f42-a213-6259dc336682"}, "b2b598d8-cdd9-4a7a-8dd0-8c40155533b7": {"doc_hash": "d5c7557cc365a34f31478646d72811ab04130112068645f1979283c8aeb53b5d", "ref_doc_id": "78c73c04-8b2f-4f42-a213-6259dc336682"}, "49fe51da-42e5-471b-b3f5-e7ff6ac0bf66": {"doc_hash": "720b6fd0ebe239fde5951a81f2e6d856d5eef8b787f3fe19576c3c7d0b5166d7", "ref_doc_id": "e11608ce-d26d-4203-8630-0d2508febe0b"}, "6f5ac479-b7b9-499a-acf6-1dbe368d3079": {"doc_hash": "d22e16d8355b5dd5c849e36045e7cf26fb408fda1b8084e5c6e02cf39d2ec203", "ref_doc_id": "e11608ce-d26d-4203-8630-0d2508febe0b"}, "a7dd5d7b-92d5-4c20-8aba-a746022a3dfb": {"doc_hash": "ef83c881b736957468a016ec7acdce428bceabfc03409494908aa87b81690709", "ref_doc_id": "e11608ce-d26d-4203-8630-0d2508febe0b"}, "73313082-2baa-41f3-b0c2-82a74cfa6c12": {"doc_hash": "30d4ef3089ec7861dc80fd6155c805fa76699e96aaeda6d61aadba66d1c0ef93", "ref_doc_id": "81e1d798-1bfd-462d-ac36-6018ccdc7ebb"}, "556b9b80-0d5d-40e9-9154-674e93acde37": {"doc_hash": "b0cc2a98c78f4e7500a2c679d63e49cf5a626e4e9a6737cdb4fa5ae647de6379", "ref_doc_id": "81e1d798-1bfd-462d-ac36-6018ccdc7ebb"}, "18993c1d-2b59-4fdd-8194-88c9447550b6": {"doc_hash": "f238411b2ee4758abbfad3c01c8681b8aaa8728782e4e361603a578e02bfde92", "ref_doc_id": "81e1d798-1bfd-462d-ac36-6018ccdc7ebb"}, "15e3fc81-5d36-441f-981a-dd3a574322b9": {"doc_hash": "12d2c9fd06ae2ae5073defb94aa4ed7099fc6515c09133d338d7b9a247443b38", "ref_doc_id": "81e1d798-1bfd-462d-ac36-6018ccdc7ebb"}, "225048c9-4a06-434a-9e0e-38a3abd9ca9a": {"doc_hash": "5e453b757c939e6a10e45f5918447ef5e05b6f462632a2fc02851752e476089a", "ref_doc_id": "27ffb3b2-48a9-4a85-b79b-a6f6013be127"}, "6cb37be7-0db5-4ce9-99b3-9b1fd93407bb": {"doc_hash": "8c0c70e9ee42953d64a55af7854efbd880358d01ce0aeec64d54be29266e5a39", "ref_doc_id": "27ffb3b2-48a9-4a85-b79b-a6f6013be127"}, "6aefbb72-eda9-46c8-a4cd-97b0df4e83c9": {"doc_hash": "45ea9133b408e829084ce174bbf17c527d9cdd823914fa0f2face7a853f06dad", "ref_doc_id": "a062f408-cca8-4285-b43d-d48467b85d84"}, "b404134d-0034-43be-8347-62aef955cc21": {"doc_hash": "b19609f23bf3609582ff22db4a38da80c8d3e197593411901fd879a3ea8ba2d6", "ref_doc_id": "a062f408-cca8-4285-b43d-d48467b85d84"}, "c35d9f8b-8107-44f9-9890-351ffaae9a53": {"doc_hash": "52754a2c00ff32cda04c7983f99ded7d7b8c9046aa7744c545f4c98f9df2a218", "ref_doc_id": "a3d78e9e-5f47-4340-b9af-46e122ecc6da"}, "3e2ec590-7284-4aa5-8d60-8e2568c54622": {"doc_hash": "49fd409f34c1c49ad088b0bc2abb2c23e4b371b53278f31af795f6ea9952f75a", "ref_doc_id": "a3d78e9e-5f47-4340-b9af-46e122ecc6da"}, "4cd8da47-c929-40a6-94d3-525925559073": {"doc_hash": "6eee2882f76139cc36af89ef5230940eb579db67d4c626bfd11554cec084a593", "ref_doc_id": "a3d78e9e-5f47-4340-b9af-46e122ecc6da"}, "26dacdb1-85af-4e94-b15c-e73a433254bd": {"doc_hash": "43f99a7e6f5bbaac54735245ccca127619c73307dd5147695615353e6a8fd0c7", "ref_doc_id": "6d9c5893-68df-4492-9028-62947bd4bd11"}, "3d7ee953-777e-4349-a7b0-cb91fbea1231": {"doc_hash": "ea2a594661cfaadd1b949c4b73c5bdc45ab822a10fa085d502e80209291f178c", "ref_doc_id": "6d9c5893-68df-4492-9028-62947bd4bd11"}, "e813a722-a20c-4d7a-961a-950a227c622c": {"doc_hash": "8accc5ed12849c2653b004d9ded6e7206fce7cb88e2efcf2bef9ccd8dd8b3436", "ref_doc_id": "6d9c5893-68df-4492-9028-62947bd4bd11"}, "f55c661b-5ee4-4233-83d0-3f117bb085e5": {"doc_hash": "d7988c3428dc869ea67bf2913218dee861006c71801f8e0b81fc8a2a018153ca", "ref_doc_id": "c9ec9ee5-d94d-443b-b077-a01837ce388e"}, "9a85fdf5-0bc2-4cb1-94ee-9ec0188131b2": {"doc_hash": "eff3ff5d802cefc20f8f09bfb24b9521f5158dbc791572a750c1d7edac522616", "ref_doc_id": "c9ec9ee5-d94d-443b-b077-a01837ce388e"}, "d3f3ed8d-a88c-418c-bb8b-8a2f33484e4e": {"doc_hash": "66deb6243f7208bce4a1ee6a9b0619fdd842bbd62549b4d0d3e446949832d7fb", "ref_doc_id": "c9ec9ee5-d94d-443b-b077-a01837ce388e"}, "af964440-86e3-47ef-a0d7-047cf8ad8bdc": {"doc_hash": "e69dcd6798fd264436fb914f46d2831413f241a7ed1470d13eeada09e400599a", "ref_doc_id": "65bb7f4c-96c9-4b42-aebb-4cf8a07de432"}, "8f6c270f-951a-4fb4-8629-0e97f2f32d39": {"doc_hash": "a8b37b7398330b9ab1445ffbb1b74aed92d5de9c7530b85bbf5f2db818c575e7", "ref_doc_id": "65bb7f4c-96c9-4b42-aebb-4cf8a07de432"}, "77564a34-bdb0-45b9-a3a0-6fda411c9422": {"doc_hash": "c76bac7c733c25ec8ad5263391f095146480af986939ee25662708ec9da261dd", "ref_doc_id": "f1034205-ec22-4323-90e1-61b097f416b6"}, "b87997ff-635c-4748-9a25-6f629de90b7e": {"doc_hash": "4fc9ee4c53a6c56e85787053cd74761605eb16e94da86631369a3c5bf89d1845", "ref_doc_id": "f1034205-ec22-4323-90e1-61b097f416b6"}, "314edc5c-7430-46da-a88a-7c78ebb917ec": {"doc_hash": "e449848341508b10f4c6aad96f803c62c182ebb3bc16521e4e47a08320f0825c", "ref_doc_id": "f1034205-ec22-4323-90e1-61b097f416b6"}, "1efb7922-cb99-4601-8920-e98196872ccd": {"doc_hash": "0c6d0603a216593c7dc7208dc4f9ec7658e0ab2ce346a5154c086b9ae2f1c0b0", "ref_doc_id": "e2be68db-4b11-48fd-8093-6a5fd63ffcc8"}, "95bd4459-e67d-4336-9aa9-ca780fd2898b": {"doc_hash": "70a47e09635b199020e76786d5514cb807206e9ffc29d6344409c8cefc697da8", "ref_doc_id": "e2be68db-4b11-48fd-8093-6a5fd63ffcc8"}, "1958fcfa-f9e1-4748-aa54-5e35debb487e": {"doc_hash": "ebe679407dfd6bf9eaa740103878a3edf8c1176a1cc94013bd1f4e5168cd71c1", "ref_doc_id": "e2be68db-4b11-48fd-8093-6a5fd63ffcc8"}, "211942f0-e7ae-4eff-a390-5de2573cff6a": {"doc_hash": "a811b3281df0a1f772676308f1dd71ae3dd441bed5374cbdaf09bf0abd59ff53", "ref_doc_id": "6921c743-b569-4c9a-b209-0dde6cda3360"}, "da73d243-33fb-40a4-b4f2-d9d5b5f58cbb": {"doc_hash": "2c8368e5d2c362321058f29e92a7db336486239fcee583d408b7a31d9f6d0908", "ref_doc_id": "6921c743-b569-4c9a-b209-0dde6cda3360"}, "44123d44-8bd9-42d6-a8b5-07061fdede13": {"doc_hash": "bd75755047ba89851f5356125421a884153395164af174106de9ab6552c1c9b6", "ref_doc_id": "6921c743-b569-4c9a-b209-0dde6cda3360"}, "e15f86a5-b099-4cac-a483-cd10482f5008": {"doc_hash": "3bc5d279a7ab5b892f33a646ad3145bff65741efc513546f2d817fcb41484b9a", "ref_doc_id": "450fe8d5-b6d6-4ba4-9a37-6b9d30d26896"}, "620c7c8b-f1a7-449a-a304-9acf984ecf5e": {"doc_hash": "0b91a3c79fe9e4a9967d15b7265b00f86fa65d168cbd42213d7851738cf41642", "ref_doc_id": "450fe8d5-b6d6-4ba4-9a37-6b9d30d26896"}, "3ecf5a22-735c-4523-a738-9b3151be3f57": {"doc_hash": "7e43b6d6fbe1c60b470c4f520ca7aceed2fe488c9e4bceaa6723212014c31137", "ref_doc_id": "450fe8d5-b6d6-4ba4-9a37-6b9d30d26896"}, "2c2aa199-5dfd-4805-9a0c-904b5adf877e": {"doc_hash": "c94cfef76144fb7bb94beeb70fdc822d6e198e5fb3389b506cf92e435ec373d3", "ref_doc_id": "a8560344-4639-4b3a-9a5c-08d39756a0a0"}, "223ad521-10c2-4306-b342-4f41b723549d": {"doc_hash": "33cfb7c85b3cc332c7f914cbf38a2a50660a013df7cbec49bc35c47d8ef98bcc", "ref_doc_id": "a8560344-4639-4b3a-9a5c-08d39756a0a0"}, "27f37863-7f4b-40b9-92f2-11c05bae0f20": {"doc_hash": "95e6021d2c779cdf6582397fa871a9bb7bbbb08bdc42317f50b587381875ce49", "ref_doc_id": "a8560344-4639-4b3a-9a5c-08d39756a0a0"}, "db23e0d0-77f2-4d09-8e4c-af0604e67fce": {"doc_hash": "08602ff26d03861e178e5c0e3aa60f8eee65421a39c0b4ad6f60fc071d63b0c0", "ref_doc_id": "a8560344-4639-4b3a-9a5c-08d39756a0a0"}, "dd58ddbb-c997-469a-8d07-741134cc24b3": {"doc_hash": "ace060457e3f5f8360b4fe280dacfe3c4ef2917adef7f88a0c9473292688d929", "ref_doc_id": "9a974675-1543-485b-8a0e-453a07de9de0"}, "ab83a312-1db2-4733-a18f-92637dc6f2c6": {"doc_hash": "22eaad051f7987e3d1db2d109466d246af72d891be278bc6ba6d22e751bb9017", "ref_doc_id": "9a974675-1543-485b-8a0e-453a07de9de0"}, "aeb221d4-a5fb-4ec2-9edc-d8c36dc7da38": {"doc_hash": "0bcc20187a9a05f54d59c68a1a279b3a014bcd78796083c4b1fbdfeee56c7bf5", "ref_doc_id": "9a974675-1543-485b-8a0e-453a07de9de0"}, "f0add988-49a7-450f-8772-912fd1c5da1f": {"doc_hash": "70e34235a269c4a70cf82314a2944250816b03dc0a3dd735773c08cf95d562b7", "ref_doc_id": "9a974675-1543-485b-8a0e-453a07de9de0"}, "3b29380d-428c-45d3-b3f6-e628bb124031": {"doc_hash": "f808e4a6824c30e1684d5e9af7c0007b68cdeeacdf72f29cc1cd2b4e3105d20a", "ref_doc_id": "9a974675-1543-485b-8a0e-453a07de9de0"}, "c46794f3-3704-4014-9924-7ad785e306e0": {"doc_hash": "0dbde532c0870319dd1399c13987dd123e2802893a4c77859e470e6b5fa3393b", "ref_doc_id": "9a974675-1543-485b-8a0e-453a07de9de0"}, "e896287b-6a51-4693-8807-337af9864bcf": {"doc_hash": "1ea3fdbbd2d1401c10cbb3a16464359fddc842e4d0ec26da46914e610b6a37e8", "ref_doc_id": "74114646-4f81-43dc-af85-77c29c539fd8"}, "27bd4969-088b-4a2a-a528-32f30f377145": {"doc_hash": "c3375d8ca0b0c9f0561c889e4ff493856593e382a13f2347aba39bb943823d4e", "ref_doc_id": "74114646-4f81-43dc-af85-77c29c539fd8"}, "4a17c2da-bbe5-46d7-a637-d0b581a4739b": {"doc_hash": "c39fa2fe7b4c8c6d53e20b3f4775d9a7cb4a2281e062b05b19908cd60a8846ef", "ref_doc_id": "74114646-4f81-43dc-af85-77c29c539fd8"}, "9bdb7640-da41-49dc-a104-fca19be3abd6": {"doc_hash": "8b49dc7aefc6a6d4b58d05e1507b71c4d32bf699717559a8f95055bb2aff0423", "ref_doc_id": "74114646-4f81-43dc-af85-77c29c539fd8"}, "cfc711af-8bde-490d-aaa1-eeadf763d8b0": {"doc_hash": "af244c5a95dd5141c0e1f34527b36b88d75b942ce424a6f4c6024e1be327b825", "ref_doc_id": "74114646-4f81-43dc-af85-77c29c539fd8"}, "b6117957-89de-4d40-abae-824c1a35c877": {"doc_hash": "250f9478567eb62249f77fc15790957a71fbd3d4bec99f4b3d7dc7800676ea5b", "ref_doc_id": "74114646-4f81-43dc-af85-77c29c539fd8"}, "032f57a4-d7fc-4322-8ec5-1bd8301f1d34": {"doc_hash": "9199e743a813345f868c8b33179abf5393fc9a61187d7625fcbbb0db704bc491", "ref_doc_id": "74114646-4f81-43dc-af85-77c29c539fd8"}, "fe3abd9e-3764-482f-a4eb-243081d39164": {"doc_hash": "5489f339cb7402ad957753fca95c414993d4b8da09f444b0f961000269cd0de0", "ref_doc_id": "74114646-4f81-43dc-af85-77c29c539fd8"}, "d620467d-3a18-4239-abab-73b16ea2c5da": {"doc_hash": "3b184aa0e048ea6bed0e502f0f53e4f4baae39dc0e33d05ea97a5ad3cdb39065", "ref_doc_id": "3d804f4d-a7c5-4462-8099-169f3811144e"}, "23dcfee9-7ee0-4946-b527-7ac6a71be049": {"doc_hash": "a141a497b10956c8d4238fef96ac792933c9fdf768152e0f46af02996b58b90c", "ref_doc_id": "3d804f4d-a7c5-4462-8099-169f3811144e"}, "6cc7c899-be62-4b61-a961-505d20e9c5a6": {"doc_hash": "09ceac09ef6cca09e03731b126df25778388906811a6d1ecb41f862fcdba23ac", "ref_doc_id": "3d804f4d-a7c5-4462-8099-169f3811144e"}, "6e47aedc-b55f-4dc2-82d3-2141c50eda72": {"doc_hash": "e64a09ce5242072a0fa24676fc0c12849e0a15ded33c7c5426628509cf0fbb1e", "ref_doc_id": "dd3bc350-7901-436f-b9b6-a997a2b19634"}, "a2766610-a13b-4dde-8eb1-22204e64340f": {"doc_hash": "4edadaa563a125f943a46473599b49f7699213a999f3ae09d633ed74de604d90", "ref_doc_id": "dd3bc350-7901-436f-b9b6-a997a2b19634"}, "5ea0e8bd-e1e1-4af1-aa03-58b9b956f981": {"doc_hash": "fd56d01aa1fc9f927e0c409c488a2f401f09e363c0b64dd21e408413019ced54", "ref_doc_id": "dd3bc350-7901-436f-b9b6-a997a2b19634"}, "9c767640-ce6a-4da5-97fa-ed1887de5c06": {"doc_hash": "90a4b8c24bfc9358b741b33891d1006c7d0c12029b6252cf06e789b5ca672fbf", "ref_doc_id": "cade7345-df33-4c0f-bd62-c80c8ba7746a"}, "c9be5112-c8c1-4b1e-97d2-04ab8633c8a6": {"doc_hash": "7c45940470633c951047beb3e869ee071a043a827bde2ebcf314dc5e3e9a24d7", "ref_doc_id": "cade7345-df33-4c0f-bd62-c80c8ba7746a"}, "6bdc2d68-c56f-4610-b42d-a24bf14587ab": {"doc_hash": "266742f0b153b9178d4916ac64daae54b4bbec31da01dd004c8e4d5c78fecd82", "ref_doc_id": "cade7345-df33-4c0f-bd62-c80c8ba7746a"}, "1e76eac9-16b4-4cbe-b998-31c0405e988f": {"doc_hash": "ce042b238e64ceaa23cc4ced147c8644e35a124ea77f3c163f77a5013034364a", "ref_doc_id": "43b6cb1d-07e3-415a-a978-f2020428c3d3"}, "e8174d8a-dd57-4e10-9fa3-67dc9502551d": {"doc_hash": "157c307754c12c767178870de04022e93c51fe5196f97571afd92762ef7af445", "ref_doc_id": "bf8a63ae-d6ac-4202-91b2-5a96a3fa89a1"}, "dd6719fb-62d9-4f96-b13a-2f522602d7e3": {"doc_hash": "2b39bde0539531ee06664c289a1c2dba806663531169644321f0a7fdef375743", "ref_doc_id": "d03d9f54-81b3-4196-a99c-9db97f30d2b1"}, "d4bf636e-2707-4b54-a69b-e0da58955e8d": {"doc_hash": "c3670f3a6a79a3bab5ab77d4f33dcaf92c2a3035418a9fbb6982a835cf916924", "ref_doc_id": "e1cc4655-10bc-4df8-be0f-7b8e5bf6e239"}, "6c93a7c0-c50b-4004-9e6d-21651b98b684": {"doc_hash": "324b502686f5dcac69e8c8a8433a0cc9fe3aa0a9542b6bd476b5133fca009cd5", "ref_doc_id": "56ec57f9-fb89-404b-90c0-2db9b4aa4340"}, "24ae36c7-1c63-4fd6-bf92-720a5854808c": {"doc_hash": "0ff181c0462c45e1c95e5a3c32d509a407ef3b7bd3a64955b21130d32d26cf97", "ref_doc_id": "129a3d8d-314d-4348-8021-1d217135191c"}, "5bcf6679-9ad8-4cba-8309-cd2fc030b30f": {"doc_hash": "e1e95cd187fa9154688cfb96a28311026992e09b4e57f78c3cb38dbd66eb994f", "ref_doc_id": "1b1bce34-5f15-445b-b63a-fb601060da3d"}, "afe6d71f-e804-48d7-91f8-58ab0bc5314c": {"doc_hash": "377b7917963b5f3dec29961b11dc9770de48e90ad70f716b4795122493027d53", "ref_doc_id": "febd1297-d15c-49b5-819a-af5360d5de5f"}, "c05171bc-bdbb-4447-9b83-2d7211b14791": {"doc_hash": "df67bc8e9d2cad381d31c5fa10f11f4e0ae38d5760a6ed3c04f4e6c239a9f010", "ref_doc_id": "2af5eadf-433a-4790-b65e-cb4559ced482"}, "ccd13d28-b94b-434f-8b90-92cdf16df7cd": {"doc_hash": "d30077fd9347e0599fa84c025db5f6d0d516df71c1958ec107a22b630f9d1959", "ref_doc_id": "d723e63d-7991-461c-b9bd-2366ccff8ec9"}, "0ffe0b6b-76d9-430c-910e-3c848a2e6057": {"doc_hash": "7776ae0e0efe19887f0660897704139546eaf6063fb2dae71c46ceeeae1fb452", "ref_doc_id": "d723e63d-7991-461c-b9bd-2366ccff8ec9"}, "4d2b869c-48ec-4b59-99c9-f973134c6cde": {"doc_hash": "4031f898e07a41e558726b722abcd2379201bbef268324ca04e70e83a807333f", "ref_doc_id": "c9c26e69-9411-4fbf-9e2d-563c1e4eaae2"}, "865f616b-588a-43ff-aa45-b471846b0025": {"doc_hash": "dd76dd74acd6bad2a5e74f288775128cf3dd953c25c4100ed78b157db2c98d64", "ref_doc_id": "61a9d5e2-dd35-47f4-928b-b92e930e5b0b"}, "9f1f1659-c08a-4ada-bb46-326301ada008": {"doc_hash": "657da89955a28b798e94e64f1e8c5f79c5e3e917a387f2657276d1673145197a", "ref_doc_id": "f2f99320-8681-427e-8ad9-6f9ffec4f753"}, "09187cd7-83b8-4393-ba2a-4a4bcda071b3": {"doc_hash": "fa56e0559c4557192080a3189113bc18f8ef3fcb2aa32b195989ef9eae75bad1", "ref_doc_id": "499f733c-5204-45b4-94d0-18bafa91b4f1"}, "d4ff86bc-7554-40a3-b2b6-8c29310f294e": {"doc_hash": "1307496121bb1c8596fc2c5317db7a3a664ddb91054b711f39c1f540c373d6d3", "ref_doc_id": "497f0518-c964-43d5-aa9f-1192b65512cf"}, "749bdb7c-bb6f-429f-9d16-85a2e8cb2888": {"doc_hash": "97b996616da62704acf94422b82663ef6fc566aaba52209811de7f4af0c71c50", "ref_doc_id": "b2655f5a-84c8-4f92-9300-c6d606b26525"}, "f178ef04-071e-4ca8-a92e-c786a73d2fda": {"doc_hash": "19ea5111dab7d50caabd151b1da0b63f8a56ead6c25efe6fc960348023f23a6c", "ref_doc_id": "0092d6d0-4c6b-47ff-98f7-07d31290fccd"}, "c9d94768-9bc1-438d-b948-adde876ad41a": {"doc_hash": "5b0d8d53755716923bb0e80f41945f4d68c0756ab402b54921043c418016a2d5", "ref_doc_id": "3dc9ec91-2f71-4e61-b257-16970c36950e"}, "d63a747a-3cfb-47bd-8e77-1296fc3a493b": {"doc_hash": "453dab452ef966847c7e1fd312ffcf2bf3ff87ec2a3e536e6eec592c74d22c9d", "ref_doc_id": "dbfcaf4d-6935-46c0-9bd3-609b4e5b0b11"}, "9ee1407d-ae29-4f01-97e5-d02c7339bfe1": {"doc_hash": "75a9a3f2b861a2d42820016db95117889362ffd681b358ebd690332ba43ed665", "ref_doc_id": "c977b057-87fc-4bcc-a9cb-efd109f7f647"}, "d2d33d92-d728-44df-acba-a36bcefc2931": {"doc_hash": "77e5a3f673186b2ba6115833a9d698009ebb3261d3b4620f29d722d6ebd9fe4e", "ref_doc_id": "294d557d-9b83-4742-bd60-5d62568ededc"}, "5815acb0-de0e-4759-8014-6e1c3e09702b": {"doc_hash": "970f8627848507ab4e6bb8b4efadc9be5d2b757e7302f0f1edb8a6e23dbc8e25", "ref_doc_id": "e1dafaea-68ff-4ec8-be24-69ce949d0dd9"}, "b9b230c6-04d1-4f46-8604-ae89941faa44": {"doc_hash": "af4a2141da137078ba43ef6d46f8ab35fb394da4ac66af1a53fce10bd1eb1778", "ref_doc_id": "0d624cea-4278-4749-a2ce-8e50aef53acb"}, "8fcc5806-c405-4dac-850f-98436af58234": {"doc_hash": "9bfa3cb34440a075f2be4c82ab6d89a80d0d3e43222b958119a69f8302b563a8", "ref_doc_id": "75c5e054-2896-4d08-a3bb-91740e395995"}, "f17a7788-cd5e-4b7d-a90f-aaf4d175d64a": {"doc_hash": "07f593523ba9f8dc2c15c239542539f2ed0a57ca62f7b7ef1435b77dcd14589f", "ref_doc_id": "b6e6393c-e92e-450d-8c9b-fc352baf87a7"}, "b96653dd-cfc1-449c-add4-142cfdb13818": {"doc_hash": "afe16513213b6280b66cf7ef819e64c1aaf213925aef1f57783cbc5d59ef51b0", "ref_doc_id": "b6e6393c-e92e-450d-8c9b-fc352baf87a7"}, "92be0ea5-e241-41dd-8789-2bca3d44c80f": {"doc_hash": "798272580aacb7394a20f454b53f3b990584eef357db9acc90d14c094e705e7c", "ref_doc_id": "53e6292d-1e83-42e4-b6dc-bceabdf1d4c0"}, "e9e869db-767a-4f3b-a95e-9d87c8bc2c70": {"doc_hash": "709752972bcd355071f9e5d730994e72dfc30e9d991ec9ac8f58e12eed15a5a1", "ref_doc_id": "53e6292d-1e83-42e4-b6dc-bceabdf1d4c0"}, "a3bf1a97-e28a-4077-b352-8a332755a038": {"doc_hash": "935a278847590dbcef1c625b013fab368bc9931274c0c36aea33a7758044b25b", "ref_doc_id": "7780c047-eb3e-473e-8acf-3b944fd6f31f"}, "038be7ad-d4cb-4ec5-98fb-c9a562b7943b": {"doc_hash": "7c4fc5cb2e5cd27814884fda23bc551e677e5c5e98425360d429c2126b6a73a9", "ref_doc_id": "6f62f37e-f4a3-43c0-9080-77f8346a2020"}, "f9d19691-7f46-4dfc-87fa-d2940fa0cb29": {"doc_hash": "94598fbf3efd209ad05828e7905b1a5f44965471c8486f93f5c6405ec92dfac3", "ref_doc_id": "308d2295-23ee-409e-a65c-3f0dc22224a9"}, "7ccc946a-9977-49a9-a3b0-d723fc008a1b": {"doc_hash": "d3f09dca999e8c63c37964b1504f146a591e76d9b57c15c3d00aaddef10c0056", "ref_doc_id": "6a568460-1181-4d32-8607-d1b2d35c8532"}, "878426e2-718f-45cb-8056-97ba0674b6cb": {"doc_hash": "f8839a41a683013d6cf9997602345f211cd319b4adb8394ce2470531093045e0", "ref_doc_id": "214bd709-c9ad-4e86-a0f4-9e49ca0f0c81"}, "45ba7052-b42c-48e0-b2e5-20294a6454a4": {"doc_hash": "004eadb9beac22ae1f5704135b0dd720e6e7a9dd8003493f254076c75c8709f1", "ref_doc_id": "214bd709-c9ad-4e86-a0f4-9e49ca0f0c81"}, "81e9dfd4-d457-472b-9040-a006650d29f4": {"doc_hash": "d51f9bab2a1034a847c93c720d2433b8dde7409b7457f950c31623217f790181", "ref_doc_id": "d8336305-9a0c-4ec9-ac8a-7228c69ebaae"}, "3a3433b8-a272-404e-b1cb-136fce12e165": {"doc_hash": "f451bf737d11b5eb6d42809d70660be9b7b8318cd363d44cce317cfe15b50bb4", "ref_doc_id": "22d45598-3642-4ba5-8f1e-9f9a1b6763ea"}, "097671fc-480e-43b8-ac0d-a0972ddab32e": {"doc_hash": "9f6912683e37e65d8e4684b1d220a0366d25a95191105e9fb4813b1cd873c1ec", "ref_doc_id": "2c0ef8eb-a886-4e70-997a-1fa14c346775"}, "5ff7012f-3855-4558-8bae-280e48d9a4a7": {"doc_hash": "8df7ac96a9e693bd3e2fceb0cebed2109e484b8fb1b4ba4b5d9eb9d3896f1f58", "ref_doc_id": "2c0ef8eb-a886-4e70-997a-1fa14c346775"}, "452ae8c7-88d5-40f0-9151-fdf48ac0e188": {"doc_hash": "65c3f4be0f4bc29968980e4e80005f37cedd11d5e308d4fcd93b7d728b0df108", "ref_doc_id": "77acc0c9-c14f-4835-a16b-09aacfab1515"}, "2a0b7b5d-e020-4a64-812c-f4bebd86f3e8": {"doc_hash": "a8747e03183c8417176ff4459c32994779809aadb0342dbb9bc3eca8c4697c34", "ref_doc_id": "a1562efc-fd6d-4a02-b226-8c2de23051dc"}, "5dce23b8-8817-4af2-9861-ee51f8f4b899": {"doc_hash": "ff710e92b27d91a4145a67fd64244182e10db09a66e18c1acd09d4e260e1570a", "ref_doc_id": "a3da02d9-0ef5-4d12-86cd-20c3bf49619e"}, "cd715fde-57b0-4c41-91b2-0741d3fe44a7": {"doc_hash": "195c8ff5b70ca66dbca0b59dbb9a6339ec3c05f5051e69846527d7dbebdb4688", "ref_doc_id": "a3da02d9-0ef5-4d12-86cd-20c3bf49619e"}, "87d4ce40-009c-469a-a94d-1496e6af08df": {"doc_hash": "deac5d20224b8352ba4f818793364dee80aef61d37c455d1950766fb87a5a0c8", "ref_doc_id": "aa8cfa7b-f1d1-45d1-8132-f4dc9ef32c7f"}, "a5eb3829-6d3f-4fa5-bef9-23e5be64d676": {"doc_hash": "5c6da190a73b626df902fe26485ea9bca03e229f784319da20875fd2a16b69a8", "ref_doc_id": "aa8cfa7b-f1d1-45d1-8132-f4dc9ef32c7f"}, "66f45117-0039-466c-86a2-f934ae47ed11": {"doc_hash": "54e84c3e6d89639829a39080a1ceba324d6a869dcd3eb513da26b31eb9e73acd", "ref_doc_id": "ae16b974-9580-4b9b-85c6-f0b1e0ec5863"}, "2ba365a7-d3b6-4621-bb18-338c94d17ab7": {"doc_hash": "32e36f521e823d82307a9a4a3ceafd2acaa920a7bfa226c2570149c2fc6b49c8", "ref_doc_id": "ae16b974-9580-4b9b-85c6-f0b1e0ec5863"}, "5130d435-96b6-4f24-a85c-e0d5adb028fd": {"doc_hash": "af176709eed95faeaacb8ef520383b3f39fc75a5a814c46b41f75e5691a02a9a", "ref_doc_id": "7a04d29d-348f-4dfd-983b-95481be8ed5d"}, "3bb17b19-bc9d-4e39-b560-beb6e1065d99": {"doc_hash": "be4d4593945cc1fd2cb5000518b2072a0d21d2780c4de0a54af1c0e3261d503c", "ref_doc_id": "909ef4bc-c346-4d4d-a14c-6437c7a77f8a"}, "aeddeb48-bda8-4ee8-bb65-08937c846c82": {"doc_hash": "77180e2f16be6bd31c46b821de6586f7ab14b845aee472fb2e74048d266dccb3", "ref_doc_id": "909ef4bc-c346-4d4d-a14c-6437c7a77f8a"}, "34b319d5-7af4-4f6f-bd03-47726fe1e2f7": {"doc_hash": "a2670634508c7791c5afba8d1d1b90e1d59ef67a0ea54776d14b63ece1ba45ce", "ref_doc_id": "293d3dd2-4207-4918-8049-d8c74b271234"}, "3f190a9c-0201-42eb-9232-22b74a9d9cf8": {"doc_hash": "94a79f953db759ec032690f44b1039b2ea037f53dcb69d517192f067f7b50ed6", "ref_doc_id": "564a9e18-4c73-4729-98a9-a9d3ab4d2ec7"}, "504fb1ce-5312-4641-92d8-e59a058f3111": {"doc_hash": "d164bf7c356ee8d9f8c8e59403d557856413d4256ef72c2a496f77daaba1e13f", "ref_doc_id": "2a6f412d-ce95-4338-b1bd-ba6ff0e7620a"}, "7fac3051-3be8-4316-9f07-4e4ffe6dafe9": {"doc_hash": "59552a2945ea736cb7f935c0b36d20637b1157b8e839d85a0fab269a0dcf8c76", "ref_doc_id": "35d4df38-3fc8-4a8e-9b3f-1e3765dc1317"}, "d47d9908-2695-4ae8-93f5-a8369c5e9acb": {"doc_hash": "db6e6b491d2ab05653b51074a8a0088569a165c7ea389282e008ab63e942ed56", "ref_doc_id": "ec0a9fe5-cbe6-48fe-a2b2-4e4ad8883689"}, "bb014b6c-51df-4c29-8da9-42ac3cda2278": {"doc_hash": "8cad2a5b4738c6467df7d130091d54f9c4ca2d2b80abcba6844c9341a38183ad", "ref_doc_id": "57d9a66c-5946-4fc4-90fe-24cb0a081bc7"}, "20bd7d70-314c-435b-a80c-ccafedbb43d2": {"doc_hash": "874d196a35f794a314e5ba91c717af118691efb22004228d73372cae57479884", "ref_doc_id": "a2c734b0-5860-4c19-9b5a-da9049c3bc6a"}, "b9d9df16-c7ce-4023-80b4-06eba53c26c3": {"doc_hash": "30344581f5763554943c8576ece92f620c16147430aaa546f951bb74f29c2bd2", "ref_doc_id": "a2c734b0-5860-4c19-9b5a-da9049c3bc6a"}, "3152c8df-8e0d-4962-8142-d1e64a1b08de": {"doc_hash": "dd06465f7df83bce74cd131fdd239a25e48bff631058a1ab5d3ca054e53a2bbf", "ref_doc_id": "8e77d825-9af7-40a6-b5a3-fe52dd525979"}, "3aa240f0-6b7c-49e5-a0f7-89d2a8249748": {"doc_hash": "16fc846bb58644198833d84ef594f95e0d6d60283456bd869f63232d39aff668", "ref_doc_id": "ac488468-5dde-4301-a83e-02b77c245e03"}, "3e49467e-d2f7-4c29-bf53-ceb56f57b491": {"doc_hash": "1ab5cfb9fc452d236d41c5f7db648aef818b3ad5bba09129093c0b5ce94bccad", "ref_doc_id": "a03b5f7c-31a3-4a1d-b1b7-17ff04bf6ba4"}, "b72acfa7-5c7e-40ac-bbb4-ba4bbca45749": {"doc_hash": "dc2ed703bbe5bc410f51ef492a44b2cb2a4a3d0c1e188c879efabdae17bb8197", "ref_doc_id": "a03b5f7c-31a3-4a1d-b1b7-17ff04bf6ba4"}, "c2796b37-ed8e-41cb-808d-d0ce9a2bbff9": {"doc_hash": "018ef2e2ab1e6419132fb190da1dfd4d1c36093cb8aae6105b7c950660379419", "ref_doc_id": "40611d6d-b3cb-4872-84be-26d52f2651f1"}, "919bd57f-597f-4e3f-b610-8d7b37ee0c01": {"doc_hash": "dac0aafca166a0011ae1ee66ad5c4ca4e583c82b6eade828dc4d91ef505cbe5f", "ref_doc_id": "40611d6d-b3cb-4872-84be-26d52f2651f1"}, "cfa1d914-4ed7-4fb1-84f2-a15c5e03a234": {"doc_hash": "d6af0184a19423e5a54851001ecbf7a75a04081558edb709f90c36b071b1bf14", "ref_doc_id": "7fba9d68-cfe4-4482-9332-5be804a45b0e"}, "9d2d5745-2280-4966-911c-b1ae144348f5": {"doc_hash": "a366bf34f1941647d2e6c743058d01f579fcd6177d49d79fcd453ba206750451", "ref_doc_id": "eac0587c-90c9-4dec-8912-292984126700"}, "cd397f0a-8f75-402b-8373-87472ec43cfb": {"doc_hash": "6c0bf9759ad9a689791834c528f2d766698a98160b4ce690803f5834e0ff1f72", "ref_doc_id": "eac0587c-90c9-4dec-8912-292984126700"}, "31ff09bb-a89b-41c5-9cdd-350d563ac944": {"doc_hash": "95449c69191ee3e522b6d23abd650a6ab3e77e54022446b643d1b65ac2b8493e", "ref_doc_id": "9bc7d0e6-1094-45e2-8915-b7c788b51d34"}, "203f969f-dbf4-4e47-b1a1-2ffc9b6caa37": {"doc_hash": "bea5c58341626794b8e7a7ce2e3ee6320dc9330ad42824004a67e220fccc2968", "ref_doc_id": "b14ab2bf-687b-4049-9439-793d9236eb40"}, "b56d0dae-7f5a-46fb-becd-b755b15efb4a": {"doc_hash": "287fbb553899eb7b706467cc4a37db304935ecc6ea7a44e2b7302554d060be3c", "ref_doc_id": "e81b6ab0-b708-4e5a-89a1-3a9951b1c48b"}, "5ef4e750-0370-45d5-ab1e-e8684528247d": {"doc_hash": "10a24075172a7a10bac56611918f49230e101a10fd334f6a381cc2dbf797dcd5", "ref_doc_id": "791c605f-8fa4-4e78-a496-e81363747043"}, "0037445d-49fe-4f0f-9a66-862f6e311a5e": {"doc_hash": "ab96286737c50c9311d16da2e550c6b1cfb5456fe21b2401f3e8da7a877b189b", "ref_doc_id": "4f1c118c-5f29-4f8c-828d-3897e47c7395"}, "99a1b0e3-b92e-407e-8904-50283ed8b19b": {"doc_hash": "5b8918078dfa2a68d3a978bf8967f81b2dd1149d8891119b9bae4637d14cc677", "ref_doc_id": "4f1c118c-5f29-4f8c-828d-3897e47c7395"}, "93a4a4fd-2f66-4a41-88da-ce881277d73c": {"doc_hash": "ed5a736d2d06a0f9b654c5cf464bfe7652057dd32241d2700a4c83043bf65842", "ref_doc_id": "4381a3ec-5afd-40c9-80fd-aa0c7006832d"}, "8e12c1ba-5d24-4324-9a88-5dfadc2d6d83": {"doc_hash": "21054a6702db8cec02cd8889baa9b93830c667908272952d4b4b8b0694f9a99c", "ref_doc_id": "e060e4b0-03ea-41b6-85e3-74028079cab7"}, "10de7292-4330-4713-90af-b3a1ae81d9d1": {"doc_hash": "190f6f31ce6f1c427d21d173e215f3730026ab4c57d70968b74b7d6102452064", "ref_doc_id": "8de63600-5448-4594-8b4c-4730801289f5"}, "ef6cbf71-32a9-405b-b5ac-4941a19fb9ce": {"doc_hash": "e7043024df9200cce6219259b82e0d73312275d1eb936b7fff0118b3174ac623", "ref_doc_id": "8de63600-5448-4594-8b4c-4730801289f5"}, "5c268854-e24b-48b5-b1d4-c7a850cc7ce7": {"doc_hash": "6d1244d7a38420053ca5e1d082f7b03f88bc4ab56cd9ef4b9b1349090d153342", "ref_doc_id": "bf53f581-7fd8-443e-a1b0-f6f068cf17b0"}, "4b6a685f-af6b-4878-93ee-36e1962b5425": {"doc_hash": "526eefc7101e0f97d41c6ce4cc7fa226fb5db0f13c7c198d49706bc618bea183", "ref_doc_id": "2271885f-5b4e-4bab-8576-17d8b95d4b5e"}, "4d40c8e2-73e5-4458-9f54-50a107f5f150": {"doc_hash": "63e9b4e3c60e209208badb004955da9001c508696d92fc4d9f2b1bc247b4d46b", "ref_doc_id": "2271885f-5b4e-4bab-8576-17d8b95d4b5e"}, "91fb7811-ff79-4b96-97b6-6b8e39dc21b8": {"doc_hash": "f41b9aef4351341c824d7f4b918ee5416a45f945b01a0c56460a1d2931d0111d", "ref_doc_id": "97e6ddf2-c869-4e4e-a168-2c79fb3c066c"}, "5a37ad69-fbe3-4e97-8f47-30ac5f856e6f": {"doc_hash": "df0f119f8400d61e70516a8ec2338724f1bb0e7ef816595c2e09fd6f4f1cca45", "ref_doc_id": "435d2bed-395c-4005-bc82-c32d54ae76dc"}, "273dcb78-e245-409e-a41e-aff7a65f45bb": {"doc_hash": "ac9556c5445c75b2643fc8f672075ce2b6e5d67b30762643a748ba5a4da61361", "ref_doc_id": "435d2bed-395c-4005-bc82-c32d54ae76dc"}, "8f53aac9-71e9-4707-a1df-664d1dfbfa9b": {"doc_hash": "8cd874f2b8eeeeb81a5d57daf104eda37696322e50f30fed232bf5e2dbd7b362", "ref_doc_id": "5b1afa22-1cf9-4b13-b9ac-88dfad11b609"}, "653a7e13-7de4-4c25-b0f2-6708c7a53239": {"doc_hash": "6544c7b2c8ca3c61fbdccd0a8771323659b531a44224b141f36b737a63e56125", "ref_doc_id": "6eacb740-4094-4656-9bce-8835a525588c"}, "4bb35870-133f-4ffb-a9bf-4bc74091b999": {"doc_hash": "4f5ddcaa5aa04941462782eec45ef592112f14d5c16a7b97b1908fa3b20183f2", "ref_doc_id": "c206e343-4de3-4480-89fe-628fdde1fc33"}, "6334f50c-ac73-460c-bfa0-6b8c4495073b": {"doc_hash": "c59619e4d1dd5a70aa7756b123633db340b004f1eef23226a205e2031318ac21", "ref_doc_id": "21503d1b-22e0-4184-97d0-dc5c03cc1614"}, "8a364295-96ee-4cdb-a0b0-d762e08aab0e": {"doc_hash": "e161d07772078e0883063f49f206babcb1b8cd6187aaf7b523f2eb9a79f9a6d3", "ref_doc_id": "030e1b01-2c6a-49ce-9127-f8f903a57931"}, "09f01a81-c12f-4e1d-854b-384baa3d5565": {"doc_hash": "9a835c158b678be0036bb875babfb7616076fd2b0eff9075f8fc637edf20db9b", "ref_doc_id": "c05d366b-a447-4e4e-9c3b-6ad3370ec275"}, "d55cb1a7-b968-4ecc-a597-736a74dbf6a3": {"doc_hash": "f8dda1c92d9eae35665e4f90d6d9c6dac88c49b3fb28194a15b40f525d2e6651", "ref_doc_id": "9ed73236-ee95-47e7-ba47-0ff771745167"}, "b68043d2-d469-4410-91fc-0a8953851951": {"doc_hash": "b2b7813cc6e1f36ccbb239167eb0eae23235a6b2376ea1441d632a99c33c2e7e", "ref_doc_id": "f57efef7-ee22-481b-a982-a19cda834a56"}, "6d2b154e-d1d7-4550-8d8f-6dca92199f25": {"doc_hash": "ffa1c07aa37124f8b3b49ee7fa4951591e2dbd446f39c00ee2762b371c49daad", "ref_doc_id": "a9ee7d11-645f-40a4-b551-3e47a094f88d"}, "8d176405-3148-4b81-bbde-e4396e0f16a1": {"doc_hash": "9783fa07af2d906976a1cb0ebcead93cafe7f3baf158b1780de324fe3f0d501c", "ref_doc_id": "8e3bbbbd-c484-4701-b55f-f3ff5bf5d270"}, "c74f8c0f-d120-4807-8c67-d3ae80e2acc2": {"doc_hash": "faabbaefcdd979408c0e0e6f99d75687d30980fbfcc735229e160e54d38a1bea", "ref_doc_id": "8e3bbbbd-c484-4701-b55f-f3ff5bf5d270"}, "dc38a370-61e6-4e20-ac16-66830f8e9c5e": {"doc_hash": "51b7688e07714c34f92de33c63f868894bdfd0eda34b54cc7d38c24260141cdd", "ref_doc_id": "246da383-007c-40f5-9e07-52978ed27ff3"}, "037f81e7-e9fe-4c3d-8e87-65b97dc7ed22": {"doc_hash": "884393920b54f91cf0f9349e7d755ad1e5cce4301e3f855f259a1c7faedff025", "ref_doc_id": "f9167ad1-3346-48a9-93e8-edfbce751368"}, "83ca01e2-b530-4f9c-8921-a59a6de9103b": {"doc_hash": "d18cdfd67e0ce9fbf7866a4c13ecad55cc0eccfd953a38c145a27d8d3c07dd14", "ref_doc_id": "8e7b362b-ba79-4efb-96cd-4cb7c846478c"}, "fc899c00-8cf5-45f5-8753-34f15a6cce81": {"doc_hash": "8579f04722c6612ce711f509e71cbeefe630220a515e75c9cf18ea8bc055f0fa", "ref_doc_id": "5bc95d67-0d72-4412-bf5a-5172e84319b8"}, "26eb9f30-a274-4936-8f07-37724ad82bdf": {"doc_hash": "28ff979d9d96b2fc418eb85293c2db20c8883a152753a91d78f212533f756027", "ref_doc_id": "f4679746-da20-41d2-a25c-795291ab8b8a"}, "0b885daa-df73-40f3-8196-24491562ff2e": {"doc_hash": "bb446952d12d24d9a5d2ac8d40a24efcf9dec30a570b362231b021fb8b767f09", "ref_doc_id": "ae226c3c-c038-4624-9284-5fbbfe47bbea"}, "adda74a5-932e-4f9e-bde8-c4566f768dc1": {"doc_hash": "610a59b2208b3471a7d1af922c2c899a63858f912db6543f5c3f20acdbd57baf", "ref_doc_id": "542c8b40-9cf3-4a9c-aad5-27012a9996a3"}, "1a053b52-2d76-4203-b3b6-48588f5991f9": {"doc_hash": "2b956eb7c148fca2754d5274d5475a5e863d17d6ed68130be250be52da3430c3", "ref_doc_id": "91bddacf-cd2f-4c81-803d-a86c7ee80760"}, "30ecc3ea-5bdd-48c5-90cf-5e4c600b8391": {"doc_hash": "79a02ef8c2d04289bcbb4076749c76875f681ef886f77f9ce11acf5c93a6f90c", "ref_doc_id": "1496756e-98b3-4bb1-a501-495032819b45"}, "8c2bf302-22dc-428e-af8b-0ab4175fbc12": {"doc_hash": "3e308d92913f9e322895ea56e77737e7a0d6073ce30b21cc937369e905042baf", "ref_doc_id": "8cf0f982-ecbc-475e-8fdf-5c64f7cecc65"}, "9ed902aa-d12c-4adb-8191-3ac599ca4888": {"doc_hash": "9aca042c55e65290f168d56c976714ab3943f8b03ecc48743b47cda1f42512a6", "ref_doc_id": "75d8f244-a93d-4b9b-9512-fb21f520f46e"}, "3b37923b-549f-432d-b007-bd493c2065e6": {"doc_hash": "4287063a13c20955decc2c04b7e0c25770033ae9c215ff22791ec5271a670497", "ref_doc_id": "bc352a85-5a34-4d4a-97c7-67b76e24a6d4"}, "97e36ee8-33f4-46ee-a23d-99b302bcb108": {"doc_hash": "1b1cc9c35e2ce4b13a67b43489066d3c9f3a01c954fec591b3660dfcdb7f7476", "ref_doc_id": "4072f42b-68f6-4a52-8031-6f80911f6710"}, "9d403057-dfd0-4fc2-a55a-3d4edf79b7dc": {"doc_hash": "ea061385eafc37ca14dbe7b7176be8ee1eca198fec976392558a81ac8642e6ae", "ref_doc_id": "49dd2f6c-e887-42e8-8e0d-2e128d60528e"}, "36103e98-c2d0-4388-8635-dfd41e18721b": {"doc_hash": "8bd0a31fcd4fc8c3c7551851c52fb47b3d442fbd1bc8deccb4abacda0aefeb4a", "ref_doc_id": "11e84fae-1e34-4e1c-9a58-86837f43a59d"}, "00765553-b1dc-41eb-a676-431fee6285b6": {"doc_hash": "c0edd802a424e5c8eb9fb08d8f98c24b33d66480ad34a8c09a05073421c99afa", "ref_doc_id": "7931f1c4-128f-4709-8056-4bf960d42db7"}, "59784df4-6d43-4d65-8593-c7a2408710cd": {"doc_hash": "aebd79d3f1a82096586140b16423ecf93e14c8edad6017dc55d226c39549f90a", "ref_doc_id": "cea44dd8-5338-4c4f-abf9-0e0d213eb9a6"}, "1a96dc00-c419-40a4-a84a-7e0296faa12d": {"doc_hash": "26af557806f1b63df914b5e0551bbf1fdc62bfd0eec2f181bea8ce2688083d5f", "ref_doc_id": "b43fddb6-756b-489a-8670-ace506a7abbb"}, "9c9aaa1d-b8e0-4114-ba64-0b9b4bcc2d0c": {"doc_hash": "68fed32203974f99e4c8e59b386fd90cbad4fc574ce0777762e88d64ad69d744", "ref_doc_id": "b43fddb6-756b-489a-8670-ace506a7abbb"}, "9b5e1659-3d32-434f-ba73-b3b92206288c": {"doc_hash": "75726bffcfe35c3b365bde478f8456d1495c40131f50fe0edc233d433876afda", "ref_doc_id": "73db6c07-77c0-4cab-a4ba-0bd3750cb631"}, "8f175936-b754-4705-be8e-2658a24f8a53": {"doc_hash": "aa414eb294c1313280d665b3e264982e18abec8fa20723d36b41c1efeb4f0bcf", "ref_doc_id": "9877bf10-b115-48fe-8c2e-66c629be8f75"}, "53daa564-9ef3-4b74-b93a-9703503803d9": {"doc_hash": "0f807f5ae9456eec25ad542bb70b34a5814441564426524c86ff31debb0631c8", "ref_doc_id": "4f3c95a1-4cfb-4d75-a2d9-fe8c5a33863d"}, "38855a54-ddd0-4b91-a2ae-1a172f92a19f": {"doc_hash": "10b913bea8eba669aec2f5b809fe4b7aea5851ac0aa8721721133a363ffb500d", "ref_doc_id": "2b56d50e-f6b5-474e-abfd-b06218e34944"}, "56db9ce1-2859-4e3a-914d-1f5d40fc3d69": {"doc_hash": "48ccb5883b15c0e9a0038d7758fb64490b036a63d4b2edc043cb112f4b9fde39", "ref_doc_id": "e93cbc83-a580-4625-87e6-17f9db8913be"}, "bdac0e30-3193-41bb-a0f4-2368c015a1e7": {"doc_hash": "71dda7070a8c6dc583d77bf175691b80d9484ab6b3b0650a4b4c9240948ed992", "ref_doc_id": "ad56a9c0-aa40-4727-bf9e-6b8ca39bdf10"}, "55a73f66-6d2a-4a61-b5e2-6a24266d1fd5": {"doc_hash": "4e7e967241fc1d09456103faa7a45fbaf179ec1d870cea1e076cba3ff8b2be42", "ref_doc_id": "1696972d-c8a4-41ab-b5ef-0228bb2b3856"}, "ee95ff2b-bbaa-4b34-985e-30e5ae959727": {"doc_hash": "53c4e584ae5782b1570cf53da873d52269b05a79e10e1f6e93240baecc4fae41", "ref_doc_id": "1696972d-c8a4-41ab-b5ef-0228bb2b3856"}, "33953426-f367-47d2-8cb9-63672f453ef8": {"doc_hash": "74ef2183d1f8338238b3d58458041acc21d42227ab47c1779063fdaecea541d8", "ref_doc_id": "e438cf8e-2226-4f9a-9a0d-22a5a48dae2b"}, "e1f0804f-a666-4753-8b26-578f03431413": {"doc_hash": "81d12abd274e094c88d2dac05594987dc945151121c35062bb9c30d1708821e5", "ref_doc_id": "e438cf8e-2226-4f9a-9a0d-22a5a48dae2b"}, "4bfdae37-632b-4259-b60e-c11eaa9069fe": {"doc_hash": "c440c29c6432b2bb369f73eb7aa5934d2f181f94d9f1bfe0f434468b387c8b70", "ref_doc_id": "c5d6ca34-cfea-462a-bb1c-af5c81b2c3be"}, "0a55a3b5-ff4c-4c4b-a71e-1be8a42c3272": {"doc_hash": "d54d5badc2f3b2e78fabc1b1e7fc15749497e53a9c31a08781cc572d749822d1", "ref_doc_id": "c5d6ca34-cfea-462a-bb1c-af5c81b2c3be"}, "a0d73bdf-9673-439e-acea-d96c7a1e2315": {"doc_hash": "21efe036235c7e1ed14d85cfce648db1419673d26b1daaba6af0c19c9b557148", "ref_doc_id": "24425805-887b-40f9-91a9-4bda703eb256"}, "6cf2fe5f-a695-4ea5-afdc-3364fa5a84d9": {"doc_hash": "1e4bab66f49934141f85acd5bdf409c8529eec34ce09e01f4ade497aaa066b02", "ref_doc_id": "c2728a74-50f1-4ac3-b094-aea4f31588e7"}, "8eaecb73-bd7a-416d-8f0a-b300a8100c9a": {"doc_hash": "f7bf773fdb5e27f07f0b17287b651f692af27cd1f96404678e2fc7b47e1054ef", "ref_doc_id": "c2728a74-50f1-4ac3-b094-aea4f31588e7"}, "5c6d26d8-9617-47c1-9ab0-97564a373aab": {"doc_hash": "a8bb52b8ab24ff525655c2906d279dee6af85374f002234249f98e70a6208916", "ref_doc_id": "c2728a74-50f1-4ac3-b094-aea4f31588e7"}, "babfc64b-7c9b-4062-b1a1-83ea22e90024": {"doc_hash": "3a5686b89309ae04f77b36e581c03e6795e112a814fcf15a018c26b09fd58319", "ref_doc_id": "31ebf525-54dd-4950-ab06-ae76adec9500"}, "499488bc-9fd3-4abd-82f5-128ccff965ad": {"doc_hash": "2586866bbabdc18143cfcf8ecfbefccf9443f60d19437eed93c73d41e654de71", "ref_doc_id": "31ebf525-54dd-4950-ab06-ae76adec9500"}, "e9e86204-cc50-4988-b71d-0ed491a4b017": {"doc_hash": "0547055519485baab4a429eb2f303c06e22d5284f4263989c3f8d9d0645df5bd", "ref_doc_id": "31ebf525-54dd-4950-ab06-ae76adec9500"}, "0caaf6dc-075e-4d7e-b147-10b5ddf4d954": {"doc_hash": "3e4269673efb18c06428ae579631bb2e526aca9c9d0d0c042c565cbfc1654f95", "ref_doc_id": "4d118d30-4238-4f1d-a4a8-31eba1249335"}, "1261f951-0cf2-470e-80c3-87ad7941476b": {"doc_hash": "5e71d01da562e49638d2f410a71e95fc760c0beec5ff7c6ddcea2e610cb13808", "ref_doc_id": "4d118d30-4238-4f1d-a4a8-31eba1249335"}, "7c35a209-1c32-4fe7-951c-7550a8901e49": {"doc_hash": "6917a5f8bf275492190c29df2c33170ad46fec66176bc585418d15517daa7df0", "ref_doc_id": "50dcb2bb-c9de-4bcc-bc44-2fa401cc6212"}, "67292fdf-6ca8-440f-b9a8-4127f785a0eb": {"doc_hash": "2420df09d0e4495afe83fdeebe3ac9a39df627003740c7e1102f80bb1c7e38f8", "ref_doc_id": "260a4db7-fd27-4359-a785-340f37d1cbdc"}, "497e538c-b613-4764-95e2-405fb062ffa4": {"doc_hash": "3b4435c8b46ceed9d34d17d509627ae335f9e1264e1a5b6e7e5df36d460b58f8", "ref_doc_id": "260a4db7-fd27-4359-a785-340f37d1cbdc"}, "f8d520b5-29b0-46b4-bdb9-2d12711e2ed2": {"doc_hash": "6034a5ac40d446c5e22c7ebc5a6498f0f804e5096b6b3233c9969addc4302a13", "ref_doc_id": "f09ace58-9832-49e1-9617-c686dee41acd"}, "71b75331-506d-46d1-a926-b482fdc132c6": {"doc_hash": "ac53cade14d7ce74bbb86cf801a9c8c48c4b56b2c53d04b4824e5e6c8d25e30f", "ref_doc_id": "f09ace58-9832-49e1-9617-c686dee41acd"}, "9b45ad80-b5bf-4146-a0e8-19fb9b268420": {"doc_hash": "ea8b4a513c1cc35c726f91070aeb4d1b52ae6f0223c3593b0d1e0d5de87051b5", "ref_doc_id": "f8412b97-801c-4078-b3f0-11a9da9c93b2"}, "b8ff4e53-098a-4183-8ed7-71f5616bf1b4": {"doc_hash": "21cb29cce0471131e45f0ea63bef50145cbe6f28f6e57d19d4c3d9a7f1ef81bd", "ref_doc_id": "5bd94dbb-390f-4db0-b3d3-61c283a2eaff"}, "ffac44c5-04d9-4f0a-ad74-cd6b77a35986": {"doc_hash": "d161c20a3d815c8e4fc9113a36c6998ed5ae201f15e643528bd14395486edc8c", "ref_doc_id": "5bd94dbb-390f-4db0-b3d3-61c283a2eaff"}, "a2ad1d21-ce00-4854-b57f-32ecdb27bcbb": {"doc_hash": "82fd641046cedf789921d89a43336c353013f88f12b359982b8037b38b0a1abd", "ref_doc_id": "3d905851-4130-45cd-8546-ca1a9beab4e7"}, "505601cb-2823-4c03-a373-1d2940df9516": {"doc_hash": "0a430732748f104f07b08f0eeb902dec55ba2546492688fa9fd5fe6ad91a2051", "ref_doc_id": "3d905851-4130-45cd-8546-ca1a9beab4e7"}, "9c9d9cba-10a8-452c-b84d-e9412c2c5e28": {"doc_hash": "8211a2b314c907d233efc321690d3c462c6c70b961698573fc5a7ce1c726062f", "ref_doc_id": "a46bb72b-542d-4b72-82af-dafa633e36f5"}, "dabd2903-dde0-4af0-8b29-92e0c3ff5312": {"doc_hash": "cee9e92a43360854c34cb19a30897027a18c3e45751e52bc75b2d4ad3c50a102", "ref_doc_id": "a46bb72b-542d-4b72-82af-dafa633e36f5"}, "27f605d3-0b8a-4100-8b97-3faaa2ef5253": {"doc_hash": "ce49be84749df523c8c8604924f5fceebe62328cafea749ef246c65f36007ec6", "ref_doc_id": "18bbd4d1-f1aa-4c0b-8c79-d081b384a8c9"}, "0b495064-fcc0-4036-b1d0-b3e5997d98f6": {"doc_hash": "090b59700c9c4b6559c9a2a31bb5ea4d5307895043653a13be3a3a10e5d013f9", "ref_doc_id": "18bbd4d1-f1aa-4c0b-8c79-d081b384a8c9"}, "27916d68-7597-44da-8636-b7db6d1e5ce8": {"doc_hash": "dfc9fc72d044d56903c90e11100fc103aca294bd7caebbd124c169c6db105592", "ref_doc_id": "fcb5e6a0-13e2-41b5-a6fa-0b6e2ddecd6f"}, "ee3ef5ff-43b0-4107-93f8-0ce34901ac0d": {"doc_hash": "2b8bdbd43a0a81aa5e93ac800fb3928ae92ed9188ed917881572bf92dfac961d", "ref_doc_id": "fcb5e6a0-13e2-41b5-a6fa-0b6e2ddecd6f"}, "d9dff639-cf7a-4060-96a8-33d19832b6bb": {"doc_hash": "85b49cc344414ccc2acc27fabfff7316727c7ae4f9862d77a538530ab3f48b36", "ref_doc_id": "8d2260b4-6745-4abf-9f33-31eaf7e2fd18"}, "18f22dff-e07d-434f-8257-a996a95895e3": {"doc_hash": "f2b26147ecc3c29240f9b423d0cb5c523df336fb64681ca4fc1fb54796c9e275", "ref_doc_id": "6c024988-e89a-4a16-bbeb-ea705895d90d"}, "4b39664a-a75a-4896-be3e-cfb7830a76a5": {"doc_hash": "71fd7ccaa0163a40c77dfc57792fcefaa7f9fb3c63160f6ae226bed077d7019d", "ref_doc_id": "6c024988-e89a-4a16-bbeb-ea705895d90d"}, "2d269d54-4104-4d9c-8173-76dab311c46a": {"doc_hash": "f94dcc464aee6b1f08b406c800c3042da11e4ba617a464d1232e51907d4bce6c", "ref_doc_id": "0079d93c-c190-4fdf-b157-3933b9b3de1b"}, "4809429d-b3f0-4ba9-b140-6fe0593159f4": {"doc_hash": "29ff47961a98cde3871615af3942812f99126e24b4dd1a20b73fa5993c2459a7", "ref_doc_id": "0079d93c-c190-4fdf-b157-3933b9b3de1b"}, "3a384c12-b903-4486-89dc-05398cd609f0": {"doc_hash": "46cce22cd9489c9366942ecc22d6c0ff55a319ca439c0de3bb530455a4407cd0", "ref_doc_id": "88dbf91d-f674-4fc7-b569-b4001345ff8d"}, "0fe670df-8ad8-4895-ba15-e18be1a6e1e0": {"doc_hash": "a5e5ea8dbf6db886dbded8aff3d4690b181bc2ecf16e278cb86d0e5da36a7c5b", "ref_doc_id": "88dbf91d-f674-4fc7-b569-b4001345ff8d"}, "5fa136b4-5338-43b1-96e3-4960f9901a58": {"doc_hash": "2ecd40d6cb49dece39b4b60a31257518bce31612f84594821b1acabf32d0d93c", "ref_doc_id": "eab224ef-ab6e-405c-b6f7-7166e27f8fca"}, "2f5e53ad-84d4-40b3-864f-d727102cf6d8": {"doc_hash": "5b0ae8ca7d8d6b27b525dfb5225b0597268dd92b06ce2dacbd7e3dda18871087", "ref_doc_id": "eab224ef-ab6e-405c-b6f7-7166e27f8fca"}, "81369ae9-b417-4f36-ab58-9e617edeff2c": {"doc_hash": "ed50a8615afb16901af24c9d9302f74eca093e6226d0c3e25138117b7eb15a66", "ref_doc_id": "df56b0b3-c088-466d-9c74-49053c197dc3"}, "e65a58d6-7d4f-4b8b-88a7-2da8c7122951": {"doc_hash": "2e223d93e38b25eff7d3b15842040a646a11b3d97e9a073af4d70431fd049945", "ref_doc_id": "df56b0b3-c088-466d-9c74-49053c197dc3"}, "766f9af4-4730-4bfb-9a05-9a461385a495": {"doc_hash": "216f16a195369dfa2ff39790b44e5b3df5d4b47d1ede137e679744ec04d892fc", "ref_doc_id": "b1772033-2f7e-40f7-afac-d11b453ab5eb"}, "3795d9ab-2754-4bae-bafb-126a1b08d4a8": {"doc_hash": "286ad482196144b308c77829d2e6d8226c45662bb0f421951ef8340c6bcf44f4", "ref_doc_id": "79fcf648-6310-445a-994a-055634fdde6e"}, "c2442074-ff90-4ac6-8a42-91c0218849aa": {"doc_hash": "4134be9b55acc16686da58f11de230108ee59017414efd347147671b9af44db8", "ref_doc_id": "79fcf648-6310-445a-994a-055634fdde6e"}, "9397c439-c579-4083-a3a4-d24a3763d2dc": {"doc_hash": "4d875a29c6b3321d419abf689888a8fcd3e7fa154e92d81e1196fb6e6e7a21b0", "ref_doc_id": "79b95236-feba-4772-8bc8-fcb7d855741b"}, "b49f114e-1fc0-4676-97ff-924787c10744": {"doc_hash": "d6fd2aeffad0b3b2ead3c1724912b60f0a5f9b0b31ea485910f7cce7b1318b11", "ref_doc_id": "79b95236-feba-4772-8bc8-fcb7d855741b"}, "c891cdad-0e83-4de1-aac7-cae84ad6237e": {"doc_hash": "2e187f6c6eb665d2bfae9f8d4c3f71b43dc3e745c1ab08d1316d7b0949dce828", "ref_doc_id": "be3e7298-81c1-4b09-a799-c4c1dae2f437"}, "98f1c7dc-f142-47d1-a1ab-22d37383732d": {"doc_hash": "ec851c4b8defedd5b1e4a36350117633e3637bbf069916eb48a6a5749f384d4f", "ref_doc_id": "be3e7298-81c1-4b09-a799-c4c1dae2f437"}, "deda66b5-f2a2-436a-bc11-fb685a99cc62": {"doc_hash": "2d08f1ac820fe058c67d0d6186d2a898f990d86b723162b7416d441ca703e928", "ref_doc_id": "fb20ccba-8a5d-462b-bee4-c62cd771bf7e"}, "ae75a1d8-4597-4619-b17d-1d9ce362a49d": {"doc_hash": "b5097c7ae070e780aa0fdd0fc339d77124957398a791c2e78faa22db0591fc3a", "ref_doc_id": "fb20ccba-8a5d-462b-bee4-c62cd771bf7e"}, "2393b753-a03b-407d-88a5-314adce19d6a": {"doc_hash": "e6793c42d25fbdfbed1e2c6f1a611697bdd8159f86dee229cd8dfb351e45b721", "ref_doc_id": "4fc61af8-c675-4b20-a609-0ed71fb58577"}, "f3098e69-0923-450f-baa3-37982a70507d": {"doc_hash": "61a90faedf0c50dd654293c2e6cc6deada0e434556e7af1a69adefe5f11c28e2", "ref_doc_id": "4fc61af8-c675-4b20-a609-0ed71fb58577"}, "d0306909-4d1b-4d4a-a842-acc3cdde6226": {"doc_hash": "830a273e0bddb7d385c6e9e3c84b1bee4de43933241db109591993d7747b2e94", "ref_doc_id": "048ba738-8346-44db-ae8a-12fc0cb71c3b"}, "b9a66ab4-db38-4e75-8c4a-e78a357244b4": {"doc_hash": "dbade4b1899ce463671699155881a98d47787cd0f4dfb7856dca9db92a0f6998", "ref_doc_id": "048ba738-8346-44db-ae8a-12fc0cb71c3b"}, "c7d2c784-d28c-4589-a66a-ac8b1cb1a2a7": {"doc_hash": "09553342684f2aab4b5bf09c2c03185ff9d112923d75afd9e5392ae894ba5c0d", "ref_doc_id": "fbc18e2c-c059-4693-b4aa-fb44fec21890"}, "9ade7fcc-69b0-4217-83c9-8c572dcd089f": {"doc_hash": "aaf1999562fb856706377b6241eb955d16ded58aad2086e62a6adb7b7365e2ee", "ref_doc_id": "fbc18e2c-c059-4693-b4aa-fb44fec21890"}, "726b0e03-553f-4f15-bbb2-fbefaab9c573": {"doc_hash": "40e5fc6903b41d287f9ef870abf05c5515ba7f744d3de5da722cbc2633e9e5c7", "ref_doc_id": "71716cb6-c757-42be-b092-8fa400362616"}, "a899fded-ec46-495c-a830-0f2904a01190": {"doc_hash": "cd49746905e5defba8a7088f07833cc242d2f8219090ca00227f3a017096e08f", "ref_doc_id": "71716cb6-c757-42be-b092-8fa400362616"}, "8b443242-7253-419e-b8aa-7313ab70eaff": {"doc_hash": "5962fc9f52472ecaec6cf3b6741d0ee355698bb5bf33bb316c0503c4a631475b", "ref_doc_id": "2c80e8b8-a470-4dbf-acbd-1e0f0dbb3c99"}, "c6ce415f-8c18-4499-9f8f-19967fc48486": {"doc_hash": "35db71673af21470e73b8e0028a61507dce6fb68145dc3c46db9056e5dd41412", "ref_doc_id": "2c80e8b8-a470-4dbf-acbd-1e0f0dbb3c99"}, "499412d8-5e74-4250-be67-4d08742a86e6": {"doc_hash": "c0ae833d8629a6e7e8f93d463ea276ef69b8e93d559f89d678eb821920f66fe6", "ref_doc_id": "9b1f5988-b92f-497c-8c79-72a1a574a741"}, "b65f2108-42cb-4bec-b2d2-b4c2a06690c5": {"doc_hash": "4cb224813951173046bc7f740416de9a4fcc2f018e3fd25f16ab0485d08aeb1a", "ref_doc_id": "c32e19bf-848d-4924-b748-f6a7f601dc13"}, "9ebe8194-2505-4d2b-a252-d209ef3ba808": {"doc_hash": "bb8b706c2e6f806ecc534f67216bf91c09a8fb3594f9b6a2056c6381cd6a15cb", "ref_doc_id": "c32e19bf-848d-4924-b748-f6a7f601dc13"}, "01de4a7b-e910-4132-9b72-cbd71f689146": {"doc_hash": "1afdcdfef9876a006629e4adc521f196b55b4fdbafc4f0b5aa24b0ed2bae0447", "ref_doc_id": "d13505f7-dd0c-498f-9eab-ca9f7072fa80"}, "7a6e7b43-95fc-4c24-bb19-5d6b02b650fe": {"doc_hash": "fb3163698fde485f902e9ad7c076133d794118bae6038716b717e15cc112b158", "ref_doc_id": "d13505f7-dd0c-498f-9eab-ca9f7072fa80"}, "ae34a677-c877-4d96-8ae8-30bce8d6f75d": {"doc_hash": "aa9957279cd51dc25231f2542a251ac4fbe22fea1b6d0e6946b6c11912697a64", "ref_doc_id": "22a197d3-9f2e-4534-820c-280bffcb0bba"}, "3904c2c2-dc9b-4b9c-bc79-4d29af8d5cef": {"doc_hash": "b6978d8fe05017bd1ba1a900cb2c8ff90087b96ce047ff7c8fcb51184a054365", "ref_doc_id": "22a197d3-9f2e-4534-820c-280bffcb0bba"}, "e60faf91-3efb-462c-b310-d163944ef639": {"doc_hash": "75f9126f5f654b43eda8aecf2716bba7af62c1b820c95c2566d873087ad18ece", "ref_doc_id": "93adc781-e6ce-428b-8f9b-576b47eda196"}, "5b6afcaf-c8bd-4082-973d-f2d70323ac92": {"doc_hash": "64ca322c11e94aaf9c6b2267336104d4b53c110c8cb0ad701c6f343c498498f7", "ref_doc_id": "93adc781-e6ce-428b-8f9b-576b47eda196"}, "516674f6-ad1d-4a4c-bb93-d9e1c0148aa1": {"doc_hash": "53ad5ebc10e897c84f83786e9a4a48ede85eb1a2309442d987328d79fcea8257", "ref_doc_id": "a132a296-bb8a-4ecf-9d1c-bde59c9013b4"}, "79a0c3b3-0bd3-41cf-8434-6e245dec08c4": {"doc_hash": "090ca9d2ce848362551cba78888e02db850fd7cd5a887680aabbc0f56cd71c8d", "ref_doc_id": "31300f5b-592a-47db-bbaa-b8c13172ff82"}, "320bb471-acb6-4906-9c1e-e8a45ecd563b": {"doc_hash": "9a8acf4d230cf3d3b8b1159e86d51a1e0450ad3f171c25c0523cadde96c7b660", "ref_doc_id": "31300f5b-592a-47db-bbaa-b8c13172ff82"}, "70c81e90-760e-41d0-8b9f-38bcc846a125": {"doc_hash": "0d330ef18ce632dfea9044eae00234dc523411b64acbe8e5f95d99ff494ef60a", "ref_doc_id": "95a10889-f1e1-4ada-93a9-5967531bd1d3"}, "2bb15505-c2b6-4761-aded-56001597b226": {"doc_hash": "ed98fed652b29e0c33fecde3a09073dcd52d4c0fdf26555b97a46ccdc02b5e17", "ref_doc_id": "95a10889-f1e1-4ada-93a9-5967531bd1d3"}, "90f5937e-07b7-477c-8631-5adc07eddd62": {"doc_hash": "f6e555f7cb435098ab5365250fdb9a9c4c53f808716107ca62567532bba91815", "ref_doc_id": "9f8eae01-241f-4769-b3dd-5ef6529bd4b3"}, "0449ccb5-86f1-4d14-9144-249563399de6": {"doc_hash": "7151ce3d33cd865f856b37213f90379bd0a3153f127bf19f08995e84ecedf9a9", "ref_doc_id": "9f8eae01-241f-4769-b3dd-5ef6529bd4b3"}, "2006f729-b181-4f6d-90c7-1697f2c0704e": {"doc_hash": "a9a07b97f88f67e44485719d600c30efb618d6693e042d1272bf1d88b316b08d", "ref_doc_id": "8535767b-9d2b-4c9c-b00f-ced9974c2a0b"}, "0c3705ab-42f6-4852-a85d-c98cadc03831": {"doc_hash": "26185a423894755907b2b305fa5aef642cc61a805216b6a72c11f809bd27100c", "ref_doc_id": "ce974273-6283-469e-8dcd-3582376f0e34"}, "8e64aea6-52ee-4a75-9bf9-f66195e913b7": {"doc_hash": "12792fad1a53b43a8b7c423ca3310be3668cfb31ccc4cacd95609f233b7b1faa", "ref_doc_id": "9af1dc8b-612a-4de7-8cdb-c73e94b51232"}, "fb531033-4263-4cbc-a385-9e4e65806411": {"doc_hash": "64228665cabd563dec95f23bc3c95ddccebb54a1b00a6d09958dfc80f7d5cbc5", "ref_doc_id": "9af1dc8b-612a-4de7-8cdb-c73e94b51232"}, "404b0742-092c-48d8-b76f-c4f24861e996": {"doc_hash": "d1834d52b4176b96db240d1995703897510052c2e554936c74bea2effe06f007", "ref_doc_id": "ef8859e9-2f3e-417b-a6de-20fdf31b652b"}, "f87f4b93-8c46-4d05-a220-8fcd06fa1f36": {"doc_hash": "c1dc6b854778e015a9e4f9252b7fbe44bbddf6d378423d49d77d663dd31a130a", "ref_doc_id": "ef8859e9-2f3e-417b-a6de-20fdf31b652b"}, "3f08d264-59a0-46f0-bf9c-a2a58d05e7b7": {"doc_hash": "3a6518b6efb2919d9b4a758011d006a75aa78476e0705939eb5197ca11835dc9", "ref_doc_id": "ff4ee3f4-1ded-4d86-8bfd-a50bd8619dfa"}, "ddaafa66-4764-439d-a26d-89b79e873de0": {"doc_hash": "68aa1c6d08547a744d636f6a14ae8e4f943152228c323ca65dcaf674d9028791", "ref_doc_id": "ff4ee3f4-1ded-4d86-8bfd-a50bd8619dfa"}, "f55541ef-d164-4e50-af8a-4eaa063d091c": {"doc_hash": "b17b5b347b4767ead7c7e9bacb12949c8ef2cad366aad8590b4c45cd852b64d4", "ref_doc_id": "7e057d4e-cb0d-433c-ad65-7571ed9e5185"}, "4f99bf68-11dd-4d0c-ba40-58b7b4b71f09": {"doc_hash": "d575cc49e19a580c43d3bfacd97a6db644722faa9251d848877abf0470d8ab3d", "ref_doc_id": "7e057d4e-cb0d-433c-ad65-7571ed9e5185"}, "6d69d2aa-5c73-4ddc-9671-dc4dc29b3352": {"doc_hash": "a360835d165249f697e87482d70df6d060e4604723ee984a0127386601d89fa4", "ref_doc_id": "8d2bfa1f-9f97-46be-8769-02f3df84764a"}, "3b0913d7-8fa2-4d39-a519-58bac86dc854": {"doc_hash": "843fcd3ec98992adc5766b465ae6d3a782954047f23ed4c12b6d0d2f14c0ad5a", "ref_doc_id": "f8f7ce99-4073-48ec-b1c8-718e9c7f2ab0"}, "11d19713-b38d-403c-8e10-68324fe5c05b": {"doc_hash": "fd419a985f62ba68de8ae9c677dfc6e26a59ad0ef55de6dd581be0d9c5ebcd69", "ref_doc_id": "f8f7ce99-4073-48ec-b1c8-718e9c7f2ab0"}, "98b1f4f4-7a4e-400f-be7a-db8270c3e719": {"doc_hash": "07ba895d6c88d1b78defd13758cd2769ebdbe79f1cb0f6d4617c6586197e115e", "ref_doc_id": "d5830389-43af-4fe3-a87e-11089ade4bd2"}, "5adcc8f2-e4f1-438f-973d-bc0068dd3089": {"doc_hash": "84a5e07bc40d66adb9e9d9033b8403ab59c3123dcc93533d7133f12be87dcc00", "ref_doc_id": "01ca76b8-edaf-446d-a53c-4b4782950ed6"}, "e10325e7-9e56-4c5e-8c68-f7c69b4ca616": {"doc_hash": "d249fac1740add97e317dcc8d35c338982c93037d4e8246356b4ab6de3e2ccae", "ref_doc_id": "01ca76b8-edaf-446d-a53c-4b4782950ed6"}, "ac2fd157-c126-47e3-bf54-e564f4187faf": {"doc_hash": "740e37c8fd5e643592b5bbe8dccb3da27808410d8c43d26d882d6784932d32e9", "ref_doc_id": "01ca76b8-edaf-446d-a53c-4b4782950ed6"}, "9aaeaa02-4e8b-4689-af22-7812713b1a54": {"doc_hash": "0a46e8b7b76129bc0784b3635531f646ca8871824c94a0d90ed643d63790b97a", "ref_doc_id": "6d1169d6-a5c3-4663-b3f4-6d70fdb63b27"}, "75803775-c402-41f5-9f16-fbb4ed43768b": {"doc_hash": "623ac19cab6a9594bb9e091d2b8cd7c30695e6957c6234bb9c727d1a41457d1f", "ref_doc_id": "6d1169d6-a5c3-4663-b3f4-6d70fdb63b27"}, "c2e1115b-0324-4880-aea8-dee246187403": {"doc_hash": "bb335a4e556354a70a7a62be1d1d9bcdc815a1d21f1971c03e4ad1cd70e131ff", "ref_doc_id": "6d1169d6-a5c3-4663-b3f4-6d70fdb63b27"}, "a418b360-33b4-449d-8a8b-8fe85e57cdc2": {"doc_hash": "81034c6c061bdc2f7f18e67f0d0369d8385e471c1edc0c1afb17309cccb1351f", "ref_doc_id": "ab567a98-8a3c-4159-ab7d-278a0e3e5a60"}, "65bc8bd3-d635-462e-a697-ccad64655763": {"doc_hash": "427c8eba1d243a30c47644811e1a8f53144eba5c867d26aceaabe48d48c0ec4b", "ref_doc_id": "ab567a98-8a3c-4159-ab7d-278a0e3e5a60"}, "e8c0feb9-bfaf-4edc-a494-b4a554359f6a": {"doc_hash": "5f949684aa3dbbea8cdbe8f42888813487a022e341ae7a24e8d48d927f657ffc", "ref_doc_id": "ab567a98-8a3c-4159-ab7d-278a0e3e5a60"}, "439d7ff4-f097-4310-8883-43ef57ed71e6": {"doc_hash": "50c1551f713fd6c7540361f43f0d777f1bd7fa869ac951a756bc111cd38e7738", "ref_doc_id": "9de117d3-7e3e-40ab-95d7-1085c37d1dd5"}, "7d0c197a-6aba-4302-8b5b-e187b3fd6650": {"doc_hash": "748a1dccab639a4e66df72ab7a7ea1a0c8be55bcb2cbf37384e6facf70832ca4", "ref_doc_id": "9de117d3-7e3e-40ab-95d7-1085c37d1dd5"}, "45ad3dcd-8963-45d5-bd31-a9f4d445f270": {"doc_hash": "03a0ce0f06bf01eb86fe997203868e0fcba406e7605b991f3ea7f71a99272ad1", "ref_doc_id": "9de117d3-7e3e-40ab-95d7-1085c37d1dd5"}, "15897be3-22d8-4294-9c39-2ea7e820a84b": {"doc_hash": "40134dd6255626d23964d91b5085abd2742835a5159dd949da6f5dc7f06582a2", "ref_doc_id": "9de117d3-7e3e-40ab-95d7-1085c37d1dd5"}, "7795c32a-6b32-4595-9c07-6f35297524dc": {"doc_hash": "c91785d9160a6410949d8f85049490f82498e268698a448099795a81149ebf57", "ref_doc_id": "d818f800-cdaf-48ab-8f7a-48b627453477"}, "4f1ff26a-c226-407b-99f8-aa5c72a34234": {"doc_hash": "be9bfaf8d61879fea12beb7a8e31e1c81c2c3119e8235953c778529d5d863055", "ref_doc_id": "d818f800-cdaf-48ab-8f7a-48b627453477"}, "6c6d928d-7b37-41cb-86f5-4cfcddb4082a": {"doc_hash": "a514a5de9de378421d7b195511e0dade42cb5d3968c4e543d6d4f3ece4107f48", "ref_doc_id": "d818f800-cdaf-48ab-8f7a-48b627453477"}, "7e90203d-7a98-4662-9c76-fd5be5a701ea": {"doc_hash": "e1daccbde5a04c8478f98dbea3ff4f542abbe1fc994000e612b17093abe744af", "ref_doc_id": "7fa8f6a9-46d7-43d1-a6bb-583df068f766"}, "17a8175e-ae59-42bd-aed2-643f0109b44c": {"doc_hash": "a787c2e3f39b4ed385592b1bb6ed9ac1eabb4ad056296879d0fc96c08d545698", "ref_doc_id": "7fa8f6a9-46d7-43d1-a6bb-583df068f766"}, "fe2be658-8c89-4a14-bd59-7903a912aac3": {"doc_hash": "f6b945bfef0383b6125a14f7057f4aeadbe9585585da2fc84c6ab66c72f1c4c9", "ref_doc_id": "7fa8f6a9-46d7-43d1-a6bb-583df068f766"}, "4e4d4504-a96a-4f0d-9ff2-8e2259900e4b": {"doc_hash": "32b3db047f05d338107e986b7bae1dd3cf7645f4c8207e6ab7ac68ef74408c87", "ref_doc_id": "1de3562f-583a-46aa-8d21-587c90caf7af"}, "9461a2bc-4a17-460a-bf08-a69c025cde9a": {"doc_hash": "a796800a0edf7f499d1a1f0b8a818a5ff684533b0964f9decb542761229ef966", "ref_doc_id": "1de3562f-583a-46aa-8d21-587c90caf7af"}, "b01e881c-95cd-4dca-a427-72a676084fe0": {"doc_hash": "1a4e218b09a37456fd0f374d8f41f41217246042a5da38142d4d620fa7d9543f", "ref_doc_id": "1de3562f-583a-46aa-8d21-587c90caf7af"}, "d0a0e96f-6f86-4a96-8075-dd8e96b5fa0f": {"doc_hash": "ff66db7d4ae6c134b72d7975ce54fa6aac9f3ed81173cb2212b264b65cd8fd76", "ref_doc_id": "7b99c844-154a-4e9d-b73e-58ec2cdab29a"}, "c8e89640-2988-4444-a9d3-557bf86c6ca1": {"doc_hash": "71b1a0da008be2fe665412fce543f79969bdde158df18fe982ecb364aa03c3d7", "ref_doc_id": "b0494a81-d4c3-4f12-93a6-7da0dcf2b21c"}, "d7abe083-cae6-48d0-80e9-9c5551ddafd5": {"doc_hash": "4d8987e7b0e87b114eb8a7089c8be372bb96cb23f62d8a57740fb9ab76b0f2f6", "ref_doc_id": "9b9c978a-8220-4fc7-885f-0dd9d04226f5"}, "ab7a3aed-fdd6-4c40-9575-fc4861198243": {"doc_hash": "cc537c247290c9a3522090a32112e538e10d7c620979f04050a7aa643c647e5b", "ref_doc_id": "9b9c978a-8220-4fc7-885f-0dd9d04226f5"}, "e28a24b7-d2fa-45d7-8224-a8e55a4d341e": {"doc_hash": "d58227850fc58bc4a8c7c57d0d16c66be3ccef63071c650e1d75ecce338d2361", "ref_doc_id": "81c9ae9b-1edb-4b53-b7e6-2162a925b758"}, "d3dae363-7918-4c9c-a15e-ae7cb37343df": {"doc_hash": "7b6be060d228ca54727894dd078353bea0f3a6001a514953c935b1f2dcf6e13f", "ref_doc_id": "81c9ae9b-1edb-4b53-b7e6-2162a925b758"}, "b91dfa36-7b76-44cb-9c59-8f525b101ffe": {"doc_hash": "97e30977f7f24049d60060c03615a3b66a085f656d3f262daaa2d9f480387cb1", "ref_doc_id": "d42e5afb-96c3-4d7c-992a-ef3a1e468e4b"}, "91edfeae-233c-4ef1-b060-4be96d9164e8": {"doc_hash": "ca6dbad641312ad6c23094edd9409965942bab00499242a7dc7082caa1dacb09", "ref_doc_id": "18fab913-8352-41c1-bcb0-ef1a64500fce"}, "20dd5452-8ba6-40b9-859d-1adc00e08a5f": {"doc_hash": "15255df6865971c3e3a7b367d505190fedda7cd66d030b001456c647524b393c", "ref_doc_id": "214f13ba-61fe-4460-9a07-55037f4a88f6"}, "f8595323-cc73-42b1-93c7-b7b283fe041e": {"doc_hash": "edb2316c360ece0c7ede5267090152b1f7ff1a151fb4751a35af394989107dc8", "ref_doc_id": "a8dcce3b-0ed4-4cb7-8f47-3bd7915f3849"}, "8a7dba6a-f778-4218-bef1-6903c754cdd4": {"doc_hash": "4e2870649cc32a113ad857c14d06882b8b6a29f8a5316588598a2a052baca08d", "ref_doc_id": "07f0fdf4-d6ec-4fb7-857e-35569f1d7b9d"}, "6e0a4055-156c-4b70-8fa8-255c79ab6d30": {"doc_hash": "c2ca72e387640339479567b93c74a149dd9e5b400303b6d5f399be51221f89b3", "ref_doc_id": "07f0fdf4-d6ec-4fb7-857e-35569f1d7b9d"}, "894f2489-e788-4ab5-884b-0e6f97681a18": {"doc_hash": "57098a8a4d7ffe353f2442ffd065a4bea3b469e599248ab4aef44b399e66e9f6", "ref_doc_id": "1f24b60f-9bea-4a3b-a677-50b88f2cf0f4"}, "5e47c1d8-90b7-4c16-8f62-4b4ab9c8d927": {"doc_hash": "68f0a8a6b98c88d16881336c8eb9bec7393c193cf4a01cfccbb410d08698df5c", "ref_doc_id": "fa797b6c-e946-45f2-82f8-945d7a7f94e1"}, "ffbc215a-138b-429c-b8b9-856bee74c51c": {"doc_hash": "3e42e4763c1a8f34a6f2ad79423a39c69c00bc8ddafc502da408ec3d07551ae5", "ref_doc_id": "fa797b6c-e946-45f2-82f8-945d7a7f94e1"}, "fea679dc-d19c-4067-a2fc-0a9e37ff62b5": {"doc_hash": "5a84aa3e968d2b563861f10bbac51d93729b099f6450c6bd1286ba61c7b7aeb1", "ref_doc_id": "d94325cd-066b-4086-b1c5-7e9667cfa643"}, "2b323375-8321-4784-857e-432bce7d874e": {"doc_hash": "24ddee628bdb754f45cde08fd189aaf195652a5fb25a2f188a7a93e3ff3a673a", "ref_doc_id": "954de1be-9c9e-4f9c-ae8a-184f5c3e0047"}, "1f6b388f-ce9c-4137-bd40-71d95e74f371": {"doc_hash": "db5a42f8ac425b529722c34d807e9f273d111f266db73b764a665c232e655093", "ref_doc_id": "954de1be-9c9e-4f9c-ae8a-184f5c3e0047"}, "55be455f-dee5-4e99-aaa9-a2863f8ec34c": {"doc_hash": "5945831be530f73b737ca79662d57359b9b21b6ed6d9360d96555e19c148e7e2", "ref_doc_id": "40e27d3b-71eb-4d03-8fef-db32a071df69"}, "68076cda-2cc2-4f05-a965-8f4814c60078": {"doc_hash": "df6f7ba9014069db1fcd238758ae4b8b03f98fd4c7e2330a25d52fe2ff9b0327", "ref_doc_id": "8732b692-cc00-4955-83e8-6f8063505d08"}, "6f03524c-f10e-421e-bc5c-b97c541fcf45": {"doc_hash": "db83737a6ec3d31b026bbc15c8c31ea5a8fa7bc59ef3112dca41998abfcce004", "ref_doc_id": "8732b692-cc00-4955-83e8-6f8063505d08"}, "4d60e967-7157-4b42-810a-c4e2b650024e": {"doc_hash": "9abded464e4ada920aab03dceea2c47201359ecd00615e4dce46fc6f6b6e0fb0", "ref_doc_id": "8732b692-cc00-4955-83e8-6f8063505d08"}, "78e202e8-8113-4907-936f-554751988c5a": {"doc_hash": "8648698091a5a7340ebf90c843c708ca5f98aa5889745ef05faeb8b53128a11a", "ref_doc_id": "8732b692-cc00-4955-83e8-6f8063505d08"}, "1d92c96a-23ee-4942-98ca-75478c0c2a39": {"doc_hash": "ab9f7f336363b443602d7443024abc9f6e3bb31f29c689770913aa0b65f55085", "ref_doc_id": "8732b692-cc00-4955-83e8-6f8063505d08"}, "b32da7f0-7b59-4327-af9b-ab0fe96b5509": {"doc_hash": "ddeb3db43ec6f9a8ffa5f3c37f6274628819ac48db81505096babbdec305246f", "ref_doc_id": "8732b692-cc00-4955-83e8-6f8063505d08"}, "38f09af6-8325-476e-9578-50bd9880c163": {"doc_hash": "c272b5850dd9acb9582ad37a5fb956730a733c224e86e3b133e92a98a4d586f6", "ref_doc_id": "8732b692-cc00-4955-83e8-6f8063505d08"}, "1a0ac1e2-6c10-4df4-9675-bf2195e44d4f": {"doc_hash": "6c561eb9783d90ed7a764156c2d8baecb757dffebcfe86891061b4f0e03650e7", "ref_doc_id": "ba8a5c9f-4382-47cc-94e5-9a3a2537bf8d"}, "55e6597d-6333-4b17-a982-05ae7b7d0481": {"doc_hash": "78f03e3467cd839a61611d5647623d382af74048f32e73de98021fc8edeefa8b", "ref_doc_id": "ba8a5c9f-4382-47cc-94e5-9a3a2537bf8d"}, "d782ffc5-c5e5-41ef-a671-476afda20ed1": {"doc_hash": "4f8ea79b77a33b55be5a477bc6132652dbf22e7e54b913259c9566b21debc276", "ref_doc_id": "ba8a5c9f-4382-47cc-94e5-9a3a2537bf8d"}, "e1a61c5c-1574-468d-a98a-e5e68523ae33": {"doc_hash": "0189a3322e14a470fae40834295dc7e8e2f6a53564f77a0ef433fec7f904684d", "ref_doc_id": "c119cca9-d28e-4455-9140-d834c68fe01b"}, "85478166-cb22-4cb2-a64f-f0b8c643b98d": {"doc_hash": "e2732bb2acb0671880d6d87b21d9267315260ec5663dbb6546cc6bbdffeefc11", "ref_doc_id": "c119cca9-d28e-4455-9140-d834c68fe01b"}, "3cc32a69-3635-4ee7-8e48-e73fc90d0a31": {"doc_hash": "b458492bb978fe1e5900433da06ff1be0f53c10bcfbb5269290d4b8eaa04bf64", "ref_doc_id": "c119cca9-d28e-4455-9140-d834c68fe01b"}}, "docstore/ref_doc_info": {"fcafdb20-17e8-445e-a7d6-7c5d1c14996d": {"node_ids": ["2fdb4fa7-c200-4201-8429-a2d681d09298", "bdeb64e2-f767-4ce0-acd2-6c5719b80cd2"], "metadata": {"page_label": "381", "file_name": "2022_22.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2022_22.pdf", "file_type": "application/pdf", "file_size": 1843017, "creation_date": "2025-11-25", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}}, "7615fb8b-f8a3-43e6-b5fa-6b7042933f04": {"node_ids": ["c5a7d310-4b5d-4878-bfa1-2409c8cfdc1a", "eb979e76-5f9d-49ee-91d4-119b07f3d765", "a1efdc81-27ff-48b6-a1ce-c8e77ffda8e4"], "metadata": {"page_label": "382", "file_name": "2022_22.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2022_22.pdf", "file_type": "application/pdf", "file_size": 1843017, "creation_date": "2025-11-25", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}}, "c5ace680-1a06-40a1-b05e-c466202222f8": {"node_ids": ["e0a959f8-33b9-4957-85c7-c395a6cb9eef", "76b2a880-f229-4fe3-946e-a2ab1650efc0", "245f742f-eb78-4522-a9d6-7afa1ef6d9be"], "metadata": {"page_label": "383", "file_name": "2022_22.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2022_22.pdf", "file_type": "application/pdf", "file_size": 1843017, "creation_date": "2025-11-25", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}}, "3f425aad-9cbd-4c0f-9788-8a1c28fc8736": {"node_ids": ["70ed48ba-8204-479b-839e-7608555fccac", "73c43bdc-bd9a-4217-8c3e-45220c47c1ec", "10869f2b-992d-4e26-bd74-960550008f0b"], "metadata": {"page_label": "384", "file_name": "2022_22.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2022_22.pdf", "file_type": "application/pdf", "file_size": 1843017, "creation_date": "2025-11-25", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}}, "15d14d4e-85d9-4ee6-82bf-cde584513288": {"node_ids": ["5fe813a4-5e82-48fb-b1d8-1b50feda60c2", "7c0a60c6-5f61-4926-895f-6d8f2e2317c3", "952777a9-ccb1-4a20-b9ee-e4e3e613353d"], "metadata": {"page_label": "385", "file_name": "2022_22.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2022_22.pdf", "file_type": "application/pdf", "file_size": 1843017, "creation_date": "2025-11-25", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}}, "3776cd45-8e7c-44c4-b92f-824e4df55a2b": {"node_ids": ["874fc012-0462-49c1-b9e9-cb33cee6af92", "d5afc1ac-b2ad-46db-a1ef-fde22601ee46"], "metadata": {"page_label": "386", "file_name": "2022_22.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2022_22.pdf", "file_type": "application/pdf", "file_size": 1843017, "creation_date": "2025-11-25", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}}, "941d163f-8a67-4980-a6a7-659a390d3f12": {"node_ids": ["24f61020-1798-4c35-914a-f6f4db55fead", "8c55acdc-aa90-42c9-b13f-eb5a2283c074", "4fc29b02-6e32-4fec-9aae-d08fa59013e2"], "metadata": {"page_label": "387", "file_name": "2022_22.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2022_22.pdf", "file_type": "application/pdf", "file_size": 1843017, "creation_date": "2025-11-25", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}}, "8570a108-4af9-44bc-b05b-0542b8b981cb": {"node_ids": ["cc2e3dfc-455c-4801-bab0-2ee4918b8104", "efe38aa5-38fc-4847-942b-f908c3404fa1", "cf136d6f-3cfb-42ea-ba45-e262ca420deb", "32df878e-ccb6-465a-b087-b932a2eae4f1"], "metadata": {"page_label": "388", "file_name": "2022_22.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2022_22.pdf", "file_type": "application/pdf", "file_size": 1843017, "creation_date": "2025-11-25", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}}, "cae001d1-adc4-43c4-86eb-3afca61af625": {"node_ids": ["1a40e132-e141-4b98-a0fe-a344cc83118a", "063b122e-f554-4cf0-8ce9-7272157bcc1f", "5aef06d6-8c6e-4c71-b920-2b8c1263762e"], "metadata": {"page_label": "389", "file_name": "2022_22.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2022_22.pdf", "file_type": "application/pdf", "file_size": 1843017, "creation_date": "2025-11-25", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}}, "2f7c8d7a-d2ef-4aad-aaba-9896ae465fd3": {"node_ids": ["03c0b38f-6305-479c-969e-ec320ac92403", "4677d591-1e95-4b09-a467-e6228ae59ef6", "b09397fa-f09d-4ff0-b5a1-ad177b774a43"], "metadata": {"page_label": "390", "file_name": "2022_22.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2022_22.pdf", "file_type": "application/pdf", "file_size": 1843017, "creation_date": "2025-11-25", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}}, "828511b8-a12b-4753-ba7b-e47d9cf3dcb7": {"node_ids": ["7ba3e3a6-a4b0-47b9-b4c7-dbe42ca09ea6", "9124c946-e401-4a32-8a0f-aaff3b5b66d4", "0155966f-6ce8-4ec7-a084-f1d776b0dc42", "d7dcb739-a0d4-4909-9b8d-0c3913e4b394"], "metadata": {"page_label": "391", "file_name": "2022_22.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2022_22.pdf", "file_type": "application/pdf", "file_size": 1843017, "creation_date": "2025-11-25", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}}, "3a972395-e60a-416e-8ee3-8753f826199b": {"node_ids": ["1bb202b5-9551-4c8d-a01c-409089254c9c", "f0b0fe86-9411-4cdc-91d4-cbb729228d87", "e5816868-b895-40ca-b935-c8d9510839b7"], "metadata": {"page_label": "392", "file_name": "2022_22.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2022_22.pdf", "file_type": "application/pdf", "file_size": 1843017, "creation_date": "2025-11-25", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}}, "9b05e3fc-b17f-4677-9647-a6dec50e6e20": {"node_ids": ["e17d8cfe-da6a-4c89-b96c-dbc6de3572ff", "8d0e428e-a991-49d7-a3e8-7e26ecf661d5"], "metadata": {"page_label": "393", "file_name": "2022_22.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2022_22.pdf", "file_type": "application/pdf", "file_size": 1843017, "creation_date": "2025-11-25", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}}, "7d6502f2-57f3-4c3f-bdc7-c90afb45915b": {"node_ids": ["5745f265-e2fc-4e88-8e18-155b236ea65a", "5252bef4-897e-42fc-a092-3088f01ea356"], "metadata": {"page_label": "394", "file_name": "2022_22.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2022_22.pdf", "file_type": "application/pdf", "file_size": 1843017, "creation_date": "2025-11-25", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}}, "4279f1b2-5420-4e50-ac08-2744d393c439": {"node_ids": ["a2a903a3-47f6-44e0-bafd-e1f521262852", "553e70cc-761d-45be-9849-0ba22b1f5203", "5c0ba1df-1189-474d-91fa-d41c9d2e5179"], "metadata": {"page_label": "395", "file_name": "2022_22.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2022_22.pdf", "file_type": "application/pdf", "file_size": 1843017, "creation_date": "2025-11-25", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}}, "0da85362-fd5e-4050-9131-3ef70de211ca": {"node_ids": ["a95b3bf3-0e78-4670-8f29-c2e50ece54ae", "4c3ae163-aa2d-4933-8fca-56a604a28081", "783c2bac-ee48-4f04-82d6-ff2cda0bc295"], "metadata": {"page_label": "396", "file_name": "2022_22.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2022_22.pdf", "file_type": "application/pdf", "file_size": 1843017, "creation_date": "2025-11-25", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}}, "af3e5d0d-5513-4835-98f2-476cfd9c6166": {"node_ids": ["655b23ba-a878-4609-875b-4daa07cdffbc", "af102b20-6331-44c9-b41a-e29d9e41cfc3", "f2aaaa25-6ee5-42e3-9331-fdd27ecb3c81"], "metadata": {"page_label": "397", "file_name": "2022_22.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2022_22.pdf", "file_type": "application/pdf", "file_size": 1843017, "creation_date": "2025-11-25", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}}, "93113a58-04e3-484d-9264-50186f64c354": {"node_ids": ["7efe0c89-0145-45e1-9506-9ba1ba22e386", "7b58cad0-3073-4098-a806-67e19794ec05", "70faf334-60ed-4408-9216-877197a4a0f1"], "metadata": {"page_label": "398", "file_name": "2022_22.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2022_22.pdf", "file_type": "application/pdf", "file_size": 1843017, "creation_date": "2025-11-25", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}}, "079d1128-1182-4299-a9eb-957a6f2268de": {"node_ids": ["058cf7ee-0382-44d7-9411-b36359d29449", "4906fad2-ac6e-4c0b-ac80-b1bf4acdc990", "a43583c4-5298-4773-b216-b8e628c41783"], "metadata": {"page_label": "409", "file_name": "2023_20-21.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2023_20-21.pdf", "file_type": "application/pdf", "file_size": 1372902, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}}, "c15526a3-5091-4246-a0a4-434fb0ca4a4d": {"node_ids": ["4baea7a8-f486-4ba9-b338-f79a0e16c12e", "8b8070ea-4dc4-4e18-922d-a1375b847187", "0452f960-a521-4c64-bf2f-e030f92ba7a7"], "metadata": {"page_label": "410", "file_name": "2023_20-21.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2023_20-21.pdf", "file_type": "application/pdf", "file_size": 1372902, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}}, "5f6a2b73-3193-4933-9e31-37d3af8dfdfc": {"node_ids": ["5aa81f2f-d413-4ee7-a3d0-9ff437be7c60", "9a96132b-91f0-4920-8f77-144aa07f0b4e", "14aad8e8-dadf-4764-9633-49aacd48798a"], "metadata": {"page_label": "411", "file_name": "2023_20-21.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2023_20-21.pdf", "file_type": "application/pdf", "file_size": 1372902, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}}, "5e71608c-4196-415a-b44c-d5e95bfff7e2": {"node_ids": ["515931d6-6a17-4ea6-a50c-7b967589a833", "d33eca29-8fb1-4b73-b950-4e6168ee138f", "acbee753-6c1e-4b34-8655-211db4f730e7"], "metadata": {"page_label": "412", "file_name": "2023_20-21.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2023_20-21.pdf", "file_type": "application/pdf", "file_size": 1372902, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}}, "de62df33-9d10-461c-93a3-ec27958e2ca0": {"node_ids": ["8a741009-a7fe-4a85-8613-863cf6d56b4e", "d448e218-66be-49f0-9ae4-424c29008da9", "f51ad937-e036-430a-ae2b-d94ea21912b0"], "metadata": {"page_label": "413", "file_name": "2023_20-21.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2023_20-21.pdf", "file_type": "application/pdf", "file_size": 1372902, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}}, "44f90b55-11c6-4256-82a9-e2ef30fbde41": {"node_ids": ["df934db4-9119-45c4-94ca-204ebfaf339c"], "metadata": {"page_label": "414", "file_name": "2023_20-21.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2023_20-21.pdf", "file_type": "application/pdf", "file_size": 1372902, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}}, "d7cbcd75-bd03-464a-b8ae-5a51caf94e39": {"node_ids": ["3cf38749-39f6-4c64-be6f-e1baede76898", "269cbc03-5966-443a-a8b5-40aae7e51523"], "metadata": {"page_label": "415", "file_name": "2023_20-21.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2023_20-21.pdf", "file_type": "application/pdf", "file_size": 1372902, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}}, "1fbfbe0c-2791-427c-987f-43948b0bb4b5": {"node_ids": ["4fe56716-f118-4a6c-93c0-ae307ad51bc9", "b359e1a2-e044-4059-a188-dea823a3c3c4"], "metadata": {"page_label": "416", "file_name": "2023_20-21.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2023_20-21.pdf", "file_type": "application/pdf", "file_size": 1372902, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}}, "594dca8c-e0a5-4bfc-a824-86502d359579": {"node_ids": ["04ebe7f3-9094-42a2-94c3-2124b936ea72", "b843c23b-2ee8-4382-aee1-75ba97b901c9", "64b28b46-fa0c-43a4-b3df-61ea93c17f89", "a50e3672-1d7f-4bee-af81-59cd61609b1d", "ed1776e9-0c0f-46ff-bfae-4891c0bda0bd"], "metadata": {"page_label": "417", "file_name": "2023_20-21.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2023_20-21.pdf", "file_type": "application/pdf", "file_size": 1372902, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}}, "d482a4d3-4034-4b44-a781-6c5c9e859994": {"node_ids": ["ed421f85-1279-41cd-bac4-a3e3a787212d", "3d1796e4-2819-4f48-bf97-2c29ff8e59ae", "28a53ade-3861-4406-aa32-e358e5e55c13", "26720d43-e80a-41f5-9012-2c51e449a2cc", "ffb266a5-eb7f-4e01-94eb-104caef7754b"], "metadata": {"page_label": "418", "file_name": "2023_20-21.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2023_20-21.pdf", "file_type": "application/pdf", "file_size": 1372902, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}}, "b1cb14d6-ae35-4f96-9313-019e65289ce6": {"node_ids": ["9e91a6eb-4572-4da5-a272-024090f74374", "c33930e5-fd98-49d9-9322-03ab6fc6c192", "8f7b14b2-880f-4431-84a8-5a1e7157c853", "c91cd50a-7c10-4140-9eb6-7a231676ef36"], "metadata": {"page_label": "419", "file_name": "2023_20-21.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2023_20-21.pdf", "file_type": "application/pdf", "file_size": 1372902, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}}, "15eaeebb-8425-4573-b4f8-ad5506a004d8": {"node_ids": ["a6490233-bb34-4703-9dd0-0ed6723205af", "dcfbfebf-4e80-41b2-b100-4cbab2852b38", "11be1cfb-f293-4ef4-8095-b3f325bc0d3c", "c21f7c64-5ebe-4898-9c4f-afc31baf427a", "a4e8da5e-065a-4439-b902-ccd022ae5dd0"], "metadata": {"page_label": "420", "file_name": "2023_20-21.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2023_20-21.pdf", "file_type": "application/pdf", "file_size": 1372902, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}}, "0b3fd5bd-b588-44f3-85d3-3e8bf2656b50": {"node_ids": ["662d137a-a681-43fe-8402-1c086d498576", "42226b1b-aea4-4a7d-96f5-be3250d84dda", "d5d50f40-ad14-4f6b-8a91-07f86ff4b776", "69c72682-29bf-4080-8613-3df5d4cfb35e"], "metadata": {"page_label": "421", "file_name": "2023_20-21.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2023_20-21.pdf", "file_type": "application/pdf", "file_size": 1372902, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}}, "22079c30-189e-47fb-9e31-1ff8663dc7a1": {"node_ids": ["94608b5c-aff4-4b58-aab7-f26613fc89a8", "f1b06c17-56e3-4038-8fce-4af042bdf511", "fb19423b-0e26-4186-9e7c-5c5aac9aa862"], "metadata": {"page_label": "422", "file_name": "2023_20-21.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2023_20-21.pdf", "file_type": "application/pdf", "file_size": 1372902, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}}, "6b4c360b-9f6c-40a8-870f-d036e6c87169": {"node_ids": ["a110bd64-fd10-48b1-a20a-4e5cf32dec25", "54a6f7e1-24e2-44f0-b6b2-6c5a49d5ca46", "4b30e0c8-7572-4896-a557-8dd115b8fc75"], "metadata": {"page_label": "423", "file_name": "2023_20-21.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2023_20-21.pdf", "file_type": "application/pdf", "file_size": 1372902, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}}, "1bf7379f-8602-4e66-af52-cc9264bdfb8b": {"node_ids": ["d737fc20-f005-4ade-b5bc-9cf786d5319e", "056a4d22-1aba-495c-90b1-9a38173466b6", "cf64b3c2-b4c8-4684-b868-dcd2d8eff077"], "metadata": {"page_label": "424", "file_name": "2023_20-21.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2023_20-21.pdf", "file_type": "application/pdf", "file_size": 1372902, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}}, "79a479cf-2a72-4463-96b0-b4880b1d4e4d": {"node_ids": ["5bf03a61-51a3-43ab-af97-94617be05f29", "9d69f9d1-d119-41ab-842b-bef2765ac58f", "9d09547d-a37a-4da6-9639-caee71004d81"], "metadata": {"page_label": "425", "file_name": "2023_20-21.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2023_20-21.pdf", "file_type": "application/pdf", "file_size": 1372902, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}}, "c530fd5c-b2f8-401a-9a29-5215a0c47658": {"node_ids": ["15939ba6-4113-420f-9138-d277c8e17549", "97716d14-bb84-4bff-9928-7e2f9da5d4e5", "728e6ba6-610e-490d-a14f-b14860d6520d"], "metadata": {"page_label": "426", "file_name": "2023_20-21.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2023_20-21.pdf", "file_type": "application/pdf", "file_size": 1372902, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}}, "3384ed57-4045-425a-b8f1-c654c2a8a73d": {"node_ids": ["cb5e4a93-c1ce-4f04-8261-261d1c27a3f4", "d9e42c6a-e2df-4dc8-a6ed-4e6943cbdf22", "847fd2e4-ee3c-46b6-8afc-22641b581e23", "c3fcf789-a758-4065-8f92-e6155bc44a3e"], "metadata": {"page_label": "427", "file_name": "2023_20-21.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2023_20-21.pdf", "file_type": "application/pdf", "file_size": 1372902, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}}, "2bed1749-f5a5-4300-9721-36e2ad829cf6": {"node_ids": ["da95f77e-63f3-42d4-8297-6feddc5b841b", "dbd9bf29-7754-4ed3-b887-f3a05e8fa8ed", "c0c24fd2-0349-4dc7-8ac6-d8f1d6eebd54"], "metadata": {"page_label": "428", "file_name": "2023_20-21.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2023_20-21.pdf", "file_type": "application/pdf", "file_size": 1372902, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}}, "e14c7d12-a39d-419c-a7ca-d0fdb0b07031": {"node_ids": ["dc0009d5-e47a-4ee9-9370-00d5844aa05f", "61de57de-f2aa-43f4-ab25-b74313ee4d8c", "5ddff8d7-c1ce-40d1-b257-fc7e8f9ff9b5"], "metadata": {"page_label": "429", "file_name": "2023_20-21.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2023_20-21.pdf", "file_type": "application/pdf", "file_size": 1372902, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}}, "99296c5d-32e1-4b4d-a657-f0e871e56802": {"node_ids": ["22ee08d7-615c-4b7b-ad9f-f4d7b98de330", "a7047167-62b3-4e36-97a2-7982c8c8cb45", "6a5a14ba-7954-491e-ba99-1b0a12c500a9"], "metadata": {"page_label": "430", "file_name": "2023_20-21.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2023_20-21.pdf", "file_type": "application/pdf", "file_size": 1372902, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}}, "908b3b4e-ed97-42f2-8ca5-d60cea7282f8": {"node_ids": ["4f469750-5982-48fe-8575-9f11431cf462", "bab16cde-4fe3-44b4-b043-ed3bb7c3c5d7", "4c5d3504-34ca-418f-9082-9a71e458a090"], "metadata": {"page_label": "431", "file_name": "2023_20-21.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2023_20-21.pdf", "file_type": "application/pdf", "file_size": 1372902, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}}, "c8282bc5-7db4-4ff5-9a00-f83862a31bdd": {"node_ids": ["a7f56be9-db3a-462b-9ea3-b4e13e3a98fa", "989bc4f7-4731-4759-939e-15fc1ff55a48", "f8b9626f-ebdf-4a24-a844-8c5553281001"], "metadata": {"page_label": "432", "file_name": "2023_20-21.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2023_20-21.pdf", "file_type": "application/pdf", "file_size": 1372902, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}}, "658041f7-1a75-45e5-9166-74a09afe9067": {"node_ids": ["88852ba1-148b-4dba-880b-d6c938012bdb", "5a08bf95-5091-4619-906e-cd1df120f674", "d032b227-7831-4594-bc88-cb74df82b9c6"], "metadata": {"page_label": "433", "file_name": "2023_20-21.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2023_20-21.pdf", "file_type": "application/pdf", "file_size": 1372902, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}}, "b3dad03b-ba50-4f54-98e8-473a177d1427": {"node_ids": ["d8435ffb-c86b-4abc-91db-9ed92cfa77c7", "aba3ddd9-7d03-41ec-93df-6615623959c6"], "metadata": {"page_label": "434", "file_name": "2023_20-21.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2023_20-21.pdf", "file_type": "application/pdf", "file_size": 1372902, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}}, "70550d91-4501-440b-ad3f-df051e933ddc": {"node_ids": ["de06f9a1-1ac7-48d8-8f6a-7044ea11082c", "c1d38ccf-9456-438d-8b53-3f75e2b65ed2", "b284a456-b0ce-4384-9c07-a900b37fcc86"], "metadata": {"page_label": "435", "file_name": "2023_20-21.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2023_20-21.pdf", "file_type": "application/pdf", "file_size": 1372902, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}}, "2078a7ef-0deb-4e51-9a34-2a6b244b2883": {"node_ids": ["9f10cf6b-5c37-49c7-9538-8df4d98968b8", "af9ac5ce-823e-41c6-83c6-891ca6c956e2", "753aeab6-4cdf-4cc0-af0b-22672272f8e3"], "metadata": {"page_label": "436", "file_name": "2023_20-21.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2023_20-21.pdf", "file_type": "application/pdf", "file_size": 1372902, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}}, "51955358-2582-40f8-8e7e-d511f8faf5a0": {"node_ids": ["16a1af56-fce2-4fab-9f94-5765cc9523be", "2fe3ea18-97a3-4e67-ba3b-2ac756633525", "77af1fe9-dced-4a0a-8bd1-45466b4264d3"], "metadata": {"page_label": "437", "file_name": "2023_20-21.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2023_20-21.pdf", "file_type": "application/pdf", "file_size": 1372902, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}}, "ba8fe3fd-a1ff-4583-be3a-beddd7a15063": {"node_ids": ["5e44687e-c9de-4923-9de4-c5bf17d6cb9d", "b4389582-5d43-4557-9285-4377c53faf73", "3d787d5e-1758-43ee-9a7a-e5114f1325a0"], "metadata": {"page_label": "438", "file_name": "2023_20-21.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2023_20-21.pdf", "file_type": "application/pdf", "file_size": 1372902, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}}, "8b00ebf7-29dc-46f4-b862-5efecbd04c5c": {"node_ids": ["772b089c-c817-44fd-bce7-935155f3d728", "b17e3e2c-c860-4977-8262-cef4d36987db", "92a06d7b-5173-4079-b573-704462dc60e7", "9d85a5bf-9aa9-45f7-9119-9e60620dbcca"], "metadata": {"page_label": "439", "file_name": "2023_20-21.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2023_20-21.pdf", "file_type": "application/pdf", "file_size": 1372902, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}}, "bcdd4836-ebbf-4c04-8e9e-8af4dec9e84a": {"node_ids": ["c31d7e66-7adc-450e-8088-6512ac569478", "ebc418e0-7168-4da3-82b6-4f84c23f3fb2"], "metadata": {"page_label": "440", "file_name": "2023_20-21.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2023_20-21.pdf", "file_type": "application/pdf", "file_size": 1372902, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}}, "6035df52-14a5-4cca-a2e5-19cff4afdafe": {"node_ids": ["78af2811-9fbc-4ccd-883f-3ff9fdcba9c2", "fd16c0f1-9ec8-4eb5-8071-81bd2f24adf8", "2d513e46-6cd2-4e08-ae60-29b85d2a0c10"], "metadata": {"page_label": "441", "file_name": "2023_20-21.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2023_20-21.pdf", "file_type": "application/pdf", "file_size": 1372902, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}}, "78c73c04-8b2f-4f42-a213-6259dc336682": {"node_ids": ["e89eb6ae-fa5d-4525-ac74-bf2e12367684", "4c25198e-e46b-4ef2-b557-9fa5793c391f", "b2b598d8-cdd9-4a7a-8dd0-8c40155533b7"], "metadata": {"page_label": "442", "file_name": "2023_20-21.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2023_20-21.pdf", "file_type": "application/pdf", "file_size": 1372902, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}}, "e11608ce-d26d-4203-8630-0d2508febe0b": {"node_ids": ["49fe51da-42e5-471b-b3f5-e7ff6ac0bf66", "6f5ac479-b7b9-499a-acf6-1dbe368d3079", "a7dd5d7b-92d5-4c20-8aba-a746022a3dfb"], "metadata": {"page_label": "443", "file_name": "2023_20-21.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2023_20-21.pdf", "file_type": "application/pdf", "file_size": 1372902, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}}, "81e1d798-1bfd-462d-ac36-6018ccdc7ebb": {"node_ids": ["73313082-2baa-41f3-b0c2-82a74cfa6c12", "556b9b80-0d5d-40e9-9154-674e93acde37", "18993c1d-2b59-4fdd-8194-88c9447550b6", "15e3fc81-5d36-441f-981a-dd3a574322b9"], "metadata": {"page_label": "444", "file_name": "2023_20-21.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2023_20-21.pdf", "file_type": "application/pdf", "file_size": 1372902, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}}, "27ffb3b2-48a9-4a85-b79b-a6f6013be127": {"node_ids": ["225048c9-4a06-434a-9e0e-38a3abd9ca9a", "6cb37be7-0db5-4ce9-99b3-9b1fd93407bb"], "metadata": {"page_label": "445", "file_name": "2023_20-21.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2023_20-21.pdf", "file_type": "application/pdf", "file_size": 1372902, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}}, "a062f408-cca8-4285-b43d-d48467b85d84": {"node_ids": ["6aefbb72-eda9-46c8-a4cd-97b0df4e83c9", "b404134d-0034-43be-8347-62aef955cc21"], "metadata": {"page_label": "446", "file_name": "2023_20-21.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2023_20-21.pdf", "file_type": "application/pdf", "file_size": 1372902, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}}, "a3d78e9e-5f47-4340-b9af-46e122ecc6da": {"node_ids": ["c35d9f8b-8107-44f9-9890-351ffaae9a53", "3e2ec590-7284-4aa5-8d60-8e2568c54622", "4cd8da47-c929-40a6-94d3-525925559073"], "metadata": {"page_label": "431", "file_name": "2023_20-21_3.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2023_20-21_3.pdf", "file_type": "application/pdf", "file_size": 363018, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}}, "6d9c5893-68df-4492-9028-62947bd4bd11": {"node_ids": ["26dacdb1-85af-4e94-b15c-e73a433254bd", "3d7ee953-777e-4349-a7b0-cb91fbea1231", "e813a722-a20c-4d7a-961a-950a227c622c"], "metadata": {"page_label": "432", "file_name": "2023_20-21_3.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2023_20-21_3.pdf", "file_type": "application/pdf", "file_size": 363018, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}}, "c9ec9ee5-d94d-443b-b077-a01837ce388e": {"node_ids": ["f55c661b-5ee4-4233-83d0-3f117bb085e5", "9a85fdf5-0bc2-4cb1-94ee-9ec0188131b2", "d3f3ed8d-a88c-418c-bb8b-8a2f33484e4e"], "metadata": {"page_label": "433", "file_name": "2023_20-21_3.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2023_20-21_3.pdf", "file_type": "application/pdf", "file_size": 363018, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}}, "65bb7f4c-96c9-4b42-aebb-4cf8a07de432": {"node_ids": ["af964440-86e3-47ef-a0d7-047cf8ad8bdc", "8f6c270f-951a-4fb4-8629-0e97f2f32d39"], "metadata": {"page_label": "434", "file_name": "2023_20-21_3.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2023_20-21_3.pdf", "file_type": "application/pdf", "file_size": 363018, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}}, "f1034205-ec22-4323-90e1-61b097f416b6": {"node_ids": ["77564a34-bdb0-45b9-a3a0-6fda411c9422", "b87997ff-635c-4748-9a25-6f629de90b7e", "314edc5c-7430-46da-a88a-7c78ebb917ec"], "metadata": {"page_label": "435", "file_name": "2023_20-21_3.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2023_20-21_3.pdf", "file_type": "application/pdf", "file_size": 363018, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}}, "e2be68db-4b11-48fd-8093-6a5fd63ffcc8": {"node_ids": ["1efb7922-cb99-4601-8920-e98196872ccd", "95bd4459-e67d-4336-9aa9-ca780fd2898b", "1958fcfa-f9e1-4748-aa54-5e35debb487e"], "metadata": {"page_label": "436", "file_name": "2023_20-21_3.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2023_20-21_3.pdf", "file_type": "application/pdf", "file_size": 363018, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}}, "6921c743-b569-4c9a-b209-0dde6cda3360": {"node_ids": ["211942f0-e7ae-4eff-a390-5de2573cff6a", "da73d243-33fb-40a4-b4f2-d9d5b5f58cbb", "44123d44-8bd9-42d6-a8b5-07061fdede13"], "metadata": {"page_label": "437", "file_name": "2023_20-21_3.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2023_20-21_3.pdf", "file_type": "application/pdf", "file_size": 363018, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}}, "450fe8d5-b6d6-4ba4-9a37-6b9d30d26896": {"node_ids": ["e15f86a5-b099-4cac-a483-cd10482f5008", "620c7c8b-f1a7-449a-a304-9acf984ecf5e", "3ecf5a22-735c-4523-a738-9b3151be3f57"], "metadata": {"page_label": "438", "file_name": "2023_20-21_3.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2023_20-21_3.pdf", "file_type": "application/pdf", "file_size": 363018, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}}, "a8560344-4639-4b3a-9a5c-08d39756a0a0": {"node_ids": ["2c2aa199-5dfd-4805-9a0c-904b5adf877e", "223ad521-10c2-4306-b342-4f41b723549d", "27f37863-7f4b-40b9-92f2-11c05bae0f20", "db23e0d0-77f2-4d09-8e4c-af0604e67fce"], "metadata": {"page_label": "439", "file_name": "2023_20-21_3.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2023_20-21_3.pdf", "file_type": "application/pdf", "file_size": 363018, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}}, "9a974675-1543-485b-8a0e-453a07de9de0": {"node_ids": ["dd58ddbb-c997-469a-8d07-741134cc24b3", "ab83a312-1db2-4733-a18f-92637dc6f2c6", "aeb221d4-a5fb-4ec2-9edc-d8c36dc7da38", "f0add988-49a7-450f-8772-912fd1c5da1f", "3b29380d-428c-45d3-b3f6-e628bb124031", "c46794f3-3704-4014-9924-7ad785e306e0"], "metadata": {"page_label": "1", "file_name": "22120_8734-d3167.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\22120_8734-d3167.pdf", "file_type": "application/pdf", "file_size": 56665, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}}, "74114646-4f81-43dc-af85-77c29c539fd8": {"node_ids": ["e896287b-6a51-4693-8807-337af9864bcf", "27bd4969-088b-4a2a-a528-32f30f377145", "4a17c2da-bbe5-46d7-a637-d0b581a4739b", "9bdb7640-da41-49dc-a104-fca19be3abd6", "cfc711af-8bde-490d-aaa1-eeadf763d8b0", "b6117957-89de-4d40-abae-824c1a35c877", "032f57a4-d7fc-4322-8ec5-1bd8301f1d34", "fe3abd9e-3764-482f-a4eb-243081d39164"], "metadata": {"page_label": "2", "file_name": "22120_8734-d3167.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\22120_8734-d3167.pdf", "file_type": "application/pdf", "file_size": 56665, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}}, "3d804f4d-a7c5-4462-8099-169f3811144e": {"node_ids": ["d620467d-3a18-4239-abab-73b16ea2c5da", "23dcfee9-7ee0-4946-b527-7ac6a71be049", "6cc7c899-be62-4b61-a961-505d20e9c5a6"], "metadata": {"page_label": "C6", "file_name": "36264_11160-ps.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\36264_11160-ps.pdf", "file_type": "application/pdf", "file_size": 267361, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}}, "dd3bc350-7901-436f-b9b6-a997a2b19634": {"node_ids": ["6e47aedc-b55f-4dc2-82d3-2141c50eda72", "a2766610-a13b-4dde-8eb1-22204e64340f", "5ea0e8bd-e1e1-4af1-aa03-58b9b956f981"], "metadata": {"page_label": "C6", "file_name": "36264_11160-ps.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\36264_11160-ps.pdf", "file_type": "application/pdf", "file_size": 267361, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}}, "cade7345-df33-4c0f-bd62-c80c8ba7746a": {"node_ids": ["9c767640-ce6a-4da5-97fa-ed1887de5c06", "c9be5112-c8c1-4b1e-97d2-04ab8633c8a6", "6bdc2d68-c56f-4610-b42d-a24bf14587ab"], "metadata": {"page_label": "C4", "file_name": "36264_11160-ps.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\36264_11160-ps.pdf", "file_type": "application/pdf", "file_size": 267361, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}}, "43b6cb1d-07e3-415a-a978-f2020428c3d3": {"node_ids": ["1e76eac9-16b4-4cbe-b998-31c0405e988f"], "metadata": {"page_label": "C5", "file_name": "36264_11160-ps.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\36264_11160-ps.pdf", "file_type": "application/pdf", "file_size": 267361, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}}, "bf8a63ae-d6ac-4202-91b2-5a96a3fa89a1": {"node_ids": ["e8174d8a-dd57-4e10-9fa3-67dc9502551d"], "metadata": {"page_label": "1", "file_name": "hc001042.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\hc001042.pdf", "file_type": "application/pdf", "file_size": 237006, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}}, "d03d9f54-81b3-4196-a99c-9db97f30d2b1": {"node_ids": ["dd6719fb-62d9-4f96-b13a-2f522602d7e3"], "metadata": {"page_label": "2", "file_name": "hc001042.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\hc001042.pdf", "file_type": "application/pdf", "file_size": 237006, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}}, "e1cc4655-10bc-4df8-be0f-7b8e5bf6e239": {"node_ids": ["d4bf636e-2707-4b54-a69b-e0da58955e8d"], "metadata": {"page_label": "3", "file_name": "hc001042.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\hc001042.pdf", "file_type": "application/pdf", "file_size": 237006, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}}, "56ec57f9-fb89-404b-90c0-2db9b4aa4340": {"node_ids": ["6c93a7c0-c50b-4004-9e6d-21651b98b684"], "metadata": {"page_label": "4", "file_name": "hc001042.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\hc001042.pdf", "file_type": "application/pdf", "file_size": 237006, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}}, "129a3d8d-314d-4348-8021-1d217135191c": {"node_ids": ["24ae36c7-1c63-4fd6-bf92-720a5854808c"], "metadata": {"page_label": "5", "file_name": "hc001042.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\hc001042.pdf", "file_type": "application/pdf", "file_size": 237006, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}}, "1b1bce34-5f15-445b-b63a-fb601060da3d": {"node_ids": ["5bcf6679-9ad8-4cba-8309-cd2fc030b30f"], "metadata": {"page_label": "6", "file_name": "hc001042.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\hc001042.pdf", "file_type": "application/pdf", "file_size": 237006, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}}, "febd1297-d15c-49b5-819a-af5360d5de5f": {"node_ids": ["afe6d71f-e804-48d7-91f8-58ab0bc5314c"], "metadata": {"page_label": "7", "file_name": "hc001042.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\hc001042.pdf", "file_type": "application/pdf", "file_size": 237006, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}}, "2af5eadf-433a-4790-b65e-cb4559ced482": {"node_ids": ["c05171bc-bdbb-4447-9b83-2d7211b14791"], "metadata": {"page_label": "8", "file_name": "hc001042.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\hc001042.pdf", "file_type": "application/pdf", "file_size": 237006, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}}, "d723e63d-7991-461c-b9bd-2366ccff8ec9": {"node_ids": ["ccd13d28-b94b-434f-8b90-92cdf16df7cd", "0ffe0b6b-76d9-430c-910e-3c848a2e6057"], "metadata": {"page_label": "9", "file_name": "hc001042.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\hc001042.pdf", "file_type": "application/pdf", "file_size": 237006, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}}, "c9c26e69-9411-4fbf-9e2d-563c1e4eaae2": {"node_ids": ["4d2b869c-48ec-4b59-99c9-f973134c6cde"], "metadata": {"page_label": "10", "file_name": "hc001042.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\hc001042.pdf", "file_type": "application/pdf", "file_size": 237006, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}}, "61a9d5e2-dd35-47f4-928b-b92e930e5b0b": {"node_ids": ["865f616b-588a-43ff-aa45-b471846b0025"], "metadata": {"page_label": "11", "file_name": "hc001042.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\hc001042.pdf", "file_type": "application/pdf", "file_size": 237006, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}}, "f2f99320-8681-427e-8ad9-6f9ffec4f753": {"node_ids": ["9f1f1659-c08a-4ada-bb46-326301ada008"], "metadata": {"page_label": "12", "file_name": "hc001042.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\hc001042.pdf", "file_type": "application/pdf", "file_size": 237006, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}}, "499f733c-5204-45b4-94d0-18bafa91b4f1": {"node_ids": ["09187cd7-83b8-4393-ba2a-4a4bcda071b3"], "metadata": {"page_label": "13", "file_name": "hc001042.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\hc001042.pdf", "file_type": "application/pdf", "file_size": 237006, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}}, "497f0518-c964-43d5-aa9f-1192b65512cf": {"node_ids": ["d4ff86bc-7554-40a3-b2b6-8c29310f294e"], "metadata": {"page_label": "14", "file_name": "hc001042.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\hc001042.pdf", "file_type": "application/pdf", "file_size": 237006, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}}, "b2655f5a-84c8-4f92-9300-c6d606b26525": {"node_ids": ["749bdb7c-bb6f-429f-9d16-85a2e8cb2888"], "metadata": {"page_label": "15", "file_name": "hc001042.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\hc001042.pdf", "file_type": "application/pdf", "file_size": 237006, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}}, "0092d6d0-4c6b-47ff-98f7-07d31290fccd": {"node_ids": ["f178ef04-071e-4ca8-a92e-c786a73d2fda"], "metadata": {"page_label": "16", "file_name": "hc001042.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\hc001042.pdf", "file_type": "application/pdf", "file_size": 237006, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}}, "3dc9ec91-2f71-4e61-b257-16970c36950e": {"node_ids": ["c9d94768-9bc1-438d-b948-adde876ad41a"], "metadata": {"page_label": "17", "file_name": "hc001042.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\hc001042.pdf", "file_type": "application/pdf", "file_size": 237006, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}}, "dbfcaf4d-6935-46c0-9bd3-609b4e5b0b11": {"node_ids": ["d63a747a-3cfb-47bd-8e77-1296fc3a493b"], "metadata": {"page_label": "18", "file_name": "hc001042.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\hc001042.pdf", "file_type": "application/pdf", "file_size": 237006, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}}, "c977b057-87fc-4bcc-a9cb-efd109f7f647": {"node_ids": ["9ee1407d-ae29-4f01-97e5-d02c7339bfe1"], "metadata": {"page_label": "19", "file_name": "hc001042.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\hc001042.pdf", "file_type": "application/pdf", "file_size": 237006, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}}, "294d557d-9b83-4742-bd60-5d62568ededc": {"node_ids": ["d2d33d92-d728-44df-acba-a36bcefc2931"], "metadata": {"page_label": "20", "file_name": "hc001042.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\hc001042.pdf", "file_type": "application/pdf", "file_size": 237006, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}}, "e1dafaea-68ff-4ec8-be24-69ce949d0dd9": {"node_ids": ["5815acb0-de0e-4759-8014-6e1c3e09702b"], "metadata": {"page_label": "21", "file_name": "hc001042.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\hc001042.pdf", "file_type": "application/pdf", "file_size": 237006, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}}, "0d624cea-4278-4749-a2ce-8e50aef53acb": {"node_ids": ["b9b230c6-04d1-4f46-8604-ae89941faa44"], "metadata": {"page_label": "22", "file_name": "hc001042.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\hc001042.pdf", "file_type": "application/pdf", "file_size": 237006, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}}, "75c5e054-2896-4d08-a3bb-91740e395995": {"node_ids": ["8fcc5806-c405-4dac-850f-98436af58234"], "metadata": {"page_label": "23", "file_name": "hc001042.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\hc001042.pdf", "file_type": "application/pdf", "file_size": 237006, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}}, "b6e6393c-e92e-450d-8c9b-fc352baf87a7": {"node_ids": ["f17a7788-cd5e-4b7d-a90f-aaf4d175d64a", "b96653dd-cfc1-449c-add4-142cfdb13818"], "metadata": {"page_label": "24", "file_name": "hc001042.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\hc001042.pdf", "file_type": "application/pdf", "file_size": 237006, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}}, "53e6292d-1e83-42e4-b6dc-bceabdf1d4c0": {"node_ids": ["92be0ea5-e241-41dd-8789-2bca3d44c80f", "e9e869db-767a-4f3b-a95e-9d87c8bc2c70"], "metadata": {"page_label": "25", "file_name": "hc001042.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\hc001042.pdf", "file_type": "application/pdf", "file_size": 237006, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}}, "7780c047-eb3e-473e-8acf-3b944fd6f31f": {"node_ids": ["a3bf1a97-e28a-4077-b352-8a332755a038"], "metadata": {"page_label": "26", "file_name": "hc001042.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\hc001042.pdf", "file_type": "application/pdf", "file_size": 237006, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}}, "6f62f37e-f4a3-43c0-9080-77f8346a2020": {"node_ids": ["038be7ad-d4cb-4ec5-98fb-c9a562b7943b"], "metadata": {"page_label": "27", "file_name": "hc001042.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\hc001042.pdf", "file_type": "application/pdf", "file_size": 237006, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}}, "308d2295-23ee-409e-a65c-3f0dc22224a9": {"node_ids": ["f9d19691-7f46-4dfc-87fa-d2940fa0cb29"], "metadata": {"page_label": "28", "file_name": "hc001042.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\hc001042.pdf", "file_type": "application/pdf", "file_size": 237006, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}}, "6a568460-1181-4d32-8607-d1b2d35c8532": {"node_ids": ["7ccc946a-9977-49a9-a3b0-d723fc008a1b"], "metadata": {"page_label": "29", "file_name": "hc001042.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\hc001042.pdf", "file_type": "application/pdf", "file_size": 237006, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}}, "214bd709-c9ad-4e86-a0f4-9e49ca0f0c81": {"node_ids": ["878426e2-718f-45cb-8056-97ba0674b6cb", "45ba7052-b42c-48e0-b2e5-20294a6454a4"], "metadata": {"page_label": "30", "file_name": "hc001042.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\hc001042.pdf", "file_type": "application/pdf", "file_size": 237006, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}}, "d8336305-9a0c-4ec9-ac8a-7228c69ebaae": {"node_ids": ["81e9dfd4-d457-472b-9040-a006650d29f4"], "metadata": {"page_label": "31", "file_name": "hc001042.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\hc001042.pdf", "file_type": "application/pdf", "file_size": 237006, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}}, "22d45598-3642-4ba5-8f1e-9f9a1b6763ea": {"node_ids": ["3a3433b8-a272-404e-b1cb-136fce12e165"], "metadata": {"page_label": "32", "file_name": "hc001042.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\hc001042.pdf", "file_type": "application/pdf", "file_size": 237006, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}}, "2c0ef8eb-a886-4e70-997a-1fa14c346775": {"node_ids": ["097671fc-480e-43b8-ac0d-a0972ddab32e", "5ff7012f-3855-4558-8bae-280e48d9a4a7"], "metadata": {"page_label": "33", "file_name": "hc001042.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\hc001042.pdf", "file_type": "application/pdf", "file_size": 237006, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}}, "77acc0c9-c14f-4835-a16b-09aacfab1515": {"node_ids": ["452ae8c7-88d5-40f0-9151-fdf48ac0e188"], "metadata": {"page_label": "34", "file_name": "hc001042.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\hc001042.pdf", "file_type": "application/pdf", "file_size": 237006, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}}, "a1562efc-fd6d-4a02-b226-8c2de23051dc": {"node_ids": ["2a0b7b5d-e020-4a64-812c-f4bebd86f3e8"], "metadata": {"page_label": "35", "file_name": "hc001042.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\hc001042.pdf", "file_type": "application/pdf", "file_size": 237006, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}}, "a3da02d9-0ef5-4d12-86cd-20c3bf49619e": {"node_ids": ["5dce23b8-8817-4af2-9861-ee51f8f4b899", "cd715fde-57b0-4c41-91b2-0741d3fe44a7"], "metadata": {"page_label": "36", "file_name": "hc001042.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\hc001042.pdf", "file_type": "application/pdf", "file_size": 237006, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}}, "aa8cfa7b-f1d1-45d1-8132-f4dc9ef32c7f": {"node_ids": ["87d4ce40-009c-469a-a94d-1496e6af08df", "a5eb3829-6d3f-4fa5-bef9-23e5be64d676"], "metadata": {"page_label": "37", "file_name": "hc001042.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\hc001042.pdf", "file_type": "application/pdf", "file_size": 237006, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}}, "ae16b974-9580-4b9b-85c6-f0b1e0ec5863": {"node_ids": ["66f45117-0039-466c-86a2-f934ae47ed11", "2ba365a7-d3b6-4621-bb18-338c94d17ab7"], "metadata": {"page_label": "38", "file_name": "hc001042.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\hc001042.pdf", "file_type": "application/pdf", "file_size": 237006, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}}, "7a04d29d-348f-4dfd-983b-95481be8ed5d": {"node_ids": ["5130d435-96b6-4f24-a85c-e0d5adb028fd"], "metadata": {"page_label": "39", "file_name": "hc001042.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\hc001042.pdf", "file_type": "application/pdf", "file_size": 237006, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}}, "909ef4bc-c346-4d4d-a14c-6437c7a77f8a": {"node_ids": ["3bb17b19-bc9d-4e39-b560-beb6e1065d99", "aeddeb48-bda8-4ee8-bb65-08937c846c82"], "metadata": {"page_label": "40", "file_name": "hc001042.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\hc001042.pdf", "file_type": "application/pdf", "file_size": 237006, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}}, "293d3dd2-4207-4918-8049-d8c74b271234": {"node_ids": ["34b319d5-7af4-4f6f-bd03-47726fe1e2f7"], "metadata": {"page_label": "41", "file_name": "hc001042.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\hc001042.pdf", "file_type": "application/pdf", "file_size": 237006, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}}, "564a9e18-4c73-4729-98a9-a9d3ab4d2ec7": {"node_ids": ["3f190a9c-0201-42eb-9232-22b74a9d9cf8"], "metadata": {"page_label": "42", "file_name": "hc001042.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\hc001042.pdf", "file_type": "application/pdf", "file_size": 237006, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}}, "2a6f412d-ce95-4338-b1bd-ba6ff0e7620a": {"node_ids": ["504fb1ce-5312-4641-92d8-e59a058f3111"], "metadata": {"page_label": "43", "file_name": "hc001042.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\hc001042.pdf", "file_type": "application/pdf", "file_size": 237006, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}}, "35d4df38-3fc8-4a8e-9b3f-1e3765dc1317": {"node_ids": ["7fac3051-3be8-4316-9f07-4e4ffe6dafe9"], "metadata": {"page_label": "44", "file_name": "hc001042.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\hc001042.pdf", "file_type": "application/pdf", "file_size": 237006, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}}, "ec0a9fe5-cbe6-48fe-a2b2-4e4ad8883689": {"node_ids": ["d47d9908-2695-4ae8-93f5-a8369c5e9acb"], "metadata": {"page_label": "45", "file_name": "hc001042.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\hc001042.pdf", "file_type": "application/pdf", "file_size": 237006, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}}, "57d9a66c-5946-4fc4-90fe-24cb0a081bc7": {"node_ids": ["bb014b6c-51df-4c29-8da9-42ac3cda2278"], "metadata": {"page_label": "46", "file_name": "hc001042.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\hc001042.pdf", "file_type": "application/pdf", "file_size": 237006, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}}, "a2c734b0-5860-4c19-9b5a-da9049c3bc6a": {"node_ids": ["20bd7d70-314c-435b-a80c-ccafedbb43d2", "b9d9df16-c7ce-4023-80b4-06eba53c26c3"], "metadata": {"page_label": "47", "file_name": "hc001042.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\hc001042.pdf", "file_type": "application/pdf", "file_size": 237006, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}}, "8e77d825-9af7-40a6-b5a3-fe52dd525979": {"node_ids": ["3152c8df-8e0d-4962-8142-d1e64a1b08de"], "metadata": {"page_label": "48", "file_name": "hc001042.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\hc001042.pdf", "file_type": "application/pdf", "file_size": 237006, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}}, "ac488468-5dde-4301-a83e-02b77c245e03": {"node_ids": ["3aa240f0-6b7c-49e5-a0f7-89d2a8249748"], "metadata": {"page_label": "49", "file_name": "hc001042.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\hc001042.pdf", "file_type": "application/pdf", "file_size": 237006, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}}, "a03b5f7c-31a3-4a1d-b1b7-17ff04bf6ba4": {"node_ids": ["3e49467e-d2f7-4c29-bf53-ceb56f57b491", "b72acfa7-5c7e-40ac-bbb4-ba4bbca45749"], "metadata": {"page_label": "50", "file_name": "hc001042.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\hc001042.pdf", "file_type": "application/pdf", "file_size": 237006, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}}, "40611d6d-b3cb-4872-84be-26d52f2651f1": {"node_ids": ["c2796b37-ed8e-41cb-808d-d0ce9a2bbff9", "919bd57f-597f-4e3f-b610-8d7b37ee0c01"], "metadata": {"page_label": "51", "file_name": "hc001042.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\hc001042.pdf", "file_type": "application/pdf", "file_size": 237006, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}}, "7fba9d68-cfe4-4482-9332-5be804a45b0e": {"node_ids": ["cfa1d914-4ed7-4fb1-84f2-a15c5e03a234"], "metadata": {"page_label": "52", "file_name": "hc001042.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\hc001042.pdf", "file_type": "application/pdf", "file_size": 237006, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}}, "eac0587c-90c9-4dec-8912-292984126700": {"node_ids": ["9d2d5745-2280-4966-911c-b1ae144348f5", "cd397f0a-8f75-402b-8373-87472ec43cfb"], "metadata": {"page_label": "53", "file_name": "hc001042.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\hc001042.pdf", "file_type": "application/pdf", "file_size": 237006, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}}, "9bc7d0e6-1094-45e2-8915-b7c788b51d34": {"node_ids": ["31ff09bb-a89b-41c5-9cdd-350d563ac944"], "metadata": {"page_label": "54", "file_name": "hc001042.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\hc001042.pdf", "file_type": "application/pdf", "file_size": 237006, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}}, "b14ab2bf-687b-4049-9439-793d9236eb40": {"node_ids": ["203f969f-dbf4-4e47-b1a1-2ffc9b6caa37"], "metadata": {"page_label": "55", "file_name": "hc001042.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\hc001042.pdf", "file_type": "application/pdf", "file_size": 237006, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}}, "e81b6ab0-b708-4e5a-89a1-3a9951b1c48b": {"node_ids": ["b56d0dae-7f5a-46fb-becd-b755b15efb4a"], "metadata": {"page_label": "56", "file_name": "hc001042.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\hc001042.pdf", "file_type": "application/pdf", "file_size": 237006, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}}, "791c605f-8fa4-4e78-a496-e81363747043": {"node_ids": ["5ef4e750-0370-45d5-ab1e-e8684528247d"], "metadata": {"page_label": "57", "file_name": "hc001042.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\hc001042.pdf", "file_type": "application/pdf", "file_size": 237006, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}}, "4f1c118c-5f29-4f8c-828d-3897e47c7395": {"node_ids": ["0037445d-49fe-4f0f-9a66-862f6e311a5e", "99a1b0e3-b92e-407e-8904-50283ed8b19b"], "metadata": {"page_label": "58", "file_name": "hc001042.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\hc001042.pdf", "file_type": "application/pdf", "file_size": 237006, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}}, "4381a3ec-5afd-40c9-80fd-aa0c7006832d": {"node_ids": ["93a4a4fd-2f66-4a41-88da-ce881277d73c"], "metadata": {"page_label": "59", "file_name": "hc001042.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\hc001042.pdf", "file_type": "application/pdf", "file_size": 237006, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}}, "e060e4b0-03ea-41b6-85e3-74028079cab7": {"node_ids": ["8e12c1ba-5d24-4324-9a88-5dfadc2d6d83"], "metadata": {"page_label": "60", "file_name": "hc001042.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\hc001042.pdf", "file_type": "application/pdf", "file_size": 237006, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}}, "8de63600-5448-4594-8b4c-4730801289f5": {"node_ids": ["10de7292-4330-4713-90af-b3a1ae81d9d1", "ef6cbf71-32a9-405b-b5ac-4941a19fb9ce"], "metadata": {"page_label": "61", "file_name": "hc001042.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\hc001042.pdf", "file_type": "application/pdf", "file_size": 237006, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}}, "bf53f581-7fd8-443e-a1b0-f6f068cf17b0": {"node_ids": ["5c268854-e24b-48b5-b1d4-c7a850cc7ce7"], "metadata": {"page_label": "62", "file_name": "hc001042.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\hc001042.pdf", "file_type": "application/pdf", "file_size": 237006, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}}, "2271885f-5b4e-4bab-8576-17d8b95d4b5e": {"node_ids": ["4b6a685f-af6b-4878-93ee-36e1962b5425", "4d40c8e2-73e5-4458-9f54-50a107f5f150"], "metadata": {"page_label": "63", "file_name": "hc001042.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\hc001042.pdf", "file_type": "application/pdf", "file_size": 237006, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}}, "97e6ddf2-c869-4e4e-a168-2c79fb3c066c": {"node_ids": ["91fb7811-ff79-4b96-97b6-6b8e39dc21b8"], "metadata": {"page_label": "64", "file_name": "hc001042.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\hc001042.pdf", "file_type": "application/pdf", "file_size": 237006, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}}, "435d2bed-395c-4005-bc82-c32d54ae76dc": {"node_ids": ["5a37ad69-fbe3-4e97-8f47-30ac5f856e6f", "273dcb78-e245-409e-a41e-aff7a65f45bb"], "metadata": {"page_label": "65", "file_name": "hc001042.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\hc001042.pdf", "file_type": "application/pdf", "file_size": 237006, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}}, "5b1afa22-1cf9-4b13-b9ac-88dfad11b609": {"node_ids": ["8f53aac9-71e9-4707-a1df-664d1dfbfa9b"], "metadata": {"page_label": "66", "file_name": "hc001042.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\hc001042.pdf", "file_type": "application/pdf", "file_size": 237006, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}}, "6eacb740-4094-4656-9bce-8835a525588c": {"node_ids": ["653a7e13-7de4-4c25-b0f2-6708c7a53239"], "metadata": {"page_label": "67", "file_name": "hc001042.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\hc001042.pdf", "file_type": "application/pdf", "file_size": 237006, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}}, "c206e343-4de3-4480-89fe-628fdde1fc33": {"node_ids": ["4bb35870-133f-4ffb-a9bf-4bc74091b999"], "metadata": {"page_label": "68", "file_name": "hc001042.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\hc001042.pdf", "file_type": "application/pdf", "file_size": 237006, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}}, "21503d1b-22e0-4184-97d0-dc5c03cc1614": {"node_ids": ["6334f50c-ac73-460c-bfa0-6b8c4495073b"], "metadata": {"page_label": "69", "file_name": "hc001042.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\hc001042.pdf", "file_type": "application/pdf", "file_size": 237006, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}}, "030e1b01-2c6a-49ce-9127-f8f903a57931": {"node_ids": ["8a364295-96ee-4cdb-a0b0-d762e08aab0e"], "metadata": {"page_label": "70", "file_name": "hc001042.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\hc001042.pdf", "file_type": "application/pdf", "file_size": 237006, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}}, "c05d366b-a447-4e4e-9c3b-6ad3370ec275": {"node_ids": ["09f01a81-c12f-4e1d-854b-384baa3d5565"], "metadata": {"page_label": "71", "file_name": "hc001042.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\hc001042.pdf", "file_type": "application/pdf", "file_size": 237006, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}}, "9ed73236-ee95-47e7-ba47-0ff771745167": {"node_ids": ["d55cb1a7-b968-4ecc-a597-736a74dbf6a3"], "metadata": {"page_label": "72", "file_name": "hc001042.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\hc001042.pdf", "file_type": "application/pdf", "file_size": 237006, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}}, "f57efef7-ee22-481b-a982-a19cda834a56": {"node_ids": ["b68043d2-d469-4410-91fc-0a8953851951"], "metadata": {"page_label": "73", "file_name": "hc001042.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\hc001042.pdf", "file_type": "application/pdf", "file_size": 237006, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}}, "a9ee7d11-645f-40a4-b551-3e47a094f88d": {"node_ids": ["6d2b154e-d1d7-4550-8d8f-6dca92199f25"], "metadata": {"page_label": "74", "file_name": "hc001042.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\hc001042.pdf", "file_type": "application/pdf", "file_size": 237006, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}}, "8e3bbbbd-c484-4701-b55f-f3ff5bf5d270": {"node_ids": ["8d176405-3148-4b81-bbde-e4396e0f16a1", "c74f8c0f-d120-4807-8c67-d3ae80e2acc2"], "metadata": {"page_label": "75", "file_name": "hc001042.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\hc001042.pdf", "file_type": "application/pdf", "file_size": 237006, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}}, "246da383-007c-40f5-9e07-52978ed27ff3": {"node_ids": ["dc38a370-61e6-4e20-ac16-66830f8e9c5e"], "metadata": {"page_label": "76", "file_name": "hc001042.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\hc001042.pdf", "file_type": "application/pdf", "file_size": 237006, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}}, "f9167ad1-3346-48a9-93e8-edfbce751368": {"node_ids": ["037f81e7-e9fe-4c3d-8e87-65b97dc7ed22"], "metadata": {"page_label": "77", "file_name": "hc001042.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\hc001042.pdf", "file_type": "application/pdf", "file_size": 237006, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}}, "8e7b362b-ba79-4efb-96cd-4cb7c846478c": {"node_ids": ["83ca01e2-b530-4f9c-8921-a59a6de9103b"], "metadata": {"page_label": "78", "file_name": "hc001042.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\hc001042.pdf", "file_type": "application/pdf", "file_size": 237006, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}}, "5bc95d67-0d72-4412-bf5a-5172e84319b8": {"node_ids": ["fc899c00-8cf5-45f5-8753-34f15a6cce81"], "metadata": {"page_label": "79", "file_name": "hc001042.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\hc001042.pdf", "file_type": "application/pdf", "file_size": 237006, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}}, "f4679746-da20-41d2-a25c-795291ab8b8a": {"node_ids": ["26eb9f30-a274-4936-8f07-37724ad82bdf"], "metadata": {"page_label": "80", "file_name": "hc001042.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\hc001042.pdf", "file_type": "application/pdf", "file_size": 237006, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}}, "ae226c3c-c038-4624-9284-5fbbfe47bbea": {"node_ids": ["0b885daa-df73-40f3-8196-24491562ff2e"], "metadata": {"page_label": "81", "file_name": "hc001042.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\hc001042.pdf", "file_type": "application/pdf", "file_size": 237006, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}}, "542c8b40-9cf3-4a9c-aad5-27012a9996a3": {"node_ids": ["adda74a5-932e-4f9e-bde8-c4566f768dc1"], "metadata": {"page_label": "82", "file_name": "hc001042.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\hc001042.pdf", "file_type": "application/pdf", "file_size": 237006, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}}, "91bddacf-cd2f-4c81-803d-a86c7ee80760": {"node_ids": ["1a053b52-2d76-4203-b3b6-48588f5991f9"], "metadata": {"page_label": "83", "file_name": "hc001042.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\hc001042.pdf", "file_type": "application/pdf", "file_size": 237006, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}}, "1496756e-98b3-4bb1-a501-495032819b45": {"node_ids": ["30ecc3ea-5bdd-48c5-90cf-5e4c600b8391"], "metadata": {"page_label": "84", "file_name": "hc001042.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\hc001042.pdf", "file_type": "application/pdf", "file_size": 237006, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}}, "8cf0f982-ecbc-475e-8fdf-5c64f7cecc65": {"node_ids": ["8c2bf302-22dc-428e-af8b-0ab4175fbc12"], "metadata": {"page_label": "85", "file_name": "hc001042.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\hc001042.pdf", "file_type": "application/pdf", "file_size": 237006, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}}, "75d8f244-a93d-4b9b-9512-fb21f520f46e": {"node_ids": ["9ed902aa-d12c-4adb-8191-3ac599ca4888"], "metadata": {"page_label": "86", "file_name": "hc001042.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\hc001042.pdf", "file_type": "application/pdf", "file_size": 237006, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}}, "bc352a85-5a34-4d4a-97c7-67b76e24a6d4": {"node_ids": ["3b37923b-549f-432d-b007-bd493c2065e6"], "metadata": {"page_label": "87", "file_name": "hc001042.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\hc001042.pdf", "file_type": "application/pdf", "file_size": 237006, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}}, "4072f42b-68f6-4a52-8031-6f80911f6710": {"node_ids": ["97e36ee8-33f4-46ee-a23d-99b302bcb108"], "metadata": {"page_label": "88", "file_name": "hc001042.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\hc001042.pdf", "file_type": "application/pdf", "file_size": 237006, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}}, "49dd2f6c-e887-42e8-8e0d-2e128d60528e": {"node_ids": ["9d403057-dfd0-4fc2-a55a-3d4edf79b7dc"], "metadata": {"page_label": "89", "file_name": "hc001042.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\hc001042.pdf", "file_type": "application/pdf", "file_size": 237006, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}}, "11e84fae-1e34-4e1c-9a58-86837f43a59d": {"node_ids": ["36103e98-c2d0-4388-8635-dfd41e18721b"], "metadata": {"page_label": "90", "file_name": "hc001042.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\hc001042.pdf", "file_type": "application/pdf", "file_size": 237006, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}}, "7931f1c4-128f-4709-8056-4bf960d42db7": {"node_ids": ["00765553-b1dc-41eb-a676-431fee6285b6"], "metadata": {"page_label": "91", "file_name": "hc001042.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\hc001042.pdf", "file_type": "application/pdf", "file_size": 237006, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}}, "cea44dd8-5338-4c4f-abf9-0e0d213eb9a6": {"node_ids": ["59784df4-6d43-4d65-8593-c7a2408710cd"], "metadata": {"page_label": "92", "file_name": "hc001042.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\hc001042.pdf", "file_type": "application/pdf", "file_size": 237006, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}}, "b43fddb6-756b-489a-8670-ace506a7abbb": {"node_ids": ["1a96dc00-c419-40a4-a84a-7e0296faa12d", "9c9aaa1d-b8e0-4114-ba64-0b9b4bcc2d0c"], "metadata": {"page_label": "1", "file_name": "orsoi_chiffres_diabete_reunion_2020.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\orsoi_chiffres_diabete_reunion_2020.pdf", "file_type": "application/pdf", "file_size": 1879778, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}}, "73db6c07-77c0-4cab-a4ba-0bd3750cb631": {"node_ids": ["9b5e1659-3d32-434f-ba73-b3b92206288c"], "metadata": {"page_label": "2", "file_name": "orsoi_chiffres_diabete_reunion_2020.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\orsoi_chiffres_diabete_reunion_2020.pdf", "file_type": "application/pdf", "file_size": 1879778, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}}, "9877bf10-b115-48fe-8c2e-66c629be8f75": {"node_ids": ["8f175936-b754-4705-be8e-2658a24f8a53"], "metadata": {"page_label": "3", "file_name": "orsoi_chiffres_diabete_reunion_2020.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\orsoi_chiffres_diabete_reunion_2020.pdf", "file_type": "application/pdf", "file_size": 1879778, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}}, "4f3c95a1-4cfb-4d75-a2d9-fe8c5a33863d": {"node_ids": ["53daa564-9ef3-4b74-b93a-9703503803d9"], "metadata": {"page_label": "4", "file_name": "orsoi_chiffres_diabete_reunion_2020.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\orsoi_chiffres_diabete_reunion_2020.pdf", "file_type": "application/pdf", "file_size": 1879778, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}}, "2b56d50e-f6b5-474e-abfd-b06218e34944": {"node_ids": ["38855a54-ddd0-4b91-a2ae-1a172f92a19f"], "metadata": {"page_label": "5", "file_name": "orsoi_chiffres_diabete_reunion_2020.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\orsoi_chiffres_diabete_reunion_2020.pdf", "file_type": "application/pdf", "file_size": 1879778, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}}, "e93cbc83-a580-4625-87e6-17f9db8913be": {"node_ids": ["56db9ce1-2859-4e3a-914d-1f5d40fc3d69"], "metadata": {"page_label": "6", "file_name": "orsoi_chiffres_diabete_reunion_2020.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\orsoi_chiffres_diabete_reunion_2020.pdf", "file_type": "application/pdf", "file_size": 1879778, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}}, "ad56a9c0-aa40-4727-bf9e-6b8ca39bdf10": {"node_ids": ["bdac0e30-3193-41bb-a0f4-2368c015a1e7"], "metadata": {"page_label": "7", "file_name": "orsoi_chiffres_diabete_reunion_2020.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\orsoi_chiffres_diabete_reunion_2020.pdf", "file_type": "application/pdf", "file_size": 1879778, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}}, "1696972d-c8a4-41ab-b5ef-0228bb2b3856": {"node_ids": ["55a73f66-6d2a-4a61-b5e2-6a24266d1fd5", "ee95ff2b-bbaa-4b34-985e-30e5ae959727"], "metadata": {"page_label": "8", "file_name": "orsoi_chiffres_diabete_reunion_2020.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\orsoi_chiffres_diabete_reunion_2020.pdf", "file_type": "application/pdf", "file_size": 1879778, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}}, "e438cf8e-2226-4f9a-9a0d-22a5a48dae2b": {"node_ids": ["33953426-f367-47d2-8cb9-63672f453ef8", "e1f0804f-a666-4753-8b26-578f03431413"], "metadata": {"page_label": "9", "file_name": "orsoi_chiffres_diabete_reunion_2020.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\orsoi_chiffres_diabete_reunion_2020.pdf", "file_type": "application/pdf", "file_size": 1879778, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}}, "c5d6ca34-cfea-462a-bb1c-af5c81b2c3be": {"node_ids": ["4bfdae37-632b-4259-b60e-c11eaa9069fe", "0a55a3b5-ff4c-4c4b-a71e-1be8a42c3272"], "metadata": {"page_label": "10", "file_name": "orsoi_chiffres_diabete_reunion_2020.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\orsoi_chiffres_diabete_reunion_2020.pdf", "file_type": "application/pdf", "file_size": 1879778, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}}, "24425805-887b-40f9-91a9-4bda703eb256": {"node_ids": ["a0d73bdf-9673-439e-acea-d96c7a1e2315"], "metadata": {"page_label": "11", "file_name": "orsoi_chiffres_diabete_reunion_2020.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\orsoi_chiffres_diabete_reunion_2020.pdf", "file_type": "application/pdf", "file_size": 1879778, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}}, "c2728a74-50f1-4ac3-b094-aea4f31588e7": {"node_ids": ["6cf2fe5f-a695-4ea5-afdc-3364fa5a84d9", "8eaecb73-bd7a-416d-8f0a-b300a8100c9a", "5c6d26d8-9617-47c1-9ab0-97564a373aab"], "metadata": {"page_label": "12", "file_name": "orsoi_chiffres_diabete_reunion_2020.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\orsoi_chiffres_diabete_reunion_2020.pdf", "file_type": "application/pdf", "file_size": 1879778, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}}, "31ebf525-54dd-4950-ab06-ae76adec9500": {"node_ids": ["babfc64b-7c9b-4062-b1a1-83ea22e90024", "499488bc-9fd3-4abd-82f5-128ccff965ad", "e9e86204-cc50-4988-b71d-0ed491a4b017"], "metadata": {"page_label": "13", "file_name": "orsoi_chiffres_diabete_reunion_2020.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\orsoi_chiffres_diabete_reunion_2020.pdf", "file_type": "application/pdf", "file_size": 1879778, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}}, "4d118d30-4238-4f1d-a4a8-31eba1249335": {"node_ids": ["0caaf6dc-075e-4d7e-b147-10b5ddf4d954", "1261f951-0cf2-470e-80c3-87ad7941476b"], "metadata": {"page_label": "14", "file_name": "orsoi_chiffres_diabete_reunion_2020.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\orsoi_chiffres_diabete_reunion_2020.pdf", "file_type": "application/pdf", "file_size": 1879778, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}}, "50dcb2bb-c9de-4bcc-bc44-2fa401cc6212": {"node_ids": ["7c35a209-1c32-4fe7-951c-7550a8901e49"], "metadata": {"page_label": "1", "file_name": "strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_type": "application/pdf", "file_size": 920218, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}}, "260a4db7-fd27-4359-a785-340f37d1cbdc": {"node_ids": ["67292fdf-6ca8-440f-b9a8-4127f785a0eb", "497e538c-b613-4764-95e2-405fb062ffa4"], "metadata": {"page_label": "2", "file_name": "strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_type": "application/pdf", "file_size": 920218, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}}, "f09ace58-9832-49e1-9617-c686dee41acd": {"node_ids": ["f8d520b5-29b0-46b4-bdb9-2d12711e2ed2", "71b75331-506d-46d1-a926-b482fdc132c6"], "metadata": {"page_label": "3", "file_name": "strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_type": "application/pdf", "file_size": 920218, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}}, "f8412b97-801c-4078-b3f0-11a9da9c93b2": {"node_ids": ["9b45ad80-b5bf-4146-a0e8-19fb9b268420"], "metadata": {"page_label": "4", "file_name": "strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_type": "application/pdf", "file_size": 920218, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}}, "5bd94dbb-390f-4db0-b3d3-61c283a2eaff": {"node_ids": ["b8ff4e53-098a-4183-8ed7-71f5616bf1b4", "ffac44c5-04d9-4f0a-ad74-cd6b77a35986"], "metadata": {"page_label": "5", "file_name": "strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_type": "application/pdf", "file_size": 920218, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}}, "3d905851-4130-45cd-8546-ca1a9beab4e7": {"node_ids": ["a2ad1d21-ce00-4854-b57f-32ecdb27bcbb", "505601cb-2823-4c03-a373-1d2940df9516"], "metadata": {"page_label": "6", "file_name": "strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_type": "application/pdf", "file_size": 920218, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}}, "a46bb72b-542d-4b72-82af-dafa633e36f5": {"node_ids": ["9c9d9cba-10a8-452c-b84d-e9412c2c5e28", "dabd2903-dde0-4af0-8b29-92e0c3ff5312"], "metadata": {"page_label": "7", "file_name": "strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_type": "application/pdf", "file_size": 920218, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}}, "18bbd4d1-f1aa-4c0b-8c79-d081b384a8c9": {"node_ids": ["27f605d3-0b8a-4100-8b97-3faaa2ef5253", "0b495064-fcc0-4036-b1d0-b3e5997d98f6"], "metadata": {"page_label": "8", "file_name": "strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_type": "application/pdf", "file_size": 920218, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}}, "fcb5e6a0-13e2-41b5-a6fa-0b6e2ddecd6f": {"node_ids": ["27916d68-7597-44da-8636-b7db6d1e5ce8", "ee3ef5ff-43b0-4107-93f8-0ce34901ac0d"], "metadata": {"page_label": "9", "file_name": "strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_type": "application/pdf", "file_size": 920218, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}}, "8d2260b4-6745-4abf-9f33-31eaf7e2fd18": {"node_ids": ["d9dff639-cf7a-4060-96a8-33d19832b6bb"], "metadata": {"page_label": "10", "file_name": "strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_type": "application/pdf", "file_size": 920218, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}}, "6c024988-e89a-4a16-bbeb-ea705895d90d": {"node_ids": ["18f22dff-e07d-434f-8257-a996a95895e3", "4b39664a-a75a-4896-be3e-cfb7830a76a5"], "metadata": {"page_label": "11", "file_name": "strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_type": "application/pdf", "file_size": 920218, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}}, "0079d93c-c190-4fdf-b157-3933b9b3de1b": {"node_ids": ["2d269d54-4104-4d9c-8173-76dab311c46a", "4809429d-b3f0-4ba9-b140-6fe0593159f4"], "metadata": {"page_label": "12", "file_name": "strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_type": "application/pdf", "file_size": 920218, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}}, "88dbf91d-f674-4fc7-b569-b4001345ff8d": {"node_ids": ["3a384c12-b903-4486-89dc-05398cd609f0", "0fe670df-8ad8-4895-ba15-e18be1a6e1e0"], "metadata": {"page_label": "13", "file_name": "strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_type": "application/pdf", "file_size": 920218, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}}, "eab224ef-ab6e-405c-b6f7-7166e27f8fca": {"node_ids": ["5fa136b4-5338-43b1-96e3-4960f9901a58", "2f5e53ad-84d4-40b3-864f-d727102cf6d8"], "metadata": {"page_label": "14", "file_name": "strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_type": "application/pdf", "file_size": 920218, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}}, "df56b0b3-c088-466d-9c74-49053c197dc3": {"node_ids": ["81369ae9-b417-4f36-ab58-9e617edeff2c", "e65a58d6-7d4f-4b8b-88a7-2da8c7122951"], "metadata": {"page_label": "15", "file_name": "strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_type": "application/pdf", "file_size": 920218, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}}, "b1772033-2f7e-40f7-afac-d11b453ab5eb": {"node_ids": ["766f9af4-4730-4bfb-9a05-9a461385a495"], "metadata": {"page_label": "16", "file_name": "strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_type": "application/pdf", "file_size": 920218, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}}, "79fcf648-6310-445a-994a-055634fdde6e": {"node_ids": ["3795d9ab-2754-4bae-bafb-126a1b08d4a8", "c2442074-ff90-4ac6-8a42-91c0218849aa"], "metadata": {"page_label": "17", "file_name": "strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_type": "application/pdf", "file_size": 920218, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}}, "79b95236-feba-4772-8bc8-fcb7d855741b": {"node_ids": ["9397c439-c579-4083-a3a4-d24a3763d2dc", "b49f114e-1fc0-4676-97ff-924787c10744"], "metadata": {"page_label": "18", "file_name": "strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_type": "application/pdf", "file_size": 920218, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}}, "be3e7298-81c1-4b09-a799-c4c1dae2f437": {"node_ids": ["c891cdad-0e83-4de1-aac7-cae84ad6237e", "98f1c7dc-f142-47d1-a1ab-22d37383732d"], "metadata": {"page_label": "19", "file_name": "strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_type": "application/pdf", "file_size": 920218, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}}, "fb20ccba-8a5d-462b-bee4-c62cd771bf7e": {"node_ids": ["deda66b5-f2a2-436a-bc11-fb685a99cc62", "ae75a1d8-4597-4619-b17d-1d9ce362a49d"], "metadata": {"page_label": "20", "file_name": "strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_type": "application/pdf", "file_size": 920218, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}}, "4fc61af8-c675-4b20-a609-0ed71fb58577": {"node_ids": ["2393b753-a03b-407d-88a5-314adce19d6a", "f3098e69-0923-450f-baa3-37982a70507d"], "metadata": {"page_label": "21", "file_name": "strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_type": "application/pdf", "file_size": 920218, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}}, "048ba738-8346-44db-ae8a-12fc0cb71c3b": {"node_ids": ["d0306909-4d1b-4d4a-a842-acc3cdde6226", "b9a66ab4-db38-4e75-8c4a-e78a357244b4"], "metadata": {"page_label": "22", "file_name": "strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_type": "application/pdf", "file_size": 920218, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}}, "fbc18e2c-c059-4693-b4aa-fb44fec21890": {"node_ids": ["c7d2c784-d28c-4589-a66a-ac8b1cb1a2a7", "9ade7fcc-69b0-4217-83c9-8c572dcd089f"], "metadata": {"page_label": "23", "file_name": "strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_type": "application/pdf", "file_size": 920218, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}}, "71716cb6-c757-42be-b092-8fa400362616": {"node_ids": ["726b0e03-553f-4f15-bbb2-fbefaab9c573", "a899fded-ec46-495c-a830-0f2904a01190"], "metadata": {"page_label": "24", "file_name": "strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_type": "application/pdf", "file_size": 920218, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}}, "2c80e8b8-a470-4dbf-acbd-1e0f0dbb3c99": {"node_ids": ["8b443242-7253-419e-b8aa-7313ab70eaff", "c6ce415f-8c18-4499-9f8f-19967fc48486"], "metadata": {"page_label": "25", "file_name": "strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_type": "application/pdf", "file_size": 920218, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}}, "9b1f5988-b92f-497c-8c79-72a1a574a741": {"node_ids": ["499412d8-5e74-4250-be67-4d08742a86e6"], "metadata": {"page_label": "26", "file_name": "strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_type": "application/pdf", "file_size": 920218, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}}, "c32e19bf-848d-4924-b748-f6a7f601dc13": {"node_ids": ["b65f2108-42cb-4bec-b2d2-b4c2a06690c5", "9ebe8194-2505-4d2b-a252-d209ef3ba808"], "metadata": {"page_label": "27", "file_name": "strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_type": "application/pdf", "file_size": 920218, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}}, "d13505f7-dd0c-498f-9eab-ca9f7072fa80": {"node_ids": ["01de4a7b-e910-4132-9b72-cbd71f689146", "7a6e7b43-95fc-4c24-bb19-5d6b02b650fe"], "metadata": {"page_label": "28", "file_name": "strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_type": "application/pdf", "file_size": 920218, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}}, "22a197d3-9f2e-4534-820c-280bffcb0bba": {"node_ids": ["ae34a677-c877-4d96-8ae8-30bce8d6f75d", "3904c2c2-dc9b-4b9c-bc79-4d29af8d5cef"], "metadata": {"page_label": "29", "file_name": "strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_type": "application/pdf", "file_size": 920218, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}}, "93adc781-e6ce-428b-8f9b-576b47eda196": {"node_ids": ["e60faf91-3efb-462c-b310-d163944ef639", "5b6afcaf-c8bd-4082-973d-f2d70323ac92"], "metadata": {"page_label": "30", "file_name": "strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_type": "application/pdf", "file_size": 920218, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}}, "a132a296-bb8a-4ecf-9d1c-bde59c9013b4": {"node_ids": ["516674f6-ad1d-4a4c-bb93-d9e1c0148aa1"], "metadata": {"page_label": "31", "file_name": "strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_type": "application/pdf", "file_size": 920218, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}}, "31300f5b-592a-47db-bbaa-b8c13172ff82": {"node_ids": ["79a0c3b3-0bd3-41cf-8434-6e245dec08c4", "320bb471-acb6-4906-9c1e-e8a45ecd563b"], "metadata": {"page_label": "32", "file_name": "strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_type": "application/pdf", "file_size": 920218, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}}, "95a10889-f1e1-4ada-93a9-5967531bd1d3": {"node_ids": ["70c81e90-760e-41d0-8b9f-38bcc846a125", "2bb15505-c2b6-4761-aded-56001597b226"], "metadata": {"page_label": "33", "file_name": "strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_type": "application/pdf", "file_size": 920218, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}}, "9f8eae01-241f-4769-b3dd-5ef6529bd4b3": {"node_ids": ["90f5937e-07b7-477c-8631-5adc07eddd62", "0449ccb5-86f1-4d14-9144-249563399de6"], "metadata": {"page_label": "34", "file_name": "strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_type": "application/pdf", "file_size": 920218, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}}, "8535767b-9d2b-4c9c-b00f-ced9974c2a0b": {"node_ids": ["2006f729-b181-4f6d-90c7-1697f2c0704e"], "metadata": {"page_label": "35", "file_name": "strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_type": "application/pdf", "file_size": 920218, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}}, "ce974273-6283-469e-8dcd-3582376f0e34": {"node_ids": ["0c3705ab-42f6-4852-a85d-c98cadc03831"], "metadata": {"page_label": "36", "file_name": "strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_type": "application/pdf", "file_size": 920218, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}}, "9af1dc8b-612a-4de7-8cdb-c73e94b51232": {"node_ids": ["8e64aea6-52ee-4a75-9bf9-f66195e913b7", "fb531033-4263-4cbc-a385-9e4e65806411"], "metadata": {"page_label": "37", "file_name": "strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_type": "application/pdf", "file_size": 920218, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}}, "ef8859e9-2f3e-417b-a6de-20fdf31b652b": {"node_ids": ["404b0742-092c-48d8-b76f-c4f24861e996", "f87f4b93-8c46-4d05-a220-8fcd06fa1f36"], "metadata": {"page_label": "38", "file_name": "strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_type": "application/pdf", "file_size": 920218, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}}, "ff4ee3f4-1ded-4d86-8bfd-a50bd8619dfa": {"node_ids": ["3f08d264-59a0-46f0-bf9c-a2a58d05e7b7", "ddaafa66-4764-439d-a26d-89b79e873de0"], "metadata": {"page_label": "39", "file_name": "strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_type": "application/pdf", "file_size": 920218, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}}, "7e057d4e-cb0d-433c-ad65-7571ed9e5185": {"node_ids": ["f55541ef-d164-4e50-af8a-4eaa063d091c", "4f99bf68-11dd-4d0c-ba40-58b7b4b71f09"], "metadata": {"page_label": "40", "file_name": "strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_type": "application/pdf", "file_size": 920218, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}}, "8d2bfa1f-9f97-46be-8769-02f3df84764a": {"node_ids": ["6d69d2aa-5c73-4ddc-9671-dc4dc29b3352"], "metadata": {"page_label": "41", "file_name": "strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_type": "application/pdf", "file_size": 920218, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}}, "f8f7ce99-4073-48ec-b1c8-718e9c7f2ab0": {"node_ids": ["3b0913d7-8fa2-4d39-a519-58bac86dc854", "11d19713-b38d-403c-8e10-68324fe5c05b"], "metadata": {"page_label": "42", "file_name": "strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_type": "application/pdf", "file_size": 920218, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}}, "d5830389-43af-4fe3-a87e-11089ade4bd2": {"node_ids": ["98b1f4f4-7a4e-400f-be7a-db8270c3e719"], "metadata": {"page_label": "43", "file_name": "strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_type": "application/pdf", "file_size": 920218, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}}, "01ca76b8-edaf-446d-a53c-4b4782950ed6": {"node_ids": ["5adcc8f2-e4f1-438f-973d-bc0068dd3089", "e10325e7-9e56-4c5e-8c68-f7c69b4ca616", "ac2fd157-c126-47e3-bf54-e564f4187faf"], "metadata": {"page_label": "44", "file_name": "strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_type": "application/pdf", "file_size": 920218, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}}, "6d1169d6-a5c3-4663-b3f4-6d70fdb63b27": {"node_ids": ["9aaeaa02-4e8b-4689-af22-7812713b1a54", "75803775-c402-41f5-9f16-fbb4ed43768b", "c2e1115b-0324-4880-aea8-dee246187403"], "metadata": {"page_label": "45", "file_name": "strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_type": "application/pdf", "file_size": 920218, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}}, "ab567a98-8a3c-4159-ab7d-278a0e3e5a60": {"node_ids": ["a418b360-33b4-449d-8a8b-8fe85e57cdc2", "65bc8bd3-d635-462e-a697-ccad64655763", "e8c0feb9-bfaf-4edc-a494-b4a554359f6a"], "metadata": {"page_label": "46", "file_name": "strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_type": "application/pdf", "file_size": 920218, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}}, "9de117d3-7e3e-40ab-95d7-1085c37d1dd5": {"node_ids": ["439d7ff4-f097-4310-8883-43ef57ed71e6", "7d0c197a-6aba-4302-8b5b-e187b3fd6650", "45ad3dcd-8963-45d5-bd31-a9f4d445f270", "15897be3-22d8-4294-9c39-2ea7e820a84b"], "metadata": {"page_label": "47", "file_name": "strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_type": "application/pdf", "file_size": 920218, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}}, "d818f800-cdaf-48ab-8f7a-48b627453477": {"node_ids": ["7795c32a-6b32-4595-9c07-6f35297524dc", "4f1ff26a-c226-407b-99f8-aa5c72a34234", "6c6d928d-7b37-41cb-86f5-4cfcddb4082a"], "metadata": {"page_label": "48", "file_name": "strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_type": "application/pdf", "file_size": 920218, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}}, "7fa8f6a9-46d7-43d1-a6bb-583df068f766": {"node_ids": ["7e90203d-7a98-4662-9c76-fd5be5a701ea", "17a8175e-ae59-42bd-aed2-643f0109b44c", "fe2be658-8c89-4a14-bd59-7903a912aac3"], "metadata": {"page_label": "49", "file_name": "strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_type": "application/pdf", "file_size": 920218, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}}, "1de3562f-583a-46aa-8d21-587c90caf7af": {"node_ids": ["4e4d4504-a96a-4f0d-9ff2-8e2259900e4b", "9461a2bc-4a17-460a-bf08-a69c025cde9a", "b01e881c-95cd-4dca-a427-72a676084fe0"], "metadata": {"page_label": "50", "file_name": "strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_type": "application/pdf", "file_size": 920218, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}}, "7b99c844-154a-4e9d-b73e-58ec2cdab29a": {"node_ids": ["d0a0e96f-6f86-4a96-8075-dd8e96b5fa0f"], "metadata": {"page_label": "51", "file_name": "strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_type": "application/pdf", "file_size": 920218, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}}, "b0494a81-d4c3-4f12-93a6-7da0dcf2b21c": {"node_ids": ["c8e89640-2988-4444-a9d3-557bf86c6ca1"], "metadata": {"page_label": "52", "file_name": "strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_type": "application/pdf", "file_size": 920218, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}}, "9b9c978a-8220-4fc7-885f-0dd9d04226f5": {"node_ids": ["d7abe083-cae6-48d0-80e9-9c5551ddafd5", "ab7a3aed-fdd6-4c40-9575-fc4861198243"], "metadata": {"page_label": "53", "file_name": "strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_type": "application/pdf", "file_size": 920218, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}}, "81c9ae9b-1edb-4b53-b7e6-2162a925b758": {"node_ids": ["e28a24b7-d2fa-45d7-8224-a8e55a4d341e", "d3dae363-7918-4c9c-a15e-ae7cb37343df"], "metadata": {"page_label": "54", "file_name": "strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_type": "application/pdf", "file_size": 920218, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}}, "d42e5afb-96c3-4d7c-992a-ef3a1e468e4b": {"node_ids": ["b91dfa36-7b76-44cb-9c59-8f525b101ffe"], "metadata": {"page_label": "55", "file_name": "strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_type": "application/pdf", "file_size": 920218, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}}, "18fab913-8352-41c1-bcb0-ef1a64500fce": {"node_ids": ["91edfeae-233c-4ef1-b060-4be96d9164e8"], "metadata": {"page_label": "56", "file_name": "strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_type": "application/pdf", "file_size": 920218, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}}, "214f13ba-61fe-4460-9a07-55037f4a88f6": {"node_ids": ["20dd5452-8ba6-40b9-859d-1adc00e08a5f"], "metadata": {"page_label": "1", "file_name": "Synth\u00e8se etudes diab\u00e8te_13.11.2023 (1).pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\Synth\u00e8se etudes diab\u00e8te_13.11.2023 (1).pdf", "file_type": "application/pdf", "file_size": 604482, "creation_date": "2025-11-26", "last_modified_date": "2025-11-18", "cleaned": true, "headlines": []}}, "a8dcce3b-0ed4-4cb7-8f47-3bd7915f3849": {"node_ids": ["f8595323-cc73-42b1-93c7-b7b283fe041e"], "metadata": {"page_label": "2", "file_name": "Synth\u00e8se etudes diab\u00e8te_13.11.2023 (1).pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\Synth\u00e8se etudes diab\u00e8te_13.11.2023 (1).pdf", "file_type": "application/pdf", "file_size": 604482, "creation_date": "2025-11-26", "last_modified_date": "2025-11-18", "cleaned": true, "headlines": []}}, "07f0fdf4-d6ec-4fb7-857e-35569f1d7b9d": {"node_ids": ["8a7dba6a-f778-4218-bef1-6903c754cdd4", "6e0a4055-156c-4b70-8fa8-255c79ab6d30"], "metadata": {"page_label": "3", "file_name": "Synth\u00e8se etudes diab\u00e8te_13.11.2023 (1).pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\Synth\u00e8se etudes diab\u00e8te_13.11.2023 (1).pdf", "file_type": "application/pdf", "file_size": 604482, "creation_date": "2025-11-26", "last_modified_date": "2025-11-18", "cleaned": true, "headlines": []}}, "1f24b60f-9bea-4a3b-a677-50b88f2cf0f4": {"node_ids": ["894f2489-e788-4ab5-884b-0e6f97681a18"], "metadata": {"page_label": "4", "file_name": "Synth\u00e8se etudes diab\u00e8te_13.11.2023 (1).pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\Synth\u00e8se etudes diab\u00e8te_13.11.2023 (1).pdf", "file_type": "application/pdf", "file_size": 604482, "creation_date": "2025-11-26", "last_modified_date": "2025-11-18", "cleaned": true, "headlines": []}}, "fa797b6c-e946-45f2-82f8-945d7a7f94e1": {"node_ids": ["5e47c1d8-90b7-4c16-8f62-4b4ab9c8d927", "ffbc215a-138b-429c-b8b9-856bee74c51c"], "metadata": {"page_label": "5", "file_name": "Synth\u00e8se etudes diab\u00e8te_13.11.2023 (1).pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\Synth\u00e8se etudes diab\u00e8te_13.11.2023 (1).pdf", "file_type": "application/pdf", "file_size": 604482, "creation_date": "2025-11-26", "last_modified_date": "2025-11-18", "cleaned": true, "headlines": []}}, "d94325cd-066b-4086-b1c5-7e9667cfa643": {"node_ids": ["fea679dc-d19c-4067-a2fc-0a9e37ff62b5"], "metadata": {"page_label": "6", "file_name": "Synth\u00e8se etudes diab\u00e8te_13.11.2023 (1).pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\Synth\u00e8se etudes diab\u00e8te_13.11.2023 (1).pdf", "file_type": "application/pdf", "file_size": 604482, "creation_date": "2025-11-26", "last_modified_date": "2025-11-18", "cleaned": true, "headlines": []}}, "954de1be-9c9e-4f9c-ae8a-184f5c3e0047": {"node_ids": ["2b323375-8321-4784-857e-432bce7d874e", "1f6b388f-ce9c-4137-bd40-71d95e74f371"], "metadata": {"page_label": "7", "file_name": "Synth\u00e8se etudes diab\u00e8te_13.11.2023 (1).pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\Synth\u00e8se etudes diab\u00e8te_13.11.2023 (1).pdf", "file_type": "application/pdf", "file_size": 604482, "creation_date": "2025-11-26", "last_modified_date": "2025-11-18", "cleaned": true, "headlines": []}}, "40e27d3b-71eb-4d03-8fef-db32a071df69": {"node_ids": ["55be455f-dee5-4e99-aaa9-a2863f8ec34c"], "metadata": {"page_label": "8", "file_name": "Synth\u00e8se etudes diab\u00e8te_13.11.2023 (1).pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\Synth\u00e8se etudes diab\u00e8te_13.11.2023 (1).pdf", "file_type": "application/pdf", "file_size": 604482, "creation_date": "2025-11-26", "last_modified_date": "2025-11-18", "cleaned": true, "headlines": []}}, "8732b692-cc00-4955-83e8-6f8063505d08": {"node_ids": ["68076cda-2cc2-4f05-a965-8f4814c60078", "6f03524c-f10e-421e-bc5c-b97c541fcf45", "4d60e967-7157-4b42-810a-c4e2b650024e", "78e202e8-8113-4907-936f-554751988c5a", "1d92c96a-23ee-4942-98ca-75478c0c2a39", "b32da7f0-7b59-4327-af9b-ab0fe96b5509", "38f09af6-8325-476e-9578-50bd9880c163"], "metadata": {"page_label": "1", "file_name": "tdb_diabete-2004.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\tdb_diabete-2004.pdf", "file_type": "application/pdf", "file_size": 94594, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}}, "ba8a5c9f-4382-47cc-94e5-9a3a2537bf8d": {"node_ids": ["1a0ac1e2-6c10-4df4-9675-bf2195e44d4f", "55e6597d-6333-4b17-a982-05ae7b7d0481", "d782ffc5-c5e5-41ef-a671-476afda20ed1"], "metadata": {"page_label": "2", "file_name": "tdb_diabete-2004.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\tdb_diabete-2004.pdf", "file_type": "application/pdf", "file_size": 94594, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}}, "c119cca9-d28e-4455-9140-d834c68fe01b": {"node_ids": ["e1a61c5c-1574-468d-a98a-e5e68523ae33", "85478166-cb22-4cb2-a64f-f0b8c643b98d", "3cc32a69-3635-4ee7-8e48-e73fc90d0a31"], "metadata": {"page_label": "3", "file_name": "tdb_diabete-2004.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\tdb_diabete-2004.pdf", "file_type": "application/pdf", "file_size": 94594, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}}}, "docstore/data": {"2fdb4fa7-c200-4201-8429-a2d681d09298": {"__data__": {"id_": "2fdb4fa7-c200-4201-8429-a2d681d09298", "embedding": null, "metadata": {"page_label": "381", "file_name": "2022_22.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2022_22.pdf", "file_type": "application/pdf", "file_size": 1843017, "creation_date": "2025-11-25", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "fcafdb20-17e8-445e-a7d6-7c5d1c14996d", "node_type": "4", "metadata": {"page_label": "381", "file_name": "2022_22.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2022_22.pdf", "file_type": "application/pdf", "file_size": 1843017, "creation_date": "2025-11-25", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "d10c6b45a0dfb27ef95edf4cd23cd9614ef422c29f6fe6eb50e79bff6ed0b03a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "bdeb64e2-f767-4ce0-acd2-6c5719b80cd2", "node_type": "1", "metadata": {}, "hash": "fc6fc0c716dd0b7256b592dc7f259411c5f486473e60c29245a65f246e4a97ac", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "N\u00b0 22 | 8 novembre 2022\nBEH 22 | 8 novembre 2022 | 381\nLa reproduction (totale ou partielle) du BEH est soumise \u00e0 l'accord pr\u00e9alable de Sant\u00e9 publique France.\nConform\u00e9ment \u00e0 l'article L. 122-5 du code de la propri\u00e9t\u00e9 intellectuelle, les courtes citations ne sont pas\nsoumises \u00e0 autorisation pr\u00e9alable, sous r\u00e9serve que soient indiqu\u00e9s clairement le nom de l'auteur et la\nsource, et qu'elles ne portent pas atteinte \u00e0 l'int\u00e9grit\u00e9 et \u00e0 l'esprit de l'\u0153uvre. Les atteintes au droit d'auteur\nattach\u00e9 au BEH sont passibles d'un contentieux devant la juridiction comp\u00e9tente.\nDirecteur de la publication : La\u00ebtitia Huiart, directrice scientifique, adjointe \u00e0 la directrice g\u00e9n\u00e9rale de\nSant\u00e9 publique France\nR\u00e9dactrice en chef : Val\u00e9rie Colombani-Cocuron, Sant\u00e9 publique France,\nR\u00e9dactrice en chef adjointe : Fr\u00e9d\u00e9rique Biton-Debernardi\nResponsable du contenu en anglais : Chlo\u00eb Chester\nSecr\u00e9tariat de r\u00e9daction : Val\u00e9rie Contactsis\nComit\u00e9 de r\u00e9daction : Rapha\u00ebl Andler, Sant\u00e9 publique France ; Thierry Blanchon, Iplesp ; Florence BodeauLivinec, EHESP ; Julie Boudet-Berquier, Sant\u00e9 publique France ; Kathleen Chami, Sant\u00e9 publique France ;\nBertrand Gagni\u00e8re, Sant\u00e9 publique France - Bretagne ; Isabelle Gr\u00e9my, ORS \u00cele-de-France ; Anne Guinard /\nDamien Mouly, Sant\u00e9 publique France - Occitanie ; Nathalie Jourdan-Da Silva, Sant\u00e9 publique France ;\nPhilippe Magne, Centre national de gestion des praticiens hospitaliers et des personnels de direction de\nla fonction publique hospitali\u00e8re ; Val\u00e9rie Oli\u00e9, Sant\u00e9 publique France ; Alexia Peyronnet, Sant\u00e9 publique\nFrance ; H\u00e9l\u00e8ne Therre, Sant\u00e9 publique France ; Sophie Vaux, Sant\u00e9 publique France ; Isabelle Villena,\nCHU Reims.\nSant\u00e9 publique France - Site Internet :\nPr\u00e9presse : Luminess\nISSN : 1953-8030\nRetrouvez ce num\u00e9ro ainsi que les archives du Bulletin \u00e9pid\u00e9miologique hebdomadaire sur\n\n// World diabetes day, November 14, 2022\nCoordination scientifique // Scientific coordination\nSandrine Fosse-Edorh\nEt pour le Comit\u00e9 de r\u00e9daction du BEH : Bertrand Gagni\u00e8re (Sant\u00e9 publique France - Bretagne), Val\u00e9rie Oli\u00e9 (Sant\u00e9 publique France)\nSOMMAIRE // Contents\n>\n\u00c9DITORIAL // Editorial\nEntred 3 est arriv\u00e9 !\n// Entred 3 has arrived!...............................................", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2216, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "bdeb64e2-f767-4ce0-acd2-6c5719b80cd2": {"__data__": {"id_": "bdeb64e2-f767-4ce0-acd2-6c5719b80cd2", "embedding": null, "metadata": {"page_label": "381", "file_name": "2022_22.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2022_22.pdf", "file_type": "application/pdf", "file_size": 1843017, "creation_date": "2025-11-25", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "fcafdb20-17e8-445e-a7d6-7c5d1c14996d", "node_type": "4", "metadata": {"page_label": "381", "file_name": "2022_22.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2022_22.pdf", "file_type": "application/pdf", "file_size": 1843017, "creation_date": "2025-11-25", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "d10c6b45a0dfb27ef95edf4cd23cd9614ef422c29f6fe6eb50e79bff6ed0b03a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2fdb4fa7-c200-4201-8429-a2d681d09298", "node_type": "1", "metadata": {"page_label": "381", "file_name": "2022_22.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2022_22.pdf", "file_type": "application/pdf", "file_size": 1843017, "creation_date": "2025-11-25", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "d5ae44572d27b25a1516e493ce7ef5ead0116052bf28353e44345ba458bf45c7", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "// Entred 3 has arrived!...............................................\nAndr\u00e9 Grimaldi\nProfesseur \u00e9m\u00e9rite, Centre hospitalier universitaire\nPiti\u00e9-Salp\u00eatri\u00e8re, Paris\nARTICLE // Article\n\u00c9tudes Entred : un dispositif\npour am\u00e9liorer la connaissance de l'\u00e9tat\nde sant\u00e9 des personnes pr\u00e9sentant\nun diab\u00e8te en France - Premiers r\u00e9sultats\nde la troisi\u00e8me \u00e9dition conduite en m\u00e9tropole\nen 2019\n// ENTRED studies: Improving knowledge\non the health status of people with diabetes\nin France - First results of the third edition\nconducted in metropolitan France, 2019 ..................\nSandrine Fosse-Edorh et coll.\nSant\u00e9 publique France, Saint-Maurice\nARTICLE // Article\nTabagisme et diab\u00e8te : le temps de l'action\n// Smoking and diabetes: Time for action .................\nVincent Durlach et coll.\nUniversit\u00e9 Reims Champagne-Ardenne, UMR CNRS 7369\nMEDyC, P\u00f4le Cardio-Thoracique, Centre hospitalier\nuniversitaire de Reims", "mimetype": "text/plain", "start_char_idx": 2145, "end_char_idx": 3055, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "c5a7d310-4b5d-4878-bfa1-2409c8cfdc1a": {"__data__": {"id_": "c5a7d310-4b5d-4878-bfa1-2409c8cfdc1a", "embedding": null, "metadata": {"page_label": "382", "file_name": "2022_22.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2022_22.pdf", "file_type": "application/pdf", "file_size": 1843017, "creation_date": "2025-11-25", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "7615fb8b-f8a3-43e6-b5fa-6b7042933f04", "node_type": "4", "metadata": {"page_label": "382", "file_name": "2022_22.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2022_22.pdf", "file_type": "application/pdf", "file_size": 1843017, "creation_date": "2025-11-25", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "0e08bb4017b77a26ce4f373b377a1e0946dac0dbf3d1705bef04fb517271d691", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "eb979e76-5f9d-49ee-91d4-119b07f3d765", "node_type": "1", "metadata": {}, "hash": "78c48ef57be890be767e9f7828a6d821a7b535a279a048cdfbf59e0d28df5795", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "382 | 8 novembre 2022 | BEH 22 Journ\u00e9e mondiale du diab\u00e8te, 14 novembre 2022\n\u00c9DITORIAL // Editorial\nENTRED 3 EST ARRIV\u00c9 !\n// ENTRED 3 HAS ARRIVED!\nAndr\u00e9 Grimaldi\nProfesseur \u00e9m\u00e9rite, Centre hospitalier universitaire Piti\u00e9-Salp\u00eatri\u00e8re, Paris\nCe num\u00e9ro th\u00e9matique du Bulletin \u00e9pid\u00e9miolo -\ngique hebdomadaire (BEH), dont la parution co\u00efn -\ncide avec la Journ\u00e9e mondiale du diab\u00e8te, livre les\ntous premiers r\u00e9sultats de la troisi\u00e8me \u00e9dition 2019\nde l'\u00e9tude \u00c9chantillon national t\u00e9moin repr\u00e9sentatif\ndes personnes diab\u00e9tiques (Entred), portant sur un\npeu moins de 10 000 adultes tir\u00e9s au sort.\nCette nouvelle version, tout en suivant une m\u00e9tho -\ndologie similaire \u00e0 celle d'Ent red 1 (2001-2003) et\nd'Entred 2 (2007-2010), a pu b\u00e9n\u00e9ficier des donn\u00e9es\ndu Syst\u00e8me national des donn\u00e9es de sant\u00e9 (SNDS)\nsur les hospitalisations, durant les 10 ann\u00e9es\npr\u00e9c\u00e9dentes. De plus, un sur- \u00e9chantillonnage\ndes personnes diab\u00e9tiques de type 1 a permis\nd'apporter des donn\u00e9es plus pr\u00e9cises sur cette\npopulation que celles fournies par les \u00e9ditions ant\u00e9 -\nrieures. Le premier article (1) de ce num\u00e9ro rapporte\nles caract\u00e9ristiques recueillies par une enqu\u00eate\naupr\u00e8s des personnes diab\u00e9tiques vivant en France\nm\u00e9tropolitaine, associ\u00e9es aux donn\u00e9es extraites du\nSNDS (des publications ult\u00e9rieures porteront sur\nles populations de La R\u00e9union, de la Guyane et des\nAntilles).\nLe premier int\u00e9r\u00eat de cette publication est de\npermettre la comparaison avec les donn\u00e9es des\n\u00e9ditions ant\u00e9rieures. En ce qui conc erne le diab\u00e8te\nde type 2, si on n'observe pas de progr\u00e8s en termes\nde poids (avec 80% de surpoids et d'ob\u00e9 sit\u00e9) et de\ntabagisme (13%), les publications ult\u00e9rieures diront si\nla diminution rapport\u00e9e de la perte de vue d'un \u0153il\net d'un mal perforant plantaire est corr\u00e9l\u00e9e, comm e\non peut le penser, \u00e0 une am\u00e9lioration de l'\u00e9quilibre\nglyc\u00e9mique. Elles devront aussi confi rmer la diminu -\ntion des comp lications coronariennes, rapport\u00e9es\npar les patients, que pourrait expliquer une plus\nlarge prescription de statines.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1998, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "eb979e76-5f9d-49ee-91d4-119b07f3d765": {"__data__": {"id_": "eb979e76-5f9d-49ee-91d4-119b07f3d765", "embedding": null, "metadata": {"page_label": "382", "file_name": "2022_22.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2022_22.pdf", "file_type": "application/pdf", "file_size": 1843017, "creation_date": "2025-11-25", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "7615fb8b-f8a3-43e6-b5fa-6b7042933f04", "node_type": "4", "metadata": {"page_label": "382", "file_name": "2022_22.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2022_22.pdf", "file_type": "application/pdf", "file_size": 1843017, "creation_date": "2025-11-25", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "0e08bb4017b77a26ce4f373b377a1e0946dac0dbf3d1705bef04fb517271d691", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c5a7d310-4b5d-4878-bfa1-2409c8cfdc1a", "node_type": "1", "metadata": {"page_label": "382", "file_name": "2022_22.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2022_22.pdf", "file_type": "application/pdf", "file_size": 1843017, "creation_date": "2025-11-25", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "36753b5972cc31c1cc2d7d7c384b71b55b979a07d69f7233e93b2497a89a746f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a1efdc81-27ff-48b6-a1ce-c8e77ffda8e4", "node_type": "1", "metadata": {}, "hash": "8f0dd0c0b73bb948fa7e9ff13fb1c13ea6f7b51f686a7f84fc93a9f9d51d6365", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Elles devront aussi confi rmer la diminu -\ntion des comp lications coronariennes, rapport\u00e9es\npar les patients, que pourrait expliquer une plus\nlarge prescription de statines. Quoi qu'il en soit, le\nvieillissement enregistr\u00e9 de la population des diab\u00e9 -\ntiques de type 2 et l'allongement de la dur\u00e9e moyenne\ndu diab\u00e8te t\u00e9moignent \u00e0 la fois du ralentissement\nde la progression de l'incidence de la maladie, et de\nl'accroissement de l'esp \u00e9rance de vie des patients\ntrait\u00e9s. Les progr\u00e8s th\u00e9rapeutiques rapport\u00e9s sont\ncertes num\u00e9riquement modestes, mais ils sont\nencourageants et engagent \u00e0 poursuivre les actions\nd'information et de formation des professionnels et\ndes patients. La grande question reste cependant\n(1) Voir \u00ab \u00c9tudes Entred : un dispositif pour am\u00e9liorer la connaissance\nde l'\u00e9tat de sant\u00e9 des personnes pr\u00e9sentant un diab\u00e8te en France -\nPremiers r\u00e9sultats de la troisi\u00e8me \u00e9dition conduite en m\u00e9tropole en 2019 \u00bb\nde Sandrine Fosse-Edorh et coll. dans ce num\u00e9ro.\ncelle de la pr\u00e9vention primaire du diab\u00e8te de type 2,\ngr\u00e2ce \u00e0 l'\u00e9quilibre alimentaire et \u00e0 l'accroissement de\nl'activit\u00e9 physique.\nLes patients diab\u00e9tiques de type 1, comm e on\npouvait s'y attendre sont plus jeunes que les diab\u00e9 -\ntiques de type 2, avec un niveau socio- culturel plus\n\u00e9lev\u00e9. Ils ont un diab\u00e8te plus ancien, pr\u00e9sentent\nmoins de comp lications macrovasculaires, mais\nnettement plus de complications microvasculaires\n(\u0153il, pied, rein, la classique \u00ab triopathie \u00bb diab\u00e9tique).\nCe qui frappe conc ernant ce diab\u00e8te qu'on appelait\njadis \u00ab maigre \u00bb est, en revanche, le pourcentage de\npatients en surpoids ou ob\u00e8ses (50%) et tabagiques\n(25%). Si bien que le ph\u00e9notype moderne du diab\u00e8te\nde type 1 associe \u00e0 la carence insulinique absolue qui\nle caract\u00e9rise le d\u00e9veloppement d'une insulinor\u00e9sis -\ntance, autrefois apanage du diab\u00e8te de type 2.\nD'apr\u00e8s ces premi\u00e8res donn\u00e9es d\u00e9claratives\nd'Entred 3, le tabagisme semble se maintenir \u00e0 un\ntaux \u00e9lev\u00e9 chez les patients diab\u00e9tiques, alors qu'il\ntend \u00e0 r\u00e9gresser dans la population g\u00e9n\u00e9rale. Il fait\nl'objet du deuxi\u00e8me article de ce num\u00e9ro (2).", "mimetype": "text/plain", "start_char_idx": 1824, "end_char_idx": 3897, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "a1efdc81-27ff-48b6-a1ce-c8e77ffda8e4": {"__data__": {"id_": "a1efdc81-27ff-48b6-a1ce-c8e77ffda8e4", "embedding": null, "metadata": {"page_label": "382", "file_name": "2022_22.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2022_22.pdf", "file_type": "application/pdf", "file_size": 1843017, "creation_date": "2025-11-25", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "7615fb8b-f8a3-43e6-b5fa-6b7042933f04", "node_type": "4", "metadata": {"page_label": "382", "file_name": "2022_22.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2022_22.pdf", "file_type": "application/pdf", "file_size": 1843017, "creation_date": "2025-11-25", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "0e08bb4017b77a26ce4f373b377a1e0946dac0dbf3d1705bef04fb517271d691", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "eb979e76-5f9d-49ee-91d4-119b07f3d765", "node_type": "1", "metadata": {"page_label": "382", "file_name": "2022_22.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2022_22.pdf", "file_type": "application/pdf", "file_size": 1843017, "creation_date": "2025-11-25", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "bcdccf8376d188901213a632343e771034877d7ca465dcbad3b70b949a318234", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "D'apr\u00e8s ces premi\u00e8res donn\u00e9es d\u00e9claratives\nd'Entred 3, le tabagisme semble se maintenir \u00e0 un\ntaux \u00e9lev\u00e9 chez les patients diab\u00e9tiques, alors qu'il\ntend \u00e0 r\u00e9gresser dans la population g\u00e9n\u00e9rale. Il fait\nl'objet du deuxi\u00e8me article de ce num\u00e9ro (2). Le tabac\njoue un r\u00f4le particuli\u00e8rement pervers, puisqu'il est\nun facteur de risque du diab\u00e8te de type 2, \u00e0 la fois\nen favorisant la r\u00e9partition abdominale visc\u00e9rale\ndes graisses, et en induisant fr\u00e9quemment lors de\nl'arr\u00eat de l'int oxication une prise de poids impor -\ntante. En plus de ses propres comp lications, notamment oncologiques et vasculaires, le tabagisme\naggrave les comp lications du diab\u00e8te et singuli\u00e8re -\nment la n\u00e9phropathie diab\u00e9tique. Si on ajoute \u00e0 ces\ndonn\u00e9es \u00e9pid\u00e9miologiques l'exi stence d'un gradient\nsocial concernant l'ob\u00e9sit\u00e9, le diab\u00e8te de type 2,\nle tabagisme, on con\u00e7oit qu'on puisse parler de\n\u00ab synd\u00e9mie \u00bb (intrication de maladies touchant de tr\u00e8s\nlarges populations et s'agg ravant r\u00e9ciproquement).\nL 'origine commune de cette synd\u00e9mie tiendrait au\nd\u00e9veloppement des comp ortements addictifs dans\nune soci\u00e9t\u00e9 de cons ommation, urbanis\u00e9e, s\u00e9denta -\nris\u00e9e, archipellis\u00e9e o\u00f9 chacun, pour lutter cont re la\nmaladie du si\u00e8cle, l'anx iod\u00e9pression, tente d'act iver\nles circuits bio-neuronaux du plaisir, sachant que\ncette derni\u00e8re est deux fois plus fr\u00e9quente chez\nles patients atteints de maladies chroniques. Mais,\nles comportements compulsifs ou la cons ommation\nde drogues qui soulagent le mal-\u00eatre dans l'ins tant,\nl'aggravent secondairement, tandis que le marke -\nting des industriels conc ern\u00e9s stimule le sentiment\n(2) Voir \u00ab Tabagisme et diab\u00e8te : le temps de l'action \u00bb de Vincent Durlach\net coll. dans ce num\u00e9ro.\n>\nAndr\u00e9 Grimaldi\nProfesseur \u00e9m\u00e9rite, Centre hospitalier universitaire Piti\u00e9-Salp\u00eatri\u00e8re, Paris.", "mimetype": "text/plain", "start_char_idx": 3651, "end_char_idx": 5443, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "e0a959f8-33b9-4957-85c7-c395a6cb9eef": {"__data__": {"id_": "e0a959f8-33b9-4957-85c7-c395a6cb9eef", "embedding": null, "metadata": {"page_label": "383", "file_name": "2022_22.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2022_22.pdf", "file_type": "application/pdf", "file_size": 1843017, "creation_date": "2025-11-25", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "c5ace680-1a06-40a1-b05e-c466202222f8", "node_type": "4", "metadata": {"page_label": "383", "file_name": "2022_22.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2022_22.pdf", "file_type": "application/pdf", "file_size": 1843017, "creation_date": "2025-11-25", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "f14886db27d370426b7b1bea94f37440400f5959289d63a58479e43e77526525", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "76b2a880-f229-4fe3-946e-a2ab1650efc0", "node_type": "1", "metadata": {}, "hash": "503fdf368adc2915c5eda69400157799da17ef5588a551a849dc6df62f2f4143", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Journ\u00e9e mondiale du diab\u00e8te, 14 novembre 2022 BEH 22 | 8 novembre 2022 | 383\nARTICLE // Article\n\u00c9TUDES ENTRED : UN DISPOSITIF POUR AM\u00c9LIORER LA CONNAISSANCE DE L'\u00c9TAT\nDE SANT\u00c9 DES PERSONNES PR\u00c9SENTANT UN DIAB\u00c8TE EN FRANCE - PREMIERS R\u00c9SULTATS\nDE LA TROISI\u00c8ME \u00c9DITION CONDUITE EN M\u00c9TROPOLE EN 2019\n// ENTRED STUDIES: IMPROVING KNOWLEDGE ON THE HEALTH STATUS OF PEOPLE WITH DIABETES IN FRANCE -\nFIRST RESULTS OF THE THIRD EDITION CONDUCTED IN METROPOLITAN FRANCE, 2019\nSandrine Fosse-Edorh 1 (), Clara Piffaretti 1, Leila Saboni 1,\nLaurence Mandereau-Bruno 1, Laetitia B\u00e9n\u00e9zet 1, V\u00e9ronique Raimond 2, Jean-Michel Race 3, Antoine Rachas 4\n1 Sant\u00e9 publique France, Saint-Maurice\n2 Haute Autorit\u00e9 de sant\u00e9, Saint-Denis\n3 Agence nationale de s\u00e9curit\u00e9 du m\u00e9dicament et des produits de sant\u00e9, Saint-Denis\n4 Caisse nationale de l'assurance maladie, Paris\nSoumis le 01.08.2022 // Date of submission: 08.01.2022\nR\u00e9sum\u00e9 // Abstract\nIntroduction - La troisi\u00e8me \u00e9dition de l'\u00e9tude \u00ab Echantillon national t\u00e9moin repr\u00e9sentatif des personnes diab\u00e9 -\ntiques \u00bb (Entred 3), men\u00e9e en 2019, a pour objectif de d\u00e9crire les caract\u00e9ristiques des personnes pr\u00e9sentant\nun diab\u00e8te de type 2 (DT2) ou de type 1 (DT1) et leur \u00e9tat de sant\u00e9. Cet article pr\u00e9sente les premiers r\u00e9sultats\nauto-d\u00e9clar\u00e9s par les personnes r\u00e9sidant en France m\u00e9tropolitaine.\nM\u00e9thodes - Un \u00e9chantillon de 9 072 personnes (\u2265 18 ans), trait\u00e9es pharmacologiquement pour un diab\u00e8te a\n\u00e9t\u00e9 tir\u00e9 au sort dans les bases de l 'Assurance maladie (r\u00e9gime g\u00e9n\u00e9ral et s\u00e9curit\u00e9 sociale des ind\u00e9pendants).\nCes personnes ont \u00e9t\u00e9 invit\u00e9es \u00e0 r\u00e9pondre \u00e0 un auto-questionnaire. Les donn\u00e9es du Syst\u00e8me national de\ndonn\u00e9es de sant\u00e9 ont \u00e9t\u00e9 extraites pour l 'ensemble de l'\u00e9chantillon. Des estimations pond\u00e9r\u00e9es ont \u00e9t\u00e9 calcu -\nl\u00e9es tenant compte du plan de sondage et du biais de non-participation par questionnaire.\nR\u00e9sultats - La population d '\u00e9tude incluait 8 728 personnes dont 3 166 (36,3%) ont r\u00e9pondu \u00e0 un question -\nnaire. Parmi elles, 2 714 \u00e9taient identifi\u00e9es comme ayant un DT2, d'\u00e2ge moyen 67,6 ans (+2 ans par rapport\n\u00e0 2007), 55,3% \u00e9taient des hommes (stable/2007), avec une anciennet\u00e9 m\u00e9diane du diab\u00e8te de 10,7 ans.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2155, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "76b2a880-f229-4fe3-946e-a2ab1650efc0": {"__data__": {"id_": "76b2a880-f229-4fe3-946e-a2ab1650efc0", "embedding": null, "metadata": {"page_label": "383", "file_name": "2022_22.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2022_22.pdf", "file_type": "application/pdf", "file_size": 1843017, "creation_date": "2025-11-25", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "c5ace680-1a06-40a1-b05e-c466202222f8", "node_type": "4", "metadata": {"page_label": "383", "file_name": "2022_22.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2022_22.pdf", "file_type": "application/pdf", "file_size": 1843017, "creation_date": "2025-11-25", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "f14886db27d370426b7b1bea94f37440400f5959289d63a58479e43e77526525", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e0a959f8-33b9-4957-85c7-c395a6cb9eef", "node_type": "1", "metadata": {"page_label": "383", "file_name": "2022_22.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2022_22.pdf", "file_type": "application/pdf", "file_size": 1843017, "creation_date": "2025-11-25", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "914f469d1101f1b0cb92f5e624ad99a7820a60714e542a0b1fef4aadbcfc0bdf", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "245f742f-eb78-4522-a9d6-7afa1ef6d9be", "node_type": "1", "metadata": {}, "hash": "069720f0ddea954713423f4d07c45a5717fa9b2ee942eabc192758615fd9f5b1", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Parmi elles, 2 714 \u00e9taient identifi\u00e9es comme ayant un DT2, d'\u00e2ge moyen 67,6 ans (+2 ans par rapport\n\u00e0 2007), 55,3% \u00e9taient des hommes (stable/2007), avec une anciennet\u00e9 m\u00e9diane du diab\u00e8te de 10,7 ans.\nEt 412 personnes \u00e9taient identifi\u00e9es comme ayant un DT1, d'\u00e2ge moyen 47 ans, 57% \u00e9taient des hommes\net 55,6% avaient une anciennet\u00e9 du diab\u00e8te \u226520 ans. Le niveau socio-\u00e9conomique des personnes DT1 \u00e9tait\nplus favorable que celui des personnes DT2. Les facteurs de risque de complications \u00e9taient fr\u00e9quents chez\nles personnes DT2, (surpoids/ob\u00e9sit\u00e9 (80,1%), hypertension trait\u00e9e (77,6%), dyslipid\u00e9mie trait\u00e9e (63,8%),\ntabagisme (13,4%), consommation d'alcool \u00e9lev\u00e9e ou s\u00e9v\u00e8re (7%)). Ces facteurs de risque \u00e9taient \u00e9galement\nfr\u00e9quents chez les personnes DT1, notamment le surpoids/ob\u00e9sit\u00e9 (49,9%), la consommation d'alcool (11,3%)\net de tabac (25,3%). Les complications macrovasculaires \u00e9taient plus fr\u00e9quemment autod\u00e9clar\u00e9es chez les\n>\nSandrine Fosse-Edorh\nSant\u00e9 publique France, Saint-Maurice\nillusoire de libert\u00e9 pour mieux assujettir leurs clients.\nLa lutte cont re cette synd\u00e9mie passe donc par une\npolitique de sant\u00e9 publique globale, dont chaque\n\u00e9l\u00e9ment doit \u00eatre \u00e9valu\u00e9. Cette \u00e9valuation r\u00e9guli\u00e8 -\nrement r\u00e9p\u00e9t\u00e9e est indispensable pour d\u00e9cider des\nactions \u00e0 poursuivre ou \u00e0 mettre en \u0153uvre.\nC'est ce qu'avait parfaitement comp ris Anne FagotCampagna qui nous a quitt\u00e9s le 19 janvier 2022.\nElle avait initi\u00e9 et conduit les \u00e9tudes Entred 1 et 2, alors\nqu'elle travaillait \u00e0 l'Institut de veille sanitaire, anc\u00eatre\nde Sant\u00e9 publique France. Elle avait rejoint la S\u00e9curit\u00e9\nsociale il y a dix ans. M\u00e9decin, \u00e0 la fois diab\u00e9tologue\net \u00e9pid\u00e9miologiste, elle savait en effet que l'efficacit\u00e9\nde l'action passe par le d\u00e9veloppement d'une relation\nconstructive entre le financeur, la S\u00e9curit\u00e9 sociale,\net la comm unaut\u00e9 m\u00e9dicale, autour de la question\ncentrale pour l'ave nir de notre syst\u00e8me de sant\u00e9,\nde la pertinence et de la qualit\u00e9 des soins. Il suffit de\nrappeler ici ses travaux sur la chirurgie bariatrique et\nla chirurgie thyro\u00efdienne. Toutes celles et tous ceux\nqui ont eu la chance de la conna\u00eetre ou de travailler\navec elle, gardent le souvenir de sa tr\u00e8s grande\ncomp\u00e9tence et de son extr\u00eame gentillesse. C'\u00e9tait\nune personnalit\u00e9 rayonnante.", "mimetype": "text/plain", "start_char_idx": 1955, "end_char_idx": 4203, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "245f742f-eb78-4522-a9d6-7afa1ef6d9be": {"__data__": {"id_": "245f742f-eb78-4522-a9d6-7afa1ef6d9be", "embedding": null, "metadata": {"page_label": "383", "file_name": "2022_22.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2022_22.pdf", "file_type": "application/pdf", "file_size": 1843017, "creation_date": "2025-11-25", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "c5ace680-1a06-40a1-b05e-c466202222f8", "node_type": "4", "metadata": {"page_label": "383", "file_name": "2022_22.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2022_22.pdf", "file_type": "application/pdf", "file_size": 1843017, "creation_date": "2025-11-25", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "f14886db27d370426b7b1bea94f37440400f5959289d63a58479e43e77526525", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "76b2a880-f229-4fe3-946e-a2ab1650efc0", "node_type": "1", "metadata": {"page_label": "383", "file_name": "2022_22.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2022_22.pdf", "file_type": "application/pdf", "file_size": 1843017, "creation_date": "2025-11-25", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "5ebd97f40cb918ab22a39445be6df5ef5dd35b45320291884425b5d4ad9b7589", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Il suffit de\nrappeler ici ses travaux sur la chirurgie bariatrique et\nla chirurgie thyro\u00efdienne. Toutes celles et tous ceux\nqui ont eu la chance de la conna\u00eetre ou de travailler\navec elle, gardent le souvenir de sa tr\u00e8s grande\ncomp\u00e9tence et de son extr\u00eame gentillesse. C'\u00e9tait\nune personnalit\u00e9 rayonnante. Le plus bel hommage\nqu'on puisse lui rendre est de poursuivre son \u0153uvre,\ndont Entred fut un volet important.\nMerci \u00e0 tous les investigateurs d'avoir entrepris\net men\u00e9 \u00e0 bien Entred 3, dont les diab\u00e9tologues\nattendent avec impatience les multiples publications\nannonc\u00e9es. \u25a0\nCiter cet article\nGrimaldi A. \u00c9ditorial. Entred 3 est arriv\u00e9 ! Bull Epid\u00e9miol\nHebd. 2022;(22): 382-3.\nbeh/2022/22/2022_22_0.html", "mimetype": "text/plain", "start_char_idx": 3898, "end_char_idx": 4605, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "70ed48ba-8204-479b-839e-7608555fccac": {"__data__": {"id_": "70ed48ba-8204-479b-839e-7608555fccac", "embedding": null, "metadata": {"page_label": "384", "file_name": "2022_22.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2022_22.pdf", "file_type": "application/pdf", "file_size": 1843017, "creation_date": "2025-11-25", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "3f425aad-9cbd-4c0f-9788-8a1c28fc8736", "node_type": "4", "metadata": {"page_label": "384", "file_name": "2022_22.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2022_22.pdf", "file_type": "application/pdf", "file_size": 1843017, "creation_date": "2025-11-25", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "d1b1b58489d5346c04f7789ef35a8342bf7923a99fefa84d5aa45cbd5e0dff24", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "73c43bdc-bd9a-4217-8c3e-45220c47c1ec", "node_type": "1", "metadata": {}, "hash": "bfaa7cd0b5132034ce625b1e8a5369a33b6afd6ea47f03497af629d34cd0d79b", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "384 | 8 novembre 2022 | BEH 22 Journ\u00e9e mondiale du diab\u00e8te, 14 novembre 2022\npersonnes DT2 : complication coronarienne (18,6%), accident vasculaire c\u00e9r\u00e9bral (7,8%). Ces proportions\n\u00e9taient respectivement de 11,5% et 3,3% pour les personnes DT1.\nDes complications microvasculaires \u00e9taient plus fr\u00e9quemment rapport\u00e9es par les personnes DT1 : perte de\nla vue d 'un \u0153il (3,7%), mal perforant plantaire actif ou ancien (12,9%). Ces proportions \u00e9taient respective -\nment de 3,2% et 6,7% parmi les personnes DT2.\nConclusion - Ces premiers r\u00e9sultats d'Entred 3 apportent un aper\u00e7u des caract\u00e9ristiques et de l'\u00e9tat de\nsant\u00e9 de la population diab\u00e9tique en France. Ils confirment que les caract\u00e9ristiques d\u00e9mographiques et socio -\n\u00e9conomiques sont tr\u00e8s disparates entre le DT1 et le DT2. La l\u00e9g\u00e8re baisse observ\u00e9e, par rapport \u00e0 2007, dans\nla fr\u00e9quence des complications autod\u00e9clar\u00e9es par les personnes DT2 et la fr\u00e9quence \u00e9lev\u00e9e des complications\nmicrovasculaires autod\u00e9clar\u00e9es par les personnes DT1 seront \u00e0 confirmer par des \u00e9tudes approfondies, portant\nnotamment sur les informations recueillies aupr\u00e8s des m\u00e9decins.\nCertaines alertes d\u00e9j\u00e0 \u00e9mises dans les \u00e9ditions pr\u00e9c\u00e9dentes peuvent \u00eatre r\u00e9it\u00e9r\u00e9es : l'ob\u00e9sit\u00e9 et le taba -\ngisme parmi les personnes DT2 restent \u00e0 un niveau tr\u00e8s \u00e9lev\u00e9. Ce niveau est tr\u00e8s \u00e9lev\u00e9 \u00e9galement parmi les\npersonnes DT1 qui conjuguent en outre une fr\u00e9quence \u00e9lev\u00e9e de consommation d 'alcool.\nIntroduction - The third edition of the National Representative Sample of people with Diabetes (ENTRED,\n\u00c9chantillon national t\u00e9moin repr\u00e9sentatif des personnes diab\u00e9tiques), conducted in 2019, aims to describe\nthe characteristics of people with type 2 diabetes (T2D) or type 1 diabetes (T1D) and their health status. This\narticle focuses on the first results self-reported by residents in metropolitan France.\nMethods - A sample of 9072 individuals (\u2265 18 years of age), pharmacologically treated for diabetes, was\nrandomly drawn from the Health Insurance databases (general scheme and social security for the selfemployed). They were asked to complete a self-questionnaire. Data from the National Health Data System\nwere extracted for the entire sample. Weighted estimates were calculated taking into account the sample\ndesign and the the bias of not participating by questionnaire.\nResults - The study population included 8728 individuals, of whom 3166 (36.3%) completed a questionnaire.\nAmong them, 2,714 were identified as having T2D, mean age 67.6 years (+2 years compared to 2007), 55.3%\nwere men (stable/2007), with a median diabetes duration of 10.7 years.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2575, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "73c43bdc-bd9a-4217-8c3e-45220c47c1ec": {"__data__": {"id_": "73c43bdc-bd9a-4217-8c3e-45220c47c1ec", "embedding": null, "metadata": {"page_label": "384", "file_name": "2022_22.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2022_22.pdf", "file_type": "application/pdf", "file_size": 1843017, "creation_date": "2025-11-25", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "3f425aad-9cbd-4c0f-9788-8a1c28fc8736", "node_type": "4", "metadata": {"page_label": "384", "file_name": "2022_22.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2022_22.pdf", "file_type": "application/pdf", "file_size": 1843017, "creation_date": "2025-11-25", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "d1b1b58489d5346c04f7789ef35a8342bf7923a99fefa84d5aa45cbd5e0dff24", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "70ed48ba-8204-479b-839e-7608555fccac", "node_type": "1", "metadata": {"page_label": "384", "file_name": "2022_22.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2022_22.pdf", "file_type": "application/pdf", "file_size": 1843017, "creation_date": "2025-11-25", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "6f1dc92684fc72e81a8b1a413713b4adb1e736af222925a794af4de99aa51f53", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "10869f2b-992d-4e26-bd74-960550008f0b", "node_type": "1", "metadata": {}, "hash": "cbd16b28b680b07b01795f782e32a89a4667f156d70928c4f60aed66d8b033a7", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Results - The study population included 8728 individuals, of whom 3166 (36.3%) completed a questionnaire.\nAmong them, 2,714 were identified as having T2D, mean age 67.6 years (+2 years compared to 2007), 55.3%\nwere men (stable/2007), with a median diabetes duration of 10.7 years. And 412 individuals were identified\nas having T1D, mean age 47 years, 57% were male and 55.6% had diabetes duration \u226520 years. The socio -\neconomic level of T1D individuals was more favorable than that of T2D individuals. Risk factors for compli -\ncations were common in T2D individuals, (overweight/obesity (80.1%), treated hypertension (77.6%), treated\ndyslipidemia (63.8%), smoking (13.4%), heavy or severe alcohol consumption (7%)). They were also common\nin T1D individuals, notably overweight/obesity (49.9%), alcohol consumption (11.3%), and smoking (25.3%).\nMacrovascular complications were more frequently self-reported in T2D: coronary complication (18.6%),\nstroke (7.8%). These proportions were 11.5% and 3.3% respectively for T1D.\nMicrovascular complications were more frequently reported by T1D individuals: loss of sight in one eye (3.7%),\nactive or old foot ulcer (12.9%). These proportions were 3.2% and 6.7% respectively among T2D individuals.\nConclusion - These first results from Entred 3 provide an overview of the characteristics and health status of\nthe diabetic population in France. They confirm the significant disparities in demographic and socioeconomic\ncharacteristics between T1D and T2D .\nThe slight decrease, compared to 2007, in the frequency of self-reported complications in T2D individuals and\nthe high frequency of self-reported microvascular complications in T1D individuals need to be confirmed by\nfurther studies, including information collected from physicians.\nSome warnings already issued in previous editions can be reiterated: obesity and smoking among T2D indi -\nciduals remain at a very high level. This level is also very high among T1D individuals who also have a high\nfrequency of alcohol consumption.\nMots-cl\u00e9s : Diab\u00e8te, Niveau socio\u00e9conomique, Complications, Facteur de risque\n// Keywords: Diabetes, Socioeconomic level, Diabetes complications, Risk factor\nIntroduction\nLe diab\u00e8te est une maladie chronique tr\u00e8s fr\u00e9quente.\nEn France, plus de 3,5 millions de personnes sont\ntrait\u00e9es pharmacologiquement pour un diab\u00e8te (1).\nDans plus de 90% des cas, il s'agi t d'un diab\u00e8te de\ntype 2.", "mimetype": "text/plain", "start_char_idx": 2295, "end_char_idx": 4710, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "10869f2b-992d-4e26-bd74-960550008f0b": {"__data__": {"id_": "10869f2b-992d-4e26-bd74-960550008f0b", "embedding": null, "metadata": {"page_label": "384", "file_name": "2022_22.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2022_22.pdf", "file_type": "application/pdf", "file_size": 1843017, "creation_date": "2025-11-25", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "3f425aad-9cbd-4c0f-9788-8a1c28fc8736", "node_type": "4", "metadata": {"page_label": "384", "file_name": "2022_22.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2022_22.pdf", "file_type": "application/pdf", "file_size": 1843017, "creation_date": "2025-11-25", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "d1b1b58489d5346c04f7789ef35a8342bf7923a99fefa84d5aa45cbd5e0dff24", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "73c43bdc-bd9a-4217-8c3e-45220c47c1ec", "node_type": "1", "metadata": {"page_label": "384", "file_name": "2022_22.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2022_22.pdf", "file_type": "application/pdf", "file_size": 1843017, "creation_date": "2025-11-25", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "8164b85455da73e34f34048579f3fa31ed1785fac38dea29cba61395aa1132aa", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "En France, plus de 3,5 millions de personnes sont\ntrait\u00e9es pharmacologiquement pour un diab\u00e8te (1).\nDans plus de 90% des cas, il s'agi t d'un diab\u00e8te de\ntype 2. En outre, selon l'\u00e9tu de Esteban (\u00c9tude de\nsant\u00e9 sur l'env ironnement, la biosurveillance, l'act ivit\u00e9 physique et la nutrition), en 2014-2016, 1,2%\ndes adultes m\u00e9tropolitains \u00e2g\u00e9s de 18 \u00e0 74 ans\n(1)\npr\u00e9sentaient un diab\u00e8te et n'\u00e9ta ient pas trait\u00e9s\npharma cologiquement et 1,7% avaient un diab\u00e8te\nm\u00e9connu 1. En cas de cont r\u00f4le insuffisant de la\nmaladie, l'\u00e9volution du diab\u00e8te, qu'il s'agi sse du\ndiab\u00e8te de type 1 ou du diab\u00e8te de type 2, peut \u00eatre\nassoci\u00e9e \u00e0 de graves comp lications. Au-del\u00e0 de\nl'impact sur la qualit\u00e9 de vie des personnes touch\u00e9es\net sur leur esp\u00e9rance de vie, ces comp lications\ninduisent des co\u00fbts en soin \u00e9lev\u00e9s pour le syst\u00e8me\nde sant\u00e9 2. N\u00e9anmoins, des traitements efficaces\nassoci\u00e9s \u00e0 des examens de d\u00e9pistage pr\u00e9coce de\nces complications permettent de retarder, voire", "mimetype": "text/plain", "start_char_idx": 4550, "end_char_idx": 5508, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "5fe813a4-5e82-48fb-b1d8-1b50feda60c2": {"__data__": {"id_": "5fe813a4-5e82-48fb-b1d8-1b50feda60c2", "embedding": null, "metadata": {"page_label": "385", "file_name": "2022_22.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2022_22.pdf", "file_type": "application/pdf", "file_size": 1843017, "creation_date": "2025-11-25", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "15d14d4e-85d9-4ee6-82bf-cde584513288", "node_type": "4", "metadata": {"page_label": "385", "file_name": "2022_22.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2022_22.pdf", "file_type": "application/pdf", "file_size": 1843017, "creation_date": "2025-11-25", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "76a3c2fa907997b864457a03b6d19293f75907d8de5645904817946b64a02a48", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7c0a60c6-5f61-4926-895f-6d8f2e2317c3", "node_type": "1", "metadata": {}, "hash": "0ee08385b789565dca1517813aaaecc283d60121884b021bfa91461c255717d7", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Journ\u00e9e mondiale du diab\u00e8te, 14 novembre 2022 BEH 22 | 8 novembre 2022 | 385\nd'\u00e9viter leur survenue. Ainsi, le diab\u00e8te constitue un\nenjeu de sant\u00e9 publique majeur pour lequel il existe\ndes leviers mobilisables pour r\u00e9duire son fardeau.\nLa surveillance \u00e9pid\u00e9miologique du diab\u00e8te en\nFrance s'est d\u00e9velopp\u00e9e autour des \u00e9tudes Entred\n(\u00c9chantillon national t\u00e9moin repr\u00e9sentatif des per -\nsonnes diab\u00e9tiques), en comp l\u00e9ment des donn\u00e9es\ndisponibles dans le Syst\u00e8me national des donn\u00e9es\nde sant\u00e9 (SNDS). Deux premi\u00e8res \u00e9ditions de\ncette \u00e9tude ont \u00e9t\u00e9 men\u00e9es en 2001 et en 2007 3,\nincluant, pour chacune d'ent re elles, approximati -\nvement 10 000 personnes trait\u00e9es pharmacologi -\nquement pour un diab\u00e8te, s\u00e9lectionn\u00e9es de fa\u00e7on\nal\u00e9atoire dans deux des principaux r\u00e9gimes d'Ass urance maladie en France couvrant pr\u00e8s de 90% de\nla population fran\u00e7aise (le r\u00e9gime g\u00e9n\u00e9ral : RG, et le\nR\u00e9gime social des ind\u00e9pendants : RSI, devenu par\nla suite la S\u00e9curit\u00e9 sociale des ind\u00e9pendants : SSI).\nLes donn\u00e9es d'enqu\u00eates (auto-questionnaires aupr\u00e8s\ndes patients et des m\u00e9decins-soignants) \u00e9taient\ncoupl\u00e9es \u00e0 des donn\u00e9es m\u00e9dico- administratives\n(consommation m\u00e9dicale, donn\u00e9es d'hospitalisation,\nstatut vital et causes m\u00e9dicales de d\u00e9c\u00e8s).\nEn 2007, la deuxi\u00e8me \u00e9dition de l'\u00e9tu de Entred a\nsoulign\u00e9 la consid\u00e9rable am\u00e9lioration de la qualit\u00e9\ndes soins d\u00e9livr\u00e9s aux personnes ayant un diab\u00e8te\nde type 2 (DT2) depuis 2001. Les profils de risque\ncardiovasculaire s'\u00e9taient am\u00e9lior\u00e9s significative -\nment 3-6 . Toutefois, les r\u00e9sultats ont soulign\u00e9 que\ndes am\u00e9liorations sp\u00e9cifiques \u00e9taient encore n\u00e9ces -\nsaires, comme un meilleur d\u00e9pistage et un meilleur\ntraitement des comp lications du diab\u00e8te, particuli\u00e8 -\nrement ophtalmologiques, podologiques et r\u00e9nales.\nDes progr\u00e8s dans le contr\u00f4le des facteurs de risque\n\u00e9taient \u00e9galement n\u00e9cessaires 3-5.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1824, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "7c0a60c6-5f61-4926-895f-6d8f2e2317c3": {"__data__": {"id_": "7c0a60c6-5f61-4926-895f-6d8f2e2317c3", "embedding": null, "metadata": {"page_label": "385", "file_name": "2022_22.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2022_22.pdf", "file_type": "application/pdf", "file_size": 1843017, "creation_date": "2025-11-25", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "15d14d4e-85d9-4ee6-82bf-cde584513288", "node_type": "4", "metadata": {"page_label": "385", "file_name": "2022_22.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2022_22.pdf", "file_type": "application/pdf", "file_size": 1843017, "creation_date": "2025-11-25", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "76a3c2fa907997b864457a03b6d19293f75907d8de5645904817946b64a02a48", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5fe813a4-5e82-48fb-b1d8-1b50feda60c2", "node_type": "1", "metadata": {"page_label": "385", "file_name": "2022_22.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2022_22.pdf", "file_type": "application/pdf", "file_size": 1843017, "creation_date": "2025-11-25", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "350e4807f8d20e0b13a52a7f23a8e2d1d7efad3f8c9827159deb15dbf8d0b5f1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "952777a9-ccb1-4a20-b9ee-e4e3e613353d", "node_type": "1", "metadata": {}, "hash": "68d649f80b9fa2cc6e5ff22fd68d33e62cd600e45567b6edf8cd79bc61186406", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Toutefois, les r\u00e9sultats ont soulign\u00e9 que\ndes am\u00e9liorations sp\u00e9cifiques \u00e9taient encore n\u00e9ces -\nsaires, comme un meilleur d\u00e9pistage et un meilleur\ntraitement des comp lications du diab\u00e8te, particuli\u00e8 -\nrement ophtalmologiques, podologiques et r\u00e9nales.\nDes progr\u00e8s dans le contr\u00f4le des facteurs de risque\n\u00e9taient \u00e9galement n\u00e9cessaires 3-5.\nUne troisi\u00e8me \u00e9dition d'Ent red a \u00e9t\u00e9 mise en \u0153uvre\nen 2019 avec comme objectifs principaux :\n1/ de d\u00e9crire et d'\u00e9tudier les \u00e9volutions des caract\u00e9ristiques des personnes trait\u00e9es pharmaco -\nlogiquement pour un diab\u00e8te, notamment leur\nniveau socio\u00e9conomique, leur \u00e9tat de sant\u00e9 li\u00e9\nau diab\u00e8te, le co\u00fbt des soins, le parcours de\nsoins, y compris les d\u00e9marches \u00e9ducatives, la\nqualit\u00e9 des soins, la qualit\u00e9 de vie, la mortalit\u00e9\npar cause sp\u00e9cifique ;\n2/ d'\u00e9tudier les sp\u00e9cificit\u00e9s de certaines popula -\ntions (les personnes ayant un diab\u00e8te de type 1\n(DT1) et les personnes r\u00e9sidant en Guyane,\n\u00e0 l'\u00eele de La R\u00e9union, en Martinique et en\nGuadeloupe) ;\n3/ de produire des donn\u00e9es de r\u00e9f\u00e9rence \u00e0 la\ndisposition de la comm unaut\u00e9 scientifique,\net notamment des programmes de sant\u00e9, afin\nde pouvoir effectuer des comp araisons \u00e0 vis\u00e9e\nd'\u00e9valuation.\nCet article vise \u00e0 d\u00e9crire les caract\u00e9ristiques et l'\u00e9ta t\nde sant\u00e9 des personnes ayant un diab\u00e8te et r\u00e9sidant\nen m\u00e9tropole, en 2019, \u00e0 partir des donn\u00e9es autod\u00e9clar\u00e9es par les personnes ou issues du SNDS.\nM\u00e9thode\n\u00c9tant donn\u00e9 la n\u00e9cessit\u00e9 d'\u00e9tu dier les \u00e9volutions\ntemporelles, chaque \u00e9dition de l'\u00e9tude Entred repose\nsur une m\u00e9thodologie similaire qui associe une\nenqu\u00eate transversale \u00e0 un suivi de cohorte passive.\nLa population source inclut tous les adultes ne vivant\npas en institution ayant b\u00e9n\u00e9fici\u00e9 d'un rembourse -\nment de traitements hypoglyc\u00e9miants oraux ou\ninjectables (classe A10 de la classification ATC\n(anatomique, th\u00e9rapeutique et chimique)) \u00e0 au\nmoins trois dates diff\u00e9rentes au cours des douze\nderniers mois (ou deux dates en cas d'au moins\nun grand cond itionnement), b\u00e9n\u00e9ficiaires d'un des\nr\u00e9gimes de l'Ass urance maladie : RG (y compris\nles sections locales mutualistes infog\u00e9r\u00e9es) et SSI\nen f\u00e9vrier 2019, r\u00e9sidant en France m\u00e9tropolitaine,\ns\u00e9lectionn\u00e9s \u00e0 partir de clefs matriculaires du\nNum\u00e9ro d'inscription au r\u00e9pertoire (NIR) 7.", "mimetype": "text/plain", "start_char_idx": 1487, "end_char_idx": 3720, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "952777a9-ccb1-4a20-b9ee-e4e3e613353d": {"__data__": {"id_": "952777a9-ccb1-4a20-b9ee-e4e3e613353d", "embedding": null, "metadata": {"page_label": "385", "file_name": "2022_22.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2022_22.pdf", "file_type": "application/pdf", "file_size": 1843017, "creation_date": "2025-11-25", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "15d14d4e-85d9-4ee6-82bf-cde584513288", "node_type": "4", "metadata": {"page_label": "385", "file_name": "2022_22.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2022_22.pdf", "file_type": "application/pdf", "file_size": 1843017, "creation_date": "2025-11-25", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "76a3c2fa907997b864457a03b6d19293f75907d8de5645904817946b64a02a48", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7c0a60c6-5f61-4926-895f-6d8f2e2317c3", "node_type": "1", "metadata": {"page_label": "385", "file_name": "2022_22.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2022_22.pdf", "file_type": "application/pdf", "file_size": 1843017, "creation_date": "2025-11-25", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "a3a6082957905b2fe7f1369e61330abcd9b64c3dbdb77e6d9a23deb0988a001d", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Afin de ne\npas s\u00e9lectionner de personnes ayant \u00e9t\u00e9 incluses\ndans les \u00e9ditions pr\u00e9c\u00e9dentes et, ainsi, de garantir\nl'ind\u00e9pendance des \u00e9chantillons, les clefs matricu -\nlaires utilis\u00e9es dans les \u00e9ditions pr\u00e9c\u00e9dentes avaient\n\u00e9t\u00e9 exclues. \u00c0 partir de cette population source,\nun premier \u00e9chantillon al\u00e9atoire de 8 058 adultes\npr\u00e9sentant un diab\u00e8te a \u00e9t\u00e9 tir\u00e9 au sort. Un \u00e9chan -\ntillon al\u00e9atoire comp l\u00e9mentaire de 1 014 personnes\n\u00e2g\u00e9es de moins de 45 ans sous insuline a \u00e9t\u00e9 tir\u00e9 au\nsort afin de sur-\u00e9chantillonner les personnes ayant\nun DT1.\nL'\u00e9 t u d e comprend quatre phases successives. Apr\u00e8s\navoir \u00e9t\u00e9 inform\u00e9es par un courrier de l'Ass urance\nmaladie de leur s\u00e9lection pour participer \u00e0 Entred 3\net invit\u00e9es \u00e0 r\u00e9pondre \u00e0 un auto-questionnaire par\nInternet ou \u00e0 transmettre leur num\u00e9ro de t\u00e9l\u00e9phone,\nles personnes n'ayant pas refus\u00e9 de participer ont\n\u00e9t\u00e9 contact\u00e9es par une infirmi\u00e8re form\u00e9e (de la plateforme Sophia de l'Ass urance maladie), pour une\nbr\u00e8ve enqu\u00eate t\u00e9l\u00e9phonique. Qu'elles aient particip\u00e9\nou non \u00e0 l'enq u\u00eate t\u00e9l\u00e9phonique, les personnes qui\nn'avaient pas comp l\u00e9t\u00e9 le questionnaire par Internet\nrecevaient un auto-questionnaire d\u00e9taill\u00e9 par voie\npostale.\n\u00c0 la fin des questionnaires, les coordonn\u00e9es des\nm\u00e9decins soignants \u00e9taient recueillies, puis une\nenqu\u00eate m\u00e9dicale par auto-questionnaire postal ou\nInternet \u00e9tait r\u00e9alis\u00e9e aupr\u00e8s de ces derniers, comprenant notamment un recueil de donn\u00e9es cliniques et\nbiologiques.\nEn parall\u00e8le de ces recueils de donn\u00e9es par ques -\ntionnaires, une extraction des donn\u00e9es du SNDS a\n\u00e9t\u00e9 effectu\u00e9e sur une p\u00e9riode de dix ans avant l'inclusion, pour l'ens emble des personnes tir\u00e9es au sort\nqui ne s'y \u00e9taient pas oppos\u00e9es, avec des extractions\nannuelles de donn\u00e9es pr\u00e9vues pour les 10 ann\u00e9es\nsuivantes, soit un recueil pr\u00e9vu sur une p\u00e9riode totale\nde vingt ans. Des indicateurs de cons ommation de\nsoins, tels que m\u00e9dicaments ou actes, ont \u00e9t\u00e9 d\u00e9ve -\nlopp\u00e9s par p\u00e9riode de 12 mois, et des indicateurs\nd'hospitalisation ont \u00e9t\u00e9 d\u00e9velopp\u00e9s sur des p\u00e9riodes\nde 12 mois et \u00e9galement de 10 ans, \u00e0 partir d'alg orithmes publi\u00e9s pr\u00e9c\u00e9demment 8.", "mimetype": "text/plain", "start_char_idx": 3721, "end_char_idx": 5811, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "874fc012-0462-49c1-b9e9-cb33cee6af92": {"__data__": {"id_": "874fc012-0462-49c1-b9e9-cb33cee6af92", "embedding": null, "metadata": {"page_label": "386", "file_name": "2022_22.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2022_22.pdf", "file_type": "application/pdf", "file_size": 1843017, "creation_date": "2025-11-25", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "3776cd45-8e7c-44c4-b92f-824e4df55a2b", "node_type": "4", "metadata": {"page_label": "386", "file_name": "2022_22.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2022_22.pdf", "file_type": "application/pdf", "file_size": 1843017, "creation_date": "2025-11-25", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "2ca64f244d6f07d27b64bc2dd52072e693d751714b215fd4881b6f1507807a04", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d5afc1ac-b2ad-46db-a1ef-fde22601ee46", "node_type": "1", "metadata": {}, "hash": "5c7963e7f68c414bf7b56335dffbf1444234b5500ad455ea34e71f4428e4831f", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "386 | 8 novembre 2022 | BEH 22 Journ\u00e9e mondiale du diab\u00e8te, 14 novembre 2022\n\u00c0 partir d 'un algorithme \u00e9pid\u00e9miologique d\u00e9ve -\nlopp\u00e9 dans les \u00e9ditions pr\u00e9c\u00e9dentes 9 ainsi que de\nl'ensemble des informations disponibles sur l'his -\ntoire du diab\u00e8te, qu'elles soient recueillies aupr\u00e8s\ndes patients ou, le cas \u00e9ch\u00e9ant, de leurs m\u00e9decins,\nou des indicateurs issus du SNDS, les personnes ont\n\u00e9t\u00e9 class\u00e9es comm e DT1, DT2, ou comm e ayant un\nautre type de diab\u00e8te.\nPar ailleurs, pour chaque personne tir\u00e9e au sort,\ndes informations auxiliaires venaient comp l\u00e9ter\nles extractions du SNDS pour les personnes ne\nles ayant pas refus\u00e9es. Ainsi, les requ\u00eates de\ns\u00e9lection de la population source int\u00e9graient des\nextractions de donn\u00e9es (sexe, \u00e2ge, traitements\nantidiab\u00e9tiques) auxquelles venaient s'ajo uter des\ninformations compl\u00e9mentaires : le g\u00e9ocodage des\nadresses postales \u00e0 l'\u00celo t regroup\u00e9 pour l'inf ormation statistique (Iris), permettant d'ass ocier un indi -\ncateur \u00e9cologique de d\u00e9savantage social (FDep) 10\n\u00e0 une unit\u00e9 g\u00e9ographique relativement fine (quar -\ntier d'environ 2 000 habitants), ainsi que le code du\npays de naissance extrait du num\u00e9ro d'ins cription\nau r\u00e9pertoire (NIR) par l'Ass urance maladie. Ces\ninformations auxiliaires ont permis d'\u00e9tu dier les\ncaract\u00e9ristiques des personnes n'aya nt pas parti -\ncip\u00e9 \u00e0 l'enq u\u00eate par questionnaire sur des crit\u00e8res\nde vuln\u00e9rabilit\u00e9 socio\u00e9conomique, d'\u00e9ta t de sant\u00e9\nou de recours aux soins. Des jeux de pond\u00e9rations\nont ainsi pu \u00eatre d\u00e9velopp\u00e9s tenant comp te \u00e0 la\nfois du plan de sondage et de la non-participation\n\u00e0 l'enqu\u00eate par questionnaire. Afin de comparer les\n\u00e9volutions des estimations avec l'\u00e9di tion men\u00e9e\nen 2007, un second jeu de pond\u00e9ration a \u00e9galement\n\u00e9t\u00e9 d\u00e9velopp\u00e9, bas\u00e9 sur la m\u00e9thodologie utilis\u00e9e\npour Entred 2 9, c'est-\u00e0-dire tenant comp te du plan\nde sondage et de la non-participation selon les\ncrit\u00e8res li\u00e9s au sexe, \u00e0 l'\u00e2ge et aux traitements anti -\ndiab\u00e9tiques uniquement.\nLes estimations sont pr\u00e9sent\u00e9es sous forme de pourcentage ou de moyenne pond\u00e9r\u00e9s, avec un intervalle\nde confiance \u00e0 95% associ\u00e9. Les comparaisons par\nrapport \u00e0 Entred 2 sont pr\u00e9sent\u00e9es en points d'\u00e9vo -\nlution des estimations pond\u00e9r\u00e9es selon la m\u00e9thodo -\nlogie Entred 2.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2222, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "d5afc1ac-b2ad-46db-a1ef-fde22601ee46": {"__data__": {"id_": "d5afc1ac-b2ad-46db-a1ef-fde22601ee46", "embedding": null, "metadata": {"page_label": "386", "file_name": "2022_22.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2022_22.pdf", "file_type": "application/pdf", "file_size": 1843017, "creation_date": "2025-11-25", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "3776cd45-8e7c-44c4-b92f-824e4df55a2b", "node_type": "4", "metadata": {"page_label": "386", "file_name": "2022_22.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2022_22.pdf", "file_type": "application/pdf", "file_size": 1843017, "creation_date": "2025-11-25", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "2ca64f244d6f07d27b64bc2dd52072e693d751714b215fd4881b6f1507807a04", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "874fc012-0462-49c1-b9e9-cb33cee6af92", "node_type": "1", "metadata": {"page_label": "386", "file_name": "2022_22.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2022_22.pdf", "file_type": "application/pdf", "file_size": 1843017, "creation_date": "2025-11-25", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "4dab18a7378e28f87e07e0d288f5ba6506e73d5525e6aa8ae7deb0d02ca5bd2e", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Les estimations sont pr\u00e9sent\u00e9es sous forme de pourcentage ou de moyenne pond\u00e9r\u00e9s, avec un intervalle\nde confiance \u00e0 95% associ\u00e9. Les comparaisons par\nrapport \u00e0 Entred 2 sont pr\u00e9sent\u00e9es en points d'\u00e9vo -\nlution des estimations pond\u00e9r\u00e9es selon la m\u00e9thodo -\nlogie Entred 2.\nR\u00e9sultats\nEn f\u00e9vrier 2019, 9 072 personnes ont \u00e9t\u00e9 s\u00e9lection -\nn\u00e9es pour participer \u00e0 Entred 3, parmi lesquelles 344\nont \u00e9t\u00e9 consid\u00e9r\u00e9es hors champ car elles n'ont pas\npu \u00eatre inform\u00e9es de leur s\u00e9lection dans l'\u00e9tu de\n( courrier retourn\u00e9 non distribu\u00e9, d\u00e9c\u00e8s avant l'env oi\ndu courrier) ou \u00e9taient institutionnalis\u00e9es. Parmi\nles 8 728 personnes consid\u00e9r\u00e9es dans le champ\nde l'enqu\u00eate (figure 1), 3 166 personnes ont parti -\ncip\u00e9 \u00e0 l'enq u\u00eate par questionnaire (36,3%), dont\n2 176 par auto-questionnaire papier, 678 par autoquestionnaire Internet et 312 par questionnaire\nt\u00e9l\u00e9phonique court uniquement. Les comm unes de\nr\u00e9sidence des participants ont \u00e9t\u00e9 cartographi\u00e9es\n(figure 2).\nPar ailleurs, des extractions de donn\u00e9es du SNDS\nont pu \u00eatre effectu\u00e9es pour 93,5% de la population\nd'\u00e9tude, soit 8 138 personnes, 568 personnes s'y\n\u00e9taient oppos\u00e9es et les donn\u00e9es n'ont pas pu \u00eatre\nappari\u00e9es pour 22 personnes.\nParmi les 8 138 personnes de la population d'\u00e9tu de\npour lesquelles un suivi de cohorte passif est\npossible, 55,0% (intervalle de confi ance \u00e0 95% :\nIC95%: [53,8-56,2]) \u00e9taient des hommes, d'un \u00e2ge\nFigure 1\nR\u00e9partition de l'\u00e9chantillon de 9 072 personnes \u00e2g\u00e9es\nde 18 ans et plus, s\u00e9lectionn\u00e9es pour participer\n\u00e0 l'\u00e9tude Entred 3\nTirage au sort\nN=9 072\nPopulation\nd'\u00e9tude\nN=8 728\nHors champ\nN=344\nParticipant\npar questionnaire\nN=3 166*\nSuivi cohorte\npassive\nN=8 138 Questionnaire\ncourt t\u00e9l\u00e9phonique\nuniquement\nN=312\nQuestionnaire\nd\u00e9taill\u00e9\nN=2 854\n* Dont N=3 014 avec un suivi de cohorte passive.\nFigure 2\nCommunes de r\u00e9sidence des participants\npar questionnaire r\u00e9sidant en m\u00e9tropole\npour l'\u00e9tude Entred 3\nSource : Entred 3, Sant\u00e9 publique France, 2022.\nNombre de participants\n(par commune contribuant \u00e0 l'enqu\u00eate)\n[1-5] [6-10] [11-20]", "mimetype": "text/plain", "start_char_idx": 1952, "end_char_idx": 3966, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "24f61020-1798-4c35-914a-f6f4db55fead": {"__data__": {"id_": "24f61020-1798-4c35-914a-f6f4db55fead", "embedding": null, "metadata": {"page_label": "387", "file_name": "2022_22.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2022_22.pdf", "file_type": "application/pdf", "file_size": 1843017, "creation_date": "2025-11-25", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "941d163f-8a67-4980-a6a7-659a390d3f12", "node_type": "4", "metadata": {"page_label": "387", "file_name": "2022_22.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2022_22.pdf", "file_type": "application/pdf", "file_size": 1843017, "creation_date": "2025-11-25", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "b46d2095d74986d642987e3d9b6a62f267c6df312af829e37c800bb7642ab40c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8c55acdc-aa90-42c9-b13f-eb5a2283c074", "node_type": "1", "metadata": {}, "hash": "d857564ebdc3e29e2c405c8a7d12a9d1e4a040b8289fead3cfda4c8033f0e2a6", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Journ\u00e9e mondiale du diab\u00e8te, 14 novembre 2022 BEH 22 | 8 novembre 2022 | 387\nmoyen de 66,8 ans [66,5-67,0]. Pr\u00e8s d'un quart d'entre\nelles (24,0% [23,0-25,0]) \u00e9taient n\u00e9es \u00e0 l'\u00e9tr anger,\net dans 11,1% [10,3-11,9] des cas, il s'agissait d'un\npays du Maghreb. Pr\u00e8s d'un quart des personnes\n(23,8% [22,7-24,8]) r\u00e9sidaient dans un Iris faisant\npartie du quintile le plus d\u00e9favoris\u00e9 de France m\u00e9tropolitaine, tandis que 14,7% [13,9-15,6] r\u00e9sidaient dans\nun Iris du quintile le plus favoris\u00e9.\nParmi les 3 166 personnes ayant r\u00e9pondu \u00e0 l'enqu\u00eate,\nquel que soit le mode, 2 714 (94,1% [93,2-94,9]) ont \u00e9t\u00e9\nclass\u00e9es comme DT2, 412 (5,1% [4,4-5,9]) comme DT1,\net 40 (0,8% [0,5-1,2]) ayant un autre type de diab\u00e8te\nou un type ind\u00e9termin\u00e9 par manque d'information.\nCaract\u00e9ristiques sociod\u00e9mographiques\net socio\u00e9conomiques\nLes caract\u00e9ristiques sociod\u00e9mographiques et socio -\n\u00e9conomiques sont pr\u00e9sent\u00e9es dans le tableau 1\nselon le type de diab\u00e8te et illustrent les sp\u00e9cifi -\ncit\u00e9s de ces deux populations. Les personnes DT2\n\u00e9taient principalement des hommes (55,3%), d'un\n\u00e2ge moyen de 67,6 ans, n\u00e9es en France dans\n76,3% des cas et n\u00e9es dans un pays du Maghreb\ndans 11,1% des cas, tandis que les personnes DT1,\n\u00e9galement \u00e0 pr\u00e9dominance masculine (57,2%)\n\u00e9taient plus jeunes, 47 ans en moyenne, et n\u00e9es en\nFrance dans 82,7% des cas.\nTableau 1\nCaract\u00e9ristiques sociod\u00e9mographiques et socio\u00e9conomiques selon le type de diab\u00e8te en 2019, et \u00e9volution depuis 2007\npour les personnes ayant un diab\u00e8te de type 2\nDiab\u00e8te de type 1\n(N=412)\nDiab\u00e8te de type 2\n(DT2) (N=2 714)\n\u00c9volution depuis 2007\n(DT2)\n% IC95% % IC95% Points\nHommes 57,2 [50,3-63,9] 55,3 [53,2-57,5] +0,5\n\u00c2ge moyen (ans) 47,0 [44,9-49,2] 67,6 [67,1-68,1] +1,8\nPays de naissance\nFrance 82,7 [76,5-87,8] 76,3 [74,3-78,2] +0,3\nMaghreb 4,", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1774, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "8c55acdc-aa90-42c9-b13f-eb5a2283c074": {"__data__": {"id_": "8c55acdc-aa90-42c9-b13f-eb5a2283c074", "embedding": null, "metadata": {"page_label": "387", "file_name": "2022_22.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2022_22.pdf", "file_type": "application/pdf", "file_size": 1843017, "creation_date": "2025-11-25", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "941d163f-8a67-4980-a6a7-659a390d3f12", "node_type": "4", "metadata": {"page_label": "387", "file_name": "2022_22.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2022_22.pdf", "file_type": "application/pdf", "file_size": 1843017, "creation_date": "2025-11-25", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "b46d2095d74986d642987e3d9b6a62f267c6df312af829e37c800bb7642ab40c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "24f61020-1798-4c35-914a-f6f4db55fead", "node_type": "1", "metadata": {"page_label": "387", "file_name": "2022_22.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2022_22.pdf", "file_type": "application/pdf", "file_size": 1843017, "creation_date": "2025-11-25", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "5cc2a1442c85426de180e0e9a35a401ee2924f774f00fc2884d8c3bd0ec57320", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4fc29b02-6e32-4fec-9aae-d08fa59013e2", "node_type": "1", "metadata": {}, "hash": "27b128895f38b8c3a3251fc9c3223ffe35257a2cbdbbfb0bf370c859582cfbb7", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "3 [53,2-57,5] +0,5\n\u00c2ge moyen (ans) 47,0 [44,9-49,2] 67,6 [67,1-68,1] +1,8\nPays de naissance\nFrance 82,7 [76,5-87,8] 76,3 [74,3-78,2] +0,3\nMaghreb 4,0 [2,3-6,3] 11,1 [9,7-12,7] -0,7\nAutre pays 13,3 [8,5-19,5] 12,6 [11,1-14,2] +0,5\nNiveau d'\u00e9tudes\nJamais scolaris\u00e9(e) 0,8 [0,2-2,2] 3,9 [3,0-5,0] -1,7\nPrimaire non termin\u00e9 0,8 [0,2-2,3] 6,0 [5,0-7,2] -5,6\nPrimaire termin\u00e9, Certificat d'\u00e9tudes primaires 3,0 [0,9-7,1] 23,7 [21,8-25,6] -10,5\nColl\u00e8ge, BEPC, CAP , BEP 37,8 [30,6-45,4] 38,3 [36,2-40,4) +9,2\nLyc\u00e9e, Bac, Bac + 1 an 20,1 [15,3-25,7] 12,4 [11,1-13,9] +3,4\nBac + 2 \u00e0 Bac + 4 ans 22,9 [18,2-28,2] 10,8 [9,6-12,2] +1,0\nBac + 5 ans et plus 14,6 [10,3-19,7] 4,9 [4,1-5,8] +4,3\nDerni\u00e8re profession exerc\u00e9e et cat\u00e9gorie professionnelle*\nArtisans, commer\u00e7ants et chefs d'entreprise 4,6 [2,0-8,8] 7,2 [6,1-8,3] -2,8\nCadres et professions intellectuelles sup\u00e9rieures 14,3 [9,2-20,7] 10,2 [8,9-11,5] +4,6\nProfessions interm\u00e9diaires 21,4 [16,4-27,1] 16,0 [14,1-17,2] -0,5\nEmploy\u00e9s 31,4 [24,8-38,6] 23,5 [21,6-25,5] +3,6\nOuvriers 15,6 [10,7-21,7] 22,6 [20,7-24,5] -3,4\nHommes ou femmes au foyer, ou n'ayant jamais travaill\u00e9 0,8 [0,2-2,2] 6,0 [4,9-7,4] -1,4\nAutres (\u00e9tudiants,", "mimetype": "text/plain", "start_char_idx": 1626, "end_char_idx": 2796, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "4fc29b02-6e32-4fec-9aae-d08fa59013e2": {"__data__": {"id_": "4fc29b02-6e32-4fec-9aae-d08fa59013e2", "embedding": null, "metadata": {"page_label": "387", "file_name": "2022_22.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2022_22.pdf", "file_type": "application/pdf", "file_size": 1843017, "creation_date": "2025-11-25", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "941d163f-8a67-4980-a6a7-659a390d3f12", "node_type": "4", "metadata": {"page_label": "387", "file_name": "2022_22.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2022_22.pdf", "file_type": "application/pdf", "file_size": 1843017, "creation_date": "2025-11-25", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "b46d2095d74986d642987e3d9b6a62f267c6df312af829e37c800bb7642ab40c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8c55acdc-aa90-42c9-b13f-eb5a2283c074", "node_type": "1", "metadata": {"page_label": "387", "file_name": "2022_22.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2022_22.pdf", "file_type": "application/pdf", "file_size": 1843017, "creation_date": "2025-11-25", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "a1cbc6972ef4a833e9e80075d926c756059b8ddff39253cfda1d37e6a8cae19a", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "6-25,5] +3,6\nOuvriers 15,6 [10,7-21,7] 22,6 [20,7-24,5] -3,4\nHommes ou femmes au foyer, ou n'ayant jamais travaill\u00e9 0,8 [0,2-2,2] 6,0 [4,9-7,4] -1,4\nAutres (\u00e9tudiants, agriculteurs) 3,7 [2,1-6,1] 0,03 [0,0-0,2] -\nManquant 8,2 [4,8-13,0] 14,9 [13,3-16,6] -1,3\nRessenti financier\nVous \u00eates \u00e0 l'aise 14,6 [10,6-19,4] 13,1 [11,7-14,5] +6,4\n\u00c7a va 41,8 [35,1-48,7] 42,7 [40,6-44,8] +5,5\nC'est juste 20,2 [15,3-25,8] 24,8 [22,9-26,7] -7,9\nVous y arrivez difficilement 15,6 [10,2-22,5] 16,1 [14,5-17,8] -3,0\nVous ne pouvez pas y arriver sans faire de dettes 7,8 [3,5-14,6] 3,4 [2,6-4,3] -0,9\nIC95% : intervalle de confiance \u00e0 95%.\n* Information recueillie uniquement dans le questionnaire d\u00e9taill\u00e9.", "mimetype": "text/plain", "start_char_idx": 2629, "end_char_idx": 3319, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "cc2e3dfc-455c-4801-bab0-2ee4918b8104": {"__data__": {"id_": "cc2e3dfc-455c-4801-bab0-2ee4918b8104", "embedding": null, "metadata": {"page_label": "388", "file_name": "2022_22.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2022_22.pdf", "file_type": "application/pdf", "file_size": 1843017, "creation_date": "2025-11-25", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "8570a108-4af9-44bc-b05b-0542b8b981cb", "node_type": "4", "metadata": {"page_label": "388", "file_name": "2022_22.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2022_22.pdf", "file_type": "application/pdf", "file_size": 1843017, "creation_date": "2025-11-25", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "0719df24b02ce213429aa95ee747b8357fc457916d13a2039a8b4e6fe4014bdd", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "efe38aa5-38fc-4847-942b-f908c3404fa1", "node_type": "1", "metadata": {}, "hash": "551b35ce8332f502adc36bb12da93d0ca7c0c87d08230eb85e935b45fd3fb342", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "388 | 8 novembre 2022 | BEH 22 Journ\u00e9e mondiale du diab\u00e8te, 14 novembre 2022\nEn termes de niveau socio\u00e9conomique, 34% des\npersonnes DT2 n'avaient pas atteint l'ens eignement\nsecondaire : 10% n'ava ient jamais \u00e9t\u00e9 scolaris\u00e9es\nou n'avaient pas termin\u00e9 l'\u00e9co le primaire et 24%\navaient suivi l'int \u00e9gralit\u00e9 de l'ens eignement primaire\n(versus moins de 5% pour les personnes DT1).\nEnviron 38% des personnes DT2 avaient un niveau\nde scolarit\u00e9 interm\u00e9diaire (coll\u00e8ge ou \u00e9quivalent),\nfr\u00e9quence identique parmi les personnes DT1. Un\npeu plus d'un quart (28,1%) des personnes DT2\navaient atteint le lyc\u00e9e ou un niveau sup\u00e9rieur,\nversus 57,6% des personnes DT1. La r\u00e9partition\ndes professions et cat\u00e9gories professionnelles\n\u00e9tait \u00e9galement diff\u00e9rente entre les personnes DT2\net celles DT1 avec une majorit\u00e9 d'emp loy\u00e9s (31,4%)\net de professions interm\u00e9diaires (21,4%) parmi\nles personnes DT1, tandis que les personnes DT2\n\u00e9taient surtout employ\u00e9s (23,5%) et ouvriers\n(22,6%). Le ressenti financier est plus \u00e9quilibr\u00e9\nentre les personnes DT2 et celles DT1, respective -\nment 55,8% et 56,4% d\u00e9claraient \u00ab \u00e7a va \u00bb ou \u00ab \u00eatre\n\u00e0 l'aise \u00bb financi\u00e8rement.\nPar rapport \u00e0 2007, les personnes DT2 \u00e9taient\nplus \u00e2g\u00e9es de 2 ans, la proportion d'hom mes\n\u00e9tait stable (+0,5 point). Le niveau d'\u00e9tu des avait\naugment\u00e9, avec une proportion de personnes\nayant atteint le niveau lyc\u00e9e ou plus progressant de\npr\u00e8s de 9 points et \u00e0 l'inv erse, celui des personnes\nayant un niveau primaire ou moins r\u00e9gressant de\n18 points. De m\u00eame, le ressenti financier \u00e9tait plus\nfavorable avec une proportion de personnes d\u00e9cla -\nrant \u00ab pas de souci \u00bb progressant de 12 points.\nHistoire de la maladie\nParmi les personnes DT2, l'anc iennet\u00e9 m\u00e9diane\ndu diab\u00e8te auto-d\u00e9clar\u00e9e \u00e9tait de 10,7 ans, et\n21% (19,3-22,8) avaient \u00e9t\u00e9 diagnostiqu\u00e9es depuis\nquatre ans ou moins, 19,7% [18,0-21,4] entre cinq\net neuf ans, 33,7% [31,6-35,7] entre 10 et 19 ans et\n25,6% [23,7-27,6] depuis plus de 20 ans.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1942, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "efe38aa5-38fc-4847-942b-f908c3404fa1": {"__data__": {"id_": "efe38aa5-38fc-4847-942b-f908c3404fa1", "embedding": null, "metadata": {"page_label": "388", "file_name": "2022_22.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2022_22.pdf", "file_type": "application/pdf", "file_size": 1843017, "creation_date": "2025-11-25", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "8570a108-4af9-44bc-b05b-0542b8b981cb", "node_type": "4", "metadata": {"page_label": "388", "file_name": "2022_22.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2022_22.pdf", "file_type": "application/pdf", "file_size": 1843017, "creation_date": "2025-11-25", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "0719df24b02ce213429aa95ee747b8357fc457916d13a2039a8b4e6fe4014bdd", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "cc2e3dfc-455c-4801-bab0-2ee4918b8104", "node_type": "1", "metadata": {"page_label": "388", "file_name": "2022_22.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2022_22.pdf", "file_type": "application/pdf", "file_size": 1843017, "creation_date": "2025-11-25", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "4c305fb01e1506722cdd038dd127fed40ce47eed1bdf500d35a103a839324559", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "cf136d6f-3cfb-42ea-ba45-e262ca420deb", "node_type": "1", "metadata": {}, "hash": "023615a8d695d25a05196cefdecf1f74d5543831c16f7016a74ef0e391b229ab", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Par rapport\n\u00e0 2007, le diab\u00e8te \u00e9tait plus ancien (+2 ans en\nm\u00e9diane) avec une \u00e9volution de -8,9 points de la\nproportion de personnes ayant un diab\u00e8te r\u00e9cent,\n-3,8 points pour le diab\u00e8te entre cinq et neuf ans\net +5,5 et +7,2 points pour un diab\u00e8te d\u00e9couvert\nrespectivement entre 10 et 19 ans et 20 ans ou plus.\nDans 70% [67,8-72,0] des cas, ce diab\u00e8te avait \u00e9t\u00e9\nd\u00e9couvert \u00e0 la suite d 'un d\u00e9pistage (+3,3 points par\nrapport \u00e0 2007), et dans 11,7% [10,3-13,3] \u00e0 l'occ asion d'une complication (-3,8 points par rapport \u00e0\n2007). La fr\u00e9quence de d\u00e9couverte sur sympt\u00f4mes\n(18,3% [16,6-20,1]) est rest\u00e9e stable par rapport \u00e0\n2007 (+0,5 point).\nAu cours des 12 derniers mois pr\u00e9c\u00e9dant le tirage\nau sort, 81,6% [79,8-83,3] des personnes DT2\navaient \u00e9t\u00e9 rembours\u00e9es de biguanides. Dans 71,2%\n[69,1-73,2] des cas, les personnes DT2 \u00e9taient trai -\nt\u00e9es uniquement par voie orale (anti diab\u00e9tiques\noraux (ADO)), et pour 34,3% [32,3 -36,4], il s'agissait\nd'une monoth\u00e9rapie. Dans 6,0% [5,1 -7,2] des cas, le\nou les ADO \u00e9taient associ\u00e9s \u00e0 un analogue du GLP1.\nDix-huit pour cent (16,3 -19,8) des personnes DT2\n\u00e9taient trait\u00e9es par insuline associ\u00e9e \u00e0 des ADO\net/ ou un analogue du GLP1. Enfin, 4,5% [3,6-5,5]\n\u00e9taient trait\u00e9es uniquement par insuline.\nPlus de la moiti\u00e9 des personnes DT1 avaient\nun diab\u00e8te diagnostiqu\u00e9 depuis plus de 20 ans\n(55,6% [48,7 -62,3]), ou entre 10 et 19 ans dans\n25,7% [20,4 -31,5] des cas. Seules 8,4% [5,7 -11,6]\ndes personnes DT1 avaient \u00e9t\u00e9 diagnostiqu\u00e9es\nr\u00e9cemment (\u2264 4 ans). Par ailleurs, 36,2% [29,8-43,0]\ndes personnes DT1 avaient \u00e9t\u00e9 rembours\u00e9es d'une\npompe \u00e0 insuline au cours des 12 derniers mois,\net 66% [58,7-72,8] de capteurs pour lecteurs de\nglyc\u00e9mie en continu.", "mimetype": "text/plain", "start_char_idx": 1943, "end_char_idx": 3633, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "cf136d6f-3cfb-42ea-ba45-e262ca420deb": {"__data__": {"id_": "cf136d6f-3cfb-42ea-ba45-e262ca420deb", "embedding": null, "metadata": {"page_label": "388", "file_name": "2022_22.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2022_22.pdf", "file_type": "application/pdf", "file_size": 1843017, "creation_date": "2025-11-25", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "8570a108-4af9-44bc-b05b-0542b8b981cb", "node_type": "4", "metadata": {"page_label": "388", "file_name": "2022_22.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2022_22.pdf", "file_type": "application/pdf", "file_size": 1843017, "creation_date": "2025-11-25", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "0719df24b02ce213429aa95ee747b8357fc457916d13a2039a8b4e6fe4014bdd", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "efe38aa5-38fc-4847-942b-f908c3404fa1", "node_type": "1", "metadata": {"page_label": "388", "file_name": "2022_22.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2022_22.pdf", "file_type": "application/pdf", "file_size": 1843017, "creation_date": "2025-11-25", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "651b6578cde1b1993e35ba7873282ba80982e9c96afdd95e025edf3c8f5d6833", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "32df878e-ccb6-465a-b087-b932a2eae4f1", "node_type": "1", "metadata": {}, "hash": "08dee1ff9e0ceb630fc4488b507a09f91e1fc18f6b745331cd03cfc0e8962cc7", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Par ailleurs, 36,2% [29,8-43,0]\ndes personnes DT1 avaient \u00e9t\u00e9 rembours\u00e9es d'une\npompe \u00e0 insuline au cours des 12 derniers mois,\net 66% [58,7-72,8] de capteurs pour lecteurs de\nglyc\u00e9mie en continu.\nAu cours des 12 derniers mois , 27,3% [21,5 -33,6]\ndes personnes DT1 et 10,6% [9,4-12,0] des\npersonnes DT2 (+2 points par rapport \u00e0 2007) ont \u00e9t\u00e9\nrembours\u00e9es pour une consultation chez un endo -\ncrinologue lib\u00e9ral. Tandis que le nombre m\u00e9dian\nde consultations ou visites en m\u00e9decine g\u00e9n\u00e9 -\nrale sur les 12 mois pr\u00e9c\u00e9dents \u00e9tait de 3,3 pour\nles personnes DT1 et 5,5 pour les personnes DT2\n(-1,3 par rapport \u00e0 2007).\nFacteurs de risque de complications\n\u00c0 l'exception du tabagisme et de la cons ommation\nd'alcool, les facteurs de risque \u00e9taient moins fr\u00e9quents\nchez les personnes DT1 que chez les personnes DT2\n(tableau 2).\nParmi les personnes DT2, l'ind ice de masse\ncorporelle (IMC) moyen \u00e9tait de 29,5 kg/m 2.\nPr\u00e8s de 40% \u00e9taient en surpoids et 40,2%\npr\u00e9sentaient une ob\u00e9sit\u00e9, dont 4% une ob\u00e9sit\u00e9\nmassive ( \u2265 4 0 k g / m2). Une hypertension \u00e9tait\nauto- d\u00e9clar\u00e9e par 61,1% des personnes DT2, un\ntraitement antihypertenseur avait \u00e9t\u00e9 rembours\u00e9\ndans les 12 mois pour 77,6% des personnes.\nUne dyslipid\u00e9mie \u00e9tait auto-d\u00e9clar\u00e9e par 58,8%\ndes personnes DT2, et un traitement hypolip\u00e9 -\nmiant rembours\u00e9 dans les 12 derniers mois chez\n63,8% d'entre elles. Concernant le tabagisme,\nce sont 13,4% des personnes DT2 qui d\u00e9claraient\nfumer occasionnellement ou tous les jours. Enfin,\n7% avaient une cons ommation d'alcool de niveau\n\u00e9lev\u00e9 ou s\u00e9v\u00e8re (selon le score de l'AUDIT-C 11).\nCompar\u00e9s \u00e0 2007, ces facteurs de risque de\ncomplication \u00e9taient stables.\nParmi les personnes DT1, 29,2% \u00e9taient en\nsurpoids, 20,7% \u00e9taient ob\u00e8ses ; 34,2% d\u00e9claraient\nune hypertension, 40,9% \u00e9taient trait\u00e9es par antihypertenseurs ; 31,5% d\u00e9claraient une dyslipid\u00e9mie\net 30,4% \u00e9taient trait\u00e9es par hypolip\u00e9miant. Plus\nd'un quart de la population de DT1 fumait occasion -\nnellement ou quotidiennement (25,3%).", "mimetype": "text/plain", "start_char_idx": 3437, "end_char_idx": 5408, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "32df878e-ccb6-465a-b087-b932a2eae4f1": {"__data__": {"id_": "32df878e-ccb6-465a-b087-b932a2eae4f1", "embedding": null, "metadata": {"page_label": "388", "file_name": "2022_22.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2022_22.pdf", "file_type": "application/pdf", "file_size": 1843017, "creation_date": "2025-11-25", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "8570a108-4af9-44bc-b05b-0542b8b981cb", "node_type": "4", "metadata": {"page_label": "388", "file_name": "2022_22.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2022_22.pdf", "file_type": "application/pdf", "file_size": 1843017, "creation_date": "2025-11-25", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "0719df24b02ce213429aa95ee747b8357fc457916d13a2039a8b4e6fe4014bdd", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "cf136d6f-3cfb-42ea-ba45-e262ca420deb", "node_type": "1", "metadata": {"page_label": "388", "file_name": "2022_22.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2022_22.pdf", "file_type": "application/pdf", "file_size": 1843017, "creation_date": "2025-11-25", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "1765809ab7abee36f1bace70e8b77ac57703160845664934c116747cd83cf82e", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Plus\nd'un quart de la population de DT1 fumait occasion -\nnellement ou quotidiennement (25,3%). Enfin, 7,4%\navaient une cons ommation d'alcool de niveau \u00e9lev\u00e9\net 3,9% s\u00e9v\u00e8re (tableau 2).\nComplications\nLes comp lications macrovasculaires \u00e9taient plus\nfr\u00e9quentes chez les personnes DT2 que chez\nles personnes DT1 (tableau 3). Ainsi, pr\u00e8s de 19%", "mimetype": "text/plain", "start_char_idx": 5313, "end_char_idx": 5655, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "1a40e132-e141-4b98-a0fe-a344cc83118a": {"__data__": {"id_": "1a40e132-e141-4b98-a0fe-a344cc83118a", "embedding": null, "metadata": {"page_label": "389", "file_name": "2022_22.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2022_22.pdf", "file_type": "application/pdf", "file_size": 1843017, "creation_date": "2025-11-25", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "cae001d1-adc4-43c4-86eb-3afca61af625", "node_type": "4", "metadata": {"page_label": "389", "file_name": "2022_22.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2022_22.pdf", "file_type": "application/pdf", "file_size": 1843017, "creation_date": "2025-11-25", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "b1f4d710103d927292b9193f69bd0532c0d26a099a278ceb44762edf5fe56a3b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "063b122e-f554-4cf0-8ce9-7272157bcc1f", "node_type": "1", "metadata": {}, "hash": "8872dd8a0505d44c0560e84f4e051f1c80f3c892f7bdb696202037540bc138d2", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Journ\u00e9e mondiale du diab\u00e8te, 14 novembre 2022 BEH 22 | 8 novembre 2022 | 389\ndes personnes DT2 avaient d\u00e9clar\u00e9 une comp lication coronarienne (infarctus du myocarde (IDM),\nangor, revascularisation coronaire), 3,4% avaient\n\u00e9t\u00e9 hospitalis\u00e9es pour un IDM dans les 10 ans,\n7,8% d\u00e9claraient avoir eu un accident vasculaire\nc\u00e9r\u00e9bral (AVC), et 2,6% avaient eu au moins une\nhospitalisation pour AVC dans les 10 ans. Ces\nproportions \u00e9taient respectivement de 11,5%,\n2,9%, 3,3% et 0% pour les DT1.\n\u00c0 l'inverse, des comp lications microvasculaires\n\u00e9taient davantage rapport\u00e9es par les personnes DT1.\nAinsi, 34,2% auto-d\u00e9claraient une r\u00e9tinopathie, 3,7%\nla perte de la vue d'un \u0153il et 31,0% un traitement au\nlaser, versus respectivement 6,8%, 3,2% et 16,8% des\npersonnes DT2.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 763, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "063b122e-f554-4cf0-8ce9-7272157bcc1f": {"__data__": {"id_": "063b122e-f554-4cf0-8ce9-7272157bcc1f", "embedding": null, "metadata": {"page_label": "389", "file_name": "2022_22.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2022_22.pdf", "file_type": "application/pdf", "file_size": 1843017, "creation_date": "2025-11-25", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "cae001d1-adc4-43c4-86eb-3afca61af625", "node_type": "4", "metadata": {"page_label": "389", "file_name": "2022_22.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2022_22.pdf", "file_type": "application/pdf", "file_size": 1843017, "creation_date": "2025-11-25", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "b1f4d710103d927292b9193f69bd0532c0d26a099a278ceb44762edf5fe56a3b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1a40e132-e141-4b98-a0fe-a344cc83118a", "node_type": "1", "metadata": {"page_label": "389", "file_name": "2022_22.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2022_22.pdf", "file_type": "application/pdf", "file_size": 1843017, "creation_date": "2025-11-25", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "4f1abbd02dd00d631689a1822d8e533a6398b839bac88e077bd015408a20da6c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5aef06d6-8c6e-4c71-b920-2b8c1263762e", "node_type": "1", "metadata": {}, "hash": "b20d332966592246c9f6e7f44836ea257819ab4beb3f85b1a02088893da77f80", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Concernant les complications podologiques, 12,9% des personnes DT1 d\u00e9claraient un\nmal perforant plantaire actif ou ancien, 2,6% avaient\neffectu\u00e9 au moins un s\u00e9jour hospitalier au cours des\nTableau 2\nFacteurs de risque de complications selon le type de diab\u00e8te en 2019 et variation depuis 2007\npour les personnes ayant un diab\u00e8te de type 2\nDiab\u00e8te de type 1\n(N=412)\nDiab\u00e8te de type 2\n(DT2) (N=2 714)\n\u00c9volution\ndepuis 2007**\n(DT2)% IC95% % IC95%\nCorpulence\nIMC moyen (kg/m2) 26,0 [25,3-26,7] 29,5 [29,2-29,7] +0\nNormal (<25 kg/m\u00b2) 50,1 [43,0-57,2] 19,9 [18,2-21,7] +0,1\nSurpoids (25-29 kg/m\u00b2) 29,2 [23,1-35,8] 39,9 [37,8-42,0] +0,5\nOb\u00e9sit\u00e9 (\u2265 30 kg/m\u00b2) 20,7 [15,0-27,4] 40,2 [38,1-42,3] -0,5\nHTA auto-d\u00e9clar\u00e9e* 34,2 [27,2-41,8] 61,1 [58,9-63,3] +1,4\nTraitement antihypertenseur rembours\u00e9 dans les 12 mois 40,9 [33,7-48,4] 77,6 [75,8-79,4] +0,7\nDyslipid\u00e9mie auto-d\u00e9clar\u00e9e* 31,5 [24,8-38,7] 58,8 [56,5-61,0] +3,6\nTraitement hypolip\u00e9miant rembours\u00e9 dans les 12 mois 30,4 [23,6-37,9] 63,8 [61,7-65,9] +1,4\nTabagisme actuel 25,3 [19,6-31,8) 13,4 [11,9-14,9] -1,1\nConsommation d'alcool*\nFaible 69,0 [61,8-75,6] 76,0 [74,0-77,9] -\nMod\u00e9r\u00e9e 19,6 [14,3-26,0] 17,0 [15,4-18,8] -\n\u00c9lev\u00e9e 7,4 [4,6-11,1] 4,7 [3,8-5,7] -\nS\u00e9v\u00e8re 3,9 [1,01-10,2] 2,3 [1,7-3,0] -\nIC95% : intervalle de confiance \u00e0 95% ; IMC : indice de masse corporelle ; HTA : hypertension art\u00e9rielle.\n* Information recueillie uniquement dans le questionnaire d\u00e9taill\u00e9.", "mimetype": "text/plain", "start_char_idx": 764, "end_char_idx": 2180, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "5aef06d6-8c6e-4c71-b920-2b8c1263762e": {"__data__": {"id_": "5aef06d6-8c6e-4c71-b920-2b8c1263762e", "embedding": null, "metadata": {"page_label": "389", "file_name": "2022_22.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2022_22.pdf", "file_type": "application/pdf", "file_size": 1843017, "creation_date": "2025-11-25", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "cae001d1-adc4-43c4-86eb-3afca61af625", "node_type": "4", "metadata": {"page_label": "389", "file_name": "2022_22.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2022_22.pdf", "file_type": "application/pdf", "file_size": 1843017, "creation_date": "2025-11-25", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "b1f4d710103d927292b9193f69bd0532c0d26a099a278ceb44762edf5fe56a3b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "063b122e-f554-4cf0-8ce9-7272157bcc1f", "node_type": "1", "metadata": {"page_label": "389", "file_name": "2022_22.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2022_22.pdf", "file_type": "application/pdf", "file_size": 1843017, "creation_date": "2025-11-25", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "c5adfed87e4ac2aa5cfdce3e73475239c4fb0964cf6283d54eff5e3777aaca9a", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "* Information recueillie uniquement dans le questionnaire d\u00e9taill\u00e9.\n** \u00c9volution pr\u00e9sent\u00e9e si l'information \u00e9tait disponible dans Entred 2.\nTableau 3\nComplications selon le type de diab\u00e8te en 2019 et variation depuis 2007 pour les personnes ayant un diab\u00e8te de type 2\nDiab\u00e8te de type 1\n(N=412)\nDiab\u00e8te de type 2\n(DT2) (N=2 714)\n\u00c9volution\ndepuis 2007**\n(DT2)% IC95% % IC95%\nComplication coronarienne auto-d\u00e9clar\u00e9e 11,5 [6,9-17,9] 18,6 [16,9-20,3] -2,4\nHospitalisation pour IDM dans les 10 ans 2,9 [0,5-8,8] 3,4 [2,6-4,3] -\nAnt\u00e9c\u00e9dent d'AVC auto-d\u00e9clar\u00e9 3,3 [1,2-7,1] 7,8 [6,6-9,0] -\nHospitalisation pour AVC dans les 10 ans 0 2,6 [1,9-3,5] -\nR\u00e9tinopathie auto-d\u00e9clar\u00e9e 34,2 [27,3-41,7] 6,8 [5,7-8,0] -\nPerte de la vue d'un \u0153il auto-d\u00e9clar\u00e9e 3,7 [1,6-7,3] 3,2 [2,4-4,1] -0,8\nTraitement au laser auto-d\u00e9clar\u00e9 31,0 [24,3-38,4] 16,8 [15,2-18,5] +1,1\nAnt\u00e9c\u00e9dent de mal perforant plantaire auto-d\u00e9clar\u00e9 12,9 [8,7-18,1] 6,7 [5,7-7,9] -3,4\nHospitalisation pour plaie du pied dans les 10 ans 2,6 [0,8-6,0] 1,6 [1,1-2,3] -\nHospitalisation pour amputation de membre inf\u00e9rieur\ndans les 10 ans 1,2 [0,1-4,3] 0,6 [0,3-1,1] -\nDialyse ou greffe r\u00e9nale dans les 10 ans 1,4 [0,2-4,5] 0,3 [0,1-0,7] -\nIC95% : intervalle de confiance \u00e0 95% ; IDM : infarctus du myocarde ; AVC : accident vasculaire c\u00e9r\u00e9bral.\n** \u00c9volution pr\u00e9sent\u00e9e si l'information \u00e9tait disponible dans Entred 2.", "mimetype": "text/plain", "start_char_idx": 2113, "end_char_idx": 3471, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "03c0b38f-6305-479c-969e-ec320ac92403": {"__data__": {"id_": "03c0b38f-6305-479c-969e-ec320ac92403", "embedding": null, "metadata": {"page_label": "390", "file_name": "2022_22.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2022_22.pdf", "file_type": "application/pdf", "file_size": 1843017, "creation_date": "2025-11-25", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "2f7c8d7a-d2ef-4aad-aaba-9896ae465fd3", "node_type": "4", "metadata": {"page_label": "390", "file_name": "2022_22.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2022_22.pdf", "file_type": "application/pdf", "file_size": 1843017, "creation_date": "2025-11-25", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "a10b5381543bb4a03146a0843b699689e5791f1566b22fd85b6f8757ed5df432", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4677d591-1e95-4b09-a467-e6228ae59ef6", "node_type": "1", "metadata": {}, "hash": "89e0d605ce7dff49c5a970b53f6342e031a3252123f7660de337d7940e7195c4", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "390 | 8 novembre 2022 | BEH 22 Journ\u00e9e mondiale du diab\u00e8te, 14 novembre 2022\n10 ann\u00e9es pr\u00e9c\u00e9dentes pour une plaie du pied et\n1,2% un s\u00e9jour pour une amputation d'un membre\ninf\u00e9rieur. Ces proportions \u00e9taient respectivement de\n6,7%, 1,6% et 0,6% parmi les DT2. Enfin, pour 1,4%\ndes personnes DT1, au moins un s\u00e9jour hospitalier\npour une dialyse ou une greffe r\u00e9nale \u00e9tait retrouv\u00e9\nau cours des 10 ans pr\u00e9c\u00e9dant le tirage au sort. Cette\nproportion \u00e9tait de 0,3% parmi les personnes DT2.\nPar rapport \u00e0 2007, l'auto-d\u00e9claration d'une complication coronarienne parmi les personnes DT2 a\ndiminu\u00e9 de 2,4 points, la perte de la vue d'un \u0153il\nde 0,8 point tandis que la d\u00e9claration d'un mal per -\nforant plantaire a \u00e9galement diminu\u00e9 de 3,4 points.\nDiscussion\nCette troisi\u00e8me \u00e9dition de l'\u00e9tu de Entred a permis\nde d\u00e9crire les caract\u00e9ristiques et l'\u00e9ta t de sant\u00e9\ndes personnes trait\u00e9es pharmacologiquement pour\nun diab\u00e8te en France en 2019 et d'observer les \u00e9volutions dans la population DT2 depuis les \u00e9ditions\npr\u00e9c\u00e9dentes. Pour la premi\u00e8re fois, un sur\u00e9chantil -\nlonnage des personnes DT1 a permis d'apporter des\n\u00e9l\u00e9ments de connaissance sur le diab\u00e8te de type 1\navec une meilleure pr\u00e9cision que celle des \u00e9ditions\nd'Entred pr\u00e9c\u00e9dentes.\nEn France m\u00e9tropolitaine, la population de per -\nsonnes DT2 a vieilli depuis 2007. L '\u00e2ge moyen en\n2019 \u00e9tait de 67 ans alors qu'il \u00e9tait de 65 ans\nen 2007, stable depuis 2001. De m\u00eame, l'anc iennet\u00e9\nm\u00e9diane du diab\u00e8te (11 ans) a augment\u00e9 de 2 ans\nalors qu'elle \u00e9tait stable entre 2001 et 2007. Ce vieil -\nlissement de la population DT2 est probablement\nle reflet de la diminution de l'inc idence du diab\u00e8te\nobserv\u00e9e en France dans une \u00e9tude pr\u00e9c\u00e9dente 12,\ncombin\u00e9e \u00e0 une diminution du taux de mortalit\u00e9\navec un allongement de l'esp\u00e9rance de vie des per -\nsonnes ayant un diab\u00e8te observ\u00e9 \u00e0 partir du suivi\nde mortalit\u00e9 effectu\u00e9 dans les pr\u00e9c\u00e9dentes \u00e9ditions\nd'Entred 13.\nLe niveau socio\u00e9conomique des personnes DT2\na \u00e9volu\u00e9 avec une progression du niveau d'\u00e9tu de\ndepuis 2007, qui refl\u00e8te probablement un effet\ng\u00e9n\u00e9rationnel avec une augmentation du niveau\nd'\u00e9tude observ\u00e9e dans l'ens emble de la population\nfran\u00e7aise.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2147, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "4677d591-1e95-4b09-a467-e6228ae59ef6": {"__data__": {"id_": "4677d591-1e95-4b09-a467-e6228ae59ef6", "embedding": null, "metadata": {"page_label": "390", "file_name": "2022_22.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2022_22.pdf", "file_type": "application/pdf", "file_size": 1843017, "creation_date": "2025-11-25", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "2f7c8d7a-d2ef-4aad-aaba-9896ae465fd3", "node_type": "4", "metadata": {"page_label": "390", "file_name": "2022_22.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2022_22.pdf", "file_type": "application/pdf", "file_size": 1843017, "creation_date": "2025-11-25", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "a10b5381543bb4a03146a0843b699689e5791f1566b22fd85b6f8757ed5df432", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "03c0b38f-6305-479c-969e-ec320ac92403", "node_type": "1", "metadata": {"page_label": "390", "file_name": "2022_22.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2022_22.pdf", "file_type": "application/pdf", "file_size": 1843017, "creation_date": "2025-11-25", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "7bd4013fe964d45cdf7b4bd8c2b8fcde604b4ecab552f048b12699c9081d820f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b09397fa-f09d-4ff0-b5a1-ad177b774a43", "node_type": "1", "metadata": {}, "hash": "2784eb7283dce7a3bcaf05f16c112a7aea93287adfd73859860b7410a3a99783", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Le niveau socio\u00e9conomique des personnes DT2\na \u00e9volu\u00e9 avec une progression du niveau d'\u00e9tu de\ndepuis 2007, qui refl\u00e8te probablement un effet\ng\u00e9n\u00e9rationnel avec une augmentation du niveau\nd'\u00e9tude observ\u00e9e dans l'ens emble de la population\nfran\u00e7aise.\nSi une accentuation de l'ob\u00e9 sit\u00e9 avait \u00e9t\u00e9 objec -\ntiv\u00e9e entre 2001 et 2007, celle-ci s'est stabilis\u00e9e\nen 2019 avec une fr\u00e9quence de l'ob\u00e9 sit\u00e9 qui reste\ntr\u00e8s \u00e9lev\u00e9e et conc erne plus de 40% de la popu -\nlation DT2, et une m\u00eame proportion de personnes\nen surpoids. De m\u00eame, le tabagisme s'est stabilis\u00e9\ndepuis 2007, \u00e0 un niveau \u00e9lev\u00e9 (13%, -1 point) pour\nune population \u00e0 tr\u00e8s haut risque de comp lications\ncardiovasculaires. Ces gains potentiels d'am\u00e9 lioration avaient d\u00e9j\u00e0 \u00e9t\u00e9 mis en \u00e9vidence dans l'\u00e9di -\ntion pr\u00e9c\u00e9dente d'Ent red, sans que la situation ait\n\u00e9volu\u00e9 depuis.\nEnfin, une hypertension et une dyslipid\u00e9mie \u00e9taient\nd\u00e9clar\u00e9es par environ 60% des personnes, et des\ntraitements antihypertenseurs ou hypolip\u00e9miants\n\u00e9taient rembours\u00e9s au cours des 12 derniers mois \u00e0\nrespectivement 78% et 64% des personnes. Il sera\ntoutefois n\u00e9cessaire de comp l\u00e9ter ces informations\navec les valeurs de pression art\u00e9rielle et de lipid\u00e9 -\nmies recueillies aupr\u00e8s des m\u00e9decins pour objec -\ntiver l'\u00e9volution du niveau de cont r\u00f4le du risque\nvasculaire. De m\u00eame, les valeurs d'HbA1c (h\u00e9mo -\nglobine glyqu\u00e9e) recueillies aupr\u00e8s des m\u00e9de -\ncins permettront d'\u00e9tudier l'\u00e9volution de l'\u00e9quilibre\nglyc\u00e9mique.\nConcernant les comp lications, les premi\u00e8res infor -\nmations auto-d\u00e9clar\u00e9es par les personnes rapportent\nune pr\u00e9valence de complications microvasculaires et\nmacrovasculaires relativement \u00e9lev\u00e9e, mais en dimi -\nnution par rapport \u00e0 2007. N\u00e9anmoins, il sera impor -\ntant d'\u00e9tudier les \u00e9volutions temporelles, \u00e0 histoire de\nla maladie et caract\u00e9ristiques socio- \u00e9conomiques et\nsociod\u00e9mographiques \u00e9quivalentes, pour conclure\n\u00e0 une v\u00e9ritable am\u00e9lioration de l'\u00e9ta t de sant\u00e9\ndes personnes DT2. Les donn\u00e9es recueillies aupr\u00e8s\ndes m\u00e9decins apporteront \u00e9galement des comp l\u00e9ments d'information.", "mimetype": "text/plain", "start_char_idx": 1900, "end_char_idx": 3931, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "b09397fa-f09d-4ff0-b5a1-ad177b774a43": {"__data__": {"id_": "b09397fa-f09d-4ff0-b5a1-ad177b774a43", "embedding": null, "metadata": {"page_label": "390", "file_name": "2022_22.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2022_22.pdf", "file_type": "application/pdf", "file_size": 1843017, "creation_date": "2025-11-25", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "2f7c8d7a-d2ef-4aad-aaba-9896ae465fd3", "node_type": "4", "metadata": {"page_label": "390", "file_name": "2022_22.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2022_22.pdf", "file_type": "application/pdf", "file_size": 1843017, "creation_date": "2025-11-25", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "a10b5381543bb4a03146a0843b699689e5791f1566b22fd85b6f8757ed5df432", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4677d591-1e95-4b09-a467-e6228ae59ef6", "node_type": "1", "metadata": {"page_label": "390", "file_name": "2022_22.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2022_22.pdf", "file_type": "application/pdf", "file_size": 1843017, "creation_date": "2025-11-25", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "12cbd2aaf9a2bee7e2c7199ad9ff8f20fbcc6b54bba5114ccf47756dd75c3b16", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Les donn\u00e9es recueillies aupr\u00e8s\ndes m\u00e9decins apporteront \u00e9galement des comp l\u00e9ments d'information. Par ailleurs, les donn\u00e9es d'hos -\npitalisation issues du SNDS rapportent de nouvelles\ninformations objectives non disponibles dans les\n\u00e9ditions pr\u00e9c\u00e9dentes : l'incidence des complications\ngraves sur une p\u00e9riode de dix ans pour les IDM, les\nAVC, les amputations et l'ins uffisance r\u00e9nale chro -\nnique terminale. Ces nouvelles donn\u00e9es pourront\n\u00e9galement \u00eatre suivies sur une p\u00e9riode prospective\nde dix ans.\nEn termes de m\u00e9thodologie d'enq u\u00eate, les donn\u00e9es\ndu SNDS permettent \u00e9galement de disposer d'inf ormations pr\u00e9cieuses sur les personnes n'aya nt pas\nparticip\u00e9 \u00e0 l'enq u\u00eate par questionnaires et ainsi\nd'approfondir l'\u00e9tude de la non-participation. La prise\nen compte de ces informations dans les jeux de\npond\u00e9ration permet de limiter les biais de s\u00e9lection.\nAinsi, tout en cons ervant une m\u00e9thodologie simi -\nlaire \u00e0 celle utilis\u00e9e dans les \u00e9ditions pr\u00e9c\u00e9dentes,\nEntred 3 a pu b\u00e9n\u00e9ficier des avanc\u00e9es technolo -\ngiques survenues au cours de la derni\u00e8re d\u00e9cennie\nen mati\u00e8re de syst\u00e8mes d'inf ormation avec le d\u00e9ve -\nloppement du SNDS.\nCes premiers r\u00e9sultats permettent \u00e9galement de\nmettre en perspective, de comparer, les informations\nconcernant les personnes DT1 et les personnes DT2.\nLa taille de notre \u00e9chantillon de personnes DT1\npermet une description plus pr\u00e9cise de cette popu -\nlation et met en lumi\u00e8re ses sp\u00e9cificit\u00e9s , ainsi que\ncelles de la pathologie qui les affecte . Ainsi, malgr\u00e9\nleur plus jeune \u00e2ge, plus de la moiti\u00e9 des adultes DT1\nont un diab\u00e8te datant de plus de vingt ans et un\nniveau socio\u00e9conomique plus favorable que celui\ndes personnes DT2. Les facteurs de risque de\ncomplications vasculaires sont fr\u00e9quents parmi les\nDT1, et notamment le surpoids incluant l'ob\u00e9 sit\u00e9\npour plus de la moiti\u00e9 de la population, et le taba -\ngisme d\u00e9clar\u00e9 par un quart d'ent re eux. Par ailleurs,\nsi les comp lications macrovasculaires sont moins\nfr\u00e9quentes chez les personnes DT1 que pour\nles personnes DT2, la pr\u00e9valence des complications\nmicrovasculaires est tr\u00e8s \u00e9lev\u00e9e, qu'il s'agi sse des", "mimetype": "text/plain", "start_char_idx": 3834, "end_char_idx": 5935, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "7ba3e3a6-a4b0-47b9-b4c7-dbe42ca09ea6": {"__data__": {"id_": "7ba3e3a6-a4b0-47b9-b4c7-dbe42ca09ea6", "embedding": null, "metadata": {"page_label": "391", "file_name": "2022_22.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2022_22.pdf", "file_type": "application/pdf", "file_size": 1843017, "creation_date": "2025-11-25", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "828511b8-a12b-4753-ba7b-e47d9cf3dcb7", "node_type": "4", "metadata": {"page_label": "391", "file_name": "2022_22.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2022_22.pdf", "file_type": "application/pdf", "file_size": 1843017, "creation_date": "2025-11-25", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "a48df3ff7deca7f4c3016ed0b522fa588c7107a6b89f86dfb7e32b46a18c983b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9124c946-e401-4a32-8a0f-aaff3b5b66d4", "node_type": "1", "metadata": {}, "hash": "4983a972d169dbb3d017d5e3b3648e652a90a8f99414765ac8fc1beed6a12f2d", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Journ\u00e9e mondiale du diab\u00e8te, 14 novembre 2022 BEH 22 | 8 novembre 2022 | 391\ncomplications ophtalmologiques, podologiques ou\nr\u00e9nales. Les donn\u00e9es recueillies aupr\u00e8s des m\u00e9de -\ncins permettront de confi rmer ces informations qui\npeuvent \u00eatre sujettes \u00e0 des biais de d\u00e9claration et\npermettront d'affiner ces premiers r\u00e9sultats.\nConclusion\nCes premiers r\u00e9sultats de la 3 e \u00e9dition de l'\u00e9tu de\nEntred nous apportent une description des caract\u00e9 -\nristiques et de l'\u00e9tat de sant\u00e9 de la population diab\u00e9tique de France m\u00e9tropolitaine en 2019, globalement\net selon le type de diab\u00e8te. Il est \u00e0 pr\u00e9sent n\u00e9ces -\nsaire de comp l\u00e9ter ces \u00e9l\u00e9ments par les informa -\ntions recueillies aupr\u00e8s des m\u00e9decins, afin d'affi ner\nl'\u00e9tude des comp lications et d'app orter des infor -\nmations sur le niveau de de cont r\u00f4le des facteurs\nde risque de comp lications, notamment l'\u00e9qu ilibre\nglyc\u00e9mique.\nD'autres analyses sont \u00e9galement \u00e0 venir pour\napporter des \u00e9l\u00e9ments de connaissance sur la\nqualit\u00e9 de vie, le recours aux soins, le recours aux\nnouveaux dispositifs et outils connect\u00e9s, les comp lications aigu\u00ebs, l'observance th\u00e9rapeutique, le reten -\ntissement professionnel, familial, social du diab\u00e8te, la\nlitt\u00e9ratie en sant\u00e9...\nUne description de l'\u00e9ta t de sant\u00e9 des personnes\npr\u00e9sentant un diab\u00e8te r\u00e9sidant dans les d\u00e9parte -\nments d'outre-mer sera \u00e9galement propos\u00e9e gr\u00e2ce\n\u00e0 un recueil de donn\u00e9es effectu\u00e9 aupr\u00e8s de plus de\n2 300 personnes.\nL 'ensemble de ces informations permettront de\ndocumenter les politiques publiques pour des orien -\ntations en mati\u00e8re de pr\u00e9vention, d'accompagnement\net de prise en charge des personnes pr\u00e9sentant un\ndiab\u00e8te. \u25a0\nRemerciements\nNous remercions chaleureusement les personnes et leurs\nm\u00e9decins qui ont g\u00e9n\u00e9reusement particip\u00e9 \u00e0 l'\u00e9tude.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1757, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "9124c946-e401-4a32-8a0f-aaff3b5b66d4": {"__data__": {"id_": "9124c946-e401-4a32-8a0f-aaff3b5b66d4", "embedding": null, "metadata": {"page_label": "391", "file_name": "2022_22.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2022_22.pdf", "file_type": "application/pdf", "file_size": 1843017, "creation_date": "2025-11-25", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "828511b8-a12b-4753-ba7b-e47d9cf3dcb7", "node_type": "4", "metadata": {"page_label": "391", "file_name": "2022_22.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2022_22.pdf", "file_type": "application/pdf", "file_size": 1843017, "creation_date": "2025-11-25", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "a48df3ff7deca7f4c3016ed0b522fa588c7107a6b89f86dfb7e32b46a18c983b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7ba3e3a6-a4b0-47b9-b4c7-dbe42ca09ea6", "node_type": "1", "metadata": {"page_label": "391", "file_name": "2022_22.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2022_22.pdf", "file_type": "application/pdf", "file_size": 1843017, "creation_date": "2025-11-25", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "83dd72595db2aac1f7b499021d78b31d56187c5b63dad20efca5a22338551f72", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0155966f-6ce8-4ec7-a084-f1d776b0dc42", "node_type": "1", "metadata": {}, "hash": "bf3b7d805dbf652601838a50fb5988785d1a48a25e5978b234db9252386abca1", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "L 'ensemble de ces informations permettront de\ndocumenter les politiques publiques pour des orien -\ntations en mati\u00e8re de pr\u00e9vention, d'accompagnement\net de prise en charge des personnes pr\u00e9sentant un\ndiab\u00e8te. \u25a0\nRemerciements\nNous remercions chaleureusement les personnes et leurs\nm\u00e9decins qui ont g\u00e9n\u00e9reusement particip\u00e9 \u00e0 l'\u00e9tude.\nNous tenons \u00e9galement \u00e0 remercier toutes les personnes qui\nont contribu\u00e9 \u00e0 la collecte des donn\u00e9es : le service Sophia\nde l'Assurance maladie; les \u00e9quipes d'Ipsos, notamment\nEmmanuelle Hoingne, Nathan Jeandet et Val\u00e9rie Blineau ;\nl'\u00e9quipe projet Entred 3 de Sant\u00e9 publique France, notam -\nment les charg\u00e9s d'\u00e9tude Emmanuelle Szego, Val\u00e9rie Henry,\nJessica Gane, C\u00e9line Lavalette et Pascal Bessonneau,\nPerrine de Crouy-Chanel qui a r\u00e9alis\u00e9 les cartes ; ainsi\nque Marjorie Boussac et David Dias de la Caisse nationale\nd'assurance maladie, qui ont proc\u00e9d\u00e9 aux extractions des\ndonn\u00e9es du SNDS ; Anne-Lyne Couillerot (Haute Autorit\u00e9\nde sant\u00e9), Hayat Bourezane (SSI), C\u00e9line Druet (Agence\nnationale de s\u00e9curit\u00e9 sanitaire de l'alimentation, de l'envi -\nronnement et du travail), et toutes les personnes qui ont\nparticip\u00e9 \u00e0 la mise en \u0153uvre de l'\u00e9tude. Enfin, nous tenons\n\u00e0 remercier les nombreux experts qui ont contribu\u00e9 \u00e0 cette\n\u00e9tude dans le cadre du Comit\u00e9 scientifique, du Comit\u00e9\nd'interface diab\u00e8te de Sant\u00e9 publique France ainsi que la\nF\u00e9d\u00e9ration fran\u00e7aise des diab\u00e9tiques, la Soci\u00e9t\u00e9 franco -\nphone du diab\u00e8te et le Coll\u00e8ge de la m\u00e9decine g\u00e9n\u00e9rale\npour leur soutien.\nNous souhaitons \u00e9galement rendre un hommage chaleu -\nreux \u00e0 Michelle Chantry qui nous a quitt\u00e9s en juillet dernier.\nEn tant que cheffe de projet d'Entred pour la Cnam, Michelle\na eu un r\u00f4le essentiel dans cette \u00e9tude et dans les \u00e9ditions\npr\u00e9c\u00e9 dentes, notamment en d\u00e9veloppant les requ\u00eates de\ns\u00e9lection des participants. Michelle a donc \u00e9t\u00e9 un acteur clef\nde la r\u00e9ussite de ce dispositif d'\u00e9tudes.\nLiens d'int\u00e9r\u00eat\nLes auteurs d\u00e9clarent n'avoir aucun lien d'int\u00e9r\u00eat au regard du\ncontenu de l'article.\nR\u00e9f\u00e9rences\n[1] Lailler G, Piffaretti C, Fuentes S, Nabe HD, Oleko A,\nCosson E, et al . Prevalence of prediabetes and undia -\ngnosed type 2 diabetes in France: Results from the national\nsurvey Esteban, 2014-2016. Diabetes Res Clin Pract. 2020;\n165:108252.\n[2] Am\u00e9liorer la qualit\u00e9 du syst\u00e8me de sant\u00e9 et ma\u00eetriser les\nd\u00e9penses.", "mimetype": "text/plain", "start_char_idx": 1425, "end_char_idx": 3750, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "0155966f-6ce8-4ec7-a084-f1d776b0dc42": {"__data__": {"id_": "0155966f-6ce8-4ec7-a084-f1d776b0dc42", "embedding": null, "metadata": {"page_label": "391", "file_name": "2022_22.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2022_22.pdf", "file_type": "application/pdf", "file_size": 1843017, "creation_date": "2025-11-25", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "828511b8-a12b-4753-ba7b-e47d9cf3dcb7", "node_type": "4", "metadata": {"page_label": "391", "file_name": "2022_22.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2022_22.pdf", "file_type": "application/pdf", "file_size": 1843017, "creation_date": "2025-11-25", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "a48df3ff7deca7f4c3016ed0b522fa588c7107a6b89f86dfb7e32b46a18c983b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9124c946-e401-4a32-8a0f-aaff3b5b66d4", "node_type": "1", "metadata": {"page_label": "391", "file_name": "2022_22.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2022_22.pdf", "file_type": "application/pdf", "file_size": 1843017, "creation_date": "2025-11-25", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "4e5d55e34f2c10609918d190f730536f6cf01aada10f74079e909a217f1f0765", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d7dcb739-a0d4-4909-9b8d-0c3913e4b394", "node_type": "1", "metadata": {}, "hash": "9d08e1fb5e2fdbcb2039320c516c9455d483472c726d69ed83c006aea093d3ba", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Prevalence of prediabetes and undia -\ngnosed type 2 diabetes in France: Results from the national\nsurvey Esteban, 2014-2016. Diabetes Res Clin Pract. 2020;\n165:108252.\n[2] Am\u00e9liorer la qualit\u00e9 du syst\u00e8me de sant\u00e9 et ma\u00eetriser les\nd\u00e9penses. Propositions de l'Assurance maladie pour 2017.\nParis: CnamTS; 2016. 178 p.\nfr/etudes-et-donnees/2016-rapport-propositions-pour-2017charges-produits\n[3] Fagot-Campagna A, Fosse S, Roudier C, Romon I,\nPenfornis A, Lecomte P, et al . Caract\u00e9ristiques, risque\nvasculaire et complications chez les personnes diab\u00e9 -\ntiques en France m\u00e9tropolitaine : d'importantes \u00e9volutions\nentre Entred 2001 et Entred 2007. Bull \u00c9pidemiol Hebd.\n2009;(42-43):450-5.\ndies-et-traumatismes/diabete/documents/article/caracte\nristiques-risque-vasculaire-et-complica tions-chez-les-per\nsonnes-diabetiques-en-france-metropoli taine-d-impor\ntantes-evolutions-entre-entre2\n[4] Assogba FG, Couchoud C, Roudier C, Pornet C, Fosse S,\nRomon I, et al. Prevalence, screening and treatment of chronic\nkidney disease in people with type 2 diabetes in France.\nThe ENTRED surveys (2001 and 2007). Diabetes Metab.\n2012;38(6):558-66.\n[5] Pornet C, Bourdel-Marchasson I, Lecomte P, Eschwege E,\nRomon I, Fosse S, et al. Trends in the quality of care for elderly\npeople with type 2 diabetes: The need for improvements in\nsafety and quality (the 2001 and 2007 ENTRED Surveys).\nDiabetes Metab. 2011;37(2):152-61.\n[6] Druet C, Roudier C, Romon I, Assogba FG, BourdelMarchasson I, et al. \u00c9chantillon national t\u00e9moin repr\u00e9sentatif\ndes personnes diab\u00e9tiques, Entred 2007-2010. Caract\u00e9ris -\ntiques, \u00e9tat de sant\u00e9, prise en charge et poids \u00e9conomique\ndes personnes diab\u00e9tiques. Saint-Maurice: Institut de veille\nsanitaire; 2012. 8 p.\ndies-et-traumatismes/diabete/documents/rapport-synthese/\nechantillon-national-temoin-representatif-des-personnesdiabetiques-entred-2007-2010.-caracteristiques-etat-desante-prise-en-charge-et-poids-ec\n[7] Tuppin P, Rudant J, Constantinou P, Gastaldi-M\u00e9nager C,\nRachas A, de Roquefeuil L, et al .", "mimetype": "text/plain", "start_char_idx": 3511, "end_char_idx": 5526, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "d7dcb739-a0d4-4909-9b8d-0c3913e4b394": {"__data__": {"id_": "d7dcb739-a0d4-4909-9b8d-0c3913e4b394", "embedding": null, "metadata": {"page_label": "391", "file_name": "2022_22.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2022_22.pdf", "file_type": "application/pdf", "file_size": 1843017, "creation_date": "2025-11-25", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "828511b8-a12b-4753-ba7b-e47d9cf3dcb7", "node_type": "4", "metadata": {"page_label": "391", "file_name": "2022_22.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2022_22.pdf", "file_type": "application/pdf", "file_size": 1843017, "creation_date": "2025-11-25", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "a48df3ff7deca7f4c3016ed0b522fa588c7107a6b89f86dfb7e32b46a18c983b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0155966f-6ce8-4ec7-a084-f1d776b0dc42", "node_type": "1", "metadata": {"page_label": "391", "file_name": "2022_22.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2022_22.pdf", "file_type": "application/pdf", "file_size": 1843017, "creation_date": "2025-11-25", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "ec90213bb7814c6b4484b45aa8b69fd62a83f5da5d3d017f88020c2205cc45fe", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Value of a national adminis -\ntrative database to guide public decisions: From the syst\u00e8me\nnational d'information interr\u00e9gimes de l'Assurance aladie\n(SNIIRAM) to the syst\u00e8me national des donn\u00e9es de sant\u00e9\n(SNDS) in France. Revue Epidemiol Sante Publique. 2017;65\nSuppl 4:S149-S167.\n[8] Fosse-Edorh S, Mandereau-Bruno L, Regnault N. Le poids\ndes complications li\u00e9es au diab\u00e8te en France en 2013. Synth\u00e8se\net perspectives. Bull \u00c9pidemiol Hebd. 2015(34-35):619-25. http://\nbeh.santepubliquefrance.fr/beh/2015/34-35/2015_34-35_1.html\n[9] Fosse S, Romon I, Druet C, Fagot-Campagna A. \u00c9chan -\ntillon national t\u00e9moin repr\u00e9sentatif des personnes diab\u00e9tiques,\nEntred 2007-2010. Rapport m\u00e9thodologique. Saint-Maurice:\nInstitut de veille sanitaire; 2012. 73 p.\nquefrance.fr/maladies-et-traumatismes/diabete/documents/\nrapport-synthese/echantillon-natio nal-temoin-representatifdes-personnes-diabetiques-en tred-2007-2010.-rapport-metho\ndologique", "mimetype": "text/plain", "start_char_idx": 5527, "end_char_idx": 6460, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "1bb202b5-9551-4c8d-a01c-409089254c9c": {"__data__": {"id_": "1bb202b5-9551-4c8d-a01c-409089254c9c", "embedding": null, "metadata": {"page_label": "392", "file_name": "2022_22.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2022_22.pdf", "file_type": "application/pdf", "file_size": 1843017, "creation_date": "2025-11-25", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "3a972395-e60a-416e-8ee3-8753f826199b", "node_type": "4", "metadata": {"page_label": "392", "file_name": "2022_22.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2022_22.pdf", "file_type": "application/pdf", "file_size": 1843017, "creation_date": "2025-11-25", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "95742f1bfe203c67154af278904dab9b584815141333fcbff2e5d606ca9d97fd", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f0b0fe86-9411-4cdc-91d4-cbb729228d87", "node_type": "1", "metadata": {}, "hash": "cc8428006afa9e9eb6579d54371faa01fbe5ce57f8ba391a2d681fa4a9ea0f5b", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "392 | 8 novembre 2022 | BEH 22 Journ\u00e9e mondiale du diab\u00e8te, 14 novembre 2022\nARTICLE // Article\nTABAGISME ET DIAB\u00c8TE : LE TEMPS DE L'ACTION\n// SMOKING AND DIABETES: TIME FOR ACTION\nVincent Durlach (), pour le groupe de travail Tabagisme et diab\u00e8te*\nUniversit\u00e9 Reims Champagne-Ardenne, UMR CNRS 7369 MEDyC, P\u00f4le Cardio-Thoracique, Centre hospitalier universitaire\nde Reims\n* Vincent Durlach, Bruno Verg\u00e8s, Abdallah Al-Salameh, Thibault Bahougne, Farid Benzerouk, Ivan Berlin, Carole Clair, Jacques\nMansourati, Alexia Rouland, St\u00e9phanie Genou-Vannobel, Isabelle Gaudy, Daniel Thomas, Philippe Thuillier, Laura Phirmis,\nClaude Chaumeil, Blandine Tramunt, Anne-Laurence Le Faou\nSoumis le 02.08.2022 // Date of submission: 08.02.2022\nR\u00e9sum\u00e9 // Abstract\nLes \u00e9tudes \u00e9pid\u00e9miologiques montrent un lien clair entre tabagisme (actif ou passif) et le risque de d\u00e9velopper\nun diab\u00e8te de type 2 (DT2). Le tabagisme majore la mortalit\u00e9 toutes causes ainsi que le risque de complications\nmacro- et micro-angiopathiques (n\u00e9phropathie chez le patient DT2, r\u00e9tinopathie et neuropathie chez le diab\u00e9 -\ntique de type 1), il participe au d\u00e9s\u00e9quilibre glyc\u00e9mique et favorise le diab\u00e8te gestationnel. Pr\u00e9venir le tabagisme\nchez le sujet \u00e0 risque de DT2 et promouvoir le sevrage tabagique chez le patient DT2 constituent donc une priorit\u00e9 de sant\u00e9 publique selon un r\u00e9cent consensus d'experts publi\u00e9 par la Soci\u00e9t\u00e9 francophone de tabacologie\n(SFT) et la Soci\u00e9t\u00e9 francophone du diab\u00e8te (SFD).\nEpidemiologic studies demonstrate a clear link between active or passive smoking and the risk of developing a\ntype 2 diabetes (T2D). Cigarette smoking increases all-cause mortality as well as the risk of macro and micro -\nvascular complications (i.e. nephropathy in T2D patient , retinopathy and neuropathy in type 1 diabetes), it alters\nglycemic control and favours gestational diabetes mellitus. Preventing cigarette smoking in patients at risk of\nT2D and promoting smoking cessation in T2D patients are public health priorities, as recently concluded in a\njoint position statement by the French-Speaking Society on Tobacco (Soci\u00e9t\u00e9 francophone de tabacologie) and\nthe French-Speaking Society of Diabetes (Soci\u00e9t\u00e9 francophone du diab\u00e8te).", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2207, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "f0b0fe86-9411-4cdc-91d4-cbb729228d87": {"__data__": {"id_": "f0b0fe86-9411-4cdc-91d4-cbb729228d87", "embedding": null, "metadata": {"page_label": "392", "file_name": "2022_22.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2022_22.pdf", "file_type": "application/pdf", "file_size": 1843017, "creation_date": "2025-11-25", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "3a972395-e60a-416e-8ee3-8753f826199b", "node_type": "4", "metadata": {"page_label": "392", "file_name": "2022_22.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2022_22.pdf", "file_type": "application/pdf", "file_size": 1843017, "creation_date": "2025-11-25", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "95742f1bfe203c67154af278904dab9b584815141333fcbff2e5d606ca9d97fd", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1bb202b5-9551-4c8d-a01c-409089254c9c", "node_type": "1", "metadata": {"page_label": "392", "file_name": "2022_22.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2022_22.pdf", "file_type": "application/pdf", "file_size": 1843017, "creation_date": "2025-11-25", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "e06f0542484f79549a9d01cc4413643a39a7a2871e32904b1b0ab542ead0f29d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e5816868-b895-40ca-b935-c8d9510839b7", "node_type": "1", "metadata": {}, "hash": "9246d2dd9285d72bfe763d26931d6b36f4f06f39d2b9c7d95bf43ff67fa57259", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Preventing cigarette smoking in patients at risk of\nT2D and promoting smoking cessation in T2D patients are public health priorities, as recently concluded in a\njoint position statement by the French-Speaking Society on Tobacco (Soci\u00e9t\u00e9 francophone de tabacologie) and\nthe French-Speaking Society of Diabetes (Soci\u00e9t\u00e9 francophone du diab\u00e8te).\nMots-cl\u00e9s : Diab\u00e8te, Tabagisme, Maladies chroniques, Relation causale, Complications, Sevrage tabagique\n// Keywords: Diabetes, Smoking, Chronic diseases, Causal relationship, Diabetes complications, Smoking cessation\nIntroduction\nLe diab\u00e8te de type 2 (DT2) et le tabagisme s'inscrivent\ndans le champ des maladies chroniques et cons tituent deux probl\u00e8mes de sant\u00e9 publique majeurs ;\nils r\u00e9duisent l'un et l'aut re sensiblement l'esp \u00e9rance\nde vie (10 ans en moyenne pour le tabagisme, 6 ans\npour le DT2) et \u00e9voluent de mani\u00e8re \u00e9pid\u00e9mique 1.\nPlus de 1 milliard d'hommes et 250 millions de femmes\nfument et l'\u00e9volution du diab\u00e8te est \u00e9pid\u00e9mique (touchant\nplus de 537 millions d'individus en 2021). Le DT2 est\nle plus fr\u00e9quent, son \u00e9volution est satellite de celle de\nl'ob\u00e9sit\u00e9 abdominale touchant de 4 \u00e0 10 % de la population 2. La pr\u00e9valence du tabagisme dans le monde est\nde l'ordre de 20,8% chez la personne DT2 et varie selon\n>\nVincent Durlach\nUniversit\u00e9 Reims Champagne-Ardenne, UMR CNRS 7369 MEDyC, P\u00f4le Cardio-Thoracique, Centre hospitalier universitaire de\nReims\n[10] Rey G, Jougla E, Fouillet A, Hemon D. Ecological associa -\ntion between a deprivation index and mortality in France over\nthe period 1997-2001: Variations with spatial scale, degree\nof urbanicity, age, gender and cause of death. BMC Public\nHealth. 2009;9:33.\n[11] Bush K, Kivlahan DR, McDonell MB, Fihn SD,\nBradley KA. The AUDIT alcohol consumption questions\n(AUDIT-C): An effective brief screening test for problem\ndrinking. Ambulatory Care Quality Improvement Project\n(ACQUIP). Alcohol Use Disorders Identification Test. Arch\nIntern Med. 1998;158(16):1789-95.\n[12] Fuentes S, Mandereau-Bruno L, Regnault N, Bernillon P,\nBonaldi C, Cosson E, et al. Is the type 2 diabetes epidemic\nplateauing in France? A nationwide population-based study.\nDiabetes Metab. 2020;46(6):472-9.\n[13] Mandereau-Bruno L, Fagot-Campagna A, Rey G,\nPiffaretti C, Antero-Jacquemin J, Latouche A, et al.", "mimetype": "text/plain", "start_char_idx": 1865, "end_char_idx": 4157, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "e5816868-b895-40ca-b935-c8d9510839b7": {"__data__": {"id_": "e5816868-b895-40ca-b935-c8d9510839b7", "embedding": null, "metadata": {"page_label": "392", "file_name": "2022_22.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2022_22.pdf", "file_type": "application/pdf", "file_size": 1843017, "creation_date": "2025-11-25", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "3a972395-e60a-416e-8ee3-8753f826199b", "node_type": "4", "metadata": {"page_label": "392", "file_name": "2022_22.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2022_22.pdf", "file_type": "application/pdf", "file_size": 1843017, "creation_date": "2025-11-25", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "95742f1bfe203c67154af278904dab9b584815141333fcbff2e5d606ca9d97fd", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f0b0fe86-9411-4cdc-91d4-cbb729228d87", "node_type": "1", "metadata": {"page_label": "392", "file_name": "2022_22.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2022_22.pdf", "file_type": "application/pdf", "file_size": 1843017, "creation_date": "2025-11-25", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "884e1c52749d6aca085dcf4e41d690f3a21143f5965de2287e8a821a6c7872ab", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Is the type 2 diabetes epidemic\nplateauing in France? A nationwide population-based study.\nDiabetes Metab. 2020;46(6):472-9.\n[13] Mandereau-Bruno L, Fagot-Campagna A, Rey G,\nPiffaretti C, Antero-Jacquemin J, Latouche A, et al. \u00c9volution de\nla mortalit\u00e9 et de la surmortalit\u00e9 \u00e0 5 ans des personnes diab\u00e9 -\ntiques trait\u00e9es pharmacologiquement en France m\u00e9tropoli -\ntaine : comparaison des cohortes Entred 2001 et Entred 2007.\nBull \u00c9pidemiol Hebd. 2016(37-38):668-75.\nbliquefrance.fr/beh/2016/37-38/2016_37-38_1.html\nCiter cet article\nFosse-Edorh S, Piffaretti C, Saboni L, Mandereau-Bruno L,\nB\u00e9n\u00e9zet L, Raimond V, et al. \u00c9tudes Entred : un dispositif pour\nam\u00e9liorer la connaissance de l'\u00e9tat de sant\u00e9 des personnes\npr\u00e9sentant un diab\u00e8te en France - Premiers r\u00e9sultats de\nla troisi\u00e8me \u00e9dition conduite en m\u00e9tropole en 2019. Bull\nEpid\u00e9miol Hebd. 2022;(22): 383-92.\nfrance.fr/beh/2022/22/2022_22_1.html", "mimetype": "text/plain", "start_char_idx": 3931, "end_char_idx": 4828, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "e17d8cfe-da6a-4c89-b96c-dbc6de3572ff": {"__data__": {"id_": "e17d8cfe-da6a-4c89-b96c-dbc6de3572ff", "embedding": null, "metadata": {"page_label": "393", "file_name": "2022_22.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2022_22.pdf", "file_type": "application/pdf", "file_size": 1843017, "creation_date": "2025-11-25", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "9b05e3fc-b17f-4677-9647-a6dec50e6e20", "node_type": "4", "metadata": {"page_label": "393", "file_name": "2022_22.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2022_22.pdf", "file_type": "application/pdf", "file_size": 1843017, "creation_date": "2025-11-25", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "9bbcc7bc26e230775b1fac88e023c8debe0010dcaff26d5cbd8d95ec9a29d4b2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8d0e428e-a991-49d7-a3e8-7e26ecf661d5", "node_type": "1", "metadata": {}, "hash": "cc666995a8c6e6bc039380cc3db18634bd98cd88fc546cd4bac26a59ab121a88", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Journ\u00e9e mondiale du diab\u00e8te, 14 novembre 2022 BEH 22 | 8 novembre 2022 | 393\nles populations. Elle repr\u00e9sente de 10 \u00e0 30% environ\ndes personnes DT1. En France, les donn\u00e9es de l'\u00e9tude\n\u00c9chantillon national t\u00e9moin repr\u00e9sentatif des personnes\ndiab\u00e9tiques (Entred), en cours de r\u00e9\u00e9valuation, montrent\nune pr\u00e9valence de 13% chez les personnes DT2 et 39%\nchez les personnes DT1 3 sachant que la pr\u00e9valence du\ntabagisme dans la population g\u00e9n\u00e9rale est de 24%.\nIl est plus fr\u00e9quent chez les hommes jeunes,\naugmente chez les femmes, et est inversement\ncorr\u00e9l\u00e9 au statut socio\u00e9conomique des patients, avec\nune pr\u00e9valence plus importante chez les patients les\nplus pr\u00e9caires (figure 1) .\nTabagisme, composition corporelle,\ninsulinor\u00e9sistance et insulinos\u00e9cr\u00e9tion 4\nIl existe un lien tr\u00e8s probable entre le tabagisme\net l'accumulation de graisse visc\u00e9rale qui fait le\nlit du syndrome m\u00e9tabolique associant variable -\nment DT2, hypertension art\u00e9rielle, hypertriglyc\u00e9ri -\nd\u00e9mie et baisse du HDL-cholest\u00e9rol survenant dans\nun contexte d'insulinor\u00e9sistance.\nEn effet, si le fumeur a en moyenne un poids inf\u00e9 -\nrieur \u00e0 celui du non-fumeur, il pr\u00e9sente en revanche\nun exc\u00e8s de tissu adipeux abdominal avec un\nrapport taille/ hanche plus \u00e9lev\u00e9 qui s'ass ocie \u00e0 une\nd\u00e9gradation de la tol\u00e9rance au glucose et des index\nd'insulinosensibilit\u00e9 5.\nSes m\u00e9canismes sont discut\u00e9s, mais font intervenir\ndes effets :\n\u2022 li\u00e9s \u00e0 la nicotine (principalement \u00e9tudi\u00e9e) : stimulation de la production d'hormones de contrer\u00e9gulation glyc\u00e9miques (cat\u00e9cholamines,\ncortisol, hormone de croissance), effet anti\u0153strog\u00e8nes (figure 2) ;\n\u2022 pro-inflammatoires de la fum\u00e9e de tabac indui -\nsant une inflammation de bas grade ;\n\u2022 de dysfonction endoth\u00e9liale li\u00e9e au stress\noxydatif et cons \u00e9quences de l'hypoxie caus\u00e9e\npar le monoxyde de carbone (CO).\nUn r\u00f4le possible des m\u00e9taux lourds contenus dans la\nfum\u00e9e de cigarette (arsenic, plus que plomb, mercure\nou cadmium) a \u00e9galement \u00e9t\u00e9 \u00e9voqu\u00e9, sachant que la\nfum\u00e9e de tabac contient de l'ordre de 4 700 substances.\nCette insulinor\u00e9sistance est favoris\u00e9e par le taba -\ngisme actif (+ 40 %) mais \u00e9galement par le tabagisme\npassif (+ 28 % ). Des facteurs g\u00e9n\u00e9tiques de pr\u00e9dis -\nposition touchant en particulier le r\u00e9cepteur cholinergique \u00e0 la nicotine pourraient \u00e9galement intervenir.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2280, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "8d0e428e-a991-49d7-a3e8-7e26ecf661d5": {"__data__": {"id_": "8d0e428e-a991-49d7-a3e8-7e26ecf661d5", "embedding": null, "metadata": {"page_label": "393", "file_name": "2022_22.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2022_22.pdf", "file_type": "application/pdf", "file_size": 1843017, "creation_date": "2025-11-25", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "9b05e3fc-b17f-4677-9647-a6dec50e6e20", "node_type": "4", "metadata": {"page_label": "393", "file_name": "2022_22.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2022_22.pdf", "file_type": "application/pdf", "file_size": 1843017, "creation_date": "2025-11-25", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "9bbcc7bc26e230775b1fac88e023c8debe0010dcaff26d5cbd8d95ec9a29d4b2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e17d8cfe-da6a-4c89-b96c-dbc6de3572ff", "node_type": "1", "metadata": {"page_label": "393", "file_name": "2022_22.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2022_22.pdf", "file_type": "application/pdf", "file_size": 1843017, "creation_date": "2025-11-25", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "e45c5168b7018313d3bf6238bf7317d6f0a99fb59962f88e1a0f65bf63e371bb", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Cette insulinor\u00e9sistance est favoris\u00e9e par le taba -\ngisme actif (+ 40 %) mais \u00e9galement par le tabagisme\npassif (+ 28 % ). Des facteurs g\u00e9n\u00e9tiques de pr\u00e9dis -\nposition touchant en particulier le r\u00e9cepteur cholinergique \u00e0 la nicotine pourraient \u00e9galement intervenir.\nL'insulinor\u00e9sistance est r\u00e9versible lors de l'arr \u00eat du\ntabagisme 6.\nM\u00e9canismes mol\u00e9culaires\n\u2022 diminution de l'exp ression de PPAR gamma,\naugmentation de la phosporylation du r\u00e9cep -\nteur de l'ins uline (qui diminue l'ins ulinosen -\nsibilit\u00e9), augmentation de la lipolyse du tissu\nadipeux et de la s\u00e9cr\u00e9tion des Very Low-Density\nLipoprotein (VLDL) (lipoprot\u00e9ines de tr\u00e8s basse\ndensit\u00e9) h\u00e9patiques ;\n\u2022 activation de la sous-unit\u00e9 alpha-7 du r\u00e9cepteur\ncholinergique \u00e0 la nicotine ;\n\u2022 anomalies \u00e9pig\u00e9n\u00e9tiques par m\u00e9thylation aber -\nrante du DNA de g\u00e8nes impliqu\u00e9s dans le risque\nde DT2.\nFigure 1\n\u00c9pid\u00e9miologie du tabagisme de la population diab\u00e9tique mondiale\nAdapt\u00e9 de 3.\nPr\u00e9valence mondiale du tabagisme\nDT2=20,8%\nDT1=10 \u00e0 30%\nFacteurs associ\u00e9s\nau comportement tabagique\nSexe masculin\n\u00c2ge jeune\nS\u00e9dentarit\u00e9\nBas niveau socio\u00e9conomique\nDT2 : 13%\nDT1 : 39%\nEn France", "mimetype": "text/plain", "start_char_idx": 2014, "end_char_idx": 3143, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "5745f265-e2fc-4e88-8e18-155b236ea65a": {"__data__": {"id_": "5745f265-e2fc-4e88-8e18-155b236ea65a", "embedding": null, "metadata": {"page_label": "394", "file_name": "2022_22.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2022_22.pdf", "file_type": "application/pdf", "file_size": 1843017, "creation_date": "2025-11-25", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "7d6502f2-57f3-4c3f-bdc7-c90afb45915b", "node_type": "4", "metadata": {"page_label": "394", "file_name": "2022_22.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2022_22.pdf", "file_type": "application/pdf", "file_size": 1843017, "creation_date": "2025-11-25", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "29d84caa04647b169ffaa188fe9f2a7f9dc5d4dd18c56a23097b6bb88cddea5a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5252bef4-897e-42fc-a092-3088f01ea356", "node_type": "1", "metadata": {}, "hash": "fc1ac798b26266f7ade2d9b999712aad260bcf4cbfef33b0e1036d875a326cf5", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "394 | 8 novembre 2022 | BEH 22 Journ\u00e9e mondiale du diab\u00e8te, 14 novembre 2022\nEn ce qui conc erne l'insulinosensibilit\u00e9 : des r\u00e9cep -\nteurs nicotiniques ont \u00e9t\u00e9 identifi\u00e9s au niveau des\nterminaisons pr\u00e9-synaptiques sympathiques des\n\u00eelots b\u00eata-pancr\u00e9atiques et des r\u00e9cepteurs postsynaptiques. Le tabagisme est associ\u00e9 \u00e0 une diminution de la fonction b\u00eata-cellulaire mais les potentiels\nm\u00e9canismes, m\u00e9di\u00e9s par la nicotine qui augmenterait\nl'apoptose des cellules b\u00eata, restent insuffisamment\ndocument\u00e9s.\nTabagisme et DT2\nLes donn\u00e9es de nombreuses \u00e9tudes d'obs ervation\nsugg\u00e8rent que le risque relatif de pr\u00e9diab\u00e8te et de\nDT2 est augment\u00e9 de 37 \u00e0 44% chez les fumeurs\npar rapport aux non-fumeurs dans diff\u00e9rentes popu -\nlations (caucasiennes, asiatiques...) 7,8. Ce risque\naugmente de mani\u00e8re dose-d\u00e9pendante 7 et a \u00e9t\u00e9\nconfirm\u00e9 par plusieurs m\u00e9ta-analyses r\u00e9centes 9 sur\ndes donn\u00e9es prospectives ; \u00e0 l'opp os\u00e9 ce risque\ndiminue avec l'arr \u00eat de cons ommation de tabac,\nnotamment apr\u00e8s 10 ans de sevrage. De mani\u00e8re\nint\u00e9ressante le risque de DT2 semble plus marqu\u00e9\nchez les hommes que chez les femmes fumeuses\ndans certaines cohortes, sans explications claires \u00e0\nce ph\u00e9nom\u00e8ne. Le tabac appara\u00eet donc comme un\nfacteur de risque ind\u00e9pendant et modifiable de DT2\ndans la population g\u00e9n\u00e9rale 3.\nNotons \u00e9galement un surcro\u00eet de risque de DT2\nli\u00e9 pour 68% \u00e0 la prise de poids lors du sevrage\ntabagique chez le non-diab\u00e9tique ; celui-ci est\nd'autant plus marqu\u00e9 5 \u00e0 7 ans apr\u00e8s le sevrage,\nest proportionnel \u00e0 l'imp ortance de la prise\nde poids, et d\u00e9cro\u00eet progressivement dans le temps\npour rejoindre un risque \u00e9quivalent \u00e0 celui du nonfumeur uniquement apr\u00e8s 30 ans de sevrage 10.\nTabagisme, mortalit\u00e9 et complications\ndu diab\u00e8te\nChez le DT2, comme chez le DT1 le tabagisme actif\nconstitue le principal facteur de risque de morta -\nlit\u00e9 toutes causes avant m\u00eame l'\u00e9qu ilibre glyc\u00e9 -\nmique, lipidique ou tensionnel 11. Le b\u00e9n\u00e9fice du\nsevrage sur ce risque de mortalit\u00e9 toutes causes\nest d'autant plus important que le sevrage aura \u00e9t\u00e9\npr\u00e9coce.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2033, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "5252bef4-897e-42fc-a092-3088f01ea356": {"__data__": {"id_": "5252bef4-897e-42fc-a092-3088f01ea356", "embedding": null, "metadata": {"page_label": "394", "file_name": "2022_22.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2022_22.pdf", "file_type": "application/pdf", "file_size": 1843017, "creation_date": "2025-11-25", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "7d6502f2-57f3-4c3f-bdc7-c90afb45915b", "node_type": "4", "metadata": {"page_label": "394", "file_name": "2022_22.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2022_22.pdf", "file_type": "application/pdf", "file_size": 1843017, "creation_date": "2025-11-25", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "29d84caa04647b169ffaa188fe9f2a7f9dc5d4dd18c56a23097b6bb88cddea5a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5745f265-e2fc-4e88-8e18-155b236ea65a", "node_type": "1", "metadata": {"page_label": "394", "file_name": "2022_22.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2022_22.pdf", "file_type": "application/pdf", "file_size": 1843017, "creation_date": "2025-11-25", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "e0153f67a87fb7f5ea01557e79e1a056ea5f36f9bcada2cd83e2b98c4b19f409", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Le b\u00e9n\u00e9fice du\nsevrage sur ce risque de mortalit\u00e9 toutes causes\nest d'autant plus important que le sevrage aura \u00e9t\u00e9\npr\u00e9coce.\nChez le patient DT1 et DT2 le tabagisme actif est\n\u00e9galement un facteur de risque des comp lications macro-angiopathiques du diab\u00e8te (infarctus\ndu myocarde, accident vasculaire c\u00e9r\u00e9bral (AVC),\nart\u00e9riopathie des membres inf\u00e9rieurs), et le risque\naugmente de mani\u00e8re dose-d\u00e9pendante ( figure 3).\nChez le patient DT2, une m\u00e9ta-analyse a montr\u00e9\nque les risques de mortalit\u00e9 cardiovasculaire, de\nmorbidit\u00e9 cardiovasculaire et de coronaropathie\nFigure 2\nM\u00e9canismes impliqu\u00e9s dans l'association entre tabac et diab\u00e8te\nGH : growth hormone (hormone de croissance) ; AGL : acides gras libres ; P : phosphorylation ; IRS1 : Insulin Receptor Substrate 1 (substrat 1 du r\u00e9cepteur\nde l'insuline) ; VLDL : Very Low-Density Lipoprotein (lipoprot\u00e9ine de tr\u00e8s basse densit\u00e9).\nAdapt\u00e9 de 3.\nhormones\nde contre-r\u00e9gulation\nR\u00e9cepteur b\u00eata-3\nR\u00e9cepteur\ncholinergique\nIRS1\n\u0152strog\u00e8nes\nAndrog\u00e8nes\nNicotine\nGH\nCortisol\nCat\u00e9cholamines\nCat\u00e9cholamines\nAGLAGL\nAGLAGL\nAGL\nAGL\nApoptose\nb\u00eata-cellulaire\ns\u00e9cr\u00e9tion VLDL lipolyse\ninsulinor\u00e9sistance insulinos\u00e9cr\u00e9tion\nadiposit\u00e9\nvisc\u00e9rale\ncaptation\ndu glucose fonction b\u00eata-cellulaire", "mimetype": "text/plain", "start_char_idx": 1909, "end_char_idx": 3126, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "a2a903a3-47f6-44e0-bafd-e1f521262852": {"__data__": {"id_": "a2a903a3-47f6-44e0-bafd-e1f521262852", "embedding": null, "metadata": {"page_label": "395", "file_name": "2022_22.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2022_22.pdf", "file_type": "application/pdf", "file_size": 1843017, "creation_date": "2025-11-25", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "4279f1b2-5420-4e50-ac08-2744d393c439", "node_type": "4", "metadata": {"page_label": "395", "file_name": "2022_22.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2022_22.pdf", "file_type": "application/pdf", "file_size": 1843017, "creation_date": "2025-11-25", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "6aac7cb8feaec2eee0b363b315e5f70e7122bcffba847e4e4c56b5a9adc3455d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "553e70cc-761d-45be-9849-0ba22b1f5203", "node_type": "1", "metadata": {}, "hash": "4dd92ee882ea6b9c5f42c6ac2097545e7e9d163d2e72b6c915be1bf1ee0f89bd", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Journ\u00e9e mondiale du diab\u00e8te, 14 novembre 2022 BEH 22 | 8 novembre 2022 | 395\n\u00e9taient de 1,49 (intervalle de confi ance \u00e0 95% :\nIC95%: [1,29-1,71]), 1,44 [1,34-1,54] et 1,51 [1,41-1,62],\nrespectivement. Une relation dose- d\u00e9pendante a\n\u00e9galement \u00e9t\u00e9 \u00e9tablie dans une \u00e9tude prospective\nr\u00e9alis\u00e9e chez des infirmi\u00e8res diab\u00e9tiques (Nurse's\nHealth Study) et dans une \u00e9tude chinoise r\u00e9cente.\nOn retrouve donc une association positive et dosed\u00e9pendante entre le tabagisme et le risque corona -\nrien chez les patients DT2. Dans la m\u00e9ta-analyse de\nPan et coll., les risques de survenue d'AVC et d'art\u00e9riopathie p\u00e9riph\u00e9rique \u00e9taient de 1,54 [1,41 -1,69],\net 2,15 [1,62-2,85] chez les patients fumeurs 3.\nEn ce qui conc erne la micro-angiopathie (n\u00e9phropa -\nthie, r\u00e9tinopathie, neuropathie) le r\u00f4le du tabagisme\ncomme facteur de risque potentiel de r\u00e9tinopathie\ndiab\u00e9tique est \u00e9tabli chez les patients atteints de\nDT1, mais discut\u00e9 chez les patients atteints de DT2 .\nIl est conn u un comme un facteur de risque de la\nn\u00e9phropathie diab\u00e9tique chez le DT2. Il existe enfin\nune association positive entre tabagisme et neuropathie diab\u00e9tique prouv\u00e9e dans le DT1, mais discut\u00e9e\ndans le DT2 12. Dans une m\u00e9ta-analyse r\u00e9cente\nportant sur 82 \u00e9tudes, le risque de r\u00e9tinopathie diab\u00e9tique \u00e9tait augment\u00e9 chez les fumeurs DT1 (risque\nrelatif : RR=1,23 ; IC95%: [1,14-1,33], p < 0,001), mais\ndiminu\u00e9 chez les fumeurs DT2 (RR=0,92 ; IC 95%:\n[0,86-0,98], p=0,02). Chez le diab\u00e9tique de type 2,\ndans une m\u00e9ta-analyse r\u00e9cente portant sur 13 \u00e9tudes\ntransversales ou prospectives, le risque de microal -\nbuminurie \u00e9tait augment\u00e9 chez les patients fumeurs\n(odds ratio : OR=2,13 (IC95%: [1,32-3,45]; p=0002) et\nil existait ainsi une relation lin\u00e9aire entre le tabagisme\net la dur\u00e9e du DT2 avec l'albuminurie 3.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1777, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "553e70cc-761d-45be-9849-0ba22b1f5203": {"__data__": {"id_": "553e70cc-761d-45be-9849-0ba22b1f5203", "embedding": null, "metadata": {"page_label": "395", "file_name": "2022_22.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2022_22.pdf", "file_type": "application/pdf", "file_size": 1843017, "creation_date": "2025-11-25", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "4279f1b2-5420-4e50-ac08-2744d393c439", "node_type": "4", "metadata": {"page_label": "395", "file_name": "2022_22.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2022_22.pdf", "file_type": "application/pdf", "file_size": 1843017, "creation_date": "2025-11-25", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "6aac7cb8feaec2eee0b363b315e5f70e7122bcffba847e4e4c56b5a9adc3455d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a2a903a3-47f6-44e0-bafd-e1f521262852", "node_type": "1", "metadata": {"page_label": "395", "file_name": "2022_22.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2022_22.pdf", "file_type": "application/pdf", "file_size": 1843017, "creation_date": "2025-11-25", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "04eb68f12aefd808a2f810143cb214c2e20fae36f8387374858735c36330a7ac", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5c0ba1df-1189-474d-91fa-d41c9d2e5179", "node_type": "1", "metadata": {}, "hash": "3aba4860fc2836175b17065c409ce65af4a9115e94a37b57ce877a2660bdf30f", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Les m\u00e9canismes impliqu\u00e9s dans l'aggravation des\ncomplications micro- et macro-angiopathiques sont\ncomplexes et intriqu\u00e9s : li\u00e9s \u00e0 l'ins ulinor\u00e9sistance\n(hypertriglyc\u00e9rid\u00e9mie, diminution du HDL-cholest\u00e9rol,\nperoxydation des LDL...), ainsi qu'\u00e0 la dysfonction\nendoth\u00e9liale associant spasme et thrombose favo -\nris\u00e9e par l'hypoxie (CO-d\u00e9pendante) et \u00e0 l'infl ammation de la paroi art\u00e9rielle.\nAutres complications 3\nLa consommation de tabac chez les sujets diab\u00e9tiques\n(la majorit\u00e9 des donn\u00e9es concernant les DT2) est associ\u00e9e \u00e0 un surrisque de survenue de cancer avec un\nrisque relatif fumeur/non-fumeur de l'ordre de 1,6 ; elle\nFigure 3\nComplications du tabagisme dans la population diab\u00e9tique\nIDM : infarctus du myocarde ; AVC: accident vasculaire c\u00e9r\u00e9bral ; LDL : Low-Density lipoprotein ; TG: triglyc\u00e9rides ; HDL : High-Density lipoprotein ;\nDT1: diab\u00e8te de type 1 ; DT2 : diab\u00e8te de type 2 ; CHC : carcinome h\u00e9pato-cellulaire ; HbA1c (h\u00e9moglobine glyqu\u00e9e).\nAdapt\u00e9 de 3.", "mimetype": "text/plain", "start_char_idx": 1778, "end_char_idx": 2749, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "5c0ba1df-1189-474d-91fa-d41c9d2e5179": {"__data__": {"id_": "5c0ba1df-1189-474d-91fa-d41c9d2e5179", "embedding": null, "metadata": {"page_label": "395", "file_name": "2022_22.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2022_22.pdf", "file_type": "application/pdf", "file_size": 1843017, "creation_date": "2025-11-25", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "4279f1b2-5420-4e50-ac08-2744d393c439", "node_type": "4", "metadata": {"page_label": "395", "file_name": "2022_22.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2022_22.pdf", "file_type": "application/pdf", "file_size": 1843017, "creation_date": "2025-11-25", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "6aac7cb8feaec2eee0b363b315e5f70e7122bcffba847e4e4c56b5a9adc3455d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "553e70cc-761d-45be-9849-0ba22b1f5203", "node_type": "1", "metadata": {"page_label": "395", "file_name": "2022_22.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2022_22.pdf", "file_type": "application/pdf", "file_size": 1843017, "creation_date": "2025-11-25", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "8c2b443cf08c34a5998b593f0410b5a0171347f048b446e2e932a3cbcef9e4d0", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Adapt\u00e9 de 3.\nContr\u00f4le glyc\u00e9mique\nComplications macrovasculaires\nInfections\nCancer\nComplications microvasculaires\n\nAutres complications\nComplications obst\u00e9tricales\nChez la femme enceinte diab\u00e9tique\nen pr\u00e9-conceptionnel, pr\u00e9dicteur de :\nD\u00e9pression\nDans le DT1, manque de donn\u00e9es\ndes \u00e9pisodes majeurs et mineurs de d\u00e9pression\ndans le DT2\ndes \u00e9v\u00e9nements cardiovasculaires\n(maladie coronarienne, IDM et AVC)\nmortalit\u00e9 cardiovasculaire\nDyslipid\u00e9mie ( LDL, TG, HDL)\nMauvais contr\u00f4le glyc\u00e9mique\n(HbA1c \u00e9lev\u00e9e)\nDans le DT1 :\nrisque hypoglyc\u00e9mique\nvariabilit\u00e9 glyc\u00e9mique\ndu risque d'hospitalisation\npour infection respiratoire, urinaire\nou cutan\u00e9e\nFacteur de risque de tuberculose\nnotamment de formes s\u00e9v\u00e8res\nDans le DT2 :\nDans le DT1, manque de donn\u00e9es\nd'au moins 60% du risque de cancer\ntoutes causes\ncancer du pancr\u00e9as\nCHC (carcinome h\u00e9patocellulaire\ncancer colorectal\nDans le DT1 :\nDans le DT2 :\nn\u00e9phropathie diab\u00e9tique\nr\u00e9tinopathie diab\u00e9tique\nneuropathie diab\u00e9tique\nn\u00e9phropathie diab\u00e9tique\n(moins clairement \u00e9tabli)\nr\u00e9tinopathie diab\u00e9tique\nneuropathie diab\u00e9tique\n(moins clairement \u00e9tabli)\nAugmentation du risque\nde parodontite\nAcc\u00e9l\u00e9ration de la perte de masse\nosseuse et augmentaton du risque\nfracturaire chez la femme m\u00e9nopaus\u00e9e\nmortalit\u00e9 p\u00e9rinatale\nmalformations cong\u00e9nitales", "mimetype": "text/plain", "start_char_idx": 2737, "end_char_idx": 4010, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "a95b3bf3-0e78-4670-8f29-c2e50ece54ae": {"__data__": {"id_": "a95b3bf3-0e78-4670-8f29-c2e50ece54ae", "embedding": null, "metadata": {"page_label": "396", "file_name": "2022_22.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2022_22.pdf", "file_type": "application/pdf", "file_size": 1843017, "creation_date": "2025-11-25", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "0da85362-fd5e-4050-9131-3ef70de211ca", "node_type": "4", "metadata": {"page_label": "396", "file_name": "2022_22.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2022_22.pdf", "file_type": "application/pdf", "file_size": 1843017, "creation_date": "2025-11-25", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "1e3e47ed1467e935a21f4949ddc132420479a6f0f829ade5262bf8c8db87f318", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4c3ae163-aa2d-4933-8fca-56a604a28081", "node_type": "1", "metadata": {}, "hash": "40d393e39bafe0d685916bb4288517b3d2f7fa24c97ce986024acbf89207e09d", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "396 | 8 novembre 2022 | BEH 22 Journ\u00e9e mondiale du diab\u00e8te, 14 novembre 2022\nest \u00e9galement li\u00e9e \u00e0 un exc\u00e8s de mortalit\u00e9 par cancer\navec un risque relatif fumeur/non-fumeur de l'ordre de\n1,4, et cet exc\u00e8s d\u00e9cro\u00eet avec le sevrage tabagique.\nLes sujets diab\u00e9tiques fumeurs actuels ont \u00e9galement\nun risque plus \u00e9lev\u00e9 d'hos pitalisation pour infection\npar rapport aux sujets diab\u00e9tiques non-fumeurs, et\nce avec un risque relatif de l'ordre de 1,3.\nLe tabagisme est associ\u00e9 \u00e0 un risque d'amp utation\nplus \u00e9lev\u00e9 chez les patients diab\u00e9tiques avec un pied\ninfect\u00e9.\nLa consommation du tabac chez les sujets diab\u00e9 -\ntiques est associ\u00e9e \u00e0 un risque accru de survenue et\nde progression de parodontopathies.\nTabagisme, diab\u00e8te, et d\u00e9pression 13,14\nLe DT2, plus volontiers d\u00e9pressif que le nondiab\u00e9tique, l'est d'autant plus qu'il fume plus de\n11 cigarettes/jour. Il existe une relation positive\nentre le nombre de cigarettes fum\u00e9es et la s\u00e9v\u00e9 -\nrit\u00e9 du syndrome d\u00e9pressif ; de plus, le tabagisme\ns'associe \u00e0 une d\u00e9gradation de la qualit\u00e9 de vie du\npatient diab\u00e9tique ainsi qu'a une augmentation des\ncomorbidit\u00e9s. La fr\u00e9quente pr\u00e9sence d'un syndrome\nd\u00e9pressif chez le diab\u00e9tique rend le sevrage d'autant\nplus difficile \u00e0 appr\u00e9hender.\nLe tabagisme appara\u00eet donc comme un facteur\nde risque ind\u00e9pendant de d\u00e9pression chez le\npatient DT2, et la pr\u00e9vention du tabagisme doit \u00eatre\nconsid\u00e9r\u00e9e afin de limiter le risque de d\u00e9veloppement\nd'une symptomatologie d\u00e9pressive.\nChez le patient DT1, les donn\u00e9es sont limit\u00e9es et ne\npermettent pas de conclure.\nTabagisme, diab\u00e8te et femme\nLe tabagisme pendant la grossesse est associ\u00e9\n\u00e0 une augmentation du risque de diab\u00e8te gesta -\ntionnel (DG) chez la femme fumeuse (OR=1,65), puis\nde diab\u00e8te patent ; \u00e0 l'opp os\u00e9, l'absence de taba -\ngisme et le sevrage du tabac (associ\u00e9e aux r\u00e8gles\nhygi\u00e9no- di\u00e9t\u00e9tiques) diminuent le risque de diab\u00e8te\ngestationnel.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1872, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "4c3ae163-aa2d-4933-8fca-56a604a28081": {"__data__": {"id_": "4c3ae163-aa2d-4933-8fca-56a604a28081", "embedding": null, "metadata": {"page_label": "396", "file_name": "2022_22.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2022_22.pdf", "file_type": "application/pdf", "file_size": 1843017, "creation_date": "2025-11-25", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "0da85362-fd5e-4050-9131-3ef70de211ca", "node_type": "4", "metadata": {"page_label": "396", "file_name": "2022_22.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2022_22.pdf", "file_type": "application/pdf", "file_size": 1843017, "creation_date": "2025-11-25", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "1e3e47ed1467e935a21f4949ddc132420479a6f0f829ade5262bf8c8db87f318", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a95b3bf3-0e78-4670-8f29-c2e50ece54ae", "node_type": "1", "metadata": {"page_label": "396", "file_name": "2022_22.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2022_22.pdf", "file_type": "application/pdf", "file_size": 1843017, "creation_date": "2025-11-25", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "19c16ddde20f11c7fd6d05af1e7425c292a4ee44f1e819999e99e6c70b3d4992", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "783c2bac-ee48-4f04-82d6-ff2cda0bc295", "node_type": "1", "metadata": {}, "hash": "d5a42d9c96f409f1e2481b94c7bbd13fc37aceab7c056787f51eb41ff89bc44a", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Le tabagisme maternel majore le risque de retard de\ncroissance intra-ut\u00e9rin, de fausse couche pr\u00e9coce,\nde grossesse extra-ut\u00e9rine, d'ano malie cong\u00e9nitale,\nd'h\u00e9matome r\u00e9troplacentaire, de placenta pr\u00e6via,\nde pr\u00e9maturit\u00e9, de mort f\u0153tale in utero , de c\u00e9sa -\nrienne, de petit poids de naissance lui-m\u00eame facteur\nde risque de surpoids, d'ob\u00e9 sit\u00e9 abdominale et de\nDT2 pour l'enfant probablement par des m\u00e9canismes\n\u00e9pig\u00e9n\u00e9tiques 15.\nDans un contexte de diab\u00e8te gestationnel chez les\nfemmes fumeuses, l'\u00e9qu ilibre glyc\u00e9mique appa -\nra\u00eet globalement moins bon avec une plus grande\nfr\u00e9quence d'instauration d'une insulinoth\u00e9rapie.\nDe plus les enfants de femmes fumeuses ont un\nrisque de DT2 augment\u00e9 de 34% en cas de taba -\ngisme actif et de 22% en cas de tabagisme passif.\nL 'association tabagisme, ob\u00e9sit\u00e9 et DT2 est par\nailleurs responsable de l'aug mentation pr\u00e9occu -\npante de l'incidence de la maladie coronarienne chez\nla femme 16.\nDans le DT1, nous manquons de donn\u00e9es.\nTabagisme et \u00e9quilibre glyc\u00e9mique 3\nL 'HbA1c (h\u00e9moglobine glyqu\u00e9e) est plus \u00e9lev\u00e9 chez\nles fumeurs actifs (+ 0,12% par 20 paquets/ann\u00e9e)\nnon DT2 et les ex-fumeurs (+ 0,03 %) que chez les\nnon-fumeurs. L 'augmentation d'HbA1c observ\u00e9e\nest corr\u00e9l\u00e9e \u00e0 celle de la cotinine urinaire (catabo -\nlite de la nicotine). Chez les patients DT1, DT2 et les\npatientes porteuses d'un DG, le tabagisme actif est\nassoci\u00e9 \u00e0 une d\u00e9t\u00e9rioration de l'\u00e9quilibre glyc\u00e9mique\navec une relation dose-d\u00e9pendante en fonction de\nla s\u00e9v\u00e9rit\u00e9 du tabagisme.\nLorsque le diab\u00e9tique est trait\u00e9 et qu'il est fumeur son\n\u00e9quilibre glyc\u00e9mique est de moins bonne qualit\u00e9 ;\ns'il est trait\u00e9 par l'ins uline, une r\u00e9sorption retard\u00e9e\nde l'insuline pourrait participer \u00e0 un \u00e9quilibre glyc\u00e9 -\nmique plus instable ; l'instabilit\u00e9 glyc\u00e9mique est plus\nfr\u00e9quente en particulier chez le DT1, le risque d'hypoglyc\u00e9mies s\u00e9v\u00e8res est augment\u00e9.", "mimetype": "text/plain", "start_char_idx": 1873, "end_char_idx": 3731, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "783c2bac-ee48-4f04-82d6-ff2cda0bc295": {"__data__": {"id_": "783c2bac-ee48-4f04-82d6-ff2cda0bc295", "embedding": null, "metadata": {"page_label": "396", "file_name": "2022_22.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2022_22.pdf", "file_type": "application/pdf", "file_size": 1843017, "creation_date": "2025-11-25", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "0da85362-fd5e-4050-9131-3ef70de211ca", "node_type": "4", "metadata": {"page_label": "396", "file_name": "2022_22.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2022_22.pdf", "file_type": "application/pdf", "file_size": 1843017, "creation_date": "2025-11-25", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "1e3e47ed1467e935a21f4949ddc132420479a6f0f829ade5262bf8c8db87f318", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4c3ae163-aa2d-4933-8fca-56a604a28081", "node_type": "1", "metadata": {"page_label": "396", "file_name": "2022_22.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2022_22.pdf", "file_type": "application/pdf", "file_size": 1843017, "creation_date": "2025-11-25", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "3f627f15e99af00997aff2ef80d1d5f596355a0eac4a7bbaac0063d0704c6ef4", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "L 'ensemble de ces \u00e9l\u00e9ments souligne donc :\n\u2022 l'int\u00e9r\u00eat de ne pas devenir fumeur lorsque\nl'on est \u00e0 risque de diab\u00e8te afin de pr\u00e9venir la\nsurvenue d'un diab\u00e8te gestationnel ou d'un\ndiab\u00e8te patent ;\n\u2022 la n\u00e9cessit\u00e9 du sevrage tabagique chez les\npatients DT1 et DT2 fumeurs pour diminuer la\nmortalit\u00e9 toutes causes et/ou cardiovasculaire,\net pour r\u00e9duire et/ ou limiter les comp lications\nmicro-angiopathiques (tableau).\nSevrage tabagique chez le diab\u00e9tique 3\nLes recommandations actuelles (European Society\nof Cardiology (ESC) - European Association For\nthe Study of Diabetes (EASD)) soulignent l'int \u00e9r\u00eat et\nla n\u00e9cessit\u00e9 du sevrage tabagique chez les sujets\npr\u00e9diab\u00e9tiques ou diab\u00e9tiques 17, m\u00eame si cette\nmesure th\u00e9rapeutique essentielle n'est pas suffisamment prise en consid\u00e9ration par les professionnels de\nsant\u00e9 en diab\u00e9tologie.\nIl ne fait cependant l'objet que de peu d'\u00e9tudes reposant sur des interventions psycho- comportementales\n(intervention br\u00e8ve, entretien motivationnel (EM),\nsoutien t\u00e9l\u00e9phonique, autosupport num\u00e9rique, acti -\nvit\u00e9 physique, \u00e9ventuellement int\u00e9gr\u00e9s dans des\nprogrammes d'\u00e9ducation th\u00e9rapeutique) associ\u00e9es\nou non \u00e0 une intervention pharmacologique (substi -\ntution nicotinique (SN), utilisation de bupropion ou de\nvar\u00e9nicline) 18.\nAinsi l'EM montre un b\u00e9n\u00e9fice, avec 1,4 \u00e0 7 fois\nplus de sevrage du tabac chez les patients DT1\net DT2. Soulignons que 85% des \u00e9tudes ayant\nmontr\u00e9 un b\u00e9n\u00e9fice de l'EM, proposent des aides", "mimetype": "text/plain", "start_char_idx": 3732, "end_char_idx": 5181, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "655b23ba-a878-4609-875b-4daa07cdffbc": {"__data__": {"id_": "655b23ba-a878-4609-875b-4daa07cdffbc", "embedding": null, "metadata": {"page_label": "397", "file_name": "2022_22.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2022_22.pdf", "file_type": "application/pdf", "file_size": 1843017, "creation_date": "2025-11-25", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "af3e5d0d-5513-4835-98f2-476cfd9c6166", "node_type": "4", "metadata": {"page_label": "397", "file_name": "2022_22.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2022_22.pdf", "file_type": "application/pdf", "file_size": 1843017, "creation_date": "2025-11-25", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "a97f0bc647a8e4715933d69f272a1a861de041bcb5a5681eead04626d306ebee", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "af102b20-6331-44c9-b41a-e29d9e41cfc3", "node_type": "1", "metadata": {}, "hash": "d9cb2723d0ac83caf4df702fcd66fc0cc82caf2df6d02b44dd8f1c59969324ec", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Journ\u00e9e mondiale du diab\u00e8te, 14 novembre 2022 BEH 22 | 8 novembre 2022 | 397\npharmacologiques dans le groupe intervention, ce\nqui ne permet pas de juger de l'efficacit\u00e9 de l'EM seul\ndans le sevrage tabagique.\nL '\u00e9tude de Canga et coll. 19 montre dans un groupe\nde 280 DT2 qu'une intervention d'aid e au sevrage\npratiqu\u00e9e par une infirmi\u00e8re tabacologue associant\nentretien, SN si n\u00e9cessaire et suivi personnalis\u00e9\npermet une r\u00e9duction significative de la cons ommation tabagique \u00e0 6 mois, et ce par rapport aux\nsoins habituels de simples cons eils d'arr\u00eat (17,0%\nvs 2,3%, p<0,001). Des \u00e9tudes d'int ervention th\u00e9ra -\npeutique portant sur des effectifs plus larges de\npatients diab\u00e9tiques sont donc ici n\u00e9cessaire s,\nen l'absence de donn\u00e9es sp\u00e9cifiques et de qualit\u00e9\nsuffisante sur l'efficacit\u00e9 et la tol\u00e9rance chez les\npatients DT1 et DT2. Il existe un accord des sp\u00e9cia -\nlistes pour consid\u00e9rer la transposition des r\u00e9sultats\ndes \u00e9valuations venant de la population g\u00e9n\u00e9rale\nnon- diab\u00e9tique fumeuse vers celle des diab\u00e9tiques\nfumeurs ( tableau).\nChez les patients diab\u00e9tiques, l'arr\u00eat du tabac doit\n\u00eatre associ\u00e9 \u00e0 des mesures hygi\u00e9no-di\u00e9t\u00e9tiques\nrenforc\u00e9es, notamment dans les premi\u00e8res ann\u00e9es\nsuivant l'arr\u00eat. Aucune donn\u00e9e \u00e0 ce jour ne permet\nde re commander la modification du traitement \u00e0\nvis\u00e9e antidiab\u00e9tique pr\u00e9alablement au sevrage.\nDans l'ann\u00e9e suivant le sevrage une surveillance\nrenforc\u00e9e des param\u00e8tres glyc\u00e9miques et du poids\nest n\u00e9cessaire.\nLe sevrage tabagique se heurte par ailleurs comm e\nchez les non-diab\u00e9tiques \u00e0 la question sensible\nde la prise de poids, susceptible de d\u00e9grader\nl'\u00e9quilibre glyc\u00e9mique et cont re laquelle le patient\ndiab\u00e9tique est sensibilis\u00e9 en permanence. Une\nm\u00e9ta- analyse portant sur 62 \u00e9tudes 20 a montr\u00e9\nque celle-ci, bien que fr\u00e9quente (prise de 4 \u00e0 5 kg\napr\u00e8s 12 mois d'abstinence), survient essentielle -\nment dans les six premiers mois suivant le sevrage,\nn'est pas in\u00e9luctable (de 16 \u00e0 21% des sujets\nperdent du poids), ceci quels que soient les trai -\ntements utilis\u00e9s (substitution nicotinique, bupro -\npion, var\u00e9nicline). Elle semble \u00eatre plus importante\nchez les femmes que chez les hommes, mais les\ndonn\u00e9es de la litt\u00e9rature sont limit\u00e9es et parfois\ncontradictoires.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2218, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "af102b20-6331-44c9-b41a-e29d9e41cfc3": {"__data__": {"id_": "af102b20-6331-44c9-b41a-e29d9e41cfc3", "embedding": null, "metadata": {"page_label": "397", "file_name": "2022_22.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2022_22.pdf", "file_type": "application/pdf", "file_size": 1843017, "creation_date": "2025-11-25", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "af3e5d0d-5513-4835-98f2-476cfd9c6166", "node_type": "4", "metadata": {"page_label": "397", "file_name": "2022_22.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2022_22.pdf", "file_type": "application/pdf", "file_size": 1843017, "creation_date": "2025-11-25", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "a97f0bc647a8e4715933d69f272a1a861de041bcb5a5681eead04626d306ebee", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "655b23ba-a878-4609-875b-4daa07cdffbc", "node_type": "1", "metadata": {"page_label": "397", "file_name": "2022_22.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2022_22.pdf", "file_type": "application/pdf", "file_size": 1843017, "creation_date": "2025-11-25", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "5109ff826cd07ffd617852ec4ef0cf3909cc9144ac4ff037e0c6a53fa35be2d8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f2aaaa25-6ee5-42e3-9331-fdd27ecb3c81", "node_type": "1", "metadata": {}, "hash": "59ec39671e04acbe21e4ab23d61f1eda03d8e4d21cdce145b51fb3ddda907235", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Elle semble \u00eatre plus importante\nchez les femmes que chez les hommes, mais les\ndonn\u00e9es de la litt\u00e9rature sont limit\u00e9es et parfois\ncontradictoires.\nDe plus, le b\u00e9n\u00e9fice du sevrage tabagique essentiel -\nlement \u00e9valu\u00e9 chez le DT2, en particulier sur le plan de\nla mortalit\u00e9 totale et cardiovasculaire est significativement sup\u00e9rieur sur le long terme au r\u00e9el inconv\u00e9nient\nrepr\u00e9sent\u00e9 par la prise de poids et/ ou la d\u00e9gradation\nde l'\u00e9quilibre glyc\u00e9mique chez le diab\u00e9tique.\nConclusion\nLe tabagisme constitue un facteur de risque d\u00e9montr\u00e9\nde pr\u00e9-diab\u00e8te, de DT2 et de DG. Il est associ\u00e9 \u00e0 une\nd\u00e9gradation de l'\u00e9qu ilibre glyc\u00e9mique.", "mimetype": "text/plain", "start_char_idx": 2072, "end_char_idx": 2699, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "f2aaaa25-6ee5-42e3-9331-fdd27ecb3c81": {"__data__": {"id_": "f2aaaa25-6ee5-42e3-9331-fdd27ecb3c81", "embedding": null, "metadata": {"page_label": "397", "file_name": "2022_22.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2022_22.pdf", "file_type": "application/pdf", "file_size": 1843017, "creation_date": "2025-11-25", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "af3e5d0d-5513-4835-98f2-476cfd9c6166", "node_type": "4", "metadata": {"page_label": "397", "file_name": "2022_22.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2022_22.pdf", "file_type": "application/pdf", "file_size": 1843017, "creation_date": "2025-11-25", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "a97f0bc647a8e4715933d69f272a1a861de041bcb5a5681eead04626d306ebee", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "af102b20-6331-44c9-b41a-e29d9e41cfc3", "node_type": "1", "metadata": {"page_label": "397", "file_name": "2022_22.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2022_22.pdf", "file_type": "application/pdf", "file_size": 1843017, "creation_date": "2025-11-25", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "d1db6eb81ffe40e398358ff40fef9929cc4fca4a36abcf16cbf615bee8808b3b", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Conclusion\nLe tabagisme constitue un facteur de risque d\u00e9montr\u00e9\nde pr\u00e9-diab\u00e8te, de DT2 et de DG. Il est associ\u00e9 \u00e0 une\nd\u00e9gradation de l'\u00e9qu ilibre glyc\u00e9mique. Il cons titue\n\u00e9galement la premi\u00e8re cause de mortalit\u00e9 chez les\nTableau\nConsensus de la Soci\u00e9t\u00e9 francophone de tabacologie et de la Soci\u00e9t\u00e9 francophone du diab\u00e8te sur le tabagisme et le diab\u00e8te\nRecommandation Grade Niveau\nde preuve\nLes professionnels de sant\u00e9 devraient en pratique quotidienne informer les patients diab\u00e9tiques sur les risques\ndu tabagisme et leur conseiller de ne pas commencer \u00e0 fumer A 1\nTous les sujets diab\u00e9tiques fumeurs devraient recevoir des conseils d'aide au sevrage tabagique et devraient \u00eatre\ninform\u00e9s des b\u00e9n\u00e9fices du sevrage tabagique A 1\nChez les femmes diab\u00e9tiques le sevrage tabagique devrait \u00eatre propos\u00e9 avant toute grossesse A 2\nIl serait important de promouvoir de nouveaux programmes de pr\u00e9vention et de sevrage tabagique sp\u00e9cifiquement\nadapt\u00e9s aux besoins des femmes diab\u00e9tiques, car leurs modalit\u00e9s d'adaptation et contextes sociaux peuvent \u00eatre\ndiff\u00e9rents de ceux des hommes diab\u00e9tiques\nC 4\nLes d\u00e9marches de sevrage tabagique chez le diab\u00e9tique devraient \u00eatre accompagn\u00e9e d'une surveillance stricte\nde l'\u00e9quilibre glyc\u00e9mique et d'intervention sur le mode de vie, telles que l'augmentation de l'activit\u00e9 physique\net la r\u00e9duction du poids\nA 2\nLa fa\u00e7on la plus efficace de promouvoir le sevrage tabagique serait d'associer des th\u00e9rapeutiques psychocomportementales et pharmacologiques C 3\nLes m\u00e9dicaments de premi\u00e8re ligne dans le sevrage tabagique, substituts nicotiniques, var\u00e9nicline et bupropion\ninclus C 3\nChez les femmes enceintes, les th\u00e9rapeutiques psychocomportementales seules seraient recommand\u00e9es,\nen raison de l'absence de donn\u00e9es document\u00e9es sur la s\u00e9curit\u00e9 des pharmacoth\u00e9rapies pendant la grossesse C 4\nLa pharmacoth\u00e9rapie dans le sevrage tabagique dure au moins 3 mois C 4\nChez les patients utilisant un traitement de substitution nicotinique il est pr\u00e9f\u00e9rable d'associer des produits\nde remplacement nicotinique de longue et de courte dur\u00e9e d'action (timbre nicotinique et formes orales :\npastilles ou gommes)\nC 4\nLa e-cigarette (ou vapoteuse) utilis\u00e9e dans le cadre du sevrage tabagique doit l'\u00eatre un temps limit\u00e9, et arr\u00eat\u00e9e\nd\u00e8s que l'abstinence est obtenue et l'urgence de fumer contr\u00f4l\u00e9e C 4\nLes recommandations ci-dessus utilisent le mod\u00e8le de gradation de la Haute Autorit\u00e9 de sant\u00e9 (HAS).\nD'apr\u00e8s 3.", "mimetype": "text/plain", "start_char_idx": 2542, "end_char_idx": 4964, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "7efe0c89-0145-45e1-9506-9ba1ba22e386": {"__data__": {"id_": "7efe0c89-0145-45e1-9506-9ba1ba22e386", "embedding": null, "metadata": {"page_label": "398", "file_name": "2022_22.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2022_22.pdf", "file_type": "application/pdf", "file_size": 1843017, "creation_date": "2025-11-25", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "93113a58-04e3-484d-9264-50186f64c354", "node_type": "4", "metadata": {"page_label": "398", "file_name": "2022_22.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2022_22.pdf", "file_type": "application/pdf", "file_size": 1843017, "creation_date": "2025-11-25", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "ec8256382c2ceee5abcbb5f68bb78f8815ba1f86e3bd12deb24977c28b7e059d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7b58cad0-3073-4098-a806-67e19794ec05", "node_type": "1", "metadata": {}, "hash": "6f82a2fdae3aa21f485ee5850ee4d657f5474579699b88391a9d048206d4cd0d", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "398 | 8 novembre 2022 | BEH 22 Journ\u00e9e mondiale du diab\u00e8te, 14 novembre 2022\nDT2 et est un d\u00e9terminant majeur des complications\nmicro-angiopathiques (n\u00e9phropathie) et macroangiopathiques. Il y a donc un b\u00e9n\u00e9fice majeur \u00e0\nd\u00e9courager toute cons ommation tabagique chez\nle patient \u00e0 risque de diab\u00e8te (pr\u00e9vention primaire),\nou \u00e0 l'aid er \u00e0 se sevrer s'il est d\u00e9j\u00e0 diab\u00e9tique et\nfumeur (pr\u00e9vention secondaire). Compte-tenu du peu\nd'\u00e9tudes sur la strat\u00e9gie sp\u00e9cifique de prise en charge\nth\u00e9rapeutique du sevrage tabagique chez les patients\ndiab\u00e9tiques, l'application des m\u00eames principes\nqu'en population g\u00e9n\u00e9rale est donc recommand\u00e9e,\nen combinant des th\u00e9rapeutiques psycho- comportementales et pharmacologiques ( tableau ). Une\nsensibilisation et une formation \u00e0 l'aid e au sevrage\ntabagique des \u00e9quipes \u00e9ducatives diab\u00e9tologiques\nsont par ailleurs indispensables. \u25a0\nRemerciements\nDans le cadre du groupe de travail Tabagisme et diab\u00e8te,\nl'auteur tient \u00e0 remercier St\u00e9phanie Genou-Vannobel et\nIsabelle Gaudy (infirmi\u00e8res tabacologues) pour leurs conseils\npertinents, ainsi que Laura Phirmis et Claude Chaumeil de la\nF\u00e9d\u00e9ration fran\u00e7aise des diab\u00e9tiques (FFD) pour leurs conseils\njudicieux.\nLiens d'int\u00e9r\u00eat\nL 'auteur d\u00e9clare ne pas avoir de liens d'int\u00e9r\u00eat au regard\ndu contenu de l'article. Il d\u00e9clare par ailleurs avoir parti -\ncip\u00e9 \u00e0 des essais cliniques pour les laboratoires Amgen,\nSanofi, Bioprojet, \u00e0 des conf\u00e9rences, colloques ou actions\nde formation pour les laboratoires Amgen, Sanofi et Servier,\nMSD et pour Preuves & Pratiques, et avoir \u00e9t\u00e9 pris en charge\n(transport, h\u00f4tel, repas), \u00e0 l'occasion de d\u00e9placements pour\ncongr\u00e8s, par les laboratoires Servier, Amgen, Sanofi, Novo\nNordisk.\nR\u00e9f\u00e9rences\n[1] T\u00f6nnies T, Rathmann W, Hoyer A, Brinks R, Kuss O.\nQuantifying the underestimation of projected global\ndiabetes prevalence by the International Diabetes Fede -\nration (IDF) Diabetes Atlas. BMJ Open Diabetes Res Care.\n2021;9(1):e002122.\n[2] Roderick P, Turner V, Readshaw A, Dogar O, Siddiqi K. The\nglobal prevalence of tobacco use in type 2 diabetes mellitus\npatients: A systematic review and meta-analysis. Diabetes Res\nClin Pract. 2019;154: 52-65.\n[3] Durlach V, Verg\u00e8s B, Al-Salameh A, Bahougne T,\nBenzerouk F, Berlin I, et al .", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2237, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "7b58cad0-3073-4098-a806-67e19794ec05": {"__data__": {"id_": "7b58cad0-3073-4098-a806-67e19794ec05", "embedding": null, "metadata": {"page_label": "398", "file_name": "2022_22.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2022_22.pdf", "file_type": "application/pdf", "file_size": 1843017, "creation_date": "2025-11-25", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "93113a58-04e3-484d-9264-50186f64c354", "node_type": "4", "metadata": {"page_label": "398", "file_name": "2022_22.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2022_22.pdf", "file_type": "application/pdf", "file_size": 1843017, "creation_date": "2025-11-25", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "ec8256382c2ceee5abcbb5f68bb78f8815ba1f86e3bd12deb24977c28b7e059d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7efe0c89-0145-45e1-9506-9ba1ba22e386", "node_type": "1", "metadata": {"page_label": "398", "file_name": "2022_22.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2022_22.pdf", "file_type": "application/pdf", "file_size": 1843017, "creation_date": "2025-11-25", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "e8dc5a1f72a90641d855bafe2f6c968ceea21b05e3039cc62db324810a40c565", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "70faf334-60ed-4408-9216-877197a4a0f1", "node_type": "1", "metadata": {}, "hash": "dd8a8a3e6d60badb6c5942062af23ad80dc7a4b1e62b2c2d68e52636aa92c9d3", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Diabetes Res\nClin Pract. 2019;154: 52-65.\n[3] Durlach V, Verg\u00e8s B, Al-Salameh A, Bahougne T,\nBenzerouk F, Berlin I, et al . Smoking and diabetes interplay:\nA comprehensive review and joint statement. Diabetes Metab.\n2022;48(6):101370.\n[4] Maddatu J, Anderson-Baucum E, Evans-Molina C. Smoking\nand the risk of type 2 diabetes. Transl Res. 2017;184:101-7.\n[5] Aeschbacher S, Schoen T, Clair C, Schillinger P, Sch\u00f6nen -\nberger, Risch M, et al . Association of smoking and nicotine\ndependence with pre-diabetes in young and healthy adults.\nSwiss Med Wkly. 2014;144:w14019.\n[6] Berlin I. Smoking-induced metabolic disorders: A review.\nDiabetes Metab. 2008;34(4 Pt 1):307-14.\n[7] Willi C, Bodenmann P, Ghali WA, Faris PD, Cornuz J. Active\nsmoking and the risk of type 2 diabetes: A systematic review\nand meta-analysis. JAMA. 2007;298(22):2654-64.\n[8] U.S. Department of Health and Human Services. The health\nconsequences of smoking - 50 years of progress: A report\nof the Surgeon General. Atlanta: Centers for Disease Control\nand Prevention; 2014.\n[9] Akter S, Goto A, Mizoue T. Smoking and the risk of\ntype 2 diabetes in Japan: A systematic review and metaanalysis. J Epidemiol. 2017;27(12):553-61.\n[10] Hu Y, Zong G, Liu G, Wang M, Rosner B, Pan A, et al .\nSmoking cessation, weight change, type 2 diabetes, and\nmortality. N Engl J Med. 2018;379(7):623-32.\n[11] Rawshani A, Rawshani A, Franz\u00e9n S, Sattar N, Eliasson B,\nSvensson AM, et al. Risk factors, mortality, and cardiovas -\ncular outcomes in patients with type 2 diabetes. N Engl J Med.\n2018;379(7):633-44.\n[12] Pan A, Wang Y, Talaei M, Hu FB, Wu T. Relation of active,\npassive, and quitting smoking with incident type 2 diabetes:\nA systematic review and meta-analysis. Lancet Diabetes\nEndocrinol. 2015;3(12):958-67.\n[13] Haire-Joshu D, Heady S, Thomas L, Schechtman K,\nFisher EB Jr. Depressive symptomatology and smoking among\npersons with diabetes. Res Nurs Health. 1994;17(4):273-82.\n[14] Clyde M, Smith KJ, Gari\u00e9py G, Schmitz N. The association\nbetween smoking and depression in a Canadian communitybased sample with type 2 diabetes. Can J Diabetes.", "mimetype": "text/plain", "start_char_idx": 2114, "end_char_idx": 4219, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "70faf334-60ed-4408-9216-877197a4a0f1": {"__data__": {"id_": "70faf334-60ed-4408-9216-877197a4a0f1", "embedding": null, "metadata": {"page_label": "398", "file_name": "2022_22.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2022_22.pdf", "file_type": "application/pdf", "file_size": 1843017, "creation_date": "2025-11-25", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "93113a58-04e3-484d-9264-50186f64c354", "node_type": "4", "metadata": {"page_label": "398", "file_name": "2022_22.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2022_22.pdf", "file_type": "application/pdf", "file_size": 1843017, "creation_date": "2025-11-25", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "ec8256382c2ceee5abcbb5f68bb78f8815ba1f86e3bd12deb24977c28b7e059d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7b58cad0-3073-4098-a806-67e19794ec05", "node_type": "1", "metadata": {"page_label": "398", "file_name": "2022_22.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2022_22.pdf", "file_type": "application/pdf", "file_size": 1843017, "creation_date": "2025-11-25", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "1b689815e8738aebb31f1b555d0d0959060c66c8ad84eba5c2e8bd19b8368af3", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Depressive symptomatology and smoking among\npersons with diabetes. Res Nurs Health. 1994;17(4):273-82.\n[14] Clyde M, Smith KJ, Gari\u00e9py G, Schmitz N. The association\nbetween smoking and depression in a Canadian communitybased sample with type 2 diabetes. Can J Diabetes.\n2013;37(3):150-5.\n[15] Ino T, Shibuya T, Saito K, Inaba Y. Relationship between\nbody mass index of offspring and maternal smoking during\npregnancy. Int J Obes. 2012;36(4):554-8.\n[16] Al-Delaimy WK, Manson JE, Solomon CG, Kawachi I,\nStampfer MJ, Willett WC, et al . Smoking and risk of coronary\nheart disease among women with type 2 diabetes mellitus.\nArch Intern Med. 2002;162(3):273-9.\n[17] Grant PJ, Cosentino F. The 2019 ESC Guidelines on\ndiabetes, pre-diabetes, and cardiovascular diseases deve -\nloped in collaboration with the EASD: New features and the\n'Ten Commandments' of the 2019 Guidelines are discussed by\nProfessor Peter J. Grant and Professor Francesco Cosentino,\nthe Task Force chairmen. Eur Heart J. 2019;40(39):3215-17.\n[18] Nagrebetsky A, Brettell R, Roberts N, Farmer A. Smoking\ncessation in adults with diabetes: A systematic review and\nmeta-analysis of data from randomised controlled trials. BMJ\nOpen. 2014;4(3):e004107.\n[19] Canga N, De Irala J, Vara E, Duaso MJ, Ferrer A, Mart\u00ednezGonz\u00e1lez MA. Intervention study for smoking cessation in\ndiabetic patients: A randomized controlled trial in both clinical\nand primary care settings. Diabetes Care. 2000;23(10):1455-60.\n[20] Aubin HJ, Farley A, Lycett D, Lahmek P, Aveyard P. Weight\ngain in smokers after quitting cigarettes: Meta-analysis. BMJ.\n2012;345:e4439.\nCiter cet article\nDurlach V. Tabagisme et diab\u00e8te : le temps de l'action. Bull\nEpid\u00e9miol Hebd. 2022;(22): 392-8.\nfrance.fr/beh/2022/22/2022_22_2.html", "mimetype": "text/plain", "start_char_idx": 3950, "end_char_idx": 5703, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "058cf7ee-0382-44d7-9411-b36359d29449": {"__data__": {"id_": "058cf7ee-0382-44d7-9411-b36359d29449", "embedding": null, "metadata": {"page_label": "409", "file_name": "2023_20-21.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2023_20-21.pdf", "file_type": "application/pdf", "file_size": 1372902, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "079d1128-1182-4299-a9eb-957a6f2268de", "node_type": "4", "metadata": {"page_label": "409", "file_name": "2023_20-21.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2023_20-21.pdf", "file_type": "application/pdf", "file_size": 1372902, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "68d8049214c3c741236485f17fd071b2ffb294969cee1d268902f1ec49207aca", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4906fad2-ac6e-4c0b-ac80-b1bf4acdc990", "node_type": "1", "metadata": {}, "hash": "55eafbe1a35a28f18837e70d0712026415fbb790d5799d7cb9b4526e7215e6c8", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "N\u00b0 20-21 | 14 novembre 2023\nBEH 20-21 | 14 novembre 2023 | 409\nLa reproduction (totale ou partielle) du BEH est soumise \u00e0 l'accord pr\u00e9alable de Sant\u00e9 publique France.\nConform\u00e9ment \u00e0 l'article L. 122-5 du code de la propri\u00e9t\u00e9 intellectuelle, les courtes citations ne sont pas\nsoumises \u00e0 autorisation pr\u00e9alable, sous r\u00e9serve que soient indiqu\u00e9s clairement le nom de l'auteur et la\nsource, et qu'elles ne portent pas atteinte \u00e0 l'int\u00e9grit\u00e9 et \u00e0 l'esprit de l'\u0153uvre. Les atteintes au droit d'auteur\nattach\u00e9 au BEH sont passibles d'un contentieux devant la juridiction comp\u00e9tente.\nDirecteur de la publication : La\u00ebtitia Huiart, directrice scientifique, adjointe \u00e0 la directrice g\u00e9n\u00e9rale de\nSant\u00e9 publique France\nR\u00e9dactrice en chef : Val\u00e9rie Colombani-Cocuron, Sant\u00e9 publique France,\nR\u00e9dactrice en chef adjointe : Fr\u00e9d\u00e9rique Biton-Debernardi\nResponsable du contenu en anglais : Chlo\u00eb Chester\nSecr\u00e9tariat de r\u00e9daction : L\u00e9a Manchec, Quentin Lacaze\nComit\u00e9 de r\u00e9daction : Rapha\u00ebl Andler, Sant\u00e9 publique France ; Thomas B\u00e9net, Sant\u00e9 publique France -\nAuvergne-Rh\u00f4ne-Alpes ; Florence Bodeau-Livinec, EHESP ; Kathleen Chami, Sant\u00e9 publique France ;\nPerrine de Crouy-Chanel, Sant\u00e9 publique France ; Olivier Dejardin, CHU Caen ; Franck de Laval,\nCespa ; Martin Herbas Ekat, CHU Brazzaville, Congo ; Matthieu Eveillard, CHU Angers ; Bertrand Gagni\u00e8re,\nSant\u00e9 publique France - Bretagne ; Isabelle Gr\u00e9my ; Anne Guinard, Sant\u00e9 publique France - Occitanie ;\nCamille Lecoffre-Bernard, Sant\u00e9 publique France ; \u00c9lodie Lebreton, Sant\u00e9 publique France ;\nVal\u00e9rie Oli\u00e9, Sant\u00e9 publique France ; Arnaud Tarantola, Sant\u00e9 publique France -\u00cele-de-France ; MariePierre Tavolacci, CHU Rouen ; H\u00e9l\u00e8ne Therre, Sant\u00e9 publique France ; Sophie Vaux, Sant\u00e9 publique France ;\nIsabelle Villena, CHU Reims ; Marianne Zeller, UFR Sciences de sant\u00e9 de Dijon.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1814, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "4906fad2-ac6e-4c0b-ac80-b1bf4acdc990": {"__data__": {"id_": "4906fad2-ac6e-4c0b-ac80-b1bf4acdc990", "embedding": null, "metadata": {"page_label": "409", "file_name": "2023_20-21.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2023_20-21.pdf", "file_type": "application/pdf", "file_size": 1372902, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "079d1128-1182-4299-a9eb-957a6f2268de", "node_type": "4", "metadata": {"page_label": "409", "file_name": "2023_20-21.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2023_20-21.pdf", "file_type": "application/pdf", "file_size": 1372902, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "68d8049214c3c741236485f17fd071b2ffb294969cee1d268902f1ec49207aca", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "058cf7ee-0382-44d7-9411-b36359d29449", "node_type": "1", "metadata": {"page_label": "409", "file_name": "2023_20-21.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2023_20-21.pdf", "file_type": "application/pdf", "file_size": 1372902, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "8e5d330ff554d5959019799fee21f8adffc791efce7691863f4b62bb83f2cb53", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a43583c4-5298-4773-b216-b8e628c41783", "node_type": "1", "metadata": {}, "hash": "486ff05e13d9ac9c5e2fd5f085dc99e9ae0ff863279c84753e29317b33b4d87a", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Sant\u00e9 publique France - Site Internet :\nPr\u00e9presse : Luminess\nISSN : 1953-8030\nRetrouvez ce num\u00e9ro ainsi que les archives du Bulletin \u00e9pid\u00e9miologique hebdomadaire sur\n\n// Diabetes in overseas France: Understanding local specificities to target action\nCoordination scientifique // Scientific coordination\nSandrine Fosse-Edorh (Sant\u00e9 publique France, Saint-Maurice)\nEt pour le Comit\u00e9 de r\u00e9daction du BEH : Perrine de Crouy-Chanel, \u00c9lodie Lebreton, H\u00e9l\u00e8ne Therre (Sant\u00e9 publique France, Saint-Maurice),\nIsabelle Gr\u00e9my\nSOMMAIRE // Contents\n>\n\u00c9DITORIAL // Editorial\nDiab\u00e8te dans les DROM : une pr\u00e9valence\ndeux fois sup\u00e9rieure \u00e0 celle de l'Hexagone\net une population de personnes vivant\navec un diab\u00e8te aux sp\u00e9cificit\u00e9s marqu\u00e9es\n// Diabetes in the French overseas departments\nand regions: Prevalence twice as high as\nin mainland France and distinct features\nin the population of people living with diabetes ........\nFran\u00e7ois Bourdillon\nAncien directeur g\u00e9n\u00e9ral de Sant\u00e9 publique France\nCaract\u00e9ristiques, \u00e9tat de sant\u00e9\net recours aux soins des personnes\npr\u00e9sentant un diab\u00e8te de type 2\nr\u00e9sidant en outre-mer : r\u00e9sultats\nde l'\u00e9tude Entred 3\n// Characteristics, health status and care\nof people with type 2 diabetes living in French\noverseas territories: ENTRED 3 study results ...........\nSandrine Fosse-Edorh et coll.\nSant\u00e9 publique France, Saint-Maurice\nPr\u00e9valence du diab\u00e8te connu\ndans 4 d\u00e9partements et r\u00e9gions\nd'outre-mer : Guadeloupe, Martinique,\nGuyane et La R\u00e9union. R\u00e9sultats\ndu Barom\u00e8tre de Sant\u00e9 publique France\nde 2021\n// Prevalence of known diabetes in four French\noverseas departments and regions:\nGuadeloupe, Martinique, French Guiana\nand Reunion Island. Results from the 2021\nSant\u00e9 publique France Health Barometer .................\nHugo Hernandez et coll.\nSant\u00e9 publique France, Saint-Maurice\nPr\u00e9valence du diab\u00e8te connu \u00e0 La R\u00e9union,\nprises en charge et caract\u00e9ristiques\ndes personnes atteintes d'un diab\u00e8te :\nexploitation des donn\u00e9es du Barom\u00e8tre\nde Sant\u00e9 publique France DROM de 2021\n// Prevalence of known diabetes in Reunion Island,\ncare and characteristics of the population: Data\nfrom the 2021 Sant\u00e9 publique France Health\nBarometer for overseas France ......................................\nMonique Ricquebourg et coll.", "mimetype": "text/plain", "start_char_idx": 1815, "end_char_idx": 4050, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "a43583c4-5298-4773-b216-b8e628c41783": {"__data__": {"id_": "a43583c4-5298-4773-b216-b8e628c41783", "embedding": null, "metadata": {"page_label": "409", "file_name": "2023_20-21.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2023_20-21.pdf", "file_type": "application/pdf", "file_size": 1372902, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "079d1128-1182-4299-a9eb-957a6f2268de", "node_type": "4", "metadata": {"page_label": "409", "file_name": "2023_20-21.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2023_20-21.pdf", "file_type": "application/pdf", "file_size": 1372902, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "68d8049214c3c741236485f17fd071b2ffb294969cee1d268902f1ec49207aca", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4906fad2-ac6e-4c0b-ac80-b1bf4acdc990", "node_type": "1", "metadata": {"page_label": "409", "file_name": "2023_20-21.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2023_20-21.pdf", "file_type": "application/pdf", "file_size": 1372902, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "c343fa17165819639e6c1853156144c3c0411fb8fd463c5c3c678c06629c73c0", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Observatoire r\u00e9gional de la sant\u00e9 de La R\u00e9union, Saint-Denis\nApproche socio-anthropologique\nde la litt\u00e9ratie en sant\u00e9 des personnes\natteintes de diab\u00e8te de type 2 \u00e0 La R\u00e9union\n// A socio-anthropological approach to health\nliteracy among people with type 2 diabetes\nin Reunion Island .......................................................\nMaryvette Balcou-Debussche\nLaboratoire Icare, Universit\u00e9 de La R\u00e9union, Saint-Denis", "mimetype": "text/plain", "start_char_idx": 4051, "end_char_idx": 4473, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "4baea7a8-f486-4ba9-b338-f79a0e16c12e": {"__data__": {"id_": "4baea7a8-f486-4ba9-b338-f79a0e16c12e", "embedding": null, "metadata": {"page_label": "410", "file_name": "2023_20-21.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2023_20-21.pdf", "file_type": "application/pdf", "file_size": 1372902, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "c15526a3-5091-4246-a0a4-434fb0ca4a4d", "node_type": "4", "metadata": {"page_label": "410", "file_name": "2023_20-21.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2023_20-21.pdf", "file_type": "application/pdf", "file_size": 1372902, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "fae853fa4f07a1f92cc07be20996a5af9f6696368c6ce35d3db092a797d78168", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8b8070ea-4dc4-4e18-922d-a1375b847187", "node_type": "1", "metadata": {}, "hash": "c92e2f6c8ccfa561aa93e76a5278d59a56e47694f0ece16fd69b3d4f6edb8301", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "410 | 14 novembre 2023 | BEH 20-21 Diab\u00e8te en outre-mer : comprendre les sp\u00e9cificit\u00e9s locales pour cibler les actions\n\u00c9DITORIAL // Editorial\nDIAB\u00c8TE DANS LES DROM : UNE PR\u00c9VALENCE DEUX FOIS SUP\u00c9RIEURE \u00c0 CELLE DE L'HEXAGONE\nET UNE POPULATION DE PERSONNES VIVANT AVEC UN DIAB\u00c8TE AUX SP\u00c9CIFICIT\u00c9S MARQU\u00c9ES\n// DIABETES IN THE FRENCH OVERSEAS DEPARTMENTS AND REGIONS: PREVALENCE TWICE\nAS HIGH AS IN MAINLAND FRANCE AND DISTINCT FEATURES IN THE POPULATION OF PEOPLE LIVING WITH DIABETES\nFran\u00e7ois Bourdillon\nAncien directeur g\u00e9n\u00e9ral de Sant\u00e9 publique France\n\u00c0 la cr\u00e9ation de Sant\u00e9 publique France en 1996, les\nd\u00e9partements et r\u00e9gions d'out re-mer (DROM) ont\n\u00e9t\u00e9 inscrits comme une priorit\u00e9 devant le cons tat\nd'un \u00e9tat de sant\u00e9 moins bon que dans l 'Hexagone\net de donn\u00e9es de surveillance trop parcellaires 1,2.\nIl s'agissait de tenir comp te des risques infectieux,\nenvironnementaux et de la forte pr\u00e9valence des\nmaladies chroniques, avec en particulier des taux de\nsurpoids et d'ob\u00e9sit\u00e9 \u00e9lev\u00e9s, faisant le lit du diab\u00e8te\net de ses comp lications, notamment l'ins uffisance\nr\u00e9nale. Il paraissait important d'\u00e9ta yer les plaidoyers\npour pouvoir d\u00e9finir des priorit\u00e9s d'act ions et de\ndisposer \u00e0 intervalles r\u00e9guliers des descriptifs de\nl'\u00e9tat de sant\u00e9 des populations r\u00e9sidant dans les\noutre-mer. Nous souhaitions disposer d'une premi\u00e8re\n\u00e9tude \u00e0 Mayotte, ce qui a \u00e9t\u00e9 fait 3,4, que les baro -\nm\u00e8tres sant\u00e9 soient \u00e9tendus aux DROM avec des\n\u00e9chantillons suffisants et que certaines \u00e9tudes sur\nle diab\u00e8te r\u00e9alis\u00e9es dans l'Hexagone (Entred) soient\nd\u00e9ploy\u00e9es dans les outre-mer. Ce num\u00e9ro th\u00e9matique\n\u00ab Diab\u00e8te en outre-mer : comprendre les sp\u00e9cificit\u00e9s\nlocales pour cibler les actions \u00bb t\u00e9moigne du travail\nr\u00e9alis\u00e9 depuis 2016. Nous disposons dor\u00e9navant de\ndonn\u00e9es pr\u00e9cieuses de pr\u00e9valence, des caract\u00e9ristiques des personnes atteintes de diab\u00e8te de type 2\nen outre-mer qui permettront je l'esp \u00e8re d'\u00e9tayer les\npolitiques publiques pour mieux pr\u00e9venir et traiter\nle diab\u00e8te et ses complications.\nNous avons la confirmation que la pr\u00e9valence\ndu dia b\u00e8te connu estim\u00e9e \u00e0 partir des donn\u00e9es du\nBarom\u00e8tre sant\u00e9 est tr\u00e8s \u00e9lev\u00e9e dans les DROM, de\nl'ordre de 12% aux Antilles et en Guyane et de 13,6%\n\u00e0 La R\u00e9union 5.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2198, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "8b8070ea-4dc4-4e18-922d-a1375b847187": {"__data__": {"id_": "8b8070ea-4dc4-4e18-922d-a1375b847187", "embedding": null, "metadata": {"page_label": "410", "file_name": "2023_20-21.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2023_20-21.pdf", "file_type": "application/pdf", "file_size": 1372902, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "c15526a3-5091-4246-a0a4-434fb0ca4a4d", "node_type": "4", "metadata": {"page_label": "410", "file_name": "2023_20-21.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2023_20-21.pdf", "file_type": "application/pdf", "file_size": 1372902, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "fae853fa4f07a1f92cc07be20996a5af9f6696368c6ce35d3db092a797d78168", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4baea7a8-f486-4ba9-b338-f79a0e16c12e", "node_type": "1", "metadata": {"page_label": "410", "file_name": "2023_20-21.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2023_20-21.pdf", "file_type": "application/pdf", "file_size": 1372902, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "baea1e78284ac0d9eb9a6b4ab105e89c9b4b3c9b6bbc487552cb0ab1c0398e01", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0452f960-a521-4c64-bf2f-e030f92ba7a7", "node_type": "1", "metadata": {}, "hash": "cf1b2eb46db4d19b989e0376e8f65a5e5aff6255eba12a692caaebe914b67fd7", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Nous avons la confirmation que la pr\u00e9valence\ndu dia b\u00e8te connu estim\u00e9e \u00e0 partir des donn\u00e9es du\nBarom\u00e8tre sant\u00e9 est tr\u00e8s \u00e9lev\u00e9e dans les DROM, de\nl'ordre de 12% aux Antilles et en Guyane et de 13,6%\n\u00e0 La R\u00e9union 5. L 'estimation pour l'Hexagone issue\nde l'\u00e9tude Esteban 2014-2016 6 est de 5,7%. Il est\nprobablement n\u00e9cessaire d'ajouter \u00e0 ces pourcentages\nla part des personnes qui se sont d\u00e9clar\u00e9es non dia -\nb\u00e9tiques, mais ayant d\u00e9clar\u00e9 qu'un m\u00e9decin leur avait\nd\u00e9j\u00e0 dit qu'ils avaient \u00ab un petit diab\u00e8te \u00bb ou \u00ab un d\u00e9but\nde diab\u00e8te, mais pas trop grave \u00bb. Les auteurs de cette\n\u00e9tude estiment cette part \u00e0 3 \u00e0 4%. Le diab\u00e8te connu\nest trait\u00e9 pharmaco logiquement \u00e0 90-93% aux Antilles\net en Guyane ; \u00e0 82% \u00e0 La R\u00e9union, ce qui est plus\n\u00e9lev\u00e9 que dans l'Hexagone (79%).\nL '\u00e9tude Entred 3, r\u00e9alis\u00e9e \u00e0 partir d'un \u00e9chantillon\nde personnes atteintes de diab\u00e8te de type 2 issu\ndes donn\u00e9es de l'Ass urance maladie 7, permet de\nd\u00e9crire leurs caract\u00e9ristiques d\u00e9mographiques et\nsocio-\u00e9conomiques, mais aussi de facteurs de\nrisque et de comp lications. Elle a \u00e9t\u00e9 \u00e9tendue pour\nla premi\u00e8re fois aux DROM. Il faut essentiellement\nen retenir pour l'out re-mer quelques sp\u00e9cificit\u00e9s par\nrapport \u00e0 l 'Hexagone : une pr\u00e9dominance f\u00e9minine,\nune part plus importante de patients avec un niveau\nsocio-\u00e9conomique d\u00e9favorable et une part impor -\ntante de patients sans Couverture maladie univer -\nselle compl\u00e9mentaire (CMU-C). La d\u00e9couverte en\nGuyane et \u00e0 La R\u00e9union d'un diab\u00e8te de type 2 chez\ndes personnes plus jeunes et de corpulence moindre\ninterroge sur l'exi stence possible de susceptibilit\u00e9\ng\u00e9n\u00e9tique ou \u00e9pig\u00e9n\u00e9tique.\nToutes ces donn\u00e9es vont permettre dans l'ave nir de\nmesurer les \u00e9volutions, donc de r\u00e9guli\u00e8rement inter -\nroger les actions de pr\u00e9vention et de soins mises en\n\u0153uvre.", "mimetype": "text/plain", "start_char_idx": 1985, "end_char_idx": 3756, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "0452f960-a521-4c64-bf2f-e030f92ba7a7": {"__data__": {"id_": "0452f960-a521-4c64-bf2f-e030f92ba7a7", "embedding": null, "metadata": {"page_label": "410", "file_name": "2023_20-21.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2023_20-21.pdf", "file_type": "application/pdf", "file_size": 1372902, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "c15526a3-5091-4246-a0a4-434fb0ca4a4d", "node_type": "4", "metadata": {"page_label": "410", "file_name": "2023_20-21.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2023_20-21.pdf", "file_type": "application/pdf", "file_size": 1372902, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "fae853fa4f07a1f92cc07be20996a5af9f6696368c6ce35d3db092a797d78168", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8b8070ea-4dc4-4e18-922d-a1375b847187", "node_type": "1", "metadata": {"page_label": "410", "file_name": "2023_20-21.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2023_20-21.pdf", "file_type": "application/pdf", "file_size": 1372902, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "f577072e385625b11ea71480f73e94a692661c33c11c59a538991e7db0df1272", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Toutes ces donn\u00e9es vont permettre dans l'ave nir de\nmesurer les \u00e9volutions, donc de r\u00e9guli\u00e8rement inter -\nroger les actions de pr\u00e9vention et de soins mises en\n\u0153uvre. D'ores et d\u00e9j\u00e0, le cons tat fait \u00e0 La R\u00e9union\npeut \u00eatre compar\u00e9 \u00e0 celui de 2014 8, montrant une\ncertaine stabilit\u00e9 des facteurs de risque (ob\u00e9sit\u00e9,\nhypertension art\u00e9rielle, faible consommation de fruits\net l\u00e9gumes, pratique d'activit\u00e9 physique insuffisante,\nexc\u00e8s de cons ommation d'alcool et de tabac (1)), ce\nqui devrait amener un renforcement du Programme\nr\u00e9unionnais de nutrition et de lutte cont re le diab\u00e8te\ntenant compte des r\u00e9sultats de l'app roche socioanthropologique de la litt\u00e9ratie en sant\u00e9 9. Cette \u00e9tude\nsouligne l'importance de bien comp rendre les repr\u00e9sentations, la motivation et les comp \u00e9tences des\nindividus \u00e0 utiliser l'information qui leur est donn\u00e9e,\nen sachant les situer dans leur contexte et environnement, notamment sociologique et familial. Il convient\n\u00e9galement de ne pas n\u00e9gliger les questions d'\u00e9du -\ncation th\u00e9rapeutique du patient, de prise en charge\net d'organisation des soins. Enfin, il faut prendre en\ncompte les \u00e9volutions alimentaires observ\u00e9es dans\nles DROM, qualifi\u00e9es par les experts de transition\nalimentaire : recul des f\u00e9culents et tubercules tradi -\ntionnels, des v\u00e9g\u00e9taux, et augmentation de cons ommation des prot\u00e9ines animales, des sucres et des\nproduits transform\u00e9s 10.\nCet \u00e9ditorial est l'occasion de rappeler que les produits\nalimentaires d'outre-mer sont volontaire ment plus\nsucr\u00e9s que dans l'Hexagone. La loi Hurel de 2013 visait\n\u00e0 garantir que la quantit\u00e9 de sucres ajout\u00e9s dans les\nproduits vendus dans les d\u00e9partements ultra marins\nne soit pas sup\u00e9rieure \u00e0 celle des produits mis sur\n(1) La lutte contre le tabac dans les DROM doit rester une priorit\u00e9 m\u00eame\nsi la pr\u00e9valence du tabagisme dans les DROM est plus faible que dans\nl'Hexagone : 21% \u00e0 la R\u00e9union, 12% aux Antilles et en Guyane et 11%\n\u00e0 Mayotte.\n>\nFran\u00e7ois Bourdillon\nAncien directeur g\u00e9n\u00e9ral de Sant\u00e9 publique France", "mimetype": "text/plain", "start_char_idx": 3591, "end_char_idx": 5594, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "5aa81f2f-d413-4ee7-a3d0-9ff437be7c60": {"__data__": {"id_": "5aa81f2f-d413-4ee7-a3d0-9ff437be7c60", "embedding": null, "metadata": {"page_label": "411", "file_name": "2023_20-21.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2023_20-21.pdf", "file_type": "application/pdf", "file_size": 1372902, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "5f6a2b73-3193-4933-9e31-37d3af8dfdfc", "node_type": "4", "metadata": {"page_label": "411", "file_name": "2023_20-21.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2023_20-21.pdf", "file_type": "application/pdf", "file_size": 1372902, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "d4c72cb77c65e8f8144b4e9479ed3761bd3e8d87267e2d46201c5f19a72d6229", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9a96132b-91f0-4920-8f77-144aa07f0b4e", "node_type": "1", "metadata": {}, "hash": "444fff20228089792248be1c04a9e7c9a8d3992c810e9b9c9fe3bc251529d005", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Diab\u00e8te en outre-mer : comprendre les sp\u00e9cificit\u00e9s locales pour cibler les actions BEH 20-21 | 14 novembre 2023 | 411\nle march\u00e9 dans l'Hex agone. La Cour des comp tes,\ndans son rapport de 2019 sur la pr\u00e9vention et la prise\nen charge de l'ob\u00e9 sit\u00e9, recommandait de simplifier\nles conditions d'application de cette loi et de mettre\nen \u0153uvre des cont r\u00f4les 11. Qu'en est-il aujourd'hui ?\nToutes ces nouvelles donn\u00e9es, je l'esp\u00e8re, donneront\nl'opportunit\u00e9 de franchir une \u00e9tape de pr\u00e9vention en\nr\u00e9interrogeant l'application de la loi Hurel sur le sucre,\nmais aussi le d\u00e9veloppement dans les outre-mer du\nNutri-Score, de l'enc adrement de la publicit\u00e9 aux\nheures de grandes \u00e9coutes des enfants, du renfor -\ncement de la taxation des boissons sucr\u00e9s (1), de la\ntaxation de mani\u00e8re effective des produits parti -\nculi\u00e8rement gras, sucr\u00e9s et sal\u00e9s (ceux qui sont les\nplus mal class\u00e9s par le Nutri-Score), de l'am\u00e9 lioration de l'off re alimentaire, de l'inc itation \u00e0 l'act ivit\u00e9\nphysique et du soutien attendu des initiatives locales\nprometteuses, comme le programme r\u00e9unionnais\nde nutrition et de lutte cont re le diab\u00e8te, ou encore\n\u00ab La Martinique bouge \u00bb, et bien d'autres... \u25a0\nR\u00e9f\u00e9rences\n[1] Bourdillon F. Agir en sant\u00e9 publique. De la connaissance \u00e0\nl'action. Chapitre 9 : Priorit\u00e9s aux Outre-Mer. Rennes: Presses\nde l'EHESP ; 2020. pp. 197-218.\n[2] Cour des comptes. La sant\u00e9 dans les outre-mer. Une res -\nponsabilit\u00e9 de la R\u00e9publique. Paris: Cour des comptes; 2014.\n287 p.\n[3] Deschamps V, Soulaimana I, Chesneau J, JezewskiSerra D, Bernillon P, Salanave B, et al. \u00c9tat nutritionnel de la\npopulation mahoraise enfants et adultes : r\u00e9sultats de l'\u00e9tude\nUnono Wa Maore 2019 et \u00e9volutions depuis 2006. Bull \u00c9pid\u00e9 -\nmiol Hebd. 2022;(9-10):179-87.\nfrance.fr/beh/2022/9-10/2022_9-10_3.html\n[4] Azaz A, Jezewski-Serra D, Ruello M, Youssouf H, Piffaretti C,\nFosse-Edorh S. Estimation de la pr\u00e9valence du diab\u00e8te et\ndu pr\u00e9diab\u00e8te \u00e0 Mayotte et caract\u00e9ristiques des personnes\ndiab\u00e9tiques, Mayotte, 2019. Bull \u00c9pid\u00e9miol Hebd. 2022;(9-10):\n164-9.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2033, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "9a96132b-91f0-4920-8f77-144aa07f0b4e": {"__data__": {"id_": "9a96132b-91f0-4920-8f77-144aa07f0b4e", "embedding": null, "metadata": {"page_label": "411", "file_name": "2023_20-21.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2023_20-21.pdf", "file_type": "application/pdf", "file_size": 1372902, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "5f6a2b73-3193-4933-9e31-37d3af8dfdfc", "node_type": "4", "metadata": {"page_label": "411", "file_name": "2023_20-21.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2023_20-21.pdf", "file_type": "application/pdf", "file_size": 1372902, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "d4c72cb77c65e8f8144b4e9479ed3761bd3e8d87267e2d46201c5f19a72d6229", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5aa81f2f-d413-4ee7-a3d0-9ff437be7c60", "node_type": "1", "metadata": {"page_label": "411", "file_name": "2023_20-21.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2023_20-21.pdf", "file_type": "application/pdf", "file_size": 1372902, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "35cf3e36d983298bf5525fefabdfc585c8c10d603fda81dbfc0b185f696db5e5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "14aad8e8-dadf-4764-9633-49aacd48798a", "node_type": "1", "metadata": {}, "hash": "a6f3a90d89ce016bc2273726bc63e45141bab1e4e398c226529122c9347f4c58", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Bull \u00c9pid\u00e9miol Hebd. 2022;(9-10):\n164-9.\n9-10_1.html\n(1) Selon l'expertise collective de l'IRD 9 : \u00ab Les consommations journali\u00e8res\nmoyennes de boissons sucr\u00e9es en Guadeloupe et Martinique sont presque\ntrois fois plus \u00e9lev\u00e9es que celles de la France hexagonale. La Guyane est\npresque au double. Les consommations \u00e0 Mayotte et \u00e0 La R\u00e9union sont\nl\u00e9g\u00e8rement sup\u00e9rieures \u00e0 celles de la France hexagonale \u00bb.\n[5] Hernandez H, Piffaretti C, Gautier A, Cosson E, FosseEdorh S. Pr\u00e9valence du diab\u00e8te connu dans 4 d\u00e9partements\net r\u00e9gions d'outre-mer : Guadeloupe, Martinique, Guyane et\nLa R\u00e9union. R\u00e9sultats du Barom\u00e8tre de Sant\u00e9 publique France\nde 2021. Bull \u00c9pid\u00e9miol Hebd. 2023;(20-21):424-31.\nsantepubliquefrance.fr/beh/2023/20-21/2023_20-21_2.html\n[6] Torres M, Salanave B, Verdot C, Deschamps V. Ad\u00e9quation\naux nouvelles recommandations alimentaires des adultes \u00e2g\u00e9s\nde 18 \u00e0 54 ans vivant en France : \u00c9tude Esteban 2014-2016.\nVolet Nutrition - Surveillance \u00e9pid\u00e9miologique. Saint-Maurice:\nSant\u00e9 publique France; 2019.\nfrance.fr/determinants-de-sante/nutrition-et-activite-physique/\ndocuments/rapport-synthese/adequation-aux-nouvelles-re\ncommandations-alimentaires-des-adultes-ages-de-18-a-54ans-vivant-en-france-etude-esteban-2014-2016.-volet-nutrition\n[7] Fosse-Edorh S, Lavalette C, Piffaretti C, Saboni L,\nBessonneau P, Mandereau Bruno L, et al . Caract\u00e9ristiques,\n\u00e9tat de sant\u00e9 et recours aux soins des personnes pr\u00e9sen -\ntant un diab\u00e8te de type 2 r\u00e9sidant en Outre-mer : r\u00e9sultats\nde l'\u00e9tude Entred 3. Bull \u00c9pid\u00e9miol Hebd. 2023;(20-21): 41223.\n20-21_1.html\n[8] Ricquebourg M, Kwan C, M\u00e9devielle S, ChopinetDijoux S, Caliez F, Thouillot F, et al . Pr\u00e9valence du diab\u00e8te\nconnu \u00e0 La R\u00e9union, prises en charge et caract\u00e9ristiques des\npersonnes atteintes d'un diab\u00e8te : exploitation des donn\u00e9es\ndu Barom\u00e8tre Sant\u00e9 DROM 2021. Bull \u00c9pid\u00e9miol Hebd. 2023;\n(20-21): 431-9.", "mimetype": "text/plain", "start_char_idx": 1993, "end_char_idx": 3856, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "14aad8e8-dadf-4764-9633-49aacd48798a": {"__data__": {"id_": "14aad8e8-dadf-4764-9633-49aacd48798a", "embedding": null, "metadata": {"page_label": "411", "file_name": "2023_20-21.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2023_20-21.pdf", "file_type": "application/pdf", "file_size": 1372902, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "5f6a2b73-3193-4933-9e31-37d3af8dfdfc", "node_type": "4", "metadata": {"page_label": "411", "file_name": "2023_20-21.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2023_20-21.pdf", "file_type": "application/pdf", "file_size": 1372902, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "d4c72cb77c65e8f8144b4e9479ed3761bd3e8d87267e2d46201c5f19a72d6229", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9a96132b-91f0-4920-8f77-144aa07f0b4e", "node_type": "1", "metadata": {"page_label": "411", "file_name": "2023_20-21.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2023_20-21.pdf", "file_type": "application/pdf", "file_size": 1372902, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "dc95b24006c409fbc09f309a496d1f4ce4f91efd0d3cb84c19347d15d9f689cb", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Pr\u00e9valence du diab\u00e8te\nconnu \u00e0 La R\u00e9union, prises en charge et caract\u00e9ristiques des\npersonnes atteintes d'un diab\u00e8te : exploitation des donn\u00e9es\ndu Barom\u00e8tre Sant\u00e9 DROM 2021. Bull \u00c9pid\u00e9miol Hebd. 2023;\n(20-21): 431-9.\n20-21/2023_20-21_3.html\n[9] Balcou-Debussche M. Approche socio-anthropologique\nde la litt\u00e9ratie en sant\u00e9 des personnes atteintes de diab\u00e8te de\ntype 2 \u00e0 La R\u00e9union. Bull \u00c9pid\u00e9miol Hebd. 2023;(20-21):440-6.\n\n20-21_4.html\n[10] M\u00e9jean C, Debussche X, Martin-Pr\u00e9vel YM, R\u00e9quillart V,\nSoler LG, Tib\u00e8re L (dir.). Alimentation et nutrition dans les\nd\u00e9partements et r\u00e9gions d'Outre-mer. Marseille: IRD \u00c9ditions;\n2020. 208 p.\n[11] Cour des comptes. La pr\u00e9vention et la prise en charge de\nl'ob\u00e9sit\u00e9. Paris: Cour des comptes; 2019. 157 p.\nccomptes.fr/fr/publications/la-prevention-et-la-prise-encharge-de-lobesite\nCiter cet article\nBourdillon F. \u00c9ditorial. Diab\u00e8te dans les DROM : une pr\u00e9valence\ndeux fois sup\u00e9rieure \u00e0 celle de l'Hexagone et une population de\npersonnes vivant avec un diab\u00e8te aux sp\u00e9cificit\u00e9s marqu\u00e9es.\nBull \u00c9pid\u00e9miol Hebd. 2023;(20-21): 410-1.\nquefrance.fr/beh/2023/20-21/2023_20-21_0.html", "mimetype": "text/plain", "start_char_idx": 3641, "end_char_idx": 4752, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "515931d6-6a17-4ea6-a50c-7b967589a833": {"__data__": {"id_": "515931d6-6a17-4ea6-a50c-7b967589a833", "embedding": null, "metadata": {"page_label": "412", "file_name": "2023_20-21.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2023_20-21.pdf", "file_type": "application/pdf", "file_size": 1372902, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "5e71608c-4196-415a-b44c-d5e95bfff7e2", "node_type": "4", "metadata": {"page_label": "412", "file_name": "2023_20-21.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2023_20-21.pdf", "file_type": "application/pdf", "file_size": 1372902, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "2e3d6cc7623fd56a7185976f9b44da2bbfb2cabe742fa884de1771c4e7b3d296", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d33eca29-8fb1-4b73-b950-4e6168ee138f", "node_type": "1", "metadata": {}, "hash": "c95ee455a88e2b52b902a6885877a933a69fd1ffcf5fda39260c82e82b8532f8", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "412 | 14 novembre 2023 | BEH 20-21 Diab\u00e8te en outre-mer : comprendre les sp\u00e9cificit\u00e9s locales pour cibler les actions\nARTICLE // Article\nCARACT\u00c9RISTIQUES, \u00c9TAT DE SANT\u00c9 ET RECOURS AUX SOINS DES PERSONNES\nPR\u00c9SENTANT UN DIAB\u00c8TE DE TYPE 2 R\u00c9SIDANT EN OUTRE-MER : R\u00c9SULTATS\nDE L'\u00c9TUDE ENTRED 3\n// CHARACTERISTICS, HEALTH STATUS AND CARE OF PEOPLE WITH TYPE 2 DIABETES LIVING IN FRENCH\nOVERSEAS TERRITORIES: ENTRED 3 STUDY RESULTS\nSandrine Fosse-Edorh 1 (), C\u00e9line Lavalette 1, Clara Piffaretti 1, Leila Saboni 1,\nPascal Bessonneau 1, Laurence Mandereau-Bruno 1, Laetitia B\u00e9n\u00e9zet 1, Frank Assogba 2, Sophie Devos 3, Fabian Thouillot 4,\nLucie L\u00e9on 2, Marguerite Kandel 5, Jean-Michel Race 6, Antoine Rachas 7 pour le groupe Entred - DROM*\n1 Sant\u00e9 publique France, Saint-Maurice\n2 Sant\u00e9 publique France - Antilles, Fort-de-France\n3 Sant\u00e9 publique France - Guyane, Cayenne\n4 Sant\u00e9 publique France - Oc\u00e9an Indien, Saint-Denis\n5 Haute Autorit\u00e9 de sant\u00e9, Saint-Denis\n6 Agence nationale de s\u00e9curit\u00e9 du m\u00e9dicament et des produits de sant\u00e9, Saint-Denis\n7 Caisse nationale de l'Assurance maladie, Paris\n* Groupe Entred - DROM : Emmanuel Cosson, Xavier Debussche, Bruno Detournay, Guy Fagherazzi, Pauline Kangambega,\nSt\u00e9phanie Leclerc, Caroline Mejean, Estelle Nobecourt, Alfred Penfornis, Jacques Rosine, Nadia Sabbah, Tiphanie Succo,\nCamille Thomassin, Fritz-Line Velayoudom\nSoumis le 17.07.2023 // Date of submission: 07.17.2023\nR\u00e9sum\u00e9 // Abstract\nIntroduction - La pr\u00e9valence du diab\u00e8te de type 2 (DT2) est particuli\u00e8rement \u00e9lev\u00e9e dans les d\u00e9parte -\nments et r\u00e9gions d'outre-mer (DROM) et les complications chroniques y sont plus fr\u00e9quentes. L 'objectif de\nnotre enqu\u00eate \u00e9tait d'\u00e9tudier les particularit\u00e9s des DROM concernant les caract\u00e9ristiques d\u00e9mographiques,\nsocio-\u00e9conomiques, l'\u00e9tat de sant\u00e9 et le recours aux soins des personnes ayant un diab\u00e8te de type 2 r\u00e9sidant\ndans quatre DROM : la Martinique, la Guadeloupe, la Guyane et La R\u00e9union.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1933, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "d33eca29-8fb1-4b73-b950-4e6168ee138f": {"__data__": {"id_": "d33eca29-8fb1-4b73-b950-4e6168ee138f", "embedding": null, "metadata": {"page_label": "412", "file_name": "2023_20-21.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2023_20-21.pdf", "file_type": "application/pdf", "file_size": 1372902, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "5e71608c-4196-415a-b44c-d5e95bfff7e2", "node_type": "4", "metadata": {"page_label": "412", "file_name": "2023_20-21.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2023_20-21.pdf", "file_type": "application/pdf", "file_size": 1372902, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "2e3d6cc7623fd56a7185976f9b44da2bbfb2cabe742fa884de1771c4e7b3d296", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "515931d6-6a17-4ea6-a50c-7b967589a833", "node_type": "1", "metadata": {"page_label": "412", "file_name": "2023_20-21.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2023_20-21.pdf", "file_type": "application/pdf", "file_size": 1372902, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "6c5bb8efefb20e5c96fb9731de519de1fb01325778f70308260a9706a5a07564", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "acbee753-6c1e-4b34-8655-211db4f730e7", "node_type": "1", "metadata": {}, "hash": "f97eecc6381195d4cbf696a54a3d34dad74093f65daa7670bc238507421a81e4", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "L 'objectif de\nnotre enqu\u00eate \u00e9tait d'\u00e9tudier les particularit\u00e9s des DROM concernant les caract\u00e9ristiques d\u00e9mographiques,\nsocio-\u00e9conomiques, l'\u00e9tat de sant\u00e9 et le recours aux soins des personnes ayant un diab\u00e8te de type 2 r\u00e9sidant\ndans quatre DROM : la Martinique, la Guadeloupe, la Guyane et La R\u00e9union.\nM\u00e9thodes - Pour l'\u00e9tude Entred 3, un \u00e9chantillon al\u00e9atoire de 12 772 adultes trait\u00e9s pharmacologiquement\npour un diab\u00e8te a \u00e9t\u00e9 tir\u00e9 au sort dans les bases de donn\u00e9es de l'Assurance maladie en septembre 2019, dont\n3 700 r\u00e9sidant dans les DROM. La population d'\u00e9tude a \u00e9t\u00e9 restreinte aux personnes ayant un DT2, identi -\nfi\u00e9es \u00e0 partir d'un algorithme \u00e9pid\u00e9miologique. Les donn\u00e9es ont \u00e9t\u00e9 recueillies par un questionnaire en face-\u00e0face. Leurs m\u00e9decins ont \u00e9t\u00e9 invit\u00e9s \u00e0 r\u00e9pondre \u00e0 un questionnaire compl\u00e9mentaire. Les donn\u00e9es du Syst\u00e8me\nnational des donn\u00e9es de sant\u00e9 (SNDS) ont \u00e9t\u00e9 extraites pour les participants et non-participants, permettant de\ncalculer des pond\u00e9rations par territoire int\u00e9grant le plan de sondage et la non-participation par questionnaires.\nLes estimations ont \u00e9t\u00e9 pond\u00e9r\u00e9es. Des tests de comparaison entre les DROM et entre les cinq territoires\nincluant l'Hexagone ont \u00e9t\u00e9 effectu\u00e9s apr\u00e8s ajustement sur le sexe et l'\u00e2ge.\nR\u00e9sultats - La population d'\u00e9tude incluait 498 personnes en Guadeloupe, 682 en Martinique, 504 en Guyane,\n586 \u00e0 la R\u00e9union et 2 714 dans l'Hexagone. Une pr\u00e9dominance f\u00e9minine \u00e9tait observ\u00e9e dans les DROM par\nrapport \u00e0 l'Hexagone. Les r\u00e9sidents de Guyane et de La R\u00e9union \u00e9taient plus jeunes (61 et 63 ans en moyenne)\npar rapport aux Antilles et \u00e0 l'Hexagone (67 et 68 ans). L '\u00e2ge au diagnostic du DT2 \u00e9tait \u00e9galement environ 5 ans\nplus jeune dans ces deux territoires. Le niveau socio-\u00e9conomique \u00e9tait plus d\u00e9favorable dans les DROM et\nla fr\u00e9quence de personnes n\u00e9es \u00e0 l'\u00e9tranger majoritaire en Guyane (53%). L 'indice de masse corporelle (IMC)\nmoyen \u00e9tait moins \u00e9lev\u00e9 \u00e0 La R\u00e9union (27,7 kg/m 2), en Guyane et Guadeloupe (28,4 kg/m 2) qu'en Martinique\n(29,3 kg/m2) et dans l'Hexagone (29,5 kg/m2). La consommation d'alcool et de tabac \u00e9tait moins fr\u00e9quente dans\nles DROM par rapport \u00e0 l'Hexagone, \u00e0 l'exception d'un tabagisme plus fr\u00e9quent \u00e0 La R\u00e9union (14%).", "mimetype": "text/plain", "start_char_idx": 1630, "end_char_idx": 3837, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "acbee753-6c1e-4b34-8655-211db4f730e7": {"__data__": {"id_": "acbee753-6c1e-4b34-8655-211db4f730e7", "embedding": null, "metadata": {"page_label": "412", "file_name": "2023_20-21.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2023_20-21.pdf", "file_type": "application/pdf", "file_size": 1372902, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "5e71608c-4196-415a-b44c-d5e95bfff7e2", "node_type": "4", "metadata": {"page_label": "412", "file_name": "2023_20-21.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2023_20-21.pdf", "file_type": "application/pdf", "file_size": 1372902, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "2e3d6cc7623fd56a7185976f9b44da2bbfb2cabe742fa884de1771c4e7b3d296", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d33eca29-8fb1-4b73-b950-4e6168ee138f", "node_type": "1", "metadata": {"page_label": "412", "file_name": "2023_20-21.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2023_20-21.pdf", "file_type": "application/pdf", "file_size": 1372902, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "992446d4e2cd9fc1d2a8b22553223b42347bfecf1583ba1a83afe87ae28c58ea", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "La consommation d'alcool et de tabac \u00e9tait moins fr\u00e9quente dans\nles DROM par rapport \u00e0 l'Hexagone, \u00e0 l'exception d'un tabagisme plus fr\u00e9quent \u00e0 La R\u00e9union (14%). Le niveau\nd'HbA1c (h\u00e9moglobine glyqu\u00e9e) moyen \u00e9tait plus \u00e9lev\u00e9 dans les DROM par rapport \u00e0 l'Hexagone (7,4%, 7,5%,\n8,0% et 7,7%, respectivement en Guadeloupe, Martinique, Guyane et La R\u00e9union vs 7,2%). La fr\u00e9quence des\ncomplications chroniques \u00e9tait sup\u00e9rieure \u00e0 La R\u00e9union, quelle qu'elle soit. Seule la fr\u00e9quence des complications podologiques et r\u00e9nales ne variait pas significativement selon les territoires.\nConclusion - Int\u00e9gr\u00e9s dans un contexte culturel, social, et sanitaire, ces r\u00e9sultats permettront d'aider les d\u00e9ci -\ndeurs \u00e0 adapter les politiques publiques en mati\u00e8re de pr\u00e9vention, d'accompagnement et de prise en charge\ndes personnes atteintes d 'un diab\u00e8te de type 2 en outre-mer.\nIntroduction - The prevalence of type 2 diabetes mellitus (T2DM) is particularly high in the French overseas\ndepartments and regions (DROM), and chronic complications are more frequent. The aim of our study was to investigate features specific to the DROM by describing the demographic and socioeconomic characteristics, health status\nand diabetes care of people living with T2DM in Martinique, Guadeloupe, French Guiana and Reunion Island.\n>\nSandrine Fosse-Edorh et coll.\nSant\u00e9 publique France, Saint-Maurice", "mimetype": "text/plain", "start_char_idx": 3676, "end_char_idx": 5044, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "8a741009-a7fe-4a85-8613-863cf6d56b4e": {"__data__": {"id_": "8a741009-a7fe-4a85-8613-863cf6d56b4e", "embedding": null, "metadata": {"page_label": "413", "file_name": "2023_20-21.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2023_20-21.pdf", "file_type": "application/pdf", "file_size": 1372902, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "de62df33-9d10-461c-93a3-ec27958e2ca0", "node_type": "4", "metadata": {"page_label": "413", "file_name": "2023_20-21.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2023_20-21.pdf", "file_type": "application/pdf", "file_size": 1372902, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "eac0283d0d374ab923f8e030ac9d1d30f1f688237cb2dd64e37378ecf4902e53", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d448e218-66be-49f0-9ae4-424c29008da9", "node_type": "1", "metadata": {}, "hash": "2fc91790a892ae47b05994d9dfea5e116205ec0936a8bcbef9514be1c89ad0de", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Diab\u00e8te en outre-mer : comprendre les sp\u00e9cificit\u00e9s locales pour cibler les actions BEH 20-21 | 14 novembre 2023 | 413\nMethods - For the Entred 3 study, a random sample of 12,772 adults treated pharmacologically for diabetes was\ndrawn from French national health insurance databases in 2019. This sample included 3,700 people residing in the\nDROM. The study population was restricted to people with T2DM, identified using an epidemio logical algorithm.\nData were collected using a face-to-face questionnaire, with subjects' physicians invited to complete a comple -\nmentary questionnaire. Data from the French National Health Data System (SNDS) were extracted for participants\nand non-participants, enabling the calculation of weights by territory that integrated the survey design and nonparticipation by questionnaire. Percentages and means were weighted. Comparison tests between the four DROM\nand between the five territories including European France were performed after adjustment for gender and age.\nResults - The study population included 498 people in Guadeloupe, 682 in Martinique, 504 in French Guiana,\n586 in Reunion Island and 2,714 in European France. A predominance of women was observed in the DROM\ncompared with European France. Patients residing in French Guiana and Reunion Island were younger (61 and\n63 years on average, respectively) than those in the French West Indies and European France (67 and 68 years,\nrespectively). Age at diagnosis of T2DM was also around 5 years younger in French Guiana and Reunion Island.\nSocioeconomic status was less favorable in the DROM, with a higher proportion of foreign-born people in\nFrench Guiana (53%). The average body mass index was lower in Reunion Island (27.7 kg/m2), French Guiana\nand Guadeloupe (28.4 kg/m2) than in Martinique (29.3 kg/m2) and European France (29.5 kg/m2). Alcohol\nand tobacco consumption were less frequent in the DROM than in European France, except a more frequent\nsmoking status in Reunion Island (14%). The mean HbA1c level was higher in the DROM than in European\nFrance (7.4%, 7.5%, 8.0% and 7.7%, respectively in Guadeloupe, Martinique, French Guiana and Reunion\nIsland, vs 7.2%). The frequency of chronic complications was higher in Reunion Island, whatever the compli -\ncation. Only the frequency of podiatric and renal complications did not vary significantly between territories.\nConclusion - Placed in a cultural, social and health context, these results will help decision-makers to adapt\npublic policies in terms of prevention, support and care for people with type 2 diabetes in overseas territories.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2601, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "d448e218-66be-49f0-9ae4-424c29008da9": {"__data__": {"id_": "d448e218-66be-49f0-9ae4-424c29008da9", "embedding": null, "metadata": {"page_label": "413", "file_name": "2023_20-21.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2023_20-21.pdf", "file_type": "application/pdf", "file_size": 1372902, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "de62df33-9d10-461c-93a3-ec27958e2ca0", "node_type": "4", "metadata": {"page_label": "413", "file_name": "2023_20-21.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2023_20-21.pdf", "file_type": "application/pdf", "file_size": 1372902, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "eac0283d0d374ab923f8e030ac9d1d30f1f688237cb2dd64e37378ecf4902e53", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8a741009-a7fe-4a85-8613-863cf6d56b4e", "node_type": "1", "metadata": {"page_label": "413", "file_name": "2023_20-21.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2023_20-21.pdf", "file_type": "application/pdf", "file_size": 1372902, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "02964abcf6b53f55bb7454d1b4955b75bf2f856571084c8a32dd02e7b71d21d8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f51ad937-e036-430a-ae2b-d94ea21912b0", "node_type": "1", "metadata": {}, "hash": "80d38f4c10f3fb4525dcfd26c3e61a0e8ca4fb9e86d65fc0f893667b6815b963", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "The frequency of chronic complications was higher in Reunion Island, whatever the compli -\ncation. Only the frequency of podiatric and renal complications did not vary significantly between territories.\nConclusion - Placed in a cultural, social and health context, these results will help decision-makers to adapt\npublic policies in terms of prevention, support and care for people with type 2 diabetes in overseas territories.\nMots-cl\u00e9s : Diab\u00e8te de type 2, Outre-mer, Niveau socio-\u00e9conomique, Facteurs de risque, Complications, Recours aux soins\n// Keywords: Type 2 diabetes, Overseas territories, Socio-economic status, Risk factors, Complications, Care management\nIntroduction\nLes d\u00e9partements et r\u00e9gions d'out re-mer (DROM)\nconnaissent des transitions d\u00e9mographique, ali mentaire et nutritionnelle rapides et profondes, impactant\nles modes de vie et cond uisant au d\u00e9veloppement\nde maladies m\u00e9taboliques telles que l'ob\u00e9 sit\u00e9 et le\ndiab\u00e8te de type 2 (DT2) 1. Ainsi, en 2021, 10,2% des\nadultes r\u00e9sidant en Gua deloupe, 9,5% de ceux de\nMartinique, 8,4% de ceux de La R\u00e9union et 3,8% de\nceux de Guyane se d\u00e9claraient atteintes d'un diab\u00e8te 2,\ntandis que cette proportion \u00e9tait de 5,7% en 2016 en\nFrance hexagonale 3. En 2021, par rapport \u00e0 la France\nenti\u00e8re et \u00e0 structure d'\u00e2ge \u00e9quivalente, les taux de\npr\u00e9valence du diab\u00e8te trait\u00e9 pharmacologiquement\n\u00e9taient 1,9 fois plus \u00e9lev\u00e9s \u00e0 La R\u00e9union, 1,8 fois en\nGuadeloupe et 1,5 fois en Guyane et Martinique (1).\nLa survenue des comp lications graves, souvent\nplus fr\u00e9quentes dans ces territoires, vient \u00e9gale -\nment alourdir le fardeau du diab\u00e8te 4. Pour exemple,\nen population diab\u00e9tique, les hospitalisations pour\namputations de membres inf\u00e9rieurs \u00e9taient, respectivement 1,5 et 1,3 fois plus fr\u00e9quentes en Martinique et\n\u00e0 La R\u00e9union, en 2021 par rapport \u00e0 la France enti\u00e8re ;\nles hospitalisations pour accident vas culaire c\u00e9r\u00e9bral\n(AVC) \u00e9taient 1,5 fois plus fr\u00e9quentes \u00e0 La R\u00e9union et\nles hospitalisations pour insuffisance r\u00e9nale chronique\nterminale, 2 fois plus fr\u00e9quentes en Martinique, 1,7 fois\n\u00e0 La R\u00e9union, 1,6 en Guyane et 1,3 en Guadeloupe 1.\nPourtant, les facteurs de risque du DT2 et les complications de tous les types de diab\u00e8te sont en grande\npartie modifiables, rendant ce fardeau \u00e9vitable.", "mimetype": "text/plain", "start_char_idx": 2174, "end_char_idx": 4433, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "f51ad937-e036-430a-ae2b-d94ea21912b0": {"__data__": {"id_": "f51ad937-e036-430a-ae2b-d94ea21912b0", "embedding": null, "metadata": {"page_label": "413", "file_name": "2023_20-21.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2023_20-21.pdf", "file_type": "application/pdf", "file_size": 1372902, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "de62df33-9d10-461c-93a3-ec27958e2ca0", "node_type": "4", "metadata": {"page_label": "413", "file_name": "2023_20-21.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2023_20-21.pdf", "file_type": "application/pdf", "file_size": 1372902, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "eac0283d0d374ab923f8e030ac9d1d30f1f688237cb2dd64e37378ecf4902e53", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d448e218-66be-49f0-9ae4-424c29008da9", "node_type": "1", "metadata": {"page_label": "413", "file_name": "2023_20-21.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2023_20-21.pdf", "file_type": "application/pdf", "file_size": 1372902, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "a0832babaf825167fb49a2ab7cf6e9be62ca0010cb5c07bf34b35ef0531f22ea", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Pourtant, les facteurs de risque du DT2 et les complications de tous les types de diab\u00e8te sont en grande\npartie modifiables, rendant ce fardeau \u00e9vitable. Il est\n(1)\ndonc essentiel de d\u00e9crire la situation \u00e9pid\u00e9miologique\ndu diab\u00e8te afin d'en comp rendre les sp\u00e9cificit\u00e9s et\nde d\u00e9velopper des actions de pr\u00e9vention. Il s'agi t\nde la finalit\u00e9 de l'\u00e9tude Entred (\u00c9chantillon national\nt\u00e9moin repr\u00e9sentatif des per sonnes diab\u00e9tiques)\nlanc\u00e9e en France d\u00e8s le d\u00e9but des ann\u00e9es 2000.\nUn des objectifs principaux de sa 3 e \u00e9dition \u00e9tait\nde d\u00e9crire les sp\u00e9cificit\u00e9s du diab\u00e8te dans quatre\nDROM : la Martinique, la Guadeloupe, la Guyane et\nLa R\u00e9union, notamment les caract\u00e9ristiques d\u00e9mo -\ngraphiques, socio-\u00e9conomiques des personnes, leur\n\u00e9tat de sant\u00e9 et leurs recours aux soins.\nMat\u00e9riel et M\u00e9thodes\nLa m\u00e9thodologie g\u00e9n\u00e9rale de l'\u00e9tu de Entred 3 a\n\u00e9t\u00e9 d\u00e9crite pr\u00e9c\u00e9demment 5. Des adultes trait\u00e9s\npharmacologiquement pour un diab\u00e8te, tir\u00e9s au\nsort dans les donn\u00e9es de l'Ass urance maladie\n\u00e0 l'\u00e9chelon local, ont \u00e9t\u00e9 invit\u00e9s \u00e0 r\u00e9pondre \u00e0 un\nquestionnaire. Les modalit\u00e9s de passation des\nquestionnaires en outre-mer ont \u00e9t\u00e9 adapt\u00e9es\npar rapport \u00e0 l'Hex agone : des enqu\u00eateurs cr\u00e9o -\nlophones se rendaient au domicile des personnes\nqui n'avaient pas r\u00e9pondu pr\u00e9alablement \u00e0 un\nquestionnaire \u00e9lectronique. Les coordonn\u00e9es de\nleur m\u00e9decin \u00e9taient recueillies et ceux-ci \u00e9taient\ninvit\u00e9s \u00e0 r\u00e9pondre \u00e0 un questionnaire m\u00e9dical\nconcernant cette personne. En outre, les donn\u00e9es\ndu Syst\u00e8me national de donn\u00e9es de sant\u00e9 (SNDS)\nont \u00e9t\u00e9 extraites pour l'ensemble des personnes\ntir\u00e9es au sort ne s'y \u00e9tant pas oppos\u00e9 (participant\nou non \u00e0 l'enq u\u00eate par questionnaire), cons tituant\n\u00e0 terme un suivi de cohorte passive sur 20 ans\n(10 ans pr\u00e9c\u00e9dant le tirage au sort et 10 ans apr\u00e8s).", "mimetype": "text/plain", "start_char_idx": 4280, "end_char_idx": 6039, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "df934db4-9119-45c4-94ca-204ebfaf339c": {"__data__": {"id_": "df934db4-9119-45c4-94ca-204ebfaf339c", "embedding": null, "metadata": {"page_label": "414", "file_name": "2023_20-21.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2023_20-21.pdf", "file_type": "application/pdf", "file_size": 1372902, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "44f90b55-11c6-4256-82a9-e2ef30fbde41", "node_type": "4", "metadata": {"page_label": "414", "file_name": "2023_20-21.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2023_20-21.pdf", "file_type": "application/pdf", "file_size": 1372902, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "dae860bfabc0f7d99381df48996d196b3564355629ec7f86ea5a52d041f9ae1a", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "414 | 14 novembre 2023 | BEH 20-21 Diab\u00e8te en outre-mer : comprendre les sp\u00e9cificit\u00e9s locales pour cibler les actions\n\u00c9chantillonnage\nPar rapport \u00e0 l'Hex agone, un sur\u00e9chantillonnage\na \u00e9t\u00e9 effectu\u00e9 afin de disposer d'une puissance\nstatistique suffisante pour d\u00e9crire les sp\u00e9cificit\u00e9s\nde chacun des quatre territoires. La population cible\nde Guadeloupe incluait \u00e9galement les \u00eeles du Sud\n(Marie-Galante, Les Saintes, et La D\u00e9sirade), tandis\nque pour la Guyane, elle se limitait \u00e0 la \u00ab Guyane\nrouti\u00e8re \u00bb (figure 1). Une phase pilote avait rapport\u00e9\ndes taux de participation proches de 70% en Guyane\net \u00e0 La R\u00e9union. Des \u00e9chantillons de 850 personnes\nont donc \u00e9t\u00e9 tir\u00e9s au sort dans ces deux territoires\net 1 000 personnes par territoire antillais.\nPond\u00e9rations\nLa disponibilit\u00e9 des donn\u00e9es auxiliaires recueil -\nlies dans les bases locales d'Assurance maladie\n(sexe, \u00e2ge, pays de naissance, zone g\u00e9ogra -\nphique de r\u00e9sidence) et dans le SNDS (donn\u00e9es\nde consommations de soins et d'hos pitalisations)\npour l'ensemble des personnes tir\u00e9es au sort a\npermis d'analyser le biais de non- participation aux\nenqu\u00eates (personnes et m\u00e9decins) dans chaque\nterritoire. Des jeux de pond\u00e9ration sp\u00e9cifiques par\nterritoire ont \u00e9t\u00e9 d\u00e9velopp\u00e9s, tenant comp te \u00e0 la fois\ndu plan de sondage et de la non- participation\n\u00e0 l'enqu\u00eate par questionnaires.\nPopulation d'\u00e9tude\nLa population d'\u00e9tude a \u00e9t\u00e9 restreinte aux personnes\nayant un DT2. Le type de diab\u00e8te a \u00e9t\u00e9 d\u00e9fini sur la\nbase d'un algorithme \u00e9pid\u00e9miologique reposant\nsur les donn\u00e9es d\u00e9claratives collect\u00e9es aupr\u00e8s des\npersonnes et de leur m\u00e9decin et d'informations issues\ndes consommations de soins. Cette classification\ndu type de diab\u00e8te a \u00e9t\u00e9 discut\u00e9e et adapt\u00e9e dans le\ncadre d'un groupe de travail regroupant des experts\nlocaux des diff\u00e9rents territoires.\nFigure 1\nCommune de r\u00e9sidence des personnes participant par questionnaire \u00e0 l'\u00e9tude Entred 3, r\u00e9sidant en outre-mer\nkm\n04 08 0k m\nGuadeloupe Guyane\nLa R\u00e9union Martinique\n50 100\nNombre de participants par commune\n(Les effectifs inf\u00e9rieurs \u00e0 5 participants ne sont pas cartographi\u00e9s)\nSource : Ign-Admin Express COG, 2022\nEnqu\u00eate Entred 3 : Sant\u00e9 publique France, 2022.\n04 08 0k m\n\nLimite du territoire inclus\ndans l'enqu\u00eate", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2217, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "3cf38749-39f6-4c64-be6f-e1baede76898": {"__data__": {"id_": "3cf38749-39f6-4c64-be6f-e1baede76898", "embedding": null, "metadata": {"page_label": "415", "file_name": "2023_20-21.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2023_20-21.pdf", "file_type": "application/pdf", "file_size": 1372902, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "d7cbcd75-bd03-464a-b8ae-5a51caf94e39", "node_type": "4", "metadata": {"page_label": "415", "file_name": "2023_20-21.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2023_20-21.pdf", "file_type": "application/pdf", "file_size": 1372902, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "0516a1652032d44e0995cadf12e998e09cfebbd37aa237ffe2ceddb70024fa5c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "269cbc03-5966-443a-a8b5-40aae7e51523", "node_type": "1", "metadata": {}, "hash": "769ea99656c62359f9b9efb2b53b41ca3d61fb99cdbf1faabdb25eb353c67330", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Diab\u00e8te en outre-mer : comprendre les sp\u00e9cificit\u00e9s locales pour cibler les actions BEH 20-21 | 14 novembre 2023 | 415\nAnalyses des donn\u00e9es\nOutre les indicateurs issus des donn\u00e9es recueillies\npar questionnaires, des indicateurs de consommation\nde soins, tels que des m\u00e9dicaments ou des actes, ont\n\u00e9t\u00e9 d\u00e9velopp\u00e9s par p\u00e9riode de 12 mois et des indi -\ncateurs d'hospitalisation ont \u00e9t\u00e9 d\u00e9velopp\u00e9s sur des\nm\u00eames p\u00e9riodes ainsi que sur 10 ans, \u00e0 partir d'algorithmes publi\u00e9s pr\u00e9c\u00e9demment 4. En compl\u00e9ment des\nsoins lib\u00e9raux, les actes et cons ultations externes\n(ACE), c'est-\u00e0-dire r\u00e9alis\u00e9s en ambulatoire par les\npraticiens exer\u00e7ant dans les h\u00f4pitaux et imput\u00e9s\nsur les enveloppes de d\u00e9penses hospitali\u00e8res, ont\n\u00e9t\u00e9 recherch\u00e9s. Par ailleurs, lorsqu'une hospitalisa -\ntion de jour (HDJ) pour surveillance du diab\u00e8te \u00e9tait\nrep\u00e9r\u00e9e au cours des 12 mois pr\u00e9c\u00e9dant le tirage\nau sort, une consultation d'endocrinologie et un\ndosage d'HbA1c (h\u00e9moglobine glyqu\u00e9e) et de microalbuminurie \u00e9taient syst\u00e9matiquement comptabilis\u00e9s.\nDes indicateurs combinant les actes/ consultations\nen lib\u00e9ral, les ACE et les HDJ ont \u00e9t\u00e9 d\u00e9velopp\u00e9s.\nPour l'estimation de l'ind ice de masse corporelle\n(IMC), en cas de valeur manquante du poids ou de la\ntaille auto-d\u00e9clar\u00e9e, la valeur \u00e9tait imput\u00e9e par celle\nrecueillie aupr\u00e8s du m\u00e9decin.\nLes estimations sont pr\u00e9sent\u00e9es sous forme de pourcentages ou de moyennes pond\u00e9r\u00e9es, avec leur intervalle de confiance \u00e0 95%. Des tests de comparaison\nentre les DROM et entre les 5 territoires incluant\nl'Hexagone ont \u00e9t\u00e9 effectu\u00e9s. Afin de tenir comp te\ndes diff\u00e9rences d\u00e9mographiques observ\u00e9es entre\nles territoires, tous les tests ont \u00e9t\u00e9 ajust\u00e9s sur le\nsexe et l'\u00e2ge \u00e0 l'aide de mod\u00e8les de r\u00e9gression logistique ou lin\u00e9aire pond\u00e9r\u00e9s.\nR\u00e9sultats\nEn septembre 2019, 3 700 personnes r\u00e9sidant en\noutre-mer ont \u00e9t\u00e9 \u00e9chantillonn\u00e9es pour participer \u00e0\nEntred 3. Parmi elles, 5 personnes \u00e9taient consid\u00e9 -\nr\u00e9es \u00ab hors champ \u00bb. Le suivi de cohorte passive a pu\n\u00eatre effectu\u00e9 pour 97,3% d'ent re elles et 63,7% ont\nparticip\u00e9 au recueil d'inf ormation par questionnaire\n(52% en Guadeloupe, 70% en Martinique, 61% en\nGuyane et 72% \u00e0 La R\u00e9union). Les comm unes de\nr\u00e9sidence des participants ont \u00e9t\u00e9 cartographi\u00e9es\n(figure 1).", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2218, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "269cbc03-5966-443a-a8b5-40aae7e51523": {"__data__": {"id_": "269cbc03-5966-443a-a8b5-40aae7e51523", "embedding": null, "metadata": {"page_label": "415", "file_name": "2023_20-21.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2023_20-21.pdf", "file_type": "application/pdf", "file_size": 1372902, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "d7cbcd75-bd03-464a-b8ae-5a51caf94e39", "node_type": "4", "metadata": {"page_label": "415", "file_name": "2023_20-21.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2023_20-21.pdf", "file_type": "application/pdf", "file_size": 1372902, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "0516a1652032d44e0995cadf12e998e09cfebbd37aa237ffe2ceddb70024fa5c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3cf38749-39f6-4c64-be6f-e1baede76898", "node_type": "1", "metadata": {"page_label": "415", "file_name": "2023_20-21.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2023_20-21.pdf", "file_type": "application/pdf", "file_size": 1372902, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "b39b3e5a5094a9003e7ff1b751fc1454f7c49406e445c7cf93ef419e760c1145", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Les comm unes de\nr\u00e9sidence des participants ont \u00e9t\u00e9 cartographi\u00e9es\n(figure 1). Des informations m\u00e9dicales ont \u00e9t\u00e9 recueillies aupr\u00e8s des m\u00e9decins soignants pour 38% des\nparticipants en Guadeloupe, 30% en Martinique,\n17% en Guyane et 49% \u00e0 La R\u00e9union.\nParmi les 2 352 personnes diab\u00e9tiques ayant parti -\ncip\u00e9 \u00e0 l'\u00e9tu de par questionnaire, 2 270 avaient\nun DT2 : 498 en Guadeloupe, 682 en Martinique,\n504 en Guyane et 586 \u00e0 La R\u00e9union. Des donn\u00e9es\nm\u00e9dicales ont pu \u00eatre recueillies aupr\u00e8s de leur\nm\u00e9decin pour 755 d'entre elles (figure 2).\nFigure 2\nR\u00e9partition de l'\u00e9chantillon des 3 700 adultes, r\u00e9sidant en outre-mer, s\u00e9lectionn\u00e9s pour participer \u00e0 l'\u00e9tude Entred 3\n\nTirage au sort\nN=3 700\nGuadeloupe N=1 000\nMartinique N=1 000\nGuyane N=850\nLa R\u00e9union N=850\nSuivi de cohorte passive\nN=3 597\nParticipation des personnes\npar questionnaire\nN=2 352\nPopulation d'\u00e9tude\nPersonnes atteintes\nd'un diab\u00e8te de type 2\nN=2 270\nGuadeloupe N=498\nMartinique N=682\nGuadeloupe N=188\nMartinique N=202\nGuyane N=84\nLa R\u00e9union N=281La R\u00e9union N=586\nGuyane N=504\nDonn\u00e9es m\u00e9dicales recueillies\npar questionnaire m\u00e9decin\nN=791\nDonn\u00e9es m\u00e9dicales des personnes\natteintes d'un diab\u00e8te de type 2\nN=755\n(Exclusion de 5 personnes\nhors-champ)", "mimetype": "text/plain", "start_char_idx": 2140, "end_char_idx": 3351, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "4fe56716-f118-4a6c-93c0-ae307ad51bc9": {"__data__": {"id_": "4fe56716-f118-4a6c-93c0-ae307ad51bc9", "embedding": null, "metadata": {"page_label": "416", "file_name": "2023_20-21.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2023_20-21.pdf", "file_type": "application/pdf", "file_size": 1372902, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "1fbfbe0c-2791-427c-987f-43948b0bb4b5", "node_type": "4", "metadata": {"page_label": "416", "file_name": "2023_20-21.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2023_20-21.pdf", "file_type": "application/pdf", "file_size": 1372902, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "9a025a2947fe0fef97b7a487e78f829c0b31f69ee766bc2856676a9432651f2f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b359e1a2-e044-4059-a188-dea823a3c3c4", "node_type": "1", "metadata": {}, "hash": "b4848ec155bbde1c9156e0201d7e1ce06f4df6372b2110615f24b9e6e7afd166", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "416 | 14 novembre 2023 | BEH 20-21 Diab\u00e8te en outre-mer : comprendre les sp\u00e9cificit\u00e9s locales pour cibler les actions\nCaract\u00e9ristiques d\u00e9mographiques\net socio-\u00e9conomiques\nLa proportion de femmes \u00e9tait plus \u00e9lev\u00e9e en\nGuadeloupe (59%), Martinique (59%), Guyane (57%)\net \u00e0 La R\u00e9union (54%) que dans l'Hex agone (45%)\n(figure 3). L '\u00e2ge moyen \u00e9tait plus jeune \u00e0 La R\u00e9union\net en Guyane (63 et 61 ans) par rapport aux Antilles\n(68 et 67 ans, en Guadeloupe et Martinique), ou\n\u00e0 l'Hexagone (68 ans). Si la grande majorit\u00e9 des\npersonnes des Antilles et de La R\u00e9union \u00e9taient\nn\u00e9es en France voire dans leur d\u00e9partement de r\u00e9si -\ndence, ce n'\u00e9ta it pas le cas en Guyane, o\u00f9 seule -\nment 43% des personnes \u00e9taient n\u00e9es en France\n(figure 3). Plus d'un quart \u00e9taient n\u00e9es \u00e0 Ha\u00efti.\nLe niveau d'\u00e9tudes \u00e9tait globalement moins \u00e9lev\u00e9\nen outre-mer (tableau 1). En particulier, 12% et 7%\ndes personnes r\u00e9sidant respectivement en Guyane\net \u00e0 La R\u00e9union n'avaient jamais \u00e9t\u00e9 scolaris\u00e9es ; ce\ntaux \u00e9tait de 1% en Martinique, 3% en Guadeloupe\net 4% dans l'Hexagone. Les r\u00e9partitions des cat\u00e9go -\nries professionnelles diff\u00e9raient de fa\u00e7on significa -\ntive entre les DROM avec notamment une proportion\nde personnes \u00ab au foyer ou n'ayant jamais travaill\u00e9 \u00bb\nplus \u00e9lev\u00e9e en Guyane (21%). Les autres indicateurs\nde niveau socio-\u00e9conomique, que ce soit la propor -\ntion de b\u00e9n\u00e9ficiaires de la Couverture maladie\nuniverselle compl\u00e9mentaire (CMU-C) ou le ressenti\nfinancier diff\u00e9raient \u00e9galement entre les DROM et\navec l'Hexagone (tableau 1).\nHistoire de la maladie\nL '\u00e2ge au diagnostic du DT2 variait selon les territoires\navec un \u00e2ge moyen plus jeune en Guyane (47 ans)\net \u00e0 La R\u00e9union (48 ans) par rapport aux Antilles\n(52 ans) ou dans l'Hex agone (54 ans) (tableau 2).\nLe DT2 \u00e9tait plus fr\u00e9quemment d\u00e9couvert \u00e0 l'occ asion d'un d\u00e9pistage aux Antilles (74% en Guadeloupe\net 79% en Martinique) et \u00e0 La R\u00e9union (76%) que\ndans l'Hexagone (68%). Cette proportion n'\u00e9ta it\nque de 59% en Guyane, toutefois l'information n'avait\npas pu \u00eatre renseign\u00e9e pour 9% des participants de\nce d\u00e9partement.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2060, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "b359e1a2-e044-4059-a188-dea823a3c3c4": {"__data__": {"id_": "b359e1a2-e044-4059-a188-dea823a3c3c4", "embedding": null, "metadata": {"page_label": "416", "file_name": "2023_20-21.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2023_20-21.pdf", "file_type": "application/pdf", "file_size": 1372902, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "1fbfbe0c-2791-427c-987f-43948b0bb4b5", "node_type": "4", "metadata": {"page_label": "416", "file_name": "2023_20-21.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2023_20-21.pdf", "file_type": "application/pdf", "file_size": 1372902, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "9a025a2947fe0fef97b7a487e78f829c0b31f69ee766bc2856676a9432651f2f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4fe56716-f118-4a6c-93c0-ae307ad51bc9", "node_type": "1", "metadata": {"page_label": "416", "file_name": "2023_20-21.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2023_20-21.pdf", "file_type": "application/pdf", "file_size": 1372902, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "51212f997fc41118265922b0a0ee96f005fce097868517c840b3e68da1cde91e", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Cette proportion n'\u00e9ta it\nque de 59% en Guyane, toutefois l'information n'avait\npas pu \u00eatre renseign\u00e9e pour 9% des participants de\nce d\u00e9partement. Enfin, le diab\u00e8te \u00e9tait d\u00e9couvert\npar des comp lications inaugurales chez 9% des\npersonnes en Guyane, 6% en Guadeloupe, 3% en\nMartinique et 8% \u00e0 La R\u00e9union, ce qui restait inf\u00e9rieur\n\u00e0 la proportion estim\u00e9e dans l'Hex agone (11%).\nFigure 3\nCaract\u00e9ristiques d\u00e9mographiques des personnes atteintes d'un diab\u00e8te de type 2 r\u00e9sidant dans les territoires d'outre-mer\net dans l'Hexagone - Entred 3\n41% 59%\n\u00c2ge moyen : 67,7 ans\nN\u00e9 en Guadeloupe : 89%\n41% 59%\n\u00c2ge moyen : 66,7 ans\nN\u00e9 en Martinique : 92%\n55% 45%\n\u00c2ge moyen : 67,6 ans\nN\u00e9 en France : 76%\n46% 54%\n\u00c2ge moyen : 62,7 ans\nN\u00e9 \u00e0 La R\u00e9union : 92%\n43% 57%\n\u00c2ge moyen : 61,1 ans\nN\u00e9 - en Guyane : 35%\n- en Ha\u00efti : 27%\n- au Br\u00e9sil : 9%\n- en France (hors Guyane) : 8%\n- au Suriname : 7%\n- dans les Cara\u00efbes (hors Ha\u00efti : 7%)\n- autre : 7%\nGuadeloupe\nMartinique\nGuyane\nLa R\u00e9union\nFrance\nhexagonale\nComparaison\ndes 4 territoires\nultramarins\nSexe p1=0,35p 2<0,0001\np2<0,0001\np4<0,0001\np1<0,0001\np3<0,0001\nPays de naissance\n\u00c2ge\nComparaison\ndes 5 territoires\nNote de bas d'infographie :\np1 : p-value du test de comparaison des 4 DROM issu d'un mod\u00e8le de r\u00e9gression logistique ajust\u00e9 sur le sexe et l'\u00e2ge\np2 : p-value du test de comparaison des 5 territoires issu d'un mod\u00e8le de r\u00e9gression logistique ajust\u00e9 sur le sexe et l'\u00e2ge\np3 : p-value du test de comparaison des 4 DROM issu d'un mod\u00e8le de r\u00e9gression lin\u00e9aire ajust\u00e9 sur le sexe et l'\u00e2ge\np4 : p-value du test de comparaison des 5 territoires issu d'un mod\u00e8le de r\u00e9gression lin\u00e9aire ajust\u00e9 sur le sexe et l'\u00e2ge", "mimetype": "text/plain", "start_char_idx": 1914, "end_char_idx": 3559, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "04ebe7f3-9094-42a2-94c3-2124b936ea72": {"__data__": {"id_": "04ebe7f3-9094-42a2-94c3-2124b936ea72", "embedding": null, "metadata": {"page_label": "417", "file_name": "2023_20-21.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2023_20-21.pdf", "file_type": "application/pdf", "file_size": 1372902, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "594dca8c-e0a5-4bfc-a824-86502d359579", "node_type": "4", "metadata": {"page_label": "417", "file_name": "2023_20-21.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2023_20-21.pdf", "file_type": "application/pdf", "file_size": 1372902, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "90a1887a8b1a652ab48ebfce3acc866d677bcc0f37c8d16a0005f3a07dd6e8b4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b843c23b-2ee8-4382-aee1-75ba97b901c9", "node_type": "1", "metadata": {}, "hash": "8037d6eca74fbbdea7cc2a2e00cdebe732a872a033aca07d0c6ea7e556c13689", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Diab\u00e8te en outre-mer : comprendre les sp\u00e9cificit\u00e9s locales pour cibler les actions BEH 20-21 | 14 novembre 2023 | 417\nPrise en charge\nL 'insulinoth\u00e9rapie \u00e9tait plus fr\u00e9quente dans les DROM\n(37% en Guyane, 35% en Guadeloupe, 33% en\nMartinique, 28% \u00e0 La R\u00e9union) que dans l'Hexagone\n(23%) (tableau 2). Le recours \u00e0 la metformine ne variait\npas de fa\u00e7on significative entre les DROM, bien que\nmoins \u00e9lev\u00e9 en Guadeloupe (76%) et Martinique\n(74%) par rapport \u00e0 la Guyane (81%) et La R\u00e9union\n(82%), proches du taux de l'Hexagone (82%). Aucune\ndiff\u00e9rence significative n'\u00e9ta it observ\u00e9e entre les\n5 territoires concernant le recours aux agonistes du\nr\u00e9cepteur du glucagon-like- peptide-1 (aGLP1) qui\nvariait de 10% en Guadeloupe \u00e0 15% en Guyane.\nLe recours aux tisanes conc ernait 41% des per -\nsonnes DT2 en Guadeloupe, 37% en Martinique,\n50% en Guyane et 44% \u00e0 La R\u00e9union.\nUn m\u00e9decin g\u00e9n\u00e9raliste avait \u00e9t\u00e9 consult\u00e9 au moins\nune fois au cours des 12 derniers mois par plus de 90%\ndes personnes aux Antilles (91% en Guadeloupe et 93%\nen Martinique), proches du taux estim\u00e9 dans l'Hex agone (93%). \u00c0 La R\u00e9union, ce taux \u00e9tait de 86% et 70%\nen Guyane. Concernant le recours annuel \u00e0 un endocrinologue en lib\u00e9ral, consultation externe ou HDJ, il variait\npeu selon les DROM (entre 15% \u00e0 La R\u00e9union et 19% en\nMartinique), tandis qu'il \u00e9tait plus \u00e9lev\u00e9 dans l'Hexagone\n(22%). Concernant les autres sp\u00e9cialistes, cardiologues,\nophtalmologues, dentistes, le recours variait forte -\nment selon les territoires. Pr\u00e8s de 71% des personnes\n\u00e0 La R\u00e9union parlaient au moins occasionnellement\navec leur m\u00e9decin dans une autre langue que le fran -\n\u00e7ais (contre 38% en Guadeloupe, 22% en Martinique et\n21% en Guyane). Le cr\u00e9ole \u00e9tait syst\u00e9matiquement cit\u00e9.\nTableau 1\nCaract\u00e9ristiques socio-\u00e9conomiques des personnes atteintes d'un diab\u00e8te de type 2 r\u00e9sidant dans les territoires d'outre-mer\n(Guadeloupe, Martinique, Guyane,", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1899, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "b843c23b-2ee8-4382-aee1-75ba97b901c9": {"__data__": {"id_": "b843c23b-2ee8-4382-aee1-75ba97b901c9", "embedding": null, "metadata": {"page_label": "417", "file_name": "2023_20-21.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2023_20-21.pdf", "file_type": "application/pdf", "file_size": 1372902, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "594dca8c-e0a5-4bfc-a824-86502d359579", "node_type": "4", "metadata": {"page_label": "417", "file_name": "2023_20-21.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2023_20-21.pdf", "file_type": "application/pdf", "file_size": 1372902, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "90a1887a8b1a652ab48ebfce3acc866d677bcc0f37c8d16a0005f3a07dd6e8b4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "04ebe7f3-9094-42a2-94c3-2124b936ea72", "node_type": "1", "metadata": {"page_label": "417", "file_name": "2023_20-21.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2023_20-21.pdf", "file_type": "application/pdf", "file_size": 1372902, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "5feffbbd49792314309fe2f69e8f4244e43cc5db0d79e2e9a8d906d61a145dd2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "64b28b46-fa0c-43a4-b3df-61ea93c17f89", "node_type": "1", "metadata": {}, "hash": "6a595e606349c8faa4f9325fcb25113676233d98c9a3d42494fad21f84588265", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Le cr\u00e9ole \u00e9tait syst\u00e9matiquement cit\u00e9.\nTableau 1\nCaract\u00e9ristiques socio-\u00e9conomiques des personnes atteintes d'un diab\u00e8te de type 2 r\u00e9sidant dans les territoires d'outre-mer\n(Guadeloupe, Martinique, Guyane, La R\u00e9union) et dans l'Hexagone - Entred 3\nGuadeloupe Martinique Guyane La R\u00e9union\np-value\nHexagone\np-value\n% [IC95%] % [IC95%] % [IC95%] % [IC95%] % [IC95%]\nB\u00e9n\u00e9ficiaire de la CMU-C 19,8 [16,3-23,7] 22,7 [19,4-26,3] 42,3 [37,6-47,1] 35,0 [31,1-39,0] <0,0001a 6,8 [5,7-8,1] <0,0001b\nNiveau d'\u00e9tudes <0,0001a <0,0001b\nJamais scolaris\u00e9 2,8 [1,4-4,9] 1,3 [0,6-2,5] 12,4 [9,5-15,8] 7,3 [5,3-9,7] 3,9 [3,0-5,0]\nPrimaire non termin\u00e9 9,6 [6,9-12,8] 9,0 [6,9-11,4] 12,8 [9,9-16,2] 18,5 [15,4-22,0] 6,0 [5,0-7,2]\nPrimaire termin\u00e9, Certificat d'\u00e9tudes\nprimaires\n35,9 [31,0-41,0] 32,4 [28,8-36,1] 16,4 [13,1-20,1] 25,9 [22,3-29,7] 23,7 [21,8-25,6]\nColl\u00e8ge, BEPC, CAP , BEP 31,9 [27,5-36,7] 32,2 [28,6-36,0] 36,5 [31,9-41,4] 36,3 [32,2-40,5] 38,3 [36,2-40,4]\nLyc\u00e9e, Bac, Bac + 1 an 13,0 [9,9-16,5] 16,4 [13,6-19,6] 16,9 [13,3-20,9] 8,1 [5,9-10,7] 12,4 [11,1-13,9]\nBac + 2 \u00e0 Bac + 4 ans 5,1 [3,2-7,6] 6,9 [5,0-9,3] 4,5 [2,5-7,5] 2,9 [1,6-4,8] 10,8 [9,6-12,2]\nBac + 5 ans et plus 1,", "mimetype": "text/plain", "start_char_idx": 1694, "end_char_idx": 2867, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "64b28b46-fa0c-43a4-b3df-61ea93c17f89": {"__data__": {"id_": "64b28b46-fa0c-43a4-b3df-61ea93c17f89", "embedding": null, "metadata": {"page_label": "417", "file_name": "2023_20-21.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2023_20-21.pdf", "file_type": "application/pdf", "file_size": 1372902, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "594dca8c-e0a5-4bfc-a824-86502d359579", "node_type": "4", "metadata": {"page_label": "417", "file_name": "2023_20-21.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2023_20-21.pdf", "file_type": "application/pdf", "file_size": 1372902, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "90a1887a8b1a652ab48ebfce3acc866d677bcc0f37c8d16a0005f3a07dd6e8b4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b843c23b-2ee8-4382-aee1-75ba97b901c9", "node_type": "1", "metadata": {"page_label": "417", "file_name": "2023_20-21.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2023_20-21.pdf", "file_type": "application/pdf", "file_size": 1372902, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "d3a01af07b88cb2175d07a2934c3a8ce4d1bc0ff6fc12945a66daa35b885a1bf", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a50e3672-1d7f-4bee-af81-59cd61609b1d", "node_type": "1", "metadata": {}, "hash": "5f73d6610a2871fa3f7c213cc939d9dd35f0884176cd9a1ebad96c35b415950b", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "4 [11,1-13,9]\nBac + 2 \u00e0 Bac + 4 ans 5,1 [3,2-7,6] 6,9 [5,0-9,3] 4,5 [2,5-7,5] 2,9 [1,6-4,8] 10,8 [9,6-12,2]\nBac + 5 ans et plus 1,8 [0,5-4,7] 1,8 [0,9-3,1] 0,5 [0,1-1,8] 1,0 [0,3-2,4] 4,9 [4,1-5,8]\nRessenti financier <0,0001a <0,0001b\nVous \u00eates \u00e0 l'aise 5,2 [3,0-8,4] 4,9 [3,3-6,9] 4,7 [2,7-7,5] 7,6 [5,5-10,2] 13,1 [11,7-14,5]\n\u00c7a va 22,1 [18,0-26,6] 27,2 [23,7-30,8] 34,6 [29,8-39,6] 26,0 [22,3-30,0] 42,7 [40,6-44,8]\nC'est juste 31,2 [26,6-36,2] 34,2 [30,4-38,1] 21,7 [18,0-25,9] 29,3 [25,6-33,3] 24,8 [22,9-26,7]\nVous y arrivez difficilement 29,4 [25,0-34,2] 28,3 [24,7-32,1] 33,1 [28,6-37,8] 28,8 [25,1-32,7] 16,1 [14,5-17,8]\nVous ne pouvez pas y arriver sans faire\nde dettes\n12,0 [9,0-15,6] 5,5 [3,8-7,6] 5,9 [3,7-8,7] 8,2 [6,1-10,8] 3,4 [2,6-4,3]\nProfession et cat\u00e9gorie socioprofessionnelle <0,0001a <0,0001b\nManquant 3,8 [2,3-6,1] 2,4 [1,3-4,0] 3,8 [2,1-6,3] 0,8 [0,2-2,2] 14,9 [13,3-16,6]\nAgriculteurs exploitants 4,3 [2,4-6,8] 2,2 [1,2-3,6] 2,1 [1,0-3,9] 5,1 [3,5-7,2] 0,3 [0,1-0,7]\nArtisans,", "mimetype": "text/plain", "start_char_idx": 2737, "end_char_idx": 3739, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "a50e3672-1d7f-4bee-af81-59cd61609b1d": {"__data__": {"id_": "a50e3672-1d7f-4bee-af81-59cd61609b1d", "embedding": null, "metadata": {"page_label": "417", "file_name": "2023_20-21.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2023_20-21.pdf", "file_type": "application/pdf", "file_size": 1372902, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "594dca8c-e0a5-4bfc-a824-86502d359579", "node_type": "4", "metadata": {"page_label": "417", "file_name": "2023_20-21.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2023_20-21.pdf", "file_type": "application/pdf", "file_size": 1372902, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "90a1887a8b1a652ab48ebfce3acc866d677bcc0f37c8d16a0005f3a07dd6e8b4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "64b28b46-fa0c-43a4-b3df-61ea93c17f89", "node_type": "1", "metadata": {"page_label": "417", "file_name": "2023_20-21.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2023_20-21.pdf", "file_type": "application/pdf", "file_size": 1372902, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "8dc829700ce001a986cc8e4b0a4c49768d20d89c264b8330417c70939ea1f57d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ed1776e9-0c0f-46ff-bfae-4891c0bda0bd", "node_type": "1", "metadata": {}, "hash": "fb1ef593db53d1518a7182e105a4bb31caf57e1bd17b06d527dc08ada6a92d98", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "8 [0,2-2,2] 14,9 [13,3-16,6]\nAgriculteurs exploitants 4,3 [2,4-6,8] 2,2 [1,2-3,6] 2,1 [1,0-3,9] 5,1 [3,5-7,2] 0,3 [0,1-0,7]\nArtisans, commer\u00e7ants et chefs d'entreprise 5,8 [3,6-8,7] 5,2 [3,7-7,1] 6,1 [4,2-8,6] 4,2 [2,6-6,3] 6,8 [5,8-8,0]\nCadres et professions intellectuelles\nsup\u00e9rieures\n3,3 [1,5-6,2] 2,8 [1,7-4,3] 2,0 [0,6-4,8] 1,3 [0,5-2,9] 10,2 [8,9-11,5]\nProfessions interm\u00e9diaires 8,3 [5,9-11,3] 10,4 [8,1-13,0] 7,1 [4,8-10,0] 8,6 [6,4-11,4] 15,6 [14,1-17,2]\nEmploy\u00e9s 41,1 [36,2-46,0] 40,7 [36,8-44,6] 33,5 [29,1-38,2] 41,2 [37,1-45,5] 23,5 [21,6-25,5]\nOuvriers 24,1 [19,9-28,6] 30,8 [27,2-34,6] 24,4 [20,4-28,7] 28,1 [24,4-32,0] 22,6 [20,7-24,5]\nHommes ou femmes au foyer\nou n'ayant jamais travaill\u00e9\n9,4 [6,5-13,1] 5,5 [3,9-7,6] 21,0 [17,0-25,4] 10,4 [8,1-13,2] 6,0 [4,9-7,4]\nIC95% : intervalle de confiance \u00e0 95% ; CMU-C : Couverture maladie universelle compl\u00e9mentaire ; DROM : d\u00e9partements et r\u00e9gions d'outre-mer.\na p-value du test de comparaison des 4 DROM issu d'un mod\u00e8le de r\u00e9gression logistique ajust\u00e9 sur le sexe et l'\u00e2ge.\nb p-value du test de comparaison des 5 territoires issu d'un mod\u00e8le de r\u00e9gression logistique ajust\u00e9 sur le sexe et l'\u00e2ge.\nNote de lecture : 19,8% (IC95%: [16,3-23,7]) des personnes diab\u00e9tiques de type 2 r\u00e9sidant en Guadeloupe b\u00e9n\u00e9ficiaient de la CMU-C.", "mimetype": "text/plain", "start_char_idx": 3606, "end_char_idx": 4896, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "ed1776e9-0c0f-46ff-bfae-4891c0bda0bd": {"__data__": {"id_": "ed1776e9-0c0f-46ff-bfae-4891c0bda0bd", "embedding": null, "metadata": {"page_label": "417", "file_name": "2023_20-21.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2023_20-21.pdf", "file_type": "application/pdf", "file_size": 1372902, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "594dca8c-e0a5-4bfc-a824-86502d359579", "node_type": "4", "metadata": {"page_label": "417", "file_name": "2023_20-21.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2023_20-21.pdf", "file_type": "application/pdf", "file_size": 1372902, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "90a1887a8b1a652ab48ebfce3acc866d677bcc0f37c8d16a0005f3a07dd6e8b4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a50e3672-1d7f-4bee-af81-59cd61609b1d", "node_type": "1", "metadata": {"page_label": "417", "file_name": "2023_20-21.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2023_20-21.pdf", "file_type": "application/pdf", "file_size": 1372902, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "56851708524c87cfbd3e60cce74cc33c26c8c11fe4fef908d265239cb16e0c3c", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "b p-value du test de comparaison des 5 territoires issu d'un mod\u00e8le de r\u00e9gression logistique ajust\u00e9 sur le sexe et l'\u00e2ge.\nNote de lecture : 19,8% (IC95%: [16,3-23,7]) des personnes diab\u00e9tiques de type 2 r\u00e9sidant en Guadeloupe b\u00e9n\u00e9ficiaient de la CMU-C. Apr\u00e8s ajustement\nsur le sexe et l'\u00e2ge des personnes, la p-value du test de comparaisons entre les DROM \u00e9tait significative (<0,0001). Apr\u00e8s ajustement sur le sexe et l'\u00e2ge\ndes personnes, la p-value du test de comparaisons entre les 5 territoires, incluant l'Hexagone, \u00e9tait significative (<0,0001).", "mimetype": "text/plain", "start_char_idx": 4644, "end_char_idx": 5195, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "ed421f85-1279-41cd-bac4-a3e3a787212d": {"__data__": {"id_": "ed421f85-1279-41cd-bac4-a3e3a787212d", "embedding": null, "metadata": {"page_label": "418", "file_name": "2023_20-21.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2023_20-21.pdf", "file_type": "application/pdf", "file_size": 1372902, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "d482a4d3-4034-4b44-a781-6c5c9e859994", "node_type": "4", "metadata": {"page_label": "418", "file_name": "2023_20-21.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2023_20-21.pdf", "file_type": "application/pdf", "file_size": 1372902, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "6ed8bd95b4e0ea773b79467364eecb135b0a55e21b39b6c35e7d644021a4a4b0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3d1796e4-2819-4f48-bf97-2c29ff8e59ae", "node_type": "1", "metadata": {}, "hash": "934c45c51831753470cf8597c671a3c020132385f42fae1e2a6160e8f6145b57", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "418 | 14 novembre 2023 | BEH 20-21 Diab\u00e8te en outre-mer : comprendre les sp\u00e9cificit\u00e9s locales pour cibler les actions\nTableau 2\nHistoire de la maladie et recours aux soins des personnes atteintes d'un diab\u00e8te de type 2 r\u00e9sidant dans les territoires\nd'outre-mer (Guadeloupe, Martinique, Guyane, La R\u00e9union) et dans l'Hexagone - Entred 3\nGuadeloupe Martinique Guyane La R\u00e9union\np-value\nHexagone\np-value% [IC95%] % [IC95%] % [IC95%] % [IC95%] % [IC95%]\nAnciennet\u00e9\nAnciennet\u00e9 moyenne (ans) 15,6 [14,4-16,8] 14,5 [13,6-15,4] 14,4 [13,4-15,4] 14,7 [13,8-15,5] 0,0535b 13,7 [13,3-14,2] <0,0001d\n\u00c2ge au diagnostic (moyenne) 52,0 [50,7-53,4] 52,2 [51,1-53,3] 46,7 [45,5-47,9] 48,1 [47,0-49,1] 0,0041b 53,8 [53,3-54,3] <0,0001d\nCirconstances de d\u00e9couverte du diab\u00e8te\nManquant 3,2 [1,6-5,6] 1,1 [0,4-2,1] 8,9 [6,4-12,0] 1,8 [0,9-3,3] <0,0001c 2,6 [1,9-3,5] <0,0001e\nComplications 6,2 [4,0-9,0] 3,2 [2,0-4,8] 8,7 [6,3-11,5] 7,8 [5,7-10,4] 11,4 [10,0-13,0]\nSympt\u00f4mes 16,3 [12,7-20,4] 16,8 [14,0-20,0] 23,4 [19,5-27,6] 14,4 [11,6-17,6] 17,8 [16,1-19,6]\nD\u00e9pistage 74,3 [69,6-78,6] 78,9 [75,6-82,0] 59,0 [54,2-63,7] 75,9 [72,2-79,5] 68,1 [66,0-70,2]\nTraitement\nADO seuls 61,5 [56,4-66,4] 61,1 [57,2-64,9] 57,5 [52,6-62,3] 65,2 [61,1-69,", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1220, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "3d1796e4-2819-4f48-bf97-2c29ff8e59ae": {"__data__": {"id_": "3d1796e4-2819-4f48-bf97-2c29ff8e59ae", "embedding": null, "metadata": {"page_label": "418", "file_name": "2023_20-21.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2023_20-21.pdf", "file_type": "application/pdf", "file_size": 1372902, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "d482a4d3-4034-4b44-a781-6c5c9e859994", "node_type": "4", "metadata": {"page_label": "418", "file_name": "2023_20-21.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2023_20-21.pdf", "file_type": "application/pdf", "file_size": 1372902, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "6ed8bd95b4e0ea773b79467364eecb135b0a55e21b39b6c35e7d644021a4a4b0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ed421f85-1279-41cd-bac4-a3e3a787212d", "node_type": "1", "metadata": {"page_label": "418", "file_name": "2023_20-21.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2023_20-21.pdf", "file_type": "application/pdf", "file_size": 1372902, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "535649a1af5de4727808682f986a490027cea45586e5e0ecd9ca95b2aa228e6d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "28a53ade-3861-4406-aa32-e358e5e55c13", "node_type": "1", "metadata": {}, "hash": "0be0ab4ac7852294b19ab33a83e598325133c40988c1e6b9667d6dd189d16068", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "0] 59,0 [54,2-63,7] 75,9 [72,2-79,5] 68,1 [66,0-70,2]\nTraitement\nADO seuls 61,5 [56,4-66,4] 61,1 [57,2-64,9] 57,5 [52,6-62,3] 65,2 [61,1-69,2] 0,0799c 71,2 [69,1-73,2] <0,0001e\nMetformine (seule ou associ\u00e9e) 75,9 [71,3-80,1] 74,3 [70,7-77,6] 80,6 [76,7-84,1] 82,1 [78,7-85,2] 0,1325c 81,6 [79,8-83,3] 0,0006e\nInsuline associ\u00e9e 27,6 [23,1-32,3] 24,7 [21,4-28,3] 32,5 [27,9-37,3] 21,7 [18,3-25,4] 0,0015c 18,0 [16,3-19,8] <0,0001e\nInsuline seule 7,0 [4,3-10,7] 7,8 [5,7-10,3] 4,2 [2,5-6,4] 6,2 [4,3-8,5] 0,5615c 4,5 [3,6-5,5] 0,0067e\naGLP1 (seul ou associ\u00e9 \u00e0 des ADO\nou de l'insuline)\n10,2 [7,5-13,3] 12,6 [10,1-15,4] 15,0 [11,6-18,9] 13,9 [11,2-17,0] 0,5617c 10,9 [9,6-12,3] 0,6925e\nTisanes\nRecours \u00e0 des tisanes 41,0 [36,2-46,0] 36,9 [33,1-40,8] 50,2 [45,3-55,2] 43,9 [39,7-48,2] 0,004c - -\nSi recours :\n\u00e0 la place des m\u00e9dicaments\n4,3 [1,7-8,7] 8,1 [5,0-12,3] 9,7 [5,8-15,0] 8,8 [5,6-13,1] 0,5104c - -\nen plus des m\u00e9dicaments 95,7 [91,3-98,3] 91,9 [87,7-95,0] 90,3 [85,0-94,2] 91,2 [86,9-94,4]\nPrise en charge m\u00e9dicale\nRemboursement pour une visite,", "mimetype": "text/plain", "start_char_idx": 1080, "end_char_idx": 2129, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "28a53ade-3861-4406-aa32-e358e5e55c13": {"__data__": {"id_": "28a53ade-3861-4406-aa32-e358e5e55c13", "embedding": null, "metadata": {"page_label": "418", "file_name": "2023_20-21.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2023_20-21.pdf", "file_type": "application/pdf", "file_size": 1372902, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "d482a4d3-4034-4b44-a781-6c5c9e859994", "node_type": "4", "metadata": {"page_label": "418", "file_name": "2023_20-21.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2023_20-21.pdf", "file_type": "application/pdf", "file_size": 1372902, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "6ed8bd95b4e0ea773b79467364eecb135b0a55e21b39b6c35e7d644021a4a4b0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3d1796e4-2819-4f48-bf97-2c29ff8e59ae", "node_type": "1", "metadata": {"page_label": "418", "file_name": "2023_20-21.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2023_20-21.pdf", "file_type": "application/pdf", "file_size": 1372902, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "10e635b98825608a7f347864be33c1e5e80f77f5bbfbc5426dd1c2a86635c4a6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "26720d43-e80a-41f5-9012-2c51e449a2cc", "node_type": "1", "metadata": {}, "hash": "4bbefd1aa260dded008356bb9fd511496ae8d66ee6bf82791f67589e2a3ed4a8", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "0] 8,8 [5,6-13,1] 0,5104c - -\nen plus des m\u00e9dicaments 95,7 [91,3-98,3] 91,9 [87,7-95,0] 90,3 [85,0-94,2] 91,2 [86,9-94,4]\nPrise en charge m\u00e9dicale\nRemboursement pour une visite,\nconsultation chez un m\u00e9decin g\u00e9n\u00e9raliste\n91,2 [87,3-94,3] 93,0 [90,8-94,9] 70,4 [65,8-74,8] 86,2 [83,0-89,0] <0,0001c 93,4 [92,2-94,5] <0,0001e\nchez un endocrinologue lib\u00e9ral\nou hospitalisation de jour\n18,5 [15,0-22,5] 18,9 [15,9-22,2] 18,3 [14,7-22,5] 15,4 [12,5-18,7] 0,2916c 21,5 [19,7-23,3] 0,0008e\nchez un cardiologue lib\u00e9ral\n39,1 [34,3-44,2] 31,5 [28,0-35,3] 35,9 [31,4-40,6] 51,8 [47,5-56,1] <0,0001c 45,7 [43,5-47,9] <0,0001e\nchez un ophtalmologue lib\u00e9ral\n56,5 [51,4-61,5] 57,3 [53,4-61,2] 37,2 [32,6-42,0] 45,6 [41,4-49,9] <0,0001c 55,4 [53,2-57,6] <0,0001e\nchez un chirurgien-dentiste ou stomatologue\nlib\u00e9ral ou en consultation externea\n29,6 [25,1-34,3] 29,2 [25,7-32,9] 27,8 [23,6-32,3] 36,1 [32,1-40,3] 0,0220c 40,0 [37,9-42,2] <0,0001e\nAu moins 3 dosages d'HbA1c en lib\u00e9ral\nou acte externea ou hospitalisation de jour\n53,8 [48,8-58,8] 46,6 [42,7-50,5] 39,0 [34,3-43,7] 51,1 [46,8-55,3] 0,0002c 58,3 [56,1-60,5] <0,0001e\nAu moins un dosage de microalbuminurie\nen lib\u00e9ral ou acte externea\nou hospitalisation de jour\n55,2 [50,1-60,2] 48,6 [44,", "mimetype": "text/plain", "start_char_idx": 1952, "end_char_idx": 3183, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "26720d43-e80a-41f5-9012-2c51e449a2cc": {"__data__": {"id_": "26720d43-e80a-41f5-9012-2c51e449a2cc", "embedding": null, "metadata": {"page_label": "418", "file_name": "2023_20-21.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2023_20-21.pdf", "file_type": "application/pdf", "file_size": 1372902, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "d482a4d3-4034-4b44-a781-6c5c9e859994", "node_type": "4", "metadata": {"page_label": "418", "file_name": "2023_20-21.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2023_20-21.pdf", "file_type": "application/pdf", "file_size": 1372902, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "6ed8bd95b4e0ea773b79467364eecb135b0a55e21b39b6c35e7d644021a4a4b0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "28a53ade-3861-4406-aa32-e358e5e55c13", "node_type": "1", "metadata": {"page_label": "418", "file_name": "2023_20-21.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2023_20-21.pdf", "file_type": "application/pdf", "file_size": 1372902, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "916cd5379c44c912ccfff65f73f86090e643c860880ad7ca13c287059f9c6aa3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ffb266a5-eb7f-4e01-94eb-104caef7754b", "node_type": "1", "metadata": {}, "hash": "6860b911113900a3d12308168f68fd1095fed180a68120873e5662d4a42050b4", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "5] 39,0 [34,3-43,7] 51,1 [46,8-55,3] 0,0002c 58,3 [56,1-60,5] <0,0001e\nAu moins un dosage de microalbuminurie\nen lib\u00e9ral ou acte externea\nou hospitalisation de jour\n55,2 [50,1-60,2] 48,6 [44,7-52,6] 47,7 [42,8-52,6] 57,8 [53,6-62,0] 0,0012c 42,6 [40,5-44,8] <0,0001e\nAu moins un dosage des anomalies\nlipidiques en lib\u00e9ral ou acte externea\n79,6 [75,0-83,6] 76,6 [73,0-79,9] 73,5 [68,6-77,9] 80,3 [76,7-83,6] 0,0694c 79,2 [77,3-81,0] 0,0605e\nParle dans une autre langue que le fran\u00e7ais avec son m\u00e9decin\nOui 38,0 [33,1-43,1] 21,7 [18,5-25,1] 21,2 [17,7-25,2] 71,0 [66,9-74,8] <0,0001c - -\nIC95% : intervalle de confiance \u00e0 95% ; ADO : anti-diab\u00e9tiques oraux ; aGLP1 : agonistes du r\u00e9cepteur du glucagon-like-peptide-1.\na actes/consultations externes : actes/consultations r\u00e9alis\u00e9s en ambulatoire par les praticiens exer\u00e7ant dans les h\u00f4pitaux et sont imput\u00e9s sur\nles enveloppes de d\u00e9penses hospitali\u00e8res.\nb p-value du test de comparaison des 4 DROM issu d'un mod\u00e8le de r\u00e9gression lin\u00e9aire ajust\u00e9 sur le sexe et l'\u00e2ge.\nc p-value du test de comparaison des 4 DROM issu d'un mod\u00e8le de r\u00e9gression logistique ajust\u00e9 sur le sexe et l'\u00e2ge.\nd p-value du test de comparaison des 5 territoires issu d'un mod\u00e8le de r\u00e9gression lin\u00e9aire ajust\u00e9 sur le sexe et l'\u00e2ge.\ne p-value du test de comparaison des 5 territoires issu d'un mod\u00e8le de r\u00e9gression logistique ajust\u00e9 sur le sexe et l'\u00e2ge.\nNote de lecture : 18,5% (IC95%: [15,0-22,5]) des personnes diab\u00e9tiques de type 2 r\u00e9sidant en Guadeloupe avaient consult\u00e9 au moins une fois\nun endocrinologue au cours des 12 mois pr\u00e9c\u00e9dant le tirage au sort. Apr\u00e8s ajustement sur le sexe et l'\u00e2ge des personnes, la p-value du test\nde comparaison entre les DROM \u00e9tait non-significative (0,2916).", "mimetype": "text/plain", "start_char_idx": 2992, "end_char_idx": 4705, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "ffb266a5-eb7f-4e01-94eb-104caef7754b": {"__data__": {"id_": "ffb266a5-eb7f-4e01-94eb-104caef7754b", "embedding": null, "metadata": {"page_label": "418", "file_name": "2023_20-21.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2023_20-21.pdf", "file_type": "application/pdf", "file_size": 1372902, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "d482a4d3-4034-4b44-a781-6c5c9e859994", "node_type": "4", "metadata": {"page_label": "418", "file_name": "2023_20-21.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2023_20-21.pdf", "file_type": "application/pdf", "file_size": 1372902, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "6ed8bd95b4e0ea773b79467364eecb135b0a55e21b39b6c35e7d644021a4a4b0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "26720d43-e80a-41f5-9012-2c51e449a2cc", "node_type": "1", "metadata": {"page_label": "418", "file_name": "2023_20-21.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2023_20-21.pdf", "file_type": "application/pdf", "file_size": 1372902, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "a35756b615ed01a5855b1e94f2a899b163a96a82523426cdb22c48a45cb8b7ca", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Apr\u00e8s ajustement sur le sexe et l'\u00e2ge des personnes, la p-value du test\nde comparaison entre les DROM \u00e9tait non-significative (0,2916). Apr\u00e8s ajustement sur le sexe et l'\u00e2ge des personnes, la p-value du test de comparaison\nentre les 5 territoires, incluant l'Hexagone, \u00e9tait significative (0,0008).", "mimetype": "text/plain", "start_char_idx": 4570, "end_char_idx": 4868, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "9e91a6eb-4572-4da5-a272-024090f74374": {"__data__": {"id_": "9e91a6eb-4572-4da5-a272-024090f74374", "embedding": null, "metadata": {"page_label": "419", "file_name": "2023_20-21.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2023_20-21.pdf", "file_type": "application/pdf", "file_size": 1372902, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "b1cb14d6-ae35-4f96-9313-019e65289ce6", "node_type": "4", "metadata": {"page_label": "419", "file_name": "2023_20-21.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2023_20-21.pdf", "file_type": "application/pdf", "file_size": 1372902, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "c168a8d3ba99c8855103d9bfba6ca7c24c7ecac74d1c8c0902d269c6788b0181", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c33930e5-fd98-49d9-9322-03ab6fc6c192", "node_type": "1", "metadata": {}, "hash": "a8a5ccbfcbc14d3bd25f9ee3b5dbda9550f93f175dab337e6da53c5bde8e3855", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Diab\u00e8te en outre-mer : comprendre les sp\u00e9cificit\u00e9s locales pour cibler les actions BEH 20-21 | 14 novembre 2023 | 419\nLe respect des 3 dosages annuels d'HbA1c re -\ncommand\u00e9s dans le cadre du suivi du diab\u00e8te variait\n\u00e9galement selon les territoires, de 39% en Guyane\n\u00e0 54% en Guadeloupe, et 58% dans l'Hex agone. Le\ndosage de la microalbuminurie \u00e9tait plus fr\u00e9quem -\nment respect\u00e9 dans tous les territoires ultramarins,\nnotamment \u00e0 La R\u00e9union (58%) et en Guadeloupe\n(55%), que dans l'Hexagone (43%).\nFacteurs de risque\nQuand il \u00e9tait rapport\u00e9, l'IMC moyen \u00e9tait moins \u00e9lev\u00e9\n\u00e0 La R\u00e9union (27,7 kg/m2), en Guyane et Guadeloupe\n(28,4 kg/m 2) qu'en Martinique (29,3 kg/m 2) et dans\nl'Hexagone (29,5 kg/m 2) (tableau 3). Toutefois, une\nfr\u00e9quence \u00e9lev\u00e9e de personnes n'ava it pas connais -\nsance de leur poids et/ou de leur taille (27% en\nGuyane, 15% en Guadeloupe, 10% \u00e0 La R\u00e9union et\n9% en Martinique). Un tabagisme actuel (quotidien\nou occasionnel) \u00e9tait le plus fr\u00e9quemment rapport\u00e9\n\u00e0 La R\u00e9union (14%), plus fr\u00e9quent que dans l'Hex agone (13%) ou en Guadeloupe (8,5%). Ce taux\n\u00e9tait moindre en Martinique (5%) et en Guyane\n(3%). Globalement, la cons ommation d'alcool\n\u00e9tait moindre dans les 4 DROM que dans l'Hex agone. La cons ommation \u00e9lev\u00e9e ou s\u00e9v\u00e8re conc ernait 7% des personnes r\u00e9sidant dans l'Hex agone,\n3% \u00e0 La R\u00e9union, 2,5% en Martinique et 1,4% en\nGuadeloupe et Guyane.\nDes diff\u00e9rences significatives d'aut o-d\u00e9claration\nd'une hypertension art\u00e9rielle \u00e9taient \u00e0 noter selon les\nterritoires, avec des taux variant de 44% en Guyane\n\u00e0 66% \u00e0 La R\u00e9union. Quant aux remboursements\nde traitements antihypertenseurs, les taux \u00e9taient\nsyst\u00e9matiquement plus \u00e9lev\u00e9s (>75%) et ne variaient\npas de fa\u00e7on significative. Les valeurs moyennes de\npression art\u00e9rielle ne diff\u00e9raient pas significative -\nment entre les territoires ultramarins mais \u00e9taient\nsignificativement plus \u00e9lev\u00e9es que dans l'Hex agone.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1894, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "c33930e5-fd98-49d9-9322-03ab6fc6c192": {"__data__": {"id_": "c33930e5-fd98-49d9-9322-03ab6fc6c192", "embedding": null, "metadata": {"page_label": "419", "file_name": "2023_20-21.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2023_20-21.pdf", "file_type": "application/pdf", "file_size": 1372902, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "b1cb14d6-ae35-4f96-9313-019e65289ce6", "node_type": "4", "metadata": {"page_label": "419", "file_name": "2023_20-21.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2023_20-21.pdf", "file_type": "application/pdf", "file_size": 1372902, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "c168a8d3ba99c8855103d9bfba6ca7c24c7ecac74d1c8c0902d269c6788b0181", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9e91a6eb-4572-4da5-a272-024090f74374", "node_type": "1", "metadata": {"page_label": "419", "file_name": "2023_20-21.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2023_20-21.pdf", "file_type": "application/pdf", "file_size": 1372902, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "17edfbf6ed21e61b86ce77d5a5645a49ce1741df10c43417095d601ea41a4048", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8f7b14b2-880f-4431-84a8-5a1e7157c853", "node_type": "1", "metadata": {}, "hash": "280459d1255558e02927521c0d677ca93ffd14470862c00d8bfec306b3b62dcd", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Quant aux remboursements\nde traitements antihypertenseurs, les taux \u00e9taient\nsyst\u00e9matiquement plus \u00e9lev\u00e9s (>75%) et ne variaient\npas de fa\u00e7on significative. Les valeurs moyennes de\npression art\u00e9rielle ne diff\u00e9raient pas significative -\nment entre les territoires ultramarins mais \u00e9taient\nsignificativement plus \u00e9lev\u00e9es que dans l'Hex agone.\nL 'autod\u00e9claration d'une dyslipid\u00e9mie et les rembour -\nsements de traitement hypolip\u00e9miant variaient selon\nles territoires (autod\u00e9claration : 29% en Guyane\n\u00e0 56% \u00e0 La R\u00e9union et 59% dans l'Hexagone ; traitements : de 42% en Guyane \u00e0 54% en Guadeloupe et\n64% dans l'Hexagone).\nEnfin, concernant l'\u00e9quilibre glyc\u00e9mique, le niveau\nmoyen d'HbA1c \u00e9tait plus faible aux Antilles (7,4%\nen Guadeloupe et 7,5% en Martinique), par rapport\n\u00e0 la Guyane (8,0%) et \u00e0 La R\u00e9union (7,7%), sans que\nla diff\u00e9rence entre les territoires ultramarins ne soit\nsignificative. Cependant, une diff\u00e9rence significative\nselon les territoires \u00e9tait observ\u00e9e apr\u00e8s l'ajo ut de\nl'Hexagone o\u00f9 la valeur moyenne d'HbA1c \u00e9tait plus\nfaible (7,2%).\nComplications\nLa fr\u00e9quence des complications chroniques du dia b\u00e8te\nvariait de fa\u00e7on significative entre les DROM et avec\nl'Hexagone, \u00e0 l'exception des complications podologiques et r\u00e9nales (tableau 4). Elles \u00e9taient sup\u00e9rieures\n\u00e0 La R\u00e9union. Concernant les complications coronariennes autod\u00e9clar\u00e9es ou les ant\u00e9c\u00e9dents d'hospitalisations pour infarctus du myocarde, les fr\u00e9quences\n\u00e9taient proches entre La R\u00e9union et l'Hex agone et\nmoindres dans les trois autres territoires ultramarins.\nPour les hospitalisations pour AVC, m\u00eame si la pr\u00e9valence restait sup\u00e9rieure \u00e0 La R\u00e9union, la diff\u00e9rence\nentre les territoires ultra marins dans leur ensemble\nn'\u00e9tait pas statistiquement significative. En revanche,\nla diff\u00e9rence devenait significative apr\u00e8s l'int \u00e9gration de l'Hex agone dans la comparaison, avec une\nvaleur plus faible dans l'Hexagone. Les comp lications ophtalmo logiques variaient \u00e9galement signi -\nficativement entre les territoires avec globalement\ndes fr\u00e9quences plus faibles dans l'Hex agone et en\nGuyane pour certains indicateurs de comp lications\n(perte de la vue d'un \u0153il, traitement au laser).", "mimetype": "text/plain", "start_char_idx": 1555, "end_char_idx": 3717, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "8f7b14b2-880f-4431-84a8-5a1e7157c853": {"__data__": {"id_": "8f7b14b2-880f-4431-84a8-5a1e7157c853", "embedding": null, "metadata": {"page_label": "419", "file_name": "2023_20-21.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2023_20-21.pdf", "file_type": "application/pdf", "file_size": 1372902, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "b1cb14d6-ae35-4f96-9313-019e65289ce6", "node_type": "4", "metadata": {"page_label": "419", "file_name": "2023_20-21.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2023_20-21.pdf", "file_type": "application/pdf", "file_size": 1372902, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "c168a8d3ba99c8855103d9bfba6ca7c24c7ecac74d1c8c0902d269c6788b0181", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c33930e5-fd98-49d9-9322-03ab6fc6c192", "node_type": "1", "metadata": {"page_label": "419", "file_name": "2023_20-21.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2023_20-21.pdf", "file_type": "application/pdf", "file_size": 1372902, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "4f0d88a842065ff8e765dc6b7e1f5b63d7a956d0451a72345cca441d90724bf3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c91cd50a-7c10-4140-9eb6-7a231676ef36", "node_type": "1", "metadata": {}, "hash": "7c765e23a5a39f19ed63006840dd554dcf8f7e4776667fcb7da65118c5560704", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Les comp lications ophtalmo logiques variaient \u00e9galement signi -\nficativement entre les territoires avec globalement\ndes fr\u00e9quences plus faibles dans l'Hex agone et en\nGuyane pour certains indicateurs de comp lications\n(perte de la vue d'un \u0153il, traitement au laser).\nDiscussion\nPour la premi\u00e8re fois, l'\u00e9tude Entred avait parmi ses\nobjectifs principaux la description des caract\u00e9ris -\ntiques d\u00e9mographiques et socio-\u00e9conomiques, de\nl'\u00e9tat de sant\u00e9 et du recours aux soins des personnes\ndiab\u00e9tiques r\u00e9sidant dans les DROM. Ces terri -\ntoires n'ont pas pu \u00eatre inclus dans la premi\u00e8re\n\u00e9dition d'Entred en 2001. Dans la seconde men\u00e9e\nen 2007, un \u00e9chantillon de personnes diab\u00e9tiques\nr\u00e9sidant dans les DROM avait \u00e9t\u00e9 inclus mais sans\nsur \u00e9chantillonnage. Le recueil de donn\u00e9es \u00e9tait\n\u00e9galement limit\u00e9 \u00e0 un questionnaire t\u00e9l\u00e9phonique\ncourt (sans distinction possible entre les Antilles et\nla Guyane) et \u00e0 des donn\u00e9es m\u00e9dicales uniquement\n\u00e0 La R\u00e9union 6. Les \u00e9tudes locales 7,8 et les donn\u00e9es\nnationales du SNDS (1) 9 ont aid\u00e9 \u00e0 d\u00e9crire le fardeau\ndu diab\u00e8te dans les DROM. Inclure cet objectif\ndans la 3 e \u00e9dition d'Entred \u00e9tait donc une priorit\u00e9.\nPour y r\u00e9pondre, la m\u00e9thodologie a \u00e9t\u00e9 adapt\u00e9e\npour obtenir des donn\u00e9es de qualit\u00e9 et dresser un\n\u00e9tat des lieux de chaque territoire et de leurs parti -\ncularit\u00e9s. Un sur\u00e9chantillonnage a \u00e9t\u00e9 r\u00e9alis\u00e9 pour\naugmenter la taille des \u00e9chantillons et donc la puis -\nsance statistique. Les outils de collecte d'inf ormations ont \u00e9t\u00e9 adapt\u00e9s, notamment en recourant \u00e0 des\nentretiens en face-\u00e0-face men\u00e9s par des enqu\u00eateurs\ncr\u00e9olophones ou ma\u00eetrisant les principales langues\net dialectes. Les acteurs locaux ont \u00e9t\u00e9 impliqu\u00e9s\ndans les diff\u00e9rentes \u00e9tapes de l'enqu\u00eate. Gr\u00e2ce \u00e0 ces\nadaptations et probablement \u00e0 une sensibilisation\nparticuli\u00e8re \u00e0 la probl\u00e9matique du diab\u00e8te dans ces\nterritoires, les taux de participation des personnes\ndiab\u00e9tiques (de 52% \u00e0 72%) \u00e9taient nettement sup\u00e9rieurs \u00e0 ceux de l'Hex agone (36%).\nUn premier constat porte sur les sp\u00e9cificit\u00e9s d\u00e9mographiques et socio-\u00e9conomiques des r\u00e9sidents ultramarins. La pr\u00e9dominance f\u00e9minine, d\u00e9crite au paravant 6,9,\ndiff\u00e8re de l'Hex agone. En outre, si l'\u00e2ge moyen aux\nAntilles \u00e9tait proche de celui dans l'Hex agone,\nles r\u00e9sidents de Guyane et de La R\u00e9union \u00e9taient plus\njeunes, avec un \u00e2ge au diagnostic du diab\u00e8te environ\n5 ans plus jeune.", "mimetype": "text/plain", "start_char_idx": 3450, "end_char_idx": 5790, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "c91cd50a-7c10-4140-9eb6-7a231676ef36": {"__data__": {"id_": "c91cd50a-7c10-4140-9eb6-7a231676ef36", "embedding": null, "metadata": {"page_label": "419", "file_name": "2023_20-21.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2023_20-21.pdf", "file_type": "application/pdf", "file_size": 1372902, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "b1cb14d6-ae35-4f96-9313-019e65289ce6", "node_type": "4", "metadata": {"page_label": "419", "file_name": "2023_20-21.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2023_20-21.pdf", "file_type": "application/pdf", "file_size": 1372902, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "c168a8d3ba99c8855103d9bfba6ca7c24c7ecac74d1c8c0902d269c6788b0181", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8f7b14b2-880f-4431-84a8-5a1e7157c853", "node_type": "1", "metadata": {"page_label": "419", "file_name": "2023_20-21.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2023_20-21.pdf", "file_type": "application/pdf", "file_size": 1372902, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "8027710fb811041fe3722d5579897d205cb0a6628ba73551ada703bfcb27d5ab", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "La pr\u00e9dominance f\u00e9minine, d\u00e9crite au paravant 6,9,\ndiff\u00e8re de l'Hex agone. En outre, si l'\u00e2ge moyen aux\nAntilles \u00e9tait proche de celui dans l'Hex agone,\nles r\u00e9sidents de Guyane et de La R\u00e9union \u00e9taient plus\njeunes, avec un \u00e2ge au diagnostic du diab\u00e8te environ\n5 ans plus jeune. Par ailleurs, les indicateurs de niveau\nsocio-\u00e9conomique refl\u00e8tent une population plus\nd\u00e9favoris\u00e9e, notamment en Guyane et \u00e0 La R\u00e9union,\navec des fr\u00e9quences \u00e9le v\u00e9es de personnes n'aya nt\n(1)", "mimetype": "text/plain", "start_char_idx": 5513, "end_char_idx": 5982, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "a6490233-bb34-4703-9dd0-0ed6723205af": {"__data__": {"id_": "a6490233-bb34-4703-9dd0-0ed6723205af", "embedding": null, "metadata": {"page_label": "420", "file_name": "2023_20-21.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2023_20-21.pdf", "file_type": "application/pdf", "file_size": 1372902, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "15eaeebb-8425-4573-b4f8-ad5506a004d8", "node_type": "4", "metadata": {"page_label": "420", "file_name": "2023_20-21.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2023_20-21.pdf", "file_type": "application/pdf", "file_size": 1372902, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "2a5e4c39827720c8db8079342a3378cbb9203925d2c67655b965ed30cd38648d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "dcfbfebf-4e80-41b2-b100-4cbab2852b38", "node_type": "1", "metadata": {}, "hash": "3d3730648228f25033ab140abe93f9b4e540ae3ff9c7f0cf4a2eb79d8addb8bc", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "420 | 14 novembre 2023 | BEH 20-21 Diab\u00e8te en outre-mer : comprendre les sp\u00e9cificit\u00e9s locales pour cibler les actions\nTableau 3\nFacteurs de risque de complications des personnes atteintes d'un diab\u00e8te de type 2 r\u00e9sidant dans les territoires d'outre-mer (Guadeloupe, Martinique, Guyane, La R\u00e9union) et dans l'Hexagone -\nEntred 3\nGuadeloupe Martinique Guyane La R\u00e9union p-value Hexagone p-value% [IC95%] % [IC95%] % [IC95%] % [IC95%] % [IC95%]\nCorpulence auto-d\u00e9clar\u00e9e\nTaille et/ou poids m\u00e9connu par la personne diab\u00e9tique 14,5 [11,0-18,5] 9,2 [7,1-11,8] 27,1 [22,9-31,6] 9,7 [7,3-12,5] <0,0001d 2,9 [2,1-3,7] <0,0001f\nIMCa moyen (kg/m\u00b2) 28,4 [27,9-28,9] 29,3 [28,8-29,8] 28,4 [27,7-29,1] 27,7 [27,2-28,1] <0,0001e 29,5 [29,2-29,7] <0,0001g\nIMCa Manquant 9,3 [6,4-12,8] 6,9 [5,1-9,1] 25,4 [21,3-29,9] 6,5 [4,5-8,9] 2,9 [2,1-3,7]\nNormala (<25 kg/m\u00b2) 29,2 [24,6-34,1] 21,8 [18,7-25,1] 22,1 [18,4-26,2] 31,9 [28,0-35,9] <0,0001d 19,3 [17,6-21,1] <0,0001f\nSurpoidsa (25-29 kg/m\u00b2) 29,9 [25,6-34,6] 33,2 [29,6-37,0] 27,7 [23,5-32,2] 34,6 [30,6-38,7] 38,8 [36,7-40,9]\nOb\u00e9sit\u00e9a (\u226530 kg/m\u00b2) 31,6 [27,1-36,4] 38,2 [34,4-42,1] 24,8 [20,5-29,4] 27,1 [23,4-31,0] 39,0 [37,0-41,1]\nChirurgie bariatrique 0,5 [0,09-1,7] 1,0 [0,4-2,2] 0,4 [0,04-1,8] 0,", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1233, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "dcfbfebf-4e80-41b2-b100-4cbab2852b38": {"__data__": {"id_": "dcfbfebf-4e80-41b2-b100-4cbab2852b38", "embedding": null, "metadata": {"page_label": "420", "file_name": "2023_20-21.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2023_20-21.pdf", "file_type": "application/pdf", "file_size": 1372902, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "15eaeebb-8425-4573-b4f8-ad5506a004d8", "node_type": "4", "metadata": {"page_label": "420", "file_name": "2023_20-21.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2023_20-21.pdf", "file_type": "application/pdf", "file_size": 1372902, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "2a5e4c39827720c8db8079342a3378cbb9203925d2c67655b965ed30cd38648d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a6490233-bb34-4703-9dd0-0ed6723205af", "node_type": "1", "metadata": {"page_label": "420", "file_name": "2023_20-21.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2023_20-21.pdf", "file_type": "application/pdf", "file_size": 1372902, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "bbd0f6c0675650dfdd08fa688d05c5d802d08ace55b14e532eade83763628e0a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "11be1cfb-f293-4ef4-8095-b3f325bc0d3c", "node_type": "1", "metadata": {}, "hash": "ee979a0b747866972ba732742ebd55f00caada5978bab67ce7264e9ee32bd7cc", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "2 [34,4-42,1] 24,8 [20,5-29,4] 27,1 [23,4-31,0] 39,0 [37,0-41,1]\nChirurgie bariatrique 0,5 [0,09-1,7] 1,0 [0,4-2,2] 0,4 [0,04-1,8] 0,3 [0,02-1,1] 0,3411d 0,8 [0,5-1,3] 0,4649f\n\u00c9quilibre glyc\u00e9mique\nHbA1c moyenne (%) 7,4 [7,1-7,6] 7,5 [7,2-7,8] 8,0 [7,4-8,5] 7,7 [7,5-7,9] 0,2332e 7,2 [7,1-7,2] <0,0001g\nHbA1c>8% 19,0 [12,5-27,1] 26,6 [19,4-35,0] 34,2 [22,1-48,0] 29,8 [23,9-36,1] 0,1672d 17,5 [14,9-20,3] 0,001f\nHypertension art\u00e9rielle\nHypertension art\u00e9rielle auto-d\u00e9clar\u00e9e 60,1 [55,1-65,0] 60,9 [56,9-64,7] 43,8 [39,0-48,7] 65,9 [61,8-69,9] <0,0001d 61,1 [58,9-63,3] <0,0001f\nTraitement antihypertenseur rembours\u00e9 dans les 12 mois 78,2 [73,9-82,2] 78,1 [74,6-81,4] 76,3 [71,6-80,5] 77,2 [73,4-80,7] 0,1901d 77,6 [75,8-79,4] 0,0532f\nPression Art\u00e9rielle Syst\u00e9mique moyenne (mmHg) 136,8 [133,1-140,5] 136,5 [133,7-139,3] 136,2 [132,7-139,6] 134,6 [132,6-136,5] 0,6392e 132,7 [131,8-133,5] 0,0010g\nPression Art\u00e9rielle Diastolique moyenne (mmHg) 79,2 [77,7-80,7] 79,1 [76,9-81,3] 79,2 [76,0-82,4] 77,7 [76,3-79,2] 0,3107e 75,9 [75,3-76,5] <0,", "mimetype": "text/plain", "start_char_idx": 1100, "end_char_idx": 2137, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "11be1cfb-f293-4ef4-8095-b3f325bc0d3c": {"__data__": {"id_": "11be1cfb-f293-4ef4-8095-b3f325bc0d3c", "embedding": null, "metadata": {"page_label": "420", "file_name": "2023_20-21.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2023_20-21.pdf", "file_type": "application/pdf", "file_size": 1372902, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "15eaeebb-8425-4573-b4f8-ad5506a004d8", "node_type": "4", "metadata": {"page_label": "420", "file_name": "2023_20-21.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2023_20-21.pdf", "file_type": "application/pdf", "file_size": 1372902, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "2a5e4c39827720c8db8079342a3378cbb9203925d2c67655b965ed30cd38648d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "dcfbfebf-4e80-41b2-b100-4cbab2852b38", "node_type": "1", "metadata": {"page_label": "420", "file_name": "2023_20-21.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2023_20-21.pdf", "file_type": "application/pdf", "file_size": 1372902, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "6aae8ef18f94fc674928d5dadb2377328aee69c748472f22750da9819d8e4c3b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c21f7c64-5ebe-4898-9c4f-afc31baf427a", "node_type": "1", "metadata": {}, "hash": "e6a20bd63a9dc56a563dae998b1b60787f45a99c07c0f1808a772f8c18825d1d", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "5] 0,0010g\nPression Art\u00e9rielle Diastolique moyenne (mmHg) 79,2 [77,7-80,7] 79,1 [76,9-81,3] 79,2 [76,0-82,4] 77,7 [76,3-79,2] 0,3107e 75,9 [75,3-76,5] <0,0001g\nDyslipid\u00e9mie\nDyslipid\u00e9mie auto-d\u00e9clar\u00e9e 39,1 [34,3-44,1] 41,4 [37,5-45,3] 29,2 [24,9-33,7] 56,3 [52,1-60,5] <0,0001d 58,8 [56,5-61,0] <0,0001f\nTraitement hypolip\u00e9miant rembours\u00e9 dans les 12 mois 54,4 [49,3-59,3] 48,1 [44,2-52,0] 41,8 [37,1-46,6] 53,4 [49,1-57,6] 0,0027d 63,8 [61,7-65,9] <0,0001f\nLDL-Cholest\u00e9rol moyen (g/L)b 0,97 [0,91-1,03] 1,00 [0,93-1,07] 1,16 [1,07-1,26] 0,93 [0,88-0,98] 0,0002e 0,98 [0,95-1,00] 0,0005g\nTriglyc\u00e9rides moyennes (g/L)c 1,16 [1,03-1,28] 1,13 [1,04-1,23] 1,27 [1,15-1,39] 1,41 [1,29-1,53] 0,0021e 1,57 [1,50-1,65] <0,0001g\nTabagisme\nTabagisme actuel 8,5 [5,9-11,8] 4,8 [3,3-6,9] 3,3 [1,6-6,2] 14,4 [11,6-17,6] <0,0001d 13,4 [11,9-14,9] <0,0001f\nConsommation d'alcool (Audit-C) 0,0369d <0,0001f\nFaible 90,6 [87,2-93,3] 90,5 [88,0-92,7] 94,5 [91,4-96,8] 85,8 [82,6-88,7] 76,0 [74,0-77,9]\nMod\u00e9r\u00e9e 8,0 [5,6-11,2] 7,0 [5,1-9,2] 4,1 [2,1-6,9] 11,0 [8,5-14,", "mimetype": "text/plain", "start_char_idx": 1983, "end_char_idx": 3029, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "c21f7c64-5ebe-4898-9c4f-afc31baf427a": {"__data__": {"id_": "c21f7c64-5ebe-4898-9c4f-afc31baf427a", "embedding": null, "metadata": {"page_label": "420", "file_name": "2023_20-21.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2023_20-21.pdf", "file_type": "application/pdf", "file_size": 1372902, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "15eaeebb-8425-4573-b4f8-ad5506a004d8", "node_type": "4", "metadata": {"page_label": "420", "file_name": "2023_20-21.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2023_20-21.pdf", "file_type": "application/pdf", "file_size": 1372902, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "2a5e4c39827720c8db8079342a3378cbb9203925d2c67655b965ed30cd38648d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "11be1cfb-f293-4ef4-8095-b3f325bc0d3c", "node_type": "1", "metadata": {"page_label": "420", "file_name": "2023_20-21.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2023_20-21.pdf", "file_type": "application/pdf", "file_size": 1372902, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "32e46b3103a39e6568267cbd2276b10ad9453e0864f508a2276b0a19599e20b5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a4e8da5e-065a-4439-b902-ccd022ae5dd0", "node_type": "1", "metadata": {}, "hash": "41a065190c09146ab0c313c6a058543977ad82cf04d0a86b9d59e5209c981229", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "0-92,7] 94,5 [91,4-96,8] 85,8 [82,6-88,7] 76,0 [74,0-77,9]\nMod\u00e9r\u00e9e 8,0 [5,6-11,2] 7,0 [5,1-9,2] 4,1 [2,1-6,9] 11,0 [8,5-14,0] 17,0 [15,4-18,8]\n\u00c9lev\u00e9e 0,7 [0,1-2,0] 1,9 [1,0-3,2] 0,9 [0,2-2,7] 2,0 [1,0-3,6] 4,7 [3,8-5,7]\nS\u00e9v\u00e8re 0,7 [0,08-2,5] 0,6 [0,2-1,5] 0,5 [0,09-1,7] 1,2 [0,4-2,4] 2,3 [1,7-3,0]\nIC95% : intervalle de confiance \u00e0 95% ; IMC : indice de masse corporelle.\na Pour les DROM, en cas de poids ou taille manquant, ne permettant pas le calcul de l'IMC auto-d\u00e9clar\u00e9, la valeur a \u00e9t\u00e9 imput\u00e9e par la valeur recueillie par le m\u00e9decin si celle-ci \u00e9tait disponible.\nb 16,9%, 22,3%, 13,0%, 6,6% et 13,1% de donn\u00e9es manquantes pour respectivement La Guadeloupe, La Martinique, La Guyane, La R\u00e9union et l'Hexagone.\nc 22,3%, 27,6%, 17,7%, 7,0% et 13,7% de donn\u00e9es manquantes pour respectivement La Guadeloupe, La Martinique, La Guyane, La R\u00e9union et l'Hexagone.\nd p-value du test de comparaison des 4 DROM issu d'un mod\u00e8le de r\u00e9gression logistique ajust\u00e9 sur le sexe et l'\u00e2ge.\ne p-value du test de comparaison des 4 DROM issu d'un mod\u00e8le de r\u00e9gression lin\u00e9aire ajust\u00e9 sur le sexe et l'\u00e2ge.\nf p-value du test de comparaison des 5 territoires issu d'un mod\u00e8le de r\u00e9gression logistique ajust\u00e9 sur le sexe et l'\u00e2ge.\ng p-value du test de comparaison des 5 territoires issu d'un mod\u00e8le de r\u00e9gression lin\u00e9aire ajust\u00e9 sur le sexe et l'\u00e2ge.\nNote de lecture : L'HbA1c moyenne des personnes atteintes d'un diab\u00e8te de type 2 r\u00e9sidant en Guadeloupe \u00e9tait de 7,4%. Apr\u00e8s ajustement sur le sexe et l'\u00e2ge des personnes, la p-value du test de comparaison entre les DROM \u00e9tait\nnon-significative (0,2332).", "mimetype": "text/plain", "start_char_idx": 2906, "end_char_idx": 4493, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "a4e8da5e-065a-4439-b902-ccd022ae5dd0": {"__data__": {"id_": "a4e8da5e-065a-4439-b902-ccd022ae5dd0", "embedding": null, "metadata": {"page_label": "420", "file_name": "2023_20-21.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2023_20-21.pdf", "file_type": "application/pdf", "file_size": 1372902, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "15eaeebb-8425-4573-b4f8-ad5506a004d8", "node_type": "4", "metadata": {"page_label": "420", "file_name": "2023_20-21.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2023_20-21.pdf", "file_type": "application/pdf", "file_size": 1372902, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "2a5e4c39827720c8db8079342a3378cbb9203925d2c67655b965ed30cd38648d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c21f7c64-5ebe-4898-9c4f-afc31baf427a", "node_type": "1", "metadata": {"page_label": "420", "file_name": "2023_20-21.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2023_20-21.pdf", "file_type": "application/pdf", "file_size": 1372902, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "ace5f4cb8f7873f211485b0fb248fdf1e6f40ccbcd1eb3852868f53e102156ae", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Note de lecture : L'HbA1c moyenne des personnes atteintes d'un diab\u00e8te de type 2 r\u00e9sidant en Guadeloupe \u00e9tait de 7,4%. Apr\u00e8s ajustement sur le sexe et l'\u00e2ge des personnes, la p-value du test de comparaison entre les DROM \u00e9tait\nnon-significative (0,2332). Apr\u00e8s ajustement sur le sexe et l'\u00e2ge des personnes, la p-value du test de comparaison entre les 5 territoires, incluant l'Hexagone, \u00e9tait significative (<0,0001).", "mimetype": "text/plain", "start_char_idx": 4239, "end_char_idx": 4657, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "662d137a-a681-43fe-8402-1c086d498576": {"__data__": {"id_": "662d137a-a681-43fe-8402-1c086d498576", "embedding": null, "metadata": {"page_label": "421", "file_name": "2023_20-21.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2023_20-21.pdf", "file_type": "application/pdf", "file_size": 1372902, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "0b3fd5bd-b588-44f3-85d3-3e8bf2656b50", "node_type": "4", "metadata": {"page_label": "421", "file_name": "2023_20-21.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2023_20-21.pdf", "file_type": "application/pdf", "file_size": 1372902, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "bbe6ab53c9105e5cbc856553cb802afa7191bc07405f54aaa0ae446060f28b01", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "42226b1b-aea4-4a7d-96f5-be3250d84dda", "node_type": "1", "metadata": {}, "hash": "8dfc2918d26b2137e4f77e9ff8809322051187225e477009b2f435a25232cbb0", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Diab\u00e8te en outre-mer : comprendre les sp\u00e9cificit\u00e9s locales pour cibler les actions BEH 20-21 | 14 novembre 2023 | 421\njamais \u00e9t\u00e9 scolaris\u00e9es et de personnes n'ayant jamais\ntravaill\u00e9. La fr\u00e9quence de personnes b\u00e9n\u00e9ficiant de\nla CMU-C y est \u00e9galement beaucoup plus \u00e9lev\u00e9e.\nL 'impact de ces in\u00e9galit\u00e9s sociales tr\u00e8s marqu\u00e9es sur\nl'\u00e9tat de sant\u00e9 des personnes atteintes d'un diab\u00e8te ,\nen lien avec le recours aux soins, m\u00e9ritera de faire\nl'objet d'une \u00e9tude sp\u00e9cifique. La Guyane se diff\u00e9 -\nrencie \u00e9galement des autres territoires ultramarins\npar la fr\u00e9quence de personnes ayant un DT2 n\u00e9es\n\u00e0 l'\u00e9tranger qui conc erne plus d'une personne sur\ndeux, notamment n\u00e9es \u00e0 Ha\u00efti. Cette proportion,\nsup\u00e9rieure \u00e0 celle observ\u00e9e en population g\u00e9n\u00e9rale 10\nlaisse supposer une pr\u00e9valence du DT2 tr\u00e8s \u00e9lev\u00e9e\nau sein de cette communaut\u00e9.\nEn termes de description de l'\u00e9ta t de sant\u00e9, nos\nr\u00e9sultats confirment des tendances d\u00e9j\u00e0 observ\u00e9es\n\u00e0 partir des donn\u00e9es du SNDS 9. Certaines comp lications chroniques du diab\u00e8te (coronariennes, AVC)\nsont plus fr\u00e9quentes \u00e0 La R\u00e9union o\u00f9 le r\u00f4le potentiel\nde certains facteurs de risque plus fr\u00e9quents, notamment le tabagisme, sur ce territoire ne peut pas \u00eatre\n\u00e9cart\u00e9. En revanche, nous n'obs ervons pas de diff\u00e9 -\nrences significatives selon les territoires conc ernant\nles complications podologiques, cont rairement aux\nr\u00e9sultats observ\u00e9s \u00e0 partir des donn\u00e9es du SNDS 9.\nCes complications \u00e9tant plus rares, un manque de\npuissance ne peut pas \u00eatre \u00e9cart\u00e9. Le suivi de cohorte\net notamment le recueil prospectif de ces comp lications permettra d'approfondir cette premi\u00e8re analyse.\nNotre \u00e9tude apporte \u00e9galement des informations\nnouvelles sur les comp lications ophtalmologiques\nqui font d\u00e9faut en France, au niveau national, car\nelles sont difficilement tra\u00e7ables \u00e0 partir des seules\ndonn\u00e9es du SNDS. L '\u00e9tude Entred 2 rapportait\nd\u00e9j\u00e0 une fr\u00e9quence qui semblait plus \u00e9lev\u00e9e de ces\ncomplications, notre \u00e9tude le confi rme avec notam -\nment une fr\u00e9quence de la r\u00e9tinopathie auto-d\u00e9clar\u00e9e\nsup\u00e9rieure en Martinique et \u00e0 La R\u00e9union. Une\nanalyse sp\u00e9cifique int\u00e9grant \u00e9galement les actes\nd'ophtalmologie recueillis gr\u00e2ce aux donn\u00e9es du\nSNDS permettra d'app rofondir ces premiers r\u00e9sul -\ntats au regard de l'anc iennet\u00e9 du diab\u00e8te, du niveau\nde contr\u00f4le glyc\u00e9mique et de la surveillance ophtal -\nmique qui diff\u00e8rent selon les territoires.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2350, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "42226b1b-aea4-4a7d-96f5-be3250d84dda": {"__data__": {"id_": "42226b1b-aea4-4a7d-96f5-be3250d84dda", "embedding": null, "metadata": {"page_label": "421", "file_name": "2023_20-21.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2023_20-21.pdf", "file_type": "application/pdf", "file_size": 1372902, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "0b3fd5bd-b588-44f3-85d3-3e8bf2656b50", "node_type": "4", "metadata": {"page_label": "421", "file_name": "2023_20-21.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2023_20-21.pdf", "file_type": "application/pdf", "file_size": 1372902, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "bbe6ab53c9105e5cbc856553cb802afa7191bc07405f54aaa0ae446060f28b01", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "662d137a-a681-43fe-8402-1c086d498576", "node_type": "1", "metadata": {"page_label": "421", "file_name": "2023_20-21.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2023_20-21.pdf", "file_type": "application/pdf", "file_size": 1372902, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "bd4c55e0deea9f4e0f031d43021c7a59b7898ca0262727ed1fa28068e437da0a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d5d50f40-ad14-4f6b-8a91-07f86ff4b776", "node_type": "1", "metadata": {}, "hash": "9fcaf9ed176de369c8d8e36e9453c6826bfece876251c2ed5334f37bfe44e487", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Une\nanalyse sp\u00e9cifique int\u00e9grant \u00e9galement les actes\nd'ophtalmologie recueillis gr\u00e2ce aux donn\u00e9es du\nSNDS permettra d'app rofondir ces premiers r\u00e9sul -\ntats au regard de l'anc iennet\u00e9 du diab\u00e8te, du niveau\nde contr\u00f4le glyc\u00e9mique et de la surveillance ophtal -\nmique qui diff\u00e8rent selon les territoires.\nLa glyc\u00e9mie (mesur\u00e9e par l'HbA1c) \u00e9tait moins bien\ncontr\u00f4l\u00e9e dans les DROM que dans l'Hex agone, en\nparticulier en Guyane et \u00e0 La R\u00e9union. Ce cons tat\navait d\u00e9j\u00e0 \u00e9t\u00e9 \u00e9tabli dans Entred 2 \u00e0 La R\u00e9union 6. Les\nautres facteurs de risque \u00e9taient proches de la situa -\ntion observ\u00e9e dans l'Hexagone, voire moins fr\u00e9quents\ncomme la cons ommation d'alcool et le tabagisme,\n\u00e0 l'exception de La R\u00e9union. Quant \u00e0 la corpulence,\nalors que l'ob\u00e9 sit\u00e9 en population g\u00e9n\u00e9rale est plus\nfr\u00e9quente dans les DROM que dans l'Hexagone 1, de\nfa\u00e7on paradoxale, l'IMC moyen des personnes atteintes\nd'un DT2 \u00e9tait plus faible \u00e0 La R\u00e9union, en Guadeloupe\net en Guyane. En Martinique, il \u00e9tait similaire \u00e0 celui\nestim\u00e9 dans l'Hexagone. Ces r\u00e9sultats ont d\u00e9j\u00e0\nTableau 4\nComplications des personnes atteintes d'un diab\u00e8te de type 2 r\u00e9sidant dans les territoires d'outre-mer (Guadeloupe, Martinique,\nGuyane, La R\u00e9union) et dans l'Hexagone - Entred 3\nGuadeloupe Martinique Guyane La R\u00e9union\np-valuea\nHexagone\np-valueb\n% [IC95%] % [IC95%] % [IC95%] % [IC95%] % [IC95%]\nComplication coronarienne\nauto-d\u00e9clar\u00e9e\n6,6 [4,4-9,4] 8,3 [6,3-10,8] 4,7 [3,0-7,1] 19,4 [16,2-22,9] <0,0001 18,6 [16,9-20,3] <0,0001\nHospitalisation pour IDM\n0,8 [0,2-2,2] 1,2 [0,5-2,5] 1,2 [0,4-2,8] 4,5 [3,0-6,7] 0,0002 3,4 [2,6-4,3] 0,0003\nAnt\u00e9c\u00e9dent d'AVC auto-d\u00e9clar\u00e9 6,8 [4,4-10,1] 9,6 [7,4-12,2] 8,2 [5,8-11,1] 12,3 [9,6-15,4] 0,0216 7,8 [6,", "mimetype": "text/plain", "start_char_idx": 2048, "end_char_idx": 3735, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "d5d50f40-ad14-4f6b-8a91-07f86ff4b776": {"__data__": {"id_": "d5d50f40-ad14-4f6b-8a91-07f86ff4b776", "embedding": null, "metadata": {"page_label": "421", "file_name": "2023_20-21.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2023_20-21.pdf", "file_type": "application/pdf", "file_size": 1372902, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "0b3fd5bd-b588-44f3-85d3-3e8bf2656b50", "node_type": "4", "metadata": {"page_label": "421", "file_name": "2023_20-21.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2023_20-21.pdf", "file_type": "application/pdf", "file_size": 1372902, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "bbe6ab53c9105e5cbc856553cb802afa7191bc07405f54aaa0ae446060f28b01", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "42226b1b-aea4-4a7d-96f5-be3250d84dda", "node_type": "1", "metadata": {"page_label": "421", "file_name": "2023_20-21.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2023_20-21.pdf", "file_type": "application/pdf", "file_size": 1372902, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "2f95010d28d054add0cec27c287948db1aba69bf9292ee09f8a2b479f9272784", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "69c72682-29bf-4080-8613-3df5d4cfb35e", "node_type": "1", "metadata": {}, "hash": "b7f3e412a8048c047ff6d06c4e271465023bd54f33d7b7846c1031d8c06690bc", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "0002 3,4 [2,6-4,3] 0,0003\nAnt\u00e9c\u00e9dent d'AVC auto-d\u00e9clar\u00e9 6,8 [4,4-10,1] 9,6 [7,4-12,2] 8,2 [5,8-11,1] 12,3 [9,6-15,4] 0,0216 7,8 [6,5-9,1] 0,0035\nHospitalisation pour AVC\n2,9 [1,6-4,8] 4,3 [2,9-6,3] 3,2 [1,7-5,4] 4,9 [3,2-7,1] 0,2320 2,6 [1,9-3,5] 0,0036\nR\u00e9tinopathie auto-d\u00e9clar\u00e9e 9,4 [6,9-12,4] 14,4 [11,7-17,4] 11,0 [8,2-14,4] 15,9 [13,0-19,2] 0,0065 6,8 [5,7-8,0] <0,0001\nPerte de la vue d'un \u0153il\nauto-d\u00e9clar\u00e9e\n2,7 [1,4-4,9] 4,4 [2,9-6,3] 1,3 [0,5-2,7] 4,6 [3,0-6,7] 0,0122 3,2 [2,4-4,1] 0,0167\nTraitement au laser auto-d\u00e9clar\u00e9 22,7 [18,6-27,2] 17,8 [14,9-20,9] 11,3 [8,6-14,4] 23,2 [19,8-27,0] 0,0014 16,7 [15,0-18,5] <0,0001\nAnt\u00e9c\u00e9dent de mal perforant\nplantaire auto-d\u00e9clar\u00e9\n7,4 [5,1-10,4] 9,9 [7,8-12,5] 6,6 [4,6-9,1] 7,9 [5,8-10,5] 0,3395 6,7 [5,7-7,9] 0,0889\nHospitalisation pour plaie du pied\n2,1 [0,7-4,7] 3,1 [1,9-4,8] 2,6 [1,2-4,8] 2,0 [1,0-3,5] 0,6587 1,6 [1,1-2,3] 0,2295\nHospitalisation pour amputation\nde membre inf\u00e9rieur dans les 10 ans\n1,2 [0,3-3,1] 1,6 [0,8-2,8] 1,6 [0,6-3,5] 1,3 [0,5-2,8] 0,", "mimetype": "text/plain", "start_char_idx": 3604, "end_char_idx": 4617, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "69c72682-29bf-4080-8613-3df5d4cfb35e": {"__data__": {"id_": "69c72682-29bf-4080-8613-3df5d4cfb35e", "embedding": null, "metadata": {"page_label": "421", "file_name": "2023_20-21.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2023_20-21.pdf", "file_type": "application/pdf", "file_size": 1372902, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "0b3fd5bd-b588-44f3-85d3-3e8bf2656b50", "node_type": "4", "metadata": {"page_label": "421", "file_name": "2023_20-21.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2023_20-21.pdf", "file_type": "application/pdf", "file_size": 1372902, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "bbe6ab53c9105e5cbc856553cb802afa7191bc07405f54aaa0ae446060f28b01", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d5d50f40-ad14-4f6b-8a91-07f86ff4b776", "node_type": "1", "metadata": {"page_label": "421", "file_name": "2023_20-21.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2023_20-21.pdf", "file_type": "application/pdf", "file_size": 1372902, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "7de1df02b34cee4ca3c8c55fe7ec1325d76542bf494a634f94ebc0260409669a", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "5] 0,6587 1,6 [1,1-2,3] 0,2295\nHospitalisation pour amputation\nde membre inf\u00e9rieur dans les 10 ans\n1,2 [0,3-3,1] 1,6 [0,8-2,8] 1,6 [0,6-3,5] 1,3 [0,5-2,8] 0,9304 0,6 [0,3-1,1] 0,1537\nDialyse ou greffe r\u00e9nale\n0,2 [0,006-1,3] 0,5 [0,1-1,4] 0,3 [0,03-1,3] 1,2 [0,5-2,6] 0,1861 0,3 [0,1-0,7] 0,2112\nIC95% : intervalle de confiance \u00e0 95% ; IDM : infarctus du myocarde ; AVC : accident vasculaire c\u00e9r\u00e9bral.\na p-value du test de comparaison des 4 DROM issu d'un mod\u00e8le de r\u00e9gression logistique ajust\u00e9 sur le sexe et l'\u00e2ge.\nb p-value du test de comparaison des 5 territoires issu d'un mod\u00e8le de r\u00e9gression logistique ajust\u00e9 sur le sexe et l'\u00e2ge.\nNote de lecture : 2,9% (IC95%: [1,6-4,8]) des personnes atteintes d'un diab\u00e8te de type 2 r\u00e9sidant en Guadeloupe avaient un ant\u00e9c\u00e9dent d'hospitalisation\npour AVC dans les 10 ans pr\u00e9c\u00e9dant le tirage au sort. Apr\u00e8s ajustement sur le sexe et l'\u00e2ge des personnes, la p-value du test de comparaison entre les\nDROM \u00e9tait non-significative (0,2320). Apr\u00e8s ajustement sur le sexe et l'\u00e2ge des personnes, la p-value du test de comparaison entre les 5 territoires,\nincluant l'Hexagone, \u00e9tait significative (0,0036).", "mimetype": "text/plain", "start_char_idx": 4460, "end_char_idx": 5602, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "94608b5c-aff4-4b58-aab7-f26613fc89a8": {"__data__": {"id_": "94608b5c-aff4-4b58-aab7-f26613fc89a8", "embedding": null, "metadata": {"page_label": "422", "file_name": "2023_20-21.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2023_20-21.pdf", "file_type": "application/pdf", "file_size": 1372902, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "22079c30-189e-47fb-9e31-1ff8663dc7a1", "node_type": "4", "metadata": {"page_label": "422", "file_name": "2023_20-21.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2023_20-21.pdf", "file_type": "application/pdf", "file_size": 1372902, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "0be02cd8a1dfe2a605fe392078b6663508e8501004279f0af28f76fce5614349", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f1b06c17-56e3-4038-8fce-4af042bdf511", "node_type": "1", "metadata": {}, "hash": "bb8332de297d62c94e8f0366973e14bde942796e7a0aa3d4377510eadf73e60b", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "422 | 14 novembre 2023 | BEH 20-21 Diab\u00e8te en outre-mer : comprendre les sp\u00e9cificit\u00e9s locales pour cibler les actions\n\u00e9t\u00e9 rapport\u00e9s dans Entred 2 6 o\u00f9 l'hyp oth\u00e8se de\nm\u00e9canismes physiopathologiques sp\u00e9cifiques du\nDT2 dans ces territoires \u00e9tait \u00e9mise, cond uisant \u00e0\nun risque de d\u00e9velopper un DT2 \u00e0 un niveau d'ob\u00e9 -\nsit\u00e9 moindre. Des \u00e9tudes am\u00e9ricaine 11 et anglaise 12\nont \u00e9galement mis en \u00e9vidence ces r\u00e9sultats et ont\nsugg\u00e9r\u00e9 d'abaisser le seuil d'IMC selon les origines\nethniques pour cibler les populations devant b\u00e9n\u00e9ficier\nd'un d\u00e9pistage du DT2.\nLa prise en charge dans les DROM passe principale -\nment par les m\u00e9decins g\u00e9n\u00e9ralistes. Le recours aux\nendocrinologues est rare (entre 15% et 19%), tandis\nque le recours au cardiologue est plus r\u00e9pandu,\nsurtout \u00e0 La R\u00e9union, o\u00f9 plus d'une personne sur\ndeux a cons ult\u00e9 au moins une fois au cours de\nl'ann\u00e9e. L 'insulinoth\u00e9rapie reste tr\u00e8s fr\u00e9quente quel\nque soit le territoire ultramarin et sup\u00e9rieure au taux\nobserv\u00e9 dans l'Hex agone. Une analyse sp\u00e9cifique\ndes d\u00e9terminants du recours \u00e0 l'insuline pourra \u00eatre\nmen\u00e9e afin d'en comp rendre les raisons.\nCertaines limites de notre \u00e9tude sont \u00e0 mentionner.\nPremi\u00e8rement, des territoires ultramarins fortement\naffect\u00e9s par le diab\u00e8te n'ont pu \u00eatre inclus, faute\nde donn\u00e9es exhaustives de l'Ass urance maladie.\nConcernant Mayotte, o\u00f9 la pr\u00e9valence du diab\u00e8te\n\u00e9tait de 12,1% en 2016 avec pr\u00e8s d'une personne sur\ndeux non diagnostiqu\u00e9e 13, les donn\u00e9es sp\u00e9cifiques\nau diab\u00e8te de l'\u00e9tu de Unono Wa Maore pourront\n\u00eatre compar\u00e9es aux r\u00e9sultats d'Ent red 3. La Guyane\nint\u00e9rieure n'a pas pu \u00eatre int\u00e9gr\u00e9e dans notre \u00e9tude\npour des raisons op\u00e9rationnelles dues notamment\n\u00e0 l'isolement g\u00e9ographique et \u00e0 un recours aux soins\nsp\u00e9cifique. Une \u00e9tude ciblant ce territoire est en\ncours en population g\u00e9n\u00e9rale et abordera le diab\u00e8te.\nDeuxi\u00e8mement, la crise sanitaire li\u00e9e \u00e0 la Covid-19\na pu affecter le recueil des donn\u00e9es, qui a d\u00fb \u00eatre interrompu pendant le premier confinement de 2020, \u00e0 des\nstades diff\u00e9rents selon les territoires.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2019, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "f1b06c17-56e3-4038-8fce-4af042bdf511": {"__data__": {"id_": "f1b06c17-56e3-4038-8fce-4af042bdf511", "embedding": null, "metadata": {"page_label": "422", "file_name": "2023_20-21.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2023_20-21.pdf", "file_type": "application/pdf", "file_size": 1372902, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "22079c30-189e-47fb-9e31-1ff8663dc7a1", "node_type": "4", "metadata": {"page_label": "422", "file_name": "2023_20-21.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2023_20-21.pdf", "file_type": "application/pdf", "file_size": 1372902, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "0be02cd8a1dfe2a605fe392078b6663508e8501004279f0af28f76fce5614349", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "94608b5c-aff4-4b58-aab7-f26613fc89a8", "node_type": "1", "metadata": {"page_label": "422", "file_name": "2023_20-21.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2023_20-21.pdf", "file_type": "application/pdf", "file_size": 1372902, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "42bdd8b72802af648d516e27332274a232baf9f332c80abd19e1bfa83ad3ced3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "fb19423b-0e26-4186-9e7c-5c5aac9aa862", "node_type": "1", "metadata": {}, "hash": "199dda4c20b7c06b26905101de7c397a42e63599450dbc6f4382e38f40722ef6", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Une \u00e9tude ciblant ce territoire est en\ncours en population g\u00e9n\u00e9rale et abordera le diab\u00e8te.\nDeuxi\u00e8mement, la crise sanitaire li\u00e9e \u00e0 la Covid-19\na pu affecter le recueil des donn\u00e9es, qui a d\u00fb \u00eatre interrompu pendant le premier confinement de 2020, \u00e0 des\nstades diff\u00e9rents selon les territoires. Cependant,\nl'impact sur les r\u00e9sultats pr\u00e9sent\u00e9s dans cet article\nest probablement faible, car l'int erruption a \u00e9t\u00e9 de\ncourte dur\u00e9e et les indicateurs de recours aux soins\npr\u00e9sent\u00e9s dans cet article portaient sur une p\u00e9riode\nde 12 mois pr\u00e9c\u00e9dant le tirage au sort, soit avant la\ncrise sanitaire. N\u00e9anmoins, cette limite devra \u00eatre prise\nen compte dans certaines analyses, notamment celles\nportant sur la qualit\u00e9 de vie. La crise sanitaire a pu\n\u00e9galement impacter la participation des m\u00e9decins,\nfortement sollicit\u00e9s par la Covid-19 et moins enclins\n\u00e0 participer \u00e0 une enqu\u00eate. Par ailleurs, le recueil des\ncoordonn\u00e9es des m\u00e9decins, aupr\u00e8s des personnes\ndiab\u00e9tiques, a \u00e9galement \u00e9t\u00e9 plus difficile dans ces\nterritoires, pouvant refl\u00e9ter un turn-over important\ndes professionnels de sant\u00e9, notamment en Guyane.\nAinsi, malgr\u00e9 le sur\u00e9chantillonnage, la taille de certains\n\u00e9chantillons peut limiter la puissance de notre \u00e9tude\net la pr\u00e9cision des indicateurs. De plus, m\u00eame si la\nqualit\u00e9 des donn\u00e9es a \u00e9t\u00e9 am\u00e9lior\u00e9e par le mode de\nrecueil en face-\u00e0-face, certains indicateurs (poids et\ntaille recueillis aupr\u00e8s des personnes et lipides aupr\u00e8s\ndes m\u00e9decins) souffrent d'une proportion importante\nde donn\u00e9es manquantes rendant les comparaisons\nd\u00e9licates. Toutefois, la pr\u00e9sence de ces donn\u00e9es\nmanquantes est \u00e9galement riche en informations. Elles\nrefl\u00e8tent notamment le manque de connaissance par\nla personne de sa corpulence, alors qu'il s'agi t d'un\n\u00e9l\u00e9ment cl\u00e9 dans la gestion du DT2. Enfin, il ne peut\n\u00eatre \u00e9cart\u00e9 que certaines personnes atteintes d'un\nautre type de diab\u00e8te que le DT2 aient \u00e9t\u00e9 incluses\n\u00e0 tort dans notre population d'\u00e9tude.\nMalgr\u00e9 ces limites, notre \u00e9tude est informative et\napporte une description fine des sp\u00e9cificit\u00e9s du DT2\ndans ces quatre territoires d'out re-mer. Nous observons des profils d\u00e9mographique, socio- \u00e9conomique,\net l'\u00e9tat de sant\u00e9 des personnes atteintes d 'un DT2\nr\u00e9sidant \u00e0 La R\u00e9union et en Guyane assez proches et\ndiff\u00e9rant de ceux des r\u00e9sidents des Antilles. Les profils\nde ces derniers semblent davantage se rapprocher\nde ceux observ\u00e9s dans l'Hex agone.", "mimetype": "text/plain", "start_char_idx": 1726, "end_char_idx": 4112, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "fb19423b-0e26-4186-9e7c-5c5aac9aa862": {"__data__": {"id_": "fb19423b-0e26-4186-9e7c-5c5aac9aa862", "embedding": null, "metadata": {"page_label": "422", "file_name": "2023_20-21.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2023_20-21.pdf", "file_type": "application/pdf", "file_size": 1372902, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "22079c30-189e-47fb-9e31-1ff8663dc7a1", "node_type": "4", "metadata": {"page_label": "422", "file_name": "2023_20-21.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2023_20-21.pdf", "file_type": "application/pdf", "file_size": 1372902, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "0be02cd8a1dfe2a605fe392078b6663508e8501004279f0af28f76fce5614349", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f1b06c17-56e3-4038-8fce-4af042bdf511", "node_type": "1", "metadata": {"page_label": "422", "file_name": "2023_20-21.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2023_20-21.pdf", "file_type": "application/pdf", "file_size": 1372902, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "69ab7576a095ced010e9e8878a89212e579b62f0711232f65da6c2afb3f98f39", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Nous observons des profils d\u00e9mographique, socio- \u00e9conomique,\net l'\u00e9tat de sant\u00e9 des personnes atteintes d 'un DT2\nr\u00e9sidant \u00e0 La R\u00e9union et en Guyane assez proches et\ndiff\u00e9rant de ceux des r\u00e9sidents des Antilles. Les profils\nde ces derniers semblent davantage se rapprocher\nde ceux observ\u00e9s dans l'Hex agone. \u00c0 La R\u00e9union et\nen Guyane, nous cons tatons un diab\u00e8te survenant\n\u00e0 un \u00e2ge plus jeune et \u00e0 un niveau de corpulence\nmoindre, sugg\u00e9rant des susceptibilit\u00e9s g\u00e9n\u00e9tiques\nparticuli\u00e8res. Ces particularit\u00e9s pourraient, en partie,\nexpliquer le moins bon \u00e9quilibre glyc\u00e9mique rapport\u00e9\npar notre \u00e9tude et la fr\u00e9quence \u00e9lev\u00e9e des comp lications chroniques. Ainsi, un levier potentiel pour\nr\u00e9duire le fardeau du DT2, pourrait passer par le rep\u00e9rage pr\u00e9coce de ces personnes au profil atypique\n(jeunes et de corpulence normale), de les orienter\nvers un endocrinologue pour r\u00e9aliser un ph\u00e9no typage\nde leur diab\u00e8te. Cette prise en charge adapt\u00e9e pour -\nrait permettre une meilleure r\u00e9ponse th\u00e9rapeutique\nafin d'am\u00e9liorer leur \u00e9quilibre glyc\u00e9mique et pr\u00e9venir\nla survenue des complications.\nConclusion\nEntred 3 permet pour la premi\u00e8re fois de dresser\nun \u00e9tat des lieux du DT2 dans quatre DROM, de\nd\u00e9crire des populations aux profils d\u00e9mographique,\nsocio-\u00e9conomique, m\u00e9tabolique tr\u00e8s sp\u00e9cifiques.\nElle confirme \u00e9galement la fr\u00e9quence \u00e9lev\u00e9e des\nfacteurs de risque et des comp lications du diab\u00e8te\nprincipalement \u00e0 La R\u00e9union et en Guyane. Int\u00e9gr\u00e9s\ndans un cont exte culturel, social, et sanitaire,\nces r\u00e9sultats permettront d'aid er les d\u00e9cideurs\n\u00e0 adapter les politiques publiques en mati\u00e8re de\npr\u00e9vention, d'accompa gnement et de prise en charge\ndes personnes atteintes d'un diab\u00e8te de type 2 en\noutre-mer afin d'en r\u00e9duire le fardeau. \u25a0\nLiens d'int\u00e9r\u00eat\nLes auteurs d\u00e9clarent ne pas avoir de liens d'int\u00e9r\u00eat au regard\ndu contenu de l'article.\nRemerciements\nLes personnes atteintes d'un diab\u00e8te et les m\u00e9decins qui\nont g\u00e9n\u00e9reusement particip\u00e9 \u00e0 l'\u00e9tude sont chaleureusement\nremerci\u00e9s.\nNous tenons \u00e9galement \u00e0 remercier le minist\u00e8re charg\u00e9 des\nOutre-mer et les agences r\u00e9gionales de sant\u00e9 de Guadeloupe,\nde Martinique, de Guyane et de La R\u00e9union qui ont contribu\u00e9\nau financement de cette \u00e9tude.\nEnfin, nous tenons \u00e0 remercier les personnes qui ont par ticip\u00e9 \u00e0\nla conception de cette \u00e9tude, \u00e0 la collecte et au traitement des\ndonn\u00e9es, notamment les \u00e9quipes d'Ipsos, Jean-Louis Solet,", "mimetype": "text/plain", "start_char_idx": 3805, "end_char_idx": 6178, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "a110bd64-fd10-48b1-a20a-4e5cf32dec25": {"__data__": {"id_": "a110bd64-fd10-48b1-a20a-4e5cf32dec25", "embedding": null, "metadata": {"page_label": "423", "file_name": "2023_20-21.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2023_20-21.pdf", "file_type": "application/pdf", "file_size": 1372902, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "6b4c360b-9f6c-40a8-870f-d036e6c87169", "node_type": "4", "metadata": {"page_label": "423", "file_name": "2023_20-21.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2023_20-21.pdf", "file_type": "application/pdf", "file_size": 1372902, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "0523f8dbca0ca428f46c74bf5dcb076ea4bd488a5f7e6ba39760f24ef3f3057e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "54a6f7e1-24e2-44f0-b6b2-6c5a49d5ca46", "node_type": "1", "metadata": {}, "hash": "a1f2cdc9966f09a25532afac8d39cb196edebfe45a4f42bec050d0c5d2b804c2", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Diab\u00e8te en outre-mer : comprendre les sp\u00e9cificit\u00e9s locales pour cibler les actions BEH 20-21 | 14 novembre 2023 | 423\nAudrey Andrieu, Jessica Gane, Val\u00e9rie Henry et Isadora Mathevet,\nPerrine de Crouy-Chanel pour la r\u00e9alisation des cartes des\nterritoires d'outre-mer, ainsi que les nombreux experts qui ont\ncontribu\u00e9 \u00e0 cette \u00e9tude dans le cadre du Comit\u00e9 scientifique,\ndu Comit\u00e9 d'interface diab\u00e8te de Sant\u00e9 publique France, ainsi\nque la F\u00e9d\u00e9ration fran\u00e7aise des diab\u00e9tiques, la Soci\u00e9t\u00e9 franco -\nphone du diab\u00e8te et le Coll\u00e8ge de la m\u00e9decine g\u00e9n\u00e9rale pour\nleur soutien.\nR\u00e9f\u00e9rences\n[1] M\u00e9jean C, Debussche X, Martin-Pr\u00e9vel Y, R\u00e9quillart V,\nSoler LG, Tib\u00e8re L (dir.). Alimentation et nutrition dans les\nd\u00e9partements et r\u00e9gions d'Outre-mer. Marseille: IRD \u00c9ditions;\n2020. 208 p.\n[2] Hernandez H, Piffaretti C, Gautier A, Cosson E, FosseEdorh S. Pr\u00e9valence du diab\u00e8te connu dans 4 d\u00e9partements\net r\u00e9gions d'outre-mer : Guadeloupe, Martinique, Guyane et\nLa R\u00e9union. R\u00e9sultats du Barom\u00e8tre de Sant\u00e9 publique France\nde 2021. Bull \u00c9pid\u00e9miol Hebd. 2023;(20-21):424-31.\nsantepubliquefrance.fr/beh/2023/20-21/2023_20-21_2.html\n[3] Lailler G, Piffaretti C, Fuentes S, Nabe HD, Oleko A,\nCosson E, et al . Prevalence of prediabetes and undia -\ngnosed type 2 diabetes in France: Results from the national\nsurvey ESTEBAN, 2014-2016. Diabetes Res Clin Pract. 2020;\n165:108252.\n[4] Fosse-Edorh S, Mandereau Bruno L, Regnault N. Le\npoids des complications li\u00e9es au diab\u00e8te en France en 2013.\nSynth\u00e8se et perspectives. Bull \u00c9pid\u00e9miol Hebd. 2015;(34-35):\n619-25.\n2015_34-35_1.html\n[5] Fosse-Edorh S, Piffaretti C, Saboni L, Mandereau-Bruno L,\nB\u00e9n\u00e9zet L, Raimond V, et al. \u00c9tudes Entred : un dispositif pour\nam\u00e9liorer la connaissance de l'\u00e9tat de sant\u00e9 des personnes\npr\u00e9sentant un diab\u00e8te en France - Premiers r\u00e9sultats de la\ntroisi\u00e8me \u00e9dition conduite en m\u00e9tropole en 2019. Bull \u00c9pid\u00e9 -\nmiol Hebd.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1875, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "54a6f7e1-24e2-44f0-b6b2-6c5a49d5ca46": {"__data__": {"id_": "54a6f7e1-24e2-44f0-b6b2-6c5a49d5ca46", "embedding": null, "metadata": {"page_label": "423", "file_name": "2023_20-21.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2023_20-21.pdf", "file_type": "application/pdf", "file_size": 1372902, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "6b4c360b-9f6c-40a8-870f-d036e6c87169", "node_type": "4", "metadata": {"page_label": "423", "file_name": "2023_20-21.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2023_20-21.pdf", "file_type": "application/pdf", "file_size": 1372902, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "0523f8dbca0ca428f46c74bf5dcb076ea4bd488a5f7e6ba39760f24ef3f3057e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a110bd64-fd10-48b1-a20a-4e5cf32dec25", "node_type": "1", "metadata": {"page_label": "423", "file_name": "2023_20-21.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2023_20-21.pdf", "file_type": "application/pdf", "file_size": 1372902, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "8b9ab9ce88e7ae2d046f238f88f514020111985fe9ffbab3c9dc3e4b630c372b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4b30e0c8-7572-4896-a557-8dd115b8fc75", "node_type": "1", "metadata": {}, "hash": "6f6b8ccad1c3d3131f806a0b0e0befa9e7d768e4e573270e47d63073398941ca", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "\u00c9tudes Entred : un dispositif pour\nam\u00e9liorer la connaissance de l'\u00e9tat de sant\u00e9 des personnes\npr\u00e9sentant un diab\u00e8te en France - Premiers r\u00e9sultats de la\ntroisi\u00e8me \u00e9dition conduite en m\u00e9tropole en 2019. Bull \u00c9pid\u00e9 -\nmiol Hebd. 2022;(22):383-92.\nfr/beh/2022/22/2022_22_1.html\n[6] Ndong JR, Romon I, Druet C, Prevot L, Hubert-Brierre R,\nPascolini E, et al. Caract\u00e9ristiques, risque vasculaire, compli -\ncations et qualit\u00e9 des soins des personnes diab\u00e9tiques\ndans les d\u00e9partements d'outre-mer et comparaison \u00e0 la\nm\u00e9tropole : Entred 2007-2010, France. Bull \u00c9pid\u00e9miol Hebd.\n2010;(42-43):432-6.\ndies-et-traumatismes/diabete/documents/article/caracteris\ntiques-risque-vasculaire-complications-et-qualite-des-soinsdes-personnes-diabetiques-dans-les-departe ments-d-outremer-et-comparaison\n[7] Chan Wan GN, Chopinet-Dijoux S, Ricquebourg M,\nSimonpieri JM. Parcours de soins des patients diab\u00e9tiques\n\u00e0 La R\u00e9union - Etude longitudinale des parcours des patients\nmis sous traitement antidiab\u00e9tique en 2010. Synth\u00e8se\ndes principaux r\u00e9sultats. Saint-Denis: Assurance Maladie\nLa R\u00e9union, Agence r\u00e9gionale de sant\u00e9 La R\u00e9union, Observa -\ntoire r\u00e9gional de sant\u00e9 Oc\u00e9an Indien ; 2020. 38 p.\nors-reunion.fr/parcours-de-soins-des-patients-diabetiquesa-la-reunion-etude-longitudinale-des.html\n[8] Sudre C, Duplan H, Bukasakakamba J, Nacher M, PeyreCosta P, Sabbah N. Diabetes Care in French Guiana: The\nGap between national guidelines and reality. Front Endocrinol\n(Lausanne). 2021;12:789391.\n[9] Fosse-Edorh S, Mandereau-Bruno L, Piffaretti C. Le poids\ndu diab\u00e8te en France en 2016. Synth\u00e8se \u00e9pid\u00e9miologique.\nSaint-Maurice: Sant\u00e9 publique France; 2018. 8 p.\nsantepubliquefrance.fr/maladies-et-traumatismes/diabete/\ndocuments/rapport-synthese/le-poids-du-diabete-en-franceen-2016.-synthese-epidemiologique\n[10] Institut national de la statistique et des \u00e9tudes \u00e9co -\nnomiques. Synth\u00e8se d\u00e9mographique de la Guyane - Une\nd\u00e9mographie toujours dynamique. Montrouge: Insee; 2017.", "mimetype": "text/plain", "start_char_idx": 1650, "end_char_idx": 3601, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "4b30e0c8-7572-4896-a557-8dd115b8fc75": {"__data__": {"id_": "4b30e0c8-7572-4896-a557-8dd115b8fc75", "embedding": null, "metadata": {"page_label": "423", "file_name": "2023_20-21.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2023_20-21.pdf", "file_type": "application/pdf", "file_size": 1372902, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "6b4c360b-9f6c-40a8-870f-d036e6c87169", "node_type": "4", "metadata": {"page_label": "423", "file_name": "2023_20-21.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2023_20-21.pdf", "file_type": "application/pdf", "file_size": 1372902, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "0523f8dbca0ca428f46c74bf5dcb076ea4bd488a5f7e6ba39760f24ef3f3057e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "54a6f7e1-24e2-44f0-b6b2-6c5a49d5ca46", "node_type": "1", "metadata": {"page_label": "423", "file_name": "2023_20-21.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2023_20-21.pdf", "file_type": "application/pdf", "file_size": 1372902, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "2ef15668360acffd3b682814315711f7fc4cbe64b8a6697f25cf55e27d6fa8aa", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Synth\u00e8se d\u00e9mographique de la Guyane - Une\nd\u00e9mographie toujours dynamique. Montrouge: Insee; 2017.\n\n[11] Araneta MRG, Kanaya AM, Hsu WC, Chang HK,\nGrandinetti A, Boyko EJ, et al. Optimum BMI cut points to\nscreen asian americans for type 2 diabetes. Diabetes Care.\n2015;38(5):814-20.\n[12] Caleyachetty R, Barber TM, Mohammed NI, Cappuccio FP,\nHardy R, Mathur R, et al . Ethnicity-specific BMI cutoffs for\nobesity based on type 2 diabetes risk in England: A populationbased cohort study. Lancet Diabetes Endocrinol. 2021;9\n(7):419-26.\n[13] Azaz A, Jezewski-Serra D, Ruello M, Hassani Y, Piffaretti C,\nFosse-Edorh S. Estimation de la pr\u00e9valence du diab\u00e8te et\ndu pr\u00e9diab\u00e8te \u00e0 Mayotte et caract\u00e9ristiques des personnes\ndiab\u00e9tiques, Mayotte, 2019. Bull \u00c9pid\u00e9miol Hebd. 2022;(9-10):\n164-9.\n2022_9-10_1.html\nCiter cet article\nFosse-Edorh S, Lavalette C, Piffaretti C, Saboni L, Bessonneau P,\nMandereau Bruno L , et al. Caract\u00e9ristiques, \u00e9tat de sant\u00e9 et\nrecours aux soins des personnes pr\u00e9sentant un diab\u00e8te de\ntype 2 r\u00e9sidant en outre-mer : r\u00e9sultats de l'\u00e9tude Entred 3. Bull\n\u00c9pid\u00e9miol Hebd. 2023;(20-21): 412-23.\nquefrance.fr/beh/2023/20-21/2023_20-21_1.html", "mimetype": "text/plain", "start_char_idx": 3504, "end_char_idx": 4656, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "d737fc20-f005-4ade-b5bc-9cf786d5319e": {"__data__": {"id_": "d737fc20-f005-4ade-b5bc-9cf786d5319e", "embedding": null, "metadata": {"page_label": "424", "file_name": "2023_20-21.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2023_20-21.pdf", "file_type": "application/pdf", "file_size": 1372902, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "1bf7379f-8602-4e66-af52-cc9264bdfb8b", "node_type": "4", "metadata": {"page_label": "424", "file_name": "2023_20-21.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2023_20-21.pdf", "file_type": "application/pdf", "file_size": 1372902, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "507d09f4218b8809f5ca0dd093ad7e9e2cf57c560756a8d77c1a5e97b7195b55", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "056a4d22-1aba-495c-90b1-9a38173466b6", "node_type": "1", "metadata": {}, "hash": "b76d473e0667f3449970ffb5c3827d6eeedfb9d2ed4a18da323342eaa24507a0", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "424 | 14 novembre 2023 | BEH 20-21 Diab\u00e8te en outre-mer : comprendre les sp\u00e9cificit\u00e9s locales pour cibler les actions\nARTICLE // Article\nPR\u00c9VALENCE DU DIAB\u00c8TE CONNU DANS 4 D\u00c9PARTEMENTS ET R\u00c9GIONS D'OUTRE-MER :\nGUADELOUPE, MARTINIQUE, GUYANE ET LA R\u00c9UNION. R\u00c9SULTATS DU BAROM\u00c8TRE\nDE SANT\u00c9 PUBLIQUE FRANCE DE 2021\n// PREVALENCE OF KNOWN DIABETES IN FOUR FRENCH OVERSEAS DEPARTMENTS AND REGIONS: GUADELOUPE,\nMARTINIQUE, FRENCH GUIANA AND REUNION ISLAND. RESULTS FROM THE 2021 SANT\u00c9 PUBLIQUE FRANCE\nHEALTH BAROMETER\nHugo Hernandez 1, Clara Piffaretti 1, Arnaud Gautier 1, Emmanuel Cosson 2, Sandrine Fosse-Edorh 1\n()\n1 Sant\u00e9 publique France, Saint-Maurice\n2 AP-HP, CHU Avicenne, Universit\u00e9 Paris 13, Sorbonne, CRNH \u00cele-de-France, Cinfo, Bobigny\nSoumis le 26.07.2023 // Date of submission: 07.26.2023\nR\u00e9sum\u00e9 // Abstract\nIntroduction - L 'objectif de notre \u00e9tude est d'estimer la pr\u00e9valence du diab\u00e8te auto-d\u00e9clar\u00e9, i.e. connu, en population g\u00e9n\u00e9rale adulte, dans quatre d\u00e9partements et r\u00e9gions d'outre-mer (DROM) : Guadeloupe, Martinique,\nGuyane et La R\u00e9union. En outre, nous explorons la notion de \u00ab petit diab\u00e8te \u00bb, d\u00e9fini dans le cadre de cette\n\u00e9tude comme \u00e9tant un \u00ab d\u00e9but de diab\u00e8te, mais pas trop grave \u00bb. Nous d\u00e9crivons \u00e9galement les caract\u00e9ris -\ntiques des personnes atteintes d 'un diab\u00e8te ainsi que leur prise en charge.\nM\u00e9thodes - Les donn\u00e9es utilis\u00e9es proviennent du Barom\u00e8tre de Sant\u00e9 Publique France DROM 2021, enqu\u00eate\ntransversale s'appuyant sur des \u00e9chantillons constitu\u00e9s par g\u00e9n\u00e9ration al\u00e9atoire de num\u00e9ros de t\u00e9l\u00e9phone. Plus\nde 6 500 personnes \u00e2g\u00e9es de 18 \u00e0 85 ans (1 511 en Guadeloupe, 1 526 en Martinique, 1 478 en Guyane et 2 004\n\u00e0 La R\u00e9union) ont \u00e9t\u00e9 interrog\u00e9es par t\u00e9l\u00e9phone sur leur connaissance d'un diab\u00e8te ou d'un \u00ab petit diab\u00e8te \u00bb, sur\nla dur\u00e9e d'\u00e9volution de celui-ci ainsi que sur leur prise en charge respective.\nR\u00e9sultats - En 2021, la pr\u00e9valence du diab\u00e8te connu s'\u00e9levait \u00e0 13,6% \u00e0 La R\u00e9union, 12,0% en Guadeloupe,\n11,6% en Guyane et 11,5% en Martinique.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1985, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "056a4d22-1aba-495c-90b1-9a38173466b6": {"__data__": {"id_": "056a4d22-1aba-495c-90b1-9a38173466b6", "embedding": null, "metadata": {"page_label": "424", "file_name": "2023_20-21.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2023_20-21.pdf", "file_type": "application/pdf", "file_size": 1372902, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "1bf7379f-8602-4e66-af52-cc9264bdfb8b", "node_type": "4", "metadata": {"page_label": "424", "file_name": "2023_20-21.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2023_20-21.pdf", "file_type": "application/pdf", "file_size": 1372902, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "507d09f4218b8809f5ca0dd093ad7e9e2cf57c560756a8d77c1a5e97b7195b55", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d737fc20-f005-4ade-b5bc-9cf786d5319e", "node_type": "1", "metadata": {"page_label": "424", "file_name": "2023_20-21.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2023_20-21.pdf", "file_type": "application/pdf", "file_size": 1372902, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "71b93b9dce88ee2e9104ef9e7a0d33ee49c645b9949765f4e44c7dab0b52d216", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "cf64b3c2-b4c8-4684-b868-dcd2d8eff077", "node_type": "1", "metadata": {}, "hash": "d1a2da676a14d63404a771f97eac384280cebba714f8cc28d72731d2aa98c4c6", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "R\u00e9sultats - En 2021, la pr\u00e9valence du diab\u00e8te connu s'\u00e9levait \u00e0 13,6% \u00e0 La R\u00e9union, 12,0% en Guadeloupe,\n11,6% en Guyane et 11,5% en Martinique. Parmi les personnes n'ayant pas d\u00e9clar\u00e9 un diab\u00e8te, la proportion\nde \u00ab petit diab\u00e8te \u00bb \u00e9tait estim\u00e9e \u00e0 4,1% en Martinique, 3,6% en Guadeloupe, 3,4% \u00e0 La R\u00e9union et 2,5% en\nGuyane. Quatre-vingt-deux pour cent des personnes ayant un diab\u00e8te connu \u00e9taient trait\u00e9es pharmacologiquement \u00e0 La R\u00e9union, alors que 90% l'\u00e9taient en Guyane, 92% en Martinique et 93% en Guadeloupe. Parmi les\npersonnes diab\u00e9tiques non trait\u00e9es pharmacologiquement r\u00e9sidant dans les 4 DROM, 42% avaient recours \u00e0\nun r\u00e9gime alimentaire, 33% \u00e0 de l'activit\u00e9 physique, 14% \u00e0 l'autosurveillance glyc\u00e9mique et 26% \u00e0 l'utilisation de\nplantes. Enfin, 44% des personnes diab\u00e9tiques non trait\u00e9es pharmacologiquement d\u00e9claraient n'utiliser aucune\nmesure de prise en charge recommand\u00e9e (35% aucune mesure et 9% seulement des plantes).\nConclusion - Notre \u00e9tude rapporte une pr\u00e9valence \u00e9lev\u00e9e du diab\u00e8te connu dans les DROM, dont une fraction\nimportante de cas non trait\u00e9s pharmacologiquement parmi lesquels plus de quatre personnes sur dix ne b\u00e9n\u00e9 -\nficient d'aucune mesure hygi\u00e9no-di\u00e9t\u00e9tique quel que soit le DROM. En outre, nous rapportons une fr\u00e9quence\n\u00e9lev\u00e9e de cas de \u00ab petit diab\u00e8te \u00bb qui repr\u00e9sente un frein potentiel \u00e0 une prise en charge adapt\u00e9e.\nIntroduction - The aim of our study was to estimate the prevalence of self-reported diabetes, i.e. known\ndiabetes, in the general adult population of four French overseas departments and regions (DROM): Guadeloupe,\nMartinique, French Guiana and Reunion Island. In addition, we explore the notion of \"mild diabetes\", i.e. \"onset\nof diabetes but not severe \". We also describe the characteristics of people living with diabetes and their\ncare pathway.\nMethods - The data come from the 2021 Sant\u00e9 Publique France DROM Health Barometer, a cross-sectional\nsurvey based on randomly generated samples of telephone numbers. More than 6,500 participants aged\nbetween 18 and 85 (1,511 in Guadeloupe, 1,526 in Martinique, 1,478 in French Guiana and 2,004 in Reunion\nIsland) were interviewed by phone about their experience of diabetes or \"mild diabetes\", how long their condition\nhad progressed and how it was managed.", "mimetype": "text/plain", "start_char_idx": 1841, "end_char_idx": 4108, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "cf64b3c2-b4c8-4684-b868-dcd2d8eff077": {"__data__": {"id_": "cf64b3c2-b4c8-4684-b868-dcd2d8eff077", "embedding": null, "metadata": {"page_label": "424", "file_name": "2023_20-21.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2023_20-21.pdf", "file_type": "application/pdf", "file_size": 1372902, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "1bf7379f-8602-4e66-af52-cc9264bdfb8b", "node_type": "4", "metadata": {"page_label": "424", "file_name": "2023_20-21.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2023_20-21.pdf", "file_type": "application/pdf", "file_size": 1372902, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "507d09f4218b8809f5ca0dd093ad7e9e2cf57c560756a8d77c1a5e97b7195b55", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "056a4d22-1aba-495c-90b1-9a38173466b6", "node_type": "1", "metadata": {"page_label": "424", "file_name": "2023_20-21.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2023_20-21.pdf", "file_type": "application/pdf", "file_size": 1372902, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "31496407ab8018cd587b9b1af828fa5cb1982c1f2a93fbc8de9f8c5a825404e5", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "More than 6,500 participants aged\nbetween 18 and 85 (1,511 in Guadeloupe, 1,526 in Martinique, 1,478 in French Guiana and 2,004 in Reunion\nIsland) were interviewed by phone about their experience of diabetes or \"mild diabetes\", how long their condition\nhad progressed and how it was managed.\nResults - In 2021, the prevalence of known diabetes was 13.6% in Reunion Island, 12.0% in Guadeloupe, 11.6%\nin French Guiana and 11.5% in Martinique. Among people who did not declare diabetes, the prevalence of \"mild\ndiabetes\" was estimated at 4.1% in Martinique, 3.6% in Guadeloupe, 3.4% in Reunion Island and 2.5% in French\nGuiana. Eighty-two percent (82%) of people with diabetes in Reunion Island were pharmacologically treated,\ncompared with 90% in French Guiana, 92% in Martinique and 93% in Guadeloupe. Among non- pharmacologicallytreated people living in the four DROMs, 42% used diet, 33% physical activity, 14% self-monitoring of blood\nglucose and 26% the use of plants. Lastly, 44% of non-pharmacologically-treated diabetics declared they were\nnot using any of the recommended measures (35% no measures at all, and 9% plants alone).\n>\nHugo Hernandez et coll.\nSant\u00e9 publique France, Saint-Maurice", "mimetype": "text/plain", "start_char_idx": 3817, "end_char_idx": 5015, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "5bf03a61-51a3-43ab-af97-94617be05f29": {"__data__": {"id_": "5bf03a61-51a3-43ab-af97-94617be05f29", "embedding": null, "metadata": {"page_label": "425", "file_name": "2023_20-21.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2023_20-21.pdf", "file_type": "application/pdf", "file_size": 1372902, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "79a479cf-2a72-4463-96b0-b4880b1d4e4d", "node_type": "4", "metadata": {"page_label": "425", "file_name": "2023_20-21.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2023_20-21.pdf", "file_type": "application/pdf", "file_size": 1372902, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "07790ae1a0af4037fa58aefd6fc8f16374286b2c85de85966e7222f31374dd87", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9d69f9d1-d119-41ab-842b-bef2765ac58f", "node_type": "1", "metadata": {}, "hash": "fbc5c863d3f77014d5036f4871c8c4c025bdcd9b09137bb0288d186ff6f64aa7", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Diab\u00e8te en outre-mer : comprendre les sp\u00e9cificit\u00e9s locales pour cibler les actions BEH 20-21 | 14 novembre 2023 | 425\nConclusion - Our study shows a high prevalence of known diabetes in the French DROMs, including a high\nproportion of non-pharmacologically treated cases, with more than four out of ten people in all DROMs not\nreceiving any specific health or dietary care. In addition, we report a high frequency of cases of \"mild diabetes\",\nwhich represents a potential obstacle to appropriate care management.\nMots-cl\u00e9s : Diab\u00e8te connu, Prise en charge, Pr\u00e9valence, D\u00e9partements et r\u00e9gions d'outre-mer\n// Keywords: Known diabetes, Care management, Prevalence, French overseas departments and regions\nIntroduction\nLe diab\u00e8te est une affection m\u00e9tabolique chronique\nqui touche 537 millions de personnes dans le monde 1.\nEn 2021, la pr\u00e9valence du diab\u00e8te trait\u00e9 pharmaco -\nlogiquement en France s'\u00e9levait \u00e0 5,4% (1). Dans les\nd\u00e9partements et r\u00e9gions d'out re-mer (DROM), en\ntenant compte de la structure d'\u00e2ge de la popula -\ntion, souvent plus jeune, ces pr\u00e9valences \u00e9taient\nfortement augment\u00e9es, voire presque doubl\u00e9es \u00e0\nLa R\u00e9union par rapport \u00e0 l'ensemble du territoire (1).\nPar ailleurs, l'Int ernational Diabetes Federation a\nestim\u00e9 qu'en 2021, pr\u00e8s d'un adulte ayant un diab\u00e8te\nsur deux (20-79 ans) ignorait son statut de diab\u00e9 -\ntique (44,7% ; 239,7 millions) 2. Cette proportion varie\nfortement selon les r\u00e9gions du monde et les pays 2.\nEn France, l'enq u\u00eate R\u00e9dia 3 men\u00e9e \u00e0 La R\u00e9union\nen 1999-2001 aupr\u00e8s de personnes \u00e2g\u00e9es de\n30 \u00e0 69 ans, rapportait une pr\u00e9valence du diab\u00e8te\nm\u00e9connu de 7,0% chez les hommes et 5,6% chez\nles femmes, repr\u00e9sentant environ un tiers de l'ensemble des cas de diab\u00e8te. Plus r\u00e9cemment, en 2019,\nl'enqu\u00eate Unono Wa Maore 4 men\u00e9e \u00e0 Mayotte,\nrapportait une pr\u00e9valence du diab\u00e8te m\u00e9connu de\n4,7% parmi les personnes \u00e2g\u00e9es de 18 \u00e0 69 ans,\nsoit pr\u00e8s de 40% de tous les cas de diab\u00e8te.\nDans l'Hexagone, deux \u00e9tudes men\u00e9es en 20132014 chez des personnes \u00e2g\u00e9es de 18 \u00e0 69 ans\net en 2014-2016 chez des personnes \u00e2g\u00e9es\nde 18 \u00e0 74 ans rapportaient une pr\u00e9valence du\ndiab\u00e8te m\u00e9connu de 1,6% 5 et 1,7% 6, respective -\nment.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2145, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "9d69f9d1-d119-41ab-842b-bef2765ac58f": {"__data__": {"id_": "9d69f9d1-d119-41ab-842b-bef2765ac58f", "embedding": null, "metadata": {"page_label": "425", "file_name": "2023_20-21.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2023_20-21.pdf", "file_type": "application/pdf", "file_size": 1372902, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "79a479cf-2a72-4463-96b0-b4880b1d4e4d", "node_type": "4", "metadata": {"page_label": "425", "file_name": "2023_20-21.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2023_20-21.pdf", "file_type": "application/pdf", "file_size": 1372902, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "07790ae1a0af4037fa58aefd6fc8f16374286b2c85de85966e7222f31374dd87", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5bf03a61-51a3-43ab-af97-94617be05f29", "node_type": "1", "metadata": {"page_label": "425", "file_name": "2023_20-21.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2023_20-21.pdf", "file_type": "application/pdf", "file_size": 1372902, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "8556ea7f64836e386293babc9c10b030ddd14a3d17a3189ef2fcbbb36e0fcee1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9d09547d-a37a-4da6-9639-caee71004d81", "node_type": "1", "metadata": {}, "hash": "0ae10dd93e00750c83499838ba5b4c42f732a9914cc0101f559b9c12719955e6", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Dans l'Hexagone, deux \u00e9tudes men\u00e9es en 20132014 chez des personnes \u00e2g\u00e9es de 18 \u00e0 69 ans\net en 2014-2016 chez des personnes \u00e2g\u00e9es\nde 18 \u00e0 74 ans rapportaient une pr\u00e9valence du\ndiab\u00e8te m\u00e9connu de 1,6% 5 et 1,7% 6, respective -\nment. D'un point de vue clinique, il est essentiel\nde diagnostiquer la maladie le plus t\u00f4t possible au\nstade asympto matique, afin de pr\u00e9venir ou retarder le\nd\u00e9veloppement de comp lications micro- et macro -\nvasculaires. Toutefois, ce diagnostic pr\u00e9coce doit \u00eatre\naccompagn\u00e9 d'une prise en charge par des mesures\nhygi\u00e9no-di\u00e9t\u00e9tiques voire un traitement pharmaco -\nlogique, visant un contr\u00f4le ad\u00e9quat de la glyc\u00e9mie.\nD'un point de vue \u00e9pid\u00e9miologique, d\u00e9crire le fardeau\ndu diab\u00e8te consiste donc \u00e0 s'int \u00e9resser au diab\u00e8te\nconnu et \u00e9galement au diab\u00e8te non diagnostiqu\u00e9,\nou plus largement au diab\u00e8te m\u00e9connu. Ce dernier\npouvant \u00eatre soit non diagnostiqu\u00e9 soit diagnostiqu\u00e9,\nmais sans que la personne ne se reconnaisse comme\natteinte par la maladie.\nEn France, la pr\u00e9valence du diab\u00e8te trait\u00e9 pharmacologiquement est bien d\u00e9crite 7, mais les informations\nconcernant le diab\u00e8te non trait\u00e9 pharmacologique -\nment et le diab\u00e8te m\u00e9connu sont plus rares. Ces\nderni\u00e8res reposent sur des enqu\u00eates transversales\n(1)\navec un examen de sant\u00e9 incluant des pr\u00e9l\u00e8vements\nbiologiques, telles que les enqu\u00eates R\u00e9dia 3, Unono\nWa Maore 4. Ces enqu\u00eates sont peu fr\u00e9quentes car\nco\u00fbteuses et difficiles \u00e0 mettre en \u0153uvre. En compl\u00e9ment de ces enqu\u00eates, un recueil d'informations\nd\u00e9claratives aupr\u00e8s de la population g\u00e9n\u00e9rale, tel\nque le Barom\u00e8tre de Sant\u00e9 publique France permet\nde d\u00e9crire la situation \u00e9pid\u00e9miologique du diab\u00e8te\nconnu, de fa\u00e7on plus r\u00e9guli\u00e8re, donc plus r\u00e9active.\nIl permet \u00e9galement d'exp lorer le diab\u00e8te m\u00e9connu\nen abordant la notion de \u00ab petit diab\u00e8te \u00bb, d\u00e9fini\ndans le cadre de cette \u00e9tude, comme un \u00ab d\u00e9but de\ndiab\u00e8te, mais pas trop grave \u00bb, parmi les personnes\nne se d\u00e9clarant pas diab\u00e9tiques.\nLes objectifs de notre \u00e9tude \u00e9taient d'est imer la\npr\u00e9valence du diab\u00e8te connu en population g\u00e9n\u00e9rale\nadulte, dans quatre DROM : Guadeloupe, Martinique,\nGuyane et La R\u00e9union, ainsi que d'exp lorer la notion\nde \u00ab petit diab\u00e8te \u00bb et de d\u00e9crire les caract\u00e9ristiques\ndes personnes conc ern\u00e9es, ainsi que leur prise\nen charge.", "mimetype": "text/plain", "start_char_idx": 1915, "end_char_idx": 4158, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "9d09547d-a37a-4da6-9639-caee71004d81": {"__data__": {"id_": "9d09547d-a37a-4da6-9639-caee71004d81", "embedding": null, "metadata": {"page_label": "425", "file_name": "2023_20-21.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2023_20-21.pdf", "file_type": "application/pdf", "file_size": 1372902, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "79a479cf-2a72-4463-96b0-b4880b1d4e4d", "node_type": "4", "metadata": {"page_label": "425", "file_name": "2023_20-21.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2023_20-21.pdf", "file_type": "application/pdf", "file_size": 1372902, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "07790ae1a0af4037fa58aefd6fc8f16374286b2c85de85966e7222f31374dd87", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9d69f9d1-d119-41ab-842b-bef2765ac58f", "node_type": "1", "metadata": {"page_label": "425", "file_name": "2023_20-21.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2023_20-21.pdf", "file_type": "application/pdf", "file_size": 1372902, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "bbe19de780a53d7e00b7288824b960e451f4d8bfd1acc10d60f19db7af2aef7e", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Les objectifs de notre \u00e9tude \u00e9taient d'est imer la\npr\u00e9valence du diab\u00e8te connu en population g\u00e9n\u00e9rale\nadulte, dans quatre DROM : Guadeloupe, Martinique,\nGuyane et La R\u00e9union, ainsi que d'exp lorer la notion\nde \u00ab petit diab\u00e8te \u00bb et de d\u00e9crire les caract\u00e9ristiques\ndes personnes conc ern\u00e9es, ainsi que leur prise\nen charge.\nM\u00e9thodes\nCette \u00e9tude a \u00e9t\u00e9 r\u00e9alis\u00e9e \u00e0 partir des donn\u00e9es du\nBarom\u00e8tre de Sant\u00e9 publique France DROM de\n2021 8,9, qui est une enqu\u00eate transversale en popu -\nlation g\u00e9n\u00e9rale men\u00e9e chez les personnes \u00e2g\u00e9es\nde 18 \u00e0 85 ans r\u00e9sidant en Guadeloupe, Martinique,\nGuyane et \u00e0 La R\u00e9union. L 'enqu\u00eate a \u00e9t\u00e9 cond uite\nentre le 7 avril et le 12 octobre 2021 aux Antilles et en\nGuyane, et du 20 avril au 13 juillet 2021 \u00e0 La R\u00e9union.\nLes \u00e9chantillons ont \u00e9t\u00e9 constitu\u00e9s \u00e0 l'aide d'une\ng\u00e9n\u00e9ration al\u00e9atoire de num\u00e9ros de t\u00e9l\u00e9phone fixes\net mobiles par les enqu\u00eateurs.\nAu total, 6 519 personnes \u00e2g\u00e9es de 18 \u00e0 85 ans ont\nparticip\u00e9 \u00e0 l'enqu\u00eate : 1 511 en Guadeloupe, 1 526 en\nMartinique, 1 478 en Guyane et 2 004 \u00e0 La R\u00e9union.\nLes taux de participation \u00e0 l'enq u\u00eate s'\u00e9levaient \u00e0\n46% en Guadeloupe et Martinique, 51% \u00e0 La R\u00e9union\net 54% en Guyane.\nAu cours d'un entretien t\u00e9l\u00e9phonique r\u00e9alis\u00e9 par\ndes enqu\u00eateurs cr\u00e9olophones, de nombreuses\nth\u00e9matiques \u00e9taient abord\u00e9es : l'environnement, les\naddictions, la vaccination, le diab\u00e8te, l'hyp ertension\nart\u00e9rielle, la Covid-19, la sant\u00e9 mentale, l'ali mentation et l'act ivit\u00e9 physique. Le diab\u00e8te conn u a \u00e9t\u00e9\nidentifi\u00e9 dans la population d'\u00e9tu de par la question\n\u00ab Un m\u00e9decin vous a-t-il d\u00e9j\u00e0 dit que vous \u00e9tiez diab\u00e9tique ? \u00bb. La notion de \u00ab petit diab\u00e8te \u00bb \u00e9tait explor\u00e9e,\nparmi ceux qui n'avaient pas d\u00e9clar\u00e9 de diab\u00e8te, par\nla question \u00ab Un m\u00e9decin vous a-t-il d\u00e9j\u00e0 dit que vous\naviez \u00ab un petit diab\u00e8te \u00bb ou un d\u00e9but de diab\u00e8te mais", "mimetype": "text/plain", "start_char_idx": 3837, "end_char_idx": 5624, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "15939ba6-4113-420f-9138-d277c8e17549": {"__data__": {"id_": "15939ba6-4113-420f-9138-d277c8e17549", "embedding": null, "metadata": {"page_label": "426", "file_name": "2023_20-21.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2023_20-21.pdf", "file_type": "application/pdf", "file_size": 1372902, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "c530fd5c-b2f8-401a-9a29-5215a0c47658", "node_type": "4", "metadata": {"page_label": "426", "file_name": "2023_20-21.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2023_20-21.pdf", "file_type": "application/pdf", "file_size": 1372902, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "d11dbd866ff65e2e0d9cd3992169b5cf442eefc184ffbf2aeb307e51139e06ee", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "97716d14-bb84-4bff-9928-7e2f9da5d4e5", "node_type": "1", "metadata": {}, "hash": "93a05f14b93de3649391da62bb8457243f74c3c3ea9ed4fad8908b6ec39e2417", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "426 | 14 novembre 2023 | BEH 20-21 Diab\u00e8te en outre-mer : comprendre les sp\u00e9cificit\u00e9s locales pour cibler les actions\npas trop grave ? \u00bb . Puis, les personnes qui avaient\nr\u00e9pondu positivement \u00e0 l'une des deux questions ont\n\u00e9t\u00e9 interrog\u00e9es sur des caract\u00e9ristiques plus sp\u00e9ci -\nfiques concernant entre autres la dur\u00e9e d'\u00e9vo lution\nde leur diab\u00e8te et sa prise en charge.\nL 'ensemble des r\u00e9sultats ont \u00e9t\u00e9 pond\u00e9r\u00e9s en tenant\ncompte des probabilit\u00e9s d'inc lusion, redress\u00e9es sur\nla structure de la population de chaque DROM selon\nles crit\u00e8res suivants : le sexe, l'\u00e2ge, la taille du foyer et\nle niveau de dipl\u00f4me issus de l'Enq u\u00eate emploi 2020\nde l'Institut national de la statistique et des \u00e9tudes\n\u00e9conomiques (Insee). Les analyses ont \u00e9t\u00e9 r\u00e9alis\u00e9es\n\u00e0 l'aide du logiciel SAS software \u00ae (version 7.1, SAS\nInstitute, Cary, NC, USA). Les proportions et les\nmoyennes sont pr\u00e9sent\u00e9es avec leur intervalle de\nconfiance \u00e0 95% associ\u00e9es (IC95%). Elles ont \u00e9t\u00e9\nestim\u00e9es pour chaque DROM en utilisant l'inf ormation disponible pour l'ensemble des quatre territoires\nce qui permet d'am\u00e9 liorer la pr\u00e9cision des indica -\nteurs. Les proportions ont \u00e9t\u00e9 compar\u00e9es \u00e0 l'aid e\ndu test du Chi2 de Rao-Scott.\nR\u00e9sultats\nPopulation d'\u00e9tude\nLes caract\u00e9ristiques de la population d'\u00e9tude sont\npr\u00e9sent\u00e9es dans le tableau 1. Il y avait une majorit\u00e9\nde femmes dans chacun des 4 DROM. La moyenne\nd'\u00e2ge globale \u00e9tait de 48,1 ans. Il existait une dispa -\nrit\u00e9 territoriale importante avec un \u00e2ge moyen sensi -\nblement plus bas en Guyane et dans une moindre\nmesure \u00e0 La R\u00e9union par rapport \u00e0 la Martinique\net la Guadeloupe.\nPr\u00e9valence du diab\u00e8te connu\nLa pr\u00e9valence du diab\u00e8te conn u s'\u00e9levait \u00e0 12,0% en\nGuadeloupe, 11,5% en Martinique, 11,6% en Guyane\net 13,6% \u00e0 La R\u00e9union (tableau 2).\nLes r\u00e9partitions selon le sexe, l'\u00e2ge, le lieu de nais -\nsance et l'ind ice de masse corporelle (IMC) sont\nd\u00e9crites dans le tableau 2. Un sex-ratio en d\u00e9faveur\ndes femmes \u00e9tait observ\u00e9 dans chaque territoire\nultramarin. On observait entre les 4 DROM une \u00e9l\u00e9vation importante de la pr\u00e9valence du diab\u00e8te conn u\nen fonction de l'\u00e2ge, avec un rapport de 1 \u00e0 10 entre\nla classe d'\u00e2ge des 18-49 ans et celle des 70-85 ans,\nquel que soit le sexe.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2197, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "97716d14-bb84-4bff-9928-7e2f9da5d4e5": {"__data__": {"id_": "97716d14-bb84-4bff-9928-7e2f9da5d4e5", "embedding": null, "metadata": {"page_label": "426", "file_name": "2023_20-21.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2023_20-21.pdf", "file_type": "application/pdf", "file_size": 1372902, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "c530fd5c-b2f8-401a-9a29-5215a0c47658", "node_type": "4", "metadata": {"page_label": "426", "file_name": "2023_20-21.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2023_20-21.pdf", "file_type": "application/pdf", "file_size": 1372902, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "d11dbd866ff65e2e0d9cd3992169b5cf442eefc184ffbf2aeb307e51139e06ee", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "15939ba6-4113-420f-9138-d277c8e17549", "node_type": "1", "metadata": {"page_label": "426", "file_name": "2023_20-21.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2023_20-21.pdf", "file_type": "application/pdf", "file_size": 1372902, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "959db8a4f0f09d6d449ac1b894b8210393c8235c47ff732c7a9cec07ad377175", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "728e6ba6-610e-490d-a14f-b14860d6520d", "node_type": "1", "metadata": {}, "hash": "8f98439dfa18063270b3f804437b3f0e523cc64c484567be0875476e53f45a5f", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Un sex-ratio en d\u00e9faveur\ndes femmes \u00e9tait observ\u00e9 dans chaque territoire\nultramarin. On observait entre les 4 DROM une \u00e9l\u00e9vation importante de la pr\u00e9valence du diab\u00e8te conn u\nen fonction de l'\u00e2ge, avec un rapport de 1 \u00e0 10 entre\nla classe d'\u00e2ge des 18-49 ans et celle des 70-85 ans,\nquel que soit le sexe.\n\u00c0 La R\u00e9union et en Guadeloupe, la pr\u00e9valence du\ndiab\u00e8te connu \u00e9tait significativement plus importante\nchez les personnes n\u00e9es dans les DROM que parmi\ncelles n\u00e9es dans l'Hexagone et dans une moindre\nmesure parmi celles n\u00e9es \u00e0 l'\u00e9tr anger. On notait, en\nGuyane, une sp\u00e9cificit\u00e9 par rapport aux autres terri -\ntoires avec une pr\u00e9valence tr\u00e8s \u00e9lev\u00e9e du diab\u00e8te\nconnu chez les femmes n\u00e9es \u00e0 l'\u00e9tr anger (16,6%),\npr\u00e9dominant notamment chez les femmes \u00e2g\u00e9es\nde plus de 70 ans.\nEnfin une pr\u00e9valence plus \u00e9lev\u00e9e \u00e9tait observ\u00e9e\nchez les personnes ayant des revenus plus faibles,\nc'est-\u00e0-dire se situant dans les deux premiers\nterciles. De la m\u00eame mani\u00e8re, il existait un gradient\nd\u00e9croissant de la pr\u00e9valence en fonction du niveau\nd'\u00e9tudes et un gradient croissant en fonction\nde l'IMC.\nLe \u00ab petit diab\u00e8te \u00bb\nLa fr\u00e9quence du \u00ab petit diab\u00e8te \u00bb parmi les per -\nsonnes n'ayant pas d\u00e9clar\u00e9 un diab\u00e8te \u00e9tait estim\u00e9e\n\u00e0 3,6% en Guadeloupe, 4,1% en Martinique, 2,5%\nen Guyane et 3,4% \u00e0 La R\u00e9union (tableau 3). Le\nsex-ratio \u00e9tait comparable \u00e0 celui du diab\u00e8te\nconnu sauf \u00e0 La R\u00e9union o\u00f9 il \u00e9tait sup\u00e9rieur chez\nles hommes par rapport aux femmes. La r\u00e9parti -\ntion selon les autres caract\u00e9ristiques sociod\u00e9mo -\ngraphiques \u00e9tait globalement \u00e9quivalente \u00e0 celle\ndu diab\u00e8te.\nCaract\u00e9ristiques et prise en charge du diab\u00e8te\net du \u00ab petit diab\u00e8te \u00bb\nLes caract\u00e9ristiques de la population ayant un\ndiab\u00e8te connu sont pr\u00e9sent\u00e9es dans le tableau 4.\nIl existait des disparit\u00e9s territoriales conc ernant\nl'anciennet\u00e9 du diab\u00e8te : en Guadeloupe, la pro -\nportion des personnes ayant un diab\u00e8te conn u\ndepuis plus de 10 ans s'\u00e9le vait \u00e0 54,8% cont re\n49,1% en Guadeloupe, 43,2% \u00e0 La R\u00e9union et\nseulement 39,8% en Guyane. Concernant le \u00ab petit\ndiab\u00e8te \u00bb, on retrouvait une anciennet\u00e9 beaucoup\nmoins importante : moins de 6 mois pour 26,5% et\nentre 6 mois et un an pour 19,5% de la population.", "mimetype": "text/plain", "start_char_idx": 1892, "end_char_idx": 4054, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "728e6ba6-610e-490d-a14f-b14860d6520d": {"__data__": {"id_": "728e6ba6-610e-490d-a14f-b14860d6520d", "embedding": null, "metadata": {"page_label": "426", "file_name": "2023_20-21.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2023_20-21.pdf", "file_type": "application/pdf", "file_size": 1372902, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "c530fd5c-b2f8-401a-9a29-5215a0c47658", "node_type": "4", "metadata": {"page_label": "426", "file_name": "2023_20-21.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2023_20-21.pdf", "file_type": "application/pdf", "file_size": 1372902, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "d11dbd866ff65e2e0d9cd3992169b5cf442eefc184ffbf2aeb307e51139e06ee", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "97716d14-bb84-4bff-9928-7e2f9da5d4e5", "node_type": "1", "metadata": {"page_label": "426", "file_name": "2023_20-21.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2023_20-21.pdf", "file_type": "application/pdf", "file_size": 1372902, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "d9205a94bab99b6e7a9913d2109fc0e220ed5c89dcfb88473b9eace6d0d4a3e5", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Concernant le \u00ab petit\ndiab\u00e8te \u00bb, on retrouvait une anciennet\u00e9 beaucoup\nmoins importante : moins de 6 mois pour 26,5% et\nentre 6 mois et un an pour 19,5% de la population.\nCependant 18,5% pr\u00e9sentai ent une anciennet\u00e9\nd'au moins 2 ans.\nLe recours \u00e0 un traitement pharmacologique variait\nsignificativement selon les DROM : 82,4% des\npersonnes ayant un diab\u00e8te conn u \u00e9taient trai -\nt\u00e9es pharmacologiquement \u00e0 La R\u00e9union, cont re\n90,1% en Guyane, 91,7% en Martinique et 93% en\nGuadeloupe (tableau 4). Parmi les personnes actuel -\nlement trait\u00e9es, pr\u00e8s de 21% d\u00e9claraient une adh\u00e9 -\nsion incompl\u00e8te, c'est -\u00e0-dire qu'elles avaient d\u00e9j\u00e0\narr\u00eat\u00e9 leur traitement au moins une fois, un chiffre\nTableau 1\nDescription de la population d'\u00e9tude chez les personnes \u00e2g\u00e9es de 18-85 ans. Barom\u00e8tre de Sant\u00e9 publique France, 2021\nGuadeloupe N=1 511 Martinique N=1 526 Guyane N=1 478 La R\u00e9union N=2 004\n[IC95%] [IC95%] [IC95%] [IC95%]\nFemmes (%) 55,5 [52,4-58,5] 55,0 [52,1-58,0] 54,4 [51,0-57,8] 53,4 [50,6-56,1]\n\u00c2ge moyen (ans) 50,7 [49,5-51,9] 52,0 [50,9-53,0] 42,0 [40,8-43,1] 46,8 [45,8-47,8]\nN : effectif ; IC95% : intervalle de confiance \u00e0 95%.", "mimetype": "text/plain", "start_char_idx": 3884, "end_char_idx": 5015, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "cb5e4a93-c1ce-4f04-8261-261d1c27a3f4": {"__data__": {"id_": "cb5e4a93-c1ce-4f04-8261-261d1c27a3f4", "embedding": null, "metadata": {"page_label": "427", "file_name": "2023_20-21.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2023_20-21.pdf", "file_type": "application/pdf", "file_size": 1372902, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "3384ed57-4045-425a-b8f1-c654c2a8a73d", "node_type": "4", "metadata": {"page_label": "427", "file_name": "2023_20-21.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2023_20-21.pdf", "file_type": "application/pdf", "file_size": 1372902, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "603df265e0576daeea03ebc8b1b19de86c29437dfa243616ed4989e2433815ee", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d9e42c6a-e2df-4dc8-a6ed-4e6943cbdf22", "node_type": "1", "metadata": {}, "hash": "34bb1c6137f6a9bfe8fbb9625f22fe23a73f8db92df1deb4971dc91b713dfd12", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Diab\u00e8te en outre-mer : comprendre les sp\u00e9cificit\u00e9s locales pour cibler les actions BEH 20-21 | 14 novembre 2023 | 427\nassez homog\u00e8ne dans les 4 territoires ultramarins.\nCe ph\u00e9nom\u00e8ne \u00e9tait plus souvent rapport\u00e9 par les\nhommes que les femmes (tableau 4). Globalement,\nles raisons des arr\u00eats de traitement cit\u00e9es \u00e9taient\nli\u00e9es au \u00ab rejet du m\u00e9dicament \u00bb (30,1%, IC95%:\n[19,4-42,5]), \u00e0 un oubli ponctuel (28,2% [19,6-38,2]),\naux effets secondaires (18,9% [ 11,0-29,4]), \u00e0 une\nrupture de m\u00e9dicaments (7,5% [2,1-18,1]), \u00e0 la substitution par des plantes (6,9% [ 2,6-14,3]), ou plus\nrarement \u00e0 une perte de poids (4,1% [1,1-10,4]) ou\nau ressenti d'un manque d'effi cacit\u00e9 du traitement\n(1,2% [0,1-4,8]). Parmi les personnes non trait\u00e9es,\n26,8% [7,8-55,2] des r\u00e9sidents de Guadeloupe\navaient d\u00e9j\u00e0 eu recours \u00e0 un traitement phar -\nmacologique, 34,8% [13,4-62,1] en Martinique,\n21,7% [2,9-58,1] en Guyane et 10,1% [3,5-21,6]\n\u00e0 La R\u00e9union.\nLes personnes pr\u00e9sentant un diab\u00e8te conn u, mais\nnon trait\u00e9es pharmacologiquement, rapportaient\nrecourir \u00e0 d'aut res types de mesures. Le plus\nsouvent, plusieurs mesures \u00e9taient cit\u00e9es, notam -\nment un r\u00e9gime alimentaire (42%), l'activit\u00e9 physique\n(33,3%), l'autosurveillance glyc\u00e9mique (14,2%)\nou encore l'uti lisation de plantes (25,9%). Enfin,\n44% des personnes avec un diab\u00e8te non trait\u00e9\npharmaco logiquement d\u00e9claraient ne recourir \u00e0\naucune mesure recommand\u00e9e dans le cadre de la\nprise en charge d'un diab\u00e8te : 34,7% citaient ne\nrecourir \u00e0 aucune mesure et 8,8% avaient d\u00e9clar\u00e9\nun recours exclusif aux plantes.\nParmi les personnes d\u00e9clarant un \u00ab petit diab\u00e8te \u00bb,\n19,5% pr\u00e9cisaient \u00eatre trait\u00e9es par des agents antihyperglyc\u00e9miants oraux. Le recours \u00e0 des strat\u00e9 -\ngies hygi\u00e9no-di\u00e9t\u00e9tiques comme le r\u00e9gime (45,7%),\nl'activit\u00e9 physique (41,4%) et l'aut osurveillance\nglyc\u00e9mique (23,2%) \u00e9tait fr\u00e9quent.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1834, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "d9e42c6a-e2df-4dc8-a6ed-4e6943cbdf22": {"__data__": {"id_": "d9e42c6a-e2df-4dc8-a6ed-4e6943cbdf22", "embedding": null, "metadata": {"page_label": "427", "file_name": "2023_20-21.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2023_20-21.pdf", "file_type": "application/pdf", "file_size": 1372902, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "3384ed57-4045-425a-b8f1-c654c2a8a73d", "node_type": "4", "metadata": {"page_label": "427", "file_name": "2023_20-21.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2023_20-21.pdf", "file_type": "application/pdf", "file_size": 1372902, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "603df265e0576daeea03ebc8b1b19de86c29437dfa243616ed4989e2433815ee", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "cb5e4a93-c1ce-4f04-8261-261d1c27a3f4", "node_type": "1", "metadata": {"page_label": "427", "file_name": "2023_20-21.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2023_20-21.pdf", "file_type": "application/pdf", "file_size": 1372902, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "e0277a968b5c4da256b96245f29bd2e25188003ed1e4bfe59453bf82819bbf02", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "847fd2e4-ee3c-46b6-8afc-22641b581e23", "node_type": "1", "metadata": {}, "hash": "8e33ebc8c7a7d3db12ec78d670bd017f279dc7827e4b6766f52acbe8e70e148b", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Parmi les personnes d\u00e9clarant un \u00ab petit diab\u00e8te \u00bb,\n19,5% pr\u00e9cisaient \u00eatre trait\u00e9es par des agents antihyperglyc\u00e9miants oraux. Le recours \u00e0 des strat\u00e9 -\ngies hygi\u00e9no-di\u00e9t\u00e9tiques comme le r\u00e9gime (45,7%),\nl'activit\u00e9 physique (41,4%) et l'aut osurveillance\nglyc\u00e9mique (23,2%) \u00e9tait fr\u00e9quent. L 'utilisation des\nplantes (24,4%) \u00e9tait cit\u00e9e dans des proportions\nproches de la population avec un diab\u00e8te non trait\u00e9\n(tableau 5) mais aucune personne n'ava it un recours\nexclusif aux plantes.\nParmi les personnes ayant un diab\u00e8te connu, seulement 3,4% de celles trait\u00e9es pharmacologiquement\net 14,5% de celles non trait\u00e9es pharmacologique -\nment n'avaient pas consult\u00e9 un m\u00e9decin g\u00e9n\u00e9raliste\ndans les douze derniers mois. Parmi les personnes\nd\u00e9clarant un \u00ab petit diab\u00e8te \u00bb, cette part s'\u00e9le vait\n\u00e0 9,8% chez celles qui prenaient un agent antihyperglyc\u00e9miant oral cont re 14,5% pour celles non\ntrait\u00e9es pharmacologiquement.\nTableau 2\nTaux de pr\u00e9valence du diab\u00e8te connu global et d\u00e9clin\u00e9 par groupe de population chez les personnes \u00e2g\u00e9es de 18-85 ans.\nBarom\u00e8tre de Sant\u00e9 publique France, 2021\nGuadeloupe N=1 511 Martinique N=1 526 Guyane N=1 478 La R\u00e9union N=2 004\n% [IC 95%] % [IC 95%] % [IC 95%] % [IC 95%]\nPr\u00e9valence du diab\u00e8te connu 12,0 [10,0-14,2] 11,5 [9,6-13,7] 11,6 [9,1-14,5] 13,6 [11,8-15,7]\nSexe\nFemmes 13,2 [10,5-16,3] 12,0 [9,4-15,0] 13,4 [9,6-18,0] 14,1 [11,7-16,7]\nHommes 10,5 [7,8-13,7] 10,9 [8,0-14,3] 9,6 [6,6-13,2] 13,1 [10,2-16,5]\nClasse d'\u00e2ge\n18-49 ans 2,2 [1,2-3,7] 2,4 [1,2-4,3] 4,5 [3,0-6,6] 5,1 [3,5-7,1]\n50-59 ans 13,8 [9,2-19,5] 9,9 [6,9-13,8] 18,5 [11,4-27,6] 16,4 [12,4-21,1]\n60-69 ans 17,", "mimetype": "text/plain", "start_char_idx": 1546, "end_char_idx": 3155, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "847fd2e4-ee3c-46b6-8afc-22641b581e23": {"__data__": {"id_": "847fd2e4-ee3c-46b6-8afc-22641b581e23", "embedding": null, "metadata": {"page_label": "427", "file_name": "2023_20-21.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2023_20-21.pdf", "file_type": "application/pdf", "file_size": 1372902, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "3384ed57-4045-425a-b8f1-c654c2a8a73d", "node_type": "4", "metadata": {"page_label": "427", "file_name": "2023_20-21.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2023_20-21.pdf", "file_type": "application/pdf", "file_size": 1372902, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "603df265e0576daeea03ebc8b1b19de86c29437dfa243616ed4989e2433815ee", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d9e42c6a-e2df-4dc8-a6ed-4e6943cbdf22", "node_type": "1", "metadata": {"page_label": "427", "file_name": "2023_20-21.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2023_20-21.pdf", "file_type": "application/pdf", "file_size": 1372902, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "3f1812818aea61251ece780a2ed12364598a1ecaf68bcee250cf52f747258d05", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c3fcf789-a758-4065-8f92-e6155bc44a3e", "node_type": "1", "metadata": {}, "hash": "c2bca55e88dfb1cbe16f15cff9d547ae68be5091de8e1a4bddc355386c9351fe", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "4 [1,2-4,3] 4,5 [3,0-6,6] 5,1 [3,5-7,1]\n50-59 ans 13,8 [9,2-19,5] 9,9 [6,9-13,8] 18,5 [11,4-27,6] 16,4 [12,4-21,1]\n60-69 ans 17,9 [13,0-23,8] 20,2 [14,7-26,7] 27,2 [16,7-39,9] 26,3 [20,4-32,9]\n70-85 ans 30,0 [22,4-38,5] 25,2 [18,4-33,1] 49,6 [31,7-67,7] 35,4 [26,7-44,9]\nLieu de naissance\nHexagone 1,2 [0,2-3,8] 5,7 [2,2-11,5] 4,6 [1,9-9,2] 3,3 [1,4-6,6]\nDROM 14,1 [11,6-16,7] 12,6 [10,3-15,0] 11,6 [8,3-15,7] 15,6 [13,4-18,0]\n\u00c0 l'\u00e9tranger ou TOM 9,0 [4,8-15,1] 7,0 [2,0-16,6] 13,1 [9,0-18,3] 9,9 [5,4-16,4]\nRevenu/unit\u00e9 de consommation\n1er tercile (revenus plus faibles) 12,0 [8,1-16,8%] 12,2 [8,4-17,0] 15,2 [10,0-21,9] 17,3 [13,5-21,6]\n2e tercile 16,2 [12,3-20,7] 13,6 [10,0-17,9] 10,2 [6,4-15,2] 15,2 [12,0-19,0]\n3e tercile (revenus plus \u00e9lev\u00e9s) 8,3 [5,8-11,5] 8,8 [6,3-11,9] 7,4 [4,7-11,1] 8,2 [5,9-11,0]\nNSP/Refus 9,4 [5,2-15,5] 11,0 [5,7-18,8] 10,8 [6,1-17,2] 12,4 [7,0-19,8]\nIndice de masse corporellea\n<25 kg/m\u00b2 7,0 [4,9-9,7] 7,3 [5,2-9,8] 5,0 [2,8-8,3] 8,1 [6,3-10,", "mimetype": "text/plain", "start_char_idx": 3027, "end_char_idx": 4002, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "c3fcf789-a758-4065-8f92-e6155bc44a3e": {"__data__": {"id_": "c3fcf789-a758-4065-8f92-e6155bc44a3e", "embedding": null, "metadata": {"page_label": "427", "file_name": "2023_20-21.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2023_20-21.pdf", "file_type": "application/pdf", "file_size": 1372902, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "3384ed57-4045-425a-b8f1-c654c2a8a73d", "node_type": "4", "metadata": {"page_label": "427", "file_name": "2023_20-21.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2023_20-21.pdf", "file_type": "application/pdf", "file_size": 1372902, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "603df265e0576daeea03ebc8b1b19de86c29437dfa243616ed4989e2433815ee", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "847fd2e4-ee3c-46b6-8afc-22641b581e23", "node_type": "1", "metadata": {"page_label": "427", "file_name": "2023_20-21.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2023_20-21.pdf", "file_type": "application/pdf", "file_size": 1372902, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "cd1d642818f9c42cdc56ee58798233d6693e725a733bfea958b678c9dcd44060", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "0 [5,7-18,8] 10,8 [6,1-17,2] 12,4 [7,0-19,8]\nIndice de masse corporellea\n<25 kg/m\u00b2 7,0 [4,9-9,7] 7,3 [5,2-9,8] 5,0 [2,8-8,3] 8,1 [6,3-10,2]\nEntre 25 et 29,9 kg/m\u00b2 13,0 [9,4-17,2] 11,0 [7,8-15,0] 14,6 [10,2-20,0] 17,0 [13,3-21,1]\n\u226530 kg/m\u00b2 21,8 [16,3-28,1] 18,6 [13,9-24,2] 20,2 [12,9-29,4] 25,9 [19,2-33,4]\nIC95% : intervalle de confiance \u00e0 95% ; N : effectif ; DROM : d\u00e9partements et r\u00e9gions d'outre-mer ; TOM : territoires d'outre-mer ; NSP : ne sait pas.\na Indice de masse corporelle = poids/taille2.", "mimetype": "text/plain", "start_char_idx": 3865, "end_char_idx": 4368, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "da95f77e-63f3-42d4-8297-6feddc5b841b": {"__data__": {"id_": "da95f77e-63f3-42d4-8297-6feddc5b841b", "embedding": null, "metadata": {"page_label": "428", "file_name": "2023_20-21.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2023_20-21.pdf", "file_type": "application/pdf", "file_size": 1372902, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "2bed1749-f5a5-4300-9721-36e2ad829cf6", "node_type": "4", "metadata": {"page_label": "428", "file_name": "2023_20-21.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2023_20-21.pdf", "file_type": "application/pdf", "file_size": 1372902, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "b74662159b1e3f4af1f31de61f6614dd98c466fc3fc4e5bafb380d904bf9182f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "dbd9bf29-7754-4ed3-b887-f3a05e8fa8ed", "node_type": "1", "metadata": {}, "hash": "1fc9c616ac27cebf97acf4f4d8c71c57149e6b9417245c26bd930baff3002b56", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "428 | 14 novembre 2023 | BEH 20-21 Diab\u00e8te en outre-mer : comprendre les sp\u00e9cificit\u00e9s locales pour cibler les actions\nTableau 3\nPr\u00e9valence du \u00ab petit diab\u00e8te \u00bb parmi les personnes \u00e2g\u00e9es de 18-85 ans n'ayant pas d\u00e9clar\u00e9 un diab\u00e8te.\nBarom\u00e8tre de Sant\u00e9 publique France, 2021\nGuadeloupe N=1 353 Martinique N=1 371 Guyane N=1 351 La R\u00e9union N=1 745\n% [IC95%] % [IC95%] % [IC95%] % [IC95%]\nPr\u00e9valence du \u00ab petit diab\u00e8te \u00bb 3,6 [2,5-5,0] 4,1 [2,9-5,7] 2,5 [1,5-4,1] 3,4 [2,4-4,6]\nSexe\nFemmes 4,0 [2,5-6,1] 4,6 [2,8-7] 3,3 [1,6-6,1] 2,8 [1,8-4,2]\nHommes 3,1 [1,6-5,3] 3,6 [2,0-6,0] 1,6 [0,7-3,2] 4,0 [2,3-6,3]\nClasse d'\u00e2ge\n18-49 ans 2,0 [0,8-4,1] 2,6 [1,2-4,9] 1,6 [0,8-2,9] 1,7 [0,8-3,1]\n50-59 ans 3,9 [1,9-7,1] 6,4 [3,4-10,9] 4,4 [1,0-11,8] 6,0 [3,2-10]\n60-69 ans 5,2 [2,6-9,2] 2,8 [1,1-5,8] 7,3 [1,9-18,0] 7,1 [3,5-12,6]\n70-85 ans 7,1 [3,0-14,0] 7,2 [3,0-14,2] - 3,7 [1,0-9,0]\nLieu de naissance\nHexagone 3,2 [0,9-7,9] 1,9 [0,2-6,9] 1,2 [0,2-3,9] 0,9 [0,1-2,7]\nDROM 3,9 [2,5-5,6] 4,1 [2,8-5,9] 2,2 [1,0-4,1] 3,8 [2,6-5,3]\n\u00c0 l'\u00e9tranger ou TOM 2,7 [0,6-7,2] 7,7 [1,7-20,3] 3,2 [1,3-6,", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1075, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "dbd9bf29-7754-4ed3-b887-f3a05e8fa8ed": {"__data__": {"id_": "dbd9bf29-7754-4ed3-b887-f3a05e8fa8ed", "embedding": null, "metadata": {"page_label": "428", "file_name": "2023_20-21.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2023_20-21.pdf", "file_type": "application/pdf", "file_size": 1372902, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "2bed1749-f5a5-4300-9721-36e2ad829cf6", "node_type": "4", "metadata": {"page_label": "428", "file_name": "2023_20-21.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2023_20-21.pdf", "file_type": "application/pdf", "file_size": 1372902, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "b74662159b1e3f4af1f31de61f6614dd98c466fc3fc4e5bafb380d904bf9182f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "da95f77e-63f3-42d4-8297-6feddc5b841b", "node_type": "1", "metadata": {"page_label": "428", "file_name": "2023_20-21.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2023_20-21.pdf", "file_type": "application/pdf", "file_size": 1372902, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "1a339b5cbf5f5d119d93e98f1fdad5615ac2447b3396ac25f0bcf1fec8d2b729", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c0c24fd2-0349-4dc7-8ac6-d8f1d6eebd54", "node_type": "1", "metadata": {}, "hash": "f287e51b24cd967389901b4681e4959b1cf058b8049c06f167f580a7be928dd2", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "7]\nDROM 3,9 [2,5-5,6] 4,1 [2,8-5,9] 2,2 [1,0-4,1] 3,8 [2,6-5,3]\n\u00c0 l'\u00e9tranger ou TOM 2,7 [0,6-7,2] 7,7 [1,7-20,3] 3,2 [1,3-6,3] 4,1 [1,1-10,4]\nRevenu/unit\u00e9 de consommation\n1er tercile (revenus plus faibles) 3,6 [1,5-7,0] 6,4 [3,2-11,3] 2,3 [0,9-4,9] 4,8 [2,6-8,0]\n2e tercile 4,3 [2,2-7,4] 4,0 [1,9-7,4] 3,3 [1,5-6,2] 3,6 [1,9-6,1]\n3e tercile (revenus plus \u00e9lev\u00e9s) 3,4 [1,7-5,8] 3,0 [1,4-5,6] 1,1 [0,3-2,8] 1,6 [0,7-3,0]\nNSP/Refus 2,8 [0,7-7,3] 3,4 [1,3-7,3] 3,4 [0,6-10,3] 3,4 [1,1-8,0]\nIndice de masse corporellea\n<25 kg/m\u00b2 3,2 [1,8-5,4] 1,6 [0,7-3,2] 2,7 [1,0-5,5] 2,7 [1,5-4,5]\nEntre 25 et 29,9 kg/m\u00b2 2,5 [1,1-4,9] 4,4 [2,3-7,5] 1,0 [0,3-2,5] 4,4 [2,5-7,5]\n\u226530 kg/m\u00b2 4,7 [2,2-8,8] 10,5 [6,1-16,6] 4,3 [1,9-8,3] 4,9 [2,5-8,5]\nIC95% : intervalle de confiance \u00e0 95% ; DROM : d\u00e9partements et r\u00e9gions d'outre-mer ; TOM : territoires d'outre-mer ; NSP : ne sait pas.\na Indice de masse corporelle = poids/taille2.\nTableau 4\nAnciennet\u00e9 du diab\u00e8te et recours au traitement pharmacologique des personnes \u00e2g\u00e9es de 18-85 ans, ayant un diab\u00e8te connu.", "mimetype": "text/plain", "start_char_idx": 951, "end_char_idx": 1990, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "c0c24fd2-0349-4dc7-8ac6-d8f1d6eebd54": {"__data__": {"id_": "c0c24fd2-0349-4dc7-8ac6-d8f1d6eebd54", "embedding": null, "metadata": {"page_label": "428", "file_name": "2023_20-21.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2023_20-21.pdf", "file_type": "application/pdf", "file_size": 1372902, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "2bed1749-f5a5-4300-9721-36e2ad829cf6", "node_type": "4", "metadata": {"page_label": "428", "file_name": "2023_20-21.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2023_20-21.pdf", "file_type": "application/pdf", "file_size": 1372902, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "b74662159b1e3f4af1f31de61f6614dd98c466fc3fc4e5bafb380d904bf9182f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "dbd9bf29-7754-4ed3-b887-f3a05e8fa8ed", "node_type": "1", "metadata": {"page_label": "428", "file_name": "2023_20-21.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2023_20-21.pdf", "file_type": "application/pdf", "file_size": 1372902, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "5f729064ba9dbd58d8832d0f59ed81c2276f0e51eb4125c090f8605ba44f50ef", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "DROM : d\u00e9partements et r\u00e9gions d'outre-mer ; TOM : territoires d'outre-mer ; NSP : ne sait pas.\na Indice de masse corporelle = poids/taille2.\nTableau 4\nAnciennet\u00e9 du diab\u00e8te et recours au traitement pharmacologique des personnes \u00e2g\u00e9es de 18-85 ans, ayant un diab\u00e8te connu.\nBarom\u00e8tre de Sant\u00e9 publique France, 2021\nGuadeloupe N=158 Martinique N=155 Guyane N=127 La R\u00e9union N=259\n% [IC95%] % [IC95%] % [IC95%] % [IC95%]\nAnciennet\u00e9 du diab\u00e8te\nMoins de 5 ans 27,0 [19,4-35,7] 27,0 [19,6-35,6] 39,9 [27,7-53,0] 35,8 [28,6-43,5]\n5 \u00e0 10 ans 23,9 [16,6-32,6] 18,2 [11,9-26,1] 20,3 [11,9-31,2] 21,1 [15,1-28,1]\nPlus de 10 ans 49,1 [39,9-58,4] 54,8 [45,2-64,2] 39,8 [27,7-53,0] 43,2 [35,6-51,0]\nRecours \u00e0 un traitement pharmacologique\nDiab\u00e8te trait\u00e9 pharmacologiquement 93,0 [87,8-96,5] 91,7 [86,2-95,5] 90,1 [83,3-94,8] 82,4 [76,3-87,5]\nA d\u00e9j\u00e0 interrompu son traitement\nparmi les personnes trait\u00e9es\npharmacologiquement\nN*=142 N*=139 N*=106 N*=207\nHommes et femmes 21,8 [14,2-31,0] 28,2 [19,2-38,7] 22,9 [14,0-34,1] 16,9 [11,2-23,9]\nFemmes 18,0 [10,0-28,7] 24,9 [15,0-37,2] 21,0 [9,8-36,8] 10,3 [5,7-16,8]\nHommes 28,0 [14,4-45,3] 32,4 [17,6-50,4] 26,1 [13,8-42,0] 24,8 [14,1-38,4]\nIC95% : intervalle de confiance \u00e0 95%.\nN* : effectif de personnes trait\u00e9es pharmacologiquement dans l'\u00e9chantillon.", "mimetype": "text/plain", "start_char_idx": 1718, "end_char_idx": 3003, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "dc0009d5-e47a-4ee9-9370-00d5844aa05f": {"__data__": {"id_": "dc0009d5-e47a-4ee9-9370-00d5844aa05f", "embedding": null, "metadata": {"page_label": "429", "file_name": "2023_20-21.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2023_20-21.pdf", "file_type": "application/pdf", "file_size": 1372902, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "e14c7d12-a39d-419c-a7ca-d0fdb0b07031", "node_type": "4", "metadata": {"page_label": "429", "file_name": "2023_20-21.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2023_20-21.pdf", "file_type": "application/pdf", "file_size": 1372902, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "3dc6d2632df4081ded09d3049ccb22ff1d8f0e927e6fe022fcef1d422790c0ef", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "61de57de-f2aa-43f4-ab25-b74313ee4d8c", "node_type": "1", "metadata": {}, "hash": "8129ac6185aff5e2c537edcbf54f77baa101f15f28e3a3101e68b23c1f1a8a22", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Diab\u00e8te en outre-mer : comprendre les sp\u00e9cificit\u00e9s locales pour cibler les actions BEH 20-21 | 14 novembre 2023 | 429\nDiscussion\nLe Barom\u00e8tre de Sant\u00e9 publique France 2021,\nenqu\u00eate sur un \u00e9chantillon probabiliste de la\npopulation g\u00e9n\u00e9rale adulte, a permis d'estimer la\npr\u00e9valence du diab\u00e8te conn u parmi les personnes\n\u00e2g\u00e9es de 18 \u00e0 85 ans r\u00e9sidant dans quatre DROM : la\nGuadeloupe, la Martinique, la Guyane et La R\u00e9union.\nGlobalement, la pr\u00e9valence \u00e9tait similaire aux\nAntilles et en Guyane (environ 12%) et plus \u00e9lev\u00e9e\n\u00e0 La R\u00e9union (13,6%), alors que la population\nr\u00e9u nionnaise s'av\u00e8re plus jeune (47 ans en moyenne)\nque la population des Antilles. De m\u00eame, en Guyane,\nla similitude du taux avec les Antilles masque une\nsituation plus d\u00e9grad\u00e9e du fait de la jeunesse de la\npopulation (42 ans en moyenne vs 51 et 52 ans en\nGuadeloupe et Martinique).\nNotre \u00e9tude a permis \u00e9galement d'est imer la part\ndu diab\u00e8te trait\u00e9 pharmacologiquement parmi les\ncas de diab\u00e8te conn u qui varie selon les territoires,\nentre 90 et 93% en Guyane et aux Antilles et 82%\n\u00e0 La R\u00e9union.\nPar rapport aux \u00e9tudes ant\u00e9rieures men\u00e9es dans\nces territoires, l'\u00e9tu de R\u00e9dia 3 men\u00e9e en 1999-2001\n\u00e0 La R\u00e9union retrouvait une pr\u00e9valence du diab\u00e8te\nconnu de 10,7% chez les hommes \u00e2g\u00e9s de 30 \u00e0 69 ans\net 11,7% chez les femmes de la m\u00eame tranche d'\u00e2ge\ntandis que l'enqu\u00eate Kannari 10,11 men\u00e9e en 2013 aux\nAntilles d\u00e9crivait une pr\u00e9valence du diab\u00e8te conn u\nde 11% en Guadeloupe et 10% en Martinique\nchez les personnes \u00e2g\u00e9es de plus de 16 ans. Ces\ndonn\u00e9es apparaissent globalement comparables\navec les r\u00e9sultats obtenus par le Barom\u00e8tre de\nSant\u00e9 publique France en tenant comp te de l'\u00e2ge\ndiff\u00e9rent des populations d'\u00e9tu des. Plus r\u00e9cemment,\nl'enqu\u00eate europ\u00e9enne EHIS 2019 12 rapportait des\ntaux standardis\u00e9s de pr\u00e9valence similaires entre les\nquatre territoires \u00e9tudi\u00e9s. N\u00e9anmoins, la compara -\nbilit\u00e9 avec notre \u00e9tude est limit\u00e9e car les taux de\npr\u00e9valence sont standardis\u00e9s sur la structure d'\u00e2ge\nde la population de l'Hex agone. De plus, la question\nrelative \u00e0 la d\u00e9claration d'un diab\u00e8te n' \u00e9tait pos\u00e9e\nqu'aux personnes ayant d\u00e9clar\u00e9 une maladie chro -\nnique au pr\u00e9alable.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2142, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "61de57de-f2aa-43f4-ab25-b74313ee4d8c": {"__data__": {"id_": "61de57de-f2aa-43f4-ab25-b74313ee4d8c", "embedding": null, "metadata": {"page_label": "429", "file_name": "2023_20-21.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2023_20-21.pdf", "file_type": "application/pdf", "file_size": 1372902, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "e14c7d12-a39d-419c-a7ca-d0fdb0b07031", "node_type": "4", "metadata": {"page_label": "429", "file_name": "2023_20-21.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2023_20-21.pdf", "file_type": "application/pdf", "file_size": 1372902, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "3dc6d2632df4081ded09d3049ccb22ff1d8f0e927e6fe022fcef1d422790c0ef", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "dc0009d5-e47a-4ee9-9370-00d5844aa05f", "node_type": "1", "metadata": {"page_label": "429", "file_name": "2023_20-21.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2023_20-21.pdf", "file_type": "application/pdf", "file_size": 1372902, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "5f61c27cedf900692f40f8a501824ccd8aa7f76645be570c228bfc6954a8719c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5ddff8d7-c1ce-40d1-b257-fc7e8f9ff9b5", "node_type": "1", "metadata": {}, "hash": "0ffd344b8cc272b63273f783fe0d19164ec12c915e1eee98445046f84b0bfba0", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "N\u00e9anmoins, la compara -\nbilit\u00e9 avec notre \u00e9tude est limit\u00e9e car les taux de\npr\u00e9valence sont standardis\u00e9s sur la structure d'\u00e2ge\nde la population de l'Hex agone. De plus, la question\nrelative \u00e0 la d\u00e9claration d'un diab\u00e8te n' \u00e9tait pos\u00e9e\nqu'aux personnes ayant d\u00e9clar\u00e9 une maladie chro -\nnique au pr\u00e9alable.\nSi nous mettons ces r\u00e9sultats en perspective avec\nceux observ\u00e9s en France hexagonale, estim\u00e9s \u00e0\npartir des donn\u00e9es de l'\u00e9tude Esteban 6 en 2014-2016\nparmi des personnes \u00e2g\u00e9es de 18 \u00e0 74 ans, la pr\u00e9valence du diab\u00e8te connu \u00e9tait de 5,7% et 79% des cas\n\u00e9taient trait\u00e9s pharmacologiquement, une proportion\nnettement moindre que dans les quatre territoires\nde notre \u00e9tude. Concernant la situation \u00e0 Mayotte,\nl'\u00e9tude Unono Wa Maore rapportait en 2019 une\npr\u00e9valence du diab\u00e8te connu de 7,3% [6,1-8,5] parmi\nles personnes \u00e2g\u00e9es de 18 \u00e0 69 ans, soit plus faible\nque dans notre \u00e9tude. Quant \u00e0 la fr\u00e9quence du\ndiab\u00e8te m\u00e9connu, elle \u00e9tait de 4,7% [3,8-5,7] 4.\nNotre \u00e9tude ne permet pas d'est imer la pr\u00e9va -\nlence du diab\u00e8te m\u00e9connu car celle-ci ne peut \u00eatre\napproch\u00e9e qu'en croisant le statut individuel du\ndiab\u00e8te conn u (d\u00e9clar\u00e9) et le statut individuel\nmesur\u00e9 par un dosage biologique. Ainsi, dans les\n\u00e9tudes \u00e9pid\u00e9miologiques telles qu'Esteban 6 ou\nUnono Wa Maore 4 ou encore R\u00e9dia 3, l'estimation\nde la pr\u00e9valence du diab\u00e8te m\u00e9connu repose sur un\ndiagnostic de diab\u00e8te \u00e9tabli pendant l'\u00e9tu de \u00e0 partir\nd'un marqueur biologique (glyc\u00e9mie \u00e0 jeun ou\nHbA1c) en l'absence de d\u00e9claration du diab\u00e8te dans\nles questionnaires. Toutefois, cette d\u00e9claration, ou\nconnaissance de son diab\u00e8te, peut d\u00e9pendre de la\nperception que la personne a de sa maladie. Dans\nune population o\u00f9 le diab\u00e8te est fr\u00e9quent et o\u00f9 les\ncomplications du diab\u00e8te sont fr\u00e9quentes, comme\nc'est le cas dans les DROM, il est possible que des\npersonnes ne prennent cons cience de leur statut\nde malade que lorsque la maladie atteint un stade\navanc\u00e9, par exemple en raison d'un traitement par\ninsuline ou du diagnostic de comp lications graves\ndu diab\u00e8te.", "mimetype": "text/plain", "start_char_idx": 1837, "end_char_idx": 3850, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "5ddff8d7-c1ce-40d1-b257-fc7e8f9ff9b5": {"__data__": {"id_": "5ddff8d7-c1ce-40d1-b257-fc7e8f9ff9b5", "embedding": null, "metadata": {"page_label": "429", "file_name": "2023_20-21.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2023_20-21.pdf", "file_type": "application/pdf", "file_size": 1372902, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "e14c7d12-a39d-419c-a7ca-d0fdb0b07031", "node_type": "4", "metadata": {"page_label": "429", "file_name": "2023_20-21.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2023_20-21.pdf", "file_type": "application/pdf", "file_size": 1372902, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "3dc6d2632df4081ded09d3049ccb22ff1d8f0e927e6fe022fcef1d422790c0ef", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "61de57de-f2aa-43f4-ab25-b74313ee4d8c", "node_type": "1", "metadata": {"page_label": "429", "file_name": "2023_20-21.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2023_20-21.pdf", "file_type": "application/pdf", "file_size": 1372902, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "67b86a98f681c569b602489317d2ce1d53691d04c506689f0f61e826a4cc9be9", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Ainsi, le diab\u00e8te conn u peut diff\u00e9rer\ndu diab\u00e8te diagnostiqu\u00e9 et nous avons explor\u00e9 ce\nconcept, pour la premi\u00e8re fois, dans le Barom\u00e8tre\nTableau 5\nMode de recours parmi les personnes ayant un diab\u00e8te \u00e2g\u00e9es de 18-85 ans non trait\u00e9es pharmacologiquement\net celles pr\u00e9sentant un \u00ab petit diab\u00e8te \u00bb. Barom\u00e8tre de Sant\u00e9 publique France, 2021\nPersonnes ayant un diab\u00e8te\nnon trait\u00e9es pharmacologiquement\nN=103\nPersonnes ayant un \u00ab petit diab\u00e8te \u00bb\nN=179\n% [IC 95%] % [IC 95%]\nMode de recoursa\nR\u00e9gime alimentaire 42,0 [29,6-55,1] 45,7 [36,1-55,6]\nActivit\u00e9 physique 33,3 [22,0-46,2] 41,4 [31,9-51,3]\nContr\u00f4le r\u00e9gulier de la glyc\u00e9mie 14,2 [7,2-24,8] 23,2 [15,4-32,6]\nPlantes 25,9 [15,1-39,4] 24,4 [16,3-34,0]\nAutres moyens 5,0 [1,4-12,3] -\nAgents anti-hyperglyc\u00e9miants - 19,5 [13,1-27,2]\nAucun moyen 34,7 [23,2-47,5] 20,4 [13,7-28,5]\na R\u00e9ponses multiples.\nN : effectif ; IC95% : intervalle de confiance \u00e0 95%.", "mimetype": "text/plain", "start_char_idx": 3851, "end_char_idx": 4749, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "22ee08d7-615c-4b7b-ad9f-f4d7b98de330": {"__data__": {"id_": "22ee08d7-615c-4b7b-ad9f-f4d7b98de330", "embedding": null, "metadata": {"page_label": "430", "file_name": "2023_20-21.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2023_20-21.pdf", "file_type": "application/pdf", "file_size": 1372902, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "99296c5d-32e1-4b4d-a657-f0e871e56802", "node_type": "4", "metadata": {"page_label": "430", "file_name": "2023_20-21.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2023_20-21.pdf", "file_type": "application/pdf", "file_size": 1372902, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "bb82f105184f441b48b766fe52bb14f9ead4bbc09e0c52113bf7d2a748ccf33f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a7047167-62b3-4e36-97a2-7982c8c8cb45", "node_type": "1", "metadata": {}, "hash": "7418a4483049d794c006e9f6817c2f8bb1d91f4e8fd0115d9eb19642b8ecc8c7", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "430 | 14 novembre 2023 | BEH 20-21 Diab\u00e8te en outre-mer : comprendre les sp\u00e9cificit\u00e9s locales pour cibler les actions\nde Sant\u00e9 publique France DROM 2021 en intro -\nduisant la notion de \u00ab petit diab\u00e8te \u00bb. Cette notion,\nqui n'a aucun fondement clinique, est cependant\ncouramment utilis\u00e9e. Notre \u00e9tude exploratoire\npermet de la quantifier et de montrer qu'environ 3%,\nvoire 4%, des personnes se d\u00e9clarant non diab\u00e9 -\ntiques d\u00e9clarent tout de m\u00eame qu'un m\u00e9decin leur\na d\u00e9j\u00e0 dit qu'ils avaient un \u00ab petit diab\u00e8te \u00bb ou \u00ab un\nd\u00e9but de diab\u00e8te, mais pas trop grave \u00bb. Nous \u00e9mettons l'hypoth\u00e8se qu'il s'agirait d'un diab\u00e8te diagnos -\ntiqu\u00e9 mais \u00ab m\u00e9connu \u00bb par la personne. Toutefois,\nnos donn\u00e9es ne permettent pas d'\u00e9ca rter d'\u00e9ventuels cas de pr\u00e9diab\u00e8te. Ce sujet m\u00e9riterait d'\u00eatr e\napprofondi dans une \u00e9tude avec un examen de sant\u00e9\npermettant d 'en mesurer l'imp act sur le niveau de\ncontr\u00f4le glyc\u00e9mique, donc sur l'\u00e9tat de sant\u00e9 de ces\npersonnes. Par ailleurs, il serait int\u00e9ressant d'\u00e9tudier\ncette notion sous un angle anthropologique afin de\nmieux en comp rendre l'origine : une repr\u00e9senta -\ntion particuli\u00e8re de la maladie, de sa gravit\u00e9 et/ou\nun discours m\u00e9dical rassurant pour rendre comp te\nd'un processus naissant, \u00e9volutif, pas \u00ab grave \u00bb.\nEn outre, il serait int\u00e9ressant de mener une \u00e9tude\nsimilaire dans l'Hexagone afin d'\u00e9tudier s'il s'agit de\nparti cularit\u00e9s des populations et du syst\u00e8me m\u00e9dical\ndes territoires ultramarins.\nUne limite de notre \u00e9tude est le manque de puissance\nstatistique et la faible pr\u00e9cision de certains indica -\nteurs r\u00e9sultant de la taille de l'\u00e9ch antillon. Elle est\nparti culi\u00e8rement marqu\u00e9e lorsque l'on \u00e9tudie le sousgroupe des personnes d\u00e9clarant un \u00ab petit diab\u00e8te \u00bb\net le sous-groupe des personnes diab\u00e9tiques non\ntrait\u00e9es pharmacologiquement en raison de leur faible\npr\u00e9valence. Cela nous a cond uit \u00e0 d\u00e9crire le recours\naux soins de ces deux populations en regroupant les\nquatre territoires ultramarins. Les particularit\u00e9s de\nces quatre territoires, mises en lumi\u00e8re dans notre\n\u00e9tude, sugg\u00e8rent que ce regroupement pr\u00e9sente\nun int\u00e9r\u00eat limit\u00e9. N\u00e9anmoins, il s'agi t d'une premi\u00e8re\nexploration qui permet de d\u00e9crire les populations\nconcern\u00e9es et d'apporter des \u00e9l\u00e9ments pour orienter\ndes \u00e9tudes comp l\u00e9mentaires qu'il serait souhaitable\nde mettre en \u0153uvre.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2292, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "a7047167-62b3-4e36-97a2-7982c8c8cb45": {"__data__": {"id_": "a7047167-62b3-4e36-97a2-7982c8c8cb45", "embedding": null, "metadata": {"page_label": "430", "file_name": "2023_20-21.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2023_20-21.pdf", "file_type": "application/pdf", "file_size": 1372902, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "99296c5d-32e1-4b4d-a657-f0e871e56802", "node_type": "4", "metadata": {"page_label": "430", "file_name": "2023_20-21.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2023_20-21.pdf", "file_type": "application/pdf", "file_size": 1372902, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "bb82f105184f441b48b766fe52bb14f9ead4bbc09e0c52113bf7d2a748ccf33f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "22ee08d7-615c-4b7b-ad9f-f4d7b98de330", "node_type": "1", "metadata": {"page_label": "430", "file_name": "2023_20-21.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2023_20-21.pdf", "file_type": "application/pdf", "file_size": 1372902, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "ae146813d332501da7188208c779cfa9555f2b9b0751ca4ef2a8cd1740c6f4b3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6a5a14ba-7954-491e-ba99-1b0a12c500a9", "node_type": "1", "metadata": {}, "hash": "5e43ebed9aaa4838a2588e05d2d73eb075b09ae26c050881952622fb6e9a390e", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "N\u00e9anmoins, il s'agi t d'une premi\u00e8re\nexploration qui permet de d\u00e9crire les populations\nconcern\u00e9es et d'apporter des \u00e9l\u00e9ments pour orienter\ndes \u00e9tudes comp l\u00e9mentaires qu'il serait souhaitable\nde mettre en \u0153uvre. En effet, les personnes qui se\nd\u00e9clarent diab\u00e9tiques mais sans aucune prise en\ncharge ou celles qui d\u00e9clarent un \u00ab petit diab\u00e8te \u00bb\nnon pris en charge sont expos\u00e9es \u00e0 une hyper -\nglyc\u00e9mie d\u00e9l\u00e9t\u00e8re pour leurs organes. Par ailleurs,\nm\u00eame si elles sont prises en charge, les personnes\nne se d\u00e9clarant pas diab\u00e9tiques mais avec un \u00ab petit\ndiab\u00e8te \u00bb sont probablement moins engag\u00e9es dans\nla gestion de leur maladie. S'il est fondamental\nd'identifier le plus t\u00f4t possible le diab\u00e8te de type 2\nau stade asymptomatique, afin d'ini tier une prise en\ncharge visant \u00e0 pr\u00e9venir ou \u00e0 retarder le d\u00e9veloppe -\nment de complications micro- et macrovasculaires 2,\nle diagnostic doit \u00eatre imm\u00e9diatement suivi par\nune prise en charge adapt\u00e9e.\nConclusion\nNotre \u00e9tude rapporte une pr\u00e9valence \u00e9lev\u00e9e de cas\nde diab\u00e8te connu, non trait\u00e9s pharmacologiquement,\nparmi lesquels plus de 4 personnes sur 10 d\u00e9clarent\nne b\u00e9n\u00e9ficier d'auc une mesure hygi\u00e9no-di\u00e9t\u00e9tique.\nNous observons \u00e9galement une fr\u00e9quence impor -\ntante de personnes diab\u00e9tiques qui n'aur aient pas\nconscience de leur maladie. Du point de vue de la\nsurveillance \u00e9pid\u00e9miologique, nos r\u00e9sultats montrent\nque les \u00e9tudes bas\u00e9es sur les donn\u00e9es du Syst\u00e8me\nnational des donn\u00e9es de sant\u00e9 (SNDS) 13, qui mettent\nen lumi\u00e8re le fardeau du diab\u00e8te dans les territoires\nultramarins \u00e0 partir des donn\u00e9es de remboursement\ndes traitements pharmacologiques, sous estiment\nla r\u00e9alit\u00e9 du probl\u00e8me de sant\u00e9 publique.\nAinsi, s'il est essentiel de renforcer les mesures de\npr\u00e9vention primaire du diab\u00e8te, qui passent en premier\nlieu par la lutte contre l'ob\u00e9sit\u00e9 et la s\u00e9dentarit\u00e9, il est\n\u00e9galement fondamental de diagnostiquer pr\u00e9cocement\nle diab\u00e8te et de r\u00e9duire le d\u00e9lai entre le diagnostic et une\nprise en charge efficace des personnes atteintes d'un\ndiab\u00e8te de type 2. Un levier d'action pourrait passer par\nune sensibilisation collective, de la population g\u00e9n\u00e9rale\net des professionnels de sant\u00e9, \u00e0 la n\u00e9cessit\u00e9 de traiter\nle diab\u00e8te d\u00e8s sa survenue, par des mesures hygi\u00e9nodi\u00e9t\u00e9tiques voire pharmaco logiques, afin de retarder la\nsurvenue des complications associ\u00e9es. \u25a0\nLiens d'int\u00e9r\u00eat\nLes auteurs d\u00e9clarent ne pas avoir de liens d'int\u00e9r\u00eat au regard\ndu contenu de l'article.", "mimetype": "text/plain", "start_char_idx": 2081, "end_char_idx": 4490, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "6a5a14ba-7954-491e-ba99-1b0a12c500a9": {"__data__": {"id_": "6a5a14ba-7954-491e-ba99-1b0a12c500a9", "embedding": null, "metadata": {"page_label": "430", "file_name": "2023_20-21.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2023_20-21.pdf", "file_type": "application/pdf", "file_size": 1372902, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "99296c5d-32e1-4b4d-a657-f0e871e56802", "node_type": "4", "metadata": {"page_label": "430", "file_name": "2023_20-21.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2023_20-21.pdf", "file_type": "application/pdf", "file_size": 1372902, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "bb82f105184f441b48b766fe52bb14f9ead4bbc09e0c52113bf7d2a748ccf33f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a7047167-62b3-4e36-97a2-7982c8c8cb45", "node_type": "1", "metadata": {"page_label": "430", "file_name": "2023_20-21.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2023_20-21.pdf", "file_type": "application/pdf", "file_size": 1372902, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "12d6ab59db71175885dc3792d079ad54555df15d0c531e452413f0ef3104d1c5", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "\u25a0\nLiens d'int\u00e9r\u00eat\nLes auteurs d\u00e9clarent ne pas avoir de liens d'int\u00e9r\u00eat au regard\ndu contenu de l'article.\nR\u00e9f\u00e9rences\n[1] International Diabetes Federation. Diabetes Atlas 10 th edi -\ntion. Brussels: IDF; 2021. 141 p.\n[2] Ogurtsova K, Guariguata L, Barengo NC, Ruiz PL, Sacre JW,\nKaruranga S, et al. IDF diabetes Atlas: Global estimates of\nundiagnosed diabetes in adults for 2021. Diabetes Res Clin\nPract. 2022;183:109118.\n[3] Favier F, Jaussent I, Le Moullec N, Debussche X, Boyer MC,\nSchwager JC, et al. Prevalence of Type 2 diabetes and central\nadiposity in La Reunion Island, the REDIA Study. Diabetes Res\nClin Pract. 2005;67(3):234-42.\n[4] Azaz A, Jezewski-Serra D, Ruello M, Hassani Y, Piffaretti C,\nFosse-Edorh S. Estimation de la pr\u00e9valence du diab\u00e8te et\ndu pr\u00e9diab\u00e8te \u00e0 Mayotte et caract\u00e9ristiques des personnes\ndiab\u00e9tiques, Mayotte, 2019. Bull \u00c9pid\u00e9miol Hebd. 2022;(9-10):\n164-9.\n9-10_1.html\n[5] Lailler G, Fuentes S, Kab S, Piffaretti C, Guion M,\nCzernichow S, et al. Prevalence and risk factors associated\nwith prediabetes and undiagnosed diabetes in France: The\nnational CONSTANCES cohort. Diabet Epidemiol Manag.\n2023;10.\n[6] Lailler G, Piffaretti C, Fuentes S, Nabe HD, Oleko A,\nCosson E, et al. Prevalence of prediabetes and undiagnosed\ntype 2 diabetes in France: Results from the national survey\nESTEBAN, 2014-2016. Diabetes Res Clin Pract. 2020;165:\n108252.\n[7] Fosse-Edorh S, Mandereau-Bruno L, Piffaretti C. Le poids\ndu diab\u00e8te en France en 2016. Synth\u00e8se \u00e9pid\u00e9miologique.\nSaint-Maurice: Sant\u00e9 publique France; 2018. 8 p.\nsantepubliquefrance.fr/maladies-et-traumatismes/diabete/\ndocuments/rapport-synthese/le-poids-du-diabete-enfrance-en-2016.-synthese-epidemiologique\n[8] Soullier N, Richard JB, Gautier A. Barom\u00e8tre de sant\u00e9\npublique France 2019. M\u00e9thode. Saint-Maurice: Sant\u00e9 publique\nFrance; 2021. 14 p.\nbarometre-de-sante-publique-france-2019-methode", "mimetype": "text/plain", "start_char_idx": 4384, "end_char_idx": 6259, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "4f469750-5982-48fe-8575-9f11431cf462": {"__data__": {"id_": "4f469750-5982-48fe-8575-9f11431cf462", "embedding": null, "metadata": {"page_label": "431", "file_name": "2023_20-21.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2023_20-21.pdf", "file_type": "application/pdf", "file_size": 1372902, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "908b3b4e-ed97-42f2-8ca5-d60cea7282f8", "node_type": "4", "metadata": {"page_label": "431", "file_name": "2023_20-21.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2023_20-21.pdf", "file_type": "application/pdf", "file_size": 1372902, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "6c54102f255173e6603018e6d78d1225353a7b0416aa54cebe2f49c5cbdba245", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "bab16cde-4fe3-44b4-b043-ed3bb7c3c5d7", "node_type": "1", "metadata": {}, "hash": "c6b9fb677b84d47b690eb99117673a3d9b864cc8ec843c72530e717ce90b4ac4", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Diab\u00e8te en outre-mer : comprendre les sp\u00e9cificit\u00e9s locales pour cibler les actions BEH 20-21 | 14 novembre 2023 | 431\nARTICLE // Article\nPR\u00c9VALENCE DU DIAB\u00c8TE CONNU \u00c0 LA R\u00c9UNION, PRISES EN CHARGE ET CARACT\u00c9RISTIQUES\nDES PERSONNES ATTEINTES D'UN DIAB\u00c8TE : EXPLOITATION DES DONN\u00c9ES DU BAROM\u00c8TRE\nDE SANT\u00c9 PUBLIQUE FRANCE DROM DE 2021\n// PREVALENCE OF KNOWN DIABETES IN REUNION ISLAND, CARE AND CHARACTERISTICS OF THE POPULATION:\nDATA FROM THE 2021 SANT\u00c9 PUBLIQUE FRANCE HEALTH BAROMETER FOR OVERSEAS FRANCE\nMonique Ricquebourg 1 (), Claire Kwan 1, S\u00e9bastien M\u00e9devielle 1, Stelly Chopinet-Dijoux 2,\nFlorence Caliez 2, Fabian Thouillot 3, Estelle Nobecourt 4, Sandrine Fosse-Edorh 5\n1 Observatoire r\u00e9gional de la sant\u00e9 de La R\u00e9union, Saint-Denis\n2 Agence r\u00e9gionale de sant\u00e9 de La R\u00e9union, Saint-Denis\n3 Sant\u00e9 publique France - Oc\u00e9an Indien, Saint-Denis\n4 CHU de La R\u00e9union, CIC1410, UFR de La R\u00e9union, Saint-Pierre\n5 Sant\u00e9 publique France, Saint-Maurice\nSoumis le 11.07.2023 // Date of submission: 07.11.2023\nR\u00e9sum\u00e9 // Abstract\nContexte - Le diab\u00e8te est une priorit\u00e9 r\u00e9gionale de sant\u00e9 \u00e0 La R\u00e9union, au regard de sa forte pr\u00e9valence,\ndes fr\u00e9quences \u00e9lev\u00e9es des facteurs de risque et des complications associ\u00e9es. Le Programme r\u00e9unionnais\nde nutrition et de lutte contre le diab\u00e8te (PRND) a \u00e9t\u00e9 mis en \u0153uvre sur la p\u00e9riode 2020-2023. L 'objectif de l'\u00e9tude\nest d'actualiser la pr\u00e9valence du diab\u00e8te connu et de d\u00e9crire les caract\u00e9ristiques des personnes diab\u00e9tiques\n\u00e0 La R\u00e9union en 2021 afin d'orienter les actions du PRND.\nM\u00e9thodes - Les donn\u00e9es du Barom\u00e8tre de Sant\u00e9 publique France DROM 2021 ont \u00e9t\u00e9 utilis\u00e9es. \u00c0 La R\u00e9union,\nun \u00e9chantillon de 2 004 personnes \u00e2g\u00e9es de 18 \u00e0 85 ans, r\u00e9sidant sur le territoire, a \u00e9t\u00e9 interrog\u00e9 par t\u00e9l\u00e9phone\nsur le diab\u00e8te. Les analyses ont \u00e9t\u00e9 pond\u00e9r\u00e9es pour tenir compte du plan de sondage et de la participation,\nafin qu'elles soient repr\u00e9sentatives de la population du territoire r\u00e9gional.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1920, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "bab16cde-4fe3-44b4-b043-ed3bb7c3c5d7": {"__data__": {"id_": "bab16cde-4fe3-44b4-b043-ed3bb7c3c5d7", "embedding": null, "metadata": {"page_label": "431", "file_name": "2023_20-21.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2023_20-21.pdf", "file_type": "application/pdf", "file_size": 1372902, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "908b3b4e-ed97-42f2-8ca5-d60cea7282f8", "node_type": "4", "metadata": {"page_label": "431", "file_name": "2023_20-21.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2023_20-21.pdf", "file_type": "application/pdf", "file_size": 1372902, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "6c54102f255173e6603018e6d78d1225353a7b0416aa54cebe2f49c5cbdba245", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4f469750-5982-48fe-8575-9f11431cf462", "node_type": "1", "metadata": {"page_label": "431", "file_name": "2023_20-21.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2023_20-21.pdf", "file_type": "application/pdf", "file_size": 1372902, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "b2107dbf23d5fbb246c4bbf97d0f9fe86a8a2fe321a2512f48b056675b62f7b3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4c5d3504-34ca-418f-9082-9a71e458a090", "node_type": "1", "metadata": {}, "hash": "6b85d4ce5ae5122f926df974df4b409d1c14bc0834cb1e6dafe16a21a91f4971", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "\u00c0 La R\u00e9union,\nun \u00e9chantillon de 2 004 personnes \u00e2g\u00e9es de 18 \u00e0 85 ans, r\u00e9sidant sur le territoire, a \u00e9t\u00e9 interrog\u00e9 par t\u00e9l\u00e9phone\nsur le diab\u00e8te. Les analyses ont \u00e9t\u00e9 pond\u00e9r\u00e9es pour tenir compte du plan de sondage et de la participation,\nafin qu'elles soient repr\u00e9sentatives de la population du territoire r\u00e9gional.\nR\u00e9sultats - \u00c0 La R\u00e9union, en 2021, la pr\u00e9valence du diab\u00e8te connu \u00e9tait de 13,6% (intervalle de confiance\n\u00e0 95%, IC95%: [11,8-15,7]) en population adulte de 18 \u00e0 85 ans et parmi les personnes non diab\u00e9tiques\nconnues, 3,4% [2,4-4,6] d\u00e9claraient avoir un \u00ab petit diab\u00e8te \u00bb. Parmi les personnes se d\u00e9clarant diab\u00e9tiques,\n64,3% connaissaient leur maladie depuis au moins 5 ans, 82,4% d\u00e9claraient \u00eatre trait\u00e9es pharmacologique -\nment, et parmi ces personnes, 16,8% avaient d\u00e9j\u00e0 arr\u00eat\u00e9 au moins une fois leur traitement. Les in\u00e9galit\u00e9s\nsociales restaient tr\u00e8s marqu\u00e9es. Les facteurs de risque associ\u00e9s au diab\u00e8te et ses complications \u00e9taient\nfr\u00e9quents : ob\u00e9sit\u00e9 (28,0%), tabagisme quotidien (20,1%), avec des comportements nutritionnels \u00e9galement\n\u00e9loign\u00e9s des recommandations.\nConclusion - La pr\u00e9valence du diab\u00e8te connu reste \u00e9lev\u00e9e \u00e0 La R\u00e9union. Les complications du diab\u00e8te \u00e9tant\nfr\u00e9quentes sur l'\u00eele, les actions portant sur la pr\u00e9vention nutritionnelle doivent se poursuivre pour r\u00e9duire les\nfacteurs de risque et l'impact des in\u00e9galit\u00e9s sociales. Les r\u00e9sultats du Barom\u00e8tre Sant\u00e9 DROM 2021 contribue -\nront \u00e0 orienter les politiques publiques, et en particulier l'actualisation en 2024 du PRND.\n>\nMonique Ricquebourg et coll.\nObservatoire r\u00e9gional de la sant\u00e9 de La R\u00e9union, Saint-Denis\n[9] Sant\u00e9 publique France. Barom\u00e8tre de Sant\u00e9 publique\nFrance 2021. Questionnaire / Volet DROM. Saint-Maurice:\nSant\u00e9 publique France; 2022. 29 p.\nfrance.fr/etudes-et-enquetes/barometres-de-sante-publiquefrance/barometre-sante-2021-dans-les-drom\n[10] Observatoire r\u00e9gional de la sant\u00e9 de Guadeloupe. Le\ndiab\u00e8te en Guadeloupe en 2013 - Enqu\u00eate Kannari 2017. BaieMahault: Observatoire r\u00e9gional de la sant\u00e9 de Guadeloupe;\n2017.\nORSaG_DIABETE_KANNARI_rapport2017.pdf\n[11] Observatoire de la sant\u00e9 de la Martinique.", "mimetype": "text/plain", "start_char_idx": 1607, "end_char_idx": 3717, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "4c5d3504-34ca-418f-9082-9a71e458a090": {"__data__": {"id_": "4c5d3504-34ca-418f-9082-9a71e458a090", "embedding": null, "metadata": {"page_label": "431", "file_name": "2023_20-21.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2023_20-21.pdf", "file_type": "application/pdf", "file_size": 1372902, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "908b3b4e-ed97-42f2-8ca5-d60cea7282f8", "node_type": "4", "metadata": {"page_label": "431", "file_name": "2023_20-21.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2023_20-21.pdf", "file_type": "application/pdf", "file_size": 1372902, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "6c54102f255173e6603018e6d78d1225353a7b0416aa54cebe2f49c5cbdba245", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "bab16cde-4fe3-44b4-b043-ed3bb7c3c5d7", "node_type": "1", "metadata": {"page_label": "431", "file_name": "2023_20-21.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2023_20-21.pdf", "file_type": "application/pdf", "file_size": 1372902, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "359b2200d6d03fe619c9de5907ed163bebd3a1dfb3fb1359b1fd6b04f971fa0a", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Le\ndiab\u00e8te en Guadeloupe en 2013 - Enqu\u00eate Kannari 2017. BaieMahault: Observatoire r\u00e9gional de la sant\u00e9 de Guadeloupe;\n2017.\nORSaG_DIABETE_KANNARI_rapport2017.pdf\n[11] Observatoire de la sant\u00e9 de la Martinique. Les principaux\nr\u00e9sultats de l'\u00e9tude Kannari en Martinique 2017.\ntinique.org/images/PDF/determinants/nutrition/Fiches_kan\nnari_-_Martinique_-_Novembre_2018_impression.pdf\n[12] Leduc A, Deroyon T, Rochereau T, Renaud A. Premiers\nr\u00e9sultats de l'enqu\u00eate sant\u00e9 europ\u00e9enne (EHIS) 2019 - M\u00e9tro -\npole, Guadeloupe, Martinique, Guyane, La R\u00e9union, Mayotte.\nLes dossiers de la Drees. 2021;78:1-98.\nrites-sante.gouv.fr/publications/les-dossiers-de-la-drees/\npremiers-resultats-de-lenquete-sante-europeenne-ehis2019-metrople-guadeloupe-martinique-guyane-lar%C3%A9union-mayotte\n[13] Fuentes S, Mandereau-Bruno L, Regnault N, Bernillon P,\nBonaldi C, Cosson E, et al. Is the type 2 diabetes epidemic\nplateauing in France? A nationwide population-based study.\nDiabetes Metab. 2020;46(6):472-9.\nCiter cet article\nHernandez H, Piffaretti C, Gautier A, Cosson E, FosseEdorh S. Pr\u00e9valence du diab\u00e8te connu dans 4 d\u00e9partements\net r\u00e9gions d'outre-mer : Guadeloupe, Martinique, Guyane et\nLa R\u00e9union. R\u00e9sultats du Barom\u00e8tre de Sant\u00e9 publique France\nde 2021. Bull \u00c9pid\u00e9miol Hebd. 2023;(20-21):424-31.\nsantepubliquefrance.fr/beh/2023/20-21/2023_20-21_2.html", "mimetype": "text/plain", "start_char_idx": 3507, "end_char_idx": 4849, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "a7f56be9-db3a-462b-9ea3-b4e13e3a98fa": {"__data__": {"id_": "a7f56be9-db3a-462b-9ea3-b4e13e3a98fa", "embedding": null, "metadata": {"page_label": "432", "file_name": "2023_20-21.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2023_20-21.pdf", "file_type": "application/pdf", "file_size": 1372902, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "c8282bc5-7db4-4ff5-9a00-f83862a31bdd", "node_type": "4", "metadata": {"page_label": "432", "file_name": "2023_20-21.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2023_20-21.pdf", "file_type": "application/pdf", "file_size": 1372902, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "b69fac6c2016f573d1687b02273b179a3def2e1c2957d23dc72eaf805148b912", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "989bc4f7-4731-4759-939e-15fc1ff55a48", "node_type": "1", "metadata": {}, "hash": "0f63e929c7b023bb29a51a6f5e921d24cc0f046be76e0f702882bfa59cda08e5", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "432 | 14 novembre 2023 | BEH 20-21 Diab\u00e8te en outre-mer : comprendre les sp\u00e9cificit\u00e9s locales pour cibler les actions\nBackground - Diabetes is a regional health priority in Reunion Island due to its high prevalence and the high\nfrequency of risk factors and associated complications. To address this, the Reunion Island Programme for\nNutrition and Diabetes Control (PRND) was set up for the period 2020-2023. The objective of the present\nstudy was to update the prevalence of diabetes and to describe the population with diabetes in Reunion Island\nfor 2021 in order to guide future actions related to the PRND .\nMethods - The used data were collected during the 2021 Health Barometer survey for French overseas depart -\nments and regions (DROM). In Reunion Island, a sample of 2,004 people aged from 18 to 85 years old residing\nin the territory were interviewed about diabetes by phone. The analyses were weighted, taking into account\nthe survey plan and participation, in order to be representative of the region's population.\nResults - In Reunion island, the prevalence of known diabetes in 2021 was 13.6% (95% confidence interval\n[95%CI]: 11.8-15.7) for the adult population aged from 18 to 85 years old . Among people who did not declare\ndiabetes, 3.4% (95%CI: 2.4-4.6) reported \"mild diabetes\". Among people who declared diabetes, 64.3% had\nbeen aware of their disease for at least 5 years and 82.4% declared being pharmacologically treated, among\nwhom 16.8% had already stopped their treatment at least once. Social inequalities related to diabetes were\nclear to observe. Risk factors associated with diabetes and its complications were frequent, including obesity\n(28.0%) and daily smoking (20.1%), as were dietary habits that diverged significantly from recommendations.\nConclusion - The prevalence of known diabetes remains high in Reunion Island. As complications linked to\ndiabetes are frequent in the region, nutritional prevention schemes must continue to help reduce risk factors\nand the impact of social inequalities. The results of the 2021 DROM Health Barometer will contribute to guiding\npublic policies, in particular to update the PRND 2024.\nMots-cl\u00e9s : Diab\u00e8te, Barom\u00e8tre, Prise en charge, Facteurs de risque, \u00cele de La R\u00e9union\n// Keywords: Diabetes, Barometer, Care, Risk factors, Reunion Island\nIntroduction\nLe diab\u00e8te, probl\u00e8me majeur de sant\u00e9 publique, touche\nen 2021 pr\u00e8s de 540 millions de personnes \u00e0 travers\nle monde. Un nombre qui ne cesse de cro\u00eetre dans\ntoutes les r\u00e9gions et qui atteindra, selon les pr\u00e9visions,\n783 millions d'individus d'ici 2045 1.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2583, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "989bc4f7-4731-4759-939e-15fc1ff55a48": {"__data__": {"id_": "989bc4f7-4731-4759-939e-15fc1ff55a48", "embedding": null, "metadata": {"page_label": "432", "file_name": "2023_20-21.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2023_20-21.pdf", "file_type": "application/pdf", "file_size": 1372902, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "c8282bc5-7db4-4ff5-9a00-f83862a31bdd", "node_type": "4", "metadata": {"page_label": "432", "file_name": "2023_20-21.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2023_20-21.pdf", "file_type": "application/pdf", "file_size": 1372902, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "b69fac6c2016f573d1687b02273b179a3def2e1c2957d23dc72eaf805148b912", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a7f56be9-db3a-462b-9ea3-b4e13e3a98fa", "node_type": "1", "metadata": {"page_label": "432", "file_name": "2023_20-21.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2023_20-21.pdf", "file_type": "application/pdf", "file_size": 1372902, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "9a350282e15d73070f000d0a01074213e35419f30b82879befabf90e6b27fb3a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f8b9626f-ebdf-4a24-a844-8c5553281001", "node_type": "1", "metadata": {}, "hash": "82736a1eb1d642b36077470c7808e5de6d3adf30ffcbaad15224689a65506ab1", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Un nombre qui ne cesse de cro\u00eetre dans\ntoutes les r\u00e9gions et qui atteindra, selon les pr\u00e9visions,\n783 millions d'individus d'ici 2045 1. Ces chiffres ne\ntiennent pas comp te de la part non n\u00e9gligeable de\npersonnes ayant un diab\u00e8te non diagnostiqu\u00e9, dont\nl'estimation a \u00e9t\u00e9 mise \u00e0 jour par la F\u00e9d\u00e9ration inter -\nnationale du diab\u00e8te (FID) : en 2021, pr\u00e8s d'un adulte\nsur deux (20-79 ans) atteint de diab\u00e8te ignorait son\nstatut diab\u00e9tique (44,7% ; 239,7 millions) 2.\nLa mondialisation d'un mode de cons ommation\noccidental avec la g\u00e9n\u00e9ralisation d'ali ments et bois -\nsons ultra-transform\u00e9s et de haute densit\u00e9 \u00e9nerg\u00e9 -\ntique, ainsi que la diminution de l'act ivit\u00e9 physique\nau profit de la s\u00e9dentarit\u00e9, impactent tr\u00e8s fortement\ncertaines zones du monde, notamment l'Afrique et le\nMoyen-Orient, o\u00f9 les augmentations du nombre de\npersonnes diab\u00e9tiques sont les plus notables 1. Si le\ndiab\u00e8te de type 1 d\u00e9pend de facteurs de risque mal\nconnus et/ou difficilement \u00e9vitables (facteurs g\u00e9n\u00e9 -\ntiques et immunit\u00e9 en particulier), le diab\u00e8te de type 2,\nrepr\u00e9sentant plus de 90% des cas de diab\u00e8te, est\nintimement li\u00e9 au mode de vie : surpoids et ob\u00e9sit\u00e9,\nalimentation, s\u00e9dentarit\u00e9 et inactivit\u00e9 physique, tabagisme 3, etc., autant de facteurs de risque majeurs sur\nlesquels la pr\u00e9vention et la modification des comportements individuels peuvent jouer un r\u00f4le important\npour pr\u00e9venir ou retarder la survenue de la maladie.\n\u00c0 La R\u00e9union, la situation est pr\u00e9occupante, avec une\nforte pr\u00e9valence du diab\u00e8te (un taux 2 fois sup\u00e9rieur\n\u00e0 celui observ\u00e9 en France hexagonale) 4-7, associ\u00e9e\n\u00e0 des complications s\u00e9v\u00e8res pour les personnes\ndiab\u00e9tiques 5,8-9. Par ailleurs, la population r\u00e9union -\nnaise cumule des facteurs de risque importants : une\nalimentation marqu\u00e9e par une faible cons ommation\nde fruits et l\u00e9gumes et un exc\u00e8s de cons ommation\nde mati\u00e8res grasses et de produits sucr\u00e9s, une insuffisance d'activit\u00e9 physique et une s\u00e9dentarit\u00e9 \u00e9lev\u00e9e,\nune surcharge pond\u00e9rale fr\u00e9 quente (45% de la population adulte en 2019) 7,10-12.", "mimetype": "text/plain", "start_char_idx": 2447, "end_char_idx": 4465, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "f8b9626f-ebdf-4a24-a844-8c5553281001": {"__data__": {"id_": "f8b9626f-ebdf-4a24-a844-8c5553281001", "embedding": null, "metadata": {"page_label": "432", "file_name": "2023_20-21.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2023_20-21.pdf", "file_type": "application/pdf", "file_size": 1372902, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "c8282bc5-7db4-4ff5-9a00-f83862a31bdd", "node_type": "4", "metadata": {"page_label": "432", "file_name": "2023_20-21.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2023_20-21.pdf", "file_type": "application/pdf", "file_size": 1372902, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "b69fac6c2016f573d1687b02273b179a3def2e1c2957d23dc72eaf805148b912", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "989bc4f7-4731-4759-939e-15fc1ff55a48", "node_type": "1", "metadata": {"page_label": "432", "file_name": "2023_20-21.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2023_20-21.pdf", "file_type": "application/pdf", "file_size": 1372902, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "641653e94c325a4f787b85af0f6070a35d877ddeaae638bd677248d4a94d3afd", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Au regard de la situation r\u00e9gionale, la sant\u00e9 nutri -\ntionnelle fait l'obj et d'une attention particuli\u00e8re sur\nle territoire : priorit\u00e9 r\u00e9gionale r\u00e9affirm\u00e9e dans le\nprojet r\u00e9gional de sant\u00e9 (PRS) 2018-2028 13,14 et mise\nen \u0153uvre d'un programme d'act ions commun, le\nProgramme r\u00e9unionnais de nutrition et de lutte contre\nle diab\u00e8te 2020-2023 (PRND) 15, \u00e9labor\u00e9 par l'Agence\nr\u00e9gionale de sant\u00e9 (ARS) et les partenaires locaux.\nL 'objectif de cette \u00e9tude est d'actualiser la pr\u00e9va -\nlence du diab\u00e8te conn u \u00e0 La R\u00e9union en 2021 et\nde d\u00e9crire la prise en charge et les caract\u00e9ristiques\ndes personnes r\u00e9unionnaises atteintes d'un diab\u00e8te .\nM\u00e9thodes\nSources de donn\u00e9es\nCette \u00e9tude a \u00e9t\u00e9 r\u00e9alis\u00e9e \u00e0 partir des donn\u00e9es d\u00e9claratives du volet r\u00e9unionnais de l'enq u\u00eate Barom\u00e8tre\nde Sant\u00e9 publique France en 2021, qui permet d'\u00e9tudier les comportements de sant\u00e9 et l'\u00e9tat de sant\u00e9 de\nla population adulte en France hexagonale et dans\nles d\u00e9partements et r\u00e9gions d'out re-mer (DROM)\n(en dehors de Mayotte). L 'enqu\u00eate Barom\u00e8tre Sant\u00e9\na \u00e9t\u00e9 renouvel\u00e9e dans les DROM, sept ans apr\u00e8s\nla premi\u00e8re \u00e9dition en 2014.\nLe recueil des donn\u00e9es, r\u00e9alis\u00e9 par l'ins titut Ipsos,\na suivi un protocole identique sur l'ensemble des territoires 16. La m\u00e9thode de recueil repose sur la g\u00e9n\u00e9 -\nration al\u00e9atoire de num\u00e9ros de t\u00e9l\u00e9phones fixes et\nmobiles et l'int errogation par t\u00e9l\u00e9phone d'adu ltes\n\u00e2g\u00e9s de 18 \u00e0 85 ans.", "mimetype": "text/plain", "start_char_idx": 4466, "end_char_idx": 5852, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "88852ba1-148b-4dba-880b-d6c938012bdb": {"__data__": {"id_": "88852ba1-148b-4dba-880b-d6c938012bdb", "embedding": null, "metadata": {"page_label": "433", "file_name": "2023_20-21.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2023_20-21.pdf", "file_type": "application/pdf", "file_size": 1372902, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "658041f7-1a75-45e5-9166-74a09afe9067", "node_type": "4", "metadata": {"page_label": "433", "file_name": "2023_20-21.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2023_20-21.pdf", "file_type": "application/pdf", "file_size": 1372902, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "590aff72d5ac3ee4159e288bafc022108b11a3e1b9f344a86beaf197ae456483", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5a08bf95-5091-4619-906e-cd1df120f674", "node_type": "1", "metadata": {}, "hash": "c659d86d851670869d1010b9daa30db8d36e46ae51f21773123cc315f7e2cb11", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Diab\u00e8te en outre-mer : comprendre les sp\u00e9cificit\u00e9s locales pour cibler les actions BEH 20-21 | 14 novembre 2023 | 433\n\u00c0 La R\u00e9union, l'enq u\u00eate s'est d\u00e9roul\u00e9e du 20 avril\nau 13 juillet 2021, aupr\u00e8s de 2 004 personnes \u00e2g\u00e9es\nde 18 \u00e0 85 ans, r\u00e9sidant sur l'\u00eele , parlant fran\u00e7ais\net/ou cr\u00e9ole.\nVariables d'int\u00e9r\u00eat\nLes adultes inclus dans l'enq u\u00eate ont \u00e9t\u00e9 interrog\u00e9s\nsur le diab\u00e8te conn u ou d\u00e9clar\u00e9 par la question \u00ab Un\nm\u00e9decin vous-a-t-il d\u00e9j\u00e0 dit que vous \u00e9tiez diab\u00e9 -\ntique ? \u00bb (en dehors d'un diab\u00e8te gestationnel). Les\npersonnes r\u00e9pondant non \u00e0 cette question ont \u00e9t\u00e9\ninterrog\u00e9es sur le \u00ab petit diab\u00e8te \u00bb : \u00ab Le m\u00e9decin\nvous a-t-il d\u00e9j\u00e0 dit que vous aviez un \u00ab petit diab\u00e8te \u00bb\nou un d\u00e9but de diab\u00e8te mais pas trop grave ? \u00bb. Cette\nderni\u00e8re question n'avait pas \u00e9t\u00e9 pos\u00e9e en 2014. Les\npersonnes d\u00e9clarant un diab\u00e8te ont ensuite \u00e9t\u00e9 interrog\u00e9es sur la dur\u00e9e depuis la premi\u00e8re annonce par\nle m\u00e9decin et leur prise en charge.\nLes donn\u00e9es sociod\u00e9mographiques, sur la sant\u00e9, sur\nl'indice de masse corporelle (IMC, calcul\u00e9 \u00e0 partir du\npoids et de la taille d\u00e9clar\u00e9s) et l'hyp ertension art\u00e9 -\nrielle (HTA) d\u00e9clar\u00e9e ont \u00e9galement \u00e9t\u00e9 utilis\u00e9es.\nLe questionnaire a par ailleurs permis d'abo rder les\nmodes de vie : la consommation quotidienne de fruits\net l\u00e9gumes ou de boissons sucr\u00e9es, les activit\u00e9s\nphysiques ou la s\u00e9dentarit\u00e9 au cours des 7 derniers\njours, le tabagisme quotidien, la cons ommation\nhebdomadaire d'alcool au cours des 12 derniers mois.\nAnalyses\nAfin d'\u00eatre repr\u00e9sentatives de la population de\nchaque DROM, les donn\u00e9es ont \u00e9t\u00e9 pond\u00e9r\u00e9es en\ntenant compte de la probabilit\u00e9 d'inc lusion (au sein\ndu m\u00e9nage et en fonction de l'\u00e9qu ipement t\u00e9l\u00e9pho -\nnique), et de la structure de la population de chaque\nd\u00e9partement via un calage sur marges en utilisant\nles variables suivantes : le sexe crois\u00e9 avec l'\u00e2ge par\ntranches d\u00e9cennales, la taille du foyer et le niveau de\ndipl\u00f4me. La population de r\u00e9f\u00e9rence est bas\u00e9e sur les\ndonn\u00e9es de l'Institut national de la statistique et des\n\u00e9tudes \u00e9conomiques (Insee) (Enqu\u00eate emploi 2020).\nL 'analyse repose dans un premier temps sur l'\u00e9tu de\ndescriptive de la pr\u00e9valence du diab\u00e8te conn u et du\n\u00ab petit diab\u00e8te \u00bb selon le sexe, l'\u00e2ge et les caract\u00e9ristiques socio-\u00e9conomiques.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2223, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "5a08bf95-5091-4619-906e-cd1df120f674": {"__data__": {"id_": "5a08bf95-5091-4619-906e-cd1df120f674", "embedding": null, "metadata": {"page_label": "433", "file_name": "2023_20-21.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2023_20-21.pdf", "file_type": "application/pdf", "file_size": 1372902, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "658041f7-1a75-45e5-9166-74a09afe9067", "node_type": "4", "metadata": {"page_label": "433", "file_name": "2023_20-21.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2023_20-21.pdf", "file_type": "application/pdf", "file_size": 1372902, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "590aff72d5ac3ee4159e288bafc022108b11a3e1b9f344a86beaf197ae456483", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "88852ba1-148b-4dba-880b-d6c938012bdb", "node_type": "1", "metadata": {"page_label": "433", "file_name": "2023_20-21.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2023_20-21.pdf", "file_type": "application/pdf", "file_size": 1372902, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "9528c200d56a5f40fbd21669459f46e6d9dcd7715abcd949972771719324db75", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d032b227-7831-4594-bc88-cb74df82b9c6", "node_type": "1", "metadata": {}, "hash": "1a32292fba9b7356c47819b3f1a96761308fbb52f8c10559423c551234ab63a1", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "L 'analyse repose dans un premier temps sur l'\u00e9tu de\ndescriptive de la pr\u00e9valence du diab\u00e8te conn u et du\n\u00ab petit diab\u00e8te \u00bb selon le sexe, l'\u00e2ge et les caract\u00e9ristiques socio-\u00e9conomiques.\nLa population d\u00e9clarant un diab\u00e8te est ensuite\nd\u00e9crite selon l'\u00e9tat de sant\u00e9, la prise en charge, les\ncaract\u00e9ristiques sociod\u00e9mographiques et les habi -\ntudes de vie.\nLes pourcentages sont pr\u00e9sent\u00e9s pond\u00e9r\u00e9s et\naccompagn\u00e9s de leur intervalle de confi ance \u00e0 95%\n(IC95%).\nR\u00e9sultats\nPr\u00e9valence du diab\u00e8te connu\net du \u00ab petit diab\u00e8te \u00bb\n\u00c0 La R\u00e9union, en 2021, 13,6% des personnes \u00e2g\u00e9es de\n18 \u00e0 85 ans ont d\u00e9clar\u00e9 un diab\u00e8te : 13,1% des hommes\net 14,1% des femmes (tableau 1). La pr\u00e9valence\ndu diab\u00e8te connu augmentait avec l'\u00e2ge pour atteindre 32,6% chez les 65-85 ans ; elle \u00e9tait significa -\ntivement plus \u00e9lev\u00e9e chez les personnes sans\ndipl\u00f4me ou avec un dipl\u00f4me inf\u00e9rieur au bacca -\nlaur\u00e9at, 2,5 fois sup\u00e9rieure chez les personnes\nretrait\u00e9es, en \u00e9tudes ou inactives par rapport aux\npersonnes qui travaillent, et 2 fois plus \u00e9lev\u00e9e\nchez les personnes avec des revenus bas ou inter -\nm\u00e9diaires (tableau 1).\nLa pr\u00e9valence du \u00ab petit diab\u00e8te \u00bb parmi les\npersonnes d\u00e9clarant ne pas \u00eatre diab\u00e9tiques \u00e9tait de\n3,4% : 4,0% des hommes et 2,8% des femmes. La\npr\u00e9valence du \u00ab petit diab\u00e8te \u00bb tendait \u00e0 augmenter\navec l'\u00e2ge, jusqu'\u00e0 65 ans (7,7% des 55-64 ans).\n\u00c9tat de sant\u00e9 globale\nParmi les personnes d\u00e9clarant un diab\u00e8te, ayant\ndonc connaissance de leur maladie, 43,5% jugeaient\nleur \u00e9tat de sant\u00e9 comm e assez bon (25,5% chez\nles personnes se d\u00e9clarant non diab\u00e9tiques) ;\n15,6% s'estimaient en mauvaise ou tr\u00e8s mauvaise\nsant\u00e9, soit une proportion 2,5 fois plus \u00e9lev\u00e9e\nque dans la population non diab\u00e9tique (5,9%).\nPar ailleurs, un quart des personnes se d\u00e9clarant\ndiab\u00e9tiques (25,4%) ont r\u00e9pondu n\u00e9gativement\n\u00e0 la question \u00ab Avez-vous une maladie chronique\nou un probl\u00e8me de sant\u00e9 durable ? \u00bb. Et 36,1% des\npersonnes se d\u00e9clarant diab\u00e9tiques ont fait \u00e9tat\nde limitations depuis au moins 6 mois dans les acti -\nvit\u00e9s habituelles \u00e0 cause d'un probl\u00e8me de sant\u00e9\n(18,3% dans la population non diab\u00e9tique).", "mimetype": "text/plain", "start_char_idx": 2036, "end_char_idx": 4118, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "d032b227-7831-4594-bc88-cb74df82b9c6": {"__data__": {"id_": "d032b227-7831-4594-bc88-cb74df82b9c6", "embedding": null, "metadata": {"page_label": "433", "file_name": "2023_20-21.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2023_20-21.pdf", "file_type": "application/pdf", "file_size": 1372902, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "658041f7-1a75-45e5-9166-74a09afe9067", "node_type": "4", "metadata": {"page_label": "433", "file_name": "2023_20-21.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2023_20-21.pdf", "file_type": "application/pdf", "file_size": 1372902, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "590aff72d5ac3ee4159e288bafc022108b11a3e1b9f344a86beaf197ae456483", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5a08bf95-5091-4619-906e-cd1df120f674", "node_type": "1", "metadata": {"page_label": "433", "file_name": "2023_20-21.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2023_20-21.pdf", "file_type": "application/pdf", "file_size": 1372902, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "2b55b81e4289b1622029bef84d6a1f9f18af69fa3b0d0f47d306311935397a14", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "\u00bb. Et 36,1% des\npersonnes se d\u00e9clarant diab\u00e9tiques ont fait \u00e9tat\nde limitations depuis au moins 6 mois dans les acti -\nvit\u00e9s habituelles \u00e0 cause d'un probl\u00e8me de sant\u00e9\n(18,3% dans la population non diab\u00e9tique).\nPrise en charge\nParmi les personnes avec un diab\u00e8te conn u, 64,2%\nl'\u00e9taient depuis au moins 5 ans (tableau 2). La majo -\nrit\u00e9 des personnes d\u00e9clarant un diab\u00e8te \u00e9taient trai -\nt\u00e9es pharmacologiquement (plus de 8 personnes\nayant un diab\u00e8te sur 10) ; et parmi elles, pr\u00e8s de 17%\navaient d\u00e9j\u00e0 arr\u00eat\u00e9 au moins une fois leur traitement\nm\u00e9dicamenteux.\nPar ailleurs, 5,3% des personnes avec un diab\u00e8te\nconnu n'ont pas vu de m\u00e9decin g\u00e9n\u00e9raliste dans les\n12 derniers mois (3 fois moins que pour la popu -\nlation non diab\u00e9tique) et 11,9% ont d\u00e9clar\u00e9 avoir\nrenonc\u00e9 \u00e0 des soins au cours des 12 derniers mois\npour des raisons financi\u00e8res (dans une proportion\ncomparable \u00e0 celle de la population non diab\u00e9tique)\n(tableau 2).\nCaract\u00e9ristiques sociod\u00e9mographiques\nLe diab\u00e8te conn u en 2021 conc ernait plus fr\u00e9 -\nquemment les femmes que les hommes (55,2%\nversus 44,8%) (tableau 3). La moyenne d'\u00e2ge \u00e9tait de\n60 ans (contre 45 ans chez les personnes d\u00e9clarant\nne pas \u00eatre diab\u00e9tiques).\nLes personnes d\u00e9clarant un diab\u00e8te pr\u00e9sentaient un\nprofil socialement plus d\u00e9favoris\u00e9 que les personnes\nnon diab\u00e9tiques : pr\u00e8s de la moiti\u00e9 sans aucun\ndipl\u00f4me, la moiti\u00e9 percevant leur situation finan -\nci\u00e8re comme juste ou difficile, et pr\u00e8s de 40% avec\ndes revenus bas (tableau 3).", "mimetype": "text/plain", "start_char_idx": 3908, "end_char_idx": 5371, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "d8435ffb-c86b-4abc-91db-9ed92cfa77c7": {"__data__": {"id_": "d8435ffb-c86b-4abc-91db-9ed92cfa77c7", "embedding": null, "metadata": {"page_label": "434", "file_name": "2023_20-21.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2023_20-21.pdf", "file_type": "application/pdf", "file_size": 1372902, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "b3dad03b-ba50-4f54-98e8-473a177d1427", "node_type": "4", "metadata": {"page_label": "434", "file_name": "2023_20-21.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2023_20-21.pdf", "file_type": "application/pdf", "file_size": 1372902, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "82b71ca3d7bf1e22307726818a115f47437dbb12d1ee6191dad19ec9934b477d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "aba3ddd9-7d03-41ec-93df-6615623959c6", "node_type": "1", "metadata": {}, "hash": "ad52b55a2dbdaf79703a322fb853f570be787ea74d8662b4f228045e9fc479b5", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "434 | 14 novembre 2023 | BEH 20-21 Diab\u00e8te en outre-mer : comprendre les sp\u00e9cificit\u00e9s locales pour cibler les actions\nTableau 1\nTaux de pr\u00e9valence du diab\u00e8te connu et du \u00ab petit diab\u00e8te a \u00bb selon le sexe, l'\u00e2ge et les caract\u00e9ristiques socio-\u00e9conomiques,\nLa R\u00e9union, 2021\nPr\u00e9valence du diab\u00e8te connu\n(population g\u00e9n\u00e9rale n=2 004)\nPr\u00e9valence du \u00ab petit diab\u00e8te \u00bba\n(population non diab\u00e9tique n=1 745)\n% [IC95%] % [IC95%]\nSexe\nHommes 13,1 [10,4-16,4] 4,0 [2,5-6,4]\nFemmes 14,1 [11,8-16,7] 2,8 [1,9-4,2]\n\u00c2ge\n18-34 ans 2,7 [1,3-5,4] 0,9 [0,2-3,6]\n35-44 ans 5,5 [3,1-9,4] 2,9 [1,2-6,6]\n45-54 ans 13,0 [9,4-17,8] 2,7 [1,5-4,6]\n55-64 ans 20,6 [16,3-25,6] 7,7 [4,7-12,4]\n65-85 ans 32,6 [26,4-39,5] 5,3 [2,6-10,7]\nDipl\u00f4me\nAucun dipl\u00f4me 20,7 [16,8-25,2] 5,6 [3,5-8,8]\n< bac 15,9 [12,7-19,7] 4,2 [2,6-6,9]\nBac ou > bac 5,3 [3,8-7,3] 1,0 [0,5-2,2]\nSituation professionnelle\nTravail 8,0 [6,1-10,6] 2,4 [1,5-3,9]\nCh\u00f4mage 13,5 [9,8-18,1] 4,6 [2,4-8,6]\nRetrait\u00e9s, \u00e9tudiants et autres inactifs 19,4 [16,0-23,3] 3,7 [2,2-6,1]\nRevenus par unit\u00e9 de consommation en terciles\n1er tercile (<530 \u20ac) 17,2 [13,6-21,6] 4,8 [2,8-8,0]\n2e tercile (530-1 170 \u20ac) 15,2 [12,1-18,9] 3,6 [2,1-6,2]\n3e tercile (\u22651 171 \u20ac) 8,2 [6,0-11,0] 1,6 [0,8-3,0]\nNSP/Refus 12,4 [7,5-19,", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1234, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "aba3ddd9-7d03-41ec-93df-6615623959c6": {"__data__": {"id_": "aba3ddd9-7d03-41ec-93df-6615623959c6", "embedding": null, "metadata": {"page_label": "434", "file_name": "2023_20-21.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2023_20-21.pdf", "file_type": "application/pdf", "file_size": 1372902, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "b3dad03b-ba50-4f54-98e8-473a177d1427", "node_type": "4", "metadata": {"page_label": "434", "file_name": "2023_20-21.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2023_20-21.pdf", "file_type": "application/pdf", "file_size": 1372902, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "82b71ca3d7bf1e22307726818a115f47437dbb12d1ee6191dad19ec9934b477d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d8435ffb-c86b-4abc-91db-9ed92cfa77c7", "node_type": "1", "metadata": {"page_label": "434", "file_name": "2023_20-21.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2023_20-21.pdf", "file_type": "application/pdf", "file_size": 1372902, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "f877d0f36734ea84daf6f29343c7030a4b0492fc0539a37a19ae80ae41070350", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "8-8,0]\n2e tercile (530-1 170 \u20ac) 15,2 [12,1-18,9] 3,6 [2,1-6,2]\n3e tercile (\u22651 171 \u20ac) 8,2 [6,0-11,0] 1,6 [0,8-3,0]\nNSP/Refus 12,4 [7,5-19,8] 3,4 [1,4-8,2]\nEnsemble 13,6 [11,8-15,7] 3,4 [2,4-4,6]\nIC95% : intervalle de confiance \u00e0 95% ; NSP : ne sait pas.\na \u00ab petit diab\u00e8te \u00bb d\u00e9fini dans l'enqu\u00eate comme \u00ab un d\u00e9but de diab\u00e8te, mais pas trop grave \u00bb.\nTableau 2\nCaract\u00e9ristiques de la prise en charge des personnes selon la connaissance du diab\u00e8te, La R\u00e9union, 2021 (n=2 004)\nPersonnes d\u00e9clarant\n\u00eatre diab\u00e9tiques\nPersonnes d\u00e9clarant\nne pas \u00eatre diab\u00e9tiques Ensemble\n% [IC95%] % [IC95%] % [IC95%]\nAnciennet\u00e9 du diab\u00e8te\nMoins de 5 ans 35,8 [28,9-43,3] - - - -\nEntre 5 et 10 ans 21,1 [15,4-28,0] - - - -\nPlus de 10 ans 43,2 [35,8-50,9] - - - -\nPersonnes trait\u00e9es pharmacologiquement\nNon 17,6 [12,8-23,7] - - - -\nOui 82,4 [76,3-87,2] - - - -\nDont ayant d\u00e9j\u00e0 arr\u00eat\u00e9 leur traitement 16,8 [11,5-23,9] - - - -\nDernier recours \u00e0 un m\u00e9decin g\u00e9n\u00e9raliste\nIl y a moins de 12 mois 94,7 [89,7-97,3] 83,8 [81,4-86,0] 85,3 [83,2-87,2]\nIl y a plus de 12 mois 5,3 [2,7-10,3] 15,6 [13,5-17,9] 14,2 [12,3-16,3]\nJamais consult\u00e9 de m\u00e9decin g\u00e9n\u00e9raliste 0,0 0,6 [0,2-1,5] 0,5 [0,2-1,3]\nRenoncement aux soins pour raison financi\u00e8re au cours des 12 derniers mois\nNon 88,1 [82,5-92,1] 88,7 [86,8-90,4] 88,6 [86,8-90,2]\nOui 11,9 [7,9-17,5] 11,3 [9,6-13,2] 11,4 [9,8-13,2]\nIC95% : intervalle de confiance \u00e0 95%.", "mimetype": "text/plain", "start_char_idx": 1097, "end_char_idx": 2473, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "de06f9a1-1ac7-48d8-8f6a-7044ea11082c": {"__data__": {"id_": "de06f9a1-1ac7-48d8-8f6a-7044ea11082c", "embedding": null, "metadata": {"page_label": "435", "file_name": "2023_20-21.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2023_20-21.pdf", "file_type": "application/pdf", "file_size": 1372902, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "70550d91-4501-440b-ad3f-df051e933ddc", "node_type": "4", "metadata": {"page_label": "435", "file_name": "2023_20-21.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2023_20-21.pdf", "file_type": "application/pdf", "file_size": 1372902, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "708f9e2064ab4ad542f26979579fc875c226a10514edf65e6119b9fff55d5de0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c1d38ccf-9456-438d-8b53-3f75e2b65ed2", "node_type": "1", "metadata": {}, "hash": "81257aca6f67c06a52cc24eae09318be6cc5274fe7c6ac3158fe701b4717ddc2", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Diab\u00e8te en outre-mer : comprendre les sp\u00e9cificit\u00e9s locales pour cibler les actions BEH 20-21 | 14 novembre 2023 | 435\nDescription de l'\u00e9tat m\u00e9tabolique\net des modes de vie\nParmi les personnes d\u00e9clarant un diab\u00e8te, le profil\nm\u00e9tabolique \u00e9tait plus d\u00e9grad\u00e9 que celui des\npersonnes se d\u00e9clarant non diab\u00e9tiques (tableau 4) :\npr\u00e8s de 70% en surcharge pond\u00e9rale, 28,0% en\nsituation d'ob\u00e9sit\u00e9 (12,6% chez les non diab\u00e9tiques),\net 46,5% souffrant d'hyp ertension art\u00e9rielle (pr\u00e8s de\n3 fois plus que chez les personnes d\u00e9clarant ne pas\n\u00eatre diab\u00e9tiques).\nLes modes de vie des personnes avec un diab\u00e8te\nconnu \u00e9taient proches de ceux des personnes ne se\nd\u00e9clarant pas diab\u00e9tiques (tableau 4) : 19,9% d\u00e9claraient manger au moins 5 fruits et l\u00e9gumes par jour,\n59,5% d\u00e9claraient une pratique d'act ivit\u00e9 physique\nconforme aux recommandations, 20,1% d\u00e9claraient\nfumer tous les jours et 21,0% boire de l'alcool chaque\nsemaine. En revanche, la cons ommation de bois -\nsons sucr\u00e9es \u00e9tait significativement moins souvent\nd\u00e9clar\u00e9e chez les personnes d\u00e9clarant un diab\u00e8te.\nDiscussion\nPr\u00e9valence du diab\u00e8te connu\nLes r\u00e9sultats du Barom\u00e8tre Sant\u00e9 DROM 2021 per -\nmettent d'actualiser \u00e0 13,6% la pr\u00e9valence du diab\u00e8te\nconnu parmi les r\u00e9unionnais \u00e2g\u00e9s de 18 \u00e0 85 ans. Cette\nestimation est coh\u00e9rente avec les donn\u00e9es r\u00e9centes\nde l'Enqu\u00eate sant\u00e9 europ\u00e9enne (EHIS 2019) 7, mais\ncette pr\u00e9valence sous-estime la situation r\u00e9elle.\nD'une part, elle ne cible que le diab\u00e8te conn u et\nd\u00e9clar\u00e9 par les personnes interrog\u00e9es. L '\u00e9dition 2021\ndu Barom\u00e8tre permet pour la premi\u00e8re fois d'apporter\nune estimation du \u00ab petit diab\u00e8te \u00bb d\u00e9clar\u00e9 (d\u00e9fini\nTableau 3\nDescription des caract\u00e9ristiques sociod\u00e9mographiques et socio-\u00e9conomiques des personnes selon la connaissance du diab\u00e8te,\nLa R\u00e9union, 2021\nPersonnes d\u00e9clarant\n\u00eatre diab\u00e9tiques\nPersonnes d\u00e9clarant\nne pas \u00eatre diab\u00e9tiques Ensemble\n% [IC95%] % [IC95%] % [IC95%]\nSexe\nHommes 44,8 [37,3-52,6] 46,9 [44,0-49,9] 46,6 [43,9-49,4]\nFemmes 55,2 [47,4-62,7] 53,1 [50,1-56,0] 53,4 [50,6-56,", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1999, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "c1d38ccf-9456-438d-8b53-3f75e2b65ed2": {"__data__": {"id_": "c1d38ccf-9456-438d-8b53-3f75e2b65ed2", "embedding": null, "metadata": {"page_label": "435", "file_name": "2023_20-21.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2023_20-21.pdf", "file_type": "application/pdf", "file_size": 1372902, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "70550d91-4501-440b-ad3f-df051e933ddc", "node_type": "4", "metadata": {"page_label": "435", "file_name": "2023_20-21.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2023_20-21.pdf", "file_type": "application/pdf", "file_size": 1372902, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "708f9e2064ab4ad542f26979579fc875c226a10514edf65e6119b9fff55d5de0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "de06f9a1-1ac7-48d8-8f6a-7044ea11082c", "node_type": "1", "metadata": {"page_label": "435", "file_name": "2023_20-21.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2023_20-21.pdf", "file_type": "application/pdf", "file_size": 1372902, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "36654f84ed0e033c3c353302a8d0376fef2ecd404752479627c9e3cd207265a0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b284a456-b0ce-4384-9c07-a900b37fcc86", "node_type": "1", "metadata": {}, "hash": "52cb41261310469fd1a37e13859085959eb7a0263cdd96baaf07b311a426447a", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "8 [37,3-52,6] 46,9 [44,0-49,9] 46,6 [43,9-49,4]\nFemmes 55,2 [47,4-62,7] 53,1 [50,1-56,0] 53,4 [50,6-56,1]\n\u00c2ge\n18-34 ans 5,4 [2,6-10,8] 31,2 [28,4-34,1] 27,7 [25,1-30,3]\n35-44 ans 6,9 [4,0-11,8] 18,9 [16,8-21,1] 17,3 [15,4-19,3]\n45-54 ans 18,5 [13,4-25,1] 19,5 [17,4-21,8] 19,4 [17,4-21,5]\n55-64 ans 27,8 [22,0-34,5] 16,9 [14,9-19,1] 18,4 [16,5-20,5]\n65-85 ans 41,4 [34,0-49,1] 13,5 [11,6-15,7] 17,3 [15,3-19,5]\nMoyenne d'\u00e2gea 59,9 [57,7-62,0] 44,8 [43,8-45,8] 46,8 [45,8-47,8]\nDipl\u00f4me\nAucun dipl\u00f4me 54,2 [46,7-61,4] 32,8 [29,9-35,8] 35,7 [33,0-38,6]\n< bac 31,4 [25,2-38,3] 26,2 [23,8-28,8] 26,9 [24,7-29,3]\nBac 7,6 [4,6-12,4] 19,2 [17,1-21,4] 17,6 [15,7-19,6]\n> bac 6,9 [4,5-10,4] 21,8 [19,7-24,0] 19,7 [17,9-21,8]\nSituation professionnelle\nTravail 23,0 [17,5-29,6] 41,6 [38,8-44,4] 39,0 [36,5-41,6]\nCh\u00f4mage 21,9 [16,2-28,8] 22,2 [19,7-24,9] 22,2 [19,8-24,7]\nRetrait\u00e9s, \u00e9tudiants et autres inactifs 55,1 [47,6-62,5] 36,2 [33,4-39,1] 38,8 [36,2-41,5]\nPerception financi\u00e8re\n\u00c0 l'aise 21,8 [16,1-28,7] 20,2 [18,0-22,6] 20,4 [18,4-22,", "mimetype": "text/plain", "start_char_idx": 1896, "end_char_idx": 2925, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "b284a456-b0ce-4384-9c07-a900b37fcc86": {"__data__": {"id_": "b284a456-b0ce-4384-9c07-a900b37fcc86", "embedding": null, "metadata": {"page_label": "435", "file_name": "2023_20-21.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2023_20-21.pdf", "file_type": "application/pdf", "file_size": 1372902, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "70550d91-4501-440b-ad3f-df051e933ddc", "node_type": "4", "metadata": {"page_label": "435", "file_name": "2023_20-21.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2023_20-21.pdf", "file_type": "application/pdf", "file_size": 1372902, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "708f9e2064ab4ad542f26979579fc875c226a10514edf65e6119b9fff55d5de0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c1d38ccf-9456-438d-8b53-3f75e2b65ed2", "node_type": "1", "metadata": {"page_label": "435", "file_name": "2023_20-21.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2023_20-21.pdf", "file_type": "application/pdf", "file_size": 1372902, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "7964c8141036b69dd87567a786f4286921e24f4106a51f9f2f2c6e83daa48cf3", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "7]\nRetrait\u00e9s, \u00e9tudiants et autres inactifs 55,1 [47,6-62,5] 36,2 [33,4-39,1] 38,8 [36,2-41,5]\nPerception financi\u00e8re\n\u00c0 l'aise 21,8 [16,1-28,7] 20,2 [18,0-22,6] 20,4 [18,4-22,7]\n\u00c7a va 27,9 [21,8-35,1] 38,9 [36,1-41,8] 37,5 [34,8-40,1]\nJuste 26,3 [20,3-33,3] 21,7 [19,5-24,2] 22,3 [20,2-24,6]\nDifficile/Dettes ou recours au cr\u00e9dit\n\u00e0 la consommation\n24,0 [17,8-31,4] 19,1 [16,9-21,6] 19,8 [17,6-22,1]\nRevenus par UC en terciles\n1er tercile (<530 \u20ac) 36,6 [29,6-44,2] 27,7 [25,1-30,5] 28,9 [26,4-31,5]\n2e tercile (530-1 170 \u20ac) 35,0 [28,3-42,3] 30,7 [28,2-33,4] 31,3 [28,9-33,8]\n3e tercile (\u22651 171 \u20ac) 14,8 [10,9-19,9] 26,4 [24,1-28,8] 24,8 [22,7-27,0]\nNSP/Refus 13,6 [8,3-21,4] 15,2 [13,0-17,7] 15,0 [12,9-17,3]\nIC95% : intervalle de confiance \u00e0 95% ; UC : unit\u00e9 de consommation ; NSP : ne sait pas.\na Ces chiffres correspondent \u00e0 une moyenne et non \u00e0 un pourcentage.", "mimetype": "text/plain", "start_char_idx": 2752, "end_char_idx": 3612, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "9f10cf6b-5c37-49c7-9538-8df4d98968b8": {"__data__": {"id_": "9f10cf6b-5c37-49c7-9538-8df4d98968b8", "embedding": null, "metadata": {"page_label": "436", "file_name": "2023_20-21.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2023_20-21.pdf", "file_type": "application/pdf", "file_size": 1372902, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "2078a7ef-0deb-4e51-9a34-2a6b244b2883", "node_type": "4", "metadata": {"page_label": "436", "file_name": "2023_20-21.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2023_20-21.pdf", "file_type": "application/pdf", "file_size": 1372902, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "eebb7ac01a90c507d65d8013cc211dc5735b044bbe106e73a99562a658d05adb", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "af9ac5ce-823e-41c6-83c6-891ca6c956e2", "node_type": "1", "metadata": {}, "hash": "bce55744e78108d61498dae0d3e87cc3a14b1057cdae90eb9b245bb52d616225", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "436 | 14 novembre 2023 | BEH 20-21 Diab\u00e8te en outre-mer : comprendre les sp\u00e9cificit\u00e9s locales pour cibler les actions\ndans le cadre de cette enqu\u00eate comme un d\u00e9but de\ndiab\u00e8te \u00ab pas trop grave \u00bb). La pr\u00e9valence cumul\u00e9e\ndu diab\u00e8te et du \u00ab petit diab\u00e8te \u00bb sur l'ens emble de\nla population interrog\u00e9e atteint 16,5% \u00e0 La R\u00e9union\nen 2021 : 13,6% pour le diab\u00e8te et 2,9% pour le\n\u00ab petit diab\u00e8te \u00bb (le r\u00e9sultat non pr\u00e9sent\u00e9 correspond\naux 3,4% des personnes d\u00e9clarant ne pas \u00eatre diab\u00e9tiques). D'autre part, cette estimation cumul\u00e9e reste\nprobablement en dessous de la r\u00e9alit\u00e9 au regard de\nla part des personnes pour lesquelles le diab\u00e8te n'est\npas diagnostiqu\u00e9 et donc non conn u par celles-ci.\nCette sous-estimation est en effet mise en pers -\npective avec les donn\u00e9es historiques de l'\u00e9tu de\nr\u00e9gionale R\u00e9dia 2001 17, qui montrait qu'un patient\ndiab\u00e9tique sur trois ignorait sa maladie. Il faut des\nenqu\u00eates sp\u00e9cifiques pour estimer la fr\u00e9quence du\ndiab\u00e8te m\u00e9connu ; un projet d'\u00e9tu de est en cours\n\u00e0 La R\u00e9union pour actualiser cette fr\u00e9quence.\nPar ailleurs, ces r\u00e9sultats montrent que les donn\u00e9es\nm\u00e9dico-administratives issues du Syst\u00e8me national\ndes donn\u00e9es de sant\u00e9 (SNDS) conc ernant les\npatients pris en charge par le syst\u00e8me de sant\u00e9 ou les\npersonnes trait\u00e9es pharmacologiquement utilis\u00e9es\ndans le cadre de la surveillance r\u00e9gionale du diab\u00e8te\nsous-estiment la r\u00e9alit\u00e9 de la situation.\nLe \u00ab petit diab\u00e8te \u00bb\nLe \u00ab petit diab\u00e8te \u00bb renvoie aux notions de \u00ab diab\u00e8te\nr\u00e9cent \u00bb et/ou \u00ab diab\u00e8te sans complication \u00bb et/ou\n\u00ab diab\u00e8te sous-estim\u00e9 pour ne pas inqui\u00e9ter le\npatient \u00bb : l'entr\u00e9e dans le diab\u00e8te peut \u00eatre mini -\nmis\u00e9e pour certaines personnes. Le petit diab\u00e8te\npeut ainsi \u00eatre conf ondu avec le pr\u00e9diab\u00e8te pour\ncertains sujets, notamment lorsque la glyc\u00e9mie \u00e0\njeun est \u00e9lev\u00e9e (facteur de conf usion pour les sujets)\net que le diagnostic n'est pas confi rm\u00e9. Les r\u00e9sul -\ntats \u00e9tant bas\u00e9s sur les donn\u00e9es d\u00e9claratives de la\npersonne, il n'est pas possible de dissocier dans les\nr\u00e9sultats ces diff\u00e9rentes notions. Ainsi, les donn\u00e9es\nne permettent pas d'\u00e9ca rter d'\u00e9ventuels cas de pr\u00e9 -\ndiab\u00e8te. La notion de pr\u00e9diab\u00e8te m\u00e9riterait aussi\nd'\u00eatre approfondie dans les \u00e9tudes.\nPlusieurs questions permettaient de d\u00e9crire l'anc iennet\u00e9 du \u00ab petit diab\u00e8te \u00bb et les prises en charge et\nrecours de ces personnes.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2302, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "af9ac5ce-823e-41c6-83c6-891ca6c956e2": {"__data__": {"id_": "af9ac5ce-823e-41c6-83c6-891ca6c956e2", "embedding": null, "metadata": {"page_label": "436", "file_name": "2023_20-21.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2023_20-21.pdf", "file_type": "application/pdf", "file_size": 1372902, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "2078a7ef-0deb-4e51-9a34-2a6b244b2883", "node_type": "4", "metadata": {"page_label": "436", "file_name": "2023_20-21.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2023_20-21.pdf", "file_type": "application/pdf", "file_size": 1372902, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "eebb7ac01a90c507d65d8013cc211dc5735b044bbe106e73a99562a658d05adb", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9f10cf6b-5c37-49c7-9538-8df4d98968b8", "node_type": "1", "metadata": {"page_label": "436", "file_name": "2023_20-21.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2023_20-21.pdf", "file_type": "application/pdf", "file_size": 1372902, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "a9eebbc7b60722c70c95e54ab5b6f3229e120a6e9d6f749ad3d5e87b0e8ecc9e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "753aeab6-4cdf-4cc0-af0b-22672272f8e3", "node_type": "1", "metadata": {}, "hash": "6d61ce36110a9821a19b3cb84a2f9858a12c2591168ed72f46ba8428892a2e8e", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Ainsi, les donn\u00e9es\nne permettent pas d'\u00e9ca rter d'\u00e9ventuels cas de pr\u00e9 -\ndiab\u00e8te. La notion de pr\u00e9diab\u00e8te m\u00e9riterait aussi\nd'\u00eatre approfondie dans les \u00e9tudes.\nPlusieurs questions permettaient de d\u00e9crire l'anc iennet\u00e9 du \u00ab petit diab\u00e8te \u00bb et les prises en charge et\nrecours de ces personnes. La puissance des effec -\ntifs ne permet pas d'app rofondir les r\u00e9sultats par\nrapport \u00e0 cette situation d\u00e9clar\u00e9e. L 'analyse explo -\nratoire des donn\u00e9es \u00e9voque cependant que la majo -\nrit\u00e9 de ces personnes connaissaient leur situation\ndepuis moins de deux ans et que les r\u00e8gles hygi\u00e9nodi\u00e9t\u00e9tiques constituaient le traitement de premi\u00e8re\nligne. Le \u00ab petit diab\u00e8te \u00bb cache probablement des\nr\u00e9alit\u00e9s plus complexes. D'une part, il ne se limite pas\n\u00e0 un diab\u00e8te r\u00e9cent, puisque plusieurs personnes\nconcern\u00e9es d\u00e9claraient \u00eatre inform\u00e9es depuis au\nmoins cinq ans. D'autre part, parmi les personnes\navec un \u00ab petit diab\u00e8te \u00bb, certaines d\u00e9claraient \u00eatre\ntrait\u00e9es pharmacologiquement. Le profil m\u00e9tabolique\net les modes de vie de ces personnes semblaient\n\u00e9galement d\u00e9grad\u00e9s par rapport \u00e0 la population non\ndiab\u00e9tique (dans une moindre mesure que chez les\npersonnes avec un diab\u00e8te conn u). La vigilance est\ndonc de mise pour ce public plus jeune (de cinq ans\nen moyenne que les personnes d\u00e9clarant \u00eatre diab\u00e9 -\ntiques), avec une maladie probablement insuffisam -\nment contr\u00f4l\u00e9e, avec un risque de comp lications, et\nn'ayant pas toujours cons cience d'\u00eatre atteint d'une\nmaladie chronique (pr\u00e8s de la moiti\u00e9 des personnes\nont r\u00e9pondu ne pas avoir de maladie chronique).", "mimetype": "text/plain", "start_char_idx": 2012, "end_char_idx": 3561, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "753aeab6-4cdf-4cc0-af0b-22672272f8e3": {"__data__": {"id_": "753aeab6-4cdf-4cc0-af0b-22672272f8e3", "embedding": null, "metadata": {"page_label": "436", "file_name": "2023_20-21.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2023_20-21.pdf", "file_type": "application/pdf", "file_size": 1372902, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "2078a7ef-0deb-4e51-9a34-2a6b244b2883", "node_type": "4", "metadata": {"page_label": "436", "file_name": "2023_20-21.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2023_20-21.pdf", "file_type": "application/pdf", "file_size": 1372902, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "eebb7ac01a90c507d65d8013cc211dc5735b044bbe106e73a99562a658d05adb", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "af9ac5ce-823e-41c6-83c6-891ca6c956e2", "node_type": "1", "metadata": {"page_label": "436", "file_name": "2023_20-21.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2023_20-21.pdf", "file_type": "application/pdf", "file_size": 1372902, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "283cccc9a113216e42ccb9dd7ac8ac22df5cc14d7c73ff95ee59aae402314053", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Ces \u00e9l\u00e9ments exploratoires sugg\u00e8rent des leviers\nTableau 4\nDescription de l'\u00e9tat m\u00e9tabolique et des modes de vie des personnes selon la connaissance du diab\u00e8te, La R\u00e9union, 2021\nPersonnes d\u00e9clarant\n\u00eatre diab\u00e9tiques\nPersonnes d\u00e9clarant\nne pas \u00eatre diab\u00e9tiques Ensemble\n% [IC95%] % [IC95%] % [IC95%]\n\u00c9tat m\u00e9tabolique\nIndice de masse corporelle (IMC)\nMaigreur ou normal (\u226425 kg/m2) 31,8 [25,4-38,8] 56,4 [53,5-59,3] 53,1 [50,3-55,8]\nSurpoids 40,3 [32,9-48,1] 31,0 [28,3-33,8] 32,3 [29,7-34,9]\nOb\u00e9sit\u00e9 28,0 [21,2-35,9] 12,6 [10,9-14,5] 14,7 [12,8-16,7]\nMoyenne IMCa 27,5 [26,8-28,2] 25,0 [24,7-25,2] 25,3 [25,1-25,6]\nHypertension art\u00e9rielle d\u00e9clar\u00e9e 46,5 [39,2-54,1] 16,7 [14,7-19,0] 20,8 [18,7-23,0]\nModes de vie\nPratique d'activit\u00e9s physiques conforme\naux recommandationsb\n59,5 [51,9-66,7] 61,0 [58,2-63,8] 60,8 [58,2-63,4]\nAu moins 5 fruits et l\u00e9gumes par jour 19,9 [14,9-26,0] 20,6 [18,5-23,0] 20,5 [18,5-22,7]\nBoissons sucr\u00e9es tous les jours 13,7 [9,1-20,0] 23,0 [20,6-25,5] 21,7 [19,6-24,0]\nTabagisme quotidien 20,1 [14,1-27,8] 19,9 [17,6-22,4] 19,9 [17,8-22,3]\nAlcool hebdomadaire 21,0 [15,3-28,1] 24,8 [22,3-27,5] 24,3 [22,0-26,8]\nIC95% : intervalle de confiance \u00e0 95%.\na Ces chiffres correspondent \u00e0 une moyenne et non \u00e0 un pourcentage.\nb Au moins 150 minutes d'activit\u00e9 physique mod\u00e9r\u00e9e par semaine ou 75 minutes d'activit\u00e9 physique intense par semaine ou une combinaison \u00e9quivalente\nd'activit\u00e9 physique mod\u00e9r\u00e9e ou intense par semaine.", "mimetype": "text/plain", "start_char_idx": 3562, "end_char_idx": 5003, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "16a1af56-fce2-4fab-9f94-5765cc9523be": {"__data__": {"id_": "16a1af56-fce2-4fab-9f94-5765cc9523be", "embedding": null, "metadata": {"page_label": "437", "file_name": "2023_20-21.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2023_20-21.pdf", "file_type": "application/pdf", "file_size": 1372902, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "51955358-2582-40f8-8e7e-d511f8faf5a0", "node_type": "4", "metadata": {"page_label": "437", "file_name": "2023_20-21.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2023_20-21.pdf", "file_type": "application/pdf", "file_size": 1372902, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "4f0635bc929e6182fbfaaf67d47bcb7bf682732852e46cedad89fde5ef53abb1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2fe3ea18-97a3-4e67-ba3b-2ac756633525", "node_type": "1", "metadata": {}, "hash": "76b638eef3351edbc1de1c8f7c473aa1c0e7e7905a5b81ce4ff6ca7469df0fb6", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Diab\u00e8te en outre-mer : comprendre les sp\u00e9cificit\u00e9s locales pour cibler les actions BEH 20-21 | 14 novembre 2023 | 437\nen termes de comm unication pour faire \u00e9voluer\nles discours et les repr\u00e9sentations des patients et\ndes professionnels de sant\u00e9.\nCaract\u00e9ristiques des personnes\nd\u00e9clarant un diab\u00e8te\nLes r\u00e9sultats de cette \u00e9tude sur un \u00e9chantillon probabiliste de la population adulte r\u00e9unionnaise retrouvent\nles m\u00eames sp\u00e9cificit\u00e9s li\u00e9es au diab\u00e8te dans notre\npopu lation que les donn\u00e9es issues du SNDS et/ou\nde l'\u00e9tude Entred 3 (1) (2) 18,19 : des personnes atteintes\nd'un diab\u00e8te (connu ou pris en charge) plus jeunes,\nplus de femmes, des personnes avec une forte pro -\nportion d'IMC \u226425 kg/m\u00b2 (maigreur ou normal)...\nConcernant les donn\u00e9es de corpulence, m\u00eame si\nl'IMC des personnes avec un diab\u00e8te est plus \u00e9lev\u00e9\nque celui des personnes d\u00e9clarant ne pas \u00eatre\ndiab\u00e9tiques, pr\u00e8s d'un tiers des personnes ayant\nun diab\u00e8te d\u00e9clarent un IMC normal. Ce r\u00e9sultat est\ncoh\u00e9rent avec les r\u00e9sultats de l'\u00e9tu de Entred 3 18 o\u00f9\nla proportion de personnes ob\u00e8ses atteintes de DT2\ndans la population r\u00e9unionnaise est plus faible et\ncelle des personnes atteintes de DT2 ayant un IMC\ndans les normes est plus \u00e9lev\u00e9e que dans l'Hexagone\net dans les autres DROM. Cela confi rme les sp\u00e9ci -\nficit\u00e9s de cette population et la n\u00e9cessit\u00e9 d'ada pter\nles discours, le d\u00e9pistage et les prises en charge.\nPersistance des constats sur les in\u00e9galit\u00e9s\nsociales et les facteurs de risque connus\nassoci\u00e9s au diab\u00e8te et \u00e0 ses complications\nLes r\u00e9sultats de l'\u00e9di tion 2021 permettent, sept ans\nplus tard, de r\u00e9it\u00e9rer les cons tats de 2014 sur notre\nterritoire 10.\nD'une part, les facteurs de risques connus du diab\u00e8te\net des complications associ\u00e9es restent fr\u00e9quemment\nd\u00e9clar\u00e9s par cette population pr\u00e9sentant un diab\u00e8te :\nob\u00e9sit\u00e9, faible cons ommation de fruits et l\u00e9gumes,\npratique insuffisante d'activit\u00e9s physiques, fr\u00e9quence\n\u00e9lev\u00e9e du tabagisme quotidien. Ces r\u00e9sultats\nsugg\u00e8rent que malgr\u00e9 la connaissance de la maladie,\nles personnes d\u00e9clarant un diab\u00e8te changent peu\nleurs comportements. Cette hypoth\u00e8se d'abs ence\nde prise de conscience est renforc\u00e9e par le fait qu'un\nquart des personnes ayant un diab\u00e8te d\u00e9clare n'avoir\naucune maladie chronique.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2225, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "2fe3ea18-97a3-4e67-ba3b-2ac756633525": {"__data__": {"id_": "2fe3ea18-97a3-4e67-ba3b-2ac756633525", "embedding": null, "metadata": {"page_label": "437", "file_name": "2023_20-21.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2023_20-21.pdf", "file_type": "application/pdf", "file_size": 1372902, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "51955358-2582-40f8-8e7e-d511f8faf5a0", "node_type": "4", "metadata": {"page_label": "437", "file_name": "2023_20-21.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2023_20-21.pdf", "file_type": "application/pdf", "file_size": 1372902, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "4f0635bc929e6182fbfaaf67d47bcb7bf682732852e46cedad89fde5ef53abb1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "16a1af56-fce2-4fab-9f94-5765cc9523be", "node_type": "1", "metadata": {"page_label": "437", "file_name": "2023_20-21.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2023_20-21.pdf", "file_type": "application/pdf", "file_size": 1372902, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "78b825853c69f600e7c5488e1ab19cd55d8a0b6e2eade1b5df8d17316a762e09", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "77af1fe9-dced-4a0a-8bd1-45466b4264d3", "node_type": "1", "metadata": {}, "hash": "f9f54d3d156d3f8a9ba1e8aa7bad44094df36791e0a153defde0371893886a15", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Ces r\u00e9sultats\nsugg\u00e8rent que malgr\u00e9 la connaissance de la maladie,\nles personnes d\u00e9clarant un diab\u00e8te changent peu\nleurs comportements. Cette hypoth\u00e8se d'abs ence\nde prise de conscience est renforc\u00e9e par le fait qu'un\nquart des personnes ayant un diab\u00e8te d\u00e9clare n'avoir\naucune maladie chronique.\nPar ailleurs, les r\u00e9sultats sur la sant\u00e9 globale\ndes personnes ayant un diab\u00e8te rendent comp te\nd'une perception de la sant\u00e9 globale et d'un \u00e9tat\nde sant\u00e9 physique plus d\u00e9grad\u00e9s par rapport\naux personnes d\u00e9clarant ne pas \u00eatre diab\u00e9 -\ntiques. L 'hypertension art\u00e9rielle impliqu\u00e9e dans la\ngen\u00e8se des complications est aussi fr\u00e9quemment\nretrouv\u00e9e chez les patients ayant un diab\u00e8te : pr\u00e8s\nd'une personne d\u00e9clarant un diab\u00e8te sur deux est\naussi hypertendue.\n(1) Sant\u00e9 publique France. Observatoire G\u00e9odes.\npubliquefrance.fr\n(2) Assurance maladie. Data pathologies.\nLes facteurs associ\u00e9s au diab\u00e8te retrouv\u00e9s dans\ncette \u00e9tude sont : le mode de vie, l'HTA, le tabac,\nla consommation d'alcool (d\u00e9l\u00e9t\u00e8re pour le diab\u00e8te\nen grande quantit\u00e9 et plus g\u00e9n\u00e9ralement facteur\nde risque de cancer en cons ommation quotidienne\nquelle que soit la quantit\u00e9). Ils montrent l'imp ortance\nd'une prise en charge globale des personnes diab\u00e9 -\ntiques et non glucocentr\u00e9e.\nIl existe donc des marges d'am\u00e9 lioration en termes\nde pr\u00e9vention, d'acc ompagnement et de comm unication aupr\u00e8s des personnes atteintes d'un diab\u00e8te\npour qu'elles int\u00e8grent des modes de vie plus favo -\nrables \u00e0 leur sant\u00e9. Les messages doivent \u00e9galement\nporter sur le tabagisme pour une population \u00e0 haut\nrisque de complications cardiovasculaires.\nD'autre part, le diab\u00e8te est une maladie chronique\nr\u00e9v\u00e9latrice des in\u00e9galit\u00e9s sociales de sant\u00e9. Le fort\ngradient socio-\u00e9conomique est retrouv\u00e9 dans cette\n\u00e9tude : les personnes les moins dipl\u00f4m\u00e9es et aux\nrevenus les plus modestes sont davantage expo -\ns\u00e9es au diab\u00e8te. Par ailleurs, les r\u00e9sultats de cette\n\u00e9tude ne permettent pas de montrer l'imp act du\ndiab\u00e8te sur le quotidien des personnes. Pour autant,\nle diab\u00e8te survenant de mani\u00e8re plus pr\u00e9coce\n\u00e0 La R\u00e9union, cela peut avoir un impact sur la vie\nsociale des personnes (notamment celles qui sont\nen \u00e2ge de travailler). Les donn\u00e9es montrent que plus\nd'un tiers des personnes ayant un diab\u00e8te d\u00e9clarent\n\u00eatre limit\u00e9es dans les activit\u00e9s du quotidien dans les\n6 derniers mois, cela peut sugg\u00e9rer un accompagnement sp\u00e9cifique au niveau social.", "mimetype": "text/plain", "start_char_idx": 1930, "end_char_idx": 4315, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "77af1fe9-dced-4a0a-8bd1-45466b4264d3": {"__data__": {"id_": "77af1fe9-dced-4a0a-8bd1-45466b4264d3", "embedding": null, "metadata": {"page_label": "437", "file_name": "2023_20-21.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2023_20-21.pdf", "file_type": "application/pdf", "file_size": 1372902, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "51955358-2582-40f8-8e7e-d511f8faf5a0", "node_type": "4", "metadata": {"page_label": "437", "file_name": "2023_20-21.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2023_20-21.pdf", "file_type": "application/pdf", "file_size": 1372902, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "4f0635bc929e6182fbfaaf67d47bcb7bf682732852e46cedad89fde5ef53abb1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2fe3ea18-97a3-4e67-ba3b-2ac756633525", "node_type": "1", "metadata": {"page_label": "437", "file_name": "2023_20-21.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2023_20-21.pdf", "file_type": "application/pdf", "file_size": 1372902, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "ef2b656a4d3fcbcd5b5dcf4cdc392fae557db2a9605f80c3e95e972caa9110c2", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Les donn\u00e9es montrent que plus\nd'un tiers des personnes ayant un diab\u00e8te d\u00e9clarent\n\u00eatre limit\u00e9es dans les activit\u00e9s du quotidien dans les\n6 derniers mois, cela peut sugg\u00e9rer un accompagnement sp\u00e9cifique au niveau social. Le volet social est\nclairement \u00e0 approfondir pour diminuer les cons \u00e9quences de la pr\u00e9carit\u00e9, mais aussi \u00e9viter la pr\u00e9ca -\nrisation qui peut r\u00e9sulter de la d\u00e9couverte d'une\nmaladie chronique et ses comp lications (incapacit\u00e9,\nd\u00e9compensation de la maladie, comp lications, perte\nd'emploi, perte de confi ance en soi...). Les donn\u00e9es\nde l'\u00e9tude Entred 3 permettront de le faire.\nLa r\u00e9duction de l'imp act sanitaire des in\u00e9galit\u00e9s\nsociales reste donc un point d'attention majeur.\nPrise en charge des personnes\nse d\u00e9clarant diab\u00e9tiques\nLes r\u00e9sultats de cette nouvelle \u00e9dition du Barom\u00e8tre\nSant\u00e9 DROM mettent en \u00e9vidence des ruptures dans\nla prise en charge des personnes ayant un diab\u00e8te :\narr\u00eat du traitement et/ou non-recours aux soins.\nCes r\u00e9sultats rejoignent ceux des autres travaux\nr\u00e9gionaux qui montrent que les parcours r\u00e9els des\npersonnes diab\u00e9tiques r\u00e9unionnaises sont souvent\n\u00e9loign\u00e9s des parcours recommand\u00e9s. La proportion\nd'arr\u00eat de traitement d\u00e9crite ici est mise en perspec -\ntive avec celles retrouv\u00e9es dans l'enq u\u00eate r\u00e9gionale\nsur les parcours de soins des patients diab\u00e9tiques\nmis sous traitement en 2010 9, o\u00f9 9% des patients\navaient arr\u00eat\u00e9 leur traitement pendant au moins deux\nans et o\u00f9 pr\u00e8s de 40% des patients avaient arr\u00eat\u00e9\nleur traitement apr\u00e8s huit ans de parcours de soins.\nLes actions de comm unication et d'acc ompagnement pour motiver les patients \u00e0 l'observance m\u00e9di -\ncamenteuse, ou les inciter \u00e0 reprendre leur traitement\nen cas d'arr\u00eat doivent se poursuivre.", "mimetype": "text/plain", "start_char_idx": 4096, "end_char_idx": 5806, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "5e44687e-c9de-4923-9de4-c5bf17d6cb9d": {"__data__": {"id_": "5e44687e-c9de-4923-9de4-c5bf17d6cb9d", "embedding": null, "metadata": {"page_label": "438", "file_name": "2023_20-21.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2023_20-21.pdf", "file_type": "application/pdf", "file_size": 1372902, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "ba8fe3fd-a1ff-4583-be3a-beddd7a15063", "node_type": "4", "metadata": {"page_label": "438", "file_name": "2023_20-21.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2023_20-21.pdf", "file_type": "application/pdf", "file_size": 1372902, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "5dd50946c28ef229c8244c52dd398888a80199032b84962170cd39f4f4d7f91f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b4389582-5d43-4557-9285-4377c53faf73", "node_type": "1", "metadata": {}, "hash": "7dc9fc8e5a953b28faa17949c68a0d44ef735e1295376f5ce643fa1dc4c410ab", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "438 | 14 novembre 2023 | BEH 20-21 Diab\u00e8te en outre-mer : comprendre les sp\u00e9cificit\u00e9s locales pour cibler les actions\nPar ailleurs, l'enqu\u00eate permettait \u00e9galement d'aborder\nles prises en charge et le recours chez les personnes\natteintes d'un diab\u00e8te non trait\u00e9 pharmacologique -\nment et chez les personnes avec un \u00ab petit diab\u00e8te \u00bb.\nLa puissance statistique n'est pas suffisante pour\napprofondir les r\u00e9sultats et montrer l'imp ortance,\nressentie par les acteurs r\u00e9gionaux, du recours aux\nplantes m\u00e9dicinales (tisanes/\u00ab zerbages p\u00e9i \u00bb) pour\nle traitement des maladies (notamment chroniques)\nsur l'\u00eele. Une \u00e9tude r\u00e9gionale sur le recours aux soins\nen 2014 montrait que l'usage des plantes conc ernait\ndeux R\u00e9unionnais adultes sur cinq ; et que le recours\naux plantes pour traiter un trouble rencontr\u00e9 variait\npeu selon les tranches d'\u00e2ge 20. L 'usage des tisanes \u00e0\nLa R\u00e9union rev\u00eat donc davantage un aspect cult urel\nqu'un effet de g\u00e9n\u00e9ration. Cet usage des rem\u00e8des\ntraditionnels est mis en exergue dans les r\u00e9sul -\ntats du Barom\u00e8tre Sant\u00e9 2021 sur l'ens emble des\nDROM 21, dans les r\u00e9sultats de la troisi\u00e8me \u00e9dition\nde l'\u00e9tude Entred 18, o\u00f9 44% des personnes diab\u00e9 -\ntiques r\u00e9unionnaises trait\u00e9es pharmaco logiquement\nd\u00e9claraient aussi un recours aux plantes, ou encore\ndans les r\u00e9sultats de l'enq u\u00eate qualitative Diab-quali\nmen\u00e9e \u00e0 La R\u00e9union 22. Une revue bibliographique des\nenqu\u00eates qualitatives r\u00e9gionales 23 sur le diab\u00e8te a\npermis de montrer que les plantes m\u00e9dicinales \u00e9taient\nl'un des quatre moyens th\u00e9rapeutiques clairement\nidentifi\u00e9s par les patients diab\u00e9tiques (avec la di\u00e9t\u00e9 -\ntique, les cachets et l'insuline). Ces travaux montrent\nque les th\u00e9rapies modernes (m\u00e9dicamenteuses ou\nnon) s'ajoutent ou supplantent les traitements tradi -\ntionnels phyto- th\u00e9rapeutiques, largement administr\u00e9s\ndans les familles dans un but pr\u00e9ventif ou curatif.\nFace \u00e0 ces cons tats renouvel\u00e9s sur les ruptures de\nprise en charge, il faut souligner que les objectifs du\nProgramme r\u00e9unionnais de nutrition et de lutte contre\nle diab\u00e8te (PRND) 15 sont de travailler sur les parcours\ndes personnes ayant un diab\u00e8te localement pour\n\u00e9viter les ruptures de suivi et de valoriser et rendre\naccessible tous les programmes d' \u00e9ducation th\u00e9ra -\npeutique du patient (ETP) pour favoriser la communication et la diffusion des informations.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2319, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "b4389582-5d43-4557-9285-4377c53faf73": {"__data__": {"id_": "b4389582-5d43-4557-9285-4377c53faf73", "embedding": null, "metadata": {"page_label": "438", "file_name": "2023_20-21.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2023_20-21.pdf", "file_type": "application/pdf", "file_size": 1372902, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "ba8fe3fd-a1ff-4583-be3a-beddd7a15063", "node_type": "4", "metadata": {"page_label": "438", "file_name": "2023_20-21.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2023_20-21.pdf", "file_type": "application/pdf", "file_size": 1372902, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "5dd50946c28ef229c8244c52dd398888a80199032b84962170cd39f4f4d7f91f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5e44687e-c9de-4923-9de4-c5bf17d6cb9d", "node_type": "1", "metadata": {"page_label": "438", "file_name": "2023_20-21.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2023_20-21.pdf", "file_type": "application/pdf", "file_size": 1372902, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "0b11d4af30e0332ab2d1023e2af75fd94d28a5925de36fee2c7994238ec04a65", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3d787d5e-1758-43ee-9a7a-e5114f1325a0", "node_type": "1", "metadata": {}, "hash": "78babe74952228ab4886650b3d67434585e7cdd287c7999329411c0a0c7376a2", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "\u00c9volution de la situation r\u00e9gionale\nLa comparaison des r\u00e9sultats entre les deux \u00e9ditions\ndu Barom\u00e8tre Sant\u00e9 DROM est tr\u00e8s limit\u00e9e, dans\nla mesure o\u00f9 les questions (hormis pour le diab\u00e8te\nconnu) et les populations d'\u00e9tudes \u00e9taient diff\u00e9rentes\nentre 2014 et 2021.\nLa pr\u00e9valence du diab\u00e8te conn u tend \u00e0 augmenter\ndans la population r\u00e9unionnaise, sans \u00eatre signi -\nficative. En se rapportant \u00e0 la population des\n18-75 ans, la part du diab\u00e8te connu est pass\u00e9 de 11,6%\n(IC95%: [9,9-13,5]) en 2014 \u00e0 13,0% [11,2-15,0] en 2021.\nCette tendance pourrait \u00eatre li\u00e9e \u00e0 une augmentation\nde l'incidence du diab\u00e8te, mais aussi au vieillisse -\nment de la population, \u00e0 l'allongement de l'esp\u00e9rance\nde vie de la population diab\u00e9tique et \u00e9galement \u00e0\nune am\u00e9lioration de la connaissance et du d\u00e9pistage\ndu diab\u00e8te au cours du temps, comme le montrent\nles r\u00e9sultats de l'enq u\u00eate Entred 3 o\u00f9 la propor -\ntion de diab\u00e8te de type 2 d\u00e9couvert sur d\u00e9pistage\nest plus importante \u00e0 La R\u00e9union (76%) que dans\nl'Hexagone (68%) 18. Ces r\u00e9sultats sont encoura -\ngeants au regard des efforts r\u00e9alis\u00e9s \u00e0 La R\u00e9union\nsur les strat\u00e9gies de d\u00e9pistage du diab\u00e8te dans le\ncadre du PRND 2020-2023 pour d\u00e9pister le plus t\u00f4t\net le plus largement possible la maladie.\nDonn\u00e9es d\u00e9claratives\nL 'ensemble des r\u00e9sultats pr\u00e9sent\u00e9s dans cet article\ns'appuient sur des donn\u00e9es d'enq u\u00eate d\u00e9claratives.\nLes r\u00e9sultats sont donc possiblement concern\u00e9s par\ndiff\u00e9rents biais (biais de couverture conc ernant principalement les personnes ne poss\u00e9dant pas de t\u00e9l\u00e9 -\nphone ou ne parlant pas le fran\u00e7ais ou le cr\u00e9ole, biais\nde non- r\u00e9ponse lorsque des personnes refusent de\nr\u00e9pondre \u00e0 l'enqu\u00eate, notamment les personnes aux\ncomportements de sant\u00e9 particuliers, biais de m\u00e9moire,\ncomme ne plus se souvenir de l'anciennet\u00e9 du diab\u00e8te,\net de d\u00e9sirabilit\u00e9 sociale, en se pr\u00e9sentant par exemple\nsous un meilleur jour aux yeux de l'enqu\u00eateur).\nConclusion\nLa pr\u00e9valence du diab\u00e8te conn u reste \u00e9lev\u00e9e \u00e0\nLa R\u00e9union, et l'ape r\u00e7u des caract\u00e9ristiques des\npersonnes d\u00e9clarant un diab\u00e8te renouvelle les\nconstats appelant \u00e0 la vigilance sur certains points\nde rupture dans la prise en charge des patients\ndiab\u00e9tiques, les in\u00e9galit\u00e9s sociales, les fr\u00e9quences\n\u00e9lev\u00e9es des facteurs de risque de complications chez\ndes personnes ayant un diab\u00e8te.", "mimetype": "text/plain", "start_char_idx": 2320, "end_char_idx": 4591, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "3d787d5e-1758-43ee-9a7a-e5114f1325a0": {"__data__": {"id_": "3d787d5e-1758-43ee-9a7a-e5114f1325a0", "embedding": null, "metadata": {"page_label": "438", "file_name": "2023_20-21.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2023_20-21.pdf", "file_type": "application/pdf", "file_size": 1372902, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "ba8fe3fd-a1ff-4583-be3a-beddd7a15063", "node_type": "4", "metadata": {"page_label": "438", "file_name": "2023_20-21.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2023_20-21.pdf", "file_type": "application/pdf", "file_size": 1372902, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "5dd50946c28ef229c8244c52dd398888a80199032b84962170cd39f4f4d7f91f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b4389582-5d43-4557-9285-4377c53faf73", "node_type": "1", "metadata": {"page_label": "438", "file_name": "2023_20-21.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2023_20-21.pdf", "file_type": "application/pdf", "file_size": 1372902, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "2d8dcf4f8ca1e3caf471272fdb613269cbd7253081b230f5abdca0e07ea6abeb", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "La survenue du diab\u00e8te et de ses complications \u00e9tant\nfr\u00e9quente \u00e0 La R\u00e9union (1) (2) 8,9,18,19, la pr\u00e9vention nutri -\ntionnelle doit \u00eatre renforc\u00e9e pour r\u00e9duire les facteurs\nde risque associ\u00e9s \u00e0 la maladie et ses complications,\nainsi que l'impact des in\u00e9galit\u00e9s sociales.\nDes analyses r\u00e9gionales comp l\u00e9mentaires sont en\ncours pour apporter des \u00e9l\u00e9ments de connaissance\nplus d\u00e9taill\u00e9s sur le diab\u00e8te d\u00e9clar\u00e9, l'ali menta -\ntion, l'activit\u00e9 physique, la s\u00e9dentarit\u00e9 et l'ob\u00e9 sit\u00e9.\nD'autres travaux nationaux (Entred 3) ou r\u00e9gio -\nnaux pourront comp l\u00e9ter les donn\u00e9es \u00e9pid\u00e9mio -\nlogiques r\u00e9gionales sur les caract\u00e9ristiques de prise\nen charge, l'\u00e9ta t de sant\u00e9 et la qualit\u00e9 de vie des\npersonnes ayant un diab\u00e8te.\nL 'ensemble de ces informations permettront de\ndocumenter les politiques publiques et en particulier\nd'orienter le prochain Programme r\u00e9unionnais de\nnutrition et de lutte cont re le diab\u00e8te (PRND) 15,\ndont l'actualisation est pr\u00e9vue en 2024, et de pour -\nsuivre la mobilisation des acteurs locaux en mati\u00e8re\nde pr\u00e9vention, d'accompagnement, d'\u00e9ducation et de\nprise en charge des personnes ayant un diab\u00e8te. \u25a0\n(1) Sant\u00e9 publique France. Observatoire G\u00e9odes.\npubliquefrance.fr\n(2) Assurance Maladie. Data pathologies.", "mimetype": "text/plain", "start_char_idx": 4592, "end_char_idx": 5818, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "772b089c-c817-44fd-bce7-935155f3d728": {"__data__": {"id_": "772b089c-c817-44fd-bce7-935155f3d728", "embedding": null, "metadata": {"page_label": "439", "file_name": "2023_20-21.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2023_20-21.pdf", "file_type": "application/pdf", "file_size": 1372902, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "8b00ebf7-29dc-46f4-b862-5efecbd04c5c", "node_type": "4", "metadata": {"page_label": "439", "file_name": "2023_20-21.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2023_20-21.pdf", "file_type": "application/pdf", "file_size": 1372902, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "281d96ff2d58ffb6d241988550da8de7621583d10637fb01662a1b4fba28a8b4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b17e3e2c-c860-4977-8262-cef4d36987db", "node_type": "1", "metadata": {}, "hash": "c3b030d470a32579f1a27c0591862cafdc6d124e584be2a49615a16a3d2bf12a", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Diab\u00e8te en outre-mer : comprendre les sp\u00e9cificit\u00e9s locales pour cibler les actions BEH 20-21 | 14 novembre 2023 | 439\nRemerciements\nLes auteurs remercient les \u00e9quipes Ipsos en charge du recueil\ndes donn\u00e9es et notamment les enqu\u00eateurs pour cette \u00e9dition\ndu Barom\u00e8tre de Sant\u00e9 publique France dans les DROM et les\nmembres du comit\u00e9 technique r\u00e9gional de l'observation de la\nth\u00e9matique \u00ab Nutrition-Ob\u00e9sit\u00e9-Diab\u00e8te \u00bb pour les \u00e9changes et\nr\u00e9flexions collectives, \u00c9tienne Billot et Dr Emmanuelle Rachou\npour leur relecture.\nLiens d'int\u00e9r\u00eat\nLes auteurs d\u00e9clarent n'avoir aucun lien d'int\u00e9r\u00eat au regard du\ncontenu de l'article.\nR\u00e9f\u00e9rences\n[1] International Diabetes Federation. IDF Diabetes Atlas 2021\n10th edition. Brussels: International Diabetes Federation; 2021.\n\n[2] Ogurtsova K, Guariguata L, Barengo NC, Ruiz PL, Sacre JW,\nKaruranga S, et al. IDF diabetes Atlas: Global estimates of\nundiagnosed diabetes in adults for 2021. Diabetes Res Clin\nPract. 2022;183:109118.\n[3] F\u00e9d\u00e9ration fran\u00e7aise des diab\u00e9tiques. Facteurs de risque du\ndiab\u00e8te. Paris: F\u00e9d\u00e9ration fran\u00e7aise des diab\u00e9tiques. https://\nwww.federationdesdiabetiques.org/information/risques\n[4] Sant\u00e9 publique France. Le diab\u00e8te en France : les chif -\nfres 2020. Saint-Maurice: Sant\u00e9 publique France; 2021. https://\nwww.santepubliquefrance.fr/les-actualites/2021/le-diabeteen-france-les-chiffres-2020\n[5] Fosse-Edorh S, Mandereau-Bruno L, Piffaretti C. Le poids\ndu diab\u00e8te en France en 2016. Synth\u00e8se \u00e9pid\u00e9miologique.\nSaint-Maurice: Sant\u00e9 publique France; 2018. 8 p.\nsantepubliquefrance.fr/maladies-et-traumatismes/diabete/\ndocuments/rapport-synthese/le-poids-du-diabete-enfrance-en-2016.-synthese-epidemiologique\n[6] Mandereau-Bruno L, Fosse-Edorh S. Pr\u00e9valence du diab\u00e8te\ntrait\u00e9 pharmacologiquement (tous types) en France en 2015.\nDisparit\u00e9s territoriales et socio-\u00e9conomiques. Bull \u00c9pid\u00e9miol\nHebd.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1854, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "b17e3e2c-c860-4977-8262-cef4d36987db": {"__data__": {"id_": "b17e3e2c-c860-4977-8262-cef4d36987db", "embedding": null, "metadata": {"page_label": "439", "file_name": "2023_20-21.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2023_20-21.pdf", "file_type": "application/pdf", "file_size": 1372902, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "8b00ebf7-29dc-46f4-b862-5efecbd04c5c", "node_type": "4", "metadata": {"page_label": "439", "file_name": "2023_20-21.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2023_20-21.pdf", "file_type": "application/pdf", "file_size": 1372902, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "281d96ff2d58ffb6d241988550da8de7621583d10637fb01662a1b4fba28a8b4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "772b089c-c817-44fd-bce7-935155f3d728", "node_type": "1", "metadata": {"page_label": "439", "file_name": "2023_20-21.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2023_20-21.pdf", "file_type": "application/pdf", "file_size": 1372902, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "92e290b6e80d68dd3a416ba235ffaeed88e2d00431f561275d117d2afb7b74df", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "92a06d7b-5173-4079-b573-704462dc60e7", "node_type": "1", "metadata": {}, "hash": "ec2cb6c3347848f55aba2fc488948e8ad4fd609442239b8af40068c1f92c6cc0", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Disparit\u00e9s territoriales et socio-\u00e9conomiques. Bull \u00c9pid\u00e9miol\nHebd. 2017;(27-28):586-91.\nbeh/2017/27-28/2017_27-28_3.html\n[7] Leduc A, Deroyon T, Rochereau T, Renaud A. Premiers\nr\u00e9sultats de l'enqu\u00eate sant\u00e9 europ\u00e9enne (EHIS) 2019 - M\u00e9tro -\npole, Guadeloupe, Martinique, Guyane, La R\u00e9union, Mayotte.\nLes Dossiers de la Drees. 2021;(78):1-89.\nsolidarites-sante.gouv.fr/publications/les-dossiers-de-ladrees/premiers-resultats-de-lenquete-sante-europeenneehis-2019-metrople-guadeloupe-martinique-guyane-lar%C3%A9union-mayotte\n[8] Ricquebourg M. Observation de la th\u00e9matique \u00ab Nutrition -\nOb\u00e9sit\u00e9 - Diab\u00e8te \u00bb \u00e0 La R\u00e9union. Tableau de bord. Saint-Denis:\nObservatoire r\u00e9gional de la sant\u00e9 La R\u00e9union; 2022. https://\nwww.ors-reunion.fr/tableau-de-bord-nutrition-obesite-dia\nbete-2022.html\n[9] Chan Wan GN, Chopinet-Dijoux S, Ricquebourg M,\nSimonpieri JM. Parcours de soins des patients diab\u00e9tiques\n\u00e0 La R\u00e9union - \u00c9tude longitudinale des parcours des patients\nmis sous traitement antidiab\u00e9tique en 2010. Synth\u00e8se des\nprincipaux r\u00e9sultats. Assurance Maladie La R\u00e9union, Agence\nr\u00e9gionale de sant\u00e9 La R\u00e9union, Observatoire r\u00e9gional de\nsant\u00e9 Oc\u00e9an Indien; 2020. 38 p.\nparcours-de-soins-des-patients-diabetiques-a-la-reunionetude-longitudinale-des.html\n[10] Guibert G, Balicchi J. Diab\u00e8te nutrition. Barom\u00e8tre Sant\u00e9\nDOM La R\u00e9union 2014. Nutrition, statut pond\u00e9ral et diab\u00e8te\n\u00e0 La R\u00e9union. In Extenso. 2015;(4):1-20.\nars.sante.fr/etude-sur-le-diabete-et-la-nutrition-la-reunionbarometre-sante-dom-la-reunion-2014\n[11] Grand\u00e9 C. Pas assez de fruits et l\u00e9gumes, trop d'huile,\nde sucre et de boissons sucr\u00e9es. Habitudes alimentaires des\nr\u00e9unionnais en 2017. Insee Analyses R\u00e9union. 2021;(57):1-4.\n\n[12] Brasset M, Levet L, Stein F. Les comportements alimen -\ntaires des R\u00e9unionnais - Un exc\u00e8s d'huile et de riz, un d\u00e9ficit\nde fruits et l\u00e9gumes. Insee Analyses R\u00e9union. 2015;(12):1-4.\n\n[13] Agence r\u00e9gionale de sant\u00e9 Oc\u00e9an Indien.", "mimetype": "text/plain", "start_char_idx": 1787, "end_char_idx": 3698, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "92a06d7b-5173-4079-b573-704462dc60e7": {"__data__": {"id_": "92a06d7b-5173-4079-b573-704462dc60e7", "embedding": null, "metadata": {"page_label": "439", "file_name": "2023_20-21.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2023_20-21.pdf", "file_type": "application/pdf", "file_size": 1372902, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "8b00ebf7-29dc-46f4-b862-5efecbd04c5c", "node_type": "4", "metadata": {"page_label": "439", "file_name": "2023_20-21.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2023_20-21.pdf", "file_type": "application/pdf", "file_size": 1372902, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "281d96ff2d58ffb6d241988550da8de7621583d10637fb01662a1b4fba28a8b4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b17e3e2c-c860-4977-8262-cef4d36987db", "node_type": "1", "metadata": {"page_label": "439", "file_name": "2023_20-21.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2023_20-21.pdf", "file_type": "application/pdf", "file_size": 1372902, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "b3f458c82829b6167cb4de124b9b55bc1d71cf5032789f47eba1279687f488c1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9d85a5bf-9aa9-45f7-9119-9e60620dbcca", "node_type": "1", "metadata": {}, "hash": "123056d43d7b79584899cdb0548f686e92e2cfb052771c61eaffc21db9df34d3", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "2021;(57):1-4.\n\n[12] Brasset M, Levet L, Stein F. Les comportements alimen -\ntaires des R\u00e9unionnais - Un exc\u00e8s d'huile et de riz, un d\u00e9ficit\nde fruits et l\u00e9gumes. Insee Analyses R\u00e9union. 2015;(12):1-4.\n\n[13] Agence r\u00e9gionale de sant\u00e9 Oc\u00e9an Indien. Projet de Sant\u00e9\n(PRS) Oc\u00e9an Indien 2018-2028. Saint-Denis: ARS-OI; 2018.\n\n[14] Agence r\u00e9gionale de sant\u00e9 Oc\u00e9an Indien. Projet de Sant\u00e9\nR\u00e9union-Mayotte. Cadre d'Orientations Strat\u00e9giques 20182028. Saint-Denis: ARS-OI; 2018.\nsante.fr/cadre-dorientations-strategiques-2018-2028-1\n[15] Agence r\u00e9gionale de sant\u00e9 La R\u00e9union. Programme r\u00e9u -\nnionnais de nutrition et de lutte contre le diab\u00e8te (PRND) 20202023. Saint-Denis: ARS La R\u00e9union; 2020.\nnion.ars.sante.fr/le-programme-reunionnais-de-nutrition-etde-lutte-contre-le-diabete-prnd-2020-2023-0\n[16] Soullier N, Richard JB, Gautier A. Barom\u00e8tre de Sant\u00e9\npublique France 2021. M\u00e9thode. Saint-Maurice: Sant\u00e9 publique\nFrance; 2022. 17 p.\nbarometre-de-sante-publique-france-2021.-methode\n[17] Lenclume V, Favier F. Cohorte R\u00c9DIA2 : Suivi des parti -\ncipants de l'enqu\u00eate R\u00c9DIA sur le diab\u00e8te de type 2 \u00e0 La R\u00e9union.\nR\u00e9sultats sur donn\u00e9es transversales (2006-2009) et longitu -\ndinales (1999-2009). Centre d'investigation clinique et d'\u00e9pi -\nd\u00e9miologie clinique de La R\u00e9union; 2014. 240 p.\nsantepubliquefrance.fr/maladies-et-traumatismes/diabete/\narticles/donnees-epidemiologiques-sur-le-diabete-en-regions\n[18] Fosse-Edorh S, Lavalette C, Piffaretti C, Saboni L,\nBessonneau P, Mandereau-Bruno L, et al. Caract\u00e9ristiques,\n\u00e9tat de sant\u00e9 et recours aux soins des personnes pr\u00e9sen -\ntant un diab\u00e8te de type 2 r\u00e9sidant en Outre-mer : r\u00e9sultats de\nl'\u00e9tude Entred 3. Bull \u00c9pid\u00e9miol Hebd. 2023;(20-21); 412-23\n\n20-21_1.html\n[19] Observatoire r\u00e9gional de la sant\u00e9 La R\u00e9union. Le diab\u00e8te\net les personnes diab\u00e9tiques \u00e0 La R\u00e9union. 14 indicateurs\ncl\u00e9s.", "mimetype": "text/plain", "start_char_idx": 3451, "end_char_idx": 5283, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "9d85a5bf-9aa9-45f7-9119-9e60620dbcca": {"__data__": {"id_": "9d85a5bf-9aa9-45f7-9119-9e60620dbcca", "embedding": null, "metadata": {"page_label": "439", "file_name": "2023_20-21.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2023_20-21.pdf", "file_type": "application/pdf", "file_size": 1372902, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "8b00ebf7-29dc-46f4-b862-5efecbd04c5c", "node_type": "4", "metadata": {"page_label": "439", "file_name": "2023_20-21.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2023_20-21.pdf", "file_type": "application/pdf", "file_size": 1372902, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "281d96ff2d58ffb6d241988550da8de7621583d10637fb01662a1b4fba28a8b4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "92a06d7b-5173-4079-b573-704462dc60e7", "node_type": "1", "metadata": {"page_label": "439", "file_name": "2023_20-21.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2023_20-21.pdf", "file_type": "application/pdf", "file_size": 1372902, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "278f070232e4b8be3ad0757882c31017d1db6666332fdceff168971f035eb300", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Bull \u00c9pid\u00e9miol Hebd. 2023;(20-21); 412-23\n\n20-21_1.html\n[19] Observatoire r\u00e9gional de la sant\u00e9 La R\u00e9union. Le diab\u00e8te\net les personnes diab\u00e9tiques \u00e0 La R\u00e9union. 14 indicateurs\ncl\u00e9s. Saint-Denis: ORS La R\u00e9union; 2022. 4 p.\nors-reunion.fr/le-diabete-et-les-personnes-diabetiques-a-lareunion-2022.html\n[20] Boulevart P. Recours aux soins \u00e0 La R\u00e9union. In Extenso.\n2016;(5):1-13.\ndefault/files/2017-01/ARS_InExtenso_Soins_n5_16sept_BD.PDF\n[21] Hernandez H, Piffaretti C, Gautier A, Cosson E, FosseEdorh S. Pr\u00e9valence du diab\u00e8te connu dans 4 d\u00e9partements\net r\u00e9gions d'outre-mer : Guadeloupe, Martinique, Guyane et\nLa R\u00e9union. R\u00e9sultats du Barom\u00e8tre de Sant\u00e9 publique France\nde 2021. Bull \u00c9pid\u00e9miol Hebd. 2023;(20-21):424-31.\nsantepubliquefrance.fr/beh/2023/20-21/2023_20-21_2.html\n[22] Balcou-Debussche M. Approche socio-anthropologique de\nla litt\u00e9ratie en sant\u00e9 des personnes atteintes de diab\u00e8te de type 2\n\u00e0 La R\u00e9union. Bull \u00c9pid\u00e9miol Hebd. 2023;(20-21):440-6. http://\nbeh.santepubliquefrance.fr/beh/2023/21-22/2023_20-21_4.html\n[23] Dougin H. \u00c9tudes qualitatives sur le diab\u00e8te de type 2\nmen\u00e9es \u00e0 La R\u00e9union depuis 1998. R\u00e9sum\u00e9s des principales\n\u00e9tudes - Synth\u00e8se g\u00e9n\u00e9rale - Discussion. Saint-Denis: ORS OI;\n2018. 70 p.\nCiter cet article\nRicquebourg M, Kwan C, M\u00e9devielle S, Chopinet-Dijoux S,\nCaliez F, Thouillot F, et al . Pr\u00e9valence du diab\u00e8te connu \u00e0\nLa R\u00e9union, prises en charge et caract\u00e9ristiques des per -\nsonnes atteintes d 'un diab\u00e8te : exploitation des donn\u00e9es\ndu Baro m\u00e8tre de Sant\u00e9 publique France DROM de 2021 . Bull\n\u00c9pid\u00e9miol Hebd. 2023;(20-21): 431-9. -\nquefrance.fr/beh/2023/20-21/2023_20-21_3.html", "mimetype": "text/plain", "start_char_idx": 5102, "end_char_idx": 6714, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "c31d7e66-7adc-450e-8088-6512ac569478": {"__data__": {"id_": "c31d7e66-7adc-450e-8088-6512ac569478", "embedding": null, "metadata": {"page_label": "440", "file_name": "2023_20-21.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2023_20-21.pdf", "file_type": "application/pdf", "file_size": 1372902, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "bcdd4836-ebbf-4c04-8e9e-8af4dec9e84a", "node_type": "4", "metadata": {"page_label": "440", "file_name": "2023_20-21.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2023_20-21.pdf", "file_type": "application/pdf", "file_size": 1372902, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "17d257c0401b81e64d91e65a4207a1005efb832bdabdd13be6cb4b293c863d2b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ebc418e0-7168-4da3-82b6-4f84c23f3fb2", "node_type": "1", "metadata": {}, "hash": "d0e2a9e0c9a5684d1836b051a0b73ac6bcac17aa0e41cd30eed17120f81b1e44", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "440 | 14 novembre 2023 | BEH 20-21 Diab\u00e8te en outre-mer : comprendre les sp\u00e9cificit\u00e9s locales pour cibler les actions\nARTICLE // Article\nAPPROCHE SOCIO-ANTHROPOLOGIQUE DE LA LITT\u00c9RATIE EN SANT\u00c9 DES PERSONNES ATTEINTES\nDE DIAB\u00c8TE DE TYPE 2 \u00c0 LA R\u00c9UNION\n// A SOCIO-ANTHROPOLOGICAL APPROACH TO HEALTH LITERACY AMONG PEOPLE WITH TYPE 2 DIABETES\nIN REUNION ISLAND\nMaryvette Balcou-Debussche ()\nLaboratoire Icare, Universit\u00e9 de La R\u00e9union, Saint-Denis\nSoumis le 04.07.2023 // Date of submission: 07.04.2023\nR\u00e9sum\u00e9 // Abstract\nIntroduction - En 2021, 13,6% de la population r\u00e9unionnaise de 15 ans et plus d\u00e9clare \u00eatre diab\u00e9tique. Maladie\nsociale en pleine expansion, le diab\u00e8te de type 2 exige des recours aux soins fr\u00e9quents, ainsi qu'une atten -\ntion quotidienne, pour combiner la pr\u00e9vention des complications et la vie familiale, sociale et professionnelle.\nLa recherche pr\u00e9sent\u00e9e dans cet article, d\u00e9velopp\u00e9e \u00e0 La R\u00e9union, s'int\u00e9resse \u00e0 la litt\u00e9ratie en sant\u00e9 en tant\nque concept multidimensionnel dynamique qui questionne les interactions entre les pratiques individuelles,\nsociales, professionnelles et organisationnelles.\nM\u00e9thodes - De 2020 \u00e0 2022, des entretiens semi-directifs ont \u00e9t\u00e9 men\u00e9s avec 24 personnes atteintes d'un\ndiab\u00e8te rencontr\u00e9es, dans la plupart des cas, \u00e0 domicile.\nR\u00e9sultats - L 'analyse des acc\u00e8s des individus \u00e0 l'information en sant\u00e9, \u00e0 leur compr\u00e9hension et \u00e0 la prise de\nd\u00e9cisions montre la diversit\u00e9 et la complexit\u00e9 de la gestion de la maladie en contexte ordinaire. En fonction\ndes dimensions consid\u00e9r\u00e9es (alimentation, activit\u00e9 physique, traitement, suivi de la maladie...), cette gestion\nordinaire est plus ou moins anxiog\u00e8ne ou sereine. L 'expert de la pathologie, le diab\u00e9tologue, appara\u00eet comme\nle \u00ab parent pauvre \u00bb des recours aux professionnels de sant\u00e9.\nDiscussion et perspectives - La recherche met en lumi\u00e8re des \u00ab personnes diab\u00e9tiques plurielles \u00bb qui font\nau mieux de leurs possibilit\u00e9s, dans les contextes qui sont les leurs. Elle ouvre sur plusieurs pr\u00e9occupations\n\u00e0 faire valoir : \u00ab accueillir en soins \u00bb la personne atteinte de maladie chronique en l'\u00e9coutant, \u00e0 travers ses mots\n(et ses maux) ; \u00e9veiller l'attention des soignants au langage en jeu lors des interactions ; repenser nos organisations en sant\u00e9 pour que les personnes souffrant de maladies chroniques puissent mieux s'y r\u00e9f\u00e9rer.\nIntroduction - In 2021, 13.6% of individuals aged 15 and above in Reunion Island reported having diabetes.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2443, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "ebc418e0-7168-4da3-82b6-4f84c23f3fb2": {"__data__": {"id_": "ebc418e0-7168-4da3-82b6-4f84c23f3fb2", "embedding": null, "metadata": {"page_label": "440", "file_name": "2023_20-21.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2023_20-21.pdf", "file_type": "application/pdf", "file_size": 1372902, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "bcdd4836-ebbf-4c04-8e9e-8af4dec9e84a", "node_type": "4", "metadata": {"page_label": "440", "file_name": "2023_20-21.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2023_20-21.pdf", "file_type": "application/pdf", "file_size": 1372902, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "17d257c0401b81e64d91e65a4207a1005efb832bdabdd13be6cb4b293c863d2b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c31d7e66-7adc-450e-8088-6512ac569478", "node_type": "1", "metadata": {"page_label": "440", "file_name": "2023_20-21.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2023_20-21.pdf", "file_type": "application/pdf", "file_size": 1372902, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "9e3d5220219e89391eb92f7ee9a07fc50fcc5bf118708a68d2248e4d98ed4daa", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Introduction - In 2021, 13.6% of individuals aged 15 and above in Reunion Island reported having diabetes.\nA fast-growing social disease, type 2 diabetes requires frequent treatment as well as daily management to\nbalance the prevention of complications amid family, social and professional commitments. Developed in\nReunion island, the research presented in this article focuses on health literacy as a dynamic, multidimensional\nconcept that questions the interactions between individual, social, professional and organisational practices.\nMethods - From 2020 to 2022, semi-structured interviews were conducted with 24 diabetics, most of whom\nwere seen at their homes.\nResults - The analysis of individuals' access to and understanding of health information, as well as their decisionmaking, highlights the diversity and complexity of illness management in ordinary contexts. Depending on the\nvariables considered (diet, physical activity, treatment, disease monitoring, etc.), this routine management is\nmore or less anxiety-provoking or relaxed for patients. The medical expert, namely the diabetologist, appears\nto be the \"poor relation\" in terms of recourse to healthcare professionals.\nDiscussion and perspectives - This research sheds light on the experiences of \"plural diabetics\" who manage\ntheir diabetes as best as they can given their specific circumstances. It highlights various areas for improvement:\nthe idea of \"welcoming\" the chronically ill person into care by listening to them express their experiences and\ndifficulties in their own words; raising awareness among caregivers about how the language used can affect\ninteractions; rethinking our healthcare organisations so that chronically ill people get better access to them.\nMots-cl\u00e9s : Diab\u00e8te, Litt\u00e9ratie en sant\u00e9, Maladie chronique, \u00cele de La R\u00e9union\n// Keywords: Diabetes, Health literacy, Chronic disease, Reunion island\nIntroduction\nD\u00e9partement fran\u00e7ais depuis 1946, l'\u00eele de La R\u00e9union\naccueille une population tr\u00e8s m\u00e9tiss\u00e9e qui s'est\nd\u00e9velopp\u00e9e \u00e0 partir de migrations successives,\nde provenances diverses (Madagascar, pays\nd'Afri que, Inde, Chine, Europe, Comores). En 2020,\nl'Institut national de la statistique et des \u00e9tudes\n\u00e9conomiques (Insee) 1 recense 863 100 habitants qui\nr\u00e9sident pour une large part dans les villes en forte\n>\nMaryvette Balcou-Debussche\nLaboratoire Icare, Universit\u00e9 de La R\u00e9union, Saint-Denis", "mimetype": "text/plain", "start_char_idx": 2337, "end_char_idx": 4734, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "78af2811-9fbc-4ccd-883f-3ff9fdcba9c2": {"__data__": {"id_": "78af2811-9fbc-4ccd-883f-3ff9fdcba9c2", "embedding": null, "metadata": {"page_label": "441", "file_name": "2023_20-21.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2023_20-21.pdf", "file_type": "application/pdf", "file_size": 1372902, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "6035df52-14a5-4cca-a2e5-19cff4afdafe", "node_type": "4", "metadata": {"page_label": "441", "file_name": "2023_20-21.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2023_20-21.pdf", "file_type": "application/pdf", "file_size": 1372902, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "76ad50e86386b98cb710652806a60f407929829287fde925d417168248040198", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "fd16c0f1-9ec8-4eb5-8071-81bd2f24adf8", "node_type": "1", "metadata": {}, "hash": "554e6b6a2fa3ea22aaceff1d128b4e091b7fcf72403a41c613a145312e22b964", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Diab\u00e8te en outre-mer : comprendre les sp\u00e9cificit\u00e9s locales pour cibler les actions BEH 20-21 | 14 novembre 2023 | 441\ncroissance (Saint-Denis, Saint-Pierre, Le Tampon...).\nDepuis les 50 derni\u00e8res ann\u00e9es, la population est\nconfront\u00e9e \u00e0 des mutations \u00e9conomiques, techno -\nlogiques, sociales et cult urelles tr\u00e8s importantes qui\ntouchent tous les domaines de la vie quotidienne\ndes individus 2.\nLa sant\u00e9 n'\u00e9ch appe pas \u00e0 ces transformations et\nla survenue de pathologies dites de civilisation\nest fortement li\u00e9e \u00e0 ces changements profonds et\nmassifs des modes de vie 3. De nombreux indicateurs\nmontrent que la transition nutritionnelle r\u00e9unionnaise\nest avanc\u00e9e : recul de la consommation de f\u00e9culents,\nmont\u00e9e des prot\u00e9ines animales, des glucides rapides\net des aliments nouveaux (fast-food, plats pr\u00e9par\u00e9s) 4.\nEn 2021, \u00e0 La R\u00e9union, 13,6% de la population de\n15 ans et plus d\u00e9clare \u00eatre diab\u00e9tique 5, ce qui est\nnettement sup\u00e9rieur \u00e0 ce qui s'observe dans la population fran\u00e7aise dans son ensemble (d\u00e9partements\net r\u00e9gions d'out re-mer -DROM- comp ris) dans\nlaquelle la pr\u00e9valence du diab\u00e8te trait\u00e9 pharmaco -\nlogiquement est estim\u00e9e \u00e0 5% 6. Maladie chronique\nembl\u00e9matique des enjeux li\u00e9s \u00e0 la transition \u00e9pid\u00e9 -\nmiologique (qui tout en se traduisant par une \u00e9volu -\ntion de la nature des causes des d\u00e9c\u00e8s, s'inscrit dans\ndes mutations \u00e9conomiques, sociales et culturelles) et\naux in\u00e9galit\u00e9s sociales de sant\u00e9 (ISS), le diab\u00e8te est le\nplus souvent \u00ab pris en charge \u00bb par le corps m\u00e9dical :\nle m\u00e9decin transmet des informations et recomman -\ndations aux patients, mais parfois sans beaucoup de\nr\u00e9sultats. La densit\u00e9 de m\u00e9decins sp\u00e9cialistes reste\nplus faible \u00e0 La R\u00e9union et les professionnels sont\nin\u00e9galement r\u00e9partis sur l'\u00eele , m\u00eame si la densit\u00e9 de\nm\u00e9decins g\u00e9n\u00e9ralistes a d\u00e9sormais d\u00e9pass\u00e9 celle\nde l'Hexagone (142 g\u00e9n\u00e9ralistes pour 100 000 habi -\ntants contre 133 en France m\u00e9tropolitaine) 7,8.\nEnviron 26% des R\u00e9unionnais ont d\u00e9j\u00e0 renonc\u00e9 \u00e0 un\nbesoin m\u00e9dical dans l'ann\u00e9e \u00e9coul\u00e9e, le principal frein\n\u00e9tant le d\u00e9lai trop long pour obtenir un rendez-vous.\nDans ce cont exte g\u00e9n\u00e9ral, nous avons mobilis\u00e9 le\nconcept de litt\u00e9ratie en sant\u00e9, polys\u00e9mique et multi -\ndimensionnel, pour questionner l'acc \u00e8s \u00e0 l'inf ormation, \u00e0 la comp r\u00e9hension et \u00e0 la prise de d\u00e9cisions\ndans des situations d'int eraction et de comm unication 9.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2327, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "fd16c0f1-9ec8-4eb5-8071-81bd2f24adf8": {"__data__": {"id_": "fd16c0f1-9ec8-4eb5-8071-81bd2f24adf8", "embedding": null, "metadata": {"page_label": "441", "file_name": "2023_20-21.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2023_20-21.pdf", "file_type": "application/pdf", "file_size": 1372902, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "6035df52-14a5-4cca-a2e5-19cff4afdafe", "node_type": "4", "metadata": {"page_label": "441", "file_name": "2023_20-21.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2023_20-21.pdf", "file_type": "application/pdf", "file_size": 1372902, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "76ad50e86386b98cb710652806a60f407929829287fde925d417168248040198", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "78af2811-9fbc-4ccd-883f-3ff9fdcba9c2", "node_type": "1", "metadata": {"page_label": "441", "file_name": "2023_20-21.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2023_20-21.pdf", "file_type": "application/pdf", "file_size": 1372902, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "eca6af53510673c76b744554e90aa41def82f85aae74b8f2021612d4c43a893d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2d513e46-6cd2-4e08-ae60-29b85d2a0c10", "node_type": "1", "metadata": {}, "hash": "94cea45b746c67cb9e4000131850e82b9102fd89c55c0acd96be16d73634d2dd", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Dans ce cont exte g\u00e9n\u00e9ral, nous avons mobilis\u00e9 le\nconcept de litt\u00e9ratie en sant\u00e9, polys\u00e9mique et multi -\ndimensionnel, pour questionner l'acc \u00e8s \u00e0 l'inf ormation, \u00e0 la comp r\u00e9hension et \u00e0 la prise de d\u00e9cisions\ndans des situations d'int eraction et de comm unication 9. Sans perspective de hi\u00e9rarchisation des\ndonn\u00e9es entre elles, le projet consiste \u00e0 analyser\nles variations des \u00ab rapports \u00bb des individus aux\ndiff\u00e9rentes dimensions de la gestion de la maladie\nen contexte ordinaire 9 : c'est la relation que chaque\nindividu entretient \u00e0 l'obj et en question ( l'alimentation, la maladie, le traitement, l'aut o-surveillance...)\nqui nous int\u00e9resse dans cet article. En recueillant\nce que les personnes atteintes d'un diab\u00e8te disent\nde leurs pratiques diversifi\u00e9es en sant\u00e9, nous cher -\nchons \u00e0 identifier ce qui leur a permis de trouver des\ninformations adapt\u00e9es, de les comp rendre et de s'en\nservir en tenant compte de leur contexte ordinaire 10.\nTerrain et m\u00e9thodes\nEn compl\u00e9ment des donn\u00e9es quantitatives issues de\nla 3e \u00e9dition de l'\u00e9tu de Entred (\u00c9chantillon national\nt\u00e9moin repr\u00e9sentatif des personnes diab\u00e9tiques,\nlanc\u00e9e en 2019), le projet vise \u00e0 esquisser les\nbesoins diversifi\u00e9s des personnes atteintes d'un\ndiab\u00e8te pour d\u00e9velopper la litt\u00e9ratie en sant\u00e9 sur\nles plans individuel et collectif, aux plans national\net r\u00e9gional 10-12. Entred 3 est bas\u00e9e sur le tirage\nau sort al\u00e9atoire d'un \u00e9chantillon de personnes\ntrait\u00e9es pharmacologiquement pour un diab\u00e8te :\n13 000 personnes diab\u00e9tiques ont \u00e9t\u00e9 s\u00e9lectionn\u00e9es\nen France - 4 000 dans les DROM, dont 850 \u00e0 La\nR\u00e9union - \u00e0 partir d'ind icateurs de ressources indi -\nviduelles et de leur environnement : le sexe, l'\u00e2ge ,\nle niveau socio- \u00e9conomique, la zone g\u00e9ographique\nde r\u00e9sidence, l'anc iennet\u00e9 du diab\u00e8te, le type de\ndiab\u00e8te. Parmi les personnes ayant r\u00e9pondu au\nquestionnaire d\u00e9taill\u00e9 et n'aya nt pas refus\u00e9 d'\u00eatr e\nrecontact\u00e9es pour d'aut res \u00e9tudes, un panel diver -\nsifi\u00e9 de 84 personnes volontaires pour un entretien\n(dont 24 R\u00e9unionnais) a \u00e9t\u00e9 cons titu\u00e9. La rencontre\navec les 24 personnes ayant accept\u00e9 de participer\n\u00e0 l'enqu\u00eate qualitative Diab-quali R\u00e9union s'est\nr\u00e9alis\u00e9e de mars 2020 \u00e0 ao\u00fbt 2022. Elles ont \u00e9t\u00e9\ncontact\u00e9es par t\u00e9l\u00e9phone et par \u00e9crit (via un cour -\nrier adress\u00e9 avant l'app el), ce qui a permis les prises\nde rendez-vous.", "mimetype": "text/plain", "start_char_idx": 2059, "end_char_idx": 4369, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "2d513e46-6cd2-4e08-ae60-29b85d2a0c10": {"__data__": {"id_": "2d513e46-6cd2-4e08-ae60-29b85d2a0c10", "embedding": null, "metadata": {"page_label": "441", "file_name": "2023_20-21.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2023_20-21.pdf", "file_type": "application/pdf", "file_size": 1372902, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "6035df52-14a5-4cca-a2e5-19cff4afdafe", "node_type": "4", "metadata": {"page_label": "441", "file_name": "2023_20-21.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2023_20-21.pdf", "file_type": "application/pdf", "file_size": 1372902, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "76ad50e86386b98cb710652806a60f407929829287fde925d417168248040198", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "fd16c0f1-9ec8-4eb5-8071-81bd2f24adf8", "node_type": "1", "metadata": {"page_label": "441", "file_name": "2023_20-21.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2023_20-21.pdf", "file_type": "application/pdf", "file_size": 1372902, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "1132cb60283d1d4768f50722c8ccd5e7137d54b2f9c1f27611bd60244e2a343e", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "La rencontre\navec les 24 personnes ayant accept\u00e9 de participer\n\u00e0 l'enqu\u00eate qualitative Diab-quali R\u00e9union s'est\nr\u00e9alis\u00e9e de mars 2020 \u00e0 ao\u00fbt 2022. Elles ont \u00e9t\u00e9\ncontact\u00e9es par t\u00e9l\u00e9phone et par \u00e9crit (via un cour -\nrier adress\u00e9 avant l'app el), ce qui a permis les prises\nde rendez-vous. Men\u00e9s par deux enqu\u00eatrices, les\nentretiens ( d'une dur\u00e9e moyenne de 30 minutes) se\nsont d\u00e9roul\u00e9s \u00e0 domicile dans la plupart des cas\n(16/24). La saturation des donn\u00e9es a \u00e9t\u00e9 atteinte au\nbout d'une quinzaine d'ent retiens (ce qui n'a pas\nemp\u00each\u00e9 de r\u00e9aliser les autres entretiens, puisque\nles personnes cont act\u00e9es avaient donn\u00e9 leur\naccord pour la rencontre). En raison de l'\u00e9pid\u00e9mie\nde Covid-19 (2020-2022), une partie des \u00e9changes\na \u00e9t\u00e9 men\u00e9e \u00e0 distance, par t\u00e9l\u00e9phone (8/24). Tous\nles entretiens ont \u00e9t\u00e9 enregistr\u00e9s et retranscrits\nint\u00e9grale ment. Pour mener les 24 entretiens, nous\navons pris appui sur la grille Diab\u00e8te, litt\u00e9ratie, sant\u00e9\n(DLS), issue de la recherche Ermi\u00e8s-ethnosocio\n(annexe) 10. Cette grille DLS met en lumi\u00e8re l'exi stence de huit variables constitutives de la gestion\ndu diab\u00e8te de type 2 en contexte ordinaire, r\u00e9parties\nen trois p\u00f4les (tableau 1).\nCes variables, et les trois p\u00f4les auxquels elles se\nrattachent, ont \u00e9t\u00e9 identifi\u00e9es \u00e0 partir des discours\ndes personnes diab\u00e9tiques sur leurs pratiques en\nsant\u00e9, mais aussi \u00e0 partir de l'obs ervation, \u00e0 domi -\ncile, de ces pratiques elles-m\u00eames 9,10. Les rapports\n\u00e0 ces huit variables sont donc tout autant le reflet\nTableau 1\nLa gestion de la maladie \u00e0 travers les 3 p\u00f4les et les 8 variables\nP\u00f4les Variables\nGestion de la maladie Alimentation\nActivit\u00e9 physique et s\u00e9dentarit\u00e9\nTraitement\nSuivi de la maladie\nSavoirs en sant\u00e9 Connaissances\nAcc\u00e8s aux savoirs\nExpertise et soutien social Relation aux professionnels de sant\u00e9\nSoutien social", "mimetype": "text/plain", "start_char_idx": 4083, "end_char_idx": 5882, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "e89eb6ae-fa5d-4525-ac74-bf2e12367684": {"__data__": {"id_": "e89eb6ae-fa5d-4525-ac74-bf2e12367684", "embedding": null, "metadata": {"page_label": "442", "file_name": "2023_20-21.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2023_20-21.pdf", "file_type": "application/pdf", "file_size": 1372902, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "78c73c04-8b2f-4f42-a213-6259dc336682", "node_type": "4", "metadata": {"page_label": "442", "file_name": "2023_20-21.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2023_20-21.pdf", "file_type": "application/pdf", "file_size": 1372902, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "7afafa8e6bda619cc4ddac766c41897a0bd3eb7402c65fcafe88713c87abf2cb", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4c25198e-e46b-4ef2-b557-9fa5793c391f", "node_type": "1", "metadata": {}, "hash": "bb9572b84b52de8dcd6265302b2d6289b1123fc6d5a2b407365712b87fa8e814", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "442 | 14 novembre 2023 | BEH 20-21 Diab\u00e8te en outre-mer : comprendre les sp\u00e9cificit\u00e9s locales pour cibler les actions\ndes pratiques individuelles, sociales, profession -\nnelles et organisationnelles pass\u00e9es qu'un puissant\nr\u00e9v\u00e9lateur des possibles leviers de d\u00e9veloppement\nde la litt\u00e9ratie en sant\u00e9.\nEn choisissant de r\u00e9aliser une analyse de cont enu\ndes discours 13, nous mettons en valeur les \u00e9l\u00e9ments\ncommuns saillants, ainsi que les variations interet/ou intra-individuelles observ\u00e9es. Deux princi -\npales \u00e9tapes ont \u00e9t\u00e9 travaill\u00e9es pour l'ana lyse :\nd'une part, le rep\u00e9rage des id\u00e9es et unit\u00e9s significa -\ntives de chaque entretien (une unit\u00e9 correspondant\n\u00e0 un message que la personne souhaite trans -\nmettre), d'autre part leur cat\u00e9gorisation en th\u00e8mes\net sous-th\u00e8mes. Les lectures ind\u00e9pendantes des\ndeux chercheurs ont \u00e9t\u00e9 crois\u00e9es afin de v\u00e9rifier\nla pertinence des d\u00e9coupages, regroupements\nd'items et cat\u00e9gorisations. Les analyses mettent\nainsi en exergue le sens que les personnes donnent\n\u00e0 leurs pratiques, de m\u00eame que les sens diversifi\u00e9s\nque l'ensemble des individus interview\u00e9s attribuent\n\u00e0 la maladie et \u00e0 sa gestion en cont exte ordinaire.\nR\u00e9sultats\nSur les 24 participants, 14 sont des hommes, ce qui\nest proche de la r\u00e9partition globale, puisque parmi\nles 83 400 R\u00e9unionnais pris en charge pour un\ndiab\u00e8te en 2020, 54% sont des femmes cont re 45%\nen France 14. La majorit\u00e9 des personnes interrog\u00e9es\n(18/24) se situe en-dessous de 65 ans, ce qui refl\u00e8te\nla survenue plus pr\u00e9coce que dans l'Hex agone avec\n53% des personnes r\u00e9unionnaises atteintes d'un\ndiab\u00e8te \u00e2g\u00e9es de moins de 65 ans 14. La grande\nmajorit\u00e9 des personnes vit en ville et du c\u00f4t\u00e9 de l'activit\u00e9 professionnelle, les personnes se r\u00e9partissent\nen trois parts \u00e0 peu pr\u00e8s \u00e9gales : profession inter -\nm\u00e9diaire (9/24), pas d'act ivit\u00e9 professionnelle (8/24)\net situation de retrait\u00e9 (7/24). Treize personnes\nsur 24 d\u00e9clarent avoir des difficult\u00e9s financi\u00e8res. Sur\nl'ensemble du groupe, 2 personnes vivent seules.\nLa majorit\u00e9 a fr\u00e9quent\u00e9 le coll\u00e8ge et/ou le lyc\u00e9e.\nDans le p\u00f4le \u00ab gestion de la maladie \u00bb, l'analyse\ndes rapports \u00e0 l'ali mentation et \u00e0 l'act ivit\u00e9 physique\nmontre que les personnes enqu\u00eat\u00e9es composent\nassez ais\u00e9ment avec les cont raintes li\u00e9es \u00e0 la pr\u00e9 -\nsence de la maladie : \u00ab Maintenant, \u00e7a a \u00e9t\u00e9 dur, mais\non va dire que j'arrive quand m\u00eame \u00e0 me cont r\u00f4ler. \u00bb\n(Diane (1)).", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2368, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "4c25198e-e46b-4ef2-b557-9fa5793c391f": {"__data__": {"id_": "4c25198e-e46b-4ef2-b557-9fa5793c391f", "embedding": null, "metadata": {"page_label": "442", "file_name": "2023_20-21.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2023_20-21.pdf", "file_type": "application/pdf", "file_size": 1372902, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "78c73c04-8b2f-4f42-a213-6259dc336682", "node_type": "4", "metadata": {"page_label": "442", "file_name": "2023_20-21.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2023_20-21.pdf", "file_type": "application/pdf", "file_size": 1372902, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "7afafa8e6bda619cc4ddac766c41897a0bd3eb7402c65fcafe88713c87abf2cb", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e89eb6ae-fa5d-4525-ac74-bf2e12367684", "node_type": "1", "metadata": {"page_label": "442", "file_name": "2023_20-21.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2023_20-21.pdf", "file_type": "application/pdf", "file_size": 1372902, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "95ba2dec989d61fe32aa00698125e4727ed2830cf82e4bac9269708a12654f65", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b2b598d8-cdd9-4a7a-8dd0-8c40155533b7", "node_type": "1", "metadata": {}, "hash": "a05e2bbfc67c7f9c06d743bc21c47a9b7cdb4e83dcc02eeb0d10217d4837e1dc", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "\u00bb\n(Diane (1)). Les changements se traduisent par\ndes suppressions ou remplacements d'aliments\n(le sucre, les produits gras), des diminutions ou\naugmentations des quantit\u00e9s (de riz, de chocolat),\ndes modifications des modes de pr\u00e9paration ou de\ncuisson. Du c\u00f4t\u00e9 de l'act ivit\u00e9 physique, la marche\nest la principale activit\u00e9 comm une : \u00ab Je maintiens\nquand m\u00eame la marche, hein, j'ess aie de faire au\nmieux. Alors, soit c'est une demi-heure, soit c'est\nune heure. \u00bb (Ra\u00efssa). Tout comme pour l'ali mentation, les rapports \u00e0 l'activit\u00e9 physique ne font pas\nvraiment l'objet de conflits entre la personne malade\net le corps soignant.\n(1) Tous les pr\u00e9noms des personnes interrog\u00e9es ont \u00e9t\u00e9 modifi\u00e9s.\nLes traitements li\u00e9s au diab\u00e8te sont g\u00e9n\u00e9rale -\nment accept\u00e9s et leurs effets sur la maladie sont\nreconnus, ce qui n'emp \u00eache pas quelques irr\u00e9gu -\nlarit\u00e9s dans la prise des comp rim\u00e9s. 15 personnes\nprennent uniquement des anti-diab\u00e9tiques oraux\n(ADO), 8 personnes comb inent les ADO et l'ins uline et une seule personne est trait\u00e9e par insuline\nuniquement. Les personnes interview\u00e9es sont\nrelativement autonomes, d'o\u00f9 le peu de cas de\nvenues r\u00e9guli\u00e8res d'un infirmier \u00e0 domicile. L 'autosurveillance glyc\u00e9mique reste anxiog\u00e8ne, ce qui se\ntraduit parfois par un sur- contr\u00f4le (plusieurs fois\npar jour) ou une absence totale, la surveillance \u00e9tant\nalors, le plus souvent, r\u00e9alis\u00e9e par le m\u00e9decin trai -\ntant : \u00ab Mais comme i pique mon doigt, ben on dirait\ni stresse \u00e0 moin aussi. \u00bb (2) (Isabelle). La mesure de\nl'h\u00e9moglobine glyqu\u00e9e est de plus en plus conn ue\ndes personnes malades, qui en font souvent une\n\u00ab boussole de vie \u00bb structurante et apaisante pour\nla gestion globale du diab\u00e8te. Le traitement par\ndiff\u00e9rentes plantes (jamblon (3), verveine, citronnelle,\nsafran, cannelle, artichaut...), est cit\u00e9 par plusieurs\npersonnes, ce qui rend comp te de l'int \u00e9r\u00eat port\u00e9 \u00e0\nla recherche de solutions \u00e0 la maladie, y comp ris \u00e0\ntravers la pluralit\u00e9 des recours aux soins. La p\u00e9riode\nde confinement a \u00e9t\u00e9 l'occasion de quelques ruptures\nde soins et de traitements, mais dans la plupart des\ncas, les personnes ont su d\u00e9velopper des strat\u00e9gies\nd'adaptation aux diff\u00e9rents temps de la pand\u00e9mie et\n\u00e0 ses contraintes : \u00ab Moi j'ai la p\u00e9toche parce que\nje suis sujet \u00e0 risques et donc j'\u00e9vite, je ne suis pas\nsortie pendant le confine ment.", "mimetype": "text/plain", "start_char_idx": 2354, "end_char_idx": 4679, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "b2b598d8-cdd9-4a7a-8dd0-8c40155533b7": {"__data__": {"id_": "b2b598d8-cdd9-4a7a-8dd0-8c40155533b7", "embedding": null, "metadata": {"page_label": "442", "file_name": "2023_20-21.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2023_20-21.pdf", "file_type": "application/pdf", "file_size": 1372902, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "78c73c04-8b2f-4f42-a213-6259dc336682", "node_type": "4", "metadata": {"page_label": "442", "file_name": "2023_20-21.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2023_20-21.pdf", "file_type": "application/pdf", "file_size": 1372902, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "7afafa8e6bda619cc4ddac766c41897a0bd3eb7402c65fcafe88713c87abf2cb", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4c25198e-e46b-4ef2-b557-9fa5793c391f", "node_type": "1", "metadata": {"page_label": "442", "file_name": "2023_20-21.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2023_20-21.pdf", "file_type": "application/pdf", "file_size": 1372902, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "7c04ae4ffdff2ce147c8ed25218d511601209070bfba059968c0e340b52bf5e6", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Mes enfants ont fait\nles courses. \u00bb (Pauline).\nD'un point de vue \u00e9tiologique, un cont inuum des\nsavoirs en sant\u00e9 se dessine \u00e0 partir des discours :\nde la cause li\u00e9e \u00e0 un seul facteur ext\u00e9rieur (sucre,\nriz...) \u00e0 une cons tellation de causes ( l'alimenta -\ntion, la famille, l'env ironnement...), en passant\npar la mauvaise alchimie entre un facteur d\u00e9favo -\nrable et un terrain pr\u00e9disposant. Les personnes\ncons truisent chacune leur fa\u00e7on de comp rendre\nla maladie : \u00ab Comme on a d\u00e9j\u00e0 dans notre corps\nles infos du diab\u00e8te, donc ben en abusant, il s'est\nd\u00e9velopp\u00e9, quoi. \u00bb (Louis). Si les causes du diab\u00e8te\nfont l'objet de nombreuses interpr\u00e9tations, elles\nr\u00e9pondent n\u00e9anmoins \u00e0 des exigences de rationa -\nlit\u00e9 qui permettent aux personnes de comp rendre\nce qui leur arrive, en lien avec les \u00e9l\u00e9ments de leur\nvie et de leurs environnements : \u00ab Si par exemple,\nvous restez allong\u00e9 toute la journ\u00e9e et tout \u00e7a, ben\nle sucre stagne en bas, voil\u00e0. Je prends \u00e7a \u00e0 peu\npr\u00e8s, ben, comm e une bouteille de jus qui a du\nsucre qui reste en bas. \u00bb (Olivier). Les comp lications\ndu diab\u00e8te sont souvent identifi\u00e9es (sur le c\u0153ur, le\npancr\u00e9as, le rein, les yeux, le sang, les organes\ng\u00e9nitaux...), mais conn ues de fa\u00e7on partielle. Les\nconnaissances sont le plus souvent cons truites\ndans un rapport instrumental \u00e0 la pathologie :\nla personne malade suit les cons eils qui lui sont\n(2) \u00ab Mais comme je pique mon doigt, ben on dirait que \u00e7a me stresse aussi. \u00bb\n(3) Fruit tropical originaire d'Inde, pr\u00e9sent \u00e0 La R\u00e9union et couramment\nutilis\u00e9 en m\u00e9decine traditionnelle.", "mimetype": "text/plain", "start_char_idx": 4680, "end_char_idx": 6233, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "49fe51da-42e5-471b-b3f5-e7ff6ac0bf66": {"__data__": {"id_": "49fe51da-42e5-471b-b3f5-e7ff6ac0bf66", "embedding": null, "metadata": {"page_label": "443", "file_name": "2023_20-21.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2023_20-21.pdf", "file_type": "application/pdf", "file_size": 1372902, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "e11608ce-d26d-4203-8630-0d2508febe0b", "node_type": "4", "metadata": {"page_label": "443", "file_name": "2023_20-21.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2023_20-21.pdf", "file_type": "application/pdf", "file_size": 1372902, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "c3c28e04b0b63062834fae1bd59100948c263d5d04e3da65f1d2f2b683010c1f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6f5ac479-b7b9-499a-acf6-1dbe368d3079", "node_type": "1", "metadata": {}, "hash": "43606767e5f2a810123dc3b643485fb1f925abefc079232b03b1becd6f2a457e", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Diab\u00e8te en outre-mer : comprendre les sp\u00e9cificit\u00e9s locales pour cibler les actions BEH 20-21 | 14 novembre 2023 | 443\ndonn\u00e9s par les personnes de r\u00e9f\u00e9rence, ce qui lui\npermet de se centrer plus sur la gestion au quoti -\ndien du diab\u00e8te que sur la pathologie elle-m\u00eame.\nL 'acc\u00e8s aux savoirs reste majoritairement li\u00e9\naux professionnels de sant\u00e9 de r\u00e9f\u00e9rence.\nSur le plan relationnel, les personnes diab\u00e9tiques\ntissent des liens tr\u00e8s \u00e9troits avec leur m\u00e9decin\ntraitant, ce qui n'emp \u00eache en rien que ces liens se\ntraduisent par des ressentis diversifi\u00e9s : confiance,\nrespect, m\u00e9fiance... : \u00ab Docteur, quand li voit,\nli gagne seulement le truc que li dit a ou l\u00e9 pas,\net pis donne a ou m\u00e9dicament. Plus trop le temps\naussi, li ! \u00bb (4) (Ulrich). Deux personnes seulement\ncitent le diab\u00e9tologue en tant qu'expert de r\u00e9f\u00e9 -\nrence pour la gestion du diab\u00e8te : paradoxalement,\nl'expert de la pathologie, le diab\u00e9tologue, est donc\nle parent pauvre des recours aux professionnels\nde sant\u00e9. Parmi les 24 personnes interview\u00e9es,\n6 mentionnent la t\u00e9l\u00e9vision ou la radio, 8 citent\nles livres, revues ou magazines et 7 \u00e9voquent\nl'acc ompagnement par l'Ass urance maladie\n(avec le programme Sofia destin\u00e9 aux personnes\natteintes d'un diab\u00e8te ). Les relations avec les\nm\u00e9decins sp\u00e9cialistes (quelle que soit la sp\u00e9cialit\u00e9) apparaissent bien plus tendues que celles qui\nlient la personne malade \u00e0 son m\u00e9decin g\u00e9n\u00e9ra -\nliste habituel : le manque d'emp athie est souvent\nreproch\u00e9, de m\u00eame que le temps trop court de la\nconsultation. La famille (notamment les parents) et\nle m\u00e9decin g\u00e9n\u00e9raliste sont les r\u00e9f\u00e9rents les plus\ncit\u00e9s en mati\u00e8re de soutien social.\nDiscussion\nLa recherche Diab-quali R\u00e9union fait suite \u00e0 deux\nprincipales recherches socio-anthropologiques\nmen\u00e9es ant\u00e9rieurement : la premi\u00e8re en 20032005 aupr\u00e8s de 42 patients atteints de diab\u00e8te de\ntype 2 15 et la suivante en 2012-2015, qui a permis\nde r\u00e9aliser une quarantaine d'ent retiens semidirectifs, \u00e0 2 ans d'int ervalle, soit un peu plus de\n80 entretiens en tout 9,10,16. La recherche quali -\ntative Diab-quali s'ins crit ainsi dans un sillon\nsocio-anthropologique d'une vingtaine d'ann \u00e9es\nde recherches et d'int erventions 9,17, ce qui nourrit\nles r\u00e9flexions sur les transformations observ\u00e9es\nchez les personnes diab\u00e9tiques de type 2.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2285, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "6f5ac479-b7b9-499a-acf6-1dbe368d3079": {"__data__": {"id_": "6f5ac479-b7b9-499a-acf6-1dbe368d3079", "embedding": null, "metadata": {"page_label": "443", "file_name": "2023_20-21.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2023_20-21.pdf", "file_type": "application/pdf", "file_size": 1372902, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "e11608ce-d26d-4203-8630-0d2508febe0b", "node_type": "4", "metadata": {"page_label": "443", "file_name": "2023_20-21.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2023_20-21.pdf", "file_type": "application/pdf", "file_size": 1372902, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "c3c28e04b0b63062834fae1bd59100948c263d5d04e3da65f1d2f2b683010c1f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "49fe51da-42e5-471b-b3f5-e7ff6ac0bf66", "node_type": "1", "metadata": {"page_label": "443", "file_name": "2023_20-21.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2023_20-21.pdf", "file_type": "application/pdf", "file_size": 1372902, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "720b6fd0ebe239fde5951a81f2e6d856d5eef8b787f3fe19576c3c7d0b5166d7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a7dd5d7b-92d5-4c20-8aba-a746022a3dfb", "node_type": "1", "metadata": {}, "hash": "24c46d779d0ee1726b7fb1f2431234480d6c2b1f66fef2175eebbf6ab7002070", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "La recherche quali -\ntative Diab-quali s'ins crit ainsi dans un sillon\nsocio-anthropologique d'une vingtaine d'ann \u00e9es\nde recherches et d'int erventions 9,17, ce qui nourrit\nles r\u00e9flexions sur les transformations observ\u00e9es\nchez les personnes diab\u00e9tiques de type 2. Selon\nune approche contrastive qui permet de mettre en\nexergue les logiques internes qui animent les indi -\nvidus (sans les comparer entre elles), mais aussi\nde \u00ab r\u00e9veiller \u00bb la recherche R\u00e9dia-Prev2 men\u00e9e\nen 2003-2005, la recherche Diab-quali R\u00e9union\napporte de nouveaux \u00e9l\u00e9ments : d'une part, elle\nconfirme l'important travail r\u00e9alis\u00e9 par toutes les\npersonnes atteintes de diab\u00e8te de type 2 en faveur\nde leur sant\u00e9 et de l'\u00e9vitement des complications\nde la maladie 9,10 ; d'autre part, elle met en avant de\nnouvelles variations, notamment du c\u00f4t\u00e9 de l'ali -\nmentation, des savoirs et du suivi de la maladie.\n(4) \u00ab Le docteur, quand tu le vois, il te dit seulement le truc qui ne va pas,\net puis il te donne un m\u00e9dicament. Il n'a plus trop le temps non plus, lui ! \u00bb\nL 'analyse des 24 entretiens montre ainsi que les\nper sonnes d\u00e9clarent g\u00e9rer plut\u00f4t ais\u00e9ment leur\nalimentation en tenant comp te des cont raintes qui\nleur sont impos\u00e9es et dans l'ensemble, les pratiques\nalimentaires apparaissent plut\u00f4t d\u00e9tendues :\nen 2003-2005 de nombreuses tensions \u00e9taient\nsoulign\u00e9es entre les personnes malades et le corps\nm\u00e9dical et l'ali mentation repr\u00e9sentait l'esp ace pri -\nvil\u00e9gi\u00e9 de cristallisation de ces tensions 15. Du point\nde vue des in\u00e9galit\u00e9s sociales de sant\u00e9, la recherche\nmet en \u00e9vidence la complexit\u00e9 de la gestion de la\nmaladie, ce qui permet de sortir de l'ima ge r\u00e9duc -\ntrice d'une influence dominante des d\u00e9terminants\nsocio- \u00e9conomiques. Ce qui s'observe chez chacun,\nc'est un ensemble de savoirs, savoir-faire et savoir\u00eatre qui se sont p\u00e9tris \u00e0 travers une histoire singu -\nli\u00e8re, o\u00f9 entrent en jeu des h\u00e9ritages, des rapports\nsociaux, des repr\u00e9sentations, des exp\u00e9riences de\nsoins, des r\u00e9ussites et des \u00e9checs, des manques\net des exc\u00e8s. \u00c0 travers les diff\u00e9rents entretiens, ce\nsont des visages pluriels de personnes r\u00e9union -\nnaises atteintes de diab\u00e8te de type 2 qui se d\u00e9voi -\nlent et au final, aucun portrait ne correspond\nen totalit\u00e9 aux exigences et attendus du monde\nm\u00e9dical.", "mimetype": "text/plain", "start_char_idx": 2021, "end_char_idx": 4280, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "a7dd5d7b-92d5-4c20-8aba-a746022a3dfb": {"__data__": {"id_": "a7dd5d7b-92d5-4c20-8aba-a746022a3dfb", "embedding": null, "metadata": {"page_label": "443", "file_name": "2023_20-21.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2023_20-21.pdf", "file_type": "application/pdf", "file_size": 1372902, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "e11608ce-d26d-4203-8630-0d2508febe0b", "node_type": "4", "metadata": {"page_label": "443", "file_name": "2023_20-21.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2023_20-21.pdf", "file_type": "application/pdf", "file_size": 1372902, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "c3c28e04b0b63062834fae1bd59100948c263d5d04e3da65f1d2f2b683010c1f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6f5ac479-b7b9-499a-acf6-1dbe368d3079", "node_type": "1", "metadata": {"page_label": "443", "file_name": "2023_20-21.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2023_20-21.pdf", "file_type": "application/pdf", "file_size": 1372902, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "d22e16d8355b5dd5c849e36045e7cf26fb408fda1b8084e5c6e02cf39d2ec203", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "\u00c0 travers les diff\u00e9rents entretiens, ce\nsont des visages pluriels de personnes r\u00e9union -\nnaises atteintes de diab\u00e8te de type 2 qui se d\u00e9voi -\nlent et au final, aucun portrait ne correspond\nen totalit\u00e9 aux exigences et attendus du monde\nm\u00e9dical. De nombreuses pratiques sociales en\nsant\u00e9 sont d\u00e9velopp\u00e9es par toutes les personnes\nmalades chroniques, ce qui conf orte l'id\u00e9e d'un r\u00e9el\ntravail r\u00e9alis\u00e9 au quotidien par la personne malade 18,\navec une adaptation effective aux cont extes de\nchacun 9,10. L 'acc\u00e8s aux savoirs reste majoritaire -\nment li\u00e9 au professionnel de sant\u00e9 de r\u00e9f\u00e9rence, ce\nqui doit encourager \u00e0 soutenir les soignants dans\nla mission \u00e9ducative et formative qui fait partie\nde leurs attributions 19.\nContrairement aux \u00e9tudes pr\u00e9c\u00e9dentes, la recherche\nDiab-quali n'a pas permis d'acc \u00e9der aux pratiques\nin situ des individus \u00e0 diff\u00e9rents moments, ce qui,\ndu point de vue des variations \u00e0 observer, cons titue\nl'une des principales limites de cette recherche.\nEn prenant appui sur l'ens emble des r\u00e9sultats 20,\nl'\u00e9tude sugg\u00e8re n\u00e9anmoins de porter une attention\nparticuli\u00e8re aux interactions langagi\u00e8res, pr\u00e9sentes\net \u00e0 venir, car elles sont en capacit\u00e9 de faire \u00e9voluer\nles acc\u00e8s aux informations des personnes malades,\nleur compr\u00e9hension des objets en jeu et leur possi -\nbilit\u00e9 de prendre des d\u00e9cisions adapt\u00e9es \u00e0 leurs\ncontextes et projets de vie. Un d\u00e9placement doit\ns'op\u00e9rer en d\u00e9laissant la focale trop souvent centr\u00e9e\nsur les personnes malades pour s'int \u00e9resser aussi\naux professionnels de sant\u00e9 et aux organisations\nde sant\u00e9. D\u00e9velopper la litt\u00e9ratie en sant\u00e9, c'est\naccepter de travailler de conc ert sur la forma -\ntion des soignants, l'acc ueil bienveillant de toutes\nles personnes malades et la restructuration de\nnos organisations de sant\u00e9, afin qu'elles soient en\nmesure d'offrir des espaces cons acr\u00e9s aux patho -\nlogies chroniques et aux dimensions sociales et\nculturelles qui leur sont \u00e9troitement li\u00e9es. L '\u00e9coute\ndes origines du diab\u00e8te, telles qu'elles sont dites\npar les personnes malades, serait pr\u00e9cieuse \u00e0 int\u00e9 -\ngrer dans la relation entre le soignant et la personne\nmalade, y compris pour renouveler les approches", "mimetype": "text/plain", "start_char_idx": 4036, "end_char_idx": 6193, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "73313082-2baa-41f3-b0c2-82a74cfa6c12": {"__data__": {"id_": "73313082-2baa-41f3-b0c2-82a74cfa6c12", "embedding": null, "metadata": {"page_label": "444", "file_name": "2023_20-21.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2023_20-21.pdf", "file_type": "application/pdf", "file_size": 1372902, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "81e1d798-1bfd-462d-ac36-6018ccdc7ebb", "node_type": "4", "metadata": {"page_label": "444", "file_name": "2023_20-21.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2023_20-21.pdf", "file_type": "application/pdf", "file_size": 1372902, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "554809fc850fd036575e31fb9b555f6e218a5c22dd355e1987205dd6ba90b9b7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "556b9b80-0d5d-40e9-9154-674e93acde37", "node_type": "1", "metadata": {}, "hash": "5ece322ec50c8d6958be66ff71e15ac1f88d9eb5d9d90ddb7bc133d3f57e48e0", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "444 | 14 novembre 2023 | BEH 20-21 Diab\u00e8te en outre-mer : comprendre les sp\u00e9cificit\u00e9s locales pour cibler les actions\nde pr\u00e9vention, de protection, d'\u00e9du cation et de for -\nmation des personnes touch\u00e9es (ou non) par un\ndiab\u00e8te et/ou une autre pathologie chronique.\nConclusion\n\u00c0 La R\u00e9union, l'ana lyse des discours des 24 per -\nsonnes atteintes de diab\u00e8te de type 2 incluses\ndans l'\u00e9tude Entred 3 montre que la gestion de la\nmaladie appara\u00eet tout aussi anxiog\u00e8ne que sereine.\nLes p\u00f4les alimentation et activit\u00e9 physique sont\nceux dans lesquels les personnes interrog\u00e9es se\nretrouvent le plus en s\u00e9r\u00e9nit\u00e9 alors que le suivi\ndu diab\u00e8te - notamment avec les mesures de\nglyc\u00e9mie -, est souvent une source d'inqui\u00e9tudes,\nen lien avec la crainte des r\u00e9sultats (parfois aussi,\nla crainte de la r\u00e9action du soignant de r\u00e9f\u00e9rence).\nLa mise en lumi\u00e8re de cette recherche avec nos\ntravaux socio-anthropologiques ant\u00e9rieurs souligne\ndes \u00e9volutions signifiantes des pratiques sociales\nen sant\u00e9 : les relations dissym\u00e9triques de d\u00e9part\nentre le corps soignant et les personnes malades\nsemblent s'att\u00e9nuer, on observe une connaissance\naccrue de la mesure de l'h\u00e9m oglobine glyqu\u00e9e, une\nautonomie plus affirm\u00e9e dans l'aut osurveillance\net un recours plus fr\u00e9quent aux diff\u00e9rents sp\u00e9cia -\nlistes (cardiologue, ophtalmologue...), sauf pour\nle diab\u00e9tologue (r\u00e9sultat qui reste \u00e0 confi rmer par\nles analyses des donn\u00e9es d'Ent red 3).\nEn mati\u00e8re de litt\u00e9ratie en sant\u00e9, l'ana lyse des \u00ab rap -\nports \u00e0 \u00bb de chaque individu \u00e0 la maladie (ou au traitement, \u00e0 l'alimentation...) n'est pas \u00e0 penser en termes\nhi\u00e9 rarchiques, ni en objectifs \u00e0 attein dre : le projet\nconsiste bien plus \u00e0 accueillir en soins la personne\nmalade chronique, \u00e0 l'\u00e9co uter, la comp rendre,\nl'encourager. Les \u00ab rapports \u00e0 \u00bb sont fonction d'un\nensemble complexe d'h\u00e9ritages divers (histoire,\nculture, religion...), de relations aux pro fessionnels\nde sant\u00e9, \u00e0 l'entourage familial et social et \u00e0 l'environnement, d'o\u00f9 une alchimie singuli\u00e8re qui se tisse\nprogressive ment et qui \u00e9volue. Nos analyses mettent\nainsi en lumi\u00e8re ces personnes diab\u00e9tiques plurielles\nqui au-del\u00e0 de l'anxi\u00e9t\u00e9 g\u00e9n\u00e9r\u00e9e par le suivi du diab\u00e8te\nfont au mieux de leurs possibilit\u00e9s, dans les contextes\nqui sont les leurs, en tenant comp te des interactions\nstructurantes dont elles ont (ou non) b\u00e9n\u00e9fici\u00e9.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2326, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "556b9b80-0d5d-40e9-9154-674e93acde37": {"__data__": {"id_": "556b9b80-0d5d-40e9-9154-674e93acde37", "embedding": null, "metadata": {"page_label": "444", "file_name": "2023_20-21.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2023_20-21.pdf", "file_type": "application/pdf", "file_size": 1372902, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "81e1d798-1bfd-462d-ac36-6018ccdc7ebb", "node_type": "4", "metadata": {"page_label": "444", "file_name": "2023_20-21.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2023_20-21.pdf", "file_type": "application/pdf", "file_size": 1372902, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "554809fc850fd036575e31fb9b555f6e218a5c22dd355e1987205dd6ba90b9b7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "73313082-2baa-41f3-b0c2-82a74cfa6c12", "node_type": "1", "metadata": {"page_label": "444", "file_name": "2023_20-21.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2023_20-21.pdf", "file_type": "application/pdf", "file_size": 1372902, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "30d4ef3089ec7861dc80fd6155c805fa76699e96aaeda6d61aadba66d1c0ef93", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "18993c1d-2b59-4fdd-8194-88c9447550b6", "node_type": "1", "metadata": {}, "hash": "da714d48b242afba395e9b83d46b183a432e08f8dc1754c923f20fb474ea179d", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Nos analyses mettent\nainsi en lumi\u00e8re ces personnes diab\u00e9tiques plurielles\nqui au-del\u00e0 de l'anxi\u00e9t\u00e9 g\u00e9n\u00e9r\u00e9e par le suivi du diab\u00e8te\nfont au mieux de leurs possibilit\u00e9s, dans les contextes\nqui sont les leurs, en tenant comp te des interactions\nstructurantes dont elles ont (ou non) b\u00e9n\u00e9fici\u00e9. \u25a0\nRemerciements\nNos remerciements vont en premier lieu aux personnes\natteintes d'un diab\u00e8te qui ont accueilli, \u00e0 leur domicile,\nJessica Caroupin et Delphine Ballet, enqu\u00eatrices qui sont tout\nautant remerci\u00e9es ici. Ils s'adressent ensuite \u00e0 l'ARS R\u00e9union\nqui, en lien avec Sant\u00e9 Publique France, a soutenu et financ\u00e9\ncette \u00e9tude. Ils s'adressent \u00e9galement \u00e0 Sandrine FosseEdorh (Sant\u00e9 publique France), Delphine Ballet ( Universit\u00e9\nde La R\u00e9union ), C\u00e9cile Fournier (Institut de recherche\net de documentation en \u00e9conomie de la sant\u00e9 (Irdes)),\nDr. Xavier Debussche ( National Health Literacy Development\nProjects network , OMS) et Pr. Richard Osborne ( Center for\nGlobal Health and Equity, Melbourne) pour leur soutien et leurs\npr\u00e9cieuses re lectures. Enfin, que soient remerci\u00e9s les acteurs\ndes institutions qui ont permis de d\u00e9velopper cette recherche :\nSant\u00e9 publique France, l'ARS La R\u00e9union, l'Irdes, l'Universit\u00e9\nde La R\u00e9union et le laboratoire Icare.\nLiens d'int\u00e9r\u00eat\nLes auteurs d\u00e9clarent ne pas avoir de liens d'int\u00e9r\u00eat au regard\ndu contenu de l'article.\nR\u00e9f\u00e9rences\n[1] Institut national de la statistique et des \u00e9tudes \u00e9conomi -\nques. Insee Flash R\u00e9union 2022, n\u00b0 243. Saint-Denis: Insee\nLa R\u00e9union-Mayotte; 2022. 5 p.\ntiques/6679068\n[2] Watin, M. G\u00e9n\u00e9ralisation des communications et change -\nment social \u00e0 La R\u00e9union. In: Ghasarian C (dir.). Anthropologies\nde La R\u00e9union. Paris: \u00c9ditions des Archives Contemporaines;\n2008. pp. 127-135.\n[3] Balcou-Debussche M. Manger et se soigner : entre manques\net exc\u00e8s. In: Wolff \u00c9 , Watin M (dir.). La R\u00e9union, une soci\u00e9t\u00e9\nen mutations. Univers cr\u00e9oles 7. Paris: Economica; 2010.\npp. 189-212.\n[4] Debussche X, Tib\u00e8re L. Pratiques alimentaires. In: M\u00e9jean C,\nDebussche X, Martin-Pr\u00e9vel Y, R\u00e9quillart V, Soler LG, Tib\u00e8re L\n(dir.). Alimentation et nutrition dans les d\u00e9partements et r\u00e9gions\nd'Outre-mer. Montpellier: IRD Editions; 2020. pp. 77-105.", "mimetype": "text/plain", "start_char_idx": 2035, "end_char_idx": 4218, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "18993c1d-2b59-4fdd-8194-88c9447550b6": {"__data__": {"id_": "18993c1d-2b59-4fdd-8194-88c9447550b6", "embedding": null, "metadata": {"page_label": "444", "file_name": "2023_20-21.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2023_20-21.pdf", "file_type": "application/pdf", "file_size": 1372902, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "81e1d798-1bfd-462d-ac36-6018ccdc7ebb", "node_type": "4", "metadata": {"page_label": "444", "file_name": "2023_20-21.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2023_20-21.pdf", "file_type": "application/pdf", "file_size": 1372902, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "554809fc850fd036575e31fb9b555f6e218a5c22dd355e1987205dd6ba90b9b7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "556b9b80-0d5d-40e9-9154-674e93acde37", "node_type": "1", "metadata": {"page_label": "444", "file_name": "2023_20-21.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2023_20-21.pdf", "file_type": "application/pdf", "file_size": 1372902, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "b0cc2a98c78f4e7500a2c679d63e49cf5a626e4e9a6737cdb4fa5ae647de6379", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "15e3fc81-5d36-441f-981a-dd3a574322b9", "node_type": "1", "metadata": {}, "hash": "35eb94ab2b6942e9dc068f9f0c5e93c6b076a09d6a5feb248a890717839c1f95", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "189-212.\n[4] Debussche X, Tib\u00e8re L. Pratiques alimentaires. In: M\u00e9jean C,\nDebussche X, Martin-Pr\u00e9vel Y, R\u00e9quillart V, Soler LG, Tib\u00e8re L\n(dir.). Alimentation et nutrition dans les d\u00e9partements et r\u00e9gions\nd'Outre-mer. Montpellier: IRD Editions; 2020. pp. 77-105.\n[5] Sant\u00e9 publique France. Barom\u00e8tre sant\u00e9 2021 dans les\nDROM. Saint-Maurice: Sant\u00e9 publique France; 2022. https://\nwww.santepubliquefrance.fr/etudes-et-enquetes/barome\ntres-de-sante-publique-france/barometre-sante-2021-dansles-drom\n[6] Mandereau-Bruno L, Fosse-Edorh S. Pr\u00e9valence du diab\u00e8te\ntrait\u00e9 pharmacologiquement (tous types) en France en 2015.\nDisparit\u00e9s territoriales et socio-\u00e9conomiques. Bull \u00c9pid\u00e9miol\nHebd. 2017;(27-28):586-91.\nbeh/2017/27-28/2017_27-28_3.html\n[7] Agence r\u00e9gionale de sant\u00e9 La R\u00e9union. Les m\u00e9decins\ng\u00e9n\u00e9ralistes \u00e0 La R\u00e9union. Saint-Denis: ARS La R\u00e9union; 2021.\n2 p.\nlistes-la-reunion\n[8] Debussche, X. Pratiques de recours aux soins. In: M\u00e9jean C,\nDebussche X, Martin-Pr\u00e9vel Y, R\u00e9quillart V, Soler LG, Tib\u00e8re L\n(dir.). Alimentation et nutrition dans les d\u00e9partements et r\u00e9gions\nd'Outre-mer. Montpellier: IRD Editions; 2020. pp. 200-21.\n[9] Balcou-Debussche M. De l'\u00e9ducation th\u00e9rapeutique\ndu patient \u00e0 la litt\u00e9ratie en sant\u00e9. Probl\u00e9matisation socioanthropologique d'objets didactiques contextualis\u00e9s. Paris:\n\u00c9ditions des Archives Contemporaines; 2016. 243 p.\n[10] Balcou-Debussche M. Interroger la litt\u00e9ratie en sant\u00e9 dans\nune perspective de transformations individuelles et sociales.\nAnalyse de l'\u00e9volution de 42 personnes diab\u00e9tiques sur trois\nans. Recherches & \u00e9ducations. 2016;16:73-86.\nnals.openedition.org/rechercheseducations/3240\n[11] Debussche X. Addressing health literacy responsiveness\nin diabetes. Diabet Epidemiol Manag. 2021;4:100033.\n[12] Bakker MM, Putrik P, Aaby A, Debussche X, Morrissey J,\nRaheim-Borge C, et al. Acting together - WHO National Health\nLiteracy Demonstration Projects (NHLDPs) address health\nliteracy needs in the European Region. Public Health Pano -\nrama.", "mimetype": "text/plain", "start_char_idx": 3957, "end_char_idx": 5941, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "15e3fc81-5d36-441f-981a-dd3a574322b9": {"__data__": {"id_": "15e3fc81-5d36-441f-981a-dd3a574322b9", "embedding": null, "metadata": {"page_label": "444", "file_name": "2023_20-21.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2023_20-21.pdf", "file_type": "application/pdf", "file_size": 1372902, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "81e1d798-1bfd-462d-ac36-6018ccdc7ebb", "node_type": "4", "metadata": {"page_label": "444", "file_name": "2023_20-21.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2023_20-21.pdf", "file_type": "application/pdf", "file_size": 1372902, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "554809fc850fd036575e31fb9b555f6e218a5c22dd355e1987205dd6ba90b9b7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "18993c1d-2b59-4fdd-8194-88c9447550b6", "node_type": "1", "metadata": {"page_label": "444", "file_name": "2023_20-21.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2023_20-21.pdf", "file_type": "application/pdf", "file_size": 1372902, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "f238411b2ee4758abbfad3c01c8681b8aaa8728782e4e361603a578e02bfde92", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Diabet Epidemiol Manag. 2021;4:100033.\n[12] Bakker MM, Putrik P, Aaby A, Debussche X, Morrissey J,\nRaheim-Borge C, et al. Acting together - WHO National Health\nLiteracy Demonstration Projects (NHLDPs) address health\nliteracy needs in the European Region. Public Health Pano -\nrama. World Health Organization. Regional Office for Europe.\n2019;5(2-3):233-43.\n[13] Bardin L. L 'analyse de contenu. Paris: Presses Universi -\ntaires de France; 2013. 296 p.\n[14] Observatoire R\u00e9gional de Sant\u00e9 La R\u00e9union. Le diab\u00e8te\net les personnes diab\u00e9tiques \u00e0 La R\u00e9union. Saint-Denis: ORS\nLa R\u00e9union; 2022. 4 p.", "mimetype": "text/plain", "start_char_idx": 5660, "end_char_idx": 6253, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "225048c9-4a06-434a-9e0e-38a3abd9ca9a": {"__data__": {"id_": "225048c9-4a06-434a-9e0e-38a3abd9ca9a", "embedding": null, "metadata": {"page_label": "445", "file_name": "2023_20-21.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2023_20-21.pdf", "file_type": "application/pdf", "file_size": 1372902, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "27ffb3b2-48a9-4a85-b79b-a6f6013be127", "node_type": "4", "metadata": {"page_label": "445", "file_name": "2023_20-21.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2023_20-21.pdf", "file_type": "application/pdf", "file_size": 1372902, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "e26f9b231dde1b2bede1575e791c34497dfec78887787ac2fffd68f18588743b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6cb37be7-0db5-4ce9-99b3-9b1fd93407bb", "node_type": "1", "metadata": {}, "hash": "ce28d986cf4f7be40cbfe61089986a5ba31c8308e0f18cc490e921ba6dce07bd", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Diab\u00e8te en outre-mer : comprendre les sp\u00e9cificit\u00e9s locales pour cibler les actions BEH 20-21 | 14 novembre 2023 | 445\n[15] Balcou-Debussche M. L '\u00e9ducation des malades chro -\nniques. Une approche ethnosociologique. Paris: \u00c9ditions des\nArchives Contemporaines; 2006. 280 p.\n[16] Debussche X, Balcou-Debussche M, Ballet D, CaroupinSoupoutevin J. Health literacy in context: Struggling to\nself-manage diabetes - A longitudinal qualitative study. BMJ\nOpen. 2022;12(6):e046759.\n[17] Balcou-Debussche M, La Hausse V, Roddier M,\nSokolowsky C, Rastami J, Besan\u00e7on S, et al . Strengthe -\nning health literacy through structured sessions for noncommunicable diseases in low-resource settings: The Learning\nNest model. Community Health Equity Res Policy. 2023.\n[18] Thievenaz J, Tourette-Turgis C, Khaldi C. Analyser le\n\u00ab travail du malade \u00bb : nouveaux enjeux pour la formation et\nla recherche en \u00e9ducation th\u00e9rapeutique. \u00c9ducation perma -\nnente. 2013;195:47-58.\n[19] Gautier A (dir). Barom\u00e8tre Sant\u00e9 M\u00e9decins g\u00e9n\u00e9ralistes 2009.\nSaint-Denis: Institut national de pr\u00e9vention et d'\u00e9ducation pour\nla sant\u00e9; 2011. 266 p.\nbarometre-sante-medecins-generalistes-2009\n[20] Diab-quali : Recherche qualitative aupr\u00e8s de personnes\ndiab\u00e9tiques sur les ressources mobilis\u00e9es dans la gestion de\nleur sant\u00e9. Laboratoire Icare, Universit\u00e9 de La R\u00e9union, Sant\u00e9\nPublique France et Irdes; 2023. 134 p.\nrecherche/projets/diab-quali-recherche-qualitative-aupresde-personnes-diabetiques-sur-les-ressources-mobiliseesdans-la-gestion-de-leur-sante.pdf\nCiter cet article\nBalcou-Debussche M. Approche socio-anthropologique de la\nlitt\u00e9ratie en sant\u00e9 des personnes atteintes de diab\u00e8te de type 2\n\u00e0 La R\u00e9union. Bull \u00c9pid\u00e9miol Hebd. 2023;(20-21):440-6. http://\nbeh.santepubliquefrance.fr/beh/2023/20-21/2023_20-21_4.html\nAnnexe\nGrille Diab\u00e8te, litt\u00e9ratie, sant\u00e9\nArgumentaire\nPour rappel, informations \u00e0 recueillir :\nD'une part, parmi les ressources personnelles : on s'int\u00e9ressera aux niveaux socio-\u00e9conomiques, aux scores\nde litt\u00e9ratie en sant\u00e9, \u00e0 l'\u00e2ge et \u00e0 l'anciennet\u00e9 du diab\u00e8te, au sexe, \u00e0 la situation familiale, etc.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2083, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "6cb37be7-0db5-4ce9-99b3-9b1fd93407bb": {"__data__": {"id_": "6cb37be7-0db5-4ce9-99b3-9b1fd93407bb", "embedding": null, "metadata": {"page_label": "445", "file_name": "2023_20-21.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2023_20-21.pdf", "file_type": "application/pdf", "file_size": 1372902, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "27ffb3b2-48a9-4a85-b79b-a6f6013be127", "node_type": "4", "metadata": {"page_label": "445", "file_name": "2023_20-21.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2023_20-21.pdf", "file_type": "application/pdf", "file_size": 1372902, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "e26f9b231dde1b2bede1575e791c34497dfec78887787ac2fffd68f18588743b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "225048c9-4a06-434a-9e0e-38a3abd9ca9a", "node_type": "1", "metadata": {"page_label": "445", "file_name": "2023_20-21.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2023_20-21.pdf", "file_type": "application/pdf", "file_size": 1372902, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "5e453b757c939e6a10e45f5918447ef5e05b6f462632a2fc02851752e476089a", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "D'autre part, parmi les ressources disponibles dans l'environnement ou \u00e0 distance : on s'int\u00e9ressera aux\ns\u00e9ances d'\u00e9ducation th\u00e9rapeutique du patient (ETP individuelles ou collectives) apport\u00e9es par un professionnel\n(m\u00e9decin, infirmi\u00e8re, infirmi\u00e8re Asal\u00e9e, di\u00e9t\u00e9ticien, \u00e9ducateur m\u00e9dico-sportif, podologue, psychologue, etc.)\nou programme d'ETP collectif, \u00e0 l'accompagnement t\u00e9l\u00e9phonique (Sophia) ou par des services num\u00e9riques,\n\u00e0 la fr\u00e9quentation d'une maison du diab\u00e8te, ou encore d'une permanence d'association de patients...\nI - Pr\u00e9sentation de l'\u00e9tude\nBonjour,\nDans le cadre de la recherche Entred \u00e0 laquelle vous avez particip\u00e9 en 2019, nous souhaitons revoir les personnes\ninterrog\u00e9es afin de comprendre leurs pratiques pour g\u00e9rer au mieux la maladie chronique.\nII- Pr\u00e9sentation du d\u00e9roulement de l'entrevue\nPour cela, nous allons \u00e9changer ensemble pendant \u00e0 peu pr\u00e8s 1 heure. Cela vous conv ient ?\nNotre \u00e9change porte sur vos pratiques en sant\u00e9, c'est-\u00e0-dire tout ce qui se rapporte \u00e0 la gestion de votre diab\u00e8te\nau quotidien (Que faites-vous au quotidien pour g\u00e9rer votre diab\u00e8te ?).", "mimetype": "text/plain", "start_char_idx": 2084, "end_char_idx": 3176, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "6aefbb72-eda9-46c8-a4cd-97b0df4e83c9": {"__data__": {"id_": "6aefbb72-eda9-46c8-a4cd-97b0df4e83c9", "embedding": null, "metadata": {"page_label": "446", "file_name": "2023_20-21.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2023_20-21.pdf", "file_type": "application/pdf", "file_size": 1372902, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "a062f408-cca8-4285-b43d-d48467b85d84", "node_type": "4", "metadata": {"page_label": "446", "file_name": "2023_20-21.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2023_20-21.pdf", "file_type": "application/pdf", "file_size": 1372902, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "e745288f4872149e140b5e41f76a9939916616c977bcfe61de16c282f6c4433f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b404134d-0034-43be-8347-62aef955cc21", "node_type": "1", "metadata": {}, "hash": "2ffeeb9af4159bdd8d194757f95d45e4d0c680bd80c8fb522979fd0b6c704cb3", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "446 | 14 novembre 2023 | BEH 20-21 Diab\u00e8te en outre-mer : comprendre les sp\u00e9cificit\u00e9s locales pour cibler les actions\nNous avons presque fini.\nJ'ai juste besoin de recueillir quelques informations.\nP\u00f4les de questionnement Questions \u00e0 aborder\nGestion de la maladie\nAlimentation\nVous voulez bien me parler de votre alimentation ?\n(Questions subsidiaires si la personne ne r\u00e9pond pas tout de suite : quelle est votre relation \u00e0 l'alimentation ?\n\u00e0 l'\u00e9quilibre alimentaire ?)\nActivit\u00e9 physique et s\u00e9dentarit\u00e9\nVous voulez bien me parler de votre activit\u00e9 physique ?\n(Questions subsidiaires si la personne ne r\u00e9pond pas tout de suite : vous pratiquez une activit\u00e9 ? Et avec le diab\u00e8te,\nc'est compliqu\u00e9 ?)\nTraitement\nVous avez un traitement ? Vous voulez bien m'en parler un peu ?\n(Questions subsidiaires si la personne ne r\u00e9pond pas tout de suite : \u00e7a change beaucoup votre vie, le traitement ?)\nSuivi de la maladie\nParlons un peu du suivi de la maladie : comment la g\u00e9rez-vous ? Les analyses, les RDV avec les professionnels\nde sant\u00e9... ?\nInformations en sant\u00e9\nConnaissances\nVous voulez bien me dire ce que c'est, pour vous, le diab\u00e8te ?\n(Questions subsidiaires si la personne ne r\u00e9pond pas tout de suite : les organes qui sont concern\u00e9s ?\nLes complications ?)\nAcc\u00e8s aux savoirs\nQu'est-ce qui vous a aid\u00e9 \u00e0 comprendre tout \u00e7a ?\nLes s\u00e9ances d'\u00e9ducation ? Internet ? Vos amis ? D'autres diab\u00e9tiques ? L'accompagnement t\u00e9l\u00e9phonique (Sophia)\nou par des services num\u00e9riques, la fr\u00e9quentation d'une maison du diab\u00e8te, ou encore d'une permanence\nd'association de patients ?\nNum\u00e9rique\nSi vous utilisez internet : que cherchez-vous comme informations sur internet ? Sur quels sites ?\n(R\u00e9f\u00e9rence e-HLQ : utiliser les nouvelles technologies pour traiter les informations en sant\u00e9 ; compr\u00e9hension\ndes concepts de sant\u00e9 et du langage ; capacit\u00e9 \u00e0 s'engager avec les services num\u00e9riques ; se sentir en s\u00e9curit\u00e9\net en contr\u00f4le ; motivation \u00e0 s'engager avec les services num\u00e9riques ; acc\u00e8s \u00e0 des services num\u00e9riques qui\nfonctionnent ; des services num\u00e9riques adapt\u00e9s aux besoins individuels)\nRelation aux professionnels\nde sant\u00e9\nEt concernant votre rapport aux professionnels de sant\u00e9 ? Comment \u00e7a se passe par rapport \u00e0 la maladie ?\n(Questions subsidiaires si la personne ne r\u00e9pond pas tout de suite : vous faites tout ce qui vous est dit ou vous\ntrouvez aussi votre propre r\u00e9ponse ?)\nSoutien social Et dans l'entourage ? Vous \u00eates soutenu(e) ? Ou vous g\u00e9rez cela seul(e) ? Ou vous vous sentez isol\u00e9(e) ?\nCovid Par rapport au Covid, comment \u00e7a s'est pass\u00e9 ?\nP\u00f4les de questionnement Questions \u00e0 aborder\nProfil sociod\u00e9mographique\nQuelle est votre ann\u00e9e de naissance ?", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2644, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "b404134d-0034-43be-8347-62aef955cc21": {"__data__": {"id_": "b404134d-0034-43be-8347-62aef955cc21", "embedding": null, "metadata": {"page_label": "446", "file_name": "2023_20-21.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2023_20-21.pdf", "file_type": "application/pdf", "file_size": 1372902, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "a062f408-cca8-4285-b43d-d48467b85d84", "node_type": "4", "metadata": {"page_label": "446", "file_name": "2023_20-21.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2023_20-21.pdf", "file_type": "application/pdf", "file_size": 1372902, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "e745288f4872149e140b5e41f76a9939916616c977bcfe61de16c282f6c4433f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6aefbb72-eda9-46c8-a4cd-97b0df4e83c9", "node_type": "1", "metadata": {"page_label": "446", "file_name": "2023_20-21.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2023_20-21.pdf", "file_type": "application/pdf", "file_size": 1372902, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "45ea9133b408e829084ce174bbf17c527d9cdd823914fa0f2face7a853f06dad", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Soutien social Et dans l'entourage ? Vous \u00eates soutenu(e) ? Ou vous g\u00e9rez cela seul(e) ? Ou vous vous sentez isol\u00e9(e) ?\nCovid Par rapport au Covid, comment \u00e7a s'est pass\u00e9 ?\nP\u00f4les de questionnement Questions \u00e0 aborder\nProfil sociod\u00e9mographique\nQuelle est votre ann\u00e9e de naissance ?\nExercez-vous une profession ? Si non, quelle est la derni\u00e8re profession que vous avez exerc\u00e9e ?\nEt au niveau revenu, vous \u00eates plut\u00f4t \u00e0 l'aise ?\nQuelle est votre situation familiale ?\nQuel est votre niveau d'\u00e9tudes scolaire ?\nPoss\u00e9dez-vous une carte vitale ? Une mutuelle ?\nSuivi m\u00e9dical et param\u00e9dical Savez-vous depuis \u00e0 peu pr\u00e8s combien de temps vous \u00eates diab\u00e9tique ?\nFaites-vous de l'auto-surveillance glyc\u00e9mique ? Si oui \u00e0 quelle fr\u00e9quence ?\nAvez-vous d'autres probl\u00e8mes de sant\u00e9 ? Si oui lesquels ?\nConnaissez-vous votre dernier pourcentage concernant l'h\u00e9moglobine glyqu\u00e9e ?", "mimetype": "text/plain", "start_char_idx": 2364, "end_char_idx": 3227, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "c35d9f8b-8107-44f9-9890-351ffaae9a53": {"__data__": {"id_": "c35d9f8b-8107-44f9-9890-351ffaae9a53", "embedding": null, "metadata": {"page_label": "431", "file_name": "2023_20-21_3.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2023_20-21_3.pdf", "file_type": "application/pdf", "file_size": 363018, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "a3d78e9e-5f47-4340-b9af-46e122ecc6da", "node_type": "4", "metadata": {"page_label": "431", "file_name": "2023_20-21_3.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2023_20-21_3.pdf", "file_type": "application/pdf", "file_size": 363018, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "369a1b4100dc59c3315f4c17c05a91b16d75e959fd46e8ca7bced4cc9f25afcb", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3e2ec590-7284-4aa5-8d60-8e2568c54622", "node_type": "1", "metadata": {}, "hash": "c6b9fb677b84d47b690eb99117673a3d9b864cc8ec843c72530e717ce90b4ac4", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Diab\u00e8te en outre-mer : comprendre les sp\u00e9cificit\u00e9s locales pour cibler les actions BEH 20-21 | 14 novembre 2023 | 431\nARTICLE // Article\nPR\u00c9VALENCE DU DIAB\u00c8TE CONNU \u00c0 LA R\u00c9UNION, PRISES EN CHARGE ET CARACT\u00c9RISTIQUES\nDES PERSONNES ATTEINTES D'UN DIAB\u00c8TE : EXPLOITATION DES DONN\u00c9ES DU BAROM\u00c8TRE\nDE SANT\u00c9 PUBLIQUE FRANCE DROM DE 2021\n// PREVALENCE OF KNOWN DIABETES IN REUNION ISLAND, CARE AND CHARACTERISTICS OF THE POPULATION:\nDATA FROM THE 2021 SANT\u00c9 PUBLIQUE FRANCE HEALTH BAROMETER FOR OVERSEAS FRANCE\nMonique Ricquebourg 1 (), Claire Kwan 1, S\u00e9bastien M\u00e9devielle 1, Stelly Chopinet-Dijoux 2,\nFlorence Caliez 2, Fabian Thouillot 3, Estelle Nobecourt 4, Sandrine Fosse-Edorh 5\n1 Observatoire r\u00e9gional de la sant\u00e9 de La R\u00e9union, Saint-Denis\n2 Agence r\u00e9gionale de sant\u00e9 de La R\u00e9union, Saint-Denis\n3 Sant\u00e9 publique France - Oc\u00e9an Indien, Saint-Denis\n4 CHU de La R\u00e9union, CIC1410, UFR de La R\u00e9union, Saint-Pierre\n5 Sant\u00e9 publique France, Saint-Maurice\nSoumis le 11.07.2023 // Date of submission: 07.11.2023\nR\u00e9sum\u00e9 // Abstract\nContexte - Le diab\u00e8te est une priorit\u00e9 r\u00e9gionale de sant\u00e9 \u00e0 La R\u00e9union, au regard de sa forte pr\u00e9valence,\ndes fr\u00e9quences \u00e9lev\u00e9es des facteurs de risque et des complications associ\u00e9es. Le Programme r\u00e9unionnais\nde nutrition et de lutte contre le diab\u00e8te (PRND) a \u00e9t\u00e9 mis en \u0153uvre sur la p\u00e9riode 2020-2023. L 'objectif de l'\u00e9tude\nest d'actualiser la pr\u00e9valence du diab\u00e8te connu et de d\u00e9crire les caract\u00e9ristiques des personnes diab\u00e9tiques\n\u00e0 La R\u00e9union en 2021 afin d'orienter les actions du PRND.\nM\u00e9thodes - Les donn\u00e9es du Barom\u00e8tre de Sant\u00e9 publique France DROM 2021 ont \u00e9t\u00e9 utilis\u00e9es. \u00c0 La R\u00e9union,\nun \u00e9chantillon de 2 004 personnes \u00e2g\u00e9es de 18 \u00e0 85 ans, r\u00e9sidant sur le territoire, a \u00e9t\u00e9 interrog\u00e9 par t\u00e9l\u00e9phone\nsur le diab\u00e8te. Les analyses ont \u00e9t\u00e9 pond\u00e9r\u00e9es pour tenir compte du plan de sondage et de la participation,\nafin qu'elles soient repr\u00e9sentatives de la population du territoire r\u00e9gional.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1920, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "3e2ec590-7284-4aa5-8d60-8e2568c54622": {"__data__": {"id_": "3e2ec590-7284-4aa5-8d60-8e2568c54622", "embedding": null, "metadata": {"page_label": "431", "file_name": "2023_20-21_3.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2023_20-21_3.pdf", "file_type": "application/pdf", "file_size": 363018, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "a3d78e9e-5f47-4340-b9af-46e122ecc6da", "node_type": "4", "metadata": {"page_label": "431", "file_name": "2023_20-21_3.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2023_20-21_3.pdf", "file_type": "application/pdf", "file_size": 363018, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "369a1b4100dc59c3315f4c17c05a91b16d75e959fd46e8ca7bced4cc9f25afcb", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c35d9f8b-8107-44f9-9890-351ffaae9a53", "node_type": "1", "metadata": {"page_label": "431", "file_name": "2023_20-21_3.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2023_20-21_3.pdf", "file_type": "application/pdf", "file_size": 363018, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "52754a2c00ff32cda04c7983f99ded7d7b8c9046aa7744c545f4c98f9df2a218", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4cd8da47-c929-40a6-94d3-525925559073", "node_type": "1", "metadata": {}, "hash": "6b85d4ce5ae5122f926df974df4b409d1c14bc0834cb1e6dafe16a21a91f4971", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "\u00c0 La R\u00e9union,\nun \u00e9chantillon de 2 004 personnes \u00e2g\u00e9es de 18 \u00e0 85 ans, r\u00e9sidant sur le territoire, a \u00e9t\u00e9 interrog\u00e9 par t\u00e9l\u00e9phone\nsur le diab\u00e8te. Les analyses ont \u00e9t\u00e9 pond\u00e9r\u00e9es pour tenir compte du plan de sondage et de la participation,\nafin qu'elles soient repr\u00e9sentatives de la population du territoire r\u00e9gional.\nR\u00e9sultats - \u00c0 La R\u00e9union, en 2021, la pr\u00e9valence du diab\u00e8te connu \u00e9tait de 13,6% (intervalle de confiance\n\u00e0 95%, IC95%: [11,8-15,7]) en population adulte de 18 \u00e0 85 ans et parmi les personnes non diab\u00e9tiques\nconnues, 3,4% [2,4-4,6] d\u00e9claraient avoir un \u00ab petit diab\u00e8te \u00bb. Parmi les personnes se d\u00e9clarant diab\u00e9tiques,\n64,3% connaissaient leur maladie depuis au moins 5 ans, 82,4% d\u00e9claraient \u00eatre trait\u00e9es pharmacologique -\nment, et parmi ces personnes, 16,8% avaient d\u00e9j\u00e0 arr\u00eat\u00e9 au moins une fois leur traitement. Les in\u00e9galit\u00e9s\nsociales restaient tr\u00e8s marqu\u00e9es. Les facteurs de risque associ\u00e9s au diab\u00e8te et ses complications \u00e9taient\nfr\u00e9quents : ob\u00e9sit\u00e9 (28,0%), tabagisme quotidien (20,1%), avec des comportements nutritionnels \u00e9galement\n\u00e9loign\u00e9s des recommandations.\nConclusion - La pr\u00e9valence du diab\u00e8te connu reste \u00e9lev\u00e9e \u00e0 La R\u00e9union. Les complications du diab\u00e8te \u00e9tant\nfr\u00e9quentes sur l'\u00eele, les actions portant sur la pr\u00e9vention nutritionnelle doivent se poursuivre pour r\u00e9duire les\nfacteurs de risque et l'impact des in\u00e9galit\u00e9s sociales. Les r\u00e9sultats du Barom\u00e8tre Sant\u00e9 DROM 2021 contribue -\nront \u00e0 orienter les politiques publiques, et en particulier l'actualisation en 2024 du PRND.\n>\nMonique Ricquebourg et coll.\nObservatoire r\u00e9gional de la sant\u00e9 de La R\u00e9union, Saint-Denis\n[9] Sant\u00e9 publique France. Barom\u00e8tre de Sant\u00e9 publique\nFrance 2021. Questionnaire / Volet DROM. Saint-Maurice:\nSant\u00e9 publique France; 2022. 29 p.\nfrance.fr/etudes-et-enquetes/barometres-de-sante-publiquefrance/barometre-sante-2021-dans-les-drom\n[10] Observatoire r\u00e9gional de la sant\u00e9 de Guadeloupe. Le\ndiab\u00e8te en Guadeloupe en 2013 - Enqu\u00eate Kannari 2017. BaieMahault: Observatoire r\u00e9gional de la sant\u00e9 de Guadeloupe;\n2017.\nORSaG_DIABETE_KANNARI_rapport2017.pdf\n[11] Observatoire de la sant\u00e9 de la Martinique.", "mimetype": "text/plain", "start_char_idx": 1607, "end_char_idx": 3717, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "4cd8da47-c929-40a6-94d3-525925559073": {"__data__": {"id_": "4cd8da47-c929-40a6-94d3-525925559073", "embedding": null, "metadata": {"page_label": "431", "file_name": "2023_20-21_3.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2023_20-21_3.pdf", "file_type": "application/pdf", "file_size": 363018, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "a3d78e9e-5f47-4340-b9af-46e122ecc6da", "node_type": "4", "metadata": {"page_label": "431", "file_name": "2023_20-21_3.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2023_20-21_3.pdf", "file_type": "application/pdf", "file_size": 363018, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "369a1b4100dc59c3315f4c17c05a91b16d75e959fd46e8ca7bced4cc9f25afcb", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3e2ec590-7284-4aa5-8d60-8e2568c54622", "node_type": "1", "metadata": {"page_label": "431", "file_name": "2023_20-21_3.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2023_20-21_3.pdf", "file_type": "application/pdf", "file_size": 363018, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "49fd409f34c1c49ad088b0bc2abb2c23e4b371b53278f31af795f6ea9952f75a", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Le\ndiab\u00e8te en Guadeloupe en 2013 - Enqu\u00eate Kannari 2017. BaieMahault: Observatoire r\u00e9gional de la sant\u00e9 de Guadeloupe;\n2017.\nORSaG_DIABETE_KANNARI_rapport2017.pdf\n[11] Observatoire de la sant\u00e9 de la Martinique. Les principaux\nr\u00e9sultats de l'\u00e9tude Kannari en Martinique 2017.\ntinique.org/images/PDF/determinants/nutrition/Fiches_kan\nnari_-_Martinique_-_Novembre_2018_impression.pdf\n[12] Leduc A, Deroyon T, Rochereau T, Renaud A. Premiers\nr\u00e9sultats de l'enqu\u00eate sant\u00e9 europ\u00e9enne (EHIS) 2019 - M\u00e9tro -\npole, Guadeloupe, Martinique, Guyane, La R\u00e9union, Mayotte.\nLes dossiers de la Drees. 2021;78:1-98.\nrites-sante.gouv.fr/publications/les-dossiers-de-la-drees/\npremiers-resultats-de-lenquete-sante-europeenne-ehis2019-metrople-guadeloupe-martinique-guyane-lar%C3%A9union-mayotte\n[13] Fuentes S, Mandereau-Bruno L, Regnault N, Bernillon P,\nBonaldi C, Cosson E, et al. Is the type 2 diabetes epidemic\nplateauing in France? A nationwide population-based study.\nDiabetes Metab. 2020;46(6):472-9.\nCiter cet article\nHernandez H, Piffaretti C, Gautier A, Cosson E, FosseEdorh S. Pr\u00e9valence du diab\u00e8te connu dans 4 d\u00e9partements\net r\u00e9gions d'outre-mer : Guadeloupe, Martinique, Guyane et\nLa R\u00e9union. R\u00e9sultats du Barom\u00e8tre de Sant\u00e9 publique France\nde 2021. Bull \u00c9pid\u00e9miol Hebd. 2023;(20-21):424-31.\nsantepubliquefrance.fr/beh/2023/20-21/2023_20-21_2.html", "mimetype": "text/plain", "start_char_idx": 3507, "end_char_idx": 4849, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "26dacdb1-85af-4e94-b15c-e73a433254bd": {"__data__": {"id_": "26dacdb1-85af-4e94-b15c-e73a433254bd", "embedding": null, "metadata": {"page_label": "432", "file_name": "2023_20-21_3.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2023_20-21_3.pdf", "file_type": "application/pdf", "file_size": 363018, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "6d9c5893-68df-4492-9028-62947bd4bd11", "node_type": "4", "metadata": {"page_label": "432", "file_name": "2023_20-21_3.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2023_20-21_3.pdf", "file_type": "application/pdf", "file_size": 363018, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "9dce1d435e2b75548564ef17da3315fcda9b70897dd65623acc5d8ddfe6fcb24", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3d7ee953-777e-4349-a7b0-cb91fbea1231", "node_type": "1", "metadata": {}, "hash": "0f63e929c7b023bb29a51a6f5e921d24cc0f046be76e0f702882bfa59cda08e5", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "432 | 14 novembre 2023 | BEH 20-21 Diab\u00e8te en outre-mer : comprendre les sp\u00e9cificit\u00e9s locales pour cibler les actions\nBackground - Diabetes is a regional health priority in Reunion Island due to its high prevalence and the high\nfrequency of risk factors and associated complications. To address this, the Reunion Island Programme for\nNutrition and Diabetes Control (PRND) was set up for the period 2020-2023. The objective of the present\nstudy was to update the prevalence of diabetes and to describe the population with diabetes in Reunion Island\nfor 2021 in order to guide future actions related to the PRND .\nMethods - The used data were collected during the 2021 Health Barometer survey for French overseas depart -\nments and regions (DROM). In Reunion Island, a sample of 2,004 people aged from 18 to 85 years old residing\nin the territory were interviewed about diabetes by phone. The analyses were weighted, taking into account\nthe survey plan and participation, in order to be representative of the region's population.\nResults - In Reunion island, the prevalence of known diabetes in 2021 was 13.6% (95% confidence interval\n[95%CI]: 11.8-15.7) for the adult population aged from 18 to 85 years old . Among people who did not declare\ndiabetes, 3.4% (95%CI: 2.4-4.6) reported \"mild diabetes\". Among people who declared diabetes, 64.3% had\nbeen aware of their disease for at least 5 years and 82.4% declared being pharmacologically treated, among\nwhom 16.8% had already stopped their treatment at least once. Social inequalities related to diabetes were\nclear to observe. Risk factors associated with diabetes and its complications were frequent, including obesity\n(28.0%) and daily smoking (20.1%), as were dietary habits that diverged significantly from recommendations.\nConclusion - The prevalence of known diabetes remains high in Reunion Island. As complications linked to\ndiabetes are frequent in the region, nutritional prevention schemes must continue to help reduce risk factors\nand the impact of social inequalities. The results of the 2021 DROM Health Barometer will contribute to guiding\npublic policies, in particular to update the PRND 2024.\nMots-cl\u00e9s : Diab\u00e8te, Barom\u00e8tre, Prise en charge, Facteurs de risque, \u00cele de La R\u00e9union\n// Keywords: Diabetes, Barometer, Care, Risk factors, Reunion Island\nIntroduction\nLe diab\u00e8te, probl\u00e8me majeur de sant\u00e9 publique, touche\nen 2021 pr\u00e8s de 540 millions de personnes \u00e0 travers\nle monde. Un nombre qui ne cesse de cro\u00eetre dans\ntoutes les r\u00e9gions et qui atteindra, selon les pr\u00e9visions,\n783 millions d'individus d'ici 2045 1.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2583, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "3d7ee953-777e-4349-a7b0-cb91fbea1231": {"__data__": {"id_": "3d7ee953-777e-4349-a7b0-cb91fbea1231", "embedding": null, "metadata": {"page_label": "432", "file_name": "2023_20-21_3.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2023_20-21_3.pdf", "file_type": "application/pdf", "file_size": 363018, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "6d9c5893-68df-4492-9028-62947bd4bd11", "node_type": "4", "metadata": {"page_label": "432", "file_name": "2023_20-21_3.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2023_20-21_3.pdf", "file_type": "application/pdf", "file_size": 363018, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "9dce1d435e2b75548564ef17da3315fcda9b70897dd65623acc5d8ddfe6fcb24", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "26dacdb1-85af-4e94-b15c-e73a433254bd", "node_type": "1", "metadata": {"page_label": "432", "file_name": "2023_20-21_3.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2023_20-21_3.pdf", "file_type": "application/pdf", "file_size": 363018, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "43f99a7e6f5bbaac54735245ccca127619c73307dd5147695615353e6a8fd0c7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e813a722-a20c-4d7a-961a-950a227c622c", "node_type": "1", "metadata": {}, "hash": "82736a1eb1d642b36077470c7808e5de6d3adf30ffcbaad15224689a65506ab1", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Un nombre qui ne cesse de cro\u00eetre dans\ntoutes les r\u00e9gions et qui atteindra, selon les pr\u00e9visions,\n783 millions d'individus d'ici 2045 1. Ces chiffres ne\ntiennent pas comp te de la part non n\u00e9gligeable de\npersonnes ayant un diab\u00e8te non diagnostiqu\u00e9, dont\nl'estimation a \u00e9t\u00e9 mise \u00e0 jour par la F\u00e9d\u00e9ration inter -\nnationale du diab\u00e8te (FID) : en 2021, pr\u00e8s d'un adulte\nsur deux (20-79 ans) atteint de diab\u00e8te ignorait son\nstatut diab\u00e9tique (44,7% ; 239,7 millions) 2.\nLa mondialisation d'un mode de cons ommation\noccidental avec la g\u00e9n\u00e9ralisation d'ali ments et bois -\nsons ultra-transform\u00e9s et de haute densit\u00e9 \u00e9nerg\u00e9 -\ntique, ainsi que la diminution de l'act ivit\u00e9 physique\nau profit de la s\u00e9dentarit\u00e9, impactent tr\u00e8s fortement\ncertaines zones du monde, notamment l'Afrique et le\nMoyen-Orient, o\u00f9 les augmentations du nombre de\npersonnes diab\u00e9tiques sont les plus notables 1. Si le\ndiab\u00e8te de type 1 d\u00e9pend de facteurs de risque mal\nconnus et/ou difficilement \u00e9vitables (facteurs g\u00e9n\u00e9 -\ntiques et immunit\u00e9 en particulier), le diab\u00e8te de type 2,\nrepr\u00e9sentant plus de 90% des cas de diab\u00e8te, est\nintimement li\u00e9 au mode de vie : surpoids et ob\u00e9sit\u00e9,\nalimentation, s\u00e9dentarit\u00e9 et inactivit\u00e9 physique, tabagisme 3, etc., autant de facteurs de risque majeurs sur\nlesquels la pr\u00e9vention et la modification des comportements individuels peuvent jouer un r\u00f4le important\npour pr\u00e9venir ou retarder la survenue de la maladie.\n\u00c0 La R\u00e9union, la situation est pr\u00e9occupante, avec une\nforte pr\u00e9valence du diab\u00e8te (un taux 2 fois sup\u00e9rieur\n\u00e0 celui observ\u00e9 en France hexagonale) 4-7, associ\u00e9e\n\u00e0 des complications s\u00e9v\u00e8res pour les personnes\ndiab\u00e9tiques 5,8-9. Par ailleurs, la population r\u00e9union -\nnaise cumule des facteurs de risque importants : une\nalimentation marqu\u00e9e par une faible cons ommation\nde fruits et l\u00e9gumes et un exc\u00e8s de cons ommation\nde mati\u00e8res grasses et de produits sucr\u00e9s, une insuffisance d'activit\u00e9 physique et une s\u00e9dentarit\u00e9 \u00e9lev\u00e9e,\nune surcharge pond\u00e9rale fr\u00e9 quente (45% de la population adulte en 2019) 7,10-12.", "mimetype": "text/plain", "start_char_idx": 2447, "end_char_idx": 4465, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "e813a722-a20c-4d7a-961a-950a227c622c": {"__data__": {"id_": "e813a722-a20c-4d7a-961a-950a227c622c", "embedding": null, "metadata": {"page_label": "432", "file_name": "2023_20-21_3.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2023_20-21_3.pdf", "file_type": "application/pdf", "file_size": 363018, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "6d9c5893-68df-4492-9028-62947bd4bd11", "node_type": "4", "metadata": {"page_label": "432", "file_name": "2023_20-21_3.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2023_20-21_3.pdf", "file_type": "application/pdf", "file_size": 363018, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "9dce1d435e2b75548564ef17da3315fcda9b70897dd65623acc5d8ddfe6fcb24", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3d7ee953-777e-4349-a7b0-cb91fbea1231", "node_type": "1", "metadata": {"page_label": "432", "file_name": "2023_20-21_3.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2023_20-21_3.pdf", "file_type": "application/pdf", "file_size": 363018, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "ea2a594661cfaadd1b949c4b73c5bdc45ab822a10fa085d502e80209291f178c", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Au regard de la situation r\u00e9gionale, la sant\u00e9 nutri -\ntionnelle fait l'obj et d'une attention particuli\u00e8re sur\nle territoire : priorit\u00e9 r\u00e9gionale r\u00e9affirm\u00e9e dans le\nprojet r\u00e9gional de sant\u00e9 (PRS) 2018-2028 13,14 et mise\nen \u0153uvre d'un programme d'act ions commun, le\nProgramme r\u00e9unionnais de nutrition et de lutte contre\nle diab\u00e8te 2020-2023 (PRND) 15, \u00e9labor\u00e9 par l'Agence\nr\u00e9gionale de sant\u00e9 (ARS) et les partenaires locaux.\nL 'objectif de cette \u00e9tude est d'actualiser la pr\u00e9va -\nlence du diab\u00e8te conn u \u00e0 La R\u00e9union en 2021 et\nde d\u00e9crire la prise en charge et les caract\u00e9ristiques\ndes personnes r\u00e9unionnaises atteintes d'un diab\u00e8te .\nM\u00e9thodes\nSources de donn\u00e9es\nCette \u00e9tude a \u00e9t\u00e9 r\u00e9alis\u00e9e \u00e0 partir des donn\u00e9es d\u00e9claratives du volet r\u00e9unionnais de l'enq u\u00eate Barom\u00e8tre\nde Sant\u00e9 publique France en 2021, qui permet d'\u00e9tudier les comportements de sant\u00e9 et l'\u00e9tat de sant\u00e9 de\nla population adulte en France hexagonale et dans\nles d\u00e9partements et r\u00e9gions d'out re-mer (DROM)\n(en dehors de Mayotte). L 'enqu\u00eate Barom\u00e8tre Sant\u00e9\na \u00e9t\u00e9 renouvel\u00e9e dans les DROM, sept ans apr\u00e8s\nla premi\u00e8re \u00e9dition en 2014.\nLe recueil des donn\u00e9es, r\u00e9alis\u00e9 par l'ins titut Ipsos,\na suivi un protocole identique sur l'ensemble des territoires 16. La m\u00e9thode de recueil repose sur la g\u00e9n\u00e9 -\nration al\u00e9atoire de num\u00e9ros de t\u00e9l\u00e9phones fixes et\nmobiles et l'int errogation par t\u00e9l\u00e9phone d'adu ltes\n\u00e2g\u00e9s de 18 \u00e0 85 ans.", "mimetype": "text/plain", "start_char_idx": 4466, "end_char_idx": 5852, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "f55c661b-5ee4-4233-83d0-3f117bb085e5": {"__data__": {"id_": "f55c661b-5ee4-4233-83d0-3f117bb085e5", "embedding": null, "metadata": {"page_label": "433", "file_name": "2023_20-21_3.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2023_20-21_3.pdf", "file_type": "application/pdf", "file_size": 363018, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "c9ec9ee5-d94d-443b-b077-a01837ce388e", "node_type": "4", "metadata": {"page_label": "433", "file_name": "2023_20-21_3.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2023_20-21_3.pdf", "file_type": "application/pdf", "file_size": 363018, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "8ef9fddd9b23ecfa15ce6b5a5fd2a5815597dc9700107d47c5d617c2b21c9c53", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9a85fdf5-0bc2-4cb1-94ee-9ec0188131b2", "node_type": "1", "metadata": {}, "hash": "c659d86d851670869d1010b9daa30db8d36e46ae51f21773123cc315f7e2cb11", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Diab\u00e8te en outre-mer : comprendre les sp\u00e9cificit\u00e9s locales pour cibler les actions BEH 20-21 | 14 novembre 2023 | 433\n\u00c0 La R\u00e9union, l'enq u\u00eate s'est d\u00e9roul\u00e9e du 20 avril\nau 13 juillet 2021, aupr\u00e8s de 2 004 personnes \u00e2g\u00e9es\nde 18 \u00e0 85 ans, r\u00e9sidant sur l'\u00eele , parlant fran\u00e7ais\net/ou cr\u00e9ole.\nVariables d'int\u00e9r\u00eat\nLes adultes inclus dans l'enq u\u00eate ont \u00e9t\u00e9 interrog\u00e9s\nsur le diab\u00e8te conn u ou d\u00e9clar\u00e9 par la question \u00ab Un\nm\u00e9decin vous-a-t-il d\u00e9j\u00e0 dit que vous \u00e9tiez diab\u00e9 -\ntique ? \u00bb (en dehors d'un diab\u00e8te gestationnel). Les\npersonnes r\u00e9pondant non \u00e0 cette question ont \u00e9t\u00e9\ninterrog\u00e9es sur le \u00ab petit diab\u00e8te \u00bb : \u00ab Le m\u00e9decin\nvous a-t-il d\u00e9j\u00e0 dit que vous aviez un \u00ab petit diab\u00e8te \u00bb\nou un d\u00e9but de diab\u00e8te mais pas trop grave ? \u00bb. Cette\nderni\u00e8re question n'avait pas \u00e9t\u00e9 pos\u00e9e en 2014. Les\npersonnes d\u00e9clarant un diab\u00e8te ont ensuite \u00e9t\u00e9 interrog\u00e9es sur la dur\u00e9e depuis la premi\u00e8re annonce par\nle m\u00e9decin et leur prise en charge.\nLes donn\u00e9es sociod\u00e9mographiques, sur la sant\u00e9, sur\nl'indice de masse corporelle (IMC, calcul\u00e9 \u00e0 partir du\npoids et de la taille d\u00e9clar\u00e9s) et l'hyp ertension art\u00e9 -\nrielle (HTA) d\u00e9clar\u00e9e ont \u00e9galement \u00e9t\u00e9 utilis\u00e9es.\nLe questionnaire a par ailleurs permis d'abo rder les\nmodes de vie : la consommation quotidienne de fruits\net l\u00e9gumes ou de boissons sucr\u00e9es, les activit\u00e9s\nphysiques ou la s\u00e9dentarit\u00e9 au cours des 7 derniers\njours, le tabagisme quotidien, la cons ommation\nhebdomadaire d'alcool au cours des 12 derniers mois.\nAnalyses\nAfin d'\u00eatre repr\u00e9sentatives de la population de\nchaque DROM, les donn\u00e9es ont \u00e9t\u00e9 pond\u00e9r\u00e9es en\ntenant compte de la probabilit\u00e9 d'inc lusion (au sein\ndu m\u00e9nage et en fonction de l'\u00e9qu ipement t\u00e9l\u00e9pho -\nnique), et de la structure de la population de chaque\nd\u00e9partement via un calage sur marges en utilisant\nles variables suivantes : le sexe crois\u00e9 avec l'\u00e2ge par\ntranches d\u00e9cennales, la taille du foyer et le niveau de\ndipl\u00f4me. La population de r\u00e9f\u00e9rence est bas\u00e9e sur les\ndonn\u00e9es de l'Institut national de la statistique et des\n\u00e9tudes \u00e9conomiques (Insee) (Enqu\u00eate emploi 2020).\nL 'analyse repose dans un premier temps sur l'\u00e9tu de\ndescriptive de la pr\u00e9valence du diab\u00e8te conn u et du\n\u00ab petit diab\u00e8te \u00bb selon le sexe, l'\u00e2ge et les caract\u00e9ristiques socio-\u00e9conomiques.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2223, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "9a85fdf5-0bc2-4cb1-94ee-9ec0188131b2": {"__data__": {"id_": "9a85fdf5-0bc2-4cb1-94ee-9ec0188131b2", "embedding": null, "metadata": {"page_label": "433", "file_name": "2023_20-21_3.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2023_20-21_3.pdf", "file_type": "application/pdf", "file_size": 363018, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "c9ec9ee5-d94d-443b-b077-a01837ce388e", "node_type": "4", "metadata": {"page_label": "433", "file_name": "2023_20-21_3.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2023_20-21_3.pdf", "file_type": "application/pdf", "file_size": 363018, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "8ef9fddd9b23ecfa15ce6b5a5fd2a5815597dc9700107d47c5d617c2b21c9c53", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f55c661b-5ee4-4233-83d0-3f117bb085e5", "node_type": "1", "metadata": {"page_label": "433", "file_name": "2023_20-21_3.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2023_20-21_3.pdf", "file_type": "application/pdf", "file_size": 363018, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "d7988c3428dc869ea67bf2913218dee861006c71801f8e0b81fc8a2a018153ca", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d3f3ed8d-a88c-418c-bb8b-8a2f33484e4e", "node_type": "1", "metadata": {}, "hash": "1a32292fba9b7356c47819b3f1a96761308fbb52f8c10559423c551234ab63a1", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "L 'analyse repose dans un premier temps sur l'\u00e9tu de\ndescriptive de la pr\u00e9valence du diab\u00e8te conn u et du\n\u00ab petit diab\u00e8te \u00bb selon le sexe, l'\u00e2ge et les caract\u00e9ristiques socio-\u00e9conomiques.\nLa population d\u00e9clarant un diab\u00e8te est ensuite\nd\u00e9crite selon l'\u00e9tat de sant\u00e9, la prise en charge, les\ncaract\u00e9ristiques sociod\u00e9mographiques et les habi -\ntudes de vie.\nLes pourcentages sont pr\u00e9sent\u00e9s pond\u00e9r\u00e9s et\naccompagn\u00e9s de leur intervalle de confi ance \u00e0 95%\n(IC95%).\nR\u00e9sultats\nPr\u00e9valence du diab\u00e8te connu\net du \u00ab petit diab\u00e8te \u00bb\n\u00c0 La R\u00e9union, en 2021, 13,6% des personnes \u00e2g\u00e9es de\n18 \u00e0 85 ans ont d\u00e9clar\u00e9 un diab\u00e8te : 13,1% des hommes\net 14,1% des femmes (tableau 1). La pr\u00e9valence\ndu diab\u00e8te connu augmentait avec l'\u00e2ge pour atteindre 32,6% chez les 65-85 ans ; elle \u00e9tait significa -\ntivement plus \u00e9lev\u00e9e chez les personnes sans\ndipl\u00f4me ou avec un dipl\u00f4me inf\u00e9rieur au bacca -\nlaur\u00e9at, 2,5 fois sup\u00e9rieure chez les personnes\nretrait\u00e9es, en \u00e9tudes ou inactives par rapport aux\npersonnes qui travaillent, et 2 fois plus \u00e9lev\u00e9e\nchez les personnes avec des revenus bas ou inter -\nm\u00e9diaires (tableau 1).\nLa pr\u00e9valence du \u00ab petit diab\u00e8te \u00bb parmi les\npersonnes d\u00e9clarant ne pas \u00eatre diab\u00e9tiques \u00e9tait de\n3,4% : 4,0% des hommes et 2,8% des femmes. La\npr\u00e9valence du \u00ab petit diab\u00e8te \u00bb tendait \u00e0 augmenter\navec l'\u00e2ge, jusqu'\u00e0 65 ans (7,7% des 55-64 ans).\n\u00c9tat de sant\u00e9 globale\nParmi les personnes d\u00e9clarant un diab\u00e8te, ayant\ndonc connaissance de leur maladie, 43,5% jugeaient\nleur \u00e9tat de sant\u00e9 comm e assez bon (25,5% chez\nles personnes se d\u00e9clarant non diab\u00e9tiques) ;\n15,6% s'estimaient en mauvaise ou tr\u00e8s mauvaise\nsant\u00e9, soit une proportion 2,5 fois plus \u00e9lev\u00e9e\nque dans la population non diab\u00e9tique (5,9%).\nPar ailleurs, un quart des personnes se d\u00e9clarant\ndiab\u00e9tiques (25,4%) ont r\u00e9pondu n\u00e9gativement\n\u00e0 la question \u00ab Avez-vous une maladie chronique\nou un probl\u00e8me de sant\u00e9 durable ? \u00bb. Et 36,1% des\npersonnes se d\u00e9clarant diab\u00e9tiques ont fait \u00e9tat\nde limitations depuis au moins 6 mois dans les acti -\nvit\u00e9s habituelles \u00e0 cause d'un probl\u00e8me de sant\u00e9\n(18,3% dans la population non diab\u00e9tique).", "mimetype": "text/plain", "start_char_idx": 2036, "end_char_idx": 4118, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "d3f3ed8d-a88c-418c-bb8b-8a2f33484e4e": {"__data__": {"id_": "d3f3ed8d-a88c-418c-bb8b-8a2f33484e4e", "embedding": null, "metadata": {"page_label": "433", "file_name": "2023_20-21_3.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2023_20-21_3.pdf", "file_type": "application/pdf", "file_size": 363018, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "c9ec9ee5-d94d-443b-b077-a01837ce388e", "node_type": "4", "metadata": {"page_label": "433", "file_name": "2023_20-21_3.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2023_20-21_3.pdf", "file_type": "application/pdf", "file_size": 363018, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "8ef9fddd9b23ecfa15ce6b5a5fd2a5815597dc9700107d47c5d617c2b21c9c53", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9a85fdf5-0bc2-4cb1-94ee-9ec0188131b2", "node_type": "1", "metadata": {"page_label": "433", "file_name": "2023_20-21_3.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2023_20-21_3.pdf", "file_type": "application/pdf", "file_size": 363018, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "eff3ff5d802cefc20f8f09bfb24b9521f5158dbc791572a750c1d7edac522616", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "\u00bb. Et 36,1% des\npersonnes se d\u00e9clarant diab\u00e9tiques ont fait \u00e9tat\nde limitations depuis au moins 6 mois dans les acti -\nvit\u00e9s habituelles \u00e0 cause d'un probl\u00e8me de sant\u00e9\n(18,3% dans la population non diab\u00e9tique).\nPrise en charge\nParmi les personnes avec un diab\u00e8te conn u, 64,2%\nl'\u00e9taient depuis au moins 5 ans (tableau 2). La majo -\nrit\u00e9 des personnes d\u00e9clarant un diab\u00e8te \u00e9taient trai -\nt\u00e9es pharmacologiquement (plus de 8 personnes\nayant un diab\u00e8te sur 10) ; et parmi elles, pr\u00e8s de 17%\navaient d\u00e9j\u00e0 arr\u00eat\u00e9 au moins une fois leur traitement\nm\u00e9dicamenteux.\nPar ailleurs, 5,3% des personnes avec un diab\u00e8te\nconnu n'ont pas vu de m\u00e9decin g\u00e9n\u00e9raliste dans les\n12 derniers mois (3 fois moins que pour la popu -\nlation non diab\u00e9tique) et 11,9% ont d\u00e9clar\u00e9 avoir\nrenonc\u00e9 \u00e0 des soins au cours des 12 derniers mois\npour des raisons financi\u00e8res (dans une proportion\ncomparable \u00e0 celle de la population non diab\u00e9tique)\n(tableau 2).\nCaract\u00e9ristiques sociod\u00e9mographiques\nLe diab\u00e8te conn u en 2021 conc ernait plus fr\u00e9 -\nquemment les femmes que les hommes (55,2%\nversus 44,8%) (tableau 3). La moyenne d'\u00e2ge \u00e9tait de\n60 ans (contre 45 ans chez les personnes d\u00e9clarant\nne pas \u00eatre diab\u00e9tiques).\nLes personnes d\u00e9clarant un diab\u00e8te pr\u00e9sentaient un\nprofil socialement plus d\u00e9favoris\u00e9 que les personnes\nnon diab\u00e9tiques : pr\u00e8s de la moiti\u00e9 sans aucun\ndipl\u00f4me, la moiti\u00e9 percevant leur situation finan -\nci\u00e8re comme juste ou difficile, et pr\u00e8s de 40% avec\ndes revenus bas (tableau 3).", "mimetype": "text/plain", "start_char_idx": 3908, "end_char_idx": 5371, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "af964440-86e3-47ef-a0d7-047cf8ad8bdc": {"__data__": {"id_": "af964440-86e3-47ef-a0d7-047cf8ad8bdc", "embedding": null, "metadata": {"page_label": "434", "file_name": "2023_20-21_3.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2023_20-21_3.pdf", "file_type": "application/pdf", "file_size": 363018, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "65bb7f4c-96c9-4b42-aebb-4cf8a07de432", "node_type": "4", "metadata": {"page_label": "434", "file_name": "2023_20-21_3.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2023_20-21_3.pdf", "file_type": "application/pdf", "file_size": 363018, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "ab3209eda1d42d498e05fa6e9a7e4600f469d4daebd47fb08fb2426d7cde8fff", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8f6c270f-951a-4fb4-8629-0e97f2f32d39", "node_type": "1", "metadata": {}, "hash": "217aabf5d5444e4d8dcd0373b9b20186101ee055db4ea130c4c64528ac31b68f", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "434 | 14 novembre 2023 | BEH 20-21 Diab\u00e8te en outre-mer : comprendre les sp\u00e9cificit\u00e9s locales pour cibler les actions\nTableau 1\nTaux de pr\u00e9valence du diab\u00e8te connu et du \u00ab petit diab\u00e8te a \u00bb selon le sexe, l'\u00e2ge et les caract\u00e9ristiques socio-\u00e9conomiques,\nLa R\u00e9union, 2021\nPr\u00e9valence du diab\u00e8te connu\n(population g\u00e9n\u00e9rale n=2 004)\nPr\u00e9valence du \u00ab petit diab\u00e8te \u00bba\n(population non diab\u00e9tique n=1 745)\n% [IC95%] % [IC95%]\nSexe\nHommes 13,1 [10,4-16,4] 4,0 [2,5-6,4]\nFemmes 14,1 [11,8-16,7] 2,8 [1,9-4,2]\n\u00c2ge\n18-34 ans 2,7 [1,3-5,4] 0,9 [0,2-3,6]\n35-44 ans 5,5 [3,1-9,4] 2,9 [1,2-6,6]\n45-54 ans 13,0 [9,4-17,8] 2,7 [1,5-4,6]\n55-64 ans 20,6 [16,3-25,6] 7,7 [4,7-12,4]\n65-85 ans 32,6 [26,4-39,5] 5,3 [2,6-10,7]\nDipl\u00f4me\nAucun dipl\u00f4me 20,7 [16,8-25,2] 5,6 [3,5-8,8]\n< bac 15,9 [12,7-19,7] 4,2 [2,6-6,9]\nBac ou > bac 5,3 [3,8-7,3] 1,0 [0,5-2,2]\nSituation professionnelle\nTravail 8,0 [6,1-10,6] 2,4 [1,5-3,9]\nCh\u00f4mage 13,5 [9,8-18,1] 4,6 [2,4-8,6]\nRetrait\u00e9s, \u00e9tudiants et autres inactifs 19,4 [16,0-23,3] 3,7 [2,2-6,1]\nRevenus par unit\u00e9 de consommation en terciles\n1er tercile (<530 \u20ac) 17,2 [13,6-21,6] 4,8 [2,8-8,0]\n2e tercile (530-1 170 \u20ac) 15,2 [12,1-18,9] 3,6 [2,1-6,2]\n3e tercile (\u22651 171 \u20ac) 8,2 [6,0-11,0] 1,6 [0,8-3,0]\nNSP/Refus 12,4 [7,", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1229, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "8f6c270f-951a-4fb4-8629-0e97f2f32d39": {"__data__": {"id_": "8f6c270f-951a-4fb4-8629-0e97f2f32d39", "embedding": null, "metadata": {"page_label": "434", "file_name": "2023_20-21_3.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2023_20-21_3.pdf", "file_type": "application/pdf", "file_size": 363018, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "65bb7f4c-96c9-4b42-aebb-4cf8a07de432", "node_type": "4", "metadata": {"page_label": "434", "file_name": "2023_20-21_3.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2023_20-21_3.pdf", "file_type": "application/pdf", "file_size": 363018, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "ab3209eda1d42d498e05fa6e9a7e4600f469d4daebd47fb08fb2426d7cde8fff", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "af964440-86e3-47ef-a0d7-047cf8ad8bdc", "node_type": "1", "metadata": {"page_label": "434", "file_name": "2023_20-21_3.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2023_20-21_3.pdf", "file_type": "application/pdf", "file_size": 363018, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "e69dcd6798fd264436fb914f46d2831413f241a7ed1470d13eeada09e400599a", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "8 [2,8-8,0]\n2e tercile (530-1 170 \u20ac) 15,2 [12,1-18,9] 3,6 [2,1-6,2]\n3e tercile (\u22651 171 \u20ac) 8,2 [6,0-11,0] 1,6 [0,8-3,0]\nNSP/Refus 12,4 [7,5-19,8] 3,4 [1,4-8,2]\nEnsemble 13,6 [11,8-15,7] 3,4 [2,4-4,6]\nIC95% : intervalle de confiance \u00e0 95% ; NSP : ne sait pas.\na \u00ab petit diab\u00e8te \u00bb d\u00e9fini dans l'enqu\u00eate comme \u00ab un d\u00e9but de diab\u00e8te, mais pas trop grave \u00bb.\nTableau 2\nCaract\u00e9ristiques de la prise en charge des personnes selon la connaissance du diab\u00e8te, La R\u00e9union, 2021 (n=2 004)\nPersonnes d\u00e9clarant\n\u00eatre diab\u00e9tiques\nPersonnes d\u00e9clarant\nne pas \u00eatre diab\u00e9tiques Ensemble\n% [IC95%] % [IC95%] % [IC95%]\nAnciennet\u00e9 du diab\u00e8te\nMoins de 5 ans 35,8 [28,9-43,3] - - - -\nEntre 5 et 10 ans 21,1 [15,4-28,0] - - - -\nPlus de 10 ans 43,2 [35,8-50,9] - - - -\nPersonnes trait\u00e9es pharmacologiquement\nNon 17,6 [12,8-23,7] - - - -\nOui 82,4 [76,3-87,2] - - - -\nDont ayant d\u00e9j\u00e0 arr\u00eat\u00e9 leur traitement 16,8 [11,5-23,9] - - - -\nDernier recours \u00e0 un m\u00e9decin g\u00e9n\u00e9raliste\nIl y a moins de 12 mois 94,7 [89,7-97,3] 83,8 [81,4-86,0] 85,3 [83,2-87,2]\nIl y a plus de 12 mois 5,3 [2,7-10,3] 15,6 [13,5-17,9] 14,2 [12,3-16,3]\nJamais consult\u00e9 de m\u00e9decin g\u00e9n\u00e9raliste 0,0 0,6 [0,2-1,5] 0,5 [0,2-1,3]\nRenoncement aux soins pour raison financi\u00e8re au cours des 12 derniers mois\nNon 88,1 [82,5-92,1] 88,7 [86,8-90,4] 88,6 [86,8-90,2]\nOui 11,9 [7,9-17,5] 11,3 [9,6-13,2] 11,4 [9,8-13,2]\nIC95% : intervalle de confiance \u00e0 95%.", "mimetype": "text/plain", "start_char_idx": 1092, "end_char_idx": 2473, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "77564a34-bdb0-45b9-a3a0-6fda411c9422": {"__data__": {"id_": "77564a34-bdb0-45b9-a3a0-6fda411c9422", "embedding": null, "metadata": {"page_label": "435", "file_name": "2023_20-21_3.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2023_20-21_3.pdf", "file_type": "application/pdf", "file_size": 363018, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "f1034205-ec22-4323-90e1-61b097f416b6", "node_type": "4", "metadata": {"page_label": "435", "file_name": "2023_20-21_3.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2023_20-21_3.pdf", "file_type": "application/pdf", "file_size": 363018, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "801aa74ddf74175c2d6283fabb51a4ddfb387dcb78486203dc71ad7c2b3c9aad", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b87997ff-635c-4748-9a25-6f629de90b7e", "node_type": "1", "metadata": {}, "hash": "81257aca6f67c06a52cc24eae09318be6cc5274fe7c6ac3158fe701b4717ddc2", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Diab\u00e8te en outre-mer : comprendre les sp\u00e9cificit\u00e9s locales pour cibler les actions BEH 20-21 | 14 novembre 2023 | 435\nDescription de l'\u00e9tat m\u00e9tabolique\net des modes de vie\nParmi les personnes d\u00e9clarant un diab\u00e8te, le profil\nm\u00e9tabolique \u00e9tait plus d\u00e9grad\u00e9 que celui des\npersonnes se d\u00e9clarant non diab\u00e9tiques (tableau 4) :\npr\u00e8s de 70% en surcharge pond\u00e9rale, 28,0% en\nsituation d'ob\u00e9sit\u00e9 (12,6% chez les non diab\u00e9tiques),\net 46,5% souffrant d'hyp ertension art\u00e9rielle (pr\u00e8s de\n3 fois plus que chez les personnes d\u00e9clarant ne pas\n\u00eatre diab\u00e9tiques).\nLes modes de vie des personnes avec un diab\u00e8te\nconnu \u00e9taient proches de ceux des personnes ne se\nd\u00e9clarant pas diab\u00e9tiques (tableau 4) : 19,9% d\u00e9claraient manger au moins 5 fruits et l\u00e9gumes par jour,\n59,5% d\u00e9claraient une pratique d'act ivit\u00e9 physique\nconforme aux recommandations, 20,1% d\u00e9claraient\nfumer tous les jours et 21,0% boire de l'alcool chaque\nsemaine. En revanche, la cons ommation de bois -\nsons sucr\u00e9es \u00e9tait significativement moins souvent\nd\u00e9clar\u00e9e chez les personnes d\u00e9clarant un diab\u00e8te.\nDiscussion\nPr\u00e9valence du diab\u00e8te connu\nLes r\u00e9sultats du Barom\u00e8tre Sant\u00e9 DROM 2021 per -\nmettent d'actualiser \u00e0 13,6% la pr\u00e9valence du diab\u00e8te\nconnu parmi les r\u00e9unionnais \u00e2g\u00e9s de 18 \u00e0 85 ans. Cette\nestimation est coh\u00e9rente avec les donn\u00e9es r\u00e9centes\nde l'Enqu\u00eate sant\u00e9 europ\u00e9enne (EHIS 2019) 7, mais\ncette pr\u00e9valence sous-estime la situation r\u00e9elle.\nD'une part, elle ne cible que le diab\u00e8te conn u et\nd\u00e9clar\u00e9 par les personnes interrog\u00e9es. L '\u00e9dition 2021\ndu Barom\u00e8tre permet pour la premi\u00e8re fois d'apporter\nune estimation du \u00ab petit diab\u00e8te \u00bb d\u00e9clar\u00e9 (d\u00e9fini\nTableau 3\nDescription des caract\u00e9ristiques sociod\u00e9mographiques et socio-\u00e9conomiques des personnes selon la connaissance du diab\u00e8te,\nLa R\u00e9union, 2021\nPersonnes d\u00e9clarant\n\u00eatre diab\u00e9tiques\nPersonnes d\u00e9clarant\nne pas \u00eatre diab\u00e9tiques Ensemble\n% [IC95%] % [IC95%] % [IC95%]\nSexe\nHommes 44,8 [37,3-52,6] 46,9 [44,0-49,9] 46,6 [43,9-49,4]\nFemmes 55,2 [47,4-62,7] 53,1 [50,1-56,0] 53,4 [50,", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1994, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "b87997ff-635c-4748-9a25-6f629de90b7e": {"__data__": {"id_": "b87997ff-635c-4748-9a25-6f629de90b7e", "embedding": null, "metadata": {"page_label": "435", "file_name": "2023_20-21_3.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2023_20-21_3.pdf", "file_type": "application/pdf", "file_size": 363018, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "f1034205-ec22-4323-90e1-61b097f416b6", "node_type": "4", "metadata": {"page_label": "435", "file_name": "2023_20-21_3.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2023_20-21_3.pdf", "file_type": "application/pdf", "file_size": 363018, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "801aa74ddf74175c2d6283fabb51a4ddfb387dcb78486203dc71ad7c2b3c9aad", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "77564a34-bdb0-45b9-a3a0-6fda411c9422", "node_type": "1", "metadata": {"page_label": "435", "file_name": "2023_20-21_3.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2023_20-21_3.pdf", "file_type": "application/pdf", "file_size": 363018, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "c76bac7c733c25ec8ad5263391f095146480af986939ee25662708ec9da261dd", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "314edc5c-7430-46da-a88a-7c78ebb917ec", "node_type": "1", "metadata": {}, "hash": "52cb41261310469fd1a37e13859085959eb7a0263cdd96baaf07b311a426447a", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "8 [37,3-52,6] 46,9 [44,0-49,9] 46,6 [43,9-49,4]\nFemmes 55,2 [47,4-62,7] 53,1 [50,1-56,0] 53,4 [50,6-56,1]\n\u00c2ge\n18-34 ans 5,4 [2,6-10,8] 31,2 [28,4-34,1] 27,7 [25,1-30,3]\n35-44 ans 6,9 [4,0-11,8] 18,9 [16,8-21,1] 17,3 [15,4-19,3]\n45-54 ans 18,5 [13,4-25,1] 19,5 [17,4-21,8] 19,4 [17,4-21,5]\n55-64 ans 27,8 [22,0-34,5] 16,9 [14,9-19,1] 18,4 [16,5-20,5]\n65-85 ans 41,4 [34,0-49,1] 13,5 [11,6-15,7] 17,3 [15,3-19,5]\nMoyenne d'\u00e2gea 59,9 [57,7-62,0] 44,8 [43,8-45,8] 46,8 [45,8-47,8]\nDipl\u00f4me\nAucun dipl\u00f4me 54,2 [46,7-61,4] 32,8 [29,9-35,8] 35,7 [33,0-38,6]\n< bac 31,4 [25,2-38,3] 26,2 [23,8-28,8] 26,9 [24,7-29,3]\nBac 7,6 [4,6-12,4] 19,2 [17,1-21,4] 17,6 [15,7-19,6]\n> bac 6,9 [4,5-10,4] 21,8 [19,7-24,0] 19,7 [17,9-21,8]\nSituation professionnelle\nTravail 23,0 [17,5-29,6] 41,6 [38,8-44,4] 39,0 [36,5-41,6]\nCh\u00f4mage 21,9 [16,2-28,8] 22,2 [19,7-24,9] 22,2 [19,8-24,7]\nRetrait\u00e9s, \u00e9tudiants et autres inactifs 55,1 [47,6-62,5] 36,2 [33,4-39,1] 38,8 [36,2-41,5]\nPerception financi\u00e8re\n\u00c0 l'aise 21,8 [16,1-28,7] 20,2 [18,0-22,6] 20,4 [18,4-22,", "mimetype": "text/plain", "start_char_idx": 1896, "end_char_idx": 2925, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "314edc5c-7430-46da-a88a-7c78ebb917ec": {"__data__": {"id_": "314edc5c-7430-46da-a88a-7c78ebb917ec", "embedding": null, "metadata": {"page_label": "435", "file_name": "2023_20-21_3.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2023_20-21_3.pdf", "file_type": "application/pdf", "file_size": 363018, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "f1034205-ec22-4323-90e1-61b097f416b6", "node_type": "4", "metadata": {"page_label": "435", "file_name": "2023_20-21_3.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2023_20-21_3.pdf", "file_type": "application/pdf", "file_size": 363018, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "801aa74ddf74175c2d6283fabb51a4ddfb387dcb78486203dc71ad7c2b3c9aad", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b87997ff-635c-4748-9a25-6f629de90b7e", "node_type": "1", "metadata": {"page_label": "435", "file_name": "2023_20-21_3.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2023_20-21_3.pdf", "file_type": "application/pdf", "file_size": 363018, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "4fc9ee4c53a6c56e85787053cd74761605eb16e94da86631369a3c5bf89d1845", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "7]\nRetrait\u00e9s, \u00e9tudiants et autres inactifs 55,1 [47,6-62,5] 36,2 [33,4-39,1] 38,8 [36,2-41,5]\nPerception financi\u00e8re\n\u00c0 l'aise 21,8 [16,1-28,7] 20,2 [18,0-22,6] 20,4 [18,4-22,7]\n\u00c7a va 27,9 [21,8-35,1] 38,9 [36,1-41,8] 37,5 [34,8-40,1]\nJuste 26,3 [20,3-33,3] 21,7 [19,5-24,2] 22,3 [20,2-24,6]\nDifficile/Dettes ou recours au cr\u00e9dit\n\u00e0 la consommation\n24,0 [17,8-31,4] 19,1 [16,9-21,6] 19,8 [17,6-22,1]\nRevenus par UC en terciles\n1er tercile (<530 \u20ac) 36,6 [29,6-44,2] 27,7 [25,1-30,5] 28,9 [26,4-31,5]\n2e tercile (530-1 170 \u20ac) 35,0 [28,3-42,3] 30,7 [28,2-33,4] 31,3 [28,9-33,8]\n3e tercile (\u22651 171 \u20ac) 14,8 [10,9-19,9] 26,4 [24,1-28,8] 24,8 [22,7-27,0]\nNSP/Refus 13,6 [8,3-21,4] 15,2 [13,0-17,7] 15,0 [12,9-17,3]\nIC95% : intervalle de confiance \u00e0 95% ; UC : unit\u00e9 de consommation ; NSP : ne sait pas.\na Ces chiffres correspondent \u00e0 une moyenne et non \u00e0 un pourcentage.", "mimetype": "text/plain", "start_char_idx": 2752, "end_char_idx": 3612, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "1efb7922-cb99-4601-8920-e98196872ccd": {"__data__": {"id_": "1efb7922-cb99-4601-8920-e98196872ccd", "embedding": null, "metadata": {"page_label": "436", "file_name": "2023_20-21_3.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2023_20-21_3.pdf", "file_type": "application/pdf", "file_size": 363018, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "e2be68db-4b11-48fd-8093-6a5fd63ffcc8", "node_type": "4", "metadata": {"page_label": "436", "file_name": "2023_20-21_3.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2023_20-21_3.pdf", "file_type": "application/pdf", "file_size": 363018, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "4fcdc2de7c7de7ae33aef3e6b1b54b5a50e57fc771755d6b2f02a8c987cc3813", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "95bd4459-e67d-4336-9aa9-ca780fd2898b", "node_type": "1", "metadata": {}, "hash": "bce55744e78108d61498dae0d3e87cc3a14b1057cdae90eb9b245bb52d616225", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "436 | 14 novembre 2023 | BEH 20-21 Diab\u00e8te en outre-mer : comprendre les sp\u00e9cificit\u00e9s locales pour cibler les actions\ndans le cadre de cette enqu\u00eate comme un d\u00e9but de\ndiab\u00e8te \u00ab pas trop grave \u00bb). La pr\u00e9valence cumul\u00e9e\ndu diab\u00e8te et du \u00ab petit diab\u00e8te \u00bb sur l'ens emble de\nla population interrog\u00e9e atteint 16,5% \u00e0 La R\u00e9union\nen 2021 : 13,6% pour le diab\u00e8te et 2,9% pour le\n\u00ab petit diab\u00e8te \u00bb (le r\u00e9sultat non pr\u00e9sent\u00e9 correspond\naux 3,4% des personnes d\u00e9clarant ne pas \u00eatre diab\u00e9tiques). D'autre part, cette estimation cumul\u00e9e reste\nprobablement en dessous de la r\u00e9alit\u00e9 au regard de\nla part des personnes pour lesquelles le diab\u00e8te n'est\npas diagnostiqu\u00e9 et donc non conn u par celles-ci.\nCette sous-estimation est en effet mise en pers -\npective avec les donn\u00e9es historiques de l'\u00e9tu de\nr\u00e9gionale R\u00e9dia 2001 17, qui montrait qu'un patient\ndiab\u00e9tique sur trois ignorait sa maladie. Il faut des\nenqu\u00eates sp\u00e9cifiques pour estimer la fr\u00e9quence du\ndiab\u00e8te m\u00e9connu ; un projet d'\u00e9tu de est en cours\n\u00e0 La R\u00e9union pour actualiser cette fr\u00e9quence.\nPar ailleurs, ces r\u00e9sultats montrent que les donn\u00e9es\nm\u00e9dico-administratives issues du Syst\u00e8me national\ndes donn\u00e9es de sant\u00e9 (SNDS) conc ernant les\npatients pris en charge par le syst\u00e8me de sant\u00e9 ou les\npersonnes trait\u00e9es pharmacologiquement utilis\u00e9es\ndans le cadre de la surveillance r\u00e9gionale du diab\u00e8te\nsous-estiment la r\u00e9alit\u00e9 de la situation.\nLe \u00ab petit diab\u00e8te \u00bb\nLe \u00ab petit diab\u00e8te \u00bb renvoie aux notions de \u00ab diab\u00e8te\nr\u00e9cent \u00bb et/ou \u00ab diab\u00e8te sans complication \u00bb et/ou\n\u00ab diab\u00e8te sous-estim\u00e9 pour ne pas inqui\u00e9ter le\npatient \u00bb : l'entr\u00e9e dans le diab\u00e8te peut \u00eatre mini -\nmis\u00e9e pour certaines personnes. Le petit diab\u00e8te\npeut ainsi \u00eatre conf ondu avec le pr\u00e9diab\u00e8te pour\ncertains sujets, notamment lorsque la glyc\u00e9mie \u00e0\njeun est \u00e9lev\u00e9e (facteur de conf usion pour les sujets)\net que le diagnostic n'est pas confi rm\u00e9. Les r\u00e9sul -\ntats \u00e9tant bas\u00e9s sur les donn\u00e9es d\u00e9claratives de la\npersonne, il n'est pas possible de dissocier dans les\nr\u00e9sultats ces diff\u00e9rentes notions. Ainsi, les donn\u00e9es\nne permettent pas d'\u00e9ca rter d'\u00e9ventuels cas de pr\u00e9 -\ndiab\u00e8te. La notion de pr\u00e9diab\u00e8te m\u00e9riterait aussi\nd'\u00eatre approfondie dans les \u00e9tudes.\nPlusieurs questions permettaient de d\u00e9crire l'anc iennet\u00e9 du \u00ab petit diab\u00e8te \u00bb et les prises en charge et\nrecours de ces personnes.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2302, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "95bd4459-e67d-4336-9aa9-ca780fd2898b": {"__data__": {"id_": "95bd4459-e67d-4336-9aa9-ca780fd2898b", "embedding": null, "metadata": {"page_label": "436", "file_name": "2023_20-21_3.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2023_20-21_3.pdf", "file_type": "application/pdf", "file_size": 363018, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "e2be68db-4b11-48fd-8093-6a5fd63ffcc8", "node_type": "4", "metadata": {"page_label": "436", "file_name": "2023_20-21_3.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2023_20-21_3.pdf", "file_type": "application/pdf", "file_size": 363018, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "4fcdc2de7c7de7ae33aef3e6b1b54b5a50e57fc771755d6b2f02a8c987cc3813", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1efb7922-cb99-4601-8920-e98196872ccd", "node_type": "1", "metadata": {"page_label": "436", "file_name": "2023_20-21_3.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2023_20-21_3.pdf", "file_type": "application/pdf", "file_size": 363018, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "0c6d0603a216593c7dc7208dc4f9ec7658e0ab2ce346a5154c086b9ae2f1c0b0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1958fcfa-f9e1-4748-aa54-5e35debb487e", "node_type": "1", "metadata": {}, "hash": "6d61ce36110a9821a19b3cb84a2f9858a12c2591168ed72f46ba8428892a2e8e", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Ainsi, les donn\u00e9es\nne permettent pas d'\u00e9ca rter d'\u00e9ventuels cas de pr\u00e9 -\ndiab\u00e8te. La notion de pr\u00e9diab\u00e8te m\u00e9riterait aussi\nd'\u00eatre approfondie dans les \u00e9tudes.\nPlusieurs questions permettaient de d\u00e9crire l'anc iennet\u00e9 du \u00ab petit diab\u00e8te \u00bb et les prises en charge et\nrecours de ces personnes. La puissance des effec -\ntifs ne permet pas d'app rofondir les r\u00e9sultats par\nrapport \u00e0 cette situation d\u00e9clar\u00e9e. L 'analyse explo -\nratoire des donn\u00e9es \u00e9voque cependant que la majo -\nrit\u00e9 de ces personnes connaissaient leur situation\ndepuis moins de deux ans et que les r\u00e8gles hygi\u00e9nodi\u00e9t\u00e9tiques constituaient le traitement de premi\u00e8re\nligne. Le \u00ab petit diab\u00e8te \u00bb cache probablement des\nr\u00e9alit\u00e9s plus complexes. D'une part, il ne se limite pas\n\u00e0 un diab\u00e8te r\u00e9cent, puisque plusieurs personnes\nconcern\u00e9es d\u00e9claraient \u00eatre inform\u00e9es depuis au\nmoins cinq ans. D'autre part, parmi les personnes\navec un \u00ab petit diab\u00e8te \u00bb, certaines d\u00e9claraient \u00eatre\ntrait\u00e9es pharmacologiquement. Le profil m\u00e9tabolique\net les modes de vie de ces personnes semblaient\n\u00e9galement d\u00e9grad\u00e9s par rapport \u00e0 la population non\ndiab\u00e9tique (dans une moindre mesure que chez les\npersonnes avec un diab\u00e8te conn u). La vigilance est\ndonc de mise pour ce public plus jeune (de cinq ans\nen moyenne que les personnes d\u00e9clarant \u00eatre diab\u00e9 -\ntiques), avec une maladie probablement insuffisam -\nment contr\u00f4l\u00e9e, avec un risque de comp lications, et\nn'ayant pas toujours cons cience d'\u00eatre atteint d'une\nmaladie chronique (pr\u00e8s de la moiti\u00e9 des personnes\nont r\u00e9pondu ne pas avoir de maladie chronique).", "mimetype": "text/plain", "start_char_idx": 2012, "end_char_idx": 3561, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "1958fcfa-f9e1-4748-aa54-5e35debb487e": {"__data__": {"id_": "1958fcfa-f9e1-4748-aa54-5e35debb487e", "embedding": null, "metadata": {"page_label": "436", "file_name": "2023_20-21_3.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2023_20-21_3.pdf", "file_type": "application/pdf", "file_size": 363018, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "e2be68db-4b11-48fd-8093-6a5fd63ffcc8", "node_type": "4", "metadata": {"page_label": "436", "file_name": "2023_20-21_3.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2023_20-21_3.pdf", "file_type": "application/pdf", "file_size": 363018, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "4fcdc2de7c7de7ae33aef3e6b1b54b5a50e57fc771755d6b2f02a8c987cc3813", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "95bd4459-e67d-4336-9aa9-ca780fd2898b", "node_type": "1", "metadata": {"page_label": "436", "file_name": "2023_20-21_3.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2023_20-21_3.pdf", "file_type": "application/pdf", "file_size": 363018, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "70a47e09635b199020e76786d5514cb807206e9ffc29d6344409c8cefc697da8", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Ces \u00e9l\u00e9ments exploratoires sugg\u00e8rent des leviers\nTableau 4\nDescription de l'\u00e9tat m\u00e9tabolique et des modes de vie des personnes selon la connaissance du diab\u00e8te, La R\u00e9union, 2021\nPersonnes d\u00e9clarant\n\u00eatre diab\u00e9tiques\nPersonnes d\u00e9clarant\nne pas \u00eatre diab\u00e9tiques Ensemble\n% [IC95%] % [IC95%] % [IC95%]\n\u00c9tat m\u00e9tabolique\nIndice de masse corporelle (IMC)\nMaigreur ou normal (\u226425 kg/m2) 31,8 [25,4-38,8] 56,4 [53,5-59,3] 53,1 [50,3-55,8]\nSurpoids 40,3 [32,9-48,1] 31,0 [28,3-33,8] 32,3 [29,7-34,9]\nOb\u00e9sit\u00e9 28,0 [21,2-35,9] 12,6 [10,9-14,5] 14,7 [12,8-16,7]\nMoyenne IMCa 27,5 [26,8-28,2] 25,0 [24,7-25,2] 25,3 [25,1-25,6]\nHypertension art\u00e9rielle d\u00e9clar\u00e9e 46,5 [39,2-54,1] 16,7 [14,7-19,0] 20,8 [18,7-23,0]\nModes de vie\nPratique d'activit\u00e9s physiques conforme\naux recommandationsb\n59,5 [51,9-66,7] 61,0 [58,2-63,8] 60,8 [58,2-63,4]\nAu moins 5 fruits et l\u00e9gumes par jour 19,9 [14,9-26,0] 20,6 [18,5-23,0] 20,5 [18,5-22,7]\nBoissons sucr\u00e9es tous les jours 13,7 [9,1-20,0] 23,0 [20,6-25,5] 21,7 [19,6-24,0]\nTabagisme quotidien 20,1 [14,1-27,8] 19,9 [17,6-22,4] 19,9 [17,8-22,3]\nAlcool hebdomadaire 21,0 [15,3-28,1] 24,8 [22,3-27,5] 24,3 [22,0-26,8]\nIC95% : intervalle de confiance \u00e0 95%.\na Ces chiffres correspondent \u00e0 une moyenne et non \u00e0 un pourcentage.\nb Au moins 150 minutes d'activit\u00e9 physique mod\u00e9r\u00e9e par semaine ou 75 minutes d'activit\u00e9 physique intense par semaine ou une combinaison \u00e9quivalente\nd'activit\u00e9 physique mod\u00e9r\u00e9e ou intense par semaine.", "mimetype": "text/plain", "start_char_idx": 3562, "end_char_idx": 5003, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "211942f0-e7ae-4eff-a390-5de2573cff6a": {"__data__": {"id_": "211942f0-e7ae-4eff-a390-5de2573cff6a", "embedding": null, "metadata": {"page_label": "437", "file_name": "2023_20-21_3.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2023_20-21_3.pdf", "file_type": "application/pdf", "file_size": 363018, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "6921c743-b569-4c9a-b209-0dde6cda3360", "node_type": "4", "metadata": {"page_label": "437", "file_name": "2023_20-21_3.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2023_20-21_3.pdf", "file_type": "application/pdf", "file_size": 363018, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "6388029f829c41909d07316dddefdbce0e6f2a39e13402e4ed32c1872ab0f2b1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "da73d243-33fb-40a4-b4f2-d9d5b5f58cbb", "node_type": "1", "metadata": {}, "hash": "76b638eef3351edbc1de1c8f7c473aa1c0e7e7905a5b81ce4ff6ca7469df0fb6", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Diab\u00e8te en outre-mer : comprendre les sp\u00e9cificit\u00e9s locales pour cibler les actions BEH 20-21 | 14 novembre 2023 | 437\nen termes de comm unication pour faire \u00e9voluer\nles discours et les repr\u00e9sentations des patients et\ndes professionnels de sant\u00e9.\nCaract\u00e9ristiques des personnes\nd\u00e9clarant un diab\u00e8te\nLes r\u00e9sultats de cette \u00e9tude sur un \u00e9chantillon probabiliste de la population adulte r\u00e9unionnaise retrouvent\nles m\u00eames sp\u00e9cificit\u00e9s li\u00e9es au diab\u00e8te dans notre\npopu lation que les donn\u00e9es issues du SNDS et/ou\nde l'\u00e9tude Entred 3 (1) (2) 18,19 : des personnes atteintes\nd'un diab\u00e8te (connu ou pris en charge) plus jeunes,\nplus de femmes, des personnes avec une forte pro -\nportion d'IMC \u226425 kg/m\u00b2 (maigreur ou normal)...\nConcernant les donn\u00e9es de corpulence, m\u00eame si\nl'IMC des personnes avec un diab\u00e8te est plus \u00e9lev\u00e9\nque celui des personnes d\u00e9clarant ne pas \u00eatre\ndiab\u00e9tiques, pr\u00e8s d'un tiers des personnes ayant\nun diab\u00e8te d\u00e9clarent un IMC normal. Ce r\u00e9sultat est\ncoh\u00e9rent avec les r\u00e9sultats de l'\u00e9tu de Entred 3 18 o\u00f9\nla proportion de personnes ob\u00e8ses atteintes de DT2\ndans la population r\u00e9unionnaise est plus faible et\ncelle des personnes atteintes de DT2 ayant un IMC\ndans les normes est plus \u00e9lev\u00e9e que dans l'Hexagone\net dans les autres DROM. Cela confi rme les sp\u00e9ci -\nficit\u00e9s de cette population et la n\u00e9cessit\u00e9 d'ada pter\nles discours, le d\u00e9pistage et les prises en charge.\nPersistance des constats sur les in\u00e9galit\u00e9s\nsociales et les facteurs de risque connus\nassoci\u00e9s au diab\u00e8te et \u00e0 ses complications\nLes r\u00e9sultats de l'\u00e9di tion 2021 permettent, sept ans\nplus tard, de r\u00e9it\u00e9rer les cons tats de 2014 sur notre\nterritoire 10.\nD'une part, les facteurs de risques connus du diab\u00e8te\net des complications associ\u00e9es restent fr\u00e9quemment\nd\u00e9clar\u00e9s par cette population pr\u00e9sentant un diab\u00e8te :\nob\u00e9sit\u00e9, faible cons ommation de fruits et l\u00e9gumes,\npratique insuffisante d'activit\u00e9s physiques, fr\u00e9quence\n\u00e9lev\u00e9e du tabagisme quotidien. Ces r\u00e9sultats\nsugg\u00e8rent que malgr\u00e9 la connaissance de la maladie,\nles personnes d\u00e9clarant un diab\u00e8te changent peu\nleurs comportements. Cette hypoth\u00e8se d'abs ence\nde prise de conscience est renforc\u00e9e par le fait qu'un\nquart des personnes ayant un diab\u00e8te d\u00e9clare n'avoir\naucune maladie chronique.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2225, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "da73d243-33fb-40a4-b4f2-d9d5b5f58cbb": {"__data__": {"id_": "da73d243-33fb-40a4-b4f2-d9d5b5f58cbb", "embedding": null, "metadata": {"page_label": "437", "file_name": "2023_20-21_3.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2023_20-21_3.pdf", "file_type": "application/pdf", "file_size": 363018, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "6921c743-b569-4c9a-b209-0dde6cda3360", "node_type": "4", "metadata": {"page_label": "437", "file_name": "2023_20-21_3.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2023_20-21_3.pdf", "file_type": "application/pdf", "file_size": 363018, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "6388029f829c41909d07316dddefdbce0e6f2a39e13402e4ed32c1872ab0f2b1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "211942f0-e7ae-4eff-a390-5de2573cff6a", "node_type": "1", "metadata": {"page_label": "437", "file_name": "2023_20-21_3.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2023_20-21_3.pdf", "file_type": "application/pdf", "file_size": 363018, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "a811b3281df0a1f772676308f1dd71ae3dd441bed5374cbdaf09bf0abd59ff53", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "44123d44-8bd9-42d6-a8b5-07061fdede13", "node_type": "1", "metadata": {}, "hash": "f9f54d3d156d3f8a9ba1e8aa7bad44094df36791e0a153defde0371893886a15", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Ces r\u00e9sultats\nsugg\u00e8rent que malgr\u00e9 la connaissance de la maladie,\nles personnes d\u00e9clarant un diab\u00e8te changent peu\nleurs comportements. Cette hypoth\u00e8se d'abs ence\nde prise de conscience est renforc\u00e9e par le fait qu'un\nquart des personnes ayant un diab\u00e8te d\u00e9clare n'avoir\naucune maladie chronique.\nPar ailleurs, les r\u00e9sultats sur la sant\u00e9 globale\ndes personnes ayant un diab\u00e8te rendent comp te\nd'une perception de la sant\u00e9 globale et d'un \u00e9tat\nde sant\u00e9 physique plus d\u00e9grad\u00e9s par rapport\naux personnes d\u00e9clarant ne pas \u00eatre diab\u00e9 -\ntiques. L 'hypertension art\u00e9rielle impliqu\u00e9e dans la\ngen\u00e8se des complications est aussi fr\u00e9quemment\nretrouv\u00e9e chez les patients ayant un diab\u00e8te : pr\u00e8s\nd'une personne d\u00e9clarant un diab\u00e8te sur deux est\naussi hypertendue.\n(1) Sant\u00e9 publique France. Observatoire G\u00e9odes.\npubliquefrance.fr\n(2) Assurance maladie. Data pathologies.\nLes facteurs associ\u00e9s au diab\u00e8te retrouv\u00e9s dans\ncette \u00e9tude sont : le mode de vie, l'HTA, le tabac,\nla consommation d'alcool (d\u00e9l\u00e9t\u00e8re pour le diab\u00e8te\nen grande quantit\u00e9 et plus g\u00e9n\u00e9ralement facteur\nde risque de cancer en cons ommation quotidienne\nquelle que soit la quantit\u00e9). Ils montrent l'imp ortance\nd'une prise en charge globale des personnes diab\u00e9 -\ntiques et non glucocentr\u00e9e.\nIl existe donc des marges d'am\u00e9 lioration en termes\nde pr\u00e9vention, d'acc ompagnement et de comm unication aupr\u00e8s des personnes atteintes d'un diab\u00e8te\npour qu'elles int\u00e8grent des modes de vie plus favo -\nrables \u00e0 leur sant\u00e9. Les messages doivent \u00e9galement\nporter sur le tabagisme pour une population \u00e0 haut\nrisque de complications cardiovasculaires.\nD'autre part, le diab\u00e8te est une maladie chronique\nr\u00e9v\u00e9latrice des in\u00e9galit\u00e9s sociales de sant\u00e9. Le fort\ngradient socio-\u00e9conomique est retrouv\u00e9 dans cette\n\u00e9tude : les personnes les moins dipl\u00f4m\u00e9es et aux\nrevenus les plus modestes sont davantage expo -\ns\u00e9es au diab\u00e8te. Par ailleurs, les r\u00e9sultats de cette\n\u00e9tude ne permettent pas de montrer l'imp act du\ndiab\u00e8te sur le quotidien des personnes. Pour autant,\nle diab\u00e8te survenant de mani\u00e8re plus pr\u00e9coce\n\u00e0 La R\u00e9union, cela peut avoir un impact sur la vie\nsociale des personnes (notamment celles qui sont\nen \u00e2ge de travailler). Les donn\u00e9es montrent que plus\nd'un tiers des personnes ayant un diab\u00e8te d\u00e9clarent\n\u00eatre limit\u00e9es dans les activit\u00e9s du quotidien dans les\n6 derniers mois, cela peut sugg\u00e9rer un accompagnement sp\u00e9cifique au niveau social.", "mimetype": "text/plain", "start_char_idx": 1930, "end_char_idx": 4315, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "44123d44-8bd9-42d6-a8b5-07061fdede13": {"__data__": {"id_": "44123d44-8bd9-42d6-a8b5-07061fdede13", "embedding": null, "metadata": {"page_label": "437", "file_name": "2023_20-21_3.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2023_20-21_3.pdf", "file_type": "application/pdf", "file_size": 363018, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "6921c743-b569-4c9a-b209-0dde6cda3360", "node_type": "4", "metadata": {"page_label": "437", "file_name": "2023_20-21_3.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2023_20-21_3.pdf", "file_type": "application/pdf", "file_size": 363018, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "6388029f829c41909d07316dddefdbce0e6f2a39e13402e4ed32c1872ab0f2b1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "da73d243-33fb-40a4-b4f2-d9d5b5f58cbb", "node_type": "1", "metadata": {"page_label": "437", "file_name": "2023_20-21_3.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2023_20-21_3.pdf", "file_type": "application/pdf", "file_size": 363018, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "2c8368e5d2c362321058f29e92a7db336486239fcee583d408b7a31d9f6d0908", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Les donn\u00e9es montrent que plus\nd'un tiers des personnes ayant un diab\u00e8te d\u00e9clarent\n\u00eatre limit\u00e9es dans les activit\u00e9s du quotidien dans les\n6 derniers mois, cela peut sugg\u00e9rer un accompagnement sp\u00e9cifique au niveau social. Le volet social est\nclairement \u00e0 approfondir pour diminuer les cons \u00e9quences de la pr\u00e9carit\u00e9, mais aussi \u00e9viter la pr\u00e9ca -\nrisation qui peut r\u00e9sulter de la d\u00e9couverte d'une\nmaladie chronique et ses comp lications (incapacit\u00e9,\nd\u00e9compensation de la maladie, comp lications, perte\nd'emploi, perte de confi ance en soi...). Les donn\u00e9es\nde l'\u00e9tude Entred 3 permettront de le faire.\nLa r\u00e9duction de l'imp act sanitaire des in\u00e9galit\u00e9s\nsociales reste donc un point d'attention majeur.\nPrise en charge des personnes\nse d\u00e9clarant diab\u00e9tiques\nLes r\u00e9sultats de cette nouvelle \u00e9dition du Barom\u00e8tre\nSant\u00e9 DROM mettent en \u00e9vidence des ruptures dans\nla prise en charge des personnes ayant un diab\u00e8te :\narr\u00eat du traitement et/ou non-recours aux soins.\nCes r\u00e9sultats rejoignent ceux des autres travaux\nr\u00e9gionaux qui montrent que les parcours r\u00e9els des\npersonnes diab\u00e9tiques r\u00e9unionnaises sont souvent\n\u00e9loign\u00e9s des parcours recommand\u00e9s. La proportion\nd'arr\u00eat de traitement d\u00e9crite ici est mise en perspec -\ntive avec celles retrouv\u00e9es dans l'enq u\u00eate r\u00e9gionale\nsur les parcours de soins des patients diab\u00e9tiques\nmis sous traitement en 2010 9, o\u00f9 9% des patients\navaient arr\u00eat\u00e9 leur traitement pendant au moins deux\nans et o\u00f9 pr\u00e8s de 40% des patients avaient arr\u00eat\u00e9\nleur traitement apr\u00e8s huit ans de parcours de soins.\nLes actions de comm unication et d'acc ompagnement pour motiver les patients \u00e0 l'observance m\u00e9di -\ncamenteuse, ou les inciter \u00e0 reprendre leur traitement\nen cas d'arr\u00eat doivent se poursuivre.", "mimetype": "text/plain", "start_char_idx": 4096, "end_char_idx": 5806, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "e15f86a5-b099-4cac-a483-cd10482f5008": {"__data__": {"id_": "e15f86a5-b099-4cac-a483-cd10482f5008", "embedding": null, "metadata": {"page_label": "438", "file_name": "2023_20-21_3.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2023_20-21_3.pdf", "file_type": "application/pdf", "file_size": 363018, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "450fe8d5-b6d6-4ba4-9a37-6b9d30d26896", "node_type": "4", "metadata": {"page_label": "438", "file_name": "2023_20-21_3.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2023_20-21_3.pdf", "file_type": "application/pdf", "file_size": 363018, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "558aabb128f14bd82988ea1f68c9f8a712be9580d6a7b9a01a87ca8a0070b53d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "620c7c8b-f1a7-449a-a304-9acf984ecf5e", "node_type": "1", "metadata": {}, "hash": "7dc9fc8e5a953b28faa17949c68a0d44ef735e1295376f5ce643fa1dc4c410ab", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "438 | 14 novembre 2023 | BEH 20-21 Diab\u00e8te en outre-mer : comprendre les sp\u00e9cificit\u00e9s locales pour cibler les actions\nPar ailleurs, l'enqu\u00eate permettait \u00e9galement d'aborder\nles prises en charge et le recours chez les personnes\natteintes d'un diab\u00e8te non trait\u00e9 pharmacologique -\nment et chez les personnes avec un \u00ab petit diab\u00e8te \u00bb.\nLa puissance statistique n'est pas suffisante pour\napprofondir les r\u00e9sultats et montrer l'imp ortance,\nressentie par les acteurs r\u00e9gionaux, du recours aux\nplantes m\u00e9dicinales (tisanes/\u00ab zerbages p\u00e9i \u00bb) pour\nle traitement des maladies (notamment chroniques)\nsur l'\u00eele. Une \u00e9tude r\u00e9gionale sur le recours aux soins\nen 2014 montrait que l'usage des plantes conc ernait\ndeux R\u00e9unionnais adultes sur cinq ; et que le recours\naux plantes pour traiter un trouble rencontr\u00e9 variait\npeu selon les tranches d'\u00e2ge 20. L 'usage des tisanes \u00e0\nLa R\u00e9union rev\u00eat donc davantage un aspect cult urel\nqu'un effet de g\u00e9n\u00e9ration. Cet usage des rem\u00e8des\ntraditionnels est mis en exergue dans les r\u00e9sul -\ntats du Barom\u00e8tre Sant\u00e9 2021 sur l'ens emble des\nDROM 21, dans les r\u00e9sultats de la troisi\u00e8me \u00e9dition\nde l'\u00e9tude Entred 18, o\u00f9 44% des personnes diab\u00e9 -\ntiques r\u00e9unionnaises trait\u00e9es pharmaco logiquement\nd\u00e9claraient aussi un recours aux plantes, ou encore\ndans les r\u00e9sultats de l'enq u\u00eate qualitative Diab-quali\nmen\u00e9e \u00e0 La R\u00e9union 22. Une revue bibliographique des\nenqu\u00eates qualitatives r\u00e9gionales 23 sur le diab\u00e8te a\npermis de montrer que les plantes m\u00e9dicinales \u00e9taient\nl'un des quatre moyens th\u00e9rapeutiques clairement\nidentifi\u00e9s par les patients diab\u00e9tiques (avec la di\u00e9t\u00e9 -\ntique, les cachets et l'insuline). Ces travaux montrent\nque les th\u00e9rapies modernes (m\u00e9dicamenteuses ou\nnon) s'ajoutent ou supplantent les traitements tradi -\ntionnels phyto- th\u00e9rapeutiques, largement administr\u00e9s\ndans les familles dans un but pr\u00e9ventif ou curatif.\nFace \u00e0 ces cons tats renouvel\u00e9s sur les ruptures de\nprise en charge, il faut souligner que les objectifs du\nProgramme r\u00e9unionnais de nutrition et de lutte contre\nle diab\u00e8te (PRND) 15 sont de travailler sur les parcours\ndes personnes ayant un diab\u00e8te localement pour\n\u00e9viter les ruptures de suivi et de valoriser et rendre\naccessible tous les programmes d' \u00e9ducation th\u00e9ra -\npeutique du patient (ETP) pour favoriser la communication et la diffusion des informations.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2319, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "620c7c8b-f1a7-449a-a304-9acf984ecf5e": {"__data__": {"id_": "620c7c8b-f1a7-449a-a304-9acf984ecf5e", "embedding": null, "metadata": {"page_label": "438", "file_name": "2023_20-21_3.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2023_20-21_3.pdf", "file_type": "application/pdf", "file_size": 363018, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "450fe8d5-b6d6-4ba4-9a37-6b9d30d26896", "node_type": "4", "metadata": {"page_label": "438", "file_name": "2023_20-21_3.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2023_20-21_3.pdf", "file_type": "application/pdf", "file_size": 363018, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "558aabb128f14bd82988ea1f68c9f8a712be9580d6a7b9a01a87ca8a0070b53d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e15f86a5-b099-4cac-a483-cd10482f5008", "node_type": "1", "metadata": {"page_label": "438", "file_name": "2023_20-21_3.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2023_20-21_3.pdf", "file_type": "application/pdf", "file_size": 363018, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "3bc5d279a7ab5b892f33a646ad3145bff65741efc513546f2d817fcb41484b9a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3ecf5a22-735c-4523-a738-9b3151be3f57", "node_type": "1", "metadata": {}, "hash": "78babe74952228ab4886650b3d67434585e7cdd287c7999329411c0a0c7376a2", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "\u00c9volution de la situation r\u00e9gionale\nLa comparaison des r\u00e9sultats entre les deux \u00e9ditions\ndu Barom\u00e8tre Sant\u00e9 DROM est tr\u00e8s limit\u00e9e, dans\nla mesure o\u00f9 les questions (hormis pour le diab\u00e8te\nconnu) et les populations d'\u00e9tudes \u00e9taient diff\u00e9rentes\nentre 2014 et 2021.\nLa pr\u00e9valence du diab\u00e8te conn u tend \u00e0 augmenter\ndans la population r\u00e9unionnaise, sans \u00eatre signi -\nficative. En se rapportant \u00e0 la population des\n18-75 ans, la part du diab\u00e8te connu est pass\u00e9 de 11,6%\n(IC95%: [9,9-13,5]) en 2014 \u00e0 13,0% [11,2-15,0] en 2021.\nCette tendance pourrait \u00eatre li\u00e9e \u00e0 une augmentation\nde l'incidence du diab\u00e8te, mais aussi au vieillisse -\nment de la population, \u00e0 l'allongement de l'esp\u00e9rance\nde vie de la population diab\u00e9tique et \u00e9galement \u00e0\nune am\u00e9lioration de la connaissance et du d\u00e9pistage\ndu diab\u00e8te au cours du temps, comme le montrent\nles r\u00e9sultats de l'enq u\u00eate Entred 3 o\u00f9 la propor -\ntion de diab\u00e8te de type 2 d\u00e9couvert sur d\u00e9pistage\nest plus importante \u00e0 La R\u00e9union (76%) que dans\nl'Hexagone (68%) 18. Ces r\u00e9sultats sont encoura -\ngeants au regard des efforts r\u00e9alis\u00e9s \u00e0 La R\u00e9union\nsur les strat\u00e9gies de d\u00e9pistage du diab\u00e8te dans le\ncadre du PRND 2020-2023 pour d\u00e9pister le plus t\u00f4t\net le plus largement possible la maladie.\nDonn\u00e9es d\u00e9claratives\nL 'ensemble des r\u00e9sultats pr\u00e9sent\u00e9s dans cet article\ns'appuient sur des donn\u00e9es d'enq u\u00eate d\u00e9claratives.\nLes r\u00e9sultats sont donc possiblement concern\u00e9s par\ndiff\u00e9rents biais (biais de couverture conc ernant principalement les personnes ne poss\u00e9dant pas de t\u00e9l\u00e9 -\nphone ou ne parlant pas le fran\u00e7ais ou le cr\u00e9ole, biais\nde non- r\u00e9ponse lorsque des personnes refusent de\nr\u00e9pondre \u00e0 l'enqu\u00eate, notamment les personnes aux\ncomportements de sant\u00e9 particuliers, biais de m\u00e9moire,\ncomme ne plus se souvenir de l'anciennet\u00e9 du diab\u00e8te,\net de d\u00e9sirabilit\u00e9 sociale, en se pr\u00e9sentant par exemple\nsous un meilleur jour aux yeux de l'enqu\u00eateur).\nConclusion\nLa pr\u00e9valence du diab\u00e8te conn u reste \u00e9lev\u00e9e \u00e0\nLa R\u00e9union, et l'ape r\u00e7u des caract\u00e9ristiques des\npersonnes d\u00e9clarant un diab\u00e8te renouvelle les\nconstats appelant \u00e0 la vigilance sur certains points\nde rupture dans la prise en charge des patients\ndiab\u00e9tiques, les in\u00e9galit\u00e9s sociales, les fr\u00e9quences\n\u00e9lev\u00e9es des facteurs de risque de complications chez\ndes personnes ayant un diab\u00e8te.", "mimetype": "text/plain", "start_char_idx": 2320, "end_char_idx": 4591, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "3ecf5a22-735c-4523-a738-9b3151be3f57": {"__data__": {"id_": "3ecf5a22-735c-4523-a738-9b3151be3f57", "embedding": null, "metadata": {"page_label": "438", "file_name": "2023_20-21_3.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2023_20-21_3.pdf", "file_type": "application/pdf", "file_size": 363018, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "450fe8d5-b6d6-4ba4-9a37-6b9d30d26896", "node_type": "4", "metadata": {"page_label": "438", "file_name": "2023_20-21_3.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2023_20-21_3.pdf", "file_type": "application/pdf", "file_size": 363018, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "558aabb128f14bd82988ea1f68c9f8a712be9580d6a7b9a01a87ca8a0070b53d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "620c7c8b-f1a7-449a-a304-9acf984ecf5e", "node_type": "1", "metadata": {"page_label": "438", "file_name": "2023_20-21_3.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2023_20-21_3.pdf", "file_type": "application/pdf", "file_size": 363018, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "0b91a3c79fe9e4a9967d15b7265b00f86fa65d168cbd42213d7851738cf41642", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "La survenue du diab\u00e8te et de ses complications \u00e9tant\nfr\u00e9quente \u00e0 La R\u00e9union (1) (2) 8,9,18,19, la pr\u00e9vention nutri -\ntionnelle doit \u00eatre renforc\u00e9e pour r\u00e9duire les facteurs\nde risque associ\u00e9s \u00e0 la maladie et ses complications,\nainsi que l'impact des in\u00e9galit\u00e9s sociales.\nDes analyses r\u00e9gionales comp l\u00e9mentaires sont en\ncours pour apporter des \u00e9l\u00e9ments de connaissance\nplus d\u00e9taill\u00e9s sur le diab\u00e8te d\u00e9clar\u00e9, l'ali menta -\ntion, l'activit\u00e9 physique, la s\u00e9dentarit\u00e9 et l'ob\u00e9 sit\u00e9.\nD'autres travaux nationaux (Entred 3) ou r\u00e9gio -\nnaux pourront comp l\u00e9ter les donn\u00e9es \u00e9pid\u00e9mio -\nlogiques r\u00e9gionales sur les caract\u00e9ristiques de prise\nen charge, l'\u00e9ta t de sant\u00e9 et la qualit\u00e9 de vie des\npersonnes ayant un diab\u00e8te.\nL 'ensemble de ces informations permettront de\ndocumenter les politiques publiques et en particulier\nd'orienter le prochain Programme r\u00e9unionnais de\nnutrition et de lutte cont re le diab\u00e8te (PRND) 15,\ndont l'actualisation est pr\u00e9vue en 2024, et de pour -\nsuivre la mobilisation des acteurs locaux en mati\u00e8re\nde pr\u00e9vention, d'accompagnement, d'\u00e9ducation et de\nprise en charge des personnes ayant un diab\u00e8te. \u25a0\n(1) Sant\u00e9 publique France. Observatoire G\u00e9odes.\npubliquefrance.fr\n(2) Assurance Maladie. Data pathologies.", "mimetype": "text/plain", "start_char_idx": 4592, "end_char_idx": 5818, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "2c2aa199-5dfd-4805-9a0c-904b5adf877e": {"__data__": {"id_": "2c2aa199-5dfd-4805-9a0c-904b5adf877e", "embedding": null, "metadata": {"page_label": "439", "file_name": "2023_20-21_3.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2023_20-21_3.pdf", "file_type": "application/pdf", "file_size": 363018, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "a8560344-4639-4b3a-9a5c-08d39756a0a0", "node_type": "4", "metadata": {"page_label": "439", "file_name": "2023_20-21_3.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2023_20-21_3.pdf", "file_type": "application/pdf", "file_size": 363018, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "c1d253b5aafe13acb22b20ae0f1627a2a4d8006ecfd4400e86ee3421c6ab7b46", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "223ad521-10c2-4306-b342-4f41b723549d", "node_type": "1", "metadata": {}, "hash": "c3b030d470a32579f1a27c0591862cafdc6d124e584be2a49615a16a3d2bf12a", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Diab\u00e8te en outre-mer : comprendre les sp\u00e9cificit\u00e9s locales pour cibler les actions BEH 20-21 | 14 novembre 2023 | 439\nRemerciements\nLes auteurs remercient les \u00e9quipes Ipsos en charge du recueil\ndes donn\u00e9es et notamment les enqu\u00eateurs pour cette \u00e9dition\ndu Barom\u00e8tre de Sant\u00e9 publique France dans les DROM et les\nmembres du comit\u00e9 technique r\u00e9gional de l'observation de la\nth\u00e9matique \u00ab Nutrition-Ob\u00e9sit\u00e9-Diab\u00e8te \u00bb pour les \u00e9changes et\nr\u00e9flexions collectives, \u00c9tienne Billot et Dr Emmanuelle Rachou\npour leur relecture.\nLiens d'int\u00e9r\u00eat\nLes auteurs d\u00e9clarent n'avoir aucun lien d'int\u00e9r\u00eat au regard du\ncontenu de l'article.\nR\u00e9f\u00e9rences\n[1] International Diabetes Federation. IDF Diabetes Atlas 2021\n10th edition. Brussels: International Diabetes Federation; 2021.\n\n[2] Ogurtsova K, Guariguata L, Barengo NC, Ruiz PL, Sacre JW,\nKaruranga S, et al. IDF diabetes Atlas: Global estimates of\nundiagnosed diabetes in adults for 2021. Diabetes Res Clin\nPract. 2022;183:109118.\n[3] F\u00e9d\u00e9ration fran\u00e7aise des diab\u00e9tiques. Facteurs de risque du\ndiab\u00e8te. Paris: F\u00e9d\u00e9ration fran\u00e7aise des diab\u00e9tiques. https://\nwww.federationdesdiabetiques.org/information/risques\n[4] Sant\u00e9 publique France. Le diab\u00e8te en France : les chif -\nfres 2020. Saint-Maurice: Sant\u00e9 publique France; 2021. https://\nwww.santepubliquefrance.fr/les-actualites/2021/le-diabeteen-france-les-chiffres-2020\n[5] Fosse-Edorh S, Mandereau-Bruno L, Piffaretti C. Le poids\ndu diab\u00e8te en France en 2016. Synth\u00e8se \u00e9pid\u00e9miologique.\nSaint-Maurice: Sant\u00e9 publique France; 2018. 8 p.\nsantepubliquefrance.fr/maladies-et-traumatismes/diabete/\ndocuments/rapport-synthese/le-poids-du-diabete-enfrance-en-2016.-synthese-epidemiologique\n[6] Mandereau-Bruno L, Fosse-Edorh S. Pr\u00e9valence du diab\u00e8te\ntrait\u00e9 pharmacologiquement (tous types) en France en 2015.\nDisparit\u00e9s territoriales et socio-\u00e9conomiques. Bull \u00c9pid\u00e9miol\nHebd.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1854, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "223ad521-10c2-4306-b342-4f41b723549d": {"__data__": {"id_": "223ad521-10c2-4306-b342-4f41b723549d", "embedding": null, "metadata": {"page_label": "439", "file_name": "2023_20-21_3.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2023_20-21_3.pdf", "file_type": "application/pdf", "file_size": 363018, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "a8560344-4639-4b3a-9a5c-08d39756a0a0", "node_type": "4", "metadata": {"page_label": "439", "file_name": "2023_20-21_3.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2023_20-21_3.pdf", "file_type": "application/pdf", "file_size": 363018, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "c1d253b5aafe13acb22b20ae0f1627a2a4d8006ecfd4400e86ee3421c6ab7b46", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2c2aa199-5dfd-4805-9a0c-904b5adf877e", "node_type": "1", "metadata": {"page_label": "439", "file_name": "2023_20-21_3.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2023_20-21_3.pdf", "file_type": "application/pdf", "file_size": 363018, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "c94cfef76144fb7bb94beeb70fdc822d6e198e5fb3389b506cf92e435ec373d3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "27f37863-7f4b-40b9-92f2-11c05bae0f20", "node_type": "1", "metadata": {}, "hash": "ec2cb6c3347848f55aba2fc488948e8ad4fd609442239b8af40068c1f92c6cc0", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Disparit\u00e9s territoriales et socio-\u00e9conomiques. Bull \u00c9pid\u00e9miol\nHebd. 2017;(27-28):586-91.\nbeh/2017/27-28/2017_27-28_3.html\n[7] Leduc A, Deroyon T, Rochereau T, Renaud A. Premiers\nr\u00e9sultats de l'enqu\u00eate sant\u00e9 europ\u00e9enne (EHIS) 2019 - M\u00e9tro -\npole, Guadeloupe, Martinique, Guyane, La R\u00e9union, Mayotte.\nLes Dossiers de la Drees. 2021;(78):1-89.\nsolidarites-sante.gouv.fr/publications/les-dossiers-de-ladrees/premiers-resultats-de-lenquete-sante-europeenneehis-2019-metrople-guadeloupe-martinique-guyane-lar%C3%A9union-mayotte\n[8] Ricquebourg M. Observation de la th\u00e9matique \u00ab Nutrition -\nOb\u00e9sit\u00e9 - Diab\u00e8te \u00bb \u00e0 La R\u00e9union. Tableau de bord. Saint-Denis:\nObservatoire r\u00e9gional de la sant\u00e9 La R\u00e9union; 2022. https://\nwww.ors-reunion.fr/tableau-de-bord-nutrition-obesite-dia\nbete-2022.html\n[9] Chan Wan GN, Chopinet-Dijoux S, Ricquebourg M,\nSimonpieri JM. Parcours de soins des patients diab\u00e9tiques\n\u00e0 La R\u00e9union - \u00c9tude longitudinale des parcours des patients\nmis sous traitement antidiab\u00e9tique en 2010. Synth\u00e8se des\nprincipaux r\u00e9sultats. Assurance Maladie La R\u00e9union, Agence\nr\u00e9gionale de sant\u00e9 La R\u00e9union, Observatoire r\u00e9gional de\nsant\u00e9 Oc\u00e9an Indien; 2020. 38 p.\nparcours-de-soins-des-patients-diabetiques-a-la-reunionetude-longitudinale-des.html\n[10] Guibert G, Balicchi J. Diab\u00e8te nutrition. Barom\u00e8tre Sant\u00e9\nDOM La R\u00e9union 2014. Nutrition, statut pond\u00e9ral et diab\u00e8te\n\u00e0 La R\u00e9union. In Extenso. 2015;(4):1-20.\nars.sante.fr/etude-sur-le-diabete-et-la-nutrition-la-reunionbarometre-sante-dom-la-reunion-2014\n[11] Grand\u00e9 C. Pas assez de fruits et l\u00e9gumes, trop d'huile,\nde sucre et de boissons sucr\u00e9es. Habitudes alimentaires des\nr\u00e9unionnais en 2017. Insee Analyses R\u00e9union. 2021;(57):1-4.\n\n[12] Brasset M, Levet L, Stein F. Les comportements alimen -\ntaires des R\u00e9unionnais - Un exc\u00e8s d'huile et de riz, un d\u00e9ficit\nde fruits et l\u00e9gumes. Insee Analyses R\u00e9union. 2015;(12):1-4.\n\n[13] Agence r\u00e9gionale de sant\u00e9 Oc\u00e9an Indien.", "mimetype": "text/plain", "start_char_idx": 1787, "end_char_idx": 3698, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "27f37863-7f4b-40b9-92f2-11c05bae0f20": {"__data__": {"id_": "27f37863-7f4b-40b9-92f2-11c05bae0f20", "embedding": null, "metadata": {"page_label": "439", "file_name": "2023_20-21_3.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2023_20-21_3.pdf", "file_type": "application/pdf", "file_size": 363018, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "a8560344-4639-4b3a-9a5c-08d39756a0a0", "node_type": "4", "metadata": {"page_label": "439", "file_name": "2023_20-21_3.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2023_20-21_3.pdf", "file_type": "application/pdf", "file_size": 363018, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "c1d253b5aafe13acb22b20ae0f1627a2a4d8006ecfd4400e86ee3421c6ab7b46", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "223ad521-10c2-4306-b342-4f41b723549d", "node_type": "1", "metadata": {"page_label": "439", "file_name": "2023_20-21_3.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2023_20-21_3.pdf", "file_type": "application/pdf", "file_size": 363018, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "33cfb7c85b3cc332c7f914cbf38a2a50660a013df7cbec49bc35c47d8ef98bcc", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "db23e0d0-77f2-4d09-8e4c-af0604e67fce", "node_type": "1", "metadata": {}, "hash": "123056d43d7b79584899cdb0548f686e92e2cfb052771c61eaffc21db9df34d3", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "2021;(57):1-4.\n\n[12] Brasset M, Levet L, Stein F. Les comportements alimen -\ntaires des R\u00e9unionnais - Un exc\u00e8s d'huile et de riz, un d\u00e9ficit\nde fruits et l\u00e9gumes. Insee Analyses R\u00e9union. 2015;(12):1-4.\n\n[13] Agence r\u00e9gionale de sant\u00e9 Oc\u00e9an Indien. Projet de Sant\u00e9\n(PRS) Oc\u00e9an Indien 2018-2028. Saint-Denis: ARS-OI; 2018.\n\n[14] Agence r\u00e9gionale de sant\u00e9 Oc\u00e9an Indien. Projet de Sant\u00e9\nR\u00e9union-Mayotte. Cadre d'Orientations Strat\u00e9giques 20182028. Saint-Denis: ARS-OI; 2018.\nsante.fr/cadre-dorientations-strategiques-2018-2028-1\n[15] Agence r\u00e9gionale de sant\u00e9 La R\u00e9union. Programme r\u00e9u -\nnionnais de nutrition et de lutte contre le diab\u00e8te (PRND) 20202023. Saint-Denis: ARS La R\u00e9union; 2020.\nnion.ars.sante.fr/le-programme-reunionnais-de-nutrition-etde-lutte-contre-le-diabete-prnd-2020-2023-0\n[16] Soullier N, Richard JB, Gautier A. Barom\u00e8tre de Sant\u00e9\npublique France 2021. M\u00e9thode. Saint-Maurice: Sant\u00e9 publique\nFrance; 2022. 17 p.\nbarometre-de-sante-publique-france-2021.-methode\n[17] Lenclume V, Favier F. Cohorte R\u00c9DIA2 : Suivi des parti -\ncipants de l'enqu\u00eate R\u00c9DIA sur le diab\u00e8te de type 2 \u00e0 La R\u00e9union.\nR\u00e9sultats sur donn\u00e9es transversales (2006-2009) et longitu -\ndinales (1999-2009). Centre d'investigation clinique et d'\u00e9pi -\nd\u00e9miologie clinique de La R\u00e9union; 2014. 240 p.\nsantepubliquefrance.fr/maladies-et-traumatismes/diabete/\narticles/donnees-epidemiologiques-sur-le-diabete-en-regions\n[18] Fosse-Edorh S, Lavalette C, Piffaretti C, Saboni L,\nBessonneau P, Mandereau-Bruno L, et al. Caract\u00e9ristiques,\n\u00e9tat de sant\u00e9 et recours aux soins des personnes pr\u00e9sen -\ntant un diab\u00e8te de type 2 r\u00e9sidant en Outre-mer : r\u00e9sultats de\nl'\u00e9tude Entred 3. Bull \u00c9pid\u00e9miol Hebd. 2023;(20-21); 412-23\n\n20-21_1.html\n[19] Observatoire r\u00e9gional de la sant\u00e9 La R\u00e9union. Le diab\u00e8te\net les personnes diab\u00e9tiques \u00e0 La R\u00e9union. 14 indicateurs\ncl\u00e9s.", "mimetype": "text/plain", "start_char_idx": 3451, "end_char_idx": 5283, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "db23e0d0-77f2-4d09-8e4c-af0604e67fce": {"__data__": {"id_": "db23e0d0-77f2-4d09-8e4c-af0604e67fce", "embedding": null, "metadata": {"page_label": "439", "file_name": "2023_20-21_3.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2023_20-21_3.pdf", "file_type": "application/pdf", "file_size": 363018, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "a8560344-4639-4b3a-9a5c-08d39756a0a0", "node_type": "4", "metadata": {"page_label": "439", "file_name": "2023_20-21_3.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2023_20-21_3.pdf", "file_type": "application/pdf", "file_size": 363018, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "c1d253b5aafe13acb22b20ae0f1627a2a4d8006ecfd4400e86ee3421c6ab7b46", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "27f37863-7f4b-40b9-92f2-11c05bae0f20", "node_type": "1", "metadata": {"page_label": "439", "file_name": "2023_20-21_3.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\2023_20-21_3.pdf", "file_type": "application/pdf", "file_size": 363018, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "95e6021d2c779cdf6582397fa871a9bb7bbbb08bdc42317f50b587381875ce49", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Bull \u00c9pid\u00e9miol Hebd. 2023;(20-21); 412-23\n\n20-21_1.html\n[19] Observatoire r\u00e9gional de la sant\u00e9 La R\u00e9union. Le diab\u00e8te\net les personnes diab\u00e9tiques \u00e0 La R\u00e9union. 14 indicateurs\ncl\u00e9s. Saint-Denis: ORS La R\u00e9union; 2022. 4 p.\nors-reunion.fr/le-diabete-et-les-personnes-diabetiques-a-lareunion-2022.html\n[20] Boulevart P. Recours aux soins \u00e0 La R\u00e9union. In Extenso.\n2016;(5):1-13.\ndefault/files/2017-01/ARS_InExtenso_Soins_n5_16sept_BD.PDF\n[21] Hernandez H, Piffaretti C, Gautier A, Cosson E, FosseEdorh S. Pr\u00e9valence du diab\u00e8te connu dans 4 d\u00e9partements\net r\u00e9gions d'outre-mer : Guadeloupe, Martinique, Guyane et\nLa R\u00e9union. R\u00e9sultats du Barom\u00e8tre de Sant\u00e9 publique France\nde 2021. Bull \u00c9pid\u00e9miol Hebd. 2023;(20-21):424-31.\nsantepubliquefrance.fr/beh/2023/20-21/2023_20-21_2.html\n[22] Balcou-Debussche M. Approche socio-anthropologique de\nla litt\u00e9ratie en sant\u00e9 des personnes atteintes de diab\u00e8te de type 2\n\u00e0 La R\u00e9union. Bull \u00c9pid\u00e9miol Hebd. 2023;(20-21):440-6. http://\nbeh.santepubliquefrance.fr/beh/2023/21-22/2023_20-21_4.html\n[23] Dougin H. \u00c9tudes qualitatives sur le diab\u00e8te de type 2\nmen\u00e9es \u00e0 La R\u00e9union depuis 1998. R\u00e9sum\u00e9s des principales\n\u00e9tudes - Synth\u00e8se g\u00e9n\u00e9rale - Discussion. Saint-Denis: ORS OI;\n2018. 70 p.\nCiter cet article\nRicquebourg M, Kwan C, M\u00e9devielle S, Chopinet-Dijoux S,\nCaliez F, Thouillot F, et al . Pr\u00e9valence du diab\u00e8te connu \u00e0\nLa R\u00e9union, prises en charge et caract\u00e9ristiques des per -\nsonnes atteintes d 'un diab\u00e8te : exploitation des donn\u00e9es\ndu Baro m\u00e8tre de Sant\u00e9 publique France DROM de 2021 . Bull\n\u00c9pid\u00e9miol Hebd. 2023;(20-21): 431-9. -\nquefrance.fr/beh/2023/20-21/2023_20-21_3.html", "mimetype": "text/plain", "start_char_idx": 5102, "end_char_idx": 6714, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "dd58ddbb-c997-469a-8d07-741134cc24b3": {"__data__": {"id_": "dd58ddbb-c997-469a-8d07-741134cc24b3", "embedding": null, "metadata": {"page_label": "1", "file_name": "22120_8734-d3167.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\22120_8734-d3167.pdf", "file_type": "application/pdf", "file_size": 56665, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "9a974675-1543-485b-8a0e-453a07de9de0", "node_type": "4", "metadata": {"page_label": "1", "file_name": "22120_8734-d3167.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\22120_8734-d3167.pdf", "file_type": "application/pdf", "file_size": 56665, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "06a99abd1f5db65ccd317b41ee8ad1cd31a0a3f59a4ab42e908a476b25875ae3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ab83a312-1db2-4733-a18f-92637dc6f2c6", "node_type": "1", "metadata": {}, "hash": "3aac592075ebe897a7af3f02221f10c61ebcbf75f431a19cb949295b85ceedd9", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "86 BEH n\u00b0 20-21/2002\nINTRODUCTION\nLe diab\u00e8te est consid\u00e9r\u00e9 depuis quelques ann\u00e9es comme un probl\u00e8me majeur de sant\u00e9 publique\net le terme d'\u00e9pid\u00e9mie est de plus en plus souvent appliqu\u00e9 au diab\u00e8te de type 2 (anciennement\nd\u00e9nomm\u00e9 diab\u00e8te non insulino-d\u00e9pendant ou diab\u00e8te de la maturit\u00e9) qui repr\u00e9sente environ\n90 % de l'ensemble des diab\u00e8tes sucr\u00e9s. Nous rapportons ici quelques donn\u00e9es \u00e9pid\u00e9miologiques concernant le diab\u00e8te de type 2 pour discuter de la r\u00e9alit\u00e9 de l'\u00e9pid\u00e9mie annonc\u00e9e.\nEn pr\u00e9ambule, il convient de souligner les grandes difficult\u00e9s rencontr\u00e9es pour estimer la pr\u00e9valence du diab\u00e8te de type 2 dans une population. En effet, l'absence habituelle de sympt\u00f4mes\ncliniques dans le diab\u00e8te de type 2 impose de mesurer syst\u00e9matiquement la glyc\u00e9mie sur un\n\u00e9chantillon repr\u00e9sentatif pour conna\u00eetre cette pr\u00e9valence. Depuis 1999, les crit\u00e8res diagnostiques\ndu diab\u00e8te ont \u00e9t\u00e9 modifi\u00e9s par l'OMS. Le changement a consist\u00e9 \u00e0 abaisser le seuil de la glyc\u00e9mie \u00e0 jeun d\u00e9finissant le diab\u00e8te pour le placer \u00e0 un niveau \u2265 1,26 g/l (7,0 mmol/l) au lieu de \u2265\n1,40 g/l (7,8 mmol/l) auparavant, mais l'\u00e9preuve d'hyperglyc\u00e9mie provoqu\u00e9e par voie orale\n(HGPO) a \u00e9t\u00e9 maintenue malgr\u00e9 les pressions de l'American Diabetes Association qui souhaitait\nla supprimer pour d\u00e9finir le diab\u00e8te uniquement par le taux de glyc\u00e9mie \u00e0 jeun. Pour r\u00e9pondre\naux crit\u00e8res de d\u00e9finition du diab\u00e8te, il est donc le plus souvent n\u00e9cessaire de recourir \u00e0 l'HGPO\navec mesure de la glyc\u00e9mie deux heures apr\u00e8s absorption de 75 grammes de glucose, ce qui est\nlourd et co\u00fbteux \u00e0 r\u00e9aliser \u00e0 grande \u00e9chelle. En cons\u00e9quence, il est extr\u00eamement difficile de\nr\u00e9pondre avec assurance \u00e0 la question pos\u00e9e sur la r\u00e9alit\u00e9 de l'\u00e9pid\u00e9mie du diab\u00e8te de type 2. De\nplus, le changement r\u00e9cent des crit\u00e8res diagnostiques du diab\u00e8te complique encore un peu plus\nla t\u00e2che pour \u00e9tablir des comparaisons dans le temps. Malgr\u00e9 tout, pour fournir un d\u00e9but de\nr\u00e9ponse, nous allons reprendre ici les pr\u00e9visions de l'OMS et pr\u00e9senter les donn\u00e9es r\u00e9cemment\ncollect\u00e9es par la Caisse nationale d'assurance maladie des travailleurs salari\u00e9s (Cnamts) dans\nnotre pays.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2105, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "ab83a312-1db2-4733-a18f-92637dc6f2c6": {"__data__": {"id_": "ab83a312-1db2-4733-a18f-92637dc6f2c6", "embedding": null, "metadata": {"page_label": "1", "file_name": "22120_8734-d3167.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\22120_8734-d3167.pdf", "file_type": "application/pdf", "file_size": 56665, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "9a974675-1543-485b-8a0e-453a07de9de0", "node_type": "4", "metadata": {"page_label": "1", "file_name": "22120_8734-d3167.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\22120_8734-d3167.pdf", "file_type": "application/pdf", "file_size": 56665, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "06a99abd1f5db65ccd317b41ee8ad1cd31a0a3f59a4ab42e908a476b25875ae3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "dd58ddbb-c997-469a-8d07-741134cc24b3", "node_type": "1", "metadata": {"page_label": "1", "file_name": "22120_8734-d3167.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\22120_8734-d3167.pdf", "file_type": "application/pdf", "file_size": 56665, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "ace060457e3f5f8360b4fe280dacfe3c4ef2917adef7f88a0c9473292688d929", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "aeb221d4-a5fb-4ec2-9edc-d8c36dc7da38", "node_type": "1", "metadata": {}, "hash": "ab4bb13e07d70b1a4a982006c155de04626fb60c23fd19ceaadcee699a4cc031", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Malgr\u00e9 tout, pour fournir un d\u00e9but de\nr\u00e9ponse, nous allons reprendre ici les pr\u00e9visions de l'OMS et pr\u00e9senter les donn\u00e9es r\u00e9cemment\ncollect\u00e9es par la Caisse nationale d'assurance maladie des travailleurs salari\u00e9s (Cnamts) dans\nnotre pays.\nLES DONN\u00c9ES INTERNATIONALES\nA partir d'une pr\u00e9valence mondiale du diab\u00e8te chez l'adulte ( \u2265 20 ans) de 4,0 % en 1995, l'OMS\npr\u00e9voit une augmentation \u00e0 5,4 % en 2025 [1], sensiblement identique dans les pays industrialis\u00e9s\net dans les pays en voie de d\u00e9veloppement (figure 1). Le diab\u00e8te de type 2 repr\u00e9sente la quasitotalit\u00e9 du diab\u00e8te de l'adulte \u00e0 l'\u00e9chelle plan\u00e9taire. Cette augmentation de 35 % en 30 ans ne\nsemble pas \u00e9norme \u00e0 premi\u00e8re vue. Pourtant, traduite en nombre de diab\u00e9tiques, le chiffre doit\npasser de 135 \u00e0 300 millions entre 1995 et 2025 (figure 2). La pr\u00e9valence est plus \u00e9lev\u00e9e actuellement dans les pays industrialis\u00e9s et elle le restera (figure 1), mais l'accroissement du nombre des\ndiab\u00e9tiques proviendra surtout des pays en d\u00e9veloppement o\u00f9 une augmentation de 171 % est\npr\u00e9vue, de 84 \u00e0 228 millions, alors que les pays industrialis\u00e9s doivent conna\u00eetre une augmentation\nde 41 % seulement, de 51 \u00e0 72 millions (figure 2). Ce contraste dans l'\u00e9volution du diab\u00e8te de type\n2 entre pr\u00e9valence et nombre de patients tient \u00e0 l'effet de la taille des populations dans les pays\nen d\u00e9veloppement. Ainsi, en 2025, plus de 75 % des diab\u00e9tiques de la plan\u00e8te r\u00e9sideront dans les\npays en d\u00e9veloppement, contre 62 % en 1995. Les pays ayant le plus de diab\u00e9tiques sont d\u00e9j\u00e0\naujourd'hui, et seront encore en 2025, dans le m\u00eame ordre : l'Inde, la Chine et les USA. Dans les\npays en d\u00e9veloppement, la plupart des diab\u00e9tiques sont \u00e2g\u00e9s de 45 \u00e0 64 ans alors que dans les\npays d\u00e9velopp\u00e9s, la majorit\u00e9 des diab\u00e9tiques a plus de 65 ans et cette tendance va s'accentuer.\nEnfin, on pr\u00e9voit que le diab\u00e8te va \u00eatre de plus en plus concentr\u00e9 dans les zones urbaines.\nLES DONN\u00c9ES FRAN\u00c7AISES\nEn France, nos connaissances sur la pr\u00e9valence du diab\u00e8te de type 2 ont progress\u00e9 r\u00e9cemment\ngr\u00e2ce aux enqu\u00eates r\u00e9alis\u00e9es par la Cnamts depuis 1998 (2, 3). La m\u00e9thodologie utilis\u00e9e par la\nCnamts repose sur les remboursements de traitements antidiab\u00e9tiques (antidiab\u00e9tiques oraux et\ninsuline) aux assur\u00e9s.", "mimetype": "text/plain", "start_char_idx": 1867, "end_char_idx": 4095, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "aeb221d4-a5fb-4ec2-9edc-d8c36dc7da38": {"__data__": {"id_": "aeb221d4-a5fb-4ec2-9edc-d8c36dc7da38", "embedding": null, "metadata": {"page_label": "1", "file_name": "22120_8734-d3167.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\22120_8734-d3167.pdf", "file_type": "application/pdf", "file_size": 56665, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "9a974675-1543-485b-8a0e-453a07de9de0", "node_type": "4", "metadata": {"page_label": "1", "file_name": "22120_8734-d3167.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\22120_8734-d3167.pdf", "file_type": "application/pdf", "file_size": 56665, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "06a99abd1f5db65ccd317b41ee8ad1cd31a0a3f59a4ab42e908a476b25875ae3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ab83a312-1db2-4733-a18f-92637dc6f2c6", "node_type": "1", "metadata": {"page_label": "1", "file_name": "22120_8734-d3167.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\22120_8734-d3167.pdf", "file_type": "application/pdf", "file_size": 56665, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "22eaad051f7987e3d1db2d109466d246af72d891be278bc6ba6d22e751bb9017", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f0add988-49a7-450f-8772-912fd1c5da1f", "node_type": "1", "metadata": {}, "hash": "46b9edb7d18c348707253d1a3c5fadae556f5151295f329714dfd205f973f618", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "La m\u00e9thodologie utilis\u00e9e par la\nCnamts repose sur les remboursements de traitements antidiab\u00e9tiques (antidiab\u00e9tiques oraux et\ninsuline) aux assur\u00e9s. Pour \u00e9valuer le nombre des diab\u00e9tiques de type 2, il faut par cons\u00e9quent\ncorriger le chiffre de pr\u00e9valence du diab\u00e8te trait\u00e9 pharmacologiquement (3,06 %) pour tenir\ncompte des diab\u00e9tiques trait\u00e9s par r\u00e9gime seul et d\u00e9duire les diab\u00e9tiques de type 1. Il faut aussi\ntenir compte des diab\u00e9tiques non diagnostiqu\u00e9s dont le nombre ne peut \u00eatre estim\u00e9 pr\u00e9cis\u00e9ment\naujourd'hui. C'est donc avec un certain degr\u00e9 d'impr\u00e9cision qu'on peut consid\u00e9rer aujourd'hui\nque le diab\u00e8te de type 2 touche pr\u00e8s de 2 000 000 de personnes en France. Sa fr\u00e9quence semble\nen forte croissance dans notre pays puisqu'en 1992 la pr\u00e9valence du diab\u00e8te de type 2 trait\u00e9 pharmacologiquement \u00e9tait estim\u00e9e \u00e0 un peu moins de 1,5 % d'apr\u00e8s une enqu\u00eate de l'INSEE sur la\nsant\u00e9 et les soins m\u00e9dicaux des Fran\u00e7ais, r\u00e9alis\u00e9e sur un \u00e9chantillon repr\u00e9sentatif de la population. Malgr\u00e9 les pr\u00e9cautions prises, sans doute la pr\u00e9valence du diab\u00e8te de type 2 \u00e9tait-elle alors\nsous-estim\u00e9e car il s'agissait de donn\u00e9es d\u00e9claratives. Il est donc vraisemblable que la pr\u00e9valence du diab\u00e8te de type 2 n'a pas vraiment doubl\u00e9 entre 1992 et 1998 et que le terme d'\u00e9pid\u00e9mie n'est pas adapt\u00e9 \u00e0 notre pays mais il para\u00eet toutefois certain que la pr\u00e9valence du diab\u00e8te de\ntype 2 a franchement augment\u00e9 r\u00e9cemment en France [4].\nLE FACTEUR \u00c2GE\nLe vieillissement des populations constitue le principal facteur d'explication de la croissance attendue du diab\u00e8te de type 2. Le vieillissement constitue en effet un important facteur de risque de diab\u00e8te de type 2 du fait \u00e0 la fois d'une augmentation de la r\u00e9sistance \u00e0 l'insuline et d'une r\u00e9duction\nde la s\u00e9cr\u00e9tion d'insuline. Or, en France, les plus de 65 ans repr\u00e9sentaient 11,4 % de la population\nen 1950. Ils sont aujourd'hui 16 %. Selon les projections de l'Insee, la proportion des plus de 65 ans\ndevrait atteindre pr\u00e8s du tiers de la population (29,2 %) en 2050. En France, l'esp\u00e9rance de vie \u00e0 la\nnaissance s'\u00e9levait en 2000 \u00e0 75,2 ans pour les hommes et \u00e0 82,7 ans pour les femmes. Chaque\nann\u00e9e, l'esp\u00e9rance de vie s'allonge d'environ trois mois pour chaque sexe.", "mimetype": "text/plain", "start_char_idx": 3947, "end_char_idx": 6158, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "f0add988-49a7-450f-8772-912fd1c5da1f": {"__data__": {"id_": "f0add988-49a7-450f-8772-912fd1c5da1f", "embedding": null, "metadata": {"page_label": "1", "file_name": "22120_8734-d3167.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\22120_8734-d3167.pdf", "file_type": "application/pdf", "file_size": 56665, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "9a974675-1543-485b-8a0e-453a07de9de0", "node_type": "4", "metadata": {"page_label": "1", "file_name": "22120_8734-d3167.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\22120_8734-d3167.pdf", "file_type": "application/pdf", "file_size": 56665, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "06a99abd1f5db65ccd317b41ee8ad1cd31a0a3f59a4ab42e908a476b25875ae3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "aeb221d4-a5fb-4ec2-9edc-d8c36dc7da38", "node_type": "1", "metadata": {"page_label": "1", "file_name": "22120_8734-d3167.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\22120_8734-d3167.pdf", "file_type": "application/pdf", "file_size": 56665, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "0bcc20187a9a05f54d59c68a1a279b3a014bcd78796083c4b1fbdfeee56c7bf5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3b29380d-428c-45d3-b3f6-e628bb124031", "node_type": "1", "metadata": {}, "hash": "38a2d19541d6992a587879762a5b02ade57a2ab44094ee30e8b115eeac47b231", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "En France, l'esp\u00e9rance de vie \u00e0 la\nnaissance s'\u00e9levait en 2000 \u00e0 75,2 ans pour les hommes et \u00e0 82,7 ans pour les femmes. Chaque\nann\u00e9e, l'esp\u00e9rance de vie s'allonge d'environ trois mois pour chaque sexe. Ainsi, en 2035, le gain\ndevrait \u00eatre de pr\u00e8s de sept ans et les esp\u00e9rances de vie devraient atteindre respectivement\n81,9 ans et 89 ans. Ces modifications d\u00e9mographiques jointes \u00e0 l'am\u00e9lioration de la qualit\u00e9 des\nsoins d\u00e9livr\u00e9s aux diab\u00e9tiques ont d\u00e9j\u00e0 amen\u00e9 un glissement du pic maximal de pr\u00e9valence du\ndiab\u00e8te vers des tranches d'\u00e2ge plus \u00e9lev\u00e9es. Ainsi, au d\u00e9but des ann\u00e9es 1990, c'est dans la\ntranche des 65-75 ans qu'on observait la plus grande fr\u00e9quence de diab\u00e8te (8,6 %) alors que dans\nl'enqu\u00eate de la CNAMTS en 1998, le pic \u00e9tait relev\u00e9 chez les 75-80 ans o\u00f9 il atteignait 14 %.\nLES FACTEURS DE RISQUE LI\u00c9S \u00c0 L'ENVIRONNEMENT\nA c\u00f4t\u00e9 de ce facteur \u00e2ge sur lequel il est \u00e9videmment impossible d'intervenir, il existe des facteurs de risque li\u00e9s \u00e0 l'environnement et au comportement, bien mis en \u00e9vidence par les \u00e9tudes\nde migrants. Ils pourraient se pr\u00eater \u00e0 des interventions permettant de r\u00e9aliser une pr\u00e9vention du\ndiab\u00e8te de type 2. L'ob\u00e9sit\u00e9 de r\u00e9partition abdominale pr\u00e9dominante (objectiv\u00e9e par la mesure\ndu tour de taille ou le rapport tour de taille/tour de hanches), est reconnue comme un important\nfacteur de risque des maladies m\u00e9taboliques et cardiovasculaires depuis les travaux de Jean\nVague dans les ann\u00e9es 1950. Ceci s'explique par l'afflux majeur des acides gras libres dans la\nveine porte en cas d'ob\u00e9sit\u00e9 abdominale, entra\u00eenant hyperinsulin\u00e9mie, insulino-r\u00e9sistance, anomalies de la tol\u00e9rance au glucose pouvant aller jusqu'au diab\u00e8te de type 2, augmentation des\nVLDL triglyc\u00e9rides et baisse du HDL-cholest\u00e9rol. Toutes ces anomalies m\u00e9taboliques auxquelles\ns'ajoute souvent l'hypertension art\u00e9rielle semblent s'articuler autour du ph\u00e9nom\u00e8ne d'insulinor\u00e9sistance, popularis\u00e9 sous le terme de syndrome X ou syndrome m\u00e9tabolique.\nLES ATTITUDES COMPORTEMENTALES\nLes modifications r\u00e9centes des attitudes comportementales (activit\u00e9 physique et alimentation)\nont largement contribu\u00e9 \u00e0 l'augmentation de l'ob\u00e9sit\u00e9 \u00e0 travers le monde, m\u00eame si la France est\nrest\u00e9e relativement \u00e9pargn\u00e9e au moins jusqu'\u00e0 une p\u00e9riode r\u00e9cente [5].", "mimetype": "text/plain", "start_char_idx": 5956, "end_char_idx": 8204, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "3b29380d-428c-45d3-b3f6-e628bb124031": {"__data__": {"id_": "3b29380d-428c-45d3-b3f6-e628bb124031", "embedding": null, "metadata": {"page_label": "1", "file_name": "22120_8734-d3167.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\22120_8734-d3167.pdf", "file_type": "application/pdf", "file_size": 56665, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "9a974675-1543-485b-8a0e-453a07de9de0", "node_type": "4", "metadata": {"page_label": "1", "file_name": "22120_8734-d3167.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\22120_8734-d3167.pdf", "file_type": "application/pdf", "file_size": 56665, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "06a99abd1f5db65ccd317b41ee8ad1cd31a0a3f59a4ab42e908a476b25875ae3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f0add988-49a7-450f-8772-912fd1c5da1f", "node_type": "1", "metadata": {"page_label": "1", "file_name": "22120_8734-d3167.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\22120_8734-d3167.pdf", "file_type": "application/pdf", "file_size": 56665, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "70e34235a269c4a70cf82314a2944250816b03dc0a3dd735773c08cf95d562b7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c46794f3-3704-4014-9924-7ad785e306e0", "node_type": "1", "metadata": {}, "hash": "ab2fb337fdc431b1b2d986f0168dc6cb1eab52c9d584e50de0d8ab36bb11c81a", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "LES ATTITUDES COMPORTEMENTALES\nLes modifications r\u00e9centes des attitudes comportementales (activit\u00e9 physique et alimentation)\nont largement contribu\u00e9 \u00e0 l'augmentation de l'ob\u00e9sit\u00e9 \u00e0 travers le monde, m\u00eame si la France est\nrest\u00e9e relativement \u00e9pargn\u00e9e au moins jusqu'\u00e0 une p\u00e9riode r\u00e9cente [5]. En effet, presque partout,\nles habitudes alimentaires ont r\u00e9cemment chang\u00e9 (augmentation des apports caloriques et de la\nconsommation d'alcool, accroissement de la consommation de graisses, surtout satur\u00e9es, r\u00e9duction de la consommation de fibres). Dans le m\u00eame temps, l'activit\u00e9 physique a \u00e9t\u00e9 r\u00e9duite. La\nconjonction de ces deux ph\u00e9nom\u00e8nes a \u00e9t\u00e9 particuli\u00e8rement nette au niveau des populations\nayant migr\u00e9 depuis les zones rurales vers les grandes cit\u00e9s. Dans tous les pays on retrouve une\npr\u00e9valence du diab\u00e8te de type 2 beaucoup plus forte \u00e0 la ville qu'\u00e0 la campagne, indiquant le r\u00f4le\nde l'activit\u00e9 physique et de l'alimentation, ainsi que, peut-\u00eatre, du stress de la vie moderne, dans\nla survenue du diab\u00e8te de type 2. Par ailleurs, des facteurs g\u00e9n\u00e9tiques modulent l'influence de\nces modifications du mode de vie, entra\u00eenant des cons\u00e9quences m\u00e9taboliques variables d'un\ngroupe ethnique \u00e0 l'autre, mais le r\u00f4le des facteurs d'environnement semble pr\u00e9dominant par\nrapport \u00e0 l'influence g\u00e9n\u00e9tique dans le risque de diab\u00e8te de type 2.\nCONCLUSION\nEn conclusion, m\u00eame si les donn\u00e9es \u00e9pid\u00e9miologiques demandent \u00e0 \u00eatre un peu mieux pr\u00e9cis\u00e9es\ndans un certain nombre de pays, la croissance du diab\u00e8te de type 2 dans le monde appara\u00eet tr\u00e8s\npr\u00e9occupante aujourd'hui du fait des graves complications que le diab\u00e8te peut entra\u00eener, sources\nde morbi-mortalit\u00e9 importante et de lourdes d\u00e9penses de sant\u00e9. Pour \u00e9viter que les pr\u00e9visions\npessimistes ne se r\u00e9alisent, il faut promouvoir d\u00e8s \u00e0 pr\u00e9sent des campagnes visant \u00e0 obtenir des\nmodifications comportementales des populations. Leur efficacit\u00e9 pour pr\u00e9venir le diab\u00e8te de type\n2 a \u00e9t\u00e9 d\u00e9montr\u00e9e [6] et elles devraient r\u00e9duire dans le m\u00eame temps la morbidit\u00e9 et la mortalit\u00e9\ncardiovasculaires. Des outils pharmacologiques pourraient \u00e9galement contribuer \u00e0 freiner la\ncroissance inqui\u00e9tante du diab\u00e8te de type 2 [6].\nR\u00c9F\u00c9RENCES\n[1] King H, Aubert RE, Herman WH. Global burden of diabetes, 1995-2025. Prevalence, numerical estimates, and\nprojections.", "mimetype": "text/plain", "start_char_idx": 7913, "end_char_idx": 10198, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "c46794f3-3704-4014-9924-7ad785e306e0": {"__data__": {"id_": "c46794f3-3704-4014-9924-7ad785e306e0", "embedding": null, "metadata": {"page_label": "1", "file_name": "22120_8734-d3167.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\22120_8734-d3167.pdf", "file_type": "application/pdf", "file_size": 56665, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "9a974675-1543-485b-8a0e-453a07de9de0", "node_type": "4", "metadata": {"page_label": "1", "file_name": "22120_8734-d3167.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\22120_8734-d3167.pdf", "file_type": "application/pdf", "file_size": 56665, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "06a99abd1f5db65ccd317b41ee8ad1cd31a0a3f59a4ab42e908a476b25875ae3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3b29380d-428c-45d3-b3f6-e628bb124031", "node_type": "1", "metadata": {"page_label": "1", "file_name": "22120_8734-d3167.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\22120_8734-d3167.pdf", "file_type": "application/pdf", "file_size": 56665, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "f808e4a6824c30e1684d5e9af7c0007b68cdeeacdf72f29cc1cd2b4e3105d20a", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Des outils pharmacologiques pourraient \u00e9galement contribuer \u00e0 freiner la\ncroissance inqui\u00e9tante du diab\u00e8te de type 2 [6].\nR\u00c9F\u00c9RENCES\n[1] King H, Aubert RE, Herman WH. Global burden of diabetes, 1995-2025. Prevalence, numerical estimates, and\nprojections. Diabetes Care 1998; 21 : 1414-31\n[2] Ricordeau P , Weill A, Vallier N, Bourrel R, Fender P , Allemand H. L'\u00e9pid\u00e9miologie du diab\u00e8te en France m\u00e9tropolitaine. Diabetes Metab 2000 ; 26 : 11-24\n[3] Ricordeau P , Weill A, Bourrel R, Vallier N, Schwartz D, Guilhot J, Fender P , Allemand H. Programme de sant\u00e9\npublique sur la prise en charge du diab\u00e8te de type 2. Evolution de la prise en charge des diab\u00e9tiques non insulinotrait\u00e9s entre 1998 et 2000. Paris, f\u00e9vrier 2002, Direction du service m\u00e9dical de la Cnamts, 92 p.\n[4] Detournay B, Vauzelle-Kervroedan F, Charles MA, Forhan A, Fagnani F, Fender P , Eschwege E. Epid\u00e9miologie, prise\nen charge et co\u00fbt du diab\u00e8te de type 2 en France en 1998. Diabetes Metab 1999 ; 26 : 356-65\n[5] Maillard G, Charles MA, Thibult N, Forhan A, Sermet C, Basdevant A, Eschwege E. Trends in the prevalence of\nobesity in the French adult population between 1980 and 1991. Int J Obes 1999; 23 : 389-94\n[6] Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle\nintervention or metformin. New Engl J Med 2002; 346 : 393-403\nDonn\u00e9es \u00e9pid\u00e9miologiques sur le diab\u00e8te de type 2\nD. Simon, Service de diab\u00e9tologie, H\u00f4pital de la Piti\u00e9, Paris - Inserm U-258, Villejuif, E. Eschwege, Inserm U-258, Villejuif\n\nIndustrialis\u00e9s Monde En voie de\nd\u00e9veloppement\n%\n\nFigure 1\nPr\u00e9vision \u00e0 30 ans de la pr\u00e9valence du diab\u00e8te chez l'adulte ( \u2265 20 ans)\nMillions\n\nIndustrialis\u00e9s En voie de\nd\u00e9veloppement\nMonde\nFigure 2\nPr\u00e9vision \u00e0 30 ans du nombre de sujets diab\u00e9tiques dans le monde\nOMS - H. King et al., Diabetes Care, 1998\nOMS - H. King et al., Diabetes Care, 1998\nIVS BEH N\u00b0 20-21 14/05/2002 15:59", "mimetype": "text/plain", "start_char_idx": 9944, "end_char_idx": 11854, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "e896287b-6a51-4693-8807-337af9864bcf": {"__data__": {"id_": "e896287b-6a51-4693-8807-337af9864bcf", "embedding": null, "metadata": {"page_label": "2", "file_name": "22120_8734-d3167.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\22120_8734-d3167.pdf", "file_type": "application/pdf", "file_size": 56665, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "74114646-4f81-43dc-af85-77c29c539fd8", "node_type": "4", "metadata": {"page_label": "2", "file_name": "22120_8734-d3167.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\22120_8734-d3167.pdf", "file_type": "application/pdf", "file_size": 56665, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "62bfbe890826ca5182264f78a1c81e409373a6909926a696cd314a88d7fa78e4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "27bd4969-088b-4a2a-a528-32f30f377145", "node_type": "1", "metadata": {}, "hash": "788cbbc38c9c8787852e8c234198b9bbba1fbfc1af78b905efd882b8527b92ec", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "BEH n\u00b0 20-21/2002 87\nINTRODUCTION\nEn juin 1999, la Caisse nationale d'assurance maladie des travailleurs salari\u00e9s (Cnamts), la Mutualit\u00e9\nsociale agricole (MSA) et l'Assurance maladie des professions ind\u00e9pendantes ont pris l'initiative de\nmettre en place un programme d'intervention en sant\u00e9 publique qui avait pour objectif de contribuer\n\u00e0 l'am\u00e9lioration de la prise en charge m\u00e9dicale des diab\u00e9tiques de type 2. Ce programme constituait\nl'une des r\u00e9ponses aux propositions de la conf\u00e9rence nationale de sant\u00e9 qui, en juin 1998, souhaitait voir \u00ab responsabiliser le m\u00e9decin et le diab\u00e9tique lors de la demande et du renouvellement de\nl'ALD \u00bb qui permet la prise en charge \u00e0 \u00ab 100 % \u00bb par l'assurance maladie des soins li\u00e9s au diab\u00e8te.\nLa m\u00eame ann\u00e9e, le Haut comit\u00e9 de sant\u00e9 publique, retenait comme une priorit\u00e9 le diab\u00e8te de type 2\nd\u00e9crit comme une \u00ab r\u00e9alit\u00e9 sanitaire pr\u00e9occupante \u00bb [1].\nMAT\u00c9RIEL ET M\u00c9THODE\nLe programme d'intervention de l'Assurance maladie consistait lors des demandes d'exon\u00e9ration\ndu ticket mod\u00e9rateur de personnes diab\u00e9tiques \u00e0 promouvoir aupr\u00e8s des m\u00e9decins traitants les\nr\u00e8gles de bonne pratique clinique pr\u00e9conis\u00e9es. Du 1\ner juin au 31 d\u00e9cembre 1999 \u00e0 chaque fois\nqu'un m\u00e9decin demandait pour un de ses patients diab\u00e9tiques, l'exon\u00e9ration du ticket mod\u00e9rateur, il \u00e9tait sollicit\u00e9 par un m\u00e9decin conseil pour s'entretenir avec lui des recommandations de\nl'Agence nationale de l'accr\u00e9ditation et de l'\u00e9valuation en sant\u00e9 (Anaes) et de l'Agence fran\u00e7aise\nde s\u00e9curit\u00e9 sanitaire des produits de sant\u00e9 (Afssaps). Trois th\u00e8mes \u00e9taient abord\u00e9s au cours de ces\nvisites : la notion d'objectif glyc\u00e9mique traduit en objectif d'HbA1c, la prise en compte du risque\ncardiovasculaire global et le d\u00e9pistage des complications.\nDurant cette p\u00e9riode, 22 940 m\u00e9decins ont \u00e9t\u00e9 contact\u00e9s par les m\u00e9decins conseils ; effectif qui\ncorrespond \u00e0 35,7 % de l'effectif total de m\u00e9decins lib\u00e9raux ou hospitaliers susceptibles de\nprendre en charge les diab\u00e9tiques de type 2. Le plus souvent (67,4 %), ces \u00e9changes entre m\u00e9decins traitants et m\u00e9decins conseils ont pris la forme d'une visite au cabinet du m\u00e9decin.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2111, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "27bd4969-088b-4a2a-a528-32f30f377145": {"__data__": {"id_": "27bd4969-088b-4a2a-a528-32f30f377145", "embedding": null, "metadata": {"page_label": "2", "file_name": "22120_8734-d3167.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\22120_8734-d3167.pdf", "file_type": "application/pdf", "file_size": 56665, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "74114646-4f81-43dc-af85-77c29c539fd8", "node_type": "4", "metadata": {"page_label": "2", "file_name": "22120_8734-d3167.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\22120_8734-d3167.pdf", "file_type": "application/pdf", "file_size": 56665, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "62bfbe890826ca5182264f78a1c81e409373a6909926a696cd314a88d7fa78e4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e896287b-6a51-4693-8807-337af9864bcf", "node_type": "1", "metadata": {"page_label": "2", "file_name": "22120_8734-d3167.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\22120_8734-d3167.pdf", "file_type": "application/pdf", "file_size": 56665, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "1ea3fdbbd2d1401c10cbb3a16464359fddc842e4d0ec26da46914e610b6a37e8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4a17c2da-bbe5-46d7-a637-d0b581a4739b", "node_type": "1", "metadata": {}, "hash": "5a17b7f56f70ecbe1e395b3acb991ac86fb41e80fec63c32f5e9184986295e19", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Le plus souvent (67,4 %), ces \u00e9changes entre m\u00e9decins traitants et m\u00e9decins conseils ont pris la forme d'une visite au cabinet du m\u00e9decin. Dans le\nm\u00eame temps, les Unions r\u00e9gionales des caisses d'assurance maladie (Urcam) ont engag\u00e9 de\nmultiples actions de sensibilisation aupr\u00e8s des usagers et des m\u00e9decins en partenariat le plus\nsouvent avec les Unions r\u00e9gionales de m\u00e9decins lib\u00e9raux (URML).\nPour l'\u00e9valuation de ce programme d'intervention, nous avions choisi de r\u00e9aliser une \u00e9tude de\ntype avant/apr\u00e8s comportant trois mesures : un audit initial se rapportant \u00e0 l'\u00e9tat des lieux de la\nprise en charge des malades en 1998 (avant la r\u00e9alisation des interventions) ; un audit interm\u00e9diaire portant sur la situation observ\u00e9e en 1999 (ann\u00e9e durant laquelle se sont d\u00e9roul\u00e9es les\ninterventions) un audit final (apr\u00e8s la r\u00e9alisation des interventions) portant sur la prise en charge\ndes malades durant l'ann\u00e9e 2000.\nCette \u00e9tude a \u00e9t\u00e9 r\u00e9alis\u00e9e en interrogeant les bases de donn\u00e9es de remboursement du R\u00e9gime\ng\u00e9n\u00e9ral de l'assurance maladie. L'utilisation de ces donn\u00e9es pour \u00e9valuer la prise en charge des\ndiab\u00e9tiques de type 2 en identifiant les prestations qui leur ont \u00e9t\u00e9 rembours\u00e9es, repose sur le\ncaract\u00e8re sp\u00e9cifique des m\u00e9dicaments antidiab\u00e9tiques. Au moment du lancement de la troisi\u00e8me\nmesure, d\u00e9but 2000, le codage des m\u00e9dicaments permettant l'identification des malades, \u00e9tait\npresque exhaustif. Le bilan final, relatif \u00e0 l'ann\u00e9e 2000, porte sur la prise en charge des 911 871\ndiab\u00e9tiques non insulino-trait\u00e9s identifi\u00e9s par les codes des m\u00e9dicaments rembours\u00e9s, soit pr\u00e8s\nde 90 % de l'ensemble des malades trait\u00e9s par m\u00e9dicaments. L'\u00e9tude initiale, r\u00e9alis\u00e9e deux ans\nplus t\u00f4t, ne portait que sur environ trois-quarts de la population de diab\u00e9tiques de type 2 rep\u00e9r\u00e9s\ncette ann\u00e9e-l\u00e0 mais, compte tenu des caract\u00e9ristiques de la mont\u00e9e en charge du codage, les\nr\u00e9sultats enregistr\u00e9s pouvaient, \u00e0 l'\u00e9poque, \u00eatre extrapol\u00e9s \u00e0 l'ensemble de cette population.\nNotre \u00e9tude s'est attach\u00e9e \u00e0 mesurer, entre 1998 et 2000, l'\u00e9volution de la prise en charge collective des malades en mati\u00e8re de suivi du contr\u00f4le glyc\u00e9mique et de d\u00e9pistage des complications\nd\u00e9g\u00e9n\u00e9ratives [2].\nLes r\u00e9sultats pr\u00e9sent\u00e9s le sont sans intervalle de confiance car la population incluse, dont l'effectif\nest tr\u00e8s important, n'est pas stricto sensu un \u00e9chantillon mais s'apparente \u00e0 une population\nexhaustive.", "mimetype": "text/plain", "start_char_idx": 1973, "end_char_idx": 4353, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "4a17c2da-bbe5-46d7-a637-d0b581a4739b": {"__data__": {"id_": "4a17c2da-bbe5-46d7-a637-d0b581a4739b", "embedding": null, "metadata": {"page_label": "2", "file_name": "22120_8734-d3167.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\22120_8734-d3167.pdf", "file_type": "application/pdf", "file_size": 56665, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "74114646-4f81-43dc-af85-77c29c539fd8", "node_type": "4", "metadata": {"page_label": "2", "file_name": "22120_8734-d3167.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\22120_8734-d3167.pdf", "file_type": "application/pdf", "file_size": 56665, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "62bfbe890826ca5182264f78a1c81e409373a6909926a696cd314a88d7fa78e4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "27bd4969-088b-4a2a-a528-32f30f377145", "node_type": "1", "metadata": {"page_label": "2", "file_name": "22120_8734-d3167.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\22120_8734-d3167.pdf", "file_type": "application/pdf", "file_size": 56665, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "c3375d8ca0b0c9f0561c889e4ff493856593e382a13f2347aba39bb943823d4e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9bdb7640-da41-49dc-a104-fca19be3abd6", "node_type": "1", "metadata": {}, "hash": "d9b869c74c49397928bb89d17235b8b7e47b5fc44fd0810b886deb3d62673964", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Les r\u00e9sultats pr\u00e9sent\u00e9s le sont sans intervalle de confiance car la population incluse, dont l'effectif\nest tr\u00e8s important, n'est pas stricto sensu un \u00e9chantillon mais s'apparente \u00e0 une population\nexhaustive. C'est aussi la raison pour laquelle les \u00e9volutions observ\u00e9es n'ont pas \u00e9t\u00e9 test\u00e9es.\nR\u00c9SULTATS\n\u00c9volution de la prise en charge des diab\u00e9tiques non insulino-trait\u00e9s entre 1998 et 2000. CNAMTS\nAnn\u00e9e 1998 Ann\u00e9e 1999 Ann\u00e9e 2000\nEffectif de la population incluse* 651 574 830 440 911 871\nAge moyen 64,3 ans 64,4 ans 64,4 ans\nSex-ratio H/F 1,07 1,09 1,10\nD\u00e9termination de l'HbA1c 41,3 % 55,0 % 60,6 %\nExamen ophtalmologique 39,1 % 41,5 % 40,9 %\nElectrocardiogramme 27,9 % 29,7 % 30,2 %\nDosage de la cholest\u00e9rol\u00e9mie 57,4 % 59,8 % 62,4 %\nDosage de la cr\u00e9atinin\u00e9mie 67,0 % 69,2 % 71,1 %\nDosage de la microalbuminurie 10,8 % 14,3 % 15,4 %\nSuivi bucco-dentaire 31,3 % 31,7 % 32,3 %\n* l'effectif s\u00e9lectionn\u00e9 d\u00e9pend du taux de mont\u00e9e en charge du codage de la pharmacie.\nLa proportion de diab\u00e9tiques non insulino-trait\u00e9s ayant b\u00e9n\u00e9fici\u00e9 au cours d'un semestre, d'au\nmoins un dosage d'HbA1c comme le recommandaient les experts de l'ANAES en janvier 1999,\nest pass\u00e9e de 41,3 % en 1998 \u00e0 60,6 % en 2000, soit une progression de 46,7 % (+ 19,3 points). A\nl'inverse durant la m\u00eame p\u00e9riode, la proportion de patients suivis uniquement par des glyc\u00e9mies\na diminu\u00e9 de moiti\u00e9 passant de 38,4% \u00e0 19,0 %.\nLe d\u00e9pistage annuel des complications ophtalmologiques, recommand\u00e9 par l'Anaes, a \u00e9t\u00e9\ndavantage r\u00e9alis\u00e9 en 2000 qu'en 1998 : 40,9 % des malades en ont b\u00e9n\u00e9fici\u00e9, versus 39,1 % soit\n24 000 malades suppl\u00e9mentaires. Il en est de m\u00eame du d\u00e9pistage des complications cardiovasculaires par un \u00e9lectrocardiogramme (ECG) : 30,2 % en 2000, versus 27,9 % en 1998. Le d\u00e9pistage\ndes anomalies lipidiques (cholest\u00e9rol\u00e9mies) a \u00e9galement progress\u00e9 : 62,4 % en 2000, versus\n57,4 % en 1998.", "mimetype": "text/plain", "start_char_idx": 4145, "end_char_idx": 6007, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "9bdb7640-da41-49dc-a104-fca19be3abd6": {"__data__": {"id_": "9bdb7640-da41-49dc-a104-fca19be3abd6", "embedding": null, "metadata": {"page_label": "2", "file_name": "22120_8734-d3167.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\22120_8734-d3167.pdf", "file_type": "application/pdf", "file_size": 56665, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "74114646-4f81-43dc-af85-77c29c539fd8", "node_type": "4", "metadata": {"page_label": "2", "file_name": "22120_8734-d3167.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\22120_8734-d3167.pdf", "file_type": "application/pdf", "file_size": 56665, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "62bfbe890826ca5182264f78a1c81e409373a6909926a696cd314a88d7fa78e4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4a17c2da-bbe5-46d7-a637-d0b581a4739b", "node_type": "1", "metadata": {"page_label": "2", "file_name": "22120_8734-d3167.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\22120_8734-d3167.pdf", "file_type": "application/pdf", "file_size": 56665, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "c39fa2fe7b4c8c6d53e20b3f4775d9a7cb4a2281e062b05b19908cd60a8846ef", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "cfc711af-8bde-490d-aaa1-eeadf763d8b0", "node_type": "1", "metadata": {}, "hash": "b5818d3580d2a08b0a0d44a1289acde6283fde6eb82871ae31a3bcbcb7ff6124", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Il en est de m\u00eame du d\u00e9pistage des complications cardiovasculaires par un \u00e9lectrocardiogramme (ECG) : 30,2 % en 2000, versus 27,9 % en 1998. Le d\u00e9pistage\ndes anomalies lipidiques (cholest\u00e9rol\u00e9mies) a \u00e9galement progress\u00e9 : 62,4 % en 2000, versus\n57,4 % en 1998. Enfin, le d\u00e9pistage des complications n\u00e9phrologiques s'est am\u00e9lior\u00e9 avec une\nplus grande fr\u00e9quence des dosages de la cr\u00e9atinin\u00e9mie (71,1 % en 2000, versus 67,0 % en 1998)\net des dosages de la microalbuminurie (15,4 % en 2000, versus 10,8 % en 1998).\nL'am\u00e9lioration de la prise en charge des diab\u00e9tiques de type 2 est plus marqu\u00e9e chez les malades\nb\u00e9n\u00e9ficiant de l'exon\u00e9ration du ticket mod\u00e9rateur pour ALD 30, et particuli\u00e8rement chez ceux\ndont l'ALD 30 \u00e9tait r\u00e9cente. Cette observation concerne tous les param\u00e8tres (dosages d'HbA1c,\nsuivi et d\u00e9pistage des complications d\u00e9g\u00e9n\u00e9ratives).\nDISCUSSION\nL'am\u00e9lioration des pratiques, plus marqu\u00e9e en 1999 (ann\u00e9e des \u00e9changes confraternels) qu'en\n2000 mais aussi plus prononc\u00e9e chez les malades en ALD, est un \u00e9l\u00e9ment en faveur d'un lien\nentre la campagne d'interventions de l'Assurance maladie et les progr\u00e8s observ\u00e9s dans la prise\nen charge collective des patients diab\u00e9tiques. Les r\u00e9sultats sont d'autant plus satisfaisants qu'ils\nsont pour l'ensemble du territoire du m\u00eame ordre de grandeur que ceux obtenus, entre 1995 et\n1996, sur une zone g\u00e9ographique limit\u00e9e pour des m\u00e9decins g\u00e9n\u00e9ralistes volontaires qui avaient\nassist\u00e9 \u00e0 des r\u00e9unions multidisciplinaires au cours desquelles les \u00e9carts aux recommandations,\nmesur\u00e9s par un audit de pratiques, \u00e9taient analys\u00e9s et discut\u00e9s [3].\nDe nombreux travaux ont d\u00e9montr\u00e9 que les visites confraternelles \u00e9taient des interventions efficaces ayant un effet important sur la mise en \u0153uvre effective des recommandations m\u00e9dicales\n[4], et c'est ce que confirme notre \u00e9tude. Cependant, la mise en place d'une telle strat\u00e9gie, \u00e0\nl'\u00e9chelle d'une collectivit\u00e9 nationale, n'a, \u00e0 notre connaissance, jamais \u00e9t\u00e9 rapport\u00e9e dans la\nlitt\u00e9rature. Ces travaux portent, g\u00e9n\u00e9ralement, sur des effectifs de l'ordre de quelques dizaines\nde m\u00e9decins ou, plus rarement, de quelques centaines de professionnels de sant\u00e9 [4] alors que\nnos interventions ont consist\u00e9 \u00e0 rencontrer pr\u00e8s de 23 000 m\u00e9decins.", "mimetype": "text/plain", "start_char_idx": 5747, "end_char_idx": 7976, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "cfc711af-8bde-490d-aaa1-eeadf763d8b0": {"__data__": {"id_": "cfc711af-8bde-490d-aaa1-eeadf763d8b0", "embedding": null, "metadata": {"page_label": "2", "file_name": "22120_8734-d3167.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\22120_8734-d3167.pdf", "file_type": "application/pdf", "file_size": 56665, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "74114646-4f81-43dc-af85-77c29c539fd8", "node_type": "4", "metadata": {"page_label": "2", "file_name": "22120_8734-d3167.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\22120_8734-d3167.pdf", "file_type": "application/pdf", "file_size": 56665, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "62bfbe890826ca5182264f78a1c81e409373a6909926a696cd314a88d7fa78e4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9bdb7640-da41-49dc-a104-fca19be3abd6", "node_type": "1", "metadata": {"page_label": "2", "file_name": "22120_8734-d3167.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\22120_8734-d3167.pdf", "file_type": "application/pdf", "file_size": 56665, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "8b49dc7aefc6a6d4b58d05e1507b71c4d32bf699717559a8f95055bb2aff0423", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b6117957-89de-4d40-abae-824c1a35c877", "node_type": "1", "metadata": {}, "hash": "9f335481a4aa5a5c634573a94302e649d14cc1e59193e6ccb9b97faee6988198", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Ces travaux portent, g\u00e9n\u00e9ralement, sur des effectifs de l'ordre de quelques dizaines\nde m\u00e9decins ou, plus rarement, de quelques centaines de professionnels de sant\u00e9 [4] alors que\nnos interventions ont consist\u00e9 \u00e0 rencontrer pr\u00e8s de 23 000 m\u00e9decins.\nPour certains param\u00e8tres, suivi ophtalmologique annuel notamment, la situation des malades en\n2000, apr\u00e8s la fin des interventions, \u00e9tait, d'un point de vue collectif, peu am\u00e9lior\u00e9e par rapport\n\u00e0 ce qu'elle \u00e9tait en 1998 (avant la campagne de visites confraternelles). Encore faudrait-il, tout\nde m\u00eame, relativiser cette observation. Avec un effectif de 1 330 000 diab\u00e9tiques de type 2\nrelevant du seul R\u00e9gime g\u00e9n\u00e9ral [5], une progression d'un seul point de la valeur de ce param\u00e8tre\nsignifie que 13 300 malades suppl\u00e9mentaires ont \u00e9t\u00e9 pris en charge par le syst\u00e8me de sant\u00e9\nconform\u00e9ment aux recommandations des experts.\nEn mati\u00e8re de d\u00e9pistage et de suivi des complications d\u00e9g\u00e9n\u00e9ratives, les progressions enregistr\u00e9es\nont \u00e9t\u00e9 modestes comparativement aux \u00e9volutions observ\u00e9es en mati\u00e8re de suivi du contr\u00f4le glyc\u00e9mique par dosages d'HbA1c. Les raisons en sont multiples (difficult\u00e9s \u00e0 prendre en consid\u00e9ration\nde nouvelles r\u00e9f\u00e9rences en contradiction avec l'enseignement re\u00e7u au cours des \u00e9tudes ; crainte de\nperdre un client ; r\u00e9ticence des malades ; impossibilit\u00e9 d'obtenir un rendez-vous ; co\u00fbt excessif de\ncertains examens, etc.) et elles expliquent que la compliance aux recommandations de bonne pratique varient d'une recommandation \u00e0 l'autre [6]. Certaines pr\u00e9conisations des experts s'av\u00e9raient\nplus difficilement acceptables que d'autres par les professionnels de sant\u00e9. C'est le cas, sans doute\nen raison du mode d'organisation de la m\u00e9decine lib\u00e9rale, de la r\u00e9alisation annuelle d'un examen\nophtalmologique et d'un bilan cardiovasculaire incluant un ECG de repos.\nLe dispositif en r\u00e9seau ou du \u00ab m\u00e9decin r\u00e9f\u00e9rent \u00bb ou son \u00e9quivalent, peut constituer une r\u00e9ponse\nadapt\u00e9e en assurant au m\u00e9decin g\u00e9n\u00e9raliste un r\u00f4le de coordination des soins et de suivi du patient\nen favorisant la communication avec sp\u00e9cialistes et param\u00e9dicaux. D'autres r\u00e9ponses sont sans\ndoute envisageables. Elles passent notamment par une plus grande responsabilisation des malades\net une incitation r\u00e9p\u00e9t\u00e9e \u00e0 obtenir du syst\u00e8me de sant\u00e9 les examens pr\u00e9conis\u00e9s. Il est probablement\ndifficile, concernant ces recommandations d'obtenir une modification sensible et durable des pratiques sans le d\u00e9veloppement de solutions impliquant l'ensemble des acteurs du syst\u00e8me de sant\u00e9.", "mimetype": "text/plain", "start_char_idx": 7729, "end_char_idx": 10234, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "b6117957-89de-4d40-abae-824c1a35c877": {"__data__": {"id_": "b6117957-89de-4d40-abae-824c1a35c877", "embedding": null, "metadata": {"page_label": "2", "file_name": "22120_8734-d3167.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\22120_8734-d3167.pdf", "file_type": "application/pdf", "file_size": 56665, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "74114646-4f81-43dc-af85-77c29c539fd8", "node_type": "4", "metadata": {"page_label": "2", "file_name": "22120_8734-d3167.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\22120_8734-d3167.pdf", "file_type": "application/pdf", "file_size": 56665, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "62bfbe890826ca5182264f78a1c81e409373a6909926a696cd314a88d7fa78e4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "cfc711af-8bde-490d-aaa1-eeadf763d8b0", "node_type": "1", "metadata": {"page_label": "2", "file_name": "22120_8734-d3167.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\22120_8734-d3167.pdf", "file_type": "application/pdf", "file_size": 56665, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "af244c5a95dd5141c0e1f34527b36b88d75b942ce424a6f4c6024e1be327b825", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "032f57a4-d7fc-4322-8ec5-1bd8301f1d34", "node_type": "1", "metadata": {}, "hash": "d0849547357c8c41a73c7eef2568e3b46d234dcbc758753d02702340e9166c5c", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "D'autres r\u00e9ponses sont sans\ndoute envisageables. Elles passent notamment par une plus grande responsabilisation des malades\net une incitation r\u00e9p\u00e9t\u00e9e \u00e0 obtenir du syst\u00e8me de sant\u00e9 les examens pr\u00e9conis\u00e9s. Il est probablement\ndifficile, concernant ces recommandations d'obtenir une modification sensible et durable des pratiques sans le d\u00e9veloppement de solutions impliquant l'ensemble des acteurs du syst\u00e8me de sant\u00e9.\nCONCLUSION\nLa mise en place d'un programme d'intervention en sant\u00e9 publique incitant les m\u00e9decins\ntraitants \u00e0 une d\u00e9marche plus proche des recommandations pour le suivi des diab\u00e9tiques a\nlargement port\u00e9 ses fruits. Une r\u00e9elle am\u00e9lioration de la prise en charge m\u00e9dicale a \u00e9t\u00e9 observ\u00e9e.\nCette \u00e9tude montre \u00e9galement que l'exploitation des donn\u00e9es de remboursement de l'assurance\nmaladie permet d'observer certains aspects de la prise en charge collective des malades.\nCes analyses statistiques en population constituent une alternative \u00e0 des enqu\u00eates lourdes m\u00eame\nsi, par construction, elles excluent certaines populations de malades (malades non d\u00e9pist\u00e9s ou\ntrait\u00e9s par r\u00e9gime seul). Elles peuvent \u00e9galement se concevoir comme le point de d\u00e9part\nd'enqu\u00eates plus qualitatives sur les freins et les leviers pour continuer d'am\u00e9liorer la prise en\ncharge m\u00e9dicale et organisationnelle des personnes atteintes de diab\u00e8te.\nR\u00c9F\u00c9RENCES\n[1] Haut comit\u00e9 de la sant\u00e9 publique. Rapport du groupe de travail diab\u00e8tes. Pr\u00e9vention, dispositif de soins et\n\u00e9ducation du patient. Minist\u00e8re de l'Emploi et de la Solidarit\u00e9. Paris. 1998.\n[2] Ricordeau P , Weill A, Bourrel R, Vallier N, Schwartz D, Guilhot J, Fender P , Allemand H. Programme de sant\u00e9\npublique sur la prise en charge du diab\u00e8te de type 2. Evolution de la prise en charge des diab\u00e9tiques non insulinotrait\u00e9s entre 1998 et 2000. Paris, F\u00e9vrier 2002, Direction du service m\u00e9dical, CNAMTS, 92 p.\n[3] Varroud-Vial M, Mechaly P , Joannidis S, Chapiro O, Pichard S, Lebigot A, Moulonguet M, Attali C, Bayle A, B\u00e9nier\nJ, Charpentier G. La coop\u00e9ration des g\u00e9n\u00e9ralistes et des diab\u00e9tologues et un audit de pratique am\u00e9liorent la prise\nen charge des diab\u00e9tiques non insulino-d\u00e9pendants. Diabetes Metab. 1999 ; 25 : 55-63.\n[4] Durieux P . Les actions de diffusion et de formation. In : P . Durieux eds. Comment am\u00e9liorer les pratiques m\u00e9dicales\n? Approche compar\u00e9e internationale. Flammarion. Paris. 1999, 11-18.", "mimetype": "text/plain", "start_char_idx": 9818, "end_char_idx": 12182, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "032f57a4-d7fc-4322-8ec5-1bd8301f1d34": {"__data__": {"id_": "032f57a4-d7fc-4322-8ec5-1bd8301f1d34", "embedding": null, "metadata": {"page_label": "2", "file_name": "22120_8734-d3167.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\22120_8734-d3167.pdf", "file_type": "application/pdf", "file_size": 56665, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "74114646-4f81-43dc-af85-77c29c539fd8", "node_type": "4", "metadata": {"page_label": "2", "file_name": "22120_8734-d3167.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\22120_8734-d3167.pdf", "file_type": "application/pdf", "file_size": 56665, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "62bfbe890826ca5182264f78a1c81e409373a6909926a696cd314a88d7fa78e4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b6117957-89de-4d40-abae-824c1a35c877", "node_type": "1", "metadata": {"page_label": "2", "file_name": "22120_8734-d3167.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\22120_8734-d3167.pdf", "file_type": "application/pdf", "file_size": 56665, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "250f9478567eb62249f77fc15790957a71fbd3d4bec99f4b3d7dc7800676ea5b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "fe3abd9e-3764-482f-a4eb-243081d39164", "node_type": "1", "metadata": {}, "hash": "383359fd86a6992fc933406d1d6cd5cc5c2955b88b7b855ed8c97afe9957526f", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Diabetes Metab. 1999 ; 25 : 55-63.\n[4] Durieux P . Les actions de diffusion et de formation. In : P . Durieux eds. Comment am\u00e9liorer les pratiques m\u00e9dicales\n? Approche compar\u00e9e internationale. Flammarion. Paris. 1999, 11-18.\n[5] Ricordeau P , Weill A, Vallier N, Bourrel R, Fender P , Allemand H. L'\u00e9pid\u00e9miologie du diab\u00e8te en France m\u00e9tropolitaine. Diabetes Metab., (Suppl. 6) 2000. 11-24.\n[6] Grol R, Dalhuijsen J, Thomas S., Int'Veld C, Ruttent G, Mokkink H. Attributes of clinical guidelines that influence\nuse of guidelines in general pratice : observational study. BMJ. 1998 ; 317 : 858-61\nImpact du programme d'intervention de l'Assurance maladie\nsur le diab\u00e8te de type 2\nA. Weill, P. Ricordeau, N. Vallier, R. Bourrel, J. Guilhot, P. Fender, H. Allemand, Caisse nationale d'assurance maladie des travailleurs salari\u00e9s, Paris\nLa d\u00e9finition et la classification des diab\u00e8tes sucr\u00e9s\nCRIT\u00c8RES DIAGNOSTIQUES DU DIAB\u00c8TE SUCR\u00c9\n1- Sympt\u00f4mes du diab\u00e8te (polyurie, polydipsie, perte de poids inexpliqu\u00e9e) + une\nglyc\u00e9mie casuelle (quelle que soit l'heure du pr\u00e9l\u00e8vement, y compris postprandiale) \u2265 2 g/l (11,1mmol/l).\n2- Glyc\u00e9mie \u00e0 jeun (8 heures ou plus de je\u00fbne) \u2265 1,26g/l (7mmol/l). Ce chiffre doit\n\u00eatre v\u00e9rifi\u00e9 un autre jour.\n3- Glyc\u00e9mie \u2265 2g/l 2 heures apr\u00e8s l'ingestion de 75g de glucose per os. La pratique\nde l'HPO (hyperglyc\u00e9mie provoqu\u00e9e par voie orale) n'est pas recommand\u00e9e en\npratique clinique.", "mimetype": "text/plain", "start_char_idx": 11958, "end_char_idx": 13362, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "fe3abd9e-3764-482f-a4eb-243081d39164": {"__data__": {"id_": "fe3abd9e-3764-482f-a4eb-243081d39164", "embedding": null, "metadata": {"page_label": "2", "file_name": "22120_8734-d3167.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\22120_8734-d3167.pdf", "file_type": "application/pdf", "file_size": 56665, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "74114646-4f81-43dc-af85-77c29c539fd8", "node_type": "4", "metadata": {"page_label": "2", "file_name": "22120_8734-d3167.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\22120_8734-d3167.pdf", "file_type": "application/pdf", "file_size": 56665, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "62bfbe890826ca5182264f78a1c81e409373a6909926a696cd314a88d7fa78e4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "032f57a4-d7fc-4322-8ec5-1bd8301f1d34", "node_type": "1", "metadata": {"page_label": "2", "file_name": "22120_8734-d3167.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\22120_8734-d3167.pdf", "file_type": "application/pdf", "file_size": 56665, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "9199e743a813345f868c8b33179abf5393fc9a61187d7625fcbbb0db704bc491", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Ce chiffre doit\n\u00eatre v\u00e9rifi\u00e9 un autre jour.\n3- Glyc\u00e9mie \u2265 2g/l 2 heures apr\u00e8s l'ingestion de 75g de glucose per os. La pratique\nde l'HPO (hyperglyc\u00e9mie provoqu\u00e9e par voie orale) n'est pas recommand\u00e9e en\npratique clinique.\nCLASSIFICATION \u00c9TIOLOGIQUES DES DIAB\u00c8TES SUCR\u00c9S\nI- Diab\u00e8te de type 1 (destruction des cellules /H9252, conduisant habituellement \u00e0 une\ncarence en insuline absolue)\nA. Li\u00e9e \u00e0 une pathologie du syst\u00e8me immunitaire\nB. Idiopathique\nII- Diab\u00e8te de type 2 (spectre variable, d'une r\u00e9sistance \u00e0 l'action de l'insuline\npr\u00e9dominante avec d\u00e9ficit insulinosecr\u00e9toire relatif \u00e0 un d\u00e9ficit insulinosecr\u00e9toire pr\u00e9dominant avec r\u00e9sistance \u00e0 l'action de l'insuline)\nIII- Autres types de diab\u00e8te sp\u00e9cifiques\nA- D\u00e9fauts g\u00e9n\u00e9tiques de la fonction des cellules /H9252\nB- D\u00e9fauts g\u00e9n\u00e9tiques de l'action d'insuline\nC- Diab\u00e8tes pancr\u00e9atiques\nD- Endocrinopathies\nE- Diab\u00e8tes induits par des m\u00e9dicaments ou des toxiques\nF- Infections\nG- Formes rares de diab\u00e8te li\u00e9es \u00e0 une pathologie du syst\u00e8me immunitaire\nH- Autres syndromes g\u00e9n\u00e9tiques s'accompagnant parfois d'un diab\u00e8te\nSource : American Diabetes Association. Report of the expert committee on the diagnosis and classification of\ndiabetes mellitus. Diabetes Care 1998 ; 21(suppl) :S5-19.\nIVS BEH N\u00b0 20-21 14/05/2002 15:59", "mimetype": "text/plain", "start_char_idx": 13141, "end_char_idx": 14413, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "d620467d-3a18-4239-abab-73b16ea2c5da": {"__data__": {"id_": "d620467d-3a18-4239-abab-73b16ea2c5da", "embedding": null, "metadata": {"page_label": "C6", "file_name": "36264_11160-ps.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\36264_11160-ps.pdf", "file_type": "application/pdf", "file_size": 267361, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "3d804f4d-a7c5-4462-8099-169f3811144e", "node_type": "4", "metadata": {"page_label": "C6", "file_name": "36264_11160-ps.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\36264_11160-ps.pdf", "file_type": "application/pdf", "file_size": 267361, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "cf9c00a682f402cdc513191e93c78b98a9160af43e39c5b352028574e6ce5108", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "23dcfee9-7ee0-4946-b527-7ac6a71be049", "node_type": "1", "metadata": {}, "hash": "6ac9ee0600c6714436aff62c9ffd14ec881326e1b0a1ff8c86f93aa450b158a8", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Hospitalisation des enfants diab\u00e9tiques en France \u00e0 partir des donn\u00e9es de l'enqu\u00eate Entred-Enfant 2007 - Institut de veille sanitaire /\nMaladies chroniques\net traumatismes\nMaladies\nchroniques\net traumatismes\nHospitalisation des enfants diab\u00e9tiques en France\n\u00e0 partir des donn\u00e9es de l'enqu\u00eate Entred-Enfant 2007\nPrincipaux r\u00e9sultats\nNovembre 2012\nIntroduction-contexte\nComme dans de nombreux autres pays, l'incidence du diab\u00e8te\nchez l'enfant augmente en France o\u00f9 elle a quasiment doubl\u00e9\nen vingt ans passant de 8 cas pour 100 000 enfants en 1988 \u00e0\n15 cas estim\u00e9s pour 100 000 en 2007 [1]. Chez les personnes\nde moins de 20 ans, l'augmentation moyenne annuelle, entre\n2006 et 2009, de la pr\u00e9valence du diab\u00e8te trait\u00e9 varie entre\n2,4 % et 3,9 % en fonction de la classe d'\u00e2ge et du sexe [2].\nL'\u00e9tude Entred-Enfant a \u00e9t\u00e9 mise en place suite aux conclusions\nde l'expertise sur la surveillance \u00e9pid\u00e9miologique du diab\u00e8te de\nl'enfant confi\u00e9e en 2007 \u00e0 l'Institut national de la sant\u00e9 et de\nla recherche m\u00e9dicale (Inserm) par l'Institut de veille sanitaire\n(InVS) [1]. L'objectif d'Entred-Enfant \u00e9tait de r\u00e9pondre \u00e0 un\nbesoin de connaissances sur les modalit\u00e9s et la qualit\u00e9 de la\nprise en charge m\u00e9dicale des enfants diab\u00e9tiques en France.\nEntred-Enfant est la premi\u00e8re \u00e9tude portant sur un \u00e9chantillon\nrepr\u00e9sentatif d'enfants trait\u00e9s pour diab\u00e8te en France [3].\nObjectifs\nL'\u00e9tude s'inscrit dans les objectifs d'Entred-Enfant. Il s'agissait\nde d\u00e9crire :\n- les caract\u00e9ristiques de l'hospitalisation des enfants\ndiab\u00e9tiques dans le cadre de la prise en charge du diab\u00e8te\nhors hospitalisations inaugurales ;\n- la fr\u00e9quence d'hospitalisation pour complications aigu\u00ebs d'un\ndiab\u00e8te d\u00e9j\u00e0 connu qui est un marqueur du contr\u00f4le de la\nmaladie ;\n- les caract\u00e9ristiques des enfants hospitalis\u00e9s.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1778, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "23dcfee9-7ee0-4946-b527-7ac6a71be049": {"__data__": {"id_": "23dcfee9-7ee0-4946-b527-7ac6a71be049", "embedding": null, "metadata": {"page_label": "C6", "file_name": "36264_11160-ps.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\36264_11160-ps.pdf", "file_type": "application/pdf", "file_size": 267361, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "3d804f4d-a7c5-4462-8099-169f3811144e", "node_type": "4", "metadata": {"page_label": "C6", "file_name": "36264_11160-ps.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\36264_11160-ps.pdf", "file_type": "application/pdf", "file_size": 267361, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "cf9c00a682f402cdc513191e93c78b98a9160af43e39c5b352028574e6ce5108", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d620467d-3a18-4239-abab-73b16ea2c5da", "node_type": "1", "metadata": {"page_label": "C6", "file_name": "36264_11160-ps.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\36264_11160-ps.pdf", "file_type": "application/pdf", "file_size": 267361, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "3b184aa0e048ea6bed0e502f0f53e4f4baae39dc0e33d05ea97a5ad3cdb39065", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6cc7c899-be62-4b61-a961-505d20e9c5a6", "node_type": "1", "metadata": {}, "hash": "c10e291b8f226603f33bff3bfb2a4615aa0c55067596048ffb585c4ccc8f1109", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Il s'agissait\nde d\u00e9crire :\n- les caract\u00e9ristiques de l'hospitalisation des enfants\ndiab\u00e9tiques dans le cadre de la prise en charge du diab\u00e8te\nhors hospitalisations inaugurales ;\n- la fr\u00e9quence d'hospitalisation pour complications aigu\u00ebs d'un\ndiab\u00e8te d\u00e9j\u00e0 connu qui est un marqueur du contr\u00f4le de la\nmaladie ;\n- les caract\u00e9ristiques des enfants hospitalis\u00e9s.\nMat\u00e9riel et m\u00e9thodes\nPopulation d'\u00e9tude\nLa population d'Entred-Enfant est constitu\u00e9e d'un \u00e9chantillon\nde 924 enfants tir\u00e9s au sort parmi les enfants b\u00e9n\u00e9ficiaires\nde la Caisse nationale de l'Assurance maladie des travailleurs\nsalari\u00e9s (CnamTS) hors sections locales mutualistes et du R\u00e9gime\ndes salari\u00e9s ind\u00e9pendants (RSI), \u00e2g\u00e9s de moins de 18 ans au\n31 juillet 2007, domicili\u00e9s en m\u00e9tropole ou dans les D\u00e9partements\nd'outre-mer et ayant b\u00e9n\u00e9fici\u00e9 d'au moins trois remboursements\nde m\u00e9dicaments antidiab\u00e9tiques oraux (ADO) et/ou d'insuline\nentre le 1\ner ao\u00fbt 2006 et le 31 juillet 2007.\nLes deux r\u00e9gimes couvrent environ 75 % de la population fran\u00e7aise.\nQuarante enfants ont \u00e9t\u00e9 exclus de l'\u00e9tude :\n- 4 enfants atteints d'un diab\u00e8te associ\u00e9 \u00e0 la mucoviscidose ;\n- 28 enfants trait\u00e9s par antidiab\u00e9tiques oraux seuls (n=19) ou\nsans traitement (n=9) sur la p\u00e9riode d'\u00e9tude ;\n- 8 enfants \"perdus de vue\" (sans aucune consommation\nm\u00e9dicale ni s\u00e9jour hospitalier sur la p\u00e9riode d'\u00e9tude).\nAu total, 884 enfants diab\u00e9tiques ont \u00e9t\u00e9 inclus dans l'\u00e9tude.\nP\u00e9riode d'\u00e9tude\nLa d\u00e9couverte d'un diab\u00e8te peut \u00eatre associ\u00e9e \u00e0 une\nhospitalisation, en particulier pour acidoc\u00e9tose, complication\naigu\u00eb souvent inaugurale du diab\u00e8te de type 1 chez l'enfant,\nou pour la mise en place d'un traitement par insuline.\nLa m\u00e9thodologie d'Entred-Enfant ne permettait pas d'identifier\nles hospitalisations inaugurales pour les d\u00e9crire. Afin d'exclure\nces hospitalisations inaugurales, la p\u00e9riode d'\u00e9tude a \u00e9t\u00e9 choisie\ndu 1\ner ao\u00fbt 2007 au 31 juillet 2008, apr\u00e8s la constitution de\nl'\u00e9chantillon des enfants diab\u00e9tiques.\nSources de donn\u00e9es\nLes donn\u00e9es de remboursements de consommation m\u00e9dicale de\nl'Assurance maladie et les s\u00e9jours hospitaliers du Programme de\nm\u00e9dicalisation des syst\u00e8mes d'information (PMSI) ont \u00e9t\u00e9 extraits\npour tous les enfants sur la p\u00e9riode d'ao\u00fbt 2007 \u00e0 juillet 2008.", "mimetype": "text/plain", "start_char_idx": 1421, "end_char_idx": 3640, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "6cc7c899-be62-4b61-a961-505d20e9c5a6": {"__data__": {"id_": "6cc7c899-be62-4b61-a961-505d20e9c5a6", "embedding": null, "metadata": {"page_label": "C6", "file_name": "36264_11160-ps.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\36264_11160-ps.pdf", "file_type": "application/pdf", "file_size": 267361, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "3d804f4d-a7c5-4462-8099-169f3811144e", "node_type": "4", "metadata": {"page_label": "C6", "file_name": "36264_11160-ps.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\36264_11160-ps.pdf", "file_type": "application/pdf", "file_size": 267361, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "cf9c00a682f402cdc513191e93c78b98a9160af43e39c5b352028574e6ce5108", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "23dcfee9-7ee0-4946-b527-7ac6a71be049", "node_type": "1", "metadata": {"page_label": "C6", "file_name": "36264_11160-ps.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\36264_11160-ps.pdf", "file_type": "application/pdf", "file_size": 267361, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "a141a497b10956c8d4238fef96ac792933c9fdf768152e0f46af02996b58b90c", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Sources de donn\u00e9es\nLes donn\u00e9es de remboursements de consommation m\u00e9dicale de\nl'Assurance maladie et les s\u00e9jours hospitaliers du Programme de\nm\u00e9dicalisation des syst\u00e8mes d'information (PMSI) ont \u00e9t\u00e9 extraits\npour tous les enfants sur la p\u00e9riode d'ao\u00fbt 2007 \u00e0 juillet 2008.\nClassification des motifs de s\u00e9jour\nLes diagnostics sont cod\u00e9s selon la 10e r\u00e9vision de la classification\ninternationale des maladies (CIM10).\nUn algorithme prenant en compte les diagnostics principaux,\nreli\u00e9s et associ\u00e9s, a permis de classer les s\u00e9jours hospitaliers\nen trois cat\u00e9gories :\n- s\u00e9jours pour complications aigu\u00ebs (acidoc\u00e9tose,\nhyperosmolarit\u00e9, hypoglyc\u00e9mie, coma diab\u00e9tique) ;\n- s\u00e9jours pour suivi du diab\u00e8te ;\n- s\u00e9jours pour un autre motif li\u00e9 ou non au diab\u00e8te.\nLa validation de l'algorithme de classification des motifs\nd'hospitalisation par comparaison aux dossiers hospitaliers n'a\npu \u00eatre effectu\u00e9e. Cependant, l'\u00e9tude de la dur\u00e9e des s\u00e9jours\nhospitaliers en fonction du motif d'hospitalisation a retrouv\u00e9\ndes r\u00e9sultats coh\u00e9rents avec la pratique, ce qui conforte la\nvalidit\u00e9 de l'algorithme utilis\u00e9.\nR\u00e9sultats\nCaract\u00e9ristiques sociod\u00e9mographiques\nSur les 884 enfants inclus dans l'\u00e9tude, 95,7 % relevaient de la\nCnamTS et 97,2 % r\u00e9sidaient en m\u00e9tropole. L'\u00e2ge moyen des\nenfants \u00e9tait de 12\u00b14 ans, la moiti\u00e9 \u00e9tait des gar\u00e7ons (50,3 %).\nUn seul enfant n'avait pas de prise en charge \u00e0 100 % en ALD\n(affection de longue dur\u00e9e) pour diab\u00e8te ou autre pathologie\net 17 % des enfants b\u00e9n\u00e9ficiaient de la couverture maladie\nuniverselle (CMU).\nL. Mandereau-Bruno1, J. Beltrand2 , I. Milovanovic3, M. Chantry4, C. Levy-Marchal3, C. Druet1\n1/ Institut de veille sanitaire (InVS) - 2/ H\u00f4pital universitaire Necker-enfants malades, service d'endocrinologie-gyn\u00e9cologie-diab\u00e9tologie - 3/ Institut national de la sant\u00e9\net de la recherche m\u00e9dicale (Inserm), CIC EC 05 - 4/ Caisse nationale de l'Assurance maladie des travailleurs salari\u00e9s (CnamTS).", "mimetype": "text/plain", "start_char_idx": 3369, "end_char_idx": 5293, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "6e47aedc-b55f-4dc2-82d3-2141c50eda72": {"__data__": {"id_": "6e47aedc-b55f-4dc2-82d3-2141c50eda72", "embedding": null, "metadata": {"page_label": "C6", "file_name": "36264_11160-ps.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\36264_11160-ps.pdf", "file_type": "application/pdf", "file_size": 267361, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "dd3bc350-7901-436f-b9b6-a997a2b19634", "node_type": "4", "metadata": {"page_label": "C6", "file_name": "36264_11160-ps.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\36264_11160-ps.pdf", "file_type": "application/pdf", "file_size": 267361, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "fed83e5525b505fb18bcd173b7fa5d40899c6cc1d85d99df1f905e8328469bc1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a2766610-a13b-4dde-8eb1-22204e64340f", "node_type": "1", "metadata": {}, "hash": "da20be8d7eeb2505ee6667d5677ceae12ce4602ae8436e8022c01d349d760839", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "/ Institut de veille sanitaire - Hospitalisation des enfants diab\u00e9tiques en France \u00e0 partir des donn\u00e9es de l'enqu\u00eate Entred-Enfant 2007\nTraitements antidiab\u00e9tiques\nTous les enfants \u00e9taient trait\u00e9s par insuline laissant penser que\nla quasi-totalit\u00e9 de l'\u00e9chantillon \u00e9tait des enfants diab\u00e9tiques de\ntype 1. Seuls 2,3 % des enfants avaient un traitement associant\nl'insuline \u00e0 un ou deux antidiab\u00e9tiques oraux, essentiellement la\nmetformine (2 %) et pour une moindre part un glinide.\nLa fr\u00e9quence d'utilisation de la pompe \u00e0 insuline \u00e9tait de 17,0 %.\nComme attendu, le pourcentage d'enfants ayant recours aux\npompes \u00e0 insuline \u00e9tait plus \u00e9lev\u00e9 parmi les plus jeunes : 33,3 %\ndes moins de 5 ans, 18,4 % des 5-9 ans, 16,6 % des 10-14 ans\net 14,0 % des 15 ans et plus (p<0,02).\nM\u00e9decins prescripteurs\nPour les enfants b\u00e9n\u00e9ficiaires de la CnamTS, le m\u00e9decin\nprincipalement en charge du diab\u00e8te a \u00e9t\u00e9 d\u00e9termin\u00e9 \u00e0 partir\ndu nombre de prescriptions sp\u00e9cifiques du diab\u00e8te rembours\u00e9es.\nL'\u00e9tude confirme que les enfants diab\u00e9tiques sont principalement\nsuivis par des m\u00e9decins hospitaliers (82 %). Seuls 7 % des enfants\nsont suivis uniquement par un m\u00e9decin g\u00e9n\u00e9raliste, 8 % sont pris\nen charge principalement par un endocrinologue lib\u00e9ral et 3 %\npar un p\u00e9diatre lib\u00e9ral.\nLe pourcentage d'enfants suivis principalement \u00e0 l'h\u00f4pital d\u00e9cro\u00eet\navec l'\u00e2ge : 95 % des moins de 5 ans, 87 % des 5-9 ans, 81 %\ndes 10-14 ans et 73 % des 15 ans et plus (p=0,001).\nCaract\u00e9ristiques de l'hospitalisation\ndes enfants diab\u00e9tiques\nUn enfant diab\u00e9tique sur deux a \u00e9t\u00e9 hospitalis\u00e9 au moins une\nfois au cours de la p\u00e9riode d'\u00e9tude (52,0 % ; IC 95 % : [48,7 % -\n55,4 %]) et 20,8 % ont eu plusieurs hospitalisations (tableau 1).\nEnviron un tiers des enfants (35,5 %) ont b\u00e9n\u00e9fici\u00e9, au cours de\nl'ann\u00e9e, d'au moins une hospitalisation pour suivi du diab\u00e8te\net 26 % ont b\u00e9n\u00e9fici\u00e9 de deux hospitalisations ou plus pour\nce motif.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1891, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "a2766610-a13b-4dde-8eb1-22204e64340f": {"__data__": {"id_": "a2766610-a13b-4dde-8eb1-22204e64340f", "embedding": null, "metadata": {"page_label": "C6", "file_name": "36264_11160-ps.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\36264_11160-ps.pdf", "file_type": "application/pdf", "file_size": 267361, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "dd3bc350-7901-436f-b9b6-a997a2b19634", "node_type": "4", "metadata": {"page_label": "C6", "file_name": "36264_11160-ps.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\36264_11160-ps.pdf", "file_type": "application/pdf", "file_size": 267361, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "fed83e5525b505fb18bcd173b7fa5d40899c6cc1d85d99df1f905e8328469bc1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6e47aedc-b55f-4dc2-82d3-2141c50eda72", "node_type": "1", "metadata": {"page_label": "C6", "file_name": "36264_11160-ps.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\36264_11160-ps.pdf", "file_type": "application/pdf", "file_size": 267361, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "e64a09ce5242072a0fa24676fc0c12849e0a15ded33c7c5426628509cf0fbb1e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5ea0e8bd-e1e1-4af1-aa03-58b9b956f981", "node_type": "1", "metadata": {}, "hash": "dc71158bff742b35b1ef554b778b33ac9b969e8f4440a459f596cd179ee25785", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Environ un tiers des enfants (35,5 %) ont b\u00e9n\u00e9fici\u00e9, au cours de\nl'ann\u00e9e, d'au moins une hospitalisation pour suivi du diab\u00e8te\net 26 % ont b\u00e9n\u00e9fici\u00e9 de deux hospitalisations ou plus pour\nce motif. Or les recommandations de la Soci\u00e9t\u00e9 internationale\npour le diab\u00e8te de l'enfant et de l'adolescent (ISPAD) de 2009\nainsi que les recommandations de la Haute autorit\u00e9 de sant\u00e9\n(HAS) d'avril 2007 pr\u00e9conisent un bilan annuel par une \u00e9quipe\nm\u00e9dicale pluridisciplinaire [4 ; 5] et on sait qu'en France de tels\nbilans sont majoritairement r\u00e9alis\u00e9s \u00e0 l'h\u00f4pital. Le pourcentage\nd'hospitalisation pour suivi du diab\u00e8te variait significativement\nen fonction de l'\u00e2ge. Il \u00e9tait de 40,5 % chez les moins de 5 ans\net de 28,1 % chez les 15 ans et plus (tableau 1).\nPar ailleurs, 12,7 % des enfants ont \u00e9t\u00e9 hospitalis\u00e9s au moins\nune fois pour complication aigu\u00eb du diab\u00e8te, 23 % d'entre eux\nayant eu deux hospitalisations ou plus pour ce motif.\nPour quelques s\u00e9jours pour lesquels un diagnostic de coma\ndiab\u00e9tique \u00e9tait mentionn\u00e9, la nature de la complication\naigu\u00eb ayant provoqu\u00e9 le coma (acidoc\u00e9tose, hypoglyc\u00e9mie,\nhyperosmolarit\u00e9) n'\u00e9tait pas pr\u00e9cis\u00e9e. De ce fait, les fr\u00e9quences\nd'hospitalisation pour chaque complication aigu\u00eb pouvaient\nvarier de 9,8 \u00e0 11,1 % pour l'acidoc\u00e9tose et de 2,3 \u00e0 3,5 % pour\nl'hypoglyc\u00e9mie.\nUne complication micro-vasculaire \u00e9tait mentionn\u00e9e pour 3,4 %\ndes enfants et adolescents (n=30).\nLa d\u00e9claration d'un coma durant l'hospitalisation, un s\u00e9jour\nen r\u00e9animation, en unit\u00e9 de soins intensifs ou en unit\u00e9 de\nsurveillance continue ou le d\u00e9c\u00e8s au cours de l'hospitalisation\nont \u00e9t\u00e9 consid\u00e9r\u00e9s comme des marqueurs de la gravit\u00e9 de\nl'hospitalisation. Aucun d\u00e9c\u00e8s n'a \u00e9t\u00e9 d\u00e9plor\u00e9 ; 1,5 % des enfants\nont \u00e9t\u00e9 hospitalis\u00e9s en r\u00e9animation, soins intensifs ou unit\u00e9 de\nsurveillance et 2,5 % des enfants ont eu un coma diab\u00e9tique.\nPour les enfants hospitalis\u00e9s, le nombre total de s\u00e9jours ne\nvariait pas en fonction de l'\u00e2ge (tableau 1). Cependant, la dur\u00e9e\nd'hospitalisation par patient \u00e9tait plus \u00e9lev\u00e9e chez les enfants\n\u00e2g\u00e9s de 10 ans et plus que chez les enfants de moins de 10 ans\n(4,4 jours en moyenne\nversus 2,7 jours (p<0,01)).", "mimetype": "text/plain", "start_char_idx": 1695, "end_char_idx": 3834, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "5ea0e8bd-e1e1-4af1-aa03-58b9b956f981": {"__data__": {"id_": "5ea0e8bd-e1e1-4af1-aa03-58b9b956f981", "embedding": null, "metadata": {"page_label": "C6", "file_name": "36264_11160-ps.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\36264_11160-ps.pdf", "file_type": "application/pdf", "file_size": 267361, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "dd3bc350-7901-436f-b9b6-a997a2b19634", "node_type": "4", "metadata": {"page_label": "C6", "file_name": "36264_11160-ps.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\36264_11160-ps.pdf", "file_type": "application/pdf", "file_size": 267361, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "fed83e5525b505fb18bcd173b7fa5d40899c6cc1d85d99df1f905e8328469bc1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a2766610-a13b-4dde-8eb1-22204e64340f", "node_type": "1", "metadata": {"page_label": "C6", "file_name": "36264_11160-ps.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\36264_11160-ps.pdf", "file_type": "application/pdf", "file_size": 267361, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "4edadaa563a125f943a46473599b49f7699213a999f3ae09d633ed74de604d90", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Pour les enfants hospitalis\u00e9s, le nombre total de s\u00e9jours ne\nvariait pas en fonction de l'\u00e2ge (tableau 1). Cependant, la dur\u00e9e\nd'hospitalisation par patient \u00e9tait plus \u00e9lev\u00e9e chez les enfants\n\u00e2g\u00e9s de 10 ans et plus que chez les enfants de moins de 10 ans\n(4,4 jours en moyenne\nversus 2,7 jours (p<0,01)).\nI Tableau 1 I\nCaract\u00e9ristiques de l'hospitalisation des enfants diab\u00e9tiques par classes d'\u00e2ge (\u00e2ge au 31/07/2007) sur une p\u00e9riode de 12 mois\nTous \u00e2ges 0-4 ans 5-9 ans 10-14 ans 15-17 ans pa\nNombre total d'enfants 884 42 190 367 285\nAu moins une hospitalisation (%)\ntoutes dur\u00e9es 52,0 59,5 51,0 54,8 48,1 ns\n< 24 heures 25,6 35,7 24,2 25,6 24,9 ns\n3\u226524 heures 35,3 33,3 35,8 38,1 31,6 ns\nHospitalisation multiple (%) 20,8 21,4 19,5 22,9 18,9 ns\nAu moins une hospitalisation pour (%)\nsuivi 35,5 40,5 37,4 39,8 28,1 <0,02\ncomplications aigu\u00ebs 12,7 14,3 10,5 15,8 9,8 0,1\nautres causes 16,4 21,4 14,7 14,7 19,0 ns\nNombre d'enfants hospitalis\u00e9s 460 25 97 201 137\nNombre de s\u00e9jours par enfant\nm\u00e9diane (Q1-Q3) 1 (1-2) 1 (1-2) 1 (1-2) 1 (1-2) 1 (1-2) ns\nDur\u00e9e totale de s\u00e9jour par enfant (jours)\nm\u00e9diane (Q1-Q3) 2 (0-5) 1 (0-3) 2 (0-4) 3 (0-6) 3 (0-6) ns\na test du Chi2 (variables qualitatives) et test de Kruskall-Wallis (variables quantitatives)", "mimetype": "text/plain", "start_char_idx": 3530, "end_char_idx": 4774, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "9c767640-ce6a-4da5-97fa-ed1887de5c06": {"__data__": {"id_": "9c767640-ce6a-4da5-97fa-ed1887de5c06", "embedding": null, "metadata": {"page_label": "C4", "file_name": "36264_11160-ps.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\36264_11160-ps.pdf", "file_type": "application/pdf", "file_size": 267361, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "cade7345-df33-4c0f-bd62-c80c8ba7746a", "node_type": "4", "metadata": {"page_label": "C4", "file_name": "36264_11160-ps.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\36264_11160-ps.pdf", "file_type": "application/pdf", "file_size": 267361, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "29bf1f51eb9623fe9f08f7af3f841e48bdda7dc935bedf51bfc3d45984bfe996", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c9be5112-c8c1-4b1e-97d2-04ab8633c8a6", "node_type": "1", "metadata": {}, "hash": "a1cd61ab4cbbb023d08be9848b0019fa1dabc0b2a7849a44ee0eb57f01ffa868", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Hospitalisation des enfants diab\u00e9tiques en France \u00e0 partir des donn\u00e9es de l'enqu\u00eate Entred-Enfant 2007 - Institut de veille sanitaire /\nMention d'un diagnostic de diab\u00e8te\n\u00e0 l'occasion du s\u00e9jour hospitalier\nOn d\u00e9nombre 834 s\u00e9jours hospitaliers pour les 460 enfants\ndiab\u00e9tiques hospitalis\u00e9s au cours de la p\u00e9riode d'\u00e9tude.\nLa mention du diab\u00e8te \u00e9tait pr\u00e9sente dans 91 % des s\u00e9jours\npermettant d'identifier comme diab\u00e9tiques 94 % des enfants\nhospitalis\u00e9s. La pr\u00e9sence d'un diagnostic de diab\u00e8te lors d'au\nmoins un s\u00e9jour \u00e9tait moins fr\u00e9quente dans le groupe des\nadolescents de 15 ans et plus : 96 % des moins de 5 ans, 98 %\ndes 5-9 ans, 97 % des 10-14 ans et 88 % des 15 ans et plus.\nCaract\u00e9ristiques des enfants hospitalis\u00e9s\nLes enfants hospitalis\u00e9s \u00e9taient en moyenne plus jeunes\net b\u00e9n\u00e9ficiaient plus souvent de la CMU. Ils \u00e9taient plus\nsouvent trait\u00e9s par insuline associ\u00e9e \u00e0 des antidiab\u00e9tiques\noraux, plus souvent porteurs d'une pompe \u00e0 insuline et plus\nsouvent suivis principalement par un praticien hospitalier\n(tableau 2).\nL'effet propre de chacun des facteurs a \u00e9t\u00e9 \u00e9tudi\u00e9 \u00e0 l'aide\nd'une r\u00e9gression logistique multivari\u00e9e. Afin de garantir une\nbonne qualit\u00e9 du mod\u00e8le, la nature du traitement, avec ou sans\nassociation d'antidiab\u00e9tiques oraux, n'a pas \u00e9t\u00e9 incluse dans\nl'analyse en raison de la forte corr\u00e9lation entre le traitement et\nl'\u00e2ge (tous les enfants de moins de 10 ans \u00e9taient trait\u00e9s par\ninsuline seule) et du faible effectif d'enfants trait\u00e9s par insuline\nassoci\u00e9 \u00e0 des ADO. L'utilisation d'une pompe \u00e0 insuline, la CMU\net le suivi par un m\u00e9decin hospitalier restaient significativement\nli\u00e9s \u00e0 l'hospitalisation apr\u00e8s prise en compte des autres facteurs.\nComme l'indique le tableau 1, la fr\u00e9quence de l'hospitalisation\nvariait en fonction de l'\u00e2ge pour les motifs de suivi (p<0,02) et \u00e9tait\n\u00e0 la limite de la significativit\u00e9 pour les motifs de complications\naigu\u00ebs (p=0,10). Les enfants \u00e2g\u00e9s de 15 \u00e0 17 ans avaient une\nfr\u00e9quence de suivi moins \u00e9lev\u00e9e que les enfants plus jeunes.\nLes classes d'\u00e2ge 0-4 ans et 10-14 ans pr\u00e9sentaient des\nfr\u00e9quences de complications aigu\u00ebs plus \u00e9lev\u00e9es ce qui pourrait\nen partie \u00eatre li\u00e9 \u00e0 la difficult\u00e9 de stabiliser le traitement \u00e0 ces\n\u00e2ges de la vie.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2203, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "c9be5112-c8c1-4b1e-97d2-04ab8633c8a6": {"__data__": {"id_": "c9be5112-c8c1-4b1e-97d2-04ab8633c8a6", "embedding": null, "metadata": {"page_label": "C4", "file_name": "36264_11160-ps.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\36264_11160-ps.pdf", "file_type": "application/pdf", "file_size": 267361, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "cade7345-df33-4c0f-bd62-c80c8ba7746a", "node_type": "4", "metadata": {"page_label": "C4", "file_name": "36264_11160-ps.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\36264_11160-ps.pdf", "file_type": "application/pdf", "file_size": 267361, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "29bf1f51eb9623fe9f08f7af3f841e48bdda7dc935bedf51bfc3d45984bfe996", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9c767640-ce6a-4da5-97fa-ed1887de5c06", "node_type": "1", "metadata": {"page_label": "C4", "file_name": "36264_11160-ps.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\36264_11160-ps.pdf", "file_type": "application/pdf", "file_size": 267361, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "90a4b8c24bfc9358b741b33891d1006c7d0c12029b6252cf06e789b5ca672fbf", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6bdc2d68-c56f-4610-b42d-a24bf14587ab", "node_type": "1", "metadata": {}, "hash": "0d54337a94a546adfda2a2481879e207a19584a654d5bf95c7734671d097f7a1", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Les enfants \u00e2g\u00e9s de 15 \u00e0 17 ans avaient une\nfr\u00e9quence de suivi moins \u00e9lev\u00e9e que les enfants plus jeunes.\nLes classes d'\u00e2ge 0-4 ans et 10-14 ans pr\u00e9sentaient des\nfr\u00e9quences de complications aigu\u00ebs plus \u00e9lev\u00e9es ce qui pourrait\nen partie \u00eatre li\u00e9 \u00e0 la difficult\u00e9 de stabiliser le traitement \u00e0 ces\n\u00e2ges de la vie.\nLes enfants b\u00e9n\u00e9ficiant de la CMU avaient plus souvent eu une\nhospitalisation pour complications aigu\u00ebs (22,0 %\nvs 10,8 %\np<0,001) et pour autres motifs (23,3 % vs 15,0 % p<0,02),\nsemblant indiquer un moins bon \u00e9tat de sant\u00e9 g\u00e9n\u00e9ral.\nLa fr\u00e9quence des hospitalisations en fonction du traitement ne\ndiff\u00e9rait ni pour le suivi du diab\u00e8te ni pour les complications\naigu\u00ebs. En revanche, la fr\u00e9quence d'hospitalisation pour autres\nmotifs \u00e9tait significativement plus \u00e9lev\u00e9e parmi les enfants\ntrait\u00e9s par insuline associ\u00e9e \u00e0 des ADO (48,7 %\nvs 32,8 %\np<0,001).\nSeule la fr\u00e9quence d'hospitalisation pour suivi du diab\u00e8te \u00e9tait\nsignificativement plus \u00e9lev\u00e9e pour les enfants porteurs d'une\npompe \u00e0 insuline compar\u00e9s aux enfants non porteurs (48,7 %\nvs 32,8 % p<0,001) en lien avec l'entretien et l'ajustement de\nla pompe.\nComme attendu, seule la fr\u00e9quence d'hospitalisation pour suivi\ndu diab\u00e8te \u00e9tait significativement plus \u00e9lev\u00e9e pour les enfants\nsuivis principalement par un praticien hospitalier (40,3 %\nvs\n15,4 % p<0,0001).\nConclusion\nL'\u00e9tude a permis d'\u00e9valuer le poids de la prise en charge\nhospitali\u00e8re des enfants diab\u00e9tiques en 2007-2008. La moiti\u00e9\ndes enfants diab\u00e9tiques \u00e9taient hospitalis\u00e9s au cours d'une\nann\u00e9e. Pour 12,7 % des enfants, l'hospitalisation \u00e9tait li\u00e9e\n\u00e0 une complication aigu\u00eb du diab\u00e8te, en partie \u00e9vitable par\nun meilleur contr\u00f4le du diab\u00e8te. Les recommandations de la\nHAS d'avril 2007 pr\u00e9conisant un bilan annuel par une \u00e9quipe\nm\u00e9dicale pluridisciplinaire semblent loin d'avoir \u00e9t\u00e9 mises en\n\u0153uvre puisque seulement un peu plus d'un tiers des enfants\n\u00e9taient hospitalis\u00e9s annuellement pour suivi de leur diab\u00e8te\net qu'en France de tels bilans sont majoritairement r\u00e9alis\u00e9s\n\u00e0 l'h\u00f4pital.\nR\u00e9f\u00e9rences bibliographiques\n[1] L\u00e9vy-Marchal C, Fagot-Campagna A, Daniel M. Surveillance\n\u00e9pid\u00e9miologique du diab\u00e8te de l'enfant. Saint-Maurice: Institut de veille\nsanitaire ; 2007.", "mimetype": "text/plain", "start_char_idx": 1894, "end_char_idx": 4091, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "6bdc2d68-c56f-4610-b42d-a24bf14587ab": {"__data__": {"id_": "6bdc2d68-c56f-4610-b42d-a24bf14587ab", "embedding": null, "metadata": {"page_label": "C4", "file_name": "36264_11160-ps.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\36264_11160-ps.pdf", "file_type": "application/pdf", "file_size": 267361, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "cade7345-df33-4c0f-bd62-c80c8ba7746a", "node_type": "4", "metadata": {"page_label": "C4", "file_name": "36264_11160-ps.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\36264_11160-ps.pdf", "file_type": "application/pdf", "file_size": 267361, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "29bf1f51eb9623fe9f08f7af3f841e48bdda7dc935bedf51bfc3d45984bfe996", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c9be5112-c8c1-4b1e-97d2-04ab8633c8a6", "node_type": "1", "metadata": {"page_label": "C4", "file_name": "36264_11160-ps.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\36264_11160-ps.pdf", "file_type": "application/pdf", "file_size": 267361, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "7c45940470633c951047beb3e869ee071a043a827bde2ebcf314dc5e3e9a24d7", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "R\u00e9f\u00e9rences bibliographiques\n[1] L\u00e9vy-Marchal C, Fagot-Campagna A, Daniel M. Surveillance\n\u00e9pid\u00e9miologique du diab\u00e8te de l'enfant. Saint-Maurice: Institut de veille\nsanitaire ; 2007. 66 p. Disponible sur\n[2] Ricci P, Bloti\u00e8re P, Weill A, Simon D, Tuppin P, Ricordeau P,\nAllemand H. Diab\u00e8te trait\u00e9 : quelles \u00e9volutions entre 2000 et 2009 en\nFrance ? Bull Epidemiol Hebd ; 2010 ; 42-43 : 425-31\n[3] Fosse S, Romon I, Druet C, Fagot-Campagna A. \u00c9chantillon national\nt\u00e9moin repr\u00e9sentatif des personnes diab\u00e9tiques, Entred 2007-2010.\nRapport m\u00e9thodologique. Saint-Maurice : Institut de veille sanitaire ;\n2012. 73 p. Disponible \u00e0 partir de l'URL :\n[4] Haute autorit\u00e9 de sant\u00e9. ALD n\u00b08 - Diab\u00e8te de type 1 chez l'enfant\net l'adolescent. Disponible sur\njcms/c_419643/ald-n8-diabete-de-type-1-chez-l-enfant-et-l-adolescent\n[5] Soci\u00e9t\u00e9 internationale pour le diab\u00e8te de l'enfant et de l'adolescent\n(ISPAD). Recommandations de consensus 2009 de l'ISPAD pour la\npratique clinique. Guide ISPAD 2009.\nI Tableau 2 I\nComparaison des caract\u00e9ristiques sociod\u00e9mographiques\net du recours aux soins des enfants diab\u00e9tiques\nhospitalis\u00e9s et non hospitalis\u00e9s\nEnfants non\nhospitalis\u00e9s\n(n=424)\nEnfants\nhospitalis\u00e9s\n(n=460)\npc\n\u00c2ge moyen (ann\u00e9es,\u00b1sm\na) 12,2\u00b10,19 11,7\u00b10,18 0,06\nGar\u00e7ons (%) 50,9 49,8 ns\nCMU (%) 13,7 20 <0,02\nTraitement (%)\nInsuline seule 99,3 96,3 <0,01\nPompe \u00e0 insuline 12,5 21,1 <0,001\nProfessionnel de sant\u00e9\nen charge du diab\u00e8te (%)b\nPraticien hospitalier 75,2 88,3 <0,0001\na \u00e9cart-type de la moyenne\nb donn\u00e9es uniquement disponibles pour le r\u00e9gime g\u00e9n\u00e9ral (n=846)\nc test du Chi2 (variables qualitatives) et test de Student (variables quantitatives)", "mimetype": "text/plain", "start_char_idx": 3911, "end_char_idx": 5551, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "1e76eac9-16b4-4cbe-b998-31c0405e988f": {"__data__": {"id_": "1e76eac9-16b4-4cbe-b998-31c0405e988f", "embedding": null, "metadata": {"page_label": "C5", "file_name": "36264_11160-ps.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\36264_11160-ps.pdf", "file_type": "application/pdf", "file_size": 267361, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "43b6cb1d-07e3-415a-a978-f2020428c3d3", "node_type": "4", "metadata": {"page_label": "C5", "file_name": "36264_11160-ps.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\36264_11160-ps.pdf", "file_type": "application/pdf", "file_size": 267361, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "32813027cbfeb7417b9fed56dcfabf545f30fcae5cd41b95f18f8a9a8de860c5", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Institut de veille sanitaire , 12 rue du Val D'Osne 94 415 Saint-Maurice Cedex France - T\u00e9l. : 33 (0)1 41 79 67 00 - Fax : 33 (0)1 41 79 67 67\nwww.invs.sante.fr - ISSN : 1956-6964 - ISBN : 978-2-11-129784-5 - ISBN-NET : 978-2-11-129785-2 - R\u00e9alisation : Service Communication - Imprim\u00e9 par : France repro -\nMaisons-Alfort - Tirage : 55 exemplaires - D\u00e9p\u00f4t l\u00e9gal : Novembre 2012\nCitation sugg\u00e9r\u00e9e :\nMandereau-Bruno L, Druet C, Beltrand J, , Milovanovic I, Chantry M, Levy-Marchal C. Hospitalisation des enfants diab\u00e9tiques en France \u00e0 partir des donn\u00e9es de\nl'enqu\u00eate Entred-Enfant 2007. Principaux r\u00e9sultats. Saint-Maurice : Institut de veille sanitaire ; 2012. 4 p. Disponible \u00e0 partir de l'URL :\nMots cl\u00e9s : diab\u00e8te, enfant, \u00e9chantillon repr\u00e9sentatif, hospitalisation, consommation m\u00e9dicale, PMSI, enqu\u00eate transversale, France.\nCe document a \u00e9t\u00e9 r\u00e9dig\u00e9 par Laurence Mandereau-Bruno et C\u00e9line Druet (InVS, D\u00e9partement maladies chroniques et traumatismes (DMCT)),\nen collaboration avec la Direction scientifique et de la qualit\u00e9 (Cellule de valorisation \u00e9ditoriale, Ceve).\nPour en savoir plus\nVous pouvez consulter le dossier th\u00e9matique \"Diab\u00e8te\" de l'InVS \u00e0 l'adresse suivante :\nUn diaporama des r\u00e9sultats de l'\u00e9tude y est disponible.\nPoints cl\u00e9s\n\u2022\t\u00c9chantillon repr\u00e9sentatif de 884 enfants diab\u00e9tiques \u00e2g\u00e9s de 12 ans en moyenne dont environ la moiti\u00e9 de gar\u00e7ons.\n\u2022\t 1 enfant diab\u00e9tique sur 2 hospitalis\u00e9 au cours d'une ann\u00e9e.\n\u2022\t 21 % des enfants avec deux s\u00e9jours hospitaliers ou plus dans l'ann\u00e9e.\n\u2022\t 35,5 % des enfants hospitalis\u00e9s pour suivi du diab\u00e8te.\n\u2022\t 12,7 % des enfants hospitalis\u00e9s pour une complication aigu\u00eb du diab\u00e8te.\n\u2022\t 3,4 % d'enfants avec au moins une hospitalisation avec mention d'une complication micro-vasculaire.\n\u2022\t Gravit\u00e9 : 2,5 % des enfants hospitalis\u00e9s pour une complication aigu\u00eb avec coma et aucun d\u00e9c\u00e8s.\n\u2022\t L'hospitalisation est li\u00e9e de fa\u00e7on ind\u00e9pendante \u00e0 plusieurs facteurs : CMU, utilisation d'une pompe \u00e0 insuline, suivi par\nun m\u00e9decin hospitalier.\n\u2022\t Mention du diab\u00e8te dans le PMSI : pour 91 % des s\u00e9jours et 94 % des enfants de la population d'\u00e9tude.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2087, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "e8174d8a-dd57-4e10-9fa3-67dc9502551d": {"__data__": {"id_": "e8174d8a-dd57-4e10-9fa3-67dc9502551d", "embedding": null, "metadata": {"page_label": "1", "file_name": "hc001042.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\hc001042.pdf", "file_type": "application/pdf", "file_size": 237006, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "bf8a63ae-d6ac-4202-91b2-5a96a3fa89a1", "node_type": "4", "metadata": {"page_label": "1", "file_name": "hc001042.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\hc001042.pdf", "file_type": "application/pdf", "file_size": 237006, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "a8c502aa20901762c698142262f714bddfb8ea9cfe6469aa289569b6d293ceac", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 0, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "dd6719fb-62d9-4f96-b13a-2f522602d7e3": {"__data__": {"id_": "dd6719fb-62d9-4f96-b13a-2f522602d7e3", "embedding": null, "metadata": {"page_label": "2", "file_name": "hc001042.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\hc001042.pdf", "file_type": "application/pdf", "file_size": 237006, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "d03d9f54-81b3-4196-a99c-9db97f30d2b1", "node_type": "4", "metadata": {"page_label": "2", "file_name": "hc001042.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\hc001042.pdf", "file_type": "application/pdf", "file_size": 237006, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "725dfd52a8231e0e8e57e8c43eed6d648f17b41cb7dbdcae93f905759a0c17b8", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 0, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "d4bf636e-2707-4b54-a69b-e0da58955e8d": {"__data__": {"id_": "d4bf636e-2707-4b54-a69b-e0da58955e8d", "embedding": null, "metadata": {"page_label": "3", "file_name": "hc001042.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\hc001042.pdf", "file_type": "application/pdf", "file_size": 237006, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "e1cc4655-10bc-4df8-be0f-7b8e5bf6e239", "node_type": "4", "metadata": {"page_label": "3", "file_name": "hc001042.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\hc001042.pdf", "file_type": "application/pdf", "file_size": 237006, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "4ada690c85ac9e3b0100ef888d44203b479fea32bd890c89ca6c77b5e0714407", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Minist\u00e8re de l'Emploi et de la Solidarit\u00e9\nHaut Comit\u00e9 de la sant\u00e9 publique\nDiab\u00e8tes\nPr\u00e9vention,\ndispositifs de soins\net \u00e9ducation\ndu patient\nMai 1998", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 149, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "6c93a7c0-c50b-4004-9e6d-21651b98b684": {"__data__": {"id_": "6c93a7c0-c50b-4004-9e6d-21651b98b684", "embedding": null, "metadata": {"page_label": "4", "file_name": "hc001042.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\hc001042.pdf", "file_type": "application/pdf", "file_size": 237006, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "56ec57f9-fb89-404b-90c0-2db9b4aa4340", "node_type": "4", "metadata": {"page_label": "4", "file_name": "hc001042.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\hc001042.pdf", "file_type": "application/pdf", "file_size": 237006, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "a17713e6a89c46ac31e8ec4474079a048842ded50ccc220ea7cd209fe7f6c69c", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "LE PHOTOCOPILLAGE MET EN DANGER L '\u00c9QUILIBRE \u00c9CONOMIQUE DES CIRCUITS DU LIVRE .\nToute reproduction, m\u00eame partielle, \u00e0 usage collectif de cet ouvrage est strictement interdite sans autorisation de l'\u00e9diteur (loi du 11 mars 1957, code de la\npropri\u00e9t\u00e9 intellectuelle du 1er juillet 1992).\n\u00a9 1998, Haut Comit\u00e9 de la sant\u00e9 publique, 8, avenue de S\u00e9gur - 75350 Paris 07 SP\nISBN 2-85952-734-6 - ISSN 1244-5622", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 402, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "24ae36c7-1c63-4fd6-bf92-720a5854808c": {"__data__": {"id_": "24ae36c7-1c63-4fd6-bf92-720a5854808c", "embedding": null, "metadata": {"page_label": "5", "file_name": "hc001042.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\hc001042.pdf", "file_type": "application/pdf", "file_size": 237006, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "129a3d8d-314d-4348-8021-1d217135191c", "node_type": "4", "metadata": {"page_label": "5", "file_name": "hc001042.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\hc001042.pdf", "file_type": "application/pdf", "file_size": 237006, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "625111e981afd15b1597461e177a4969f3594c33b84f160daafa2f78277c10bd", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "VDiab\u00e8tes. Pr\u00e9vention, dispositifs de soins, \u00e9ducation... / Mai 1998\nSaisine VII\nAvis du Haut Comit\u00e9 de la sant\u00e9 publique IX\nIntroduction 1\nLes diab\u00e8tes 5\nLa maladie 5\nHistoire et repr\u00e9sentations des diab\u00e8tes 18\nLes trois enjeux des diab\u00e8tes 29\nStructurer et rationaliser les dispositifs de soins sp\u00e9cialis\u00e9s 29\nFavoriser une v\u00e9ritable \u00e9ducation du patient 42\nReconna\u00eetre comme l\u00e9gitime le souhait des patients qui revendiquent davantage d'autonomie 48\nPropositions 53\nObjectifs d'une politique de sant\u00e9 publique 53\nMesures g\u00e9n\u00e9rales pour le diab\u00e8te et les maladies chroniques 55\nLa pr\u00e9vention des diab\u00e8tes 58\nAnnexes 67\nSOMMAIRE", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 629, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "5bcf6679-9ad8-4cba-8309-cd2fc030b30f": {"__data__": {"id_": "5bcf6679-9ad8-4cba-8309-cd2fc030b30f", "embedding": null, "metadata": {"page_label": "6", "file_name": "hc001042.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\hc001042.pdf", "file_type": "application/pdf", "file_size": 237006, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "1b1bce34-5f15-445b-b63a-fb601060da3d", "node_type": "4", "metadata": {"page_label": "6", "file_name": "hc001042.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\hc001042.pdf", "file_type": "application/pdf", "file_size": 237006, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "de3d891550d3bf7cf6ba31dd2691a126acf71f07fa5e58e82e8a97d7dce2454d", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 0, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "afe6d71f-e804-48d7-91f8-58ab0bc5314c": {"__data__": {"id_": "afe6d71f-e804-48d7-91f8-58ab0bc5314c", "embedding": null, "metadata": {"page_label": "7", "file_name": "hc001042.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\hc001042.pdf", "file_type": "application/pdf", "file_size": 237006, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "febd1297-d15c-49b5-819a-af5360d5de5f", "node_type": "4", "metadata": {"page_label": "7", "file_name": "hc001042.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\hc001042.pdf", "file_type": "application/pdf", "file_size": 237006, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "c02cada3a6b144b7e7668528f48c1302986671997f50671f00554239879ceb66", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "VIIDiab\u00e8tes. Pr\u00e9vention, dispositifs de soins, \u00e9ducation... / Mai 1998\nR\u00c9PUBLIQUE FRAN\u00c7AISE\nMinist\u00e8re des Affaires sociales,\nde la Sant\u00e9 et de la Ville\nMinistre d\u00e9l\u00e9gu\u00e9 \u00e0 la Sant\u00e9\nDirection g\u00e9n\u00e9rale de la Sant\u00e9 Paris, le 7 juin 1994\n\nMonsieur le Vice-Pr\u00e9sident,\nLe diab\u00e8te touche environ un million de personnes en France.\nLa prise en charge est assur\u00e9e essentiellement par les g\u00e9n\u00e9ralistes (91 % des patients). L'\u00e9ducation du diab\u00e9tique est un enjeu\nessentiel pour la qualit\u00e9 de la prise en charge.\nUn colloque a \u00e9t\u00e9 organis\u00e9 sous l'\u00e9gide de l'Organisation mondiale de la sant\u00e9 et de la F\u00e9d\u00e9ration internationale du diab\u00e8te en\nItalie \u00e0 Saint-Vincent en 1989. Au cours de ce colloque a \u00e9t\u00e9 r\u00e9dig\u00e9e une d\u00e9claration d\u00e9finissant \u00e0 l'\u00e9chelle europ\u00e9enne les moyens\nd'am\u00e9liorer la prise en charge des patients atteints de diab\u00e8te\nsucr\u00e9. Les suites de la d\u00e9claration ont \u00e9t\u00e9 en France la cr\u00e9ation du\nConseil sup\u00e9rieur du diab\u00e8te regroupant des repr\u00e9sentants de\nl'Association fran\u00e7aise des diab\u00e9tiques, de l'Association de langue\nfran\u00e7aise pour l'\u00e9tude du diab\u00e8te et des maladies m\u00e9taboliques,\nde l'Aide aux jeunes diab\u00e9tiques, et de la Ligue des diab\u00e9tiques\nde France. L'Association fran\u00e7aise des diab\u00e9tiques a sensibilis\u00e9\nses adh\u00e9rents par une demande d'adh\u00e9sion personnelle \u00e0 la d\u00e9claration de Saint-Vincent. Des recommandations internationales\nde bonne pratique en mati\u00e8re de diab\u00e8te ont \u00e9t\u00e9 adopt\u00e9es par le\nConseil sup\u00e9rieur du diab\u00e8te qui a par ailleurs pr\u00e9sent\u00e9 la d\u00e9claration aux repr\u00e9sentants de l'assurance maladie et un projet de\ndistribution d'un carnet de sant\u00e9 pour diab\u00e9tiques (qui serait distribu\u00e9 par les caisses) est en cours. Enfin, un registre pour le\ndiab\u00e8te infanto-juv\u00e9nile a \u00e9t\u00e9 cr\u00e9\u00e9.\n\u00c0 l'\u00e9vidence, un effort de coordination des diff\u00e9rents acteurs\ndans ce domaine est souhaitable et j'aimerais qu'un groupe de travail pilot\u00e9 par le Haut Comit\u00e9 de la sant\u00e9 publique soit charg\u00e9 d'une\nmission de r\u00e9flexion et de propositions d'actions de sant\u00e9 publique\ndans le domaine du diab\u00e8te sucr\u00e9. Cette pr\u00e9occupation rejoint \u00e9galement la demande qui vous a \u00e9t\u00e9 faite relative \u00e0 l'\u00e9ducation des\nmalades atteints d'affections chroniques.\nJe vous serais reconnaissant de bien vouloir me donner votre\navis sur ce projet et vous prie de croire, Monsieur le Vice-Pr\u00e9sident, \u00e0 l'assurance de ma consid\u00e9ration distingu\u00e9e.\nLe directeur g\u00e9n\u00e9ral de la Sant\u00e9\nJean-Fran\u00e7ois Girard\nP.J. : D\u00e9claration de Saint-Vincent\nMonsieur le Vice-Pr\u00e9sident\nHaut Comit\u00e9 de la sant\u00e9 publique", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2467, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "c05171bc-bdbb-4447-9b83-2d7211b14791": {"__data__": {"id_": "c05171bc-bdbb-4447-9b83-2d7211b14791", "embedding": null, "metadata": {"page_label": "8", "file_name": "hc001042.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\hc001042.pdf", "file_type": "application/pdf", "file_size": 237006, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "2af5eadf-433a-4790-b65e-cb4559ced482", "node_type": "4", "metadata": {"page_label": "8", "file_name": "hc001042.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\hc001042.pdf", "file_type": "application/pdf", "file_size": 237006, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "127e56c2fbed8422b103ad179b3b5f54d4b27d66ededa43628bd9a98cbed082b", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 0, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "ccd13d28-b94b-434f-8b90-92cdf16df7cd": {"__data__": {"id_": "ccd13d28-b94b-434f-8b90-92cdf16df7cd", "embedding": null, "metadata": {"page_label": "9", "file_name": "hc001042.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\hc001042.pdf", "file_type": "application/pdf", "file_size": 237006, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "d723e63d-7991-461c-b9bd-2366ccff8ec9", "node_type": "4", "metadata": {"page_label": "9", "file_name": "hc001042.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\hc001042.pdf", "file_type": "application/pdf", "file_size": 237006, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "78bf85fd2e9b9a2c54e02e6f6625924369a36c1dcd769d351511c6e55553d92f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0ffe0b6b-76d9-430c-910e-3c848a2e6057", "node_type": "1", "metadata": {}, "hash": "7804e38b8d90f9f723ea20e2a90876917c8235f77c0bafa5f7bbed37bfee59a4", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "IXDiab\u00e8tes. Pr\u00e9vention, dispositifs de soins, \u00e9ducation... / Mai 1998\nAvis du Haut Comit\u00e9 de la sant\u00e9 publique\nLe diab\u00e8te est en France une r\u00e9alit\u00e9 sanitaire pr\u00e9occupante. Environ 120 000 personnes d\u00e9pendent d'un traitement quotidien par\nl'insuline pour leur survie et 1 200 000 personnes pr\u00e9sentent un\ndiab\u00e8te non insulino-d\u00e9pendant. Ces derni\u00e8res sont expos\u00e9es aux\nm\u00eames complications d\u00e9g\u00e9n\u00e9ratives que les diab\u00e9tiques insulinod\u00e9pendants mais, faute d'un diagnostic pr\u00e9coce de la maladie\nlongtemps insidieuse, ces complications sont le plus souvent\nd\u00e9couvertes \u00e0 un stade avanc\u00e9 de leur \u00e9volution.\nCes deux populations posent des probl\u00e8mes de prise en charge tr\u00e8s\ndiff\u00e9rents. En effet, si elles pr\u00e9sentent en commun un \u00e9tat d'hyperglyc\u00e9mie chronique et un risque \u00e9lev\u00e9 de complications d\u00e9g\u00e9n\u00e9ratives, leur expression clinique et leur profil \u00e9volutif diff\u00e8rent.\nLe diab\u00e8te insulino-d\u00e9pendant (DID) est dans l'ensemble correctement pris en charge en France : la gravit\u00e9 de la maladie\nest \u00e9vidente. Elle b\u00e9n\u00e9ficie d'un int\u00e9r\u00eat privil\u00e9gi\u00e9 de la part des\nautorit\u00e9s sanitaires et sociales ainsi que des diab\u00e9tologues qui\nles prennent en charge. Affection chronique souvent intriqu\u00e9e avec\nd'autres facteurs de risque vasculaire et infectieux, le diab\u00e8te\nexige du malade une participation active \u00e0 la gestion quotidienne\nde son traitement. Cette \u00ab auto-prise en charge \u00bb suppose une\n\u00e9ducation initiale, habituellement assur\u00e9e en milieu hospitalier,\npuis une formation continue et un soutien dans lesquels plusieurs\nassociations jouent d\u00e9j\u00e0 un r\u00f4le essentiel.\nLa situation est bien diff\u00e9rente pourle diab\u00e8te non insulino-d\u00e9pendant (DNID). Le d\u00e9pistage manque d'efficacit\u00e9, l'action des m\u00e9decins g\u00e9n\u00e9ralistes para\u00eet tr\u00e8s insuffisante, l'\u00e9ducation face au risque\net \u00e0 la maladie est inadapt\u00e9e, la coordination entre les acteurs\nsanitaires et sociaux n'est pas satisfaisante, l'organisation hospitali\u00e8re de la diab\u00e9tologie est largement perfectible alors que\nl'\u00e9valuation m\u00e9dico-\u00e9conomique est quasi inexistante. Au total, la\nfaible observance th\u00e9rapeutique des malades est g\u00e9n\u00e9ratrice\nde co\u00fbts importants et en partie inutiles car sans b\u00e9n\u00e9fice pour\nles personnes ou les populations concern\u00e9es. Le vieillissement\nde la population risque d'aggraver inexorablement cet \u00e9tat de fait\npar l'augmentation du nombre de diab\u00e9tiques \u00e2g\u00e9s atteints de\npolypathologies. Les progr\u00e8s diagnostiques et th\u00e9rapeutiques ne\nsemblent pas devoir apporter \u00e0 court terme des progr\u00e8s sensibles.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2461, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "0ffe0b6b-76d9-430c-910e-3c848a2e6057": {"__data__": {"id_": "0ffe0b6b-76d9-430c-910e-3c848a2e6057", "embedding": null, "metadata": {"page_label": "9", "file_name": "hc001042.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\hc001042.pdf", "file_type": "application/pdf", "file_size": 237006, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "d723e63d-7991-461c-b9bd-2366ccff8ec9", "node_type": "4", "metadata": {"page_label": "9", "file_name": "hc001042.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\hc001042.pdf", "file_type": "application/pdf", "file_size": 237006, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "78bf85fd2e9b9a2c54e02e6f6625924369a36c1dcd769d351511c6e55553d92f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ccd13d28-b94b-434f-8b90-92cdf16df7cd", "node_type": "1", "metadata": {"page_label": "9", "file_name": "hc001042.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\hc001042.pdf", "file_type": "application/pdf", "file_size": 237006, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "d30077fd9347e0599fa84c025db5f6d0d516df71c1958ec107a22b630f9d1959", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Le vieillissement\nde la population risque d'aggraver inexorablement cet \u00e9tat de fait\npar l'augmentation du nombre de diab\u00e9tiques \u00e2g\u00e9s atteints de\npolypathologies. Les progr\u00e8s diagnostiques et th\u00e9rapeutiques ne\nsemblent pas devoir apporter \u00e0 court terme des progr\u00e8s sensibles.\nR\u00e9fl\u00e9chir sur la pr\u00e9vention, les dispositifs de soins et l'\u00e9ducation\ndans le cas du diab\u00e8te, c'est \u00e9galement aborder les questions\nplus g\u00e9n\u00e9rales de la prise en charge au long cours de maladies", "mimetype": "text/plain", "start_char_idx": 2186, "end_char_idx": 2655, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "4d2b869c-48ec-4b59-99c9-f973134c6cde": {"__data__": {"id_": "4d2b869c-48ec-4b59-99c9-f973134c6cde", "embedding": null, "metadata": {"page_label": "10", "file_name": "hc001042.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\hc001042.pdf", "file_type": "application/pdf", "file_size": 237006, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "c9c26e69-9411-4fbf-9e2d-563c1e4eaae2", "node_type": "4", "metadata": {"page_label": "10", "file_name": "hc001042.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\hc001042.pdf", "file_type": "application/pdf", "file_size": 237006, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "8462d64ac5017f540dd3689a0806b19130ded53817e7dd60d326166a53102be2", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "chroniques comme l'hypertension art\u00e9rielle, les cardiopathies\nisch\u00e9miques... (les maladies dites de \u00ab civilisation \u00bb), mais \u00e9galement la maladie de Parkinson, ou l'asthme...\nLe HCSP distingue trois enjeux majeurs \u00e0 propos des diab\u00e8tes\net plus g\u00e9n\u00e9ralement des maladies chroniques :\n1. Structurer et rationaliser les dispositifs de soins sp\u00e9cialis\u00e9s,\n2. Favoriser une v\u00e9ritable \u00e9ducation des patients dans la gestion\nde leur maladie,\n3. Reconna\u00eetre comme l\u00e9gitime le souhait des patients qui revendiquent davantage d'autonomie.\nPar rapport \u00e0 ces enjeux, le HCSP propose cinq principes devant\nguider une politique de sant\u00e9 publique :\n1. Pr\u00e9venir \u00e0 tout \u00e2ge et \u00e0 tous les stades : \u00e9viter l'entr\u00e9e dans\nla maladie, d\u00e9pister le plus pr\u00e9cocement possible, retarder les\n\u00e9volutions,\n2. Coordonner et \u00e9valuer les dispositifs de soins sp\u00e9cialis\u00e9s,\n3. Autonomiser et responsabiliser autant que possible les patients\nen rompant avec les habitudes de prise en charge centr\u00e9es de\nmani\u00e8re exclusive sur l'h\u00f4pital,\n4. D\u00e9centraliser la prise en charge au plus pr\u00e8s de la vie quotidienne,\n5. D\u00e9cloisonner la r\u00e9flexion en substituant une logique de besoin\ndes individus et des populations aux logiques de strat\u00e9gies des\nacteurs sanitaires et des professionnels.\nLes propositions du HCSP\nElles concernent chacune des \u00e9tapes du d\u00e9veloppement du diab\u00e8te non insulino-d\u00e9pendant.\n1. Dans le cas des diab\u00e8tes comme dans le cas des autres maladies chroniques dites \u00ab de civilisation \u00bb, la pr\u00e9vention g\u00e9n\u00e9rale\npasse par l'information syst\u00e9matique de la population sur les\nbonnes pratiques hygi\u00e9no-di\u00e9t\u00e9tiques (alimentation, activit\u00e9 physique...). Cette information est difficile dans un environnement o\u00f9\nles messages diffus\u00e9s aupr\u00e8s de la population sont souvent contradictoires et parfois non scientifiquement fond\u00e9s. Elle doit trouver\nappui :\nG aupr\u00e8s de l'\u00c9ducation nationale par l'int\u00e9gration de ces recommandations dans les programmes scolaires ;\nX\nAvis du Haut Comit\u00e9 de la sant\u00e9 publique\nHaut Comit\u00e9 de la Sant\u00e9 Publique", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2000, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "865f616b-588a-43ff-aa45-b471846b0025": {"__data__": {"id_": "865f616b-588a-43ff-aa45-b471846b0025", "embedding": null, "metadata": {"page_label": "11", "file_name": "hc001042.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\hc001042.pdf", "file_type": "application/pdf", "file_size": 237006, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "61a9d5e2-dd35-47f4-928b-b92e930e5b0b", "node_type": "4", "metadata": {"page_label": "11", "file_name": "hc001042.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\hc001042.pdf", "file_type": "application/pdf", "file_size": 237006, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "071f0ce5b61812b3274dbdf30916e3df8f1d39da0cc47e65aa2ab150ee0d4848", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "XIDiab\u00e8tes. Pr\u00e9vention, dispositifs de soins, \u00e9ducation... / Mai 1998\nG dans la multiplication de r\u00e9seaux fonctionnels ou de programmes locaux d'information et de formation, qui dans certains cas particuliers pourraient prendre la forme de v\u00e9ritables\nconservatoires de sant\u00e9, mais qui s'appuieraient avant tout\nsur des \u00e9changes entre les associations d'usagers et les\nprofessionnels de sant\u00e9 m\u00e9dicaux et param\u00e9dicaux.\nLes actions d'\u00e9ducation devraient \u00eatre diversifi\u00e9es selon les\ntranches d'\u00e2ge des populations concern\u00e9es, le stade d'\u00e9volution\ndu diab\u00e8te ou des maladies chroniques, l'association \u00e0 d'autres\nfacteurs de risque vasculaire, car dans ce cas particulier la pr\u00e9vention doit \u00eatre commune et globale.\n2. Le d\u00e9pistage du DNIDdoit s'adresser prioritairement aux familles\ndont un membre est atteint par cette maladie. En respectant des\npr\u00e9cautions \u00e9thiques, ce type de d\u00e9pistage para\u00eet au HCSP devoir\n\u00eatre syst\u00e9matique.\nIl doit s'adresser \u00e9galement \u00e0 tout patient s\u00e9dentaire et ayant une\nsurcharge pond\u00e9rale, ainsi qu'aux porteurs d'autres facteurs de\nrisque vasculaire.\nPlus g\u00e9n\u00e9ralement le d\u00e9pistage non cibl\u00e9 des diab\u00e8tes doit rester, en l'\u00e9tat actuel de nos connaissances, r\u00e9serv\u00e9 \u00e0 des programmes exp\u00e9rimentaux.\n3. La pr\u00e9vention au stade de la maladie d\u00e9clar\u00e9ea pour but d'\u00e9viter les complications li\u00e9es \u00e0 la persistance de l'hyperglyc\u00e9mie,\nphase de la maladie de co\u00fbt maximal, tant humain que financier.\nLes objectifs sont leur diagnostic pr\u00e9coce, le ralentissement de\nleur \u00e9volution vers l'infirmit\u00e9, la d\u00e9pendance, le d\u00e9c\u00e8s pr\u00e9matur\u00e9.\nLes patients ont besoin de l'intervention r\u00e9p\u00e9t\u00e9e de diff\u00e9rents soignants et sp\u00e9cialistes.\nD\u00e8s le diagnostic de DNID port\u00e9, le patient doit se voir proposer :\nG une \u00e9ducation nutritionnelle continue,\nG une surveillance adapt\u00e9e,\nG des informations compl\u00e8tes sur sa maladie.\nPlus globalement, le HCSP recommande :\nG D'adopter l'objectif de 30 % de patients atteints de DNID\n\u00e9quilibr\u00e9s par les seules mesures hygi\u00e9no-di\u00e9t\u00e9tiques, \u00e0\nl'image des pays europ\u00e9ens voisins (actuellement ce pourcentage en France ne d\u00e9passe pas 10 %) ;", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2075, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "9f1f1659-c08a-4ada-bb46-326301ada008": {"__data__": {"id_": "9f1f1659-c08a-4ada-bb46-326301ada008", "embedding": null, "metadata": {"page_label": "12", "file_name": "hc001042.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\hc001042.pdf", "file_type": "application/pdf", "file_size": 237006, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "f2f99320-8681-427e-8ad9-6f9ffec4f753", "node_type": "4", "metadata": {"page_label": "12", "file_name": "hc001042.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\hc001042.pdf", "file_type": "application/pdf", "file_size": 237006, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "f218d1695336fb8c882503b9c6a9b436fd5678db04c27752f7a96c4bdbd1011a", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "G De favoriser, dans le cadre de la Formation m\u00e9dicale continue obligatoire des professionnels de sant\u00e9, en particulier\ndes m\u00e9decins g\u00e9n\u00e9ralistes, en liaison avec les universit\u00e9s\nm\u00e9dicales, la formation au d\u00e9pistage des signes initiaux de\nla maladie, au conseil hygi\u00e9no-di\u00e9t\u00e9tique, \u00e0 la coordination\ndes interventions de divers professionnels de sant\u00e9 (di\u00e9t\u00e9ticiens, travailleurs sociaux, infirmi\u00e8res...) aupr\u00e8s des\npatients ;\nG De permettre une prise en charge forfaitaire de l'activit\u00e9\nd'\u00e9ducation dans le cadre des activit\u00e9s des r\u00e9seaux fonctionnels ou des programmes locaux \u00e9voqu\u00e9s plus haut ;\nG De reconna\u00eetre la place de l'\u00e9ducation sanitaire sp\u00e9cifiquement dans les consultations et les h\u00f4pitaux de jour, par l'identification d'un acte r\u00e9pertori\u00e9 d'\u00e9ducation prenant en compte\nl'intervention des diff\u00e9rents personnels de sant\u00e9.\nG D'int\u00e9grer aux crit\u00e8res de prise en charge par la S\u00e9curit\u00e9\nsociale des patients atteints de DNID au titre des affections\nde longue dur\u00e9e, l'adoption par le m\u00e9decin de bonnes pratiques de suivi, en particulier en ce qui concerne la p\u00e9riodicit\u00e9 des actes de conseil et de d\u00e9pistage des complications,\ndes examens biologiques et cliniques et de surveillance\nde l'\u00e9quilibre th\u00e9rapeutique.\nL'essentiel de ces recommandations s'applique \u00e9galement au\nDID, mais elles semblent d'ores et d\u00e9j\u00e0 r\u00e9alis\u00e9es en grande partie. Il convient que les pouvoirs publics poursuivent leur soutien\naux associations de malades qui ont prouv\u00e9 leur efficacit\u00e9.\nQuel que soit le diab\u00e8te consid\u00e9r\u00e9, une politique d'accr\u00e9ditation\nde centres de r\u00e9f\u00e9rence r\u00e9gionaux ou interr\u00e9gionaux multidisciplinaires en diab\u00e9tologie, le financement forfaitaire de leurs actions,\nla reconnaissance du r\u00f4le essentiel de certains acteurs (m\u00e9decins de formation diff\u00e9rente, infirmiers, di\u00e9t\u00e9ticiennes, podologues)\nsont n\u00e9cessaires pour rattraper le retard fran\u00e7ais.\nLe d\u00e9veloppement simultan\u00e9 des trois niveaux : r\u00e9seaux fonctionnels ou programmes locaux, consultations et h\u00f4pitaux de jour,\ncentres de r\u00e9f\u00e9rence r\u00e9gionaux ou interr\u00e9gionaux, appara\u00eet indispensable.\nEnfin, le HCSP recommande :\nG De poursuivre la r\u00e9flexion sur les diab\u00e8tes et les autres maladies chroniques, permettant en particulier de d\u00e9finir une\nXII\nAvis du Haut Comit\u00e9 de la sant\u00e9 publique\nHaut Comit\u00e9 de la Sant\u00e9 Publique", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2280, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "09187cd7-83b8-4393-ba2a-4a4bcda071b3": {"__data__": {"id_": "09187cd7-83b8-4393-ba2a-4a4bcda071b3", "embedding": null, "metadata": {"page_label": "13", "file_name": "hc001042.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\hc001042.pdf", "file_type": "application/pdf", "file_size": 237006, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "499f733c-5204-45b4-94d0-18bafa91b4f1", "node_type": "4", "metadata": {"page_label": "13", "file_name": "hc001042.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\hc001042.pdf", "file_type": "application/pdf", "file_size": 237006, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "ce3ffa3d3689ee5f8f81b7db365eee3701643246b1ac0463820e8322cda910a1", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "XIIIDiab\u00e8tes. Pr\u00e9vention, dispositifs de soins, \u00e9ducation... / Mai 1998\nm\u00e9thodologie d'analyse des probl\u00e8mes de sant\u00e9 publique pos\u00e9s\npar la n\u00e9cessit\u00e9 de prises en charge au long cours ;\nG De lancer un programme de recherche et d'\u00e9valuation des\ndispositifs de soins les plus adapt\u00e9s, en particulier au plan\n\u00e9conomique ;\nG De favoriser le d\u00e9veloppement de programmes r\u00e9gionaux de\nsant\u00e9 qui soient exemplaires en faveur de la pr\u00e9vention et\nde la prise en charge \u00e0 chacun des stades des maladies\nchroniques, comme cela pourrait \u00eatre le cas par exemple\npour les diab\u00e8tes et l'hypertension art\u00e9rielle dans les DOMTOM. La cr\u00e9ation de p\u00f4les de sant\u00e9 charg\u00e9s de la coordination et de l'animation dans ce domaine devrait \u00eatre\nenvisag\u00e9e, en les inscrivant dans une perspective g\u00e9n\u00e9rale de promotion de la sant\u00e9 \u00e0 l'\u00e9chelle r\u00e9gionale.\nAvis adopt\u00e9 par le Haut Comit\u00e9 de la sant\u00e9 publique\nlors de sa s\u00e9ance pl\u00e9ni\u00e8re du 20 mai 1998", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 916, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "d4ff86bc-7554-40a3-b2b6-8c29310f294e": {"__data__": {"id_": "d4ff86bc-7554-40a3-b2b6-8c29310f294e", "embedding": null, "metadata": {"page_label": "14", "file_name": "hc001042.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\hc001042.pdf", "file_type": "application/pdf", "file_size": 237006, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "497f0518-c964-43d5-aa9f-1192b65512cf", "node_type": "4", "metadata": {"page_label": "14", "file_name": "hc001042.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\hc001042.pdf", "file_type": "application/pdf", "file_size": 237006, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "51367757fb0a4620063b96d4fa9a758547b89e1c9be08442347e70cca51c5df0", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 0, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "749bdb7c-bb6f-429f-9d16-85a2e8cb2888": {"__data__": {"id_": "749bdb7c-bb6f-429f-9d16-85a2e8cb2888", "embedding": null, "metadata": {"page_label": "15", "file_name": "hc001042.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\hc001042.pdf", "file_type": "application/pdf", "file_size": 237006, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "b2655f5a-84c8-4f92-9300-c6d606b26525", "node_type": "4", "metadata": {"page_label": "15", "file_name": "hc001042.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\hc001042.pdf", "file_type": "application/pdf", "file_size": 237006, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "5a6b66fd3fe6329334aa57835dbfcfdc9500bbfd2d542442610abb9906ecc5f5", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "1Diab\u00e8tes. Pr\u00e9vention, dispositifs de soins, \u00e9ducation... / Mai 1998\nINTRODUCTION\nLe terme de diab\u00e8te d\u00e9signe un ensemble d'affections graves, et\nde longue dur\u00e9e, responsables d'une morbidit\u00e9 et d'une mortalit\u00e9\nconsid\u00e9rables dans notre pays. Les diab\u00e8tes, outre des risques sp\u00e9cifiques, sont sources de complications invalidantes et co\u00fbteuses.\nMaladies chroniques, les diab\u00e8tes entra\u00eenent pour le patient un\ntraitement quotidien, jusqu'\u00e0 la fin de la vie. Il n'existe donc pas\nactuellement de traitements curatifs. La mise en \u0153uvre des traitements passe par une organisation m\u00e9dicalis\u00e9e de soins mais\naussi par une vigilance importante et permanente du patient qui\ndoit acqu\u00e9rir une r\u00e9elle comp\u00e9tence face \u00e0 la maladie. \u00c0 ce titre,\nles diab\u00e8tes sont parfois consid\u00e9r\u00e9s comme le mod\u00e8le des maladies chroniques.\nPour la pr\u00e9valence des diab\u00e8tes, notre pays occupe une place\nmoyenne en Europe. L'\u00e9tiologie des diab\u00e8tes, malgr\u00e9 l'identification de certains facteurs de risques g\u00e9n\u00e9tiques et environnementaux, reste incompl\u00e8tement connue.\nLa d\u00e9finition du diab\u00e8te a pris longtemps des significations diff\u00e9rentes, la caract\u00e9risation actuelle des deux formes principales\nde diab\u00e8te (insulino-d\u00e9pendant, non insulino-d\u00e9pendant) est d'abord\nfond\u00e9e sur les sp\u00e9cificit\u00e9s des traitements. D'autres arguments,\nen particulier du point de vue de la sant\u00e9 publique, justifiaient,\nnous a-t-il sembl\u00e9, l'utilisation du pluriel dans la d\u00e9nomination :\nles diab\u00e8tes.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1444, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "f178ef04-071e-4ca8-a92e-c786a73d2fda": {"__data__": {"id_": "f178ef04-071e-4ca8-a92e-c786a73d2fda", "embedding": null, "metadata": {"page_label": "16", "file_name": "hc001042.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\hc001042.pdf", "file_type": "application/pdf", "file_size": 237006, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "0092d6d0-4c6b-47ff-98f7-07d31290fccd", "node_type": "4", "metadata": {"page_label": "16", "file_name": "hc001042.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\hc001042.pdf", "file_type": "application/pdf", "file_size": 237006, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "763b0e6f92fa4a06756bbee01754e5a154929498267f6e47445a1aed2c777d6e", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Introduction :\nHaut Comit\u00e9 de la Sant\u00e9 Publique\nDiff\u00e9rents progr\u00e8s ont permis une nette am\u00e9lioration de la prise\nen charge du diab\u00e8te insulino-d\u00e9pendant, dont les principales complications aigu\u00ebs et chroniques peuvent \u00eatre aujourd'hui \u00e9vit\u00e9es\nou retard\u00e9es. La pr\u00e9vention, le traitement et la prise en charge du\ndiab\u00e8te non insulino-d\u00e9pendant, en revanche, n'apparaissent pas\nactuellement satisfaisants du point de vue de la sant\u00e9 publique.\nEn France, la prise en charge des diab\u00e8tes s'inscrit depuis quelques\nann\u00e9es dans des pr\u00e9occupations formalis\u00e9es en 1989 par la D\u00e9claration de Saint-Vincent (Annexe II). Cette d\u00e9claration marque le\nd\u00e9but d'une \u00e9volution qui concerne l'ensemble de la prise en\ncharge des diab\u00e8tes, et se fonde principalement sur le concept,\nr\u00e9cemment tr\u00e8s valoris\u00e9, d'\u00e9ducation du patient. N\u00e9anmoins, cette\n\u00e9ducation appara\u00eet pens\u00e9e dans une approche tr\u00e8s m\u00e9dicalis\u00e9e\net ne prend pas suffisamment en compte d'autres aspects du\nrisque vasculaire global.\nDans un tel contexte, des lacunes importantes du syst\u00e8me actuel\nde prise en charge des diff\u00e9rentes formes de diab\u00e8tes demeurent : les priorit\u00e9s de la recherche sont mal d\u00e9finies, les donn\u00e9es\n\u00e9pid\u00e9miologiques sont incompl\u00e8tes, l'organisation de la prise\nen charge et de l'\u00e9ducation du patient est ax\u00e9e largement autour\nde l'apparition des complications \u00e0 un stade tardif d'\u00e9volution de\nla maladie, la prise en charge est tr\u00e8s hospitalo-centr\u00e9e.\nEn cela les diab\u00e8tes peuvent \u00e9galement \u00eatre consid\u00e9r\u00e9s comme\nun mod\u00e8le embl\u00e9matique d'un ensemble de pathologies qui, par\nleurs cons\u00e9quences sanitaires, \u00e9conomiques et sociales constituent d\u00e9sormais l'un des enjeux majeurs de la sant\u00e9 publique :\nles maladies chroniques.\nNombreuses, diverses, les maladies chroniques sont caract\u00e9ris\u00e9es par le fait que la m\u00e9decine ne peut pas les gu\u00e9rir compl\u00e8tement. Le patient doit donc apprendre \u00e0 vivre longtemps avec sa\nmaladie. Leur d\u00e9finition, comme nous le verrons, ne fait pas\naujourd'hui l'objet d'un consensus absolu, et m\u00eale des crit\u00e8res\nm\u00e9dicaux \u00e0 d'autres beaucoup plus juridiques ou sociaux.\nCe rapport n'a pas vocation \u00e0 exposer l'ensemble des probl\u00e8mes\nscientifiques li\u00e9s aux diab\u00e8tes. Il entend r\u00e9pondre \u00e0 deux questions : quels sont les d\u00e9fis que les diab\u00e8tes posent au syst\u00e8me\nde sant\u00e9 ? quelles dispositions permettraient d'am\u00e9liorer leur pr\u00e9vention et leur prise en charge ?\nNous le verrons, ces questions soul\u00e8vent des d\u00e9bats complexes.\nLa premi\u00e8re partie du rapport proposera une \u00ab photographie \u00bb des\naspects \u00e9pid\u00e9miologiques et m\u00e9dicaux des diab\u00e8tes. Elle exa-", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2536, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "c9d94768-9bc1-438d-b948-adde876ad41a": {"__data__": {"id_": "c9d94768-9bc1-438d-b948-adde876ad41a", "embedding": null, "metadata": {"page_label": "17", "file_name": "hc001042.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\hc001042.pdf", "file_type": "application/pdf", "file_size": 237006, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "3dc9ec91-2f71-4e61-b257-16970c36950e", "node_type": "4", "metadata": {"page_label": "17", "file_name": "hc001042.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\hc001042.pdf", "file_type": "application/pdf", "file_size": 237006, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "95f2f6dfc68dc3a3aa88fd53d7b0edac537ddb511bf42d2c91394d585efca1c1", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "3Diab\u00e8tes. Pr\u00e9vention, dispositifs de soins, \u00e9ducation... / Mai 1998\nminera aussi l'histoire de la compr\u00e9hension m\u00e9dicale des troubles\net de leurs causes ainsi que celle de leurs repr\u00e9sentations sociales.\nLa deuxi\u00e8me partie du rapport examinera trois enjeux pos\u00e9s par\nle d\u00e9veloppement des diab\u00e8tes en tant que maladies chroniques :\n1. La n\u00e9cessit\u00e9 d'une adaptation et d'une organisation des dispositifs de soins :\n2. La n\u00e9cessit\u00e9 de mettre en place de v\u00e9ritables proc\u00e9dures d'\u00e9ducation du patient \u00e0 la sant\u00e9.\n3. L'\u00e9mergence d'une attitude des patients caract\u00e9ris\u00e9e par une\nimplication croissante pouvant parfois \u00eatre qualifi\u00e9e de \u00ab consum\u00e9risme m\u00e9dical \u00bb.\nEnfin, la troisi\u00e8me partie proposera diff\u00e9rentes dispositions permettant l'am\u00e9lioration de la prise en charge des diab\u00e8tes. Ces\ndispositions concernent : le syst\u00e8me actuel de pr\u00e9vention ; le syst\u00e8me de soins ; et, ce troisi\u00e8me point \u00e9tant bien moins cern\u00e9\naujourd'hui, le mouvement d'autonomisation des patients.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 968, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "d63a747a-3cfb-47bd-8e77-1296fc3a493b": {"__data__": {"id_": "d63a747a-3cfb-47bd-8e77-1296fc3a493b", "embedding": null, "metadata": {"page_label": "18", "file_name": "hc001042.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\hc001042.pdf", "file_type": "application/pdf", "file_size": 237006, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "dbfcaf4d-6935-46c0-9bd3-609b4e5b0b11", "node_type": "4", "metadata": {"page_label": "18", "file_name": "hc001042.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\hc001042.pdf", "file_type": "application/pdf", "file_size": 237006, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "090832958a314349b757d78c3d19aaa333f5168c700881b1156cfbb1f34d7ec5", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 0, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "9ee1407d-ae29-4f01-97e5-d02c7339bfe1": {"__data__": {"id_": "9ee1407d-ae29-4f01-97e5-d02c7339bfe1", "embedding": null, "metadata": {"page_label": "19", "file_name": "hc001042.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\hc001042.pdf", "file_type": "application/pdf", "file_size": 237006, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "c977b057-87fc-4bcc-a9cb-efd109f7f647", "node_type": "4", "metadata": {"page_label": "19", "file_name": "hc001042.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\hc001042.pdf", "file_type": "application/pdf", "file_size": 237006, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "3b2bfb19fee7fc2058e161e7c47a70f862b78e550d5ad71c244d28b6c6239460", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "5Diab\u00e8tes. Pr\u00e9vention, dispositifs de soins, \u00e9ducation... / Mai 1998\nD\u00e9finition\nLes diab\u00e8tes\nQuels sont les probl\u00e8mes sanitaires pos\u00e9s par les diab\u00e8tes et\nquelle est leur importance ? Quels sont les crit\u00e8res retenus pour\nles mesurer ?\nIl est important de pr\u00e9ciser que nous avons prioritairement mis\nen avant les aspects li\u00e9s au diab\u00e8te non insulino-d\u00e9pendant par\ncomparaison \u00e0 ceux li\u00e9s au diab\u00e8te insulino-d\u00e9pendant. Nous tenterons, tout au long de ce rapport, de justifier ce choix qui nous\npara\u00eet le plus pertinent du point de vue de la sant\u00e9 publique.\nLa maladie\nLa d\u00e9finition des diab\u00e8tes est une question particuli\u00e8rement difficile, sans doute centrale, et d'une br\u00fblante actualit\u00e9 puisque\nl'OMS se pr\u00e9pare \u00e0 adopter de nouveaux crit\u00e8res de diagnostic.\nNotre sentiment est que la primaut\u00e9 habituelle accord\u00e9e aux\naspects \u00e9pid\u00e9miologiques dans la d\u00e9finition des diab\u00e8tes ne rend\npas compte de l'ensemble des questions soulev\u00e9es. Bien que\nconnus depuis longtemps, les diab\u00e8tes ont \u00e9t\u00e9 progressivement\nd\u00e9finis gr\u00e2ce \u00e0 des crit\u00e8res de diagnostic cliniques et biologiques.\nL'OMS est parvenue en 1985 \u00e0 proposer une classification des\ndiab\u00e8tes (Tableau I).\nCette classification a mis fin \u00e0 une rigueur \u00e9pid\u00e9miologique insuffisante jusque-l\u00e0. Le groupe de travail de l'OMS distingue deux", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1286, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "d2d33d92-d728-44df-acba-a36bcefc2931": {"__data__": {"id_": "d2d33d92-d728-44df-acba-a36bcefc2931", "embedding": null, "metadata": {"page_label": "20", "file_name": "hc001042.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\hc001042.pdf", "file_type": "application/pdf", "file_size": 237006, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "294d557d-9b83-4742-bd60-5d62568ededc", "node_type": "4", "metadata": {"page_label": "20", "file_name": "hc001042.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\hc001042.pdf", "file_type": "application/pdf", "file_size": 237006, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "fc61e44c713b6a9159377244a02e56343290e8ecd27cd9d1e89541f8223b088a", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "formes principales de diab\u00e8te sucr\u00e9 qui peuvent \u00eatre pr\u00e9sent\u00e9es en fonction de crit\u00e8res cliniques : insulino-d\u00e9pendant ou non\ninsulino-d\u00e9pendant ou en fonction de crit\u00e8res physiopathologiques :\ntype 1 ou type 2. Ces deux d\u00e9finitions ne se recoupent pas absolument.\nCes deux cat\u00e9gories principales de diab\u00e8te sont caract\u00e9ris\u00e9es par\nla m\u00eame d\u00e9finition de l'OMS :\n\u00ab Le diab\u00e8te est un \u00e9tat d'hyperglyc\u00e9mie, c'est-\u00e0-dire de concentration excessive de glucose dans le sang, qui peut r\u00e9sulter de\nnombreux facteurs g\u00e9n\u00e9tiques et environnementaux agissant souvent de concert\n1 \u00bb.\n\nLes diab\u00e8tes\nHaut Comit\u00e9 de la Sant\u00e9 Publique\nTableau I\nClassification du diab\u00e8te sucr\u00e9 et des cat\u00e9gories connexes d'intol\u00e9rance au glucose.\nA - Groupes cliniques\nDiab\u00e8te sucr\u00e9\nG Diab\u00e8te insulino-d\u00e9pendant\nG Diab\u00e8te non insulino-d\u00e9pendant\n\u2022 avec ob\u00e9sit\u00e9\n\u2022 sans ob\u00e9sit\u00e9\nG Diab\u00e8te sucr\u00e9 li\u00e9 \u00e0 la malnutrition\nG Autres types de diab\u00e8tes associ\u00e9s \u00e0 certains \u00e9tats et syndromes\n\u2022 affections pancr\u00e9atiques\n\u2022 affections d'\u00e9tiologie virale\n\u2022 affections provoqu\u00e9es par un m\u00e9dicament ou une substance chimique\n\u2022 anomalies de l'insuline et de ses r\u00e9cepteurs\n\u2022 syndromes d'origine g\u00e9n\u00e9tique\n\u2022 divers\nDiminution de la tol\u00e9rance au glucose\nG avec ob\u00e9sit\u00e9\nG sans ob\u00e9sit\u00e9\nG association avec certains \u00e9tats et syndromes\nDiab\u00e8te sucr\u00e9 gravidique\nB - Groupes \u00e0 risque statistique (sujets ayant une tol\u00e9rance normale au glucose\nmais un risque de diab\u00e8te notablement accru)\nAnomalie pr\u00e9alable de la tol\u00e9rance au glucose\nAnomalie potentielle de la tol\u00e9rance au glucose\nD'apr\u00e8s le rapport du Groupe d'\u00e9tude de l'OMS, 1985.\n1. OMS, Deuxi\u00e8me rapport du Comit\u00e9 d'experts sur le diab\u00e8te sucr\u00e9, 1985.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1644, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "5815acb0-de0e-4759-8014-6e1c3e09702b": {"__data__": {"id_": "5815acb0-de0e-4759-8014-6e1c3e09702b", "embedding": null, "metadata": {"page_label": "21", "file_name": "hc001042.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\hc001042.pdf", "file_type": "application/pdf", "file_size": 237006, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "e1dafaea-68ff-4ec8-be24-69ce949d0dd9", "node_type": "4", "metadata": {"page_label": "21", "file_name": "hc001042.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\hc001042.pdf", "file_type": "application/pdf", "file_size": 237006, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "3c498cb4bf7b42702944e254e02373de14da88ccf7c54b15fbffff585330d142", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "7Diab\u00e8tes. Pr\u00e9vention, dispositifs de soins, \u00e9ducation... / Mai 1998\nToutes deux repr\u00e9sentent des maladies chroniques, c'est-\u00e0-dire\n\u00ab d'\u00e9volution lente, de longue dur\u00e9e 2 \u00bb. Les diab\u00e8tes sont des\nmaladies qui durent toute la vie, m\u00eame si certaines pr\u00e9cautions\nalimentaires, une activit\u00e9 physique r\u00e9guli\u00e8re, et, si n\u00e9cessaire,\ndes traitements m\u00e9dicamenteux, dont l'insuline, permettent de\nralentir l'\u00e9volution des complications et d'att\u00e9nuer les principaux sympt\u00f4mes. Ils frappent des individus de tous \u00e2ges et entra\u00eenent un mauvais \u00e9tat de sant\u00e9 permanent. Ils sont \u00e9galement\nsources de risques accrus pour des complications diverses, fr\u00e9quentes et graves. Ils entra\u00eenent des d\u00e9c\u00e8s pr\u00e9matur\u00e9s.\n\u00c0 la suite des travaux du groupe d'\u00e9tude de l'OMS, deux principaux crit\u00e8res de diagnostic ont \u00e9t\u00e9 propos\u00e9s.\nLe premier repose sur la glyc\u00e9mie \u00e0 jeun, le groupe de travail proposant le diagnostic de diab\u00e8te pour tous les individus pr\u00e9sentant\ndes sympt\u00f4mes francs associ\u00e9s \u00e0 des glyc\u00e9mies \u00e9lev\u00e9es.\nIl faut cependant noter la mauvaise reproductibilit\u00e9 d'un dosage\nisol\u00e9 de la glyc\u00e9mie\n3. Par ailleurs, jusqu'\u00e0 une p\u00e9riode r\u00e9cente,\naucun consensus n'existait, ni sur la m\u00e9thodologie des \u00e9preuves\nd'hyperglyc\u00e9mie, ni sur les crit\u00e8res de diagnostic fond\u00e9s sur leurs\nr\u00e9sultats. C'est pourquoi a \u00e9t\u00e9 propos\u00e9e une seconde m\u00e9thode,\nreposant sur une \u00e9preuve d'hyperglyc\u00e9mie provoqu\u00e9e par la prise\nde 75 g de glucose. La principale limite de cette deuxi\u00e8me m\u00e9thode\nprovient du fait que les valeurs-limites qui ont \u00e9t\u00e9 fix\u00e9es (deux\nheures apr\u00e8s charge) proviennent d'\u00e9tudes \u00e9pid\u00e9miologiques portant sur un nombre d'individus relativement faible.\nNotons qu'en France le dosage de la glyc\u00e9mie est l'examen biologique le plus demand\u00e9 : 8 % de la totalit\u00e9 des examens biologiques prescrits en 1992 (source : CNAMTS) c'est-\u00e0-dire\n24,3 millions d'examens.\n2. Masson, m\u00e9decine et biologie. incomplet\n3. Le chiffre obtenu n'est confirm\u00e9 que dans 20 % des cas lors d'un r\u00e9cent contr\u00f4le.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1958, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "b9b230c6-04d1-4f46-8604-ae89941faa44": {"__data__": {"id_": "b9b230c6-04d1-4f46-8604-ae89941faa44", "embedding": null, "metadata": {"page_label": "22", "file_name": "hc001042.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\hc001042.pdf", "file_type": "application/pdf", "file_size": 237006, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "0d624cea-4278-4749-a2ce-8e50aef53acb", "node_type": "4", "metadata": {"page_label": "22", "file_name": "hc001042.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\hc001042.pdf", "file_type": "application/pdf", "file_size": 237006, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "ceeb2b3a93e7520e72f5ba8d7a648c986ebe9b3175ec5185f9dae3ee62415aaf", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "En tout \u00e9tat de cause, les valeurs actuellement accept\u00e9es sont\nles suivantes :\n\nLes diab\u00e8tes\nHaut Comit\u00e9 de la Sant\u00e9 Publique\nTableau II\nValeurs diagnostiques de l'\u00e9preuve d'hyperglyc\u00e9mie provoqu\u00e9e par voie orale\nConcentration en glucose (mmol/l(mg/dl))\nSang total Plasma\nveineux capillaire veineux capillaire\nDiab\u00e8te sucr\u00e9\nValeur \u00e0 jeun > 6,7 > 6,7 > 7,8 > 7,8\n(\u2265 120) ( \u2265 120) ( \u2265 140) ( \u2265 140)\nValeur apr\u00e8s charge < 10,0 > 11,1 > 11,1 > 12,2\nglucos\u00e9e ( \u2265 180) ( \u2265 200) ( \u2265 200) ( \u2265 220)\nDiminution de la\ntol\u00e9rance au glucose\nValeur \u00e0 jeun < 6,7 < 6,7 < 7,8 < 7,8\n(< 120) (< 120) (< 140) (< 140)\nValeur apr\u00e8s charge 6,7 - 10,0 7,8 - 11,1 7,8 - 11,1 8,9 - 12,2\nglucos\u00e9e (120 - 180) (140 - 200) (140 - 200) (160 - 220)\nD'apr\u00e8s le rapport du Groupe d'\u00e9tude de l'OMS, 1985.\nEnfin, les m\u00e9thodes de dosage de l'h\u00e9moglobine glyqu\u00e9e ne sont\npas standardis\u00e9es, interdisant \u00e0 l'heure actuelle leur utilisation\nen tant que crit\u00e8re diagnostique malgr\u00e9 l'int\u00e9r\u00eat qu'elles pr\u00e9sentent. Le dosage permet en effet de rep\u00e9rer la qualit\u00e9 de la r\u00e9gulation glyc\u00e9mique sur une p\u00e9riode de plusieurs semaines pr\u00e9c\u00e9dant\nla prise de sang.\nPrincipales complications\nLes deux principaux types de diab\u00e8te induisent \u00e0 la fois des manifestations cliniques communes et des manifestations sp\u00e9cifiques.\nParmi ces derni\u00e8res, les complications aigu\u00ebs du diab\u00e8te insulinod\u00e9pendant sont des urgences m\u00e9taboliques (malaises voire comas),\npar hyperglyc\u00e9mie et acidoc\u00e9tose (insuline non prescrite ou insuffisamment dos\u00e9e), mais aussi par hypoglyc\u00e9mie r\u00e9sultant de l'administration de quantit\u00e9s inadapt\u00e9es d'insuline.\nEn revanche, les complications chroniques et d\u00e9g\u00e9n\u00e9ratives peuvent survenir pour les deux types de diab\u00e8te : r\u00e9tinopathies, insuffisances r\u00e9nales, micro- et macro-angiopathies, neuropathies.\nNous y reviendrons.\nLes deux types de diab\u00e8te peuvent \u00e9galement occasionner des\ntroubles graves lors de la grossesse. Pour le diab\u00e8te non insulino-", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1916, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "8fcc5806-c405-4dac-850f-98436af58234": {"__data__": {"id_": "8fcc5806-c405-4dac-850f-98436af58234", "embedding": null, "metadata": {"page_label": "23", "file_name": "hc001042.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\hc001042.pdf", "file_type": "application/pdf", "file_size": 237006, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "75c5e054-2896-4d08-a3bb-91740e395995", "node_type": "4", "metadata": {"page_label": "23", "file_name": "hc001042.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\hc001042.pdf", "file_type": "application/pdf", "file_size": 237006, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "457ca713c984c1fbcda72bc725a1337c3d1f53a92b9f881e5ab01d177135255f", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "9Diab\u00e8tes. Pr\u00e9vention, dispositifs de soins, \u00e9ducation... / Mai 1998\nd\u00e9pendant, cette \u00e9tape de la vie repr\u00e9sente, en outre, le moment\nprivil\u00e9gi\u00e9 de d\u00e9couverte de l'\u00e9tat diab\u00e9tique, puisqu'un poids anormalement \u00e9lev\u00e9 du nouveau-n\u00e9 peut t\u00e9moigner d'un fort risque de\ndiab\u00e8te de la m\u00e8re et/ou de l'enfant.\nC'est bien la probabilit\u00e9 forte de complications graves, parce que\ntr\u00e8s invalidantes et co\u00fbteuses, qui rend cruciale la recherche de\nbons crit\u00e8res de diagnostic et de classification des diab\u00e8tes. Dans\nle cas du DNID, les d\u00e9bats actuels nous paraissent pouvoir \u00eatre\nr\u00e9sum\u00e9s de la mani\u00e8re suivante.\n1. Il existe des points de vue divergents sur le statut de l'hyperglyc\u00e9mie quand elle est \u00e9lev\u00e9e et qu'elle atteint ou d\u00e9passe le\nseuil de 1,40 g/litre (seuil que l'OMS propose d'abaisser \u00e0\n1,20 g/litre).\nFaut-il la consid\u00e9rer comme un facteur de risque vasculaire\n(macroangiopathie) parmi d'autres au m\u00eame titre que l'hypertension art\u00e9rielle, les dyslipid\u00e9mies avec lesquelles elle est souvent intriqu\u00e9e ?\nExiste t-il un continuum du risque pour le patient dans le temps,\ncorr\u00e9l\u00e9 aux niveaux successifs de la glyc\u00e9mie ? Faut-il, au contraire,\nassocier de fa\u00e7on privil\u00e9gi\u00e9e l'appellation \u00ab diab\u00e8te \u00bb \u00e0 la pr\u00e9sence\nde complications microangiopathiques ?\n2. Dans le cas des DNID, il semble bien que, malgr\u00e9 la constance\nde l'hyperglyc\u00e9mie, les m\u00e9canismes physiopathologiques soient\nfortement h\u00e9t\u00e9rog\u00e8nes. En particulier s'il existe en g\u00e9n\u00e9ral une\nr\u00e9sistance \u00e0 l'action de l'insuline, sa s\u00e9cr\u00e9tion peut-\u00eatre normale, augment\u00e9e ou abaiss\u00e9e.\nEn r\u00e9sum\u00e9, il importe que la d\u00e9finition des diab\u00e8tes, leur classification, la validation de leurs crit\u00e8res diagnostiques permettent\nla prise en charge la plus efficace des personnes et des populations confront\u00e9es \u00e0 ces probl\u00e8mes pathologiques. C'est donc,\nnous semble-t-il, une approche pragmatique et non acad\u00e9mique\nqui doit pr\u00e9valoir.\nDeux exemples serviront \u00e0 expliciter ce point :\n1. Pour un patient ayant une h\u00e9r\u00e9dit\u00e9 familiale de DNID et ne ma\u00eetrisant pas son poids, le risque pathog\u00e8ne pr\u00e9c\u00e8de longuement\ndans le temps la pr\u00e9sence de l'hyperglyc\u00e9mie.\n2. Pour une population de patients atteints de surcharge pond\u00e9rale et/ou d'hypertension art\u00e9rielle, et/ou de dyslipid\u00e9mies,\net/ou de tabagisme et/ou d'hyperglyc\u00e9mie, la n\u00e9cessit\u00e9 de pouvoir b\u00e9n\u00e9ficier d'une (r\u00e9)\u00e9ducation di\u00e9t\u00e9tique et d'une (r\u00e9)\u00e9du-", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2344, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "f17a7788-cd5e-4b7d-a90f-aaf4d175d64a": {"__data__": {"id_": "f17a7788-cd5e-4b7d-a90f-aaf4d175d64a", "embedding": null, "metadata": {"page_label": "24", "file_name": "hc001042.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\hc001042.pdf", "file_type": "application/pdf", "file_size": 237006, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "b6e6393c-e92e-450d-8c9b-fc352baf87a7", "node_type": "4", "metadata": {"page_label": "24", "file_name": "hc001042.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\hc001042.pdf", "file_type": "application/pdf", "file_size": 237006, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "06d09412e31428b5ca41344209b7c051195bbb3cbe1e55475577e2797d3e1eab", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b96653dd-cfc1-449c-add4-142cfdb13818", "node_type": "1", "metadata": {}, "hash": "ff86f7133f2407c0e432abfb3bb1f4ac8022485992cc40ac3df430654b0157ad", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "\u00c9pid\u00e9miologie\ndes diab\u00e8tes\net des\ncomplications\nd\u00e9g\u00e9n\u00e9ratives\ncation physique sera commune dans les pratiques et dans les\nprincipes m\u00eame si les crit\u00e8res d'efficacit\u00e9 de cette d\u00e9marche\ndevront \u00eatre individualis\u00e9s.\nL'histoire naturelle des diab\u00e8tes peut \u00eatre tr\u00e8s diff\u00e9rente. Pour le\ndiab\u00e8te non insulino-d\u00e9pendant, en effet, la maladie \u00e9volue longuement de mani\u00e8re asymptomatique, et l'entr\u00e9e en maladie n'est\npas ais\u00e9ment identifiable. Le calcul de la fr\u00e9quence de la maladie\nrepose donc sur l'estimation d'une pr\u00e9valence \u00e0 partir d'\u00e9chantillons transversaux. Pour le diab\u00e8te insulino-d\u00e9pendant, en\nrevanche, le d\u00e9but de la maladie est toujours identifi\u00e9 car accompagn\u00e9 de sympt\u00f4mes s\u00e9v\u00e8res. L'\u00e9tude est donc fond\u00e9e sur le\nrecueil syst\u00e9matique des informations m\u00e9dicales au moment du\ndiagnostic, et le calcul d'une incidence dans une r\u00e9gion donn\u00e9e\nest possible (existence de registres).\nNous ne pr\u00e9senterons dans ce rapport que les donn\u00e9es concernant directement les objectifs qui lui ont \u00e9t\u00e9 assign\u00e9s. Pour une\nanalyse plus d\u00e9taill\u00e9e de l'\u00e9pid\u00e9miologie des diab\u00e8tes et de leurs\ncomplications, nous ne pouvons que renvoyer aux ouvrages sp\u00e9cialis\u00e9s\n4.\nLe diab\u00e8te est une maladie tr\u00e8s fr\u00e9quente en France, puisque l'on\n\u00e9value le nombre de patients entre un million deux cent mille et\nun million cinq cent mille, ce qui repr\u00e9sente un taux de pr\u00e9valence\nde l'ordre de 2 \u00e0 2,5 % tous \u00e2ges confondus, dont 8 % d'insulinod\u00e9pendants soit environ 120 000 patients.\nToutes formes confondues, il est int\u00e9ressant de noter que la\nfr\u00e9quence des diab\u00e8tes dans la population augmente rapidement\n\u00e0 partir de 45 ans pour culminer entre 55 et 75 ans. Par ailleurs,\nle vieillissement de la population permet de pr\u00e9dire une augmentation sensible du nombre de patients diab\u00e9tiques \u00e2g\u00e9s atteints\nde polypathologies et posant des probl\u00e8mes complexes et lourds\nde prise en charge. D'ores et d\u00e9j\u00e0, 43 % des patients sont \u00e2g\u00e9s\nde plus de 65 ans. Une singularit\u00e9 fran\u00e7aise est un sex ratiovariant\nde 1,2 \u00e0 1,4 suivant les diff\u00e9rentes \u00e9tudes, la population masculine \u00e9tant surrepr\u00e9sent\u00e9e. L'estimation de la fr\u00e9quence des cas\nnon d\u00e9pist\u00e9s est plus d\u00e9licate. Des actions de d\u00e9pistage r\u00e9alis\u00e9es selon les crit\u00e8res OMS ont permis d'estimer \u00e0 un taux de\n0,4 %, tous \u00e2ges confondus, la pr\u00e9valence de diab\u00e8tes non diagnostiqu\u00e9s dans la population g\u00e9n\u00e9rale, ce qui repr\u00e9senterait environ 250 000 personnes.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2370, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "b96653dd-cfc1-449c-add4-142cfdb13818": {"__data__": {"id_": "b96653dd-cfc1-449c-add4-142cfdb13818", "embedding": null, "metadata": {"page_label": "24", "file_name": "hc001042.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\hc001042.pdf", "file_type": "application/pdf", "file_size": 237006, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "b6e6393c-e92e-450d-8c9b-fc352baf87a7", "node_type": "4", "metadata": {"page_label": "24", "file_name": "hc001042.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\hc001042.pdf", "file_type": "application/pdf", "file_size": 237006, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "06d09412e31428b5ca41344209b7c051195bbb3cbe1e55475577e2797d3e1eab", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f17a7788-cd5e-4b7d-a90f-aaf4d175d64a", "node_type": "1", "metadata": {"page_label": "24", "file_name": "hc001042.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\hc001042.pdf", "file_type": "application/pdf", "file_size": 237006, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "07f593523ba9f8dc2c15c239542539f2ed0a57ca62f7b7ef1435b77dcd14589f", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "L'estimation de la fr\u00e9quence des cas\nnon d\u00e9pist\u00e9s est plus d\u00e9licate. Des actions de d\u00e9pistage r\u00e9alis\u00e9es selon les crit\u00e8res OMS ont permis d'estimer \u00e0 un taux de\n0,4 %, tous \u00e2ges confondus, la pr\u00e9valence de diab\u00e8tes non diagnostiqu\u00e9s dans la population g\u00e9n\u00e9rale, ce qui repr\u00e9senterait environ 250 000 personnes.\n\nLes diab\u00e8tes\nHaut Comit\u00e9 de la Sant\u00e9 Publique\n4. Cf. notamment l'ouvrage r\u00e9cent et tr\u00e8s document\u00e9 de C\u00e9cile Delcourt et Laure Papoz, Le Diab\u00e8te et ses complications dans la population fran\u00e7aise , Inserm, Paris, 1996.", "mimetype": "text/plain", "start_char_idx": 2060, "end_char_idx": 2588, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "92be0ea5-e241-41dd-8789-2bca3d44c80f": {"__data__": {"id_": "92be0ea5-e241-41dd-8789-2bca3d44c80f", "embedding": null, "metadata": {"page_label": "25", "file_name": "hc001042.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\hc001042.pdf", "file_type": "application/pdf", "file_size": 237006, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "53e6292d-1e83-42e4-b6dc-bceabdf1d4c0", "node_type": "4", "metadata": {"page_label": "25", "file_name": "hc001042.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\hc001042.pdf", "file_type": "application/pdf", "file_size": 237006, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "45030031b0a71fd5155585335c42f82805ef71350bd6ca102f588245c44522f9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e9e869db-767a-4f3b-a95e-9d87c8bc2c70", "node_type": "1", "metadata": {}, "hash": "d4e4728dc697d1ebb1ae226ed53918ae6733b79fd0877da1818680ef91769f80", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "11Diab\u00e8tes. Pr\u00e9vention, dispositifs de soins, \u00e9ducation... / Mai 1998\nDe mani\u00e8re g\u00e9n\u00e9rale, la pr\u00e9valence des diab\u00e8tes est en augmentation dans l'ensemble des pays industrialis\u00e9s. Si, en Europe,\nla pr\u00e9valence est estim\u00e9e \u00e0 2 %, elle varie de 1,6 % (Irlande du\nNord) \u00e0 3,2 % (Espagne). Tous \u00e2ges confondus, la pr\u00e9valence\nen France serait comprise entre 2 et 2,6 % et celle des \u00c9tats-Unis\n- dont on peut craindre qu'ils repr\u00e9sentent l'avenir des pays postindustriels europ\u00e9ens - approche de 6 %. Pr\u00e8s de 30 % des diab\u00e9tiques observ\u00e9s sont atteints de complications isol\u00e9es et/ou\ndiversement associ\u00e9es entre elles (r\u00e9tinopathies, cataractes,\nn\u00e9phropathies, neuropathies, art\u00e9riopathies). En France m\u00e9tropolitaine, les diab\u00e9tiques repr\u00e9sentent par exemple 7 % des insuffisants r\u00e9naux. Les n\u00e9phropathies diab\u00e9tiques sont observ\u00e9es\nchez 94 % des DID et chez 37 % des DNID.\nLes diab\u00e8tes, sous leurs deux formes principales, repr\u00e9sentent\ndonc du point de vue \u00e9pid\u00e9miologique un probl\u00e8me de sant\u00e9\npublique important en France comme dans le reste du monde.\nMais ce constat global doit conduire \u00e0 une analyse plus fine, cherchant \u00e0 mettre en \u00e9vidence des caract\u00e9ristiques sp\u00e9cifiques \u00e0\nchacune de ces deux formes.\nLe diab\u00e8te non insulino-d\u00e9pendant\nLe diab\u00e8te non insulino-d\u00e9pendant (DNID) affecte plus d'un million de personnes en France (bien que certaines estimations soient\nencore sup\u00e9rieures). Il se d\u00e9clare g\u00e9n\u00e9ralement vers la cinquantaine, bien que certains de ces diab\u00e8tes tardifs n\u00e9cessitent des\ntraitements \u00e0 l'insuline et doivent \u00e0 ce titre \u00eatre rang\u00e9s, du point\nde vue clinique, dans la cat\u00e9gorie des diab\u00e8tes insulino-n\u00e9cessitants.\nLes tendances temporelles montrent une augmentation du nombre\nde diab\u00e9tiques non insulino-d\u00e9pendants recens\u00e9s. Ce ph\u00e9nom\u00e8ne,\nqui pourrait s'expliquer partiellement par une meilleure identification des cas, est \u00e9galement d\u00fb \u00e0 un allongement de l'esp\u00e9rance\nde vie globale de la population, mais aussi, semble-t-il, \u00e0 une augmentation du risque individuel possiblement li\u00e9 aux \u00e9volutions des\ncomportements alimentaires. D'apr\u00e8s ces r\u00e9sultats, on peut\nattendre une forte augmentation des diab\u00e8tes non insulino-d\u00e9pendants autour de l'an 2000 (lorsque les classes d'\u00e2ge du \u00ab babyboom \u00bb atteindront l'\u00e2ge critique). Certaines projections annoncent\nm\u00eame une augmentation du nombre absolu des diab\u00e8tes de plus\nde 40 % dans la tranche active des 45-55 ans.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2379, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "e9e869db-767a-4f3b-a95e-9d87c8bc2c70": {"__data__": {"id_": "e9e869db-767a-4f3b-a95e-9d87c8bc2c70", "embedding": null, "metadata": {"page_label": "25", "file_name": "hc001042.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\hc001042.pdf", "file_type": "application/pdf", "file_size": 237006, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "53e6292d-1e83-42e4-b6dc-bceabdf1d4c0", "node_type": "4", "metadata": {"page_label": "25", "file_name": "hc001042.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\hc001042.pdf", "file_type": "application/pdf", "file_size": 237006, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "45030031b0a71fd5155585335c42f82805ef71350bd6ca102f588245c44522f9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "92be0ea5-e241-41dd-8789-2bca3d44c80f", "node_type": "1", "metadata": {"page_label": "25", "file_name": "hc001042.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\hc001042.pdf", "file_type": "application/pdf", "file_size": 237006, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "798272580aacb7394a20f454b53f3b990584eef357db9acc90d14c094e705e7c", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "D'apr\u00e8s ces r\u00e9sultats, on peut\nattendre une forte augmentation des diab\u00e8tes non insulino-d\u00e9pendants autour de l'an 2000 (lorsque les classes d'\u00e2ge du \u00ab babyboom \u00bb atteindront l'\u00e2ge critique). Certaines projections annoncent\nm\u00eame une augmentation du nombre absolu des diab\u00e8tes de plus\nde 40 % dans la tranche active des 45-55 ans.\nLe diab\u00e8te de type 2 est en pleine expansion dans les DOM-TOM,\nmais il est in\u00e9galement r\u00e9parti dans les diff\u00e9rentes communaut\u00e9s.", "mimetype": "text/plain", "start_char_idx": 2050, "end_char_idx": 2508, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "a3bf1a97-e28a-4077-b352-8a332755a038": {"__data__": {"id_": "a3bf1a97-e28a-4077-b352-8a332755a038", "embedding": null, "metadata": {"page_label": "26", "file_name": "hc001042.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\hc001042.pdf", "file_type": "application/pdf", "file_size": 237006, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "7780c047-eb3e-473e-8acf-3b944fd6f31f", "node_type": "4", "metadata": {"page_label": "26", "file_name": "hc001042.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\hc001042.pdf", "file_type": "application/pdf", "file_size": 237006, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "5bb361ad94cf680eefc4f15f48752fa394a439fa649db6f5f37d21cf4b1bb614", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Notons que l'abaissement probable du seuil de glyc\u00e9mie retenu\npar l'OMS de 1,40 g/l \u00e0 1,20 g/l, comme crit\u00e8re d'entr\u00e9e dans\nles maladies diab\u00e9tiques va conduire \u00e0 consid\u00e9rablement augmenter le nombre de patients \u00ab d\u00e9crits comme diab\u00e9tiques de\ntype 2 \u00bb. On peut estimer que leur nombre s'accro\u00eetrait de plusieurs centaines de milliers en France. Il est facile d'imaginer les\ncons\u00e9quences que cette nouvelle d\u00e9finition risque d'induire dans\nl'organisation de la prise en charge.\nLe r\u00f4le des facteurs g\u00e9n\u00e9tiques dans la maladie est indiscutable\n5 ;\nson apparition est souvent pr\u00e9c\u00e9d\u00e9e par l'installation du syndrome\nd'insulino-r\u00e9sistance, celui-ci succ\u00e9dant lui-m\u00eame \u00e0 une ob\u00e9sit\u00e9\nandro\u00efde pr\u00e9coce (Figure 1).\nIl existe donc un continuum \u00e0 partir de pr\u00e9dispositions g\u00e9n\u00e9tiques,\nconjugu\u00e9es pr\u00e9cocement \u00e0 des facteurs environnementaux, et\nl'apparition ult\u00e9rieure et tardive de la maladie diab\u00e9tique.\n\u00c0 c\u00f4t\u00e9 de l'\u00e9ducation du patient, au stade de la maladie d\u00e9clar\u00e9e,\non entrevoit la n\u00e9cessit\u00e9 incontournable d'une r\u00e9flexion sur la pr\u00e9vention primaire du DNID. Il en est de m\u00eame pour le choix des indicateurs retenus pour \u00e9valuer l'impact d'une politique de sant\u00e9\npublique face \u00e0 cette pathologie. D'ores et d\u00e9j\u00e0, il appara\u00eet que\nprivil\u00e9gier les indicateurs d\u00e9crivant la pr\u00e9sence et la prise en charge\ndes complications risque de restreindre le d\u00e9bat aux aspects\nles plus techniques et les plus m\u00e9dicalis\u00e9s, surtout les plus ultimes\ndans l'histoire de la maladie.\nIl est remarquable que 53 % des hommes et 69 % des femmes\natteints de diab\u00e8te pr\u00e9sentent une surcharge pond\u00e9rale.\nLes ant\u00e9c\u00e9dents de diab\u00e8te chez les parents au premier degr\u00e9\nconcernent 60 % des diab\u00e8tiques dans le cas du DNID.\nEn r\u00e9sum\u00e9 le diab\u00e8te non insulino-d\u00e9pendant peut \u00eatre d\u00e9crit\nen trois \u00e9tapes principales :\nG La premi\u00e8re est celle de la pr\u00e9disposition. La pr\u00e9disposition\nob\u00e9it \u00e0 des facteurs g\u00e9n\u00e9tiques et \u00e0 des facteurs environnementaux, dont la conjugaison aboutit \u00e0 la seconde \u00e9tape.\nLa recherche m\u00e9dicale visant \u00e0 caract\u00e9riser les pr\u00e9dispositions g\u00e9n\u00e9tiques fait aujourd'hui l'objet d'efforts intenses,\nqui n'aboutissent pas pour l'instant \u00e0 de v\u00e9ritables dispositifs d'intervention pr\u00e9ventive pour identifier et corriger des\nfacteurs de risque \u00e9lev\u00e9s.\n\nLes diab\u00e8tes\nHaut Comit\u00e9 de la Sant\u00e9 Publique\n5. 60 % des diab\u00e9tiques NID pr\u00e9sentent des ant\u00e9c\u00e9dents parentaux de diab\u00e8te.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2350, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "038be7ad-d4cb-4ec5-98fb-c9a562b7943b": {"__data__": {"id_": "038be7ad-d4cb-4ec5-98fb-c9a562b7943b", "embedding": null, "metadata": {"page_label": "27", "file_name": "hc001042.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\hc001042.pdf", "file_type": "application/pdf", "file_size": 237006, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "6f62f37e-f4a3-43c0-9080-77f8346a2020", "node_type": "4", "metadata": {"page_label": "27", "file_name": "hc001042.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\hc001042.pdf", "file_type": "application/pdf", "file_size": 237006, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "f93594907bc364512421834e1c7bb10573ae01878f210cfc75e4bdc54228d9d9", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "13Diab\u00e8tes. Pr\u00e9vention, dispositifs de soins, \u00e9ducation... / Mai 1998\nG La seconde \u00e9tape est celle de la maladie d\u00e9clar\u00e9e non encore\ncompliqu\u00e9e . Au cours de cette p\u00e9riode, le contr\u00f4le de la glyc\u00e9mie est g\u00e9n\u00e9ralement encore possible et efficace. Malheureusement, l'absence fr\u00e9quente de sympt\u00f4mes g\u00eanants\nou douloureux n'incite gu\u00e8re le patient \u00e0 se traiter s\u00e9rieusement. Il est pourtant d\u00e9montr\u00e9 qu'un traitement correct\net pr\u00e9coce \u00e9viterait ou retarderait longtemps le passage\nPr\u00e9disposition g\u00e9n\u00e9tique\nOb\u00e9sit\u00e9\nandro\u00ef de\nSurcharge\nS\u00e9dentarit\u00e9\nStress tabac/alcool\nSurcharge calorique\nSyndrome pluri-m\u00e9tabolique\nHTA DNID Maladies\nc\u00e9r\u00e9brovasculaires\nMaladies\ncoronariennes\nMicroangiopathies\nMacroangiopathies\nN\u00e9phropathies R \u00e9tinopathies\nDyalise C \u00e9cit\u00e9\nNeuropathies\nPied diab\u00e9tique\nArt\u00e9rite des membres\ninf\u00e9rieurs\nFigure 1 :\nCauses et cons\u00e9quences\ndu DNIDGilles Errieau 13/1195", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 875, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "f9d19691-7f46-4dfc-87fa-d2940fa0cb29": {"__data__": {"id_": "f9d19691-7f46-4dfc-87fa-d2940fa0cb29", "embedding": null, "metadata": {"page_label": "28", "file_name": "hc001042.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\hc001042.pdf", "file_type": "application/pdf", "file_size": 237006, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "308d2295-23ee-409e-a65c-3f0dc22224a9", "node_type": "4", "metadata": {"page_label": "28", "file_name": "hc001042.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\hc001042.pdf", "file_type": "application/pdf", "file_size": 237006, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "98a04cd57ab487642d80b2a59bc9092930ab04fe20c540aefddae2ab5422e6f3", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "au troisi\u00e8me et dernier stade, le plus souvent dramatique,\nde la maladie. Pour des raisons sur lesquelles nous reviendrons, cette prise de conscience se heurte, dans le cas\ndu DNID, \u00e0 des difficult\u00e9s particuli\u00e8res.\nG La troisi\u00e8me \u00e9tape est marqu\u00e9e par l'apparition des complications d\u00e9g\u00e9n\u00e9ratives communes \u00e0 toutes les formes de\ndiab\u00e8tes et des d\u00e9ficiences graves (c\u00e9cit\u00e9, amputation, insuffisance coronarienne...).\nLes complications d\u00e9g\u00e9n\u00e9ratives chez les diab\u00e9tiques non insulino-d\u00e9pendants ont \u00e9t\u00e9 \u00e9tudi\u00e9es en France dans le cadre de l'\u00e9tude\nCODIAB\n6. Celle-ci r\u00e9v\u00e8le que si la plupart des diagnostics de diab\u00e8te non insulino-d\u00e9pendant sont pos\u00e9s \u00e0 l'occasion d'un dosage\nsyst\u00e9matique de la glyc\u00e9mie, un quart des hommes et 18 % des\nfemmes pr\u00e9sentaient d\u00e9j\u00e0 des signes cardinaux de diab\u00e8te. Par\nailleurs, la r\u00e9tinopathie est pr\u00e9sente chez environ 30 % des diab\u00e9tiques, la microalbuminurie et la prot\u00e9inurie, dont on sait qu'elles\npr\u00e9c\u00e8dent l'insuffisance r\u00e9nale dans 27 % des cas, les neuropathies p\u00e9riph\u00e9riques dans 32 % des cas, les complications cardio-vasculaires (cardiopathies isch\u00e9miques et/ou art\u00e9riopathies\ndes membres inf\u00e9rieurs) environ 20 % des cas. Notons ici que les\ndiab\u00e9tiques non insulino-d\u00e9pendants semblent b\u00e9n\u00e9ficier comme\nle reste de la population fran\u00e7aise d'une relativement faible pr\u00e9valence des maladies cardio-vasculaires. Suivant la nature de ces\ncomplications, la fr\u00e9quence et la gravit\u00e9 sont tant\u00f4t li\u00e9es \u00e0 la dur\u00e9e\ndu diab\u00e8te, tant\u00f4t \u00e0 l'\u00e2ge du patient, tant\u00f4t aux deux. Ces complications sont encore plus graves en cas d'association du diab\u00e8te avec d'autres facteurs de risque cardio-vasculaires\n(hypertension art\u00e9rielle, dyslipid\u00e9mie, tabagisme). Ainsi, dans\nl'\u00e9tude CODIAB, la moiti\u00e9 des patients \u00e9taient trait\u00e9s par un antihypertenseur et pr\u00e8s de 20 % par des hypolip\u00e9miants. Il s'agit\ndonc d'une population polym\u00e9dicament\u00e9e.\nIl existe \u00e0 chaque stade des possibilit\u00e9s (diff\u00e9rentes) d'intervention telles que l'\u00e9volution vers le stade suivant peut \u00eatre enray\u00e9e\nou retard\u00e9e.\nPourquoi cette \u00e9volution para\u00eet-elle souvent si difficile \u00e0 enrayer,\nen particulier par les m\u00e9decins g\u00e9n\u00e9ralistes dont on dit volontiers\nqu'ils devraient assurer prioritairement la prise en charge des\npatients atteints de DNID ?\n\nLes diab\u00e8tes\nHaut Comit \u00e9 de la Sant \u00e9 Publique\n6. C. Delcourt, L. Papoz, op. cit., -78.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2328, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "7ccc946a-9977-49a9-a3b0-d723fc008a1b": {"__data__": {"id_": "7ccc946a-9977-49a9-a3b0-d723fc008a1b", "embedding": null, "metadata": {"page_label": "29", "file_name": "hc001042.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\hc001042.pdf", "file_type": "application/pdf", "file_size": 237006, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "6a568460-1181-4d32-8607-d1b2d35c8532", "node_type": "4", "metadata": {"page_label": "29", "file_name": "hc001042.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\hc001042.pdf", "file_type": "application/pdf", "file_size": 237006, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "a4a78a5d526fa3cab66d0f90442c3f3d3eeb57ce927e067f62369f5e19c2a16f", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "15Diab\u00e8tes. Pr\u00e9vention, dispositifs de soins, \u00e9ducation... / Mai 1998\nLa difficult\u00e9 para\u00eet tenir d'une part \u00e0 la longueur de la p\u00e9riode\nasymptomatique qui pr\u00e9c\u00e8de l'apparition des complications. Elle\ntient \u00e9galement \u00e0 l'anciennet\u00e9 voire \u00e0 l'archa\u00efsme dans l'histoire\ndu sujet des comportements \u00e0 modifier, en particulier les comportements alimentaires. Elle tient enfin probablement, nous y\nreviendrons, \u00e0 la place du DNID dans le regard m\u00e9dical.\nCe contexte favorise vraisemblablement l'ambivalence du patient\net du m\u00e9decin, m\u00eame s'ils sont correctement inform\u00e9s des risques\nde complications graves et invalidantes. On pressent donc la complexit\u00e9 d'installation d'une \u00ab alliance th\u00e9rapeutique \u00bb entre le patient\net le m\u00e9decin g\u00e9n\u00e9raliste.\nEnviron un million de patients sont trait\u00e9s par des hypoglyc\u00e9miants\noraux et seulement dix \u00e0 vingt pour cent par le r\u00e9gime seul, ce qui\nest le plus bas des taux europ\u00e9ens.\nL'efficacit\u00e9 th\u00e9rapeutique du r\u00e9gime di\u00e9t\u00e9tique a pourtant \u00e9t\u00e9\nlargement valid\u00e9e. Nous avons \u00e9voqu\u00e9 la grande fr\u00e9quence de\ncoprescriptions m\u00e9dicamenteuses chez les patients atteints de\ndiab\u00e8te non insulino-d\u00e9pendant. On peut craindre qu'\u00e9merge en\nFrance un mod\u00e8le de soins pour ce type de patients o\u00f9 l'addition de m\u00e9dicaments correspondant \u00e0 autant de facteurs de\nrisque vasculaire soit la r\u00e9ponse univoque \u00e0 une prise en charge\ndu risque vasculaire global. Il existe manifestement un d\u00e9s\u00e9quilibre entre l'information surabondante des m\u00e9decins (qui retentit indirectement sur celle des patients) sur les hypoglyc\u00e9miants\noraux et celle qu'ils re\u00e7oivent si rarement sur les principes hyg\u00e9nio-di\u00e9t\u00e9tiques et les moyens de les mettre en \u0153uvre. Ce d\u00e9s\u00e9quilibre a des effets pervers tant sur l'attitude des m\u00e9decins que\nsur celle des diab\u00e9tiques quant au regard qu'ils portent \u00e0 cette\nmaladie.\nNotons par contre que la prescription d'insuline chez les diab\u00e9tiques de type 2 reste en France faible, bien qu'elle soit en augmentation.\nLe diab\u00e8te insulino-d\u00e9pendant\nLe diab\u00e8te insulino-d\u00e9pendant (DID) concerne environ 90 000 \u00e0\n120 000 personnes en France dont environ 30 000 ont moins de\ntrente ans. Un nombre \u00e9gal de patients re\u00e7oit \u00e9galement de l'insuline sans pour autant \u00eatre insulino-d\u00e9pendant.\nQuatre mille nouveaux cas sont identifi\u00e9s chaque ann\u00e9e, qui\ncorrespondent \u00e0 un nombre comparable de d\u00e9c\u00e8s. Comme dans\nla plupart des pays m\u00e9diterran\u00e9ens, cette incidence est relativement faible. D'apr\u00e8s le registre \u00e9pid\u00e9miologique europ\u00e9en", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2444, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "878426e2-718f-45cb-8056-97ba0674b6cb": {"__data__": {"id_": "878426e2-718f-45cb-8056-97ba0674b6cb", "embedding": null, "metadata": {"page_label": "30", "file_name": "hc001042.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\hc001042.pdf", "file_type": "application/pdf", "file_size": 237006, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "214bd709-c9ad-4e86-a0f4-9e49ca0f0c81", "node_type": "4", "metadata": {"page_label": "30", "file_name": "hc001042.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\hc001042.pdf", "file_type": "application/pdf", "file_size": 237006, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "e5e47e1b8144f9d0a18d03586b3b2ebfdbec0e33a2848c54088876cb253a9ab8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "45ba7052-b42c-48e0-b2e5-20294a6454a4", "node_type": "1", "metadata": {}, "hash": "46284b25446b496614113df19456a7c10f2d38a6a4959fd61c9ad9ce4f919e68", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "EURODIAB7, l'incidence annuelle du DID en France, en dessous\nde 20 ans, serait de 7,3/100 000, et le taux standardis\u00e9 entre\n0 et 14 ans serait de 7,8/100 000, alors qu'il varie entre\n6,5/100 000 (Italie du Sud) et 42,9/100 000 (Finlande). Le\nrapport du nombre d'hommes au nombre de femmes varie de 1,2\n\u00e0 1,4. En France, les projections d\u00e9mographiques (fond\u00e9es sur\nl'hypoth\u00e8se d'une incidence constante), laissent penser que le\nnombre de DID suivra les courbes de natalit\u00e9, et que le nombre\nde diab\u00e9tiques de moins de 25 ans devrait baisser d'environ 10 %\nentre 1990 et 2000.\nCe type de diab\u00e8te affecte des individus beaucoup plus jeunes\nque le DNID, et souvent des enfants. On note des ant\u00e9c\u00e9dents\nchez des parents de premier degr\u00e9 dans 8 % des cas, un peu plus\nsouvent du c\u00f4t\u00e9 paternel. On note \u00e9galement une proportion non\nn\u00e9gligeable de sujets ne pr\u00e9sentant ni le ph\u00e9notype HLA DR3,\nni le ph\u00e9notype HLA-DR4 : 11 % des cas dans le registre du DID.\nLe d\u00e9terminisme g\u00e9n\u00e9tique existe donc, mais n'est pas absolument pr\u00e9dictif. Selon certains r\u00e9sultats actuels, les m\u00e9canismes\nd'action mettraient probablement en jeu une auto-immunit\u00e9 dirig\u00e9e contre les cellules de Langerhans du pancr\u00e9as, et entra\u00eenant\ndonc une baisse de la s\u00e9cr\u00e9tion d'insuline.\nL'injection d'insuline offre d'excellents r\u00e9sultats mais entra\u00eene de\nnombreuses contraintes, \u00e0 commencer par la n\u00e9cessit\u00e9 de pratiquer des injections quotidiennes. D'autres voies th\u00e9rapeutiques\nsont envisag\u00e9es, comme la greffe pancr\u00e9atique ou la seule greffe\nde cellules de Langerhans.\nLes complications d\u00e9g\u00e9n\u00e9ratives sont les m\u00eames que celles du\ndiab\u00e8te non insulino-d\u00e9pendant. Dans le cas de la r\u00e9tinopathie,\nla fr\u00e9quence et la gravit\u00e9 sont \u00e9troitement corr\u00e9l\u00e9es \u00e0 l'anciennet\u00e9 du diab\u00e8te.\nDu fait de la gravit\u00e9 des complications, la n\u00e9cessit\u00e9 du traitement\ns'impose aux patients et \u00e0 leurs familles d'autant plus que, concernant des individus beaucoup plus jeunes, ce traitement n'exige\npas la modification des comportements anciens.\nLa sp\u00e9cificit\u00e9 du traitement par l'insuline rend habituelle et souhaitable la prise en charge par un diab\u00e9tologue. C'est heureusement le plus souvent le cas.\n\nLes diab\u00e8tes\nHaut Comit \u00e9 de la Sant \u00e9 Publique\n7. A. Green, EAM Gale, C.C., \u00ab Paterson.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2230, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "45ba7052-b42c-48e0-b2e5-20294a6454a4": {"__data__": {"id_": "45ba7052-b42c-48e0-b2e5-20294a6454a4", "embedding": null, "metadata": {"page_label": "30", "file_name": "hc001042.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\hc001042.pdf", "file_type": "application/pdf", "file_size": 237006, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "214bd709-c9ad-4e86-a0f4-9e49ca0f0c81", "node_type": "4", "metadata": {"page_label": "30", "file_name": "hc001042.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\hc001042.pdf", "file_type": "application/pdf", "file_size": 237006, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "e5e47e1b8144f9d0a18d03586b3b2ebfdbec0e33a2848c54088876cb253a9ab8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "878426e2-718f-45cb-8056-97ba0674b6cb", "node_type": "1", "metadata": {"page_label": "30", "file_name": "hc001042.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\hc001042.pdf", "file_type": "application/pdf", "file_size": 237006, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "f8839a41a683013d6cf9997602345f211cd319b4adb8394ce2470531093045e0", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "La sp\u00e9cificit\u00e9 du traitement par l'insuline rend habituelle et souhaitable la prise en charge par un diab\u00e9tologue. C'est heureusement le plus souvent le cas.\n\nLes diab\u00e8tes\nHaut Comit \u00e9 de la Sant \u00e9 Publique\n7. A. Green, EAM Gale, C.C., \u00ab Paterson. Incidence of childhood-onset insulin dependent\ndiabetes mellitus \u00bb, The EURODIAB ACE Study, Lancet, 1992, 339:905-908.", "mimetype": "text/plain", "start_char_idx": 1983, "end_char_idx": 2349, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "81e9dfd4-d457-472b-9040-a006650d29f4": {"__data__": {"id_": "81e9dfd4-d457-472b-9040-a006650d29f4", "embedding": null, "metadata": {"page_label": "31", "file_name": "hc001042.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\hc001042.pdf", "file_type": "application/pdf", "file_size": 237006, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "d8336305-9a0c-4ec9-ac8a-7228c69ebaae", "node_type": "4", "metadata": {"page_label": "31", "file_name": "hc001042.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\hc001042.pdf", "file_type": "application/pdf", "file_size": 237006, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "56d22c74a5b3095724840c17fca877c17ca7962f899620d814eb8fcd075de57e", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "17Diab\u00e8tes. Pr\u00e9vention, dispositifs de soins, \u00e9ducation... / Mai 1998\nL'intervention d'autres sp\u00e9cialistes est elle aussi indispensable\npour soigner les complications aigu\u00ebs et d\u00e9g\u00e9n\u00e9ratives.\nL'\u00e9ducation des patients est en particulier prise en charge par\nl'association Aide aux jeunes diab\u00e9tiques, fond\u00e9e en 1956, qui\nassure diff\u00e9rents services, et organise des colonies de vacances\ndestin\u00e9es aux jeunes diab\u00e9tiques. L'AJD a ouvert de nombreux\nlieux d'apprentissage de l'auto-prise en charge. Il faut souligner\nque ce type de prise en charge en France constitue un ind\u00e9niable\nsucc\u00e8s du point de vue des exigences de la sant\u00e9 publique\npuisqu'environ les deux tiers des nouveaux jeunes patients atteints\nde DID en b\u00e9n\u00e9ficient. Les r\u00e9sultats sont tr\u00e8s probants.\nDeux r\u00e9alit\u00e9s distinctes\nDiab\u00e8te insulino-d\u00e9pendant et diab\u00e8te non insulino-d\u00e9pendant\nrepr\u00e9sentent, on le voit, deux r\u00e9alit\u00e9s bien distinctes, souvent partiellement confondues dans les politiques de prise en charge.\nCette confusion n'est pas sans poser probl\u00e8me, et des actions\nplus sp\u00e9cifiques sont d\u00e9sormais n\u00e9cessaires. C'est pourquoi\non rappelle ici les grandes lignes de d\u00e9marcation entre ces deux\naffections, qui peuvent \u00eatre r\u00e9sum\u00e9es dans le tableau III.\nTableau III\nPrincipales caract\u00e9ristiques du DNID et du DID\nDNID DID\n(1) Crit\u00e8re OMS de 1985.\n1 000 000 \u00e0 1 200 000 (1)\napr\u00e8s 50 ans. R\u00f4le majeur\nde la surcharge pond\u00e9rale\nd\u00e9g\u00e9n\u00e9ratives\ndi\u00e9t\u00e9tique, exercices physiques, sulfamides, biguanides\nm\u00e9decins g\u00e9n\u00e9ralistes, diab\u00e9tologues et services sp\u00e9cialis\u00e9s dans les atteintes\n\u00e9volu\u00e9es\ncompliance th\u00e9rapeutique\nfaible, maladie insidieuse\ntr\u00e8s insuffisante\n90 \u00e0 120 000\nenfants et adultes jeunes\naigu\u00ebs et d\u00e9g\u00e9n\u00e9ratives\ninsuline et di\u00e9t\u00e9tique\ndiab\u00e9tologues\nservices sp\u00e9cialis\u00e9s :\npodologues, ophtalmologistes, cardiologues, orthop\u00e9distes, n\u00e9phrologues\nobligation de se soigner,\nmaladie \u00e9vidente\nsouvent de tr\u00e8s bon niveau\nNombre de cas\n\u00c2ge de la d\u00e9couverte\nComplications\nTraitement\nPrise en charge\nPerception de la maladie\n\u00c9ducation des malades", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2009, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "3a3433b8-a272-404e-b1cb-136fce12e165": {"__data__": {"id_": "3a3433b8-a272-404e-b1cb-136fce12e165", "embedding": null, "metadata": {"page_label": "32", "file_name": "hc001042.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\hc001042.pdf", "file_type": "application/pdf", "file_size": 237006, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "22d45598-3642-4ba5-8f1e-9f9a1b6763ea", "node_type": "4", "metadata": {"page_label": "32", "file_name": "hc001042.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\hc001042.pdf", "file_type": "application/pdf", "file_size": 237006, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "23ec2f85ebbfc8902b30c128527f8523557d3aa240e9ad2a798993d3cc8a6df1", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "L'histoire\nm\u00e9dicale\nLes autres \u00ab diab\u00e8tes \u00bb\nEnfin, il convient de mentionner pour m\u00e9moire le fait que d'autres\npathologies, aux incidences beaucoup plus rares, ont longtemps\n\u00e9t\u00e9 d\u00e9sign\u00e9es sous le terme de \u00ab diab\u00e8te \u00bb parce qu'entra\u00eenant des\nsympt\u00f4mes \u00e9quivalents. C'est en particulier le cas du \u00ab diab\u00e8te\ninsipide \u00bb, qui entra\u00eene une polyurie, mais sans hyperglyc\u00e9mie.\nHistoire\net repr\u00e9sentations des diab\u00e8tes\nLa constitution de la repr\u00e9sentation scientifique du diab\u00e8te r\u00e9sulte\nd'une longue histoire, et cette histoire m\u00e9dicale est sans doute\nl'un des d\u00e9terminants importants des pratiques actuelles,tant du\nfait de son influence sur les repr\u00e9sentations des m\u00e9decins et\nsur celles des patients que du fait de ses r\u00e9percussions sur l'organisation de la profession m\u00e9dicale. C'est pourquoi il est utile qu'une\napproche de sant\u00e9 publique s'attache \u00e0 retracer la longue \u00e9mergence d'une entit\u00e9 pathologique recouvrant deux maladies distinctes, la vari\u00e9t\u00e9 des syst\u00e8mes d'interpr\u00e9tation qui ont \u00e9t\u00e9 propos\u00e9s,\nleurs connotations (parfois hygi\u00e9nistes ou morales), et la construction progressive des solutions th\u00e9rapeutiques. Le bref r\u00e9sum\u00e9 que\nnous proposerons de cette histoire montrera \u00e0 quel point les repr\u00e9sentations scientifiques et populaires, mais aussi les th\u00e9rapies et\nles recherches mises en \u0153uvre reposent sur cette histoire.\nLa place du \u00ab diab\u00e8te \u00bb dans l'histoire de la m\u00e9decine occidentale\nest singuli\u00e8re.\nDe par sa symptomatologie (abondance d'urine et soif excessive),\nil a pu \u00eatre rep\u00e9r\u00e9 depuis la plus haute antiquit\u00e9, et \u00eatre observ\u00e9\net d\u00e9crit \u00e0 tous les \u00e2ges de la m\u00e9decine. Certes, les observations\nont progressivement conduit \u00e0 distinguer des formes de diab\u00e8te\ndiff\u00e9rentes, mais tardivement, et sans toujours dissiper l'id\u00e9e que\nle DID repr\u00e9sentait la forme la plus aboutie de la maladie.\nDe par sa complexit\u00e9, le diab\u00e8te mobilise des approches m\u00e9dicales vari\u00e9es. Son \u00e9tude et son traitement ont ainsi permis \u00e0 la\nplupart des disciplines qui constituent la m\u00e9decine moderne\nd'\u00e9prouver la pertinence de son approche : chimie, anatomie, physiologie, biologie, chirurgie, pr\u00e9vention m\u00e9dicalis\u00e9e, immunologie,\ng\u00e9n\u00e9tique. Cette situation particuli\u00e8re en fait un objet m\u00e9dical\nsurinvesti,v\u00e9ritable symbole des progr\u00e8s de la m\u00e9decine (que l'on\nsonge aux succ\u00e8s de Claude Bernard et au triomphe de l'appli18\nLes diab\u00e8tes\nHaut Comit \u00e9 de la Sant \u00e9 Publique", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2361, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "097671fc-480e-43b8-ac0d-a0972ddab32e": {"__data__": {"id_": "097671fc-480e-43b8-ac0d-a0972ddab32e", "embedding": null, "metadata": {"page_label": "33", "file_name": "hc001042.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\hc001042.pdf", "file_type": "application/pdf", "file_size": 237006, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "2c0ef8eb-a886-4e70-997a-1fa14c346775", "node_type": "4", "metadata": {"page_label": "33", "file_name": "hc001042.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\hc001042.pdf", "file_type": "application/pdf", "file_size": 237006, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "4d8d74bc74cdf43ac27a20fcd0686431b822f54236ea7ee4f793710051cff805", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5ff7012f-3855-4558-8bae-280e48d9a4a7", "node_type": "1", "metadata": {}, "hash": "d15d2c2b5f3361b012779270559f0a73cc5b220d1136cfb0e497559fbb774601", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "19Diab\u00e8tes. Pr\u00e9vention, dispositifs de soins, \u00e9ducation... / Mai 1998\ncation de la m\u00e9decine exp\u00e9rimentale \u00e0 la question de la r\u00e9gulation de la glyc\u00e9mie). Mais elle en fait \u00e9galement un terrain d'affrontement d'approches parfois divergentes, et souvent mises en\n\u0153uvre par des communaut\u00e9s m\u00e9dicales ayant peu de rapports\nentre elles.\nNous distinguerons \u00e0 cet effet quatre grandes \u00e9tapes\n8 : l'\u00e9mergence de l'approche pr\u00e9chimique, l'approche chimique, l'utilisation de l'insuline, et les recherches actuelles. Au fil de ces quatre\n\u00e9tapes, nous verrons se constituer une repr\u00e9sentation du diab\u00e8te,\nqui conditionne largement les pratiques actuelles, et que nous\nanalyserons dans le chapitre suivant.\nLa p\u00e9riode pr\u00e9chimique\nL'Europe, l'Inde, la Chine, bien que n'identifiant pas toujours\nl'ensemble des sympt\u00f4mes qui contribuent aujourd'hui \u00e0 la d\u00e9finition du diab\u00e8te, connaissent depuis la plus haute antiquit\u00e9 cette\nmaladie qui provoque une augmentation de la soif et de la faim,\nune exag\u00e9ration de la s\u00e9cr\u00e9tion r\u00e9nale, une modification de la composition de l'urine, et de terribles et nombreuses complications.\nEn Occident, \u00e0 l'exception peut-\u00eatre d'Hippocrate, la pathologie a\n\u00e9t\u00e9 d\u00e9crite par les plus grands noms de l'histoire de la m\u00e9decine :\nAristote, Celse, Ar\u00e9t\u00e9e de Cappadoce, Galien, Avicenne, Paracelse,\net de nombreux autres. D\u00e9crivant la maladie avec des degr\u00e9s\nde pr\u00e9cision divers, mais permettant toujours de l'identifier dans\nune terminologie moderne, ils mirent en \u0153uvre tous les moyens\npour expliquer ces sympt\u00f4mes. La vari\u00e9t\u00e9 des hypoth\u00e8ses explicatives constitue \u00e0 cet effet un t\u00e9moignage impressionnant de la\nrichesse des syst\u00e8mes d'explication des troubles de la sant\u00e9 successivement mis en \u0153uvre.\nL'approche chimique de Willis porte sur la caract\u00e9risation progressive du sucre dans l'urine du diab\u00e9tique.\nEn 1776, le m\u00e9decin anglais Matthew Dobson d\u00e9montre nettement la pr\u00e9sence de sucre dans les urines diab\u00e9tiques.\nEn 1797, le m\u00e9decin \u00e9cossais John Rollo souligne le r\u00f4le de l'hyperglyc\u00e9mie dans le diab\u00e8te sucr\u00e9, et affirme que le caract\u00e8re sucr\u00e9\ndes urines n'est qu'un effet secondaire. Il tente, avec un relatif\nsucc\u00e8s, de traiter un diab\u00e8te (qui \u00e9tait non insulino-d\u00e9pendant)\npar la prescription d'un r\u00e9gime alimentaire appropri\u00e9.\n8.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2257, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "5ff7012f-3855-4558-8bae-280e48d9a4a7": {"__data__": {"id_": "5ff7012f-3855-4558-8bae-280e48d9a4a7", "embedding": null, "metadata": {"page_label": "33", "file_name": "hc001042.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\hc001042.pdf", "file_type": "application/pdf", "file_size": 237006, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "2c0ef8eb-a886-4e70-997a-1fa14c346775", "node_type": "4", "metadata": {"page_label": "33", "file_name": "hc001042.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\hc001042.pdf", "file_type": "application/pdf", "file_size": 237006, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "4d8d74bc74cdf43ac27a20fcd0686431b822f54236ea7ee4f793710051cff805", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "097671fc-480e-43b8-ac0d-a0972ddab32e", "node_type": "1", "metadata": {"page_label": "33", "file_name": "hc001042.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\hc001042.pdf", "file_type": "application/pdf", "file_size": 237006, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "9f6912683e37e65d8e4684b1d220a0366d25a95191105e9fb4813b1cd873c1ec", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Il tente, avec un relatif\nsucc\u00e8s, de traiter un diab\u00e8te (qui \u00e9tait non insulino-d\u00e9pendant)\npar la prescription d'un r\u00e9gime alimentaire appropri\u00e9.\n8. Les r\u00e9sum\u00e9s succincts que nous donnerons de la p\u00e9riode pr\u00e9chimique et de la p\u00e9riode chimique s'inspirent de l'ouvrage de Jean-Jacques Peumery, Histoire illustr\u00e9e du diab\u00e8te , Roger\nDacosta, Paris, 1987.", "mimetype": "text/plain", "start_char_idx": 2109, "end_char_idx": 2460, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "452ae8c7-88d5-40f0-9151-fdf48ac0e188": {"__data__": {"id_": "452ae8c7-88d5-40f0-9151-fdf48ac0e188", "embedding": null, "metadata": {"page_label": "34", "file_name": "hc001042.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\hc001042.pdf", "file_type": "application/pdf", "file_size": 237006, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "77acc0c9-c14f-4835-a16b-09aacfab1515", "node_type": "4", "metadata": {"page_label": "34", "file_name": "hc001042.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\hc001042.pdf", "file_type": "application/pdf", "file_size": 237006, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "adea90d143896e7c8fb5cbac1ca3f70ada8b0e1bac99c2880f995cf0dcaa86fe", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Identifiant la corr\u00e9lation entre le diab\u00e8te et la pr\u00e9sence de sucre\ndans l'organisme, la m\u00e9decine commence alors \u00e0 proposer des\nsyst\u00e8mes d'interpr\u00e9tation fond\u00e9s sur un d\u00e9s\u00e9quilibre alimentaire.\nMais au XIX\ne si\u00e8cle, progressivement, l'attention des m\u00e9decins\nse focalise sur la pr\u00e9sence de sucre dans le sang. La recherche\nd'une physiologie du sucre devient possible.\nCette \u00ab pr\u00e9histoire du diab\u00e8te \u00bb est sans aucun doute \u00e0 l'origine\nde repr\u00e9sentations qui d\u00e9passent largement l'univers m\u00e9dical et\np\u00e8sent sur la repr\u00e9sentation du diab\u00e9tique , au prix de durables malentendus\n9 : l'hyperglyc\u00e9mie est en effet facilement associ\u00e9e \u00e0 une\nconsommation excessive de sucre, et donc \u00e0 l'image d'un diab\u00e9tique aimant les plaisirs de la table et, en particulier, l'alimentation sucr\u00e9e. Cette id\u00e9e persistante n\u00e9glige le fait que les sucres\nde l'organisme proviennent majoritairement de la d\u00e9gradation des\ngraisses et alcools, tandis que les sucres ing\u00e9r\u00e9s sont fr\u00e9quemment, pour leur part, directement utilis\u00e9s par l'organisme. Il semble\nn\u00e9anmoins que cette repr\u00e9sentation persiste largement de nos\njours dans les repr\u00e9sentations populaires de cette maladie.\nVers la d\u00e9couverte de l'insuline\nClaude Bernard a un r\u00f4le essentiel dans la gen\u00e8se du traitement\ninsulinique du diab\u00e8te. L'\u00e9tude de la r\u00e9gulation de la glyc\u00e9mie animale repr\u00e9sente une pr\u00e9occupation constante de sa recherche.\nOn en trouve la trace dans nombre de ses \u00e9crits, et son dernier\nouvrage, en 1877 (un an avant sa mort), est pr\u00e9cis\u00e9ment compos\u00e9 de ses Le\u00e7ons sur le diab\u00e8te et la glycog\u00e9nie animale.\nClaude Bernard d\u00e9montre la fonction glycog\u00e9nique du foie, qui\nconstitue sans doute sa plus belle d\u00e9couverte. Par la suite, il identifiera \u00e9galement le r\u00f4le du syst\u00e8me nerveux dans la r\u00e9gulation de\nla glyc\u00e9mie, et r\u00e9ussira \u00e0 cr\u00e9er un \u00ab diab\u00e8te artificiel \u00bb gr\u00e2ce \u00e0 une\nc\u00e9l\u00e8bre \u00ab piq\u00fbre dans le plancher du quatri\u00e8me ventricule \u00bb.\n\u00c0 l'issue de ses travaux, le diab\u00e8te est connu comme un \u00ab trouble\nde la nutrition \u00bb (au sens o\u00f9 le sucre provient de la transformation\ndes aliments), d\u00fb au fonctionnement du foie contr\u00f4l\u00e9 par le syst\u00e8me nerveux. Mais la cause directe du dysfonctionnement du foie,\nainsi que les traitements possibles \u00e9chappent toujours \u00e0 la m\u00e9decine.\n\nLes diab\u00e8tes\nHaut Comit \u00e9 de la Sant \u00e9 Publique\n9. Le diab\u00e8te est avant tout envisag\u00e9 \u00e0 son stade d\u00e9clar\u00e9 et sa repr\u00e9sentation comme une\nmaladie caract\u00e9ris\u00e9e par une tr\u00e8s longue p\u00e9riode asymptomatique n\u00e9cessite de ce fait une\nv\u00e9ritable conversion du regard m\u00e9dical.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2485, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "2a0b7b5d-e020-4a64-812c-f4bebd86f3e8": {"__data__": {"id_": "2a0b7b5d-e020-4a64-812c-f4bebd86f3e8", "embedding": null, "metadata": {"page_label": "35", "file_name": "hc001042.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\hc001042.pdf", "file_type": "application/pdf", "file_size": 237006, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "a1562efc-fd6d-4a02-b226-8c2de23051dc", "node_type": "4", "metadata": {"page_label": "35", "file_name": "hc001042.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\hc001042.pdf", "file_type": "application/pdf", "file_size": 237006, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "77876c9c9f0be33d38829555b7a0ae441d55c4d73541b1a71c383421d395f9f1", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "21Diab\u00e8tes. Pr\u00e9vention, dispositifs de soins, \u00e9ducation... / Mai 1998\nLa fin du XIXe si\u00e8cle marque \u00e9galement les progr\u00e8s de la clinique.\nLes complications du diab\u00e8te font l'objet de descriptions de plus\nen plus rigoureuses. \u00c0 la fin du si\u00e8cle, Oscar Minkowski obtient\nexp\u00e9rimentalement un diab\u00e8te sucr\u00e9 par pancr\u00e9atomie. Il confirme\nainsi le r\u00f4le majeur du pancr\u00e9as dans le contr\u00f4le de la glyc\u00e9mie.\n\u00c0 cette \u00e9poque, les m\u00e9canismes du diab\u00e8te sont de mieux en\nmieux cern\u00e9s, mais les possibilit\u00e9s th\u00e9rapeutiques restent inexistantes. Le pronostic du diab\u00e8te est quasiment toujours fatal :\n\u00ab marasme \u00bb, phtisie pulmonaire, gangr\u00e8ne, apoplexie c\u00e9r\u00e9brale,\nou m\u00eame fermentation alcoolique. Les premi\u00e8res r\u00e9elles possibilit\u00e9s th\u00e9rapeutiques sont cependant proches, et surviendront\navec la d\u00e9couverte de l'insuline.\nEn 1921, deux chercheurs canadiens, Banting et Best r\u00e9ussirent\n\u00e0 purifier l'hormone antidiab\u00e9tique du pancr\u00e9as (pancr\u00e9ine) qui\navait \u00e9t\u00e9 isol\u00e9e par le physiologiste roumain Nicolas-Constantin\nPaulesco. Cette avanc\u00e9e s'inscrit dans un intense effort de\nrecherche d'\u00e9lucidation des m\u00e9canismes du contr\u00f4le endocrine\nde la glyc\u00e9mie.\nD\u00e8s 1922, les premi\u00e8res exp\u00e9riences de traitement par injection de l'insuline furent entreprises par Banting et le directeur\nde son laboratoire, MacLeod. Les r\u00e9sultats ne se font pas attendre :\napr\u00e8s d\u00e9termination des dosages requis, le patient diab\u00e9tique est\ntotalement affranchi de son hyperglyc\u00e9mie. Dans les deux ann\u00e9es\nsuivantes (1922-1923), des laboratoires pharmaceutiques engag\u00e8rent la production industrielle de l'insuline.\nLe succ\u00e8s du traitement par l'insuline fut spectaculaire, \u00e0 tel point\nque, d\u00e8s 1923, Banting et MacLeod obtinrent le prix Nobel de\nm\u00e9decine. Rappelons que la m\u00e9decine de 1920, m\u00e9decine d'avant\nles antibiotiques, ne disposait pas d'un arsenal th\u00e9rapeutique tr\u00e8s\nlarge et efficace.\nL'histoire de la d\u00e9couverte de l'insuline, traitement magique, continue manifestement \u00e0 influencer les repr\u00e9sentations m\u00e9dicales\ncontemporaires.\nLes recherches et traitements modernes\nLe traitement par l'insuline fait, aujourd'hui encore, la preuve\nde son efficacit\u00e9 et reste le plus employ\u00e9 dans le traitement du\ndiab\u00e8te. Cependant, c'est un traitement palliatif, qui supprime les\neffets d'un trouble sans en supprimer la cause. Il introduit de\nce fait beaucoup de contraintes, d'autant qu'il exige en outre une", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2361, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "5dce23b8-8817-4af2-9861-ee51f8f4b899": {"__data__": {"id_": "5dce23b8-8817-4af2-9861-ee51f8f4b899", "embedding": null, "metadata": {"page_label": "36", "file_name": "hc001042.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\hc001042.pdf", "file_type": "application/pdf", "file_size": 237006, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "a3da02d9-0ef5-4d12-86cd-20c3bf49619e", "node_type": "4", "metadata": {"page_label": "36", "file_name": "hc001042.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\hc001042.pdf", "file_type": "application/pdf", "file_size": 237006, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "49a31532048c1cc86e6a77f49ff2827320e67b1eaa2996bb6d1a57c6a78ea6dd", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "cd715fde-57b0-4c41-91b2-0741d3fe44a7", "node_type": "1", "metadata": {}, "hash": "f24787a3eca5abaad339f28afa242945c4d08c32723c1f9ac59ddccf90cc1e45", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "surveillance \u00e9troite du comportement alimentaire (qui est \u00e9galement exig\u00e9e des patients non insulino-d\u00e9pendants). C'est pourquoi la recherche ne s'est heureusement pas arr\u00eat\u00e9e, loin de\nl\u00e0, avec la d\u00e9couverte de l'insuline. Depuis la Deuxi\u00e8me Guerre\nmondiale, les r\u00e9sultats se sont multipli\u00e9s, notamment en ce qui\nconcerne le diab\u00e8te insulino-d\u00e9pendant.\nLes antibiotiques ont marqu\u00e9 une autre r\u00e9volution dans la th\u00e9rapeutique du diab\u00e8te, en permettant le traitement des nombreuses\ncomplications infectieuses qui pesaient jusque-l\u00e0 sur la sant\u00e9 des\npatients diab\u00e9tiques.\nParall\u00e8lement, la recherche s'est diversifi\u00e9e. Le danger de mort\n\u00e9tant en quelque sorte \u00e9cart\u00e9, il est devenu possible de rechercher l'am\u00e9lioration de l'efficacit\u00e9 des soins et du confort de vie.\nC'est pourquoi, outre les progr\u00e8s des approches physiologiques\nou biologiques (y compris gr\u00e2ce aux tentatives de greffes), cette\np\u00e9riode a \u00e9t\u00e9 marqu\u00e9e par les travaux portant sur l'\u00e9pid\u00e9miologie,\nle d\u00e9pistage et la pr\u00e9vention. Pourtant, il semble, \u00e0 la lueur de\ndivers indices, dont la proportion des publications dans les revues\nscientifiques, que se sont constitu\u00e9es implicitement une diab\u00e9tologie \u00ab noble \u00bb qui manie l'insuline et une diab\u00e9tologie \u00ab moins\nprestigieuse \u00bb, celle du DNID.\nOn peut pr\u00e9senter la riche histoire du diab\u00e8te apr\u00e8s-guerre en\nquatre \u00e9tapes.\nG La p\u00e9riode de 1945 \u00e0 1956 voit l'am\u00e9lioration consid\u00e9rable\ndes traitements th\u00e9rapeutiques du diab\u00e8te, et singuli\u00e8rement du DID. C'est elle qui voit aussi la mise en \u0153uvre de\ntraitements par sulfamides hypoglyc\u00e9miants. Par ailleurs, la\nrecherche aboutit \u00e0 la caract\u00e9risation de la structure mol\u00e9culaire de l'insuline, tandis que de premiers outils de suivi\nth\u00e9rapeutique sont mis en place tel le dosage de l'insuline plasmatique.\nG Entre 1957 et 1970 : du point de vue th\u00e9rapeutique, cette\np\u00e9riode voit la mise en \u0153uvre des premiers traitements par\nles \u00ab biguanides \u00bb, mais voit \u00e9galement de grands progr\u00e8s\ndans le traitement des complications ophtalmologiques\n(lasers, vitrectomie), ou r\u00e9nales (dialyse). On tente aussi,\navec succ\u00e8s, les premi\u00e8res greffes du pancr\u00e9as.\nDu point de vue du diagnostic et du suivi, on notera l'acquisition du dosage radio-immunologique de l'insulin\u00e9mie, ou encore\nle diagnostic de la r\u00e9tinopathie par angiographie. Mais cette p\u00e9riode\nvoit \u00e9galement l'\u00e9mergence des approches \u00e9pid\u00e9miologiques et\nde l'\u00e9valuation des traitements.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2392, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "cd715fde-57b0-4c41-91b2-0741d3fe44a7": {"__data__": {"id_": "cd715fde-57b0-4c41-91b2-0741d3fe44a7", "embedding": null, "metadata": {"page_label": "36", "file_name": "hc001042.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\hc001042.pdf", "file_type": "application/pdf", "file_size": 237006, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "a3da02d9-0ef5-4d12-86cd-20c3bf49619e", "node_type": "4", "metadata": {"page_label": "36", "file_name": "hc001042.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\hc001042.pdf", "file_type": "application/pdf", "file_size": 237006, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "49a31532048c1cc86e6a77f49ff2827320e67b1eaa2996bb6d1a57c6a78ea6dd", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5dce23b8-8817-4af2-9861-ee51f8f4b899", "node_type": "1", "metadata": {"page_label": "36", "file_name": "hc001042.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\hc001042.pdf", "file_type": "application/pdf", "file_size": 237006, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "ff710e92b27d91a4145a67fd64244182e10db09a66e18c1acd09d4e260e1570a", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Du point de vue du diagnostic et du suivi, on notera l'acquisition du dosage radio-immunologique de l'insulin\u00e9mie, ou encore\nle diagnostic de la r\u00e9tinopathie par angiographie. Mais cette p\u00e9riode\nvoit \u00e9galement l'\u00e9mergence des approches \u00e9pid\u00e9miologiques et\nde l'\u00e9valuation des traitements. C'est ainsi que le premier grand\n\nLes diab\u00e8tes\nHaut Comit \u00e9 de la Sant \u00e9 Publique", "mimetype": "text/plain", "start_char_idx": 2104, "end_char_idx": 2474, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "87d4ce40-009c-469a-a94d-1496e6af08df": {"__data__": {"id_": "87d4ce40-009c-469a-a94d-1496e6af08df", "embedding": null, "metadata": {"page_label": "37", "file_name": "hc001042.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\hc001042.pdf", "file_type": "application/pdf", "file_size": 237006, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "aa8cfa7b-f1d1-45d1-8132-f4dc9ef32c7f", "node_type": "4", "metadata": {"page_label": "37", "file_name": "hc001042.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\hc001042.pdf", "file_type": "application/pdf", "file_size": 237006, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "199c6404c93e2b566e3ee7c47701ab599a11fb5e80d7bcaaa6040a923907da5a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a5eb3829-6d3f-4fa5-bef9-23e5be64d676", "node_type": "1", "metadata": {}, "hash": "8fb0ddb0f361abe8f88d51e0e260efd3bc50c10cd1bcc81a241edebc97368ba7", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "23Diab\u00e8tes. Pr\u00e9vention, dispositifs de soins, \u00e9ducation... / Mai 1998\nessai th\u00e9rapeutique est entrepris dans le DNID et montre que les\ncomplications macrovasculaires ne sont pas r\u00e9duites par les traitements hypoglyc\u00e9miants.\nG Les ann\u00e9es 1970-1980 sont marqu\u00e9es par la tentative de\nresponsabilisation des patients. C'est ainsi que l'on doit\nnoter la d\u00e9finition du r\u00f4le de l'\u00e9ducation comme outil th\u00e9rapeutique majeur, signal\u00e9e par la cr\u00e9ation, \u00e0 l'instigation\nde m\u00e9decins, de nombreuses associations de formation\net d'encadrement des patients diab\u00e9tiques (l\u00e0 encore, le\nplus souvent orient\u00e9s vers le DID, pour des raisons tenant\nautant au statut de cette forme de diab\u00e8te qu'\u00e0 l'\u00e2ge de son\napparition). Cet effort est renforc\u00e9 par la mise en place\ndes techniques d'auto-surveillance glyc\u00e9mique.\nSur le plan de la recherche, cette p\u00e9riode est marqu\u00e9e par la d\u00e9couverte de l'h\u00e9moglobine glyqu\u00e9e comme marqueur cumulatif de\nl'\u00e9quilibre du diab\u00e8te sucr\u00e9, par l'identification de la corr\u00e9lation\nentre le risque de diab\u00e8te et certains marqueurs HLA, et par la\nd\u00e9couverte des m\u00e9canismes auto-immuns dans le DID.\nSur le plan th\u00e9rapeutique, les techniques de greffe se pr\u00e9cisent,\navec en particulier les premi\u00e8res greffes d'\u00eelots pancr\u00e9atiques.\nEnfin, la mise en place d'une politique de sant\u00e9 publique en mati\u00e8re\nde diab\u00e8te se poursuit, avec en particulier la d\u00e9finition d'objectifs\nth\u00e9rapeutiques (normoglyc\u00e9mie).\nG Les ann\u00e9es 1980-1995 voient l'essor des approches g\u00e9n\u00e9tiques de la pr\u00e9diction ou du d\u00e9pistage des diab\u00e8tes.\nSur le plan de la sant\u00e9 publique, les crit\u00e8res diagnostiques de diab\u00e8te sucr\u00e9 sont d\u00e9finis durant cette p\u00e9riode ainsi que la n\u00e9cessit\u00e9 d'une prise en charge th\u00e9rapeutique globale. Mais surtout\ncette p\u00e9riode voit l'irruption des consid\u00e9rations socio-\u00e9conomiques\ndans la r\u00e9flexion sur le diab\u00e8te. Enfin, la prise de conscience des\nrisques de iatrog\u00e9nie conduit \u00e0 la g\u00e9n\u00e9ralisation du mat\u00e9riel d'injection \u00e0 usage unique.\nLa recherche biologique, pour sa part, permet la d\u00e9couverte des\ncauses auto-immunes de DID, la caract\u00e9risation de l'insulinor\u00e9sistance au centre de la pathog\u00e9nie du DNID.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2105, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "a5eb3829-6d3f-4fa5-bef9-23e5be64d676": {"__data__": {"id_": "a5eb3829-6d3f-4fa5-bef9-23e5be64d676", "embedding": null, "metadata": {"page_label": "37", "file_name": "hc001042.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\hc001042.pdf", "file_type": "application/pdf", "file_size": 237006, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "aa8cfa7b-f1d1-45d1-8132-f4dc9ef32c7f", "node_type": "4", "metadata": {"page_label": "37", "file_name": "hc001042.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\hc001042.pdf", "file_type": "application/pdf", "file_size": 237006, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "199c6404c93e2b566e3ee7c47701ab599a11fb5e80d7bcaaa6040a923907da5a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "87d4ce40-009c-469a-a94d-1496e6af08df", "node_type": "1", "metadata": {"page_label": "37", "file_name": "hc001042.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\hc001042.pdf", "file_type": "application/pdf", "file_size": 237006, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "deac5d20224b8352ba4f818793364dee80aef61d37c455d1950766fb87a5a0c8", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Enfin, la prise de conscience des\nrisques de iatrog\u00e9nie conduit \u00e0 la g\u00e9n\u00e9ralisation du mat\u00e9riel d'injection \u00e0 usage unique.\nLa recherche biologique, pour sa part, permet la d\u00e9couverte des\ncauses auto-immunes de DID, la caract\u00e9risation de l'insulinor\u00e9sistance au centre de la pathog\u00e9nie du DNID. Elle voit \u00e9galement\nle d\u00e9veloppement des approches g\u00e9n\u00e9tiques du DID et du DNID,\nqui aboutit aujourd'hui \u00e0 de nombreux r\u00e9sultats, sans pour autant\nlaisser entrevoir d'application th\u00e9rapeutique \u00e0 court terme : le\nd\u00e9terminisme du diab\u00e8te semble clairement plurifactoriel, et la\nrecherche de solutions th\u00e9rapeutiques se heurte aujourd'hui \u00e0\nl'impossibilit\u00e9 d'identifier les \u00ab cibles g\u00e9n\u00e9tiques \u00bb. En revanche,", "mimetype": "text/plain", "start_char_idx": 1811, "end_char_idx": 2512, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "66f45117-0039-466c-86a2-f934ae47ed11": {"__data__": {"id_": "66f45117-0039-466c-86a2-f934ae47ed11", "embedding": null, "metadata": {"page_label": "38", "file_name": "hc001042.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\hc001042.pdf", "file_type": "application/pdf", "file_size": 237006, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "ae16b974-9580-4b9b-85c6-f0b1e0ec5863", "node_type": "4", "metadata": {"page_label": "38", "file_name": "hc001042.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\hc001042.pdf", "file_type": "application/pdf", "file_size": 237006, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "17053b3b34c00fff3ef991acc7c31633a3735f392bc7632dbd326c42b6f89d4e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2ba365a7-d3b6-4621-bb18-338c94d17ab7", "node_type": "1", "metadata": {}, "hash": "fcb547287241e1f846cc0d9675a7bd9fb84513162cb150ae7c5d593191869293", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "les corr\u00e9lations identifi\u00e9es entre certains marqueurs g\u00e9n\u00e9tiques\net le risque de diab\u00e8te ouvrent d'ores et d\u00e9j\u00e0 la voie \u00e0 des\napproches pr\u00e9dictives, qui peuvent conduire \u00e0 pr\u00e9ciser les strat\u00e9gies de d\u00e9pistage.\nEn octobre 1989, les repr\u00e9sentants des minist\u00e8res de la Sant\u00e9\net des associations de patients de tous les pays europ\u00e9ens se sont\nr\u00e9unis avec des sp\u00e9cialistes du diab\u00e8te sous l'\u00e9gide du bureau europ\u00e9en de l'OMS et de la section europ\u00e9enne de la F\u00e9d\u00e9ration internationale du diab\u00e8te (IDF), \u00e0 Saint-Vincent, en Italie. Cette r\u00e9union\na abouti \u00e0 l'adoption de la D\u00e9claration de Saint-Vincent (Annexe II),\nqui sert aujourd'hui de texte de r\u00e9f\u00e9rence pour la lutte contre le diab\u00e8te. Celle-ci fixe deux objectifs g\u00e9n\u00e9raux : l'am\u00e9lioration durable\nde l'\u00e9tat de sant\u00e9 des diab\u00e9tiques, pour permettre une vie proche\nde la normale en qualit\u00e9 comme en dur\u00e9e, et la pr\u00e9vention et les\nsoins du diab\u00e8te et de ses complications. Ces deux objectifs sont\nd\u00e9clin\u00e9s en diff\u00e9rents buts, \u00e0 \u00e9ch\u00e9ance de cinq ans, concernant la\nprise en charge, le traitement, et la recherche en Europe.\nSuite \u00e0 cette disposition, diff\u00e9rents programmes de recherche\neurop\u00e9ens sont lanc\u00e9s, parmi lesquels on peut signaler le programme DIABCARE ou le programme \u00e9pid\u00e9miologique EURODIAB\nd\u00e9j\u00e0 cit\u00e9s.\nComme le montre ce bref r\u00e9sum\u00e9, la deuxi\u00e8me partie du XX\ne si\u00e8cle\nvoit la recherche sur le diab\u00e8te s'amplifier, et produire des r\u00e9sultats. Contrairement \u00e0 une repr\u00e9sentation encore tr\u00e8s r\u00e9pandue,\nles connaissances sur la maladie \u00e9voluent consid\u00e9rablement,\net chaque d\u00e9cennie voit proposer et exp\u00e9rimenter des voies th\u00e9rapeutiques nouvelles.\nLa tendance lourde pouvant caract\u00e9riser cette fin de si\u00e8cle est sans\ndoute la prise de conscience de la n\u00e9cessit\u00e9 de la pr\u00e9vention,\nles traitements du diab\u00e8te restant difficiles et co\u00fbteux. Cette notion\ns'appuie aujourd'hui principalement sur deux voies de travail : la\nconstitution \u00e0 partir des ann\u00e9es soixante-dix d'associations de diab\u00e9tiques, qui, contrairement \u00e0 d'autres associations de malades\n(ou de handicap\u00e9s), restent extr\u00eamement m\u00e9dicalis\u00e9es, mais aussi\nl'espoir, aujourd'hui non couronn\u00e9 de succ\u00e8s (les diab\u00e8tes sont le\nplus souvent contr\u00f4l\u00e9s par un d\u00e9terminisme polyg\u00e9n\u00e9tique), de\nla mise en place rapide de techniques g\u00e9n\u00e9tiques appartenant \u00e0\nce que l'on appelle souvent la m\u00e9decine pr\u00e9dictive.\nLa mise en point de m\u00e9dicaments hypoglyc\u00e9miants efficaces, plus\nmaniables, ayant moins d'effets secondaires est possible m\u00eame\nsi nous avons vu qu'ils ne pouvaient repr\u00e9senter actuellement des\nr\u00e9ponses th\u00e9rapeutiques.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2531, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "2ba365a7-d3b6-4621-bb18-338c94d17ab7": {"__data__": {"id_": "2ba365a7-d3b6-4621-bb18-338c94d17ab7", "embedding": null, "metadata": {"page_label": "38", "file_name": "hc001042.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\hc001042.pdf", "file_type": "application/pdf", "file_size": 237006, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "ae16b974-9580-4b9b-85c6-f0b1e0ec5863", "node_type": "4", "metadata": {"page_label": "38", "file_name": "hc001042.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\hc001042.pdf", "file_type": "application/pdf", "file_size": 237006, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "17053b3b34c00fff3ef991acc7c31633a3735f392bc7632dbd326c42b6f89d4e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "66f45117-0039-466c-86a2-f934ae47ed11", "node_type": "1", "metadata": {"page_label": "38", "file_name": "hc001042.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\hc001042.pdf", "file_type": "application/pdf", "file_size": 237006, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "54e84c3e6d89639829a39080a1ceba324d6a869dcd3eb513da26b31eb9e73acd", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "La mise en point de m\u00e9dicaments hypoglyc\u00e9miants efficaces, plus\nmaniables, ayant moins d'effets secondaires est possible m\u00eame\nsi nous avons vu qu'ils ne pouvaient repr\u00e9senter actuellement des\nr\u00e9ponses th\u00e9rapeutiques.\n\nLes diab\u00e8tes\nHaut Comit \u00e9 de la Sant \u00e9 Publique", "mimetype": "text/plain", "start_char_idx": 2315, "end_char_idx": 2580, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "5130d435-96b6-4f24-a85c-e0d5adb028fd": {"__data__": {"id_": "5130d435-96b6-4f24-a85c-e0d5adb028fd", "embedding": null, "metadata": {"page_label": "39", "file_name": "hc001042.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\hc001042.pdf", "file_type": "application/pdf", "file_size": 237006, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "7a04d29d-348f-4dfd-983b-95481be8ed5d", "node_type": "4", "metadata": {"page_label": "39", "file_name": "hc001042.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\hc001042.pdf", "file_type": "application/pdf", "file_size": 237006, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "2daf7b7fa7ef2544a14403d831808c8825d7c3d6bbe13991a67ceae7ea70e828", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "25Diab\u00e8tes. Pr\u00e9vention, dispositifs de soins, \u00e9ducation... / Mai 1998\nLes\nrepr\u00e9sentations\nComme nous l'avons signal\u00e9, cette lente constitution d'un savoir\nm\u00e9dical sur le diab\u00e8te s'est accompagn\u00e9e de la construction progressive de repr\u00e9sentations de la maladie, tant professionnelles\nque populaires, qui p\u00e8sent aujourd'hui encore sur l'ensemble\ndu dispositif.\nLe terrain de l'\u00e9preuve du discours m\u00e9dical\nLe diab\u00e8te a \u00e9t\u00e9 le terrain d'application, et parfois celui de la\nd\u00e9monstration, de nombreuses approches m\u00e9dicales innovantes.\nSi les troubles d'origine monog\u00e9nique sont aujourd'hui l'objet\nd'efforts de recherche importants, ils concernent en g\u00e9n\u00e9ral des\npopulations beaucoup plus restreintes que pour les diab\u00e8tes, dont\nnous montrerons le poids socio-\u00e9conomique. Objets d'une\nrecherche importante, les diab\u00e8tes sont donc sans doute \u00e9galement le lieu d'\u00e9mergence de probl\u00e8mes \u00e9thiques que soul\u00e8vent\nces techniques (tentation d'usages non m\u00e9dicaux des r\u00e9sultats,\nrisque de d\u00e9rive \u00ab coercitive \u00bb de la pr\u00e9vention, etc.).\nLes repr\u00e9sentations morales du sucre\nSans attendre que ces questions se posent r\u00e9ellement, la repr\u00e9sentation m\u00e9dicale du diab\u00e8te semble \u00e9galement h\u00e9riter d'une\nlongue r\u00e9flexion sur le statut du sucre dans la maladie. La caract\u00e9risation du sucre dans les urines et dans le sang des patients\ndiab\u00e9tiques, pour tardive qu'elle soit, pr\u00e9c\u00e8de de loin l'\u00e9lucidation\ndes m\u00e9canismes pathog\u00e8nes : pendant longtemps, le diab\u00e8te est\nune maladie du sucre. Or, cette substance h\u00e9rite elle-m\u00eame d'une\nhistoire longue et complexe, o\u00f9 se m\u00ealent et s'affrontent les\nlectures les plus vari\u00e9es : m\u00e9decine, \u00e9conomie, th\u00e9ologie, politique... Les repr\u00e9sentations actuelles du sucre, telles qu'elles se\nmanifestent par exemple dans les innombrables r\u00e9gimes sant\u00e9\nqui se succ\u00e8dent depuis plus de trente ans, h\u00e9ritent de cette histoire et conditionnent tant l'attitude des m\u00e9decins que celle du\ngrand public.\nSans entrer dans la pr\u00e9sentation d'une histoire universelle du\nsucre, signalons les principaux enjeux qui se sont constitu\u00e9s autour\nde cette substance initialement cr\u00e9dit\u00e9e de nombreuses vertus\nth\u00e9rapeutiques. Le sucre a \u00e9t\u00e9 jusqu'au XVII\ne si\u00e8cle l'objet d'importants d\u00e9bats th\u00e9ologiques, portant notamment sur la question de\nsa lic\u00e9it\u00e9 pendant la p\u00e9riode de car\u00eame. De mani\u00e8re significative,\nces d\u00e9bats th\u00e9ologiques se sont tr\u00e8s t\u00f4t fond\u00e9s sur des argumentations m\u00e9dicales, la consommation de sucre \u00e9tant jug\u00e9e licite\npar ceux qui y voyaient une drogue curative (parmi lesquels saint\nThomas d'Aquin), et jug\u00e9e bl\u00e2mable par ceux qui y voyaient une", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2554, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "3bb17b19-bc9d-4e39-b560-beb6e1065d99": {"__data__": {"id_": "3bb17b19-bc9d-4e39-b560-beb6e1065d99", "embedding": null, "metadata": {"page_label": "40", "file_name": "hc001042.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\hc001042.pdf", "file_type": "application/pdf", "file_size": 237006, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "909ef4bc-c346-4d4d-a14c-6437c7a77f8a", "node_type": "4", "metadata": {"page_label": "40", "file_name": "hc001042.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\hc001042.pdf", "file_type": "application/pdf", "file_size": 237006, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "0456000c02de83903367efdd264ea06f817a6d18ffbe1216279104cced5bb6aa", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "aeddeb48-bda8-4ee8-bb65-08937c846c82", "node_type": "1", "metadata": {}, "hash": "59259ede31a821b9f33e71e804d459d55981d7f97ee44b237e9cb94798657ca4", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "substance \u00e0 la douceur trompeuse. Le d\u00e9bat th\u00e9ologique a \u00e9galement recouvert un autre d\u00e9bat m\u00e9dical avec l'opposition de la\nth\u00e9orie humorale (inspir\u00e9e de Galien) et de la th\u00e9orie chimique\n(fond\u00e9e sur les approches alchimiques de Paracelse). Dans la\nth\u00e9orie humorale, qui consid\u00e8re la sant\u00e9 comme r\u00e9sultant de l'harmonie de quatre humeurs, chaque aliment poss\u00e8de une \u00ab qualit\u00e9 \u00bb\ncorrespondant ou s'opposant \u00e0 ces humeurs. Le sucre est consid\u00e9r\u00e9 comme un aliment \u00ab chaud \u00bb et \u00ab humide \u00bb, fondamentalement bienfaisant. Le principal danger r\u00e9sulte de sa consommation\nexcessive. La coloration morale de ce discours de l'exc\u00e8s se maintiendra jusqu'\u00e0 nos jours. La m\u00e9decine alchimique de Paracelse,\npour sa part, beaucoup plus proche d'une r\u00e9flexion chimique, d\u00e9veloppera un discours beaucoup plus violemment saccharophobique.\nOr, tandis que l'approche gal\u00e9nique se maintiendra en France\njusqu'au XIX\ne si\u00e8cle, l'approche chimique conna\u00eetra un grand succ\u00e8s en Angleterre. Par leurs origines ou par conversion, tous les\nparacelsiens seront des protestants (\u00e0 l'exception de quelques\njans\u00e9nistes). \u00c0 travers la question du statut m\u00e9dical du sucre\nse jouait d\u00e9j\u00e0, au XVI\ne si\u00e8cle, la question du rapport au plaisir,\net plus encore, la question du r\u00f4le de la m\u00e9decine dans l'\u00e9quilibre\n(m\u00e9dico-moral) entre le plaisir et la sant\u00e9.\nLe courant saccharophobe se prolongera dans tout le XXe si\u00e8cle,\net, si les connotations morales sont moins fermement articul\u00e9es :\n\u00ab La mani\u00e8re dont les m\u00e9decins parlent aux m\u00e9dias est rarement\npurement \"technique\", m\u00e9dicale. Le discours m\u00e9dical aborde tr\u00e8s\nfr\u00e9quemment les th\u00e8mes sous un angle fortement moralisateur. (...)\nEn d'autres termes, tout se passe comme si les m\u00e9decins aimaient\nparler, aujourd'hui comme jadis, morale, comme s'ils aimaient\ndonner des conseils ou des prescriptions non seulement sanitaires mais aussi \u00e9thiques. Et tout se passe \u00e9galement comme\nsi les m\u00e9dias s\u00e9lectionnaient volontiers ce type de d\u00e9clarations.\nParmi les grandes tentations de la m\u00e9decine (...) figure celle d'exercer son autorit\u00e9 sur les corps sains, sur la vie quotidienne, donc\nsur les m\u0153urs\n10.\u00bb\nLa lecture du statut sanitaire du sucre est donc l'objet d'une interpr\u00e9tation morale : morale de la mesure, morale de la d\u00e9fiance\nenvers le plaisir (m\u00e9fiance envers les \u00ab paroles sucr\u00e9es \u00bb), morale\nde la m\u00e9dicalisation des m\u0153urs.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2340, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "aeddeb48-bda8-4ee8-bb65-08937c846c82": {"__data__": {"id_": "aeddeb48-bda8-4ee8-bb65-08937c846c82", "embedding": null, "metadata": {"page_label": "40", "file_name": "hc001042.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\hc001042.pdf", "file_type": "application/pdf", "file_size": 237006, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "909ef4bc-c346-4d4d-a14c-6437c7a77f8a", "node_type": "4", "metadata": {"page_label": "40", "file_name": "hc001042.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\hc001042.pdf", "file_type": "application/pdf", "file_size": 237006, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "0456000c02de83903367efdd264ea06f817a6d18ffbe1216279104cced5bb6aa", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3bb17b19-bc9d-4e39-b560-beb6e1065d99", "node_type": "1", "metadata": {"page_label": "40", "file_name": "hc001042.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\hc001042.pdf", "file_type": "application/pdf", "file_size": 237006, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "be4d4593945cc1fd2cb5000518b2072a0d21d2780c4de0a54af1c0e3261d503c", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Ce statut moral a encore \u00e9t\u00e9 renforc\u00e9 par les approches \u00e9conomiques (le XVII\ne si\u00e8cle, qui est celui\nde la banalisation de cette \u00ab \u00e9pice \u00bb, gr\u00e2ce \u00e0 une production devenue industrielle, marque \u00e9galement l'acm\u00e9 de l'interrogation\n\nLes diab\u00e8tes\nHaut Comit \u00e9 de la Sant \u00e9 Publique\n10. Cl. Fischler, \u00ab Les aventures de la douceur \u00bb, in Manger la vie, Autrement, 1994, s\u00e9rie\nMutations/mangeurs. .", "mimetype": "text/plain", "start_char_idx": 2341, "end_char_idx": 2731, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "34b319d5-7af4-4f6f-bd03-47726fe1e2f7": {"__data__": {"id_": "34b319d5-7af4-4f6f-bd03-47726fe1e2f7", "embedding": null, "metadata": {"page_label": "41", "file_name": "hc001042.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\hc001042.pdf", "file_type": "application/pdf", "file_size": 237006, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "293d3dd2-4207-4918-8049-d8c74b271234", "node_type": "4", "metadata": {"page_label": "41", "file_name": "hc001042.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\hc001042.pdf", "file_type": "application/pdf", "file_size": 237006, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "176fbb47bac59d694c60b6293bdba063204842d6810a249128754311e5350a13", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "27Diab\u00e8tes. Pr\u00e9vention, dispositifs de soins, \u00e9ducation... / Mai 1998\nmorale), mais aussi philosophiques : on distingue, dans les mouvements saccharophiles fran\u00e7ais du XIXe si\u00e8cle, une nette influence\nrousseauiste marqu\u00e9e par la confiance envers la nature (les fruits,\nla f\u00e9minit\u00e9), et envers le progr\u00e8s (les technologies du raffinage).\nAujourd'hui, le diab\u00e8te non insulino-d\u00e9pendant reste bien souvent\nper\u00e7u comme li\u00e9 \u00e0 l'abus de sucre, h\u00e9ritant ainsi de l'ensemble\nde ces r\u00e9flexions moralisantes. Cette repr\u00e9sentation ob\u00e8re sans\ndoute en grande partie le r\u00f4le important des graisses et de l'alcool,\nmais cette derni\u00e8re pr\u00e9cision ne fait que renforcer \u00e0 son tour le\nconstat que le DNID para\u00eet encore trop souvent per\u00e7u aujourd'hui\ncomme un stigmate de la jouissance. Cette ambigu\u00eft\u00e9 du statut\nde la pathologie diab\u00e9tique acquise concourt sans doute \u00e0 la d\u00e9pr\u00e9ciation relative du DNID par rapport au DID. Par ailleurs, cette association diab\u00e8te/sucre contribue \u00e0 renforcer le sentiment que la\nphase asymptomatique n'est pas \u00e0 proprement parler une maladie, et donc \u00e0 fonder des approches de sant\u00e9 publique beaucoup\nplus fond\u00e9es sur le soin curatif (apr\u00e8s l'apparition de l'hyperglyc\u00e9mie) que sur le soin pr\u00e9ventif.\nL'ambivalence de la repr\u00e9sentation subjective\nEn ce qui concerne le DNID, la repr\u00e9sentation subjective du patient\ncr\u00e9e d'autres difficult\u00e9s pour l'entreprise d'\u00e9ducation \u00e0 la sant\u00e9.\nPour des raisons diverses, la soci\u00e9t\u00e9 fran\u00e7aise actuelle, malgr\u00e9\nune alimentation d'ensemble relativement \u00e9quilibr\u00e9e, laisse la\nplace \u00e0 de nombreux troubles des comportements alimentaires.\nLes comportements de privation et de boulimie, ou leur alternance,\nen particulier chez les jeunes femmes, ne sont pas rares. On peut\nainsi, sans exclure en rien les interpr\u00e9tations psychologiques, distinguer le r\u00f4le contradictoire de deux sollicitations fortes : la valorisation du plaisir, de la consommation, et donc des comportements\nalimentaires charg\u00e9s en sucre ou en graisses et la valorisation de\nla plastique du corps.\nLes troubles du comportement alimentaire concernent sans doute\nplus particuli\u00e8rement la jeunesse, mais on conna\u00eet encore fort mal\nle lien entre ces d\u00e9s\u00e9quilibres et la prise de poids qui peut se\nmanifester dix ou vingt ans plus tard, annon\u00e7ant le syndrome d'insulino-r\u00e9sistance.\nL'individu, entre ces deux sollicitations, adopte des habitudes alimentaires qui le satisfont, et lui offrent une certaine jouissance.\nLes premi\u00e8res manifestations de la maladie ne sont en rien un\nsympt\u00f4me, mais simplement l'indication, par le m\u00e9decin, d'un\nexc\u00e8s de sucre dans le sang. Elles conduisent le m\u00e9decin \u00e0 deman-", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2615, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "3f190a9c-0201-42eb-9232-22b74a9d9cf8": {"__data__": {"id_": "3f190a9c-0201-42eb-9232-22b74a9d9cf8", "embedding": null, "metadata": {"page_label": "42", "file_name": "hc001042.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\hc001042.pdf", "file_type": "application/pdf", "file_size": 237006, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "564a9e18-4c73-4729-98a9-a9d3ab4d2ec7", "node_type": "4", "metadata": {"page_label": "42", "file_name": "hc001042.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\hc001042.pdf", "file_type": "application/pdf", "file_size": 237006, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "960100b3242c606bdf1484c670902265a5f9fc8c140fbea54b38ee9c77c943f2", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "der au patient une modification de ses habitudes alimentaires,\nv\u00e9cue alors comme une privation, sans b\u00e9n\u00e9fice directement perceptible. La difficult\u00e9 de ce type de pr\u00e9vention est \u00e9vidente. Elle\nest encore renforc\u00e9e par la repr\u00e9sentation populaire du traitement\npar l'insuline et de son efficacit\u00e9 ou tout simplement de la normalisation de la glyc\u00e9mie du seul fait d'un traitement oral.\nPour le grand public, en somme, le diab\u00e8te est soit une non-maladie (mais un simple indice r\u00e9sultant des analyses sanguines), soit\nune maladie qui se traite parfaitement \u00e0 l'insuline. Pour toutes\nces raisons, il convient d'accorder une grande importance au syst\u00e8me global de prise en charge du diab\u00e8te, et d'examiner, dans\nune optique de sant\u00e9 publique, les raisons du succ\u00e8s limit\u00e9 des\npolitiques de pr\u00e9vention.\n\nLes diab\u00e8tes\nHaut Comit \u00e9 de la Sant \u00e9 Publique", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 846, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "504fb1ce-5312-4641-92d8-e59a058f3111": {"__data__": {"id_": "504fb1ce-5312-4641-92d8-e59a058f3111", "embedding": null, "metadata": {"page_label": "43", "file_name": "hc001042.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\hc001042.pdf", "file_type": "application/pdf", "file_size": 237006, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "2a6f412d-ce95-4338-b1bd-ba6ff0e7620a", "node_type": "4", "metadata": {"page_label": "43", "file_name": "hc001042.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\hc001042.pdf", "file_type": "application/pdf", "file_size": 237006, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "8508ef1d9ee590d8918a5a8a56cf298029c8ae0bc02d5b0e994f383d57c6ff79", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "29Diab\u00e8tes. Pr\u00e9vention, dispositifs de soins, \u00e9ducation... / Mai 1998\nLes trois enjeux\ndes diab\u00e8tes\nLes grandes caract\u00e9ristiques des diab\u00e8tes que nous avons analys\u00e9es dans le chapitre pr\u00e9c\u00e9dent expliquent les lacunes du dispositif actuel de leur prise en charge. Sa r\u00e9organisation repr\u00e9sente\nde v\u00e9ritables enjeux pour le syst\u00e8me de sant\u00e9.\nStructurer et rationaliser\nle dispositif de soins sp\u00e9cialis\u00e9s\nUn deuxi\u00e8me effet de l'\u00e9mergence et du d\u00e9veloppement des diab\u00e8tes est la n\u00e9cessit\u00e9 d'une r\u00e9flexion d'ensemble sur les structures de soins (entendus comme l'ensemble des acteurs -\nm\u00e9dicaux, scientifiques, associatifs ou administratifs - associ\u00e9s\ndans la prise en charge de la maladie). Cette r\u00e9flexion devra en\nparticulier entreprendre l'\u00e9valuation du syst\u00e8me de soins, de\nmani\u00e8re \u00e0 l'am\u00e9liorer, l'organiser, et parfois le rationaliser en particulier sous l'aspect \u00e9conomique.\nOr, l'exp\u00e9rience prouve que ce dispositif, s'il est souvent d'une\nefficacit\u00e9 ind\u00e9niable, est en g\u00e9n\u00e9ral organis\u00e9 de mani\u00e8re quasi\nspontan\u00e9e, et se d\u00e9veloppe en l'absence de tout crit\u00e8re permettant d'en entreprendre l'\u00e9valuation.\nL'objet de ce rapport est aussi de d\u00e9terminer les \u00e9l\u00e9ments qui\ndevraient permettre cette \u00e9valuation.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1206, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "7fac3051-3be8-4316-9f07-4e4ffe6dafe9": {"__data__": {"id_": "7fac3051-3be8-4316-9f07-4e4ffe6dafe9", "embedding": null, "metadata": {"page_label": "44", "file_name": "hc001042.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\hc001042.pdf", "file_type": "application/pdf", "file_size": 237006, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "35d4df38-3fc8-4a8e-9b3f-1e3765dc1317", "node_type": "4", "metadata": {"page_label": "44", "file_name": "hc001042.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\hc001042.pdf", "file_type": "application/pdf", "file_size": 237006, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "7d1ebbf2b950e13677447d260a8fe5e24b275373511123674dc41593c94f0bd3", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "La prise\nen charge\ndu diab\u00e8te\nen France\nL'organisation de la prise en charge\nPrise en charge m\u00e9dicale\nLe d\u00e9pistage et l'\u00e9valuation de l'incidence du diab\u00e8te restent non\nsatisfaisants, puisque certains acteurs estiment, comme nous\nl'avons vu, qu'un nombre trop important de patients restent longtemps non identifi\u00e9s et sont d\u00e9j\u00e0 porteurs de complications lors\ndu diagnostic initial. La variabilit\u00e9 des donn\u00e9es disponibles est\n\u00e0 cet \u00e9gard \u00e9difiante. Elle est renforc\u00e9e d'une part par le fait\nque les principales complications du diab\u00e8te ne sont pas toujours\ncatalogu\u00e9es par les caisses d'assurance-maladie comme secondaires au diab\u00e8te et d'autre part par l'adoption possible \u00e0 br\u00e8ve\n\u00e9ch\u00e9ance de nouveaux crit\u00e8res de diagnostic.\nAu prix de gros efforts, la prise en charge du DID para\u00eet, dans\nl'ensemble, correcte. En revanche, la prise en charge du DNID\nreste tr\u00e8s insuffisante . Il appara\u00eet en effet que, pour cette pathologie :\nG Le d\u00e9pistage manque d'efficacit\u00e9 : comme nous l'avons d\u00e9j\u00e0\nnot\u00e9, malgr\u00e9 la connaissance de facteurs de risque soit g\u00e9n\u00e9tiques, soit li\u00e9s aux modes de vie, le diagnostic est port\u00e9\ntrop tardivement au stade de la maladie d\u00e9j\u00e0 compliqu\u00e9e.\nG L'action des m\u00e9decins g\u00e9n\u00e9ralistes para\u00eet tr\u00e8s insuffisante.\nCertaines enqu\u00eates dont DIABCARE d\u00e9montrent que, une fois\nle diagnostic port\u00e9, nombre de patients diab\u00e9tiques ne b\u00e9n\u00e9ficient pas d'une surveillance ad\u00e9quate de leur maladie. Cet\n\u00e9tat de fait r\u00e9sulte probablement d'une formation insuffisante,\nen particulier vis-\u00e0-vis des objectifs du traitement.\nG L'\u00e9ducation des malades est d\u00e9fectueuse, notamment sur\nle plan de la di\u00e9t\u00e9tique et de l'\u00e9ducation physique. \u00c0 l'\u00e9vidence, le nombre de structures \u00e9ducatives disponibles est\nd\u00e9risoire par rapport \u00e0 la population potentiellement concern\u00e9e de 1 200 000 patients atteints de DNID.\nG La coordination entre les m\u00e9decins g\u00e9n\u00e9ralistes et les diab\u00e9tologues (lib\u00e9raux ou hospitaliers) est insatisfaisante,\nfaute d'un partage des objectifs \u00e0 partir d'une r\u00e9flexion de\nsant\u00e9 publique, faute \u00e9galement de la d\u00e9finition pr\u00e9alable\ndes responsabilit\u00e9s respectives.\nG Le recours aux auxiliaires m\u00e9dicaux (infirmiers, podologues,\net surtout di\u00e9t\u00e9ticiennes) est trop limit\u00e9. Pourtant, plusieurs\nexp\u00e9riences ont d\u00e9montr\u00e9 la vitalit\u00e9 et l'efficacit\u00e9 de l'implication de ces professionnels.\n\nLes trois enjeux des diab\u00e8tes\nHaut Comit \u00e9 de la Sant \u00e9 Publique", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2361, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "d47d9908-2695-4ae8-93f5-a8369c5e9acb": {"__data__": {"id_": "d47d9908-2695-4ae8-93f5-a8369c5e9acb", "embedding": null, "metadata": {"page_label": "45", "file_name": "hc001042.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\hc001042.pdf", "file_type": "application/pdf", "file_size": 237006, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "ec0a9fe5-cbe6-48fe-a2b2-4e4ad8883689", "node_type": "4", "metadata": {"page_label": "45", "file_name": "hc001042.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\hc001042.pdf", "file_type": "application/pdf", "file_size": 237006, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "957d0f3c42a138669d89573e376fab27d81b12024aca8038f2036390bfaf5af8", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "31Diab\u00e8tes. Pr\u00e9vention, dispositifs de soins, \u00e9ducation... / Mai 1998\nG La faible compliance th\u00e9rapeutique des malades est globalement g\u00e9n\u00e9ratrice de co\u00fbts de sant\u00e9 importants, par\nl'absence de pr\u00e9vention des complications ou leur d\u00e9pistage\ntrop tardif.\nG L'organisation hospitali\u00e8re de la diab\u00e9tologie est largement\nperfectible. Rappelons que la diab\u00e9tologie n'existe pas en\ntant que sp\u00e9cialit\u00e9 m\u00e9dicale d'exercice sp\u00e9cifique reconnu.\nLes troubles associ\u00e9s sont pris en charge par diff\u00e9rents sp\u00e9cialistes peu coordonn\u00e9s faute de consensus sur les proc\u00e9dures de surveillance et d'\u00e9valuation des prises en charge.\nPourtant, la validit\u00e9 de cette coordination a d\u00e9j\u00e0 \u00e9t\u00e9 d\u00e9montr\u00e9e dans des \u00ab centres de r\u00e9f\u00e9rence \u00bb ou des r\u00e9seaux fonctionnels.\nLa d\u00e9finition de centres de r\u00e9f\u00e9rence a \u00e9t\u00e9 largement \u00e9labor\u00e9e\ndans le cadre de la D\u00e9claration de Saint-Vincent. Elle pr\u00e9figure les\ncrit\u00e8res de l'accr\u00e9ditation des services hospitaliers, pr\u00e9vue dans\nles ordonnances de f\u00e9vrier et avril 1996. Leurs missions s'articulent autour de quatre priorit\u00e9s :\n1. d\u00e9livrer, de mani\u00e8re exemplaire, des soins de qualit\u00e9 aux diab\u00e9tiques, qu'il s'agisse de l'initiation, du suivi des traitements\npar l'insuline, du d\u00e9pistage pr\u00e9coce et de la prise en charge\nefficace des complications dans :\nG la r\u00e9tinopathie diab\u00e9tique,\nG le pied diab\u00e9tique,\nG les n\u00e9phropathies diab\u00e9tiques,\nG les complications vasculaires, en particulier les coronopathies silencieuses.\n2. la formation initiale et l'apport d'expertise dans la formation\ncontinue de l'ensemble des personnels m\u00e9dicaux, param\u00e9dicaux et de tous les professionnels impliqu\u00e9s dans la prise\nen charge des diab\u00e9tiques.\n3. la recherche, en particulier \u00e9pid\u00e9miologique, mais aussi clinique, biologique et th\u00e9rapeutique.\n4. l'\u00e9valuation et la formation des bonnes pratiques cliniques\nen diab\u00e9tologie\n11.\n11. Guide d\u00e9fini par l'Association de langue fran\u00e7aise d'\u00e9tude du diab\u00e8te et des \u00e9tudes m\u00e9taboliques (ALFEDIAM).", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1934, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "bb014b6c-51df-4c29-8da9-42ac3cda2278": {"__data__": {"id_": "bb014b6c-51df-4c29-8da9-42ac3cda2278", "embedding": null, "metadata": {"page_label": "46", "file_name": "hc001042.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\hc001042.pdf", "file_type": "application/pdf", "file_size": 237006, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "57d9a66c-5946-4fc4-90fe-24cb0a081bc7", "node_type": "4", "metadata": {"page_label": "46", "file_name": "hc001042.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\hc001042.pdf", "file_type": "application/pdf", "file_size": 237006, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "168342127d5f7c1712b1dc1fdabfd25112176d8fc89aff19e2c419c5388a8fe4", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Au-del\u00e0 des diab\u00e9tologues et des personnels param\u00e9dicaux comp\u00e9tents en diab\u00e9tologie, l'excellence de ces centres requiert la\ncollaboration de m\u00e9decins de diff\u00e9rentes sp\u00e9cialit\u00e9s m\u00e9dicales\n(ophtalmologistes, cardiologues, orthop\u00e9distes, chirurgiens vasculaires, podologues, etc.). Ceux-ci doivent \u00eatre form\u00e9s, dans le\ncadre de l'exercice de leur sp\u00e9cialit\u00e9, aux sp\u00e9cificit\u00e9s de la prise\nen charge des complications du diab\u00e8te. Les dispositions r\u00e9centes\nouvertes par les ordonnances d'avril 1996 prescrivent, par conventions, une organisation interhospitali\u00e8re en r\u00e9seaux permettant\nde f\u00e9d\u00e9rer les comp\u00e9tences n\u00e9cessaires \u00e0 la poursuite de ces\nobjectifs.\nLes services de \u00ab diab\u00e9tologie \u00bb\nDans de nombreux h\u00f4pitaux g\u00e9n\u00e9raux, les malades diab\u00e9tiques\nsont pris en charge par des services de m\u00e9decine interne ou plus\nrarement dans des structures plus sp\u00e9cialis\u00e9es en endocrinologie et/ou diab\u00e9tologie. Ces structures \u00e9tablies de longue date,\ndont les chefs de services sont diab\u00e9tologues et/ou endocrinologues ont un personnel form\u00e9 \u00e0 la diab\u00e9tologie et assurent des\nprestations de qualit\u00e9. Leur r\u00e9partition est toutefois in\u00e9gale sur\nle territoire national.\nEssentiellement pour des raisons d'opportunit\u00e9 li\u00e9es au coefficient d'occupation de leurs lits, certains h\u00f4pitaux g\u00e9n\u00e9raux ont\nd\u00e9cid\u00e9 de cr\u00e9er ex nihilodes \u00ab services de diab\u00e9tologie \u00bb. Or, actuellement :\nG Aucun texte r\u00e9glementaire ne fixe les conditions de prise en\ncharge des patients diab\u00e9tiques.\nG La diab\u00e9tologie ne fait pas l'objet d'une qualification ordinale. En cons\u00e9quence, le concours de praticien hospitalier\nn'individualise pas cette sp\u00e9cialit\u00e9 au sein de la discipline\n\u00ab m\u00e9decine \u00bb.\nG La loi du 31 juillet 1991 portant r\u00e9forme hospitali\u00e8re donne\ncomp\u00e9tence au conseil d'administration des \u00e9tablissements\nde soins pour \u00e9riger tous services dans un souci de sant\u00e9\npublique.\nLa difficult\u00e9 vient donc de l'h\u00e9t\u00e9rog\u00e9n\u00e9it\u00e9 de la qualit\u00e9 des soins\ndispens\u00e9s par les diff\u00e9rents centres. Il appara\u00eet clairement que\nl'accr\u00e9ditation des services hospitaliers par l'ANAES et la r\u00e9gulation op\u00e9r\u00e9e par les agences r\u00e9gionales de l'hospitalisation\ndevraient, \u00e0 terme, garantir la qualit\u00e9 des soins hospitaliers en\ndiab\u00e9tologie.\n\nLes trois enjeux des diab\u00e8tes\nHaut Comit \u00e9 de la Sant \u00e9 Publique", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2243, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "20bd7d70-314c-435b-a80c-ccafedbb43d2": {"__data__": {"id_": "20bd7d70-314c-435b-a80c-ccafedbb43d2", "embedding": null, "metadata": {"page_label": "47", "file_name": "hc001042.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\hc001042.pdf", "file_type": "application/pdf", "file_size": 237006, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "a2c734b0-5860-4c19-9b5a-da9049c3bc6a", "node_type": "4", "metadata": {"page_label": "47", "file_name": "hc001042.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\hc001042.pdf", "file_type": "application/pdf", "file_size": 237006, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "1723c371ce4bc43eeddf2f46c0bb8e3a42273d2b950ab4ad33b1cdf0d9b78a23", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b9d9df16-c7ce-4023-80b4-06eba53c26c3", "node_type": "1", "metadata": {}, "hash": "a37ca99513f02bc4fbb20d1c7c94cb1e48ba4b84e41bf0a23bcfb6af530b50bd", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "33Diab\u00e8tes. Pr\u00e9vention, dispositifs de soins, \u00e9ducation... / Mai 1998\nPour autant, il ne para\u00eet pas souhaitable de multiplier le nombre\ndes centres de r\u00e9f\u00e9rence, qui ont plus vocation \u00e0 l'exemplarit\u00e9 ou\n\u00e0 l'exp\u00e9rimentation qu'\u00e0 la satisfaction de tous les besoins de\nsoins de diab\u00e9tologie dans les r\u00e9gions concern\u00e9es. Leur r\u00f4le se\nsitue par ailleurs en aval d'autres dispositions sanitaires dans le\nchamp de la diab\u00e9tologie : pr\u00e9vention, d\u00e9pistage, prise en charge\net surveillance des malades non encore atteints de complications.\nLes associations\nOn compte en France diff\u00e9rentes associations impliqu\u00e9es dans la\nprise en charge du diab\u00e8te. Parmi celles-ci, outre l'association\nAide aux jeunes diab\u00e9tiques (AJD), d\u00e9j\u00e0 cit\u00e9e, on trouve en particulier deux associations de malades : l'Association fran\u00e7aise\ndes diab\u00e9tiques (AFD, fond\u00e9e en 1938, reconnue d'utilit\u00e9 publique\nen 1976, ouverte \u00e0 tous les diab\u00e9tiques, la plus importante par\nle nombre d'adh\u00e9rents, 30 000 environ), et la Ligue des diab\u00e9tiques de France (LDF, fond\u00e9e en 1940 par des diab\u00e9tiques, reconnue d'utilit\u00e9 publique en 1992).\nOn trouve \u00e9galement une soci\u00e9t\u00e9 savante, l'Association de langue\nfran\u00e7aise d'\u00e9tude du diab\u00e8te et des maladies m\u00e9taboliques (ALFEDIAM), qui regroupe la quasi-totalit\u00e9 des diab\u00e9tologues de langue\nfran\u00e7aise et dispose d'une branche param\u00e9dicale. Outre son r\u00f4le\nmoteur en mati\u00e8re de recherche en diab\u00e9tologie, l'ALFEDIAM propose un ensemble de r\u00e8gles de bonnes pratiques cliniques.\nCes quatre associations ont cr\u00e9\u00e9 en 1992, une structure de coordination originale et consensuelle, le Conseil sup\u00e9rieur du diab\u00e8te\n(CSD), charg\u00e9 d'assurer l'harmonisation et la coordination des\nobjectifs et des moyens de la lutte contre le diab\u00e8te. Cette structure m\u00e9riterait de se voir confier par d\u00e9l\u00e9gation des pouvoirs publics,\nun r\u00f4le d'observation des probl\u00e8mes sanitaires li\u00e9s au diab\u00e8te.\nCependant, cette mission justifierait l'ouverture du CSD \u00e0 d'autres\nparticipants et \u00e0 d'autres comp\u00e9tences permettant de situer en\npermanence le diab\u00e8te dans une perspective de sant\u00e9 publique,\nen particulier vis-\u00e0-vis d'une politique globale de pr\u00e9vention des\nmaladies cardio-vasculaires.\nEnfin, il existe une association europ\u00e9enne, l'EASD/AEED (Association europ\u00e9enne pour l'\u00e9tude du diab\u00e8te) qui rassemble des\nstructures de diff\u00e9rents pays, et a pris une part importante dans\nle d\u00e9veloppement du r\u00f4le \u00e9ducatif de l'h\u00f4pital.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2392, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "b9d9df16-c7ce-4023-80b4-06eba53c26c3": {"__data__": {"id_": "b9d9df16-c7ce-4023-80b4-06eba53c26c3", "embedding": null, "metadata": {"page_label": "47", "file_name": "hc001042.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\hc001042.pdf", "file_type": "application/pdf", "file_size": 237006, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "a2c734b0-5860-4c19-9b5a-da9049c3bc6a", "node_type": "4", "metadata": {"page_label": "47", "file_name": "hc001042.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\hc001042.pdf", "file_type": "application/pdf", "file_size": 237006, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "1723c371ce4bc43eeddf2f46c0bb8e3a42273d2b950ab4ad33b1cdf0d9b78a23", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "20bd7d70-314c-435b-a80c-ccafedbb43d2", "node_type": "1", "metadata": {"page_label": "47", "file_name": "hc001042.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\hc001042.pdf", "file_type": "application/pdf", "file_size": 237006, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "874d196a35f794a314e5ba91c717af118691efb22004228d73372cae57479884", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Enfin, il existe une association europ\u00e9enne, l'EASD/AEED (Association europ\u00e9enne pour l'\u00e9tude du diab\u00e8te) qui rassemble des\nstructures de diff\u00e9rents pays, et a pris une part importante dans\nle d\u00e9veloppement du r\u00f4le \u00e9ducatif de l'h\u00f4pital.\nMalgr\u00e9 la pr\u00e9sence de ce tissu associatif, force est de constater que le corps m\u00e9dical continue d'y exercer une grande autorit\u00e9\n(l'autonomisation des patients, ou l'attitude de consum\u00e9risme", "mimetype": "text/plain", "start_char_idx": 2155, "end_char_idx": 2582, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "3152c8df-8e0d-4962-8142-d1e64a1b08de": {"__data__": {"id_": "3152c8df-8e0d-4962-8142-d1e64a1b08de", "embedding": null, "metadata": {"page_label": "48", "file_name": "hc001042.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\hc001042.pdf", "file_type": "application/pdf", "file_size": 237006, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "8e77d825-9af7-40a6-b5a3-fe52dd525979", "node_type": "4", "metadata": {"page_label": "48", "file_name": "hc001042.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\hc001042.pdf", "file_type": "application/pdf", "file_size": 237006, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "d7c7ebefed55e94d554c234f5d6e9219ad9bf789ae92b8c46e616cc2ba19f35b", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "m\u00e9dical, qui caract\u00e9risent d'autres formes d'organisations de\npatients, ne sont sans doute pas assez d\u00e9velopp\u00e9es en mati\u00e8re\nde diab\u00e8te), et les associations ne r\u00e9ussissent que difficilement\n\u00e0 impliquer les patients souffrant de DNID. Malgr\u00e9 des efforts m\u00e9ritoires, le r\u00f4le modeste des associations de diab\u00e9tiques nous\npara\u00eet, nous y reviendrons, une caract\u00e9ristique de notre pays.\nL'industrie pharmaceutique\nL'industrie pharmaceutique est impliqu\u00e9e dans la lutte contre le\ndiab\u00e8te \u00e0 diff\u00e9rents niveaux, et ne se limite pas \u00e0 la recherche en\nmati\u00e8re de pr\u00e9vention, de diagnostic et de traitement.\nElle d\u00e9veloppe de nouveaux produits, m\u00e9dicaments et appareils,\nqui peuvent apporter de r\u00e9elles innovations en mati\u00e8re de traitement, mais \u00e9galement viser l'am\u00e9lioration du confort d'utilisation\net du suivi th\u00e9rapeutique. Notons que dans le cas du DNID, l'autosurveillance quotidienne de la glyc\u00e9mie ne permet pas l'ajustement des prises m\u00e9dicamenteuses.\nL'industrie pharmaceutique s'implique \u00e9galement dans la formation et l'\u00e9ducation, qu'il s'agisse de formation professionnelle\n(r\u00e9unions d'information et de formation) ou du grand public (mise\n\u00e0 disposition de brochures, ou de m\u00e9thodes interactives ou\nludiques, transmises par l'interm\u00e9diaire des m\u00e9decins, infirmi\u00e8res,\ndi\u00e9t\u00e9ticiennes et pharmaciens). N\u00e9anmoins, pour les m\u00e9dicaments\nhypoglyc\u00e9miants, y compris l'insuline, l'industrie pharmaceutique\npratique une information permanente, intensive, redondante, ce\nqui appara\u00eet parfois comme une surinformation en regard d'une\ninsuffisance flagrante d'information et de formation des m\u00e9decins\net des patients sur l'int\u00e9r\u00eat des mesures hyg\u00e9nio-di\u00e9t\u00e9tiques et\nsur leur mise en \u0153uvre efficace. Cela ne va pas, bien s\u00fbr, sans\nentra\u00eener des cons\u00e9quences diverses.\nL'\u00e9valuation\nL'\u00e9valuation de la qualit\u00e9 des soins est une condition primordiale\npour am\u00e9liorer l'efficacit\u00e9 du dispositif de prise en charge des diab\u00e9tiques. Cette \u00e9valuation doit s'appuyer tout \u00e0 la fois sur des\n\u00ab outils \u00bb valid\u00e9s comme ceux du programme DIABCARE et sur une\nvolont\u00e9 de les diffuser syst\u00e9matiquement.\nAspects \u00e9conomiques\nL'approche \u00e9conomique d'une maladie peut recouvrir deux grands\naspects : l'\u00e9valuation des co\u00fbts directs et indirects de la maladie,\net la recherche d'une optimisation des ressources consacr\u00e9es\n\nLes trois enjeux des diab\u00e8tes\nHaut Comit \u00e9 de la Sant \u00e9 Publique", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2352, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "3aa240f0-6b7c-49e5-a0f7-89d2a8249748": {"__data__": {"id_": "3aa240f0-6b7c-49e5-a0f7-89d2a8249748", "embedding": null, "metadata": {"page_label": "49", "file_name": "hc001042.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\hc001042.pdf", "file_type": "application/pdf", "file_size": 237006, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "ac488468-5dde-4301-a83e-02b77c245e03", "node_type": "4", "metadata": {"page_label": "49", "file_name": "hc001042.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\hc001042.pdf", "file_type": "application/pdf", "file_size": 237006, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "c0378ccaf3f0245cd91dadf406f0b0591956eb2be84e86228265ee9f6f3c6421", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "35Diab\u00e8tes. Pr\u00e9vention, dispositifs de soins, \u00e9ducation... / Mai 1998\n\u00e0 la maladie, permettant de d\u00e9terminer les meilleures strat\u00e9gies en termes de co\u00fbts-avantages.\nLe co\u00fbt des diab\u00e8tes et de leur prise en charge\nAu niveau international, de nombreuses \u00e9tudes ont tent\u00e9 d'estimer les co\u00fbts directs et indirects du diab\u00e8te. Cependant, il est difficile de tirer des conclusions \u00e0 partir d'\u00e9tudes qui concernent des\npays (et des syst\u00e8mes de prise en charge) diff\u00e9rents, des groupes\nethniques diff\u00e9rents, \u00e9tudi\u00e9s sur des longueurs de temps diff\u00e9rentes, sans toujours bien pr\u00e9ciser les limites des co\u00fbts pris en\ncompte (Tableau IV).\nLes co\u00fbts directs sont le plus souvent estim\u00e9s autour de 9 000 F\npar an pour un patient atteint de DID et de 6 500 F par an pour\nun patient atteint de DNID (valeur 1996). Mais ces chiffres, \u00e9tablis \u00e0 partir d'\u00e9chantillons peu nombreux, sur des p\u00e9riodes courtes,\nne prennent pas toujours bien en compte les complications plus\nrares, qui sont sources de co\u00fbts importants.\nLes co\u00fbts indirects, li\u00e9s notamment aux arr\u00eats de travail, sont\nimportants mais pr\u00e9sentent une variabilit\u00e9 encore sup\u00e9rieure entre\nles \u00e9tudes.\nL'ensemble des co\u00fbts devraient augmenter, tant du fait de l'accroissement du nombre de diab\u00e9tiques que du d\u00e9veloppement des traitements. \u00c0 titre d'exemple, l'\u00e9tude de Currie a permis de constater\nune augmentation de ces co\u00fbts de + 10 % par an entre 1991\net 1994 au Pays de Galles\n12.\nLes r\u00e9sultats sur les co\u00fbts des complications sont encore plus\ndivergents, et le plus souvent donn\u00e9s s\u00e9par\u00e9ment suivant le type\nde complication consid\u00e9r\u00e9e.\nPour les complications cardio-vasculaires, les prescriptions pharmaceutiques seraient, \u00e0 \u00e2ge \u00e9gal, trois fois plus importantes dans\nune population diab\u00e9tique, et le poids des m\u00e9dicaments cardiovasculaires repr\u00e9senterait 29 % de cette prescription. En France,\nen 1991, le co\u00fbt des hypotenseurs et des hypolip\u00e9miants prescrits aux diab\u00e9tiques est estim\u00e9 \u00e0 1,1 milliard de francs.\nAux \u00c9tats-Unis, le co\u00fbt de traitement du pied diab\u00e9tique a \u00e9t\u00e9\nestim\u00e9 \u00e0 12 500 $ en moyenne par hospitalisation (avec une dur\u00e9e\nmoyenne de s\u00e9jour de 19 jours). En France, ce co\u00fbt a \u00e9t\u00e9 \u00e9va12. Currie C.J., Peters J.R. (1995), \u00ab Trends in the volume and cost of prescribings for diabetes \u00bb, British Journal of Medical Economics, 8 (1):1-9.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2295, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "3e49467e-d2f7-4c29-bf53-ceb56f57b491": {"__data__": {"id_": "3e49467e-d2f7-4c29-bf53-ceb56f57b491", "embedding": null, "metadata": {"page_label": "50", "file_name": "hc001042.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\hc001042.pdf", "file_type": "application/pdf", "file_size": 237006, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "a03b5f7c-31a3-4a1d-b1b7-17ff04bf6ba4", "node_type": "4", "metadata": {"page_label": "50", "file_name": "hc001042.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\hc001042.pdf", "file_type": "application/pdf", "file_size": 237006, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "a052bbd8e16be5760a7eec9d2c7a109d4e3d103d42b1e21089a158abe8385669", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b72acfa7-5c7e-40ac-bbb4-ba4bbca45749", "node_type": "1", "metadata": {}, "hash": "15685804ec2b670efdb76ec23c76e2c260780874b95a008550205e620df3cec6", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "lu\u00e9 \u00e0 70 000 F, soit 14 000 $. Le co\u00fbt d'une amputation, pour sa\npart, est estim\u00e9 \u00e0 80 000 F. Au total, compte tenu de l'incidence\nde ces troubles, les co\u00fbts annuels relatifs au \u00ab pied diab\u00e9tique \u00bb\nsont donc estim\u00e9s \u00e0 2,5 milliards de francs (1,5 milliard pour les\nhospitalisations, 800 millions pour les amputations, 200 millions\npour le suivi ambulatoire).\nEn France, le co\u00fbt moyen d'un dialys\u00e9 est estim\u00e9 \u00e0 320 000 F par\nan (entre 250 000 et 400 000 F). 7 % des dialys\u00e9s sont diab\u00e9tiques. Le co\u00fbt de la dialyse des patients diab\u00e9tiques peut donc\n\u00eatre estim\u00e9 \u00e0 470 millions de francs en 1995. Ces donn\u00e9es sont\n\u00e0 la fois parcellaires et tr\u00e8s h\u00e9t\u00e9rog\u00e8nes.\nL'optimisation de la prise en charge du diab\u00e8te\nLes r\u00e9sultats des \u00e9tudes \u00e9conomiques sont particuli\u00e8rement utiles\n\u00e0 l'approche de sant\u00e9 publique lorsqu'ils sont ensuite int\u00e9gr\u00e9s\n\u00e0 la mise en \u0153uvre d'une politique d'optimisation des modalit\u00e9s de prise en charge des diab\u00e8tes.\nL'approche \u00e9conomique doit d\u00e9terminer les moyens d'am\u00e9liorer\nl'efficience des syst\u00e8mes existants, ce qui suppose l'\u00e9valuation\ndes co\u00fbts occasionn\u00e9s par les dispositions permettant une d\u00e9tection plus pr\u00e9coce du diab\u00e8te, une meilleure prise en charge de\nson traitement, une r\u00e9duction du nombre et de la gravit\u00e9 des complications.\nEn France, les mesures co\u00fbt-efficacit\u00e9 des strat\u00e9gies de sant\u00e9\nsont quasiment inexistantes. Ainsi, concernant les actions effectu\u00e9es dans la lign\u00e9e de la d\u00e9claration de Saint-Vincent, les co\u00fbts\nengag\u00e9s eux-m\u00eames sont fort mal connus, et l'on ne dispose que\nde donn\u00e9es partielles.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1538, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "b72acfa7-5c7e-40ac-bbb4-ba4bbca45749": {"__data__": {"id_": "b72acfa7-5c7e-40ac-bbb4-ba4bbca45749", "embedding": null, "metadata": {"page_label": "50", "file_name": "hc001042.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\hc001042.pdf", "file_type": "application/pdf", "file_size": 237006, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "a03b5f7c-31a3-4a1d-b1b7-17ff04bf6ba4", "node_type": "4", "metadata": {"page_label": "50", "file_name": "hc001042.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\hc001042.pdf", "file_type": "application/pdf", "file_size": 237006, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "a052bbd8e16be5760a7eec9d2c7a109d4e3d103d42b1e21089a158abe8385669", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3e49467e-d2f7-4c29-bf53-ceb56f57b491", "node_type": "1", "metadata": {"page_label": "50", "file_name": "hc001042.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\hc001042.pdf", "file_type": "application/pdf", "file_size": 237006, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "1ab5cfb9fc452d236d41c5f7db648aef818b3ad5bba09129093c0b5ce94bccad", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "En France, les mesures co\u00fbt-efficacit\u00e9 des strat\u00e9gies de sant\u00e9\nsont quasiment inexistantes. Ainsi, concernant les actions effectu\u00e9es dans la lign\u00e9e de la d\u00e9claration de Saint-Vincent, les co\u00fbts\nengag\u00e9s eux-m\u00eames sont fort mal connus, et l'on ne dispose que\nde donn\u00e9es partielles. L'\u00e9ducation des patients peut par exemple\nco\u00fbter 900 F par an (1994) et par patient dans un centre comme\nle CETRADIM du centre hospitalier de Roubaix (budget de\n900 000 F/an pour 900 \u00e0 1 100 patients suivis annuellement) ;\ndix fois plus pour l'association AJD, qui dispose d'un budget de\n12 millions de francs pour 8 900 enfants suivis (mais il s'agit\nde patients atteints de DID), ou en moyenne 250 F par patient\npour la Maison du diab\u00e8te de Marcq-en-Bar\u0153ul, qui dispose de\ndeux salari\u00e9s, une documentaliste et 14 b\u00e9n\u00e9voles, et a accueilli,\nen 7 ans, 7 000 diab\u00e9tiques avec un budget de fonctionnement\nannuel de 250 000 F. Ces \u00e9valuations concernent des r\u00e9alit\u00e9s\ntr\u00e8s disparates du point de vue de la dur\u00e9e et de l'ampleur de\nla formation, de l'importance du recours au b\u00e9n\u00e9volat, ou du degr\u00e9\nde la participation financi\u00e8re des patients.\nCes co\u00fbts doivent en outre \u00eatre augment\u00e9s de ceux de la formation des formateurs, qui connaissent les m\u00eames diff\u00e9rences.\n\nLes trois enjeux des diab\u00e8tes\nHaut Comit \u00e9 de la Sant \u00e9 Publique", "mimetype": "text/plain", "start_char_idx": 1259, "end_char_idx": 2564, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "c2796b37-ed8e-41cb-808d-d0ce9a2bbff9": {"__data__": {"id_": "c2796b37-ed8e-41cb-808d-d0ce9a2bbff9", "embedding": null, "metadata": {"page_label": "51", "file_name": "hc001042.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\hc001042.pdf", "file_type": "application/pdf", "file_size": 237006, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "40611d6d-b3cb-4872-84be-26d52f2651f1", "node_type": "4", "metadata": {"page_label": "51", "file_name": "hc001042.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\hc001042.pdf", "file_type": "application/pdf", "file_size": 237006, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "271c23c609c0fe52113c9645a57bfa3b932a506f6573fb03855ee2d91d0d9ced", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "919bd57f-597f-4e3f-b610-8d7b37ee0c01", "node_type": "1", "metadata": {}, "hash": "766b45563578665c4f2bb78f37b43f1bd8c7e283a57c49c45e4e0dd33eebb06c", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "37Diab\u00e8tes. Pr\u00e9vention, dispositifs de soins, \u00e9ducation... / Mai 1998\nTableau IV\nPr\u00e9sentation r\u00e9sum\u00e9e de quelques \u00e9tudes sur le co\u00fb t des diab\u00e8 tes\nAuteurs\nHuse, 1989\nWeinberger,\n\nLuin,\nWilliams,\n\nOlson et al.,\n\nTriomphe\net al., 1988\nTriomphe\net al., 1991\nAnn\u00e9e\net\npays\n\nUSA\n\nUSA\n\n(rapport\u00e9\n\u00e0 valeurs\n\nAngleterre\net Galles\nSu\u00e8de\n\nFrance\n\nFrance\nM\u00e9thodologie\n\u00e9tudes de\nco\u00fbts sur des\ndonn\u00e9es\n\u00e9pid\u00e9miologiques de\npr\u00e9valence\n\u00e9tudes de\nco\u00fbts sur des\ndonn\u00e9es de\npr\u00e9valence\nchez des personnes \u00e2g\u00e9es\nsurco\u00fbt des\ndiab\u00e8tes sur\n28 000 habitants < 65 ans\nd'une m\u00eame\nville\n109 patients,\nrembours\u00e9s \u00e0\n100 %, apr\u00e8s\nconsultation\nm\u00e9decin\nconseil\n263 patients\nrecrut\u00e9s sur\n10 sites MG\net hospitaliers\nType\nde\ndiab\u00e8 te\nDNID\nDNID\nCo\u00fb ts annuels\ndirects\nactes m\u00e9dicaux\npharmacie\n11,6 milliards\nde dollars\n1 970 $ par\nactes m\u00e9dicaux\npharmacie\n5,6 milliards de\nco\u00fbts directs\n1 206 \u00a3 par\nsurco\u00fbt 800 $\npar patient\ncontr\u00f4le\nsurco\u00fbt 600 $\npar patient\nCo\u00fbt par patient\nDID : 7 711 F\nDNID : 5 892 F\nCo\u00fbt par patient\nDID 10 512 F\nDNID 7 374 F\nCo\u00fb ts\nannuels\nindirects\narr\u00eats de\ntravail\nd\u00e9c\u00e8s avant\nretraite\n8,2 milliards\nde dollars\n1 390 $ par\nperte de\nproduction\nli\u00e9e \u00e0 la\nmaladie :\n7 000 $ par\nArr\u00eats de\ntravail\nDID 4 467 F\nDNID 1 016 F\nTotaux\n19,8\nmilliards de\n3 360 $ par\nCo\u00fbt par\nDID 12 178 F\nDNID 6 908 F\nRemarques\nco\u00fbts directs des\ncomplications\ncirculatoires :\n3,8 milliards de\nvisuelles :\n387 millions de\nneuropathiques :\n240 millions de\nPr\u00e9valence :\n5,8 millions de\npersonnes\nco\u00fbts sup\u00e9rieurs\nde 50 % \u00e0 ceux\nd'une population\nde r\u00e9f\u00e9rence\n86 % des co\u00fbts\nli\u00e9s \u00e0 l'hospitalisation et aux\nPr\u00e9valence :\n1,1 %\nCes 1 \u00e0 2 %\nconsomment\n4 \u00e0 5 % des\nd\u00e9penses de\nsoins\npar rapport \u00e0 la\npopulation\nmoyenne :\ndeux fois plus de\njours d'hospitalisation,", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1718, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "919bd57f-597f-4e3f-b610-8d7b37ee0c01": {"__data__": {"id_": "919bd57f-597f-4e3f-b610-8d7b37ee0c01", "embedding": null, "metadata": {"page_label": "51", "file_name": "hc001042.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\hc001042.pdf", "file_type": "application/pdf", "file_size": 237006, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "40611d6d-b3cb-4872-84be-26d52f2651f1", "node_type": "4", "metadata": {"page_label": "51", "file_name": "hc001042.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\hc001042.pdf", "file_type": "application/pdf", "file_size": 237006, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "271c23c609c0fe52113c9645a57bfa3b932a506f6573fb03855ee2d91d0d9ced", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c2796b37-ed8e-41cb-808d-d0ce9a2bbff9", "node_type": "1", "metadata": {"page_label": "51", "file_name": "hc001042.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\hc001042.pdf", "file_type": "application/pdf", "file_size": 237006, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "018ef2e2ab1e6419132fb190da1dfd4d1c36093cb8aae6105b7c950660379419", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "1 %\nCes 1 \u00e0 2 %\nconsomment\n4 \u00e0 5 % des\nd\u00e9penses de\nsoins\npar rapport \u00e0 la\npopulation\nmoyenne :\ndeux fois plus de\njours d'hospitalisation, arr\u00eats\nd\u00e9finitifs de\ntravail et arr\u00eats\nde travail\nConsommation\ndes DID 16 %\nsup\u00e9rieure \u00e0 la\nmoyenne des\nFran\u00e7ais", "mimetype": "text/plain", "start_char_idx": 1581, "end_char_idx": 1831, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "cfa1d914-4ed7-4fb1-84f2-a15c5e03a234": {"__data__": {"id_": "cfa1d914-4ed7-4fb1-84f2-a15c5e03a234", "embedding": null, "metadata": {"page_label": "52", "file_name": "hc001042.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\hc001042.pdf", "file_type": "application/pdf", "file_size": 237006, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "7fba9d68-cfe4-4482-9332-5be804a45b0e", "node_type": "4", "metadata": {"page_label": "52", "file_name": "hc001042.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\hc001042.pdf", "file_type": "application/pdf", "file_size": 237006, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "007db78694479157212307b4fb4a8f86d6f7755e8bfa3a0ed9e02b9694eb80d1", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "L'\u00e9valuation des r\u00e9sultats des actions ainsi men\u00e9es conna\u00eet elle\naussi de graves lacunes. L'une des \u00e9valuations entreprises, le\nbilan du CETRADIM, montre n\u00e9anmoins, apr\u00e8s dix ans de fonctionnement, que, compar\u00e9e avec des structures hospitali\u00e8res\nde m\u00eame recrutement mais ne comportant pas de centre d'\u00e9ducation et de traitement en alternative \u00e0 l'hospitalisation, cette\nstructure r\u00e9duit sensiblement le nombre de journ\u00e9es d'hospitalisation classique. Par ailleurs, entre 1992 et 1994, on a constat\u00e9\ndans les services concern\u00e9s du centre hospitalier de Roubaix, une\nbaisse de 28,6 % du nombre de journ\u00e9es d'hospitalisation.\nLe rapprochement des co\u00fbts et des avantages, pour sa part, n'a\npas \u00e9t\u00e9 effectu\u00e9 en France dans des \u00e9tudes m\u00e9thodologiquement\ncontr\u00f4l\u00e9es.\nQuelques \u00e9tudes co\u00fbts-avantages effectu\u00e9es \u00e0 l'\u00e9tranger\nDes \u00e9valuations de situations, r\u00e9elles ou simul\u00e9es, ont \u00e9t\u00e9 effectu\u00e9es \u00e0 l'\u00e9tranger. Elles montrent l'int\u00e9r\u00eat des strat\u00e9gies de pr\u00e9vention et d'encadrement.\nUn essai de plus de six ans, men\u00e9 aux \u00c9tats-Unis sur des DID,\na ainsi montr\u00e9 qu'une th\u00e9rapeutique intensive, et un contr\u00f4le appropri\u00e9 du glucose diminuait le risque de r\u00e9tinopathie de 54 % et la\nprogression de la n\u00e9phropathie de 60 %. Un mod\u00e8le de simulation \u00e9labor\u00e9 aux \u00c9tats-Unis montre qu'un d\u00e9pistage syst\u00e9matique\nde la r\u00e9tinopathie chez les patients atteints de DNID \u00e9pargnerait alors 248 millions de dollars, et ferait gagner 54 000 ann\u00e9es\nde vue aux personnes susceptibles de devenir aveugles.\nDans le cas du DNID, les programmes de formation et de sensibilisation ont particuli\u00e8rement \u00e9t\u00e9 \u00e9tudi\u00e9s en Allemagne. Un programme d'information sur la maladie et les bases d'un r\u00e9gime\nhypocalorique, ainsi qu'un programme d'\u00e9ducation des m\u00e9decins\ng\u00e9n\u00e9ralistes aux risques de complications, a abouti en un an \u00e0\nune r\u00e9duction de 50 % des prescriptions d'antidiab\u00e9tiques oraux.\nDes analyses plus fines ont montr\u00e9 que le co\u00fbt d'un programme\nde formation des m\u00e9decins est int\u00e9gralement compens\u00e9, en moins\nd'un an, par la diminution de la consommation d'antidiab\u00e9tiques\noraux.\nAux \u00c9tats-Unis, les \u00e9valuations des centres de formation et de traitement des diab\u00e9tiques ont montr\u00e9 l'importance des b\u00e9n\u00e9fices\n\u00e9conomiques retir\u00e9s en termes de r\u00e9duction des comas et des\namputations, ainsi que de r\u00e9duction de la consommation d'insuline et d'antidiab\u00e9tiques oraux. Les strat\u00e9gies recourant \u00e0 l'\u00e9ducation d\u00e9gagent un ratio co\u00fbt-efficacit\u00e9 favorable.\n\nLes trois enjeux des diab\u00e8tes\nHaut Comit \u00e9 de la Sant \u00e9 Publique", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2476, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "9d2d5745-2280-4966-911c-b1ae144348f5": {"__data__": {"id_": "9d2d5745-2280-4966-911c-b1ae144348f5", "embedding": null, "metadata": {"page_label": "53", "file_name": "hc001042.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\hc001042.pdf", "file_type": "application/pdf", "file_size": 237006, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "eac0587c-90c9-4dec-8912-292984126700", "node_type": "4", "metadata": {"page_label": "53", "file_name": "hc001042.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\hc001042.pdf", "file_type": "application/pdf", "file_size": 237006, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "4a1de5081bc0224cece1872bc2a002adf35c68e12e3142ab87f4992b7a446824", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "cd397f0a-8f75-402b-8373-87472ec43cfb", "node_type": "1", "metadata": {}, "hash": "359d1f3971f69e57abbb5920d485a748be4b4084fb18b56e35865be6dcc91ebb", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "39Diab\u00e8tes. Pr\u00e9vention, dispositifs de soins, \u00e9ducation... / Mai 1998\nPrincipaux\npoints forts et\npoints faibles\ndu dispositif\nfran\u00e7ais\nde soins\nSelon Assal13, citant Bartlett14, une revue des \u00e9tudes co\u00fbts efficacit\u00e9 des actions d'\u00e9ducation du patient montre qu'un dollar\ninvesti dans ce type d'action entra\u00eene entre trois et quatre dollars\nd'\u00e9conomie.\nAu total, l'insuffisance flagrante en France de recherches \u00e9conomiques autour du diab\u00e8te repr\u00e9sente un handicap important\npour l'\u00e9mergence d'une politique de sant\u00e9 efficace concernant\ncette pathologie.\n\u00c0 l'issue de cette analyse, il appara\u00eet clairement que le dispositif fran\u00e7ais de prise en charge du diab\u00e8te, s'il peut se pr\u00e9valoir de\nquelques beaux succ\u00e8s, poss\u00e8de des points forts et des points\nfaibles, dont la compr\u00e9hension permettrait une am\u00e9lioration notable\nde son efficacit\u00e9. C'est pourquoi il peut \u00eatre utile de r\u00e9capituler\nces diff\u00e9rents r\u00e9sultats dans un tableau d'ensemble (Tableau V).\n13. Assal J. Ph., \u00ab Cost effectiveness of diabetes education \u00bb, Pharmaco Economics, 1995\n(suppl.), 8:68-71.\n14. Bartlett E., \u00ab Cost Benefit analysis of patient education \u00bb,Patient Education Couns, 1995,\n96:87-91.\nTableau V\nPoints forts et points faibles du dispositif fran\u00e7 ais de soins du diab\u00e8 te\nPoints forts Points faible\nD\u00e9s\u00e9quilibre entre les repr\u00e9sentations du\nDID et du DNID (diab\u00e9tologie \u00ab noble \u00bb de\nl'insuline et diab\u00e9tologie \u00ab vulgaire \u00bb des gros)\nMauvaise organisation de la pr\u00e9vention\ndu DNID et prise en charge trop tardive\n(pr\u00e9-complications)\nOrganisation des soins cloisonn\u00e9e et\nhospitalo-centr\u00e9e\nMauvaise articulation des g\u00e9n\u00e9ralistes\net des diab\u00e9tologues\nUn d\u00e9ficit important des connaissances\net donn\u00e9es \u00e9conomiques sur la prise en\ncharge du diab\u00e8te\n\u00c9valuation difficile de la qualit\u00e9 du\ndispositif de soins sp\u00e9cialis\u00e9s\nDifficult\u00e9s d'\u00e9valuation de l'efficacit\u00e9 des\nefforts d'\u00e9ducation des patients souffrant\nde DNID (vraisemblablement m\u00e9diocre)\n\u00ab Confusion \u00bb entre les missions d'\u00e9ducation et de soins et les acteurs en charge\nde l'une et de l'autre\nInsuffisance de liens entre la diab\u00e9tologie\net d'autres disciplines face \u00e0 la pr\u00e9vention\net \u00e0 la prise en charge des complications\ncardio-vasculaires\nTradition scientifique ancienne et continue.\nProbl\u00e8me bien identifi\u00e9.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2241, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "cd397f0a-8f75-402b-8373-87472ec43cfb": {"__data__": {"id_": "cd397f0a-8f75-402b-8373-87472ec43cfb", "embedding": null, "metadata": {"page_label": "53", "file_name": "hc001042.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\hc001042.pdf", "file_type": "application/pdf", "file_size": 237006, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "eac0587c-90c9-4dec-8912-292984126700", "node_type": "4", "metadata": {"page_label": "53", "file_name": "hc001042.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\hc001042.pdf", "file_type": "application/pdf", "file_size": 237006, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "4a1de5081bc0224cece1872bc2a002adf35c68e12e3142ab87f4992b7a446824", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9d2d5745-2280-4966-911c-b1ae144348f5", "node_type": "1", "metadata": {"page_label": "53", "file_name": "hc001042.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\hc001042.pdf", "file_type": "application/pdf", "file_size": 237006, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "a366bf34f1941647d2e6c743058d01f579fcd6177d49d79fcd453ba206750451", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Probl\u00e8me bien identifi\u00e9.\nExistence de moyens fiables et simples de\ndiagnostic\nExistence d'un corps de sp\u00e9cialistes\ncomp\u00e9tents\nEnseignement satisfaisant\nRecherche dynamique\nIndustrie pharmaceutique performante\n(efficacit\u00e9 de l'insuline)\nTr\u00e8s bonne organisation des soins des\njeunes souffrant de DID (\u00e9ducation,\npr\u00e9vention des complications)", "mimetype": "text/plain", "start_char_idx": 2217, "end_char_idx": 2556, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "31ff09bb-a89b-41c5-9cdd-350d563ac944": {"__data__": {"id_": "31ff09bb-a89b-41c5-9cdd-350d563ac944", "embedding": null, "metadata": {"page_label": "54", "file_name": "hc001042.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\hc001042.pdf", "file_type": "application/pdf", "file_size": 237006, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "9bc7d0e6-1094-45e2-8915-b7c788b51d34", "node_type": "4", "metadata": {"page_label": "54", "file_name": "hc001042.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\hc001042.pdf", "file_type": "application/pdf", "file_size": 237006, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "4eaaec8c087205be477bd6ff580331427b5188018f5aee750fb1cc4ecf209a23", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Les dispositifs\nde soins des\nautres maladies\nchroniques\nEn France, la plupart des maladies chroniques (\u00e0 l'exception peut\u00eatre des douleurs dorsales, dont le statut est particuli\u00e8rement\ncomplexe) disposent d'un dispositif de soins sp\u00e9cialis\u00e9s qui,\ns'il n'est pas tr\u00e8s organis\u00e9, est relativement complet. En revanche,\nrares sont les maladies chroniques pour lesquelles la structuration de l'offre est r\u00e9elle et organis\u00e9e. La plupart des dispositifs\nrepr\u00e9sentent une simple entit\u00e9 hospitalo-universitaire, tandis que,\nsur le terrain, la logique de l'offre semble pr\u00e9valoir. Cette situation laisse subsister, suivant les zones d'observation, un certain nombre de \u00ab r\u00e9gions aveugles \u00bb.\nPourtant, l'une des sp\u00e9cificit\u00e9s de la maladie chronique r\u00e9side justement dans le rapport \u00e0 la structure de soins, qui, lorsque la maladie est d\u00e9clar\u00e9e, est fr\u00e9quente, durable, et r\u00e9guli\u00e8re, et lorsqu'elle\nne l'est pas, n\u00e9cessite le recours \u00e0 l'ensemble des formes de pr\u00e9vention (primaire, secondaire et tertiaire - pr\u00e9vention des complications).\nLa mise en place des syst\u00e8mes de pr\u00e9vention des maladies chroniques est rendue d'autant plus complexe que les sp\u00e9cificit\u00e9s de\nces maladies exigent \u00e0 la fois une prise en charge capable de respecter la revendication d'autonomie du patient (cf. II.3\n), et son\ninformation. Il doit par exemple apprendre \u00e0 reconna\u00eetre (et parfois \u00e0 signaler) le rapport qui existe entre la maladie chronique et\nles diff\u00e9rentes formes de complications qu'elle peut entra\u00eener.\nEnfin, \u00e0 la n\u00e9cessit\u00e9 d'organiser sectoriellement les dispositifs\nde soins de chaque maladie chronique, s'ajoute l'urgence d'une\nr\u00e9flexion globale sur les soins de ces pathologies. Cette r\u00e9flexion\ndevrait en particulier s'attacher \u00e0 deux objectifs :\nG la d\u00e9finition d'une m\u00e9thodologie d'\u00e9valuation (en particulier\nsous l'angle des besoins des patients et de l'efficacit\u00e9 de\nla prise en charge) ;\nG la d\u00e9finition de r\u00e8gles de r\u00e9organisation (restructuration,\nrationalisation).\nEn m\u00eame temps, ces deux r\u00e9flexions devront pouvoir disposer\nd'outils permettant d'appr\u00e9hender la variabilit\u00e9 et les sp\u00e9cificit\u00e9s\ndes diff\u00e9rents dispositifs, et devront en particulier pouvoir reposer sur une typologie pr\u00e9cise des diff\u00e9rentes formes de maladie\nchronique et de leurs syst\u00e8mes de prise en charge.\n\nLes trois enjeux des diab\u00e8tes\nHaut Comit \u00e9 de la Sant \u00e9 Publique", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2334, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "203f969f-dbf4-4e47-b1a1-2ffc9b6caa37": {"__data__": {"id_": "203f969f-dbf4-4e47-b1a1-2ffc9b6caa37", "embedding": null, "metadata": {"page_label": "55", "file_name": "hc001042.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\hc001042.pdf", "file_type": "application/pdf", "file_size": 237006, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "b14ab2bf-687b-4049-9439-793d9236eb40", "node_type": "4", "metadata": {"page_label": "55", "file_name": "hc001042.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\hc001042.pdf", "file_type": "application/pdf", "file_size": 237006, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "74537f71f804410130dff3bf54e1877d7d90d6ba9f613f21a6fe8a4ef91c2b07", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "41Diab\u00e8tes. Pr\u00e9vention, dispositifs de soins, \u00e9ducation... / Mai 1998\nLes crit\u00e8res\npour\nl'\u00e9valuation des\ndispositifs de\nsoins des\nautres maladies\nchroniques\nL'\u00e9valuation des dispositifs de soins devra donc d\u00e9finir les crit\u00e8res\nde leur analyse. Le choix de ces crit\u00e8res est important, et devra\ntenir compte du fait que, loin de pr\u00e9senter une sorte de \u00ab photographie \u00bb objective du fonctionnement d'un syst\u00e8me de soins, ils\nen repr\u00e9sentent \u00e9galement une interpr\u00e9tation, et risquent d'en\ninduire une orientation.\nC'est ainsi que le suivi du diab\u00e8 te qui serait fond\u00e9 exclusivement\nsur le contr\u00f4 le du taux de complications orienterait le dispositif\nvers une politique largement hospitalo-centr \u00e9e, tandis qu '\u00e0\nl'inverse, un suivi syst \u00e9matique du contr\u00f4 le glyc\u00e9mique orienterait le syst\u00e8 me vers une logique nettement plus pr\u00e9ventive et\nambulatoire.\nPour nourrir un tel d\u00e9bat, il est d'ores et d\u00e9j\u00e0 possible de proposer un premier ensemble de crit\u00e8res, issu des analyses pr\u00e9c\u00e9dentes, qui pourra \u00e9tayer la r\u00e9flexion. Ces crit\u00e8res peuvent,\nanalytiquement, \u00eatre divis\u00e9s en trois cat\u00e9gories :\nG les crit\u00e8res issus des caract\u00e9ristiques propres de la maladie,\nG les crit\u00e8res issus des caract\u00e9ristiques du savoir m\u00e9dical sur\nla maladie,\nG et les crit\u00e8res issus des caract\u00e9ristiques \u00ab sociales \u00bb de la\nmaladie.\nCrit\u00e8res issus des caract\u00e9ristiques propres de la maladie\n\u2022 incidence,\n\u2022 distribution g\u00e9ographique,\n\u2022 \u00e9volutivit\u00e9 de la maladie,\n\u2022 degr\u00e9 d'invalidit\u00e9,\n\u2022 risque vital,\n\u2022 \u00e2ge de survenue.\nCrit\u00e8res issus des caract\u00e9ristiques du savoir m\u00e9dical\nsur la maladie\n\u2022 existence ou non d'un corps de sp\u00e9cialistes,\n\u2022 niveau de formation des g\u00e9n\u00e9ralistes,\n\u2022 \u00e9tat de la coop\u00e9ration entre les sp\u00e9cialistes et les g\u00e9n\u00e9ralistes,\n\u2022 existence ou non d'un syst\u00e8me d'\u00e9ducation du patient,", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1768, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "b56d0dae-7f5a-46fb-becd-b755b15efb4a": {"__data__": {"id_": "b56d0dae-7f5a-46fb-becd-b755b15efb4a", "embedding": null, "metadata": {"page_label": "56", "file_name": "hc001042.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\hc001042.pdf", "file_type": "application/pdf", "file_size": 237006, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "e81b6ab0-b708-4e5a-89a1-3a9951b1c48b", "node_type": "4", "metadata": {"page_label": "56", "file_name": "hc001042.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\hc001042.pdf", "file_type": "application/pdf", "file_size": 237006, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "0bc12746449ebcc2e6edd5f8393385af84b7ae8d0a71d26900f2c3c65834c35a", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "\u2022 existence ou non de crit\u00e8res de diagnostic et d'indicateurs\nde suivi,\n\u2022 existence ou non de dispositifs d'\u00e9valuation de la prise en\ncharge,\n\u2022 co\u00fbt de la prise en charge,\n\u2022 \u00e9tat des th\u00e9rapeutiques et de la recherche th\u00e9rapeutique.\nCrit\u00e8res issus des caract\u00e9ristiques \u00ab sociales \u00bb de la maladie\n\u2022 existence ou non d'un point de vue consum\u00e9riste et d'une\nvie associative active,\n\u2022 repr\u00e9sentations sociales de la maladie,\n\u2022 structuration m\u00e9dico-sociale autour de la maladie,\n\u2022 existence ou non de revendications des patients.\n\u00c0 l'heure actuelle, rares sont les crit\u00e8res pour lesquels on poss\u00e8de des donn\u00e9es compl\u00e8tes et fiables, portant sur chacune des\nmaladies chroniques. La production et la validation de ces donn\u00e9es apparaissent comme un pr\u00e9requis incontournable pour la\nmise en place d'une v\u00e9ritable politique de sant\u00e9 publique vis-\u00e0-vis\ndes maladies chroniques. Elles sont une condition indispensable,\nsinon suffisante, \u00e0 la mise en place de r\u00e9seaux de soins si souvent \u00e9voqu\u00e9s r\u00e9cemment.\nFavoriser\nune v\u00e9ritable \u00e9ducation\ndu patient\nLe poids sanitaire des maladies chroniques, les souffrances\nqu'elles occasionnent, le co\u00fbt de leur traitement (augment\u00e9 du\nfait de leur longueur) rendent n\u00e9cessaire, on l'a soulign\u00e9, la mise\nen place de strat\u00e9gies de pr\u00e9vention. Ce besoin de pr\u00e9vention vise\naussi bien les maladies, lorsque cela est possible, que leurs complications, au stade de la maladie d\u00e9clar\u00e9e.\nParmi les diff\u00e9rentes strat\u00e9gies de pr\u00e9vention disponibles (modification des comportements alimentaires, d\u00e9pistage pr\u00e9coce, voire\nrecherche des pr\u00e9dispositions g\u00e9n\u00e9tiques, attention aux facteurs\nenvironnementaux, taxation des substances nocives, etc.), il existe\nune voie consid\u00e9r\u00e9e depuis quelques ann\u00e9es comme particuli\u00e8rement prometteuse : celle de l'\u00e9ducation des patients.\n\nLes trois enjeux des diab\u00e8tes\nHaut Comit \u00e9 de la Sant \u00e9 Publique", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1849, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "5ef4e750-0370-45d5-ab1e-e8684528247d": {"__data__": {"id_": "5ef4e750-0370-45d5-ab1e-e8684528247d", "embedding": null, "metadata": {"page_label": "57", "file_name": "hc001042.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\hc001042.pdf", "file_type": "application/pdf", "file_size": 237006, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "791c605f-8fa4-4e78-a496-e81363747043", "node_type": "4", "metadata": {"page_label": "57", "file_name": "hc001042.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\hc001042.pdf", "file_type": "application/pdf", "file_size": 237006, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "7ab6c0722c821d4a444cc84e417fc9cc10416a9a9146135ba5da3bc3281869cb", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "43Diab\u00e8tes. Pr\u00e9vention, dispositifs de soins, \u00e9ducation... / Mai 1998\nOrigines\net \u00e9volutions\nr\u00e9centes de la\nd\u00e9marche 15\nL'\u00e9ducation du patient vise aujourd'hui deux objectifs compl\u00e9mentaires :\nG l'\u00e9ducation pour la sant\u00e9, qui s'efforce de transmettre des\nr\u00e8gles g\u00e9n\u00e9rales d'hygi\u00e8ne et de comportement et s'inscrit plus g\u00e9n\u00e9ralement dans une optique de sant\u00e9 publique,\nG et l'\u00e9ducation stricto sensu du patient, qui cherche \u00e0 assurer la prise en charge de la maladie par le patient lui-m\u00eame\n(dans le cadre d'une autonomisation croissante), et qui est,\n\u00e0 tort ou \u00e0 raison, beaucoup plus souvent mise en \u0153uvre\npar des sp\u00e9cialistes de ces maladies.\nQuelle que soit la pertinence de cette distinction, l'\u00e9ducation pour\nla sant\u00e9 et l'\u00e9ducation du patient apparaissent aujourd'hui comme\ndes enjeux majeurs de sant\u00e9 publique pour plusieurs raisons, dont\ncertaines ont d\u00e9j\u00e0 \u00e9t\u00e9 \u00e9voqu\u00e9es dans ce rapport :\nG la conscience toujours vive de l'importance des mesures\nd'hygi\u00e8ne et de comportements pour la pr\u00e9vention d'un\nnombre important de troubles ;\nG le d\u00e9veloppement des maladies chroniques et l'augmentation, actuelle et pr\u00e9visible, des malades de longue dur\u00e9e avec\nle vieillissement de la population ;\nG le d\u00e9veloppement de nouveaux types de relations entre les\npatients et les m\u00e9decins, induisent, de la part des malades,\nl'exigence d'une plus grande concertation, et de la part des\nm\u00e9decins la n\u00e9cessit\u00e9 d'une implication active du patient\ndans la mise en \u0153uvre des traitements des diab\u00e8tes et des\nmaladies chroniques ;\nG les questions pos\u00e9es par le financement de la protection\nsociale et la n\u00e9cessit\u00e9 de concevoir de nouvelles modalit\u00e9s\nde pr\u00e9vention ;\nG le d\u00e9veloppement des techniques m\u00e9dicales de pr\u00e9vention,\nqui permettent aujourd'hui des \u00e9valuations personnalis\u00e9es\ndes risques et induisent, chez le m\u00e9decin comme chez le\nmalade, la revendication de d\u00e9marches de pr\u00e9vention.\nLa gen\u00e8se du projet contemporain d'\u00e9ducation pour la sant\u00e9 et\nd'\u00e9ducation du patient conduirait donc \u00e0 impliquer des r\u00e9flexions\nd'origines tr\u00e8s diverses : m\u00e9dicale, sociale, \u00e9conomique, juridique,\n15. Ce chapitre est largement redevable du rapport du Pr Palicot (ENSP), ainsi que des \u00e9l\u00e9ments du dossier publi\u00e9 dans la revue du HCSP, Actualit\u00e9 et dossier en sant\u00e9 publique,\n\u00ab L'\u00e9ducation pour la sant\u00e9, du discours \u00e0 la pratique \u00bb, n\u00b0 16, septembre 1996.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2330, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "0037445d-49fe-4f0f-9a66-862f6e311a5e": {"__data__": {"id_": "0037445d-49fe-4f0f-9a66-862f6e311a5e", "embedding": null, "metadata": {"page_label": "58", "file_name": "hc001042.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\hc001042.pdf", "file_type": "application/pdf", "file_size": 237006, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "4f1c118c-5f29-4f8c-828d-3897e47c7395", "node_type": "4", "metadata": {"page_label": "58", "file_name": "hc001042.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\hc001042.pdf", "file_type": "application/pdf", "file_size": 237006, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "64150d83559a56867732a7efa3ea7afc198f980b53c5bb4f37fff5bb102fef51", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "99a1b0e3-b92e-407e-8904-50283ed8b19b", "node_type": "1", "metadata": {}, "hash": "0733259ae7c7a7f5d37aa31f8d3110f25df53db09f49d92968d55cbc6855dedd", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "\u00e9thique, ou parfois utopique. Mais nous nous contenterons dans\ncette partie du rapport de montrer comment ce projet s'est progressivement objectiv\u00e9 et s'est de plus en plus dot\u00e9 de structures\nop\u00e9rationnelles et administratives.\nLe besoin d'une \u00e9ducation du patient est, \u00e0 la limite, aussi ancien\nque la m\u00e9decine elle-m\u00eame. Il a d'ailleurs souvent \u00e9t\u00e9 d\u00e9fini comme\nun \u00e9l\u00e9ment \u00e0 part enti\u00e8re des devoirs impliqu\u00e9s par le serment\nd'Hippocrate. Le ph\u00e9nom\u00e8ne r\u00e9cent est sans doute la n\u00e9cessit\u00e9 affich\u00e9e de favoriser une r\u00e9elle autonomie du patient, et de\nsubstituer aux rapports de pouvoir et \u00e0 la relation de compliance\nune v\u00e9ritable possibilit\u00e9 de communication et de n\u00e9gociation entre\nle m\u00e9decin et le malade.\nAu cours du XIX\ne si\u00e8cle, en Europe, par exemple, le mouvement\nhygi\u00e9niste montre que la maladie n'est pas une simple entit\u00e9 m\u00e9dicale, mais que son apparition est bien souvent li\u00e9e \u00e0 des caract\u00e8res sociaux. \u00c0 la suite des travaux de Pasteur sont mises en place\ndes mesures prophylactiques efficaces et vari\u00e9es. L'\u00ab \u00e9ducation \u00bb\ndes m\u00e8res (st\u00e9rilisation du lait), qui permet la ma\u00eetrise des diarrh\u00e9es infantiles, la pratique de l'antisepsie dans les services hospitaliers, qui r\u00e9duit la mortalit\u00e9 post-chirurgicale, ou la distribution\nd'eau potable non pollu\u00e9e, pour pr\u00e9venir la typho\u00efde, sont autant\nde dispositions qui n\u00e9cessitent une formation des patients ou des\npersonnels m\u00e9dicaux et apportent de r\u00e9els r\u00e9sultats. Parall\u00e8lement,\nil faut bien admettre que la p\u00e9riode de gloire de la m\u00e9decine pastorienne aboutira malgr\u00e9 tout \u00e0 rel\u00e9guer le courant hygi\u00e9niste et la\nm\u00e9decine sociale au second plan. Malgr\u00e9 l'importance des efforts\nengag\u00e9s lors des batailles contre les \u00ab fl\u00e9aux sociaux \u00bb (tuberculose, syphilis, alcoolisme), malgr\u00e9 l'adoption, en 1902, de la loi de\nsant\u00e9 publique r\u00e9clam\u00e9e depuis longtemps par les hygi\u00e9nistes, la\nsant\u00e9 publique, l'hygi\u00e8ne ou la m\u00e9decine sociale resteront longtemps des disciplines mineures, et les m\u00e9decins de sant\u00e9 publique\nresteront un sous-groupe d\u00e9valoris\u00e9 du corps m\u00e9dical.\nDe grands changements de la m\u00e9decine surviennent apr\u00e8s la\nDeuxi\u00e8me Guerre mondiale qui vont conduire \u00e0 modifier cette situation.\nBien que l'unit\u00e9 de l'ensemble qualifi\u00e9 de \u00ab maladies chroniques \u00bb\nsoit parfois discutable, cet ensemble d'affections poss\u00e8de ind\u00e9niablement certaines caract\u00e9ristiques communes, conduisant parfois certains auteurs, telle Claudine Herzlich, \u00e0 parler de l'apparition\nd'un \u00ab nouveau malade \u00bb.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2440, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "99a1b0e3-b92e-407e-8904-50283ed8b19b": {"__data__": {"id_": "99a1b0e3-b92e-407e-8904-50283ed8b19b", "embedding": null, "metadata": {"page_label": "58", "file_name": "hc001042.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\hc001042.pdf", "file_type": "application/pdf", "file_size": 237006, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "4f1c118c-5f29-4f8c-828d-3897e47c7395", "node_type": "4", "metadata": {"page_label": "58", "file_name": "hc001042.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\hc001042.pdf", "file_type": "application/pdf", "file_size": 237006, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "64150d83559a56867732a7efa3ea7afc198f980b53c5bb4f37fff5bb102fef51", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0037445d-49fe-4f0f-9a66-862f6e311a5e", "node_type": "1", "metadata": {"page_label": "58", "file_name": "hc001042.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\hc001042.pdf", "file_type": "application/pdf", "file_size": 237006, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "ab96286737c50c9311d16da2e550c6b1cfb5456fe21b2401f3e8da7a877b189b", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Bien que l'unit\u00e9 de l'ensemble qualifi\u00e9 de \u00ab maladies chroniques \u00bb\nsoit parfois discutable, cet ensemble d'affections poss\u00e8de ind\u00e9niablement certaines caract\u00e9ristiques communes, conduisant parfois certains auteurs, telle Claudine Herzlich, \u00e0 parler de l'apparition\nd'un \u00ab nouveau malade \u00bb.\n\u00c0 partir des ann\u00e9es soixante-dix, ce nouveau malade va justifier\n(ou exiger), la mise en place de v\u00e9ritables strat\u00e9gies d'\u00e9duca44\nLes trois enjeux des diab\u00e8tes\nHaut Comit \u00e9 de la Sant \u00e9 Publique", "mimetype": "text/plain", "start_char_idx": 2151, "end_char_idx": 2635, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "93a4a4fd-2f66-4a41-88da-ce881277d73c": {"__data__": {"id_": "93a4a4fd-2f66-4a41-88da-ce881277d73c", "embedding": null, "metadata": {"page_label": "59", "file_name": "hc001042.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\hc001042.pdf", "file_type": "application/pdf", "file_size": 237006, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "4381a3ec-5afd-40c9-80fd-aa0c7006832d", "node_type": "4", "metadata": {"page_label": "59", "file_name": "hc001042.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\hc001042.pdf", "file_type": "application/pdf", "file_size": 237006, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "e8f94d271fd1de14447fe299f6aa5a8b7546ff197ba6e838a1c610a4b9d03fea", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "45Diab\u00e8tes. Pr\u00e9vention, dispositifs de soins, \u00e9ducation... / Mai 1998\nLes acteurs\net les m\u00e9thodes\ntion dans un mouvement qui ira s'amplifiant jusqu'\u00e0 nos jours, et\nconcernera aussi bien les associations de patients, les structures\nhospitali\u00e8res, que le Conseil de l'Europe, le bureau europ\u00e9en\nde l'OMS, ou des associations scientifiques telles que l'EASD/AEED\n(Association europ\u00e9enne pour l'\u00e9tude du diab\u00e8te), ou son sousgroupe sp\u00e9cialis\u00e9 le \u00ab Diabete education study group \u00bb (DESG) dont\nil existe une section de langue fran\u00e7aise.\nD\u00e8s 1979, la CEE \u00e9ditait une charte europ\u00e9enne du malade usager de l'h\u00f4pital, qui abordait notamment le droit du malade d'accepter ou de refuser un traitement (consentement \u00e9clair\u00e9), et le droit\nd'\u00eatre inform\u00e9 de ce qui concerne son \u00e9tat de sant\u00e9, \u00ab et de participer aux d\u00e9cisions pouvant avoir des cons\u00e9quences sur son\nbien-\u00eatre. \u00bb\nEn 1989, la D\u00e9claration de Saint-Vincent accordait une large place\n\u00e0 la formation du patient diab\u00e9tique et fixait des objectifs d'\u00e9ducation, rapidement mis en \u0153uvre par des associations comme la\nF\u00e9d\u00e9ration internationale du diab\u00e8te, l'EASD/AEED, et les associations nationales.\nEn France, la loi hospitali\u00e8re de 1991 inclut l'\u00e9ducation \u00e0 la sant\u00e9\ndans les objectifs prioritaires de l'h\u00f4pital (mais sans y affecter\ndes moyens sp\u00e9cifiques). Des comit\u00e9s r\u00e9gionaux et d\u00e9partementaux\npour la sant\u00e9 (96) relaient le CFES (soutenu par la direction g\u00e9n\u00e9rale de la Sant\u00e9 et les caisses de s\u00e9curit\u00e9 sociale), association\nqui joue en la mati\u00e8re un r\u00f4le d'expert et de r\u00e9f\u00e9rent. Depuis 1994,\nle budget de l'\u00c9tat contribue \u00e0 financer ces comit\u00e9s r\u00e9gionaux\n(\u00e0 hauteur de 80 000 F) et l'on observe une am\u00e9lioration significative de leurs m\u00e9thodes et une certaine professionnalisation de\nleurs membres.\nUne \u00e9tude coordonn\u00e9e par le professeur Palicot (ENSP) montrait\nen 1992 que l'\u00e9ducation des patients diab\u00e9tiques \u00e9tait de loin\nl'activit\u00e9 \u00e9ducative dominante en milieu hospitalier.\nEn France, la responsabilit\u00e9 de l'\u00e9ducation pour la sant\u00e9 et de\nl'\u00e9ducation du patient, en particulier diab\u00e9tique, est partag\u00e9e entre\nde tr\u00e8s nombreux acteurs. Un r\u00e9cent rapport\n16 montrait par exemple\nl'implication de structures aussi diverses que :\nG L'\u00c9tat : direction g\u00e9n\u00e9rale de la Sant\u00e9, qui assure la \u00ab tutelle \u00bb\ndu CFES, direction de la S\u00e9curit\u00e9 sociale, direction des H\u00f4pitaux, direction des Relations internationales, d\u00e9l\u00e9gations\n16. Rapport sur l'information et l'\u00e9ducation sanitaires dans le syst\u00e8me de sant\u00e9 fran\u00e7ais :\n\u00e9tat des lieux et propositions , Annick Morel, direction g\u00e9n\u00e9rale de la Sant\u00e9, 1995.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2547, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "8e12c1ba-5d24-4324-9a88-5dfadc2d6d83": {"__data__": {"id_": "8e12c1ba-5d24-4324-9a88-5dfadc2d6d83", "embedding": null, "metadata": {"page_label": "60", "file_name": "hc001042.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\hc001042.pdf", "file_type": "application/pdf", "file_size": 237006, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "e060e4b0-03ea-41b6-85e3-74028079cab7", "node_type": "4", "metadata": {"page_label": "60", "file_name": "hc001042.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\hc001042.pdf", "file_type": "application/pdf", "file_size": 237006, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "bf096b7633ace6f06098486ee1985292014f6919ab03dfec17fefa9daa7189bc", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "aux missions sp\u00e9cifiques, organismes ou dispositifs sous\ntutelle des minist\u00e8res sanitaires et sociaux (HCSP, Agence du\nm\u00e9dicament), services d\u00e9concentr\u00e9s de l'\u00c9tat (DDASS, DRASS),\net enfin d'autres minist\u00e8res (Jeunesse et Sports, \u00c9conomie,\nTransports, Travail, Agriculture et D\u00e9fense nationale...).\nG Les collectivit\u00e9s territoriales qui ont un r\u00f4le tr\u00e8s important\ndepuis les lois sur la d\u00e9centralisation et la restructuration\ndes services d\u00e9partementaux ;\nG Les caisses de s\u00e9curit\u00e9 sociale, qui fonctionnent dans ce\ndomaine gr\u00e2ce \u00e0 deux types de ressources : le Fonds national de pr\u00e9vention, d'\u00e9ducation et d'information sanitaires\n(FNPEIS) et les fonds d'action sanitaire et sociale ;\nG Les soci\u00e9t\u00e9s mutualistes ;\nG Les grandes associations nationales (de d\u00e9fense des\nmalades, d'aide sociale et psychologique, d'aide \u00e0 la\nrecherche, de pr\u00e9vention et d'\u00e9ducation, de communication),\nLigue contre le cancer ;\nG Les services ad hoc mis en place dans les structures hospitali\u00e8res.\n\u00c0 l'heure actuelle, les r\u00e9sultats de diverses \u00e9tudes montrent que,\ndans les milieux hospitaliers, les d\u00e9marches d'\u00e9ducation des\npatients restent le plus souvent le fait de professions param\u00e9dicales, et en particulier des infirmi\u00e8res, qui semblent, de plus en\nplus souvent, jouer le r\u00f4le de maillon entre le m\u00e9decin et le malade.\nDans l'ensemble, les outils d'\u00e9ducation pour la sant\u00e9 comme\nd'\u00e9ducation du patient peuvent \u00eatre qualifi\u00e9s d'artisanaux. Les\nactions d'\u00e9ducation du patient sont encore relativement rares, et\nle plus souvent issues d'initiatives spontan\u00e9es (certaines pouvant\nse pr\u00e9valoir de tr\u00e8s beaux succ\u00e8s). L'\u00e9ducation pour la sant\u00e9,\nsi elle repose sur un ensemble de fonctionnaires et de membres\nd'associations tr\u00e8s engag\u00e9s, marque cependant le pas dans diff\u00e9rents domaines. Les \u00e9valuations tr\u00e8s positives des r\u00e9sultats\ndes diff\u00e9rentes tentatives laissent penser que cette d\u00e9marche\nsouffre sans doute d'un d\u00e9ficit de moyens.\nLa recherche sur l'\u00e9ducation b\u00e9n\u00e9ficie de l'ensemble de courants\nde recherche p\u00e9dagogique, qui a pris une importance singuli\u00e8re\nces derni\u00e8res ann\u00e9es (notamment apr\u00e8s la mise en place de la\ncommission pour l'\u00e9ducation de l'Unesco), particuli\u00e8rement aux\n\u00c9tats-Unis\n17.\n\nLes trois enjeux des diab\u00e8tes\nHaut Comit \u00e9 de la Sant \u00e9 Publique\n17. Cf. par exemple une revue des efforts de la recherche p\u00e9dagogique dans le livrede Go\u00e9ry\nDelac\u00f4te, Savoir apprendre, Odile Jacob, Paris, 1995.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2397, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "10de7292-4330-4713-90af-b3a1ae81d9d1": {"__data__": {"id_": "10de7292-4330-4713-90af-b3a1ae81d9d1", "embedding": null, "metadata": {"page_label": "61", "file_name": "hc001042.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\hc001042.pdf", "file_type": "application/pdf", "file_size": 237006, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "8de63600-5448-4594-8b4c-4730801289f5", "node_type": "4", "metadata": {"page_label": "61", "file_name": "hc001042.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\hc001042.pdf", "file_type": "application/pdf", "file_size": 237006, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "cbb01b2bf83c694af1faff69e6a1986977120ce5ff698984cb94a23f3cc9b44c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ef6cbf71-32a9-405b-b5ac-4941a19fb9ce", "node_type": "1", "metadata": {}, "hash": "cd91244a44213ac05f803ac84838970a3930deb950a2bee66bc49c3b8ef73df4", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "47Diab\u00e8tes. Pr\u00e9vention, dispositifs de soins, \u00e9ducation... / Mai 1998\nL'effort\nd'institutionnalisation\nL'\u00e9ducation du patient diab\u00e9tique, on l'a signal\u00e9, utilise des techniques de tous ordres. Cependant, depuis les ann\u00e9es soixantedix, on assiste \u00e0 un effort de structuration d'une pratique \u00e9ducative,\nimportant de nombreux outils et concepts de disciplines connexes\ntelle que la p\u00e9dagogie, la psychologie, ou la dynamique des\ngroupes. Cet effort, on l'a soulign\u00e9, se produit hors de toute\ncontrainte professionnelle (il ne s'agit pas de \u00ab formations validantes \u00bb) et de mani\u00e8re relativement d\u00e9coupl\u00e9e des pratiques professionnelles. Elle emprunte des savoirs h\u00e9t\u00e9rog\u00e8nes et produit\nun intense effort de th\u00e9orisation, dont le premier r\u00e9sultat est sans\naucun doute la d\u00e9signation d'\u00ab experts \u00bb, quelque peu autoproclam\u00e9s, en mati\u00e8re d'\u00e9ducation du patient et d'\u00e9ducation pour la\nsant\u00e9. Cet effort se produit en outre dans des structures hospitali\u00e8res ou para-hospitali\u00e8res, ob\u00e9issant le plus souvent \u00e0 des partitions sectorielles, nosographiques et \u00e9triqu\u00e9es qui ne\ncorrespondent pas toujours \u00e0 la r\u00e9alit\u00e9 v\u00e9cue par les patients.\nDans le Livre blanc sur l'\u00e9ducation des diab\u00e9tiques , propos\u00e9\npar la section de langue fran\u00e7aise du \u00ab Diabete education study\ngroup \u00bb, on voit ainsi tout un chapitre consacr\u00e9 \u00e0 \u00ab la n\u00e9cessit\u00e9\nd'institutionnalisation \u00bb de l'\u00e9ducation du patient.\nCette situation int\u00e9ressante est loin de ne pr\u00e9senter que des avantages. Le premier de ses d\u00e9fauts est de s'adresser prioritairement\n\u00e0 des patients d\u00e9j\u00e0 ins\u00e9r\u00e9s dans les structures hospitali\u00e8res, c'est\u00e0-dire atteints par la maladie, \u00e0 un stade \u00e9volu\u00e9.\nOn a d\u00e9j\u00e0 soulign\u00e9 \u00e9galement le risque qu'entra\u00eene le fait, pour\nla d\u00e9marche d'\u00e9ducation du patient, de ne pas savoir sortir de\nl'h\u00f4pital. La premi\u00e8re cons\u00e9quence est de garder une grande d\u00e9pendance envers des structures dont le premier objectif est le soin\ncuratif et qui peuvent \u00e0 tout moment se d\u00e9sengager de la d\u00e9marche.\nOn a \u00e9galement soulign\u00e9 le fait que les s\u00e9parations entre ces diff\u00e9rentes d\u00e9marches peuvent sembler artificielles et mises en\n\u0153uvre par des professionnels appartenant \u00e0 des univers \u00e9tanches.\nL'\u00e9ducation du patient est bien souvent concurrente de fait de\nl'\u00e9ducation \u00e0 la sant\u00e9, l\u00e0 o\u00f9 les deux d\u00e9marches devraient \u00eatre\ncompl\u00e9mentaires.\nOn peut \u00e9galement marquer quelque perplexit\u00e9 devant la revendication d'une approche fond\u00e9e sur les r\u00e9sultats les plus r\u00e9cents\nd'une recherche p\u00e9dagogique dont on conna\u00eet, en France, les\nlacunes et les difficult\u00e9s.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2498, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "ef6cbf71-32a9-405b-b5ac-4941a19fb9ce": {"__data__": {"id_": "ef6cbf71-32a9-405b-b5ac-4941a19fb9ce", "embedding": null, "metadata": {"page_label": "61", "file_name": "hc001042.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\hc001042.pdf", "file_type": "application/pdf", "file_size": 237006, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "8de63600-5448-4594-8b4c-4730801289f5", "node_type": "4", "metadata": {"page_label": "61", "file_name": "hc001042.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\hc001042.pdf", "file_type": "application/pdf", "file_size": 237006, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "cbb01b2bf83c694af1faff69e6a1986977120ce5ff698984cb94a23f3cc9b44c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "10de7292-4330-4713-90af-b3a1ae81d9d1", "node_type": "1", "metadata": {"page_label": "61", "file_name": "hc001042.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\hc001042.pdf", "file_type": "application/pdf", "file_size": 237006, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "190f6f31ce6f1c427d21d173e215f3730026ab4c57d70968b74b7d6102452064", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "L'\u00e9ducation du patient est bien souvent concurrente de fait de\nl'\u00e9ducation \u00e0 la sant\u00e9, l\u00e0 o\u00f9 les deux d\u00e9marches devraient \u00eatre\ncompl\u00e9mentaires.\nOn peut \u00e9galement marquer quelque perplexit\u00e9 devant la revendication d'une approche fond\u00e9e sur les r\u00e9sultats les plus r\u00e9cents\nd'une recherche p\u00e9dagogique dont on conna\u00eet, en France, les\nlacunes et les difficult\u00e9s. De nombreux jeunes enseignants ont\nfait l'exp\u00e9rience des limites d'une approche cherchant avant tout\nla l\u00e9gitimit\u00e9 th\u00e9orique dans un domaine o\u00f9 la qualit\u00e9 de la relation humaine et la maturit\u00e9 de l'enseignant devraient \u00eatre consid\u00e9r\u00e9es comme des \u00e9l\u00e9ments primordiaux.", "mimetype": "text/plain", "start_char_idx": 2141, "end_char_idx": 2766, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "5c268854-e24b-48b5-b1d4-c7a850cc7ce7": {"__data__": {"id_": "5c268854-e24b-48b5-b1d4-c7a850cc7ce7", "embedding": null, "metadata": {"page_label": "62", "file_name": "hc001042.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\hc001042.pdf", "file_type": "application/pdf", "file_size": 237006, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "bf53f581-7fd8-443e-a1b0-f6f068cf17b0", "node_type": "4", "metadata": {"page_label": "62", "file_name": "hc001042.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\hc001042.pdf", "file_type": "application/pdf", "file_size": 237006, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "34a48aa82348e4f72294cab127662cbcc876925b4596b3d72e9b5b8eb2992c36", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "L'aspiration\n\u00e0 un nouveau\nmod\u00e8le de\nprise en charge\nMais, plus profond\u00e9ment, on peut se demander dans quelle mesure\nles d\u00e9marches actuelles, qui consid\u00e8rent comme normal le fait\nd'attribuer l'essentiel de la responsabilit\u00e9 de l'\u00e9ducation au m\u00e9decin ne reposent pas sur une possible confusion des r\u00f4les. Le r\u00f4le\ndu m\u00e9decin, en effet, est avant tout de soigner, et cette vocation\npremi\u00e8re a de nombreuses cons\u00e9quences sur les caract\u00e9ristiques\nm\u00eames de la relation m\u00e9decin-malade, avec en particulier l'adoption par de nombreux praticiens d'une attitude de neutralit\u00e9 face\naux principaux choix de vie du patient. La relation m\u00e9dicale s'inspire, au moins en partie, de ce qui, en psychanalyse, est explicit\u00e9\ncomme une relation de transfert et de contre-transfert.\nLa relation \u00e9ducative, en revanche, est essentiellement une relation normative et fond\u00e9e, autant que faire se peut, sur une relation d'exemplarit\u00e9 et d'identification.\nIl est tr\u00e8s loin d'\u00eatre certain que la juxtaposition de ces deux\nregistres soit une chose positive ou tout simplement compatible,\nqu'elle ne risque pas d'induire chez le patient une confusion sur\nl'identit\u00e9 r\u00e9elle du m\u00e9decin. Il convient \u00e9galement d'analyser avec\nla plus grande rigueur, en dehors de ce type de consid\u00e9ration, les\nconditions requises pour que la d\u00e9marche d'\u00e9ducation soit la plus\nefficace possible sous l'aspect de la promotion de la sant\u00e9\npublique. C'est \u00e0 ces conditions que l'\u00e9ducation des patients,\net d'abord des patients diab\u00e9tiques, trouvera son efficacit\u00e9 et sa\nl\u00e9gitimit\u00e9.\nReconna\u00eetre comme l\u00e9gitime\nle souhait des patients qui\nrevendiquent davantage d'autonomie\nAu-del\u00e0 des questions qu'elles posent aux responsables de la\nsant\u00e9 publique, les diab\u00e8tes et les maladies chroniques repr\u00e9sentent avant tout un bouleversement pour les malades euxm\u00eames, et leur d\u00e9veloppement explique sans aucun doute\nquelques-unes des \u00e9volutions r\u00e9centes les plus marquantes du\nrapport du patient au syst\u00e8me de sant\u00e9.\nAvec les maladies chroniques comme les diab\u00e8tes, appara\u00eet en\nFrance un nouveau type de rapport \u00e0 la maladie : les patients sont\nsollicit\u00e9s, mobilis\u00e9s quotidiennement par leur maladie. Ils deviennent des experts de leur propre maladie, et des acteurs majeurs\ndes soins, tant par l'information qu'ils transmettent au m\u00e9decin\n\nLes trois enjeux des diab\u00e8tes\nHaut Comit \u00e9 de la Sant \u00e9 Publique", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2340, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "4b6a685f-af6b-4878-93ee-36e1962b5425": {"__data__": {"id_": "4b6a685f-af6b-4878-93ee-36e1962b5425", "embedding": null, "metadata": {"page_label": "63", "file_name": "hc001042.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\hc001042.pdf", "file_type": "application/pdf", "file_size": 237006, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "2271885f-5b4e-4bab-8576-17d8b95d4b5e", "node_type": "4", "metadata": {"page_label": "63", "file_name": "hc001042.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\hc001042.pdf", "file_type": "application/pdf", "file_size": 237006, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "551468edc5a6fa728ffbed887662fc5ae52153836267311d23e338629476d8f0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4d40c8e2-73e5-4458-9f54-50a107f5f150", "node_type": "1", "metadata": {}, "hash": "c443554d03b83e23a039eed6e2f58cf9b51dc75f2e13b91a7129aefb11d29289", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "49Diab\u00e8tes. Pr\u00e9vention, dispositifs de soins, \u00e9ducation... / Mai 1998\nLes facteurs de\nrenforcement\nde la nouvelle\nattitude\ndes patients\nque par la part qu'ils peuvent prendre \u00e0 la mise en place des traitements. C'est ainsi que, selon Coussaert, \u00ab le XX e si\u00e8cle voit\nl'apparition d'un nouveau personnage dans le th\u00e9\u00e2tre de la sant\u00e9,\npersonnage qui tient du docteur et du malade, mais qui s'en\ndistingue au plus haut point : l'auto-soignant. D\u00e9cisionnaire d'une\nm\u00e9decine dont il n'est pas un professionnel, gestionnaire d'une\nsant\u00e9 dont il n'est plus profane, l'auto-soignant met la science qui\nle produit en devoir de renouer avec un art de vivre. Un art dont\nil faut reconna\u00eetre qu'il reste largement \u00e0 inventer \u00bb.\nCes \u00e9volutions induisent des modifications radicales des rapports entre les patients et les syst\u00e8 mes de soins dont les cons\u00e9quences doivent \u00ea tre tir\u00e9es.\n\u00c0 l'origine fortement m\u00e9dicalis\u00e9s, ces comportements ont \u00e9t\u00e9 renforc\u00e9s par des mouvements sociaux favorables, qui ont pris naissance aux \u00c9tats-Unis, puis se sont r\u00e9pandus en Europe. Sous\nla pression de groupes de consommateurs, de m\u00e9decins (souvent\npsychiatres), d'infirmi\u00e8res et de personnels param\u00e9dicaux et de\ngroupes de juristes, le mod\u00e8le m\u00e9dical se d\u00e9place de la relation\nsoignant/soign\u00e9 \u00e0 un mod\u00e8le plus global. Au cours des ann\u00e9es\nsoixante se structurent les premiers mouvements de consommateurs, associations d'entraide, associations de d\u00e9fense des\ndroits du patient. Ces mouvements se concr\u00e9tisent notamment\npar l'\u00e9mergence d'une revendication du grand public pour plus\nd'information et une participation aux d\u00e9cisions en mati\u00e8re d'information et de choix du traitement. Ils ne sont pas \u00e9trangers \u00e0 l'irruption, peu apr\u00e8s, des r\u00e9flexions sur l'\u00e9thique biom\u00e9dicale\n18.\nIls concourent, de mani\u00e8re le plus souvent informelle, \u00e0 tracer les\ncontours d'un nouveau mod\u00e8le d'approche des probl\u00e8mes de sant\u00e9\ndont les principales caract\u00e9ristiques ont alors pu \u00eatre r\u00e9sum\u00e9es\ndans le tableau VI.\nPlus r\u00e9cemment, cette position active du patient a \u00e9t\u00e9 renforc\u00e9e par plusieurs facteurs : modification de la repr\u00e9sentation\nde la m\u00e9decine dans le cas de certaines maladies (avec, par\nexemple en France, les cons\u00e9quences de la transmission du sida\n\u00e0 de nombreux h\u00e9mophiles) ; relative impuissance de la m\u00e9decine\nface \u00e0 certaines situations chroniques (nouvelles maladies chro18.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2342, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "4d40c8e2-73e5-4458-9f54-50a107f5f150": {"__data__": {"id_": "4d40c8e2-73e5-4458-9f54-50a107f5f150", "embedding": null, "metadata": {"page_label": "63", "file_name": "hc001042.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\hc001042.pdf", "file_type": "application/pdf", "file_size": 237006, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "2271885f-5b4e-4bab-8576-17d8b95d4b5e", "node_type": "4", "metadata": {"page_label": "63", "file_name": "hc001042.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\hc001042.pdf", "file_type": "application/pdf", "file_size": 237006, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "551468edc5a6fa728ffbed887662fc5ae52153836267311d23e338629476d8f0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4b6a685f-af6b-4878-93ee-36e1962b5425", "node_type": "1", "metadata": {"page_label": "63", "file_name": "hc001042.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\hc001042.pdf", "file_type": "application/pdf", "file_size": 237006, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "526eefc7101e0f97d41c6ce4cc7fa226fb5db0f13c7c198d49706bc618bea183", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Plus r\u00e9cemment, cette position active du patient a \u00e9t\u00e9 renforc\u00e9e par plusieurs facteurs : modification de la repr\u00e9sentation\nde la m\u00e9decine dans le cas de certaines maladies (avec, par\nexemple en France, les cons\u00e9quences de la transmission du sida\n\u00e0 de nombreux h\u00e9mophiles) ; relative impuissance de la m\u00e9decine\nface \u00e0 certaines situations chroniques (nouvelles maladies chro18. \u00ab Le mod\u00e8le paternaliste, bien que tol\u00e9rable \u00e0 une \u00e9poque o\u00f9 tout \u00e9tait plus simple, tend\n\u00e0 dispara\u00eetre au profit d'une \u00e9thique m\u00e9dicale ax\u00e9e davantage sur la collaboration m\u00e9decin-patient ou m\u00e9decin-famille lors de la prise en commun des d\u00e9cisions \u00bb, D.J. Roy,\nJ.R. Williams, B.M. Dickens, J.-L. Baudouin, La bio\u00e9thique, ses fondements, ses controverses, \u00c9ditions du Renouveau p\u00e9dagogique, Saint-Laurent (Qu\u00e9bec), 1995, .", "mimetype": "text/plain", "start_char_idx": 1965, "end_char_idx": 2765, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "91fb7811-ff79-4b96-97b6-6b8e39dc21b8": {"__data__": {"id_": "91fb7811-ff79-4b96-97b6-6b8e39dc21b8", "embedding": null, "metadata": {"page_label": "64", "file_name": "hc001042.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\hc001042.pdf", "file_type": "application/pdf", "file_size": 237006, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "97e6ddf2-c869-4e4e-a168-2c79fb3c066c", "node_type": "4", "metadata": {"page_label": "64", "file_name": "hc001042.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\hc001042.pdf", "file_type": "application/pdf", "file_size": 237006, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "0047634df51ff63169669d67164d79fa5c538263aa19665e5e458fda82c5129d", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "niques, handicaps), qui peuvent \u00eatre accompagn\u00e9es mais jamais\ncompl\u00e8tement gu\u00e9ries ; organisation de malades d\u00e9sireux de pr\u00e9senter un front uni face au syst\u00e8me m\u00e9dical, mais aussi \u00e0 d'autres\nforces sociales (comme par exemple les malades du sida face aux\ncompagnies d'assurance) ; \u00e9volutions de la notion de responsabilit\u00e9 m\u00e9dicale ; ou encore l'implication de structures associatives\ndans la prise en charge, l'orientation ou le financement de la\nrecherche (le plus bel exemple \u00e9tant, en France, l'implication de\nl'AFM dans la recherche sur les maladies g\u00e9n\u00e9tiques et son r\u00f4le\nd\u00e9terminant dans le financement et l'orientation du programme\nG\u00e9n\u00e9thon).\nCette \u00e9volution des mentalit\u00e9s entra\u00eene une mobilisation des\npatients, et la diffusion de plus en plus grande des comportements\nde consommateurs avertis. De nombreux signes objectifs en t\u00e9moignent, parmi lesquels on peut signaler l'\u00e9mergence d'un nombre\ncroissant d'associations de patients ou encore le succ\u00e8s des publications (revues ou ouvrages) visant \u00e0 la vulgarisation des savoirs\nm\u00e9dicaux. \u00c0 cet \u00e9gard, il est int\u00e9ressant d'observer le d\u00e9veloppement de collections \u00e9ditoriales enti\u00e8res consacr\u00e9es \u00e0 la prise\nen charge de la maladie par le patient et son entourage. L'une\nd'entre elles s'ouvre sur la d\u00e9claration d'intention suivante : \u00ab Toute\nmaladie est un \u00e9v\u00e9nement qui implique des \u00e9changes entre trois\n\nLes trois enjeux des diab\u00e8tes\nHaut Comit \u00e9 de la Sant \u00e9 Publique\nTableau VI\nLes deux mod\u00e8 les d'approche des probl\u00e8 mes de sant\u00e919\nMOD\u00c8 LE GLOBAL\nMod\u00e8le ouvert\nLa maladie r\u00e9sulte de facteurs complexes,\norganiques, humains et sociaux.\nElle affecte l'individu, la famille et l'environnement\nElle demande une approche continue, de la\npr\u00e9vention \u00e0 la r\u00e9adaptation, qui tienne\ncompte des facteurs organiques, psychologiques et sociaux\nPar des professionnels de la sant\u00e9 travaillant en collaboration\nDans un syst\u00e8me ouvert et interd\u00e9pendant,\navec la communaut\u00e9\nMOD\u00c8 LE M\u00c9 DICAL\nMod\u00e8le ferm\u00e9\nLa maladie est principalement organique\nElle affecte l'individu\nElle doit \u00eatre diagnostiqu\u00e9e et trait\u00e9e\n(approche curative)\nPar des m\u00e9decins\nDans un syst\u00e8me autonome, centr\u00e9 autour\nd'h\u00f4pitaux dirig\u00e9s par des m\u00e9decins\n19. J.-A. Bury, Les services de psychologie m\u00e9dicale et de psychosomatique, pierre angulaire\nde l'enseignement des Sciences humaines en m\u00e9decine, Revue de m\u00e9decine psychosomatique, 1979, 21:477-489.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2365, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "5a37ad69-fbe3-4e97-8f47-30ac5f856e6f": {"__data__": {"id_": "5a37ad69-fbe3-4e97-8f47-30ac5f856e6f", "embedding": null, "metadata": {"page_label": "65", "file_name": "hc001042.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\hc001042.pdf", "file_type": "application/pdf", "file_size": 237006, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "435d2bed-395c-4005-bc82-c32d54ae76dc", "node_type": "4", "metadata": {"page_label": "65", "file_name": "hc001042.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\hc001042.pdf", "file_type": "application/pdf", "file_size": 237006, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "d6300c8e441e48e82ffd7e98b7870ab86af4b8c5fecf63c7f122bfed87155ed5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "273dcb78-e245-409e-a41e-aff7a65f45bb", "node_type": "1", "metadata": {}, "hash": "cc7670bab25879b7f17181a2543cab18954dd0c5e0fa1ce7269e1a5e1a672440", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "51Diab\u00e8tes. Pr\u00e9vention, dispositifs de soins, \u00e9ducation... / Mai 1998\nLes \u00e9volutions\npr\u00e9visibles\ndans le cas\ndes diab\u00e8tes\npartenaires : le malade, son entourage, son m\u00e9decin. La gu\u00e9rison\net le mieux-\u00eatre d\u00e9pendent de la nature de ces \u00e9changes, et de\nleur renforcement mutuel. On peut vivre seul sa maladie. Mais\npour r\u00e9unir toutes les chances de gu\u00e9rir, mieux vaut \u00eatre trois partenaires \u00e0 la combattre\n20. \u00bb On est bien loin de \u00ab l'autorit\u00e9 d'Esculape \u00bb, selon laquelle le m\u00e9decin, qui poss\u00e9dait le savoir (du latin\nsapientia, c'est-\u00e0-dire sagesse) aurait b\u00e9n\u00e9fici\u00e9 en m\u00eame temps\nd'une autorit\u00e9 morale fond\u00e9e sur la connaissance et l'exp\u00e9rience\ntechnique mais aussi sur la connaissance de ce qui est bon et\nsouhaitable\n21.\nMais cette \u00e9volution est \u00e9galement favoris\u00e9e par des facteurs plus\nstrictement \u00e9conomiques pesant sur le syst\u00e8me de sant\u00e9 lui-m\u00eame,\nla mont\u00e9e de la pr\u00e9valence des maladies chroniques entra\u00eenant\nune v\u00e9ritable n\u00e9cessit\u00e9 de l'auto-prise en charge des patients,\nseule \u00e0 m\u00eame de limiter des hospitalisations au profit de formules\nmoins on\u00e9reuses. \u00c0 cet \u00e9gard, il est particuli\u00e8rement int\u00e9ressant\nde suivre l'\u00e9volution de concepts comme celui de responsabilit\u00e9\n\u00e0 l'\u00e9gard de sa propre sant\u00e9, r\u00e9guli\u00e8rement remobilis\u00e9, et dont la\npremi\u00e8re cons\u00e9quence est la tentation de faire peser sur l'individu une responsabilit\u00e9 financi\u00e8re \u00e0 l'\u00e9gard de troubles qu'il aurait\npu, ou d\u00fb, pr\u00e9venir.\nCe mouvement ne peut certes pas \u00eatre g\u00e9n\u00e9ralis\u00e9. On a vu qu'il\n\u00e9tait peu r\u00e9pandu dans le cas sp\u00e9cifique des diab\u00e8tes, probablement sous l'effet de la faible mobilisation des patients atteints\nde DNID. Il est beaucoup moins marqu\u00e9 en France que dans\nd'autres pays europ\u00e9ens du Nord ou aux \u00c9tats-Unis. Mais ses\ncons\u00e9quences sont d'ores et d\u00e9j\u00e0 perceptibles et p\u00e8seront, dans\nun proche avenir, sur l'\u00e9volution de l'organisation des soins des\nmaladies chroniques.\nIl est probable que la revendication d'une participation des malades\naux d\u00e9cisions de sant\u00e9 publique, comme \u00e0 la mise en place de\ndispositions juridiques (aides aux malades) ira croissant.\nCette \u00e9volution peut ouvrir sur de nouvelles possibilit\u00e9s pour la\nprise en charge des diab\u00e8tes et le d\u00e9veloppement de la sant\u00e9\npublique pour peu que la m\u00e9decine sache accompagner le d\u00e9sir\nde participation par la transmission d'un savoir unitaire sur les diff\u00e9rents aspects de la maladie.\n20. \u00c9douard Zarifian, Introduction aux ouvrages de la collection \u00ab La Sant\u00e9 au quotidien \u00bb,\nOdile Jacob, Paris. Incomplet\n21.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2462, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "273dcb78-e245-409e-a41e-aff7a65f45bb": {"__data__": {"id_": "273dcb78-e245-409e-a41e-aff7a65f45bb", "embedding": null, "metadata": {"page_label": "65", "file_name": "hc001042.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\hc001042.pdf", "file_type": "application/pdf", "file_size": 237006, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "435d2bed-395c-4005-bc82-c32d54ae76dc", "node_type": "4", "metadata": {"page_label": "65", "file_name": "hc001042.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\hc001042.pdf", "file_type": "application/pdf", "file_size": 237006, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "d6300c8e441e48e82ffd7e98b7870ab86af4b8c5fecf63c7f122bfed87155ed5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5a37ad69-fbe3-4e97-8f47-30ac5f856e6f", "node_type": "1", "metadata": {"page_label": "65", "file_name": "hc001042.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\hc001042.pdf", "file_type": "application/pdf", "file_size": 237006, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "df0f119f8400d61e70516a8ec2338724f1bb0e7ef816595c2e09fd6f4f1cca45", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "20. \u00c9douard Zarifian, Introduction aux ouvrages de la collection \u00ab La Sant\u00e9 au quotidien \u00bb,\nOdile Jacob, Paris. Incomplet\n21. T. Paterson, Notes on Aesculapian Authority. Manuscrit non publi\u00e9, in M. Siegler et\nH. Osmond Aesculapian Authority, Hasting Center Report, 1973, 1:42, note 3.", "mimetype": "text/plain", "start_char_idx": 2337, "end_char_idx": 2622, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "8f53aac9-71e9-4707-a1df-664d1dfbfa9b": {"__data__": {"id_": "8f53aac9-71e9-4707-a1df-664d1dfbfa9b", "embedding": null, "metadata": {"page_label": "66", "file_name": "hc001042.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\hc001042.pdf", "file_type": "application/pdf", "file_size": 237006, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "5b1afa22-1cf9-4b13-b9ac-88dfad11b609", "node_type": "4", "metadata": {"page_label": "66", "file_name": "hc001042.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\hc001042.pdf", "file_type": "application/pdf", "file_size": 237006, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "d1e6ea3569253ce6e4d8828147297a45b2eeb1431b573f8b32b97a8d70ee6c7f", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 0, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "653a7e13-7de4-4c25-b0f2-6708c7a53239": {"__data__": {"id_": "653a7e13-7de4-4c25-b0f2-6708c7a53239", "embedding": null, "metadata": {"page_label": "67", "file_name": "hc001042.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\hc001042.pdf", "file_type": "application/pdf", "file_size": 237006, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "6eacb740-4094-4656-9bce-8835a525588c", "node_type": "4", "metadata": {"page_label": "67", "file_name": "hc001042.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\hc001042.pdf", "file_type": "application/pdf", "file_size": 237006, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "e0424d60c3ee6a78df9a2351583c5525247e9effb10cea0205a84fa95c12cac4", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "53Diab\u00e8tes. Pr\u00e9vention, dispositifs de soins, \u00e9ducation... / Mai 1998\nPropositions\nObjectifs d'une politique\nde sant\u00e9 publique\n\u00c0 l'\u00e9vidence, les analyses de ce rapport t\u00e9moignent d'un profond\nd\u00e9ficit de la r\u00e9flexion sur la sant\u00e9 publique dans le domaine des\nmaladies chroniques. Les diab\u00e8tes, qui repr\u00e9sentent, parmi les\nmaladies chroniques, un ensemble pathologique connu depuis longtemps, observ\u00e9, trait\u00e9 et faisant l'objet de lourds investissements\nde recherche et de formation, n'\u00e9chappent pas \u00e0 ce constat.\nC'est donc tout le dispositif qui doit \u00eatre r\u00e9organis\u00e9 et rationalis\u00e9,\nen tenant compte des cinq exigences fondamentales qui ressortent de ce rapport.\n1. Pr\u00e9venir \u00e0 tout \u00e2 ge. Les diab\u00e8tes et les maladies chroniques,\npar d\u00e9finition, sont combattus et ralentis par la m\u00e9decine, mais\nne peuvent pas \u00eatre gu\u00e9ris ni supprim\u00e9s. Toute avanc\u00e9e de\nla pathologie est irr\u00e9m\u00e9diable, donc douloureuse et contraignante pour le patient, lourde et co\u00fbteuse pour le syst\u00e8me\nde sant\u00e9. La pr\u00e9vention doit serrer au plus pr\u00e8s l'histoire naturelle de la maladie : \u00e9viter l'entr\u00e9e dans la maladie, d\u00e9pister le\nplus pr\u00e9cocement possible, retarder les \u00e9volutions.\n2. Coordonner et \u00e9valuer les diff\u00e9rents dispositifs de soins sp\u00e9cialis\u00e9s qui sont g\u00e9n\u00e9ralement mis en place de mani\u00e8re spontan\u00e9e et non coordonn\u00e9e. On a pu montrer que leur \u00e9valuation,", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1337, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "4bb35870-133f-4ffb-a9bf-4bc74091b999": {"__data__": {"id_": "4bb35870-133f-4ffb-a9bf-4bc74091b999", "embedding": null, "metadata": {"page_label": "68", "file_name": "hc001042.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\hc001042.pdf", "file_type": "application/pdf", "file_size": 237006, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "c206e343-4de3-4480-89fe-628fdde1fc33", "node_type": "4", "metadata": {"page_label": "68", "file_name": "hc001042.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\hc001042.pdf", "file_type": "application/pdf", "file_size": 237006, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "edd9b5ce03c0db4a3a4291fe4df143e3f5532c7f3b8cf8f131e7961a1da58d3a", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "sur les plans th\u00e9rapeutique comme \u00e9conomique souffre de\ngraves d\u00e9ficits. Une telle entreprise s'av\u00e8re aujourd'hui indispensable et n\u00e9cessitera probablement de v\u00e9ritables travaux de\nrecherche pr\u00e9alables, comme par exemple une typologie des\nmaladies chroniques permettant \u00e0 son tour une \u00e9valuation\ndu dispositif global de soins des maladies chroniques. Une telle\nentreprise est le pr\u00e9alable n\u00e9cessaire \u00e0 toute rationalisation\ndu syst\u00e8me actuel.\n3. Autonomiser. Du fait de leur dur\u00e9e, de la relative impuissance\nde la m\u00e9decine et de la situation d'expert de sa propre maladie qui est celle du patient, ces nouveaux troubles appellent\nune autonomisation des patients. Ceux-ci la r\u00e9clament d'ailleurs\nde plus en plus souvent, par exemple par l'interm\u00e9diaire de\nnombreuses associations. Cette autonomisation est en outre\nune exigence financi\u00e8re pour l'ensemble du syst\u00e8me de sant\u00e9.\nElle exigera la rupture de la logique hospitalo-centr\u00e9e actuellement pr\u00e9\u00e9minente, ainsi qu'une participation de plus en plus\nactive des structures associatives aux processus de d\u00e9cision\ncomme \u00e0 la gestion des structures de prise en charge. On mesure\nl'int\u00e9r\u00eat \u00e0 voir \u00e9merger de v\u00e9ritables agences r\u00e9gionales de sant\u00e9,\ncapables d'\u00eatre les ma\u00eetres d'\u0153uvre d'une telle \u00e9volution.\n4. D\u00e9centraliser la prise en charge.Le diab\u00e8te ou la maladie chronique devient un \u00e9tat d\u00e9finitif pour le patient et fait partie int\u00e9grante de sa vie. Pour \u00eatre vivable, elle doit \u00eatre prise en charge\nen serrant au plus pr\u00e8s la vie quotidienne : la prise en charge\nne peut se limiter \u00e0 l'h\u00f4pital, qui n'est pas con\u00e7u pour un tel\naccompagnement ; elle ne peut pas non plus \u00eatre pens\u00e9e de\nmani\u00e8re rigide et centralis\u00e9e. C'est aux r\u00e9gions de fixer les\nobjectifs de sant\u00e9 publique et les moyens adapt\u00e9s aux r\u00e9alit\u00e9s\nlocales de ces maladies.\n5. D\u00e9cloisonner la r\u00e9flexion. Les diab\u00e8tes, comme la plupart des\nmaladies chroniques, on l'a soulign\u00e9, s'inscrivent dans des unit\u00e9s pathologiques plus larges dont elles ne repr\u00e9sentent qu'une\nforme de d\u00e9veloppement possible. L'hyperglyc\u00e9mie, par exemple,\nprend place dans un ensemble de facteurs de risque parmi lesquels on trouve l'hypertension art\u00e9rielle, l'usage du tabac,\nles hyperlip\u00e9mies, etc. Ces risques entrem\u00eal\u00e9s provoquent des\neffets communs. La distinction trop pouss\u00e9e entre les maladies r\u00e9sultantes (r\u00e9parties entre des sp\u00e9cialit\u00e9s cloisonn\u00e9es)\nconduit \u00e0 des strat\u00e9gies de pr\u00e9vention, de soins et de prise en\ncharge contradictoires et parfois trop rigides. Il faudrait substituer une logique de besoin des individus et des populations\naux logiques de strat\u00e9gies des acteurs sanitaires et des professionnels.\n\nPropositions\nHaut Comit \u00e9 de la Sant \u00e9 Publique", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2659, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "6334f50c-ac73-460c-bfa0-6b8c4495073b": {"__data__": {"id_": "6334f50c-ac73-460c-bfa0-6b8c4495073b", "embedding": null, "metadata": {"page_label": "69", "file_name": "hc001042.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\hc001042.pdf", "file_type": "application/pdf", "file_size": 237006, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "21503d1b-22e0-4184-97d0-dc5c03cc1614", "node_type": "4", "metadata": {"page_label": "69", "file_name": "hc001042.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\hc001042.pdf", "file_type": "application/pdf", "file_size": 237006, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "b8c9723ab0a251966c7fd81ae7348751f44b47b4937cefa3a0469a59328e2f36", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "55Diab\u00e8tes. Pr\u00e9vention, dispositifs de soins, \u00e9ducation... / Mai 1998\nCr\u00e9ation\nde r\u00e9seaux\nfonctionnels ou\nde programmes\nlocaux\nd'information\net de formation\nCes cinq exigences, qui ressortent des analyses de l'ensemble\nde ce rapport, guident les diff\u00e9rentes propositions qui suivent. Si\nles propositions peuvent \u00eatre analys\u00e9es et discut\u00e9es en fonction des priorit\u00e9s politiques, des possibilit\u00e9s techniques et budg\u00e9taires et de tout crit\u00e8re de ce type, les objectifs qui les guident\nrestent, eux, valides, ind\u00e9pendamment de ces consid\u00e9rations.\nMesures g\u00e9n\u00e9rales pour le diab\u00e8te\net les maladies chroniques\nFavoriser une \u00e9ducation \u00e0 la sant\u00e9 accessible \u00e0 tous, mener des\nactions d'\u00e9ducation des patients hors de l'h\u00f4pital, int\u00e9grer les\nmilieux associatifs \u00e0 la prise en charge des maladies chroniques,\ntous ces objectifs de sant\u00e9 publique exigent l'existence de programmes ou de r\u00e9seaux locaux aptes \u00e0 mener des actions \u00e9ducatives de proximit\u00e9, \u00e0 accueillir et orienter les individus et \u00e0 faire\npasser au plus grand nombre des messages de sant\u00e9 publique.\nIl faudrait aussi reconna\u00eetre la place de l'\u00e9ducation sanitaire sp\u00e9cifiquement dans les consultations et les h\u00f4pitaux de jour, par\nl'identification d'un acte r\u00e9pertori\u00e9 d'\u00e9ducation prenant en compte\nl'intervention des diff\u00e9rents personnels de sant\u00e9.\nLes messages, tels qu'ils sont par exemple diffus\u00e9s par les m\u00e9dias,\nsupposent en effet trop souvent un destinataire passif et ignorant.\nIl importe au contraire de cr\u00e9er des lieux capables d'accueillir les\ndemandes pr\u00e9cises des patients et d'apporter une \u00e9coute et une\nr\u00e9ponse non limit\u00e9es aux objectifs de soins.\nLa cr\u00e9ation de conservatoires de sant\u00e9, implant\u00e9s dans les communes importantes ou dans les chefs-lieux de cantons et con\u00e7us\nsp\u00e9cifiquement pour cette strat\u00e9gie, pourrait permettre d'implanter localement l'activit\u00e9 des r\u00e9seaux ou des programmes lorsque\ncela est possible.\nCes conservatoires ne doivent pas \u00eatre des structures de soin.\nImplant\u00e9s dans ou hors de l'h\u00f4pital, largement ouverts au public,\ncapables, le cas \u00e9ch\u00e9ant, d'accueillir des associations de malades,\nils doivent rassembler en un m\u00eame lieu des professionnels diff\u00e9rents parmi lesquels : \u00e9ducateurs, assistantes sociales, infirmi\u00e8res, psychologues, m\u00e9decins g\u00e9n\u00e9ralistes, etc.\n22.\n22. Certaines structures comme le centre Epidaure de Montpellier, la Maison des associations de sant\u00e9 de Rennes, certains CRES, sont d'une exemplarit\u00e9 certaine dans cette\nperspective.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2446, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "8a364295-96ee-4cdb-a0b0-d762e08aab0e": {"__data__": {"id_": "8a364295-96ee-4cdb-a0b0-d762e08aab0e", "embedding": null, "metadata": {"page_label": "70", "file_name": "hc001042.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\hc001042.pdf", "file_type": "application/pdf", "file_size": 237006, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "030e1b01-2c6a-49ce-9127-f8f903a57931", "node_type": "4", "metadata": {"page_label": "70", "file_name": "hc001042.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\hc001042.pdf", "file_type": "application/pdf", "file_size": 237006, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "6a678fbe59618471fb58a1b6ae2ec71b8cd3cea7ca66a44ef87b4f573a775f12", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Cr\u00e9ation\nde p\u00f4les\nr\u00e9gionaux\nd'excellence\nIl faudrait permettre, dans le cadre de ces r\u00e9seaux fonctionnels,\nune prise en charge forfaitaire des activit\u00e9s d'\u00e9ducation.\nParmi les missions des r\u00e9seaux, on retiendra en particulier :\nG la diffusion d'une information sanitaire g\u00e9n\u00e9rale (mise \u00e0 disposition de brochures, organisation de conf\u00e9rences ou\nd'enseignements, etc.) ;\nG l'h\u00e9bergement d'associations de malades qui trouveront sur\nplace les locaux leur permettant de r\u00e9unir leurs adh\u00e9rents\net d'organiser des formations ;\nG des sessions de formation ou d'\u00e9ducation \u00e0 la sant\u00e9 ;\nG la possibilit\u00e9 de rencontrer les diff\u00e9rents membres de l'\u00e9quipe\nde professionnels avec un accueil de type \u00ab guichet unique \u00bb ;\nG la possibilit\u00e9 de participer \u00e0 des actions de pr\u00e9vention et de\nd\u00e9pistage.\nPour coordonner les conservatoires de sant\u00e9 entre eux, articuler\nleurs actions \u00e0 celles des dispositifs de soins, d\u00e9finir des objectifs de sant\u00e9 publique et recueillir des informations \u00e9pid\u00e9miologiques, il sera sans doute utile de concevoir des p\u00f4les r\u00e9gionaux\nd'excellence qui seront \u00e0 la sant\u00e9 publique ce que les centres de\nr\u00e9f\u00e9rence sont aux soins.\nCes p\u00f4les d'excellence seront en particulier responsables :\nG De la d\u00e9finition de m\u00e9thodologies de travail, puisqu'ils seront\n\u00e0 m\u00eame d'analyser, dans une approche transversale, les\nr\u00e9sultats des actions entreprises dans les conservatoires\nde sant\u00e9 ;\nG De la mise \u00e0 disposition de moyens organisationnels facilitant la coordination des actions des r\u00e9seaux fonctionnels\net Conservatoires de Sant\u00e9 et leur articulation avec les structures en charge de soins, de la pr\u00e9vention, de l'\u00e9ducation \u00e0\nla sant\u00e9 (qui devrait en particulier mobiliser l'\u00c9ducation nationale), de la prise en charge des patients et m\u00eame des dispositifs sanitaires et sociaux ;\nG De la distribution de moyens financiers et p\u00e9dagogiques (brochures), en collaboration avec les agences r\u00e9gionales d'hospitalisation.\nCette mission de coordination devra s'attacher \u00e0 pr\u00e9server la marge\nde man\u0153uvre et de cr\u00e9ation des conservatoires de sant\u00e9. On a\n\nPropositions\nHaut Comit \u00e9 de la Sant \u00e9 Publique", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2093, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "09f01a81-c12f-4e1d-854b-384baa3d5565": {"__data__": {"id_": "09f01a81-c12f-4e1d-854b-384baa3d5565", "embedding": null, "metadata": {"page_label": "71", "file_name": "hc001042.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\hc001042.pdf", "file_type": "application/pdf", "file_size": 237006, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "c05d366b-a447-4e4e-9c3b-6ad3370ec275", "node_type": "4", "metadata": {"page_label": "71", "file_name": "hc001042.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\hc001042.pdf", "file_type": "application/pdf", "file_size": 237006, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "12a72a255fe96aa913bf28625febbeed82fe82fa78ec695219ec9610cf47c3e1", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "57Diab\u00e8tes. Pr\u00e9vention, dispositifs de soins, \u00e9ducation... / Mai 1998\nPoursuivre\nla r\u00e9flexion sur\nles maladies\nchroniques\ninsist\u00e9 en effet sur la n\u00e9cessit\u00e9 en la mati\u00e8re de rompre la logique\ntrop exclusivement hospitalo-centr\u00e9e et de laisser ouverte la possibilit\u00e9 d'une implication forte des patients. Les \u00ab r\u00e9seaux \u00bb d\u00e9crits\ndans ces lignes doivent donc \u00eatre pens\u00e9s \u00e0 partir des besoins\net des revendications des patients et non pas \u00e0 partir des\ncontraintes administratives ou professionnelles des acteurs.\nEnfin, l'ensemble de ce dispositif gagnerait \u00e0 s'appuyer sur une\nr\u00e9flexion organis\u00e9e \u00e0 l'\u00e9chelle nationale, et outrepassant les fronti\u00e8res habituellement trac\u00e9es entre les diff\u00e9rentes maladies chroniques.\nDevant le besoin de coordonner les efforts de recherche, les\nlogiques de soins, les entreprises de pr\u00e9vention, d'\u00e9ducation \u00e0 la\nsant\u00e9 ou d'\u00e9ducation des patients et les l\u00e9gitimes aspirations des\npatients \u00e0 prendre en charge leurs propres maladies, les champs\nprofessionnels ont mis en place des structures sp\u00e9cialis\u00e9es. Le\nConseil sup\u00e9rieur du diab\u00e8te en est l'exemple le plus abouti.\nCes structures apportent de notables r\u00e9sultats, mais maintiennent un cloisonnement dont on a montr\u00e9 qu'il \u00e9tait pr\u00e9judiciable\n\u00e0 une prise en charge globale. Les efforts issus de ces entreprises\npeuvent en effet s'av\u00e9rer contradictoires ou redondants. Plus fr\u00e9quemment, l'inscription du patient dans une fili\u00e8re sp\u00e9cifique peut\nretarder consid\u00e9rablement la prise en charge d'autres troubles\nassoci\u00e9s au m\u00eame ensemble de causes. Il arrive par exemple\nqu'un patient diab\u00e9tique ne soit adress\u00e9 aux services de soins en\nn\u00e9phrologie que tr\u00e8s tardivement, \u00e0 un stade de l'\u00e9volution de sa\nmaladie o\u00f9 la pr\u00e9vention est impensable et o\u00f9 le traitement curatif s'impose.\nLes missions de cette instance seraient en particulier :\nG De rassembler les donn\u00e9es r\u00e9gionales (\u00e9pid\u00e9miologiques,\n\u00e9conomiques) disponibles et d'en proposer une publication\net une interpr\u00e9tation r\u00e9guli\u00e8re ;\nG D'impulser et d'organiser une politique de recherche m\u00e9dico\u00e9conomique ;\nG De fournir aux partenaires impliqu\u00e9s dans la prise en charge\ndes diff\u00e9rentes maladies chroniques une instance de dialogue capable de favoriser l'\u00e9change des points de vue et la\nconstitution d'une approche commune (tout comme, dans\nun autre registre, le Comit\u00e9 consultatif national d'\u00e9thique\na permis la d\u00e9finition d'un vocabulaire et d'une probl\u00e9matisation communs aux m\u00e9decins, juristes, philosophes, etc.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2447, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "d55cb1a7-b968-4ecc-a597-736a74dbf6a3": {"__data__": {"id_": "d55cb1a7-b968-4ecc-a597-736a74dbf6a3", "embedding": null, "metadata": {"page_label": "72", "file_name": "hc001042.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\hc001042.pdf", "file_type": "application/pdf", "file_size": 237006, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "9ed73236-ee95-47e7-ba47-0ff771745167", "node_type": "4", "metadata": {"page_label": "72", "file_name": "hc001042.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\hc001042.pdf", "file_type": "application/pdf", "file_size": 237006, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "2b5c1b7b2cdd2a91e0111361764eaf49463da8f4b91133907c862d146b442187", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Lancement\nd'un\nprogramme de\nrecherche sur\nl'\u00e9valuation des\ndispositifs\nde soins\nqui a sans doute jou\u00e9 un r\u00f4le pr\u00e9\u00e9minent dans l'\u00e9laboration\ndu dispositif l\u00e9gislatif) ;\nG De jouer un r\u00f4le de partenaire et d'informateur pour les\ndiff\u00e9rents dispositifs d'\u00e9ducation du patient et d'\u00e9ducation\n\u00e0 la sant\u00e9 ;\nG De jouer un r\u00f4le de partenaire et d'informateur pour la formation m\u00e9dicale continue.\nLes lacunes rencontr\u00e9es dans l'\u00e9valuation des dispositifs actuels\nde prise en charge et de soin des maladies chroniques comme\ndans l'\u00e9valuation des diff\u00e9rentes approches d'\u00e9ducation du patient\net d'\u00e9ducation \u00e0 la sant\u00e9 sont d'une telle ampleur qu'elles ne sauraient \u00eatre abord\u00e9es sans un v\u00e9ritable effort de recherche.\nCelui-ci devra porter aussi bien sur la m\u00e9thodologie m\u00eame de\nl'entreprise d'\u00e9valuation que sur le recueil de donn\u00e9es d'une qualit\u00e9 permettant l'\u00e9valuation des co\u00fbts et de l'efficacit\u00e9 des diff\u00e9rentes tentatives.\nDu point de vue de la m\u00e9thodologie, il importe de d\u00e9terminer\nl'ensemble des crit\u00e8res permettant de caract\u00e9riser les sp\u00e9cificit\u00e9s de chacune des maladies chroniques, et d'en \u00e9tablir une typologie satisfaisant aussi bien les exigences de la description correcte\ndes probl\u00e8mes que celles de l'analyse et de la rationalisation des\ndispositifs.\nDu point de vue du recueil des donn\u00e9es, on manque aussi bien\nde donn\u00e9es \u00e9pid\u00e9miologiques que de donn\u00e9es \u00e9conomiques, et\nm\u00eame d'un contr\u00f4le syst\u00e9matique des besoins et des moyens.\nUn tel travail ne peut \u00eatre men\u00e9 qu'au niveau des r\u00e9gions et avec\nune implication active de ces derni\u00e8res.\nEnfin, la d\u00e9marche de rationalisation des diff\u00e9rentes actions n'\u00e9tant\nen France que tr\u00e8s peu document\u00e9e, il sera n\u00e9cessaire de recourir \u00e0 d'importantes donn\u00e9es internationales, en recherchant en\nparticulier les exemples d'entreprises ayant fait la preuve de leur\nefficacit\u00e9.\nLa pr\u00e9vention des diab\u00e8tes\nEn l'\u00e9tat actuel des connaissances et des structures m\u00e9dicales,\nla pr\u00e9vention reste de tr\u00e8s loin l'approche la plus importante pour\nles maladies chroniques comme pour le diab\u00e8te. Il faut rassembler ici sous le terme de pr\u00e9vention l'ensemble des d\u00e9marches\n\nPropositions\nHaut Comit \u00e9 de la Sant \u00e9 Publique", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2150, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "b68043d2-d469-4410-91fc-0a8953851951": {"__data__": {"id_": "b68043d2-d469-4410-91fc-0a8953851951", "embedding": null, "metadata": {"page_label": "73", "file_name": "hc001042.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\hc001042.pdf", "file_type": "application/pdf", "file_size": 237006, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "f57efef7-ee22-481b-a982-a19cda834a56", "node_type": "4", "metadata": {"page_label": "73", "file_name": "hc001042.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\hc001042.pdf", "file_type": "application/pdf", "file_size": 237006, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "1ca78c08f56b7a42de6e0e4f303fa9fb06e08b4f3b721c6242d173874eb24a21", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "59Diab\u00e8tes. Pr\u00e9vention, dispositifs de soins, \u00e9ducation... / Mai 1998\nqui peuvent emp\u00eacher ou ralentir le d\u00e9veloppement de la maladie\nou de ses complications (Figure 2).\nPlus la maladie est envisag\u00e9e \u00e0 un stade pr\u00e9coce, plus cette pr\u00e9vention est g\u00e9n\u00e9rale \u00e0 l'ensemble des maladies cardio-vasculaires.\nMais avec l'approche des complications sp\u00e9cifiques, elle doit \u00eatre\nadapt\u00e9e aux caract\u00e9ristiques de l'histoire naturelle de la maladie\net devient beaucoup plus sp\u00e9cifique. Il existe donc des objectifs\nFigure 2 :\nR\u00f4 les respectifs de l'\u00e9ducation\net de la m\u00e9dicalisation\nau cours de l'histoire naturelle\ndu diab\u00e8 te non insulino-d\u00e9pendant.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 637, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "6d2b154e-d1d7-4550-8d8f-6dca92199f25": {"__data__": {"id_": "6d2b154e-d1d7-4550-8d8f-6dca92199f25", "embedding": null, "metadata": {"page_label": "74", "file_name": "hc001042.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\hc001042.pdf", "file_type": "application/pdf", "file_size": 237006, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "a9ee7d11-645f-40a4-b551-3e47a094f88d", "node_type": "4", "metadata": {"page_label": "74", "file_name": "hc001042.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\hc001042.pdf", "file_type": "application/pdf", "file_size": 237006, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "bced8b4c115c0a8c50fd8e3da170dcde9f97f0b8b8a645da2ad21225153220a1", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Rappels\nsur l'histoire\nnaturelle\ndes diab\u00e8tes\nLa pr\u00e9vention\nau stade des\npr\u00e9dispositions\nde pr\u00e9vention sp\u00e9cifiques aux diab\u00e8tes et singuli\u00e8rement au DNID\ndont on a soulign\u00e9 dans ce rapport les limites de la prise en charge\nactuelle.\nLes exigences de pr\u00e9vention des autres maladies chroniques et\nde leurs complications sont elles aussi sp\u00e9cifiques et ne sauraient\n\u00eatre expos\u00e9es dans le cadre de ce rapport.\nComme l'a rappel\u00e9 le rapport (Figure 1), les diab\u00e8tes peuvent \u00eatre\nd\u00e9crits comme la succession de trois grandes \u00e9tapes, dont l'\u00e2ge\nde survenue, la vitesse d'\u00e9volution et l'ampleur des cons\u00e9quences\nvarient en fonction du diab\u00e8te consid\u00e9r\u00e9.\nLa premi\u00e8re \u00e9tape est celle de la pr\u00e9disposition. Celle-ci int\u00e8gre\ndes facteurs g\u00e9n\u00e9tiques, des facteurs physiologiques ou immunitaires (notamment pour le DID) des facteurs de comportement\net d'environnement (le r\u00f4le de l'alimentation \u00e9tant plus pr\u00e9gnant\npour le DNID). Une pr\u00e9disposition au diab\u00e8te n'est pas un trouble,\nmais les comportements (alimentation, pratique du sport, usage\ndu tabac) influeront consid\u00e9rablement les \u00e9volutions ult\u00e9rieures.\nCette \u00e9tape \u00e9volue tr\u00e8s brutalement vers le diab\u00e8te dans le cas\ndu DID, et beaucoup plus lentement dans le cas du DNID pour\nlequel on observe le plus fr\u00e9quemment un passage par une phase\nde surcharge pond\u00e9rale puis le ph\u00e9nom\u00e8ne d'insulino-r\u00e9sistance\n(hyperglyc\u00e9mie, hypertension art\u00e9rielle et dyslipid\u00e9mie).\nLa maladie d\u00e9clar\u00e9e non compliqu\u00e9e se caract\u00e9rise essentiellement par une hyperglyc\u00e9mie, mais n'entra\u00eene somme toute que\nfort peu de troubles pour le patient.\nLes complications communes sont nombreuses et peuvent \u00eatre\ntr\u00e8s graves. Il est quasiment impossible d'en \u00e9viter d\u00e9finitivement\nla survenue, mais une strat\u00e9gie appropri\u00e9e peut en ralentir consid\u00e9rablement l'\u00e9volution.\nLes exigences de la pr\u00e9vention au stade des pr\u00e9dispositions sont\navant tout des exigences de d\u00e9pistage et d'\u00e9ducation.\nLe d\u00e9pistage peut porter sur des caract\u00e9ristiques g\u00e9n\u00e9tiques,\nfamiliale ou comportementales (comportement alimentaire, s\u00e9dentarit\u00e9, usage du tabac). \u00c0 tout \u00e2ge, le d\u00e9pistage doit concerner les\npopulations \u00e0 risque, mais \u00e9galement, lorsque cela est possible,\n\u00eatre pratiqu\u00e9 de mani\u00e8re opportuniste.\n\nPropositions\nHaut Comit \u00e9 de la Sant \u00e9 Publique", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2244, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "8d176405-3148-4b81-bbde-e4396e0f16a1": {"__data__": {"id_": "8d176405-3148-4b81-bbde-e4396e0f16a1", "embedding": null, "metadata": {"page_label": "75", "file_name": "hc001042.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\hc001042.pdf", "file_type": "application/pdf", "file_size": 237006, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "8e3bbbbd-c484-4701-b55f-f3ff5bf5d270", "node_type": "4", "metadata": {"page_label": "75", "file_name": "hc001042.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\hc001042.pdf", "file_type": "application/pdf", "file_size": 237006, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "ba4ceb60ddc29611482565cc355f98eb5c9359b381f89360c71a78f9eae9cdad", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c74f8c0f-d120-4807-8c67-d3ae80e2acc2", "node_type": "1", "metadata": {}, "hash": "4eccf5963481e6d8699324d246373950ca696962ef8f7cc04f73bae2c2ddcb3d", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "61Diab\u00e8tes. Pr\u00e9vention, dispositifs de soins, \u00e9ducation... / Mai 1998\nL'\u00e9ducation \u00e0 la sant\u00e9 devrait pour sa part \u00eatre men\u00e9e \u00e0 plus\ngrande \u00e9chelle, en impliquant l'\u00c9ducation nationale.\nLe d\u00e9pistage du DNIDdoit s'adresser aux familles des DNID d\u00e9clar\u00e9s (puisque pr\u00e8s de 80 % des DNID ont une h\u00e9r\u00e9dit\u00e9 diab\u00e9tique\nconnue ou m\u00e9connue), aux sujets des deux sexes dont l'index de\nmasse corporelle est sup\u00e9rieur \u00e0 25, mais aussi aux femmes (et\nleurs apparent\u00e9s g\u00e9n\u00e9tiques) ayant donn\u00e9 naissance \u00e0 des enfants\nde plus de 4 kg et/ou ayant des ant\u00e9c\u00e9dents obst\u00e9tricaux (avortements \u00e0 r\u00e9p\u00e9tition, enfants mort-n\u00e9s) \u00e9vocateurs d'une h\u00e9r\u00e9dit\u00e9\ndiab\u00e9tique.\nLes sujets chez lesquels un risque est d\u00e9tect\u00e9 devront d\u00e8s ce\nstade b\u00e9n\u00e9ficier d'une \u00e9ducation \u00e0 la sant\u00e9 qui devra int\u00e9grer des\naspects pratiques et quotidiens. Des exp\u00e9riences tr\u00e8s satisfaisantes ont ainsi \u00e9t\u00e9 men\u00e9es, le plus souvent par des infirmi\u00e8res\nvolontaires, qui montrent l'int\u00e9r\u00eat de ne pas se limiter \u00e0 quelques\nconseils de di\u00e9t\u00e9tique, mais au contraire de proposer une formation culinaire pratique et concr\u00e8te.\nCes d\u00e9pistages pourraient \u00eatre propos\u00e9s dans des conservatoires\nde sant\u00e9, mais doivent \u00e9galement \u00eatre effectu\u00e9s en milieu m\u00e9dical et hospitalier.\nL'\u00e9ducation \u00e0 la sant\u00e9 des sujets \u00e0 risque de DNID, et en particulier l'\u00e9ducation \u00e0 l'hygi\u00e8ne de vie (int\u00e9grant la promotion de\nl'exercice physique r\u00e9gulier), l'\u00e9ducation nutritionnelle (sp\u00e9cifiquement ax\u00e9e sur la sant\u00e9 et \u00e0 ce titre d\u00e9marqu\u00e9e des tr\u00e8s nombreux messages portant sur l'alimentation) et la lutte contre le\ntabagisme et l'alcoolisme concerne l'ensemble de la population.\nL'\u00c9ducation nationale, qui concerne aujourd'hui tous les Fran\u00e7ais\net qui offre l'opportunit\u00e9 d'explications d\u00e9taill\u00e9es devrait \u00eatre l'un\ndes acteurs majeurs de cette politique. Pour des actions plus sp\u00e9cifiques, le d\u00e9veloppement des conservatoires de sant\u00e9 mentionn\u00e9s au chapitre pr\u00e9c\u00e9dent pourrait fournir des outils appropri\u00e9s.\nLe d\u00e9pistage du DID concerne les familles ayant d\u00e9j\u00e0 un diab\u00e8te insulino-d\u00e9pendant, des marqueurs g\u00e9n\u00e9tiques HLA et/ou\ndes marqueurs immunologiques sous forme d'anticorps circulants.\nCes crit\u00e8res indiquent un risque plus \u00e9lev\u00e9 de maladie, mais le\nd\u00e9terminisme appara\u00eet moins net que celui qui existe en mati\u00e8re\nde DNID.\nCette action devrait \u00eatre effectu\u00e9e comme un acte volontaire, mais\naussi dans le cadre de programmes de recherche coordonn\u00e9s multicentriques au niveau r\u00e9gional (p\u00f4les r\u00e9gionaux d'excellence).", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2438, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "c74f8c0f-d120-4807-8c67-d3ae80e2acc2": {"__data__": {"id_": "c74f8c0f-d120-4807-8c67-d3ae80e2acc2", "embedding": null, "metadata": {"page_label": "75", "file_name": "hc001042.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\hc001042.pdf", "file_type": "application/pdf", "file_size": 237006, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "8e3bbbbd-c484-4701-b55f-f3ff5bf5d270", "node_type": "4", "metadata": {"page_label": "75", "file_name": "hc001042.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\hc001042.pdf", "file_type": "application/pdf", "file_size": 237006, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "ba4ceb60ddc29611482565cc355f98eb5c9359b381f89360c71a78f9eae9cdad", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8d176405-3148-4b81-bbde-e4396e0f16a1", "node_type": "1", "metadata": {"page_label": "75", "file_name": "hc001042.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\hc001042.pdf", "file_type": "application/pdf", "file_size": 237006, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "9783fa07af2d906976a1cb0ebcead93cafe7f3baf158b1780de324fe3f0d501c", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Ces crit\u00e8res indiquent un risque plus \u00e9lev\u00e9 de maladie, mais le\nd\u00e9terminisme appara\u00eet moins net que celui qui existe en mati\u00e8re\nde DNID.\nCette action devrait \u00eatre effectu\u00e9e comme un acte volontaire, mais\naussi dans le cadre de programmes de recherche coordonn\u00e9s multicentriques au niveau r\u00e9gional (p\u00f4les r\u00e9gionaux d'excellence). Les\nr\u00e9sultats pourraient en outre permettre l'ouverture d'un registre", "mimetype": "text/plain", "start_char_idx": 2110, "end_char_idx": 2508, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "dc38a370-61e6-4e20-ac16-66830f8e9c5e": {"__data__": {"id_": "dc38a370-61e6-4e20-ac16-66830f8e9c5e", "embedding": null, "metadata": {"page_label": "76", "file_name": "hc001042.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\hc001042.pdf", "file_type": "application/pdf", "file_size": 237006, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "246da383-007c-40f5-9e07-52978ed27ff3", "node_type": "4", "metadata": {"page_label": "76", "file_name": "hc001042.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\hc001042.pdf", "file_type": "application/pdf", "file_size": 237006, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "86aa8c8c2c0b1c8b9c173d4e78cfd92ff63e29f1064d5a6b3a3e624cc4b56ac7", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "La pr\u00e9vention\nau stade\nde la maladie\nd\u00e9clar\u00e9e\nd'incidence nationale de la maladie (il existe d\u00e9j\u00e0 des registres\nr\u00e9gionaux de ce type).\nMalgr\u00e9 une connaissance de plus en plus pr\u00e9cise des ph\u00e9nom\u00e8nes\nresponsables de la maladie, la pr\u00e9vention ne pourra malheureusement pas, en l'\u00e9tat actuel des connaissances, enrayer l'\u00e9volution vers la mise sous insuline. Cependant, elle permettra de\nralentir quelque peu cette \u00e9volution et surtout de pr\u00e9parer la mise\nsous insuline en amor\u00e7ant l'\u00e9ducation du patient et en l'int\u00e9grant\n\u00e0 des structures de type Association des jeunes diab\u00e9tiques.\nLorsque les premiers signes de diab\u00e8te sont install\u00e9s (ob\u00e9sit\u00e9\nandro\u00efde, hypertension art\u00e9rielle, hyperglyc\u00e9mie sup\u00e9rieure \u00e0\n1,4 g\n23 \u00e0 jeun et 2 g apr\u00e8s le repas ou taux trop \u00e9lev\u00e9 d'h\u00e9moglobine glyqu\u00e9e), la pr\u00e9vention doit essentiellement porter sur les\nrisques d'installation d'une hyperglyc\u00e9mie permanente et d'apparition des complications.\nLes risques et les m\u00e9thodes sont, dans l'ensemble, communs\naux deux formes de diab\u00e8tes, mais, comme on l'a montr\u00e9, la\nvitesse d'\u00e9volution de la maladie et la facilit\u00e9 d'\u00e9ducation des\npatients distinguent en profondeur ces deux pathologies. Malgr\u00e9 ces diff\u00e9rences de contexte, ces deux d\u00e9marches supposent :\nun objectif (normalisation de la glyc\u00e9mie au long des 24 heures,\nnormalisation de la tension art\u00e9rielle, normalisation des lipides\nsanguins), une m\u00e9thode (arr\u00eat du tabac, \u00e9ducation nutritionnelle,\npratique d'une activit\u00e9 physique, surveillance des signes avantcoureurs des complications).\nDans le cas du DNID , cette pr\u00e9vention est difficile \u00e0 mettre en\n\u0153uvre, car cette affection n'est qu'exceptionnellement g\u00eanante\nou invalidante pour les patients, tout en exigeant des modifications profondes du mode de vie. Ces derni\u00e8res sont fr\u00e9quemment\nper\u00e7ues comme diminuant la qualit\u00e9 de la vie. La repr\u00e9sentation g\u00e9n\u00e9rale du DNID au sein de la profession m\u00e9dicale ne facilite pas la d\u00e9marche.\nPourtant, sit\u00f4t le DNID diagnostiqu\u00e9, il faut que soient propos\u00e9s\nau patient :\nG une \u00e9ducation nutritionnelle planifi\u00e9e ;\nG des r\u00e8gles \u00e9crites de surveillance sp\u00e9cifiques, r\u00e9guli\u00e8rement\n\u00e9valu\u00e9es ;\n\nPropositions\nHaut Comit \u00e9 de la Sant \u00e9 Publique\n23. En attendant la probable r\u00e9vision des crit\u00e8res OMS.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2220, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "037f81e7-e9fe-4c3d-8e87-65b97dc7ed22": {"__data__": {"id_": "037f81e7-e9fe-4c3d-8e87-65b97dc7ed22", "embedding": null, "metadata": {"page_label": "77", "file_name": "hc001042.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\hc001042.pdf", "file_type": "application/pdf", "file_size": 237006, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "f9167ad1-3346-48a9-93e8-edfbce751368", "node_type": "4", "metadata": {"page_label": "77", "file_name": "hc001042.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\hc001042.pdf", "file_type": "application/pdf", "file_size": 237006, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "f01d10dee3714f8031e5fd2bb34b91b98c8fcdb86d8a429a71cb3dfd5f9d6cf3", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "63Diab\u00e8tes. Pr\u00e9vention, dispositifs de soins, \u00e9ducation... / Mai 1998\nG les informations minimales que tout diab\u00e9tique doit conna\u00eetre ;\nG une information sur ses droits et ses devoirs tels qu'ils sont\nd\u00e9finis par la D\u00e9claration de Saint-Vincent.\nPour ce faire, il importe que les professions m\u00e9dicales (g\u00e9n\u00e9ralistes, sp\u00e9cialistes du diab\u00e8te, di\u00e9t\u00e9ticiens) soient form\u00e9es au\nrep\u00e9rage des premiers sympt\u00f4mes et inform\u00e9es de l'existence\ndes r\u00e9seaux fonctionnels et conservatoires de sant\u00e9, afin d'\u00eatre\ncapables de prescrire le recours \u00e0 ces institutions. Les conservatoires, pour leur part, doivent pouvoir fournir des sessions de\nformation compatibles avec des horaires de personnes actives et\nconformes \u00e0 des cahiers des charges valid\u00e9s.\n\u00c0 l'heure actuelle, cette \u00e9ducation est pratiqu\u00e9e en ambulatoire\nou dans des centres, sans reconnaissance de cette activit\u00e9 et\nsans imputation budg\u00e9taire sp\u00e9cifique (sauf pour l'enfant diab\u00e9tique). Il serait souhaitable de reconna\u00eetre le caract\u00e8re th\u00e9rapeutique de cette \u00e9ducation et de la doter des moyens n\u00e9cessaires.\nCes d\u00e9marches d'\u00e9ducation des patients devront en outre faire\nl'objet d'\u00e9valuations r\u00e9guli\u00e8res dans un objectif d'am\u00e9lioration.\nOn pourra en particulier utiliser, pour initier la d\u00e9marche, les cahiers\ndes charges propos\u00e9s et r\u00e9guli\u00e8rement r\u00e9\u00e9valu\u00e9s par l'ALFEDIAM,\nle DESG ou l'EASD.\nEn ce qui concerne les DID, la pr\u00e9vention est relativement plus\nfacile \u00e0 mettre en \u0153uvre, tant parce que les dangers sont plus\nais\u00e9ment perceptibles que parce que les patients sont plus jeunes\net rencontrent un tissu associatif tr\u00e8s organis\u00e9. Cependant, les\nrisques demeurent : aux complications s'ajoutent les risques\npropres de l'insulinoth\u00e9rapie, qui, lorsqu'elle est mise en route\nsans \u00e9ducation ni information, peut devenir approximative et donc\ndangereuse, et quelquefois abusivement co\u00fbteuse (notamment\nlorsque des injections sont pratiqu\u00e9es, sans raison valable, \u00e0 des\nhoraires dits \u00ab de nuit \u00bb).\nL'articulation du travail des associations \u00e0 celui de structures plus\nsp\u00e9cifiquement charg\u00e9es de l'\u00e9ducation \u00e0 la sant\u00e9, comme les\nconservatoires de sant\u00e9, permettrait \u00e0 la fois de renforcer le\nr\u00f4le de ces associations en t\u00e9moignant de leur insertion dans\nle dispositif global de soin et de compl\u00e9ter leur action par celle\ndes diff\u00e9rents professionnels de sant\u00e9 mobilis\u00e9s.\nQuel que soit le type de diab\u00e8 te consid\u00e9r\u00e9, et, de mani\u00e8re g\u00e9n\u00e9rale, pour l'ensemble des maladies chroniques, l'absence de strat\u00e9gie globale d'\u00e9ducation, comme celle d'un suivi r\u00e9gulier,\naboutissent \u00e0 une situation assez pr\u00e9occupante.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2554, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "83ca01e2-b530-4f9c-8921-a59a6de9103b": {"__data__": {"id_": "83ca01e2-b530-4f9c-8921-a59a6de9103b", "embedding": null, "metadata": {"page_label": "78", "file_name": "hc001042.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\hc001042.pdf", "file_type": "application/pdf", "file_size": 237006, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "8e7b362b-ba79-4efb-96cd-4cb7c846478c", "node_type": "4", "metadata": {"page_label": "78", "file_name": "hc001042.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\hc001042.pdf", "file_type": "application/pdf", "file_size": 237006, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "9395faaf730f9bee72a690173a2b57fe3c181b76246c724ab23dfa0343bbd950", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Pourtant, les nouvelles possibilit\u00e9s offertes par les ordonnances\ndu printemps 1996 offrent un cadre permettant :\nG la reconnaissance des centres d'\u00e9ducation par l'accr\u00e9ditation (contrat d'objectifs et d'\u00e9valuation) ;\nG la prise en compte des consultations infirmi\u00e8res, de celles\nde di\u00e9t\u00e9ticiens, de p\u00e9dicures, de podologues... ;\nG le financement forfaitaire de ces actions, en particulier dans\nle cadre d'exp\u00e9rimentation des r\u00e9seaux et fili\u00e8res de soins.\nDans ces phases de diab\u00e8te secondaire, l'\u00e9ducation est cependant loin d'\u00eatre le seul objectif. Toute une strat\u00e9gie de soins\ndoit \u00eatre d\u00e9velopp\u00e9e pour retarder au maximum l'apparition des\ncomplications. Cette strat\u00e9gie exige une surveillance r\u00e9guli\u00e8re\net le d\u00e9pistage des premiers signes de ces complications.\nLa d\u00e9finition des objectifs et le choix des indicateurs correspondant \u00e0 cette phase posent des probl\u00e8mes m\u00e9thodologiques. Il\nn'est par exemple pas indiff\u00e9rent de choisir comme indicateur prioritaire de qualit\u00e9 des soins le maintien des glyc\u00e9mies normales\nplut\u00f4t que celui du pourcentage des complications d\u00e9pist\u00e9es. De\ntels choix engagent en effet des strat\u00e9gies de pr\u00e9vention diff\u00e9rentes, intervenant \u00e0 des stades diff\u00e9rents d'\u00e9volution des complications, et mobilisant des professionnels diff\u00e9rents.\nUne v\u00e9ritable pr\u00e9vention engage de pr\u00e9f\u00e9rence les m\u00e9decins g\u00e9n\u00e9ralistes et porte sur le contr\u00f4le glyc\u00e9mique. Ceux-ci ont, pour ce\nfaire, \u00e0 mettre en place, au niveau r\u00e9gional, des proc\u00e9dures cr\u00e9dibles de recueil des donn\u00e9es, de formation, d'\u00e9valuation, et obtenir les moyens leur permettant d'assurer cette mission.\nL'informatisation prochaine du dossier du patient et l'instauration\nd'une FMC obligatoire devraient permettre la diffusion d'une culture de qualit\u00e9 des soins aupr\u00e8s des patients comme des m\u00e9decins, en particulier g\u00e9n\u00e9ralistes. L'informatisation permettant\nd'\u00e9valuer la p\u00e9riodicit\u00e9 et l'exhaustivit\u00e9 du recueil des donn\u00e9es\ntout en ouvrant la voie aux comparaisons \u00e9pid\u00e9miologiques permettra la mise en \u0153uvre de la surveillance pr\u00e9conis\u00e9e \u00e0 ce stade\npar la D\u00e9claration de Saint-Vincent\n24. C'est l'un des \u00e9l\u00e9ments\ncapables de favoriser l'\u00ab alliance th\u00e9rapeutique \u00bb entre les patients\net les soignants.\n\nPropositions\nHaut Comit \u00e9 de la Sant \u00e9 Publique\n24. Gr\u00e2ce \u00e0 des programmes informatis\u00e9s de surveillance, type DIABCARE (fiches standardis\u00e9es de recueil annuel de donn\u00e9es individuelles).", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2369, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "fc899c00-8cf5-45f5-8753-34f15a6cce81": {"__data__": {"id_": "fc899c00-8cf5-45f5-8753-34f15a6cce81", "embedding": null, "metadata": {"page_label": "79", "file_name": "hc001042.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\hc001042.pdf", "file_type": "application/pdf", "file_size": 237006, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "5bc95d67-0d72-4412-bf5a-5172e84319b8", "node_type": "4", "metadata": {"page_label": "79", "file_name": "hc001042.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\hc001042.pdf", "file_type": "application/pdf", "file_size": 237006, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "ee018c62bb027f3872e67810b8b89a61862dc748d92fb48a670479191b39fe8e", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "65Diab\u00e8tes. Pr\u00e9vention, dispositifs de soins, \u00e9ducation... / Mai 1998\nLa pr\u00e9vention\nau stade des\ncomplications\nLes principales complications sont communes aux deux formes\nde diab\u00e8te. Leur nature, leur gravit\u00e9 et leurs \u00e9volutions semblent de m\u00eame nature et de m\u00eame fr\u00e9quence. Elles repr\u00e9sentent\n\u00e9galement la phase de co\u00fbt maximal de la maladie, avec des pathologies lourdes, n\u00e9cessitant fr\u00e9quemment une hospitalisation lourde\net co\u00fbteuse comme dans l'exemple des insuffisances r\u00e9nales.\nComme le rappelait la D\u00e9claration de Saint-Vincent, une pr\u00e9vention efficace n\u00e9cessite tout d'abordun diagnostic aussi pr\u00e9coce\nque possible des complications et ensuite de nombreux efforts\nvisant \u00e0 stopper ou \u00e0 freiner l'\u00e9volution de ces complications vers\nles infirmit\u00e9s, la d\u00e9pendance ou la mort pr\u00e9matur\u00e9e.\nLa prise en charge, tout en gardant \u00e0 l'esprit l'objectif d'autonomisation des patients, devra probablement s'effectuer dans une\nstructure \u00e9troitement associ\u00e9e \u00e0 l'h\u00f4pital. Elle fait toujours appel\n\u00e0 une \u00e9quipe multidisciplinaire dont les interventions doivent \u00eatre\nparfaitement coordonn\u00e9es. L'absence de coordination est le plus\nsouvent la cause d'aggravation ou d'\u00e9chec du traitement. Les\nsoins doivent donc \u00eatre organis\u00e9s en r\u00e9seau et le patient doit \u00eatre\nsuivi par plusieurs sp\u00e9cialistes.\nEn cas d'hospitalisation, celle-ci doit \u00eatre effectu\u00e9e dans des\ncentres accr\u00e9dit\u00e9s, harmonieusement r\u00e9partis sur le territoire,\ncomp\u00e9tents sur des complications sp\u00e9cifiques (par exemple le\npied diab\u00e9tique) et des centres ressources pour les autres structures de soins r\u00e9gionales.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1566, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "26eb9f30-a274-4936-8f07-37724ad82bdf": {"__data__": {"id_": "26eb9f30-a274-4936-8f07-37724ad82bdf", "embedding": null, "metadata": {"page_label": "80", "file_name": "hc001042.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\hc001042.pdf", "file_type": "application/pdf", "file_size": 237006, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "f4679746-da20-41d2-a25c-795291ab8b8a", "node_type": "4", "metadata": {"page_label": "80", "file_name": "hc001042.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\hc001042.pdf", "file_type": "application/pdf", "file_size": 237006, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "7997724eb7e679161ae7989953c6639182b233ff2d573431f65ee206ad7410f7", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 0, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "0b885daa-df73-40f3-8196-24491562ff2e": {"__data__": {"id_": "0b885daa-df73-40f3-8196-24491562ff2e", "embedding": null, "metadata": {"page_label": "81", "file_name": "hc001042.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\hc001042.pdf", "file_type": "application/pdf", "file_size": 237006, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "ae226c3c-c038-4624-9284-5fbbfe47bbea", "node_type": "4", "metadata": {"page_label": "81", "file_name": "hc001042.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\hc001042.pdf", "file_type": "application/pdf", "file_size": 237006, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "2b271dc30df7333e596765ba1380d40578a87a28936aff9a9f20880ff3de128c", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "67Diab\u00e8tes. Pr\u00e9vention, dispositifs de soins, \u00e9ducation... / Mai 1998\nAnnexe I\nAnnexe II\nLISTE DES ANNEXES\nComposition du groupe de travail et personnes auditionn\u00e9es.\nD\u00e9claration de Saint-Vincent.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 196, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "adda74a5-932e-4f9e-bde8-c4566f768dc1": {"__data__": {"id_": "adda74a5-932e-4f9e-bde8-c4566f768dc1", "embedding": null, "metadata": {"page_label": "82", "file_name": "hc001042.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\hc001042.pdf", "file_type": "application/pdf", "file_size": 237006, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "542c8b40-9cf3-4a9c-aad5-27012a9996a3", "node_type": "4", "metadata": {"page_label": "82", "file_name": "hc001042.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\hc001042.pdf", "file_type": "application/pdf", "file_size": 237006, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "020030301c91340cde41dba799bdc56cda2ee5de0ea65f33a31e93d8e37593e3", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 0, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "1a053b52-2d76-4203-b3b6-48588f5991f9": {"__data__": {"id_": "1a053b52-2d76-4203-b3b6-48588f5991f9", "embedding": null, "metadata": {"page_label": "83", "file_name": "hc001042.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\hc001042.pdf", "file_type": "application/pdf", "file_size": 237006, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "91bddacf-cd2f-4c81-803d-a86c7ee80760", "node_type": "4", "metadata": {"page_label": "83", "file_name": "hc001042.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\hc001042.pdf", "file_type": "application/pdf", "file_size": 237006, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "9b5a13d36330cac63a172593496b75d9031c04a3253614cf6d5bac72ca370440", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "69Diab\u00e8tes. Pr\u00e9vention, dispositifs de soins, \u00e9ducation... / Mai 1998\nAnnexe I Composition du groupe de travail\net personnes auditionn\u00e9es\nLe groupe de travail a \u00e9t\u00e9 anim\u00e9 par G. Errieau et J.-C. Sailly, membres\ndu Haut Comit\u00e9 de la sant\u00e9 publique, et comprenait :\nM. le Pr J.-J. Altman, h\u00f4pital La\u00ebnnec, Paris\nM. le Dr J.-M. Angel\u00e9, direction g\u00e9n\u00e9rale de la Sant\u00e9\nM. le Dr M. Cahan\u00e9, Aide aux jeunes diab\u00e9tiques, Paris\nM. le Pr G. Cathelineau, ALFEDIAM, Paris, repr\u00e9sentant la D\u00e9claration\nde Saint-Vincent\nM. le Dr J.-M. Cohen, Open Rome, Paris\nM. le Pr P. Drouin, Conseil sup\u00e9rieur du diab\u00e8te, Paris\nMme le Dr E. Eschw\u00e8ge, Inserm U 21, Villejuif\nM. le Dr P. Grandmottet, Besan\u00e7on\nM. C. Juino, Association fran\u00e7aise des diab\u00e9tiques, Paris\nMme le Dr L. Kleinebreil, repr\u00e9sentant Diabcare France\nM. le Dr P. Massabie, Ligue des diab\u00e9tiques de France, Pau\nMme le Dr L. Papoz, Inserm U 500, Montpellier\nM. le Dr Ph. Tard, Cnamts, \u00c9chelon national du service m\u00e9dical\nAuditions en s\u00e9ance\nM. le Dr P. Costagliola, association CEREAL, Besan\u00e7on\nM. le Pr J.-M. Daninos, Syndicat national des sp\u00e9cialistes en endocrinologie et des maladies m\u00e9taboliques, Paris\nM. C. Fischler, CETSAH/CNRS, Paris\nM. le Pr Fontaine, clinique du pied, CHRU de Lille\nM. le Dr J.-L. Grenier, CETRADIM, centre hospitalier de Roubaix\nM. le Pr A. Grimaldi, h\u00f4pital de la Piti\u00e9-Salp\u00e9tri\u00e8re, Paris\nMmes B. Hanicotte et C. Joncquez, Maison du diab\u00e8te, Marcq-enBar\u0153ul\nM. le Pr J.-F. d'Ivernois, IPCEM, Puteaux\nMme Th. Lebrun, CRESGE, Lille\nMme S. Lion, Lifescan (Johnson & Johnson), Boulogne-Billancourt\nMme le Dr A.-M. Magnier, Paris\nM. R. Motta, consultant\nM. le Pr R. Mornex, GREPED, h\u00f4pital E.-Herriot, Lyon", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1671, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "30ecc3ea-5bdd-48c5-90cf-5e4c600b8391": {"__data__": {"id_": "30ecc3ea-5bdd-48c5-90cf-5e4c600b8391", "embedding": null, "metadata": {"page_label": "84", "file_name": "hc001042.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\hc001042.pdf", "file_type": "application/pdf", "file_size": 237006, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "1496756e-98b3-4bb1-a501-495032819b45", "node_type": "4", "metadata": {"page_label": "84", "file_name": "hc001042.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\hc001042.pdf", "file_type": "application/pdf", "file_size": 237006, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "2bea62b19c495900aac0fdb89b9b47814df173aaf7346323396fe14835beecf2", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Mme le Dr Nuttens, Mme le Dr Vambergue, Mme le Dr Verier-Mine,\ngroupe Diagest, CHRU de Lille\nM. le Dr J.-C. Puget, association Asthme, Paris\nM. le Dr Ph. Renou, ASAVED, centre hospitalier Le Mans\nMme F. Rossi-Pacini, ALFEDIAM Param\u00e9dical, Paris\nM. le Dr M. Varroud-Vial, CSD Essonne\nM. le Pr P. Vexiau, DESG de langue fran\u00e7aise, h\u00f4pital Saint-Louis, Paris\nNous remercions M. le Dr D. Cordonnier (CHRU de Grenoble) et Mme\nTh. Lebrun (CRESGE, Lille) pour leurs contributions \u00e9crites.\nDes entretiens et contacts particuliers ont eu lieu avec :\nMmes B. Roussille et B. Sandrin-Berthon, Comit\u00e9 fran\u00e7ais d'\u00e9ducation pour la sant\u00e9\nM. le Pr J. Arveiller, Sciences de l'\u00e9ducation, Universit\u00e9 de Caen\nM. le Pr M. Aufray, Inalco, Paris\nM. le Pr Palicot, ENSP, Rennes\nM. le Dr J.-L. Gallais, SFMG, Paris\nLe groupe de travail tient tout particuli\u00e8rement \u00e0 remercier Mlle C. Le\nGrand, qui a assur\u00e9 la logistique, ainsi que M. H. Verdier pour sa contribution et sa participation \u00e0 la r\u00e9daction du pr\u00e9sent rapport.\n\nAnnexes\nHaut Comit \u00e9 de la Sant \u00e9 Publique", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1042, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "8c2bf302-22dc-428e-af8b-0ab4175fbc12": {"__data__": {"id_": "8c2bf302-22dc-428e-af8b-0ab4175fbc12", "embedding": null, "metadata": {"page_label": "85", "file_name": "hc001042.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\hc001042.pdf", "file_type": "application/pdf", "file_size": 237006, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "8cf0f982-ecbc-475e-8fdf-5c64f7cecc65", "node_type": "4", "metadata": {"page_label": "85", "file_name": "hc001042.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\hc001042.pdf", "file_type": "application/pdf", "file_size": 237006, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "df5499291180da5533021d817239e445e071053e5d8f2e82f68c8f8a2669a5c0", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "71Diab\u00e8tes. Pr\u00e9vention, dispositifs de soins, \u00e9ducation... / Mai 1998\nAnnexe II D\u00e9claration de Saint-Vincent\nDiab\u00e8te sucr\u00e9\nPrise en charge, traitement\net recherche en Europe\nLes repr\u00e9sentants des minist\u00e8res de la Sant\u00e9 et des Associations de\npatients de tous les pays europ\u00e9ens se sont r\u00e9unis avec des sp\u00e9cialistes\ndu diab\u00e8te sous l'\u00e9gide du bureau r\u00e9gional pour l'Europe de l'Organisation mondiale de la sant\u00e9 et de la section europ\u00e9enne de la F\u00e9d\u00e9ration\ninternationale du diab\u00e8te (IDF) \u00e0 Saint-Vincent (Italie) du 10 au 12 octobre\n1989.\nIls ont propos\u00e9 \u00e0 l'unanimit\u00e9 les recommandations suivantes et ont\ndemand\u00e9 instamment qu'elles soient pr\u00e9sent\u00e9es dans tous les pays\nd'Europe pour y \u00eatre appliqu\u00e9es.\nLe diab\u00e8te sucr\u00e9 est un probl\u00e8me de sant\u00e9 majeur et de plus en plus\nr\u00e9pandu en Europe, qui frappe les individus de tous \u00e2ges et tous les pays.\nIl entra\u00eene un mauvais \u00e9tat de sant\u00e9 durable et il repr\u00e9sente une cause de\nd\u00e9c\u00e8s pr\u00e9matur\u00e9. Il menace au moins dix millions de citoyens europ\u00e9ens.\nIl appartient aux gouvernements nationaux et aux minist\u00e8res de la Sant\u00e9\nde cr\u00e9er des conditions permettant de r\u00e9duire consid\u00e9rablement les\nlourdes cons\u00e9quences de cette maladie et le nombre de d\u00e9c\u00e8s qu'elle\nprovoque. Les pays doivent reconna\u00eetre officiellement le probl\u00e8me repr\u00e9sent\u00e9 par le diab\u00e8te et d\u00e9gager les ressources pour le r\u00e9soudre. Il faut,\naux niveaux local, national et europ\u00e9en, \u00e9laborer des programmes de pr\u00e9vention, de diagnostic et de traitement du diab\u00e8te, et en particulier de\nses complications - c\u00e9cit\u00e9, insuffisance r\u00e9nale, gangr\u00e8ne et amputation,\ncardiopathie isch\u00e9mique acc\u00e9l\u00e9r\u00e9e, accident vasculaire c\u00e9r\u00e9bral, grossesses pathologiques. L'investissement d'aujourd'hui touchera demain\nses fruits : une att\u00e9nuation des souffrances humaines, ainsi que des \u00e9conomies massives en ressources humaines et mat\u00e9rielles.\nLes objectifs g\u00e9n\u00e9raux, et les buts \u00e0 \u00e9ch\u00e9ance de cinq ans \u00e9num\u00e9r\u00e9s cidessous, peuvent \u00eatre atteints par des actions organis\u00e9es des services", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1968, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "9ed902aa-d12c-4adb-8191-3ac599ca4888": {"__data__": {"id_": "9ed902aa-d12c-4adb-8191-3ac599ca4888", "embedding": null, "metadata": {"page_label": "86", "file_name": "hc001042.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\hc001042.pdf", "file_type": "application/pdf", "file_size": 237006, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "75d8f244-a93d-4b9b-9512-fb21f520f46e", "node_type": "4", "metadata": {"page_label": "86", "file_name": "hc001042.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\hc001042.pdf", "file_type": "application/pdf", "file_size": 237006, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "c79613c32cde6fba9fa3576b3e650ff0c5e72f214c862e80697a29e74fa62546", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Objectifs\ng\u00e9n\u00e9raux\npour les patients\ndiab\u00e9tiques,\nadultes et enfants\nButs \u00e0 \u00e9ch\u00e9ance\nde cinq ans\nm\u00e9dicaux, avec la coop\u00e9ration active des patients diab\u00e9tiques, de leurs\nfamilles, amis et coll\u00e8gues, et de leurs associations, dans les domaines\nsuivants :\nG Prise en charge par les sujets diab\u00e9tiques de leur maladie et \u00e9ducation permettant cette prise en charge.\nG Planification, prestation et contr\u00f4le de la qualit\u00e9 des syst\u00e8mes\nde soin.\nG Organisation \u00e0 l'\u00e9chelon national, r\u00e9gional et international de la diffusion d'informations sur le maintien de la sant\u00e9.\nG Promotion et application de la recherche.\nG Am\u00e9liorer durablement l'\u00e9tat de sant\u00e9 et permettre une vie proche\nde la normale, en qualit\u00e9 et en dur\u00e9e.\nG Pr\u00e9venir et soigner le diab\u00e8te et ses complications en intensifiant\nl'effort de recherche.\nConcevoir, entreprendre et \u00e9valuer des programmes coh\u00e9rents pour d\u00e9tecter et combattre le diab\u00e8te et ses complications, en faisant appel principalement \u00e0 l'auto-prise en charge et au soutien de la collectivit\u00e9.\nSensibiliser davantage la population et les professionnels de la sant\u00e9\naux possibilit\u00e9s actuelles et aux besoins futurs concernant la pr\u00e9vention\ndes complications du diab\u00e8te et du diab\u00e8te lui-m\u00eame.\nOrganiser la formation et l'enseignement en mati\u00e8re de prise en charge\net de traitement du diab\u00e8te, pour les patients diab\u00e9tiques de tout \u00e2ge,\npour leur famille, leurs amis et coll\u00e8gues, ainsi que pour l'\u00e9quipe soignante.\nVeiller \u00e0 ce que les soins aux enfants diab\u00e9tiques soient dispens\u00e9s par\ndes personnes et des \u00e9quipes sp\u00e9cialis\u00e9es \u00e0 la fois dans le traitement\ndu diab\u00e8te et des enfants, et que les familles ayant un enfant diab\u00e9tique b\u00e9n\u00e9ficient du soutien social, \u00e9conomique et affectif n\u00e9cessaire.\nRenforcer les centres d'excellence existants pour le traitement du diab\u00e8te, l'\u00e9ducation et la recherche sur le diab\u00e8te. Cr\u00e9er de nouveaux centres\nl\u00e0 o\u00f9 le besoin s'en fait sentir et o\u00f9 le potentiel existe.\nPromouvoir l'ind\u00e9pendance, l'\u00e9galit\u00e9 et l'autonomie pour tous les sujets\ndiab\u00e9tiques - enfants, adolescents, personnes dans la vie active et personnes \u00e2g\u00e9es.\nSupprimer les obstacles \u00e0 l'int\u00e9gration la plus compl\u00e8te possible des\ncitoyens diab\u00e9tiques dans la soci\u00e9t\u00e9.\nMettre en \u0153uvre des mesures efficaces pour pr\u00e9venir les complications co\u00fbteuses :\nG R\u00e9duire d'un tiers ou plus les nouveaux cas de c\u00e9cit\u00e9 dus au diab\u00e8te.\nG R\u00e9duire d'au moins un tiers le nombre de personnes atteignant\nle stade de l'insuffisance r\u00e9nale terminale.\n\nAnnexes\nHaut Comit \u00e9 de la Sant \u00e9 Publique", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2496, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "3b37923b-549f-432d-b007-bd493c2065e6": {"__data__": {"id_": "3b37923b-549f-432d-b007-bd493c2065e6", "embedding": null, "metadata": {"page_label": "87", "file_name": "hc001042.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\hc001042.pdf", "file_type": "application/pdf", "file_size": 237006, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "bc352a85-5a34-4d4a-97c7-67b76e24a6d4", "node_type": "4", "metadata": {"page_label": "87", "file_name": "hc001042.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\hc001042.pdf", "file_type": "application/pdf", "file_size": 237006, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "9e49d20588e94d124c6c3613f55f0fbae6529e1142281f23466e2144ff9a758c", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "73Diab\u00e8tes. Pr\u00e9vention, dispositifs de soins, \u00e9ducation... / Mai 1998\nG R\u00e9duire de moiti\u00e9 le nombre d'amputations dues \u00e0 la gangr\u00e8ne diab\u00e9tique.\nG R\u00e9duire la morbidit\u00e9 et la mortalit\u00e9 dues aux cardiopathies isch\u00e9miques chez les patients diab\u00e9tiques par des programmes \u00e9nergiques de r\u00e9duction des facteurs de risque.\nG Faire en sorte que l'issue de la grossesse, chez la femme diab\u00e9tique, se rapproche de l'issue de la grossesse chez la femme\nnon diab\u00e9tique.\nMettre en place des syst\u00e8mes de contr\u00f4le et de surveillance utilisant\nl'informatique de pointe pour s'assurer de la qualit\u00e9 des soins dispens\u00e9s aux patients diab\u00e9tiques et des analyses de laboratoire, ainsi que\ndes techniques servant au diagnostic, au traitement et \u00e0 l'auto-prise\nen charge du diab\u00e8te.\nPromouvoir la collaboration europ\u00e9enne et internationale au niveau de\nprogrammes de recherche et d\u00e9veloppement sur le diab\u00e8te, par le biais\ndes organismes nationaux, r\u00e9gionaux et des organismes travaillant avec\nl'OMS, en coop\u00e9ration active avec les associations de diab\u00e9tiques.\nIntervenir d'urgence dans l'esprit du programme \u00ab Sant\u00e9 pour tous \u00bb de\nl'OMS pour cr\u00e9er un m\u00e9canisme commun entre l'OMS et l'IDF- R\u00e9gion\neurop\u00e9enne, afin d'entreprendre, d'acc\u00e9l\u00e9rer et de faciliter la mise en\n\u0153uvre de ces recommandations.\nLors de la conclusion de la r\u00e9union de Saint-Vincent, tous les participants\nse sont formellement engag\u00e9s d\u00e8s leur retour dans leurs pays \u00e0 prendre\ndes mesures \u00e9nergiques et r\u00e9solues en vue de la mise en \u0153uvre de ces\nrecommandations.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1510, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "97e36ee8-33f4-46ee-a23d-99b302bcb108": {"__data__": {"id_": "97e36ee8-33f4-46ee-a23d-99b302bcb108", "embedding": null, "metadata": {"page_label": "88", "file_name": "hc001042.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\hc001042.pdf", "file_type": "application/pdf", "file_size": 237006, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "4072f42b-68f6-4a52-8031-6f80911f6710", "node_type": "4", "metadata": {"page_label": "88", "file_name": "hc001042.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\hc001042.pdf", "file_type": "application/pdf", "file_size": 237006, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "eae3326a81acab76b58a7a19fbcdffce61dab5506ec0a4ef8d1b28c3fb6f525d", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 0, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "9d403057-dfd0-4fc2-a55a-3d4edf79b7dc": {"__data__": {"id_": "9d403057-dfd0-4fc2-a55a-3d4edf79b7dc", "embedding": null, "metadata": {"page_label": "89", "file_name": "hc001042.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\hc001042.pdf", "file_type": "application/pdf", "file_size": 237006, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "49dd2f6c-e887-42e8-8e0d-2e128d60528e", "node_type": "4", "metadata": {"page_label": "89", "file_name": "hc001042.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\hc001042.pdf", "file_type": "application/pdf", "file_size": 237006, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "bae0af2c187062bb123e53fb3289434519aaedbcf51927a5633e79a2c5f196ec", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "75Diab\u00e8tes. Pr\u00e9vention, dispositifs de soins, \u00e9ducation... / Mai 1998\nIntroduction\nTABLE DES MATI\u00c8RES\nSaisine V\nAvis du Haut Comit\u00e9 de la sant\u00e9 publique VII\n\nLes diab\u00e8tes 5\nLa maladie 5\nD\u00e9finition 5\nPrincipales complications 8\n\u00c9pid\u00e9miologie des diab\u00e8tes et des complications d\u00e9g\u00e9n\u00e9ratives 10\nLe diab\u00e8te non insulino-d\u00e9pendant 11\nLe diab\u00e8te insulino-d\u00e9pendant 15\nDeux r\u00e9alit\u00e9s distinctes 17\nHistoire et repr\u00e9sentations des diab\u00e8tes 18\nL'histoire m\u00e9dicale 18\nLa p\u00e9riode pr\u00e9chimique 19\nVers la d\u00e9couverte de l'insuline 20\nLes recherches et traitements modernes 21\nLes repr\u00e9sentations 25\nLe terrain \u00e0 l'\u00e9preuve du discours m\u00e9dical 25\nLes repr\u00e9sentations morales du sucre 25\nL'ambivalence de la repr\u00e9sentation subjective 27\nLes trois enjeux des diab\u00e8tes 29\nStructurer et rationaliser les dispositifs de soins sp\u00e9cialis\u00e9s 29\nLa prise en charge du diab\u00e8te en France 30\nL'organisation de la prise en charge 30\nAspects \u00e9conomiques 34\nPrincipaux points forts et points faibles du dispositif\nfran\u00e7ais de soins 39", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1001, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "36103e98-c2d0-4388-8635-dfd41e18721b": {"__data__": {"id_": "36103e98-c2d0-4388-8635-dfd41e18721b", "embedding": null, "metadata": {"page_label": "90", "file_name": "hc001042.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\hc001042.pdf", "file_type": "application/pdf", "file_size": 237006, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "11e84fae-1e34-4e1c-9a58-86837f43a59d", "node_type": "4", "metadata": {"page_label": "90", "file_name": "hc001042.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\hc001042.pdf", "file_type": "application/pdf", "file_size": 237006, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "414444c2125c1ecae08c1209e31c589b56e1af017e30b9bfc87448abec4f039e", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Annexes\nLes dispositifs de soins des autres maladies chroniques 40\nLes crit\u00e8res pour l'\u00e9valuation des dispositifs de soins\ndes autres maladies chroniques 41\nFavoriser une v\u00e9ritable \u00e9ducation du patient 42\nOrigines et \u00e9volutions r\u00e9centes de la d\u00e9marche 43\nLes acteurs et les m\u00e9thodes 45\nL'effort d'institutionnalisation 47\nReconna\u00eetre comme l\u00e9gitime le souhait des patients\nqui revendiquent davantage d'autonomie 48\nL'aspiration \u00e0 un nouveau mod\u00e8le de prise en charge 48\nLes facteurs de renforcement de la nouvelle attitude des\npatients 49\nLes \u00e9volutions pr\u00e9visibles dans le cas des diab\u00e8tes 51\nPropositions 53\nObjectifs d'une politique de sant\u00e9 publique 53\nMesures g\u00e9n\u00e9rales pour le diab\u00e8te et les maladies chroniques 55\nCr\u00e9ation de r\u00e9seaux fonctionnels ou de programmes\nlocaux d'information et de formation 55\nCr\u00e9ation de p\u00f4les r\u00e9gionaux d'excellence 56\nPoursuivre la r\u00e9flexion sur les maladies chroniques 57\nLancement d'un programme de recherche sur l'\u00e9valuation\ndes dispositifs de soins 58\nLa pr\u00e9vention des diab\u00e8tes 58\nRappels sur l'histoire naturelle des diab\u00e8tes 60\nLa pr\u00e9vention au stade des pr\u00e9dispositions 60\nLa pr\u00e9vention au stade de la maladie d\u00e9clar\u00e9e 62\nLa pr\u00e9vention au stade des complications 65\nAnnexe I. Composition du groupe de travail et personnes\nauditionn\u00e9es 69\nAnnexe II. D\u00e9claration de Saint-Vincent 71\n\nTable des mati\u00e8res\nHaut Comit \u00e9 de la Sant \u00e9 Publique", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1380, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "00765553-b1dc-41eb-a676-431fee6285b6": {"__data__": {"id_": "00765553-b1dc-41eb-a676-431fee6285b6", "embedding": null, "metadata": {"page_label": "91", "file_name": "hc001042.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\hc001042.pdf", "file_type": "application/pdf", "file_size": 237006, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "7931f1c4-128f-4709-8056-4bf960d42db7", "node_type": "4", "metadata": {"page_label": "91", "file_name": "hc001042.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\hc001042.pdf", "file_type": "application/pdf", "file_size": 237006, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "87c6d998f756f3eb916619066ac8d1a659ff34a08b1985a324e904a42dd43dc1", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Achev\u00e9 d'imprimer\nsur les presses de Calligraphy Print, Rennes\nMise en page : Buroscope\nD\u00e9p\u00f4t l\u00e9gal : octobre 1998", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 114, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "59784df4-6d43-4d65-8593-c7a2408710cd": {"__data__": {"id_": "59784df4-6d43-4d65-8593-c7a2408710cd", "embedding": null, "metadata": {"page_label": "92", "file_name": "hc001042.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\hc001042.pdf", "file_type": "application/pdf", "file_size": 237006, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "cea44dd8-5338-4c4f-abf9-0e0d213eb9a6", "node_type": "4", "metadata": {"page_label": "92", "file_name": "hc001042.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\hc001042.pdf", "file_type": "application/pdf", "file_size": 237006, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "f5867c23f0da70b9d677bb7b17e3cbddaed43365e1d3044cb4c0035e1ef9dd54", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 0, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "1a96dc00-c419-40a4-a84a-7e0296faa12d": {"__data__": {"id_": "1a96dc00-c419-40a4-a84a-7e0296faa12d", "embedding": null, "metadata": {"page_label": "1", "file_name": "orsoi_chiffres_diabete_reunion_2020.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\orsoi_chiffres_diabete_reunion_2020.pdf", "file_type": "application/pdf", "file_size": 1879778, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "b43fddb6-756b-489a-8670-ace506a7abbb", "node_type": "4", "metadata": {"page_label": "1", "file_name": "orsoi_chiffres_diabete_reunion_2020.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\orsoi_chiffres_diabete_reunion_2020.pdf", "file_type": "application/pdf", "file_size": 1879778, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "dcda86a7d0a21c1d424b0fefcbb387bbd71e2b69961505de276db09b4277cd5c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9c9aaa1d-b8e0-4114-ba64-0b9b4bcc2d0c", "node_type": "1", "metadata": {}, "hash": "6cfc2dada3c7adfc85648770b445f30b34be101bee13341412a74870268ae66f", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Le diab\u00e8te et les personnes diab\u00e9tiques\n\u00e0 La R\u00e9union\nChiffres cl\u00e9s - Edition 2020\n\nCe document est la 4\u00e8me \u00e9dition des chiffres cl\u00e9s sur le diab\u00e8te\n\u00e0 La R\u00e9union, destin\u00e9 aux acteurs de la lutte contre le diab\u00e8te.\nFinanc\u00e9 par l'ARS La R\u00e9union et r\u00e9al is\u00e9 par l'ORS OI en\ncollaboration avec le comit\u00e9 technique de l'observation , i l\npropose une s\u00e9lection d'indicateurs cibl\u00e9s et disponibles sur le\ndiab\u00e8te et les diab\u00e9tiques \u00e0 La R\u00e9union. L'objectif est de\nrassembler et de pr\u00e9senter de mani\u00e8re synth\u00e9tique de s\nchiffres r\u00e9cents, de n ature et d'origine diverses sur la\nfr\u00e9quence de la maladie, la prise en charge des personnes\ndiab\u00e9tiques, la survenue des complications, les co\u00fbts li\u00e9s au\ndiab\u00e8te, ... Les donn\u00e9es sont issues de diff\u00e9rentes sources\nd'informations loca les ou nationales et sont exploit\u00e9es par\ndiff\u00e9rents partenaires. Certaines sources de donn\u00e9es sont\nactualis\u00e9es en routine (annuellement ou tous les 2 \u00e0 3 ans ),\nd'autres sont issues d'enqu\u00eates r\u00e9guli\u00e8res ou ponctuelles.\nEn raison des perturbations li\u00e9es \u00e0 l '\u00e9pid\u00e9mie de Covid -19,\ncertaines donn\u00e9es n'ont pu \u00eatre actualis\u00e9es cette ann\u00e9e.\nCette \u00e9dition int\u00e8gre des chiffres cl\u00e9s sur la fr\u00e9quence de la\nmaladie, la prise en charge et la surveillance des patients, les\ncomplications et les f acteurs de risque mais au ssi des zooms\navec des donn\u00e9es sp\u00e9cifiques : r\u00e9sultats d'\u00e9tudes sur la\npr\u00e9valence et l'incidence du diab\u00e8te trait\u00e9, le parcours des\npatients diab\u00e9tiques, le plan r\u00e9gional, les dis positifs de prise\nen charge, de pr\u00e9vention et d'observation, la covid 19, ...\nMerci aux partenaires pour leur contribution \u00e0 ce travail.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1601, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "9c9aaa1d-b8e0-4114-ba64-0b9b4bcc2d0c": {"__data__": {"id_": "9c9aaa1d-b8e0-4114-ba64-0b9b4bcc2d0c", "embedding": null, "metadata": {"page_label": "1", "file_name": "orsoi_chiffres_diabete_reunion_2020.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\orsoi_chiffres_diabete_reunion_2020.pdf", "file_type": "application/pdf", "file_size": 1879778, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "b43fddb6-756b-489a-8670-ace506a7abbb", "node_type": "4", "metadata": {"page_label": "1", "file_name": "orsoi_chiffres_diabete_reunion_2020.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\orsoi_chiffres_diabete_reunion_2020.pdf", "file_type": "application/pdf", "file_size": 1879778, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "dcda86a7d0a21c1d424b0fefcbb387bbd71e2b69961505de276db09b4277cd5c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1a96dc00-c419-40a4-a84a-7e0296faa12d", "node_type": "1", "metadata": {"page_label": "1", "file_name": "orsoi_chiffres_diabete_reunion_2020.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\orsoi_chiffres_diabete_reunion_2020.pdf", "file_type": "application/pdf", "file_size": 1879778, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "26af557806f1b63df914b5e0551bbf1fdc62bfd0eec2f181bea8ce2688083d5f", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Sommaire\n\nUne maladie fr\u00e9quente \u00e0 La R\u00e9union ...................................... 1\nLa prise en charge des patients diab\u00e9tiques par le syst\u00e8me de\nsant\u00e9 en 2018 .......................................................................... 2\nZOOM : Evolution de la pr\u00e9valence et de l'incidence du\ndiab\u00e8te de type 2 (DT2) trait\u00e9 pharmacologiquement en\nFrance entre 2010 et 2017 ...................................................... 3\nUne surveillance n\u00e9cessaire pour la prise en charge des\npatients diab\u00e9tiques ................................................................ 4\nUne prise en charge essentielle pour r\u00e9duire les risques de\ncomplications .......................................................................... 5\nZOOM : Parcours de soins des patients diab\u00e9tiques\nr\u00e9unionnais mis en traitement en 2010 .................................. 6\nDes facteurs de risque bien pr\u00e9sents sur l'\u00eele .......................... 7\nZOOM : Le diab\u00e8te, une priorit\u00e9 r\u00e9gionale de sant\u00e9 ............... 8\nLe diab\u00e8te, \u00ab \u00e7a se prend en charge \u00bb ..................................... 9\nLe diab\u00e8te, \u00ab \u00e7a se pr\u00e9vient \u00bb ................................................ 10\nLe diab\u00e8te, \u00ab \u00e7a s'observe \u00bb .................................................. 10\nDiab\u00e8te et Covid-19 ............................................................... 11\nM\u00e9thodologie ........................................................................ 13\nL'essentiel ......................................................................... 14\n\nUne maladie fr\u00e9quente \u00e0 La R\u00e9union\n\nIl est difficile de conna\u00eetre pr\u00e9cis\u00e9ment le n ombre de personnes diab\u00e9tiques dans la population r\u00e9unionnaise. Les donn\u00e9es des bases\nm\u00e9dico-administratives permettent uniquement de rep\u00e9rer les personnes diab\u00e9tiques prises en charge par le syst\u00e8me de sant\u00e9.\n\nRemarques : Les patients pris en charge pour diab\u00e8te sont ceux hospitalis\u00e9s et/ou en ALD et/ou ayant un traitement m\u00e9dicamenteux pour un diab\u00e8te (de type\n1 ou de type 2). Sont prises en compte uniquement les donn\u00e9es du R\u00e9gime G\u00e9n\u00e9ral et des sections mutualistes (cf. m\u00e9thodologie en ).\nSources : SNIIRAM/SNDS (Cartographies des pathologies et des d\u00e9penses) - Exploitation Assurance Maladie ; Statistiques ALD - Exploitation Assurance\nmaladie (DRSM R\u00e9union) ; PMSI (ATIH) - Exploitation ORS OI", "mimetype": "text/plain", "start_char_idx": 1602, "end_char_idx": 3894, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "9b5e1659-3d32-434f-ba73-b3b92206288c": {"__data__": {"id_": "9b5e1659-3d32-434f-ba73-b3b92206288c", "embedding": null, "metadata": {"page_label": "2", "file_name": "orsoi_chiffres_diabete_reunion_2020.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\orsoi_chiffres_diabete_reunion_2020.pdf", "file_type": "application/pdf", "file_size": 1879778, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "73db6c07-77c0-4cab-a4ba-0bd3750cb631", "node_type": "4", "metadata": {"page_label": "2", "file_name": "orsoi_chiffres_diabete_reunion_2020.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\orsoi_chiffres_diabete_reunion_2020.pdf", "file_type": "application/pdf", "file_size": 1879778, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "17c3171f7f1a26548fc24b8ba79620dbbafe324b3e9e237c4cd31b83afdbc33f", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "La prise en charge des patients diab\u00e9tiques par le syst\u00e8me de sant\u00e9 en 2018\n\nEvolution annuelle \u00e0 La R\u00e9union et comparaisons en 2018\n\nRemarques : Les patients pris en charge pour diab\u00e8te sont ceux hospitalis\u00e9s et/ou en ALD et/ou ayant un traitement m\u00e9dicamenteux pour un diab\u00e8te (de type\n1 ou de type 2). Sont prises en compte uniquement les donn\u00e9es du R\u00e9gime G\u00e9n\u00e9ral et des sections mutualistes (cf. m\u00e9thodologie en ).\nSource : SNIIRAM/SNDS, cartographie des pathologies et des d\u00e9penses - Exploitation Assurance Maladie\n\nCaract\u00e9ristiques des patients diab\u00e9tiques r\u00e9unionnais pris en charge en 2018\n\n2 500 personnes diab\u00e9tiques de moins de 35 ans\n\nSource : SNIIRAM/SNDS, cartographie des pathologies et des d\u00e9penses - Exploitation Assurance Maladie\n\nD\u00e9penses rembours\u00e9es pour la prise en charge du diab\u00e8te en France en 2018\n\nSource : SNIIRAM/SNDS, cartographie des pathologies et des d\u00e9penses - Exploitation Assurance Maladie\nEnfants et adolescents de moins de 15 ans\n0,2 %\n(200 patients)\nNational : 0,4%\nLes 15-64 ans\n54,5 %\n(38 800 patients)\nNational : 38,7%\nLes 65 ans et +\n45,2 %\n(32 200 patients)\nNational : 60,9%\n\nL'augmentation ne refl\u00e8te pas n\u00e9cessairement une hausse de la fr\u00e9quence du diab\u00e8te dans la population r\u00e9unionnaise.\nD'autres explications peuvent \u00ea tre envisag\u00e9es : meilleur d\u00e9pistage, augmentation des patients inscrits en ALD, et/ou\nhospitalis\u00e9s et/ou trait\u00e9s, r\u00e9entr\u00e9es dans le parcours, ...\n\nX 2\nLa fr\u00e9quence r\u00e9gionale des patients\npris en charge pour diab\u00e8te est 2 fois\nplus \u00e9lev\u00e9e que la moyenne nationale\nLa R\u00e9union : fr\u00e9quence de patients pris\nen charge la plus \u00e9lev\u00e9e des r\u00e9gions\nfran\u00e7aises (en tenant compte des\neffets li\u00e9s \u00e0 l'\u00e2ge)\nLe nombre de\npatients pris en\ncharge augmente", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1707, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "8f175936-b754-4705-be8e-2658a24f8a53": {"__data__": {"id_": "8f175936-b754-4705-be8e-2658a24f8a53", "embedding": null, "metadata": {"page_label": "3", "file_name": "orsoi_chiffres_diabete_reunion_2020.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\orsoi_chiffres_diabete_reunion_2020.pdf", "file_type": "application/pdf", "file_size": 1879778, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "9877bf10-b115-48fe-8c2e-66c629be8f75", "node_type": "4", "metadata": {"page_label": "3", "file_name": "orsoi_chiffres_diabete_reunion_2020.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\orsoi_chiffres_diabete_reunion_2020.pdf", "file_type": "application/pdf", "file_size": 1879778, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "39d60ea5351cb79572b840dafe39a67e30097ca966c2dbd839b1606069da84cb", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Evolution de la pr\u00e9va lence et de l'incidence du diab\u00e8te de type 2\n(DT2) trait\u00e9 pharmacologiquement en France entre 2010 et 2017\n\nFace au manque de donn\u00e9es sur l'\u00e9volution de l'incidence et de la pr\u00e9valence du diab\u00e8te en France, une \u00e9tude nationale a\n\u00e9t\u00e9 r\u00e9alis\u00e9e, gr\u00e2ce aux donn\u00e9es du Syst\u00e8me National des Donn\u00e9es en Sant\u00e9 (SNDS), pour :\n- d\u00e9terminer les taux de pr\u00e9valence et d'incidence du diab\u00e8te de type 2 (DT2) entre 2010 et 2017,\n- \u00e9valuer les tendances annuelles de la pr\u00e9valence et de l'incidence du diab\u00e8te de type 2 sur cette p \u00e9riode.\nLes analyses ont port\u00e9 sur les patients diab\u00e9tiques de type 2 trait\u00e9s pharmocologiquement , de 45 ans ou plus, identifi\u00e9s \u00e0\npartir d'un algorithme valid\u00e9 utilisant les donn\u00e9es de remboursement des antidiab\u00e9tiques. Les r\u00e9sultats ont \u00e9t\u00e9 analys\u00e9s\nselon le sexe, l'\u00e2ge et la r\u00e9gion.\n\nPr\u00e9valence du DT2 plus \u00e9lev\u00e9e \u00e0 La R\u00e9union et dans les autres DROM\n\nPr\u00e9valence standardis\u00e9e (sur l'\u00e2ge)* du DT2 en France en 2017 chez les hommes et les femmes \u00e2g\u00e9es de 45 ans et +, selon la r\u00e9gion\n\nSource : Fuentes S, et al. Is the type 2 diabetes epidemic plateauing in France ? A nationwide population-bases study. Diabetes Metab (2020).\n\nL\u00e9g\u00e8re hausse de la pr\u00e9valence et baisse de l'incidence du DT2 en France, avec des\ndisparit\u00e9s r\u00e9gionales entre 2010 et 2017\n\nUne baisse de l'incidence du DT2 plus marqu\u00e9e \u00e0 La R\u00e9union entre 2010 et 2017\n\nLes indicateurs r\u00e9gionaux indiquent une baisse annuelle plus importante de\nl'incidence du diab\u00e8te de type 2 \u00e0 La R\u00e9union par rapport \u00e0 l'\u00e9volution nationale,\nquel que soit le sexe.\nCette tendance est encourageante au regard de l'ensemble des actions men\u00e9es\npar les acteurs locaux sur le territoire depuis plusieurs ann\u00e9es p our la lutte\ncontre le diab\u00e8te.\n\nPour en savoir plus : Fuentes S, et al. Is the type 2 diabetes epidemic plateauing in France ? A nationwide population-bases study. Diabetes\nMetab (2020).", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1885, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "53daa564-9ef3-4b74-b93a-9703503803d9": {"__data__": {"id_": "53daa564-9ef3-4b74-b93a-9703503803d9", "embedding": null, "metadata": {"page_label": "4", "file_name": "orsoi_chiffres_diabete_reunion_2020.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\orsoi_chiffres_diabete_reunion_2020.pdf", "file_type": "application/pdf", "file_size": 1879778, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "4f3c95a1-4cfb-4d75-a2d9-fe8c5a33863d", "node_type": "4", "metadata": {"page_label": "4", "file_name": "orsoi_chiffres_diabete_reunion_2020.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\orsoi_chiffres_diabete_reunion_2020.pdf", "file_type": "application/pdf", "file_size": 1879778, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "2dd0e397f5fe6aaed5b39ced745c9de32750ee2167dd47c27b3d40aa9539dd94", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Une surveillance n\u00e9cessaire pour la prise en charge des patients diab\u00e9tiques\nDes recommandations de suivi ont \u00e9t\u00e9 \u00e9labor\u00e9es par la Haute Autorit\u00e9 de Sant\u00e9 (HAS)\n\nLes parcours des patients\ndiab\u00e9tiques souvent en \u00e9cart\navec l es recommandations\nde suivi de la maladie\n\nMais u ne surveillance\nsup\u00e9rieure aux objectifs de\nsuivi (80% des diab\u00e9tiques)\npour la cr\u00e9atinine et les\nlipides\n\nUn suivi d es patients qui\ns'am\u00e9liore entre 2016 et\n\nDes indicateurs de suivi des\npatients diab\u00e9tiques\nmeilleurs sur le territoire\npour certains crit\u00e8res de\nsurveillance\n\nFr\u00e9quence de suivi des examens recommand\u00e9s parmi les patients trait\u00e9s\npharmacologiquement en 2019 \u00e0 La R\u00e9union\n\nEvolution de la fr\u00e9quence de suivi des examens recommand\u00e9s parmi les patients\ntrait\u00e9s pharmacologiquement \u00e0 La R\u00e9union entre 2016 et 2019\n\nPart des patients trait\u00e9s pharmacologiquement en 2019 avec le suivi\nrecommand\u00e9* \u00e0 La R\u00e9union et en France\n\n>= 1 dosage de cr\u00e9atinine\n>= 1 dosage des lipides\n>= 1 consultation ophtalmologique\nDans les 2 ann\u00e9es\n>= 1 dosage de la microalbuminurie\nDans l'ann\u00e9e\n>= 3 dosages de l'HbA1c\n>= 1 consultation cardiologie ou ECG\n>= 1 consultation dentaire\nObjectif de suivi respect\u00e9 :\n8 patients sur 10\nUn suivi \u00e0 renforcer pour\natteindre l'objectif de suivi\n8 patients sur 10\n\n0 20 40 60 80 100\n>= 1 cons. dentaire\n>=1 cons. cardiologie ou ECG\n>=3 dosages HbA1c\n>=1 dosage de la microalbuminurie\n>= 1cons. d'ophtalmologie/2 ans\n>=1 dosage des lipides\n>=1 dosage de cr\u00e9atinine\n2019 2016\n\n0 20 40 60 80 100\n>= 1 cons. dentaire\n>=1 cons. cardiologie ou ECG\n>=3 dosages HbA1c\n>=1 dosage de la microalbuminurie\n>= 1cons. d'ophtalmologie/2 ans\n>=1 dosage des lipides\n>=1 dosage de cr\u00e9atinine\nR\u00e9union France", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1693, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "38855a54-ddd0-4b91-a2ae-1a172f92a19f": {"__data__": {"id_": "38855a54-ddd0-4b91-a2ae-1a172f92a19f", "embedding": null, "metadata": {"page_label": "5", "file_name": "orsoi_chiffres_diabete_reunion_2020.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\orsoi_chiffres_diabete_reunion_2020.pdf", "file_type": "application/pdf", "file_size": 1879778, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "2b56d50e-f6b5-474e-abfd-b06218e34944", "node_type": "4", "metadata": {"page_label": "5", "file_name": "orsoi_chiffres_diabete_reunion_2020.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\orsoi_chiffres_diabete_reunion_2020.pdf", "file_type": "application/pdf", "file_size": 1879778, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "95ad371b65f05be30ad8a4794991d3db5324f2d50844a199152e2d444c20210f", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Une prise en charge essentielle pour r\u00e9duire les risques de complications\nUn diab\u00e8te non suivi peut causer de graves complications de sant\u00e9\n\nLe diab\u00e8te non suivi peut provoquer des cons\u00e9quences graves sur la sant\u00e9 des patients, avec un impact dommageable sur\nplusieurs organes du corps, principalement : les reins (n\u00e9phropathie), les yeux (r\u00e9tinopathie), le syst\u00e8me neurologique\n(neuropathie), le c\u0153ur (infarctus), les vaisseaux sanguins (hypertension, art\u00e9rioscl\u00e9rose, accident vasculaire c\u00e9r\u00e9bral [AVC],\netc.), ...Un bon contr\u00f4le du diab\u00e8te r\u00e9duit les complications \u00e0 long terme.\nChaque ann\u00e9e, des patients diab\u00e9tiques sont concern\u00e9s par les complications graves et fr\u00e9quentes li\u00e9es \u00e0 leur diab\u00e8te.\n\nPr\u00e8s d'un millier de personnes diab\u00e9tiques sont dialys\u00e9es \u00e0 La R\u00e9union en 2018\n\nSource : Registre REIN / Agence de la biom\u00e9decine\n\nLes AVC et les plaies du pied, complications les\nplus fr\u00e9quentes chez les patients diab\u00e9tiques\ntrait\u00e9s pharmacologiquement en 2019\n\nNombre de patients diab\u00e9tiques trait\u00e9s pharmacologiquement\nhospitalis\u00e9s en 2019 selon la complication\n\n*Taux brut d'incidence des complications\n\nLes patients diab\u00e9tiques r\u00e9unionnais plus\nconcern\u00e9s par les complications r\u00e9nales (x 1,7),\nles AVC (x 1,5) et les amputations (x 1,1) par\nrapport \u00e0 la situation nationale\n(en tenant compte des effets li\u00e9s \u00e0 l'\u00e2ge)\n\nLe diab\u00e8te cause un d\u00e9c\u00e8s\ntous les 1,5 jours\n\nLes d\u00e9c\u00e8s directement li\u00e9s au diab\u00e8te\n(p\u00e9riode 2014-2016)\n\n20% des d\u00e9c\u00e8s sont pr\u00e9 matur\u00e9s\n(avant 65 ans) : soit 50 d\u00e9c\u00e8s en\nmoyenne chaque ann\u00e9e\n\nLes hommes 2 fois plus concern\u00e9s\npar la mortalit\u00e9 pr\u00e9matur\u00e9e\n\nUne mortalit\u00e9 3 fois plus \u00e9lev\u00e9e sur\nl'\u00eele par rapport \u00e0 la m\u00e9tropole (4\nfois plus pour les d\u00e9c\u00e8s pr\u00e9matur\u00e9s)\n\nUne mortalit\u00e9 en baisse\n\nSource : SNIIRAM/SNDS - Exploitation Sant\u00e9 publique France (m\u00e9thodologie en p13) Source : Inserm c\u00e9pidc\n\nd\u00e9c\u00e8s directement dus au diab\u00e8te (comas\nou d\u00e9com pensation aigue) en moyenne\npar an (p\u00e9riode 2014-2016)6", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1924, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "56db9ce1-2859-4e3a-914d-1f5d40fc3d69": {"__data__": {"id_": "56db9ce1-2859-4e3a-914d-1f5d40fc3d69", "embedding": null, "metadata": {"page_label": "6", "file_name": "orsoi_chiffres_diabete_reunion_2020.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\orsoi_chiffres_diabete_reunion_2020.pdf", "file_type": "application/pdf", "file_size": 1879778, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "e93cbc83-a580-4625-87e6-17f9db8913be", "node_type": "4", "metadata": {"page_label": "6", "file_name": "orsoi_chiffres_diabete_reunion_2020.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\orsoi_chiffres_diabete_reunion_2020.pdf", "file_type": "application/pdf", "file_size": 1879778, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "49adeef016bacb0129b725a48e03b089324c83367637734b9593a4eb84ba367d", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Parcours de soins des patients diab\u00e9tiques r\u00e9unionnais mis en\ntraitement en 2010\n\nUne \u00e9tude a \u00e9t\u00e9 r\u00e9alis\u00e9e par l'ARS, l'Assur ance Maladie et l'ORS pour d\u00e9crire la prise en charge sur 8 ans des personnes\navec une mise sous traitement antidiab\u00e9tique en 2010 \u00e0 La R\u00e9union o\u00f9 la pr\u00e9valence du diab\u00e8te et de ses complications est\nimportante. A partir des bases m\u00e9dico -administratives du SNDS (Syst\u00e8me National des Donn\u00e9es de Sant\u00e9), les b\u00e9n\u00e9ficiaires\nadultes (>= 18 ans), affili\u00e9s \u00e0 une caisse d'Assurance Maladie \u00e0 La R\u00e9union, ayant eu un remboursement d'au moins 3\nantidiab\u00e9tiques \u00e0 des dates diff\u00e9rentes, ont \u00e9t\u00e9 s\u00e9lectionn\u00e9s. Les caract\u00e9r istiques sociod\u00e9mographiques, la nature des\ntraitements antidiab\u00e9tiques, les examens de suivi m\u00e9dicaux et biologiques recommand\u00e9s, et les complications ont \u00e9t\u00e9\nexplor\u00e9s. Ces donn\u00e9es ont \u00e9t\u00e9 compar\u00e9es \u00e0 l'\u00e9chantillon national (EGB).\n\nDes parcours r\u00e9els en \u00e9cart avec le parcours \u00ab recommand\u00e9 \u00bb\nDes ruptures \u00e0 diff\u00e9rents niveaux et moments\n\nSource : Etude \u00ab parcours de soins des patients mis sous traitement antidiab\u00e9tique en 2010 \u00e0 La R\u00e9union \u00bb (ARS/Assurance Maladie/ORS)\nTTT : traitement\n\nSurvenue pr\u00e9coce des complications\n1 patient sur 2 avec au moins une complication apr\u00e8s 8 ans de parcours\n\nSource : Etude \u00ab parcours de soins des patients mis sous traitement antidiab\u00e9tique en 2010 \u00e0 La R\u00e9union \u00bb (ARS/Assurance Maladie/ORS)\n* Suivi d\u00e9fini selon le nombre de consultations trimestrielles r\u00e9alis\u00e9es chez le m\u00e9decin traitant (recommandation HAS)\nAVC\n4%\nPlaies du\npied\n7%\nIdM\n6%\nAmputations\n2%\nLes principales complications observ\u00e9es au bout de 8 ans\nLa R\u00e9union affiche\nune sur-fr\u00e9quence\ndes amputations et\ndes AVC par rapport\nau niveau national\nX 2,4\nPour les\namputations\nX 1,5\nPour les\nAVC\nR\u00f4le primordial du m\u00e9decin traitant dans le suivi\nUn moindre suivi m\u00e9dical et biologique lorsque\nles consultations chez le m\u00e9decin traitant ne sont\npas r\u00e9guli\u00e8res\nUne fr\u00e9quence des AVC et des amputations plus \u00e9lev\u00e9e\nchez les patients moins bien suivis*\nMeilleur d\u00e9pistage des plaies du pied et de l'infarctus du\nmyocarde chez les patients bien suivis*\n\n\uf0e0Un diagnostic, r\u00e9alis\u00e9 plus t\u00f4t, permet de pr\u00e9venir de\nplus grandes complications", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2171, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "bdac0e30-3193-41bb-a0f4-2368c015a1e7": {"__data__": {"id_": "bdac0e30-3193-41bb-a0f4-2368c015a1e7", "embedding": null, "metadata": {"page_label": "7", "file_name": "orsoi_chiffres_diabete_reunion_2020.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\orsoi_chiffres_diabete_reunion_2020.pdf", "file_type": "application/pdf", "file_size": 1879778, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "ad56a9c0-aa40-4727-bf9e-6b8ca39bdf10", "node_type": "4", "metadata": {"page_label": "7", "file_name": "orsoi_chiffres_diabete_reunion_2020.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\orsoi_chiffres_diabete_reunion_2020.pdf", "file_type": "application/pdf", "file_size": 1879778, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "7d2001aa97dae90348d3e22497abdfd753467d999da23cb0db8d910e2a8e7029", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Des facteurs de risque bien pr\u00e9sents sur l'\u00eele\nUne maladie et des complications souvent \u00e9vitables en agissant sur les comportements\nLes facteurs de risque favorisant l'apparition et le d\u00e9veloppement du diab\u00e8te (de type 2) sont divers : surpoids, s\u00e9dentarit\u00e9,\ntabac, alcool, cholest\u00e9rol, hypertension, ...Tous ces facteurs peuvent troubler l'\u00e9quilibre glyc\u00e9mique et \u00eatre \u00e9galement \u00e0\nl'origine de complications du diab\u00e8te.\n\nUne surcharge pond\u00e9rale fr\u00e9quente, des comportements nutritionnels \u00e9loign\u00e9s des\nrecommandations\n\nSource : Barom\u00e8tre Sant\u00e9 Dom 2014 (Sant\u00e9 publique France, ex Inpes)\n\nDes prises en charges de l'ob\u00e9sit\u00e9 en augmentation, en particulier chez les femmes\n\nSurcharge pond\u00e9rale (surpoids +\nob\u00e9sit\u00e9)\n4 personnes sur 10\nSituation d'ob\u00e9sit\u00e9\n1 personne sur 10\n(14% des femmes vs 8% des hommes)\nMoins de 5 fruits et l\u00e9gumes / jour\n9 personne sur 10\n(93% des 15-25 ans vs 89% des 50 ans et +)\nDes sodas tous les jours\n3 personnes sur 10\n(30% des 15-25 ans vs 10% des 50 ans et +)\nPas d'activit\u00e9 physique r\u00e9guli\u00e8re\n6 personnes sur 10\n(63% des femmes vs 55% des hommes)\nAbsence d'activit\u00e9 physique\n1 personne sur 10\n(14% des femmes vs 8% des hommes)", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1155, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "55a73f66-6d2a-4a61-b5e2-6a24266d1fd5": {"__data__": {"id_": "55a73f66-6d2a-4a61-b5e2-6a24266d1fd5", "embedding": null, "metadata": {"page_label": "8", "file_name": "orsoi_chiffres_diabete_reunion_2020.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\orsoi_chiffres_diabete_reunion_2020.pdf", "file_type": "application/pdf", "file_size": 1879778, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "1696972d-c8a4-41ab-b5ef-0228bb2b3856", "node_type": "4", "metadata": {"page_label": "8", "file_name": "orsoi_chiffres_diabete_reunion_2020.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\orsoi_chiffres_diabete_reunion_2020.pdf", "file_type": "application/pdf", "file_size": 1879778, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "dde34d779610541c4742369207b1a7c72f5626889d64cfa35090bc3bee97ab79", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ee95ff2b-bbaa-4b34-985e-30e5ae959727", "node_type": "1", "metadata": {}, "hash": "37d5a0347edc0cd4dcb5aa91b2e44f00680bb5ddd984774591d94b5672ab074c", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Le diab\u00e8te, une priorit\u00e9 r\u00e9gionale de sant\u00e9\nLe Programme R\u00e9unionnais de Nutrition et de lutte contre le Diab\u00e8te (PRND)\n\nLe 6 novembre 2020, l'ARS La R\u00e9union et 12 partenaires (Acad\u00e9mie de La R\u00e9union , DAAF, DJSCS, R\u00e9gion, Conseil\nD\u00e9partemental, Association des maires, Assurance Maladie, Mutualit\u00e9 de La R\u00e9union, Tip@sant\u00e9 (inter URPS), SEDMER, CIC\nR\u00e9union, France Assos Sant\u00e9), s e sont engag\u00e9s pour les 3 ann\u00e9es \u00e0 venir dans le Programme R\u00e9unionnais de N utrition et de\nlutte contre le Diab\u00e8te (PRND).\nLe PRND a l'ambition d'agir sur les habitudes de vie de la population (alimentation et activit\u00e9 physique), et d'am\u00e9liorer les\nsoins apport\u00e9s aux personnes diab\u00e9tiques (d\u00e9pistage, diagnostic, parcours de soins).\nCette nouvelle feuille de route s'appuie sur les travaux des partenaires lors de la conf\u00e9rence de consensus du diab\u00e8te en\n2016 et du s\u00e9minaire diab\u00e8te en 2018 mais aussi sur les r\u00e9sultats de l'\u00e9tude des parcours de soins des patients diab\u00e9tiques \u00e0\nLa R\u00e9union, d\u00e9crivant la prise en charge de 3 597 patients diab\u00e9tiques mis sous traitement en 2010 et suivis pendant 8 ans ,\nde 2010 \u00e0 2018 (Cf. r\u00e9sultats p6).\n\nLe Programme R\u00e9unionnais de Nutrition et de lutte\ncontre le Diab\u00e8te (PRND) 2020-2023\nLe plan d'actions associant 13 signataires a \u00e9t\u00e9 d\u00e9fini avec les acteurs de\nsant\u00e9 et de pr\u00e9vention et les repr\u00e9sentants de patients. C'est la nouvelle\nfeuille de route partag\u00e9e, marquant l'accentuation n\u00e9cessaire de l'action\npublique sur un probl\u00e8me majeur de sant\u00e9 publique pour notre territoire.\n\nLe PRND : 3 d\u00e9fis, 5 objectifs\n\nLe PRND r\u00e9pond \u00e0 3 d\u00e9fis :\n- R\u00e9duire les facteurs de risque par des programmes de pr\u00e9vention\n- D\u00e9pister pr\u00e9cocement au stade de pr\u00e9-diab\u00e8te\n- Traiter conform\u00e9ment aux recommandations de parcours pour r\u00e9duire les complications.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1766, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "ee95ff2b-bbaa-4b34-985e-30e5ae959727": {"__data__": {"id_": "ee95ff2b-bbaa-4b34-985e-30e5ae959727", "embedding": null, "metadata": {"page_label": "8", "file_name": "orsoi_chiffres_diabete_reunion_2020.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\orsoi_chiffres_diabete_reunion_2020.pdf", "file_type": "application/pdf", "file_size": 1879778, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "1696972d-c8a4-41ab-b5ef-0228bb2b3856", "node_type": "4", "metadata": {"page_label": "8", "file_name": "orsoi_chiffres_diabete_reunion_2020.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\orsoi_chiffres_diabete_reunion_2020.pdf", "file_type": "application/pdf", "file_size": 1879778, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "dde34d779610541c4742369207b1a7c72f5626889d64cfa35090bc3bee97ab79", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "55a73f66-6d2a-4a61-b5e2-6a24266d1fd5", "node_type": "1", "metadata": {"page_label": "8", "file_name": "orsoi_chiffres_diabete_reunion_2020.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\orsoi_chiffres_diabete_reunion_2020.pdf", "file_type": "application/pdf", "file_size": 1879778, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "4e7e967241fc1d09456103faa7a45fbaf179ec1d870cea1e076cba3ff8b2be42", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Le PRND : 3 d\u00e9fis, 5 objectifs\n\nLe PRND r\u00e9pond \u00e0 3 d\u00e9fis :\n- R\u00e9duire les facteurs de risque par des programmes de pr\u00e9vention\n- D\u00e9pister pr\u00e9cocement au stade de pr\u00e9-diab\u00e8te\n- Traiter conform\u00e9ment aux recommandations de parcours pour r\u00e9duire les complications.\n\nLe PRND porte 5 objectifs :\n\nPour t\u00e9l\u00e9charger le PRND et sa synth\u00e8se :\nOBJECTIF N\u00b05 : COMMUNICATION ET PARTAGE DE DONNEES\nAm\u00e9liorer la communication sur les donn\u00e9es \u00e9pid\u00e9miologiques relatives au diab\u00e8te et sur la pr\u00e9vention ainsi que sur le\nparcours de soins\n\nOBJECTIF N\u00b04 : OBSERVATION DU DIABETE\nProduire des donn\u00e9es d'observation du diab\u00e8te et de ses complications et partager les donn\u00e9es de connaissance avec les\npatients et professionnels \u00e0 des fins de d\u00e9cision\n\nOBJECTIF N\u00b03 : PARCOURS DE SOINS DES PATIENTS DIABETIQUES\nAm\u00e9liorer la qualit\u00e9 du parcours de soins des patients diab\u00e9tiques afin de diminuer la survenue des complications\n\nOBJECTIF N\u00b02 : REPERAGE ET DEPISTAGE DU PRE-DIABETE ET DU DIABETE\nMettre en \u0153uvre une strat\u00e9gie de d\u00e9pistage du pr\u00e9 -diab\u00e8te et du diab\u00e8te et am\u00e9liorer l'orientation des patients vers les\ndispositifs de pr\u00e9vention et de soins existants\n\nOBJECTIF N\u00b01 : PREVENTION DU DIABETE/ACTIONS DE SANTE NUTRITIONNELLE\nAgir sur les facteurs de risque du diab\u00e8te et de l'ob\u00e9sit\u00e9", "mimetype": "text/plain", "start_char_idx": 1508, "end_char_idx": 2773, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "33953426-f367-47d2-8cb9-63672f453ef8": {"__data__": {"id_": "33953426-f367-47d2-8cb9-63672f453ef8", "embedding": null, "metadata": {"page_label": "9", "file_name": "orsoi_chiffres_diabete_reunion_2020.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\orsoi_chiffres_diabete_reunion_2020.pdf", "file_type": "application/pdf", "file_size": 1879778, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "e438cf8e-2226-4f9a-9a0d-22a5a48dae2b", "node_type": "4", "metadata": {"page_label": "9", "file_name": "orsoi_chiffres_diabete_reunion_2020.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\orsoi_chiffres_diabete_reunion_2020.pdf", "file_type": "application/pdf", "file_size": 1879778, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "f42cffbb5de45e574cbd1c732ae8d75f28643cb02ba0ad22ef90ea833dcd67b6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e1f0804f-a666-4753-8b26-578f03431413", "node_type": "1", "metadata": {}, "hash": "ed48d96ce750295eee15684a942ce3f613f124c9c0d995a6320af594d5f3d3ce", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Le diab\u00e8te, \u00ab \u00e7a se prend en charge \u00bb\nDes dispositifs existent pour accompagner les personnes diab\u00e9tiques, pour trouver des\nsolutions afin d'\u00e9viter les ruptures de soins\n\nCe document n'a pas vocation \u00e0 recenser de mani\u00e8re exhaustive les actions de prise en charge du diab\u00e8te. L'objectif\nest de faire des zooms sur des actions innovantes ou r\u00e9gionales.\n\nSource : SOPHIA / DRSM R\u00e9union\n\nSource ARS La R\u00e9union Source : UCEP 2.0\nSOPHIA : un service pour accompagner les malades chroniques\n\nSOPHIA est le service d'accompagnement des malades chroniques de l'Assurance Maladie. Il aide les patients \u00e0 mieux\nconna\u00eetre leur maladie (asthme, diab\u00e8te) et \u00e0 adapter leurs habitudes. L'obj ectif est d'am\u00e9liorer la qualit\u00e9 de vie des\npatients tout en limitant les risques de complication.\n\nAu 01/10/2020 :\n\n11 500 patients\navaient adh\u00e9r\u00e9 au service SOPHIA.\n\nChaque ann\u00e9e, le dispositif SOPHIA identifie des publics\nprioritaires par rapport \u00e0 des crit\u00e8res d'\u00e9cart aux soins.\nEn 2018, le public prioritaire \u00e9tait d\u00e9fini comme les patients\n\u00e9ligibles n'ayant pas r\u00e9alis\u00e9 les 3 examens de suivi des yeux,\ndes reins et des dents recommand\u00e9s sur 2017. A noter que\nla s\u00e9lection des \u00e9carts aux soi ns change d'ann\u00e9e en ann\u00e9e\npour d\u00e9finir le public cible au regard des r\u00e9sultats d'une part\net dans le but d'\u00e9largir la cible. Sur l'ann\u00e9e 2018 :\n\n580 nouvelles adh\u00e9sions au dispositif SOPHIA Diab\u00e8te\n\uf0e0 358 consid\u00e9r\u00e9s en public prioritaire (62%)\n\nLe programme d'Education Th\u00e9rapeutique du Patient (ETP)\n\nL'\u00e9ducation th\u00e9rapeutique du patient est une m\u00e9thode\nde sensibilisation, d'information et d'apprentissage qui\nest propos\u00e9e aux patients afin de mieux comprendre leur\nmaladie chronique, d'agir et de r\u00e9soudre les difficult\u00e9s au\nquotidien.\nA La R\u00e9union, 10 programmes d'ETP sont autoris\u00e9s sur\nle diab\u00e8te par l'Agence de sant\u00e9 (ARS).\n\nEn 2020, parmi les programmes d'ETP autoris\u00e9s par l'ARS :\n\nUne vingtaine d'autres programme s concernent les\nmaladies nutritionnelles, cardiovasculaires ou r\u00e9nales.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1974, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "e1f0804f-a666-4753-8b26-578f03431413": {"__data__": {"id_": "e1f0804f-a666-4753-8b26-578f03431413", "embedding": null, "metadata": {"page_label": "9", "file_name": "orsoi_chiffres_diabete_reunion_2020.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\orsoi_chiffres_diabete_reunion_2020.pdf", "file_type": "application/pdf", "file_size": 1879778, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "e438cf8e-2226-4f9a-9a0d-22a5a48dae2b", "node_type": "4", "metadata": {"page_label": "9", "file_name": "orsoi_chiffres_diabete_reunion_2020.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\orsoi_chiffres_diabete_reunion_2020.pdf", "file_type": "application/pdf", "file_size": 1879778, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "f42cffbb5de45e574cbd1c732ae8d75f28643cb02ba0ad22ef90ea833dcd67b6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "33953426-f367-47d2-8cb9-63672f453ef8", "node_type": "1", "metadata": {"page_label": "9", "file_name": "orsoi_chiffres_diabete_reunion_2020.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\orsoi_chiffres_diabete_reunion_2020.pdf", "file_type": "application/pdf", "file_size": 1879778, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "74ef2183d1f8338238b3d58458041acc21d42227ab47c1779063fdaecea541d8", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "A La R\u00e9union, 10 programmes d'ETP sont autoris\u00e9s sur\nle diab\u00e8te par l'Agence de sant\u00e9 (ARS).\n\nEn 2020, parmi les programmes d'ETP autoris\u00e9s par l'ARS :\n\nUne vingtaine d'autres programme s concernent les\nmaladies nutritionnelles, cardiovasculaires ou r\u00e9nales.\n\nZoom sur le programme d'ETP \u00ab RunDIABETE \u00bb\nParmi les programmes autoris\u00e9s par l'ARS R\u00e9union, l'Unit\u00e9\nr\u00e9gionale de Coordination et d'appui \u00e0 l'Education\nth\u00e9rapeutique des Patients ( UCEP) propose depuis juin\n2020 le programme r\u00e9gional d'ETP, RunDIABETE , qui\ns'adresse \u00e0 toutes les personnes diab\u00e9tiques de type 2 ainsi\nqu'\u00e0 leurs proches. L'ETP permet d'aider le patient \u00e0 mieux\ncomprendre sa maladie et \u00e0 s'impliquer dans son suivi.\n\nAu 01/11/2020 :\n\nEn savoir plus : 0800 444 974 / /\nwww.ucep.re\n\n56% 44%\nAge moyen\n63 ans\nCaract\u00e9ristiques des\npatients adh\u00e9rents\nAu 30/06/2019\nIdentification des publics prioritaires par\nrapport aux \u00e9carts aux soins", "mimetype": "text/plain", "start_char_idx": 1716, "end_char_idx": 2626, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "4bfdae37-632b-4259-b60e-c11eaa9069fe": {"__data__": {"id_": "4bfdae37-632b-4259-b60e-c11eaa9069fe", "embedding": null, "metadata": {"page_label": "10", "file_name": "orsoi_chiffres_diabete_reunion_2020.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\orsoi_chiffres_diabete_reunion_2020.pdf", "file_type": "application/pdf", "file_size": 1879778, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "c5d6ca34-cfea-462a-bb1c-af5c81b2c3be", "node_type": "4", "metadata": {"page_label": "10", "file_name": "orsoi_chiffres_diabete_reunion_2020.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\orsoi_chiffres_diabete_reunion_2020.pdf", "file_type": "application/pdf", "file_size": 1879778, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "9657ff1c0e7f665e52a9e915fce7249c31b296d10a462888677c18e2ed2c1795", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0a55a3b5-ff4c-4c4b-a71e-1be8a42c3272", "node_type": "1", "metadata": {}, "hash": "10a65c8bd1f3f112205da2fffb0de1a723b0c7403be1b0475227b2c5b5265558", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Le diab\u00e8te, \u00ab \u00e7a se pr\u00e9vient \u00bb\nLe diab\u00e8te est \u00e9vitable, la pr\u00e9vention du diab\u00e8te est une priorit\u00e9\n\nDe nombreuses actions de pr\u00e9vention sont mise en \u0153uvre sur le territoire r\u00e9unionnais par de multiples\npartenaires et \u00e0 diff\u00e9rents \u00e9chelons g\u00e9ographiques et aupr\u00e8s de diff\u00e9rents publics.\nCe document n'a pas vocation \u00e0 recenser de mani\u00e8re exhaustive les actions de pr\u00e9vention du diab\u00e8te. L'objectif\nest de faire des zooms sur des actions innovantes ou r\u00e9gionales.\n\nLe diab\u00e8te, \u00ab \u00e7a s'observe \u00bb\nMieux conna\u00eetre pour mieux agir\n\nVoici des exemples de travaux r\u00e9gionaux ou nationaux, d\u00e9clin\u00e9s r\u00e9gionalement, qui vont permettre d'am\u00e9liorer les\nconnaissances sur la probl\u00e9matique du diab\u00e8te sur le territoire.\n\nLe programme \u00ab dites non au diab\u00e8te \u00bb\n\n\u00ab Dites non au diab\u00e8te \u00bb est un programme d e\npr\u00e9vention du diab\u00e8te de type 2 qui vise \u00e0 pr\u00e9venir ou\nretarder l'apparition du diab\u00e8te chez les personnes \u00e0\nrisques. La participation au programme \u00ab Dites non au\ndiab\u00e8te \u00bb est gratuite, enti\u00e8rement prise en charge par\nl'Assurance Maladie et bas\u00e9e sur le volontariat.\nCe programme exp\u00e9rimental est pilot\u00e9 par l'Assurance\nMaladie et le Minist\u00e8re de la sant\u00e9 et se d\u00e9roule sur trois\nterritoires :\n- La R\u00e9union (974),\n- Seine-Saint-Denis (93),\n- Bas-Rhin (67).\n\n503 personnes pr\u00e9-diab\u00e9tiques\nInscrites au programme au 31/10/2020\n(inscriptions valid\u00e9es)\n\nSource : CGSS R\u00e9union\nEtude ENTRED : recueil en cours\nSant\u00e9 publique France en partenariat avec l'Assurance Maladie, la S\u00e9curit\u00e9 sociale des Ind\u00e9pendants, la Haute Autorit\u00e9 de\nsant\u00e9 (HAS) et l'Agence Nationale de S\u00e9curit \u00e9 du M\u00e9dicament (ANSM), a lanc\u00e9 la troisi\u00e8me \u00e9dition de l'\u00e9tude Entred\n(Echantillon National T\u00e9moin Repr\u00e9sentatif des personnes Diab\u00e9tiques), aupr\u00e8s de 13 000 personnes diab\u00e9tiques en\nm\u00e9tropole et dans les d\u00e9partements d'Outre -mer. L'\u00e9tude est soutenue par la Soci\u00e9t\u00e9 francophone du diab\u00e8te, la\nF\u00e9d\u00e9ration fran\u00e7aise des diab\u00e9tiques (association des personnes diab\u00e9tiques), le Coll\u00e8ge de la M\u00e9decine g\u00e9n\u00e9rale et, en\nOutre-mer, par les ARS des territoires concern\u00e9s. Cette \u00e9tude nationale sur le diab\u00e8te vise \u00e0 mieux conna\u00eetre les besoins et\nle suivi des personnes diab\u00e9tiques en France. L'objectif est d'a m\u00e9liorer la qualit\u00e9 des soins et donc la sant\u00e9 et la qualit\u00e9 de\nvie de ces personnes.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2251, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "0a55a3b5-ff4c-4c4b-a71e-1be8a42c3272": {"__data__": {"id_": "0a55a3b5-ff4c-4c4b-a71e-1be8a42c3272", "embedding": null, "metadata": {"page_label": "10", "file_name": "orsoi_chiffres_diabete_reunion_2020.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\orsoi_chiffres_diabete_reunion_2020.pdf", "file_type": "application/pdf", "file_size": 1879778, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "c5d6ca34-cfea-462a-bb1c-af5c81b2c3be", "node_type": "4", "metadata": {"page_label": "10", "file_name": "orsoi_chiffres_diabete_reunion_2020.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\orsoi_chiffres_diabete_reunion_2020.pdf", "file_type": "application/pdf", "file_size": 1879778, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "9657ff1c0e7f665e52a9e915fce7249c31b296d10a462888677c18e2ed2c1795", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4bfdae37-632b-4259-b60e-c11eaa9069fe", "node_type": "1", "metadata": {"page_label": "10", "file_name": "orsoi_chiffres_diabete_reunion_2020.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\orsoi_chiffres_diabete_reunion_2020.pdf", "file_type": "application/pdf", "file_size": 1879778, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "c440c29c6432b2bb369f73eb7aa5934d2f181f94d9f1bfe0f434468b387c8b70", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Cette \u00e9tude nationale sur le diab\u00e8te vise \u00e0 mieux conna\u00eetre les besoins et\nle suivi des personnes diab\u00e9tiques en France. L'objectif est d'a m\u00e9liorer la qualit\u00e9 des soins et donc la sant\u00e9 et la qualit\u00e9 de\nvie de ces personnes. La R\u00e9union est particuli\u00e8rement concern\u00e9e par cette pathologie et cette \u00e9tude r\u00e9pond aux besoins\nd'informations de l'ensemble des acteurs locaux de sant\u00e9 agissant dans le domaine du diab\u00e8te.\nAvancement de l'enqu\u00eate \u00e0 La R\u00e9union :\nA La R\u00e9union, 850 patients ont \u00e9t\u00e9 invit\u00e9s \u00e0 participer \u00e0 cette enqu\u00eate entre septembre 2019 et mi-mars 2020. Le volet\npatient de l'enqu\u00eate a pu \u00eatre finalis\u00e9 avant le confinement du 16/03/202 0, avec un excellent taux de r\u00e9ponse de 72%.\nLe terrain d'enqu\u00eate pour le volet \"m\u00e9decins\" \u00e0 La R\u00e9union a \u00e9t\u00e9 lanc \u00e9 le 24 ao\u00fbt 2020 par l'envoi de courriers invitant les\nm\u00e9decins \u00e0 remplir et transmettre un questionnaire individuel concernant le suivi de leur(s) patient(s). 516 m\u00e9decins sont\nconcern\u00e9s sur notre territoire. Le recueil est en cours ; la participation des m\u00e9decins est toujours possible.\n\nPour en savoir plus :\n\nEtude PREDIABRUN : mise en place\n\nPREDIABRUN, est une \u00e9tude de recherche coordonn\u00e9e par le Centre d'Inves tigation Clinique (CIC Inserm 1410) du CHU de\nLa R\u00e9union, et visant \u00e0 recruter 2 000 personnes pr\u00e9diab\u00e9tiques \u00e0 La R\u00e9union et les suivre sur 5 ans (apr\u00e8s recrutement et\nsuivi par les m\u00e9decins traitants). C'est le m\u00e9decin traitant qui inclut et suit les pat ients dans PREDIABRUN. L'\u00e9tude a pour\nobjectif de mieux conna\u00eetre le pr\u00e9diab\u00e8te et la transition du pr\u00e9diab\u00e8te vers le diab\u00e8te pour faire reculer le diab\u00e8te \u00e0 La\nR\u00e9union.\nPour en savoir plus :", "mimetype": "text/plain", "start_char_idx": 2026, "end_char_idx": 3659, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "a0d73bdf-9673-439e-acea-d96c7a1e2315": {"__data__": {"id_": "a0d73bdf-9673-439e-acea-d96c7a1e2315", "embedding": null, "metadata": {"page_label": "11", "file_name": "orsoi_chiffres_diabete_reunion_2020.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\orsoi_chiffres_diabete_reunion_2020.pdf", "file_type": "application/pdf", "file_size": 1879778, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "24425805-887b-40f9-91a9-4bda703eb256", "node_type": "4", "metadata": {"page_label": "11", "file_name": "orsoi_chiffres_diabete_reunion_2020.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\orsoi_chiffres_diabete_reunion_2020.pdf", "file_type": "application/pdf", "file_size": 1879778, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "f4c96853d99960c02d15d6ece6e67c7de5cc468cce4aa7efececab1a0c2c8cfb", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Diab\u00e8te et Covid-19\n\nDans le contexte d'\u00e9pid\u00e9mie, le diab\u00e8te est devenu rapidement une comorbidit\u00e9 majeure de la gravit\u00e9 de la Covid -19.\nAu regard de la fr\u00e9quence \u00e9lev\u00e9e du diab\u00e8te \u00e0 La R\u00e9union, les pr\u00e9occupations locales sont importantes pour les acteurs de la\nprise en charge des patients diab\u00e9tiques et pour les patients eux-m\u00eames.\nLe premier cas confirm\u00e9 de Covid-19 a \u00e9t\u00e9 recens\u00e9 le 11 mars 2020 \u00e0 La R\u00e9union. Du 17 mars 2020 au 11 mai 2020, la\npopulation r\u00e9unionnaise a v\u00e9cu les r\u00e8gles de confine ment strictes mises en vigueur en France pour faire face \u00e0 la crise\nsanitaire li\u00e9e \u00e0 la Covid -19. Et pendant cette p\u00e9riode de confinement, 25 personnes, avec un r\u00e9sultat positif pour Covid -19,\nont d\u00e9clar\u00e9 \u00eatre diab\u00e9tiques lors des investigations : soit 6% de l'ensemble des cas confirm\u00e9s selon les donn\u00e9es\nd'investigation de la cellule r\u00e9gionale de Sant\u00e9 publique France.\nL'ORS OI, dans le cadre du p\u00f4le d'animation de l'observation du diab\u00e8te \u00e0 L a R\u00e9union, a souhait\u00e9 mettre \u00e0 disposition des\n\u00e9l\u00e9ments sur les patients diab\u00e9tiques \u00e0 La R\u00e9union depuis le d\u00e9but de la crise sanitaire.\n\nEpid\u00e9mie et recours aux soins des patients diab\u00e9tiques r\u00e9unionnais\n\nDeux indicateurs ont \u00e9t\u00e9 s\u00e9lectionn\u00e9s pour illustrer le recours aux soins des patients diab\u00e9tiques pendant la crise sanitaire en\nraison de leur disponibilit\u00e9 et accessibilit\u00e9 : la r\u00e9alisation du dosage d'h\u00e9moglobine glyqu\u00e9e et les consultations hospitali\u00e8res\npendant le confinement et apr\u00e8s le confinement.\n\nUn acc\u00e8s aux soins difficile\npour les patients\ndiab\u00e9tiques pendant le\nconfinement\n\nBaisse des r\u00e9alisations des\ndosages d'h\u00e9moglobine glyqu\u00e9e\npour diff\u00e9ren tes raisons (y\ncompris la moindre fr\u00e9quentation\ndes m\u00e9decins g\u00e9n\u00e9ralistes et les\nfermetures ou r\u00e9ductions\nd'horaires des laboratoires).\n\nBaisse mod\u00e9r\u00e9e des con sultations\nhospitali\u00e8res gr\u00e2ce \u00e0 la\nt\u00e9l\u00e9consultation mise en place\npour garantir la continuit\u00e9 des\nsoins des patients.\n\nUn \u00ab Retour \u00e0 la normale \u00bb\npour le recours aux soins\nsur la p\u00e9riode de mai \u00e0\njuillet 2020\n\nNombre de dosages d'HbA1c r\u00e9alis\u00e9s dans les laboratoires priv\u00e9s de l' \u00eele entre\n2019 et 2020\n\nSource : R\u00e9seaux de laboratoires priv\u00e9s (Cerballiance et Reunilab)\n\nConsultations hospitali\u00e8res externes pour la prise en charge des patients\ndiab\u00e9tiques : comparaison du nombre de consultations sur place et de\nt\u00e9l\u00e9consultations pour le CHU de La R\u00e9union entre 2019 et 2020\n\nSource : CHU de La R\u00e9union", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2389, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "6cf2fe5f-a695-4ea5-afdc-3364fa5a84d9": {"__data__": {"id_": "6cf2fe5f-a695-4ea5-afdc-3364fa5a84d9", "embedding": null, "metadata": {"page_label": "12", "file_name": "orsoi_chiffres_diabete_reunion_2020.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\orsoi_chiffres_diabete_reunion_2020.pdf", "file_type": "application/pdf", "file_size": 1879778, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "c2728a74-50f1-4ac3-b094-aea4f31588e7", "node_type": "4", "metadata": {"page_label": "12", "file_name": "orsoi_chiffres_diabete_reunion_2020.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\orsoi_chiffres_diabete_reunion_2020.pdf", "file_type": "application/pdf", "file_size": 1879778, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "4122faef2f03f252372327de6eabe112e8b05f407b0c0a5681b63ceafc6206bb", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8eaecb73-bd7a-416d-8f0a-b300a8100c9a", "node_type": "1", "metadata": {}, "hash": "39ab76bfa28419a6a86efb05316038747a7ac14636ea7b5faa52b7be5c23cfbc", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Etude CORONADO (CORONAVIRUS SARSCOV2 & DIABETES OUTCOMES)\n\nCORONADO (CORONAVIRUS SARSCOV2 & DIABETES OUTCOMES) est la premi\u00e8re \u00e9tude sp\u00e9cifiquemen t d\u00e9di\u00e9e aux\npersonnes atteintes de diab\u00e8te infect\u00e9es par le SRAS -CoV-2 et admises \u00e0 l'h\u00f4pital. CORONADO, initiative promue par le CHU\nde Nantes et port\u00e9e par les acteu rs de la diab\u00e9tologie fran\u00e7aise, a pour objectif de mieux comprendre les caract\u00e9ristique s et\nle pronostic des patients diab\u00e9tiques hospitalis\u00e9s pour Covid -19 et d'\u00e9valuer le risque de forme s\u00e9v\u00e8re parmi ces patients . Le\ncrit\u00e8re principal d'\u00e9valuation de la s\u00e9v\u00e9rit\u00e9 d e la Covid-19 est l'intubation ou le d\u00e9c\u00e8s des patients dans les 7 jours suiv ant\nl'hospitalisation. C'est une \u00e9tude observationnelle multicentrique \u00e0 l'\u00e9chelle nationale r\u00e9alis\u00e9e dans 68 centres\n(m\u00e9tropolitains et outre -mer) du 10 mars au 10 avril 2020. Le Centre Hospitalier Universitaire de La R\u00e9union a particip\u00e9 \u00e0\nl'enqu\u00eate. Sur la p\u00e9riode, pr\u00e8s de 3 000 patients ont \u00e9t\u00e9 inclus sur l'ensemble du territoire (dont 23 patients r\u00e9unionnais).\n\n1\u00e8re vague de r\u00e9sultats\nSont pr\u00e9sent\u00e9s ci -apr\u00e8s les premiers r\u00e9sultats de l'\u00e9tude [2]. Cette analyse interm\u00e9diaire (R\u00e9sultats \u00e0 J7 apr\u00e8s l'admi ssion \u00e0\nl'h\u00f4pital) repose sur les donn\u00e9es de 53 centres hospitaliers sur la p\u00e9riode du 10 au 31 mars 2020.\nEn r\u00e9sum\u00e9, les premiers r\u00e9sultats de l'\u00e9tude CORONADO sur les 1 317 patients diab\u00e9tiques hospitalis\u00e9s pour Covid-19 :\nLe profil des patients analys\u00e9s :\n\u2022 majoritairement des hommes (65 % d'hommes), \u00e2g\u00e9s de 70 ans en moyenne\n\u2022 majoritairement atteints d'un diab\u00e8te de type 2 : 89% (diab\u00e8te type 1 :3%)\n\u2022 HbA1c moyenne de 8,1%\n\u2022 3% des diab\u00e8tes d\u00e9couverts \u00e0 cette occasion1\n\u2022 47% sont atteints de complications microvasculaires et 41% de complications macrovasculaires\nPronostic et facteurs de risque :\n\u2022 Le risque pour un patient diab\u00e9tique d'\u00eatre intub\u00e9 dans les 7 jours suivants l'admission \u00e0 l'h\u00f4pital pour Covid -19 est de\n20,3%, le risque de d\u00e9c\u00e8s est de 10,6%. 31,1% de patients diab\u00e9tiques ont \u00e9t\u00e9 admis en r\u00e9animation tandis que 18 % d'entre\neux ont regagn\u00e9 leur domicile \u00e0 7 jours du d\u00e9but d'hospitalisation.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2103, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "8eaecb73-bd7a-416d-8f0a-b300a8100c9a": {"__data__": {"id_": "8eaecb73-bd7a-416d-8f0a-b300a8100c9a", "embedding": null, "metadata": {"page_label": "12", "file_name": "orsoi_chiffres_diabete_reunion_2020.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\orsoi_chiffres_diabete_reunion_2020.pdf", "file_type": "application/pdf", "file_size": 1879778, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "c2728a74-50f1-4ac3-b094-aea4f31588e7", "node_type": "4", "metadata": {"page_label": "12", "file_name": "orsoi_chiffres_diabete_reunion_2020.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\orsoi_chiffres_diabete_reunion_2020.pdf", "file_type": "application/pdf", "file_size": 1879778, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "4122faef2f03f252372327de6eabe112e8b05f407b0c0a5681b63ceafc6206bb", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6cf2fe5f-a695-4ea5-afdc-3364fa5a84d9", "node_type": "1", "metadata": {"page_label": "12", "file_name": "orsoi_chiffres_diabete_reunion_2020.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\orsoi_chiffres_diabete_reunion_2020.pdf", "file_type": "application/pdf", "file_size": 1879778, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "1e4bab66f49934141f85acd5bdf409c8529eec34ce09e01f4ade497aaa066b02", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5c6d26d8-9617-47c1-9ab0-97564a373aab", "node_type": "1", "metadata": {}, "hash": "d72dc77b342f665e3f7a97c349e3e52676fa1260b40906427f397316f17707ef", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "31,1% de patients diab\u00e9tiques ont \u00e9t\u00e9 admis en r\u00e9animation tandis que 18 % d'entre\neux ont regagn\u00e9 leur domicile \u00e0 7 jours du d\u00e9but d'hospitalisation.\n\u2022 Les complications microvasculaires et les complications cardiovasculaires sont associ\u00e9es au ris que de d\u00e9c\u00e8s \u00e0 7 jours,\nind\u00e9pendamment de l'\u00e2ge ou de la corpulence.\n\u2022 L'hbA1c (t\u00e9moin du contr\u00f4le glyc\u00e9mique chronique ) n'a pas d 'impact sur la gravit\u00e9\nimm\u00e9diate ; mais la glyc\u00e9mie \u00e0 l'entr\u00e9e (t\u00e9moin d'un d\u00e9s\u00e9quilibre aigu) est corr\u00e9l\u00e9e.\n\u2022 L'IMC est positivement et ind\u00e9pendamment associ\u00e9 au crit\u00e8re principal de s\u00e9v\u00e9rit\u00e9 : une\nob\u00e9sit\u00e9 est un facteur pronostique aggravant ind\u00e9pendant, quel que soit l'\u00e2ge.\n\u2022 Les personnes \u00e2g\u00e9es avec un diab\u00e8te de longue dur\u00e9e et des complications li\u00e9es au\ndiab\u00e8te avanc\u00e9es et/ou avec le syndrome d'apn\u00e9e de sommeil (SAOS) ont un risque accru de d\u00e9c\u00e8s pr\u00e9coce.\n\n2\u00e8me vague de r\u00e9sultats\nComme les donn\u00e9es concernant le type de diab\u00e8te sont rares, les \u00e9quipes de recherche ont souhait\u00e9 analyser les\ncaract\u00e9ristiques cliniques et pronostiques pr\u00e9coces des patients avec un diab\u00e8te de type 1 (DT1), hospitalis\u00e9s pour COVID -19.\nCette 2\u00e8me phase d'analyse repose sur les donn\u00e9es de 68 centres hospitaliers sur la p\u00e9riode du 10 mars au 10 avril 2020.\nLes principaux r\u00e9sultats de cette 2\u00e8me analyse porte sur 2 608 patients diab\u00e9tiques hospitalis\u00e9s pour Covid-19 :\n\u2022 56 patients diab\u00e9tiques de type 1, soit une pr\u00e9valence de 2,1% inf\u00e9rieure \u00e0 celle estim\u00e9e en population g\u00e9n\u00e9rale (6%).\n\u2022 Principales caract\u00e9ristiq ues des patients DT1 de l'\u00e9tude : pr\u00e9 dominance masculine\n(55%), un \u00e2ge moyen de 56 ans, un IMC de 25,8 kg/m\u00b2.\n\u2022 L'\u00e2ge est le principal facteur influen\u00e7ant le pronostic de gravit\u00e9. L'hypertension, est\nassoci\u00e9e aux formes s\u00e9v\u00e8res de Covid -19, en raison de l'\u00e2ge des patients. L'HbA1c ou les\ncomplications macro ou micro vasculaires n'ont pas d' impact sur la s\u00e9v\u00e9rit\u00e9 des formes\nde Covid-19 (malgr\u00e9 un ajustement sur l'\u00e2ge).\n\nR\u00e9f\u00e9rences bibliographiques :\n- Cariou B, Hadjadj S, Wargny M, et al. Phenotypic characteristics and prognosis of inpatients with COVID -19 and diabetes: the CORONADO study,\nDiabetologia, mai 2020.\n- Wargny M., Gourdy P., Ludwig L., et al.", "mimetype": "text/plain", "start_char_idx": 1953, "end_char_idx": 4111, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "5c6d26d8-9617-47c1-9ab0-97564a373aab": {"__data__": {"id_": "5c6d26d8-9617-47c1-9ab0-97564a373aab", "embedding": null, "metadata": {"page_label": "12", "file_name": "orsoi_chiffres_diabete_reunion_2020.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\orsoi_chiffres_diabete_reunion_2020.pdf", "file_type": "application/pdf", "file_size": 1879778, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "c2728a74-50f1-4ac3-b094-aea4f31588e7", "node_type": "4", "metadata": {"page_label": "12", "file_name": "orsoi_chiffres_diabete_reunion_2020.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\orsoi_chiffres_diabete_reunion_2020.pdf", "file_type": "application/pdf", "file_size": 1879778, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "4122faef2f03f252372327de6eabe112e8b05f407b0c0a5681b63ceafc6206bb", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8eaecb73-bd7a-416d-8f0a-b300a8100c9a", "node_type": "1", "metadata": {"page_label": "12", "file_name": "orsoi_chiffres_diabete_reunion_2020.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\orsoi_chiffres_diabete_reunion_2020.pdf", "file_type": "application/pdf", "file_size": 1879778, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "f7bf773fdb5e27f07f0b17287b651f692af27cd1f96404678e2fc7b47e1054ef", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "R\u00e9f\u00e9rences bibliographiques :\n- Cariou B, Hadjadj S, Wargny M, et al. Phenotypic characteristics and prognosis of inpatients with COVID -19 and diabetes: the CORONADO study,\nDiabetologia, mai 2020.\n- Wargny M., Gourdy P., Ludwig L., et al. Type 1 Diabetes in people hospitalized for Covid-19 : new insights from the Coronado Study.\nLes r\u00e9sultats de l'ensemble des donn\u00e9es sont en cours de publication.\n\n1 A La R\u00e9union : pr\u00e8s d'1patient sur 3 a d\u00e9couvert son diab\u00e8te \u00e0 l'h\u00f4pital. R\u00e9sultat \u00e0 interpr\u00e9ter avec prudence en raison de la faiblesse des effectifs locaux.", "mimetype": "text/plain", "start_char_idx": 3872, "end_char_idx": 4435, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "babfc64b-7c9b-4062-b1a1-83ea22e90024": {"__data__": {"id_": "babfc64b-7c9b-4062-b1a1-83ea22e90024", "embedding": null, "metadata": {"page_label": "13", "file_name": "orsoi_chiffres_diabete_reunion_2020.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\orsoi_chiffres_diabete_reunion_2020.pdf", "file_type": "application/pdf", "file_size": 1879778, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "31ebf525-54dd-4950-ab06-ae76adec9500", "node_type": "4", "metadata": {"page_label": "13", "file_name": "orsoi_chiffres_diabete_reunion_2020.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\orsoi_chiffres_diabete_reunion_2020.pdf", "file_type": "application/pdf", "file_size": 1879778, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "9373e4c0f52baa4b202c2d0fc1edd51e446ef6f50cf8efe8abe7473dd98ad386", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "499488bc-9fd3-4abd-82f5-128ccff965ad", "node_type": "1", "metadata": {}, "hash": "6887779afe9bd1dd1f4da6712eae169ff4500760e64bc5a88df15fc3ea64f62a", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "M\u00e9thodologie\n\nCe document r\u00e9alis\u00e9 \u00e0 la dema nde de l'ARS La R\u00e9union par l'ORS OI, pr\u00e9sente les indicateurs cl\u00e9s sur le diab\u00e8te \u00e0 La R\u00e9union \u00e0 partir des\nsources d'informations locales et nationales disponibles. Le document int\u00e8gre \u00e9galement des zooms en fonction des ressources\ndisponibles. Ce travai l se fait en lien avec les membre s du comit\u00e9 technique de l'observation du diab\u00e8te \u00e0 La R\u00e9union r\u00e9unissant les\npartenaires suivants : ARS OI, CGSS, CHU, CIC 1410, Cellule R\u00e9union de Sant\u00e9 publique France, COTRIM, DRSM, Mutualit\u00e9 de La R\u00e9union,\nORS OI. Merci aux membres du comit\u00e9 technique de l'observation du diab\u00e8te.\n\nD\u00e9finitions\n- Diab\u00e8te de type 1 : le corps ne produit pas assez d'insuline.\n- Diab\u00e8te de type 2 : le corps n'utilise pas correctement l'insuline qu'il produit.\n- Diab\u00e8te gestationnel : hyperglyc\u00e9mie temporaire pendant la grossesse.\n- Le nombre de personnes diab\u00e9tiques pris en charge par le syst\u00e8me de sant\u00e9 a \u00e9t\u00e9 d\u00e9fini et construit par l'Assurance Maladie dans le\ncadre de la cartographie des pathologies et des d\u00e9penses. Il correspond aux personnes aya nt re\u00e7u au moins 3 d\u00e9livrances (\u00e0 diff\u00e9rentes\ndates) d'antidiab\u00e9tiques oraux ou injectables (insuline ou autre) (ou au moins 2 en cas d'au moins 1 grand conditionnement) a u cours\ndes ann\u00e9es n et n -1, et/ou personnes ayant une Affection de Longue Dur\u00e9e au c ours de l'ann\u00e9e n avec codes CIM -10 de diab\u00e8te et/ou\npersonnes hospitalis\u00e9es en MCO (m\u00e9decine, chirurgie, obst\u00e9trique) au cours des ann\u00e9es n \u00e0 n -1 avec codes CIM10 de diab\u00e8te\n(diagnostic principal ou reli\u00e9), et/ou personnes hospitalis\u00e9es en MCO au cours de s ann\u00e9es n \u00e0 n -1 pour une complication du diab\u00e8te\n(diagnostic principal ou reli\u00e9) avec un code CIM10 de diab\u00e8te en diagnostic associ\u00e9, ou en diagnostic principal ou reli\u00e9. Sont prises en\ncompte uniquement les donn\u00e9es du R\u00e9gime g\u00e9n\u00e9ral et des sections mutualistes (93% de la population).\n- Le nombre de personnes trait\u00e9es pharmacologiquement est issu de la m\u00e9thodologie de Sant\u00e9 publique France. Il correspond au\nnombre de personnes ayant eu une d\u00e9livrance de traitement antidiab\u00e9tique \u00e0 au moins 3 dates diff\u00e9rente s (2 si au moins un grand\nconditionnement) au cours de l'ann\u00e9e. Les traitements antidiab\u00e9tiques correspondent \u00e0 la classe A10 de la classification Anat omical\nTherapeutic Chemical (ATC). Ils comprennent les antidiab\u00e9tiques oraux, l'insuline et les analogues du GLP-1.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2379, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "499488bc-9fd3-4abd-82f5-128ccff965ad": {"__data__": {"id_": "499488bc-9fd3-4abd-82f5-128ccff965ad", "embedding": null, "metadata": {"page_label": "13", "file_name": "orsoi_chiffres_diabete_reunion_2020.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\orsoi_chiffres_diabete_reunion_2020.pdf", "file_type": "application/pdf", "file_size": 1879778, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "31ebf525-54dd-4950-ab06-ae76adec9500", "node_type": "4", "metadata": {"page_label": "13", "file_name": "orsoi_chiffres_diabete_reunion_2020.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\orsoi_chiffres_diabete_reunion_2020.pdf", "file_type": "application/pdf", "file_size": 1879778, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "9373e4c0f52baa4b202c2d0fc1edd51e446ef6f50cf8efe8abe7473dd98ad386", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "babfc64b-7c9b-4062-b1a1-83ea22e90024", "node_type": "1", "metadata": {"page_label": "13", "file_name": "orsoi_chiffres_diabete_reunion_2020.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\orsoi_chiffres_diabete_reunion_2020.pdf", "file_type": "application/pdf", "file_size": 1879778, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "3a5686b89309ae04f77b36e581c03e6795e112a814fcf15a018c26b09fd58319", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e9e86204-cc50-4988-b71d-0ed491a4b017", "node_type": "1", "metadata": {}, "hash": "013aac0e84cac78a3ec98df817afac2ba4f8b6f6c81204f7cea3c3670a5f564d", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Les traitements antidiab\u00e9tiques correspondent \u00e0 la classe A10 de la classification Anat omical\nTherapeutic Chemical (ATC). Ils comprennent les antidiab\u00e9tiques oraux, l'insuline et les analogues du GLP-1.\n- Le nombre de patients hospitalis\u00e9s pour complications du diab\u00e8te a \u00e9t\u00e9 d\u00e9fini selon la m\u00e9thodologie de Sant\u00e9 publique France.\nCompte tenu de l'\u00e9volution de l'utilisation des codes CIM10 relatifs aux maladies cardiovasculaires, il n'est plus poss ible d'identifier les\ninfarctus du myocarde (IDM) comme les \u00e9ditions pr\u00e9c\u00e9dentes. D\u00e9sormais, la d\u00e9finition des IDM est restreinte aux IDM STEMI (\u00e0 savoir\nles infarctus du myocarde aigus avec \u00e9l\u00e9vation du segment ST).\n- Les personnes pr\u00e9 -diab\u00e9tiques sont cell es avec une glyc\u00e9mie plus \u00e9lev\u00e9e que la normale, mais pas suffisamment pour \u00e9tablir le\ndiagnostic du diab\u00e8te. Il s'agit d'un signal d'alarme. Un pr\u00e9 -diab\u00e8te se caract\u00e9rise par une glyc\u00e9mie (taux de glucose dans le sang) plus\n\u00e9lev\u00e9e que la normale et sous l e seuil de diagnostic du diab\u00e8te, c'est -\u00e0-dire une glyc\u00e9mie \u00e0 jeun se situant entre 1,1g/L et 1,26 g/L et\nune h\u00e9moglobine glyqu\u00e9e (HbA1c) se situant entre 5,7% et 6,4%, selon les crit\u00e8res propos\u00e9s par l'Organisation mondiale de la sant\u00e9.\n\nRemarques g\u00e9n\u00e9rales sur les indicateurs et limites\n- Il n'est pas possible de quantifier et de d\u00e9crire pr\u00e9cis\u00e9ment les personnes diab\u00e9tiques. Les personnes diab\u00e9tiques ne sont pa s\nsyst\u00e9matiquement rep\u00e9rables \u00e0 travers les bases de donn\u00e9es m\u00e9dico -administratives (exemples : les personnes ignorant leur diab\u00e8te,\nles personnes non d\u00e9pist\u00e9es, les personnes non diagnostiqu\u00e9es, les personnes non prises en charge, les personnes prises en ch arge\nuniquement par des conseils hygi\u00e9no-di\u00e9t\u00e9tiques, ...). Au del\u00e0 des enqu\u00eates en population g\u00e9 n\u00e9rale fournissant une estimation de la\nfr\u00e9quence du diab\u00e8te, l'indicateur le plus proche de la r\u00e9alit\u00e9 actuellement est le nombre de patients diab\u00e9tiques pris en charge par le\nsyst\u00e8me de sant\u00e9 (d\u00e9finition ci-dessus).\n- Le nombre et la part des personnes concern\u00e9es par les complications du diab\u00e8te sont \u00e9galement difficilement mesurables. Les bases de\ndonn\u00e9es disponibles ne permettent pas de quantifier la survenue annuelle de toutes les complications li\u00e9es au diab\u00e8te ; seule une\nenqu\u00eate en population g\u00e9n\u00e9rale permettrait de le faire. Le registre REIN permet en revanche de recenser les patients diab\u00e9tiques\ninsuffisants r\u00e9naux.", "mimetype": "text/plain", "start_char_idx": 2176, "end_char_idx": 4555, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "e9e86204-cc50-4988-b71d-0ed491a4b017": {"__data__": {"id_": "e9e86204-cc50-4988-b71d-0ed491a4b017", "embedding": null, "metadata": {"page_label": "13", "file_name": "orsoi_chiffres_diabete_reunion_2020.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\orsoi_chiffres_diabete_reunion_2020.pdf", "file_type": "application/pdf", "file_size": 1879778, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "31ebf525-54dd-4950-ab06-ae76adec9500", "node_type": "4", "metadata": {"page_label": "13", "file_name": "orsoi_chiffres_diabete_reunion_2020.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\orsoi_chiffres_diabete_reunion_2020.pdf", "file_type": "application/pdf", "file_size": 1879778, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "9373e4c0f52baa4b202c2d0fc1edd51e446ef6f50cf8efe8abe7473dd98ad386", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "499488bc-9fd3-4abd-82f5-128ccff965ad", "node_type": "1", "metadata": {"page_label": "13", "file_name": "orsoi_chiffres_diabete_reunion_2020.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\orsoi_chiffres_diabete_reunion_2020.pdf", "file_type": "application/pdf", "file_size": 1879778, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "2586866bbabdc18143cfcf8ecfbefccf9443f60d19437eed93c73d41e654de71", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Les bases de\ndonn\u00e9es disponibles ne permettent pas de quantifier la survenue annuelle de toutes les complications li\u00e9es au diab\u00e8te ; seule une\nenqu\u00eate en population g\u00e9n\u00e9rale permettrait de le faire. Le registre REIN permet en revanche de recenser les patients diab\u00e9tiques\ninsuffisants r\u00e9naux.\n- Les donn\u00e9es de mortalit\u00e9 concernent uniquement les d\u00e9c\u00e8s pour lesquels le diab\u00e8te appara\u00eet en cause initiale du d\u00e9c\u00e8s. La mor talit\u00e9\nli\u00e9e au diab\u00e8te est sous-estim\u00e9e pour diff\u00e9rentes raisons m\u00e9thodologiques.\n- Le diab\u00e8te est un probl\u00e8me de sant\u00e9 qui fait l'objet d'une surveillance r\u00e9gionale et nationale. De nombreuses donn\u00e9es sont d\u00e9 j\u00e0\ndisponibles. Plusieurs dispositifs d'observation existent et sont g\u00e9r\u00e9s par diff\u00e9rents partenaires. Ces partenaires analysent les donn\u00e9es\nde l'observation sur le diab\u00e8te en fonction de le urs besoins, leurs objectifs et leur m\u00e9thodologie. Ces constats expliquent les \u00e9carts de\nchiffres qui peuvent appara\u00eetre \u00e0 travers les diff\u00e9rentes donn\u00e9es mises \u00e0 disposition. Il faut rester vigilant au cadre m\u00e9thodologique des\ndonn\u00e9es pr\u00e9sent\u00e9es (d\u00e9finition, p\u00e9riode, m\u00e9thode de calcul, source, ...). Par cons\u00e9quent, les indicateurs ne couvrent pas\nn\u00e9cessairement les m\u00eames p\u00e9riodes d e temps ou les m\u00eames publics. Par ailleurs, les sources de donn\u00e9es et les m\u00e9thodes de recueil\net d'analyse \u00e9voluent, certains indicateurs peuvent appara\u00eetre ou dispara\u00eetre.\n- L'actualisation des donn\u00e9es d\u00e9pend de la mise \u00e0 disposition des donn\u00e9es par les par tenaires. Les donn\u00e9es pr\u00e9sent\u00e9es sont les\nderni\u00e8res disponibles au moment de la r\u00e9alisation de ce document.\n\nUtilisation et diffusion des informations disponibles\nCe document est plac\u00e9 en acc\u00e8s gratuit sur le site internet de l'ORS et de ses partenaires. L es partenaires peuvent utiliser les informations\ndans leurs propres outils de communication \u00e0 condition de mentionner la source des donn\u00e9es associ\u00e9e \u00e0 chacun des diff\u00e9rents indicateurs.", "mimetype": "text/plain", "start_char_idx": 4263, "end_char_idx": 6172, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "0caaf6dc-075e-4d7e-b147-10b5ddf4d954": {"__data__": {"id_": "0caaf6dc-075e-4d7e-b147-10b5ddf4d954", "embedding": null, "metadata": {"page_label": "14", "file_name": "orsoi_chiffres_diabete_reunion_2020.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\orsoi_chiffres_diabete_reunion_2020.pdf", "file_type": "application/pdf", "file_size": 1879778, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "4d118d30-4238-4f1d-a4a8-31eba1249335", "node_type": "4", "metadata": {"page_label": "14", "file_name": "orsoi_chiffres_diabete_reunion_2020.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\orsoi_chiffres_diabete_reunion_2020.pdf", "file_type": "application/pdf", "file_size": 1879778, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "d81bce3521d2397e1765b1f9e91fc956e1a18eedd6355dc162c5937d821dddb6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1261f951-0cf2-470e-80c3-87ad7941476b", "node_type": "1", "metadata": {}, "hash": "714ac1ce6100af10e28734f045e1836da24248becb604366c94075d7e1510bf6", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "L'essentiel : Le diab\u00e8te, une situation particuli\u00e8re \u00e0 La R\u00e9union\n\nCe document est la 4 \u00e8me \u00e9dition des chiffres cl\u00e9s sur le diab\u00e8te et les patients diab\u00e9tiques \u00e0 La R\u00e9union, destin\u00e9 aux acteurs\nde la lutte contre le diab\u00e8te. Il pr\u00e9sente les donn\u00e9es disponibles \u00e0 l'occasion de la journ\u00e9e de lutte contre le diab\u00e8te, le 14\nnovembre. Les donn\u00e9es sont fournies par diff\u00e9rents partenaires locaux ou nationaux , leur actualisation d\u00e9pend de la mise \u00e0\ndisposition des donn\u00e9es par ces partenaires : les donn\u00e9es ne couvrent pas n\u00e9cessairement les m\u00eames p\u00e9riodes ou les m\u00eames\npublics ou les m\u00eames m\u00e9thodologies, et peuvent \u00eatre fournies avec des d\u00e9lais variables (n -1, n-2, n-3). Les donn\u00e9es pr\u00e9sent\u00e9es\nici sont les derni\u00e8res disponibles au moment de la r\u00e9alisation de ce document.\n\nLa situation \u00e0 La R\u00e9union\n\uf06e Le diab\u00e8te est une maladie chronique fr\u00e9quente sur l'\u00eele : 71 200 R\u00e9unionnais pris en charge en 2018 pour leur diab\u00e8te,\nsoit environ un R\u00e9unionnais sur 10.\n\uf06e La personne diab\u00e9tique ne sait pas toujours qu'elle est malade : 1 diab\u00e9tique sur 3 ignore sa maladie\n\uf06e La maladie concerne davantage les femmes et augmente avec l'\u00e2ge : 3 personnes sur 10 sont diab\u00e9tiques apr\u00e8s 65 ans.\n\uf06e 2 femmes enceintes sur 10 sont concern\u00e9es par un diab\u00e8te gestationnel.\n\uf06e Les facteurs de risques favorisant l'apparition et le d\u00e9veloppement du diab\u00e8te sont bien pr\u00e9sents au sei n de la population\nr\u00e9unionnaise : ob\u00e9sit\u00e9, surpoids, comportements nutritionnels \u00e9loign\u00e9s de certaines recommandations, ... 1 R\u00e9unionnais\nsur 10 est en situation d'ob\u00e9sit\u00e9, 9 personnes sur 10 ne mangent pas les 5 fruits et l\u00e9gumes recommand\u00e9s par jour, une\npersonne sur 10 ne d\u00e9clare aucune activit\u00e9 physique\n\uf06e La prise en charge des patients diab\u00e9tiques est essentielle pour r\u00e9duire les risques de complications mais il existe des\n\u00e9carts par rapport au parcours de soins recommand\u00e9 : recours aux soins et r\u00e9alisatio n des examens p\u00e9riodiques\ninsuffisants. Une \u00e9tude r\u00e9gionale confirme les \u00e9carts aux soins en termes d'observance du traitement et de suivi m\u00e9dical\net biologique, avec des cassures dans le parcours de soins \u00e0 1 an et \u00e0 6 ans.\n\uf06e Un diab\u00e8te non suivi peut cause r de graves complications de sant\u00e9 : un millier de patients diab\u00e9tiques sont dialys\u00e9s en\n2018, 250 d\u00e9c\u00e8s sont directement li\u00e9s au diab\u00e8te en moyenne chaque ann\u00e9e.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2300, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "1261f951-0cf2-470e-80c3-87ad7941476b": {"__data__": {"id_": "1261f951-0cf2-470e-80c3-87ad7941476b", "embedding": null, "metadata": {"page_label": "14", "file_name": "orsoi_chiffres_diabete_reunion_2020.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\orsoi_chiffres_diabete_reunion_2020.pdf", "file_type": "application/pdf", "file_size": 1879778, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "4d118d30-4238-4f1d-a4a8-31eba1249335", "node_type": "4", "metadata": {"page_label": "14", "file_name": "orsoi_chiffres_diabete_reunion_2020.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\orsoi_chiffres_diabete_reunion_2020.pdf", "file_type": "application/pdf", "file_size": 1879778, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "d81bce3521d2397e1765b1f9e91fc956e1a18eedd6355dc162c5937d821dddb6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0caaf6dc-075e-4d7e-b147-10b5ddf4d954", "node_type": "1", "metadata": {"page_label": "14", "file_name": "orsoi_chiffres_diabete_reunion_2020.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\orsoi_chiffres_diabete_reunion_2020.pdf", "file_type": "application/pdf", "file_size": 1879778, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "3e4269673efb18c06428ae579631bb2e526aca9c9d0d0c042c565cbfc1654f95", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "\uf06e Un diab\u00e8te non suivi peut cause r de graves complications de sant\u00e9 : un millier de patients diab\u00e9tiques sont dialys\u00e9s en\n2018, 250 d\u00e9c\u00e8s sont directement li\u00e9s au diab\u00e8te en moyenne chaque ann\u00e9e. Une \u00e9tude r\u00e9gionale met en \u00e9vidence la\nsurvenue pr\u00e9coce des complications : au moins un patient sur avec une complication 8 ans apr\u00e8s sa mise sous traitement.\nElle r\u00e9v\u00e8le \u00e9galement une plus grande gravit\u00e9 des complications parmi les patients qui ne consultent pas r\u00e9guli\u00e8rement\nleur m\u00e9decin traitant.\n\nSituation r\u00e9gionale par rapport au niveau national\n\uf06e Le profil des patients diab\u00e9tiques r\u00e9unionnais diff\u00e8re du profil des patients m\u00e9tropolitains : surrepr\u00e9sentation des\nfemmes, des patients plus jeunes.\n\uf06e La fr\u00e9quence du diab\u00e8te est 2 fois plus \u00e9lev\u00e9e sur l'\u00eele en 2018 ; La R\u00e9union est la r\u00e9gion fran\u00e7aise la plus concern\u00e9e par la\nprise en charge du diab\u00e8te en 2018.\n\uf06e Les indicateurs de surveillance des patients diab\u00e9tiques sont meilleurs au niveau r\u00e9gional en termes de r\u00e9alisation des\nexamens et de consultations recommand\u00e9s, plus particuli\u00e8rement pour la surveillance cardiologique et r\u00e9nale ...\n\uf06e ... Mais les indicateurs d'observance du traitement et de recours au m\u00e9decin traitant paraissent moins fr\u00e9quents.\n\uf06e ... Mais les diab\u00e9tiques r\u00e9unionnais sont davantage concern\u00e9s par les AVC, les amputations et les complication s r\u00e9nales.\nLa mortalit\u00e9 li\u00e9e au diab\u00e8te est \u00e9galement plus fr\u00e9quente sur l'\u00eele par rapport \u00e0 la situation m\u00e9tropolitaine.\n\nEvolution de la situation r\u00e9gionale\n\uf06e Les indicateurs sur le diab\u00e8te envoient des signaux positifs en termes d'\u00e9volution sur notre terr itoire : un suivi qui\ns'am\u00e9liore globalement, une mortalit\u00e9 li\u00e9e au diab\u00e8te en baisse, une augmentation de la prise en charge du diab\u00e8te , ...\n\uf06e L'analyse des donn\u00e9es d'incidence et de pr\u00e9valence du diab\u00e8te de type 2 trait\u00e9 pharmacologiquement montre \u00e9galement\ndes \u00e9volutions encourageantes pour notre territoire : plus forte baisse de l'incidence du diab\u00e8te sur l'\u00eele.\n\uf06e Ces r\u00e9sultats traduisent les efforts et la mobilisation des acteurs locaux pour lutter contre cette maladie en termes de\npr\u00e9vention et prise en charge des patients pour \u00e9viter ou r\u00e9duire la survenue de la maladie et ses complications.\n\uf06e L'actualisation r\u00e9guli\u00e8re des indicateurs est essentielle pour suivre l'\u00e9volution de la maladie. Les prochaines donn\u00e9es\npermettront d'affiner les tendances sur la pr\u00e9valence et l'incidence du diab\u00e8te au niveau r\u00e9gional.\n\nR\u00e9alisation : ORS OI / Financement : ARS La R\u00e9union / Merci \u00e0 l'ensemble des partenaires et relecteurs", "mimetype": "text/plain", "start_char_idx": 2104, "end_char_idx": 4626, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "7c35a209-1c32-4fe7-951c-7550a8901e49": {"__data__": {"id_": "7c35a209-1c32-4fe7-951c-7550a8901e49", "embedding": null, "metadata": {"page_label": "1", "file_name": "strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_type": "application/pdf", "file_size": 920218, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "50dcb2bb-c9de-4bcc-bc44-2fa401cc6212", "node_type": "4", "metadata": {"page_label": "1", "file_name": "strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_type": "application/pdf", "file_size": 920218, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "867273c60bbeddc645e94fd9092dbfc2b256c159013fc8c3a0cbd16d32684bef", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "RECOMMANDER\nLES BONNES PRATIQUES\n\nRECOMMANDATION\n\nStrat\u00e9gie\nth\u00e9rapeutique du\npatient vivant avec\nun diab\u00e8te de\ntype 2\n\nValid\u00e9 par le Coll\u00e8ge le 30 mai 2024", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 155, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "67292fdf-6ca8-440f-b9a8-4127f785a0eb": {"__data__": {"id_": "67292fdf-6ca8-440f-b9a8-4127f785a0eb", "embedding": null, "metadata": {"page_label": "2", "file_name": "strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_type": "application/pdf", "file_size": 920218, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "260a4db7-fd27-4359-a785-340f37d1cbdc", "node_type": "4", "metadata": {"page_label": "2", "file_name": "strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_type": "application/pdf", "file_size": 920218, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "256e8e77ee5bc21959e3079a1c8f9b8cfa35b8a816975399589861f1fbcb0175", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "497e538c-b613-4764-95e2-405fb062ffa4", "node_type": "1", "metadata": {}, "hash": "879ecd44c69c680de06f7a4b17be213242be668883550a0c92793651d019927b", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "HAS \u2022 Strat\u00e9gie th\u00e9rapeutique du patient vivant avec un diab\u00e8te de type 2 \u2022 mai 2024 2\n\nLes recommandations de bonne pratique (RBP) sont d\u00e9finies dans le champ de la sant\u00e9 comme\ndes propositions d\u00e9velopp\u00e9es m\u00e9thodiquement pour aider le praticien et le patient \u00e0 rechercher les\nsoins les plus appropri\u00e9s dans des circonstances cliniques donn\u00e9es.\nLes RBP sont des synth\u00e8ses rigoureuses de l'\u00e9tat de l'art et des donn\u00e9es de la science \u00e0 un temps\ndonn\u00e9, d\u00e9crites dans l 'argumentaire scientifique. Elles ne sauraient dispenser le professionnel de\nsant\u00e9 de faire preuve de discernement dans sa prise en charge du patient, qui doit \u00eatre celle qu 'il\nestime la plus appropri\u00e9e, en fonction de ses propres constatations et des pr\u00e9f\u00e9rences du patient.\nCette recommandation de bonne pratique a \u00e9t\u00e9 \u00e9labor\u00e9e selon la m\u00e9thode r\u00e9sum\u00e9e dans\nl'argumentaire scientifique et d\u00e9crite dans le guide m\u00e9thodologique de la HAS disponible sur son\nsite : \u00c9laboration de recommandations de bonne pratique - M\u00e9thode recommandations pour la\npratique clinique.\nLes objectifs de cette recommandation, la population et les professionnels concern\u00e9s par sa mise\nen \u0153uvre sont bri\u00e8vement pr\u00e9sent\u00e9s en derni\u00e8re page (fiche descriptive) et d\u00e9taill\u00e9s dans\nl'argumentaire scientifique.\nCe dernier ainsi que la synth\u00e8se de la recommandation sont t\u00e9l\u00e9chargeables sur www.has-sante.fr.\n\nGrade des recommandations\nA\nPreuve scientifique \u00e9tablie\nFond\u00e9e sur des \u00e9tudes de fort niveau de preuve (niveau de preuve 1) : essais comparatifs\nrandomis\u00e9s de forte puissance et sans biais majeur ou m\u00e9ta -analyse d'essais comparatifs\nrandomis\u00e9s, analyse de d\u00e9cision bas\u00e9e sur des \u00e9tudes bien men\u00e9es.\nB\nPr\u00e9somption scientifique\nFond\u00e9e sur une pr\u00e9somption scientifique fournie par des \u00e9tudes de niveau interm\u00e9diaire de\npreuve (niveau de preuve 2), comme des essais comparatifs randomis\u00e9s de faible\npuissance, des \u00e9tudes comparatives non randomis\u00e9es bien men\u00e9es, des \u00e9tudes de cohorte.\nC\nFaible niveau de preuve\nFond\u00e9e sur des \u00e9tudes de moindre niveau de preuve, comme des \u00e9tudes cas -t\u00e9moins\n(niveau de preuve 3), des \u00e9tudes r\u00e9trospectives, des s\u00e9ries de cas, des \u00e9tudes comparatives\ncomportant des biais importants (niveau de preuve 4).\nAE\nAccord d'experts\nEn l'absence d'\u00e9tudes, les recommandations sont fond\u00e9es sur un accord entre experts du\ngroupe de travail, apr\u00e8s consultation du groupe de lecture. L'absence de gradation ne signifie\npas que les recommandations ne sont pas pertinentes et utiles.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2447, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "497e538c-b613-4764-95e2-405fb062ffa4": {"__data__": {"id_": "497e538c-b613-4764-95e2-405fb062ffa4", "embedding": null, "metadata": {"page_label": "2", "file_name": "strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_type": "application/pdf", "file_size": 920218, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "260a4db7-fd27-4359-a785-340f37d1cbdc", "node_type": "4", "metadata": {"page_label": "2", "file_name": "strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_type": "application/pdf", "file_size": 920218, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "256e8e77ee5bc21959e3079a1c8f9b8cfa35b8a816975399589861f1fbcb0175", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "67292fdf-6ca8-440f-b9a8-4127f785a0eb", "node_type": "1", "metadata": {"page_label": "2", "file_name": "strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_type": "application/pdf", "file_size": 920218, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "2420df09d0e4495afe83fdeebe3ac9a39df627003740c7e1102f80bb1c7e38f8", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "AE\nAccord d'experts\nEn l'absence d'\u00e9tudes, les recommandations sont fond\u00e9es sur un accord entre experts du\ngroupe de travail, apr\u00e8s consultation du groupe de lecture. L'absence de gradation ne signifie\npas que les recommandations ne sont pas pertinentes et utiles. Elle doit, en revanche, inciter\n\u00e0 engager des \u00e9tudes compl\u00e9mentaires.", "mimetype": "text/plain", "start_char_idx": 2183, "end_char_idx": 2517, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "f8d520b5-29b0-46b4-bdb9-2d12711e2ed2": {"__data__": {"id_": "f8d520b5-29b0-46b4-bdb9-2d12711e2ed2", "embedding": null, "metadata": {"page_label": "3", "file_name": "strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_type": "application/pdf", "file_size": 920218, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "f09ace58-9832-49e1-9617-c686dee41acd", "node_type": "4", "metadata": {"page_label": "3", "file_name": "strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_type": "application/pdf", "file_size": 920218, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "bc8ce18ec8907ff2d67bf5006e95a82b1a47d81b7e87181ac6891d650b53366f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "71b75331-506d-46d1-a926-b482fdc132c6", "node_type": "1", "metadata": {}, "hash": "0cf01185cb715631c6ce317becf61bee46caa099e89721606333cc7f82599e46", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "HAS \u2022 Strat\u00e9gie th\u00e9rapeutique du patient vivant avec un diab\u00e8te de type 2 \u2022 mai 2024 3\nDescriptif de la publication\n\nTitre Strat\u00e9gie th\u00e9rapeutique du patient vivant avec un\ndiab\u00e8te de type 2\n\nM\u00e9thode de travail Fiche m\u00e9mo\nObjectif(s) Les objectifs de cette fiche m\u00e9mo sont d 'actualiser les recommandations \u00ab Strat\u00e9gie\nm\u00e9dicamenteuse du contr\u00f4le glyc\u00e9mique du DT2 \u00bb \u00e9mises en 2013.\nCibles concern\u00e9es M\u00e9decins g\u00e9n\u00e9ralistes, m\u00e9decins sp\u00e9cialistes endocrinologue s diab\u00e9tologues\nnutritionnistes (EDN), et tout professionnel qui prend en charge les patients vivant avec\nun DT2 en ville ou dans le cadre des \u00e9tablissements de soins publics ou priv\u00e9s :\npharmaciens, infirmier s, infirmier s de pratique avanc\u00e9e, professionnels d 'activit\u00e9\nphysique adapt\u00e9e (enseignants APA, masseur s-kin\u00e9sith\u00e9rapeutes, ergoth\u00e9rapeutes,\npsychomotriciens), di\u00e9t\u00e9ticiens nutritionnistes, podologues, etc.\nDemandeur HAS\nPromoteur(s) Haute Autorit\u00e9 de sant\u00e9 (HAS)\nPilotage du projet Coordination : Sophie Blanchard, docteur en sciences biologiques et m\u00e9dicales, chef de\nprojet, service des bonnes pratiques de la HAS (chef de service : Dr Pierre Gabach)\nSecr\u00e9tariat : Mme Sladana Praizovic\nRecherche documentaire Emmanuelle Blondet, documentaliste ; Maud Lef\u00e8vre, assistante documentaliste (chef fe\nde service : Fr\u00e9d\u00e9rique Pag\u00e8s)\nAuteurs Dr Ana\u00efs Cloppet-Fontaine, g\u00e9riatre ; Dr Guillaume Grenet, endocrinologue ; Dr Thomas\nPinto, m\u00e9decin g\u00e9n\u00e9raliste ; Sophie Blanchard, docteur en sciences biologiques et\nm\u00e9dicales\nConflits d'int\u00e9r\u00eats Les membres du groupe de travail ont communiqu\u00e9 leurs d\u00e9clarations publiques\nd'int\u00e9r\u00eats \u00e0 la HAS. Elles sont consultables sur le site Elles ont\n\u00e9t\u00e9 analys\u00e9es selon la grille d'analyse du guide des d\u00e9clarations d'int\u00e9r\u00eats et de gestion\ndes conflits d 'int\u00e9r\u00eats de la HAS. Les int\u00e9r\u00eats d\u00e9clar\u00e9s par les membres du groupe de\ntravail ont \u00e9t\u00e9 consid\u00e9r\u00e9s comme \u00e9tant compatibles avec leur participation \u00e0 ce travail.\nValidation Version du 30 mai 2024\nActualisation\nAutres formats\n\nCe document ainsi que sa r\u00e9f\u00e9rence bibliographique sont t\u00e9l\u00e9chargeables sur www.has-sante.fr\nHaute Autorit\u00e9 de sant\u00e9 - Service communication information\n5, avenue du Stade de France - 93218 SAINT-DENIS LA PLAINE CEDEX. T\u00e9l.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2207, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "71b75331-506d-46d1-a926-b482fdc132c6": {"__data__": {"id_": "71b75331-506d-46d1-a926-b482fdc132c6", "embedding": null, "metadata": {"page_label": "3", "file_name": "strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_type": "application/pdf", "file_size": 920218, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "f09ace58-9832-49e1-9617-c686dee41acd", "node_type": "4", "metadata": {"page_label": "3", "file_name": "strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_type": "application/pdf", "file_size": 920218, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "bc8ce18ec8907ff2d67bf5006e95a82b1a47d81b7e87181ac6891d650b53366f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f8d520b5-29b0-46b4-bdb9-2d12711e2ed2", "node_type": "1", "metadata": {"page_label": "3", "file_name": "strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_type": "application/pdf", "file_size": 920218, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "6034a5ac40d446c5e22c7ebc5a6498f0f804e5096b6b3233c9969addc4302a13", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Validation Version du 30 mai 2024\nActualisation\nAutres formats\n\nCe document ainsi que sa r\u00e9f\u00e9rence bibliographique sont t\u00e9l\u00e9chargeables sur www.has-sante.fr\nHaute Autorit\u00e9 de sant\u00e9 - Service communication information\n5, avenue du Stade de France - 93218 SAINT-DENIS LA PLAINE CEDEX. T\u00e9l. : +33 (0)1 55 93 70 00\n\u00a9 Haute Autorit\u00e9 de sant\u00e9 - mai 2024 - ISBN : 978-2-11-172146-3", "mimetype": "text/plain", "start_char_idx": 1920, "end_char_idx": 2294, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "9b45ad80-b5bf-4146-a0e8-19fb9b268420": {"__data__": {"id_": "9b45ad80-b5bf-4146-a0e8-19fb9b268420", "embedding": null, "metadata": {"page_label": "4", "file_name": "strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_type": "application/pdf", "file_size": 920218, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "f8412b97-801c-4078-b3f0-11a9da9c93b2", "node_type": "4", "metadata": {"page_label": "4", "file_name": "strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_type": "application/pdf", "file_size": 920218, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "526f08d34e727ad22e053cc3eb6f81382b79bd247602fd33479b2266cea5db69", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "HAS \u2022 Strat\u00e9gie th\u00e9rapeutique du patient vivant avec un diab\u00e8te de type 2 \u2022 mai 2024 4\nSommaire\n\nPr\u00e9ambule 5\n1. G\u00e9n\u00e9ralit\u00e9s sur la prise en charge globale du patient vivant avec un DT2 9\n2. Strat\u00e9gie de prise en charge non m\u00e9dicamenteuse (population g\u00e9n\u00e9rale) 11\n2.1. Lutte contre la s\u00e9dentarit\u00e9, promotion de l'activit\u00e9 physique et activit\u00e9 physique adapt\u00e9e 11\n2.2. Prise en charge nutritionnelle 14\n2.3. \u00c9ducation th\u00e9rapeutique du patient 15\n3. Strat\u00e9gie de prise en charge m\u00e9dicamenteuse (population g\u00e9n\u00e9rale) 17\n3.1. G\u00e9n\u00e9ralit\u00e9s sur la PEC m\u00e9dicamenteuse 17\n3.2. Recommandations PEC m\u00e9dicamenteuse en mono et bith\u00e9rapie 20\n3.3. Recommandations PEC m\u00e9dicamenteuse en trith\u00e9rapie et/ou insulinoth\u00e9rapie 23\n4. Strat\u00e9gie de prise en charge pour des populations particuli\u00e8res 27\n4.1. Personne \u00e2g\u00e9e de plus de 75 ans 27\n4.2. Personne en situation d'ob\u00e9sit\u00e9 avec un IMC > 30 kg/m2 29\n4.3. Personnes avec insuffisance cardiaque 32\n4.4. Personnes avec maladie cardiovasculaire av\u00e9r\u00e9e 32\n4.5. Patients avec une maladie r\u00e9nale chronique 33\n4.6. Femmes vivant avec un DT2 enceintes ou envisageant de l'\u00eatre 34\nTable des annexes 36\nR\u00e9f\u00e9rences bibliographiques 44\nParticipants 52\nAbr\u00e9viations et acronymes 55", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1198, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "b8ff4e53-098a-4183-8ed7-71f5616bf1b4": {"__data__": {"id_": "b8ff4e53-098a-4183-8ed7-71f5616bf1b4", "embedding": null, "metadata": {"page_label": "5", "file_name": "strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_type": "application/pdf", "file_size": 920218, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "5bd94dbb-390f-4db0-b3d3-61c283a2eaff", "node_type": "4", "metadata": {"page_label": "5", "file_name": "strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_type": "application/pdf", "file_size": 920218, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "7081f8eaedbd9795fd6e82ad9ca7769f5d2b8517febfe5303166ba2c94eed3d3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ffac44c5-04d9-4f0a-ad74-cd6b77a35986", "node_type": "1", "metadata": {}, "hash": "8e4dbd4c6950eb51d5dee5f05144bb3bc635c2a49f4d043cd8a8adfafbee7f08", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "HAS \u2022 Strat\u00e9gie th\u00e9rapeutique du patient vivant avec un diab\u00e8te de type 2 \u2022 mai 2024 5\nPr\u00e9ambule\nRappels\nLe diab\u00e8te de type 2 (DT2) est une maladie chronique m\u00e9tabolique, qui se caract\u00e9rise par l'association\nd'une insulinor\u00e9sistance et d'une carence relative en insuline dont t\u00e9moigne un exc\u00e8s durable de la\nconcentration de glucose dans le sang, appel\u00e9 hyperglyc\u00e9mie.\nLe DT2 est souvent marqu\u00e9 cliniquement par un syndrome m\u00e9tabolique, un surpoids ou une ob\u00e9sit\u00e9,\ndes ant\u00e9c\u00e9dents familiaux de diab\u00e8te fr\u00e9quents, des ant\u00e9c\u00e9dents obst\u00e9tricaux (diab\u00e8te gestationnel,\nmacrosomie). En cas de pr\u00e9sentation atypique (carence en insuline, perte de poids ou hyperglyc\u00e9mie\nmajeure), il faut \u00e9voquer un autre type de diab\u00e8te (DT1, secondaire, monog\u00e9nique).\nSelon les recommandations de bonne pratique en cours, le DT2 est d\u00e9fini par :\n\u2012 une glyc\u00e9mie sup\u00e9rieure \u00e0 1,26 g/l (7,0 mmol/l) apr\u00e8s un je\u00fbne de 8 heures et v\u00e9rifi\u00e9e \u00e0 deux\nreprises ;\n\u2012 ou la pr\u00e9sence de sympt\u00f4mes de diab\u00e8te (polyurie, polydipsie, amaigrissement) associ\u00e9e \u00e0 une\nglyc\u00e9mie (sur plasma veineux) sup\u00e9rieure ou \u00e9gale \u00e0 2 g/l (11,1 mmol/l) ;\n\u2012 ou une glyc\u00e9mie (sur plasma veineux) sup\u00e9rieure ou \u00e9gale \u00e0 2 g/l (11,1 mmol/l) 2 heures apr\u00e8s\nune charge orale de 75 g de glucose (crit\u00e8res propos\u00e9s par l 'Organisation mondiale de la\nsant\u00e9).\nLe DT2 conduit \u00e0 des complications microvasculaires (r\u00e9tinopathie, n\u00e9phropathie et neuropathie) et\nmacrovasculaires (cardiopathie isch\u00e9mique, insuffisance cardiaque non isch\u00e9mique, art\u00e9riopathie oblit\u00e9rante des membres inf\u00e9rieurs, accident vasculaire c\u00e9r\u00e9bral isch\u00e9mique, maladie vasculaire r\u00e9nale,\netc.).\nLa prise en charge du patient atteint d'un DT2 a pour objectif de r\u00e9duire la morbi-mortalit\u00e9, notamment\npar un contr\u00f4le glyc\u00e9mique correct , la pr\u00e9vention, le d\u00e9pistage et le traitement de ses complications\nvasculaires et r\u00e9nales ainsi que l'am\u00e9lioration de la qualit\u00e9 de vie du patient.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1888, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "ffac44c5-04d9-4f0a-ad74-cd6b77a35986": {"__data__": {"id_": "ffac44c5-04d9-4f0a-ad74-cd6b77a35986", "embedding": null, "metadata": {"page_label": "5", "file_name": "strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_type": "application/pdf", "file_size": 920218, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "5bd94dbb-390f-4db0-b3d3-61c283a2eaff", "node_type": "4", "metadata": {"page_label": "5", "file_name": "strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_type": "application/pdf", "file_size": 920218, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "7081f8eaedbd9795fd6e82ad9ca7769f5d2b8517febfe5303166ba2c94eed3d3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b8ff4e53-098a-4183-8ed7-71f5616bf1b4", "node_type": "1", "metadata": {"page_label": "5", "file_name": "strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_type": "application/pdf", "file_size": 920218, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "21cb29cce0471131e45f0ea63bef50145cbe6f28f6e57d19d4c3d9a7f1ef81bd", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "La prise en charge du patient atteint d'un DT2 a pour objectif de r\u00e9duire la morbi-mortalit\u00e9, notamment\npar un contr\u00f4le glyc\u00e9mique correct , la pr\u00e9vention, le d\u00e9pistage et le traitement de ses complications\nvasculaires et r\u00e9nales ainsi que l'am\u00e9lioration de la qualit\u00e9 de vie du patient.\n\nActualisation 2024\nLes objectifs de cette fiche m\u00e9mo sont d'actualiser les recommandations \u00ab Strat\u00e9gie m\u00e9dicamenteuse\ndu contr\u00f4le glyc\u00e9mique du DT2 \u00bb \u00e9mises en 2013 et de se voir prolonger par l'actualisation du parcours\nde soins sur la prise en charge des adultes atteints de diab\u00e8te de type 2.\nLes principaux enjeux de cette actualisation sont :\n\u2012 l'int\u00e9gration de th\u00e9rapeutiques non m\u00e9dicamenteuses dans une prise en charge globale du\npatient diagnostiqu\u00e9 avec un DT2 ;\n\u2012 l'actualisation des recommandations sur la strat\u00e9gie th\u00e9rapeutique int\u00e9grant les donn\u00e9es\ndiffus\u00e9es post\u00e9rieurement aux recommandations de 2013 ;\n\u2012 pr\u00e9parer l'actualisation du parcours de soins du DT2 de l'adulte de 2014.\n\nCette mise \u00e0 jour ne concerne pas les recommandations portant sur :\n\u2012 la red\u00e9finition des objectifs glyc\u00e9miques ou la place de l'autosurveillance glyc\u00e9mique qui restent\nmaintenues selon les recommandations de bonne pratique en cours (voir annexe pour rappel) ;\n\u2012 la prise en charge du diab\u00e8te gestationnel ;\n\u2012 la t\u00e9l\u00e9surveillance m\u00e9dicale du patient diab\u00e9tique.", "mimetype": "text/plain", "start_char_idx": 1601, "end_char_idx": 2948, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "a2ad1d21-ce00-4854-b57f-32ecdb27bcbb": {"__data__": {"id_": "a2ad1d21-ce00-4854-b57f-32ecdb27bcbb", "embedding": null, "metadata": {"page_label": "6", "file_name": "strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_type": "application/pdf", "file_size": 920218, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "3d905851-4130-45cd-8546-ca1a9beab4e7", "node_type": "4", "metadata": {"page_label": "6", "file_name": "strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_type": "application/pdf", "file_size": 920218, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "9b3003d24747e1f96cfd67e8415f3390d05a2c8b064b89d40acbf7cfe38a9ed6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "505601cb-2823-4c03-a373-1d2940df9516", "node_type": "1", "metadata": {}, "hash": "66366f2355e7a9316703f76e2504b392c9a7e555b70ce8048d06ef4b1256385a", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "HAS \u2022 Strat\u00e9gie th\u00e9rapeutique du patient vivant avec un diab\u00e8te de type 2 \u2022 mai 2024 6\nElle ne porte pas non plus sur le volet m\u00e9dico-\u00e9conomique de la prise en charge du patient diab\u00e9tique.\nInt\u00e9gration des travaux HAS les plus r\u00e9cents\nLes recommandations de bonne pratique RBP 202 4 int\u00e8grent les travaux r\u00e9cents de la HAS en lien\navec la th\u00e9matique et s'y r\u00e9f\u00e8rent le cas \u00e9ch\u00e9ant (voir liste non exhaustive en annexe). Si besoin, les\nrecommandations pourront les compl\u00e9ter.\n\nPopulations concern\u00e9es\nCes RBP portent sur la p rise en charge globale (int\u00e9grant les volets non m\u00e9dicamenteux et m\u00e9dicamenteux) du patient diagnostiqu\u00e9 avec un DT2, en 1re ligne, 2e ligne, 3e ligne.\nLes populations concern\u00e9es sont :\n\u2012 population g\u00e9n\u00e9rale ;\n\u2012 et certaines populations sp\u00e9cifiques avec une particularit\u00e9 de prise en charge :\n\u2022 chez la personne \u00e2g\u00e9e de plus de 75 ans,\n\u2022 chez la personne pr\u00e9sentant une ob\u00e9sit\u00e9 avec un IMC > 35 kg/m2,\n\u2022 chez la personne pr\u00e9sentant une maladie r\u00e9nale chronique,\n\u2022 chez la personne pr\u00e9sentant une insuffisance cardiaque,\n\u2022 chez la personne pr\u00e9sentant une maladie cardiovasculaire av\u00e9r\u00e9e,\n\u2022 chez la femme enceinte (ou envisageant de l'\u00eatre).\n\nProfessionnels concern\u00e9s\nM\u00e9decins g\u00e9n\u00e9ralistes, m\u00e9decins sp\u00e9cialistes endocrinologues diab\u00e9tologues nutritionnistes (EDN),\net tout professionnel qui prend en charge les patients vivant avec un DT2 en ville ou dans le cadre des\n\u00e9tablissements de soins publics ou priv\u00e9s : pharmaciens, infirmiers, infirmiers de pratique avanc\u00e9e,\nprofessionnels d'activit\u00e9 physique adapt\u00e9e (enseignants APA, masseurs-kin\u00e9sith\u00e9rapeutes, ergoth\u00e9rapeutes, psychomotriciens), di\u00e9t\u00e9ticiens, nutritionnistes, podologues, etc.\n\nAvertissement\nComme lors des pr\u00e9c\u00e9dentes recommandations \u00ab Strat\u00e9gie m\u00e9dicamenteuse du contr\u00f4le glyc\u00e9mique\ndu DT2 \u00bb \u00e9mises en 2013, les crit\u00e8res de jugement et les objectifs th\u00e9rapeutiques, incluant les crit\u00e8res\nde suivi, sont un point central dans les discussions entre les experts du domaine.\nEn effet, bien qu'aucune corr\u00e9lation n'ait d\u00e9montr\u00e9 le lien entre la r\u00e9duction de l'HbA1c et l'am\u00e9lioration\nde la morbi-mortalit\u00e9, les \u00e9tudes portant sur la variation de ce crit\u00e8re de jugement biologique interm\u00e9diaire constituent toujours le socle des \u00e9tudes fournies pour l'obtention de l'AMM.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2256, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "505601cb-2823-4c03-a373-1d2940df9516": {"__data__": {"id_": "505601cb-2823-4c03-a373-1d2940df9516", "embedding": null, "metadata": {"page_label": "6", "file_name": "strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_type": "application/pdf", "file_size": 920218, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "3d905851-4130-45cd-8546-ca1a9beab4e7", "node_type": "4", "metadata": {"page_label": "6", "file_name": "strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_type": "application/pdf", "file_size": 920218, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "9b3003d24747e1f96cfd67e8415f3390d05a2c8b064b89d40acbf7cfe38a9ed6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a2ad1d21-ce00-4854-b57f-32ecdb27bcbb", "node_type": "1", "metadata": {"page_label": "6", "file_name": "strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_type": "application/pdf", "file_size": 920218, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "82fd641046cedf789921d89a43336c353013f88f12b359982b8037b38b0a1abd", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "En effet, bien qu'aucune corr\u00e9lation n'ait d\u00e9montr\u00e9 le lien entre la r\u00e9duction de l'HbA1c et l'am\u00e9lioration\nde la morbi-mortalit\u00e9, les \u00e9tudes portant sur la variation de ce crit\u00e8re de jugement biologique interm\u00e9diaire constituent toujours le socle des \u00e9tudes fournies pour l'obtention de l'AMM.\nToutefois, et en compl\u00e9ment, les r\u00e9sultats d'\u00e9tudes sur des crit\u00e8res de jugement cardiovasculaires ont\n\u00e9t\u00e9 g\u00e9n\u00e9r\u00e9s et sont d\u00e9sormais disponibles pour les classes des traitements m\u00e9dicamenteux de l'hyperglyc\u00e9mie (TMH) les plus r\u00e9centes, \u00e0 savoir les iDPP4, les aGLP1 et les iSGLT21. Ces donn\u00e9es ont\n\n1 En effet, \u00e0 la suite de la survenue de probl\u00e8mes de tol\u00e9rance cardiovasculaire avec la rosiglitazone ( thiazolidinedione), la FDA, depuis\n2008, et l 'EMA, depuis 2012, exigent que les laboratoires fournissent , en vue de l 'obtention ou du maintien d 'une AMM, une \u00e9tude de\ntol\u00e9rance cardiovasculaire afin de d\u00e9montrer que le m\u00e9dicament n'augmente pas les \u00e9v\u00e8nements cardiovasculaires par rapport au placebo\nsur la base d 'un crit\u00e8re de jugement cardiovasculaire composite, \u00e0 savoir le crit\u00e8re composite 3P -MACE (3 points Major Adverse Cardiac\nEvents).", "mimetype": "text/plain", "start_char_idx": 1962, "end_char_idx": 3111, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "9c9d9cba-10a8-452c-b84d-e9412c2c5e28": {"__data__": {"id_": "9c9d9cba-10a8-452c-b84d-e9412c2c5e28", "embedding": null, "metadata": {"page_label": "7", "file_name": "strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_type": "application/pdf", "file_size": 920218, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "a46bb72b-542d-4b72-82af-dafa633e36f5", "node_type": "4", "metadata": {"page_label": "7", "file_name": "strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_type": "application/pdf", "file_size": 920218, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "722852345518740746e1491cf3f7d43aec2eeadf9bc14c816d9f4262e0ebaf5b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "dabd2903-dde0-4af0-8b29-92e0c3ff5312", "node_type": "1", "metadata": {}, "hash": "20c9a3fea6f462fffe8395852e981ad170585773e7a2b35235e06e0ace80a07b", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "HAS \u2022 Strat\u00e9gie th\u00e9rapeutique du patient vivant avec un diab\u00e8te de type 2 \u2022 mai 2024 7\npour cons\u00e9quences des \u00e9volutions importante s dans la PEC m\u00e9dicamenteuse retenues par les plus\nr\u00e9centes RBP internationales.\nH\u00e9moglobine glyqu\u00e9e HbA1c\nL'utilisation du crit\u00e8re HbA1c comme crit\u00e8re interm\u00e9diaire avait d\u00e9j\u00e0 \u00e9t\u00e9 discut\u00e9e pendant l'\u00e9laboration\nde la RBP HAS en 2013 et avait conduit \u00e0 de fortes discussions au sein du pr\u00e9c\u00e9dent groupe d'experts\net \u00e0 l'\u00e9laboration de recommandations majoritairement bas\u00e9es sur un accord d'experts (AE).\nEn effet, il est discut\u00e9 que m\u00eame si l'HbA1c est un facteur pronostique bien corr\u00e9l\u00e9 au risque de complications, les crit\u00e8res de jugement interm\u00e9diaires (comme d 'autres car non sp\u00e9cifiques au domaine\nde la diab\u00e9tologie) exposent notamment \u00e0 deux \u00e9cueils principaux :\n\u2012 s'assurer que le b\u00e9n\u00e9fice du traitement sur le crit\u00e8re interm\u00e9diaire est effectivement corr\u00e9l\u00e9 \u00e0\nun b\u00e9n\u00e9fice clinique (r\u00e9sultats contrast\u00e9s et parfois contradictoires des \u00e9tudes d'intensification\ndans le DT2) ;\n\u2012 et ne permet pas de capturer les risques iatrog\u00e8nes par ailleurs des th\u00e9rapeutiques utilis\u00e9 es\npour traiter le crit\u00e8re interm\u00e9diaire (exemple : effets ind\u00e9sirables au -del\u00e0 des hypoglyc\u00e9mies\ndans l'histoire du traitement du DT2).\nObjectifs glyc\u00e9miques et pr\u00e9vention des complications cardiovasculaires et r\u00e9nales\nLes membres du groupe de travail (GT) ont convenu que le taux HbA1c est maintenant mis en parall\u00e8le\navec des \u00e9v\u00e8nements et complications cardiovasculaires et/ou r\u00e9nales, en particulier dans de r\u00e9centes\nRBP (par exemple , les RBP anglaises NICE 2022, RBP am\u00e9ricaines ADA 2023, et RBP conjointes\nam\u00e9ricaines/europ\u00e9ennes ADA/EASD 202 3, Australian Evidence -Based Clinical Guidelines for\nDiabetes 2024, etc.).\nLes traitements utilis\u00e9s dans le DT2 ont pour objectif de baisser le taux d'HbA1c mais \u00e0 HbA1c constante, l'efficacit\u00e9 des traitements sur la pr\u00e9vention des \u00e9v\u00e8nements cardiovasculaires/r\u00e9naux n'est pas\nidentique selon la mol\u00e9cule choisie.\nLe groupe a rappel\u00e9 qu'au-del\u00e0 de l'effet commun de baisse de l'HbA1c, certains traitements r\u00e9cents\nont des effets propres protecteurs cardio vasculaires et r\u00e9naux qui peuvent \u00eatre consid\u00e9r\u00e9s dans le\nchoix th\u00e9rapeutique.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2198, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "dabd2903-dde0-4af0-8b29-92e0c3ff5312": {"__data__": {"id_": "dabd2903-dde0-4af0-8b29-92e0c3ff5312", "embedding": null, "metadata": {"page_label": "7", "file_name": "strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_type": "application/pdf", "file_size": 920218, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "a46bb72b-542d-4b72-82af-dafa633e36f5", "node_type": "4", "metadata": {"page_label": "7", "file_name": "strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_type": "application/pdf", "file_size": 920218, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "722852345518740746e1491cf3f7d43aec2eeadf9bc14c816d9f4262e0ebaf5b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9c9d9cba-10a8-452c-b84d-e9412c2c5e28", "node_type": "1", "metadata": {"page_label": "7", "file_name": "strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_type": "application/pdf", "file_size": 920218, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "8211a2b314c907d233efc321690d3c462c6c70b961698573fc5a7ce1c726062f", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Le groupe a rappel\u00e9 qu'au-del\u00e0 de l'effet commun de baisse de l'HbA1c, certains traitements r\u00e9cents\nont des effets propres protecteurs cardio vasculaires et r\u00e9naux qui peuvent \u00eatre consid\u00e9r\u00e9s dans le\nchoix th\u00e9rapeutique.\nEn raison de la qualit\u00e9 m\u00e9thodologique de niveau souvent \u00ab faible \u00e0 mod\u00e9r\u00e9 \u00bb des m\u00e9ta-analyses et/ou\ndes \u00e9tudes incluses dans les m\u00e9ta-analyses, il pourra \u00eatre \u00e9labor\u00e9 par les membres du GT des recommandations en vue de proposer des recherches cliniques futures manquantes ; il s'agira d'assurer une\nplus-value suppl\u00e9mentaire \u00e0 ces travaux. En effet, certaines questions majeures n'ont pas encore de\nr\u00e9ponse par des donn\u00e9es probantes de haut niveau de preuve (par exemple, le traitement pharmacologique de 1re intention chez les patients n'ayant pas d'indication sp\u00e9cifique des m\u00e9dicaments \u00e0 haut\nniveau de preuve d\u00e9j\u00e0 rapport\u00e9). Ces recommandations pour la recherche clinique pourront asseoir la\njustification d'\u00e9tudes afin d'apporter des r\u00e9ponses de haut niveau de preuve aux questions non r\u00e9solues par l'\u00e9tat de l'art actuel.\nPar ailleurs, selon le GT, i l est recommand\u00e9 d'\u00e9valuer r\u00e9guli\u00e8rement les traitements de la prise en\ncharge, de les adapter, selon les r\u00e9sultats obtenus sur les objectifs d\u00e9finis avec le patient (contr\u00f4le\nglyc\u00e9mique, pr\u00e9vention et/ou traitement des complications ), leur \u00e9volution et en cas d 'hypoglyc\u00e9mie\net/ou d'effets ind\u00e9sirables. Il doit pouvoir \u00eatre envisag\u00e9 un arr\u00eat ou une d\u00e9sescalade des traitements,\nselon les situations et si les objectifs sont atteints ou la situation normalis\u00e9e.\n\nLe 3P-MACE comprend le d\u00e9c\u00e8s cardiovasculaire, l 'infarctus du myocarde non mortel, l 'accident vasculaire c\u00e9r\u00e9bral (AVC) non mortel. \u00c0\nnoter, l'utilisation parfois du crit\u00e8re de jugement 4P-MACE, avec l'ajout du crit\u00e8re hospitalisation pour angor instable, en sus des crit\u00e8res du\n3P-MACE.", "mimetype": "text/plain", "start_char_idx": 1978, "end_char_idx": 3812, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "27f605d3-0b8a-4100-8b97-3faaa2ef5253": {"__data__": {"id_": "27f605d3-0b8a-4100-8b97-3faaa2ef5253", "embedding": null, "metadata": {"page_label": "8", "file_name": "strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_type": "application/pdf", "file_size": 920218, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "18bbd4d1-f1aa-4c0b-8c79-d081b384a8c9", "node_type": "4", "metadata": {"page_label": "8", "file_name": "strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_type": "application/pdf", "file_size": 920218, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "e33c1ff0a6a3bc279fc4c183fbc7a9f97c3ee1bd1e65320a69fbadd68d01c37e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0b495064-fcc0-4036-b1d0-b3e5997d98f6", "node_type": "1", "metadata": {}, "hash": "56d2a5ac588bb587d20c628e371aa1dca979d641c74977bb4b17988b5cc70309", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "HAS \u2022 Strat\u00e9gie th\u00e9rapeutique du patient vivant avec un diab\u00e8te de type 2 \u2022 mai 2024 8\nUne d\u00e9marche globale centr\u00e9e sur le patient\nLe diab\u00e8te est une pathologie chronique multifactorielle et \u00e9volutive.\nLa prise en charge du patient vivant avec un DT2 est aussi plurielle et doit \u00eatre r\u00e9\u00e9valu\u00e9e r\u00e9guli\u00e8rement\ndans toutes ses composantes : modifications th\u00e9rapeutiques du mode de vie (programme nutritionnel,\nactivit\u00e9 physique, etc.), \u00e9ducation th\u00e9rapeutique et traitements m\u00e9dicamenteux.\nL'objectif th\u00e9rapeutique doit \u00eatre individualis\u00e9 en fonction du profil des patients vivant avec un DT2\n(population g\u00e9n\u00e9rale ou plus sp\u00e9cifique, pr\u00e9sence ou non de comorbidit\u00e9s et de facteurs de risque\ncardiovasculaire, complications du diab\u00e8te, etc.) et peut donc \u00e9voluer au cours du temps.\nDans le cadre d 'une prise en charge personnalis\u00e9e et individualis\u00e9e du patient vivant avec un DT2,\nune \u00e9ducation th\u00e9rapeutique et la mise en place de mesures de modification th\u00e9rapeutique du mode\nde vie (programme nutritionnel, activit\u00e9 physique/activit\u00e9 physique adapt\u00e9e, lutte contre la s\u00e9dentarit\u00e9,\netc.) efficaces sont un pr\u00e9alable indispensable au d\u00e9marrage d'un traitement m\u00e9dicamenteux et leur\napplication doit \u00eatre poursuivie tout au long de la prise en charge.\nLa strat\u00e9gie th\u00e9rapeutique du patient vivant avec un DT2 est multifactorielle et repose sur un ensemble\nd'\u00e9l\u00e9ments \u00e0 consid\u00e9rer pour d\u00e9finir la d\u00e9marche centr\u00e9e sur le patient : l'objectif d'HbA1c cibl\u00e9, les\nant\u00e9c\u00e9dents et la pr\u00e9vention des complications cardiovasculaires et r\u00e9nales, l 'efficacit\u00e9 attendue des\ntraitements, leur tol\u00e9rance, leur s\u00e9curit\u00e9, leur co\u00fbt ainsi que les pr\u00e9f\u00e9rences du patient.\nLors du choix d'une classe th\u00e9rapeutique d\u00e9termin\u00e9e, la d\u00e9marche centr\u00e9e sur le patient implique la\nprise en compte du profil du patient (prise en compte de ses besoins, situation, pr\u00e9f\u00e9rences, acceptabilit\u00e9) et les caract\u00e9ristiques de l 'antidiab\u00e9tique envisag\u00e9 (indications et contre -indications, efficacit\u00e9\nsur le taux d 'HbA1c, impacts protecteurs sur les complications cardiovasculaires et r\u00e9nales , risque\nd'hypoglyc\u00e9mie, effet sur le poids, effets secondaires, modalit\u00e9s d'administration, etc.).", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2156, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "0b495064-fcc0-4036-b1d0-b3e5997d98f6": {"__data__": {"id_": "0b495064-fcc0-4036-b1d0-b3e5997d98f6", "embedding": null, "metadata": {"page_label": "8", "file_name": "strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_type": "application/pdf", "file_size": 920218, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "18bbd4d1-f1aa-4c0b-8c79-d081b384a8c9", "node_type": "4", "metadata": {"page_label": "8", "file_name": "strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_type": "application/pdf", "file_size": 920218, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "e33c1ff0a6a3bc279fc4c183fbc7a9f97c3ee1bd1e65320a69fbadd68d01c37e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "27f605d3-0b8a-4100-8b97-3faaa2ef5253", "node_type": "1", "metadata": {"page_label": "8", "file_name": "strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_type": "application/pdf", "file_size": 920218, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "ce49be84749df523c8c8604924f5fceebe62328cafea749ef246c65f36007ec6", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Tout au long de la prise en charge, de mani\u00e8re r\u00e9guli\u00e8re et \u00e0 chaque changement de traitement, il est\nn\u00e9cessaire de reconsid\u00e9rer le maintien ou l'arr\u00eat de la strat\u00e9gie m\u00e9dicamenteuse (efficacit\u00e9, tol\u00e9rance,\npr\u00e9f\u00e9rences du patient) et d'assurer l'\u00e9ducation th\u00e9rapeutique du patient, sa connaissance et son adh\u00e9sion (en particulier lors du passage \u00e0 un traitement injectable).", "mimetype": "text/plain", "start_char_idx": 2157, "end_char_idx": 2531, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "27916d68-7597-44da-8636-b7db6d1e5ce8": {"__data__": {"id_": "27916d68-7597-44da-8636-b7db6d1e5ce8", "embedding": null, "metadata": {"page_label": "9", "file_name": "strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_type": "application/pdf", "file_size": 920218, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "fcb5e6a0-13e2-41b5-a6fa-0b6e2ddecd6f", "node_type": "4", "metadata": {"page_label": "9", "file_name": "strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_type": "application/pdf", "file_size": 920218, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "565723967a199baa8103a46434551bcf438baaf1035a401252ed88abbba8987b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ee3ef5ff-43b0-4107-93f8-0ce34901ac0d", "node_type": "1", "metadata": {}, "hash": "ae171d1365affe63b3fff0f2b7d4f9df6237ddd0c5ea2dc07d68d34f2433ffb3", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "HAS \u2022 Strat\u00e9gie th\u00e9rapeutique du patient vivant avec un diab\u00e8te de type 2 \u2022 mai 2024 9\n1. G\u00e9n\u00e9ralit\u00e9s sur la prise en charge globale\ndu patient vivant avec un DT2\nLe diab\u00e8te est une pathologie chronique multifactorielle et \u00e9volutive. La prise en charge (PEC) globale\ndu patient diab\u00e9tique est aussi plurielle et doit \u00eatre r\u00e9\u00e9valu\u00e9e r\u00e9guli\u00e8rement dans toutes ses composantes, que cela soit les traitements m\u00e9dicamenteux ou les modifications th\u00e9rapeutiques du mode de\nvie (MTMV) : programme nutritionnel, activit\u00e9 physique , activit\u00e9 physique adapt\u00e9e, \u00e9ducation th\u00e9rapeutique, etc.\nTableau 1. Recommandations DT2 - g\u00e9n\u00e9ralit\u00e9s sur la prise en charge (PEC) globale\nGRADE N\u00b0\nA\nR.1 La prise en charge globale devrait inclure le d\u00e9pistage et la prise en charge de tous\nles facteurs de risque cardiovasculaire , notamment : tabac, hypertension art\u00e9rielle,\ns\u00e9dentarit\u00e9, ob\u00e9sit\u00e9, dyslipid\u00e9mie, etc.\nC\nR.2 Il est recommand\u00e9 d'individualiser la prise en charge non m\u00e9dicamenteuse et m\u00e9dicamenteuse des patients vivant avec un DT2 en fonction du profil des patients , de\nleurs besoins et de leurs pr\u00e9f\u00e9rences.\nB\nR.3 Le diab\u00e8te est \u00e9volutif et il est recommand\u00e9 de r\u00e9\u00e9valuer sa prise en charge r\u00e9guli\u00e8rement dans toutes ses composantes : mesures non m\u00e9dicamenteuses et traitements\nm\u00e9dicamenteux.\nB\nR.4 La mise en place de mesures efficaces de modification th\u00e9rapeutique du mode de vie\n(MTMV) est indispensable \u00e0 la prise en charge du patient vivant avec un DT2 : programme nutritionnel, lutte contre la s\u00e9dentarit\u00e9, activit\u00e9 physique/activ it\u00e9 physique\nadapt\u00e9e, prise en charge du sommeil, \u00e9ducation th\u00e9rapeutique, etc.\nCes MTMV peuvent \u00eatre envisag\u00e9es seules en 1re intention, sauf dans certaines situations particuli\u00e8res (par exemple, hyperglyc\u00e9mie majeure au diagnostic ou patients\n\u00e0 haut risque CV).\nLeur application est poursuivie tout au long de la prise en charge , en association au\nchamp du contr\u00f4le glyc\u00e9mique \u00e0 travers la strat\u00e9gie m\u00e9dicamenteuse de contr\u00f4le des\nglyc\u00e9mies.\nR.5 Dans le cadre d'une prise en charge personnalis\u00e9e et individualis\u00e9e du patient vivant\navec un DT2, l'\u00e9ducation th\u00e9rapeutique du patient (ETP) mise en \u0153uvre par les professionnels de sant\u00e9 et associations sont recommand\u00e9s d\u00e8s le diagnostic de DT2 et\ntout au long de sa prise en charge.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2260, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "ee3ef5ff-43b0-4107-93f8-0ce34901ac0d": {"__data__": {"id_": "ee3ef5ff-43b0-4107-93f8-0ce34901ac0d", "embedding": null, "metadata": {"page_label": "9", "file_name": "strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_type": "application/pdf", "file_size": 920218, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "fcb5e6a0-13e2-41b5-a6fa-0b6e2ddecd6f", "node_type": "4", "metadata": {"page_label": "9", "file_name": "strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_type": "application/pdf", "file_size": 920218, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "565723967a199baa8103a46434551bcf438baaf1035a401252ed88abbba8987b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "27916d68-7597-44da-8636-b7db6d1e5ce8", "node_type": "1", "metadata": {"page_label": "9", "file_name": "strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_type": "application/pdf", "file_size": 920218, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "dfc9fc72d044d56903c90e11100fc103aca294bd7caebbd124c169c6db105592", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "R.5 Dans le cadre d'une prise en charge personnalis\u00e9e et individualis\u00e9e du patient vivant\navec un DT2, l'\u00e9ducation th\u00e9rapeutique du patient (ETP) mise en \u0153uvre par les professionnels de sant\u00e9 et associations sont recommand\u00e9s d\u00e8s le diagnostic de DT2 et\ntout au long de sa prise en charge.\nR.6 La PEC du patient vivant avec un DT2 se doit d'\u00eatre globale avec pour objectifs :\n\u2012 l'atteinte de la cible glyc\u00e9mique fix\u00e9e pour/avec le patient ;\n\u2012 la pr\u00e9vention de la morbi-mortalit\u00e9 li\u00e9e aux complications cardiovasculaires et\ndes complications microvasculaires (r\u00e9nales, r\u00e9tiniennes et neuropathiques) ;\n\u2012 l'am\u00e9lioration de la qualit\u00e9 de vie.\nR.7 Tout au long de la prise en charge, de mani\u00e8re r\u00e9guli\u00e8re et \u00e0 chaque consultation, il\nest n\u00e9cessaire de reconsid\u00e9rer l'instauration, le maintien, l'intensification ou l'arr\u00eat de", "mimetype": "text/plain", "start_char_idx": 1972, "end_char_idx": 2792, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "d9dff639-cf7a-4060-96a8-33d19832b6bb": {"__data__": {"id_": "d9dff639-cf7a-4060-96a8-33d19832b6bb", "embedding": null, "metadata": {"page_label": "10", "file_name": "strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_type": "application/pdf", "file_size": 920218, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "8d2260b4-6745-4abf-9f33-31eaf7e2fd18", "node_type": "4", "metadata": {"page_label": "10", "file_name": "strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_type": "application/pdf", "file_size": 920218, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "79b60996aa4002dfa896f01a6752f9506209e3103b98c7671080bde8430dd146", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "HAS \u2022 Strat\u00e9gie th\u00e9rapeutique du patient vivant avec un diab\u00e8te de type 2 \u2022 mai 2024 10\nla strat\u00e9gie m\u00e9dicamenteuse (efficacit\u00e9, tol\u00e9rance, pr\u00e9f\u00e9rences du patient) et d'assurer l'\u00e9ducation th\u00e9rapeutique du patient, sa connaissance, son observance et son adh\u00e9sion (en particulier lors du passage \u00e0 un traitement injectable).\nAE\nR.8 Recommandation pour la recherche clinique\nLe groupe de travail rel\u00e8ve le besoin d'\u00e9tudes sur la place d'autres \u00e9l\u00e9ments \u00e0 inclure\ndans la PEC du patient vivant avec un DT2, en particulier : qualit\u00e9 de vie, troubles du\nsommeil, sant\u00e9 mentale, cancer, d\u00e9terminants sociaux, traitements (corticoth\u00e9rapie\nou immunosuppression pour greffe), etc.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 671, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "18f22dff-e07d-434f-8257-a996a95895e3": {"__data__": {"id_": "18f22dff-e07d-434f-8257-a996a95895e3", "embedding": null, "metadata": {"page_label": "11", "file_name": "strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_type": "application/pdf", "file_size": 920218, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "6c024988-e89a-4a16-bbeb-ea705895d90d", "node_type": "4", "metadata": {"page_label": "11", "file_name": "strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_type": "application/pdf", "file_size": 920218, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "6fb660378e942feac9ff68c6bdd5e107e36b95a78d1dadcce89624879374d67a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4b39664a-a75a-4896-be3e-cfb7830a76a5", "node_type": "1", "metadata": {}, "hash": "68e52099fad31890a064959e1c03111ab685076523dfe14f433dd446649a2ce1", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "HAS \u2022 Strat\u00e9gie th\u00e9rapeutique du patient vivant avec un diab\u00e8te de type 2 \u2022 mai 2024 11\n2. Strat\u00e9gie de prise en charge non\nm\u00e9dicamenteuse (population g\u00e9n\u00e9rale)\nLa strat\u00e9gie de prise en charge non m\u00e9dicamenteuse du patient vivant avec un DT2 int\u00e8gre :\n\u2794 les mesures visant \u00e0 la modification th\u00e9rapeutique du mode de vie (MTMV) qui, par d\u00e9finition,\nincluent la prise en charge nutritionnelle et l'activit\u00e9 physique au sens large2, etc.\n\u2794 l'\u00e9ducation th\u00e9rapeutique du patient (ETP).\nTableau 2. Recommandations DT2 - PEC non m\u00e9dicamenteuse\nGRADE N\u00b0\nC\nR.10 La mise en place de mesures visant \u00e0 la modification th\u00e9rapeutique du mode de\nvie (MTMV) est indispensable \u00e0 la prise en charge du patient vivant avec un DT2.\nLeur application doit \u00eatre poursuivie tout au long de la prise en charge.\nAE\nR.11 L'\u00e9ducation th\u00e9rapeutique (ETP) r\u00e9guli\u00e8re et structur\u00e9e, est indispensable \u00e0 la\nprise en charge des patients vivant avec un DT2.\nA\nR.12\n\nLa pr\u00e9vention du tabagisme et la promotion du sevrage tabagique font partie de\nla prise en charge du patient diab\u00e9tique et selon les modalit\u00e9s d\u00e9crites dans les\nrecommandations de bonne pratique en cours3.\n2.1. Lutte contre la s\u00e9dentarit\u00e9, promotion de l'activit\u00e9 physique et\nactivit\u00e9 physique adapt\u00e9e\nChez le patient vivant avec un DT2 comme dans la population g\u00e9n\u00e9rale, les b\u00e9n\u00e9fices de l 'activit\u00e9\nphysique (AP) sont nombreux sur la sant\u00e9, la condition physique et pour le maintien de l 'autonomie\navec l'avanc\u00e9e en \u00e2ge.\nLes b\u00e9n\u00e9fices attendus pour les patients vivant avec un DT2 sont une am\u00e9lioration de la sensibilit\u00e9 \u00e0\nl'insuline, une am\u00e9lioration des facteurs de risque de progression du diab\u00e8te, une diminution du risque\nde complications cardiovasculaires, une am\u00e9lioration de la qualit\u00e9 de vie, une am\u00e9lioration de l'\u00e9quilibre glyc\u00e9mique, une diminution de la mortalit\u00e9, etc.\nL'activit\u00e9 physique adapt\u00e9e est une th\u00e9rapeutique \u00e0 part enti\u00e8re, seule ou en association avec les\ntraitements m\u00e9dicamenteux, dans de nombreuses maladies chroniques, facteurs de risque et situations de perte d'autonomie.\n\n2 En France, des recommandations sur l'alimentation et l'activit\u00e9 physique sont d\u00e9finies et diffus\u00e9es par les pouvoirs publics dans le\ncadre du programme national nutrition-sant\u00e9 (PNNS) en 2001.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2233, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "4b39664a-a75a-4896-be3e-cfb7830a76a5": {"__data__": {"id_": "4b39664a-a75a-4896-be3e-cfb7830a76a5", "embedding": null, "metadata": {"page_label": "11", "file_name": "strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_type": "application/pdf", "file_size": 920218, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "6c024988-e89a-4a16-bbeb-ea705895d90d", "node_type": "4", "metadata": {"page_label": "11", "file_name": "strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_type": "application/pdf", "file_size": 920218, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "6fb660378e942feac9ff68c6bdd5e107e36b95a78d1dadcce89624879374d67a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "18f22dff-e07d-434f-8257-a996a95895e3", "node_type": "1", "metadata": {"page_label": "11", "file_name": "strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_type": "application/pdf", "file_size": 920218, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "f2b26147ecc3c29240f9b423d0cb5c523df336fb64681ca4fc1fb54796c9e275", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "2 En France, des recommandations sur l'alimentation et l'activit\u00e9 physique sont d\u00e9finies et diffus\u00e9es par les pouvoirs publics dans le\ncadre du programme national nutrition-sant\u00e9 (PNNS) en 2001. Le PNNS est un plan de sant\u00e9 publique visant \u00e0 am\u00e9liorer l '\u00e9tat de\nsant\u00e9 de la population en agissant sur l 'un de ses d\u00e9terminants majeurs : la nutrition, entendue comme l 'alimentation et l 'activit\u00e9\nphysique. Voir Recommandations sur l'alimentation, l'activit\u00e9 physique & la s\u00e9dentarit\u00e9 pour les adultes , Sant\u00e9 publique France,\njanvier 2019.\n3 \u00c0 la date de l 'actualisation (mai 2024), la RBP \u00ab Arr\u00eat de la consommation de tabac : du d\u00e9pistage individuel au maintien de\nl'abstinence en premiers recours \u00bb \u00e9mise en 2014 est en cours d'actualisation (voir note de cadrage juillet 2023). Ces recommandations auront vocation \u00e0 s'inscrire dans le futur programme national de lutte contre le tabac 2023-2027 (PNLT) en cours d'\u00e9laboration\npar le minist\u00e8re de la Sant\u00e9 et de la Pr\u00e9vention.", "mimetype": "text/plain", "start_char_idx": 2039, "end_char_idx": 3020, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "2d269d54-4104-4d9c-8173-76dab311c46a": {"__data__": {"id_": "2d269d54-4104-4d9c-8173-76dab311c46a", "embedding": null, "metadata": {"page_label": "12", "file_name": "strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_type": "application/pdf", "file_size": 920218, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "0079d93c-c190-4fdf-b157-3933b9b3de1b", "node_type": "4", "metadata": {"page_label": "12", "file_name": "strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_type": "application/pdf", "file_size": 920218, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "c7249d00f3e3898f152819d1a4093a0de781011773b6c922f758ed3e2e9219f9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4809429d-b3f0-4ba9-b140-6fe0593159f4", "node_type": "1", "metadata": {}, "hash": "0b84286b297d8343ce3ed4e828200cfde4b5523aa848920fb670025770bff378", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "HAS \u2022 Strat\u00e9gie th\u00e9rapeutique du patient vivant avec un diab\u00e8te de type 2 \u2022 mai 2024 12\nLes recommandations se r\u00e9f\u00e9r ant essentiellement aux travaux de la HAS concernant l'activit\u00e9 physique s'appuient donc sur les travaux r\u00e9cents de la HAS \u00e9mis en 20224, en particulier le \u00ab R\u00e9f\u00e9rentiel\nde prescription d'activit\u00e9 physique et sportive. DT2 \u00bb, juillet 2022.\nTableau 3. Recommandations DT2 - PEC non m\u00e9dicamenteuse - APA\nGRADE N\u00b0\nR.13 L'activit\u00e9 physique est une th\u00e9rapeutique \u00e0 part enti\u00e8re recommand\u00e9e dans la prise\nen charge initiale* du patient vivant avec un DT2, d\u00e8s le diagnostic et tout au long de\nsa prise en charge (grade B).\n* Sauf dans certaines situations particuli\u00e8res (par exemple, hyperglyc\u00e9mie majeure au diagnostic\nou patients \u00e0 haut risque ou tr\u00e8s haut risque CV) et lorsqu'une APA est longue \u00e0 mettre en place.\nR.14 Il est recommand\u00e9 d'encourager les sujets vivant avec un DT2 \u00e0 pratiquer une activit\u00e9\nphysique r\u00e9guli\u00e8re selon les modalit\u00e9s (dur\u00e9e, intensit\u00e9, fr\u00e9quence, accompagnement, contre-indication) d\u00e9crites dans les recommandations de bonne pratique en\ncours*.\n* Cf. recommandations OMS, travaux de la HAS dans le cadre de la \u00ab Consultation et prescription\nm\u00e9dicale d'activit\u00e9 physique \u00e0 des fins de sant\u00e9 \u00bb, d\u00e9c. 2022.\nR.15 Il est recommand\u00e9 d'encourager les patients vivant avec un DT2 \u00e0 diminuer le temps\ntotal de s\u00e9dentarit\u00e9 (facteur de risque ind\u00e9pendant de DT2) (grade B).\nC\nR.16 Il est recommand\u00e9 d'encourager les patients vivant avec un DT2 \u00e0 rompre les temps\nprolong\u00e9s assis en se levant et en bougeant au moins une minute toutes les heures\n(grade C).\nR.17 Les exercices d'assouplissement sont conseill\u00e9s, mais ils n'ont pas d'effet sur la sensibilit\u00e9 \u00e0 l'insuline, la glyc\u00e9mie ou la composition corporelle (grade AE).\nR.18 Il faut parfois commencer par des AP de faible dur\u00e9e et/ou de faible intensit\u00e9, et en\nl'absence de contre-indication et en cas de bonne tol\u00e9rance, augmenter progressivement en dur\u00e9e et/ou \u00e0 des intensit\u00e9s \u00e9lev\u00e9es, pour de meilleurs r\u00e9sultats (grade AE).\nR.19 Une \u00e9valuation m\u00e9dicale minimale est recommand\u00e9e avant de commencer ou d'augmenter une AP d'intensit\u00e9 au moins mod\u00e9r\u00e9e (grade AE).\nUne consultation m\u00e9dicale d'AP est pr\u00e9conis\u00e9e avant toute pratique d'AP d'intensit\u00e9\n\u00e9lev\u00e9e.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2240, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "4809429d-b3f0-4ba9-b140-6fe0593159f4": {"__data__": {"id_": "4809429d-b3f0-4ba9-b140-6fe0593159f4", "embedding": null, "metadata": {"page_label": "12", "file_name": "strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_type": "application/pdf", "file_size": 920218, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "0079d93c-c190-4fdf-b157-3933b9b3de1b", "node_type": "4", "metadata": {"page_label": "12", "file_name": "strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_type": "application/pdf", "file_size": 920218, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "c7249d00f3e3898f152819d1a4093a0de781011773b6c922f758ed3e2e9219f9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2d269d54-4104-4d9c-8173-76dab311c46a", "node_type": "1", "metadata": {"page_label": "12", "file_name": "strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_type": "application/pdf", "file_size": 920218, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "f94dcc464aee6b1f08b406c800c3042da11e4ba617a464d1232e51907d4bce6c", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "R.19 Une \u00e9valuation m\u00e9dicale minimale est recommand\u00e9e avant de commencer ou d'augmenter une AP d'intensit\u00e9 au moins mod\u00e9r\u00e9e (grade AE).\nUne consultation m\u00e9dicale d'AP est pr\u00e9conis\u00e9e avant toute pratique d'AP d'intensit\u00e9\n\u00e9lev\u00e9e. Les patients vivant avec un DT2 inactifs ou avec facteur(s) de risque cardiovasculaire (RCV) associ\u00e9(s) peuvent en b\u00e9n\u00e9ficier avant la pratique d 'une AP d'intensit\u00e9 mod\u00e9r\u00e9e. Elle peut se justifier pour des besoins d'accompagnement d'une\nAP, en cas de motivation faible ou pour une \u00e9ducation du patient sur la maladie, ses\nm\u00e9dicaments et leurs interactions avec l'AP (grade AE).\nR.20 Un bilan m\u00e9dical annuel du diab\u00e8te est recommand\u00e9 : \u00e9valuation du RCV, recherche\nde neuropathie p\u00e9riph\u00e9rique, de r\u00e9tinopathie et de n\u00e9phropathie et \u00e9valuation du\ngrade de risque podologique (grade AE).\n\n4 Le guide de consultation et de prescription m\u00e9dicale d'activit\u00e9 physique \u00e0 des fins de sant\u00e9 chez l'adulte aborde toutes les \u00e9tapes,\ndu rep\u00e9rage du patient inactif \u00e0 risque pour l 'activit\u00e9 physique \u00e0 la prescription (activit\u00e9 physique ordinaire, programmes d 'activit\u00e9\nphysique adapt\u00e9e...), la dispensation et au suivi de l'activit\u00e9 physique. Des fiches/r\u00e9f\u00e9rentiels par pathologie et \u00e9tat de sant\u00e9, et leur\nsynth\u00e8se, sont mis \u00e0 disposition des professionnels de sant\u00e9 pour les guider dans leur consultation et leur prescription m\u00e9dicale\nd'AP, accompagn\u00e9s de fiches d'information \u00e0 remettre aux patients. De m\u00eame, sont disponibles deux fiches d'informations g\u00e9n\u00e9rales\ncommunes \u00e0 toutes les pathologies, sur l'APA pour les professionnels et sur l'AP pour les patients.", "mimetype": "text/plain", "start_char_idx": 2013, "end_char_idx": 3598, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "3a384c12-b903-4486-89dc-05398cd609f0": {"__data__": {"id_": "3a384c12-b903-4486-89dc-05398cd609f0", "embedding": null, "metadata": {"page_label": "13", "file_name": "strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_type": "application/pdf", "file_size": 920218, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "88dbf91d-f674-4fc7-b569-b4001345ff8d", "node_type": "4", "metadata": {"page_label": "13", "file_name": "strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_type": "application/pdf", "file_size": 920218, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "de5720e351db73c14dac9fad258282dea94938adb81497d3606a95acb597c9f3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0fe670df-8ad8-4895-ba15-e18be1a6e1e0", "node_type": "1", "metadata": {}, "hash": "34c581aba80e435188d27f12b719ef2a5e81162c3bb58cfbef46de443fe64a34", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "HAS \u2022 Strat\u00e9gie th\u00e9rapeutique du patient vivant avec un diab\u00e8te de type 2 \u2022 mai 2024 13\nUne consultation avec un sp\u00e9cialiste endocrinologue diab\u00e9tologue nutritionniste\n(EDN) est requise pour les patients vivant avec un DT2 trait\u00e9s par insulinoth\u00e9rapie\nintensive (basal-bolus) et/ou les patients vivant avec un DT2 qui ne sont pas \u00e0 l'\u00e9quilibre glyc\u00e9mique apr\u00e8s la prise en charge initiale en m\u00e9decine g\u00e9n\u00e9rale (grade AE).\nC\nR.21 Une \u00e9preuve d'effort est pr\u00e9conis\u00e9e avant une AP d'intensit\u00e9 \u00e9lev\u00e9e ou chez un patient vivant avec un DT2 ayant le souhait d'activit\u00e9 sportive intense ou de comp\u00e9tition\n(grade C).\nR.22 La prescription d'activit\u00e9 physique est individualis\u00e9e et adapt\u00e9e au niveau initial d'activit\u00e9 physique et aux capacit\u00e9s physiques des patients, aux comportements de s\u00e9dentarit\u00e9 ainsi qu'\u00e0 leurs pr\u00e9f\u00e9rences (grade AE).\nR.23 Les patients avec un DT2 doivent souvent \u00eatre motiv\u00e9s, suivis et accompagn\u00e9s sur\nles effets b\u00e9n\u00e9fiques de l 'AP, les risques (signes \u00e9vocateurs d 'isch\u00e9mie myocardique) et leur pr\u00e9vention (pr\u00e9vention des ulc\u00e8res des pieds), les m\u00e9dicaments et leurs\ninteractions avec l'AP, notamment le risque d'hypoglyc\u00e9mie (grade AE).\nR.24 Prescrire un programme d'AP adapt\u00e9e d'endurance et de renforcement musculaire,\nd'une dur\u00e9e de 3 mois, renouvelable, \u00e0 raison de 2 \u00e0 3 s\u00e9ances par semaine (grade\nAE).\nR.25 Tous les professionnels de sant\u00e9 en contact avec des patients vivant avec un DT2\ndoivent se renseigner sur les structures d'orientation ou de dispensation d'AP \u00e0 des\nfins de sant\u00e9 existantes sur son territoire (par exemple , aupr\u00e8s des maisons sport -\nsant\u00e9) (grade AE).\nR.26 Il est recommand\u00e9 que l es patients vivant avec un DT2 b\u00e9n\u00e9ficient d'une prise en\ncharge de l'APA ou au mieux aient acc\u00e8s \u00e0 un parcours de soins global comme cela\na \u00e9t\u00e9 fait pour les sujets atteints de cancer, ce qui permettrait de faciliter l'acc\u00e8s, entre\nautres, \u00e0 la pratique de l'activit\u00e9 physique, une prise en charge nutritionnelle (grade\nAE).", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1959, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "0fe670df-8ad8-4895-ba15-e18be1a6e1e0": {"__data__": {"id_": "0fe670df-8ad8-4895-ba15-e18be1a6e1e0", "embedding": null, "metadata": {"page_label": "13", "file_name": "strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_type": "application/pdf", "file_size": 920218, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "88dbf91d-f674-4fc7-b569-b4001345ff8d", "node_type": "4", "metadata": {"page_label": "13", "file_name": "strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_type": "application/pdf", "file_size": 920218, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "de5720e351db73c14dac9fad258282dea94938adb81497d3606a95acb597c9f3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3a384c12-b903-4486-89dc-05398cd609f0", "node_type": "1", "metadata": {"page_label": "13", "file_name": "strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_type": "application/pdf", "file_size": 920218, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "46cce22cd9489c9366942ecc22d6c0ff55a319ca439c0de3bb530455a4407cd0", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "R.26 Il est recommand\u00e9 que l es patients vivant avec un DT2 b\u00e9n\u00e9ficient d'une prise en\ncharge de l'APA ou au mieux aient acc\u00e8s \u00e0 un parcours de soins global comme cela\na \u00e9t\u00e9 fait pour les sujets atteints de cancer, ce qui permettrait de faciliter l'acc\u00e8s, entre\nautres, \u00e0 la pratique de l'activit\u00e9 physique, une prise en charge nutritionnelle (grade\nAE).\nR.27 Il est recommand\u00e9 de porter attention aux points de vigilance \u00e0 l'activit\u00e9 physique tels\nque d\u00e9crits dans les travaux de r\u00e9f\u00e9rence HAS (grade AE), en particulier :\n\u2012 signes et sympt\u00f4mes \u00e9vocateurs d 'isch\u00e9mie myocardique chez les patients\nvivant avec un DT2 ;\n\u2012 signes ou sympt\u00f4mes d'hypoglyc\u00e9mie chez les patients vivant avec un DT2\nsous traitement insulinos\u00e9cr\u00e9teur ou sous insuline ;\n\u2012 patients vivant avec un DT2 avec une r\u00e9tinopathie non stabilis\u00e9e (en cas\nd'exercice \u00e0 glotte ferm\u00e9e) ;\n\u2012 patients vivant avec un DT2 avec une neuropathie p\u00e9riph\u00e9rique ayant des\nrisques major\u00e9s d'ulc\u00e8re de pied ;\n\u2012 etc.\nR.28 Il est recommand\u00e9 de porter attention aux situations particuli\u00e8res d'AP d\u00e9crites dans\nles travaux de r\u00e9f\u00e9rence HAS qui n\u00e9cessitent une adaptation ou une s\u00e9curisation de\nla pratique \u00e0 l'activit\u00e9 physique pour des populations fragiles (grade AE), en particulier :", "mimetype": "text/plain", "start_char_idx": 1605, "end_char_idx": 2839, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "5fa136b4-5338-43b1-96e3-4960f9901a58": {"__data__": {"id_": "5fa136b4-5338-43b1-96e3-4960f9901a58", "embedding": null, "metadata": {"page_label": "14", "file_name": "strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_type": "application/pdf", "file_size": 920218, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "eab224ef-ab6e-405c-b6f7-7166e27f8fca", "node_type": "4", "metadata": {"page_label": "14", "file_name": "strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_type": "application/pdf", "file_size": 920218, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "daafb1eb8d8024f222deea0dcb4ccdfca805cae995ed07983d5ad6595b94ab9e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2f5e53ad-84d4-40b3-864f-d727102cf6d8", "node_type": "1", "metadata": {}, "hash": "b617f9ff343f4e6bf4c399fc1c8d26678c4c20d5e3e55d9bb53c0d5e8cee192a", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "HAS \u2022 Strat\u00e9gie th\u00e9rapeutique du patient vivant avec un diab\u00e8te de type 2 \u2022 mai 2024 14\n\u2012 patients vivant avec un DT2 dont l 'instabilit\u00e9 glyc\u00e9mique expose au risque\nd'hypoglyc\u00e9mie r\u00e9actionnelle pendant l 'effort, ou d 'hyperglyc\u00e9mie instable\n(seuil : 2,5 g au d\u00e9but de l'activit\u00e9 physique) ;\n\u2012 AP avec une man\u0153uvre de Valsalva ou \u00e0 glotte ferm\u00e9e chez certains patients\n(r\u00e9tinopathie prolif\u00e9rante) ;\n\u2012 pr\u00e9sence d'un mal perforant plantaire ;\n\u2012 personne \u00e2g\u00e9e \u00e0 risque de d\u00e9shydratation ;\n\u2012 etc.\nR.29 Recommandations pour la recherche clinique\nLe groupe de travail rel\u00e8ve le besoin d '\u00e9tudes pour r\u00e9pondre \u00e0 certaines questions\nd'int\u00e9r\u00eat :\n\u2012 Comment maintenir l'AP sur le long terme ?\n\u2012 Quel est l'effet de la substitution isotemporale de la s\u00e9dentarit\u00e9 par de l'AP de\nfaible intensit\u00e9 sur l '\u00e9quilibre du DT2 ? (Exemple : peut-on remplacer 1 h de\ntemps pass\u00e9 assis - ex. : passer de 12 h/j \u00e0 11 h/j - par de l 'AP de faible\nintensit\u00e9 ?)\n\u2012 Quels sont les r\u00e9sultats des programmes conjoints de rupture des temps prolong\u00e9s de s\u00e9dentarit\u00e9 (ex. : se lever toutes les heures et bouger) et AP vs AP\nseule sur AP et \u00e9quilibre du diab\u00e8te ?\n\n2.2. Prise en charge nutritionnelle\nTableau 4. Recommandations DT2 - PEC non m\u00e9dicamenteuse - NUT\nGRADE N\u00b0\nC\nR.30 Il est recommand\u00e9 la mise en place d'un programme complet et global de modification du mode de vie, d\u00e8s le diagnostic , comprenant une alimentation \u00e9quilibr\u00e9e et\nl'atteinte des objectifs d'activit\u00e9 physique adapt\u00e9e dans le but d'am\u00e9liorer l'\u00e9quilibre\nglyc\u00e9mique (grade C).\nC\nR.31 Il est recommand\u00e9 de mettre en place un plan global de modification th\u00e9rapeutique\ndu mode de vie associant activit\u00e9 physique et modification comportementale\n(grade C).\nR.32 Il est recommand\u00e9 d'individualiser et d'adapter la prise en charge du patient \u00e0 sa\nsituation (\u00e2ge, poids initial, comportement alimentaire, niveau socio -\u00e9conomique,\nlitt\u00e9ratie en sant\u00e9) (grade AE).\nAE R.33 Le poids est \u00e0 surveiller syst\u00e9matiquement \u00e0 chaque consultation.\nR.34 Une perte de 5 % du poids ou plus au diagnostic permet une am\u00e9lioration m\u00e9tabolique significative (glyc\u00e9mique, lipidique, tensionnelle) pour la plupart des personnes vivant avec un diab\u00e8te et en situation de surpoids ou d'ob\u00e9sit\u00e9.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2206, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "2f5e53ad-84d4-40b3-864f-d727102cf6d8": {"__data__": {"id_": "2f5e53ad-84d4-40b3-864f-d727102cf6d8", "embedding": null, "metadata": {"page_label": "14", "file_name": "strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_type": "application/pdf", "file_size": 920218, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "eab224ef-ab6e-405c-b6f7-7166e27f8fca", "node_type": "4", "metadata": {"page_label": "14", "file_name": "strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_type": "application/pdf", "file_size": 920218, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "daafb1eb8d8024f222deea0dcb4ccdfca805cae995ed07983d5ad6595b94ab9e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5fa136b4-5338-43b1-96e3-4960f9901a58", "node_type": "1", "metadata": {"page_label": "14", "file_name": "strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_type": "application/pdf", "file_size": 920218, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "2ecd40d6cb49dece39b4b60a31257518bce31612f84594821b1acabf32d0d93c", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "AE R.33 Le poids est \u00e0 surveiller syst\u00e9matiquement \u00e0 chaque consultation.\nR.34 Une perte de 5 % du poids ou plus au diagnostic permet une am\u00e9lioration m\u00e9tabolique significative (glyc\u00e9mique, lipidique, tensionnelle) pour la plupart des personnes vivant avec un diab\u00e8te et en situation de surpoids ou d'ob\u00e9sit\u00e9.\nCet objectif est individualis\u00e9 et adapt\u00e9 \u00e0 chaque patient (\u00e2ge, comorbidit\u00e9s, contexte socio-\u00e9conomique...).", "mimetype": "text/plain", "start_char_idx": 1897, "end_char_idx": 2315, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "81369ae9-b417-4f36-ab58-9e617edeff2c": {"__data__": {"id_": "81369ae9-b417-4f36-ab58-9e617edeff2c", "embedding": null, "metadata": {"page_label": "15", "file_name": "strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_type": "application/pdf", "file_size": 920218, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "df56b0b3-c088-466d-9c74-49053c197dc3", "node_type": "4", "metadata": {"page_label": "15", "file_name": "strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_type": "application/pdf", "file_size": 920218, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "18ef31c8f318aff1b1499cd13637a422ee834c2505bc325e00d5ea0964b81abe", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e65a58d6-7d4f-4b8b-88a7-2da8c7122951", "node_type": "1", "metadata": {}, "hash": "cdaa710a8031f168d6e56a1ba9340f89a6f8d2e83f5f00baee5e8d83232d748b", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "HAS \u2022 Strat\u00e9gie th\u00e9rapeutique du patient vivant avec un diab\u00e8te de type 2 \u2022 mai 2024 15\nAR\nR.35 En fonction des objectifs sur le poids, l'impact attendu des traitements m\u00e9dicamenteux sur le poids est \u00e0 consid\u00e9rer lors du choix des traitements (grade AE).\nR.36 Les ajustements alimentaires, s'ils sont n\u00e9cessaires, doivent tenir compte des habitudes du patient, de son comportement alimentaire et ses habitudes alimentaires\n(incluant la recherche de trouble du comportement alimentaire - TCA), de sa motivation, de ses possibilit\u00e9s de changement et de son entourage.\nR.37 Il est recommand\u00e9 de toujours prendre en compte le rapport b\u00e9n\u00e9fices/risques lors\nde la prescription d'une restriction calorique.\nLes r\u00e9gimes de restriction quantitative ou qualitative sont fortement d\u00e9conseill\u00e9s\nchez les personnes \u00e0 risque de d\u00e9nutrition et de sarcop\u00e9nie, en particulier chez les\npersonnes \u00e2g\u00e9es en situation de fragilit\u00e9.\nR.38 Recommandation pour la recherche clinique\nIl est recommand\u00e9 la poursuite des \u00e9tudes sur les effets de l'alimentation m\u00e9diterran\u00e9enne en pr\u00e9vention primaire et secondaire des RCV chez les patients vivant\navec un DT2 (grade AE).\n\n2.3. \u00c9ducation th\u00e9rapeutique du patient\nLa maladie chronique confronte les patients \u00e0 une surveillance quotidienne de leur \u00e9tat de sant\u00e9, \u00e0 la\nn\u00e9cessit\u00e9 de faire face aux crises, de prendre r\u00e9guli\u00e8rement des traitements et de savoir prendre des\ninitiatives, de s'adapter en permanence \u00e0 la situation et \u00e0 l'\u00e9volution de la maladie, de trouver un \u00e9quilibre, d'associer les parents d'un enfant malade, les proches, \u00e0 cette gestion quotidienne. La gestion\nquotidienne d'une ou plusieurs maladies chroniques demande au patient des changements ou des\nadaptations importantes qui peuvent \u00eatre difficiles \u00e0 mettre en \u0153uvre sans acquisition de comp\u00e9tences.\nLes modifications progressives et durables des habitudes de vie s'appuient sur une d\u00e9marche p\u00e9dagogique, \u00e9ducation th\u00e9rapeutique du patient (ETP), mise en \u0153uvre par des professionnels form\u00e9s \u00e0\nl'ETP au moyen de s\u00e9ances d'\u00e9ducation th\u00e9rapeutique personnalis\u00e9es. Les comp\u00e9tences d'am\u00e9lioration des habitudes de vie sont d\u00e9velopp\u00e9es de mani\u00e8re simultan\u00e9e avec les comp\u00e9tences d'adaptation\nou psychosociales. Ces deux registres de comp\u00e9tences sont indissociables dans la vie quotidienne et\nleur acquisition n\u00e9cessite un accompagnement pour gagner progressivement en autonomie.\nUne ETP permet aux patients d 'acqu\u00e9rir et de mobiliser fr\u00e9quemment des comp\u00e9tences d'autosoins\net d'adaptation, de les renforcer et de les maintenir dans le temps .", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2532, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "e65a58d6-7d4f-4b8b-88a7-2da8c7122951": {"__data__": {"id_": "e65a58d6-7d4f-4b8b-88a7-2da8c7122951", "embedding": null, "metadata": {"page_label": "15", "file_name": "strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_type": "application/pdf", "file_size": 920218, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "df56b0b3-c088-466d-9c74-49053c197dc3", "node_type": "4", "metadata": {"page_label": "15", "file_name": "strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_type": "application/pdf", "file_size": 920218, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "18ef31c8f318aff1b1499cd13637a422ee834c2505bc325e00d5ea0964b81abe", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "81369ae9-b417-4f36-ab58-9e617edeff2c", "node_type": "1", "metadata": {"page_label": "15", "file_name": "strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_type": "application/pdf", "file_size": 920218, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "ed50a8615afb16901af24c9d9302f74eca093e6226d0c3e25138117b7eb15a66", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Ces deux registres de comp\u00e9tences sont indissociables dans la vie quotidienne et\nleur acquisition n\u00e9cessite un accompagnement pour gagner progressivement en autonomie.\nUne ETP permet aux patients d 'acqu\u00e9rir et de mobiliser fr\u00e9quemment des comp\u00e9tences d'autosoins\net d'adaptation, de les renforcer et de les maintenir dans le temps . Compl\u00e9mentaire de la strat\u00e9gie\nth\u00e9rapeutique, elle peut encourager le patient \u00e0 assumer un r\u00f4le actif au sein de l '\u00e9quipe de soins et\nfaciliter l'autogestion de sa ou ses maladies ou sympt\u00f4mes chroniques.\nLes recommandations du groupe de travail DT2 concernant l'\u00e9ducation th\u00e9rapeutique du patient s'appuient sur les travaux r\u00e9cents HAS sur la th\u00e9matique, en particulier :\n\u2794 guide \u00ab \u00c9valuation de l'efficacit\u00e9 et de l 'efficience d'un programme d'\u00e9ducation th\u00e9rapeutique\ndans les maladies chroniques \u00bb, HAS 2018 ;\n\u2794 fiches \u00ab D\u00e9marche centr\u00e9e sur le patient : information, conseil, \u00e9ducation th\u00e9rapeutique, suivi \u00bb,\nHAS, juin 2015.\nIl est relev\u00e9 dans la pratique que les programmes ETP peuvent \u00eatre tr\u00e8s variables selon les territoires\nfran\u00e7ais et complexes \u00e0 monter. Il existe des in\u00e9galit\u00e9s d 'acc\u00e8s : les personnes les plus pr\u00e9caires y", "mimetype": "text/plain", "start_char_idx": 2199, "end_char_idx": 3371, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "766f9af4-4730-4bfb-9a05-9a461385a495": {"__data__": {"id_": "766f9af4-4730-4bfb-9a05-9a461385a495", "embedding": null, "metadata": {"page_label": "16", "file_name": "strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_type": "application/pdf", "file_size": 920218, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "b1772033-2f7e-40f7-afac-d11b453ab5eb", "node_type": "4", "metadata": {"page_label": "16", "file_name": "strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_type": "application/pdf", "file_size": 920218, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "f24016b8a6cb13098c11c5fb864cb1b2a0b73e98b4fbd7b84c2d10d616fa3616", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "HAS \u2022 Strat\u00e9gie th\u00e9rapeutique du patient vivant avec un diab\u00e8te de type 2 \u2022 mai 2024 16\nont souvent moins acc\u00e8s. Dans le cadre de ses travaux r\u00e9cents5, il a \u00e9t\u00e9 retenu que l'accompagnement\nest une d\u00e9marche permettant de soutenir et d'encourager l'engagement de la personne et de favoriser\nl'autonomie en sant\u00e9. Il vise \u00e0 renforcer les capacit\u00e9s de la personne \u00e0 op\u00e9rer ses propres choix pour\nam\u00e9liorer sa sant\u00e9 , d\u00e9finie au sens le plus large. Cet accompagnement met en \u0153uvre des actions\nd'information, d'\u00e9ducation, de conseil et de soutien, et est du ressort de tout professionnel impliqu\u00e9\ndans le parcours de soins.\nTableau 5. Recommandations DT2 - PEC non m\u00e9dicamenteuse - ETP\nGRADE N\u00b0\nR.39 Il est recommand\u00e9 que l a PEC \u00e9ducative soit globale et int \u00e8gre toutes ses\ncomposantes (grade AE).\nR.40 Le d\u00e9ploiement sur le territoire de programmes d '\u00e9ducation th\u00e9rapeutique pris en\ncharge par l'assurance maladie devrait \u00eatre favoris\u00e9 pour y inclure les plus pr\u00e9caires\n(grade C).\nR.41 Il faut favoriser l'acc\u00e8s \u00e0 une \u00e9ducation structur\u00e9e d\u00e8s le diagnostic, personnalis\u00e9e,\nport\u00e9e par une \u00e9quipe multidisciplinaire afin que le patient vivant avec un DT2 puisse\nacqu\u00e9rir des comp\u00e9tences d 'autogestion de sa maladie, comp\u00e9tences qu 'il faudra\nv\u00e9rifier et renforcer au cours du suivi. Les technologies peuvent \u00eatre un support utile\nen compl\u00e9ment (grade C).\nR.42 Cette \u00e9ducation permet d'am\u00e9liorer la qualit\u00e9 de vie li\u00e9e \u00e0 la sant\u00e9 et l'auto-efficacit\u00e9,\nainsi que l'\u00e9quilibre glyc\u00e9mique au diagnostic en associant programmes nutritionnels\net activit\u00e9 physique (grade C).\nR.43 Des programmes structur\u00e9s d'ETP et une posture \u00e9ducative accompagnant cette d\u00e9marche permettent la cr\u00e9ation d'une alliance avec le patient et son \u00e9quipe soignante\nqui est fondamentale pour l'obtention de r\u00e9sultats (grade AE).\nR.44 Il est recommand\u00e9 que l'\u00e9quipe en charge de l'ETP s'adapte au mode de vie du patient, \u00e0 ses habitudes ainsi qu'\u00e0 ses facteurs culturels et socio-\u00e9conomiques, afin de\nfavoriser cette alliance th\u00e9rapeutique n\u00e9cessaire \u00e0 tout changement du mode de vie\n(grade AE).\n\n5 Cette d\u00e9finition est adapt\u00e9e du guide \u00ab Soutenir et encourager l'engagement des usagers dans les secteurs social, m\u00e9dico-social\net sanitaire \u00bb, HAS 2020 (has-sante.fr).", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2233, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "3795d9ab-2754-4bae-bafb-126a1b08d4a8": {"__data__": {"id_": "3795d9ab-2754-4bae-bafb-126a1b08d4a8", "embedding": null, "metadata": {"page_label": "17", "file_name": "strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_type": "application/pdf", "file_size": 920218, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "79fcf648-6310-445a-994a-055634fdde6e", "node_type": "4", "metadata": {"page_label": "17", "file_name": "strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_type": "application/pdf", "file_size": 920218, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "08dbe0a50fb522e780ce1bfd2b33b776d3864f02faab3492cb54b38347d86672", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c2442074-ff90-4ac6-8a42-91c0218849aa", "node_type": "1", "metadata": {}, "hash": "ead2ae8d908b118a5c6b60e108da551180017bff1b6ba0f1ce111e0d1e7cb5e3", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "HAS \u2022 Strat\u00e9gie th\u00e9rapeutique du patient vivant avec un diab\u00e8te de type 2 \u2022 mai 2024 17\n3. Strat\u00e9gie de prise en charge\nm\u00e9dicamenteuse (population g\u00e9n\u00e9rale)\nLes mol\u00e9cules propos\u00e9es au patient vivant avec un DT2 sont qualifi\u00e9es de normoglyc\u00e9miantes ou de\nmol\u00e9cules anti-hyperglyc\u00e9miantes. Par convention, il est retenu dans ce texte le terme global de traitements m\u00e9dicamenteux de l'hyperglyc\u00e9mie (TMH).\n3.1. G\u00e9n\u00e9ralit\u00e9s sur la PEC m\u00e9dicamenteuse\nLa prise en charge m\u00e9dicamenteuse du patient vivant avec un DT2 reste globale, individualis\u00e9e et\nimplique une d\u00e9cision m\u00e9dicale partag\u00e9e (DMP).\nLa prise en charge m\u00e9dicamenteuse est propos\u00e9e quand la mise en place des MTMV n'a pas permis\nd'atteindre les objectifs d\u00e9finis initialement avec le malade et en tenant compte du statut cardiovasculaire et r\u00e9nal du malade.\nLa prise en charge m\u00e9dicamenteuse du patient vivant avec un DT2 a connu ces derni\u00e8res ann\u00e9es une\n\u00e9volution importante, en particulier avec les traitements m\u00e9dicamenteux de l 'hyperglyc\u00e9mie (TMH)\ncomme les inhibiteurs du SGLT2 (iSGLT2) et les agonistes du r\u00e9cepteur au GLP1 (aGLP1) en raison\nde leurs propri\u00e9t\u00e9s majeures sur la gestion et la pr\u00e9vention des complications cardiovasculaires et\nr\u00e9nales.\nSi la litt\u00e9rature est marqu\u00e9e par une rapide et constante \u00e9volution des donn\u00e9es d '\u00e9valuation clinique\ndes diff\u00e9rents m\u00e9dicaments, elle est aussi caract\u00e9ris\u00e9e par des niveaux de preuve h\u00e9t\u00e9rog\u00e8nes selon\nles mol\u00e9cules et les dates des donn\u00e9es disponibles6. Il peut en r\u00e9sulter une difficult\u00e9 pour atteindre un\nconsensus dans leur hi\u00e9rarchisation.\nDans les RBP les plus r\u00e9centes, nationales et internationales, cette \u00e9volution se traduit par la proposition de plusieurs options possibles en parall\u00e8le, tr\u00e8s en amont de la strat\u00e9gie m\u00e9dicamenteuse, int\u00e9grant les r\u00e9centes classes th\u00e9rapeutiques hypoglyc\u00e9miantes, en raison notamment des donn\u00e9es sur\nleurs effets en pr\u00e9vention des \u00e9v\u00e8nements cardiovasculaires ainsi que sur la volont\u00e9 d 'une prise en\ncharge individualis\u00e9e centr\u00e9e sur le patient vivant avec un DT2.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2024, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "c2442074-ff90-4ac6-8a42-91c0218849aa": {"__data__": {"id_": "c2442074-ff90-4ac6-8a42-91c0218849aa", "embedding": null, "metadata": {"page_label": "17", "file_name": "strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_type": "application/pdf", "file_size": 920218, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "79fcf648-6310-445a-994a-055634fdde6e", "node_type": "4", "metadata": {"page_label": "17", "file_name": "strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_type": "application/pdf", "file_size": 920218, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "08dbe0a50fb522e780ce1bfd2b33b776d3864f02faab3492cb54b38347d86672", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3795d9ab-2754-4bae-bafb-126a1b08d4a8", "node_type": "1", "metadata": {"page_label": "17", "file_name": "strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_type": "application/pdf", "file_size": 920218, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "286ad482196144b308c77829d2e6d8226c45662bb0f421951ef8340c6bcf44f4", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Ainsi, concernant la pratique clinique, il appara\u00eet important de pouvoir proposer les traitements ayant\nmontr\u00e9 un b\u00e9n\u00e9fice cardiovasculaire, cardiaque et/ou r\u00e9nal avec un niveau de preuve fort (niveau de\npreuve 1), d\u00e8s une premi\u00e8re ligne le cas \u00e9ch\u00e9ant, ind\u00e9pendamment d'une prescription de metformine\nd'une part et du niveau d'HbA1c d'autre part (hors risque d'hypoglyc\u00e9mie). Ainsi, en l'occurrence :\n\n6 L'analyse critique des donn\u00e9es probantes fait \u00e9tat d'\u00e9tudes de niveau de preuve h\u00e9t\u00e9rog\u00e8ne selon les mol\u00e9cules et les dates des donn\u00e9es\ndisponibles.\nLa litt\u00e9rature semble s'accorder sur un niveau de preuve qualifi\u00e9 de faible du b\u00e9n\u00e9fice clinique de la metformine, compens\u00e9 par son moindre\nco\u00fbt, son effet normoglyc\u00e9miant et l'absence du risque d'hypoglyc\u00e9mie ou de prise de poids avec cette classe.\nLes effets cliniques des nouveaux m\u00e9dicaments hypoglyc\u00e9miants tels que les iSGLT2 et les aGLP1 ont \u00e9t\u00e9 estim\u00e9s dans des essais randomis\u00e9s de grande ampleur mais en ajout \u00e0 la metformine en 1 re ligne, et essentiellement chez des patients en pr\u00e9vention cardiovasculaire\nsecondaire ou au moins \u00e0 haut risque cardiovasculaire. De plus, les effets cliniques des iSGLT2 et des aGLP1 n'ont pu \u00eatre compar\u00e9s que\nvia des comparaisons indirectes dans des m\u00e9ta -analyses en r\u00e9seau (valeur exploratoire et non d\u00e9monstratrice), en ce qui concerne les\ndonn\u00e9es issues d'\u00e9tudes randomis\u00e9es de grande ampleur.\nL'analyse critique de la litt\u00e9rature montre ainsi le manque de donn\u00e9es comparatives de haut niveau de preuve (randomis\u00e9es sur une \u00e9valuation d'un crit\u00e8re clinique fort) sur cette question du choix du traitement m\u00e9dicamenteux en 1 re ligne, tant sur la question de la metformine\nversus un iSGLT2 ou un agoniste du r\u00e9cepteur au GLP1, que sur le choix \u00e0 privil\u00e9gier entre iSGLT2 et aGLP1, en dehors de leurs indications\nparticuli\u00e8res respectives.\nEn raison des niveaux de preuve h\u00e9t\u00e9rog\u00e8nes associ\u00e9s aux donn\u00e9es et des questions encore en suspens, l'actualisation des recommandations 2023 sur le traitement m\u00e9dicamenteux de 1re ligne se d\u00e9cline en deux types avec des recommandations pour la pratique clinique et des\nrecommandations pour la recherche clinique, afin de permettre les am\u00e9liorations constantes des donn\u00e9es acquises et l 'actualisation des\nrecommandations.", "mimetype": "text/plain", "start_char_idx": 2025, "end_char_idx": 4289, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "9397c439-c579-4083-a3a4-d24a3763d2dc": {"__data__": {"id_": "9397c439-c579-4083-a3a4-d24a3763d2dc", "embedding": null, "metadata": {"page_label": "18", "file_name": "strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_type": "application/pdf", "file_size": 920218, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "79b95236-feba-4772-8bc8-fcb7d855741b", "node_type": "4", "metadata": {"page_label": "18", "file_name": "strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_type": "application/pdf", "file_size": 920218, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "32c1d982f2938175404c2a026046bf6a5a7fb416df5239e39d2804d10671b58f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b49f114e-1fc0-4676-97ff-924787c10744", "node_type": "1", "metadata": {}, "hash": "79f3e7b738afe5c212f663286d1f9d5e970a9c2df9c981e0ffa0d78e81b89d82", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "HAS \u2022 Strat\u00e9gie th\u00e9rapeutique du patient vivant avec un diab\u00e8te de type 2 \u2022 mai 2024 18\n\u2794 les iSGLT2 pour la pr\u00e9vention d'\u00e9v\u00e8nements cardiovasculaires, la pr\u00e9vention d'hospitalisation\npour insuffisance cardiaque et la pr\u00e9vention de l'insuffisance r\u00e9nale terminale ;\n\u2794 les aGLP1 pour la pr\u00e9vention d'\u00e9v\u00e8nements cardiovasculaires.\n\nTableau 6. Recommandations DT2 - PEC m\u00e9dicamenteuse - g\u00e9n\u00e9ralit\u00e9s\nGRADE N\u00b0\nTout au long de la prise en charge et \u00e0 chaque \u00e9tape (suivi, r\u00e9\u00e9valuation)\nR.45 Quelle que soit l'\u00e9tape de la strat\u00e9gie th\u00e9rapeutique, il est recommand\u00e9 :\n\u2012 d'assurer une d\u00e9marche centr\u00e9e sur le patient dans le cadre d'une d\u00e9cision\nm\u00e9dicale partag\u00e9e (prise en compte de ses besoins, pr\u00e9f\u00e9rences, contraintes et ressources, effets ind\u00e9sirables) ;\n\u2012 de prendre en compte l 'environnement social, familial et culturel du patient\n(activit\u00e9 professionnelle, rythme des repas...) et son profil m\u00e9dico-psychologique (niveau de litt\u00e9ratie en sant\u00e9, situation de fragilit\u00e9, isolement, pr\u00e9carit\u00e9...) ;\n\u2012 de r\u00e9\u00e9valuer l'application des mesures de modifications th\u00e9rapeutiques du\nmode de vie (MTMV) et de les renforcer si n\u00e9cessaire (grade AE).\nR.46 Tout au long de la prise en charge, de mani\u00e8re r\u00e9guli\u00e8re et \u00e0 chaque changement\nde traitement, il est n\u00e9cessaire (grade AE) :\n\u2012 d'effectuer une \u00e9valuation pour reconsid\u00e9rer le maintien ou l'arr\u00eat de la strat\u00e9gie (efficacit\u00e9, tol\u00e9rance, acceptabilit\u00e9 et pr\u00e9f\u00e9rences du patient), voire la\npossibilit\u00e9 de d\u00e9sescalade m\u00e9dicamenteuse ;\n\u2012 d'assurer une \u00e9ducation th\u00e9rapeutique du patient (en particulier lors du passage \u00e0 un traitement injectable) ;\n\u2012 de proposer des s\u00e9ances d'accompagnement th\u00e9rapeutique dans le cadre\nde la t\u00e9l\u00e9surveillance m\u00e9dicale7, en cas de traitement \u00e0 l'insuline pour optimiser le contr\u00f4le glyc\u00e9mique ou en cas de d\u00e9s\u00e9quilibre glyc\u00e9mique ;\n\u2012 de consid\u00e9rer les impacts sociaux ( en particulier selon la l\u00e9gislation en\ncours : aptitude \u00e0 la conduite, ouverture du march\u00e9 du travail, etc.).\nR.47 Il est recommand\u00e9 de fixer le rythme des consultations en fonction des caract\u00e9ristiques du patient et de l'atteinte des objectifs.\nApr\u00e8s l'atteinte des objectifs, une consultation tous les 3 \u00e0 6 mois est g\u00e9n\u00e9ralement\nsuffisante par son \u00e9quipe de soins primaires (grade AE).", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2229, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "b49f114e-1fc0-4676-97ff-924787c10744": {"__data__": {"id_": "b49f114e-1fc0-4676-97ff-924787c10744", "embedding": null, "metadata": {"page_label": "18", "file_name": "strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_type": "application/pdf", "file_size": 920218, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "79b95236-feba-4772-8bc8-fcb7d855741b", "node_type": "4", "metadata": {"page_label": "18", "file_name": "strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_type": "application/pdf", "file_size": 920218, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "32c1d982f2938175404c2a026046bf6a5a7fb416df5239e39d2804d10671b58f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9397c439-c579-4083-a3a4-d24a3763d2dc", "node_type": "1", "metadata": {"page_label": "18", "file_name": "strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_type": "application/pdf", "file_size": 920218, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "4d875a29c6b3321d419abf689888a8fcd3e7fa154e92d81e1196fb6e6e7a21b0", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "R.47 Il est recommand\u00e9 de fixer le rythme des consultations en fonction des caract\u00e9ristiques du patient et de l'atteinte des objectifs.\nApr\u00e8s l'atteinte des objectifs, une consultation tous les 3 \u00e0 6 mois est g\u00e9n\u00e9ralement\nsuffisante par son \u00e9quipe de soins primaires (grade AE).\nR.48 Si l'objectif d\u00e9fini initialement avec le patient n 'est pas atteint malgr\u00e9 la mise en\nplace des mesures MTMV, un traitement m\u00e9dicamenteux sera propos\u00e9 et d\u00e9fini\navec le patient (grade AE).\n\n7 L'accompagnement th\u00e9rapeutique est une composante de l'activit\u00e9 de t\u00e9l\u00e9surveillance m\u00e9dicale compl\u00e9mentaire et non substitutif\nde l'\u00e9ducation th\u00e9rapeutique. HAS. T\u00e9l\u00e9surveillance m\u00e9dicale du patient diab\u00e9tique. 2022", "mimetype": "text/plain", "start_char_idx": 1951, "end_char_idx": 2643, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "c891cdad-0e83-4de1-aac7-cae84ad6237e": {"__data__": {"id_": "c891cdad-0e83-4de1-aac7-cae84ad6237e", "embedding": null, "metadata": {"page_label": "19", "file_name": "strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_type": "application/pdf", "file_size": 920218, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "be3e7298-81c1-4b09-a799-c4c1dae2f437", "node_type": "4", "metadata": {"page_label": "19", "file_name": "strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_type": "application/pdf", "file_size": 920218, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "89c53b05964aa1ec20e18309b0440dcfa6f4db0e1307d55f8b305f5dac031f14", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "98f1c7dc-f142-47d1-a1ab-22d37383732d", "node_type": "1", "metadata": {}, "hash": "762e48f1b21170a2c14f545c02db1e86466e516dea581c774b32cf556885fdb3", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "HAS \u2022 Strat\u00e9gie th\u00e9rapeutique du patient vivant avec un diab\u00e8te de type 2 \u2022 mai 2024 19\nR.49 Afin de favoriser leur tol\u00e9rance, les traitements seront d\u00e9marr\u00e9s aux doses minimales recommand\u00e9es qui seront augment\u00e9es progressivement jusqu 'aux doses\nmaximales tol\u00e9r\u00e9es ou jusqu'\u00e0 l'atteinte de l'objectif et ce, dans le respect des CI et\nde l'adaptation de la posologie \u00e0 la fonction r\u00e9nale, cardiaque, etc.\nIls seront pris selon les r\u00e8gles pharmacologiques de prescription (horaire par rapport aux repas, nombre de prises, etc.) (grade AE).\nR.50 La r\u00e9\u00e9valuation du traitement est n\u00e9cessaire apr\u00e8s un intervalle de 3 \u00e0 6 mois - plus\nrapidement en cas de signes cliniques li\u00e9s \u00e0 l 'hyperglyc\u00e9mie ou aux effets ind\u00e9sirables (\u00e9v\u00e8nements gastro-intestinaux, hypoglyc\u00e9mie, prise de poids, autres effets\nind\u00e9sirables, etc.) et en portant une attention particuli\u00e8re \u00e0 l'observance (grade AE).\nR.51 Dans tous les cas, il est recommand\u00e9 d'informer le patient des avantages et inconv\u00e9nients des traitements propos\u00e9s et de tenir compte de leur acceptabilit\u00e9 (grade\nAE).\nR.52 Lors de l'introduction d'un m\u00e9dicament susceptible d'induire des hypoglyc\u00e9mies, il\nest important d'apprendre au patient \u00e0 pr\u00e9venir, identifier ses sympt\u00f4mes et prendre\nen charge une hypoglyc\u00e9mie.\nDans cette situation, la mise en place d'une autosurveillance glyc\u00e9mique et la prescription d'un lecteur de glyc\u00e9mie sont discut\u00e9es et l'utilisation de celui-ci encourag\u00e9e\n(grade AE).\nR.53 Il est recommand\u00e9 de ne pas associer deux m\u00e9dicaments de m\u00eame m\u00e9canisme\nd'action (grade AE).\nR.54 En raison des difficult\u00e9s d'acc\u00e8s aux sp\u00e9cialistes dans le parcours de soins, la prescription de toutes les mol\u00e9cules devrait pouvoir \u00eatre r\u00e9alis\u00e9e par les m\u00e9decins sp\u00e9cialistes du diab\u00e8te ainsi que par les m\u00e9decins traitants (grade AE).", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1781, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "98f1c7dc-f142-47d1-a1ab-22d37383732d": {"__data__": {"id_": "98f1c7dc-f142-47d1-a1ab-22d37383732d", "embedding": null, "metadata": {"page_label": "19", "file_name": "strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_type": "application/pdf", "file_size": 920218, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "be3e7298-81c1-4b09-a799-c4c1dae2f437", "node_type": "4", "metadata": {"page_label": "19", "file_name": "strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_type": "application/pdf", "file_size": 920218, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "89c53b05964aa1ec20e18309b0440dcfa6f4db0e1307d55f8b305f5dac031f14", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c891cdad-0e83-4de1-aac7-cae84ad6237e", "node_type": "1", "metadata": {"page_label": "19", "file_name": "strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_type": "application/pdf", "file_size": 920218, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "2e187f6c6eb665d2bfae9f8d4c3f71b43dc3e745c1ab08d1316d7b0949dce828", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "R.53 Il est recommand\u00e9 de ne pas associer deux m\u00e9dicaments de m\u00eame m\u00e9canisme\nd'action (grade AE).\nR.54 En raison des difficult\u00e9s d'acc\u00e8s aux sp\u00e9cialistes dans le parcours de soins, la prescription de toutes les mol\u00e9cules devrait pouvoir \u00eatre r\u00e9alis\u00e9e par les m\u00e9decins sp\u00e9cialistes du diab\u00e8te ainsi que par les m\u00e9decins traitants (grade AE).\n\u00c0 l'initiation des traitements m\u00e9dicamenteux\nR.55 Dans le cadre de la d\u00e9cision m\u00e9dicale partag\u00e9e avec le patient, les \u00e9l\u00e9ments d\u00e9terminants pour effectuer le choix des m\u00e9dicaments \u00e0 consid\u00e9rer sont :\n\u2012 les circonstances cliniques individuelles du patient, par exemple les comorbidit\u00e9s : la pr\u00e9sence ou non de pathologies cardiovasculaires et/ou r\u00e9nales,\nle risque cardiovasculaire (selon les d\u00e9finitions d\u00e9crites dans les recommandations de bonne pratique en co urs), les contre-indications, le poids et les\nrisques li\u00e9s \u00e0 la polym\u00e9dication ;\n\u2012 les pr\u00e9f\u00e9rences et les besoins individuels de la personne ;\n\u2012 l'efficacit\u00e9 des traitements m\u00e9dicamenteux en termes de r\u00e9ponse m\u00e9tabolique, mais aussi de protection cardiovasculaire et r\u00e9nale ;\n\u2012 l'innocuit\u00e9 et la tol\u00e9rabilit\u00e9 du traitement m\u00e9dicamenteux ;\n\u2012 les exigences en mati\u00e8re de surveillance (grade AE).\nC\nR.56 Au-del\u00e0 de la recherche de l'\u00e9quilibre glyc\u00e9mique, et m\u00eame lorsque celui-ci est atteint, il est recommand\u00e9 que la PEC m\u00e9dicamenteuse tienne compte des autres\nb\u00e9n\u00e9fices associ\u00e9s des mol\u00e9cules en termes de pr\u00e9vention et de gestion cardiovasculaire, r\u00e9nale et \u00e9galement de leur impact pond\u00e9ral (grade C).", "mimetype": "text/plain", "start_char_idx": 1441, "end_char_idx": 2946, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "deda66b5-f2a2-436a-bc11-fb685a99cc62": {"__data__": {"id_": "deda66b5-f2a2-436a-bc11-fb685a99cc62", "embedding": null, "metadata": {"page_label": "20", "file_name": "strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_type": "application/pdf", "file_size": 920218, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "fb20ccba-8a5d-462b-bee4-c62cd771bf7e", "node_type": "4", "metadata": {"page_label": "20", "file_name": "strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_type": "application/pdf", "file_size": 920218, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "82c8329c784128afb560294e625ea31c3d8872eaa11fbf8b92ec639a05bd596b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ae75a1d8-4597-4619-b17d-1d9ce362a49d", "node_type": "1", "metadata": {}, "hash": "65601bc5a97b3c166ba2c4ec16027173e3ae0bb6bda1d5fbfcefa709349a4c74", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "HAS \u2022 Strat\u00e9gie th\u00e9rapeutique du patient vivant avec un diab\u00e8te de type 2 \u2022 mai 2024 20\nAE\nR.57 En cas de situation de sympt\u00f4mes d'hyperglyc\u00e9mie ou de diab\u00e8te tr\u00e8s d\u00e9s\u00e9quilibr\u00e9\n(grade AE) :\n\u2012 en cas de sympt\u00f4mes d 'hyperglyc\u00e9mie (syndrome polyuro -polydipsique,\namaigrissement) ou de diab\u00e8te tr\u00e8s d\u00e9s\u00e9quilibr\u00e9 avec des glyc\u00e9mies r\u00e9p\u00e9t\u00e9es sup\u00e9rieures \u00e0 3 g/l ou un taux d'HbA1c sup\u00e9rieur \u00e0 10 %, une bith\u00e9rapie, voire une insulinoth\u00e9rapie peuvent \u00eatre instaur\u00e9es d'embl\u00e9e ;\n\u2012 dans cette situation, lors de la r\u00e9\u00e9valuation du traitement, si le diab\u00e8te est\nbien contr\u00f4l\u00e9, on pourra \u00eatre amen\u00e9 \u00e0 revenir sur le sch\u00e9ma g\u00e9n\u00e9ral.\n3.2. Recommandations PEC m\u00e9dicamenteuse en mono et bith\u00e9rapie\nTableau 7. Recommandations DT2 - PEC m\u00e9dicamenteuse - 1re ligne - monoth\u00e9rapie et bith\u00e9rapie (suite)\nGRADE N\u00b0\nEn monoth\u00e9rapie\nR.58 En l 'absence de signes cliniques (syndrome polyuro -polydipsique, amaigrissement), d'hyperglyc\u00e9mie s\u00e9v\u00e8re ou autres situations particuli\u00e8res, le traitement est\nd\u00e9but\u00e9 par une monoth\u00e9rapie (grade C).\nR.59 La metformine reste \u00e0 ce jour le traitement recommand\u00e9 en 1 re intention en raison\nde son anciennet\u00e9, de son faible co\u00fbt, de son profil de tol\u00e9rance ainsi que de ses\neffets sur l'HbA1c (grade C).\nEn cas de contre-indication ou d'intol\u00e9rance \u00e0 la MET\nR.60 En cas d 'intol\u00e9rance ou de contre -indication \u00e0 la metformine chez les sujets\npr\u00e9sentant une insuffisance cardiaque chronique, une maladie cardiovasculaire art\u00e9rioscl\u00e9reuse \u00e9tablie, une n\u00e9phropathie diab\u00e9tique ou les sujets \u00e0 haut risque cardiovasculaire, il est recommand\u00e9 de prescrire un iSGLT2 (grade C).\nAE\n\nR.61 En cas d 'intol\u00e9rance ou de contre -indication \u00e0 la metformine , il est recommand\u00e9 de prescrire une des autres alternatives possibles adapt\u00e9e aux autres param\u00e8tres du patient (statut cardiovasculaire, r\u00e9nal, cardiaque, \u00e2ge, etc.)", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1823, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "ae75a1d8-4597-4619-b17d-1d9ce362a49d": {"__data__": {"id_": "ae75a1d8-4597-4619-b17d-1d9ce362a49d", "embedding": null, "metadata": {"page_label": "20", "file_name": "strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_type": "application/pdf", "file_size": 920218, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "fb20ccba-8a5d-462b-bee4-c62cd771bf7e", "node_type": "4", "metadata": {"page_label": "20", "file_name": "strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_type": "application/pdf", "file_size": 920218, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "82c8329c784128afb560294e625ea31c3d8872eaa11fbf8b92ec639a05bd596b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "deda66b5-f2a2-436a-bc11-fb685a99cc62", "node_type": "1", "metadata": {"page_label": "20", "file_name": "strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_type": "application/pdf", "file_size": 920218, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "2d08f1ac820fe058c67d0d6186d2a898f990d86b723162b7416d441ca703e928", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "AE\n\nR.61 En cas d 'intol\u00e9rance ou de contre -indication \u00e0 la metformine , il est recommand\u00e9 de prescrire une des autres alternatives possibles adapt\u00e9e aux autres param\u00e8tres du patient (statut cardiovasculaire, r\u00e9nal, cardiaque, \u00e2ge, etc.) et selon ordre\nde pr\u00e9f\u00e9rence (grade AE) :\n\u2012 iSGLT2 ou un aGLP1* pour leurs effets cardio et n\u00e9phroprotecteurs, ou leur\nimpact pond\u00e9ral ;\n\u2012 iDPP4, option la plus simple pour la pratique clinique en l 'absence d'insuffisance cardiaque, de maladie cardiovasculaire art\u00e9rioscl\u00e9reuse \u00e9tablie, de\nn\u00e9phropathie diab\u00e9tique ou d'un haut risque cardiovasculaire).\nD'autres alternatives remboursables sont possibles : sulfamide hypoglyc\u00e9miant (\u00e0\nrisque d'hypoglyc\u00e9mies s\u00e9v\u00e8res)**, r\u00e9paglinide (si la prise alimentaire est irr\u00e9guli\u00e8re, en surveillant les glyc\u00e9mies digitales), inhibiteur des alpha 1 glucosidases intestinales.\n* \u00c0 la date de l 'actualisation (mai 2024), les iSGLT2 (empagliflozine, dapagliflozine, canagliflozine ),\nles aGLP1 (liraglutide, dulaglutide, s\u00e9maglutide) et les iDPP4 (sitagliptine, saxagliptine, vildagliptine,\nlinagliptine) disposent d'une AMM en monoth\u00e9rapie en cas de CI ou d'intol\u00e9rance \u00e0 la metformine mais\nne sont pas rembours\u00e9s dans cette indication (sauf la sitagliptine chez l 'insuffisant r\u00e9nal) \u00e0 la suite\nd'un SMR insuffisant en absence de donn\u00e9es probantes. Cette situation pourrait faire l 'objet d'une", "mimetype": "text/plain", "start_char_idx": 1585, "end_char_idx": 2957, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "2393b753-a03b-407d-88a5-314adce19d6a": {"__data__": {"id_": "2393b753-a03b-407d-88a5-314adce19d6a", "embedding": null, "metadata": {"page_label": "21", "file_name": "strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_type": "application/pdf", "file_size": 920218, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "4fc61af8-c675-4b20-a609-0ed71fb58577", "node_type": "4", "metadata": {"page_label": "21", "file_name": "strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_type": "application/pdf", "file_size": 920218, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "89e1ddcafd2ffe006ae0941cc3dd34ed7e0f65331486e32b90180416858cb204", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f3098e69-0923-450f-baa3-37982a70507d", "node_type": "1", "metadata": {}, "hash": "62cc5ebcace0ebfaeed18368460721fab9587cd1e994fe71499174923e7efd04", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "HAS \u2022 Strat\u00e9gie th\u00e9rapeutique du patient vivant avec un diab\u00e8te de type 2 \u2022 mai 2024 21\n\u00e9ventuelle \u00e9valuation par la commission de la transparence si des donn\u00e9es pertinentes \u00e9taient d\u00e9pos\u00e9es.\n** La prescription des sulfamides hypoglyc\u00e9miants en monoth\u00e9rapie n 'est plus la strat\u00e9gie pr\u00e9f\u00e9rentielle recommand\u00e9e en raison des risques d 'hypoglyc\u00e9mies s\u00e9v\u00e8res et de l 'existence de mol\u00e9cules\nayant des effets b\u00e9n\u00e9fiques clairement d\u00e9montr\u00e9s sur les complications cardiovasculaires et r\u00e9nales.\nEn bith\u00e9rapie avec la MET\nEn bith\u00e9rapie, selon le statut cardiovasculaire et r\u00e9nal initial du patient\nR.62 La prise en charge m\u00e9dicamenteuse, au-del\u00e0 de l'atteinte de l'objectif d'HbA1c pr\u00e9alablement fix\u00e9 et de sa stabilisation , tient compte des autres b\u00e9n\u00e9fices et effets\nind\u00e9sirables des mol\u00e9cules : impact sur le poids, effet sur le risque cardiovasculaire\net/ou r\u00e9nal (grade C).\nAE\nR.63 L'\u00e9valuation du statut cardiovasculaire et r\u00e9nal est n\u00e9cessaire pour choisir la 2e mol\u00e9cule d\u00e9finissant la bith\u00e9rapie (grade AE).\nEn bith\u00e9rapie (avec la MET), en pr\u00e9vention secondaire\nEn pr\u00e9sence d 'insuffisance cardiaque, d'une maladie cardiovasculaire ath\u00e9romateuse/art\u00e9rioscl\u00e9reuse \u00e9tablie ou d'une maladie r\u00e9nale chronique\nR.64 La pr\u00e9sence d'un ant\u00e9c\u00e9dent de maladie cardiovasculaire doit faire envisager\net id\u00e9alement proposer un traitement par iSGLT2 ou aGLP1, ind\u00e9pendamment de\nl'HbA1c et d'un traitement par metformine (grade A).\nR.65 La pr\u00e9sence d'une insuffisance cardiaque est une indication en soi de prescription d'iSGLT2* en association aux autres classes th\u00e9rapeutiques recommand\u00e9es\nchez tous les patients, quelle que soit la dose de metformine et ind\u00e9pendamment\nde la valeur d'HbA1c, quitte \u00e0 all\u00e9ger le traitement anti-hyperglyc\u00e9miant par ailleurs\nsi besoin.\n* \u00c0 la date de l 'actualisation (mai 2024), les mol\u00e9cules disponibles sont la dapagliflozine et\nl'empagliflozine.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1871, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "f3098e69-0923-450f-baa3-37982a70507d": {"__data__": {"id_": "f3098e69-0923-450f-baa3-37982a70507d", "embedding": null, "metadata": {"page_label": "21", "file_name": "strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_type": "application/pdf", "file_size": 920218, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "4fc61af8-c675-4b20-a609-0ed71fb58577", "node_type": "4", "metadata": {"page_label": "21", "file_name": "strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_type": "application/pdf", "file_size": 920218, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "89e1ddcafd2ffe006ae0941cc3dd34ed7e0f65331486e32b90180416858cb204", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2393b753-a03b-407d-88a5-314adce19d6a", "node_type": "1", "metadata": {"page_label": "21", "file_name": "strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_type": "application/pdf", "file_size": 920218, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "e6793c42d25fbdfbed1e2c6f1a611697bdd8159f86dee229cd8dfb351e45b721", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "* \u00c0 la date de l 'actualisation (mai 2024), les mol\u00e9cules disponibles sont la dapagliflozine et\nl'empagliflozine.\nR.66 La pr\u00e9sence d'une maladie r\u00e9nale chronique malgr\u00e9 un traitement standard optimal de la maladie r\u00e9nale doit faire envisager et id\u00e9alement proposer un iSGLT2,\nen association avec la MET, d\u00e8s que la dose optimale tol\u00e9r\u00e9e de la MET ajust\u00e9e \u00e0\nla fonction r\u00e9nale est acquise et ind\u00e9pendamment de la valeur de l'HbA1c (grade A).\nR.67 Malgr\u00e9 l'absence de donn\u00e9es directes sur cette population, l 'albuminurie pathologique pr\u00e9disposant \u00e0 la fois \u00e0 une insuffisance r\u00e9nale chronique et \u00e0 un risque CV\naccru, la prescription d'un iSGLT2, ind\u00e9pendamment de l'HbA1c, peut \u00eatre envisag\u00e9e chez les patients avec maladie r\u00e9nale, en association avec MET (grade C).\nR.68 \u00c0 l'initiation du traitement avec un iSGLT2, il est recommand\u00e9 d '\u00e9valuer le risque\nd'acidoc\u00e9toses diab\u00e9tiques (ex . : r\u00e9currence d '\u00e9pisode, maladie intercurrente, r\u00e9gime tr\u00e8s faible en glucides ou c\u00e9tog\u00e8ne) en raison du risque d'acidoc\u00e9toses associ\u00e9es aux iSGLT2 (grade C).\nAE\nR.69 La prescription des sulfamides hypoglyc\u00e9miants en bith\u00e9rapie en association avec\nMET n'est plus la strat\u00e9gie pr\u00e9f\u00e9rentielle recommand\u00e9e en raison des risques d'hypoglyc\u00e9mies s\u00e9v\u00e8res et de l 'existence de mol\u00e9cules ayant des effets b\u00e9n\u00e9fi ques", "mimetype": "text/plain", "start_char_idx": 1758, "end_char_idx": 3056, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "d0306909-4d1b-4d4a-a842-acc3cdde6226": {"__data__": {"id_": "d0306909-4d1b-4d4a-a842-acc3cdde6226", "embedding": null, "metadata": {"page_label": "22", "file_name": "strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_type": "application/pdf", "file_size": 920218, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "048ba738-8346-44db-ae8a-12fc0cb71c3b", "node_type": "4", "metadata": {"page_label": "22", "file_name": "strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_type": "application/pdf", "file_size": 920218, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "b56f9b265f740c590cbb320df7e4a2fa5c43c4be45bbe432c3033dacacd3b888", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b9a66ab4-db38-4e75-8c4a-e78a357244b4", "node_type": "1", "metadata": {}, "hash": "7c5bb2b3515b2da90c9603941c0798b919974f07a8096115619670889508c7c3", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "HAS \u2022 Strat\u00e9gie th\u00e9rapeutique du patient vivant avec un diab\u00e8te de type 2 \u2022 mai 2024 22\nclairement d\u00e9montr\u00e9s sur les complications cardiovasculaires et r\u00e9nales\n(grade AE).\nEn bith\u00e9rapie avec la MET, en pr\u00e9vention primaire\nEn pr\u00e9vention primaire chez le patient \u00e0 haut risque cardiovasculaire\nB\nR.70 Avec un moins fort niveau de preuve, en association avec la MET (\u00e0 dose maximale\ntol\u00e9r\u00e9e et sauf CI), l 'ajout d'un iSGLT2 ou d'un aGLP1 est recommand\u00e9 chez les\npatients en pr\u00e9vention primaire \u00e0 haut niveau de risque cardiovasculaire (grade B).\nR.71 En association de la MET (\u00e0 dose maximale tol\u00e9r\u00e9e et sauf CI), d\u00e8s que la dose\nmaximale tol\u00e9r\u00e9e de la MET est acquise et ind\u00e9pendamment de la valeur du taux\nHbA1c, et sous couvert d'un suivi r\u00e9tinien (en raison du risque de baisse rapide de\nl'HbA1c), il est recommand\u00e9 l 'ajout de aGLP1 \u00e0 dose antidiab\u00e9tique, si pr\u00e9sence\nob\u00e9sit\u00e9 (IMC > ou \u00e9gale \u00e0 30 kg/m2) (grade C).\nR.72 La prescription des analogues du GLP1 \u00e0 des doses anti -ob\u00e9sit\u00e9 se fait selon les\nmodalit\u00e9s d\u00e9crites dans les recommandations de bonne pratique en cours *\n(grade C).\nR.73 La pr\u00e9sence d'une maladie h\u00e9patique m\u00e9tabolique (NASH, NAFLD)** ou d'une ob\u00e9sit\u00e9 s\u00e9v\u00e8re pourrait orienter pr\u00e9f\u00e9rentiellement vers un aGLP1 (grade C).\n* En particulier \u00ab Ob\u00e9sit\u00e9 de l'adulte : prise en charge de 2 e et 3e niveaux - Partie I : prise en charge m\u00e9dicale \u00bb, juin 2022 ; **\nAvec NAFLD (Non Alcoholic Fatty Liver Disease) : st\u00e9atose h\u00e9patique non alcoolique ; NASH (Non-Alcoholic SteatoHepatitis) :\nst\u00e9atoh\u00e9patite.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1517, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "b9a66ab4-db38-4e75-8c4a-e78a357244b4": {"__data__": {"id_": "b9a66ab4-db38-4e75-8c4a-e78a357244b4", "embedding": null, "metadata": {"page_label": "22", "file_name": "strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_type": "application/pdf", "file_size": 920218, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "048ba738-8346-44db-ae8a-12fc0cb71c3b", "node_type": "4", "metadata": {"page_label": "22", "file_name": "strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_type": "application/pdf", "file_size": 920218, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "b56f9b265f740c590cbb320df7e4a2fa5c43c4be45bbe432c3033dacacd3b888", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d0306909-4d1b-4d4a-a842-acc3cdde6226", "node_type": "1", "metadata": {"page_label": "22", "file_name": "strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_type": "application/pdf", "file_size": 920218, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "830a273e0bddb7d385c6e9e3c84b1bee4de43933241db109591993d7747b2e94", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "* En particulier \u00ab Ob\u00e9sit\u00e9 de l'adulte : prise en charge de 2 e et 3e niveaux - Partie I : prise en charge m\u00e9dicale \u00bb, juin 2022 ; **\nAvec NAFLD (Non Alcoholic Fatty Liver Disease) : st\u00e9atose h\u00e9patique non alcoolique ; NASH (Non-Alcoholic SteatoHepatitis) :\nst\u00e9atoh\u00e9patite.\n\nEn bith\u00e9rapie avec la MET, e n pr\u00e9vention primaire chez le patient \u00e0 risque cardiovasculaire\nmod\u00e9r\u00e9\nAE\nR.74 En bith\u00e9rapie avec la MET, chez le patient \u00e0 risque cardiovasculaire mod\u00e9r\u00e9 ,\nil est recommand\u00e9 de (grade AE) :\n\u2012 viser la plus faible iatrog\u00e9nie (\u00e9viter les hypoglyc\u00e9mies et facteurs de prise\nde poids) ;\n\u2012 int\u00e9grer par ordre pr\u00e9f\u00e9rentiel et selon le profil du patient (en particulier\nnombre et type de facteurs de risque) :\n1. un iSGLT2 ou un aGLP1 pour leurs b\u00e9n\u00e9fices cardio et n\u00e9phroprotecteurs,\nou leur impact sur le poids,\n2. un iDPP4, option la plus simple pour la pratique clinique,\n3. voire un sulfamide hypoglyc\u00e9miant,\n4. ou du r\u00e9paglinide si la prise alimentaire est irr\u00e9guli\u00e8re, en surveillant les\nglyc\u00e9mies capillaires,\n5. un inhibiteur des alpha 1 glucosidases intestinales.\nRecommandation pour la recherche clinique\nAE\nR.75 Recommandation pour la recherche clinique\nEnfin, afin de pouvoir am\u00e9liorer la prise en charge du traitement m\u00e9dicamenteux de\n1re intention, il appara\u00eet n\u00e9cessaire de recommander (grade AE) :\n\u2012 la production de donn\u00e9es scientifiques de haut niveau de preuve, c 'est-\u00e0dire via des \u00e9tudes randomis\u00e9es, permettant des comparaisons directes\nentre les trois options metformine/iSGLT2/aGLP1, sur des crit\u00e8res cliniques,", "mimetype": "text/plain", "start_char_idx": 1244, "end_char_idx": 2778, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "c7d2c784-d28c-4589-a66a-ac8b1cb1a2a7": {"__data__": {"id_": "c7d2c784-d28c-4589-a66a-ac8b1cb1a2a7", "embedding": null, "metadata": {"page_label": "23", "file_name": "strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_type": "application/pdf", "file_size": 920218, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "fbc18e2c-c059-4693-b4aa-fb44fec21890", "node_type": "4", "metadata": {"page_label": "23", "file_name": "strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_type": "application/pdf", "file_size": 920218, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "29eb13a3fe5fb4c33a4de211be73b6847bb2ce0da694933b637a99de407135a1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9ade7fcc-69b0-4217-83c9-8c572dcd089f", "node_type": "1", "metadata": {}, "hash": "9b06da77a856cf51b8637fa990eec7fdb120c45c2f1fe01787cedc960c369882", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "HAS \u2022 Strat\u00e9gie th\u00e9rapeutique du patient vivant avec un diab\u00e8te de type 2 \u2022 mai 2024 23\nnotamment en 1re ligne/chez les personnes sans ant\u00e9c\u00e9dent r\u00e9no-cardiovasculaire ;\n\u2012 le d\u00e9veloppement de bases de connaissances dynamiques (actualisation en\ntemps r\u00e9el, qualifi\u00e9e de mode Living guidelines, selon les standards internationaux) incluant une approche de cumul des preuves pour guider la prise de\nd\u00e9cision en termes de besoin ou non d'\u00e9tude clinique suppl\u00e9mentaire.\n\n3.3. Recommandations PEC m\u00e9dicamenteuse en trith\u00e9rapie et/ou\ninsulinoth\u00e9rapie\nTableau 8. Recommandations DT2 - PEC m\u00e9dicamenteuse - trith\u00e9rapies (suite)\nGRADE N\u00b0\nEn trith\u00e9rapie antidiab\u00e9tique, hors insuline\nR.76 En l'absence de r\u00e9sultats sur les objectifs initiaux de la PEC d'une premi\u00e8re bith\u00e9rapie avec MET (\u00e0 dose maximale tol\u00e9r\u00e9e), il est envisageable de proposer\nune autre bith\u00e9rapie chez un patient indemne de complications (grade AE).\nC\nR.77 En l'absence de r\u00e9sultats sur les objectifs initiaux de la PEC apr\u00e8s \u00e9chec d'un ou\nplusieurs sch\u00e9mas m\u00e9dicamenteux par bith\u00e9rapie avec MET (\u00e0 dose maximale\ntol\u00e9r\u00e9e), il est recommand\u00e9 de proposer une trith\u00e9rapie (grade C).\nC\nR.78 En trith\u00e9rapie avec MET (\u00e0 dose optimale tol\u00e9r\u00e9e), les sch\u00e9mas th\u00e9rapeutiques\nsuivants peuvent \u00eatre propos\u00e9s (grade C), sous r\u00e9serve d'absence d'association\ncontre-indiqu\u00e9e ou d'intol\u00e9rance \u00e0 une mol\u00e9cule et par ordre pr\u00e9f\u00e9rentiel :\n\u2012 iSGLT2 ou aGLP1 si ces mol\u00e9cules ne sont pas d\u00e9j\u00e0 inclu ses dans la\nPEC ;\n\u2012 iDPP4 en l'absence d'aGLP1 d\u00e9j\u00e0 inclus dans la PEC et en l'absence de\nCI \u00e0 l'association ;\n\u2012 sulfamide hypoglyc\u00e9miant en surveillant la prise de poids et la survenue\nd'hypoglyc\u00e9mies ;\n\u2012 r\u00e9paglinide (demi-vie courte) et en raison de sa \u00ab non-CI \u00bb en cas de maladie r\u00e9nale ;\n\u2012 voire inhibiteurs des alphaglucosidases intestinales.\nR.79 Dans le cas d'une strat\u00e9gie m\u00e9dicamenteuse incluant une insuline, ou une quadrith\u00e9rapie, la sollicitation de l'avis d'un sp\u00e9cialiste EDN (endocrinologue diab\u00e9tologue nutritionniste) est encourag\u00e9e (grade AE).", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1999, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "9ade7fcc-69b0-4217-83c9-8c572dcd089f": {"__data__": {"id_": "9ade7fcc-69b0-4217-83c9-8c572dcd089f", "embedding": null, "metadata": {"page_label": "23", "file_name": "strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_type": "application/pdf", "file_size": 920218, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "fbc18e2c-c059-4693-b4aa-fb44fec21890", "node_type": "4", "metadata": {"page_label": "23", "file_name": "strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_type": "application/pdf", "file_size": 920218, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "29eb13a3fe5fb4c33a4de211be73b6847bb2ce0da694933b637a99de407135a1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c7d2c784-d28c-4589-a66a-ac8b1cb1a2a7", "node_type": "1", "metadata": {"page_label": "23", "file_name": "strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_type": "application/pdf", "file_size": 920218, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "09553342684f2aab4b5bf09c2c03185ff9d112923d75afd9e5392ae894ba5c0d", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "R.79 Dans le cas d'une strat\u00e9gie m\u00e9dicamenteuse incluant une insuline, ou une quadrith\u00e9rapie, la sollicitation de l'avis d'un sp\u00e9cialiste EDN (endocrinologue diab\u00e9tologue nutritionniste) est encourag\u00e9e (grade AE).\nR.80 Il n'y a pas lieu d'associer GLP1 et iDPP4, association pour laquelle il n'a pas \u00e9t\u00e9\nrapport\u00e9 de b\u00e9n\u00e9fice particulier, ni d 'associer deux mol\u00e9cules de m\u00eame m\u00e9canisme d'action (grade AE).\nEn trith\u00e9rapie \u00ab avec insuline \u00bb", "mimetype": "text/plain", "start_char_idx": 1786, "end_char_idx": 2225, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "726b0e03-553f-4f15-bbb2-fbefaab9c573": {"__data__": {"id_": "726b0e03-553f-4f15-bbb2-fbefaab9c573", "embedding": null, "metadata": {"page_label": "24", "file_name": "strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_type": "application/pdf", "file_size": 920218, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "71716cb6-c757-42be-b092-8fa400362616", "node_type": "4", "metadata": {"page_label": "24", "file_name": "strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_type": "application/pdf", "file_size": 920218, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "de62b78c3b6dc44b1b955b1f08b0423e5a68f425ec29ae3db59da93e4fba7837", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a899fded-ec46-495c-a830-0f2904a01190", "node_type": "1", "metadata": {}, "hash": "0402e1f4cd4db059c070d591eccadee030e2f1e1a551aedfd70797eb2dac5944", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "HAS \u2022 Strat\u00e9gie th\u00e9rapeutique du patient vivant avec un diab\u00e8te de type 2 \u2022 mai 2024 24\nR.81 L'instauration d'une insulinoth\u00e9rapie est l'objet d'une discussion avec le patient\n(et/ou son entourage) dans le cadre de l '\u00e9ducation th\u00e9rapeutique. Elle est accompagn\u00e9e et id\u00e9alement pr\u00e9c\u00e9d\u00e9e d 'une autosurveillance glyc\u00e9mique et fai t\nl'objet d'un apprentissage par le patient et/ou son aidant (grade AE).\nR.82 L'instauration d 'une insulinoth\u00e9rapie n\u00e9cessite la d\u00e9finition d 'objectifs glyc\u00e9miques clairs, la r\u00e9alisation d'une autosurveillance glyc\u00e9mique, l'adaptation des\ndoses d'insuline afin d'atteindre les objectifs glyc\u00e9miques, la connaissance des\nmoyens de pr\u00e9venir et de corriger les hypoglyc\u00e9mies et la r\u00e9alisation ad\u00e9quate\nde l'injection d'insuline (grade AE).\nR.83 L'int\u00e9r\u00eat de maintenir les antidiab\u00e9tiques non insuliniques doit \u00eatre \u00e9valu\u00e9 en\nfonction des b\u00e9n\u00e9fices attendus pour chacune des mol\u00e9cules, des associations\nm\u00e9dicamenteuses et des pr\u00e9f\u00e9rences du patient (grade AE).\nR.84 Chez les patients vivant avec un DT2 sous insuline8, l'utilisation d'un dispositif\nde mesure continue du glucose ( \u00ab capteurs \u00bb) est encourag\u00e9e afin d'\u00e9viter les\ncomplications associ\u00e9es au traitement, en particulier les hypoglyc\u00e9mies s\u00e9v\u00e8res,\net doit faire l'objet d'un accompagnement \u00e0 son utilisation et \u00e0 l'interpr\u00e9tation des\ndonn\u00e9es (grade AE).\nR.85 Pour le choix d'un sch\u00e9ma d'insulinoth\u00e9rapie, le recours au sp\u00e9cialiste endocrinologue diab\u00e9tologue nutritionniste (EDN) est recommand\u00e9 , particuli\u00e8rement\nlorsqu'un sch\u00e9ma \u00e0 plusieurs injections est envisag\u00e9 (grade AE).\nCe choix d\u00e9pend de plusieurs param\u00e8tres, tels que :\n\u2012 les objectifs glyc\u00e9miques (glyc\u00e9mie et HbA1c) et la capacit\u00e9 du patient \u00e0\nles atteindre ;\n\u2012 les profils glyc\u00e9miques : y a-t-il une hyperglyc\u00e9mie \u00e0 jeun ? Est-elle isol\u00e9e\nou associ\u00e9e \u00e0 une ou plusieurs hyperglyc\u00e9mies postprandiales ? Quelle\nest l'ampleur du d\u00e9s\u00e9quilibre glucidique ?", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1903, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "a899fded-ec46-495c-a830-0f2904a01190": {"__data__": {"id_": "a899fded-ec46-495c-a830-0f2904a01190", "embedding": null, "metadata": {"page_label": "24", "file_name": "strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_type": "application/pdf", "file_size": 920218, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "71716cb6-c757-42be-b092-8fa400362616", "node_type": "4", "metadata": {"page_label": "24", "file_name": "strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_type": "application/pdf", "file_size": 920218, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "de62b78c3b6dc44b1b955b1f08b0423e5a68f425ec29ae3db59da93e4fba7837", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "726b0e03-553f-4f15-bbb2-fbefaab9c573", "node_type": "1", "metadata": {"page_label": "24", "file_name": "strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_type": "application/pdf", "file_size": 920218, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "40e5fc6903b41d287f9ef870abf05c5515ba7f744d3de5da722cbc2633e9e5c7", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Est-elle isol\u00e9e\nou associ\u00e9e \u00e0 une ou plusieurs hyperglyc\u00e9mies postprandiales ? Quelle\nest l'ampleur du d\u00e9s\u00e9quilibre glucidique ? ;\n\u2012 la pr\u00e9sence de complications, en particulier r\u00e9tiniennes et cardiovasculaires ;\n\u2012 le mode de vie du patient : le type d 'alimentation (horaires des repas et\ncharge glucidique) et l'activit\u00e9 physique (r\u00e9guli\u00e8re ou fluctuante) ;\n\u2012 le choix du patient : le patient accepte -t-il le traitement par insuline ? Si\noui, quel nombre d'injections ?\nDe ce fait, le choix d'un traitement insulinique repose sur une expertise des soignants \u00e0 transmettre au patient ou \u00e0 la personne qui prendra en charge ce traitement.\nR.86 Le recours \u00e0 un sp\u00e9cialiste EDN sera envisag\u00e9 pour instaurer ou optimiser le\nsch\u00e9ma insulinique en cas de difficult\u00e9 \u00e0 atteindre les objectifs glyc\u00e9miques fix\u00e9s\n(grade AE).\n\n8 \u00c0 la date de l'actualisation (mai 2024), des syst\u00e8mes de mesure du glucose interstitiel (en continu ou flash) sont indiqu\u00e9s et\nrembours\u00e9s chez les patients vivant avec un DT2 trait\u00e9s par insulinoth\u00e9rapie intensifi\u00e9e (par pompe externe ou \u2265 3 injections par\njour) et certains syst\u00e8mes sont indiqu\u00e9s chez les patients vivant avec un DT2 trait\u00e9s par insulinoth\u00e9rapie non intensifi\u00e9e\n(< 3 injections d'insuline par jour) et dont l'\u00e9quilibre glyc\u00e9mique est insuffisant (HbA1c \u2265 8 %), pour exemple : FREESTYLE LIBRE\n2 (avis de la HAS du 18 octobre 2022, rembours\u00e9 depuis l 'arr\u00eat\u00e9 du 13 juin 2023), DEXCOM ONE (avis de la HAS du 30 janvier\n2024).", "mimetype": "text/plain", "start_char_idx": 1775, "end_char_idx": 3236, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "8b443242-7253-419e-b8aa-7313ab70eaff": {"__data__": {"id_": "8b443242-7253-419e-b8aa-7313ab70eaff", "embedding": null, "metadata": {"page_label": "25", "file_name": "strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_type": "application/pdf", "file_size": 920218, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "2c80e8b8-a470-4dbf-acbd-1e0f0dbb3c99", "node_type": "4", "metadata": {"page_label": "25", "file_name": "strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_type": "application/pdf", "file_size": 920218, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "2a7cf27af7af97badd766cfddfc323b4059a4f65e75ff857ffe6b2723626a3b2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c6ce415f-8c18-4499-9f8f-19967fc48486", "node_type": "1", "metadata": {}, "hash": "247680684680509bcbad71deda926c5880abc7e64ae62acc963f3310797ef42d", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "HAS \u2022 Strat\u00e9gie th\u00e9rapeutique du patient vivant avec un diab\u00e8te de type 2 \u2022 mai 2024 25\nR.87 Lors de la mise en place prudente et s\u00e9cure en ambulatoire de l'insulinoth\u00e9rapie,\nil est recommand\u00e9, en adjonction \u00e0 une monoth\u00e9rapie ou \u00e0 une bith\u00e9rapie, de\nd\u00e9buter (grade AE) :\n\u2012 par une injection quotidienne basale (analogues lents de l 'insuline, insuline interm\u00e9diaire) selon la situation du patient (en particulier, risque d'hypoglyc\u00e9mies nocturnes) ;\n\u2012 la mise en route d 'une insulinoth\u00e9rapie basale n\u00e9cessite une phase de\npr\u00e9paration (cod\u00e9cision avec le patient), ainsi qu'une \u00e9ducation th\u00e9rapeutique du patient (et de son entourage). Elle doit \u00eatre accompagn\u00e9e et id\u00e9alement pr\u00e9c\u00e9d\u00e9e de la mise en place d 'une autosurveillance glyc\u00e9mique\net faire l 'objet d'un apprentissage. Le m\u00e9decin peut alors s 'appuyer sur\nles professionnels de proximit\u00e9 (pharmaciens ou infirmiers).\nL'instauration d'une insuline interm\u00e9diaire ou analogue lente pourra se faire avec\nles r\u00e8gles de pratique suivantes :\n\u2012 prescription d'une dose initiale faible (\u00e0 titre indicatif , en g\u00e9n\u00e9ral de\n0,1 unit\u00e9/kg par 24 heures, en dehors de situation o\u00f9 le contr\u00f4le doit \u00eatre\nobtenu rapidement pour une pathologie intercurrente ou un diab\u00e8te en\nvoie de d\u00e9compensation) ;\n\u2012 d\u00e9finition d'un objectif pour la glyc\u00e9mie \u00e0 jeun au r\u00e9veil selon l 'objectif\nd'HbA1c personnalis\u00e9 du patient ;\n\u2012 adaptation des doses d'insuline tous les 3 jours en fonction des glyc\u00e9mies\nau r\u00e9veil et de l'objectif fix\u00e9 (\u00e0 titre indicatif, la dose peut \u00eatre augment\u00e9e\nou r\u00e9duite de 1 ou 2 UI, sauf cas particulier) ;\n\u2012 r\u00e9\u00e9valuation du traitement (ADO et/ou insuline) r\u00e9guli\u00e8rement et selon besoin en cas d'hypoglyc\u00e9mies fr\u00e9quentes ou d'une hypoglyc\u00e9mie s\u00e9v\u00e8re ;\n\u2012 autonomisation du patient par une d\u00e9marche d'\u00e9ducation th\u00e9rapeutique ;\n\u2012 suivi rapproch\u00e9 pour v\u00e9rifier la bonne r\u00e9alisation, l'efficacit\u00e9 et la tol\u00e9rance\nde l'insulinoth\u00e9rapie, modifier le protocole et adapter les doses si n\u00e9cessaire ;\n\u2012 recours \u00e9ventuel \u00e0 un(e) infirmier(\u00e8re) pour r\u00e9aliser l 'insulinoth\u00e9rapie\n(adaptation des doses selon la prescription...) sur la base d 'un exemple\nde protocole d'adaptation \u00e9crit.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2128, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "c6ce415f-8c18-4499-9f8f-19967fc48486": {"__data__": {"id_": "c6ce415f-8c18-4499-9f8f-19967fc48486", "embedding": null, "metadata": {"page_label": "25", "file_name": "strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_type": "application/pdf", "file_size": 920218, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "2c80e8b8-a470-4dbf-acbd-1e0f0dbb3c99", "node_type": "4", "metadata": {"page_label": "25", "file_name": "strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_type": "application/pdf", "file_size": 920218, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "2a7cf27af7af97badd766cfddfc323b4059a4f65e75ff857ffe6b2723626a3b2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8b443242-7253-419e-b8aa-7313ab70eaff", "node_type": "1", "metadata": {"page_label": "25", "file_name": "strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_type": "application/pdf", "file_size": 920218, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "5962fc9f52472ecaec6cf3b6741d0ee355698bb5bf33bb316c0503c4a631475b", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "R.88 Si l'objectif glyc\u00e9mique n'est pas atteint malgr\u00e9 la mise en place de l'insulinoth\u00e9rapie, celle -ci sera intensifi\u00e9e. Les diff\u00e9rents sch\u00e9mas possibles sont\n(grade AE) :\n\u2012 pr\u00e9f\u00e9rentiellement, un sch\u00e9ma basal-bolus : insuline ou analogue d'action\nlente et insuline ou analogue d 'action rapide ou ultrarapide avant un ou\nplusieurs repas de la journ\u00e9e ;\n\u2012 sch\u00e9ma de 1 \u00e0 2 injections par jour d'insuline (m\u00e9lange d'insuline \u00e0 action\nrapide ou ultrarapide et d'insuline \u00e0 action interm\u00e9diaire ou lente).\nEn pr\u00e9sence de diab\u00e8te tr\u00e8s d\u00e9s\u00e9quilibr\u00e9\nR.89 En cas de diab\u00e8te tr\u00e8s d\u00e9s\u00e9quilibr\u00e9, avec des glyc\u00e9mies sup\u00e9rieures \u00e0 3 g/l r\u00e9p\u00e9t\u00e9es et/ou une HbA1c > ou = 10 %, un sch\u00e9ma insulinique intensifi\u00e9 pourra", "mimetype": "text/plain", "start_char_idx": 2129, "end_char_idx": 2832, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "499412d8-5e74-4250-be67-4d08742a86e6": {"__data__": {"id_": "499412d8-5e74-4250-be67-4d08742a86e6", "embedding": null, "metadata": {"page_label": "26", "file_name": "strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_type": "application/pdf", "file_size": 920218, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "9b1f5988-b92f-497c-8c79-72a1a574a741", "node_type": "4", "metadata": {"page_label": "26", "file_name": "strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_type": "application/pdf", "file_size": 920218, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "055d50e06cd0f9e53035d2f0416c6dfd3b09221927939d1d18cd6cc224e3aa54", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "HAS \u2022 Strat\u00e9gie th\u00e9rapeutique du patient vivant avec un diab\u00e8te de type 2 \u2022 mai 2024 26\n\u00eatre instaur\u00e9 d'embl\u00e9e avec avis d'un sp\u00e9cialiste EDN et en prenant en compte\nle risque de r\u00e9tinopathie sous-jacent (grade AE).", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 215, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "b65f2108-42cb-4bec-b2d2-b4c2a06690c5": {"__data__": {"id_": "b65f2108-42cb-4bec-b2d2-b4c2a06690c5", "embedding": null, "metadata": {"page_label": "27", "file_name": "strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_type": "application/pdf", "file_size": 920218, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "c32e19bf-848d-4924-b748-f6a7f601dc13", "node_type": "4", "metadata": {"page_label": "27", "file_name": "strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_type": "application/pdf", "file_size": 920218, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "e1934ab4b8ba6870ba753e4b82b9487b59c982f244ee7f8e2b2ee7b1de860bf6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9ebe8194-2505-4d2b-a252-d209ef3ba808", "node_type": "1", "metadata": {}, "hash": "12818b7959408526ab80d3eadbc867bea1c2c19a77206c44e59e0e21641a6e6e", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "HAS \u2022 Strat\u00e9gie th\u00e9rapeutique du patient vivant avec un diab\u00e8te de type 2 \u2022 mai 2024 27\n4. Strat\u00e9gie de prise en charge pour des\npopulations particuli\u00e8res\nLes populations particuli\u00e8res sont les suivantes :\n\u2012 personne \u00e2g\u00e9e de plus de 75 ans ;\n\u2012 personne ob\u00e8se avec un IMC > 30 kg/m2 ;\n\u2012 personne pr\u00e9sentant une maladie r\u00e9nale chronique ;\n\u2012 personne pr\u00e9sentant une insuffisance cardiaque ;\n\u2012 personne pr\u00e9sentant une maladie cardiovasculaire av\u00e9r\u00e9e ;\n\u2012 femme enceinte ou envisageant de l'\u00eatre.\n4.1. Personne \u00e2g\u00e9e de plus de 75 ans\nIl est rappel\u00e9 qu'habituellement, en m\u00e9decine et en g\u00e9riatrie, il est d'usage de consid\u00e9rer une personne\ncomme \u00e2g\u00e9e \u00e0 partir de 75 ans et de distinguer sa prise en charge selon son \u00e9tat de sant\u00e9 (personnes\ndites \u00ab vigoureuses \u00bb, personnes dites \u00ab fragiles \u00bb et personnes dites \u00ab malades \u00bb)9 10.\nTableau 9. Recommandations DT2 - personnes \u00e2g\u00e9es de plus de 75 ans\nGRADE N\u00b0\nAE\nR.90 Comme chez les sujets plus jeunes, quelle que soit l'\u00e9tape de la strat\u00e9gie th\u00e9rapeutique, il est recommand\u00e9 (grade AE) :\n\u2012 d'assurer une d\u00e9marche centr\u00e9e sur le patient (prise en compte de ses besoins, pr\u00e9f\u00e9rences, contraintes et ressources, des effets ind\u00e9sirables) et\nd'assurer un processus de d\u00e9cision m\u00e9dicale partag\u00e9e ;\n\u2012 de prendre en compte l 'environnement social, familial et culturel du patient\n(activit\u00e9s, rythme des repas...), son profil m\u00e9dico-psychologique (situation de\nfragilit\u00e9, isolement, pr\u00e9carit\u00e9...) , mais aussi ses capacit\u00e9s fonctionnelles\n(physiques et cognitives) et son niveau d'autonomie, ainsi que le niveau d'accompagnement autour du patient (capacit\u00e9 \u00e0 r\u00e9aliser le traitement, capacit\u00e9\n\u00e0 assurer la surveillance de la glyc\u00e9mie, etc.).\nAE\nR.91 En cas de suspicion de fragilit\u00e9 , un bilan g\u00e9riatrique peut \u00eatre pr\u00e9conis\u00e9 selon les\nmodalit\u00e9s d\u00e9crites dans les recommandations existantes (cf. grille de d\u00e9pistage de\nla fragilit\u00e9 des patients, HAS, 2013) (grade AE).", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1898, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "9ebe8194-2505-4d2b-a252-d209ef3ba808": {"__data__": {"id_": "9ebe8194-2505-4d2b-a252-d209ef3ba808", "embedding": null, "metadata": {"page_label": "27", "file_name": "strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_type": "application/pdf", "file_size": 920218, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "c32e19bf-848d-4924-b748-f6a7f601dc13", "node_type": "4", "metadata": {"page_label": "27", "file_name": "strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_type": "application/pdf", "file_size": 920218, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "e1934ab4b8ba6870ba753e4b82b9487b59c982f244ee7f8e2b2ee7b1de860bf6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b65f2108-42cb-4bec-b2d2-b4c2a06690c5", "node_type": "1", "metadata": {"page_label": "27", "file_name": "strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_type": "application/pdf", "file_size": 920218, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "4cb224813951173046bc7f740416de9a4fcc2f018e3fd25f16ab0485d08aeb1a", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "AE\nR.91 En cas de suspicion de fragilit\u00e9 , un bilan g\u00e9riatrique peut \u00eatre pr\u00e9conis\u00e9 selon les\nmodalit\u00e9s d\u00e9crites dans les recommandations existantes (cf. grille de d\u00e9pistage de\nla fragilit\u00e9 des patients, HAS, 2013) (grade AE).\n\n9 Trois cat\u00e9gories de personnes \u00e2g\u00e9es peuvent \u00eatre individualis\u00e9es en fonction de leur \u00e9tat de sant\u00e9 apr\u00e8s 75 ans :\n- les personnes dites \u00ab vigoureuses \u00bb : en bon \u00e9tat de sant\u00e9, ind\u00e9pendantes et bien int\u00e9gr\u00e9es socialement, c 'est-\u00e0-dire autonomes\nd'un point de vue d\u00e9cisionnel et fonctionnel, qui sont assimilables aux adultes plus jeunes ;\n- les personnes dites \u00ab fragiles \u00bb : \u00e0 l'\u00e9tat de sant\u00e9 interm\u00e9diaire et \u00e0 risque de basculer dans la cat\u00e9gorie des malades. Elles sont\nd\u00e9crites comme une population vuln\u00e9rable, avec des limitations fonctionnelles motrices et cognitives et une baisse des capaci t\u00e9s\nd'adaptation ;\n- les personnes dites \u00ab malades \u00bb : d\u00e9pendantes, en mauvais \u00e9tat de sant\u00e9 en raison d 'une polypathologie chronique \u00e9volu\u00e9e g\u00e9n\u00e9ratrice de handicaps et d'un isolement social.\n10 Arr\u00eat\u00e9 du 28 mars 2022 fixant la liste des affections m\u00e9dicales incompatibles ou compatibles avec ou sans am\u00e9nagements ou\nrestrictions pour l'obtention, le renouvellement ou le maintien du permis de conduire ou pouvant donner lieu \u00e0 la d\u00e9livrance de permis\nde conduire de dur\u00e9e de validit\u00e9 limit\u00e9e (refonte).", "mimetype": "text/plain", "start_char_idx": 1672, "end_char_idx": 3007, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "01de4a7b-e910-4132-9b72-cbd71f689146": {"__data__": {"id_": "01de4a7b-e910-4132-9b72-cbd71f689146", "embedding": null, "metadata": {"page_label": "28", "file_name": "strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_type": "application/pdf", "file_size": 920218, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "d13505f7-dd0c-498f-9eab-ca9f7072fa80", "node_type": "4", "metadata": {"page_label": "28", "file_name": "strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_type": "application/pdf", "file_size": 920218, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "e42be77134942f28f0d3c62cca88082e8225f6f5e3a68e288ada8855032ef623", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7a6e7b43-95fc-4c24-bb19-5d6b02b650fe", "node_type": "1", "metadata": {}, "hash": "732eda43e039c9086d0139ad9eb9a95327391c814418df71e8031c45e5da3c2c", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "HAS \u2022 Strat\u00e9gie th\u00e9rapeutique du patient vivant avec un diab\u00e8te de type 2 \u2022 mai 2024 28\nR.92 Dans le cadre d'un bilan g\u00e9riatrique, il est recommand\u00e9 de r\u00e9aliser une \u00e9valuation\ndes domaines m\u00e9dicaux, psychologiques, sociaux et fonctionnels (capacit\u00e9s d'autogestion notamment). Des troubles cognitifs et les syndromes g\u00e9riatriques (notamment la fragilit\u00e9) doivent \u00eatre recherch\u00e9s selon les recommandations existantes\n(cf. Comment rep\u00e9rer la fragilit\u00e9 en soins ambulatoires, HAS , 2013). Les objectifs\nseront fix\u00e9s en fonction de cette \u00e9valuation (grade AE).\nR.93 Chez les sujets \u00e2g\u00e9s, il est recommand\u00e9 d'\u00eatre prudent sur toute intervention sur le\nmode de vie, en particulier celle visant l'alimentation et la prescription de r\u00e9gimes\nrestrictifs qui peuvent provoquer une d\u00e9nutrition et une sarcop\u00e9nie. Ces patients\nsont en effet expos\u00e9s au risque de d\u00e9nutrition en raison de modifications de l'app\u00e9tit,\nde la diminution de l'activit\u00e9 physique ou de la pr\u00e9sence d'un \u00e9tat d\u00e9pressif qui exercent une influence n\u00e9gative sur la prise alimentaire.\nUne \u00e9valuation des apports alimentaires r\u00e9guliers, le d\u00e9pistage r\u00e9gulier de la sarcop\u00e9nie et de la d\u00e9nutrition sont recommand\u00e9s et toute modification de l'alimentation\ndoit \u00eatre envisag\u00e9e au cas par cas (ex . : ob\u00e9sit\u00e9 majeure, ob\u00e9sit\u00e9 sarcop\u00e9nique,\netc.) (grade AE).\n\nR.94 Les recommandations sur les mesures MTMV sont les m\u00eames que celles existantes\npour les populations \u00e2g\u00e9es fragiles non diab\u00e9tiques et ne sont pas plus restrictives\n(grade AE).\nB\nR.95 La pratique r\u00e9guli\u00e8re d 'une activit\u00e9 physique adapt\u00e9e est recommand\u00e9e chez les\nsujets \u00e2g\u00e9s vivant avec un DT2 avant toute prise en charge m\u00e9dicamenteuse, d\u00e8s\nle diagnostic et tout au long de la prise en charge (grade B).\nB\nR.96 Selon les recommandations les plus r\u00e9centes, les objectifs recommand\u00e9s chez les\nsujets \u00e2g\u00e9s de plus de 65 ans sont (grade B) :\n\u2012 au moins 150 \u00e0 300 minutes d'activit\u00e9 physique a\u00e9robie d'intensit\u00e9 mod\u00e9r\u00e9e\nou au moins 75 \u00e0 150 minutes d'activit\u00e9 physique a\u00e9robie d'intensit\u00e9 \u00e9lev\u00e9e ;\n\u2012 des activit\u00e9s de renforcement musculaire d'intensit\u00e9 mod\u00e9r\u00e9e ou plus soutenue faisant travailler les principaux groupes musculaires deux fois par semaine ou plus ;\n\u2012 des activit\u00e9s d'\u00e9quilibre au moins 3 fois par semaine.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2231, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "7a6e7b43-95fc-4c24-bb19-5d6b02b650fe": {"__data__": {"id_": "7a6e7b43-95fc-4c24-bb19-5d6b02b650fe", "embedding": null, "metadata": {"page_label": "28", "file_name": "strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_type": "application/pdf", "file_size": 920218, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "d13505f7-dd0c-498f-9eab-ca9f7072fa80", "node_type": "4", "metadata": {"page_label": "28", "file_name": "strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_type": "application/pdf", "file_size": 920218, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "e42be77134942f28f0d3c62cca88082e8225f6f5e3a68e288ada8855032ef623", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "01de4a7b-e910-4132-9b72-cbd71f689146", "node_type": "1", "metadata": {"page_label": "28", "file_name": "strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_type": "application/pdf", "file_size": 920218, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "1afdcdfef9876a006629e4adc521f196b55b4fdbafc4f0b5aa24b0ed2bae0447", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "R.97 Il est recommand\u00e9 d'adapter l'activit\u00e9 physique aux capacit\u00e9s fonctionnelles des sujets \u00e2g\u00e9s et \u00e0 leur situation (adapt\u00e9e \u00e0 leurs envies, leurs pr\u00e9f\u00e9rences, leurs modes\nde vie, leurs ressources, etc.) . Des pr\u00e9cautions particuli\u00e8res sont respect\u00e9es chez\nles sujets \u00e0 risque de d\u00e9shydratation et de chutes et rel\u00e8vent d'un accompagnement\nd'un professionnel de l'APA (grade AE).\nR.98 Le choix des th\u00e9rapeutiques TMH prend en compte le risque nutritionnel et le risque\naccru d'hypoglyc\u00e9mies aux cons\u00e9quences plus d\u00e9l\u00e9t\u00e8res chez les sujets \u00e2g\u00e9s ainsi\nque la pr\u00e9vention secondaire d'\u00e9v\u00e8nements cardiovasculaires (grade AE).\nC\nR.99 Si la situation le permet (pour les personnes dont la fonction r\u00e9nale n'est pas alt\u00e9r\u00e9e\net pour lesquelles la s\u00e9curit\u00e9 de la prise m\u00e9dicamenteuse est assur\u00e9e), la metformine est le traitement de 1 re intention, en portant une attention particuli\u00e8re aux\ntroubles digestifs et nutritionnels, en particulier amaigrissements et carence en vitamine B12 (grade C).", "mimetype": "text/plain", "start_char_idx": 2232, "end_char_idx": 3221, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "ae34a677-c877-4d96-8ae8-30bce8d6f75d": {"__data__": {"id_": "ae34a677-c877-4d96-8ae8-30bce8d6f75d", "embedding": null, "metadata": {"page_label": "29", "file_name": "strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_type": "application/pdf", "file_size": 920218, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "22a197d3-9f2e-4534-820c-280bffcb0bba", "node_type": "4", "metadata": {"page_label": "29", "file_name": "strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_type": "application/pdf", "file_size": 920218, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "5c46fa94ac8153cdcdce5c1c8c759a2b00496154631ac93fe32e7684d22a5b66", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3904c2c2-dc9b-4b9c-bc79-4d29af8d5cef", "node_type": "1", "metadata": {}, "hash": "26a9ec38652c169716be4a55cf3986e23022466b78eecb029d6a9c7d438c35fb", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "HAS \u2022 Strat\u00e9gie th\u00e9rapeutique du patient vivant avec un diab\u00e8te de type 2 \u2022 mai 2024 29\nR.100\n\nLes indications des iSGLT2 et aGLP1 sont identiques aux sujets jeunes mais ils sont\nutilis\u00e9s avec prudence du fait du risque d 'hypovol\u00e9mie et de perte de poids. Leur\ntol\u00e9rance est \u00e9valu\u00e9e r\u00e9guli\u00e8rement (grade AE).\nC\nR.101 En cas de contre-indication ou de mauvaise tol\u00e9rance \u00e0 la MET, les iDPP4 peuvent\n\u00eatre l'alternative \u00e0 privil\u00e9gier compte tenu de leur profil de tol\u00e9rance et de leur simplicit\u00e9 de mise en \u0153uvre si l'\u00e9cart \u00e0 l'objectif glyc\u00e9mique n'est pas trop important et\nen l'absence de maladie cardiovasculaire art\u00e9rioscl\u00e9reuse \u00e9tablie, de haut risque\ncardiovasculaire, d'insuffisance cardiaque ou de maladie r\u00e9nale chronique (grade\nC).\nEn cas d'intol\u00e9rance ou de contre -indication \u00e0 la metformine et aux iDPP4, il peut\n\u00eatre envisag\u00e9 de prescrire d'autres alternatives possibles (grade C) :\n\u2012 r\u00e9paglinide si la prise alimentaire est irr\u00e9guli\u00e8re, en raison de son administration \u00e0 chaque repas (demi-vie courte).\nR.102 En raison des risques d'hypoglyc\u00e9mies, les sulfamides sont \u00e0 utiliser avec pr\u00e9caution chez les personnes \u00e2g\u00e9es selon leur situation (vigoureuses ou non) et impliquent une surveillance accrue (grade AE).\nLorsqu'il existe une alternative, l 'instauration des sulfamides, en particulier ceux \u00e0\nlongue dur\u00e9e d'action, chez les personnes les plus \u00e2g\u00e9es n 'est pas recommand\u00e9e\nR.103 Il est recommand\u00e9 de r\u00e9\u00e9valuer les objectifs glyc\u00e9miques r\u00e9guli\u00e8rement. Il faut \u00e9viter l e surtraitement et une d\u00e9sintensification peut \u00eatre propos\u00e9e pour r\u00e9duire le\nrisque iatrog\u00e9nique, en particulier d'hypoglyc\u00e9mies (grade AE).\nR.104 Lorsque les TMH ne peuvent pas \u00eatre utilis\u00e9s, l 'insulinoth\u00e9rapie est recommand\u00e9e\nLe recours \u00e0 une tierce personne - professionnel de sant\u00e9, proche aidant - peut\n\u00eatre envisag\u00e9, ainsi que celui \u00e0 un dispositif de mesure continue du glucose\nR.105 Pour les personnes \u00e2g\u00e9es dites \u00ab fragiles \u00bb ou \u00ab malades \u00bb, et si l'\u00e9cart \u00e0 l'objectif\nest faible (moins de 0,5 % en valeur absolue d'HbA1c), l'absence de traitement m\u00e9dicamenteux peut \u00eatre envisag\u00e9e en maintenant une surveillance de l'\u00e9quilibre glyc\u00e9mique (grade AE).\n\n4.2.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2155, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "3904c2c2-dc9b-4b9c-bc79-4d29af8d5cef": {"__data__": {"id_": "3904c2c2-dc9b-4b9c-bc79-4d29af8d5cef", "embedding": null, "metadata": {"page_label": "29", "file_name": "strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_type": "application/pdf", "file_size": 920218, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "22a197d3-9f2e-4534-820c-280bffcb0bba", "node_type": "4", "metadata": {"page_label": "29", "file_name": "strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_type": "application/pdf", "file_size": 920218, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "5c46fa94ac8153cdcdce5c1c8c759a2b00496154631ac93fe32e7684d22a5b66", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ae34a677-c877-4d96-8ae8-30bce8d6f75d", "node_type": "1", "metadata": {"page_label": "29", "file_name": "strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_type": "application/pdf", "file_size": 920218, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "aa9957279cd51dc25231f2542a251ac4fbe22fea1b6d0e6946b6c11912697a64", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "4.2. Personne en situation d'ob\u00e9sit\u00e9 avec un IMC > 30 kg/m2\nLes recommandations peuvent se r\u00e9f\u00e9rer aux r\u00e9cents travaux de la HAS sur la prise en charge du\npatient en surpoids ou en ob\u00e9sit\u00e9, en particulier :\n\u2012 le guide du parcours de soins \u00ab Surpoids et ob\u00e9sit\u00e9 de l'adulte \u00bb, f\u00e9vrier 2023\n\u2012 la recommandation de bonne pratique \u00ab Ob\u00e9sit\u00e9 de l'adulte : prise en charge de 2e et 3e niveaux\n- Partie I : prise en charge m\u00e9dicale \u00bb, juin 2022 ;\n\u2012 le rapport d'\u00e9valuation des technologies de sant\u00e9 \u00ab Chirurgie m\u00e9tabolique : traitement chirurgical du DT2 \u00bb, octobre 2022.", "mimetype": "text/plain", "start_char_idx": 2151, "end_char_idx": 2715, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "e60faf91-3efb-462c-b310-d163944ef639": {"__data__": {"id_": "e60faf91-3efb-462c-b310-d163944ef639", "embedding": null, "metadata": {"page_label": "30", "file_name": "strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_type": "application/pdf", "file_size": 920218, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "93adc781-e6ce-428b-8f9b-576b47eda196", "node_type": "4", "metadata": {"page_label": "30", "file_name": "strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_type": "application/pdf", "file_size": 920218, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "98ae1dabfc3d5b05730bcc50632960ca90e9aa3574fad6ff7b05fe7a870246ae", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5b6afcaf-c8bd-4082-973d-f2d70323ac92", "node_type": "1", "metadata": {}, "hash": "c1e6206d7c5f03597276c90d7f31e7ebbed63f3e71990ee05550eef67fa6acae", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "HAS \u2022 Strat\u00e9gie th\u00e9rapeutique du patient vivant avec un diab\u00e8te de type 2 \u2022 mai 2024 30\nTableau 10. Recommandations - PEC - population sp\u00e9cifique - personnes en ob\u00e9sit\u00e9 IMC > 30 kg/m2\nGRADE N\u00b0\nR.106 La prise en charge du patient vivant avec un DT2 en situation d'ob\u00e9sit\u00e9 doit \u00eatre\nindividualis\u00e9e et adapt\u00e9e \u00e0 sa situation (\u00e2ge, poids initial et \u00e9volution pond\u00e9rale,\ncomportement alimentaire, activit\u00e9 physique, niveau socio-\u00e9conomique, litt\u00e9ratie\nen sant\u00e9) (grade AE).\nR.107 Le poids est \u00e0 surveiller lors des consultations.\nUn objectif de perte d 'au moins 5 % du poids corporel au diagnostic est adapt\u00e9\npour la plupart des patients en surpoids ou en ob\u00e9sit\u00e9. En fonction des objectifs\nsur le poids, l 'impact attendu des traitements m\u00e9dicamenteux sur le poids est \u00e0\nconsid\u00e9rer lors du choix des traitements (grade AE).\nAu-del\u00e0 de l'objectif, toute perte de poids a un impact b\u00e9n\u00e9fique sur l'\u00e9quilibre glyc\u00e9mique du patient vivant avec un DT2 (grade AE).\nR.108 La d\u00e9marche \u00e9ducative et au mieux l'\u00e9ducation th\u00e9rapeutique sont au c\u0153ur de la\nprise en charge (grade AE).\nR.109 La d\u00e9marche \u00e9ducative d\u00e9bute par une \u00e9valuation de l'alimentation (\u00e9quilibre, qualit\u00e9, rythme, comportement) afin de conna\u00eetre et de comprendre les habitudes du\npatient et ce qui peut faire obstacle au changement de ses habitudes pour aller\nvers une alimentation plus \u00e9quilibr\u00e9e.\nIl est recommand\u00e9 de ne pas promouvoir le r\u00e9\u00e9quilibrage alimentaire sans s'enqu\u00e9rir des habitudes du patient, de sa motivation, de l 'existence possible de\ntroubles du comportement alimentaire, de ses possibilit\u00e9s de changement et de\nson entourage.\nR.110 La prescription d'un r\u00e9\u00e9quilibrage alimentaire (qualitatif ou quantitatif) prend en\ncompte le rapport b\u00e9n\u00e9fices/risques (en particulier le risque de renforcement d'une\nrestriction cognitive \u00e0 risque de TCA pour la population g\u00e9n\u00e9rale et l e risque de\nsarcop\u00e9nie et de d\u00e9nutrition chez la personne \u00e2g\u00e9e).\nLes personnes \u00e2g\u00e9es en situation d'ob\u00e9sit\u00e9, surtout les plus fragiles, ne devraient\njamais b\u00e9n\u00e9ficier de restriction quantitative ou qualitative, la pr\u00e9vention de la d\u00e9nutrition et de la sarcop\u00e9nie \u00e9tant la priorit\u00e9 chez ces patients (grade AE).", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2159, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "5b6afcaf-c8bd-4082-973d-f2d70323ac92": {"__data__": {"id_": "5b6afcaf-c8bd-4082-973d-f2d70323ac92", "embedding": null, "metadata": {"page_label": "30", "file_name": "strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_type": "application/pdf", "file_size": 920218, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "93adc781-e6ce-428b-8f9b-576b47eda196", "node_type": "4", "metadata": {"page_label": "30", "file_name": "strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_type": "application/pdf", "file_size": 920218, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "98ae1dabfc3d5b05730bcc50632960ca90e9aa3574fad6ff7b05fe7a870246ae", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e60faf91-3efb-462c-b310-d163944ef639", "node_type": "1", "metadata": {"page_label": "30", "file_name": "strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_type": "application/pdf", "file_size": 920218, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "75f9126f5f654b43eda8aecf2716bba7af62c1b820c95c2566d873087ad18ece", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Les personnes \u00e2g\u00e9es en situation d'ob\u00e9sit\u00e9, surtout les plus fragiles, ne devraient\njamais b\u00e9n\u00e9ficier de restriction quantitative ou qualitative, la pr\u00e9vention de la d\u00e9nutrition et de la sarcop\u00e9nie \u00e9tant la priorit\u00e9 chez ces patients (grade AE).\nC\nR.111 Il est recommand\u00e9 de mettre en place autour du patient vivant avec un DT2 et en\nsituation d'ob\u00e9sit\u00e9 un plan global de modification th\u00e9rapeutique du mode de vie\nMTMV associant activit\u00e9 physique et modification comportementale, en particulier\navec une AP ou APA selon les recommandations existantes (grade C).\nTraitement m\u00e9dicamenteux\nC\nR.112 En ajout de la recherche de l'\u00e9quilibre glyc\u00e9mique, et m\u00eame \u00e0 sa normalisation ou\nvaleur constante d 'HbA1c, la PEC m\u00e9dicamenteuse tient compte des autres aspects associ\u00e9s des mol\u00e9cules, notamment de leur impact sur le poids (grade C).\nR.113 En association de la MET\nD\u00e8s que la dose optimale tol\u00e9r\u00e9e de la MET est acquise et ind\u00e9pendamment de la\nvaleur d'HbA1c, sous couvert d 'un suivi r\u00e9tinien (en raison du risque de baisse", "mimetype": "text/plain", "start_char_idx": 1914, "end_char_idx": 2935, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "516674f6-ad1d-4a4c-bb93-d9e1c0148aa1": {"__data__": {"id_": "516674f6-ad1d-4a4c-bb93-d9e1c0148aa1", "embedding": null, "metadata": {"page_label": "31", "file_name": "strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_type": "application/pdf", "file_size": 920218, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "a132a296-bb8a-4ecf-9d1c-bde59c9013b4", "node_type": "4", "metadata": {"page_label": "31", "file_name": "strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_type": "application/pdf", "file_size": 920218, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "8408ff504b54843eb8f5005ccf89fee13fa4c4647534143b055e1175f29e3f6f", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "HAS \u2022 Strat\u00e9gie th\u00e9rapeutique du patient vivant avec un diab\u00e8te de type 2 \u2022 mai 2024 31\nrapide de l'HbA1c), il est recommand\u00e9 l'ajout de l'aGLP1 \u00e0 dose antidiab\u00e9tique ou\n\u00e0 dose anti -ob\u00e9sit\u00e9*, si pr\u00e9sence d'une ob\u00e9sit\u00e9 ( limite IMC > ou \u00e9gale \u00e0 30)\n(grade AE).\n* Selon AMM et conditions de remboursement en cours.\nC\nR.120 La prescription des aGLP1 \u00e0 des doses anti -ob\u00e9sit\u00e9 se fait selon les modalit\u00e9s\nd\u00e9crites dans les recommandations de bonne pratique en cours pour la prise en\ncharge de l'ob\u00e9sit\u00e9 de 2e et 3e niveaux (grade C).\nC\nR.121 La pr\u00e9sence d'une st\u00e9atose h\u00e9patique ou d'une ob\u00e9sit\u00e9 s\u00e9v\u00e8re oriente pr\u00e9f\u00e9rentiellement vers un aGLP1 (grade C).\nPlace de la chirurgie bariatrique ou m\u00e9tabolique\nAE\nR.122 Le recours \u00e0 la chirurgie bariatrique peut \u00eatre discut\u00e9 individuellement selon les\nindications et modalit\u00e9s d\u00e9crites dans les recommandations de bonne pratique\nfran\u00e7aises existantes qui se d\u00e9clinent selon le niveau de s\u00e9v\u00e9rit\u00e9 de l'ob\u00e9sit\u00e9**\n(grade AE).\nAE\nR.123 Il existe une certaine variabilit\u00e9 de la r\u00e9ponse glyc\u00e9mique apr\u00e8s chirurgie bariatrique ou m\u00e9tabolique (amplitude de la r\u00e9duction glyc\u00e9mique, d\u00e9sintensification\nm\u00e9dicamenteuse, dur\u00e9e de l 'effet) qui n\u00e9cessite une surveillance , en particulier\nchez les patients vivant avec un DT2, insulinotrait\u00e9s, patients avec longue dur\u00e9e\nde diab\u00e8te connu, etc. (grade AE).\nLes r\u00e9missions de diab\u00e8te observ\u00e9es apr\u00e8s chirurgie bariatrique pouvant \u00eatre seulement transitoires, une surveillance \u00e0 long terme est pr\u00e9conis\u00e9e, en particulier \u00e0\nl'occasion de circonstances connues pour alt\u00e9rer le contr\u00f4le glyc\u00e9mique (ex. : cortico\u00efdes, etc.) (grade AE).\n\n* Selon AMM et conditions de remboursement en cours.\n** \u00c0 la date de l'actualisation (mai 2024) :\n\u2022 voir les indications \u00e0 la chirurgie bariatrique si ob\u00e9sit\u00e9 s\u00e9v\u00e8re (IMC sup\u00e9rieur ou \u00e9gal \u00e0 35 kg/m2 avec complications, ou IMC sup\u00e9rieur ou \u00e9gal \u00e0 40 kg/m2 sans complication ;\n\u2022 voir les indications \u00e0 la chirurgie dite m\u00e9tabolique si ob\u00e9sit\u00e9 mod\u00e9r\u00e9e d\u00e9finie par IMC sup\u00e9rieur ou \u00e9gal \u00e0\n30 kg/m2 et inf\u00e9rieur \u00e0 35 kg/m2, pour les patients vivant avec un diab\u00e8te.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2070, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "79a0c3b3-0bd3-41cf-8434-6e245dec08c4": {"__data__": {"id_": "79a0c3b3-0bd3-41cf-8434-6e245dec08c4", "embedding": null, "metadata": {"page_label": "32", "file_name": "strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_type": "application/pdf", "file_size": 920218, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "31300f5b-592a-47db-bbaa-b8c13172ff82", "node_type": "4", "metadata": {"page_label": "32", "file_name": "strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_type": "application/pdf", "file_size": 920218, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "72d10ff142968c0c45a2cb65bbdc3a7a367034c4b6297799c1579f8fb4132bfc", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "320bb471-acb6-4906-9c1e-e8a45ecd563b", "node_type": "1", "metadata": {}, "hash": "9031869dd97e89c4b1cb220978d7b5331475d2f49021e7f4d4eab33452b51a86", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "HAS \u2022 Strat\u00e9gie th\u00e9rapeutique du patient vivant avec un diab\u00e8te de type 2 \u2022 mai 2024 32\n4.3. Personnes avec insuffisance cardiaque\n\nTableau 11. Recommandations DT2 - PEC m\u00e9dicamenteuse - population sp\u00e9cifique - personnes DT2 avec\ninsuffisance cardiaque\nGRADE N\u00b0\nR.124 La metformine peut \u00eatre maintenue chez les patients insuffisants cardiaques compens\u00e9s en l'absence d'intol\u00e9rance ou de contre-indication, afin d'atteindre l'objectif\nd'HbA1c fix\u00e9 (grade B).\nA\nR.125 Tout patient vivant avec un DT2 et ayant une insuffisance cardiaque doit b\u00e9n\u00e9ficier\nd'un iSGLT2 en l'absence de contre-indication ou de mauvaise tol\u00e9rance et quel\nque soit le taux d 'HbA1c pour diminuer la mortalit\u00e9 et le risque d 'hospitalisation\npour insuffisance cardiaque (grade A).\nR.126 En cas d'intol\u00e9rance ou de contre-indication, les aGLP-1 sont une alternative aux\niSGLT2 en association avec la metformine, mais doivent \u00eatre \u00e9vit\u00e9s en cas d 'insuffisance cardiaque instable ou d 'hospitalisation pour insuffisance cardiaque\n(grade A).\nR.127 La sitagliptine peut \u00eatre utilis\u00e9e en cas d'insuffisance cardiaque si n\u00e9cessaire pour\nam\u00e9liorer le contr\u00f4le glyc\u00e9mique car les donn\u00e9es ne montrent pas de surrisque\nd'hospitalisation pour insuffisance cardiaque associ\u00e9 \u00e0 cette mol\u00e9cule (grade B).\n\n4.4. Personnes avec maladie cardiovasculaire av\u00e9r\u00e9e\nLes ant\u00e9c\u00e9dents de complications macrovasculaires pouvant \u00eatre consid\u00e9r\u00e9s comme av\u00e9r\u00e9s sont :\n\u2012 infarctus du myocarde (IDM) ;\n\u2012 atteinte coronarienne av\u00e9r\u00e9e (tronc commun ou atteinte tritronculaire ou atteinte de l'interventriculaire ant\u00e9rieure [IVA] proximale) ;\n\u2012 art\u00e9riopathie oblit\u00e9rante des membres inf\u00e9rieurs (AOMI) symptomatique ;\n\u2012 accident vasculaire c\u00e9r\u00e9bral.\nTableau 12.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1697, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "320bb471-acb6-4906-9c1e-e8a45ecd563b": {"__data__": {"id_": "320bb471-acb6-4906-9c1e-e8a45ecd563b", "embedding": null, "metadata": {"page_label": "32", "file_name": "strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_type": "application/pdf", "file_size": 920218, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "31300f5b-592a-47db-bbaa-b8c13172ff82", "node_type": "4", "metadata": {"page_label": "32", "file_name": "strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_type": "application/pdf", "file_size": 920218, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "72d10ff142968c0c45a2cb65bbdc3a7a367034c4b6297799c1579f8fb4132bfc", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "79a0c3b3-0bd3-41cf-8434-6e245dec08c4", "node_type": "1", "metadata": {"page_label": "32", "file_name": "strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_type": "application/pdf", "file_size": 920218, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "090ca9d2ce848362551cba78888e02db850fd7cd5a887680aabbc0f56cd71c8d", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Tableau 12. Recommandations DT2 - PEC m\u00e9dicamenteuse - population sp\u00e9cifique - personnes avec maladie\ncardiovasculaire av\u00e9r\u00e9e\nGRADE N\u00b0\nA\nR.128 En pr\u00e9sence d'une maladie cardiovasculaire clinique av\u00e9r\u00e9e, il est recommand\u00e9\nde prescrire ou au moins d 'envisager la prescription d'un iSGLT2i ou d'un aGLP1,\nind\u00e9pendamment de l'HbA1c et des autre s TMH, quitte \u00e0 r\u00e9duire les autres hypoglyc\u00e9miants pour pr\u00e9venir le risque d'hypoglyc\u00e9mie si besoin (grade A).\nAE\nR.129 En pr\u00e9sence d'une maladie cardiovasculaire clinique av\u00e9r\u00e9e, la prescription de\nl'association d'un iSGLT2 et d'un aGLP1 doit \u00eatre propos\u00e9e pr\u00e9f\u00e9rentiellement par\nrapport aux autres TMH quand l'objectif d'HbA1c n'est pas atteint, quitte \u00e0 r\u00e9duire\nles autres anti-hyperglyc\u00e9miants pour pr\u00e9venir le risque d 'hypoglyc\u00e9mie si besoin\n(grade AE).", "mimetype": "text/plain", "start_char_idx": 1686, "end_char_idx": 2487, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "70c81e90-760e-41d0-8b9f-38bcc846a125": {"__data__": {"id_": "70c81e90-760e-41d0-8b9f-38bcc846a125", "embedding": null, "metadata": {"page_label": "33", "file_name": "strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_type": "application/pdf", "file_size": 920218, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "95a10889-f1e1-4ada-93a9-5967531bd1d3", "node_type": "4", "metadata": {"page_label": "33", "file_name": "strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_type": "application/pdf", "file_size": 920218, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "c4f287670264d45579e65c7faf4945bc4ffaa2f1e3be30d6aaa89ffd38d57d2a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2bb15505-c2b6-4761-aded-56001597b226", "node_type": "1", "metadata": {}, "hash": "cc050f8d4df53975adb37b22417a6783007f4baf13f153da5dd4ade69deb63a4", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "HAS \u2022 Strat\u00e9gie th\u00e9rapeutique du patient vivant avec un diab\u00e8te de type 2 \u2022 mai 2024 33\nB\nR.130 En pr\u00e9sence d'une maladie cardiovasculaire asymptomatique r\u00e9v\u00e9l\u00e9e par un\nexamen d'imagerie vasculaire ou par un test fonctionnel, il peut \u00eatre envisag\u00e9 :\n\u2012 la prescription d 'un iSGLT2 (ex. : si dysfonction systolique ou diastolique\nasymptomatique) ;\n\u2012 ou la prescription d'un aGLP1 (ex. : si score calcique \u00e0 400 sans dysfonction\ndu VG).\nEt ce, ind\u00e9pendamment de l'HbA1c et des autres traitements anti-hyperglyc\u00e9miants,\nquitte \u00e0 r\u00e9duire les autres anti-hyperglyc\u00e9miants pour pr\u00e9venir le risque d'hypoglyc\u00e9mie si besoin (grade B).\n\n4.5. Patients avec une maladie r\u00e9nale chronique\nLa maladie r\u00e9nale chronique d\u00e9signe la diminution plus ou moins importante des fonctions des reins,\nquelle qu'en soit la cause. Les reins perdent, de fa\u00e7on durable et irr\u00e9versible, leur capacit\u00e9 \u00e0 filtrer\ncorrectement le sang de l'organisme. Le stade de maladie r\u00e9nale chronique est d\u00e9fini \u00e0 partir du DFG\nestim\u00e9 (DFGe) et de la pr\u00e9sence de marqueurs d'atteinte r\u00e9nale (voir annexe).\nLes recommandations peuvent se r\u00e9f\u00e9rer aux r\u00e9cents travaux de la HAS en lien avec la th\u00e9 matique,\nen particulier :\n\u2012 guide du parcours de soins - Maladie r\u00e9nale chronique de l'adulte (MRC), septembre 2023.\nTableau 13. Recommandations DT2 - PEC m\u00e9dicamenteuse - population sp\u00e9cifique - maladie r\u00e9nale chronique\nGRADE N\u00b0\nA\nR.131 En pr\u00e9sence d'une maladie r\u00e9nale chronique chez un patient sous traitement optimal (IEC/ARAII), il est recommand\u00e9 de prescrire ou au moins d 'envisager, si le\nd\u00e9bit de filtration glom\u00e9rulaire le permet, la prescription d'un iSGLT2, ind\u00e9pendamment de l'HbA1c et des autr es TMH, quitte \u00e0 r\u00e9duire les autres hypoglyc\u00e9miants\npour pr\u00e9venir le risque d'hypoglyc\u00e9mie si besoin (grade A).", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1768, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "2bb15505-c2b6-4761-aded-56001597b226": {"__data__": {"id_": "2bb15505-c2b6-4761-aded-56001597b226", "embedding": null, "metadata": {"page_label": "33", "file_name": "strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_type": "application/pdf", "file_size": 920218, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "95a10889-f1e1-4ada-93a9-5967531bd1d3", "node_type": "4", "metadata": {"page_label": "33", "file_name": "strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_type": "application/pdf", "file_size": 920218, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "c4f287670264d45579e65c7faf4945bc4ffaa2f1e3be30d6aaa89ffd38d57d2a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "70c81e90-760e-41d0-8b9f-38bcc846a125", "node_type": "1", "metadata": {"page_label": "33", "file_name": "strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_type": "application/pdf", "file_size": 920218, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "0d330ef18ce632dfea9044eae00234dc523411b64acbe8e5f95d99ff494ef60a", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "AE\nR.132 En pr\u00e9sence d'une maladie r\u00e9nale chronique chez un patient sous traitement optimal (IEC/ARAII) et d '\u00e9chec ou intol\u00e9rance \u00e0 un iSGLT2, il peut \u00eatre propos\u00e9 de\nprivil\u00e9gier un arGLP1 comme TMH, ind\u00e9pendamment de l 'HbA1c et des autre s\ntraitements normoglyc\u00e9miants, quitte \u00e0 r\u00e9duire les autres hypoglyc\u00e9miants pour\npr\u00e9venir le risque d'hypoglyc\u00e9mie si besoin (grade AE).\nAE\nR.133 Assurer le suivi et porter les points d'attention concernant la n\u00e9phroprotection des\npatients vivant avec un DT2 selon les recommandations existantes (voir guide parcours de soins - Maladie r\u00e9nale chronique) (grade AE).", "mimetype": "text/plain", "start_char_idx": 1769, "end_char_idx": 2375, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "90f5937e-07b7-477c-8631-5adc07eddd62": {"__data__": {"id_": "90f5937e-07b7-477c-8631-5adc07eddd62", "embedding": null, "metadata": {"page_label": "34", "file_name": "strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_type": "application/pdf", "file_size": 920218, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "9f8eae01-241f-4769-b3dd-5ef6529bd4b3", "node_type": "4", "metadata": {"page_label": "34", "file_name": "strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_type": "application/pdf", "file_size": 920218, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "95149a8ee75b9c24deea03240038771e21d37fbc580648499b79de28d108f4c0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0449ccb5-86f1-4d14-9144-249563399de6", "node_type": "1", "metadata": {}, "hash": "74595aaf95fedd20025bc0e63931b0133bca81445edf0acce35268d60909879c", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "HAS \u2022 Strat\u00e9gie th\u00e9rapeutique du patient vivant avec un diab\u00e8te de type 2 \u2022 mai 2024 34\n4.6. Femmes vivant avec un DT2 enceintes ou envisageant de l'\u00eatre\nLes recommandations concernent les femmes vivant avec un DT2 enceintes ou envisageant de l'\u00eatre.\nIl est rappel\u00e9 que ces recommandations ne traitent pas du diab\u00e8te gestationnel11.\nTableau 14. Proposition de recommandations pr\u00e9liminaires DT2 - PEC m\u00e9dicamenteuse - population sp\u00e9cifique -\nfemmes enceintes\nGRADE N\u00b0\nA\nR.134 La grossesse doit \u00eatre planifi\u00e9e, ce qui implique une contraception efficace en l'absence de d\u00e9sir de grossesse et d'\u00e9quilibre glyc\u00e9mique (grade A).\nL'HbA1c doit \u00eatre inf\u00e9rieure \u00e0 6,5 % en p\u00e9riode pr\u00e9conceptionnelle. En raison des\nrisques de malformation corr\u00e9l\u00e9s \u00e0 l 'HbA1c, il est conseill\u00e9 d 'obtenir un \u00e9quilibre\nglyc\u00e9mique au moins 2 mois avant le d\u00e9but d'une grossesse planifi\u00e9e.\nR.135 L'information de toute femme vivant avec un DT2 en \u00e2ge de procr\u00e9er est n\u00e9cessaire concernant la n\u00e9cessit\u00e9 :\n\u2012 de planifier une grossesse ;\n\u2012 de viser une HbA1c < 6,5 % ;\n\u2012 d'adapter les th\u00e9rapeutiques et de recourir \u00e0 un traitement par insuline dans\nle but de diminuer les complications materno -f\u0153tales et n\u00e9onatales\n(grade AE).\nR.136 La prise en charge de toute femme vivant avec un DT2 ayant un projet de grossesse doit \u00eatre individualis\u00e9e, par le m\u00e9decin EDN et en lien avec l '\u00e9quipe d'obst\u00e9trique et le m\u00e9decin traitant (grade AE).\nR.137 Il est recommand\u00e9 (grade AE) :\n\u2012 d'assurer une d\u00e9marche centr\u00e9e sur la patiente (prise en compte de ses\nbesoins, pr\u00e9f\u00e9rences, contraintes et ressources, des effets ind\u00e9sirables) et\nd'assurer un processus de d\u00e9cision partag\u00e9e ;\n\u2012 de prendre en compte l 'environnement social, familial et culturel de la patiente, son profil m\u00e9dico -psychologique (situation de fragilit\u00e9, isolement,\npr\u00e9carit\u00e9...), mais aussi ses capacit\u00e9s fonctionnelles et son niveau d 'autonomie, ainsi que le niveau d'accompagnement autour de la patiente (capacit\u00e9 \u00e0 r\u00e9aliser le traitement, capacit\u00e9 \u00e0 assurer la surveillance de la\nglyc\u00e9mie, etc.).", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2027, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "0449ccb5-86f1-4d14-9144-249563399de6": {"__data__": {"id_": "0449ccb5-86f1-4d14-9144-249563399de6", "embedding": null, "metadata": {"page_label": "34", "file_name": "strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_type": "application/pdf", "file_size": 920218, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "9f8eae01-241f-4769-b3dd-5ef6529bd4b3", "node_type": "4", "metadata": {"page_label": "34", "file_name": "strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_type": "application/pdf", "file_size": 920218, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "95149a8ee75b9c24deea03240038771e21d37fbc580648499b79de28d108f4c0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "90f5937e-07b7-477c-8631-5adc07eddd62", "node_type": "1", "metadata": {"page_label": "34", "file_name": "strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_type": "application/pdf", "file_size": 920218, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "f6e555f7cb435098ab5365250fdb9a9c4c53f808716107ca62567532bba91815", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "R.138 Il est recommand\u00e9 d'informer la femme enceinte vivant avec un DT2 sur la n\u00e9cessit\u00e9 de maintenir les mesures MTMV, en particulier la pratique de l'AP et APA selon\nles recommandations de bonne pratique en cours ( cf. AP/APA femme enceinte)\n(grade AE).\nB\nR.139 Les glyc\u00e9mies doivent \u00eatre maintenues aussi proches que possible de la normale\nen tenant compte du risque d'hypoglyc\u00e9mie, en particulier pendant le 1er trimestre.\n\n11 Le diab\u00e8te gestationnel est un trouble de la tol\u00e9rance glucidique conduisant \u00e0 une hyperglyc\u00e9mie de s\u00e9v\u00e9rit\u00e9 variable, d\u00e9buta nt\nou diagnostiqu\u00e9 pour la premi\u00e8re fois pendant la grossesse, quels que soient le traitement n\u00e9cessaire et l '\u00e9volution dans le post -\npartum (OMS).", "mimetype": "text/plain", "start_char_idx": 2028, "end_char_idx": 2734, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "2006f729-b181-4f6d-90c7-1697f2c0704e": {"__data__": {"id_": "2006f729-b181-4f6d-90c7-1697f2c0704e", "embedding": null, "metadata": {"page_label": "35", "file_name": "strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_type": "application/pdf", "file_size": 920218, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "8535767b-9d2b-4c9c-b00f-ced9974c2a0b", "node_type": "4", "metadata": {"page_label": "35", "file_name": "strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_type": "application/pdf", "file_size": 920218, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "62c5d7a983414622c6a626f173212b4ea9de78d2fafcdf1492c84b2c029dfb9a", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "HAS \u2022 Strat\u00e9gie th\u00e9rapeutique du patient vivant avec un diab\u00e8te de type 2 \u2022 mai 2024 35\nIl est donc conseill\u00e9 que les glyc\u00e9mies \u00e0 jeun restent inf\u00e9rieures \u00e0 0 ,95 g/L et les\npostprandiales inf\u00e9rieures \u00e0 1,20 g/L.\nLa patiente doit \u00eatre inform\u00e9e du risque d 'hypoglyc\u00e9mie associ\u00e9 \u00e0 ces objectifs\nglyc\u00e9miques (grade B).\nB\nR.140 L'insuline associant insuline lente et analogue rapide est le traitement de choix.\nLes autres traitements doivent \u00eatre arr\u00eat\u00e9s en pr\u00e9conceptionnel (grade B).\nAE\nR.141 Durant la grossesse, l '\u00e9quilibre glyc\u00e9mique doit \u00eatre \u00e9valu\u00e9 par des glyc\u00e9mies\ncapillaires pluriquotidiennes. L'utilisation d'un capteur de surveillance du glucose\ninterstitiel peut \u00eatre discut\u00e9e au cas par cas avec l'\u00e9quipe soignante (grade AE).\nAE\nR.142 Recommandation pour la recherche clinique\nIl est \u00e0 noter que l 'exp\u00e9rience clinique de l 'utilisation des insulines d\u00e9gludec et\nglulisine est tr\u00e8s limit\u00e9e et m\u00e9riterait l'acquisition de donn\u00e9es compl\u00e9mentaires sur\ncette population (grade AE).", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 991, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "0c3705ab-42f6-4852-a85d-c98cadc03831": {"__data__": {"id_": "0c3705ab-42f6-4852-a85d-c98cadc03831", "embedding": null, "metadata": {"page_label": "36", "file_name": "strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_type": "application/pdf", "file_size": 920218, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "ce974273-6283-469e-8dcd-3582376f0e34", "node_type": "4", "metadata": {"page_label": "36", "file_name": "strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_type": "application/pdf", "file_size": 920218, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "891af55de6a9c374fd339d3f6926f567a65bf05e405cb6ea541f491ca8c34bf6", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "HAS \u2022 Strat\u00e9gie th\u00e9rapeutique du patient vivant avec un diab\u00e8te de type 2 \u2022 mai 2024 36\nTable des annexes\n\nAnnexe 1. Travaux \u00e9labor\u00e9s par la HAS en lien avec la th\u00e9matique 37\nAnnexe 2. Listes des recommandations de bonne pratique s\u00e9lectionn\u00e9es 38\nAnnexe 3. Rappel des objectifs glyc\u00e9miques cibles selon le profil du patient 42\nAnnexe 4. \u00c9valuation du stade de la maladie r\u00e9nale chronique, HAS, juillet 2021 43", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 409, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "8e64aea6-52ee-4a75-9bf9-f66195e913b7": {"__data__": {"id_": "8e64aea6-52ee-4a75-9bf9-f66195e913b7", "embedding": null, "metadata": {"page_label": "37", "file_name": "strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_type": "application/pdf", "file_size": 920218, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "9af1dc8b-612a-4de7-8cdb-c73e94b51232", "node_type": "4", "metadata": {"page_label": "37", "file_name": "strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_type": "application/pdf", "file_size": 920218, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "64026de9005f4680dbc8759c3cc35713f9a1e994a228a45b7b0a88370920e10d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "fb531033-4263-4cbc-a385-9e4e65806411", "node_type": "1", "metadata": {}, "hash": "52e05205cd716d37d67eb6dcf6e7181d936db6b5eacfebc2018c724cbb238c78", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "HAS \u2022 Strat\u00e9gie th\u00e9rapeutique du patient vivant avec un diab\u00e8te de type 2 \u2022 mai 2024 37\nAnnexe 1. Travaux \u00e9labor\u00e9s par la HAS en lien avec la th\u00e9matique\nLes recommandations de bonne pratique RBP 2023 int\u00e8grent les travaux r\u00e9cents de la HAS en lien\navec la th\u00e9matique et s'y r\u00e9f\u00e8rent le cas \u00e9ch\u00e9ant. Si besoin , les recommandations pourront les compl\u00e9ter en particulier.\nPatients avec un diab\u00e8te\n\u2212 DT2 de l'adulte, guide parcours de soins, Haute Autorit\u00e9 de sant\u00e9, 2014 (en cours d'actualisation\nT4 2024)\n\u2212 T\u00e9l\u00e9surveillance m\u00e9dicale : r\u00e9f\u00e9rentiels des fonctions et organisations des soins, e-sant\u00e9, janv.\n2022, dont le r\u00e9f\u00e9rentiel \u00ab T\u00e9l\u00e9surveillance m\u00e9dicale du patient diab\u00e9tique \u00bb\nActivit\u00e9 physique\n\u2212 Guide de consultation et prescription m\u00e9dicale d'activit\u00e9 physique \u00e0 des fins de sant\u00e9 chez l'adulte,\n\n\u2212 Guide des connaissances sur l'activit\u00e9 physique et la s\u00e9dentarit\u00e9, 2022\n\u2212 Fiche de synth\u00e8se de prescription d'activit\u00e9 physique, Diab\u00e8te de type 2, 2022\n\u2212 Promotion, consultation et prescription m\u00e9dicale d'activit\u00e9 physique et sportive pour la sant\u00e9, HAS,\noctobre 2018\n\u00c9ducation th\u00e9rapeutique\n\u2212 Guide - \u00c9ducation th\u00e9rapeutique du patient (ETP) : \u00e9valuation de l'efficacit\u00e9 et de l'efficience dans\nles maladies chroniques, 2018\n\u2212 Structuration d'un programme d'\u00e9ducation th\u00e9rapeutique du patient dans le champ des maladies\nchroniques, guide m\u00e9thodologique, 2007, mise \u00e0 jour 2008\n\u2212 Guide du parcours de soins - Surpoids et ob\u00e9sit\u00e9 chez l'adulte, janvier 2023, mis \u00e0 jour f\u00e9vrier\n\nPatients avec surpoids ou ob\u00e9sit\u00e9\n\u2212 Guide du parcours de soins - Surpoids et ob\u00e9sit\u00e9 de l'adulte, f\u00e9vrier 2023\n\u2212 Ob\u00e9sit\u00e9 de l'adulte : prise en charge de 2e et 3e niveaux - Partie I : prise en charge m\u00e9dicale, recommandation de bonne pratique, juin 2022\n\u2212 Chirurgie m\u00e9tabolique : traitement chirurgical du DT2, rapport d'\u00e9valuation des technologies de\nsant\u00e9, octobre 2022\nPersonnes \u00e2g\u00e9es\n\u2212 Prendre en charge une personne \u00e2g\u00e9e polypathologique en soins primaires, outil d'am\u00e9lioration\ndes pratiques professionnelles, juin 2015\n\u2212 Comment rep\u00e9rer la fragilit\u00e9 en soins ambulatoires ?", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2066, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "fb531033-4263-4cbc-a385-9e4e65806411": {"__data__": {"id_": "fb531033-4263-4cbc-a385-9e4e65806411", "embedding": null, "metadata": {"page_label": "37", "file_name": "strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_type": "application/pdf", "file_size": 920218, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "9af1dc8b-612a-4de7-8cdb-c73e94b51232", "node_type": "4", "metadata": {"page_label": "37", "file_name": "strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_type": "application/pdf", "file_size": 920218, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "64026de9005f4680dbc8759c3cc35713f9a1e994a228a45b7b0a88370920e10d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8e64aea6-52ee-4a75-9bf9-f66195e913b7", "node_type": "1", "metadata": {"page_label": "37", "file_name": "strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_type": "application/pdf", "file_size": 920218, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "12792fad1a53b43a8b7c423ca3310be3668cfb31ccc4cacd95609f233b7b1faa", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Outil d'am\u00e9lioration des pratiques professionnelles, juin 2013\nPersonnes avec maladie r\u00e9nale chronique\n\u2212 Guide du parcours de soins - Maladie r\u00e9nale chronique de l'adulte (MRC), septembre 2023\nFemmes enceintes\nFiche de synth\u00e8se et r\u00e9f\u00e9rentiel - Prescription d'activit\u00e9 physique et sportive pendant la grossesse et\nen post -partum, juillet 2019", "mimetype": "text/plain", "start_char_idx": 2067, "end_char_idx": 2410, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "404b0742-092c-48d8-b76f-c4f24861e996": {"__data__": {"id_": "404b0742-092c-48d8-b76f-c4f24861e996", "embedding": null, "metadata": {"page_label": "38", "file_name": "strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_type": "application/pdf", "file_size": 920218, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "ef8859e9-2f3e-417b-a6de-20fdf31b652b", "node_type": "4", "metadata": {"page_label": "38", "file_name": "strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_type": "application/pdf", "file_size": 920218, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "1a7c6828958f1a3ed70e2b0b3e2615223a58335b466ed4ddd801fb7d4aeced2b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f87f4b93-8c46-4d05-a220-8fcd06fa1f36", "node_type": "1", "metadata": {}, "hash": "b98042e05571c47689febd969c2b436e4e7923a6a45d18cbf3eab828bfafe981", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "HAS \u2022 Strat\u00e9gie th\u00e9rapeutique du patient vivant avec un diab\u00e8te de type 2 \u2022 mai 2024 38\nAnnexe 2. Listes des recommandations de bonne pratique s\u00e9lectionn\u00e9es\nIl a \u00e9t\u00e9 identifi\u00e9 et s\u00e9lectionn\u00e9 pour analyse critique les recommandations de bonne pratique, rapports\nd'\u00e9valuation technologique, guides list\u00e9s ci-apr\u00e8s :\n\u2012 le cas \u00e9ch\u00e9ant, la version actualis\u00e9e (partielle ou compl\u00e8te) la plus r\u00e9cente a \u00e9t\u00e9 privil\u00e9gi\u00e9e sur\nles versions ant\u00e9rieures et ce, tout au long des travaux du GT ;\n\u2012 les membres du GT ou du GL ont par ailleurs pu signaler des r\u00e9f\u00e9rences compl\u00e9mentaires.\nPrise en charge globale (m\u00e9dicamenteuse et non m\u00e9dicamenteuse)\nNational Institute for Health and Care Excellence (NICE)\n1. Type 2 diabetes in adults: management, National Institute for Health and Care Excellence ,\n2015 (1), avec actualisation partielle 2020 et actualisation 2022 (2, 3)\n2. Type 2 diabetes in adults: management, National Institute for Health and Care Excellence ,\n2020 (2)\n3. Canagliflozin, dapagliflozin and empagliflozin as monotherapies for treating type 2 diabetes,\nNational Institute for Health and Care Excellence, 2016 (4)\n4. Empagliflozin in combination therapy for treating type 2 diabetes, Technology appraisal\nguidance, National Institute for Health and Care Excellence, 2015 (5)\nScottish Intercollegiate Network (SIGN)\n5. Management of diabetes, A national clinical guideline. N\u00b0 116, Scottish Intercollegiate Network,\n2017 (6) and quick reference book (7)\nAmerican Diabetes Association (ADA)\n6. Standards of medical care in diabetes, American Diabetes Association (ADA), 2023 (8)\n7. Standards of medical care in diabetes, American Diabetes Association (ADA), 2022 (9)\n8. Addendum. 11. Chronic Kidney Disease and Risk Management: Standards of Medical Care in\nDiabetes - 2022: Diabetes Care 2022 (10)\n9. Addendum. 10. Cardiovascular Disease and Risk Management: Standards of Medical Care in\nDiabetes - 2022 (11)\n10. Standards of medical care in diabetes, American Diabetes Association (ADA), 2017 (12)\nAmerican Diabetes Association/European Association for the Study of Diabetes (ADA EASD)\n11. Management of hyperglycaemia in type 2 diabetes, 2022. A consensus report by the American\nDiabetes Association (ADA) and the European Association for the Study of Diabetes (EASD),\n2022 (13, 14)\n12.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2290, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "f87f4b93-8c46-4d05-a220-8fcd06fa1f36": {"__data__": {"id_": "f87f4b93-8c46-4d05-a220-8fcd06fa1f36", "embedding": null, "metadata": {"page_label": "38", "file_name": "strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_type": "application/pdf", "file_size": 920218, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "ef8859e9-2f3e-417b-a6de-20fdf31b652b", "node_type": "4", "metadata": {"page_label": "38", "file_name": "strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_type": "application/pdf", "file_size": 920218, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "1a7c6828958f1a3ed70e2b0b3e2615223a58335b466ed4ddd801fb7d4aeced2b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "404b0742-092c-48d8-b76f-c4f24861e996", "node_type": "1", "metadata": {"page_label": "38", "file_name": "strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_type": "application/pdf", "file_size": 920218, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "d1834d52b4176b96db240d1995703897510052c2e554936c74bea2effe06f007", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Standards of medical care in diabetes, American Diabetes Association (ADA), 2017 (12)\nAmerican Diabetes Association/European Association for the Study of Diabetes (ADA EASD)\n11. Management of hyperglycaemia in type 2 diabetes, 2022. A consensus report by the American\nDiabetes Association (ADA) and the European Association for the Study of Diabetes (EASD),\n2022 (13, 14)\n12. New American Diabetes Association (ADA)/European Association for the Study of Diabetes\n(EASD) guidelines for the pharmacotherapy of type 2 diabetes: Placing them into a practicing\nphysician's perspective, 2020 (15)\n13. 2019 Update to Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report\nby the American Diabetes Association (ADA) and the European Association for the Study of\nDiabetes (EASD) 2020 (16)\n14. Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American\nDiabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)\n2018 (17)\nSoci\u00e9t\u00e9 francophone du diab\u00e8te (SFD)\n15. Quand et comment utiliser les inhibiteurs de la SGLT2 ou gliflozines en pratique clinique ? Un\nconsensus propos\u00e9 par la Soci\u00e9t\u00e9 francophone du diab\u00e8te (SFD), la Soci\u00e9t\u00e9 fran\u00e7aise de", "mimetype": "text/plain", "start_char_idx": 1915, "end_char_idx": 3128, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "3f08d264-59a0-46f0-bf9c-a2a58d05e7b7": {"__data__": {"id_": "3f08d264-59a0-46f0-bf9c-a2a58d05e7b7", "embedding": null, "metadata": {"page_label": "39", "file_name": "strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_type": "application/pdf", "file_size": 920218, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "ff4ee3f4-1ded-4d86-8bfd-a50bd8619dfa", "node_type": "4", "metadata": {"page_label": "39", "file_name": "strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_type": "application/pdf", "file_size": 920218, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "7f309f26783c57679ccbc0783c5eddacd95afdaf1e17a1cf365ecaeb8b3086d0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ddaafa66-4764-439d-a26d-89b79e873de0", "node_type": "1", "metadata": {}, "hash": "9a846b262572dbfc09e4eba9681f37b2fe9d28e9ad601fbc2039fff21f09431e", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "HAS \u2022 Strat\u00e9gie th\u00e9rapeutique du patient vivant avec un diab\u00e8te de type 2 \u2022 mai 2024 39\ncardiologie (SFC), le Coll\u00e8ge national des cardiologues fran\u00e7ais (CNCF) et la Soci\u00e9t\u00e9\nfrancophone de n\u00e9phrologie, dialyse et transplantation (SFND), 2023 (18)\n16. Prise de position de la Soci\u00e9t\u00e9 francophone du diab\u00e8te (SFD) sur les strat\u00e9gies d'utilisation des\ntraitements anti-hyperglyc\u00e9miants dans le diab\u00e8te de type 2, 2021 (19)\n17. Prise de position de la Soci\u00e9t\u00e9 francophone du diab\u00e8te (SFD) : \u00e9valuation du rapport b\u00e9n\u00e9ficesrisques des inhibiteurs de SGLT2, 2019 (20)\n18. Prise de position de la Soci\u00e9t\u00e9 francophone du diab\u00e8te (SFD) sur la prise en charge\nm\u00e9dicamenteuse de l'hyperglyc\u00e9mie du patient diab\u00e9tique de type 2, 2017 (21)\nHaute Autorit\u00e9 de sant\u00e9 (HAS)\n19. Guide du parcours de soins - Surpoids et ob\u00e9sit\u00e9 de l'adulte, f\u00e9vrier 2023 (22)\n20. Guide du parcours de soins - Maladie r\u00e9nale chronique de l'adulte (MRC), septembre 2023 (22)\n21. Chirurgie m\u00e9tabolique : traitement chirurgical du diab\u00e8te de type 2 - Rapport d '\u00e9valuation,\noctobre 2022 (24)\n22. Ob\u00e9sit\u00e9 de l'adulte : prise en charge de 2 e et 3e niveaux - Partie I : prise en charge m\u00e9dicale,\nrecommandation de bonne pratique, juin 2022 (25)\n23. Guide - \u00c9ducation th\u00e9rapeutique du patient (ETP) : \u00e9valuation de l'efficacit\u00e9 et de l 'efficience\ndans les maladies chroniques, 2018 (26)\n24. Guide de consultation et prescription m\u00e9dicale d 'activit\u00e9 physique \u00e0 des fins de sant\u00e9 chez\nl'adulte, 2022 (27)\n25. Guide des connaissances sur l'activit\u00e9 physique et la s\u00e9dentarit\u00e9, 2022 (28)\n26. Fiche de synth\u00e8se de prescription d'activit\u00e9 physique - Diab\u00e8te de type 2, 2022 (29)\n27. Diab\u00e8te de type 2 de l'adulte, guide parcours de soins, Haute Autorit\u00e9 de sant\u00e9, 2014 (30)\nAutres agences ou soci\u00e9t\u00e9s savantes\n28. BMJ rapid recom mendation, Benefits and harms of drug treatment for type 2 diabetes:\nsystematic review and network meta -analysis of randomized controlled trials , 2023 (31)\n(actualisation de la m\u00e9ta-analyse en r\u00e9seau publi\u00e9e par Li, 2021 (32))\n29.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2016, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "ddaafa66-4764-439d-a26d-89b79e873de0": {"__data__": {"id_": "ddaafa66-4764-439d-a26d-89b79e873de0", "embedding": null, "metadata": {"page_label": "39", "file_name": "strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_type": "application/pdf", "file_size": 920218, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "ff4ee3f4-1ded-4d86-8bfd-a50bd8619dfa", "node_type": "4", "metadata": {"page_label": "39", "file_name": "strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_type": "application/pdf", "file_size": 920218, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "7f309f26783c57679ccbc0783c5eddacd95afdaf1e17a1cf365ecaeb8b3086d0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3f08d264-59a0-46f0-bf9c-a2a58d05e7b7", "node_type": "1", "metadata": {"page_label": "39", "file_name": "strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_type": "application/pdf", "file_size": 920218, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "3a6518b6efb2919d9b4a758011d006a75aa78476e0705939eb5197ca11835dc9", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "BMJ rapid recom mendation, Benefits and harms of drug treatment for type 2 diabetes:\nsystematic review and network meta -analysis of randomized controlled trials , 2023 (31)\n(actualisation de la m\u00e9ta-analyse en r\u00e9seau publi\u00e9e par Li, 2021 (32))\n29. Diabetic kidney disease in type 2 diabetes: a consensus statement from the Swiss Societies of\nDiabetes and Nephrology, 2023 (33)\n30. 2023 AACE Consensus Statement: Comprehensive Type 2 Diabetes Management Algorithm ,\n2023 (34)\n31. Diabetes Management in Chronic Kidney Disease: A Consensus Report by the American\nDiabetes Association (ADA) and kidney disease: Improving Global Outcomes (KDIGO), 2022\n(35, 36)\n32. Canadian Cardiovascular Society Guideline for Use of GLP -1 Receptor Agonists and SGLT2\nInhibitors for Cardiorenal Risk Reduction in Adults, 2022 (37)\n33. Australian Evidence -Based Clinical Guidelines for Diabetes, Living Evidence for Diabetes\nConsortium, 2022 (38)\n34. BMJ rapid recommendation, SGLT-2 inhibitors or GLP-1 receptor agonists for adults with type\n2 diabetes: a clinical practice guideline, 2021, Li12 (32) (en lien avec (39-41))\n35. Clinical practice guidelines for management of hyperglycaemia in adults with diabetic kidney\ndisease, 2022 (42)", "mimetype": "text/plain", "start_char_idx": 1768, "end_char_idx": 2990, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "f55541ef-d164-4e50-af8a-4eaa063d091c": {"__data__": {"id_": "f55541ef-d164-4e50-af8a-4eaa063d091c", "embedding": null, "metadata": {"page_label": "40", "file_name": "strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_type": "application/pdf", "file_size": 920218, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "7e057d4e-cb0d-433c-ad65-7571ed9e5185", "node_type": "4", "metadata": {"page_label": "40", "file_name": "strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_type": "application/pdf", "file_size": 920218, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "a8491ae0eaffcb2585a3579f13683c4ca6b5522a2b3eb09426654e0ce7628754", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4f99bf68-11dd-4d0c-ba40-58b7b4b71f09", "node_type": "1", "metadata": {}, "hash": "91fb3024ea645cd6fea5c0e4964f6ebe49fdb107476d50c6c93e363792375e3e", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "HAS \u2022 Strat\u00e9gie th\u00e9rapeutique du patient vivant avec un diab\u00e8te de type 2 \u2022 mai 2024 40\n36. Diabetes Management in Chronic Kidney Disease: Synopsis of the 2020 KDIGO Clinical\nPractice, Guideline Kidney Disease Improving Global Outcomes (KDIGO), 2021 (43)\n37. ESC Guidelines on diabetes, pre -diabetes, and cardiovascular diseases developed in\ncollaboration with the EASD, 2020 (44)\n38. Recommandations de la Soci\u00e9t\u00e9 suisse d'endocrinologie et de diab\u00e9tologie (SGED-SSED) pour\nle traitement du diab\u00e8te de type 2, Soci\u00e9t\u00e9 suisse d'endocrinologie et de diab\u00e9tologie, 2020 (45)\n39. Diabetes Canada 2018 clinical practice guidelines: Key messages for family physicians caring\nfor patients living with type 2 diabetes, Ivers, 2019 (46)\n40. General practice management of type 2 diabetes: 2016-18, Royal Australian College of General\nPractitioners (RACGP), 2016-2018 (47)\n41. Consensus statement by the American Association of Clinical Endocrinologists and American\nCollege of Endocrinology on the comprehensive type 2 diabetes management algorithm - 2017\nexecutive summary, American Association of Clinical Endocrinologists (AACE/ACE), 2017 (48)\n42. Diabetes medications for adults with type 2 diabetes: an update. Comparative effectiveness\nReview n\u00b0173, Agency for Healthcare Research and Quality (ARHQ), 2016 (49)\n43. Diab\u00e8te sucr\u00e9 de type 2. Recommandations de bonne pratique, Soci\u00e9t\u00e9 scientifique de\nm\u00e9decine g\u00e9n\u00e9rale, 2015 (50)\n44. Impact of Regulatory Guidance on Evaluating Cardiovascular Risk of New Glucose -Lowering\nTherapies to Treat Type 2 Diabetes Mellitus: Lessons Learned and Future Directions, Sharma,\n2020 (51)\n45. Guideline recommendations and the positioning of newer drugs in type 2 diabetes care , Marx,\n2021 (52)\n46. Cardiovascular, renal and liver protection with novel antidiabetic agents beyond blood glucose\nlowering in type 2 diabetes: consensus article from the European Society of Hypertension\nWorking Group on Obesity, Diabetes and the High-risk Patient, Kotsis, 2020 (53)\n47. SGLT-2 inhibitors and GLP -1 receptor agonists for nephroprotection and cardioprotection in\npatients with diabetes mellitus and chronic kidney disease. A consensus statement by the\nEURECA-m and the DIABESITY working groups of the ERA-EDTA, Sarafidis, 2019 (54)\n48. Pharmacological treatment for Type 2 diabetes integrating findings from cardiovascular\noutcome trials: an expert consensus in the UK, Bain, 2019 (55)\n49.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2419, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "4f99bf68-11dd-4d0c-ba40-58b7b4b71f09": {"__data__": {"id_": "4f99bf68-11dd-4d0c-ba40-58b7b4b71f09", "embedding": null, "metadata": {"page_label": "40", "file_name": "strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_type": "application/pdf", "file_size": 920218, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "7e057d4e-cb0d-433c-ad65-7571ed9e5185", "node_type": "4", "metadata": {"page_label": "40", "file_name": "strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_type": "application/pdf", "file_size": 920218, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "a8491ae0eaffcb2585a3579f13683c4ca6b5522a2b3eb09426654e0ce7628754", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f55541ef-d164-4e50-af8a-4eaa063d091c", "node_type": "1", "metadata": {"page_label": "40", "file_name": "strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_type": "application/pdf", "file_size": 920218, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "b17b5b347b4767ead7c7e9bacb12949c8ef2cad366aad8590b4c45cd852b64d4", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "A consensus statement by the\nEURECA-m and the DIABESITY working groups of the ERA-EDTA, Sarafidis, 2019 (54)\n48. Pharmacological treatment for Type 2 diabetes integrating findings from cardiovascular\noutcome trials: an expert consensus in the UK, Bain, 2019 (55)\n49. Effectiveness and safety of dipeptidyl peptidase 4 inhibitors in the management of type 2\ndiabetes in older adults: a systematic review and development of recommendations to reduce\ninappropriate prescribing, Schott, 2017 (56)\n50. Oral Pharmacologic Treatment of Type 2 Diabetes Mellitus: A Clinical Practice Guideline Update\nfrom the American College of Physicians; American College of Physicians (ACP), 2017 (57)\n51. Optimal use recommendations for second - and third - line therapy for patients with type 2\ndiabetes, Canadian Agency for Drugs and Technologies in Health, 2013 (58)\n52. Efficacy and safety of metformin in the management of type 2 diabetes mellitus in older adults:\na systematic review for the development of recommendations to reduce potentially\ninappropriate prescribing, Schlender, 2017 (59)\n53. Effectiveness and safety of dipeptidyl peptidase 4 inhibitors in the management of type 2\ndiabetes in older adults: a systematic review and development of recommendations to reduce\ninappropriate prescribing, Schott, 2017 (56)\nPrise en charge non m\u00e9dicamenteuse\nHaute Autorit\u00e9 de sant\u00e9 (HAS)", "mimetype": "text/plain", "start_char_idx": 2153, "end_char_idx": 3526, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "6d69d2aa-5c73-4ddc-9671-dc4dc29b3352": {"__data__": {"id_": "6d69d2aa-5c73-4ddc-9671-dc4dc29b3352", "embedding": null, "metadata": {"page_label": "41", "file_name": "strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_type": "application/pdf", "file_size": 920218, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "8d2bfa1f-9f97-46be-8769-02f3df84764a", "node_type": "4", "metadata": {"page_label": "41", "file_name": "strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_type": "application/pdf", "file_size": 920218, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "efb0254fdc8b7c5b80e84ca36bb70f53fbef0f1363eb61fef8aa2f76d093ac66", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "HAS \u2022 Strat\u00e9gie th\u00e9rapeutique du patient vivant avec un diab\u00e8te de type 2 \u2022 mai 2024 41\n54. Activit\u00e9 physique. Pr\u00e9vention et traitement des maladies chroniques, Institut national de la sant\u00e9\net de la recherche m\u00e9dicale, 2019 (60)\n55. Guide de consultation et prescription m\u00e9dicale d 'activit\u00e9 physique \u00e0 des fins de sant\u00e9 chez\nl'adulte, 2022 (27)\n56. Guide des connaissances sur l'activit\u00e9 physique et la s\u00e9dentarit\u00e9, 2022 (28)\n57. Fiche de synth\u00e8se de prescription d'activit\u00e9 physique - Diab\u00e8te de type 2, 2022 (29)\n58. Promotion, consultation et prescription m\u00e9dicale d 'activit\u00e9 physique et sportive pour la sant\u00e9,\nHaute Autorit\u00e9 de sant\u00e9, 2018 (61)\nAutres\n59. Exercise recommendations for patients with type 2 diabetes, Dugan, 2016 (62)\n60. Physical activity and type 2 diabetes. Recomm endations of the SFD (Francophone Diabetes\nSociety) diabetes and physical activity working group, 2013 (63)\n61. Diabetes UK evidence -based nutrition guidelines for the prevention and management of\ndiabetes, Dyson, 2018 (64)", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1015, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "3b0913d7-8fa2-4d39-a519-58bac86dc854": {"__data__": {"id_": "3b0913d7-8fa2-4d39-a519-58bac86dc854", "embedding": null, "metadata": {"page_label": "42", "file_name": "strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_type": "application/pdf", "file_size": 920218, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "f8f7ce99-4073-48ec-b1c8-718e9c7f2ab0", "node_type": "4", "metadata": {"page_label": "42", "file_name": "strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_type": "application/pdf", "file_size": 920218, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "fa8706b9a35afdacd8b458effdcd63cfc2dbb115be844cc93520d2e8611ebea3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "11d19713-b38d-403c-8e10-68324fe5c05b", "node_type": "1", "metadata": {}, "hash": "e9b425d655b0de461b65884a75fbfabab4b927825a4f0297c24050c3614f2cd0", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "HAS \u2022 Strat\u00e9gie th\u00e9rapeutique du patient vivant avec un diab\u00e8te de type 2 \u2022 mai 2024 42\nAnnexe 3. Rappel des objectifs glyc\u00e9miques cibles selon le profil du patient vivant\navec un DT2\nCette section rappelle les objectifs glyc\u00e9miques retenus lors des pr\u00e9c\u00e9dentes recommandations (2013)\npour pr\u00e9venir les risques li\u00e9s \u00e0 l 'hyperglyc\u00e9mie et aux effets ind\u00e9sirables des traitements chez les\npatients vivant avec un DT2 (cas g\u00e9n\u00e9ral) et dans quatre sous -populations particuli\u00e8res : les sujets\n\u00e2g\u00e9s, les personnes ayant des ant\u00e9c\u00e9dents cardiovasculaires, les insuffisants r\u00e9naux chroniques et\nles femmes enceintes ou envisageant de l'\u00eatre.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 634, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "11d19713-b38d-403c-8e10-68324fe5c05b": {"__data__": {"id_": "11d19713-b38d-403c-8e10-68324fe5c05b", "embedding": null, "metadata": {"page_label": "42", "file_name": "strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_type": "application/pdf", "file_size": 920218, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "f8f7ce99-4073-48ec-b1c8-718e9c7f2ab0", "node_type": "4", "metadata": {"page_label": "42", "file_name": "strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_type": "application/pdf", "file_size": 920218, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "fa8706b9a35afdacd8b458effdcd63cfc2dbb115be844cc93520d2e8611ebea3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3b0913d7-8fa2-4d39-a519-58bac86dc854", "node_type": "1", "metadata": {"page_label": "42", "file_name": "strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_type": "application/pdf", "file_size": 920218, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "843fcd3ec98992adc5766b465ae6d3a782954047f23ed4c12b6d0d2f14c0ad5a", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Profil du patient HbA1c cible\nCas g\u00e9n\u00e9ral\nLa plupart des patients avec DT2 \u2264 7 %\nDT2 nouvellement diagnostiqu\u00e9 dont l'esp\u00e9rance de vie est > 15 ans et sans\nant\u00e9c\u00e9dent cardiovasculaire\n\u2264 6,5 %\nDT2 avec comorbidit\u00e9 grave av\u00e9r\u00e9e et/ou une esp\u00e9rance de vie limit\u00e9e\n(< 5 ans)\nDT2 avec des complications macrovasculaires \u00e9volu\u00e9es\nDT2 ayant une longue dur\u00e9e d'\u00e9volution du diab\u00e8te (> 10 ans) et pour lesquels\nla cible de 7 % s'av\u00e8re difficile \u00e0 atteindre car l'intensification m\u00e9dicamenteuse\nprovoque des hypoglyc\u00e9mies s\u00e9v\u00e8res\nPersonnes \u00e2g\u00e9es\nDites \u00ab vigoureuses \u00bb, dont l'esp\u00e9rance de vie est jug\u00e9e satisfaisante \u2264 7 %\nDites \u00ab fragiles \u00bb, \u00e0 l'\u00e9tat de sant\u00e9 interm\u00e9diaire et \u00e0 risque de basculer dans\nla cat\u00e9gorie des malades \u2264 8 %\nDites \u00ab malades \u00bb, d\u00e9pendantes, en mauvais \u00e9tat de sant\u00e9 en raison d 'une\npolypathologie chronique \u00e9volu\u00e9e g\u00e9n\u00e9ratrice de handicaps et d'un isolement\nsocial\n\u2264 9 %\net/ou glyc\u00e9mies\ncapillaires pr\u00e9prandiales entre\n1 et 2 g/l\nPatients avec ant\u00e9c\u00e9dent de complication\nmacrovasculaire\nConsid\u00e9r\u00e9e comme non \u00e9volu\u00e9e \u2264 7 %\nConsid\u00e9r\u00e9e comme \u00e9volu\u00e9e : infarctus du myocarde (IDM) avec insuffisance\ncardiaque, atteinte coronarienne s\u00e9v\u00e8re (tronc commun ou atteinte tritronculaire ou atteinte de l'interventriculaire ant\u00e9rieur proximal), atteinte polyart\u00e9rielle\n(au moins deux territoires art\u00e9riels symptomatiques), art\u00e9riopathie oblit\u00e9rante\ndes membres inf\u00e9rieurs symptomatique et accident vasculaire c\u00e9r\u00e9bral r\u00e9cent\n(< 6 mois)\nPatients avec insuffisance r\u00e9nale chronique (IRC)/maladie\nr\u00e9nale chronique\n(MRC)\nIRC mod\u00e9r\u00e9e (stades 3A et 3B) \u2264 7 %\nIRC s\u00e9v\u00e8re ou terminale (stades 5 et 5)\nPatientes enceintes\nou envisageant de\nl'\u00eatre\nAvant d'envisager la grossesse \u2264 6,5 %\nDurant la grossesse\n\u2264 6,5 %\net glyc\u00e9mies\n< 0,95 g/l \u00e0 jeun et\n< 1,20 g/l en postprandial \u00e0\n2 heures", "mimetype": "text/plain", "start_char_idx": 635, "end_char_idx": 2416, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "98b1f4f4-7a4e-400f-be7a-db8270c3e719": {"__data__": {"id_": "98b1f4f4-7a4e-400f-be7a-db8270c3e719", "embedding": null, "metadata": {"page_label": "43", "file_name": "strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_type": "application/pdf", "file_size": 920218, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "d5830389-43af-4fe3-a87e-11089ade4bd2", "node_type": "4", "metadata": {"page_label": "43", "file_name": "strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_type": "application/pdf", "file_size": 920218, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "ad2062005db33e89bb55112275d0cfb78ff5752537a96db3af9e4352358a3a26", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "HAS \u2022 Strat\u00e9gie th\u00e9rapeutique du patient vivant avec un diab\u00e8te de type 2 \u2022 mai 2024 43\nAnnexe 4. \u00c9valuation du stade de la maladie r\u00e9nale chronique, HAS, juillet 2021\nLe stade de maladie r\u00e9nale chronique est d\u00e9fini \u00e0 partir du DFG estim\u00e9 (DFGe) et de la pr\u00e9sence de\nmarqueurs d'atteinte r\u00e9nale (tableau ci-apr\u00e8s). Le stade 3 d'insuffisance r\u00e9nale mod\u00e9r\u00e9e int\u00e8gre deux\nniveaux de s\u00e9v\u00e9rit\u00e9 (stade 3A et 3B).\nTableau. Classification des stades d'\u00e9volution de la maladie r\u00e9nale chronique, HAS, 2021 [2023]\nStade DFGe (ml/min/1,73 m\u00b2) D\u00e9finition\n1 > 90 Maladie r\u00e9nale chronique* avec DFG normal ou augment\u00e9\n2 Entre 60 et 89 Maladie r\u00e9nale chronique* avec DFG l\u00e9g\u00e8rement diminu\u00e9\n3 Stade 3A : entre 45 et 59\nStade 3B : entre 30 et 44\nInsuffisance r\u00e9nale chronique mod\u00e9r\u00e9e\n4 Entre 15 et 29 Insuffisance r\u00e9nale chronique s\u00e9v\u00e8re\n5 < 15 Insuffisance r\u00e9nale chronique terminale\n* Avec marqueurs d'atteinte r\u00e9nale : albuminurie, h\u00e9maturie, leucocyturie, ou anomalies morphologiques\nou histologiques, ou marqueurs de dysfonction tubulaire, persistant plus de 3 mois (deux ou trois examens cons\u00e9cutifs).", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1089, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "5adcc8f2-e4f1-438f-973d-bc0068dd3089": {"__data__": {"id_": "5adcc8f2-e4f1-438f-973d-bc0068dd3089", "embedding": null, "metadata": {"page_label": "44", "file_name": "strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_type": "application/pdf", "file_size": 920218, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "01ca76b8-edaf-446d-a53c-4b4782950ed6", "node_type": "4", "metadata": {"page_label": "44", "file_name": "strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_type": "application/pdf", "file_size": 920218, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "65bf1c8537e8f7602622e876461fe0e10eb9b71a2581a669d8f07f5c5841dd68", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e10325e7-9e56-4c5e-8c68-f7c69b4ca616", "node_type": "1", "metadata": {}, "hash": "8e9c6d55299b46bdb9ed110ca631a5c297adb60e4807109cf879f5761d92e5d5", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "HAS \u2022 Strat\u00e9gie th\u00e9rapeutique du patient vivant avec un diab\u00e8te de type 2 \u2022 mai 2024 44\nR\u00e9f\u00e9rences bibliographiques\n\n1. National Institute for Health and Care Excellence. Type 2\ndiabetes in adults: management. London: NICE; 2015.\n\n2. National Institute for Health and Care Excellence. Type 2\ndiabetes in adults: management. London: NICE; 2020.\n\n3. National Institute for Health and Care Excellence. Type 2\ndiabetes in adults: choosing medicines. Summary of the advice\nNICE guideline on type 2 diabetes in adults: management.\nLondon: NICE; 2022.\n\n4. National Institute for Health and Care Excellence.\nCanaglifloxin, dapaglifloxin and empagliflozin as monotherapies\nfor treating type 2 diabetes. London: NICE; 2016.\n\n5. National Institute for health and Care Excellence.\nEmpaglifozin in combination therapy for treating type 2\ndiabetes. Technology appraisal guidance. London: NICE; 2015.\n\n6. Scottish Intercollegiate Network, Healthcare Improvement\nScotland. Pharmacological management of glycaemic control in\npeople with type 2 diabetes. SIGN 154. Edinburgh: SIGN;\n2017.\n\n7. Scottish Intercollegiate Network, Healthcare Improvement\nScotland. Management of diabetes. Quick reference guide.\nEdinburgh: SIGN; 2017.\n\n8. American Diabetes Association, ElSayed NA, Aleppo G,\nAroda VR, Bannuru RR, Brown FM, et al. Standards of Care in\nDiabetes-2023. Diabetes Care 2023;46(Supplement_1).\n\n9. American Diabetes Association. Standards of medical care in\ndiabetes - 2022. Diabetes Care 2022;45(Suppl 1).\n\n10. American Diabetes Association, Draznin B, Aroda VR,\nBakris G, Benson G, Brown FM, et al. 11. Chronic kidney\ndisease and risk management: standards of medical care in\nDiabetes-2022. Diabetes Care 2022;45(Supplement_1):S175s84.\n\n11. American Diabetes Association, Draznin B, Aroda VR,\nBakris G, Benson G, Brown FM, et al. 10. Cardiovascular\ndisease and risk management: Standards of medical care in\nDiabetes-2022. Diabetes Care 2022;45(Supplement_1):S144s74.\n\n12. American Diabetes Association. Standards of medical care\nin diabetes - 2017. Diabetes Care 2017;40(Suppl 1).\n\n13. American Diabetes Association, European Association for\nthe Study of Diabetes, Davies MJ, Aroda VR, Collins BS,\nGabbay RA, et al.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2203, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "e10325e7-9e56-4c5e-8c68-f7c69b4ca616": {"__data__": {"id_": "e10325e7-9e56-4c5e-8c68-f7c69b4ca616", "embedding": null, "metadata": {"page_label": "44", "file_name": "strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_type": "application/pdf", "file_size": 920218, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "01ca76b8-edaf-446d-a53c-4b4782950ed6", "node_type": "4", "metadata": {"page_label": "44", "file_name": "strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_type": "application/pdf", "file_size": 920218, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "65bf1c8537e8f7602622e876461fe0e10eb9b71a2581a669d8f07f5c5841dd68", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5adcc8f2-e4f1-438f-973d-bc0068dd3089", "node_type": "1", "metadata": {"page_label": "44", "file_name": "strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_type": "application/pdf", "file_size": 920218, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "84a5e07bc40d66adb9e9d9033b8403ab59c3123dcc93533d7133f12be87dcc00", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ac2fd157-c126-47e3-bf54-e564f4187faf", "node_type": "1", "metadata": {}, "hash": "8009a394a8cab6ad1ec5cd4e0ca1f5630d7a404e96a0b77070729bf2a1d7cc7c", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Diabetes Care 2022;45(Supplement_1):S144s74.\n\n12. American Diabetes Association. Standards of medical care\nin diabetes - 2017. Diabetes Care 2017;40(Suppl 1).\n\n13. American Diabetes Association, European Association for\nthe Study of Diabetes, Davies MJ, Aroda VR, Collins BS,\nGabbay RA, et al. Management of hyperglycaemia in type 2\ndiabetes, 2022. A consensus report by the American Diabetes\nof Diabetes (EASD). Diabetologia 2022;65(12):1925-66.\n\n14. American Diabetes Association, European Association for\nthe Study of Diabetes, Davies MJ, Aroda VR, Collins BS,\nGabbay RA, et al.. Management of hyperglycemia in type 2\nDiabetes, 2022. A consensus report by the American Diabetes\nof Diabetes (EASD). Diabetes Care 2022;45(11):2753-86.\n\n15. New American Diabetes Association (ADA), European\nAssociation for the Study of Diabetes (EASD), Katsiki N,\nFerrannini E, Mantzoros C. New American Diabetes\nAssociation (ADA)/European Association for the Study of\nDiabetes (EASD) guidelines for the pharmacotherapy of type 2\ndiabetes: Placing them into a practicing physician's\nperspective. Metabolism 2020;107:154218.\n\n16. American Diabetes Association, European Association for\nthe Study of Diabetes, Buse JB, Wexler DJ, Tsapas A, Rossing\nP, et al. 2019 Update to: management of hyperglycemia in type\n2 diabetes, 2018. a consensus report by the American\nDiabetes Association (ADA) and the European Association for\nthe Study of Diabetes (EASD). Diabetes Care 2020;43(2):48793.\n\n17. American Diabetes Association, European Association for\nthe Study of Diabetes, Davies MJ, D'Alessio DA, Fradkin J,\nKernan WN, et al. Management of hyperglycaemia in type 2\ndiabetes, 2018. A consensus report by the American Diabetes\nof Diabetes (EASD). Diabetologia 2018;61(12):2461-98.\n\n18. Soci\u00e9t\u00e9 francophone du diab\u00e8te (SFD), Soci\u00e9t\u00e9 fran\u00e7aise\nde cardiologie (SFC), Coll\u00e8ge national des cardiologues\nfran\u00e7ais (CNCF), Soci\u00e9t\u00e9 francophone de n\u00e9phrologie dialyse\net transplantation (SFNDT), Di\u00e9vart F, Darmon P, et al. Quand\net comment utiliser les inhibiteurs de la SGLT2 ou gliflozines en\npratique clinique ?", "mimetype": "text/plain", "start_char_idx": 1910, "end_char_idx": 3992, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "ac2fd157-c126-47e3-bf54-e564f4187faf": {"__data__": {"id_": "ac2fd157-c126-47e3-bf54-e564f4187faf", "embedding": null, "metadata": {"page_label": "44", "file_name": "strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_type": "application/pdf", "file_size": 920218, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "01ca76b8-edaf-446d-a53c-4b4782950ed6", "node_type": "4", "metadata": {"page_label": "44", "file_name": "strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_type": "application/pdf", "file_size": 920218, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "65bf1c8537e8f7602622e876461fe0e10eb9b71a2581a669d8f07f5c5841dd68", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e10325e7-9e56-4c5e-8c68-f7c69b4ca616", "node_type": "1", "metadata": {"page_label": "44", "file_name": "strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_type": "application/pdf", "file_size": 920218, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "d249fac1740add97e317dcc8d35c338982c93037d4e8246356b4ab6de3e2ccae", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Quand\net comment utiliser les inhibiteurs de la SGLT2 ou gliflozines en\npratique clinique ? Un consensus propos\u00e9 par la Soci\u00e9t\u00e9\nfrancophone du diab\u00e8te (SFD), la Soci\u00e9t\u00e9 fran\u00e7aise de\ncardiologie (SFC), le Coll\u00e8ge national des cardiologues fran\u00e7ais\n(CNCF) et la Soci\u00e9t\u00e9 francophone de n\u00e9phrologie, dialyse et\ntransplantation (SFNDT). Nephrol Ther 2023;19(4):251-77.\n\n19. Soci\u00e9t\u00e9 Francophone du Diab\u00e8te (SFD), Darmon P,\nBauduceau B, Bordier L, Detournay B, Gourdy P, et al. Prise de\nposition de la Soci\u00e9t\u00e9 Francophone du Diab\u00e8te (SFD) sur les\nstrat\u00e9gies d'utilisation des traitements anti-hyperglyc\u00e9miants\ndans le diab\u00e8te de type 2 - 2021. M\u00e9decine des Maladies\nM\u00e9taboliques 2021;15(8):781-801.\n\n20. Soci\u00e9t\u00e9 Francophone du Diab\u00e8te (SFD), Darmon P,\nBauduceau B, Bordier L, Bringer J, Charbrier G, et al. Prise de\nposition de la Soci\u00e9t\u00e9 Francophone du Diab\u00e8te (SFD) :\n\u00e9valuation du rapport b\u00e9n\u00e9fices-risques des inhibiteurs de\nSGLT2. Med Mal Metab 2019;13(2):195-209.\n\n21. Soci\u00e9t\u00e9 Francophone du Diab\u00e8te (SFD), Darmon P,\nBauduceau B, Bordier L, Bringer J, Charbrier G, et al. Prise de\nposition de la Soci\u00e9t\u00e9 Francophone du Diab\u00e8te (SFD) sur la\nprise en charge m\u00e9dicamenteuse de l'hyperglyc\u00e9mie du patient\ndiab\u00e9tique de type 2. Med Mal Metab 2017;11(6):577-93.", "mimetype": "text/plain", "start_char_idx": 3901, "end_char_idx": 5155, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "9aaeaa02-4e8b-4689-af22-7812713b1a54": {"__data__": {"id_": "9aaeaa02-4e8b-4689-af22-7812713b1a54", "embedding": null, "metadata": {"page_label": "45", "file_name": "strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_type": "application/pdf", "file_size": 920218, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "6d1169d6-a5c3-4663-b3f4-6d70fdb63b27", "node_type": "4", "metadata": {"page_label": "45", "file_name": "strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_type": "application/pdf", "file_size": 920218, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "394017b06bfebd063c93a224241c6db4d4cbd16eb9353d95e29d5f32f338797e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "75803775-c402-41f5-9f16-fbb4ed43768b", "node_type": "1", "metadata": {}, "hash": "9e1eef73ac157946e62721a98d7030fc1d221a731f33d071218e8c2da316d929", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "HAS \u2022 Strat\u00e9gie th\u00e9rapeutique du patient vivant avec un diab\u00e8te de type 2 \u2022 mai 2024 45\n22. Haute Autorit\u00e9 de Sant\u00e9, Caisse nationale de l'assurance\nmaladie. Guide du parcours de soins : surpoids et ob\u00e9sit\u00e9 de\nl'adulte. Saint-Denis La Plaine: HAS; 2024.\n\n23. Haute Autorit\u00e9 de Sant\u00e9, Caisse nationale de l'assurance\nmaladie. Guide du parcours de soins - Maladie r\u00e9nale\nchronique de l'adulte (MRC). Saint-Denis La Plaine: HAS;\n2023.\n\n24. Haute Autorit\u00e9 de Sant\u00e9. Chirurgie m\u00e9tabolique : traitement\nchirurgical du diab\u00e8te de type 2. Saint-Denis La Plaine: HAS;\n\n25. Haute Autorit\u00e9 de la Sant\u00e9, F\u00e9d\u00e9ration Fran\u00e7aise de\nNutrition. Ob\u00e9sit\u00e9 de l'adulte : prise en charge de 2e et 3e\nniveaux. Partie I : Prise en charge m\u00e9dicale. Saint-Denis La\nPlaine: HAS; 2022.\n\n26. Haute Autorit\u00e9 de la Sant\u00e9. Education th\u00e9rapeutique du\npatient. \u00c9valuation de l'efficacit\u00e9 et de l'efficience dans les\nmaladies chroniques. Actualisation de l'analyse de la litt\u00e9rature.\nSaint-Denis La Plaine: HAS; 2018.\n\n27. Haute Autorit\u00e9 de la Sant\u00e9. Consultation et prescription\nm\u00e9dicale d'activit\u00e9 physique \u00e0 des fins de sant\u00e9 chez l'adulte.\nSaint-Denis La Plaine: HAS; 2022.\n\n28. Haute Autorit\u00e9 de la Sant\u00e9. Guide des connaissances sur\nl'activit\u00e9 physique et la s\u00e9dentarit\u00e9. Saint-Denis La Plaine:\nHAS; 2022.\n\n29. Haute Autorit\u00e9 de la Sant\u00e9. Diab\u00e8te de type 2. Prescription\nd'activit\u00e9 physique. Synth\u00e8se. Saint-Denis La Plaine: HAS;\n\n30. Haute Autorit\u00e9 de Sant\u00e9. Diab\u00e8te de type 2 de l'adulte.\nGuide parcours de soins. Saint-Denis La Plaine: HAS; 2014.\n\n31. Shi Q, Nong K, Vandvik PO, Guyatt GH, Schnell O, Ryd\u00e9n\nL, et al. Benefits and harms of drug treatment for type 2\ndiabetes: systematic review and network meta-analysis of\nrandomised controlled trials. BMJ 2023;381:e074068.\n\n32. Li S, Vandvik PO, Lytvyn L, Guyatt GH, Palmer SC,\nRodriguez-Gutierrez R, et al.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1831, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "75803775-c402-41f5-9f16-fbb4ed43768b": {"__data__": {"id_": "75803775-c402-41f5-9f16-fbb4ed43768b", "embedding": null, "metadata": {"page_label": "45", "file_name": "strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_type": "application/pdf", "file_size": 920218, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "6d1169d6-a5c3-4663-b3f4-6d70fdb63b27", "node_type": "4", "metadata": {"page_label": "45", "file_name": "strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_type": "application/pdf", "file_size": 920218, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "394017b06bfebd063c93a224241c6db4d4cbd16eb9353d95e29d5f32f338797e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9aaeaa02-4e8b-4689-af22-7812713b1a54", "node_type": "1", "metadata": {"page_label": "45", "file_name": "strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_type": "application/pdf", "file_size": 920218, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "0a46e8b7b76129bc0784b3635531f646ca8871824c94a0d90ed643d63790b97a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c2e1115b-0324-4880-aea8-dee246187403", "node_type": "1", "metadata": {}, "hash": "c78971cb2f8072eb734764bcf4366db449cb2771958e3083a8cbd5ea4d69c100", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Benefits and harms of drug treatment for type 2\ndiabetes: systematic review and network meta-analysis of\nrandomised controlled trials. BMJ 2023;381:e074068.\n\n32. Li S, Vandvik PO, Lytvyn L, Guyatt GH, Palmer SC,\nRodriguez-Gutierrez R, et al. SGLT-2 inhibitors or GLP-1\nreceptor agonists for adults with type 2 diabetes: a clinical\npractice guideline. BMJ 2021;373:n1091.\n\n33. Zanchi A, Jehle AW, Lamine F, Vogt B, Czerlau C, Bilz S,\net al. Diabetic kidney disease in type 2 diabetes: a consensus\nstatement from the Swiss Societies of Diabetes and\nNephrology. Swiss Med Wkly 2023;153:40004.\n\n34. American Association of Clinical Endocrinologists, Samson\nSL, Vellanki P, Blonde L, Christofides EA, Galindo RJ, et al.\nAmerican association of clinical endocrinology consensus\nstatement: Comprehensive type 2 diabetes management\nalgorithm - 2023 Update. Endocrine practice 2023;29(5):30540.\n\n35. de Boer IH, Khunti K, Sadusky T, Tuttle KR, Neumiller JJ,\nRhee CM, et al. Diabetes management in chronic kidney\ndisease: a consensus report by the American Diabetes\nAssociation (ADA) and Kidney Disease: Improving Global\nOutcomes (KDIGO). Diabetes Care 2022;45(12):3075-90.\n\n36. de Boer IH, Khunti K, Sadusky T, Tuttle KR, Neumiller JJ,\nRhee CM, et al. Diabetes management in chronic kidney\ndisease: a consensus report by the American Diabetes\nAssociation (ADA) and Kidney Disease: Improving Global\nOutcomes (KDIGO). Kidney Int 2022;102(5):974-89.\n\n37. Canadian Cardiovascular Society, Mancini GBJ, O'Meara\nE, Zieroth S, Bernier M, Cheng AYY, et al. 2022 Canadian\ncardiovascular society guideline for use of glp-1 receptor\nagonists and sglt2 inhibitors for cardiorenal risk reduction in\nadults. Can J Cardiol 2022;38(8):1153-67.\n\n38. Living Evidence for Diabetes Consortium, Australian\nDiabetes Society (ADS), Diabetes Australia (DA), Australian\nDiabetes Educators Association (ADEA), Australasian\nPaediatric Endocrine Group (APEG). Australian evidencebased clinical guidelines for diabetes [En ligne]. Sydney: ADS;\n\n39. Palmer SC, Tendal B, Mustafa RA, Vandvik PO, Li S, Hao\nQ, et al.", "mimetype": "text/plain", "start_char_idx": 1590, "end_char_idx": 3665, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "c2e1115b-0324-4880-aea8-dee246187403": {"__data__": {"id_": "c2e1115b-0324-4880-aea8-dee246187403", "embedding": null, "metadata": {"page_label": "45", "file_name": "strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_type": "application/pdf", "file_size": 920218, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "6d1169d6-a5c3-4663-b3f4-6d70fdb63b27", "node_type": "4", "metadata": {"page_label": "45", "file_name": "strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_type": "application/pdf", "file_size": 920218, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "394017b06bfebd063c93a224241c6db4d4cbd16eb9353d95e29d5f32f338797e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "75803775-c402-41f5-9f16-fbb4ed43768b", "node_type": "1", "metadata": {"page_label": "45", "file_name": "strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_type": "application/pdf", "file_size": 920218, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "623ac19cab6a9594bb9e091d2b8cd7c30695e6957c6234bb9c727d1a41457d1f", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "38. Living Evidence for Diabetes Consortium, Australian\nDiabetes Society (ADS), Diabetes Australia (DA), Australian\nDiabetes Educators Association (ADEA), Australasian\nPaediatric Endocrine Group (APEG). Australian evidencebased clinical guidelines for diabetes [En ligne]. Sydney: ADS;\n\n39. Palmer SC, Tendal B, Mustafa RA, Vandvik PO, Li S, Hao\nQ, et al. Sodium-glucose cotransporter protein-2 (SGLT-2)\ninhibitors and glucagon-like peptide-1 (GLP-1) receptor\nagonists for type 2 diabetes: systematic review and network\nmeta-analysis of randomised controlled trials. Bmj\n2021;372:m4573.\n\n40. Li J, He K, Ge J, Li C, Jing Z. Efficacy and safety of the\nglucagon-like peptide-1 receptor agonist oral semaglutide in\npatients with type 2 diabetes mellitus: A systematic review and\nmeta-analysis. Diabetes Res Clin Pract 2021;172:108656.\n\n41. Li X, Zhang Q, Zhu L, Wang G, Ge P, Hu A, et al. Effects of\nSGLT2 inhibitors on cardiovascular, renal, and major safety\noutcomes in heart failure: A meta-analysis of randomized\ncontrolled trials. Int J Cardiol 2021;332:119-26.\n\n42. Karalliedde J, Winocour P, Chowdhury TA, De P, Frankel\nAH, Montero RM, et al. Clinical practice guidelines for\nmanagement of hyperglycaemia in adults with diabetic kidney\ndisease. Diabet Med 2022;39(4):e14769.\n\n43. Kidney Disease Improving Global Outcomes (KDIGO),\nNavaneethan SD, Zoungas S, Caramori ML, Chan JCN,\nHeerspink HJL, et al. Diabetes management in chronic kidney\ndisease: Synopsis of the 2020 kdigo clinical practice guideline.\nAnn Intern Med 2021;174(3):385-94.", "mimetype": "text/plain", "start_char_idx": 3310, "end_char_idx": 4853, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "a418b360-33b4-449d-8a8b-8fe85e57cdc2": {"__data__": {"id_": "a418b360-33b4-449d-8a8b-8fe85e57cdc2", "embedding": null, "metadata": {"page_label": "46", "file_name": "strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_type": "application/pdf", "file_size": 920218, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "ab567a98-8a3c-4159-ab7d-278a0e3e5a60", "node_type": "4", "metadata": {"page_label": "46", "file_name": "strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_type": "application/pdf", "file_size": 920218, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "2d820f6852dfeeaca50598e0e09f713c89115eb77158e0900ecacfb8d82e450c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "65bc8bd3-d635-462e-a697-ccad64655763", "node_type": "1", "metadata": {}, "hash": "26fbd8a6bed46c1e7f01311657ae1a2c950157903eb3bbb7a8e833ba90f66752", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "HAS \u2022 Strat\u00e9gie th\u00e9rapeutique du patient vivant avec un diab\u00e8te de type 2 \u2022 mai 2024 46\n44. European Society of Cardiology, European Association for\nthe Study of Diabetes, Cosentino F, Grant PJ, Aboyans V,\nBailey CJ, et al. 2019 ESC Guidelines on diabetes, prediabetes, and cardiovascular diseases developed in\ncollaboration with the EASD. Eur Heart J 2020;41(2):255-323.\n\n45. Soci\u00e9t\u00e9 suisse d'Endocronologie et de Diab\u00e9tologie,\nLehmann R, Gastaldi G, Czock A, Egli M, Fischer-Taeschler D,\net al. Recommandations de la Soci\u00e9t\u00e9 Suisse d'Endocrinologie\net de Diab\u00e9tologie (SGED-SSED) pour le traitement du diab\u00e8te\nde type 2 (2020) : SSED; 2020.\n\n/61_Empfehlungen_Facharzt/2020_Swiss_Recomm_Medis_FR\n_def.pdf\n\n46. Ivers NM, Jiang M, Alloo J, Singer A, Ngui D, Casey CG, et\nal. Diabetes Canada 2018 clinical practice guidelines: Key\nmessages for family physicians caring for patients living with\ntype 2 diabetes. Can Fam Phys 2019;65(1):14-24.\n\n47. Royal Australian College of General Practitioners. General\npractice management of type 2 diabetes: 2016-18. East\nMelbourne: RACGP; 2016.\n\n48. American Association of Clinical Endocrinologists,\nAmerican College of Endocrinology, Garber AJ, Abrahamson\nMJ, Barzilay JI, Blonde L, et al. Consensus statement by the\nAmerican Association of Clinical Endocrinologists and\nAmerican College of Endocrinology on the comprehensive type\n2 diabetes management algorithm - 2017 executive summary\nEndocr Pract 2017;23(2):207-38.\n\n49. Agency for Healthcare Research and Quality, Effective\nHealth Care Program. Diabetes medications for adults with type\n2 diabetes: an update. Comparative effectiveness Review\nn\u00b0173. Rockville (MD): AHRQ; 2016.\n\n5/diabetes-update-2016-report.pdf\n\n50. Soci\u00e9t\u00e9 scientifique de m\u00e9decine g\u00e9n\u00e9rale, Bastiaens H,\nBenhalima K, Cloetens H, Feyen L, Nobels F, et al. Diab\u00e8te\nsucr\u00e9 de type 2. Recommandations de bonne pratique.\nBruxelles: SSMG; 2015.\n\nbonne_pratique/Diabete_type_II.pdf\n\n51. Sharma A, Pagidipati NJ, Califf RM, McGuire DK, Green\nJB, Demets D, et al.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2017, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "65bc8bd3-d635-462e-a697-ccad64655763": {"__data__": {"id_": "65bc8bd3-d635-462e-a697-ccad64655763", "embedding": null, "metadata": {"page_label": "46", "file_name": "strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_type": "application/pdf", "file_size": 920218, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "ab567a98-8a3c-4159-ab7d-278a0e3e5a60", "node_type": "4", "metadata": {"page_label": "46", "file_name": "strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_type": "application/pdf", "file_size": 920218, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "2d820f6852dfeeaca50598e0e09f713c89115eb77158e0900ecacfb8d82e450c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a418b360-33b4-449d-8a8b-8fe85e57cdc2", "node_type": "1", "metadata": {"page_label": "46", "file_name": "strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_type": "application/pdf", "file_size": 920218, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "81034c6c061bdc2f7f18e67f0d0369d8385e471c1edc0c1afb17309cccb1351f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e8c0feb9-bfaf-4edc-a494-b4a554359f6a", "node_type": "1", "metadata": {}, "hash": "025efbcadf20f9025cac87b6242fe542e3b852d2b4a83215455a948c6865d2ed", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Diab\u00e8te\nsucr\u00e9 de type 2. Recommandations de bonne pratique.\nBruxelles: SSMG; 2015.\n\nbonne_pratique/Diabete_type_II.pdf\n\n51. Sharma A, Pagidipati NJ, Califf RM, McGuire DK, Green\nJB, Demets D, et al. Impact of regulatory guidance on\nevaluating cardiovascular risk of new glucose-lowering\ntherapies to treat type 2 diabetes mellitus: lessons learned and\nfuture Directions. Circulation 2020;141(10):843-62.\n\n52. Marx N, Davies MJ, Grant PJ, Mathieu C, Petrie JR,\nCosentino F, et al. Guideline recommendations and the\npositioning of newer drugs in type 2 diabetes care. The lancet.\nDiabetes & endocrinology 2021;9(1):46-52.\n\n53. European Society of Hypertension working Group on\nObesity, Diabetes and the High-risk Patient, Kotsis V, Jordan J,\nStabouli S, Antza C, et al. Cardiovascular, renal and liver\nprotection with novel antidiabetic agents beyond blood glucose\nlowering in type 2 diabetes: consensus article from the\nEuropean Society of Hypertension Working Group on Obesity,\nDiabetes and the High-risk Patient. J Hypertens\n2020;38(3):377-86.\n\n54. Sarafidis P, Ferro CJ, Morales E, Ortiz A, Malyszko J, Hojs\nR, et al. SGLT-2 inhibitors and GLP-1 receptor agonists for\nnephroprotection and cardioprotection in patients with diabetes\nmellitus and chronic kidney disease. A consensus statement by\nthe EURECA-m and the DIABESITY working groups of the\nERA-EDTA. Nephrol Dial Transplant : 2019;34(2):208-30.\n\n55. Bain SC, Bakhai A, Evans M, Green A, Menown I, Strain\nWD. Pharmacological treatment for Type 2 diabetes integrating\nfindings from cardiovascular outcome trials: an expert\nconsensus in the UK. Diabet Med 2019;36(9):1063-71.\n\n56. Schott G, Martinez YV, Ediriweera de Silva RE, RenomGuiteras A, V\u00f6gele A, Reeves D, et al. Effectiveness and safety\nof dipeptidyl peptidase 4 inhibitors in the management of type 2\ndiabetes in older adults: a systematic review and development\nof recommendations to reduce inappropriate prescribing. BMC\nGeriatr 2017;17(Suppl 1):226.\n\n57. American College of Physicians, Qaseem A, Barry MJ,\nHumphrey LL, Forciea MA. Oral pharmacologic treatment of\ntype 2 diabetes mellitus: a clinical practice guideline update\nfrom the American College of Physicians.", "mimetype": "text/plain", "start_char_idx": 1819, "end_char_idx": 4006, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "e8c0feb9-bfaf-4edc-a494-b4a554359f6a": {"__data__": {"id_": "e8c0feb9-bfaf-4edc-a494-b4a554359f6a", "embedding": null, "metadata": {"page_label": "46", "file_name": "strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_type": "application/pdf", "file_size": 920218, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "ab567a98-8a3c-4159-ab7d-278a0e3e5a60", "node_type": "4", "metadata": {"page_label": "46", "file_name": "strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_type": "application/pdf", "file_size": 920218, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "2d820f6852dfeeaca50598e0e09f713c89115eb77158e0900ecacfb8d82e450c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "65bc8bd3-d635-462e-a697-ccad64655763", "node_type": "1", "metadata": {"page_label": "46", "file_name": "strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_type": "application/pdf", "file_size": 920218, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "427c8eba1d243a30c47644811e1a8f53144eba5c867d26aceaabe48d48c0ec4b", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "BMC\nGeriatr 2017;17(Suppl 1):226.\n\n57. American College of Physicians, Qaseem A, Barry MJ,\nHumphrey LL, Forciea MA. Oral pharmacologic treatment of\ntype 2 diabetes mellitus: a clinical practice guideline update\nfrom the American College of Physicians. Ann Intern Med\n2017;166(4):279-90.\n\n58. Canadian Agency for Drugs and Technologies in Health.\nOptimal use recommendations for second- and thrird- line\ntherapy for patients with type 2 diabetes. Ottawa: CADTH;\n2013.\n\n_2nd_3rd-line_e.pdf\n\n59. Schlender L, Martinez YV, Adeniji C, Reeves D, Faller B,\nSommerauer C, et al. Efficacy and safety of metformin in the\nmanagement of type 2 diabetes mellitus in older adults: a\nsystematic review for the development of recommendations to\nreduce potentially inappropriate prescribing. BMC Geriatr\n2017;17(Suppl 1):227.\n\n60. Institut national de la sant\u00e9 et de la recherche m\u00e9dical.\nActivit\u00e9 physique. Pr\u00e9vention et traitement des maladies\nchroniques. Paris: EDP Sciences; 2019.\n\n61. Haute Autorit\u00e9 de Sant\u00e9. Promotion, consultation et\nprescription m\u00e9dicale d'activit\u00e9 physique et sportive pour la\nsant\u00e9. Saint-Denis La Plaine: HAS; 2018.\n\n62. Dugan JA. Exercise recommendations for patients with type\n2 diabetes. JAAPA 2016;29(1):13-8;quiz 1.\n\n63. Soci\u00e9t\u00e9 Francophone du Diab\u00e8te (SFD), Duclos M, Oppert\nJM, Verges B, Coliche V, Gautier JF, et al. Physical activity and\ntype 2 diabetes. Recommandations of the SFD (Francophone\nDiabetes Society) diabetes and physical activity working group.\nDiabetes Metab 2013;39(3):205-16.\n\n64. Dyson PA, Twenefour D, Breen C, Duncan A, Elvin E, Goff\nL, et al. Diabetes UK evidence-based nutrition guidelines for\nthe prevention and management of diabetes. Diabetic Med\n2018;35(5):541-7.", "mimetype": "text/plain", "start_char_idx": 3755, "end_char_idx": 5465, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "439d7ff4-f097-4310-8883-43ef57ed71e6": {"__data__": {"id_": "439d7ff4-f097-4310-8883-43ef57ed71e6", "embedding": null, "metadata": {"page_label": "47", "file_name": "strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_type": "application/pdf", "file_size": 920218, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "9de117d3-7e3e-40ab-95d7-1085c37d1dd5", "node_type": "4", "metadata": {"page_label": "47", "file_name": "strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_type": "application/pdf", "file_size": 920218, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "6f631fc360d23c4c910c7f33f14e0007551480ea3385b66d8da336363328d249", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7d0c197a-6aba-4302-8b5b-e187b3fd6650", "node_type": "1", "metadata": {}, "hash": "af834abd452236d60d5523108d09bac4621381f1ce8b651106fed08df0b13682", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "HAS \u2022 Strat\u00e9gie th\u00e9rapeutique du patient vivant avec un diab\u00e8te de type 2 \u2022 mai 2024 47\n\n65. Haute Autorit\u00e9 de Sant\u00e9. Avis 21 juillet 2021- R\u00e9\u00e9valuation.\nDulaglutide - TRULICITY 0,75 mg, 1,5 mg, 3 mg, 4,5 mg,\nsolution injectable. Ex\u00e9natide - BYETTA 5 \u03bcg, 10 \u03bcg, solution\ninjectable - BYDUREON 2 mg, poudre et solvant pour\nsuspension injectable. Liraglutide - VICTOZA 6 mg/mL, solution\ninjectable. Liraglutide/insuline d\u00e9gludec XULTOPHY 100\nunit\u00e9s/mL, solution injectable. Lixis\u00e9natide LYXUMIA, 10 \u03bcg, 20\n\u03bcg, solution injectable. Lixis\u00e9natide/insuline glargine SULIQUA\n100 unit\u00e9s/mL+ 33 microgrammes, 100 unit\u00e9s/ml+50\nmicrogrammes, solution injectable. S\u00e9maglutide OZEMPIC\n0,25 mg, 0,5 mg, 1 mg, solution injectable . RYBELSUS 3 mg,\n7 mg, 14 mg, comprim\u00e9 . . Saint-Denis La Plaine: HAS; 2021.\n\n66. Haute Autorit\u00e9 de Sant\u00e9. Avis 21 juillet 2021 -\nR\u00e9\u00e9valuation. Alogliptine - VIPIDIA 6,25 mg, 12,5 mg, 25 mg,\ncomprim\u00e9 pellicul\u00e9. Alogliptine/metformine VIPDOMET 12,5\nmg/1000 mg, comprim\u00e9 pellicul\u00e9. Linagliptine - TRAJENTA 5\nmg, comprim\u00e9 pellicul\u00e9. Linagliptine/metformine JENTADUETO\n2,5 mg/1000 mg, comprim\u00e9 pellicul\u00e9. Saxagliptine - ONGLYZA\n5 mg, comprim\u00e9 pellicul\u00e9. Saxagliptine/metformine -\nKOMBOGLYZE 2,5 mg/1000 mg, comprim\u00e9 pellicul\u00e9.\nSitagliptine - JANUVIA 25 mg, 50 mg, 100 mg, comprim\u00e9\npellicul\u00e9 XELEVIA 25 mg, 50 mg, 100 mg, comprim\u00e9 pellicul\u00e9.\nSitagliptine/metformine - JANUMET 50 mg/1000 mg, comprim\u00e9\npellicul\u00e9 - ELMETIA 50 mg/1000 mg, comprim\u00e9 pellicul\u00e9.\nVildagliptine - GALVUS 50 mg, comprim\u00e9.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1504, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "7d0c197a-6aba-4302-8b5b-e187b3fd6650": {"__data__": {"id_": "7d0c197a-6aba-4302-8b5b-e187b3fd6650", "embedding": null, "metadata": {"page_label": "47", "file_name": "strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_type": "application/pdf", "file_size": 920218, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "9de117d3-7e3e-40ab-95d7-1085c37d1dd5", "node_type": "4", "metadata": {"page_label": "47", "file_name": "strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_type": "application/pdf", "file_size": 920218, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "6f631fc360d23c4c910c7f33f14e0007551480ea3385b66d8da336363328d249", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "439d7ff4-f097-4310-8883-43ef57ed71e6", "node_type": "1", "metadata": {"page_label": "47", "file_name": "strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_type": "application/pdf", "file_size": 920218, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "50c1551f713fd6c7540361f43f0d777f1bd7fa869ac951a756bc111cd38e7738", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "45ad3dcd-8963-45d5-bd31-a9f4d445f270", "node_type": "1", "metadata": {}, "hash": "435cd5acb59ccbe5ebd153534f3f6458fca7f8e7bcc1a4ce9a7bfa9c6188e655", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Sitagliptine/metformine - JANUMET 50 mg/1000 mg, comprim\u00e9\npellicul\u00e9 - ELMETIA 50 mg/1000 mg, comprim\u00e9 pellicul\u00e9.\nVildagliptine - GALVUS 50 mg, comprim\u00e9.\nVildagliptine/metformine EUCREAS 50 mg/1000 mg, comprim\u00e9\npellicul\u00e9. Saint-Denis La Plaine: HAS; 2021.\n\n20.pdf\n\n67. Sant\u00e9 publique France, Delamaire C, Escalon H, Noirot L.\n\u00c9tat des connaissances recommandations relatives \u00e0\nl'alimentation, \u00e0 l'activit\u00e9 physique et \u00e0 la s\u00e9dentarit\u00e9 pour les\nadultes. Saint-Maurice: SPF; 2019.\n\n68. Scottish Intercollegiate Network, Healthcare Improvement\nScotland. Management of diabetes. A national clinical\nguideline. N\u00b0 116 Edinburgh: SIGN; 2017.\n\n69. Cooke S, Pennington K, Jones A, Bridle C, Smith MF,\nCurtis F. Effects of exercise, cognitive, and dual-task\ninterventions on cognition in type 2 diabetes mellitus: A\nsystematic review and meta-analysis. PLoS ONE\n2020;15(5):e0232958.\n\n70. Gajanand T, Keating SE, Brown WJ, Hordern MD, Fassett\nRG, Coombes JS. Comparing the efficacy of supervised and\nunsupervised exercise training on glycaemic control in type 2\ndiabetes: a systematic review. Curr Diabetes Rev\n2020;16(6):570-9.\n\n71. Garc\u00eda-Molina L, Lewis-Mikhael AM, Riquelme-Gallego B,\nCano-Ib\u00e1\u00f1ez N, Oliveras-L\u00f3pez MJ, Bueno-Cavanillas A.\nImproving type 2 diabetes mellitus glycaemic control through\nlifestyle modification implementing diet intervention: a\nsystematic review and meta-analysis. Eur J Nutr\n2020;59(4):1313-28.\n\n72. Qin J, Chen Y, Guo S, You Y, Xu Y, Wu J, et al. Effect of tai\nchi on quality of life, body mass index, and waist-hip ratio in\npatients with type 2 diabetes mellitus: A systematic review and\nmeta-analysis. Front Endocrinol (Lausanne) 2020;11:543627.\n\n73. Jang JE, Cho Y, Lee BW, Shin ES, Lee SH. Effectiveness\nof exercise intervention in reducing body weight and\nglycosylated hemoglobin levels in patients with type 2 diabetes\nmellitus in korea: A systematic review and meta-analysis.\nDiabetes Metab J 2019;43(3):302-18.\n\n74. Liao F, An R, Pu F, Burns S, Shen S, Jan YK.", "mimetype": "text/plain", "start_char_idx": 1352, "end_char_idx": 3344, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "45ad3dcd-8963-45d5-bd31-a9f4d445f270": {"__data__": {"id_": "45ad3dcd-8963-45d5-bd31-a9f4d445f270", "embedding": null, "metadata": {"page_label": "47", "file_name": "strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_type": "application/pdf", "file_size": 920218, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "9de117d3-7e3e-40ab-95d7-1085c37d1dd5", "node_type": "4", "metadata": {"page_label": "47", "file_name": "strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_type": "application/pdf", "file_size": 920218, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "6f631fc360d23c4c910c7f33f14e0007551480ea3385b66d8da336363328d249", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7d0c197a-6aba-4302-8b5b-e187b3fd6650", "node_type": "1", "metadata": {"page_label": "47", "file_name": "strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_type": "application/pdf", "file_size": 920218, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "748a1dccab639a4e66df72ab7a7ea1a0c8be55bcb2cbf37384e6facf70832ca4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "15897be3-22d8-4294-9c39-2ea7e820a84b", "node_type": "1", "metadata": {}, "hash": "d84d51dd06f738f117825a864ab24309e4482458132a52067c0b0ed7659b5363", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Jang JE, Cho Y, Lee BW, Shin ES, Lee SH. Effectiveness\nof exercise intervention in reducing body weight and\nglycosylated hemoglobin levels in patients with type 2 diabetes\nmellitus in korea: A systematic review and meta-analysis.\nDiabetes Metab J 2019;43(3):302-18.\n\n74. Liao F, An R, Pu F, Burns S, Shen S, Jan YK. Effect of\nexercise on risk factors of diabetic foot ulcers: A systematic\nreview and meta-analysis. Am J Phys Med Rehabil\n2019;98(2):103-16.\n\n75. Mosalman Haghighi M, Mavros Y, Fiatarone Singh MA. The\neffects of structured exercise or lifestyle behavior interventions\non long-term physical activity level and health outcomes in\nindividuals with type 2 diabetes: A systematic review, metaanalysis, and meta-regression. J Phys Act Health\n2018;15(9):697-707.\n\n76. Pan B, Ge L, Xun YQ, Chen YJ, Gao CY, Han X, et al.\nExercise training modalities in patients with type 2 diabetes\nmellitus: a systematic review and network meta-analysis. Int J\nBehav Nutr Phys Act 2018;15(1):72.\n\n77. Byrne H, Caulfield B, De Vito G. Effects of self-directed\nexercise programmes on individuals with type 2 diabetes\nmellitus: A systematic review evaluating their effect on HbA(1c)\nand other metabolic outcomes, physical characteristics,\ncardiorespiratory fitness and functional outcomes. Sports Med\n2017;47(4):717-33.\n\n78. Cradock KA, \u00d3Laighin G, Finucane FM, Gainforth HL,\nQuinlan LR, Ginis KA. Behaviour change techniques targeting\nboth diet and physical activity in type 2 diabetes: A systematic\nreview and meta-analysis. Int J Behav Nutr Phys Act\n2017;14(1):18.\n\n79. Grace A, Chan E, Giallauria F, Graham PL, Smart NA.\nClinical outcomes and glycaemic responses to different aerobic\nexercise training intensities in type II diabetes: a systematic\nreview and meta-analysis. Cardiovasc Diabetol 2017;16(1):37.\n\n80. Nery C, Moraes SRA, Novaes KA, Bezerra MA, Silveira\nPVC, Lemos A. Effectiveness of resistance exercise compared\nto aerobic exercise without insulin therapy in patients with type\n2 diabetes mellitus: a meta-analysis. Braz J Phys Ther\n2017;21(6):400-15.\n\n81. Gregg EW, Wing R. Looking again at the Look AHEAD\nstudy. Lancet. Diabet Endocrinol 2017;5(10):763-4.\n\n82.", "mimetype": "text/plain", "start_char_idx": 3029, "end_char_idx": 5198, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "15897be3-22d8-4294-9c39-2ea7e820a84b": {"__data__": {"id_": "15897be3-22d8-4294-9c39-2ea7e820a84b", "embedding": null, "metadata": {"page_label": "47", "file_name": "strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_type": "application/pdf", "file_size": 920218, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "9de117d3-7e3e-40ab-95d7-1085c37d1dd5", "node_type": "4", "metadata": {"page_label": "47", "file_name": "strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_type": "application/pdf", "file_size": 920218, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "6f631fc360d23c4c910c7f33f14e0007551480ea3385b66d8da336363328d249", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "45ad3dcd-8963-45d5-bd31-a9f4d445f270", "node_type": "1", "metadata": {"page_label": "47", "file_name": "strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_type": "application/pdf", "file_size": 920218, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "03a0ce0f06bf01eb86fe997203868e0fcba406e7605b991f3ea7f71a99272ad1", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Braz J Phys Ther\n2017;21(6):400-15.\n\n81. Gregg EW, Wing R. Looking again at the Look AHEAD\nstudy. Lancet. Diabet Endocrinol 2017;5(10):763-4.\n\n82. Baum A, Scarpa J, Bruzelius E, Tamler R, Basu S,\nFaghmous J. Targeting weight loss interventions to reduce\ncardiovascular complications of type 2 diabetes: a machine\nlearning-based post-hoc analysis of heterogeneous treatment\neffects in the Look AHEAD trial. Lancet. Diabet Endocrinol\n2017;5(10):808-15.\n\n83. Look AHEAD Research Group. Eight-year weight losses\nwith an intensive lifestyle intervention: the look AHEAD study.\nObesity 2014;22(1):5-13.", "mimetype": "text/plain", "start_char_idx": 5052, "end_char_idx": 5648, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "7795c32a-6b32-4595-9c07-6f35297524dc": {"__data__": {"id_": "7795c32a-6b32-4595-9c07-6f35297524dc", "embedding": null, "metadata": {"page_label": "48", "file_name": "strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_type": "application/pdf", "file_size": 920218, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "d818f800-cdaf-48ab-8f7a-48b627453477", "node_type": "4", "metadata": {"page_label": "48", "file_name": "strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_type": "application/pdf", "file_size": 920218, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "90b8225f45bc8cc7e14601c8ac800fcbba61b7a3ec2505f986f3cf2cb3bf08eb", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4f1ff26a-c226-407b-99f8-aa5c72a34234", "node_type": "1", "metadata": {}, "hash": "c52f4978c95853b2b9ed126e80d2ea8bb56ea94cc063703b7335795a5aa52b68", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "HAS \u2022 Strat\u00e9gie th\u00e9rapeutique du patient vivant avec un diab\u00e8te de type 2 \u2022 mai 2024 48\n\n84. Kuna ST, Reboussin DM, Strotmeyer ES, Millman RP,\nZammit G, Walkup MP, et al. Effects of weight loss on\nobstructive sleep apnea severity. Ten-year results of the sleep\nAHEAD study. Am J Respir Crit Care Med 2021;203(2):221-9.\n\n85. Goldenberg JZ, Day A, Brinkworth GD, Sato J, Yamada S,\nJ\u00f6nsson T, et al. Efficacy and safety of low and very low\ncarbohydrate diets for type 2 diabetes remission: systematic\nreview and meta-analysis of published and unpublished\nrandomized trial data. Bmj 2021;372:m4743.\n\n86. Huang YS, Zheng Q, Yang H, Fu X, Zhang X, Xia C, et al.\nEfficacy of intermittent or continuous very low-energy diets in\noverweight and obese individuals with type 2 diabetes mellitus:\nA systematic review and meta-analyses. J Diabetes Res\n2020;2020:4851671.\n\n87. Silverii GA, Botarelli L, Dicembrini I, Girolamo V,\nSantagiuliana F, Monami M, et al. Low-carbohydrate diets and\ntype 2 diabetes treatment: a meta-analysis of randomized\ncontrolled trials. Acta Diabetol 2020;57(11):1375-82.\n\n88. Austin G, Ferguson JJA, Garg ML. Effects of plant-based\ndiets on weight status in type 2 diabetes: A systematic review\nand meta-analysis of randomised controlled trials. Nutrients\n2021;13(11).\n\n89. Chiavaroli L, Lee D, Ahmed A, Cheung A, Khan TA, Blanco\nS, et al. Effect of low glycaemic index or load dietary patterns\non glycaemic control and cardiometabolic risk factors in\ndiabetes: systematic review and meta-analysis of randomised\ncontrolled trials. Bmj 2021;374:n1651.\n\n90. Haute Autorit\u00e9 de la Sant\u00e9. Strat\u00e9gie m\u00e9dicamenteuse du\ncontr\u00f4le glyc\u00e9mique du diab\u00e8te de type 2. Saint-Denis La\nPlaine: HAS; 2013.\n\n91. Aminuddin HB, Jiao N, Jiang Y, Hong J, Wang W.\nEffectiveness of smartphone-based self-management\ninterventions on self-efficacy, self-care activities, health-related\nquality of life and clinical outcomes in patients with type 2\ndiabetes: A systematic review and meta-analysis. Int J Nurs\nStud 2021;116:103286.\n\n92.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2022, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "4f1ff26a-c226-407b-99f8-aa5c72a34234": {"__data__": {"id_": "4f1ff26a-c226-407b-99f8-aa5c72a34234", "embedding": null, "metadata": {"page_label": "48", "file_name": "strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_type": "application/pdf", "file_size": 920218, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "d818f800-cdaf-48ab-8f7a-48b627453477", "node_type": "4", "metadata": {"page_label": "48", "file_name": "strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_type": "application/pdf", "file_size": 920218, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "90b8225f45bc8cc7e14601c8ac800fcbba61b7a3ec2505f986f3cf2cb3bf08eb", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7795c32a-6b32-4595-9c07-6f35297524dc", "node_type": "1", "metadata": {"page_label": "48", "file_name": "strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_type": "application/pdf", "file_size": 920218, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "c91785d9160a6410949d8f85049490f82498e268698a448099795a81149ebf57", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6c6d928d-7b37-41cb-86f5-4cfcddb4082a", "node_type": "1", "metadata": {}, "hash": "d645f1e25cb39cfc014437889a8e6e83670cbe9eae980fc5f23319d53853f3be", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "91. Aminuddin HB, Jiao N, Jiang Y, Hong J, Wang W.\nEffectiveness of smartphone-based self-management\ninterventions on self-efficacy, self-care activities, health-related\nquality of life and clinical outcomes in patients with type 2\ndiabetes: A systematic review and meta-analysis. Int J Nurs\nStud 2021;116:103286.\n\n92. Tay JHT, Jiang Y, Hong J, He H, Wang W. Effectiveness of\nlay-led, group-based self-management interventions to improve\nglycated hemoglobin (HbA1c), self-efficacy, and emergency\nvisit rates among adults with type 2 diabetes: A systematic\nreview and meta-analysis. Int J Nurs Stud 2021;113:103779.\n\n93. Berhe KK, Gebru HB, Kahsay HB. Effect of motivational\ninterviewing intervention on HgbA1C and depression in people\nwith type 2 diabetes mellitus (systematic review and metaanalysis). PLoS ONE 2020;15(10):e0240839.\n\n94. Caro-Bautista J, Kaknani-Uttumchandani S, Garc\u00eda-Mayor\nS, Villa-Estrada F, Morilla-Herrera JC, Le\u00f3n-Campos \u00c1, et al.\nImpact of self-care programmes in type 2 diabetes mellitus\npopulation in primary health care: Systematic review and metaanalysis. J Clin Nurs 2020;29(9-10):1457-76.\n\n95. Dening J, Islam SMS, George E, Maddison R. Web-based\ninterventions for dietary behavior in adults with type 2 diabetes:\nSystematic review of randomized controlled trials. J Med\nInternet Res 2020;22(8):e16437.\n\n96. Liu K, Xie Z, Or CK. Effectiveness of mobile app-assisted\nself-care interventions for improving patient outcomes in type 2\ndiabetes and/or hypertension: Systematic review and metaanalysis of randomized controlled trials. JMIR Mhealth Uhealth\n2020;8(8):e15779.\n\n97. Tanaka R, Shibayama T, Sugimoto K, Hidaka K. Diabetes\nself-management education and support for adults with newly\ndiagnosed type 2 diabetes mellitus: A systematic review and\nmeta-analysis of randomized controlled trials. Diabetes Res\nClin Pract 2020;169:108480.\n\n98. He Q, Zhao X, Wang Y, Xie Q, Cheng L. Effectiveness of\nsmartphone application-based self-management interventions\nin patients with type 2 diabetes: A systematic review and metaanalysis of randomized controlled trials. J Adv Nurs\n2022;78(2):348-62.\n\n99.", "mimetype": "text/plain", "start_char_idx": 1704, "end_char_idx": 3828, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "6c6d928d-7b37-41cb-86f5-4cfcddb4082a": {"__data__": {"id_": "6c6d928d-7b37-41cb-86f5-4cfcddb4082a", "embedding": null, "metadata": {"page_label": "48", "file_name": "strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_type": "application/pdf", "file_size": 920218, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "d818f800-cdaf-48ab-8f7a-48b627453477", "node_type": "4", "metadata": {"page_label": "48", "file_name": "strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_type": "application/pdf", "file_size": 920218, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "90b8225f45bc8cc7e14601c8ac800fcbba61b7a3ec2505f986f3cf2cb3bf08eb", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4f1ff26a-c226-407b-99f8-aa5c72a34234", "node_type": "1", "metadata": {"page_label": "48", "file_name": "strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_type": "application/pdf", "file_size": 920218, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "be9bfaf8d61879fea12beb7a8e31e1c81c2c3119e8235953c778529d5d863055", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Diabetes Res\nClin Pract 2020;169:108480.\n\n98. He Q, Zhao X, Wang Y, Xie Q, Cheng L. Effectiveness of\nsmartphone application-based self-management interventions\nin patients with type 2 diabetes: A systematic review and metaanalysis of randomized controlled trials. J Adv Nurs\n2022;78(2):348-62.\n\n99. Wang X, Li Q, Liu Y, Jiang H, Chen W. Intermittent fasting\nversus continuous energy-restricted diet for patients with type 2\ndiabetes mellitus and metabolic syndrome for glycemic control:\nA systematic review and meta-analysis of randomized\ncontrolled trials. Diabetes Res Clin Pract 2021;179:109003.\n\n100. Monami M, Candido R, Pintaudi B, Targher G, Mannucci\nE. Effect of metformin on all-cause mortality and major adverse\ncardiovascular events: An updated meta-analysis of\nrandomized controlled trials. Nutr Metab Cardiovasc Dis\n2021;31(3):699-704.\n\n101. Ghosh-Swaby OR, Goodman SG, Leiter LA, Cheng A,\nConnelly KA, Fitchett D, et al. Glucose-lowering drugs or\nstrategies, atherosclerotic cardiovascular events, and heart\nfailure in people with or at risk of type 2 diabetes: an updated\nsystematic review and meta-analysis of randomised\ncardiovascular outcome trials. Lancet Diabetes Endocrinol\n2020;8(5):418-35.\n\n102. Gnesin F, Thuesen AC, K\u00e4hler LK, Madsbad S,\nHemmingsen B. Metformin monotherapy for adults with type 2\ndiabetes mellitus. Cochrane Database of Systematic Reviews\n2020;(6).\n\n103. Tsapas A, Avgerinos I, Karagiannis T, Malandris K,\nManolopoulos A, Andreadis P, et al. Comparative effectiveness\nof glucose-lowering drugs for type 2 diabetes: A systematic\nreview and network meta-analysis. Ann Intern Med\n2020;173(4):278-86.\n\n104. Zhang Z, Cao Y, Tao Y, E M, Tang J, Liu Y, et al.\nSulfonylurea and fracture risk in patients with type 2 diabetes\nmellitus: A meta-analysis. Diabetes Res Clin Pract\n2020;159:107990.\n\n105. Lavalle-Cobo A, Masson W, Lobo M, Masson G, Molinero\nG. Glucagon-like Peptide-1 receptor agonists and\ncardioprotective benefit in patients with type 2 diabetes without\nbaseline metformin: A systematic review and update meta-", "mimetype": "text/plain", "start_char_idx": 3530, "end_char_idx": 5587, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "7e90203d-7a98-4662-9c76-fd5be5a701ea": {"__data__": {"id_": "7e90203d-7a98-4662-9c76-fd5be5a701ea", "embedding": null, "metadata": {"page_label": "49", "file_name": "strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_type": "application/pdf", "file_size": 920218, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "7fa8f6a9-46d7-43d1-a6bb-583df068f766", "node_type": "4", "metadata": {"page_label": "49", "file_name": "strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_type": "application/pdf", "file_size": 920218, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "306aab113d76cc5ef066b3984121f61a81ad18662ebb2508b3b96be6821af510", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "17a8175e-ae59-42bd-aed2-643f0109b44c", "node_type": "1", "metadata": {}, "hash": "c88a322792ee7e43c3bd26f68b0bf88871ef8c20900e8585ea97fb9c999df76e", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "HAS \u2022 Strat\u00e9gie th\u00e9rapeutique du patient vivant avec un diab\u00e8te de type 2 \u2022 mai 2024 49\nanalysis. High Blood Press Cardiovasc Prev 2021;28(6):60512.\n\n106. Haute Autorit\u00e9 de sant\u00e9, Commission de la Transparence.\nAvis 18 novembre 2020. R\u00e9\u00e9valuation.\nDapagliflozine/metformine - Xigduo 5mg/100mg, comprim\u00e9\npellicul\u00e9 Saint-Denis La Plaine: HAS; 2020.\n\n107. Sundstr\u00f6m J, Kristofi R, Ostlund O, Bennet L, Eliasson B,\nJansson S, et al. A registry-based randomised trial comparing\nan SGLT2 inhibitor and metformin as standard treatment of\nearly stage type 2 diabetes (SMARTEST): Rationale, design\nand protocol. J Diabetes Complications 2021;35(10):107996.\n\n108. Cao H, Rao X, Jia J, Yan T, Li D. Effects of sodiumglucose co-transporter-2 inhibitors on kidney, cardiovascular,\nand safety outcomes in patients with advanced chronic kidney\ndisease: a systematic review and meta-analysis of randomized\ncontrolled trials. Acta Diabetol 2023;60(3):325-35.\n\n109. Ghosal S, Sinha B. Finerenone in type 2 diabetes and\nrenal outcomes: A random-effects model meta-analysis. Front\nEndocrinol 2023;14:1114894.\n\n110. Li J, Ji C, Zhang W, Lan L, Ge W. Effect of new glucoselowering drugs on stroke in patients with type 2 diabetes: A\nsystematic review and Meta-analysis. J Diabetes Complications\n2023;37(1):108362.\n\n111. Mannucci E, Gallo M, Giaccari A, Candido R, Pintaudi B,\nTargher G, et al. Effects of glucose-lowering agents on\ncardiovascular and renal outcomes in subjects with type 2\ndiabetes: An updated meta-analysis of randomized controlled\ntrials with external adjudication of events. Diabetes Obes Metab\n2023;25(2):444-53.\n\n112. Yang S, Shen W, Zhang HZ, Wang CX, Yu WQ, Wu QH.\nEfficacy and safety of finerenone for prevention of\ncardiovascular events in type 2 diabetes mellitus with chronic\nkidney disease: A meta-analysis of randomized controlled trials.\nJ Cardiovasc Pharmacol 2023;81(1):55-62.\n\n113. Haute Autorit\u00e9 de la Sant\u00e9, Commission de la\ntransparence. Examen inscription : KERENDIA 10 - 20 mg (CT19845) - BAYER HEALTHCARE SAS. Saint-Denis La Plaine:\nHAS; 2022.\n\n114.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2067, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "17a8175e-ae59-42bd-aed2-643f0109b44c": {"__data__": {"id_": "17a8175e-ae59-42bd-aed2-643f0109b44c", "embedding": null, "metadata": {"page_label": "49", "file_name": "strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_type": "application/pdf", "file_size": 920218, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "7fa8f6a9-46d7-43d1-a6bb-583df068f766", "node_type": "4", "metadata": {"page_label": "49", "file_name": "strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_type": "application/pdf", "file_size": 920218, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "306aab113d76cc5ef066b3984121f61a81ad18662ebb2508b3b96be6821af510", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7e90203d-7a98-4662-9c76-fd5be5a701ea", "node_type": "1", "metadata": {"page_label": "49", "file_name": "strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_type": "application/pdf", "file_size": 920218, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "e1daccbde5a04c8478f98dbea3ff4f542abbe1fc994000e612b17093abe744af", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "fe2be658-8c89-4a14-bd59-7903a912aac3", "node_type": "1", "metadata": {}, "hash": "8c138fcb5f4215c4e36d3ac2075a1a78f0a9ba51a7e1b1dbc2b49dc8fa4d87b1", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "J Cardiovasc Pharmacol 2023;81(1):55-62.\n\n113. Haute Autorit\u00e9 de la Sant\u00e9, Commission de la\ntransparence. Examen inscription : KERENDIA 10 - 20 mg (CT19845) - BAYER HEALTHCARE SAS. Saint-Denis La Plaine:\nHAS; 2022.\n\n114. Lipscombe L, Butalia S, Dasgupta K, Eurich DT,\nMacCallum L, Shah BR, et al. pharmacologic glycemic\nmanagement of type 2 diabetes in adults: 2020 update. Can J\nDiabetes 2020;44(7):575-91.\n\n115. Karagiannis T, Tsapas A, Athanasiadou E, Avgerinos I,\nLiakos A, Matthews DR, et al. GLP-1 receptor agonists and\nSGLT2 inhibitors for older people with type 2 diabetes: A\nsystematic review and meta-analysis. Diabetes Res Clin Pract\n2021;174:108737.\n\n116. Giugliano D, Longo M, Maiorino MI, Bellastella G, Chiodini\nP, Solerte SB, et al. Efficacy of SGLT-2 inhibitors in older adults\nwith diabetes: Systematic review with meta-analysis of\ncardiovascular outcome trials. Diabetes Res Clin Pract\n2020;162:108114.\n\n117. Liu J, Li L, Li S, Wang Y, Qin X, Deng K, et al. Sodiumglucose co-transporter-2 inhibitors and the risk of diabetic\nketoacidosis in patients with type 2 diabetes: A systematic\nreview and meta-analysis of randomized controlled trials.\nDiabetes Obes Metab 2020;22(9):1619-27.\n\n118. Pinto LC, Rados DV, Remonti LR, Viana LV, Pulz GT,\nCarpena MP, et al. Patient-centered management of type 2\ndiabetes mellitus based on specific clinical scenarios:\nSystematic review, meta-analysis and trial sequential analysis.\nJ Clin Endocrinol Metab 2020;105(11).\n\n119. Guo M, Gu J, Teng F, Chen J, Ma X, Chen Q, et al. The\nefficacy and safety of combinations of SGLT2 inhibitors and\nGLP-1 receptor agonists in the treatment of type 2 diabetes or\nobese adults: a systematic review and meta-analysis.\nEndocrine 2020;67(2):294-304.\n\n120. Maula A, Kai J, Woolley AK, Weng S, Dhalwani N, Griffiths\nFE, et al. Educational weight loss interventions in obese and\noverweight adults with type 2 diabetes: a systematic review and\nmeta-analysis of randomized controlled trials. Diabet Med\n2020;37(4):623-35.\n\n121.", "mimetype": "text/plain", "start_char_idx": 1847, "end_char_idx": 3859, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "fe2be658-8c89-4a14-bd59-7903a912aac3": {"__data__": {"id_": "fe2be658-8c89-4a14-bd59-7903a912aac3", "embedding": null, "metadata": {"page_label": "49", "file_name": "strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_type": "application/pdf", "file_size": 920218, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "7fa8f6a9-46d7-43d1-a6bb-583df068f766", "node_type": "4", "metadata": {"page_label": "49", "file_name": "strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_type": "application/pdf", "file_size": 920218, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "306aab113d76cc5ef066b3984121f61a81ad18662ebb2508b3b96be6821af510", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "17a8175e-ae59-42bd-aed2-643f0109b44c", "node_type": "1", "metadata": {"page_label": "49", "file_name": "strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_type": "application/pdf", "file_size": 920218, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "a787c2e3f39b4ed385592b1bb6ed9ac1eabb4ad056296879d0fc96c08d545698", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Endocrine 2020;67(2):294-304.\n\n120. Maula A, Kai J, Woolley AK, Weng S, Dhalwani N, Griffiths\nFE, et al. Educational weight loss interventions in obese and\noverweight adults with type 2 diabetes: a systematic review and\nmeta-analysis of randomized controlled trials. Diabet Med\n2020;37(4):623-35.\n\n121. Cai X, Qiu SH, Yin H, Sun ZL, Ju CP, Z\u00fcgel M, et al.\nPedometer intervention and weight loss in overweight and\nobese adults with Type 2 diabetes: a meta-analysis. Diabet\nMed 2016;33(8):1035-44.\n\n122. Hasan MT, Awad AK, Shih M, Attia AN, Aboeldahab H,\nBendary M, et al. Meta-analysis on the safety and efficacy of\nsodium glucose cotransporters 2 inhibitors in patients with heart\nfailure with and without diabetes. Am J Cardiol 2023;187:93-9.\n\n123. Obata S, Miyamoto Y, Slipczuk L, Takagi H, Kuno T.\nEffects of glucagon-like peptide-1 receptor agonists on patients\nwith heart failure: a meta-analysis of randomized controlled\ntrials. J Cardiovasc Med 2023;24(2):132-7.\n\n124. Lu Y, Li F, Fan Y, Yang Y, Chen M, Xi J. Effect of SGLT-2\ninhibitors on cardiovascular outcomes in heart failure patients:\nA meta-analysis of randomized controlled trials. Eur J Intern\nMed 2021;87:20-8.\n\n125. Salah HM, Al'Aref SJ, Khan MS, Al-Hawwas M,\nVallurupalli S, Mehta JL, et al. Effects of sodium-glucose\ncotransporter 1 and 2 inhibitors on cardiovascular and kidney\noutcomes in type 2 diabetes: A meta-analysis update. Am\nHeart J 2021;233:86-91.\n\n126. Salah HM, Al'Aref SJ, Khan MS, Al-Hawwas M,\nVallurupalli S, Mehta JL, et al. Effect of sodium-glucose\ncotransporter 2 inhibitors on cardiovascular and kidney\noutcomes-Systematic review and meta-analysis of randomized\nplacebo-controlled trials. Am Heart J 2021;232:10-22.\n\n127. Arnott C, Li Q, Kang A, Neuen BL, Bompoint S, Lam CSP,\net al. Sodium-glucose cotransporter 2 inhibition for the\nprevention of cardiovascular events in patients with type 2", "mimetype": "text/plain", "start_char_idx": 3557, "end_char_idx": 5441, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "4e4d4504-a96a-4f0d-9ff2-8e2259900e4b": {"__data__": {"id_": "4e4d4504-a96a-4f0d-9ff2-8e2259900e4b", "embedding": null, "metadata": {"page_label": "50", "file_name": "strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_type": "application/pdf", "file_size": 920218, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "1de3562f-583a-46aa-8d21-587c90caf7af", "node_type": "4", "metadata": {"page_label": "50", "file_name": "strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_type": "application/pdf", "file_size": 920218, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "30f53aec5bd6a3a35552761c32561316d061c9c5bf7a9af8653670ec24d52e12", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9461a2bc-4a17-460a-bf08-a69c025cde9a", "node_type": "1", "metadata": {}, "hash": "9ab7eb04ec3c304b2de4f252fcdf1486ec8eaf72e794223bfe65a4be4ac7bac6", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "HAS \u2022 Strat\u00e9gie th\u00e9rapeutique du patient vivant avec un diab\u00e8te de type 2 \u2022 mai 2024 50\ndiabetes mellitus: A systematic review and meta-analysis. J Am\nHeart Assoc 2020;9(3):e014908.\n\n128. Guo WQ, Li L, Su Q, Dai WR, Ye ZL. Effect of dipeptidyl\npeptidase-4 inhibitors on heart failure: A network meta-analysis.\nValue Health 2017;20(10):1427-30.\n\n129. Zelniker TA, Wiviott SD, Raz I, Im K, Goodrich EL, Bonaca\nMP, et al. SGLT2 inhibitors for primary and secondary\nprevention of cardiovascular and renal outcomes in type 2\ndiabetes: a systematic review and meta-analysis of\ncardiovascular outcome trials. Lancet 2019;393(10166):31-9.\n\n130. Kelsey MD, Nelson AJ, Green JB, Granger CB, Peterson\nED, McGuire DK, et al. Guidelines for cardiovascular risk\nreduction in patients with type 2 diabetes: JACC Guideline\nComparison. J Am Coll Cardiol 2022;79(18):1849-57.\n\n131. Lee MC, Hua YM, Yang CT, Kuo FH, Chang WT, Tang\nHJ, et al. Clinical efficacy of SGLT2 inhibitors with different\nSGLT1/SGLT2 selectivity in cardiovascular outcomes among\npatients with and without heart failure: A systematic review and\nmeta-analysis of randomized trials. Medicine\n2022;101(51):e32489.\n\n132. Vukadinovi\u0107 D, Abdin A, Anker SD, Rosano GMC,\nMahfoud F, Packer M, et al. Side effects and treatment initiation\nbarriers of sodium-glucose cotransporter 2 inhibitors in heart\nfailure: a systematic review and meta-analysis. Eur J Heart Fail\n2022;24(9):1625-32.\n\n133. Giugliano D, Longo M, Caruso P, Maiorino MI, Bellastella\nG, Esposito K. Sodium-glucose co-transporter-2 inhibitors for\nthe prevention of cardiorenal outcomes in type 2 diabetes: An\nupdated meta-analysis. Diabetes Obes Metab\n2021;23(7):1672-6.\n\n134. Shen C, Tan S, Yang J. Effects of continuous use of\nmetformin on cardiovascular outcomes in patients with type 2\ndiabetes after acute myocardial infarction: A protocol for\nsystematic review and meta-analysis. Medicine (Baltimore)\n2021;100(15):e25353.\n\n135. Chen HB, Yang YL, Yu TH, Li YH. SGLT2 inhibitors for the\ncomposite of cardiorenal outcome in patients with chronic\nkidney disease: A systematic review and meta-analysis of\nrandomized controlled trials.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2143, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "9461a2bc-4a17-460a-bf08-a69c025cde9a": {"__data__": {"id_": "9461a2bc-4a17-460a-bf08-a69c025cde9a", "embedding": null, "metadata": {"page_label": "50", "file_name": "strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_type": "application/pdf", "file_size": 920218, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "1de3562f-583a-46aa-8d21-587c90caf7af", "node_type": "4", "metadata": {"page_label": "50", "file_name": "strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_type": "application/pdf", "file_size": 920218, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "30f53aec5bd6a3a35552761c32561316d061c9c5bf7a9af8653670ec24d52e12", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4e4d4504-a96a-4f0d-9ff2-8e2259900e4b", "node_type": "1", "metadata": {"page_label": "50", "file_name": "strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_type": "application/pdf", "file_size": 920218, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "32b3db047f05d338107e986b7bae1dd3cf7645f4c8207e6ab7ac68ef74408c87", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b01e881c-95cd-4dca-a427-72a676084fe0", "node_type": "1", "metadata": {}, "hash": "40e59ca7171e257445a298be38bd78242362249c064b1a44eedf1c2d3d5d98c6", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Medicine (Baltimore)\n2021;100(15):e25353.\n\n135. Chen HB, Yang YL, Yu TH, Li YH. SGLT2 inhibitors for the\ncomposite of cardiorenal outcome in patients with chronic\nkidney disease: A systematic review and meta-analysis of\nrandomized controlled trials. Eur J Pharmacol\n2022;936:175354.\n\n136. Mali N, Su F, Ge J, Fan WX, Zhang J, Ma J. Efficacy of\nliraglutide in patients with diabetic nephropathy: a metaanalysis of randomized controlled trials. BMC Endocr Disord\n2022;22(1):93.\n\n137. Singh AK, Singh A, Singh R, Misra A. Finerenone in\ndiabetic kidney disease: A systematic review and critical\nappraisal. Diabetes Metab Syndr 2022;16(10):102638.\n\n138. Duo Y, Gao J, Yuan T, Zhao W. Effect of sodium-glucose\ncotransporter 2 inhibitors on the rate of decline in kidney\nfunction: A systematic review and meta-analysis. J Diabetes\n2023;15(1):58-70.\n\n139. Zou CY, Sun Y, Liang J. Comparative efficacy of diabetes\nmedications on liver enzymes and fat fraction in patients with\nnonalcoholic fatty liver disease: A network meta-analysis. Clin\nRes Hepatol Gastroenterol 2023;47(1):102053.\n\n140. Shubrook JH, Neumiller JJ, Wright E. Management of\nchronic kidney disease in type 2 diabetes: screening, diagnosis\nand treatment goals, and recommendations. Postgrad Med\n2022;134(4):376-87.\n\n141. Simental-Mend\u00eda M, Linden-Torres E, S\u00e1nchez-Garc\u00eda A,\nSahebkar A, Simental-Mend\u00eda LE. Effect of glucagon-like\npeptide-1 receptor agonists on renal function: A meta-analysis\nof randomized controlled trials. Br J Clin Pharmacol\n2022;88(8):3566-76.\n\n142. Tsukamoto S, Morita R, Yamada T, Urate S, Azushima K,\nUneda K, et al. Cardiovascular and kidney outcomes of\ncombination therapy with sodium-glucose cotransporter-2\ninhibitors and mineralocorticoid receptor antagonists in patients\nwith type 2 diabetes and chronic kidney disease: A systematic\nreview and network meta-analysis. Diabetes Res Clin Pract\n2022;194:110161.\n\n143. Butalia S, Gutierrez L, Lodha A, Aitken E, Zakariasen A,\nDonovan L. Short- and long-term outcomes of metformin\ncompared with insulin alone in pregnancy: a systematic review\nand meta-analysis. Diabet Med 2017;34(1):27-36.\n\n144.", "mimetype": "text/plain", "start_char_idx": 1894, "end_char_idx": 4024, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "b01e881c-95cd-4dca-a427-72a676084fe0": {"__data__": {"id_": "b01e881c-95cd-4dca-a427-72a676084fe0", "embedding": null, "metadata": {"page_label": "50", "file_name": "strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_type": "application/pdf", "file_size": 920218, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "1de3562f-583a-46aa-8d21-587c90caf7af", "node_type": "4", "metadata": {"page_label": "50", "file_name": "strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_type": "application/pdf", "file_size": 920218, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "30f53aec5bd6a3a35552761c32561316d061c9c5bf7a9af8653670ec24d52e12", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9461a2bc-4a17-460a-bf08-a69c025cde9a", "node_type": "1", "metadata": {"page_label": "50", "file_name": "strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_type": "application/pdf", "file_size": 920218, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "a796800a0edf7f499d1a1f0b8a818a5ff684533b0964f9decb542761229ef966", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Diabetes Res Clin Pract\n2022;194:110161.\n\n143. Butalia S, Gutierrez L, Lodha A, Aitken E, Zakariasen A,\nDonovan L. Short- and long-term outcomes of metformin\ncompared with insulin alone in pregnancy: a systematic review\nand meta-analysis. Diabet Med 2017;34(1):27-36.\n\n144. Canadian Agency for Drugs and Technologies in Health,\nMarchand DK, Subramonian A, Featherstone R, Spry C.\nPioglitazone for Type 2 Diabetes mellitus and prediabetes: a\nreview of safety. Ottawa: CADTH; 2020.\n\nglitazone%20AE%20Final.pdf\n\n145. Soci\u00e9t\u00e9 Francophone du Diab\u00e8te (SFD), Duclos M, Berne\nC, Tschudnowsky M, Descatoire A, Gautier JF, et al. Prise de\nposition de la Soci\u00e9t\u00e9 Francophone du Diab\u00e8te (SFD) sur\nl'activit\u00e9 physique chez les patients avec un diab\u00e8te de type 1.\nMed Mal Metab 2019;13(6):483-535.\n\n146. Sociedad Espanola de Diabetes, Gomez-Peralta F,\nEscalada San Mart\u00edn FJ, Men\u00e9ndez Torre E, Mata Cases M,\nFerrer Garc\u00eda JC, et al. Spanish Diabetes Society (SED)\nrecommendations for the pharmacologic treatment of\nhyperglycemia in type 2 diabetes: 2018 Update.\nEndocrinologia, diabetes y nutricion 2018;65(10):611-24.\n\n147. Soci\u00e9t\u00e9 scientifique de m\u00e9decine g\u00e9n\u00e9rale. Diab\u00e8te de\ntype II : traitement m\u00e9dicamenteux de l'hyperglyc\u00e9mie.\nBruxelles: SSMG; 2015.\n\nbonne_pratique/fiche5-SSMG.pdf\n\n148. Fosse-Edorh S, Piffaretti C, Saboni L, Mandereau-Bruno\nL, B\u00e9n\u00e9zet L, Raimond V, et al. \u00c9tudes Entred : un dispositif\npour am\u00e9liorer la connaissance de l'\u00e9tat de sant\u00e9 des\npersonnes pr\u00e9sentant un diab\u00e8te en France - Premiers\nr\u00e9sultats de la troisi\u00e8me \u00e9dition conduite en m\u00e9tropole en 2019.\nBEH 2022;22:383-92.\n\n149. Haute Autorit\u00e9 de Sant\u00e9. Prescription d'activit\u00e9 physique\net sportive Diab\u00e8te de type 2. Saint-Denis La Plaine: HAS;\n2018.", "mimetype": "text/plain", "start_char_idx": 3751, "end_char_idx": 5469, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "d0a0e96f-6f86-4a96-8075-dd8e96b5fa0f": {"__data__": {"id_": "d0a0e96f-6f86-4a96-8075-dd8e96b5fa0f", "embedding": null, "metadata": {"page_label": "51", "file_name": "strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_type": "application/pdf", "file_size": 920218, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "7b99c844-154a-4e9d-b73e-58ec2cdab29a", "node_type": "4", "metadata": {"page_label": "51", "file_name": "strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_type": "application/pdf", "file_size": 920218, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "4164fb1dfddd7c131bc7df4311d979acf7f3b27409182294c82467205f44f7aa", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "HAS \u2022 Strat\u00e9gie th\u00e9rapeutique du patient vivant avec un diab\u00e8te de type 2 \u2022 mai 2024 51\n\n150. Caspersen CJ, Powell KE, Christenson GM. Physical\nactivity, exercise, and physical fitness: definitions and\ndistinctions for health-related research. Public Health Rep\n1985;100(2):126-31.\n\n151. World Health Organization Regional Office for Europe.\nTherapeutic patient education: continuing education\nprogrammes for health care providers in the field of prevention\nof chronic diseases. Copenhagen: WHO; 1998.\n\n152. Haute Autorit\u00e9 de Sant\u00e9. D\u00e9marche centr\u00e9e sur le patient.\nInformation, conseil, \u00e9ducation th\u00e9rapeutique, suivi. SaintDenis La Plaine: HAS; 2015.\n\n153. Haute Autorit\u00e9 de Sant\u00e9. Pr\u00e9vention et d\u00e9pistage du\ndiab\u00e8te de type 2 et des maladies li\u00e9es au diab\u00e8te. Saint-Denis\nLa Plaine: HAS; 2014.\n\n154. Haute Autorit\u00e9 de Sant\u00e9. Surpoids et ob\u00e9sit\u00e9 de l'adulte :\nprise en charge m\u00e9dicale de premier recours. Saint-Denis La\nPlaine: HAS; 2012.\n\n155. Haute Autorit\u00e9 de Sant\u00e9. Ob\u00e9sit\u00e9 : prise en charge\nchirurgicale chez l'adulte. Saint-Denis La Plaine: HAS; 2009.\n\n156. Agence nationale de s\u00e9curit\u00e9 du m\u00e9dicament et des\nproduits de sant\u00e9. Metformine et risque d'acidose lactique en\ncas d'insuffisance r\u00e9nale. Saint-Denis: ANSM; 2021.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1229, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "c8e89640-2988-4444-a9d3-557bf86c6ca1": {"__data__": {"id_": "c8e89640-2988-4444-a9d3-557bf86c6ca1", "embedding": null, "metadata": {"page_label": "52", "file_name": "strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_type": "application/pdf", "file_size": 920218, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "b0494a81-d4c3-4f12-93a6-7da0dcf2b21c", "node_type": "4", "metadata": {"page_label": "52", "file_name": "strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_type": "application/pdf", "file_size": 920218, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "5fd648241537fe05f6711984d6374b98ca5699e5efe83728e32d7de1c1013b0e", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "HAS \u2022 Strat\u00e9gie th\u00e9rapeutique du patient vivant avec un diab\u00e8te de type 2 \u2022 mai 2024 52\nParticipants\n\nLes organismes professionnels et associations de patients et d'usagers suivants ont \u00e9t\u00e9 sollicit\u00e9s pour\nproposer des experts convi\u00e9s \u00e0 titre individuel dans les groupes de travail/lecture :\n\nF\u00e9d\u00e9ration fran\u00e7aise de nutrition*\nDiab\u00e8te Lab*\nSoci\u00e9t\u00e9 francophone de n\u00e9phrologie, dialyse et\ntransplantation*\nConseil national professionnel de m\u00e9decine\nphysique et de r\u00e9adaptation*\nF\u00e9d\u00e9ration fran\u00e7aise des psychologues et de\npsychologie (FFPP)\nF\u00e9d\u00e9ration fran\u00e7aise des diab\u00e9tiques*\nConseil national professionnel d'endocrinologie,\ndiab\u00e9tologie et nutrition*\nColl\u00e8ge infirmier fran\u00e7ais\nConseil national professionnel de m\u00e9decine du\nsport\nSoci\u00e9t\u00e9 fran\u00e7aise des professionnels en activit\u00e9\nphysique adapt\u00e9e*\nSoci\u00e9t\u00e9 fran\u00e7aise de nutrition*\nAssociation fran\u00e7aise des di\u00e9t\u00e9ticiens\nnutritionnistes*\nColl\u00e8ge de la masso-kin\u00e9sith\u00e9rapie\nColl\u00e8ge de pharmacie d'officine et de pharmacie\nhospitali\u00e8re*\nConseil national professionnel de g\u00e9riatrie*\nConseil national professionnel de gyn\u00e9cologie\nobst\u00e9trique et gyn\u00e9cologie m\u00e9dicale*\nSoci\u00e9t\u00e9 fran\u00e7aise de cardiologie*\nConseil national professionnel de cardiologie*\nSoci\u00e9t\u00e9 francophone du diab\u00e8te*\nColl\u00e8ge de la m\u00e9decine g\u00e9n\u00e9rale*\nConseil national professionnel des infirmiers en\npratique avanc\u00e9e (CNP IPA)*\n\n(*) Organismes professionnels et associations de patients et d 'usagers ayant propos\u00e9 des experts pour les groupes de travail/lecture\n\nGroupe de travail\nDr Ana\u00efs Cloppet-Fontaine, g\u00e9riatre, Paris - charg\u00e9e de projet\nDr Guillaume Grenet, endocrinologue, pharmacologue, Lyon - charg\u00e9 de projet\nDr Thomas Pinto, m\u00e9decin g\u00e9n\u00e9raliste, assistant universitaire \u00e0 Sorbonne Universit\u00e9, Livry-Gargan -\ncharg\u00e9 de projet\nSophie Blanchard, docteur en sciences biologiques et m\u00e9dicales, chef de projet HAS, Saint-Denis\n\nMme Caroline Airiau, pharmacienne hospitali\u00e8re,\nCholet\nMme Marie -Alix Alix, pharmacienne lib\u00e9rale,\nWasselonne\nMme Sylvie Bigar\u00e9, infirmi\u00e8re lib\u00e9rale, Verny\nPr R\u00e9my Boussageon, m\u00e9decin g\u00e9n\u00e9raliste,\nLyon, jusqu'au 13/11/2023*\nDr Sandrine Brug\u00e8re, gyn\u00e9cologue, Bordeaux\nPr Sybil Charri\u00e8re, m\u00e9decin nutritionniste, Lyon\nM. Claude Chaumeil, usager du syst\u00e8me de sant\u00e9\nPr Jacques Delarue, m\u00e9decin nutritionniste, Brest", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2256, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "d7abe083-cae6-48d0-80e9-9c5551ddafd5": {"__data__": {"id_": "d7abe083-cae6-48d0-80e9-9c5551ddafd5", "embedding": null, "metadata": {"page_label": "53", "file_name": "strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_type": "application/pdf", "file_size": 920218, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "9b9c978a-8220-4fc7-885f-0dd9d04226f5", "node_type": "4", "metadata": {"page_label": "53", "file_name": "strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_type": "application/pdf", "file_size": 920218, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "89be740b826ff6edc521c7b585b386c90c2b58053136be77674a9724e045ef1a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ab7a3aed-fdd6-4c40-9575-fc4861198243", "node_type": "1", "metadata": {}, "hash": "a6f45999be79664a1edb4b0c4c4994347268721fce804ace142378181b3d88bc", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "HAS \u2022 Strat\u00e9gie th\u00e9rapeutique du patient vivant avec un diab\u00e8te de type 2 \u2022 mai 2024 53\nDr Jean du Breuillac, m\u00e9decin g\u00e9n\u00e9raliste,\nTh\u00e9nezay\nPr Martine Duclos, endocrinologue, m\u00e9decin du\nsport, physiologiste, Clermont-Ferrand\nDr Bertrand Dussol, n\u00e9phrologue, Marseille ,\njusqu'au 22/03/23\nPr \u00c9tienne Larger, diab\u00e9tologue, Paris\nMme Nathalie Masseboeuf, cadre de sant\u00e9,\ndi\u00e9t\u00e9ticienne nutritionniste, Fr\u00e9jus-Saint-Rapha\u00ebl\nMme Murielle Mercidieu, infirmi\u00e8re, Melun\nDr Nicolas Naiditch, sociologue, Paris\nPr Vincent Rigalleau, nutrition, Pessac\nDr Manuel Sanchez, g\u00e9riatre, Paris\nMme Virginie Serabian, cadre de sant\u00e9, Melun\nDr Jean-Fran\u00e7ois Th\u00e9baut, usager du syst\u00e8me de\nsant\u00e9\nM. Mathieu Vergnault, enseignant en activit\u00e9\nphysique adapt\u00e9e, Asni\u00e8res-sur-Seine\n\n(*) expert ne souhaitant pas endosser cette recommandation de bonne pratique\n\nGroupe de lecture\nPr Denis Angoulvant, cardiologue, Tours\nPr Judith Aron-Wisnewsky, endocrinologue, Paris\nDr Patrick Assyag, cardiologue, Paris\nPr Antoine Avignon, endocrinologue, Montpellier\nDr Pierre Bataille, n\u00e9phrologue, Boulogne -surMer\nDr Cl\u00e9mence B\u00e9chade, n\u00e9phrologue, Caen\nDr Amaury Ben Henda, n\u00e9phrologue, Bois -\nBernard\nPr \u00c9ric Bertin, m\u00e9decin nutritionniste, Reims\nDr Jacques Birg\u00e9, m\u00e9decin g\u00e9n\u00e9raliste, Boulay -\nMoselle\nDr Nicole Bornsztein, m\u00e9decin g\u00e9n\u00e9raliste, \u00c9vry\nDr Anne-Sophie Boureau, g\u00e9riatre, Nantes\nDr Thierry Brillac, m\u00e9decin g\u00e9n\u00e9raliste, Toulouse\nM. Arnaud Bubeck, usager du syst\u00e8me de sant\u00e9\nMme Carole Cantayre, di\u00e9t\u00e9ticienne\nnutritionniste, Nice\nPr Claire Carette, m\u00e9decin endocrinologue,\ndiab\u00e9tologue et nutritionniste, Paris\nMme Mireille Castelain, di\u00e9t\u00e9ticienne\nnutritionniste, Montpellier\nPr Bogdan Catargi, endocrinologue, Bordeaux\nDr Claude Colas, diab\u00e9tologue, Paris\nPr Jean-Paul Cristol, biologiste, Montpellier\nPr Patrice Darmon, endocrinologue, Marseille\nDr Annette Delabar, m\u00e9decin g\u00e9n\u00e9raliste, \u00c9vry\nPr Philippe Deruelle, gyn\u00e9cologue -\nobst\u00e9tricien, Montpellier\nDr Jean -Claude D ib, cardiologue, Neuilly -surSeine\nMme Marie -Charlotte Druart,", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2014, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "ab7a3aed-fdd6-4c40-9575-fc4861198243": {"__data__": {"id_": "ab7a3aed-fdd6-4c40-9575-fc4861198243", "embedding": null, "metadata": {"page_label": "53", "file_name": "strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_type": "application/pdf", "file_size": 920218, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "9b9c978a-8220-4fc7-885f-0dd9d04226f5", "node_type": "4", "metadata": {"page_label": "53", "file_name": "strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_type": "application/pdf", "file_size": 920218, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "89be740b826ff6edc521c7b585b386c90c2b58053136be77674a9724e045ef1a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d7abe083-cae6-48d0-80e9-9c5551ddafd5", "node_type": "1", "metadata": {"page_label": "53", "file_name": "strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_type": "application/pdf", "file_size": 920218, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "4d8987e7b0e87b114eb8a7089c8be372bb96cb23f62d8a57740fb9ab76b0f2f6", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "diab\u00e9tologue, Paris\nPr Jean-Paul Cristol, biologiste, Montpellier\nPr Patrice Darmon, endocrinologue, Marseille\nDr Annette Delabar, m\u00e9decin g\u00e9n\u00e9raliste, \u00c9vry\nPr Philippe Deruelle, gyn\u00e9cologue -\nobst\u00e9tricien, Montpellier\nDr Jean -Claude D ib, cardiologue, Neuilly -surSeine\nMme Marie -Charlotte Druart, infirmi\u00e8re en\npratique avanc\u00e9e, Paris\nPr Pierre -Henri Ducluzeau, endocrinologue,\nTours\nDr Olivier Dupuy, endocrinologue, Paris\nDr Kristell Faure, m\u00e9decin biologiste, Sanary-surMer\nPr Patrice Flore, Physiologie/Physiopathologie de\nl'exercice, Grenoble\nDr Yoann Gaboreau, m\u00e9decin g\u00e9n\u00e9raliste, Portede-Savoie\nDr Alain Gautier, endocrinologue, CessonS\u00e9vign\u00e9\nPr Natacha Germain, endocrinologue, Saint\u00c9tienne\nDr Michel Gerson, endocrinologue, Strasbourg\nPr Pierre Gourdy, endocrinologue, Toulouse\nM. Axel Gross, infirmier pu\u00e9riculteur, Metz\nDr C\u00e9cile Gu\u00e9rard-Detuncq, pharmacienne, PontAudemer", "mimetype": "text/plain", "start_char_idx": 1714, "end_char_idx": 2603, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "e28a24b7-d2fa-45d7-8224-a8e55a4d341e": {"__data__": {"id_": "e28a24b7-d2fa-45d7-8224-a8e55a4d341e", "embedding": null, "metadata": {"page_label": "54", "file_name": "strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_type": "application/pdf", "file_size": 920218, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "81c9ae9b-1edb-4b53-b7e6-2162a925b758", "node_type": "4", "metadata": {"page_label": "54", "file_name": "strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_type": "application/pdf", "file_size": 920218, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "0700afdf5d62ea70da13df038bbf4d990280b1403fecd2387343c6b7b2613eae", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d3dae363-7918-4c9c-a15e-ae7cb37343df", "node_type": "1", "metadata": {}, "hash": "ddf33009485415f23f91615d15f91fa5b5e5465ae268d906bc2392c691cc349b", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "HAS \u2022 Strat\u00e9gie th\u00e9rapeutique du patient vivant avec un diab\u00e8te de type 2 \u2022 mai 2024 54\nDr Walid-Michel Haddad, ophtalmologue,\nAvranches\nMme Laurie Hamant, di\u00e9t\u00e9ticienne nutritionniste,\nBesan\u00e7on\nDr Patrick Hindlet, pharmacien, Paris\nDr Lori Kepenekian, endocrinologue , Caluire -etCuire\nPr Laurent Kodjikian, ophtalmologue, Lyon\nDr Marie -Laure Lalanne -Mistrih, endocrinologue\net m\u00e9decin nutritionniste , Les Abymes,\nGuadeloupe\nDr Dalila Lalej, endocrinologue, Pontault -\nCombault\nMme Mariannick Le Bot, pharmacienne, Brest\nM. Brendan Le Dar\u00e9, pharmacien, Rennes\nM. S\u00e9bastien Le Garf, PhD, enseignant en\nAPA, Nice\nDr Emmanuelle Lecornet-Sokol, endocrinologue,\nParis\nDr Ga\u00eblle Lethielleux, endocrinologue, Paris\nDr B\u00e9atrice Lognos, m\u00e9decin g\u00e9n\u00e9raliste, Saint -\nGeorges d'Orques\nDr Dany-Michel Marcadet, cardiologue, Paris\nDr Roland Marduel, ophtalmologue, Le Chesnay\nM. Gautier Marty, infirmier de pratique avanc\u00e9e,\nParis\nDr Betty Mathieu, pharmacienne, N\u00eemes\nMme Pierrette Meury Abraham, infirmi\u00e8re en\npratique avanc\u00e9e , docteur en sant\u00e9 publique,\nGuadeloupe\nPr Philippe Moulin, endocrinologue, Lyon\nPr Estelle Nobecourt, endocrinologue, Saint -\nPierre, La R\u00e9union\nMme M\u00e9line Pagnier, infirmi\u00e8re de pratique\navanc\u00e9e, Pontarlier\nDr Bruno Pavy, cardiologue, Machecoul\nPr Alfred Penfornis, endocrinologue, Corbeil -\nEssonnes\nPr Jean-Michel Petit, endocrinologue, Dijon\nMme Laura Phirmis, usag\u00e8re du syst\u00e8me de\nsant\u00e9\nPr Alain Pradignac, endocrinologue, Strasbourg\nMme \u00c9velyne Ribal, infirmi\u00e8re en pratique\navanc\u00e9e, Montpellier\nDr Olivia Ronsin, endocrinologue, Marseille\nDr Julie Sarfati, endocrinologue, Paris\nPr Andr\u00e9 Scheen, endocrinologue, Li\u00e8ge,\nBelgique\nMme Ga\u00eblle Soriano, di\u00e9t\u00e9ticienne nutritionniste,\nToulouse\nPr Ariane Sultan, endocrinologue, Montpellier\nDr Rachid Tahiri, ophtalmologue, Granville\nPr Paul Valensi, endocrinologue, Aubervilliers\nMme Annie Vannier, di\u00e9t\u00e9ticienne nutritionniste,\nLe Creusot\nPr Bruno Verg\u00e8s, endocrinologue, Dijon\nDr C\u00e9dric Villain, g\u00e9riatre,", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1979, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "d3dae363-7918-4c9c-a15e-ae7cb37343df": {"__data__": {"id_": "d3dae363-7918-4c9c-a15e-ae7cb37343df", "embedding": null, "metadata": {"page_label": "54", "file_name": "strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_type": "application/pdf", "file_size": 920218, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "81c9ae9b-1edb-4b53-b7e6-2162a925b758", "node_type": "4", "metadata": {"page_label": "54", "file_name": "strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_type": "application/pdf", "file_size": 920218, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "0700afdf5d62ea70da13df038bbf4d990280b1403fecd2387343c6b7b2613eae", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e28a24b7-d2fa-45d7-8224-a8e55a4d341e", "node_type": "1", "metadata": {"page_label": "54", "file_name": "strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_type": "application/pdf", "file_size": 920218, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "d58227850fc58bc4a8c7c57d0d16c66be3ccef63071c650e1d75ecce338d2361", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "di\u00e9t\u00e9ticienne nutritionniste,\nToulouse\nPr Ariane Sultan, endocrinologue, Montpellier\nDr Rachid Tahiri, ophtalmologue, Granville\nPr Paul Valensi, endocrinologue, Aubervilliers\nMme Annie Vannier, di\u00e9t\u00e9ticienne nutritionniste,\nLe Creusot\nPr Bruno Verg\u00e8s, endocrinologue, Dijon\nDr C\u00e9dric Villain, g\u00e9riatre, Caen\nDr H\u00e9l\u00e8ne Vollot, endocrinologue, Hagondange\nM. Mathias Willame, kin\u00e9sith\u00e9rapeute, N\u00eemes\nDr Xavier Zanlonghi, ophtalmologue, Rennes\nDr Catherine Zanuttini-Vogt, m\u00e9decin g\u00e9n\u00e9raliste,\nValr\u00e9as\n\nRemerciements\nLa HAS tient \u00e0 remercier l 'ensemble des participants cit\u00e9s ci-dessus ainsi que le Pr Jean-Luc Faillie,\npharmacologue, responsable du centre r\u00e9gional de pharmacovigilance, Montpellier", "mimetype": "text/plain", "start_char_idx": 1677, "end_char_idx": 2373, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "b91dfa36-7b76-44cb-9c59-8f525b101ffe": {"__data__": {"id_": "b91dfa36-7b76-44cb-9c59-8f525b101ffe", "embedding": null, "metadata": {"page_label": "55", "file_name": "strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_type": "application/pdf", "file_size": 920218, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "d42e5afb-96c3-4d7c-992a-ef3a1e468e4b", "node_type": "4", "metadata": {"page_label": "55", "file_name": "strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_type": "application/pdf", "file_size": 920218, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "b4b2a975411b8e151c2e5853f4a2ed6355670695496e6e6eadcd5fe65d97e2a2", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "HAS \u2022 Strat\u00e9gie th\u00e9rapeutique du patient vivant avec un diab\u00e8te de type 2 \u2022 mai 2024 55\nAbr\u00e9viations et acronymes\n\nADO Antidiab\u00e9tique oral\nASG Autosurveillance glyc\u00e9mique\naGLP1 Agonistes (analogues) du glucagon-like-peptide-1\nDFG D\u00e9bit de filtration glom\u00e9rulaire\nEDN Endocrinologue diab\u00e9tologue nutritionniste\nETP \u00c9ducation th\u00e9rapeutique du patient\nHbA1c H\u00e9moglobine glyqu\u00e9e A1c\nHAS Haute Autorit\u00e9 de sant\u00e9\niDPP4 Inhibiteurs de dipeptidylpeptidase-4\niSGLT2 Inhibiteurs des cotransporteurs sodium-glucose de type 2\nIMC Indice de masse corporelle\nIRC Insuffisance r\u00e9nale chronique\nMET Metformine\nMTMV Modifications th\u00e9rapeutiques du mode de vie\nTMH Traitements m\u00e9dicamenteux de l'hyperglyc\u00e9mie\nSULF Sulfamides", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 707, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "91edfeae-233c-4ef1-b060-4be96d9164e8": {"__data__": {"id_": "91edfeae-233c-4ef1-b060-4be96d9164e8", "embedding": null, "metadata": {"page_label": "56", "file_name": "strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_type": "application/pdf", "file_size": 920218, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "18fab913-8352-41c1-bcb0-ef1a64500fce", "node_type": "4", "metadata": {"page_label": "56", "file_name": "strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf", "file_type": "application/pdf", "file_size": 920218, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "afec437a1211aa4f56cfeb2bbc7d38fff9804847438187b30ea9c50a963dd591", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Retrouvez tous nos travaux sur\nwww.has-sante.fr\nD\u00e9velopper la qualit\u00e9 dans le champ\nsanitaire, social et m\u00e9dico-social\n\n\u00a9 Haute Autorit\u00e9 de sant\u00e9 - mai 2024 - ISBN : 978-2-11-172146-3", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 183, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "20dd5452-8ba6-40b9-859d-1adc00e08a5f": {"__data__": {"id_": "20dd5452-8ba6-40b9-859d-1adc00e08a5f", "embedding": null, "metadata": {"page_label": "1", "file_name": "Synth\u00e8se etudes diab\u00e8te_13.11.2023 (1).pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\Synth\u00e8se etudes diab\u00e8te_13.11.2023 (1).pdf", "file_type": "application/pdf", "file_size": 604482, "creation_date": "2025-11-26", "last_modified_date": "2025-11-18", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "214f13ba-61fe-4460-9a07-55037f4a88f6", "node_type": "4", "metadata": {"page_label": "1", "file_name": "Synth\u00e8se etudes diab\u00e8te_13.11.2023 (1).pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\Synth\u00e8se etudes diab\u00e8te_13.11.2023 (1).pdf", "file_type": "application/pdf", "file_size": 604482, "creation_date": "2025-11-26", "last_modified_date": "2025-11-18", "cleaned": true, "headlines": []}, "hash": "7543fc4842cd97be00d67a07455d004fd4ba21adb4ec4eae1eeff1068ea52e5b", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Synth\u00e8se des donn\u00e9es sur le diab\u00e8te \u00e0 La R\u00e9union\n14 novembre 2023\n\nLa lutte contre le diab\u00e8te \u00e0 La R\u00e9union constitue un enjeu majeur pour l'ensemble des acteurs locaux.\nLe 14 novembre, Journ\u00e9e mondiale du diab\u00e8te, l'A gence R\u00e9gionale de Sant\u00e9 La R\u00e9union, l'Observatoire\nR\u00e9gional de la Sant\u00e9 et Sant\u00e9 Publique France ont publi\u00e9 les chiffres actualis\u00e9s sur l a maladie \u00e0 La\nR\u00e9union. Ces donn\u00e9es sont issues de travaux men\u00e9s , au niveau local , par l'ORS dans le cadre du\nProgramme R\u00e9unionnais de Nutrition et de lutte contre le Diab\u00e8te (PRND), et au niveau national, de la\npublication par Sant\u00e9 Publique France de deux \u00e9tudes , dont une \u00e9tendue pour la premi\u00e8re fois aux\nD\u00e9partements et R\u00e9gions d'Outre-Mer.\n\nA La R\u00e9union comme dans les autres DROM, la pr\u00e9valence du diab\u00e8te de type 2 est particuli\u00e8rement\n\u00e9l\u00e9v\u00e9e et les complications chroniques y sont plus fr\u00e9quentes. En 2021, la pr\u00e9valence du diab\u00e8te connu\nconcerne 13,6% des r\u00e9unionnais adultes de 18 \u00e0 85 ans, soit plus du double de l'Hexagone (5,7%) . S'y\najoutent 2,9% de personnes d\u00e9clarant un \u00ab petit diab\u00e8te \u00bb.\n\nPar rapport aux autres territoires, l a situation r\u00e9unionnaise se caract\u00e9rise par une sur -repr\u00e9sentation\ndes femmes, un niveau socio-\u00e9conomique plus d\u00e9favorable des personnes atteintes, une fr\u00e9quence plus\n\u00e9lev\u00e9e des complications du diab\u00e8te et une entr\u00e9e plus jeune dans la maladie.\n\nAu-del\u00e0 des constats partag\u00e9s avec les autres DROM , les \u00e9tudes permettent de d\u00e9gager des\nparticularit\u00e9s pour La R\u00e9union, et justifient la plus-value, soulign\u00e9e par Sant\u00e9 Publique France, du PRND,\nqualifi\u00e9 d' \u00ab initiative locale prometteuse \u00bb.\nCes nouvelles analyses vont permettre de r\u00e9ajuster la politique r\u00e9gionale au travers du prochain PRND\n2024-2028 pour mieux pr\u00e9venir le diab\u00e8te et ses complications.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1762, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "f8595323-cc73-42b1-93c7-b7b283fe041e": {"__data__": {"id_": "f8595323-cc73-42b1-93c7-b7b283fe041e", "embedding": null, "metadata": {"page_label": "2", "file_name": "Synth\u00e8se etudes diab\u00e8te_13.11.2023 (1).pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\Synth\u00e8se etudes diab\u00e8te_13.11.2023 (1).pdf", "file_type": "application/pdf", "file_size": 604482, "creation_date": "2025-11-26", "last_modified_date": "2025-11-18", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "a8dcce3b-0ed4-4cb7-8f47-3bd7915f3849", "node_type": "4", "metadata": {"page_label": "2", "file_name": "Synth\u00e8se etudes diab\u00e8te_13.11.2023 (1).pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\Synth\u00e8se etudes diab\u00e8te_13.11.2023 (1).pdf", "file_type": "application/pdf", "file_size": 604482, "creation_date": "2025-11-26", "last_modified_date": "2025-11-18", "cleaned": true, "headlines": []}, "hash": "e88bdaf9c32320b31b7c8cb1e084354cc96d906dabaeee31925ed2e69a4272eb", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "L'observation du diab\u00e8te \u00e0 La R\u00e9union\n\nLe Comit\u00e9 technique Observation du PRND : un atout pour notre territoire\nSuite \u00e0 la Conf\u00e9rence de consensus sur le diab\u00e8te en 2016, les acteurs locaux ont souhait\u00e9 une animation\nr\u00e9gionale sur le partage des donn\u00e9es d'observation, leur production, leur interpr\u00e9tation et leur diffusion\nafin de consolider la culture commune et de disposer d'analyses permettant d'orienter les interventions.\nPour porter cette animation r\u00e9gionale, l'ARS a missionn\u00e9 l'ORS de La R\u00e9union qui travaille de mani\u00e8re\n\u00e9troite avec l'Assurance maladie et d'autres experts r\u00e9gionaux en statistiques, \u00e9pid\u00e9miologie et\nendocrinologie. Ces travaux, r\u00e9alis\u00e9s dans le cadre du Comit\u00e9 technique \u00ab Observation diab\u00e8te-ob\u00e9sit\u00e9nutrition \u00bb du PRND , permettent depuis 2017 de suivre de mani\u00e8re sp\u00e9cifique l'\u00e9volution et la\ncaract\u00e9risation du diab\u00e8te \u00e0 La R\u00e9union. Pour cette ann\u00e9e 2023, l'ORS propose deux supports \u00e0 diffuser :\nl'un \u00e0 destination du grand public et l'autre pour les acteurs locaux.\n\nDes travaux nationaux consolidant et compl\u00e9tant les connaissances : Sant\u00e9 Publique France publie un\nBulletin Epid\u00e9miologique Hebdomadaire (BEH) consacr\u00e9 au \u00ab Diab\u00e8te en outre-mer \u00bb\nCe Bulletin Epid\u00e9miologique Hebdomadaire (BEH) th\u00e9matique sera diffus\u00e9 le 14 novembre 2023. Les\narticles pr\u00e9sentent les derni\u00e8res donn\u00e9es disponibles sur le diab\u00e8te de type 2 dans quatre DROM\n(Guadeloupe, Martinique, Guyane et La R\u00e9union), \u00e0 partir de l'\u00e9dition 2021 du Barom\u00e8tre de Sant\u00e9\npublique France et de la 3\u00e8me \u00e9dition d'Entred (Echantillon national t\u00e9moin repr\u00e9sentatif des personnes\ndiab\u00e9tiques) conduite en 2019-2020.\nLa publication de ce BEH permet de compl\u00e9ter la connaissance de la population atteinte par le diab\u00e8te\n\u00e0 La R\u00e9union.\nIl est disponible sur le site de Sant\u00e9 Publique France.\n\nLe diab\u00e8te \u00e0 La R\u00e9union : les points-cl\u00e9s\n\nLes diff\u00e9rents \u00e9l\u00e9ments qui figurent ci -apr\u00e8s sont extraits des travaux locaux et nationaux cit\u00e9s ci -dessus.\nLes r\u00e9sultats peuvent donc varier en fonction des sources et des m\u00e9thodologies d'enqu\u00eate, mais sont\nglobalement convergents entre eux.\n\nDe nombreux r\u00e9unionnais concern\u00e9s par le diab\u00e8te\n\nPr\u00e9valence du diab\u00e8te connu\n\nRetrouvez l'ensemble des indicateurs cl\u00e9s du diab\u00e8te \u00e0 La R\u00e9union dans la publication de l'ORS\n>>> Support grand public :\nCliquez ici\n\n>>> Support visant \u00e0 fournir aux professionnels du territoire des donn\u00e9es plus d\u00e9taill\u00e9es :\nCliquez ici", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2391, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "8a7dba6a-f778-4218-bef1-6903c754cdd4": {"__data__": {"id_": "8a7dba6a-f778-4218-bef1-6903c754cdd4", "embedding": null, "metadata": {"page_label": "3", "file_name": "Synth\u00e8se etudes diab\u00e8te_13.11.2023 (1).pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\Synth\u00e8se etudes diab\u00e8te_13.11.2023 (1).pdf", "file_type": "application/pdf", "file_size": 604482, "creation_date": "2025-11-26", "last_modified_date": "2025-11-18", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "07f0fdf4-d6ec-4fb7-857e-35569f1d7b9d", "node_type": "4", "metadata": {"page_label": "3", "file_name": "Synth\u00e8se etudes diab\u00e8te_13.11.2023 (1).pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\Synth\u00e8se etudes diab\u00e8te_13.11.2023 (1).pdf", "file_type": "application/pdf", "file_size": 604482, "creation_date": "2025-11-26", "last_modified_date": "2025-11-18", "cleaned": true, "headlines": []}, "hash": "bcecfc5aea09d24687bbcccd2b4925325606f672508542bf811472effee5c028", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6e0a4055-156c-4b70-8fa8-255c79ab6d30", "node_type": "1", "metadata": {}, "hash": "5d4dccf20473a2b3a224d9ea0d65dbc9a3779496af78266bfa0ec956b201f746", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Pr\u00e9valence du \u00ab petit diab\u00e8te \u00bb ou \u00ab d\u00e9but de diab\u00e8te \u00bb\nCertaines personnes minimisent leur atteinte par le diab\u00e8te en faisant \u00e9tat d'un \u00ab petit diab\u00e8te \u00bb ou d'un\n\u00ab d\u00e9but de diab\u00e8te \u00bb alors consid\u00e9r\u00e9 comme peu ou pas grave . Pour la premi\u00e8re fois, le Barom\u00e8tre de\nSant\u00e9 Publique France DROM de 2021 permet d'appr\u00e9cier cette r\u00e9alit\u00e9.\nAinsi parmi les personnes qui ne se sont pas d\u00e9clar\u00e9es diab\u00e9tiques, la proportion de ceux faisant \u00e9tat\nd'un \u00ab petit diab\u00e8te \u00bb est de 3,4% \u00e0 La R\u00e9union, soit une estimation de 2,9% de \u00ab petit diab\u00e8te \u00bb chez\nles adultes de 18-85 ans.\nLa fr\u00e9quence du \u00ab petit diab\u00e8te \u00bb est jug\u00e9e \u00e9lev\u00e9e et\nrepr\u00e9sente un frein potentiel \u00e0 une prise en charge adapt\u00e9e\net pr\u00e9coce permettant de pr\u00e9venir l'aggravation de la\nmaladie et ses complications.\nParmi les personnes se d\u00e9c larant avoir un \u00ab petit diab\u00e8te \u00bb\npeuvent figurer des patients pr\u00e9diab\u00e9tiques. Des act ions\nsp\u00e9cifiques doivent \u00eatre d\u00e9ploy\u00e9es pour faciliter la prise de\nconscience des patients et favoriser une prise en charge\nn\u00e9cessaire.\n\nDes personnes atteintes d'un diab\u00e8te qui ignorent leur maladie\nLes chiffres de pr\u00e9valence sous-estiment la sit uation r\u00e9elle \u00e0 La R\u00e9union , comme dans l'ensemble du\nmonde : une part significative de la population ignore sa sit uation vis -\u00e0-vis du di ab\u00e8te du fait d'une\nabsence de recours au diagnostic.\nL'enqu\u00eate REDIA, men\u00e9e \u00e0 La R\u00e9union en 1999-2001 aupr\u00e8s des personnes \u00e2g\u00e9es de 30-69 ans, rapportait\nune pr\u00e9valence du diab\u00e8te m\u00e9connu \u00e9quivalent \u00e0 1/3 des cas de diab\u00e8te. Un projet d'\u00e9tude en cours \u00e0\nLa R\u00e9union permettra d'actualiser cette donn\u00e9e et de mesurer les progr\u00e8s du diagnostic du diab\u00e8te.\n\nCaract\u00e9ristiques des personnes diab\u00e9tiques r\u00e9unionnaises\n\nMieux conna\u00eetre les personnes atteintes d'un diab\u00e8te \u00e0 La R\u00e9union est indispensable pour mieux les\naccompagner et mettre en place des mesures permettant de consolider l'offre de prise en charge et de\npr\u00e9vention.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1889, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "6e0a4055-156c-4b70-8fa8-255c79ab6d30": {"__data__": {"id_": "6e0a4055-156c-4b70-8fa8-255c79ab6d30", "embedding": null, "metadata": {"page_label": "3", "file_name": "Synth\u00e8se etudes diab\u00e8te_13.11.2023 (1).pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\Synth\u00e8se etudes diab\u00e8te_13.11.2023 (1).pdf", "file_type": "application/pdf", "file_size": 604482, "creation_date": "2025-11-26", "last_modified_date": "2025-11-18", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "07f0fdf4-d6ec-4fb7-857e-35569f1d7b9d", "node_type": "4", "metadata": {"page_label": "3", "file_name": "Synth\u00e8se etudes diab\u00e8te_13.11.2023 (1).pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\Synth\u00e8se etudes diab\u00e8te_13.11.2023 (1).pdf", "file_type": "application/pdf", "file_size": 604482, "creation_date": "2025-11-26", "last_modified_date": "2025-11-18", "cleaned": true, "headlines": []}, "hash": "bcecfc5aea09d24687bbcccd2b4925325606f672508542bf811472effee5c028", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8a7dba6a-f778-4218-bef1-6903c754cdd4", "node_type": "1", "metadata": {"page_label": "3", "file_name": "Synth\u00e8se etudes diab\u00e8te_13.11.2023 (1).pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\Synth\u00e8se etudes diab\u00e8te_13.11.2023 (1).pdf", "file_type": "application/pdf", "file_size": 604482, "creation_date": "2025-11-26", "last_modified_date": "2025-11-18", "cleaned": true, "headlines": []}, "hash": "4e2870649cc32a113ad857c14d06882b8b6a29f8a5316588598a2a052baca08d", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Caract\u00e9ristiques des personnes diab\u00e9tiques r\u00e9unionnaises\n\nMieux conna\u00eetre les personnes atteintes d'un diab\u00e8te \u00e0 La R\u00e9union est indispensable pour mieux les\naccompagner et mettre en place des mesures permettant de consolider l'offre de prise en charge et de\npr\u00e9vention.\n\nParmi les personnes atteintes d'un diab\u00e8te \u00e0 La R\u00e9union, les sp\u00e9cificit\u00e9s suivantes se dessinent :\n\u2022 Une proportion plus importante de femmes ;\n\n\u2022 Un \u00e2ge moyen plus jeune ;\n\n\u2022 Des indicateurs socio -\u00e9conomiques\nrefl\u00e8tant une population plus\nd\u00e9favoris\u00e9e (moindre niveau\nd'\u00e9tudes et de revenus) ;\n\n\u2022 L'entr\u00e9e dans la maladie se fait de\nmani\u00e8re plus pr\u00e9coce \u00e0 La R\u00e9union\n(5 ans plus t\u00f4t), en moyenne vers 48\nans ;\n\n\u2022 Un taba gisme actuel plus\nfr\u00e9quemment rapport\u00e9 par les\npersonnes se d\u00e9clarant diab\u00e9tiques ;\nPour les R\u00e9unionnais concern\u00e9s par\n\u00ab un petit diab\u00e8te \u00bb :\n>> Rapprochez-vous de votre m\u00e9decin\nafin de faire le point sur votre situation.\n\nPour les personnes pr\u00e9diab\u00e9tiques :\n>> B\u00e9n\u00e9ficiez du programme\nd'accompagnement sp\u00e9cifique\nRunPREDIABETE en appelant le 0800\n444 974\nLa pr\u00e9valence du diab\u00e8te connu est tr\u00e8s importante dans les DROM. A La R\u00e9union, 13,6% des adultes\nr\u00e9unionnais de 18 \u00e0 85 ans se d\u00e9clarent diab\u00e9tiques, soit plus du double de l'Hexagone (5,7%). Cette\nproportion s'\u00e9l\u00e8ve \u00e0 33% pour les r\u00e9unionnais de 65 ans - 85 ans.", "mimetype": "text/plain", "start_char_idx": 1620, "end_char_idx": 2933, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "894f2489-e788-4ab5-884b-0e6f97681a18": {"__data__": {"id_": "894f2489-e788-4ab5-884b-0e6f97681a18", "embedding": null, "metadata": {"page_label": "4", "file_name": "Synth\u00e8se etudes diab\u00e8te_13.11.2023 (1).pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\Synth\u00e8se etudes diab\u00e8te_13.11.2023 (1).pdf", "file_type": "application/pdf", "file_size": 604482, "creation_date": "2025-11-26", "last_modified_date": "2025-11-18", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "1f24b60f-9bea-4a3b-a677-50b88f2cf0f4", "node_type": "4", "metadata": {"page_label": "4", "file_name": "Synth\u00e8se etudes diab\u00e8te_13.11.2023 (1).pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\Synth\u00e8se etudes diab\u00e8te_13.11.2023 (1).pdf", "file_type": "application/pdf", "file_size": 604482, "creation_date": "2025-11-26", "last_modified_date": "2025-11-18", "cleaned": true, "headlines": []}, "hash": "4bd9afd0e299c1be63100f1e8a0cb66363e160109ac0f07976d59e0d040a419b", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "\u2022 Une part importante des personnes diab\u00e9tiques interrog\u00e9es dans l'\u00e9tude ENTRED 3 d\u00e9clarent\nune hypertension art\u00e9rielle (66%) avec une pression art\u00e9rielle significativement plus \u00e9lev\u00e9e.\n\n\u2022 Des personnes diab\u00e9tiques avec un indice de masse corporelle (IMC) \u226425 kg/m\u00b2 ( seuil au-del\u00e0\nduquel la personne est consid\u00e9r\u00e9e en surpoids ) ; cette situation peut \u00e9voquer des facteurs de\npr\u00e9-disposition g\u00e9n\u00e9tique propres aux populations r\u00e9unionnaises.\nM\u00eame si l'IMC des personnes avec un diab\u00e8te est plus \u00e9lev\u00e9 que celui des personnes d\u00e9clarant\nne pas \u00eatre diab\u00e9tiques, pr\u00e8s d'un tiers des personnes ayant un diab\u00e8te d\u00e9clarent un IMC normal.\nCe r\u00e9sultat est coh\u00e9rent avec l'\u00e9tude ENTRED 3 o\u00f9 , quand il \u00e9tait rapport\u00e9, l'IMC moyen \u00e9tait\nmoins \u00e9lev\u00e9 \u00e0 La R\u00e9union (27,7 kg/m\u00b2 versus 29,5 kg/m\u00b2 dans l'Hexagone).\n\nR\u00e9partition des patients diab\u00e9tiques selon l'\u00e2ge et le territoire de r\u00e9sidence\n\nLes \u00e9l\u00e9ments ci-apr\u00e8s permettent de visualiser la r\u00e9partition des patients diab\u00e9tiques r\u00e9unionnais pris\nen charge selon l'\u00e2ge et leur territoire de r\u00e9sidence.\n\nLes R\u00e9unionnais d\u00e9couvrent leur diab\u00e8te le plus souvent par le biais du d\u00e9pistage :\nun \u00e9l\u00e9ment encourageant\n\nA La R\u00e9union, le diab\u00e8te de type 2 est plus fr\u00e9quemment d\u00e9couvert \u00e0 l'occasion d'un d\u00e9pistage : 76%\ndes personnes diab\u00e9tiques contre 68% pour l'Hexagone. A contrario, le diab\u00e8te est d\u00e9couvert par des\ncomplications inaugurales dans 8% des cas \u00e0 La R\u00e9union, contre 11% dans l'Hexagone.\nCes \u00e9l\u00e9ments sont encourageants et invite nt \u00e0 renforcer les actions d\u00e9j\u00e0 engag\u00e9es d ans le cadre du\nPRND en faveur d'un d\u00e9pistage renforc\u00e9 du diab\u00e8te.\n\nD'un point de vue clinique, il est essentiel de diagnostiquer le diab\u00e8te le plus t\u00f4t possible , d\u00e8s le stade\nasymptomatique, afin de pr\u00e9venir ou retarder le d\u00e9veloppement de la maladie et d'\u00e9viter les\ncomplications vasculaires.\n\nPour se faire d\u00e9pister :\n\n- Fa\u00eetes le d\u00e9pistage en vous rendant chez votre m\u00e9decin ;\n\n- Calculez votre risque de diab\u00e8te avec un test qui ne vous prendra qu'une minute :\nFindRisk P\u00e9i - Calculez votre risque diab\u00e8te en une minute | Masant\u00e9.re (masante.re)\n\n- Rendez-vous sur une des actions de d\u00e9pistage organis\u00e9es dans l'\u00eele", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2140, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "5e47c1d8-90b7-4c16-8f62-4b4ab9c8d927": {"__data__": {"id_": "5e47c1d8-90b7-4c16-8f62-4b4ab9c8d927", "embedding": null, "metadata": {"page_label": "5", "file_name": "Synth\u00e8se etudes diab\u00e8te_13.11.2023 (1).pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\Synth\u00e8se etudes diab\u00e8te_13.11.2023 (1).pdf", "file_type": "application/pdf", "file_size": 604482, "creation_date": "2025-11-26", "last_modified_date": "2025-11-18", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "fa797b6c-e946-45f2-82f8-945d7a7f94e1", "node_type": "4", "metadata": {"page_label": "5", "file_name": "Synth\u00e8se etudes diab\u00e8te_13.11.2023 (1).pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\Synth\u00e8se etudes diab\u00e8te_13.11.2023 (1).pdf", "file_type": "application/pdf", "file_size": 604482, "creation_date": "2025-11-26", "last_modified_date": "2025-11-18", "cleaned": true, "headlines": []}, "hash": "247d13cb72930add9ca4ba1f190ad757bdcefa2c9f59b17404bf9fd67480d6cd", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ffbc215a-138b-429c-b8b9-856bee74c51c", "node_type": "1", "metadata": {}, "hash": "202068fabbcd45ea930d2d79785eb3e2ea3c0ff20ae39f9ec66a7b45850a70a7", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Le diab\u00e8te concerne aussi les femmes enceintes\n\nEn 2022, 2 femmes enceintes sur 10 ont d\u00e9velopp\u00e9 un diab\u00e8te pendant leur grossesse (diab\u00e8te\ngestationnel). Une offre de prise en charge permet un accompagnement de ces femmes.\n\nPourquoi une pr\u00e9valence plus \u00e9lev\u00e9e du diab\u00e8te \u00e0 La R\u00e9union ?\n\nLes causes d'une pr\u00e9valence importante du diab\u00e8te sont probablement multifactorielles :\n- L'impact des facteurs de risque qui sont tr\u00e8s marqu\u00e9s parmi la population r\u00e9unionnaise :\n\u2022 La pr\u00e9valence du surpoids et de l'ob\u00e9sit\u00e9, m\u00eame s'il appara\u00eet qu'une proportion de personne\nayant un poids \u00ab normal \u00bb (IMC \u2264 25 kg/m\u00b2) est plus importante parmi les diab\u00e9tiques \u00e0 La\nR\u00e9union que dans l'Hexagone ;\n\u2022 Des comportements nutritionnels d\u00e9favorables : une alimentation riche en prot\u00e9ine, en gras,\nsucre et sel ; une consommation importante de boissons sucr\u00e9es ; une faible consommation\nde l\u00e9gumes ; et une pratique insuffisante de l'activit\u00e9 physique ;\n\n- Des indicateurs sociaux d\u00e9favorables ;\n\n- Les progr\u00e8s du d\u00e9pistage et du diagnostic qui permettent d'identifier davantage de personnes\ndiab\u00e9tiques qui ignoraient pr\u00e9c\u00e9demment leur maladie ;\n\n- Le vieillissement engag\u00e9 de la population r\u00e9unionnaise, l'incidence du diab\u00e8te augmentant\nsignficativement avec l'avanc\u00e9e en \u00e2ge ;\n\n- L'esp\u00e9rance de vie de la population diab\u00e9tique\n\n- Enfin l'existence d'un diab\u00e8te de type 2 chez des personnes plus jeunes et de corpulence\nmoindre \u00e0 La R\u00e9union interroge les experts sur l'existence possible d'une origine g\u00e9n\u00e9tique ou\n\u00e9pig\u00e9n\u00e9tique de la maladie.\n\nDes facteurs de risque bien pr\u00e9sents sur l'\u00eele\n\nComme les autres DROM, La R\u00e9union conna\u00eet une transition d\u00e9mographique et nutritionnelle rapide et\nprofonde, impactant les modes de vie et conduisant au d\u00e9veloppement des maladies m\u00e9taboliques\ntelles que l'ob\u00e9sit\u00e9 et le diab\u00e8te de type 2.\nLes comportements nutritionnels inadapt\u00e9s jouent un r\u00f4le important dans l'apparition de la maladie .", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1911, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "ffbc215a-138b-429c-b8b9-856bee74c51c": {"__data__": {"id_": "ffbc215a-138b-429c-b8b9-856bee74c51c", "embedding": null, "metadata": {"page_label": "5", "file_name": "Synth\u00e8se etudes diab\u00e8te_13.11.2023 (1).pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\Synth\u00e8se etudes diab\u00e8te_13.11.2023 (1).pdf", "file_type": "application/pdf", "file_size": 604482, "creation_date": "2025-11-26", "last_modified_date": "2025-11-18", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "fa797b6c-e946-45f2-82f8-945d7a7f94e1", "node_type": "4", "metadata": {"page_label": "5", "file_name": "Synth\u00e8se etudes diab\u00e8te_13.11.2023 (1).pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\Synth\u00e8se etudes diab\u00e8te_13.11.2023 (1).pdf", "file_type": "application/pdf", "file_size": 604482, "creation_date": "2025-11-26", "last_modified_date": "2025-11-18", "cleaned": true, "headlines": []}, "hash": "247d13cb72930add9ca4ba1f190ad757bdcefa2c9f59b17404bf9fd67480d6cd", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5e47c1d8-90b7-4c16-8f62-4b4ab9c8d927", "node_type": "1", "metadata": {"page_label": "5", "file_name": "Synth\u00e8se etudes diab\u00e8te_13.11.2023 (1).pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\Synth\u00e8se etudes diab\u00e8te_13.11.2023 (1).pdf", "file_type": "application/pdf", "file_size": 604482, "creation_date": "2025-11-26", "last_modified_date": "2025-11-18", "cleaned": true, "headlines": []}, "hash": "68f0a8a6b98c88d16881336c8eb9bec7393c193cf4a01cfccbb410d08698df5c", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Les comportements nutritionnels inadapt\u00e9s jouent un r\u00f4le important dans l'apparition de la maladie . A\nLa R\u00e9union, l es facteurs de risques favorisant l'apparition et le d\u00e9veloppement du diab\u00e8te sont bien\npr\u00e9sents en population g\u00e9n\u00e9rale, notamment des comportements nutritionnels \u00e9loign\u00e9s des recommandations :\n\u2022 pr\u00e8s d'un r\u00e9unionnais sur 2 est en surcharge pond\u00e9rale (47%), et l'ob\u00e9sit\u00e9 concerne 15% de la\npopulation \u00e2g\u00e9e de 18 \u00e0 85 ans en 2021 ;\n\n\u2022 seuls 21% des r\u00e9unionnais d\u00e9clarent manger 5 fruits ou l\u00e9gumes par jour ;\n\n\u2022 seuls 40% des r\u00e9unionnais d\u00e9clarent une pratique d'activit\u00e9 physique conform e aux recommandations qui sont de 30 minutes de marche ou de v\u00e9lo par jour.", "mimetype": "text/plain", "start_char_idx": 1811, "end_char_idx": 2491, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "fea679dc-d19c-4067-a2fc-0a9e37ff62b5": {"__data__": {"id_": "fea679dc-d19c-4067-a2fc-0a9e37ff62b5", "embedding": null, "metadata": {"page_label": "6", "file_name": "Synth\u00e8se etudes diab\u00e8te_13.11.2023 (1).pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\Synth\u00e8se etudes diab\u00e8te_13.11.2023 (1).pdf", "file_type": "application/pdf", "file_size": 604482, "creation_date": "2025-11-26", "last_modified_date": "2025-11-18", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "d94325cd-066b-4086-b1c5-7e9667cfa643", "node_type": "4", "metadata": {"page_label": "6", "file_name": "Synth\u00e8se etudes diab\u00e8te_13.11.2023 (1).pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\Synth\u00e8se etudes diab\u00e8te_13.11.2023 (1).pdf", "file_type": "application/pdf", "file_size": 604482, "creation_date": "2025-11-26", "last_modified_date": "2025-11-18", "cleaned": true, "headlines": []}, "hash": "25428a7abac15344813e5f8e8e8f0236def60f663af832b41eddfc1c4b61d72d", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Evolution de la situation r\u00e9gionale\n\nLa comparaison des r\u00e9sultats entre les deux \u00e9ditions du Barom\u00e8tre Sant\u00e9 DROM et les donn\u00e9es produites\npar l'ORS sont convergentes.\n\nLa pr\u00e9valence du diab\u00e8te connu tend \u00e0 augmenter dans la po pulation r\u00e9unionnaise adulte. En se\nrapportant \u00e0 la population des 18-75 ans, la part du diab\u00e8te connu est pass\u00e9 de 11,6% en 2014 \u00e0 13% en\n2021 (13,6% pour les 18 - 85 ans). Cette tendance doit \u00eatre mise en relation avec le vieillissement de la\npopulation, l'allongement de l'esp\u00e9rance de vie de la population diab\u00e9tique mais \u00e9galement avec une\nam\u00e9lioration du d\u00e9pistage du diab\u00e8te comme le montrent les r\u00e9sultats de l'\u00e9tude ENTRED 3 o\u00f9 la\nproportion de diab\u00e8te de type 2 d\u00e9couvert suite \u00e0 d\u00e9pistage est plus importante \u00e0 La R\u00e9union (76%) que\ndans l'Hexagone (68%).\n\nUne prise en charge des patients diab\u00e9tiques r\u00e9unionnais qui reste \u00e0 am\u00e9liorer\n\nLa prise en charge des patients diab\u00e9tiques r\u00e9unionnais passe principalement par les m\u00e9decins\ng\u00e9n\u00e9ralistes : 96% des patients diab\u00e9tiques ont consult\u00e9 un m\u00e9decin g\u00e9n\u00e9raliste en 2021.\nLe recours aux endocrinologues reste faible : seul 18% des patients pris en charge en 2021 ont cons ult\u00e9\nun endocrinologue alors que ce recours est plus \u00e9lev\u00e9 dans l'Hexagone. Cela peut s'expliquer par le fait\nque le territoire r\u00e9unionnais ne dispose que de 29 endocrinologues (en 2022).\n\nParmi les patients diab\u00e9tiques pris en charge en 2021, 88% ont recours \u00e0 un traitement pharmacologique.\nL'insulinoth\u00e9rapie est tr\u00e8s fr\u00e9quente et sup\u00e9rieure au taux observ\u00e9 dans l'Hexagone.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1535, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "2b323375-8321-4784-857e-432bce7d874e": {"__data__": {"id_": "2b323375-8321-4784-857e-432bce7d874e", "embedding": null, "metadata": {"page_label": "7", "file_name": "Synth\u00e8se etudes diab\u00e8te_13.11.2023 (1).pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\Synth\u00e8se etudes diab\u00e8te_13.11.2023 (1).pdf", "file_type": "application/pdf", "file_size": 604482, "creation_date": "2025-11-26", "last_modified_date": "2025-11-18", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "954de1be-9c9e-4f9c-ae8a-184f5c3e0047", "node_type": "4", "metadata": {"page_label": "7", "file_name": "Synth\u00e8se etudes diab\u00e8te_13.11.2023 (1).pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\Synth\u00e8se etudes diab\u00e8te_13.11.2023 (1).pdf", "file_type": "application/pdf", "file_size": 604482, "creation_date": "2025-11-26", "last_modified_date": "2025-11-18", "cleaned": true, "headlines": []}, "hash": "b6e93499e7624c9d8e1e502d74d946074085ca909afc94f3b87f99758bdd8315", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1f6b388f-ce9c-4137-bd40-71d95e74f371", "node_type": "1", "metadata": {}, "hash": "2623615485f2fe26eef9ad8f126674391f3667614133edf9d1ee181629b24fc7", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Les r\u00e9sultats de la nouvelle \u00e9dition du Barom\u00e8tre Sant\u00e9 DROM 2021 mettent en \u00e9vidence des ruptures\ndans la prise en charge des personnes ayant un diab\u00e8te :\narr\u00eat du traitement et/ou non recours a ux soins. Ces\nr\u00e9sultats rejoignent ceux des travaux r\u00e9gionaux qui montrent\nque les parcours r\u00e9els des patients diab\u00e9tiques r\u00e9unionnais\nsont souvent \u00e9loign\u00e9s des parcours de soin recommand\u00e9s.\nCette observation est coh\u00e9rente avec l'enqu\u00eate r\u00e9gionale\nsur les parcours de soins des patients diab\u00e9tiques mis sous\ntraitement en 2010 : 9% des patients avaient arr\u00eat\u00e9 leur\ntraitement au moins 2 ans et pr\u00e8s de 40% des patients\navaient arr\u00eat\u00e9 leur traitement apr\u00e8s huit ans de parcours de\nsoins.\n\nL'Etude Barom\u00e8tre Sant\u00e9 DROM 2021 rapporte que, parmi les personnes diab\u00e9tiques connues non\ntrait\u00e9es pharmacologiquement, 4 sur 10 d\u00e9clarent ne recourir \u00e0 aucune mesure hygi\u00e9no -di\u00e9t\u00e9tique :\n34,7% disent n'appliquer aucune mesure et 8,8% d\u00e9cla rent un recours exclusif aux plantes dont\nl'efficacit\u00e9 pharmacologique sur le diab\u00e8te n'a pas \u00e9t\u00e9 d\u00e9montr\u00e9e (ensemble des DROM).\n\nUn taux de complications \u00e9lev\u00e9 sur l'\u00eele\n\nA La R\u00e9union, la survenue des complications graves vient alourdir le fardeau du diab\u00e8te : insuffisance\nr\u00e9nale, complications ophtalmologiques et podologiques . Le taux de complications \u00e9lev\u00e9 est\nprobablement d\u00fb \u00e0 un diagnostic tardif, un suivi insuffisant, une observance fragile des traitements, une\nfaible modification des comportements nutritionnels des personnes atteintes. Pour exemple, la glyc\u00e9mie\ndes personnes diab\u00e9tiques (mesur\u00e9e par l'HbA1c) est moins bien contr\u00f4l\u00e9e \u00e0 La R\u00e9union que dans\nl'Hexagone (Entred 3).\n\nPour les patients diab\u00e9tiques :\n- les hospitalisations pour amputations de membres inf\u00e9rieurs \u00e9taient 1,3 fois plus fr\u00e9quentes \u00e0 La\nR\u00e9union en 2021 par rapport \u00e0 la France enti\u00e8re ;\n- les hospitalisations pour accident vasculaire c\u00e9r\u00e9bral (AVC) \u00e9taient 1,5 fois plus fr\u00e9quentes ;\n- les hospitalisations pour insuffisance r\u00e9nale chronique terminale 1,7 fois plus fr\u00e9quentes.\n\nEn terme de description de l'\u00e9tat de sant\u00e9 des patients diab\u00e9tiques , les r\u00e9sultats de ENTRED 3\nconfirment des tendances d\u00e9j\u00e0 observ\u00e9es.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2134, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "1f6b388f-ce9c-4137-bd40-71d95e74f371": {"__data__": {"id_": "1f6b388f-ce9c-4137-bd40-71d95e74f371", "embedding": null, "metadata": {"page_label": "7", "file_name": "Synth\u00e8se etudes diab\u00e8te_13.11.2023 (1).pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\Synth\u00e8se etudes diab\u00e8te_13.11.2023 (1).pdf", "file_type": "application/pdf", "file_size": 604482, "creation_date": "2025-11-26", "last_modified_date": "2025-11-18", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "954de1be-9c9e-4f9c-ae8a-184f5c3e0047", "node_type": "4", "metadata": {"page_label": "7", "file_name": "Synth\u00e8se etudes diab\u00e8te_13.11.2023 (1).pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\Synth\u00e8se etudes diab\u00e8te_13.11.2023 (1).pdf", "file_type": "application/pdf", "file_size": 604482, "creation_date": "2025-11-26", "last_modified_date": "2025-11-18", "cleaned": true, "headlines": []}, "hash": "b6e93499e7624c9d8e1e502d74d946074085ca909afc94f3b87f99758bdd8315", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2b323375-8321-4784-857e-432bce7d874e", "node_type": "1", "metadata": {"page_label": "7", "file_name": "Synth\u00e8se etudes diab\u00e8te_13.11.2023 (1).pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\Synth\u00e8se etudes diab\u00e8te_13.11.2023 (1).pdf", "file_type": "application/pdf", "file_size": 604482, "creation_date": "2025-11-26", "last_modified_date": "2025-11-18", "cleaned": true, "headlines": []}, "hash": "24ddee628bdb754f45cde08fd189aaf195652a5fb25a2f188a7a93e3ff3a673a", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "En terme de description de l'\u00e9tat de sant\u00e9 des patients diab\u00e9tiques , les r\u00e9sultats de ENTRED 3\nconfirment des tendances d\u00e9j\u00e0 observ\u00e9es. Certaines complications chroniques du diab\u00e8te ( affections\ncoronariennes, AVC) sont plus fr\u00e9quentes \u00e0 La R\u00e9union o\u00f9 le r\u00f4le potentiel de certains facteurs de risque\nplus fr\u00e9quents, notamment le tabagisme chez les patients diab\u00e9tiques, ne peut pas \u00eatre \u00e9cart\u00e9.\nPar ailleurs, l'\u00e9tude confirme que la fr\u00e9quence de la r\u00e9tinopathie est sup\u00e9rieure \u00e0 La R\u00e9union .\nLes actions de communication et\nd'accompagnement pour motiver les\npatients \u00e0 l'observance de leur\ntraitement, ou les inciter \u00e0 reprendre\nleur traitement en cas d'arr\u00eat, doivent\nse poursuivre, ainsi que la diffusion\ndes recommandations en mati\u00e8re de\nsuivi et de prise en charge.\nMalgr\u00e9 la connaissance de la maladie :\n- les personnes d\u00e9clarant un diab\u00e8te changent peu leur comportement nutritionnel\n(alimentation, activit\u00e9 physique),\n- un quart d'entre elles ne se consid\u00e8rent pas comme atteintes d'une maladie chronique.\n\nCette difficile prise de conscience des patients justifie de renforcer les programmes d'\u00e9ducation\nth\u00e9rapeutique d\u00e8s l'annonce du diagnostic de diab\u00e8te ou de pr\u00e9-diab\u00e8te.", "mimetype": "text/plain", "start_char_idx": 1998, "end_char_idx": 3183, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "55be455f-dee5-4e99-aaa9-a2863f8ec34c": {"__data__": {"id_": "55be455f-dee5-4e99-aaa9-a2863f8ec34c", "embedding": null, "metadata": {"page_label": "8", "file_name": "Synth\u00e8se etudes diab\u00e8te_13.11.2023 (1).pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\Synth\u00e8se etudes diab\u00e8te_13.11.2023 (1).pdf", "file_type": "application/pdf", "file_size": 604482, "creation_date": "2025-11-26", "last_modified_date": "2025-11-18", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "40e27d3b-71eb-4d03-8fef-db32a071df69", "node_type": "4", "metadata": {"page_label": "8", "file_name": "Synth\u00e8se etudes diab\u00e8te_13.11.2023 (1).pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\Synth\u00e8se etudes diab\u00e8te_13.11.2023 (1).pdf", "file_type": "application/pdf", "file_size": 604482, "creation_date": "2025-11-26", "last_modified_date": "2025-11-18", "cleaned": true, "headlines": []}, "hash": "81e840bbb37b51cce539766e971daa88d0aaa820b713b2ab46065398c1f99d5a", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Ces \u00e9l\u00e9ments soulignent que la pr\u00e9vention des complications constitue un enjeu fort pour La R\u00e9union .\nLes complications li\u00e9es au diab\u00e8te sont en grande partie \u00e9vitables . Pour l'ARS et ses partenaires, il est\ndonc essentiel d'approfondir les analyses et de renforcer l es actions de pr\u00e9vention en direction des\npersonnes diab\u00e9tiques. L'ORS, l'Assurance maladie et leurs partenaires travaillent ainsi actuellement \u00e0\nune \u00e9tude de parcours des patients diab\u00e9tiques ayant subi une amputation afin de mieux comprendre\nce qui a conduit \u00e0 ces situations. Les r\u00e9sultats seront interpr\u00eat\u00e9s en lien avec les professionnels de sant\u00e9\n(m\u00e9decin, podologues...) et permettront de d\u00e9gager un plan d'actions sp\u00e9c ifiques.\nDes travaux similaires seront men\u00e9s par la suite sur les complications ophtalmologiques.\n\nLe recours aux tisanes est confirm\u00e9\n\nLe ressenti des acteurs locaux sur le recours important aux\nplantes m\u00e9dicinales (tisanes/zerbage p\u00e9i) pour le traitement\ndu diab\u00e8te est confirm\u00e9.\nUne \u00e9tude r\u00e9gionale sur le recours aux soins en 2014 montrait\nque l'usage des plantes concernait 2 R\u00e9unionnais adultes sur\n5 avec un faible effet de g\u00e9n\u00e9ration. Cet usage des tisanes\nest mis en exergue dans les r\u00e9sultats du Barom\u00e8tre San t\u00e9\n2021 sur l'ensemble des DROM et dans les r\u00e9sultats de la 3\u00e8me\n\u00e9dition de l'\u00e9tude ENTRED, o\u00f9 44% des personnes diab\u00e9tiques r\u00e9u nionnaises trait\u00e9es\npharmacologiquement d\u00e9claraient aussi un recours aux plantes. Ce constat est confirm\u00e9 dans l'\u00e9tude\nqualitative Diab -quali R\u00e9union. Une revue bibliographique des enqu\u00eates qualitatives r\u00e9gionales sur le\ndiab\u00e8te a permis \u00e9galement de montr er que les plantes m\u00e9dicinales \u00e9taient l'un des 4 moyens\nth\u00e9rapeutiques clairement identifi\u00e9s par les patients diab\u00e9tiques (avec la di\u00e9t\u00e9tique, les cachets et\nl'insuline).\nCes travaux montrent que les th\u00e9rapies modernes et les traitements traditionnels phyto-th\u00e9rapeutiques\ns'ajoutent, ces derniers, largement utilis\u00e9s dans les familles r\u00e9unionnaises, pouvant supplanter les\npremi\u00e8res.\n\n44% des patients r\u00e9unionnais suivis\npour leur diab\u00e8te ont recours aux\ntisanes ; parmi eux, 91% le font en\nplus des m\u00e9dicaments et 9% des\npersonnes \u00e0 la place des\nm\u00e9dicaments (Entred 3).", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2175, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "68076cda-2cc2-4f05-a965-8f4814c60078": {"__data__": {"id_": "68076cda-2cc2-4f05-a965-8f4814c60078", "embedding": null, "metadata": {"page_label": "1", "file_name": "tdb_diabete-2004.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\tdb_diabete-2004.pdf", "file_type": "application/pdf", "file_size": 94594, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "8732b692-cc00-4955-83e8-6f8063505d08", "node_type": "4", "metadata": {"page_label": "1", "file_name": "tdb_diabete-2004.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\tdb_diabete-2004.pdf", "file_type": "application/pdf", "file_size": 94594, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "7872a7048bddb485851050cf32311e88fdd73ac1f47b3d9cd0e930d3c7e90724", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6f03524c-f10e-421e-bc5c-b97c541fcf45", "node_type": "1", "metadata": {}, "hash": "29a80599ab7edd19d934eaa87d7a08687097d364fd5d79295e28025448269f87", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "2EVHUYDWRLUH5pJLRQDO GH/D6DQWpGHOD5pXQLRQ 1RYHPEUH\nUXHGX*pQpUDOGH*DXOOH\u00b1 6DLQW'HQLV\u00b1 \u00b1 KWWSZZZRUVUXQQHW\n',$%(7(\nj/D5pXQLRQ\n&217(;7(1$7,21$/\n/HGLDEqWHVXFUpHVWXQHPDODGLHFKURQLTXHFDUDFWpULVpHSDUXQ\nWDX[WURS pOHYp GH VXFUH GDQV OH VDQJ GH IDoRQ SOXV RXPRLQV\nSHUPDQHQWH , O HQ H [LVWH GHX [ W\\SHV OH G LDEqWH LQVXOL QR\nGpSHQGDQWW\\SHHWOHGLDEqWHQRQLQVXOLQR GpSHQGDQWW\\SH\n/H GLDEqWH GH W\\SH GpEXWH OH SOXV VRXYHQWDYDQW DQV GH\nIDoRQUDSLGHYRLUHEUXWDOH/HGLDEqWHGHW\\SHHVWXQHPDODGLH\nG\u00b6LQVWDOODWLRQSURJUHVVLYHpYROXDQWGXUDQWGHQRPEUHXVHVDQQp HV\nGH PDQLqUHLQVLGLHXVHVDQVPDQLIHVWDWLRQFOLQLTXH&H W\\SH GH\nGLDEqWHUHSUpVHQWHGHVFDVGHGLDEqWH,OHVWjO\u00b6RULJLQHGH\nQRPEUHXVHVFRPSOLFDWLRQVGpJpQpUDWLYHVLGHQWLTXHVjFHOOHVGX\nGLDEqWHGHW\\SHTXLSHXYHQWUpYpOHUODPDODGLHHWHQIRQW WRXWH\nOD J UDYLWp DWWHLQWHV GH OD UpWLQH OH G LDEqWH H VW O\nXQH GH V\nSUHPLqUHV F DXVHV GH FpFLWp H Q )UDQFH DWWHLQWH GH V QHUIV\nSpULSKpULTXHV DQJRU LQIDUFWXV GX P\\RFDUGH RX HQ FRUH\nLQVXIILVDQFHUpQDOH\n,", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 939, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "6f03524c-f10e-421e-bc5c-b97c541fcf45": {"__data__": {"id_": "6f03524c-f10e-421e-bc5c-b97c541fcf45", "embedding": null, "metadata": {"page_label": "1", "file_name": "tdb_diabete-2004.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\tdb_diabete-2004.pdf", "file_type": "application/pdf", "file_size": 94594, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "8732b692-cc00-4955-83e8-6f8063505d08", "node_type": "4", "metadata": {"page_label": "1", "file_name": "tdb_diabete-2004.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\tdb_diabete-2004.pdf", "file_type": "application/pdf", "file_size": 94594, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "7872a7048bddb485851050cf32311e88fdd73ac1f47b3d9cd0e930d3c7e90724", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "68076cda-2cc2-4f05-a965-8f4814c60078", "node_type": "1", "metadata": {"page_label": "1", "file_name": "tdb_diabete-2004.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\tdb_diabete-2004.pdf", "file_type": "application/pdf", "file_size": 94594, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "df6f7ba9014069db1fcd238758ae4b8b03f98fd4c7e2330a25d52fe2ff9b0327", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4d60e967-7157-4b42-810a-c4e2b650024e", "node_type": "1", "metadata": {}, "hash": "abec55bc5fa213cfeec26892c37319a22e147bfcf1b7b2f50294703ef660df69", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "OV\u00b6DJLWG\u00b6XQHPDODGLHGHFLYLOLVDWLRQOLpHDXPRGHG HYLHTXLVH\nGpYHORSSHVXUXQWHUUDLQJpQpWLTXHSUpGLVSRVDQW/DVpGHQWDULWp\nFURLVVDQWHGHVSRSXODWLRQVO\u00b6H[FqVGHVDSSRUWVpQHUJpWLTXHVOD\nFRPSRVLWLRQ HQ PDFURQXWULPHQWV GH O\u00b6DOLPHQWDWLRQ H W OD\nVXUFKDUJH SRQGpUDOH FRPSWHQW SDUPL O HV IDFWHXUV GH ULVTXH\nHQYLURQQHPHQWDX[OHVPLHX[UHFRQQXV$LQVLRQFRQVWDWHTX\nDX\nQLYHDXPRQGLDOODSUpYDOHQFHGXGLDEqWHGHW\\SHYDULHVHORQOHV\nJURXSHVHWKQLTXHVO\u00b6XUEDQLVDWLRQOH FRQWH[WHVRFLDOFXOWXUHOHW\npFRQRPLTXH\n(Q )UDQFH OD S UpYDOHQFH GX G LDEqWH D p Wp HVVHQW LHOOHPHQW\npYDOXpHVXUODEDVHGHVYHQWHVGHPpGLFDPHQWVDQWLGLDEpWLTXHV\nj SDUWLU G\u00b6HQTXrWHVUpDOLVpHV VXU GHV pFKDQWLOORQVDOpDWRLUHVGH\nPpGHFLQVJpQpUDOLVWHVRXGHPpQDJHVHWjSDUWLUG\u00b6DQDO\\VHVGHV\nILFKLHUVGHPDODGHVGHVFDLVVHVG\u00b6DVVXUDQFHPDODGLH(Q\nOHV GRQQpHV GH OD &1$076 RQW SHUPLV G\nHVWLPHU j OD\nSURSRUWLRQ GH SHUVRQQHVDWWHLQWHVGH GLDEqWH GH W\\SH WUDLWpHV\nSDU PpGLFDPHQWV VRLW HQYLURQ SHUVRQQHV &HWWH\nHVWLPDWLRQ QH WLHQW FHSHQGDQWSDV FRPSWH GH OD SURSRUWLRQ GH\nGLDEqWHV QRQ GLDJQRVWLTXpV/\nDQDO\\VH GHV WDX[ GH SUpYDOHQFH\nSDU UpJLRQ UpYqOH XQH YDULDELOLWp JpRJUDSKLTXH LPSRUWDQWH ,", "mimetype": "text/plain", "start_char_idx": 939, "end_char_idx": 2010, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "4d60e967-7157-4b42-810a-c4e2b650024e": {"__data__": {"id_": "4d60e967-7157-4b42-810a-c4e2b650024e", "embedding": null, "metadata": {"page_label": "1", "file_name": "tdb_diabete-2004.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\tdb_diabete-2004.pdf", "file_type": "application/pdf", "file_size": 94594, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "8732b692-cc00-4955-83e8-6f8063505d08", "node_type": "4", "metadata": {"page_label": "1", "file_name": "tdb_diabete-2004.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\tdb_diabete-2004.pdf", "file_type": "application/pdf", "file_size": 94594, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "7872a7048bddb485851050cf32311e88fdd73ac1f47b3d9cd0e930d3c7e90724", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6f03524c-f10e-421e-bc5c-b97c541fcf45", "node_type": "1", "metadata": {"page_label": "1", "file_name": "tdb_diabete-2004.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\tdb_diabete-2004.pdf", "file_type": "application/pdf", "file_size": 94594, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "db83737a6ec3d31b026bbc15c8c31ea5a8fa7bc59ef3112dca41998abfcce004", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "78e202e8-8113-4907-936f-554751988c5a", "node_type": "1", "metadata": {}, "hash": "7c721b737ec9257603f7673d91a6bef71882bd34d5edbba11e018891ea7b0ee6", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "OV\nYDULHQWGHSRXUOD&RUVHjSRXUOD%UHWDJQH\n8QH HQTXr WH GH GpS LVWDJH UpDOLVpH HQ SRSX ODWLRQ JpQp UDOH\nSURJUDPPH021,&$D SHUPLVG\nHVWLPHUj OH\nQRPEUH GH SH UVRQQHV GLDEpWLTXHV QRQ G LDJQRVWLTXpHV\nSUpDODEOHPHQW $X WRWDO SUqV GH PLOOLRQ GH SH UVRQQHV HQ\n)UDQFHGHODSRSXODWLRQVHUDLHQWDWWHLQWHVG\u00b6XQGLDEqWHGH\nW\\SH HWFHWWH SUpYDOHQFH SRXUUDLWDWWHLQGUH j GDQVOHV\nWHUULWRLUHVG\nRXWUHPHU\n3HXGHWUDYDX[RQWpWpFRQVDFUpVjO\u00b6pYROXWLRQGHODSUpYDOHQFH\nGX G LDEqWH PDLV WRXV UDSSRUWHQW XQH DXJ PHQWDWLRQ GH OD\nIUpTXHQFH GH FHWWH PDODGLH 0rPH VL XQH SD UWLH GH FHWWH\nDXJPHQWDWLRQGLIILFLOHPHQWPHVXUDEOHSD UDLOOHXUVHVWDWWULEXDEOH\nj XQH S OXV JUDQGH FRXYHUWXUH VDQLWDLUH H W j XQ PHLOOHXU\nGpSLVWDJHQRWDPPHQWGDQVOHVSD\\VHQYRLHGHGpYHORSSHPHQW\nLOQ\nHQHVWSDVPRLQVYUDLTXH\u00a9O\u00b6pSLGpPLHGHGLDEqWH\u00aaHVWUpHOOH\nHWQHFHVVHGHSURJUHVVHU/HVIDFWHXUVGH FHWWHFURLVVDQFHVRQW\nO\u00b6DXJPHQWDWLRQGXQRPEUHGHSHUVRQQHVkJpHVO\u00b6DFFURLVVHPHQW\nGHODSUpYDOHQFHGHO\u00b6REpVLWpHWGHODVXUFKDUJHSRQGpUDOHDLQVL\nTXHOHVPRGLILFDWLRQVGHVPRGHVGHYLH\n&RQWUDLUHPHQWjFHTXLHVWSRXUO\nLQVWDQWGpFULWGDQVOHGLDEqWHGH\nW\\SHSOXVLHXUVpWXGHVVXJJqUHQWTX\nXQHSUpYHQWLRQSULPDLUHGX\nGLDEqWH GH W\\SH H VW SRVVLEOH HQ PDLQWHQDQW XQH", "mimetype": "text/plain", "start_char_idx": 2010, "end_char_idx": 3129, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "78e202e8-8113-4907-936f-554751988c5a": {"__data__": {"id_": "78e202e8-8113-4907-936f-554751988c5a", "embedding": null, "metadata": {"page_label": "1", "file_name": "tdb_diabete-2004.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\tdb_diabete-2004.pdf", "file_type": "application/pdf", "file_size": 94594, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "8732b692-cc00-4955-83e8-6f8063505d08", "node_type": "4", "metadata": {"page_label": "1", "file_name": "tdb_diabete-2004.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\tdb_diabete-2004.pdf", "file_type": "application/pdf", "file_size": 94594, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "7872a7048bddb485851050cf32311e88fdd73ac1f47b3d9cd0e930d3c7e90724", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4d60e967-7157-4b42-810a-c4e2b650024e", "node_type": "1", "metadata": {"page_label": "1", "file_name": "tdb_diabete-2004.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\tdb_diabete-2004.pdf", "file_type": "application/pdf", "file_size": 94594, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "9abded464e4ada920aab03dceea2c47201359ecd00615e4dce46fc6f6b6e0fb0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1d92c96a-23ee-4942-98ca-75478c0c2a39", "node_type": "1", "metadata": {}, "hash": "1e848e49047a0293049abbd42efc10881f94e032069ad24d09247b0a8f4e42e4", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "GH W\\SH H VW SRVVLEOH HQ PDLQWHQDQW XQH FHUWDLQH\nK\\JLqQHGHYLHDFWLYLWpSK\\VLTXHQXWULWLRQ\\FRPSULVFKH]GHV\nSHUVRQQHV j ULVTXH HQ VXUSRLGV RX DYHF XQH LQWROpUDQFH DX\nJOXFRVH\n6HORQXQHSURSRVLWLRQGHO\n$1$(6OHGpSLVWDJHRSSRUWXQLVWHGX\nGLDEqWHGHW\\SHSDUXQHPHVXUHGHODJO\\FpPLHjMHXQGHYUDLW\nrWUHUpDOLVpFKH]OHVSHUVRQQHVjULVTXHGHSOXVGHDQVF\nHVW\njGLUHFHOOHVD\\DQWDXPRLQVXQGHVIDFWHXUVGHULVTXHVXLYD QWV\nRULJLQHQRQFDXFDVLHQQHHWRXPLJUDQWDQWpFpGHQWVIDPLOLDX[GH\nGLDEqWH DQWpFpGHQWV SHUVRQQHOV GH G LDEqWH WHPSRUDLUHPHQW\nLQGXLWDQWpFpGHQWGHGLDEqWHJHVWDWLRQQHORXHQIDQWGHSRLGVGH\nQDLVVDQFH!NJ K\\SHUWHQVLRQ DUWpULHOOH VXUSRLGV RX\nG\\VOLSLGpPLH\n/D S ULVH HQ FKDUJH GX SD WLHQW GLDEpWLTXH DVVRFLH pGXFDWLRQ\nQXWULWLRQQHOOH WUDLWHPHQW PpGLFDPHQWHX[ HW SUpYHQWLRQ GH V\nFRPSOLFDWLRQVGHODPDODGLH\n6,78$7,21$/$5(81,21\nx /DSUpYDOHQFHGXGLDEqWHDpWpUpDFWXDOLVpHUpFHPPHQW\nJUkFHj O\u00b6pWXGH5(',$ 5pXQLRQ'LDEqWH UpDOLVpHHQ\nSD U XQH pTX LSH GH FKHUFKHXUV ,QVHUP 8 H W\nG\u00b6KRVSLWDOLHUV GH O\u00b6vOH >@ /\u00b6pWXGH D SHUPLV G\u00b6pWDEOLU XQH\nSUpYDOHQFH GX GLDEqWH GDQV OD SRSXODWLRQ UpXQLRQQDLVH GH\nDQV j GH G LDEpWLTXHV F RQQXV HW GH\nGLDEpWLTXHV GpSLVWpV VRLW XQ WDX[ HVWLPp GH", "mimetype": "text/plain", "start_char_idx": 3090, "end_char_idx": 4195, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "1d92c96a-23ee-4942-98ca-75478c0c2a39": {"__data__": {"id_": "1d92c96a-23ee-4942-98ca-75478c0c2a39", "embedding": null, "metadata": {"page_label": "1", "file_name": "tdb_diabete-2004.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\tdb_diabete-2004.pdf", "file_type": "application/pdf", "file_size": 94594, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "8732b692-cc00-4955-83e8-6f8063505d08", "node_type": "4", "metadata": {"page_label": "1", "file_name": "tdb_diabete-2004.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\tdb_diabete-2004.pdf", "file_type": "application/pdf", "file_size": 94594, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "7872a7048bddb485851050cf32311e88fdd73ac1f47b3d9cd0e930d3c7e90724", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "78e202e8-8113-4907-936f-554751988c5a", "node_type": "1", "metadata": {"page_label": "1", "file_name": "tdb_diabete-2004.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\tdb_diabete-2004.pdf", "file_type": "application/pdf", "file_size": 94594, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "8648698091a5a7340ebf90c843c708ca5f98aa5889745ef05faeb8b53128a11a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b32da7f0-7b59-4327-af9b-ab0fe96b5509", "node_type": "1", "metadata": {}, "hash": "669318c93c65d3636de0dc92f8237b57a7acadac5942fa4bbfe0a08df8f07784", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "/\u00b6pWXGH D SHUPLV G\u00b6pWDEOLU XQH\nSUpYDOHQFH GX GLDEqWH GDQV OD SRSXODWLRQ UpXQLRQQDLVH GH\nDQV j GH G LDEpWLTXHV F RQQXV HW GH\nGLDEpWLTXHV GpSLVWpV VRLW XQ WDX[ HVWLPp GH HQ\nSRSXODWLRQ JpQpUDOH /H WDX[ GH \u00a9 GLDEqWH FRQQX \u00aa HVW SOXV\nGH IRLVV XSpULHXU jFHOXL REVHUYpHQ PpWURSROH /D\nSUpYDOHQFHGXGLDEqWHHVWPD[LPDOHFKH]OHVDQV\nFKH]OHVKRPPHVFRQWUHFKH]OHVIHPPHV\nx $SUqV XQHUHODWLYH VWDELOLWp OHQRPEUHGH GpFqV OLpVDX\nGLDEqWH FRQQDvW XQH SURJUHVVLRQ UpJXOLqUH GHSXLV OD SpULRGH\n/H QRPEUH GH GpFqV D SUHVTXH GRXEOp FHV\nGHUQLqUHVGpFHQQLHVSDVVDQWGHGpFqVHQPR\\HQQHVXUOD\nSpULRGH j HQ VRLW XQH\nDXJPHQWDWLRQ G H DYHF XQH pYROXWLRQ SOXV PDUTXpH\nFKH]OHVKRPPHVFRQWUHFKH]OHVIHPPHV\nx (QDYHFSOXVGHGpFqVHQUHJLVWUpVOHGLDEqWH\nUHSUpVHQWH X QH SD UW FURLVVDQWH GDQ V OD PRUWDOLWp WRXWHV\nFDXVHVFRQIRQGXHVVRLWGHO\u00b6HQVHPEOHGHVGpFqV\nx $YHF XQH WHQGDQFH J OREDOH j OD KDXVVH OH WDX[ GH\nPRUWDOLWp D WWHLQW SRX U K DELWDQWV V XU OD Sp ULRGH\n/D VXUPRUWDOLWp PDVFXOLQH SD U GLDEqWH Q \u00b6HVW\nSUpVHQWH TX\u00b6DYDQW DQV $XGHOj GH FHW kJH OHV WDX[ GH\nPRUWDOLWp IpPLQLQV GpSDVVHQW FHX[ GHV KRPPHV DYHF GHV\npFDUWVFURLVVDQWV\nx 0DLV WRXV kJHV F RQIRQGXV OD PRUWDOLWp IpPLQLQH H VW\nOpJqUHPHQW VXSpULHXUH j FHOOH GH V", "mimetype": "text/plain", "start_char_idx": 4028, "end_char_idx": 5187, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "b32da7f0-7b59-4327-af9b-ab0fe96b5509": {"__data__": {"id_": "b32da7f0-7b59-4327-af9b-ab0fe96b5509", "embedding": null, "metadata": {"page_label": "1", "file_name": "tdb_diabete-2004.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\tdb_diabete-2004.pdf", "file_type": "application/pdf", "file_size": 94594, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "8732b692-cc00-4955-83e8-6f8063505d08", "node_type": "4", "metadata": {"page_label": "1", "file_name": "tdb_diabete-2004.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\tdb_diabete-2004.pdf", "file_type": "application/pdf", "file_size": 94594, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "7872a7048bddb485851050cf32311e88fdd73ac1f47b3d9cd0e930d3c7e90724", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1d92c96a-23ee-4942-98ca-75478c0c2a39", "node_type": "1", "metadata": {"page_label": "1", "file_name": "tdb_diabete-2004.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\tdb_diabete-2004.pdf", "file_type": "application/pdf", "file_size": 94594, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "ab9f7f336363b443602d7443024abc9f6e3bb31f29c689770913aa0b65f55085", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "38f09af6-8325-476e-9578-50bd9880c163", "node_type": "1", "metadata": {}, "hash": "4393465ebce1d05ccf80f476cd4aa51d1d2844d88c42fd300dbd0d61ad513366", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "OHV WDX[ GH\nPRUWDOLWp IpPLQLQV GpSDVVHQW FHX[ GHV KRPPHV DYHF GHV\npFDUWVFURLVVDQWV\nx 0DLV WRXV kJHV F RQIRQGXV OD PRUWDOLWp IpPLQLQH H VW\nOpJqUHPHQW VXSpULHXUH j FHOOH GH V KRPPHV FRQWUDLUHPHQW\nDX[ DXWUHV SULQFLSDOHV F DXVHV GH Gp FqV LQGLFH GH\nVXUPRUWDOLWpGH\nx /HGLDEqWHHVWUHVSRQVDEOHGHIRLVSOXVGHGpFqVj/D\n5pXQLRQTX\u00b6HQPpWURSROHjVWUXFWXUHG\u00b6kJHFRPSDUDEOHSUqV\nGHIRLVSOXVFKH]OHVUpXQLRQQDLVHV\nx 6XUODSpULRGHjOHGLDEqWHHVWjO\u00b6RULJLQHGH\nDGPLVVLRQVHQDIIHFWLRQVGHORQJXHGXUpH&HQRPEUH\nD S URJUHVVp GH GHSXLV OD Sp ULRGH\nFKH] OHV KRPPHV HW FKH] OHV IHPPHV /H GLDEqWH\nUHSUpVHQWH D LQVL O H qPH PRWLI G\u00b6DGPLVVLRQ HQ $/'\nMXVWHGHUULqUHOHVPDODGLHVFDUGLRYDVFXODLUHV HQ\n$ VWUXFWXUH G \u00b6kJH FRPSDUDEOH OD IUpTXHQFH GH FHV\nDGPLVVLRQVHVWVXSpULHXUHGHjODPR\\HQQHQDWLRQDOH\nx /H G LDEqWH UHSUpVHQWH VpMRXUV KRVSLWDOLHUV HQ\nVRLWXQHSDUWFURLVVDQWHGH SDUPLO\u00b6HQVHPEOHGHV\nPRWLIV GH UHFRXUV DX[ pWDEOLVVHPHQWV GH VRLQV /H QRPEUH\nG\u00b6DGPLVSRXUGLDEqWHHVWIRLVSOXVpOHYpLFLTX\u00b6HQPpWURSROH\nGH IDoRQ SOXV SURQRQFpH FKH] OHV IHPPHV IUpTXHQFH GHV\nDGPLVVLRQVPXOWLSOLpHSDU\nx /\u00b6pWXGHPHQpHSDUOHVVHUYLFHVPpGLFDX[VXUODSULVHHQ\nFKDUJH GX G LDEqWH >@ D SHUPLV G\u00b6HVWLPHU O\u00b6LQFLGHQFH GH", "mimetype": "text/plain", "start_char_idx": 5015, "end_char_idx": 6141, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "38f09af6-8325-476e-9578-50bd9880c163": {"__data__": {"id_": "38f09af6-8325-476e-9578-50bd9880c163", "embedding": null, "metadata": {"page_label": "1", "file_name": "tdb_diabete-2004.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\tdb_diabete-2004.pdf", "file_type": "application/pdf", "file_size": 94594, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "8732b692-cc00-4955-83e8-6f8063505d08", "node_type": "4", "metadata": {"page_label": "1", "file_name": "tdb_diabete-2004.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\tdb_diabete-2004.pdf", "file_type": "application/pdf", "file_size": 94594, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "7872a7048bddb485851050cf32311e88fdd73ac1f47b3d9cd0e930d3c7e90724", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b32da7f0-7b59-4327-af9b-ab0fe96b5509", "node_type": "1", "metadata": {"page_label": "1", "file_name": "tdb_diabete-2004.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\tdb_diabete-2004.pdf", "file_type": "application/pdf", "file_size": 94594, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "ddeb3db43ec6f9a8ffa5f3c37f6274628819ac48db81505096babbdec305246f", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "FKH] OHV IHPPHV IUpTXHQFH GHV\nDGPLVVLRQVPXOWLSOLpHSDU\nx /\u00b6pWXGHPHQpHSDUOHVVHUYLFHVPpGLFDX[VXUODSULVHHQ\nFKDUJH GX G LDEqWH >@ D SHUPLV G\u00b6HVWLPHU O\u00b6LQFLGHQFH GH V\nFRPSOLFDWLRQVDVVRFLpHVjFHWWHSDWKRORJLHODUpWLQRSDWKLHHW\nODQpSKURSDWKLHVRQWOHVSOXVIUpTXHQWHVGH\nx /H U\\WKPH GH UpDOLVDWLRQ GH V H[DPHQV GH VXUYHLOODQFH\nGXGLDEqWHGHW\\SHH VWHQGHojGHVREMHFWLIVGHSUpYHQWLRQ\nGHV FRPSOLFDWLRQV GH FHWWH PDODGLH QRWDPPHQW HQ FH TXL\nFRQFHUQH OH FRQWU{OH G H O\u00b6K\\SHUJO\\FpPLH TXL Q\u00b6HVW SDV\nFRQIRUPH DX[ UHFRPPDQGDWLRQV GH O\u00b6$1$(6 SRXU SOXV G\u00b6XQ\nSDWLHQWVXLYLVXU\n/HV GLIIpUHQWHV GRQQpHV pSLGpPLRORJLTXHV SUpVHQWpHV V RQW\nFRKpUHQWHV DYHF OD IRUWH SUpYDOHQFH GX GLDEqWH VXU O\u00b6vOH /D\n5pXQLRQDSSDUDvW HQVXUPRUWDOLWpH WVXUPRUELGLWpSD UUDSSRUW\njODPpWURSROH\njOD\n5pXQLRQ\n/$6$17(2%6(59((", "mimetype": "text/plain", "start_char_idx": 5983, "end_char_idx": 6739, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "1a0ac1e2-6c10-4df4-9675-bf2195e44d4f": {"__data__": {"id_": "1a0ac1e2-6c10-4df4-9675-bf2195e44d4f", "embedding": null, "metadata": {"page_label": "2", "file_name": "tdb_diabete-2004.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\tdb_diabete-2004.pdf", "file_type": "application/pdf", "file_size": 94594, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "ba8a5c9f-4382-47cc-94e5-9a3a2537bf8d", "node_type": "4", "metadata": {"page_label": "2", "file_name": "tdb_diabete-2004.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\tdb_diabete-2004.pdf", "file_type": "application/pdf", "file_size": 94594, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "3f89606a44044f220f87663d04acdf8634e9ff4daa2a9b469591e62231f9e56c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "55e6597d-6333-4b17-a982-05ae7b7d0481", "node_type": "1", "metadata": {}, "hash": "cddf8e2a18b631088ef9299dbe67ee286a7b5dcab7dafc383e6023f469ab3143", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "2EVHUYDWRLUH5pJLRQDO GH/D6DQWpGHOD5pXQLRQ 1RYHPEUH\nUXHGX*pQpUDOGH*DXOOH\u00b1 6DLQW'HQLV\u00b1 \u00b1 KWWSZZZRUVUXQQHW\n',$%(7(\n7$8;'(35(9$/(1&('8',$%(7(&2118'(3,67(\n$/$5(81,213238/$7,21'(6$16 (1\n+200(6 )(00(6\nFRQQX\nGpSLVWp\n7RWDO 'LDEqWH\nFRQQX\nGpSLVWp\n7RWDO\n6RXUFH (WXGH5(',$,16(50>@ \rWDX[DMXVWp\n(92/87,21'8120%5(\r '('(&(6/,(6$8',$%(7($\n/$5(81,216(/21/( 6(;(\n\n+RPPHV )HPPHV\n6RXUFH ,16(50&(3,'&)1256 \r'RQQpHVOLVVpHVVXUDQV\nO\u00b6DQQpHILJXUDQWVXUOHJUDSKHHVWO\u00b6DQQpHFHQWUDOHGHODSpULRGHWULHQQDOH\n120%5('('(&(6/,(6 $8',$%(7((1\n(92/87,21'(38,6\n(IIHFWLI 3DUWGDQVODPRUWDOLWp\nWRWDOHHQ\n7DX[EUXWGH\nPRUWDOLWpSRXU\nKDE\n+RPPHV\n(QVHPEOH\n6RXUFH ,16(50&(3,'&\u00b1 ([SORLWDWLRQ'5$66>@\n7$8;%587'(0257$/,7(3$5',$%(7(6(/21 /\u00b6$*(\n(7/(6(;($/$5(81,2102<(11(\n\nHW\n+RPPHV )HPPHV\n6RXUFH ,16(50&(3,'&)1256\n7$8;&203$5$7,)6'(0257$/,7(3$5',$%(7(\n(13285+$%,7$176\n\n5(81,21 0(75232/(\n+RP P H V\n6RXUFH ,16(50&(3,'&\u00b1 ([SORLWDWLRQ'5$66>@\n120%5('\u00b6$'0,66,216(1$))(&7,21'(/21*8(\n'85((3285',$%(7($ /$5(81,2102<(11(\n\n+RPPHV )HPPHV 7RWDO (YROXWLRQ\nGHSXLV\n0RLQVGHDQV\nDQVHW\n7RWDO\n6RXUFH &1$076&$1$0&&06$\n6(-2856'$16/(6(7$%/,", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1051, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "55e6597d-6333-4b17-a982-05ae7b7d0481": {"__data__": {"id_": "55e6597d-6333-4b17-a982-05ae7b7d0481", "embedding": null, "metadata": {"page_label": "2", "file_name": "tdb_diabete-2004.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\tdb_diabete-2004.pdf", "file_type": "application/pdf", "file_size": 94594, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "ba8a5c9f-4382-47cc-94e5-9a3a2537bf8d", "node_type": "4", "metadata": {"page_label": "2", "file_name": "tdb_diabete-2004.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\tdb_diabete-2004.pdf", "file_type": "application/pdf", "file_size": 94594, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "3f89606a44044f220f87663d04acdf8634e9ff4daa2a9b469591e62231f9e56c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1a0ac1e2-6c10-4df4-9675-bf2195e44d4f", "node_type": "1", "metadata": {"page_label": "2", "file_name": "tdb_diabete-2004.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\tdb_diabete-2004.pdf", "file_type": "application/pdf", "file_size": 94594, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "6c561eb9783d90ed7a764156c2d8baecb757dffebcfe86891061b4f0e03650e7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d782ffc5-c5e5-41ef-a671-476afda20ed1", "node_type": "1", "metadata": {}, "hash": "e96e4a0003bf007436ba39e838d163e34265c956a46e9e293d5de114bc0a2003", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "21'(/21*8(\n'85((3285',$%(7($ /$5(81,2102<(11(\n\n+RPPHV )HPPHV 7RWDO (YROXWLRQ\nGHSXLV\n0RLQVGHDQV\nDQVHW\n7RWDO\n6RXUFH &1$076&$1$0&&06$\n6(-2856'$16/(6(7$%/,66(0(176'(62,16 '(\n&2857('85((3285',$%(7($/$5(81,21(1\nQ ,&5\r (YROXWLRQ\n+RPPHV\n(QVHPEOH\n6RXUFH '5((6306,\u00b1 GRQQpHVGRPLFLOLpHVHWUHGUHVVpHV '5$66>@\n,&5 ,QGLFH&RPSDUDWLIGH5HFRXUVKRVSLWDOLHUYRLUGpILQLWLRQFLDSUqV\n)5(48(1&('(65(0%2856(0(176'(75$,7(0(176\n$17,',$%(7,48(6(7'(675$,7(0(176$662&,(6\nHIIHFWLIV ,&\n7UDLWHPHQWDQWLGLDEpWLTXHV\n0RQRWKpUDSLHG\u00b6$'2\r > @\n%LWKpUDSLHG\u00b6$'2\r > @\n7ULWKpUDSLHG\u00b6$'2\r > @\n,QVXOLQH $'2\r > @\n$EVHQFHGHWUDLWHPHQW > @\n7UDLWHPHQWLQFRQQX > @\n$XWUHVWUDLWHPHQWV\n'RQWjYLVpHFDUGLRYDVFXODLUH > @\n'RQWK\\SROLSpPLDQWV > @\n6RXUFH 6HUYLFHPpGLFDO &*66>@ \r$QWLGLDEqWLTXHRUDX[\nVHORQOHPpGHFLQWUDLWDQW\n)5(48(1&('(6&203/,&$7,216$662&,((6$8\n',$%(7(,'(17,),((6 3$5/(0('(&,175$,7$17\nQ HIIHFWLIV ,&\n\u00af,/\n5pWLQRSDWKLH > @\n&DWDUDFWH > @\n&pFLWp > @\n$57(5(6\n&RURQDURSDWKLHVDLJXsVFKURQLTXHV > @\n$UWpULRSDWKLHSpULSKpULTXH > @\n$9&PrPHUpJUHVVLI > @\n1(5)6\n1HXURSDWKLHV > @\n3LHGGLDEpWLTXH > @\n5(,16\n1pSKURSDWKLH > @\n,", "mimetype": "text/plain", "start_char_idx": 900, "end_char_idx": 1950, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "d782ffc5-c5e5-41ef-a671-476afda20ed1": {"__data__": {"id_": "d782ffc5-c5e5-41ef-a671-476afda20ed1", "embedding": null, "metadata": {"page_label": "2", "file_name": "tdb_diabete-2004.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\tdb_diabete-2004.pdf", "file_type": "application/pdf", "file_size": 94594, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "ba8a5c9f-4382-47cc-94e5-9a3a2537bf8d", "node_type": "4", "metadata": {"page_label": "2", "file_name": "tdb_diabete-2004.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\tdb_diabete-2004.pdf", "file_type": "application/pdf", "file_size": 94594, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "3f89606a44044f220f87663d04acdf8634e9ff4daa2a9b469591e62231f9e56c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "55e6597d-6333-4b17-a982-05ae7b7d0481", "node_type": "1", "metadata": {"page_label": "2", "file_name": "tdb_diabete-2004.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\tdb_diabete-2004.pdf", "file_type": "application/pdf", "file_size": 94594, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "78f03e3467cd839a61611d5647623d382af74048f32e73de98021fc8edeefa8b", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "16\n1pSKURSDWKLH > @\n,QVXIILVDQFHUpQDOHFKURQLTXH\nGLDO\\VpH\n> @\n$875(6\n,PSXLVVDQFHPDVFXOLQH > @\n$PSXWDWLRQ > @\n6RXUFH 6HUYLFHPpGLFDO\u00b1 &*66>@\n$'(48$7,21'868,9,0(',&$/'8',$%(7(75$,7($8\n68,9,5(&200$1'(3$5 /\u00b6$1$(6\n\n%LODQOLSLGLTXHDQ\n0HV XUHGHO\n\n+E$&\nPRLV\n%LODQRSKWODPRORJLTXH\n&RQVXOWDWLRQ\nGHQWDLUHDQ\n0HV XUHGHOD\nFUpDWLQLQpPLHDQ\n([ DPHQGHVSLHGV\n0HV XUHGHOD\nPLFURDOEXPLQXULH\n6RXUFH 6HUYLFHPpGLFDO\u00b1 &*66>@", "mimetype": "text/plain", "start_char_idx": 1929, "end_char_idx": 2323, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "e1a61c5c-1574-468d-a98a-e5e68523ae33": {"__data__": {"id_": "e1a61c5c-1574-468d-a98a-e5e68523ae33", "embedding": null, "metadata": {"page_label": "3", "file_name": "tdb_diabete-2004.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\tdb_diabete-2004.pdf", "file_type": "application/pdf", "file_size": 94594, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "c119cca9-d28e-4455-9140-d834c68fe01b", "node_type": "4", "metadata": {"page_label": "3", "file_name": "tdb_diabete-2004.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\tdb_diabete-2004.pdf", "file_type": "application/pdf", "file_size": 94594, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "fdfff8aef86036636c3d83c2826cf5b117e668fc2d9d0fec453b2790f384a786", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "85478166-cb22-4cb2-a64f-f0b8c643b98d", "node_type": "1", "metadata": {}, "hash": "cff02ca6e140dcc145e0e9f2ca893a4163335ac497ae6b962a8641ff670e28e9", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "2EVHUYDWRLUH5pJLRQDO GH/D6DQWpGHOD5pXQLRQ 1RYHPEUH\nUXHGX*pQpUDOGH*DXOOH\u00b1 6DLQW'HQLV\u00b1 \u00b1 KWWSZZZRUVUXQQHW\n',$%(7(\n'pILQLWLRQV\n3UpYDOHQFH QRPEUHGHFDVjXQPRPHQWGRQQp\n$/' $IIHFWLRQ GH /RQJXH 'XUpH YRLU ILFKH \u00a9 $IIHFWLRQ GH /RQJXH\n'XUpH \u00aa\n$'2 DQWLGLDEpWLTXH R UDX[ /H G LDEqWH GH W\\SH VH WUDLWH SD U\nDQWLGLDEpWLTXHV RUDX[ HW SDUIRLV SDU DQWLGLDEpWTLXHV RUDX[ HW LQVXOLQH\nLQMHFWDEOH /HV GLDEpWLTXHV GH W\\SH QH VRQW WUDLWpV TXH SDU LQVXOLQH\nLQMHFWDEOH\n,QGLFH FRPSDUDWLI GH UHFRXUV DX[ pWDEOLVVHPHQWV GH VRLQV ,&5\n/\u00b6LQGLFH FRPSDUDWLI GH UHFRXUV KRVSLWDOLHU SHUPHW GH FRPSDUHU\nJOREDOHPHQWRXSRXUXQGLDJQRVWLFG\u00b6KRVSLWDOLVDWLRQGRQQpODIUpTXHQFH\nGHV V pMRXUV KRVSLWDOLHUV GDQV OD UpJLRQ RX GpSDUWHPHQW DYHF OD\nPR\\HQQHQDWLRQDOH&\u00b6HVWOHUDSSRUWHQEDVHGXQRPEUHREVHUYpDX\nQRPEUH\u00a9 DWWHQGX \u00aaF\u00b6HVWjGLUHTXLVHUDLWREWHQXVLOHVWDX[VSpFLILTXHV\nSDUVH[HHWkJHpWDLHQWLGHQWLTXHVDX[WDX[QDWLRQDX[\n/\u00b6,&5)UDQFH PpWURSROLWDLQH pWDQW pJDO j XQ ,", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 900, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "85478166-cb22-4cb2-a64f-f0b8c643b98d": {"__data__": {"id_": "85478166-cb22-4cb2-a64f-f0b8c643b98d", "embedding": null, "metadata": {"page_label": "3", "file_name": "tdb_diabete-2004.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\tdb_diabete-2004.pdf", "file_type": "application/pdf", "file_size": 94594, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "c119cca9-d28e-4455-9140-d834c68fe01b", "node_type": "4", "metadata": {"page_label": "3", "file_name": "tdb_diabete-2004.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\tdb_diabete-2004.pdf", "file_type": "application/pdf", "file_size": 94594, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "fdfff8aef86036636c3d83c2826cf5b117e668fc2d9d0fec453b2790f384a786", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e1a61c5c-1574-468d-a98a-e5e68523ae33", "node_type": "1", "metadata": {"page_label": "3", "file_name": "tdb_diabete-2004.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\tdb_diabete-2004.pdf", "file_type": "application/pdf", "file_size": 94594, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "0189a3322e14a470fae40834295dc7e8e2f6a53564f77a0ef433fec7f904684d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3cc32a69-3635-4ee7-8e48-e73fc90d0a31", "node_type": "1", "metadata": {}, "hash": "a4a84557c4cd06a4ab7b4e3c6fc7f63c2acfec1fa434801766cc4725ffb0902c", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "&5)UDQFH PpWURSROLWDLQH pWDQW pJDO j XQ ,&5 GH VLJQLILH\nXQHIUpTXHQFHGHVVpMRXUVKRVSLWDOLHUVVXSpULHXUHGHjODPR\\HQQH\nQDWLRQDOH\n7DX[FRPSDUDWLI /HWDX[FRPSDUDWLIRXWDX[VWDQGDUGLVpGLUHFWHVWOH\nWDX[TXHO\u00b6RQREVHUYHUDLWGDQVODUpJLRQRXOHGpSDUWHPHQWVLHOOHDYDLWOD\nPrPHVWUXFWXUH SDUkJHTXHOD SRSXODWLRQGHUpIpUHQFHSRSXODWLRQGH\n)UDQFH PpWURSROLWDLQH JpQpUDOHPHQW 8Q WDX[ FRPSDUDWLI SHUPHW GH\nFRPSDUHU OD VLWXDWLRQ GH WHUULWRLUHV HQ pOLPLQDQW OHV HIIHWV OLpV DX[\nGLIIpUHQFHVGHVWUXFWXUHSDUkJH\n5HSqUHVELEOLRJUDSKLTXHVHWVRXUFHV\n>@ 3UpYDOHQFH RI 7\\SH 'LDEHWHV DQG FHQWUDO DGLSRVLW\\ LQ / D\n5pXQLRQ,VODQG (WXGH5(',$\n))DYLHU,-DXVVHQW1/H0RXOOHFHWDO\n'DQV\u00a9 'LDEHWHV5HV&OLQ3UDFW \u00aa \u00b1 VRXVSUHVVH\n>@3ULVHHQFKDUJHPpGLFDOHGXGLDEqWHj/DUpXQLRQ\n(WXGHG\u00b6XQpFKDQWLOORQGHEpQpILFLDLUHVGHO\u00b6$VVXUDQFH0DODGLH\n'LUHFWLRQGX6HUYLFH0pGLFDOGHO\u00b6vOHGH/D5pXQLRQ\n'DQV \u00a9 %XOOHWLQ G\u00b6LQIRUPDWLRQ GX 6HUYLFH 0pGLFDO \u00aa Q \u00b1 VHSWHPEUH\n>@$QDO\\VHGHVFRPSRVDQWHVGHODPRUWDOLWpj/D5pXQLRQHQ\n'5$66GH/D5pXQLRQ \u00b1 6HUYLFHV(WXGHVHWVWDWLVWLTXHVDRW\n>@ $QDO\\VH GH OD PRUELGLWp KRVSLWDOLqUH j /D 5pXQLRQ GH j\n\n'RQQpHVGX306,", "mimetype": "text/plain", "start_char_idx": 859, "end_char_idx": 1899, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "3cc32a69-3635-4ee7-8e48-e73fc90d0a31": {"__data__": {"id_": "3cc32a69-3635-4ee7-8e48-e73fc90d0a31", "embedding": null, "metadata": {"page_label": "3", "file_name": "tdb_diabete-2004.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\tdb_diabete-2004.pdf", "file_type": "application/pdf", "file_size": 94594, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "c119cca9-d28e-4455-9140-d834c68fe01b", "node_type": "4", "metadata": {"page_label": "3", "file_name": "tdb_diabete-2004.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\tdb_diabete-2004.pdf", "file_type": "application/pdf", "file_size": 94594, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "fdfff8aef86036636c3d83c2826cf5b117e668fc2d9d0fec453b2790f384a786", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "85478166-cb22-4cb2-a64f-f0b8c643b98d", "node_type": "1", "metadata": {"page_label": "3", "file_name": "tdb_diabete-2004.pdf", "file_path": "D:\\Documents\\DEV\\dev_ia_simplon\\briefs\\diabete-rag\\documents\\tdb_diabete-2004.pdf", "file_type": "application/pdf", "file_size": 94594, "creation_date": "2025-11-26", "last_modified_date": "2025-11-25", "cleaned": true, "headlines": []}, "hash": "e2732bb2acb0671880d6d87b21d9267315260ec5663dbb6546cc6bbdffeefc11", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "UHGUHVVpHVSDUOD'5((6\n'5$66GH/D5pXQLRQ \u00b1 6HUYLFHVWDWLVWLTXHS\n>@ 3UDWLTXHV H W FRQQDLVVDQFHV GHV 5pXQLRQQDLV Y LVjYLV GX\nGLDEqWHGHO\u00b6DOLPHQWDWLRQHWGHO\u00b6DFWLYLWpSK\\VLTXH\n2EVHUYDWRLUH5pJLRQDOGHOD6DQWpGH/D5pXQLRQVHSWHPEUHS\n>@6XUYHLOODQFHGXGLDEqWH\u00b1 (WXGH(175(' %LODQG\u00b6pWDSH\n((VFKZHJH\n'DQV \u00a9 %XOOHWLQ (SLGpPLRORJLTXH +HEGRPDGDLUH \u00aa 1XPpUR VSpFLDO\nFRQVDFUpDXGLDEqWHQ GpFHPEUH,196S\n>@3ULQFLSHGXGpSLVWDJHGXGLDEqWHGHW\\SH\n$*(1&(1DWLRQDOHG\u00b6DFFUpGLWDWLRQHWG\u00b6pYDOXDWLRQHQVDQWpIpYULHU\n>@'RQQpHVpSLGpPLRORJLTXHVVXUOHGLDEqWHGHW\\SH\n'6LPRQ\n'DQV \u00a9 %XOOHWLQ (SLGpPLRORJLTXH +HEGRPDGDLUH \u00aa 1XPpUR VSpFLDO\nFRQVDFUpDXGLDEqWHQ PDL\u00b1 ,196\u00b1 S\n>@/\u00b6pSLGpPLRORJLHGXGLDEqWHHQ)UDQFHPpWURSROLWDLQH\n35LFRUGHDX$:HLOO19DOOLHUHWDO\n\u00b3'LDEHWHV\t0HWDEROLVP\u00b4YROVX SSOVHSWHPEUH \u00b1 SS\n>@ (WXGH SURVSHFWLYH V XU OHV DPSXWDWLRQV GHV PHPEUHV\nLQIpULHXUHVFKH]OHVSDWLHQWVGLDEpWLTXHVjO\u00b6vOHGH/D5pXQLRQ\n2EVHUYDWRLUH5pJLRQDOGHOD6DQWpGH/D5pXQLRQGpFHPEUHS", "mimetype": "text/plain", "start_char_idx": 1899, "end_char_idx": 2792, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}}}